DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Part 412

[CMS-1632-F and IFC]

RIN-0938-AS41

Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System Policy Changes and Fiscal Year 2016 Rates; Revisions of Quality Reporting Requirements for Specific Providers, including Changes Related to the Electronic Health Record Incentive Program; Extensions of the Medicare-Dependent, Small Rural Hospital Program and the Low-Volume Payment Adjustment for Hospitals

AGENCY: Centers for Medicare and Medicaid Services (CMS), HHS.

ACTION: Final rule; interim final rule with comment period.

SUMMARY: We are revising the Medicare hospital inpatient prospective payment systems (IPPSS) for operating and capital-related costs of acute care hospitals to implement changes arising from our continuing experience with these systems for FY 2016. Some of these changes implement certain statutory provisions contained in the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively known as the Affordable Care Act), the Pathway for Sustainable Growth Reform (SGR) Act of 2013, the Protecting Access to Medicare Act of 2014, the Improving Medicare Post-Acute Care Transformation Act of 2014, the
Medicare Access and CHIP Reauthorization Act of 2015, and other legislation. We also are addressing the update of the rate-of-increase limits for certain hospitals excluded from the IPPS that are paid on a reasonable cost basis subject to these limits for FY 2016. As an interim final rule with comment period, we are implementing the statutory extensions of the Medicare-dependent, small rural hospital (MDH) Program and changes to the payment adjustment for low-volume hospitals under the IPPS.

We also are updating the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs) for FY 2016 and implementing certain statutory changes to the LTCH PPS under the Affordable Care Act and the Pathway for Sustainable Growth Rate (SGR) Reform Act of 2013 and the Protecting Access to Medicare Act of 2014.

In addition, we are establishing new requirements or revising existing requirements for quality reporting by specific providers (acute care hospitals, PPS-exempt cancer hospitals, and LTCHs) that are participating in Medicare, including related provisions for eligible hospitals and critical access hospitals participating in the Medicare Electronic Health Record (EHR) Incentive Program. We also are updating policies relating to the Hospital Value-Based Purchasing (VBP) Program, the Hospital Readmissions Reduction Program, and the Hospital-Acquired Condition (HAC) Reduction Program.

DATES: Effective Date: This final rule is effective on October 1, 2015.
Applicability Date: The provisions of the interim final rule with comment period portion of this rule (presented in section IV.L. of the preamble) are applicable for discharges on or after April 1, 2015 and on or before September 30, 2017.

Comment Period: To be assured consideration, comments on the interim final rule with comment period presented in section IV.L. of this document must be received at one of the addresses provided in the ADDRESSES section no later than 5 p.m. EST on September 29, 2015.

ADDRESSES: In commenting, please refer to file code CMS-1632-IFC. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission.

You may submit comments in one of four ways (no duplicates, please):

1. **Electronically.** You may (and we encourage you to) submit electronic comments on this regulation to [http://www.regulations.gov](http://www.regulations.gov). Follow the instructions under the “submit a comment” tab.

2. **By regular mail.** You may mail written comments to the following address ONLY:

   Centers for Medicare & Medicaid Services,
   
   Department of Health and Human Services,
   
   Attention: CMS-1632-IFC,
   
   P.O. Box 8013,
   
   Baltimore, MD 21244-1850.
Please allow sufficient time for mailed comments to be received before the close of the comment period.

3. **By express or overnight mail.** You may send written comments via express or overnight mail to the following address ONLY:

Centers for Medicare & Medicaid Services,
Department of Health and Human Services,
Attention: CMS-1632-IFC,
Mail Stop C4-26-05,
7500 Security Boulevard,
Baltimore, MD 21244-1850.

4. **By hand or courier.** If you prefer, you may deliver (by hand or courier) your written comments before the close of the comment period to either of the following addresses:

   a. For delivery in Washington, DC—
Centers for Medicare & Medicaid Services,
Department of Health and Human Services,
Room 445-G, Hubert H. Humphrey Building,
200 Independence Avenue, S.W.,
Washington, DC 20201.

   (Because access to the interior of the Hubert H. Humphrey Building is not readily available to persons without Federal Government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of
the building. A stamp-in clock is available for persons wishing to retain a proof of filing
by stamping in and retaining an extra copy of the comments being filed.)

b. For delivery in Baltimore, MD—

Centers for Medicare & Medicaid Services,
Department of Health and Human Services,
7500 Security Boulevard,
Baltimore, MD 21244-1850.

If you intend to deliver your comments to the Baltimore address, please call the
telephone number (410) 786-7195 in advance to schedule your arrival with one of our
staff members.

Comments mailed to the addresses indicated as appropriate for hand or courier
delivery may be delayed and received after the comment period.

For information on viewing public comments, we refer readers to the beginning of
the “SUPPLEMENTARY INFORMATION” section.

FOR FURTHER INFORMATION CONTACT:

Ing-Jye Cheng, (410) 786-4548 and Donald Thompson, (410) 786-4487,
Operating Prospective Payment, MS-DRGs, Deficit Reduction Act Hospital-Acquired
Acquired Conditions—Present on Admission (DRA HAC-POA) Program,
Hospital-Acquired Conditions Reduction Program, Hospital Readmission Reductions
Program, Wage Index, New Medical Service and Technology Add-On Payments,
Hospital Geographic Reclassifications, Graduate Medical Education, Capital Prospective
Payment, Excluded Hospitals, Medicare Disproportionate Share Hospital (DSH),
Medicare-dependent, small rural hospital (MDH), and Low Volume Hospital Payment Adjustment Issues.

Michele Hudson, (410) 786-4487, Long-Term Care Hospital Prospective Payment System and MS-LTC-DRG Relative Weights Issues.

Siddhartha Mazumdar, (410) 786-6673, Rural Community Hospital Demonstration Program Issues.

Cindy Tourison, (410) 786-1093, Hospital Inpatient Quality Reporting and Hospital Value-Based Purchasing--Program Administration, Validation, and Reconsideration Issues.

Pierre Yong, (410) 786-8896, Hospital Inpatient Quality Reporting--Measures Issues Except Hospital Consumer Assessment of Healthcare Providers and Systems Issues.

Elizabeth Goldstein, (410) 786-6665, Hospital Inpatient Quality Reporting--Hospital Consumer Assessment of Healthcare Providers and Systems Measures Issues.

Mary Pratt, (410) 786-6867, LTCH Quality Data Reporting Issues.

Kim Spalding Bush, (410) 786-3232, Hospital Value-Based Purchasing Efficiency Measures Issues.

James Poyer, (410) 786-2261, PPS-Exempt Cancer Hospital Quality Reporting Issues.

Deborah Krauss, (410) 786-5264, and Alexandra Mugge, (410-786-4457), EHR Incentive Program Clinical Quality Measure Related Issues.
Elizabeth Myers, (410) 786-4751, EHR Incentive Program Nonclinical Quality Measure Related Issues.

Lauren Wu, (202) 690-7151, Certified EHR Technology Related Issues.

Kellie Shannon, (410) 786-0416, Simplified Cost Allocation Methodology Issues

SUPPLEMENTARY INFORMATION:

Electronic Access

_Inspection of Public Comments:_ All public comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all public comments received before the close of the comment period on the following Web site as soon as possible after they have been received: [http://www.regulations.gov](http://www.regulations.gov). Follow the search instructions on that Web site to view public comments.

This _Federal Register_ document is also available from the _Federal Register_ online database through Federal Digital System (FDsys), a service of the U.S. Government Printing Office. This database can be accessed via the Internet at: [http://www.gpo.gov/fdsys](http://www.gpo.gov/fdsys).

Tables Available Only through the Internet on the CMS Web Site

In the past, a majority of the tables referred to throughout this preamble and in the Addendum to the proposed rule and the final rule were published in the _Federal Register_ as part of the annual proposed and final rules. However, beginning in FY 2012, some of the IPPS tables and LTCH PPS tables are no longer published in the _Federal Register_. Instead, these tables are generally only available through the Internet. The IPPS tables...
for this final rule are available through the Internet on the CMS Web site at:

http://www.cms.hhs.gov/Medicare/medicare-Fee-for-Service-

Payment/AcuteInpatientPPS/index.html. Click on the link on the left side of the screen titled, “FY 2016 IPPS Final Rule Home Page” or “Acute Inpatient – Files for Download”. The LTCH PPS tables for this FY 2016 final rule are available through the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-

Payment/LongTermCareHospitalPPS/index.html under the list item for Regulation Number CMS-1632-F. For further details on the contents of the tables referenced in this final rule, we refer readers to section VI. of the Addendum to this final rule.

Readers who experience any problems accessing any of the tables that are posted on the CMS Web sites identified above should contact Michael Treitel at (410) 786-4552.

**Acronyms**

3M 3M Health Information System
AAMC Association of American Medical Colleges
ACGME Accreditation Council for Graduate Medical Education
ACoS American College of Surgeons
AHA American Hospital Association
AHIC American Health Information Community
AHIMA American Health Information Management Association
AHRQ Agency for Healthcare Research and Quality
AJCC American Joint Committee on Cancer
ALOS Average length of stay
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALTHA</td>
<td>Acute Long Term Hospital Association</td>
</tr>
<tr>
<td>AMA</td>
<td>American Medical Association</td>
</tr>
<tr>
<td>AMGA</td>
<td>American Medical Group Association</td>
</tr>
<tr>
<td>AMI</td>
<td>Acute myocardial infarction</td>
</tr>
<tr>
<td>AOA</td>
<td>American Osteopathic Association</td>
</tr>
<tr>
<td>APR DRG</td>
<td>All Patient Refined Diagnosis Related Group System</td>
</tr>
<tr>
<td>APRN</td>
<td>Advanced practice registered nurse</td>
</tr>
<tr>
<td>ASITN</td>
<td>American Society of Interventional and Therapeutic Neuroradiology</td>
</tr>
<tr>
<td>ASPE</td>
<td>Assistant Secretary for Planning and Evaluation [DHHS]</td>
</tr>
<tr>
<td>ATRA</td>
<td>American Taxpayer Relief Act of 2012, Pub. L. 112-240</td>
</tr>
<tr>
<td>BLS</td>
<td>Bureau of Labor Statistics</td>
</tr>
<tr>
<td>CABG</td>
<td>Coronary artery bypass graft [surgery]</td>
</tr>
<tr>
<td>CAH</td>
<td>Critical access hospital</td>
</tr>
<tr>
<td>CARE</td>
<td>[Medicare] Continuity Assessment Record &amp; Evaluation [Instrument]</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>CART</td>
<td>CMS Abstraction &amp; Reporting Tool</td>
</tr>
<tr>
<td>CAUTI</td>
<td>Catheter-associated urinary tract infection</td>
</tr>
<tr>
<td>CBSAs</td>
<td>Core-based statistical areas</td>
</tr>
<tr>
<td>CC</td>
<td>Complication or comorbidity</td>
</tr>
<tr>
<td>CCN</td>
<td>CMS Certification Number</td>
</tr>
<tr>
<td>CCR</td>
<td>Cost-to-charge ratio</td>
</tr>
<tr>
<td>CDAC</td>
<td>[Medicare] Clinical Data Abstraction Center</td>
</tr>
<tr>
<td>CDAD</td>
<td><em>Clostridium difficile</em>-associated disease</td>
</tr>
<tr>
<td>CDC</td>
<td>Center for Disease Control and Prevention</td>
</tr>
<tr>
<td>CERT</td>
<td>Comprehensive error rate testing</td>
</tr>
<tr>
<td>CDI</td>
<td><em>Clostridium difficile</em> (C. difficile)</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>CLABSI</td>
<td>Central line-associated bloodstream infection</td>
</tr>
<tr>
<td>CIPI</td>
<td>Capital input price index</td>
</tr>
<tr>
<td>CMI</td>
<td>Case-mix index</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicare &amp; Medicaid Services</td>
</tr>
<tr>
<td>CMSA</td>
<td>Consolidated Metropolitan Statistical Area</td>
</tr>
<tr>
<td>COLA</td>
<td>Cost-of-living adjustment</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CPI</td>
<td>Consumer price index</td>
</tr>
<tr>
<td>CQM</td>
<td>Clinical quality measure</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>CY</td>
<td>Calendar year</td>
</tr>
<tr>
<td>DACA</td>
<td>Data Accuracy and Completeness Acknowledgement</td>
</tr>
<tr>
<td>DPP</td>
<td>Disproportionate patient percentage</td>
</tr>
<tr>
<td>DRG</td>
<td>Diagnosis-related group</td>
</tr>
<tr>
<td>DSH</td>
<td>Disproportionate share hospital</td>
</tr>
<tr>
<td>EBRT</td>
<td>External Beam Radiotherapy</td>
</tr>
<tr>
<td>ECI</td>
<td>Employment cost index</td>
</tr>
<tr>
<td>eCQM</td>
<td>Electronic clinical quality measure</td>
</tr>
<tr>
<td>EDB</td>
<td>[Medicare] Enrollment Database</td>
</tr>
<tr>
<td>EHR</td>
<td>Electronic health record</td>
</tr>
<tr>
<td>EMR</td>
<td>Electronic medical record</td>
</tr>
<tr>
<td>EP</td>
<td>Eligible professional</td>
</tr>
<tr>
<td>FAH</td>
<td>Federation of American Hospitals</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FFY</td>
<td>Federal fiscal year</td>
</tr>
<tr>
<td>FPL</td>
<td>Federal poverty line</td>
</tr>
<tr>
<td>FQHC</td>
<td>Federally qualified health center</td>
</tr>
<tr>
<td>FR</td>
<td>Federal Register</td>
</tr>
<tr>
<td>FTE</td>
<td>Full-time equivalent</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal year</td>
</tr>
</tbody>
</table>
GAF   Geographic Adjustment Factor  
GME   Graduate medical education  
HAC   Hospital-acquired condition  
HAI   Healthcare-associated infection  
HCAHPS Hospital Consumer Assessment of Healthcare Providers and Systems  
HCFA  Health Care Financing Administration  
HCO   High-cost outlier  
HCP   Healthcare personnel  
HCRIS Hospital Cost Report Information System  
HHA   Home health agency  
HHS   Department of Health and Human Services  
HICAN Health Insurance Claims Account Number  
HIPC  Health Information Policy Council  
HIS   Health information system  
HIT   Health information technology  
HMO   Health maintenance organization  
HPMP  Hospital Payment Monitoring Program  
HSA   Health savings account  
HSCRC [Maryland] Health Services Cost Review Commission  
HSRV  Hospital-specific relative value
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSRVcc</td>
<td>Hospital-specific relative value cost center</td>
</tr>
<tr>
<td>HQA</td>
<td>Hospital Quality Alliance</td>
</tr>
<tr>
<td>HQI</td>
<td>Hospital Quality Initiative</td>
</tr>
<tr>
<td>HwH</td>
<td>Hospital-within-hospital</td>
</tr>
<tr>
<td>IBR</td>
<td>Intern- and Resident-to-Bed Ratio</td>
</tr>
<tr>
<td>ICD-9-CM</td>
<td>International Classification of Diseases, Ninth Revision, Clinical Modification</td>
</tr>
<tr>
<td>ICD-10-CM</td>
<td>International Classification of Diseases, Tenth Revision, Clinical Modification</td>
</tr>
<tr>
<td>ICD-10-PCS</td>
<td>International Classification of Diseases, Tenth Revision, Procedure Coding System</td>
</tr>
<tr>
<td>ICR</td>
<td>Information collection requirement</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>IGI</td>
<td>IHS Global Insight, Inc.</td>
</tr>
<tr>
<td>IHS</td>
<td>Indian Health Service</td>
</tr>
<tr>
<td>IME</td>
<td>Indirect medical education</td>
</tr>
<tr>
<td>I-O</td>
<td>Input-Output</td>
</tr>
<tr>
<td>IOM</td>
<td>Institute of Medicine</td>
</tr>
<tr>
<td>IPF</td>
<td>Inpatient psychiatric facility</td>
</tr>
<tr>
<td>IPFQR</td>
<td>Inpatient Psychiatric Facility Quality Reporting [Program]</td>
</tr>
<tr>
<td>IPPS</td>
<td>[Acute care hospital] inpatient prospective payment system</td>
</tr>
<tr>
<td>IRF</td>
<td>Inpatient rehabilitation facility</td>
</tr>
</tbody>
</table>
IQR  Inpatient Quality Reporting
LAMCs  Large area metropolitan counties
LOS  Length of stay
LTC-DRG  Long-term care diagnosis-related group
LTCH  Long-term care hospital
LTCH QRP  Long-Term Care Hospital Quality Reporting Program
MAC  Medicare Administrative Contractor
MAP  Measure Application Partnership
MCC  Major complication or comorbidity
MCE  Medicare Code Editor
MCO  Managed care organization
MDC  Major diagnostic category
MDH  Medicare-dependent, small rural hospital
MedPAC  Medicare Payment Advisory Commission
MedPAR  Medicare Provider Analysis and Review File
MEI  Medicare Economic Index
MGCRB  Medicare Geographic Classification Review Board
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRHFP</td>
<td>Medicare Rural Hospital Flexibility Program</td>
</tr>
<tr>
<td>MRSA</td>
<td>Methicillin-resistant <em>Staphylococcus aureus</em></td>
</tr>
<tr>
<td>MSA</td>
<td>Metropolitan Statistical Area</td>
</tr>
<tr>
<td>MS-DRG</td>
<td>Medicare severity diagnosis-related group</td>
</tr>
<tr>
<td>MS-LTC-DRG</td>
<td>Medicare severity long-term care diagnosis-related group</td>
</tr>
<tr>
<td>MU</td>
<td>Meaningful Use [EHR Incentive Program]</td>
</tr>
<tr>
<td>NAICS</td>
<td>North American Industrial Classification System</td>
</tr>
<tr>
<td>NALTH</td>
<td>National Association of Long Term Hospitals</td>
</tr>
<tr>
<td>NCD</td>
<td>National coverage determination</td>
</tr>
<tr>
<td>NCHS</td>
<td>National Center for Health Statistics</td>
</tr>
<tr>
<td>NCQA</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td>NCVHS</td>
<td>National Committee on Vital and Health Statistics</td>
</tr>
<tr>
<td>NECMA</td>
<td>New England County Metropolitan Areas</td>
</tr>
<tr>
<td>NHSN</td>
<td>National Healthcare Safety Network</td>
</tr>
<tr>
<td>NQF</td>
<td>National Quality Forum</td>
</tr>
<tr>
<td>NQS</td>
<td>National Quality Strategy</td>
</tr>
<tr>
<td>NTIS</td>
<td>National Technical Information Service</td>
</tr>
<tr>
<td>NTTAA</td>
<td>National Technology Transfer and Advancement Act of 1991,</td>
</tr>
</tbody>
</table>
NUBC  National Uniform Billing Code
NVHRI  National Voluntary Hospital Reporting Initiative
OACT  [CMS] Office of the Actuary
OES  Occupational employment statistics
OIG  Office of the Inspector General
OMB  [Executive] Office of Management and Budget
ONC  Office of the National Coordinator for Health Information Technology
OQR  [Hospital] Outpatient Quality Reporting
O.R.  Operating room
OSCAR  Online Survey Certification and Reporting [System]
PAC  Postacute care
PCH  PPS-exempt cancer hospital
PCHQR  PPS-exempt cancer hospital quality reporting
PMSAs  Primary metropolitan statistical areas
POA  Present on admission
PPI  Producer price index
PPS  Prospective payment system
PRM  Provider Reimbursement Manual
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProPAC</td>
<td>Prospective Payment Assessment Commission</td>
</tr>
<tr>
<td>PRRB</td>
<td>Provider Reimbursement Review Board</td>
</tr>
<tr>
<td>PRTFs</td>
<td>Psychiatric residential treatment facilities</td>
</tr>
<tr>
<td>PSF</td>
<td>Provider-Specific File</td>
</tr>
<tr>
<td>PSI</td>
<td>Patient safety indicator</td>
</tr>
<tr>
<td>PS&amp;R</td>
<td>Provider Statistical and Reimbursement [System]</td>
</tr>
<tr>
<td>PQRS</td>
<td>Physician Quality Reporting System</td>
</tr>
<tr>
<td>QIG</td>
<td>Quality Improvement Group [CMS]</td>
</tr>
<tr>
<td>QRDA</td>
<td>Quality Reporting Data Architecture</td>
</tr>
<tr>
<td>RFA</td>
<td>Regulatory Flexibility Act, Pub. L. 96-354</td>
</tr>
<tr>
<td>RHC</td>
<td>Rural health clinic</td>
</tr>
<tr>
<td>RHQDAPU</td>
<td>Reporting hospital quality data for annual payment update</td>
</tr>
<tr>
<td>RNHCI</td>
<td>Religious nonmedical health care institution</td>
</tr>
<tr>
<td>RPL</td>
<td>Rehabilitation psychiatric long-term care (hospital)</td>
</tr>
<tr>
<td>RRC</td>
<td>Rural referral center</td>
</tr>
<tr>
<td>RSMR</td>
<td>Risk-standardized mortality rate</td>
</tr>
<tr>
<td>RSRR</td>
<td>Risk-standard readmission rate</td>
</tr>
<tr>
<td>RTI</td>
<td>Research Triangle Institute, International</td>
</tr>
<tr>
<td>RUCAs</td>
<td>Rural-urban commuting area codes</td>
</tr>
<tr>
<td>RY</td>
<td>Rate year</td>
</tr>
<tr>
<td>SAF</td>
<td>Standard Analytic File</td>
</tr>
<tr>
<td>SCH</td>
<td>Sole community hospital</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>SCHIP</td>
<td>State Child Health Insurance Program</td>
</tr>
<tr>
<td>SCIP</td>
<td>Surgical Care Improvement Project</td>
</tr>
<tr>
<td>SFY</td>
<td>State fiscal year</td>
</tr>
<tr>
<td>SGR</td>
<td>Sustainable Growth Rate</td>
</tr>
<tr>
<td>SIC</td>
<td>Standard Industrial Classification</td>
</tr>
<tr>
<td>SNF</td>
<td>Skilled nursing facility</td>
</tr>
<tr>
<td>SOCs</td>
<td>Standard occupational classifications</td>
</tr>
<tr>
<td>SOM</td>
<td>State Operations Manual</td>
</tr>
<tr>
<td>SSI</td>
<td>Surgical site infection</td>
</tr>
<tr>
<td>SSI</td>
<td>Supplemental Security Income</td>
</tr>
<tr>
<td>SSO</td>
<td>Short-stay outlier</td>
</tr>
<tr>
<td>SUD</td>
<td>Substance use disorder</td>
</tr>
<tr>
<td>TEP</td>
<td>Technical expert panel</td>
</tr>
<tr>
<td>THA/TKA</td>
<td>Total hip arthroplasty/Total knee arthroplasty</td>
</tr>
<tr>
<td>TPS</td>
<td>Total Performance Score</td>
</tr>
<tr>
<td>UHDDS</td>
<td>Uniform hospital discharge data set</td>
</tr>
<tr>
<td>UMRA</td>
<td>Unfunded Mandate Reform Act, Pub. L. 104-4</td>
</tr>
<tr>
<td>VBP</td>
<td>[Hospital] Value Based Purchasing [Program]</td>
</tr>
<tr>
<td>VTE</td>
<td>Venous thromboembolism</td>
</tr>
</tbody>
</table>
Table of Contents

I. Executive Summary and Background
   A. Executive Summary
      1. Purpose and Legal Authority
      3. Summary of Costs and Benefits
   B. Summary
      1. Acute Care Hospital Inpatient Prospective Payment System (IPPS)
      2. Hospitals and Hospital Units Excluded from the IPPS
      3. Long-Term Care Hospital Prospective Payment System (LTCH PPS)
      4. Critical Access Hospitals (CAHs)
      5. Payments for Graduate Medical Education (GME)
   C. Summary of Provisions of Recent Legislation Discussed in this Final Rule and Interim Final Rule with Comment Period
      1. Patient Protection and Affordable Care Act (Pub. L. 111-148) and the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152)
      5. Improving Medicare Post-Acute Care Transformation Act of 2014
D. Issuance of a Notice of Proposed Rulemaking

E. Public Comments Received in Response to the FY 2016 IPPS/LTCH PPS Proposed Rule

II. Changes to Medicare Severity Diagnosis-Related Group (MS-DRG) Classifications and Relative Weights

A. Background

B. MS-DRG Reclassifications

C. Adoption of the MS-DRGs in FY 2008

D. FY 2016 MS-DRG Documentation and Coding Adjustment

1. Background on the Prospective MS-DRG Documentation and Coding Adjustments for FY 2008 and FY 2009 Authorized by Pub. L. 110-90

2. Adjustment to the Average Standardized Amounts Required by Pub. L. 110-90
   a. Prospective Adjustment Required by Section 7(b)(1)(A) of Pub. L. 110-90
   b. Recoupment or Repayment Adjustments in FYs 2010 through 2012 Required by Section 7(b)(1)(B) Pub. L. 110-90

3. Retrospective Evaluation of FY 2008 and FY 2009 Claims Data

4. Prospective Adjustments for FY 2008 and FY 2009 Authorized by Section 7(b)(1)(A) of Pub. L. 110-90

5. Recoupment or Repayment Adjustment Authorized by Section 7(b)(1)(B) of Pub. L. 110-90

6. Recoupment or Repayment Adjustment Authorized by Section 631 of the American Taxpayer Relief Act of 2012 (ATRA)
E. Refinement of the MS-DRG Relative Weight Calculation

1. Background

2. Discussion for FY 2016 and Summary of Public Comments Received in Response to Our Solicitation of Comments on Nonstandard Cost Center Codes

F. Adjustment to MS-DRGs for Preventable Hospital-Acquired Conditions (HACs), Including Infections, for FY 2016

1. Background

2. HAC Selection

3. Present on Admission (POA) Indicator Reporting

4. HACs and POA Reporting in Preparation for Transition to ICD-10-CM and ICD-10-PCS

5. Changes to the HAC Program for FY 2016

6. RTI Program Evaluation

7. RTI Report on Evidence-Based Guidelines

G. Changes to Specific MS-DRG Classifications

1. Discussion of Changes to Coding System and Basis for MS-DRG Updates

   a. Conversion of MS-DRGs to the International Classification of Diseases, 10th Edition (ICD-10)

   b. Basis for FY 2016 MS-DRG Updates

2. MDC 1 (Diseases and Disorders of the Nervous System): Endovascular Embolization (Coiling) Procedures

3. MDC 5 (Diseases and Disorders of the Circulatory System)
a. Adding Severity Levels to MS-DRGs 245 through 251

b. Percutaneous Intracardiac Procedures

c. Zilver® PTX Drug-Eluting Peripheral Stent (ZPTX®)

d. Percutaneous Mitral Valve Repair System-- Revision of ICD-10-PCS

Version 32 Logic

e. Major Cardiovascular Procedures: Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft

4. MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue)

a. Revision of Hip or Knee Replacement: Revision of ICD-10 Version 32 Logic

b. Spinal Fusion

5. MDC 14 (Pregnancy, Childbirth and the Puerperium): MS-DRG 775 (Vaginal Delivery with Complicating Diagnosis)

6. MDC 21 (Injuries, Poisoning and Toxic Effects of Drugs): CroFab Antivenin Drug

7. MDC 22 (Burns): Additional Severity of Illness Level for MS-DRG 927 (Extensive Burns or Full Thickness Burns with Mechanical Ventilation 96 + Hours with Skin Graft)

8. Medicare Code Editor (MCE) Changes

9. Changes to Surgical Hierarchies

10. Changes to the MS-DRG Diagnosis Codes for FY 2016
a. Major Complications or Comorbidities (MCCs) and Complications or Comorbidities (CCs) Severity Levels for FY 2016

b. Coronary Atherosclerosis Due to Calcified Coronary Lesion
c. Hydronephrosis

11. Complications or Comorbidity (CC) Exclusions List for FY 2016

a. Background
b. CC Exclusions List for FY 2016

12. Review of Procedure Codes in MS-DRGs 981 through 983, 984 through 986, and 987 through 989

a. Moving Procedure Codes from MS-DRGs 981 through 983 or MS-DRGs 987 through 989 into MDCs
b. Reassignment of Procedures among MS-DRGs 981 through 983, 984 through 986, and 987 through 989
c. Adding Diagnosis or Procedure Codes to MDCs

13. Changes to the ICD-9-CM Coding System in FY 2016

a. ICD-10 Coordination and Maintenance Committee
b. Code Freeze

14. Other Policy Change: Recalled/Replaced Devices

15. Out of Scope Public Comments

H. Recalibration of the FY 2016 MS-DRG Relative Weights

1. Data Sources for Developing the Relative Weights
2. Methodology for Calculation of the Relative Weights
3. Development of National Average CCRs

4. Discussion and Acknowledgement of Public Comments Received on Expanding the Bundled Payments for Care Improvement (BPCI) Initiative
   a. Background
   b. Considerations for Potential Model Expansion

I. Add-On Payments for New Services and Technologies
   1. Background
   2. Public Input Before Publication of a Notice of Proposed Rulemaking on Add-On Payments
   3. Implementation of ICD-10-PCS Section “X” Codes for Certain New Medical Services and Technologies for FY 2016

4. FY 2016 Status of Technologies Approved for FY 2015 Add-On Payments
   a. Glucarpidase (Voraxaze®)
   b. Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft
   c. Kcentra™
   d. Argus® II Retinal Prosthesis System
   e. Zilver®PTX® Drug-Eluting Peripheral Stent
   f. CardioMEMS™ HF (Heart Failure) Monitoring System
   g. MitraClip® System
   h. Responsive Neurostimulator (RNS® System)

5. FY 2016 Applications for New Technology Add-On Payments
   a. Blinatumomab (BLINCYTO™)
b. DIAMONDBACK® 360 Coronary Orbital Atherectomy System

c. CRESEMBA® (Isavuconazonium)

d. LUTONIX® Drug Coated Balloon (DCB) Percutaneous Transluminal Angioplasty (PTA) and IN.PACT™Admiral™ Paclixel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

e. VERASENSE™ Knee Balancer System (VKS)

f. WATCHMAN® Left Atrial Appendage Closure Technology

III. Changes to the Hospital Wage Index for Acute Care Hospitals

A. Background

1. Legislative Authority

2. Core-Based Statistical Areas (CBSAs) for the Hospital Wage Index

B. Worksheet S-3 Wage Data for the FY 2016 Wage Index

1. Included Categories of Costs

2. Excluded Categories of Costs

3. Use of Wage Index Data by Suppliers and Providers Other Than Acute Care Hospitals under the IPPS

C. Verification of Worksheet S-3 Wage Data

D. Method for Computing the FY 2016 Unadjusted Wage Index

E. Occupational Mix Adjustment to the FY 2016 Wage Index

1. Development of Data for the FY 2016 Occupational Mix Adjustment Based on the 2013 Medicare Wage Index Occupational Mix Survey

2. New 2013 Occupational Mix Survey Data for the FY 2016 Wage Index
3. Calculation of the Occupational Mix Adjustment for FY 2016

F. Analysis and Implementation of the Occupational Mix Adjustment and the FY 2016 Occupational Mix Adjusted Wage Index

G. Transitional Wage Indexes
   1. Background
   2. Transition for Hospitals in Urban Areas That Became Rural
   3. Transition for Hospitals Deemed Urban under Section 1886(d)(8)(B) of the Act Where the Urban Area Became Rural under the New OMB Delineations
   4. Expiring Transition for Hospitals That Experience a Decrease in Wage Index under the New OMB Delineations
   5. Budget Neutrality

H. Application of the Rural, Imputed, and Frontier Floors
   1. Rural Floor
   2. Imputed Floor for FY 2016
   3. State Frontier Floor
   I. FY 2016 Wage Index Tables

J. Revisions to the Wage Index Based on Hospital Redesignations and Reclassifications
   1. General Policies and Effects of Reclassification and Redesignation
   2. FY 2016 MGCRB Reclassifications and Redesignation Issues
      a. FY 2016 Reclassification Requests and Approvals
      b. Applications for Reclassifications for FY 2017
3. Redesignations of Hospitals under Section 1886(d)(8)(B) of the Act (Lugar)

4. Waiving Lugar Redesignation for the Out-Migration Adjustment

K. Out-Migration Adjustment Based on Commuting Patterns of Hospital Employees

1. Background

2. New Data Source for the FY 2016 Out-Migration Adjustment

3. FY 2016 Out-Migration Adjustment

4. Use of Out-Migration Data Applied for FY 2014 or FY 2015 for 3 Years

L. Process for Requests for Wage Index Data Corrections

M. Labor-Related Share for the FY 2016 Wage Index

N. Changes to 3-Year Average for the FY 2017 Wage Index Pension Costs and Change to Wage Index Timeline Regarding Pension Costs for FY 2017 and Subsequent Years

O. Clarification of Allocation of Pension Costs for the Wage Index

IV. Other Decisions and Changes to the IPPS for Operating Costs and Indirect Medical Education (IME) Costs

A. Changes in the Inpatient Hospital Updates for FY 2016 (§§ 412.64(d) and 412.211(c))

1. FY 2016 Inpatient Hospital Update

2. FY 2016 Puerto Rico Hospital Update

B. Rural Referral Centers (RRCs): Annual Updates to Case-Mix Index (CMI) and Discharge Criteria (§ 412.96)
1. Case-Mix Index (CMI)

2. Discharges

C. Indirect Medical Education (IME) Payment Adjustment for FY 2016

(§ 412.105)

D. FY 2016 Payment Adjustment for Medicare Disproportionate Share Hospitals (DSHs) (§ 412.106)

1. Background

2. Impact on Medicare DSH Payment Adjustment of the Continued Implementation of New OMB Labor Market Area Delineations

3. Payment Adjustment Methodology for Medicare Disproportionate Share Hospitals (DSHs) under Section 3133 of the Affordable Care Act

   a. General Discussion

   b. Eligibility for Empirically Justified Medicare DSH Payments and Uncompensated Care Payments

   c. Empirically Justified Medicare DSH Payments

   d. Uncompensated Care Payments

E. Hospital Readmissions Reduction Program: Changes for FY 2016 Through FY 2017 (§§ 412.150 through 412.154)

1. Statutory Basis for the Hospital Readmissions Reduction Program

2. Regulatory Background

3. Overview of Policies Changes for the FY 2016 and FY 2017 Hospital Readmissions Reduction Program
4. Refinement of Hospital 30-Day, All Cause, Risk-Standardized Readmission Rate (RSSR) Following Pneumonia Hospitalization Measure Cohort (NQF #0506) for FY 2017 Payment Determination and Subsequent Years
   a. Background
   b. Overview of Measure Cohort Change
   c. Risk Adjustment
   d. Anticipated Effect of Refinement of Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSSR) Following Pneumonia Hospitalization Measure (NQF #0506) Cohort
   e. Calculating the Excess Readmissions Ratio

5. Maintenance of Technical Specifications for Quality Measures

6. Floor Adjustment Factor for FY 2016 (§ 412.154(c)(2))

7. Applicable Period for FY 2016

   a. Background
   b. Calculation of Aggregate Payments

9. Extraordinary Circumstances Exception Policy for the Hospital Readmissions Reduction Program Beginning FY 2016 and for Subsequent Years
   a. Background
   b. Requests for an Extraordinary Circumstances Exception

F. Hospital Value-Based Purchasing (VBP) Program: Policy Changes for the FY 2018 Program Year and Subsequent Years
1. Background
   a. Statutory Background and Overview of Past Program Years
   b. FY 2016 Program Year Payment Details

2. Retention, Removal, Expansion, and Updating of Quality Measures for FY 2018 Program Year
   a. Retention of Previously Adopted Hospital VBP Program Measures for the FY 2018 Program Year
   b. Removal of Two Measures
   c. New Measure for the FY 2018 Program Year: 3-Item Care Transition Measure (CTM-3) (NQF #0228)
   d. Removal of Clinical Care—Process Subdomain for the FY 2018 Program Year and Subsequent Years
   e. NHSN Measures Standard Population Data
   f. Summary of Previously Adopted and New Measures for the FY 2018 Program Year

3. Previously Adopted and New Measures for the FY 2019, FY 2021, and Subsequent Program Years
a. Intent to Propose in Future Rulemaking to Include Selected Ward (Non-Intensive Care Unit (ICU)) Locations in Certain NHSN Measures Beginning with the FY 2019 Program Year

b. New Measure for the FY 2021 Program Year: Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization (NQF #1893)

c. Summary of Previously Adopted and New Measures for the FY 2019 and FY 2021 and Subsequent Program Years

4. Possible Measure Topics for Future Program Years

5. Previously Adopted and New Baseline and Performance Periods for the FY 2018 Program Year

a. Background

b. Baseline and Performance Periods for the Patient and Caregiver-Centered Experience of Care/Care Coordination Domain for the FY 2018 Program Year

c. Baseline and Performance Periods for NHSN Measures and PC-01 in the Safety Domain for the FY 2018 Program Year

d. Baseline and Performance Periods for the Efficiency and Cost Reduction Domain for the FY 2018 Program Year

e. Summary of Previously Finalized and New Baseline and Performance Periods for the FY 2018 Program Year

6. Previously Adopted and New Baseline and Performance Periods for Future Program Years
a. Previously Adopted Baseline and Performance Periods for the FY 2019 Program

b. Baseline and Performance Periods for the PSI-90 Measure in the Safety Domain in the FY 2020 Program Years

c. Baseline and Performance Periods for the Clinical Care Domain for the FY 2021 Program Year

7. Performance Standards for the Hospital VBP Program

a. Background

b. Technical Updates

c. Performance Standards for the FY 2018 Program Year

d. Previously Adopted Performance Standards for Certain Measures for the FY 2019 Program Year

e. Previously Adopted and New Performance Standards for Certain Measures for the FY 2020 Program Year

f. Performance Standards for Certain Measures for the FY 2021 Program Year

8. FY 2018 Program Year Scoring Methodology

a. Domain Weighting for the FY 2018 Program Year for Hospitals That Receive a Score on All Domains

b. Domain Weighting for the FY 2018 Program Year for Hospitals Receiving Scores on Fewer than Four Domains

G. Changes to the Hospital-Acquired Condition (HAC) Reduction Program

1. Background
2. Statutory Basis for the HAC Reduction Program

3. Overview of Previous HAC Reduction Program Rulemaking

4. Implementation of the HAC Reduction Program for FY 2016

5. Changes for Implementation of the HAC Reduction Program for FY 2017
   a. Applicable Time Period for the FY 2017 HAC Reduction Program
   b. Narrative Rule Used in Calculation of the Domain 2 Score for the FY 2017 HAC Reduction Program
   c. Domain 1 and Domain 2 Weights for the FY 2017 HAC Reduction Program

6. Measure Refinements for the FY 2018 HAC Reduction Program
   a. Inclusion of Select Ward (Non-Intensive Care Unit (ICU)) Locations in Certain CDC NHSN Measures Beginning in the FY 2018 Program Year
   b. Update to CDC NHSN Measures Standard Population Data

7. Maintenance of Technical Specifications for Quality Measures

8. Extraordinary Circumstances Exception Policy for the HAC Reduction Program Beginning in FY 2016 and for Subsequent Years
   a. Background
   b. Requests for an Extraordinary Circumstances Exception

H. Simplified Cost Allocation Methodology

1. Background

2. Proposed Regulatory Changes

3. Summary of Public Comments, Our Responses, and Final Policy

I. Rural Community Hospital Demonstration Program
1. Background

2. FY 2016 Budget Neutrality Offset Amount

J. Changes to MS-DRGs Subject to the Postacute Care Transfer Policy (§ 412.4)

1. Background

2. Changes to the Postacute Care Transfer MS-DRGs

K. Short Inpatient Hospital Stays

L. Interim Final Rule with Comment Period Implementing Legislative Extensions Relating to the Payment Adjustment for Low-Volume Hospitals and the Medicare-Dependent, Small Rural Hospital (MDH) Program

1. Recent Legislation

2. Payment Adjustment for Low-Volume Hospitals (§ 412.101)
   a. Background

   b. Implementation of Provisions of the MACRA for FY 2015

   c. Low-Volume Hospital Definition and Payment Adjustment for FY 2016

3. Medicare-Dependent, Small Rural Hospital (MDH) Program (§ 412.108)
   a. Background for MDH Program

   b. MACRA Provisions for Extension of the MDH Program

4. Response to Comments

5. Waiver of Notice of Proposed Rulemaking and Delay in Effective Date

6. Collection of Information Requirements

7. Impact of Legislative Changes

V. Changes to the IPPS for Capital-Related Costs
A. Overview

B. Additional Provisions

1. Exception Payments

2. New Hospitals

3. Hospitals Located in Puerto Rico

C. Annual Update for FY 2016

VI. Changes for Hospitals Excluded from the IPPS

A. Rate-of-Increase in Payments to Excluded Hospitals for FY 2016

B. Report of Adjustment (Exceptions) Payments

C. Out of Scope Comments Relating to Critical Access Hospitals (CAHs)

Inpatient Services

VII. Changes to the Long-Term Care Hospital Prospective Payment System (LTCH PPS) for FY 2016

A. Background of the LTCH PPS

1. Legislative and Regulatory Authority

2. Criteria for Classification as an LTCH

a. Classification as an LTCH

b. Hospitals Excluded from the LTCH PPS

3. Limitation on Charges to Beneficiaries

4. Administrative Simplification Compliance Act (ASCA) and Health Insurance Portability and Accountability Act (HIPAA) Compliance

B. Application of Site Neutral Payment Rate (New § 412.522)
1. Overview

2. Application of the Site Neutral Payment Rate under the LTCH PPS

3. Criteria for Exclusion from the Site Neutral Payment Rate
   b. Implementation of Criterion for a Principal Diagnosis Relating to a Psychiatric Diagnosis or to Rehabilitation
      c. Addition of Definition of “Subsection (d) Hospital” to LTCH Regulations
      d. Interpretation of “Immediately Preceded” by a Subsection (d) Hospital Discharge
   e. Implementation of Intensive Care Unit (ICU) Criterion
   f. Implementation of the Ventilator Criterion

4. Determination of the Site Neutral Payment Rate (Proposed New § 412.522(c))
   a. General
   b. Blended Payment Rate for FY 2016 and FY 2017
   c. LTCH PPS Standard Federal Payment Rate

5. Application of Certain Exiting LTCH PPS Payment Adjustments to Payments Made under the Site Neutral Payment Rate

6. LTCH Discharge Payment Percentage

7. Additional LTCH PPS Policy Considerations Related to the Implementation of the Site Neutral Payment Rate Required by Section 1206(a) of Pub. L. 113-67
   a. MS-LTC-DRG Relative Payment Weights
   b. High-Cost Outliers
c. Limitation on Charges to Beneficiaries

C. Medicare Severity Long-Term Care Diagnosis-Related Group (MS-LTC-DRG) Classifications and Relative Weights for FY 2016

1. Background

2. Patient Classifications into MS-LTC-DRGs
   a. Background
   b. Changes to the MS-LTC-DRGs for FY 2016

3. Development of the FY 2016 MS-LTC-DRG Relative Weights
   a. General Overview of the Development of the MS-LTC-DRG Relative Weights
   b. Development of the MS-LTC-DRG Relative Weights for FY 2016
   c. Data
   d. Hospital-Specific Relative Value (HSRV) Methodology
   e. Treatment of Severity Levels in Developing the MS-LTC-DRG Relative Weights
   f. Low-Volume MS-LTC-DRGs
   g. Steps for Determining the Proposed FY 2016 MS-LTC-DRG Relative Weights

D. Changes to the LTCH PPS Standard Payment Rates for FY 2016

1. Overview of Development of the LTCH PPS Standard Federal Payment Rates

2. FY 2016 LTCH PPS Annual Market Basket Update
   a. Overview
   b. Revision of Certain Market Basket Updates as Required by the Affordable Care Act
c. Adjustment to the Annual Update to the LTCH PPS Standard Federal Rate under the Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

d. Market Basket under the LTCH PPS for FY 2016

e. Annual Market Basket Update for LTCHs for FY 2016

E. Moratoria on the Establishment of LTCHs and LTCH Satellite Facilities and on the Increase in Number of Beds in Existing LTCHs and LTCH Satellite Facilities

F. Changes to Average Length of Stay Criterion under Pub. L. 113-67 (§ 412.23)

VIII. Quality Data Reporting Requirements for Specific Providers and Suppliers for FY 2016

A. Hospital Inpatient Quality Reporting (IQR) Program

1. Background

a. History of the Hospital IQR Program

b. Maintenance of Technical Specifications for Quality Measures

c. Public Display of Quality Measures

2. Process for Retaining Previously Adopted Hospital IQR Program Measures for Subsequent Payment Determinations

3. Removal and Suspension of Hospital IQR Program Measures

a. Considerations in Removing Quality Measures from the Hospital IQR Program

b. Removal of Hospital IQR Program Measures for the FY 2018 Payment Determination and Subsequent Years

4. Previously Adopted Hospital IQR Program Measures for the FY 2017 Payment Determination and Subsequent Years
a. Background

b. NHSN Measures Standard Population Data

5. Expansion and Updating of Quality Measures

6. Refinements of Existing Measures in the Hospital IQR Program
   a. Refinement of Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization (NQF #0468) Measure Cohort
   b. Refinement of Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization (NQF #0468) Measure Cohort

7. Additional Hospital IQR Program Measures for the FY 2018 and FY 2019 Payment Determinations and Subsequent Years
   a. Hospital Survey on Patient Safety Culture
   b. Clinical Episode-Based Payment Measures
   c. Hospital-Level, Risk-Standardized Payment Associated with a 90-Day Episode-of-Care for Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)
   d. Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction
   e. Excess Days in Acute Care after Hospitalization for Heart Failure
   f. Summary of Previously Adopted and New Hospital IQR Program Measure Set for the FY 2018 and FY 2019 Payment Determinations and Subsequent Years

8. Electronic Clinical Quality Measures
a. Previously Adopted Voluntarily Reported Electronic Clinical Quality Measures for the FY 2017 Payment Determination

b. Clarification of the Venous Thromboembolism (VTE) Prophylaxis (STK – 01) Measure (NQF #0434)

c. Requirements for Hospitals to Report Electronic Clinical Quality Measures for the FY 2018 Payment Determination and Subsequent Years

9. Future Considerations for Electronically Specified Measures: Consideration to Implement a New Type of Measure that Utilizes Core Clinical Data Elements

a. Background

b. Overview of Core Clinical Data Elements

c. Core Clinical Data Elements Development

d. Core Clinical Data Elements Feasibility Testing Using Readmission and Mortality Models

e. Use of Core Clinical Data Elements in Hospital Quality Measures for the Hospital IQR Program

f. Content Exchange Standard Considerations for Core Clinical Data Elements

10. Form, Manner, and Timing of Quality Data Submission

a. Background

b. Procedural Requirements for the FY 2018 Payment Determination and Subsequent Years

c. Data Submission Requirements for Chart-Abstracted Measures
d. Alignment of the Medicare EHR Incentive Program Reporting for Eligible Hospitals and CAHs with the Hospital IQR Program

e. Sampling and Case Thresholds for the FY 2018 Payment Determination and Subsequent Years

f. HCAHPS Requirements for the FY 2018 Payment Determination and Subsequent Years

g. Data Submission Requirements for Structural Measures for the FY 2018 Payment Determination and Subsequent Years

h. Data Submission and Reporting Requirements for Healthcare-Associated Infection (HAI) Measures Reported via NHSN

11. Modifications to the Existing Processes for Validation of Hospital IQR Program Data

a. Background

b. Modifications to the Existing Processes for Validation of Chart-Abstracted Hospital IQR Program Data

12. Data Accuracy and Completeness Acknowledgement Requirements for the FY 2018 Payment Determination and Subsequent Years

13. Public Display Requirements for the FY 2018 Payment Determination and Subsequent Years

14. Reconsideration and Appeal Procedures for the FY 2018 Payment Determination and Subsequent Years
15. Hospital IQR Program Extraordinary Circumstances Extensions or Exemptions

B. PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program

1. Statutory Authority

2. Removal of Six Surgical Care Improvement Project (SCIP) Measures from the PCHQR Program Beginning with Fourth Quarter (Q4) 2015 Discharges and for Subsequent Years

3. New Quality Measures Beginning with the FY 2018 Program
   a. Considerations in the Selection of Quality Measures
   b. Summary of New Measures
   c. CDC NHSN Facility-Wide Inpatient Hospital-Onset Clostridium difficile (C. difficile) Infection (CDI) Outcome Measure (NQF #1717)
      d. CDC NHSN Facility-Wide Inpatient Hospital-Onset Methicillin-Resistant Staphylococcus Aureus (MSRA) Bacteremia Outcome Measure (NQF #1716)
      e. CDC NHSN Influenza Vaccination Coverage Among Healthcare Personnel (HCP) Measure (NQF #0431) (CDC NHSN HCP Measure)

4. Possible New Quality Measure Topics for Future Years

5. Maintenance of Technical Specifications for Quality Measures

6. Public Display Requirements
   a. Background
   b. Additional Public Display Requirements

7. Form, Manner, and Timing of Data Submission
a. Background

b. Reporting Requirements for the Proposed New Measures: CDC NHSN CDI (NQF #1717), CDC NHSN MRSA (NQF #1716), and CDC NHSN HCP (NQF #0431)

C. Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

1. Background and Statutory Authority

2. General Considerations Used for Selection, Resource Use, and Other Quality Measures for the LTCH QRP

3. Policy for Retention of LTCH QRP Measures Adopted for Previous Payment Determinations

4. Policy for Adopting Changes to LTCH QRP Measures

5. Previously Adopted Quality Measures

   a. Previously Adopted Quality Measures for the FY 2015 and FY 2016 Payment Determinations and Subsequent Years

   b. Previously Adopted Quality Measures for the FY 2017 and FY 2018 Payment Determinations and Subsequent Years

6. Previously Adopted LTCH QRP Quality Measures for the FY 2018 Payment Determinations and Subsequent Years

   a. Policy to Reflect NQF Endorsement: All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512)
b. Policy to Address the IMPACT Act of 2014: Quality Measure Addressing the Domain of Skin Integrity and Changes in Skin Integrity: Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678)

c. Policy to Address the IMPACT Act of 2014: Quality Measure Addressing the Domain of Incidence of Major Falls: Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674)

d. Policy to Address the IMPACT Act of 2014: Quality Measure Addressing the Domain of Functional Status, Cognitive Function, and Changes in Function and Cognitive Function: Application of Percent of LTCH Patients With an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; under NQF review)

7. LTCH QRP Quality Measures for the FY 2019 Payment Determination and Subsequent Years

8. LTCH QRP Quality Measures and Concepts under Consideration for Future Years

9. Form, Manner, and Timing of Quality Data Submission for the FY 2016 Payment Determinations and Subsequent Years

   a. Background

   b. Timing for New LTCHs to Begin Reporting Data to CMS for the FY 2017 Payment Determinations and Subsequent Years
c. Revisions to Previously Adopted Data Submission Timelines under the LTCH QRP for the FY 2017 and FY 2018 Payment Determinations and Subsequent Years and Data Collection and Data Submission Timelines for Quality Measures in this Final Rule

10. Previously Adopted LTCH QRP Data Completion Thresholds for the FY 2016 Payment Determination and Subsequent Years

11. Future LTCH QRP Data Validation Process

12. Public Display of Quality Measure Data for the LTCH QRP

13. Previously Adopted and New LTCH QRP Reconsideration and Appeals Procedures for the FY 2017 Payment Determination and Subsequent Years

14. Previously Adopted and New LTCH QRP Submission Exception and Extension Requirements for the FY 2017 Payment Determination and Subsequent Years

D. Clinical Quality Measurement for Eligible Hospitals and Critical Access Hospitals (CAHs) Participating in the EHR Incentive Programs in 2016

1. Background

2. CQM Reporting for the Medicare and Medicaid EHR Incentive Programs in 2016

   a. Background

   b. CQM Reporting Period for the Medicare and Medicaid EHR Incentive Programs for CY 2016

   c. CQM Form and Method for the Medicare EHR Incentive Programs for 2016


4. CQM Development and Certification Cycle
IX. MedPAC Recommendations

X. Other Required Information

A. Requests for Data from the Public

B. Collection of Information Requirements

1. Statutory Requirement for Solicitation of Comments

2. ICRs for Add-On Payments for New Services and Technologies

3. ICRs for the Occupational Mix Adjustment to the FY 2016 Wage Index (Hospital Wage Index Occupational Mix Survey)

4. Hospital Applications for Geographic Reclassifications by the MGCRB

5. ICRs for the Hospital Inpatient Quality Reporting (IQR) Program

6. ICRs for PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program

7. ICRs for Hospital Value-Based Purchasing (VBP) Program

8. ICRs for the Long-Term Care Hospital Quality Reporting Program (LTCHQR)

Regulation Text

Addendum—Schedule of Standardized Amounts, Update Factors, and Rate-of-Increase Percentages Effective with Cost Reporting Periods Beginning on or after October 1, 2015 and Payment Rates for LTCHs Effective with Discharges Occurring on or after October 1, 2015

I. Summary and Background

II. Changes to the Prospective Payment Rates for Hospital Inpatient Operating Costs for Acute Care Hospitals for FY 2016

A. Calculation of the Adjusted Standardized Amount
B. Adjustments for Area Wage Levels and Cost-of-Living

C. MS-DRG Relative Weights

D. Calculation of the Prospective Payment Rates

III. Changes to Payment Rates for Acute Care Hospital Inpatient Capital-Related Costs for FY 2016

A. Determination of Federal Hospital Inpatient Capital-Related Prospective Payment Rate Update

B. Calculation of the Inpatient Capital-Related Prospective Payments for FY 2016

C. Capital Input Price Index

IV. Changes to Payment Rates for Excluded Hospitals: Rate-of-Increase Percentages for FY 2016

V. Updates to the Payment Rates for the LTCH PPS for FY 2016

A. LTCH PPS Standard Federal Payment Rate for FY 2016

1. Background

2. Development of the FY 2016 LTCH PPS Standard Federal Rate

B. Adjustment for Area Wage Levels under the LTCH PPS Standard Federal Payment Rate for FY 2016

1. Background

2. Geographic Classifications (Labor Market Areas) for the LTCH PPS Standard Federal Payment Rate

3. Labor-Related Share for the LTCH PPS Standard Federal Payment Rate
4. Wage Index for FY 2016 for the LTCH PPS Standard Federal Payment Rate

5. Budget Neutrality Adjustment for Changes to the LTCH PPS Standard Federal Payment Rate Area Wage Level Adjustment

C. LTCH PPS Cost-of-Living Adjustment (COLA) for LTCHs Located in Alaska and Hawaii

D. Adjustment for LTCH PPS High-Cost Outlier (HCO) Cases

1. Overview

2. Determining LTCH CCRs under the LTCH PPS

3. High-Cost Outlier Payments for LTCH PPS Standard Federal Payment Rate Cases

4. High-Cost Outlier Payments for Site Neutral Payment Rate Cases

E. Update to the IPPS Comparable/Equivalent Amounts to Reflect the Statutory Changes to the IPPS DSH Payment Adjustment Methodology

F. Computing the Adjusted LTCH PPS Federal Prospective Payments for FY 2016

VI. Tables Referenced in this Final Rule and Interim Final Rule with Comment Period and Available through the Internet on the CMS Web Site

Appendix A--Economic Analyses

I. Regulatory Impact Analysis

A. Introduction

B. Need

C. Objectives of the IPPS
D. Limitations of Our Analysis

E. Hospitals Included in and Excluded from the IPPS

F. Effects on Hospitals and Hospital Units Excluded from the IPPS

G. Quantitative Effects of the Policy Changes under the IPPS for Operating Costs

1. Basis and Methodology of Estimates

2. Analysis of Table I

3. Impact Analysis of Table II

H. Effects of Other Policy Changes

1. Effects of Policy on MS-DRGs for Preventable HACs, Including Infections

2. Effects of Policy Relating to New Medical Service and Technology Add-On Payments

3. Effects of Changes in Medicare DSH Payments for FY 2016

4. Effects of Reductions under the Hospital Readmissions Reduction Program

5. Effects of Changes under the FY 2016 Hospital Value-Based Purchasing (VBP) Program

6. Effects of Changes to the HAC Reduction Program for FY 2016

7. Effects of Modification of the Simplified Cost Allocation Methodology

8. Effects of Implementation of Rural Community Hospital Demonstration Program

9. Effects of Changes to List of MS-DRGs Subject to Postacute Care Transfer and DRG Special Pay Policy

I. Effects of Changes in the Capital IPPS
1. General Considerations

2. Results

J. Effects of Payment Rate Changes and Policy Changes under the LTCH PPS
   1. Introduction and General Considerations
   2. Impact on Rural Hospitals
   3. Anticipated Effects of LTCH PPS Payment Rate Changes and Policy Changes
   4. Effect on the Medicare Program
   5. Effect on Medicare Beneficiaries

K. Effects of Requirements for Hospital Inpatient Quality Reporting (IQR) Program
   L. Effects of Requirements for the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program for FY 2016
   M. Effects of Requirements for the LTCH Quality Reporting Program (LTCH QRP) for FY 2016 through FY 2020

II. Alternatives Considered

III. Overall Conclusion
   A. Acute Care Hospitals
   B. LTCHs

IV. Accounting Statements and Tables
   A. Acute Care Hospitals
B. LTCHs

V. Regulatory Flexibility Act (RFA) Analysis

VI. Impact on Small Rural Hospitals

VII. Unfunded Mandate Reform Act (UMRA) Analysis

VIII. Executive Order 12866

Appendix B: Recommendation of Update Factors for Operating Cost Rates of Payment for Inpatient Hospital Services

I. Background

II. Inpatient Hospital Updates for FY 2016

A. FY 2016 Inpatient Hospital Update

B. Update for SCHs and MDHs for FY 2016

C. FY 2016 Puerto Rico Hospital Update

D. Update for Hospitals Excluded from the IPPS for FY 2016

E. Update for LTCHs for FY 2016

III. Secretary’s Recommendation

IV. MedPAC Recommendation for Assessing Payment Adequacy and Updating Payments in Traditional Medicare
I. Executive Summary and Background

A. Executive Summary

1. Purpose and Legal Authority

This final rule makes payment and policy changes under the Medicare inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals as well as for certain hospitals and hospital units excluded from the IPPS. In addition, it makes payment and policy changes for inpatient hospital services provided by long-term care hospitals (LTCHs) under the long-term care hospital prospective payment system (LTCH PPS). It also makes policy changes to programs associated with Medicare IPPS hospitals, IPPS-excluded hospitals, and LTCHs.

This interim final rule with comment period implements the provisions of the Medicare Access and CHIP Reauthorization Act of 2015 which extended the MDH Program and changes to the low-volume payment adjustment for hospitals through FY 2017.

Under various statutory authorities, we are making changes to the Medicare IPPS, to the LTCH PPS, and to other related payment methodologies and programs for FY 2016 and subsequent fiscal years. These statutory authorities include, but are not limited to, the following:

- Section 1886(d) of the Social Security Act (the Act), which sets forth a system of payment for the operating costs of acute care hospital inpatient stays under Medicare Part A (Hospital Insurance) based on prospectively set rates. Section 1886(g) of the Act
requires that, instead of paying for capital-related costs of inpatient hospital services on a reasonable cost basis, the Secretary use a prospective payment system (PPS).

- Section 1886(d)(1)(B) of the Act, which specifies that certain hospitals and hospital units are excluded from the IPPS. These hospitals and units are: rehabilitation hospitals and units; LTCHs; psychiatric hospitals and units; children's hospitals; cancer hospitals; and short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa. Religious nonmedical health care institutions (RNHCIs) are also excluded from the IPPS.

- Sections 123(a) and (c) of Pub. L. 106-113 and section 307(b)(1) of Pub. L. 106-554 (as codified under section 1886(m)(1) of the Act), which provide for the development and implementation of a prospective payment system for payment for inpatient hospital services of long-term care hospitals (LTCHs) described in section 1886(d)(1)(B)(iv) of the Act.

- Sections 1814(l), 1820, and 1834(g) of the Act, which specify that payments are made to critical access hospitals (CAHs) (that is, rural hospitals or facilities that meet certain statutory requirements) for inpatient and outpatient services and that these payments are generally based on 101 percent of reasonable cost.

- Section 1866(k) of the Act, as added by section 3005 of the Affordable Care Act, which establishes a quality reporting program for hospitals described in section 1886(d)(1)(B)(v) of the Act, referred to as “PPS-Exempt Cancer Hospitals.”

- Section 1886(d)(4)(D) of the Act, which addresses certain hospital-acquired conditions (HACs), including infections. Section 1886(d)(4)(D) of the Act specifies that,
by October 1, 2007, the Secretary was required to select, in consultation with the Centers for Disease Control and Prevention (CDC), at least two conditions that: (a) are high cost, high volume, or both; (b) are assigned to a higher paying MS-DRG when present as a secondary diagnosis (that is, conditions under the MS-DRG system that are complications or comorbidities (CCs) or major complications or comorbidities (MCCs); and (c) could reasonably have been prevented through the application of evidence-based guidelines.

Section 1886(d)(4)(D) of the Act also specifies that the list of conditions may be revised, again in consultation with CDC, from time to time as long as the list contains at least two conditions. Section 1886(d)(4)(D)(iii) of the Act requires that hospitals, effective with discharges occurring on or after October 1, 2007, submit information on Medicare claims specifying whether diagnoses were present on admission (POA). Section 1886(d)(4)(D)(i) of the Act specifies that effective for discharges occurring on or after October 1, 2008, Medicare no longer assigns an inpatient hospital discharge to a higher paying MS-DRG if a selected condition is not POA.

- Section 1886(a)(4) of the Act, which specifies that costs of approved educational activities are excluded from the operating costs of inpatient hospital services. Hospitals with approved graduate medical education (GME) programs are paid for the direct costs of GME in accordance with section 1886(h) of the Act. A payment for indirect medical education (IME) is made under section 1886(d)(5)(B) of the Act.

- Section 1886(b)(3)(B)(viii) of the Act, which requires the Secretary to reduce the applicable percentage increase in payments to a subsection (d) hospital for a fiscal
year if the hospital does not submit data on measures in a form and manner, and at a time, specified by the Secretary.

- Section 1886(o) of the Act, which requires the Secretary to establish a Hospital Value-Based Purchasing (VBP) Program under which value-based incentive payments are made in a fiscal year to hospitals meeting performance standards established for a performance period for such fiscal year.

- Section 1886(p) of the Act, as added by section 3008 of the Affordable Care Act, which establishes an adjustment to hospital payments for hospital-acquired conditions (HACs), or a Hospital-Acquired Condition (HAC) Reduction Program, under which payments to applicable hospitals are adjusted to provide an incentive to reduce hospital-acquired conditions.

- Section 1886(q) of the Act, as added by section 3025 of the Affordable Care Act and amended by section 10309 of the Affordable Care Act, which establishes the “Hospital Readmissions Reduction Program” effective for discharges from an “applicable hospital” beginning on or after October 1, 2012, under which payments to those hospitals under section 1886(d) of the Act will be reduced to account for certain excess readmissions.

- Section 1886(r) of the Act, as added by section 3133 of the Affordable Care Act, which provides for a reduction to disproportionate share hospital payments under section 1886(d)(5)(F) of the Act and for a new uncompensated care payment to eligible hospitals. Specifically, section 1886(r) of the Act requires that, for fiscal year 2014 and each subsequent fiscal year, subsection (d) hospitals that would otherwise receive a
disproportionate share hospital payment made under section 1886(d)(5)(F) of the Act will receive two separate payments: (1) 25 percent of the amount they previously would have received under section 1886(d)(5)(F) of the Act for DSH ("the empirically justified amount"), and (2) an additional payment for the DSH hospital’s proportion of uncompensated care, determined as the product of three factors. These three factors are: (1) 75 percent of the payments that would otherwise be made under section 1886(d)(5)(F) of the Act; (2) 1 minus the percent change in the percent of individuals under the age of 65 who are uninsured (minus 0.1 percentage points for FY 2014, and minus 0.2 percentage points for FY 2015 through FY 2017); and (3) a hospital’s uncompensated care amount relative to the uncompensated care amount of all DSH hospitals expressed as a percentage.

- Section 1886(m)(6) of the Act, as added by section 1206(a)(1) of the Pathway for SGR Reform Act of 2013 (Pub. L. 113-67), which provided for the establishment of site neutral payment rate criteria under the LTCH PPS with implementation beginning in FY 2016.

- Section 1206(b)(1) of the Pathway for SGR Reform Act of 2013, which further amended section 114(c) of the MMSEA, as amended by section 4302(a) of the ARRA and sections 3106(c) and 10312(a) of the Affordable Care Act, by retroactively reestablishing and extending the statutory moratorium on the full implementation of the 25-percent threshold payment adjustment policy under the LTCH PPS so that the policy will be in effect for 9 years (except for “grandfathered” hospital-within-hospitals (HwHs), which are permanently exempt from this policy); and section 1206(b)(2) (as
amended by section 112(b) of Pub. L. 113-93), which together further amended section 114(d) of the MMSEA, as amended by section 4302(a) of the ARRA and sections 3106(c) and 10312(a) of the Affordable Care Act to establish a new moratoria (subject to certain defined exceptions) on the development of new LTCHs and LTCH satellite facilities and a new moratorium on increases in the number of beds in existing LTCHs and LTCH satellite facilities beginning January 1, 2015 and ending on September 30, 2017; and section 1206(d), which instructs the Secretary to evaluate payments to LTCHs classified under section 1886(b)(1)(C)(iv)(II) of the Act and to adjust payment rates in FY 2015 or FY 2016 under the LTCH PPS, as appropriate, based upon the evaluation findings.

- Section 1886(m)(5)(D)(iv) of the Act, as added by section 1206(c) of the Pathway for SGR Reform Act of 2013, which provides for the establishment, no later than October 1, 2015, of a functional status quality measure under the LTCH QRP for change in mobility among inpatients requiring ventilator support.

- Section 1899B of the Act, as added by the Improving Medicare Post-Acute Care Transformation Act of 2014 (the IMPACT Act of 2014), which imposes new data reporting requirements for certain postacute care providers, including LTCHs.

- Section 1886(d)(12) of the Act, as amended by section 204 of the Medicare Access and CHIP Reauthorization Act of 2015, which extended, through FY 2017, changes to the inpatient hospital payment adjustment for certain low-volume hospitals; and section 1886(d)(5)(G) of the Act, as amended by section 205 of the Medicare Access
and CHIP Reauthorization Act of 2015, which extended, through FY 2017, the Medicare-dependent, small rural hospital (MDH) program.


a. MS-DRG Documentation and Coding Adjustment

Section 631 of the American Taxpayer Relief Act (ATRA, Pub. L. 112-240) amended section 7(b)(1)(B) of Pub. L. 110-90 to require the Secretary to make a recoupment adjustment to the standardized amount of Medicare payments to acute care hospitals to account for changes in MS-DRG documentation and coding that do not reflect real changes in case-mix, totaling $11 billion over a 4-year period of FYs 2014, 2015, 2016, and 2017. This adjustment represents the amount of the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Pub. L. 110-90 until FY 2013. Prior to the ATRA, this amount could not have been recovered under Pub. L. 110-90.

While our actuaries estimated that a –9.3 percent adjustment to the standardized amount would be necessary if CMS were to fully recover the $11 billion recoupment required by section 631 of the ATRA in one year, it is often our practice to delay or phase in rate adjustments over more than one year, in order to moderate the effects on rates in any one year. Therefore, consistent with the policies that we have adopted in many similar cases, we made a -0.8 percent recoupment adjustment to the standardized amount in FY 2014 and FY 2015. For FY 2016, we are making an additional –0.8 percent recoupment adjustment to the standardized amount.
b. Reduction of Hospital Payments for Excess Readmissions

We are making changes in policies to the Hospital Readmissions Reduction Program, which is established under section 1886(q) of the Act, as added by section 3025 of the Affordable Care Act. The Hospital Readmissions Reduction Program requires a reduction to a hospital’s base operating DRG payment to account for excess readmissions of selected applicable conditions. For FYs 2013 and 2014, these conditions are acute myocardial infarction, heart failure, and pneumonia. For FY 2014, we established additional exclusions to the three existing readmission measures (that is, the excess readmission ratio) to account for additional planned readmissions. We also established additional readmissions measures, chronic obstructive pulmonary disease (COPD), and total hip arthroplasty and total knee arthroplasty (THA/TKA), to be used in the Hospital Readmissions Reduction Program for FY 2015 and future years. We expanded the readmissions measures for FY 2017 and future years by adding a measure of patients readmitted following coronary artery bypass graft (CABG) surgery.

In this final rule, we are making a refinement to the pneumonia readmissions measure, which expands the measure cohort for the FY 2017 payment determination and subsequent years. Specifically, we are finalizing a modified version of the expanded pneumonia cohort from what we had specified in the FY 2016 IPPS/LTCH PPS proposed rule such that the modified version includes patients with a principal discharge diagnosis of pneumonia or aspiration pneumonia, and patients with a principal discharge diagnosis of sepsis with a secondary diagnosis of pneumonia coded
as present on admission. However, we are not including patients with a principal discharge diagnosis of respiratory failure or patients with a principal discharge diagnosis of sepsis if they are coded as having severe sepsis as we had previously proposed. In addition, we are adopting an extraordinary circumstance exception policy that will align with existing extraordinary circumstance exception policies for other IPPS quality reporting and payment programs and will allow hospitals that experience an extraordinary circumstance (such as a hurricane or flood) to request a waiver for use of data from the affected time period.

c. Hospital Value-Based Purchasing (VBP) Program

Section 1886(o) of the Act requires the Secretary to establish a Hospital VBP Program under which value-based incentive payments are made in a fiscal year to hospitals based on their performance on measures established for a performance period for such fiscal year.

For FY 2016, we are adopting one additional measure beginning with the FY 2018 program year and one measure beginning with the FY 2021 program year. We also are removing two measures beginning with the FY 2018 program year. In addition, we are moving one measure to the Safety domain and removing the Clinical Care—Process subdomain and renaming the Clinical Care—Outcomes subdomain as the Clinical Care domain. Finally, we are signaling our intent to propose in future rulemaking to expand one measure and to update the standard population data we use to calculate several measures beginning with the FY 2019 program year.
d. Hospital-Acquired Condition (HAC) Reduction Program

Section 1886(p) of the Act, as added under section 3008(a) of the Affordable Care Act, establishes an incentive to hospitals to reduce the incidence of hospital-acquired conditions by requiring the Secretary to make an adjustment to payments to applicable hospitals effective for discharges beginning on October 1, 2014 and for subsequent program years. This 1-percent payment reduction applies to a hospital whose ranking is in the top quartile (25 percent) of all applicable hospitals, relative to the national average, of conditions acquired during the applicable period and on all of the hospital’s discharges for the specified fiscal year. The amount of payment shall be equal to 99 percent of the amount of payment that would otherwise apply to such discharges under section 1886(d) or 1814(b)(3) of the Act, as applicable.

In this final rule, we are making three changes to existing Hospital-Acquired Condition Reduction Program policies: (1) an expansion to the population covered by the central line-associated bloodstream infection (CLABSI) and catheter-associated urinary tract infection (CAUTI) measures to include patients in select nonintensive care unit sites within a hospital; (2) an adjustment to the relative contribution of each domain to the Total HAC Score which is used to determine if a hospital will receive the payment adjustment; and (3) a policy that will align with existing extraordinary circumstance exception policies for other IPPS quality reporting and payment programs and will allow hospitals to request a waiver for use of data from the affected time period.
e. DSH Payment Adjustment and Additional Payment for Uncompensated Care

Section 3133 of the Affordable Care Act modified the Medicare disproportionate share hospital (DSH) payment methodology beginning in FY 2014. Under section 1886(r) of the Act, which was added by section 3133 of the Affordable Care Act, starting in FY 2014, DSHs will receive 25 percent of the amount they previously would have received under the statutory formula for Medicare DSH payments in section 1886(d)(5)(F) of the Act. The remaining amount, equal to 75 percent of what otherwise would have been paid as Medicare DSH payments, will be paid as additional payments after the amount is reduced for changes in the percentage of individuals that are uninsured. Each Medicare DSH hospital will receive an additional payment based on its share of the total amount of uncompensated care for all Medicare DSH hospitals for a given time period.

In this final rule, we are updating our estimates of the three factors used to determine uncompensated care payments for FY 2016. We are continuing to use the methodology we established in FY 2015 to calculate the uncompensated care payment amounts for merged hospitals such that we combine uncompensated care data for the hospitals that have undergone a merger in order to calculate their relative share of uncompensated care. We also are changing the time period of the data used to calculate the uncompensated care payment amounts to be distributed.

f. Changes to the LTCH PPS

Under the current LTCH PPS, all discharges are paid under the LTCH PPS standard Federal payment rate. In this final rule, we are implementing section 1206 of
the Pathway for SGR Reform Act, which requires the establishment of an alternative site neutral payment rate for Medicare discharges from an LTCH that fail to meet certain statutory defined criteria, beginning with LTCH discharges occurring in cost reporting periods beginning on or after October 1, 2015. We include provisions regarding the application of the site neutral payment rate and the criteria for exclusion from the site neutral payment rate, as well as provisions on a number of methodological and implementation issues, such as the criterion for a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation, the intensive care unit (ICU) criterion, the ventilator criterion, the definition of “immediately preceded” by a subsection (d) hospital discharge, limitation on beneficiary charges in the context of the new site neutral payment rate, and the transitional blended payment rate methodology for FY 2016 and FY 2017.

In addition, we are making changes to address certain statutory requirements related to an LTCH’s average length of stay criterion and discharge payment percentage. We also are providing technical clarifications relating to our FY 2015 implementation of the new statutory moratoria on the establishment of new LTCHs and LTCH satellite facilities (subject to certain defined exceptions) and on bed increases in existing LTCHs and LTCH satellite facilities as well as making a technical revision to the regulations to more clearly reflect our established policies.

g. Hospital Inpatient Quality Reporting (IQR) Program

Under section 1886(b)(3)(B)(viii) of the Act, hospitals are required to report data on measures selected by the Secretary for the Hospital IQR Program in order to receive
the full annual percentage increase in payments. In past years, we have established measures for reporting data and the process for submittal and validation of the data.

In this final rule, we are updating considerations for measure removal and retention. In addition, we are removing nine chart-abstracted measures for the FY 2018 payment determination and subsequent years: six of these measures are “topped-out” (STK-01, STK-06, STK-08, VTE-1, VTE-2, and VTE-3) and two of the measures are suspended (IMM-1 and SCIP-Inf-4). However, we are retaining the electronic versions of five of the chart-abstracted measures finalized for removal.

We are refining two previously adopted measures for the FY 2018 payment determination and subsequent years. We are also adding seven new measures: three new claims-based measures and one structural measure for the FY 2018 payment determination and subsequent years; and three new claims-based measures for the FY 2019 payment determination and subsequent years.

Further, for the FY 2018 payment determination, we are requiring hospitals to report a minimum of 4 electronic clinical quality measures. Under this modification to our proposal, no NQS domain distribution will be required. We are requiring that hospitals submit one quarter of electronic clinical quality measure data from either Q3 or Q4 of CY 2016 with a submission deadline of February 28, 2017. For the reporting of electronic clinical quality measures, hospitals may be certified either to the CEHRT 2014 or 2015 Edition, but must submit using the QRDA I format. We plan to finalize public reporting of electronic data in next year’s rulemaking after the conclusion and assessment of the validation pilot. Six previously adopted measures (ED-1, ED-2, PC-01, STK-04,
VTE-5, and VTE-6) must still be submitted via chart-abstraction regardless of whether they are also submitted as electronic clinical quality measures. We are also continuing our policy regarding STK-01 to clarify that hospitals need not report the STK-01 measure as part of the STK measure set if reporting electronically, because no electronic specification existed for STK-01. Beginning with the FY 2018 payment determination, we are expanding our previously established extraordinary circumstances extensions/exemptions policy (79 FR 50277) to allow hospitals to utilize the existing Extraordinary Circumstances Exception (ECE) form to request exemptions based on hardships in reporting eCQMs.

Finally, we are modifying the existing processes for validation of chart-abstracted Hospital IQR Program data to remove one stratum.

h. Long-Term Care Quality Reporting Program (LTCH QRP)

Section 3004(a) of the Affordable Care Act amended section 1886(m)(5) of the Act to require the Secretary to establish the Long-Term Care Hospital Quality Reporting Program (LTCH QRP). This program applies to all hospitals certified by Medicare as LTCHs. Beginning with the FY 2014 payment determination and subsequent years, the Secretary is required to reduce any annual update to the standard Federal rate for discharges occurring during such fiscal year by 2 percentage points for any LTCH that does not comply with the requirements established by the Secretary.

The IMPACT Act of 2014 amended the Act in ways that affect the LTCH QRP. Specifically, section 2(a) of the IMPACT Act of 2014 added section 1899B of the Act, and section 2(c)(3) of the IMPACT Act of 2014 amended section 1886(m)(5) of the Act.
Under section 1899B(a)(1) of the Act, the Secretary must require post-acute care (PAC) providers (defined in section 1899B(a)(2)(A) of the Act to include HHAs, SNFs, IRFs, and LTCHs) to submit standardized patient assessment data in accordance with section 1899B(b) of the Act, data on quality measures required under section 1899B(c)(1) of the Act, and data on resource use and other measures required under section 1899B(d)(1) of the Act. The Act also sets out specified application dates for each of the measures. The Secretary must specify the quality, resource use, and other measures not later than the applicable specified application date defined in section 1899B(a)(2)(E) of the Act.

In this final rule, we are establishing three previously finalized quality measures: one measure establishes the newly NQF-endorsed status of that quality measure; two other measures are for the purpose of establishing the cross-setting use of the previously finalized quality measures, in order to satisfy the IMPACT Act of 2014 requirement of adopting quality measures under the domains of skin integrity and falls with major injury. We are adopting an application of a fourth previously finalized LTCH functional status measure in order to meet the requirement of the IMPACT Act of 2014 to adopt a cross-setting measure under the domain of functional status, such as self-care or mobility. All four measures affect the FY 2018 annual payment update determination and beyond.

In addition, we will publicly report LTCH quality data beginning in fall 2016, on a CMS Web site, such as Hospital Compare. We will initially publicly report quality data on four quality measures.

Finally, we are lengthening our quarterly data submission deadlines from 45 days to 135 days beyond the end of each calendar year quarter beginning with quarter four (4)
2015 quality data. We are making this change in order to align with other quality reporting programs, and to allow an appropriate amount of time for LTCHs to review and correct quality data prior to the public posting of that data.

3. Summary of Costs and Benefits

- **Adjustment for MS-DRG Documentation and Coding Changes.** We are making a −0.8 percent recoupment adjustment to the standardized amount for FY 2016 to implement, in part, the requirement of section 631 of the ATRA that the Secretary make an adjustment totaling $11 billion over a 4-year period of FYs 2014, 2015, 2016, and 2017. This recoupment adjustment represents the amount of the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Pub. L. 110-90 until FY 2013. Prior to the ATRA, this amount could not have been recovered under Pub. L. 110-90.

  While our actuaries estimated that a −9.3 percent recoupment adjustment to the standardized amount would be necessary if CMS were to fully recover the $11 billion recoupment required by section 631 of the ATRA in FY 2014, it is often our practice to delay or phase in rate adjustments over more than one year, in order to moderate the effects on rates in any one year. Therefore, consistent with the policies that we have adopted in many similar cases and the adjustment we made for FY 2014, we are making a −0.8 percent recoupment adjustment to the standardized amount in FY 2016. Taking into account the cumulative effects of this adjustment and the adjustments made in FYs 2014 and 2015, we currently estimate that approximately $5 to $6 billion would be left to recover under section 631 of the ATRA by the end of FY 2016. We have not yet
addressed the specific amount of the final adjustment required under section 631 of the ATRA for FY 2017. We intend to address this adjustment in the FY 2017 IPPS rulemaking. However, we note that section 414 of the MACRA (Pub. L. 114-10), enacted on April 16, 2015, replaced the single positive adjustment we intended to make in FY 2018 with a 0.5 percent positive adjustment for each of FYs 2018 through 2023. The provision under section 414 of the MACRA does not impact our FY 2016 recoupment adjustment, and we will address this MACRA provision in future rulemaking.

- **Changes to the Hospital Readmissions Reduction Program.** We are making a refinement to the pneumonia readmissions measure, which will expand the measure cohort for the FY 2017 payment determination and subsequent years. In addition, we are adopting an extraordinary circumstance exception policy that will align with existing extraordinary circumstance exception policies for other IPPS quality reporting and payment programs and will allow hospitals that experience an extraordinary circumstance (such as a hurricane or flood) to request a waiver for use of data from the affected time period. These changes will not significantly impact the program in FY 2016, but could impact future years, depending on actual experience.

Overall, in this final rule, we estimate that 2,666 hospitals will have their base operating DRG payments reduced by their proxy FY 2016 hospital-specific readmissions adjustment. As a result, we estimate that the Hospital Readmissions Reduction Program will save approximately $420 million in FY 2016, an increase of $6 million over the estimated FY 2015 savings.
• **Value-Based Incentive Payments under the Hospital VBP Program.** We estimate that there will be no net financial impact to the Hospital VBP Program for the FY 2016 program year in the aggregate because, by law, the amount available for value-based incentive payments under the program in a given year must be equal to the total amount of base operating MS-DRG payment amount reductions for that year, as estimated by the Secretary. The estimated amount of base operating MS-DRG payment amount reductions for the FY 2016 program year and, therefore, the estimated amount available for value-based incentive payments for FY 2016 discharges is approximately $1.5 billion.

• **Changes to the HAC Reduction Program for FY 2016.** We are making three changes to existing HAC Reduction Program policies: (1) an expansion to the population covered by the central line-associated bloodstream infection (CLABSI) and catheter-associated urinary tract infection (CAUTI) measures to include patients in select nonintensive care unit sites within a hospital; (2) an adjustment to the relative contribution of each domain to the Total HAC Score that is used to determine if a hospital will receive the payment adjustment; and (3) a policy that will align with existing extraordinary circumstance exception policies for other IPPS quality reporting and payment programs and will allow hospitals to request a waiver for use of data from the affected period. Hospitals in the top quartile of HAC scores will continue to have their HAC Reduction Program payment adjustment applied, as required by law. However, because a hospital’s Total HAC score and its ranking in comparison to other hospitals in any given year depend on several different factors, any significant impact
due to the HAC Reduction Program changes for FY 2016, including which hospitals receive the adjustment, will depend on actual experience.

- **Medicare DSH Payment Adjustment and Additional Payment for Uncompensated Care.** Under section 1886(r) of the Act (as added by section 3313 of the Affordable Care Act), disproportionate share hospital payments to hospitals under section 1886(d)(5)(F) of the Act are reduced and an additional payment for uncompensated care is made to eligible hospitals beginning in FY 2014. Hospitals that receive Medicare DSH payments will receive 25 percent of the amount they previously would have received under the current statutory formula for Medicare DSH payments in section 1886(d)(5)(F) of the Act. The remainder, equal to an estimate of 75 percent of what otherwise would have been paid as Medicare DSH payments, will be the basis for determining the additional payments for uncompensated care after the amount is reduced for changes in the percentage of individuals that are uninsured and additional statutory adjustments. Each hospital that receives Medicare DSH payments will receive an additional payment for uncompensated care based on its share of the total uncompensated care amount reported by Medicare DSHs. The reduction to Medicare DSH payments is not budget neutral.

For FY 2016, we are providing that the 75 percent of what otherwise would have been paid for Medicare DSH is adjusted to approximately 63.69 percent of the amount to reflect changes in the percentage of individuals that are uninsured and additional statutory adjustments. In other words, approximately 47.76 percent (the product of 75 percent and 63.69 percent) of our estimate of Medicare DSH payments prior to the application of
section 3133 of the Affordable Care Act is available to make additional payments to hospitals for their relative share of the total amount of uncompensated care. We project that Medicare DSH payments and additional payments for uncompensated care made for FY 2016 will reduce payments overall by approximately 1 percent as compared to the Medicare DSH payments and uncompensated care payments distributed in FY 2015. The additional payments have redistributive effects based on a hospital’s uncompensated care amount relative to the uncompensated care amount for all hospitals that are estimated to receive Medicare DSH payments, and the payment amount is not directly tied to a hospital’s number of discharges.

- **Implementation of Legislative Extensions Relating to the Payment Adjustment for Low-Volume Hospitals and the Medicare-Dependent, Small Rural Hospital Program.** The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114-10) extended certain provisions relating to the payment adjustment for low-volume hospitals under section 1886(d)(12) of the Act and extended the Medicare-dependent, small rural hospital (MDH) Program. Section 204 of the MACRA extended the temporary changes to the low-volume hospital qualifying criteria and payment adjustment for IPPS hospital discharges occurring on or after April 1, 2015 through September 30, 2017. Section 205 of the MACRA extended the MDH program for IPPS hospital discharges occurring on or after April 1, 2015 through September 30, 2017. We project that IPPS payments for FY 2016 will increase by approximately $322 million as a result of the statutory extensions of certain provisions of
the low-volume hospital payment adjustment and approximately $96 million for the MDH program compared to such payments in absence of these extensions.

- **Update to the LTCH PPS Payment Rates and Other Payment Factors.**

  Based on the best available data for the 419 LTCHs in our data base, we estimate that the changes to the payment rates and factors that we are presenting in the preamble and Addendum of this final rule, including the application of the new site neutral payment rate required by section 1886(m)(6)(A) of the Act, the update to the LTCH PPS standard Federal payment rate for FY 2016, and the changes to short-stay outlier and high-cost outlier payments will result in an estimated decrease in payments from FY 2015 of approximately $250 million.

- **Hospital Inpatient Quality Reporting (IQR) Program.** In this final rule, we are removing nine measures for the FY 2018 payment determination and subsequent years. We are adding seven measures to the Hospital IQR Program for the payment determination; four for the FY 2018 payment determination and subsequent years and three for FY 2019 payment determination and subsequent years. We also are requiring hospitals to report 4 of the 28 Hospital IQR Program electronic clinical quality measures that align with the Medicare EHR Incentive Program. We estimate that our policies for the adoption and removal of measures will result in total hospital costs of $169 million across 3,300 IPPS hospitals.

- **Changes in LTCH Payments Related to the LTCH QRP Proposals.** We believe that the increase in costs to LTCHs related to our LTCH QRP policies in this
final rule is zero. We refer readers to sections VIII.C. of the preamble of this final rule for detailed discussion of the policies.

B. Summary

1. Acute Care Hospital Inpatient Prospective Payment System (IPPS)

   Section 1886(d) of the Social Security Act (the Act) sets forth a system of payment for the operating costs of acute care hospital inpatient stays under Medicare Part A (Hospital Insurance) based on prospectively set rates. Section 1886(g) of the Act requires the Secretary to use a prospective payment system (PPS) to pay for the capital-related costs of inpatient hospital services for these “subsection (d) hospitals.” Under these PPSs, Medicare payment for hospital inpatient operating and capital-related costs is made at predetermined, specific rates for each hospital discharge. Discharges are classified according to a list of diagnosis-related groups (DRGs).

   The base payment rate is comprised of a standardized amount that is divided into a labor-related share and a nonlabor-related share. The labor-related share is adjusted by the wage index applicable to the area where the hospital is located. If the hospital is located in Alaska or Hawaii, the nonlabor-related share is adjusted by a cost-of-living adjustment factor. This base payment rate is multiplied by the DRG relative weight.

   If the hospital treats a high percentage of certain low-income patients, it receives a percentage add-on payment applied to the DRG-adjusted base payment rate. This add-on payment, known as the disproportionate share hospital (DSH) adjustment, provides for a percentage increase in Medicare payments to hospitals that qualify under either of two statutory formulas designed to identify hospitals that serve a disproportionate share of
low-income patients. For qualifying hospitals, the amount of this adjustment varies based on the outcome of the statutory calculations. The Affordable Care Act revised the Medicare DSH payment methodology and provided for a new additional Medicare payment that considers the amount of uncompensated care provided by the hospital. Payment under this methodology began in FY 2014.

If the hospital is an approved teaching hospital, it receives a percentage add-on payment for each case paid under the IPPS, known as the indirect medical education (IME) adjustment. This percentage varies, depending on the ratio of residents to beds.

Additional payments may be made for cases that involve new technologies or medical services that have been approved for special add-on payments. To qualify, a new technology or medical service must demonstrate that it is a substantial clinical improvement over technologies or services otherwise available, and that, absent an add-on payment, it would be inadequately paid under the regular DRG payment.

The costs incurred by the hospital for a case are evaluated to determine whether the hospital is eligible for an additional payment as an outlier case. This additional payment is designed to protect the hospital from large financial losses due to unusually expensive cases. Any eligible outlier payment is added to the DRG-adjusted base payment rate, plus any DSH, IME, and new technology or medical service add-on adjustments.

Although payments to most hospitals under the IPPS are made on the basis of the standardized amounts, some categories of hospitals are paid in whole or in part based on their hospital-specific rate, which is determined from their costs in a base year. For
example, sole community hospitals (SCHs) receive the higher of a hospital-specific rate based on their costs in a base year (the highest of FY 1982, FY 1987, FY 1996, or FY 2006) or the IPPS Federal rate based on the standardized amount. SCHs are the sole source of care in their areas. Specifically, section 1886(d)(5)(D)(iii) of the Act defines an SCH as a hospital that is located more than 35 road miles from another hospital or that, by reason of factors such as isolated location, weather conditions, travel conditions, or absence of other like hospitals (as determined by the Secretary), is the sole source of hospital inpatient services reasonably available to Medicare beneficiaries. In addition, certain rural hospitals previously designated by the Secretary as essential access community hospitals are considered SCHs.

We note that the Medicare Access and CHIP Reauthorization Act of 2015 (Pub. L. 114-10), enacted on April 16, 2015, extended the Medicare-dependent, small rural hospital (MDH) program through FY 2017. Through and including FY 2006, an MDH received the higher of the Federal rate or the Federal rate plus 50 percent of the amount by which the Federal rate was exceeded by the higher of its FY 1982 or FY 1987 hospital-specific rate. For discharges occurring on or after October 1, 2007, through FY 2017, an MDH receives the higher of the Federal rate or the Federal rate plus 75 percent of the amount by which the Federal rate is exceeded by the highest of its FY 1982, FY 1987, or FY 2002 hospital-specific rate. MDHs are a major source of care for Medicare beneficiaries in their areas. Section 1886(d)(5)(G)(iv) of the Act defines an MDH as a hospital that is located in a rural area, has no more than 100 beds, is not an SCH, and has a high percentage of Medicare discharges (not less than 60 percent of its
inpatient days or discharges in its cost reporting year beginning in FY 1987 or in two of its three most recently settled Medicare cost reporting years).

Section 1886(g) of the Act requires the Secretary to pay for the capital-related costs of inpatient hospital services “in accordance with a prospective payment system established by the Secretary.” The basic methodology for determining capital prospective payments is set forth in our regulations at 42 CFR 412.308 and 412.312. Under the capital IPPS, payments are adjusted by the same DRG for the case as they are under the operating IPPS. Capital IPPS payments are also adjusted for IME and DSH, similar to the adjustments made under the operating IPPS. In addition, hospitals may receive outlier payments for those cases that have unusually high costs.

The existing regulations governing payments to hospitals under the IPPS are located in 42 CFR Part 412, Subparts A through M.

2. Hospitals and Hospital Units Excluded from the IPPS

Under section 1886(d)(1)(B) of the Act, as amended, certain hospitals and hospital units are excluded from the IPPS. These hospitals and units are: rehabilitation hospitals and units; long-term care hospitals (LTCHs); psychiatric hospitals and units; children’s hospitals; certain cancer hospitals; and short-term acute care hospitals located in Guam, the U.S. Virgin Islands, the Northern Mariana Islands, and American Samoa. Religious nonmedical health care institutions (RNHCIs) are also excluded from the IPPS. Various sections of the Balanced Budget Act of 1997 (BBA, Pub. L. 105-33), the Medicare, Medicaid and SCHIP [State Children’s Health Insurance Program] Balanced Budget Refinement Act of 1999 (BBRA, Pub. L. 106-113), and the Medicare, Medicaid,
and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA, Pub. L. 106-554) provide for the implementation of PPSs for rehabilitation hospitals and units (referred to as inpatient rehabilitation facilities (IRFs)), LTCHs, and psychiatric hospitals and units (referred to as inpatient psychiatric facilities (IPFs)). (We note that the annual updates to the LTCH PPS are now included as part of the IPPS annual update document. Updates to the IRF PPS and IPF PPS are issued as separate documents.) Children's hospitals, certain cancer hospitals, short-term acute care hospitals located in Guam, the U.S. Virgin Islands, the Northern Mariana Islands, and American Samoa, and RNHCIs continue to be paid solely under a reasonable cost-based system subject to a rate-of-increase ceiling on inpatient operating costs, as updated annually by the percentage increase in the IPPS operating market basket.

The existing regulations governing payments to excluded hospitals and hospital units are located in 42 CFR Parts 412 and 413.

3. Long-Term Care Hospital Prospective Payment System (LTCH PPS)

The Medicare prospective payment system (PPS) for LTCHs applies to hospitals described in section 1886(d)(1)(B)(iv) of the Act effective for cost reporting periods beginning on or after October 1, 2002. The LTCH PPS was established under the authority of section 123 of the BBRA and section 307(b) of the BIPA (as codified under section 1886(m)(1) of the Act). During the 5-year (optional) transition period, a LTCH’s payment under the PPS was based on an increasing proportion of the LTCH Federal rate with a corresponding decreasing proportion based on reasonable cost principles. Effective for cost reporting periods beginning on or after October 1, 2006, all LTCHs are
paid 100 percent of the Federal rate. Section 1206(a) of Pub. L. 113-67 established the site neutral payment rate under the LTCH PPS. Under this statute, based on a rolling effective date that is linked to the date on which a given LTCH’s Federal FY 2016 cost reporting period begins, LTCHs will be paid for LTCH discharges at the new site neutral payment rate unless the discharge meets the patient criteria for payment at the LTCH PPS standard Federal payment rate. The existing regulations governing payment under the LTCH PPS are located in 42 CFR Part 412, Subpart O.

4. Critical Access Hospitals (CAHs)

Under sections 1814(l), 1820, and 1834(g) of the Act, payments made to critical access hospitals (CAHs) (that is, rural hospitals or facilities that meet certain statutory requirements) for inpatient and outpatient services are generally based on 101 percent of reasonable cost. Reasonable cost is determined under the provisions of section 1861(v)(1)(A) of the Act and existing regulations under 42 CFR Part 413.

5. Payments for Graduate Medical Education (GME)

Under section 1886(a)(4) of the Act, costs of approved educational activities are excluded from the operating costs of inpatient hospital services. Hospitals with approved graduate medical education (GME) programs are paid for the direct costs of GME in accordance with section 1886(h) of the Act. The amount of payment for direct GME costs for a cost reporting period is based on the hospital’s number of residents in that period and the hospital’s costs per resident in a base year. The existing regulations governing payments to the various types of hospitals are located in 42 CFR Part 413.

C. Summary of Provisions of Recent Legislation Discussed in this Final Rule
The American Taxpayer Relief Act of 2012 (ATRA) (Pub. L. 112-240), enacted on January 2, 2013, made a number of changes that affect the IPPS. We announced changes related to certain IPPS provisions for FY 2013 in accordance with sections 605 and 606 of Pub. L. 112-240 in a notice that appeared in the Federal Register on March 7, 2013 (78 FR 14689).

The Pathway for SGR Reform Act of 2013 (Pub. L. 113-67), enacted on December 26, 2013, also made a number of changes that affect the IPPS and the LTCH PPS. We implemented changes related to the low-volume hospital payment adjustment and MDH provisions for FY 2014 in accordance with sections 1105 and 1106 of Pub. L. 113-67 in an interim final rule with comment period that appeared in the Federal Register on March 18, 2014 (79 FR 15022).

The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93), enacted on April 1, 2014, also made a number of changes that affect the IPPS and LTCH PPS.

The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act of 2014) (Pub. L. 113-185), enacted on October 6, 2014, made a number of changes that affect the Long-Term Care Quality Reporting Program (LTCH QRP).


1. American Taxpayer Relief Act of 2012 (ATRA) (Pub. L. 112-240)

In this final rule, we are making policy changes to implement section 631 of the American Taxpayer Relief Act of 2012, which amended section 7(b)(1)(B) of Pub. L.
110-90 and requires a recoupment adjustment to the standardized amounts under section 1886(d) of the Act based upon the Secretary’s estimates for discharges occurring in FY 2014 through FY 2017 to fully offset $11 billion (which represents the amount of the increase in aggregate payments from FYs 2008 through 2013 for which an adjustment was not previously applied).


In this final rule, we are providing clarifications to prior policy changes, making new policy changes, and discussing the need for future policy changes to implement provisions under section 1206 of the Pathway for SGR Reform Act of 2013. These include:

- Section 1206(a), which provides for the establishment of patient criteria for exclusion from the new site neutral payment rate under the LTCH PPS, beginning in FY 2016.

- Section 1206(a)(3), which requires changes to the LTCH average length of stay criterion.

- Section 1206(b)(1), which further amended section 114(c) of the MMSEA, as amended by section 4302(a) of the ARRA and sections 3106(c) and 10312(a) of the Affordable Care Act by retroactively reestablishing, and extending, the statutory moratorium on the full implementation of the 25-percent threshold payment adjustment policy under the LTCH PPS so that the policy will be in effect for 9 years (except for grandfathered hospitals-within-hospitals (HwHs), which it permanently exempted from this policy).
Section 1206(b)(2), which amended section 114(d) of the MMSEA, as amended by section 4302(a) of the ARRA and sections 3106(c) and 10312(a) of the Affordable Care Act to establish new moratoria (subject to certain defined exceptions) on the development of new LTCHs and LTCH satellite facilities and a new moratorium on increases in the number of beds in existing LTCHs and LTCH satellite facilities.


In this final rule, we are clarifying or discussing our prior policy changes that implemented the following provisions (or portions of the following provisions) of the Protecting Access to Medicare Act of 2014 that are applicable to the IPPS and the LTCH PPS for FY 2016:

- Section 112, which makes certain changes to Medicare LTCH provisions, including modifications to the statutory moratoria on the establishment of new LTCHs and LTCH satellite facilities.

- Section 212, which prohibits the Secretary from requiring implementation of ICD-10 code sets before October 1, 2015.


In this final rule, we are implementing portions of section 2 of the IMPACT Act of 2014, which, in part, requires LTCHs, among other postacute care providers, to report standardized patient assessment data, data on quality measures, and data on resource use and other measures.

In this document, as an interim final rule with comment period, we are implementing sections 204 and 205 of the Medicare Access and CHIP Reauthorization Act of 2015, which extended the MDH program and changes to the low-volume payment adjustment for hospitals through FY 2017.

D. Issuance of Notice of Proposed Rulemaking

Earlier this year, we published a proposed rule that set forth proposed changes for the Medicare IPPS for operating costs and for capital-related costs of acute care hospitals for FY 2016. The proposed rule appeared in the Federal Register on April 30, 2015 (80 FR 24324). We also set forth proposed changes to payments to certain hospitals that continue to be excluded from the IPPS and paid on a reasonable cost basis. In addition, in the proposed rule, we set forth proposed changes to the payment rates, factors, and other payment rate policies under the LTCH PPS for FY 2016.

Below is a summary of the major changes that we proposed to make.

1. Proposed Changes to MS-DRG Classifications and Recalibrations of Relative Weights

In section II. of the preamble of the proposed rule, we included:

- Proposed changes to MS-DRG classifications based on our yearly review, including a discussion of the conversion of MS-DRGs to ICD-10 and the implementation of the ICD-10-CM and ICD-10-PCS systems.

- Proposed application of the documentation and coding adjustment for FY 2016 resulting from implementation of the MS-DRG system.

- Proposed recalibrations of the MS-DRG relative weights.
● Proposed changes to hospital-acquired conditions (HACs) and a discussion of HACs, including infections, that would be subject to the statutorily required adjustment in MS-DRG payments for FY 2016.

● A discussion of the FY 2016 status of new technologies approved for add-on payments for FY 2015 and a presentation of our evaluation and analysis of the FY 2016 applicants for add-on payments for high-cost new medical services and technologies (including public input, as directed by Pub. L. 108-173, obtained in a town hall meeting).

2. Proposed Changes to the Hospital Wage Index for Acute Care Hospitals

In section III. of the preamble to the proposed rule, we proposed revisions to the wage index for acute care hospitals and the annual update of the wage data. Specific issues addressed included the following:

● The proposed FY 2016 wage index update using wage data from cost reporting periods beginning in FY 2012.

● Calculation of the proposed occupational mix adjustment for FY 2016 based on the 2013 Occupational Mix Survey.

● Analysis and implementation of the proposed FY 2016 occupational mix adjustment to the wage index for acute care hospitals.

● Application of the rural floor, the proposed imputed rural floor, and the frontier State floor.

● Transitional wage indexes relating to the continued use of the revised OMB labor market area delineations based on 2010 Decennial Census data.
● Proposed revisions to the wage index for acute care hospitals based on hospital redesignations and reclassifications.

● The proposed out-migration adjustment to the wage index for acute care hospitals for FY 2016 based on commuting patterns of hospital employees who reside in a county and work in a different area with a higher wage index. Beginning in FY 2016, we proposed new out-migration adjustments based on commuting patterns obtained from 2010 Decennial Census data.

● The timetable for reviewing and verifying the wage data used to compute the proposed FY 2016 hospital wage index.

● Determination of the labor-related share for the proposed FY 2016 wage index.

● Proposed changes to the 3-year average pension policy and proposed changes to the wage index timetable regarding pension cost for FY 2017 and subsequent years.

● Clarification of the allocation of pension costs for the wage index.

3. Other Decisions and Proposed Changes to the IPPS for Operating Costs and Indirect Medical Education (IME) Costs

In section IV. of the preamble of the proposed rule, we discussed proposed changes or clarifications of a number of the provisions of the regulations in 42 CFR Parts 412 and 413, including the following:

● Proposed changes to the inpatient hospital updates for FY 2016, including the adjustment for hospitals that are not meaningful EHR users under section 1886(b)(3)(B)(ix) of the Act.
The proposed updated national and regional case-mix values and discharges for purposes of determining RRC status.

- The statutorily required IME adjustment factor for FY 2016.
- Proposal for determining Medicare DSH payments and the additional payments for uncompensated care for FY 2016.
- Proposed changes to the measures and payment adjustments under the Hospital Readmissions Reduction Program.
- Proposed changes to the requirements and provision of value-based incentive payments under the Hospital Value-Based Purchasing Program.
- Proposed requirements for payment adjustments to hospitals under the HAC Reduction Program for FY 2016.
- Proposed elimination of the election by hospitals to use the simplified cost allocation methodology for Medicare cost reports.
- Discussion of the Rural Community Hospital Demonstration Program and a proposal for making a budget neutrality adjustment for the demonstration program.
- Proposed changes in postacute care transfer policies as a result of proposed new MS-DRGs.
- A statement of our intent to discuss issues related to short inpatient hospital stays, long outpatient stays with observation services, and the related -0.2 percent IPPS payment adjustment in the CY 2016 hospital outpatient prospective payment system proposed rule.

4. Proposed FY 2016 Policy Governing the IPPS for Capital-Related Costs
In section V. of the preamble to the proposed rule, we discussed the proposed payment policy requirements for capital-related costs and capital payments to hospitals for FY 2016.

5. Proposed Changes to the Payment Rates for Certain Excluded Hospitals:

Rate-of-Increase Percentages

In section VI. of the preamble of the proposed rule, we discussed proposed changes to payments to certain excluded hospitals for FY 2016.

6. Proposed Changes to the LTCH PPS

In section VII. of the preamble of the proposed rule, we set forth—

- Proposed changes to the LTCH PPS Federal payment rates, factors, and other payment rate policies under the LTCH PPS for FY 2016.

- Proposals to implement section 1206(a)(1) of the Pathway for SGR Reform Act, which established the site neutral payment rate as the default means of paying for discharges in LTCH cost reporting periods beginning on or after October 1, 2015.

- Provisions to make technical clarifications regarding the moratoria on the establishment of new LTCHs and LTCH satellite facilities and on bed increases in existing LTCHs and LTCH satellite facilities that were established by section 1206(b)(2) of the Pathway for SGR Reform, as amended, as well as a proposal to make a technical revision to the regulations to more clearly reflect our established policies.

- Proposal to revise the average length of stay criterion for LTCHs to implement section 1206(a)(3) of the Pathway for SGR Reform Act.
7. Proposed Changes Relating to Quality Data Reporting for Specific Providers and Suppliers

In section VIII. of the preamble of the proposed rule, we addressed—

- Proposed requirements for the Hospital Inpatient Quality Reporting (IQR) Program as a condition for receiving the full applicable percentage increase.
- Proposed changes to the requirements for the quality reporting program for PPS-exempt cancer hospitals (PCHQR Program).
- Proposed changes to the requirements under the LTCH Quality Reporting Program (LTCH QRP).
- Proposed changes to align the reporting and submission timelines for the electronic submission of clinical quality measures for the Medicare Electronic Health Record (EHR) Incentive Program for eligible hospitals and CAHs with the reporting and submission of timelines for the Hospital IQR Program. (We note that the proposal included in the proposed rule to establish in regulations an EHR technology certification criterion for reporting clinical quality measures is not being finalized in this final rule but will be addressed in a future rulemaking.)

8. Determining Prospective Payment Operating and Capital Rates and Rate-of-Increase Limits for Acute Care Hospitals

In the Addendum to the proposed rule, we set forth proposed changes to the amounts and factors for determining the proposed FY 2016 prospective payment rates for operating costs and capital-related costs for acute care hospitals. We also proposed to establish the threshold amounts for outlier cases. In addition, we addressed the update
factors for determining the rate-of-increase limits for cost reporting periods beginning in FY 2016 for certain hospitals excluded from the IPPS.

9. Determining Standard Federal Payment Rates for LTCHs

In the Addendum to the proposed rule, we set forth proposed changes to the amounts and factors for determining the proposed FY 2016 LTCH PPS standard Federal payment rate. We proposed to establish the adjustments for wage levels, the labor-related share, the cost-of-living adjustment, and high-cost outliers, including the fixed-loss amount, and the LTCH cost-to-charge ratios (CCRs) under the LTCH PPS.

10. Impact Analysis

In Appendix A of the proposed rule, we set forth an analysis of the impact that the proposed changes would have on affected acute care hospitals, LTCHs, and PCHs.

11. Recommendation of Update Factors for Operating Cost Rates of Payment for Hospital Inpatient Services

In Appendix B of the proposed rule, as required by sections 1886(e)(4) and (e)(5) of the Act, we provided our recommendations of the appropriate percentage changes for FY 2016 for the following:

- A single average standardized amount for all areas for hospital inpatient services paid under the IPPS for operating costs of acute care hospitals (and hospital-specific rates applicable to SCHs).

- Target rate-of-increase limits to the allowable operating costs of hospital inpatient services furnished by certain hospitals excluded from the IPPS.
• The standard Federal payment rate for hospital inpatient services furnished by LTCHs.

12. Discussion of Medicare Payment Advisory Commission Recommendations

Under section 1805(b) of the Act, MedPAC is required to submit a report to Congress, no later than March 15 of each year, in which MedPAC reviews and makes recommendations on Medicare payment policies. MedPAC’s March 2015 recommendations concerning hospital inpatient payment policies address the update factor for hospital inpatient operating costs and capital-related costs for hospitals under the IPPS. We addressed these recommendations in Appendix B of the proposed rule. For further information relating specifically to the MedPAC March 2015 report or to obtain a copy of the report, contact MedPAC at (202) 220-3700 or visit MedPAC’s Web site at: http://www.medpac.gov.

E. Public Comments Received in Response to the FY 2016 IPPS/LTCH PPS Proposed Rule

We received approximately 361 timely pieces of correspondence containing multiple comments on the FY 2016 IPPS/LTCH PPS proposed rule. We note that some of these public comments were outside of the scope of the proposed rule. These out-of-scope public comments are mentioned but not addressed with the policy responses in this final rule. Summaries of the public comments that are within the scope of the proposed rule and our responses to those public comments are set forth in the various sections of this final rule under the appropriate heading.
II. Changes to Medicare Severity Diagnosis-Related Group (MS-DRG) Classifications and Relative Weights

A. Background

Section 1886(d) of the Act specifies that the Secretary shall establish a classification system (referred to as diagnosis-related groups (DRGs)) for inpatient discharges and adjust payments under the IPPS based on appropriate weighting factors assigned to each DRG. Therefore, under the IPPS, Medicare pays for inpatient hospital services on a rate per discharge basis that varies according to the DRG to which a beneficiary’s stay is assigned. The formula used to calculate payment for a specific case multiplies an individual hospital’s payment rate per case by the weight of the DRG to which the case is assigned. Each DRG weight represents the average resources required to care for cases in that particular DRG, relative to the average resources used to treat cases in all DRGs.

Congress recognized that it would be necessary to recalculate the DRG relative weights periodically to account for changes in resource consumption. Accordingly, section 1886(d)(4)(C) of the Act requires that the Secretary adjust the DRG classifications and relative weights at least annually. These adjustments are made to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources.

B. MS-DRG Reclassifications

For general information about the MS-DRG system, including yearly reviews and changes to the MS-DRGs, we refer readers to the previous discussions in the FY 2010
IPPS/RY 2010 LTCH PPS final rule (74 FR 43764 through 43766), the FY 2011 IPPS/LTCH PPS final rule (75 FR 50053 through 50055), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51485 through 51487), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53273), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50512), and the FY 2015 IPPS/LTCH PPS final rule (79 FR 49871).

C. Adoption of the MS-DRGs in FY 2008

For information on the adoption of the MS-DRGs in FY 2008, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47140 through 47189).

D. FY 2016 MS-DRG Documentation and Coding Adjustment

1. Background on the Prospective MS-DRG Documentation and Coding Adjustments for FY 2008 and FY 2009 Authorized by Pub. L. 110-90

In the FY 2008 IPPS final rule with comment period (72 FR 47140 through 47189), we adopted the MS-DRG patient classification system for the IPPS, effective October 1, 2007, to better recognize severity of illness in Medicare payment rates for acute care hospitals. The adoption of the MS-DRG system resulted in the expansion of the number of DRGs from 538 in FY 2007 to 745 in FY 2008. By increasing the number of MS-DRGs and more fully taking into account patient severity of illness in Medicare payment rates for acute care hospitals, MS-DRGs encourage hospitals to improve their documentation and coding of patient diagnoses.

In the FY 2008 IPPS final rule with comment period (72 FR 47175 through 47186), we indicated that the adoption of the MS-DRGs had the potential to lead to increases in aggregate payments without a corresponding increase in actual patient
severity of illness due to the incentives for additional documentation and coding. In that
final rule with comment period, we exercised our authority under
section 1886(d)(3)(A)(vi) of the Act, which authorizes us to maintain budget neutrality
by adjusting the national standardized amount, to eliminate the estimated effect of
changes in coding or classification that do not reflect real changes in case-mix. Our
actuaries estimated that maintaining budget neutrality required an adjustment
of -4.8 percent to the national standardized amount. We provided for phasing in
this -4.8 percent adjustment over 3 years. Specifically, we established prospective
documentation and coding adjustments of -1.2 percent for FY 2008, -1.8 percent for
FY 2009, and -1.8 percent for FY 2010.

On September 29, 2007, Congress enacted the TMA [Transitional Medical
Assistance], Abstinence Education, and QI [Qualifying Individuals] Programs Extension
Act of 2007 (Pub. L. 110-90). Section 7(a) of Pub. L. 110-90 reduced the documentation
and coding adjustment made as a result of the MS-DRG system that we adopted in the
FY 2008 IPPS final rule with comment period to -0.6 percent for FY 2008
and -0.9 percent for FY 2009, and we finalized the FY 2008 adjustment through
rulemaking, effective October 1, 2007 (72 FR 66886).

For FY 2009, section 7(a) of Pub. L. 110-90 required a documentation and coding
adjustment of -0.9 percent, and we finalized that adjustment through rulemaking effective
October 1, 2008 (73 FR 48447). The documentation and coding adjustments established
in the FY 2008 IPPS final rule with comment period, which reflected the amendments
made by section 7(a) of Pub. L. 110-90, are cumulative. As a result, the -0.9 percent
documentation and coding adjustment for FY 2009 was in addition to the -0.6 percent adjustment for FY 2008, yielding a combined effect of -1.5 percent.

2. Adjustment to the Average Standardized Amounts Required by Pub. L. 110-90

a. Prospective Adjustment Required by Section 7(b)(1)(A) of Pub. L. 110-90

Section 7(b)(1)(A) of Pub. L. 110-90 requires that, if the Secretary determines that implementation of the MS–DRG system resulted in changes in documentation and coding that did not reflect real changes in case-mix for discharges occurring during FY 2008 or FY 2009 that are different than the prospective documentation and coding adjustments applied under section 7(a) of Pub. L. 110-90, the Secretary shall make an appropriate adjustment under section 1886(d)(3)(A)(vi) of the Act.

Section 1886(d)(3)(A)(vi) of the Act authorizes adjustments to the average standardized amounts for subsequent fiscal years in order to eliminate the effect of such coding or classification changes. These adjustments are intended to ensure that future annual aggregate IPPS payments are the same as the payments that otherwise would have been made had the prospective adjustments for documentation and coding applied in FY 2008 and FY 2009 reflected the change that occurred in those years.

b. Recoupment or Repayment Adjustments in FYs 2010 through 2012 Required by Section 7(b)(1)(B) Pub. L. 110-90

If, based on a retroactive evaluation of claims data, the Secretary determines that implementation of the MS–DRG system resulted in changes in documentation and coding that did not reflect real changes in case-mix for discharges occurring during FY 2008 or FY 2009 that are different from the prospective documentation and coding adjustments
applied under section 7(a) of Pub. L. 110-90, section 7(b)(1)(B) of Pub. L. 110-90 requires the Secretary to make an additional adjustment to the standardized amounts under section 1886(d) of the Act. This adjustment must offset the estimated increase or decrease in aggregate payments for FYs 2008 and 2009 (including interest) resulting from the difference between the estimated actual documentation and coding effect and the documentation and coding adjustment applied under section 7(a) of Pub. L. 110-90. This adjustment is in addition to making an appropriate adjustment to the standardized amounts under section 1886(d)(3)(A)(vi) of the Act as required by section 7(b)(1)(A) of Pub. L. 110-90. That is, these adjustments are intended to recoup (or repay, in the case of underpayments) spending in excess of (or less than) spending that would have occurred had the prospective adjustments for changes in documentation and coding applied in FY 2008 and FY 2009 matched the changes that occurred in those years. Pub. L. 110-90 requires that the Secretary only make these recoupment or repayment adjustments for discharges occurring during FYs 2010, 2011, and 2012.

3. Retrospective Evaluation of FY 2008 and FY 2009 Claims Data

In order to implement the requirements of section 7 of Pub. L. 110-90, we performed a retrospective evaluation of the FY 2008 data for claims paid through December 2008 using the methodology first described in the FY 2009 IPPS/LTCH PPS final rule (73 FR 43768 and 43775) and later discussed in the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43768 through 43772). We performed the same analysis for FY 2009 claims data using the same methodology as we did for FY 2008 claims (75 FR 50057 through 50068). The results of the analysis for the FY 2011 IPPS/LTCH
PPS proposed and final rules, and subsequent evaluations in FY 2012, supported that the 5.4 percent estimate accurately reflected the FY 2009 increases in documentation and coding under the MS-DRG system. We were persuaded by both MedPAC’s analysis (as discussed in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50064 through 50065)) and our own review of the methodologies recommended by various commenters that the methodology we employed to determine the required documentation and coding adjustments was sound.

As in prior years, the FY 2008, FY 2009, and FY 2010 MedPAR files are available to the public to allow independent analysis of the FY 2008 and FY 2009 documentation and coding effects. Interested individuals may still order these files through the CMS Web site at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/LimitedDataSets/ by clicking on MedPAR Limited Data Set (LDS)-Hospital (National). This CMS Web page describes the file and provides directions and further detailed instructions for how to order.

Persons placing an order must send the following: a Letter of Request, the LDS Data Use Agreement and Research Protocol (refer to the Web site for further instructions), the LDS Form, and a check (refer to the Website for the required payment amount) to:

Mailing address if using the U.S. Postal Service:

Centers for Medicare & Medicaid Services,

RDDC Account,

Accounting Division,
4. Prospective Adjustments for FY 2008 and FY 2009 Authorized by Section 7(b)(1)(A) of Pub. L. 110-90

In the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43767 through 43777), we opted to delay the implementation of any documentation and coding adjustment until a full analysis of case-mix changes based on FY 2009 claims data could be completed. We refer readers to the FY 2010 IPPS/RY LTCH PPS final rule for a detailed description of our proposal, responses to comments, and finalized policy. After analysis of the FY 2009 claims data for the FY 2011 IPPS/LTCH PPS final rule (75 FR 50057 through 50073), we found a total prospective documentation and coding effect of 5.4 percent. After accounting for the -0.6 percent and the -0.9 percent documentation and coding adjustments in FYs 2008 and 2009, we found a remaining documentation and coding effect of 3.9 percent. As we have discussed, an additional cumulative adjustment of -3.9 percent would be necessary to meet the requirements of section 7(b)(1)(A) of Pub. L. 110-90 to make an adjustment to the average standardized amounts in order to eliminate the full effect of the documentation and coding changes.
that do not reflect real changes in case-mix on future payments. Unlike section 7(b)(1)(B) of Pub. L. 110-90, section 7(b)(1)(A) does not specify when we must apply the prospective adjustment, but merely requires us to make an “appropriate” adjustment. Therefore, as we stated in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50061), we believed the law provided some discretion as to the manner in which we applied the prospective adjustment of -3.9 percent. As we discussed extensively in the FY 2011 IPPS/LTCH PPS final rule, it has been our practice to moderate payment adjustments when necessary to mitigate the effects of significant downward adjustments on hospitals, to avoid what could be widespread, disruptive effects of such adjustments on hospitals. Therefore, we stated that we believed it was appropriate to not implement the -3.9 percent prospective adjustment in FY 2011 because we finalized a -2.9 percent recoupment adjustment for that fiscal year. Accordingly, we did not propose a prospective adjustment under section 7(b)(1)(A) of Pub. L. 110-90 for FY 2011 (75 FR 23868 through 23870). We noted that, as a result, payments in FY 2011 (and in each future fiscal year until we implemented the requisite adjustment) would be higher than they would have been if we had implemented an adjustment under section 7(b)(1)(A) of Pub. L. 110-90.

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51489 and 51497), we indicated that, because further delay of this prospective adjustment would result in a continued accrual of unrecoverable overpayments, it was imperative that we implement a prospective adjustment for FY 2012, while recognizing CMS’ continued desire to mitigate the effects of any significant downward adjustments to hospitals. Therefore, we
implemented a -2.0 percent prospective adjustment to the standardized amount instead of the full -3.9 percent.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53274 through 53276), we completed the prospective portion of the adjustment required under section 7(b)(1)(A) of Pub. L. 110-90 by finalizing a -1.9 percent adjustment to the standardized amount for FY 2013. We stated that this adjustment would remove the remaining effect of the documentation and coding changes that do not reflect real changes in case-mix that occurred in FY 2008 and FY 2009. We believed that it was imperative to implement the full remaining adjustment, as any further delay would result in an overstated standardized amount in FY 2013 and any future fiscal years until a full adjustment was made.

We noted again that delaying full implementation of the prospective portion of the adjustment required under section 7(b)(1)(A) of Pub. L. 110-90 until FY 2013 resulted in payments in FY 2010 through FY 2012 being overstated. These overpayments could not be recovered by CMS because section 7(b)(1)(B) of Pub. L. 110-90 limited recoupments to overpayments made in FY 2008 and FY 2009.

5. Recoupment or Repayment Adjustment Authorized by Section 7(b)(1)(B) of Pub. L. 110-90

Section 7(b)(1)(B) of Pub. L. 110-90 requires the Secretary to make an adjustment to the standardized amounts under section 1886(d) of the Act to offset the estimated increase or decrease in aggregate payments for FY 2008 and FY 2009 (including interest) resulting from the difference between the estimated actual documentation and coding effect and the documentation and coding adjustments applied under section 7(a) of
Pub. L. 110-90. This determination must be based on a retrospective evaluation of claims data. Our actuaries estimated that there was a 5.8 percentage point difference resulting in an increase in aggregate payments of approximately $6.9 billion. Therefore, as discussed in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50062 through 50067), we determined that an aggregate adjustment of -5.8 percent in FYs 2011 and 2012 would be necessary in order to meet the requirements of section 7(b)(1)(B) of Pub. L. 110-90 to adjust the standardized amounts for discharges occurring in FYs 2010, 2011, and/or 2012 to offset the estimated amount of the increase in aggregate payments (including interest) in FYs 2008 and 2009.

It is often our practice to phase in payment rate adjustments over more than one year in order to moderate the effect on payment rates in any one year. Therefore, consistent with the policies that we have adopted in many similar cases, in the FY 2011 IPPS/LTCH PPS final rule, we made an adjustment to the standardized amount of -2.9 percent, representing approximately one-half of the aggregate adjustment required under section 7(b)(1)(B) of Pub. L. 110-90, for FY 2011. An adjustment of this magnitude allowed us to moderate the effects on hospitals in one year while simultaneously making it possible to implement the entire adjustment within the timeframe required under section 7(b)(1)(B) of Pub. L. 110-90 (that is, no later than FY 2012). For FY 2012, in accordance with the timeframes set forth by section 7(b)(1)(B) of Pub. L. 110-90, and consistent with the discussion in the FY 2011 IPPS/LTCH PPS final rule, we completed the recoupment adjustment by implementing the remaining -2.9 percent adjustment, in addition to removing the effect of
the -2.9 percent adjustment to the standardized amount finalized for FY 2011 (76 FR 51489 and 51498). Because these adjustments, in effect, balanced out, there was no year-to-year change in the standardized amount due to this recoupment adjustment for FY 2012. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53276), we made a final +2.9 percent adjustment to the standardized amount, completing the recoupment portion of section 7(b)(1)(B) of Pub. L. 110-90. We note that with this positive adjustment, according to our estimates, all overpayments made in FY 2008 and FY 2009 have been fully recaptured with appropriate interest, and the standardized amount has been returned to the appropriate baseline.

6. Recoupment or Repayment Adjustment Authorized by Section 631 of the American Taxpayer Relief Act of 2012 (ATRA)

   Section 631 of the ATRA amended section 7(b)(1)(B) of Pub. L. 110-90 to require the Secretary to make a recoupment adjustment or adjustments totaling $11 billion by FY 2017. This adjustment represents the amount of the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Pub. L. 110-90 until FY 2013. As discussed earlier, this delay in implementation resulted in overstated payment rates in FYs 2010, 2011, and 2012. The resulting overpayments could not have been recovered under Pub. L. 110-90. Similar to the adjustments authorized under section 7(b)(1)(B) of Pub. L. 110-90, the adjustment required under section 631 of the ATRA is a one-time recoupment of a prior overpayment, not a permanent reduction to payment rates. Therefore, we anticipated that any adjustment made to reduce payment rates in one year would
eventually be offset by a single positive adjustment in FY 2018, once the necessary amount of overpayment was recovered. However, we note that section 414 of the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015, Pub. L. 114-10, enacted on April 16, 2015, replaced the single positive adjustment we intended to make in FY 2018 with a 0.5 percent positive adjustment for each of FYs 2018 through 2023. The provision under section 414 of the MACRA does not impact our FY 2016 adjustment, and we will address this MACRA provision in future rulemaking.

As we stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50515 through 50517), our actuaries estimate that a -9.3 percent adjustment to the standardized amount would be necessary if CMS were to fully recover the $11 billion recoupment required by section 631 of the ATRA in FY 2014. It is often our practice to phase in payment rate adjustments over more than one year, in order to moderate the effect on payment rates in any one year. Therefore, consistent with the policies that we have adopted in many similar cases, and after consideration of the public comments we received, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50515 through 50517), we implemented a -0.8 percent recoupment adjustment to the standardized amount in FY 2014. We stated that if adjustments of approximately -0.8 percent are implemented in FYs 2014, 2015, 2016, and 2017, using standard inflation factors, we estimate that the entire $11 billion will be accounted for by the end of the statutory 4-year timeline. As estimates of any future adjustments are subject to slight variations in total savings, we did not provide for specific adjustments for FYs 2015, 2016, or 2017 at that time. We stated that we believed that this level of adjustment for FY 2014 was a reasonable and fair approach that
satisfies the requirements of the statute while mitigating extreme annual fluctuations in payment rates.

Consistent with the approach discussed in the FY 2014 IPPS/LTCH PPS final rule for recouping the $11 billion required by section 631 of the ATRA, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49873 through 49874), we implemented an additional -0.8 percent recoupment adjustment to the standardized amount for FY 2015. We estimated that this level of adjustment, combined with leaving the -0.8 percent adjustment made for FY 2014 in place, would recover up to $2 billion in FY 2015. When combined with the approximately $1 billion adjustment made in FY 2014, we estimated that approximately $8 billion would be left to recover under section 631 of the ATRA.

Consistent with the approach discussed in the FY 2014 IPPS/LTCH PPS final rule for recouping the $11 billion required by section 631 of the ATRA, we proposed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24342) to implement a -0.8 percent recoupment adjustment to the standardized amount for FY 2016. We estimated that this level of adjustment, combined with leaving the -0.8 percent adjustments made for FY 2014 and FY 2015 in place, would recover up to $3 billion in FY 2016.

Comment: Several commenters restated their previous position, as set forth in comments submitted in response to the FY 2014 and FY 2015 IPPS/LTCH PPS proposed rules and summarized in the FY 2014 IPPS/LTCH PPS final rule, that CMS overstated the impact of documentation and coding effects for prior years. The commenters cited potential deficiencies in the CMS methodology and disagreed that the congressionally mandated adjustment is warranted. However, the majority of these commenters
conceded that CMS is required by section 631 of the ATRA to recover $11 billion by FY 2017, and supported CMS’ policy to phase in the adjustments over a 4-year period.

**Response:** We refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50515 through 50517) for our response to the commenters’ position that CMS overstated the impact of documentation and coding effects. We appreciate the commenters’ acknowledgement that we are required by section 631 of the ATRA to recover $11 billion by FY 2017.

After consideration of the public comments we received, we are finalizing the proposal to make an additional -0.8 percent recoupment adjustment to the standardized amount for FY 2016. Taking into account the cumulative effects of this adjustment and the adjustments made in FYs 2014 and 2015, we currently estimate that approximately $5 to $6 billion would be left to recover under section 631 of the ATRA by the end of FY 2016. As we explained in the FY 2014 and FY 2015 IPPS/LTCH PPS final rules, estimates of any future adjustments are subject to variations in total estimated savings. Therefore, we have not yet addressed the specific amount of the final adjustment required under section 631 of the ATRA for FY 2017. We intend to address this adjustment in the FY 2017 IPPS rulemaking. As stated earlier, we also note that section 414 of the MACRA (Pub. L. 114-10), enacted on April 16, 2015, replaced the single positive adjustment we intended to make in FY 2018 with a 0.5 percent positive adjustment for each of FYs 2018 through 2023. The provision under section 414 of the MACRA does not impact our FY 2016 recoupment adjustment, and we will address this MACRA provision in future rulemaking.
E. Refinement of the MS-DRG Relative Weight Calculation

1. Background

Beginning in FY 2007, we implemented relative weights for DRGs based on cost report data instead of charge information. We refer readers to the FY 2007 IPPS final rule (71 FR 47882) for a detailed discussion of our final policy for calculating the cost-based DRG relative weights and to the FY 2008 IPPS final rule with comment period (72 FR 47199) for information on how we blended relative weights based on the CMS DRGs and MS-DRGs.

As we implemented cost-based relative weights, some public commenters raised concerns about potential bias in the weights due to “charge compression,” which is the practice of applying a higher percentage charge markup over costs to lower cost items and services, and a lower percentage charge markup over costs to higher cost items and services. As a result, the cost-based weights would undervalue high-cost items and overvalue low-cost items if a single cost-to-charge ratio (CCR) is applied to items of widely varying costs in the same cost center. To address this concern, in August 2006, we awarded a contract to the Research Triangle Institute, International (RTI) to study the effects of charge compression in calculating the relative weights and to consider methods to reduce the variation in the CCRs across services within cost centers. For a detailed summary of RTI’s findings, recommendations, and public comments that we received on the report, we refer readers to the FY 2009 IPPS/LTC PPS final rule (73 FR 48452 through 48453). In addition, we refer readers to RTI’s July 2008 final report titled “Refining Cost to Charge Ratios for Calculating APC and MS-DRG Relative Payment

In the FY 2009 IPPS final rule (73 FR 48458 through 48467), in response to the RTI’s recommendations concerning cost report refinements, we discussed our decision to pursue changes to the cost report to split the cost center for Medical Supplies Charged to Patients into one line for “Medical Supplies Charged to Patients” and another line for “Implantable Devices Charged to Patients.” We acknowledged, as RTI had found, that charge compression occurs in several cost centers that exist on the Medicare cost report. However, as we stated in the FY 2009 IPPS final rule, we focused on the CCR for Medical Supplies and Equipment because RTI found that the largest impact on the MS-DRG relative weights could result from correcting charge compression for devices and implants. In determining the items that should be reported in these respective cost centers, we adopted the commenters’ recommendations that hospitals should use revenue codes established by the AHA’s National Uniform Billing Committee to determine the items that should be reported in the “Medical Supplies Charged to Patients” and the “Implantable Devices Charged to Patients” cost centers. Accordingly, a new subscripted line for “Implantable Devices Charged to Patients” was created in July 2009. This new subscripted cost center has been available for use for cost reporting periods beginning on or after May 1, 2009.

As we discussed in the FY 2009 IPPS final rule (73 FR 48458) and in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68519 through 68527), in addition to the findings regarding implantable devices, RTI also found that the costs and
charges of computed tomography (CT) scans, magnetic resonance imaging (MRI), and cardiac catheterization differ significantly from the costs and charges of other services included in the standard associated cost center. RTI also concluded that both the IPPS and the OPPS relative weights would better estimate the costs of those services if CMS were to add standard cost centers for CT scans, MRIs, and cardiac catheterization in order for hospitals to report separately the costs and charges for those services and in order for CMS to calculate unique CCRs to estimate the costs from charges on claims data. In the FY 2011 IPPS/LTCH PPS final rule (75 FR 50075 through 50080), we finalized our proposal to create standard cost centers for CT scans, MRIs, and cardiac catheterization, and to require that hospitals report the costs and charges for these services under new cost centers on the revised Medicare cost report Form CMS-2552-10. (We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50075 through 50080) for a detailed discussion of the reasons for the creation of standard cost centers for CT scans, MRIs, and cardiac catheterization.) The new standard cost centers for CT scans, MRIs, and cardiac catheterization are effective for cost reporting periods beginning on or after May 1, 2010, on the revised cost report Form CMS-2552-10.

In the FY 2009 IPPS final rule (73 FR 48468), we stated that, due to what is typically a 3-year lag between the reporting of cost report data and the availability for use in ratesetting, we anticipated that we might be able to use data from the new “Implantable Devices Charged to Patients” cost center to develop a CCR for “Implantable Devices Charged to Patients” in the FY 2012 or FY 2013 IPPS rulemaking cycle. However, as noted in the FY 2010 IPPS/RYY 2010 LTCH PPS final rule (74 FR 43782), due to delays
in the issuance of the revised cost report Form CMS 2552-10, we determined that a new CCR for “Implantable Devices Charged to Patients” might not be available before FY 2013. Similarly, when we finalized the decision in the FY 2011 IPPS/LTCH PPS final rule to add new cost centers for CT scans, MRIs, and cardiac catheterization, we explained that data from any new cost centers that may be created will not be available until at least 3 years after they are first used (75 FR 50077). In preparation for the FY 2012 IPPS/LTCH PPS rulemaking, we checked the availability of data in the “Implantable Devices Charged to Patients” cost center on the FY 2009 cost reports, but we did not believe that there was a sufficient amount of data from which to generate a meaningful analysis in this particular situation. Therefore, we did not propose to use data from the “Implantable Devices Charged to Patients” cost center to create a distinct CCR for “Implantable Devices Charged to Patients” for use in calculating the MS-DRG relative weights for FY 2012. We indicated that we would reassess the availability of data for the “Implantable Devices Charged to Patients” cost center for the FY 2013 IPPS/LTCH PPS rulemaking cycle and, if appropriate, we would propose to create a distinct CCR at that time.

During the development of the FY 2013 IPPS/LTCH PPS proposed and final rules, hospitals were still in the process of transitioning from the previous cost report Form CMS-2552-96 to the new cost report Form CMS-2552-10. Therefore, we were able to access only those cost reports in the FY 2010 HCRIS with fiscal year begin dates on or after October 1, 2009, and before May 1, 2010; that is, those cost reports on Form CMS-2552-96. Data from the Form CMS-2552-10 cost reports were not available
because cost reports filed on the Form CMS-2552-10 were not accessible in the HCRIS. Further complicating matters was that, due to additional unforeseen technical difficulties, the corresponding information regarding charges for implantable devices on hospital claims was not yet available to us in the MedPAR file. Without the breakout in the MedPAR file of charges associated with implantable devices to correspond to the costs of implantable devices on the cost report, we believed that we had no choice but to continue computing the relative weights with the current CCR that combines the costs and charges for supplies and implantable devices. We stated in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53281 through 53283) that when we do have the necessary data for supplies and implantable devices on the claims in the MedPAR file to create distinct CCRs for the respective cost centers for supplies and implantable devices, we hoped that we would also have data for an analysis of creating distinct CCRs for CT scans, MRIs, and cardiac catheterization, which could then be finalized through rulemaking. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53281), we stated that, prior to proposing to create these CCRs, we would first thoroughly analyze and determine the impacts of the data, and that distinct CCRs for these new cost centers would be used in the calculation of the relative weights only if they were first finalized through rulemaking.

At the time of the development of the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27506 through 27507), we had a substantial number of hospitals completing all, or some, of these new cost centers on the FY 2011 Medicare cost reports, compared to prior years. We stated that we believed that the analytic findings described using the FY 2011 cost report data and FY 2012 claims data supported our original decision to
break out and create new cost centers for implantable devices, MRIs, CT scans, and cardiac catheterization, and we saw no reason to further delay proposing to implement the CCRs of each of these cost centers. Therefore, beginning in FY 2014, we proposed a policy to calculate the MS–DRG relative weights using 19 CCRs, creating distinct CCRs from cost report data for implantable devices, MRIs, CT scans, and cardiac catheterization.

We refer readers to the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27507 through 27509) and final rule (78 FR 50518 through 50523) in which we presented data analyses using distinct CCRs for implantable devices, MRIs, CT scans, and cardiac catheterization. The FY 2014 IPPS/LTCH PPS final rule also set forth our responses to public comments we received on our proposal to implement these CCRs. As explained in more detail in the FY 2014 IPPS/LTCH PPS final rule, we finalized our proposal to use 19 CCRs to calculate MS-DRG relative weights beginning in FY 2014—the then existing 15 cost centers and the 4 new CCRs for implantable devices, MRIs, CT scans, and cardiac catheterization. Therefore, beginning in FY 2014, we calculate the IPPS MS-DRG relative weights using 19 CCRs, creating distinct CCRs for implantable devices, MRIs, CT scans, and cardiac catheterization.

2. Discussion for FY 2016 and Summary of Public Comments Received in Response to Request on Nonstandard Cost Center Codes

Consistent with the policy established beginning for FY 2014, we calculated the MS–DRG relative weights for FY 2016 using two data sources: the MedPAR file as the claims data source and the HCRIS as the cost report data source. We adjusted the
charges from the claims to costs by applying the 19 national average CCRs developed from the cost reports. The description of the calculation of the 19 CCRs and the MS-DRG relative weights for FY 2016 is included in section II.H.3. of the preamble of this final rule.

In preparing to calculate the 19 national average CCRs developed from the cost reports, we reviewed the HCRIS data and noticed inconsistencies in hospitals’ cost reporting and use of nonstandard cost center codes. In addition, we discovered that hospitals typically report the nonstandard codes with standard cost centers that are different from the standard cost centers to which CMS maps and “rolls up” each nonstandard code in compiling the HCRIS. As stated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24344), we are concerned that inconsistencies in hospitals’ use of nonstandard codes, coupled with differences in the way hospitals and CMS map these nonstandard codes to standard lines, may have implications for the calculation of the 19 CCRs and the aspects of the IPPS that rely on the CCRs (for example, the calculation of the MS-DRG relative weights).

The Medicare cost report Form CMS-2552-10, Worksheet A, includes preprinted cost center codes that reflect the standard cost center descriptions by category (General Service, Routine, and Ancillary) used in most hospitals. Each preprinted standard cost center is assigned a unique 5-digit code. The preprinted 5-digit codes provide standardized meaning for data analysis, and are automatically coded by CMS-approved cost report software. To accommodate hospitals that have additional cost centers that are sufficiently different from the preprinted standard cost centers, CMS identified additional
cost centers known as “nonstandard” cost centers. Each nonstandard cost center must be labeled appropriately and reported under a specific standard cost center. For example, under the standard cost center “Electrocardiology” with its 5-digit code of 06900, there are six nonstandard cost centers (for EKG and EEG, Electromyography, Cardiopulmonary, Stress Test, Cardiology, and Holter Monitor), each with a unique 5-digit code.

The instructions for the Medicare cost report Form CMS-2552-10 explain the purpose and requirements related to the standard and nonstandard cost centers. Specifically, in CMS Pub. 15-2, Chapter 40, Section 4013, the instructions for Worksheet A of Form CMS-2552-10 state:

“Cost center coding is a methodology for standardizing the meaning of cost center labels as used by health care providers on the Medicare cost report. Form CMS-2552-10 provides for preprinted cost center descriptions on Worksheet A. In addition, a space is provided for a cost center code. The preprinted cost center labels are automatically coded by CMS approved cost reporting software. These cost center descriptions are hereafter referred to as the standard cost centers. Additionally, nonstandard cost center descriptions have been identified through analysis of frequently used labels.

The use of this coding methodology allows providers to continue to use labels for cost centers that have meaning within the individual institution. The five digit cost center codes that are associated with each provider label in their electronic file provide standardized meaning for data analysis. You are required to compare any added or
changed label to the descriptions offered on the standard or nonstandard cost center tables. A description of cost center coding and the table of cost center codes are in §4095, Table 5.”

Section 4095 of CMS Pub. 15-2 (pages 40-805 and 40-806) further provides that: “Both the standard and nonstandard cost center descriptions along with their cost center codes are shown on Table 5 . . . . Cost center codes may only be used in designated lines in accordance with the classification of the cost center(s), i.e., lines 1 through 23 may only contain cost center codes within the general service cost center category of both standard and nonstandard coding. For example, in the general service cost center category for Operation of Plant cost, line 7 and subscripts thereof should only contain cost center codes of 00700-00719 and nonstandard cost center codes. This logic must hold true for all other cost center categories, i.e., ancillary, inpatient routine, outpatient, other reimbursable, special purpose, and non-reimbursable cost centers.”

Table 5 of Section 4095, Chapter 40, of CMS Pub. 15-2 (pages 40-807 through 40-810) lists the electronic reporting specifications for each standard cost center, its 5-digit code, and, separately, the nonstandard cost center descriptions and their 5-digit codes. While the nonstandard codes are categorized by General Service Cost Centers, Inpatient Routine Service Cost Centers, and Ancillary Service Cost Centers, among others, Table 5 does not map the nonstandard cost centers and codes to specific standard cost centers. In addition, the CMS-approved cost reporting software does not restrict the use of nonstandard codes to specific standard cost centers. Furthermore, the software does not prevent hospitals from manually entering in a name for a nonstandard cost
center code that may be different from the name that CMS assigned to that nonstandard cost center code. For example, Table 5 specifies that the 5-digit code for the Ancillary Service nonstandard cost center “Acupuncture” is 03020. When CMS creates the HCRIS SAS files, CMS maps all codes 03020 to standard line 53, “Anesthesiology”. However, a review of the December 31, 2014 update of the FY 2013 HCRIS SAS files, from which the proposed 19 CCRs for FY 2016 were calculated, revealed that, of the 3,172 times that nonstandard code 03020 was reported by hospitals, it is called “Acupuncture” only 122 times. Instead, hospitals use various names for nonstandard code 03020, such as “Cardiopulmonary,” “Sleep Lab,” “Diabetes Center,” or “Wound Care”.

As noted above, the Ancillary Service standard cost center for “Anesthesiology”, line 53 of Worksheet A and subsequent worksheets of the Medicare cost report Form CMS-2552-10 (and its associated nonstandard cost center code 03020 “Acupuncture”) is an example of a cost center that is subject to inconsistent reporting. Our review of the FY 2013 HCRIS as-submitted cost reports from which the proposed 19 CCRs for FY 2016 were calculated revealed that, regardless of the actual name hospitals assigned to nonstandard code 03020 (for example, “Acupuncture” or otherwise), hospitals reported this code almost 100 percent of the time on standard line 76, “Other Ancillary,” and never on standard line 53, “Anesthesiology.” Yet, as noted above, CMS (and previously HCFA, under earlier versions of the Medicare cost report), in creating the HCRIS

---

2To view how CMS rolls up the codes to create the HCRIS SAS files, we refer readers to http://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Cost-Reports/Hospital-2010-formhtml. On this page, click on “Hospital-2010-SAS.ZIP (SAS datasets and documentation)”, and from the zip file, choose the Excel spreadsheet “2552-10 SAS FILE RECORD LAYOUT AND CROSSWALK TO 96.xlsx”. The second tab of this spreadsheet is “NEW ROLLUPS”, and shows the standard and nonstandard 5-digit codes (columns B and C) that CMS rolls up to each standard line (column G).
database, has had the longstanding practice of mapping and rolling up all instances of nonstandard code 03020 to standard line 53, “Anesthesiology,” not to standard line 76, “Other Ancillary. Therefore, the version of the HCRIS SAS files created by CMS, which CMS uses for ratesetting purposes, may differ somewhat from the as-submitted cost reports of hospitals because CMS moves various nonstandard cost centers based on cost center codes, not cost center descriptions, from the standard cost centers in which hospitals report them and places them in different standard cost centers based on CMS’ roll-up specifications.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24345), we highlighted the discrepancy in the reporting of nonstandard code 03020 “Acupuncture” because the placement of nonstandard code 03020 and its related costs and charges seem to have the most significant implications for the calculation of one of the 19 CCRs, the Anesthesia CCR. As stated in section II.H.3. of the preamble of the proposed rule (80 FR 24413), the proposed FY 2016 CCR for Anesthesia was 0.108. We calculated this proposed CCR based on the December 31, 2014 update of the FY 2013 HCRIS, with the nonstandard cost center codes of 03020 through 03029 rolled up to standard line 53, “Anesthesiology.” That is, under the CMS’ HCRIS specifications, we rolled up the following 5-digit codes to standard line 53, “Anesthesiology”2: standard codes for “Anesthesiology” 05300 through 05329; and nonstandard codes for “Acupuncture” 03020 through 03029. For simulation purposes, we also created a version of the December 31, 2014 update of the FY 2013 HCRIS which retained nonstandard codes 03020 through 03029 on standard line 76, “Other Ancillary,” where hospitals actually reported them.

2 Ibid.
reported these codes on their as-submitted FY 2013 cost reports. When all reported uses of nonstandard codes 03020 through 03029 remain on standard line 76, “Other Ancillary,” we calculated that the Anesthesia CCR would be 0.084 (instead of 0.108 as proposed in section II.H.3. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule). We also looked at the effect on the other 18 CCRs. In the version of HCRIS we created for simulation purposes, by keeping the nonstandard cost center codes in standard line 76, “Other Ancillary,” where hospitals typically report them, rather than remapping them according to CMS specifications, three other CCRs also were affected, although not quite as significantly as the Anesthesia CCR. As proposed in section II.H.3. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule, the proposed FY 2016 Cardiology CCR was 0.119. However, when all cardiology-related nonstandard codes were rolled up to standard line 76, “Other Ancillary”, and not to standard line 69, “Electrocardiology” as under CMS’ usual practice, the Cardiology CCR was 0.113. In addition, as proposed in section II.H.3. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule, the proposed FY 2016 Radiology CCR was 0.159. However, when all radiology-related nonstandard codes were rolled up to standard line 76, “Other Ancillary”, and not to standard lines 54 (Radiology-Diagnostic), 55 (Radiology-Therapeutic), and 56 (Radioisotope) as under CMS’ usual practice, the Radiology CCR was 0.161. Most notably, the CCR that was most impacted was the “Other Services” CCR. As proposed in section II.H.3. of the preamble of the FY 2016 proposed rule, the “Other Services” CCR was 0.367. However, if all nonstandard cost center codes remained in line 76, “Other Ancillary” as hospitals have reported them in
their FY 2013 as-submitted cost reports, instead of CMS applying its usual practice of rolling up these lines to the applicable “Electrocardiology” and “Radiology” standard cost centers, among others, the “Other Services” CCR was 0.291. We note that we observed minimal or no differences in the remaining 15 CCRs, when their associated nonstandard cost centers were rolled up to their specific standard cost centers, versus being rolled up to the standard line 76, “Other Ancillary.”

The differences in these CCRs computed from the HCRIS that was compiled by applying CMS’ current rollup procedures of assigning nonstandard codes to specific standard cost centers, as compared to following hospitals’ general practice of reporting nonstandard codes “en masse” on line 76, “Other Ancillary,” have implications for the aspects of the IPPS that rely on the CCRs (for example, the calculation of the MS-DRG relative weights). In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24345), we discussed that some questions arise: whether CMS’ procedures for mapping and rolling up nonstandard cost centers to specific standard cost centers should be updated; whether hospital reporting practices are imprecise; or whether there is a combination of both of these questions. CMS’ rollup procedures were developed many years ago based on historical analysis of hospitals’ cost reporting practices and health care services furnished. It may be that it would be appropriate for CMS to reevaluate its rollup procedures based on hospitals’ more current cost reporting practices and contemporary health care services provided. However, one factor complicating the determination of the most accurate standard cost centers to which each respective nonstandard cost center should be mapped is hospitals’ own inconsistent reporting practices. For example, it may
be determined that CMS should no longer be mapping and rolling up nonstandard cost center “Acupuncture” and its associated 5-digit codes 03020 through 03029 to standard cost center line 53, “Anesthesiology.” However, determining which other standard line “Acupuncture” and its associated 5-digit codes 03020 through 03029 should be mapped to is unclear, given that, as mentioned above, out of the 3,172 times that codes 03020 through 03029 were reported in the FY 2013 HCRIS file, hospitals called these codes “Acupuncture” only 122 times, and instead called these codes a variety of other names (such as Cardiopulmonary, Sleep Lab, Wound Care, Diabetes Center, among others). Therefore, without being able to determine the true nature of the services that were actually provided, it is difficult to know which standard cost center to map these services. That is, the question arises as to whether the service provided was acupuncture because a hospital reported code 03020, or whether the service provided was cardiopulmonary, which was the name a hospital assigned to code 03020. Furthermore, if the service provided was in fact cardiopulmonary, then, as Table 5 of Section 4095 of CMS Pub. 15-2 indicates, the correct nonstandard code for cardiopulmonary is 03160, not 03020. A related question would be, if the hospital provided cardiopulmonary services, which are clearly related to cardiology, why did the hospital report those costs and charges on line 76, “Other Ancillary,” instead of subscripting standard line 69, “Electrocardiology,” and reporting the cardiopulmonary costs and charges there.

In summary, we stated in the FY 2016 IPPS/LTCH PPS proposed rule that we believe that the differences between the standard cost centers to which CMS assigns nonstandard codes when CMS rolls up cost report data to create the HCRIS SAS
database, and the standard cost centers to which hospitals tend to assign and use nonstandard codes, coupled with the inconsistencies found in hospitals’ use and naming of the nonstandard codes, have implications for the aspects of the IPPS that rely on the CCRs. For example, we have explained above and provided examples of how the CCRs used to calculate the MS-DRG relative weights could change, based on where certain nonstandard codes are reported and rolled up in the cost reports. However, before considering changes to our longstanding practices, in the proposed rule, we solicited public comments from stakeholders as to how to improve the use of nonstandard cost center codes. We indicated that one option might be for CMS to allow only certain nonstandard codes to be used with certain standard cost centers, meaning that CMS might require that the CMS-approved cost reporting software “lock in” those nonstandard codes with their assigned standard cost centers. For example, if a hospital wishes to subscript a standard cost center, the cost reporting software might allow the hospital to choose only from a predetermined set of nonstandard codes. Therefore, for example, if a hospital wished to report Cardiopulmonary costs and charges on its cost report, the only place that the hospital could do that under this approach would be from a drop down list of cardiology-related services on standard line 69, “Electrocardiology,” and not on another line (not even line 76, “Other Ancillary”). We stated that some flexibility could be maintained, but within certain limits, in consideration of unique services that hospitals might provide.

Below we summarize the public comments that we received in response to our solicitation of comments on nonstandard cost center codes.
Comment: Several commenters expressed concern that issues related to reporting of costs and charges in the nonstandard cost centers could affect the validity of the CCRs used to develop the relative weights. The commenters requested that CMS provide more cost reporting instruction so that the accuracy and validity of the CCRs could be improved, through more detailed examples of how cost report and claims data are used for ratesetting, identifying what revenue codes and services should be associated with specific cost centers, and providing detailed instructions regarding cost allocation methods. The commenters believed that these types of actions would resolve some of the inconsistencies in hospital cost reporting. Several commenters supported more specific guidance and data processing on cost reporting and supported CMS’ idea to “lock in” certain nonstandard codes with specific cost centers in the cost reporting softwares, but wanted to retain flexibility in terms of available options.

Commenters requested that CMS work with stakeholders through methods such as additional engagement with the provider community and convening a technical workgroup to receive stakeholder input. Several commenters requested that CMS provide sufficient advance notice when cost reporting process changes are made, noting that it would take time for hospitals to implement changes to their internal cost reporting processes. The commenters were generally supportive of efforts to improve the cost reporting process and cost estimation accuracy. One commenter stated that inconsistencies in reporting of nonstandard cost centers compound the problems the commenter raised in earlier public comments regarding allocation of capital costs and the new CCRs for MRIs and CT scans. Other commenters stated generally that the use of
distinct CCRs for MRI and CT scans produces “payment rates that lack face validity” and recommended that CMS not finalize the use of the MRI and CT scan CCRs.

Response: We appreciate the input that stakeholders have provided in response to the request for comment on how to improve the use of nonstandard cost center codes. As discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24344 through 24346), we noticed inconsistencies in hospital cost reporting of nonstandard cost centers and were concerned about the implication that some of these discrepancies might have on the aspects of the IPPS that rely on CCRs. However, we did not propose any changes to the methodology or data sources for the FY 2016 CCRs and relative weights.

We appreciate the request that CMS provide more detailed instructions regarding appropriate cost reporting methodologies. We believe that the desire for more specific direction in how to report should be balanced by the need for flexibility in cost reporting based on each hospital’s own internal charge structure. That balance also applies to cost allocation methodologies. As discussed in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50523) and in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50077 through 50079), we encouraged hospitals over the past several years to use the most precise cost reporting methods in response to the new cost report lines such as the MRI and CT scan standard cost centers, which, in most cases, corresponded to the recommended cost allocation statistic. We believe that more precise cost allocation could mitigate concerns related to the accuracy of the MRI and CT scan CCRs. However, we recognized that hospitals have varying resources and capability for assigning costs and charges on the cost report, which is why in most cases we have allowed greater flexibility. As
commenters noted, an instance in which we have specifically provided guidance was in connection with the decision to split the cost center for Medical Supplies Charged to Patients into one line for “Medical Supplies Charged to Patients” and another line for “Implantable Devices Charged to Patients,” where we listed the revenue codes for which charges would properly be associated with these two cost centers (we refer readers to the FY 2009 IPPS/LTCH PPS final rule (73 FR 48462 through 48463). For that specific change to address charge compression in the “Medical Supplies” cost center, the separation between the types of services associated with each cost center is more distinct and therefore more easily identifiable by revenue code, which may not be true of all nonstandard and standard cost centers. Regarding the comments stating that use of distinct CCRs for MRI and CT scans produce “payment rates that lack face validity” and that CMS not finalize use of the MRI and CT scan CCRs, we note that we did not make any proposals regarding the use of the MRI and CT scans in particular in the relative weights calculation for FY 2016. As we have done since FY 2014, we are using the MRI and CT scan CCRs to calculate the IPPS relative weights for FY 2016. We also note that we have previously addressed stakeholder concerns related to the CT scan and MRI standard cost centers in setting the IPPS relative weights. For a detailed discussion of the CT scan and MRI standard cost centers, we refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50520 through 50523), and the FY 2011 IPPS/LTCH PPS final rule (75 FR 50077 through 50079).

We appreciate the comments that stakeholders submitted and will continue to explore ways in which we can improve the accuracy of the cost report data and calculated
CCRs used in the cost estimation process. To the extent possible, we will continue to seek stakeholder input in efforts to limit the impact on providers. In the interim, while we are considering these public comments, as we proposed, we are using the 19 CCRs for FY 2016 (listed in section II.H.3. of the preamble of this final rule) that were calculated from the March 2015 update of the FY 2013 HCRIS, created in accordance with CMS’ current longstanding procedures for mapping and rolling up nonstandard cost center codes. As we did with the FY 2015 IPPS/LTCH PPS final rule, we are providing the version of the HCRIS from which we calculated these 19 CCRs on the FY 2016 IPPS Final Rule Home Page at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page.html.  

3 Ibid.
F. Adjustment to MS-DRGs for Preventable Hospital-Acquired Conditions (HACs),
Including Infections for FY 2016

1. Background

Section 1886(d)(4)(D) of the Act addresses certain hospital-acquired conditions (HACs), including infections. This provision is part of an array of Medicare tools that we are using to promote increased quality and efficiency of care. Under the IPPS, hospitals are encouraged to treat patients efficiently because they receive the same DRG payment for stays that vary in length and in the services provided, which gives hospitals an incentive to avoid unnecessary costs in the delivery of care. In some cases, conditions acquired in the hospital do not generate higher payments than the hospital would otherwise receive for cases without these conditions. To this extent, the IPPS encourages hospitals to avoid complications.

However, the treatment of these conditions can generate higher Medicare payments in two ways. First, if a hospital incurs exceptionally high costs treating a patient, the hospital stay may generate an outlier payment. However, because the outlier payment methodology requires that hospitals experience large losses on outlier cases before outlier payments are made, hospitals have an incentive to prevent outliers.

Second, under the MS-DRG system that took effect in FY 2008 and that has been refined through rulemaking in subsequent years, certain conditions can generate higher payments even if the outlier payment requirements are not met. Under the MS-DRG system, there are currently 261 sets of MS-DRGs that are split into 2 or 3 subgroups based on the presence or absence of a complication or comorbidity (CC) or a major complication or
comorbidity (MCC). The presence of a CC or an MCC generally results in a higher payment.

Section 1886(d)(4)(D) of the Act specifies that, by October 1, 2007, the Secretary was required to select, in consultation with the Centers for Disease Control and Prevention (CDC), at least two conditions that: (a) are high cost, high volume, or both; (b) are assigned to a higher paying MS-DRG when present as a secondary diagnosis (that is, conditions under the MS-DRG system that are CCs or MCCs); and (c) could reasonably have been prevented through the application of evidence-based guidelines. Section 1886(d)(4)(D) of the Act also specifies that the list of conditions may be revised, again in consultation with the CDC, from time to time as long as the list contains at least two conditions.

Effective for discharges occurring on or after October 1, 2008, under the authority of section 1886(d)(4)(D) of the Act, Medicare no longer assigns an inpatient hospital discharge to a higher paying MS-DRG if a selected condition is not present on admission (POA). Thus, if a selected condition that was not POA manifests during the hospital stay, it is considered a HAC and the case is paid as though the secondary diagnosis was not present. However, even if a HAC manifests during the hospital stay, if any nonselected CC or MCC appears on the claim, the claim will be paid at the higher MS-DRG rate. In addition, Medicare continues to assign a discharge to a higher paying MS-DRG if a selected condition is POA. When a HAC is not POA, payment can be affected in a manner shown in the diagram below.
2. HAC Selection

Beginning in FY 2007, we have set forth proposals, and solicited and responded to public comments, to implement section 1886(d)(4)(D) of the Act through the IPPS annual rulemaking process. For specific policies addressed in each rulemaking cycle, including a detailed discussion of the collaborative interdepartmental process and public input regarding selected and potential candidate HACs, we refer readers to the following rules: the FY 2007 IPPS proposed rule (71 FR 24100) and final rule (71 FR 48051 through 48053); the FY 2008 IPPS proposed rule (72 FR 24716 through 24726) and final rule with comment period (72 FR 47200 through 47218); the FY 2009 IPPS proposed rule (73 FR 23547) and final rule (73 FR 48471); the FY 2010 IPPS/RY 2010 LTCH PPS proposed rule (74 FR 24106) and final rule (74 FR 43782); the FY 2011 IPPS/LTCH PPS proposed rule (75 FR 23880) and final rule (75 FR 50080); the FY 2012 IPPS/LTCH PPS
proposed rule (76 FR 25810 through 25816) and final rule (76 FR 51504 through 51522); the FY 2013 IPPS/LTCH PPS proposed rule (77 FR 27892 through 27898) and final rule (77 FR 53283 through 53303); the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27509 through 27512) and final rule (78 FR 50523 through 50527), and the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28000 through 28003) and final rule (79 FR 49876 through 49880). A complete list of the 14 current categories of HACs is included on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/Hospital-Acquired_Conditions.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/Hospital-Acquired_Conditions.html).

3. Present on Admission (POA) Indicator Reporting

Collection of POA indicator data is necessary to identify which conditions were acquired during hospitalization for the HAC payment provision as well as for broader public health uses of Medicare data. In previous rulemaking, we provided both CMS and CDC Web site resources that are available to hospitals for assistance in this reporting effort. For detailed information regarding these sites and materials, including the application and use of POA indicators, we refer the reader to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51506 through 51507).

Currently, as we have discussed in the prior rulemaking cited under section II.I.2. of the preamble of this final rule, the POA indicator reporting requirement only applies to IPPS hospitals and Maryland hospitals because they are subject to this HAC provision. Non-IPPS hospitals, including CAHs, LTCHs, IRFs, IPFs, cancer hospitals, children’s hospitals, RNHCIs, and the Department of Veterans Affairs/Department of Defense hospitals, are exempt from POA reporting.
There are currently four POA indicator reporting options, “Y”, “W”, “N”, and “U”, as defined by the ICD-9-CM Official Guidelines for Coding and Reporting. We note that prior to January 1, 2011, we also used a POA indicator reporting option “1”. However, beginning on or after January 1, 2011, hospitals were required to begin reporting POA indicators using the 5010 electronic transmittal standards format. The 5010 format removes the need to report a POA indicator of “1” for codes that are exempt from POA reporting. We issued CMS instructions on this reporting change as a One-Time Notification, Pub. No. 100-20, Transmittal No. 756, Change Request 7024, effective on August 13, 2010, which can be located at the following link on the CMS Web site: http://www.cms.gov/manuals/downloads/Pub100_20.pdf. The current POA indicators and their descriptors are shown in the chart below:

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>Indicates that the condition was present on admission.</td>
</tr>
<tr>
<td>W</td>
<td>Affirms that the hospital has determined that, based on data and clinical judgment, it is not possible to document when the onset of the condition occurred.</td>
</tr>
<tr>
<td>N</td>
<td>Indicates that the condition was not present on admission.</td>
</tr>
<tr>
<td>U</td>
<td>Indicates that the documentation is insufficient to determine if the condition was present at the time of admission.</td>
</tr>
</tbody>
</table>

Under the HAC payment policy, we treat HACs coded with “Y” and “W” indicators as POA and allow the condition on its own to cause an increased payment at the CC and MCC level. We treat HACs coded with “N” and “U” indicators as Not Present on Admission (NPOA) and do not allow the condition on its own to cause an increased payment at the CC and MCC level. We refer readers to the following rules for
a detailed discussion of POA indicator reporting: the FY 2009 IPPS proposed rule (73 FR 23559) and final rule (73 FR 48486 through 48487); the FY 2010 IPPS/RY 2010 LTCH PPS proposed rule (74 FR 24106) and final rule (74 FR 43784 through 43785); the FY 2011 IPPS/LTCH PPS proposed rule (75 FR 23881 through 23882) and final rule (75 FR 50081 through 50082); the FY 2012 IPPS/LTCH PPS proposed rule (76 FR 25812 through 25813) and final rule (76 FR 51506 through 51507); the FY 2013 IPPS/LTCH PPS proposed rule (77 FR 27893 through 27894) and final rule (77 FR 53284 through 53285); the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27510 through 27511) and final rule (78 FR 50524 through 50525), and the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28001 through 28002) and final rule (79 FR 49877 through 49878).

In addition, as discussed previously in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53324), the 5010 format allows the reporting and, effective January 1, 2011, the processing of up to 25 diagnoses and 25 procedure codes. As such, it is necessary to report a valid POA indicator for each diagnosis code, including the principal diagnosis and all secondary diagnoses up to 25.

4. HACs and POA Reporting in Preparation for Transition to ICD-10-CM and ICD-10-PCS

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51506 and 51507), in preparation for the transition to the ICD-10-CM and ICD-10-PCS code sets, we indicated that further information regarding the use of the POA indicator with the
ICD-10-CM/ICD-10-PCS classifications as they pertain to the HAC policy would be discussed in future rulemaking.

At the March 5, 2012 and the September 19, 2012 meetings of the ICD-9-CM Coordination and Maintenance Committee, an announcement was made with regard to the availability of the ICD-9-CM HAC list translation to ICD-10-CM and ICD-10-PCS code sets. Participants were informed that the list of the ICD-9-CM selected HACs had been translated into codes using the ICD-10-CM and ICD-10-PCS classification system. It was recommended that the public review this list of ICD-10-CM/ICD-10-PCS code translations of the selected HACs available on the CMS Web site at:
http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. We encouraged the public to submit comments on these translations through the HACs Web page using the CMS ICD-10-CM/PCS HAC Translation Feedback Mailbox that was set up for this purpose under the Related Links section titled “CMS HAC Feedback.” We also encouraged readers to review the educational materials and draft code sets available for ICD-10-CM/PCS on the CMS Web site at:
http://www.cms.gov/ICD10/. Lastly, we provided information regarding the ICD-10 MS-DRG Conversion Project on the CMS Web site at:
http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/icd10_hacs.html.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50525), we stated that the final HAC list translation from ICD-9-CM to ICD-10-CM/ICD-10-PCS would be subject to formal rulemaking. We again encouraged readers to review the educational materials and
updated draft code sets available for ICD-10-CM/ICD-10-PCS on the CMS Web site at: http://www.cms.gov/ICD10/. In addition, we stated that the draft ICD-10-CM Coding Guidelines could be viewed on the CDC Web site at: http://www.cdc.gov/nchs/icd/icd10cm.htm.

However, prior to engaging in rulemaking for the FY 2015 DRA HAC program, on April 1, 2014, the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-93) was enacted, which specified that the Secretary may not adopt ICD-10 prior to October 1, 2015. Accordingly, the U.S. Department of Health and Human Services released a final rule in the Federal Register on August 4, 2014 (79 FR 45128 through 45134) that included a new compliance date that requires the use of ICD-10 beginning October 1, 2015. The August 4, 2014 final rule is available for viewing on the Internet at: http://www.gpo.gov/fdsys/pkg/FR-2014-08-04/pdf/2014-18347.pdf. That final rule also requires HIPAA covered entities to continue to use ICD-9-CM through September 30, 2015. Further information on the ICD-10 rules can be found on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD10/Statute_Regulations.html.

As described in section II.F.5. of the preamble of this final rule, we are implementing the HAC list translations from ICD-9-CM to ICD-10-CM/ICD-10-PCS in this FY 2016 IPPS/LTCH PPS final rule.

5. Changes to the HAC Program for FY 2016

As discussed in section II.G. 1. a. of the preamble of this final rule, for FY 2016, we are implementing the ICD-10 MS-DRGs Version 33 as the replacement logic for the ICD-9-CM MS-DRGs Version 32. As part of our DRA HAC update for FY 2016, we
proposed to implement the ICD-10-CM/PCS Version 33 HAC list to replace the ICD-9-CM Version 32 HAC list.

CMS prepared the ICD-10 MS-DRGs Version 32 based on the FY 2015 MS-DRGs (Version 32) that we finalized in the FY 2015 IPPS/LTCH PPS final rule. In November 2014, we posted a Definitions Manual of the ICD-10 MS-DRGs Version 32 on the ICD-10 MS-DRG Conversion Project Web site at: http://www.cms.hhs.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. The HAC code list translations from ICD-9-CM to ICD-10-CM/PCS are located in Appendix I of the ICD-10-CM/PCS MS-DRG Version 32 Definitions Manual. The link to this Manual (available in both text and HTML formats) is located in the Downloads section of the ICD-10 MS-DRG Conversion Project Web site.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24348 through 24349), we solicited public comments on how well the ICD-10-CM/PCS Version 32 HAC list replicates the ICD-9-CM Version 32 HAC list. We did not receive any public comments on our list of ICD-10 translations for the HAC list. Therefore, we are finalizing our proposal to implement the ICD-10-CM/PCS Version 33 HAC list to replace the ICD-9-CM Version 32 HAC list.

With respect to the current categories of the HACs, in the FY 2016 IPPS/LTCH PPS proposed rule, we did not propose to add or remove any categories for FY 2016.

Comment: Two commenters suggested that CMS expand the current HAC category of Iatrogenic Pneumothorax with Venous Catheterization to include Iatrogenic Pneumothorax with Thoracentesis and to also add Accidental Puncture/Bleeding with
Paracentesis as a HAC category. The commenters cited various studies and asserted that both of these conditions satisfy the established criteria of being high cost, high volume, or both; being assigned to a higher paying MS-DRG when present as a secondary diagnosis (that is, conditions under the MS-DRG system that are CCs or MCCs); and could reasonably have been prevented through the application of evidence-based guidelines. Both commenters also listed a series of ICD-10-CM and ICD-10-PCS codes that they requested CMS to consider for inclusion in each of these recommended new HAC categories. The commenters believed that adding these two conditions would improve patient care and result in cost savings to the Medicare program.

Response: We recognize and appreciate the commenters’ recommendations for refinements to the HAC list. We also thank the commenters for their commitment to working with CMS on reducing complications resulting in better patient care and cost savings. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49879), we responded to similar comments and noted that we would take them under consideration for future rulemaking. While we did not propose to expand or add these specific HAC categories (Iatrogenic Pneumothorax with Thoracentesis and Accidental Puncture/Bleeding with Paracentesis) for FY 2016, in response to a public comment received last year, we did engage our contractor, RTI, to begin researching available evidence-based guidelines for these conditions. As discussed in section II.F.7. of the preamble to this final rule, RTI has completed their annual evidence-based guidelines report and, in addition, has developed a separate excerpt report that summarizes the two conditions recommended by the commenters under consideration. We encourage readers to review the separate
document titled, “Evidence-based Guidelines Pertaining to Select Thoracentesis- and Paracentesis-Related Conditions,” which is available via the Internet on the CMS Hospital-Acquired Conditions Web page in the “Downloads” section at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/index.html?redirect=/HospitalAcqCond/. We reiterate that we continue to encourage public dialogue about refinements to the HAC list through written stakeholder comments.

We were unable to fully evaluate each of these two recommended conditions against all the established criteria, as well as review the references the commenters submitted, or perform detailed analysis of the ICD-10 codes that the commenters listed in time for discussion in this FY 2016 IPPS/LTCH PPS final rule. However, we intend to consider these public comments as we develop proposed changes to the HAC-POA program for FY 2017.

Comment: One commenter urged CMS to remove the Falls and Trauma HAC category from the HAC-POA program. The commenter stated that the statutory criterion that a condition could reasonably have been prevented through the application of evidence-based guidelines is not met for preventing falls. The commenter also stated that this HAC may lead to unintended consequences such as “creating an epidemic of immobility in hospitals” and excessive orders for bed rest and motion detection devices. The commenter recommended that CMS develop quality measures and incentivize hospitals to create Acute Care for Elders (ACE) units that focus on this specific population as another option. According to the commenter, studies of the ACE initiative
determined better outcomes. For example, the commenter noted results of the ACE program model indicated a reduction in falls, delirium, and functional decline for patients, as well as shorter lengths of stay in a hospital, a decrease in the number of discharges to a nursing home, a reduction in 30-day readmissions, and reduced health care costs.

Response: We acknowledge the commenter’s comments regarding the Falls and Trauma HAC category. With respect to the commenter’s statement that one of the statutory criteria (that is, could reasonably have been prevented through the application of evidence-based guidelines) is not being met for the prevention of falls, we note that, as mentioned in response to an earlier comment, our contractor, RTI, has completed the 2015 Report for Evidence-Based Guidelines, which is available via the Internet on the CMS Hospital-Acquired Conditions Web page in the “Downloads” section at:

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/index.html?redirect=/HospitalAcqCond/.

We further note that evidence-based guidelines for falls prevention exist and refer the reader to the findings in this report directly related to falls. We also point out that, while the commenter requested the removal of the entire Falls and Trauma HAC category, falls are only one component (or condition) in the HAC category. The Falls and Trauma HAC category also includes conditions related to trauma, such as intracranial injuries, crushing injuries, burns, and other injuries (for example, frostbite, heat stroke, drowning, and suffocation). Therefore, we do not agree with the commenter’s suggestion to remove the Falls and Trauma HAC category from the HAC-POA program.
In response to the commenter’s recommendation that CMS establish quality measures and incentive payments for hospitals, we point out that currently, under various CMS quality reporting programs, there are measures specifically related to falls. On October 6, 2014, the Improving Medicare Post-Acute Care Transformation Act of 2014 (the IMPACT Act) (Pub. L. 113-185) was enacted, which specified under section 1899B(c)(1) of the Act that the Secretary shall require postacute care providers to report data on quality measures relating to functional status, skin integrity, medication reconciliation and incidence of major falls. Prior to the IMPACT Act, the NQF #0674 measure, Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay), was finalized in the LTCHQR Program and the IRF QR Program. As such, we believe these measures specified in the IMPACT Act align with the CMS Quality Strategy,\(^4\) which incorporates the three broad aims of the National Quality Strategy\(^5\):

- **Better Care**: Improve the overall quality of care by making healthcare more patient-centered, reliable, accessible and safe;

- **Healthy People, Healthy Communities**: Improve the health of the U.S. population by supporting proven interventions to address behavioral, social and environmental determinants of health in addition to delivering higher-quality care; and

- **Affordable Care**: Reduce the cost of quality healthcare for individuals, families, employers, and government.


Comment: One commenter requested that CMS incorporate untreated malnutrition, including disease-related malnutrition, as a HAC category. The commenter indicated there are three common types of malnutrition diagnoses that can be attributed to adults in healthcare settings: (1) starvation-relation malnutrition; (2) chronic disease-related malnutrition; and (3) acute disease or injury-related malnutrition. The commenter also noted that hospital-acquired malnutrition from inadequate feeding practices is widespread. According to the commenter, screening patients for the detection of malnutrition allows for further follow-up sessions if warranted. In addition, the commenter stated that, through the process of early detection, the prevention and treatment for disease-related malnutrition will lead to improved outcomes such as patients acquiring fewer complications, hospitalizations, and readmissions.

The commenter suggested that CMS also advocate for the creation of quality measures that encourage nutrition screening, assessment, and intervention to be included in various quality reporting programs or other agency initiatives that focus on measuring quality of care.

Response: We appreciate the commenter’s suggestion. As stated previously, we did not propose to add or remove any HAC categories for FY 2016. Therefore, we will consider this topic for future rulemaking. We encourage the commenter to submit the specific list of conditions, including the ICD-10 coded data identifying the various types of malnutrition that the commenter is recommending as a candidate condition, along with any additional supporting documentation, for the other established criteria for a HAC as referenced earlier in this section.
With regard to the commenter’s recommendation to develop quality measures related to malnutrition in other quality reporting programs, we note that the quality reporting programs that involve measures are separate and distinct from the Deficit Reduction Act (DRA) HAC program. We refer the reader to section VII. of this FY 2016 IPPS/LTCH PPS final rule for information related to those programs.

We also refer readers to section II.F.6. of the FY 2008 IPPS final rule with comment period (72 FR 47202 through 47218) and to section II.F.7. of the FY 2009 IPPS final rule (73 FR 48774 through 48491) for detailed discussion supporting our determination regarding each of the current conditions. We refer readers to the FY 2013 IPPS/LTCH PPS proposed rule (77 FR 27892 through 27898) and final rule (77 FR 53285 through 53292) for the HAC policy for FY 2013, the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27509 through 27512) and final rule (78 FR 50523 through 50527) for the HAC policy for FY 2014, and the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28000 through 28003) and final rule (79 FR 49876 through 49880) for the HAC policy for FY 2015.

After consideration of the public comments we received, as we proposed, we are not adding or removing any HAC categories for FY 2016. However, as described more fully in section III.F.7. of the preamble of this final rule, we will continue to monitor contemporary evidence-based guidelines for selected, candidate, and previously considered HACs that provide specific recommendations for the prevention of the corresponding conditions in the acute hospital setting and may use this information to
inform future rulemaking. In addition, we continue to encourage public dialogue about refinements to the HAC list through written stakeholder comments.

6. RTI Program Evaluation

On September 30, 2009, a contract was awarded to RTI to evaluate the impact of the Hospital-Acquired Condition-Present on Admission (HAC-POA) provisions on the changes in the incidence of selected conditions, effects on Medicare payments, impacts on coding accuracy, unintended consequences, and infection and event rates. This was an intra-agency project with funding and technical support from CMS, OPHS, AHRQ, and CDC. The evaluation also examined the implementation of the program and evaluated additional conditions for future selection. The contract with RTI ended on November 30, 2012. Summary reports of RTI’s analysis of the FYs 2009, 2010, and 2011 Med PAR data files for the HAC-POA program evaluation were included in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50085 through 50101), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51512 through 51522), and the FY 2013 IPPS/LTCH PPS final rule (77 FR 53292 through 53302). Summary and detailed data also were made publicly available on the CMS Web site at: 
http://www.cms.gov/HospitalAcqCond/01_Overview.asp and the RTI Web site at: 

In addition to the evaluation of HAC and POA Med PAR claims data, RTI also conducted analyses on readmissions due to HACs, the incremental costs of HACs to the health care system, a study of spillover effects and unintended consequences, as well as an updated analysis of the evidence-based guidelines for selected and previously
considered HACs. Reports on these analyses have been made publicly available on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/index.html.

7. RTI Reports on Evidence-Based Guidelines

The RTI program evaluation included a report that provided references for all evidence-based guidelines available for each of the selected, candidate, and previously considered HACs that provided specific recommendations for the prevention of the corresponding conditions. Guidelines were primarily identified using the AHRQ National Guidelines Clearing House (NGCH) and the CDC, along with relevant professional societies. Guidelines published in the United States were used, if available. In the absence of U.S. guidelines for a specific condition, international guidelines were included.

RTI prepared a final report to summarize its findings regarding these guidelines. This report is titled “Evidence-Based Guidelines for Selected, Candidate, and Previously Considered Hospital-Acquired Conditions” and can be found on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/Downloads/Evidence-Based-Guidelines.pdf.

Subsequent to this final report, RTI was awarded a new Evidence-Based Guidelines Monitoring contract. Under this monitoring contract, RTI annually provides a summary report of the contemporary evidence-based guidelines for selected, candidate, and previously considered HACs that provide specific recommendations for the prevention of the corresponding conditions in the acute care hospital setting. We
received RTI’s 2015 report and are making it available to the public on the CMS Hospital-Acquired Conditions Web page in the “Downloads” section at:

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/index.html?redirect=/HospitalAcqCond/.
G. Changes to Specific MS-DRG Classifications

1. Discussion of Changes to Coding System and Basis for MS-DRG Updates

a. Conversion of MS-DRGs to the International Classification of Diseases, 10th Revision (ICD-10)

Providers use the code sets under the ICD-9-CM coding system to report diagnoses and procedures for Medicare hospital inpatient services under the MS-DRG system. A later coding edition, the ICD-10 coding system, includes the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) for diagnosis coding and the International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) for inpatient hospital procedure coding, as well as the Official ICD-10-CM and ICD-10-PCS Guidelines for Coding and Reporting. The ICD-10 coding system was initially adopted for transactions conducted on or after October 1, 2013, as described in the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Administrative Simplification: Modifications to Medical Data Code Set Standards to Adopt ICD-10-CM and ICD-10-PCS Final Rule published in the Federal Register on January 16, 2009 (74 FR 3328 through 3362) (hereinafter referred to as the “ICD-10-CM and ICD-10-PCS final rule”). However, the Secretary of Health and Human Services issued a final rule that delayed the compliance date for ICD-10 from October 1, 2013, to October 1, 2014. That final rule, entitled “Administrative Simplification: Adoption of a Standard for a Unique Health Plan Identifier; Addition to the National Provider Identifier Requirements; and a Change to the Compliance Date for ICD-10-CM and ICD-10-PCS Medical Data Code Sets,” CMS-0040-F, was published in

The anticipated move to ICD-10 necessitated the development of an ICD-10-CM/ICD-10-PCS version of the MS-DRGs. CMS began a project to convert the ICD-9-CM-based MS-DRGs to ICD-10 MS-DRGs. In response to the FY 2011 IPPS/LTCH PPS proposed rule, we received public comments on the creation of the ICD-10 version of the MS-DRGs, which will be implemented at the same time as ICD-10 (75 FR 50127 and 50128). While we did not propose an ICD-10 version of the MS-DRGs in the FY 2011 IPPS/LTCH PPS proposed rule, we noted that we have been actively involved in converting current MS-DRGs from ICD-9-CM codes to ICD-10 codes and sharing this information through the ICD-10 (previously ICD-9-CM) Coordination and Maintenance Committee. We undertook this early conversion project to assist other payers and providers in understanding how to implement their own
conversion projects. We posted ICD-10 MS-DRGs based on Version 26.0 (FY 2009) of the MS-DRGs. We also posted a paper that describes how CMS went about completing this project and suggestions for other payers and providers to follow. Information on the ICD-10 MS-DRG conversion project can be found on the ICD-10 MS-DRG Conversion Project Web site at: http://www.cms.hhs.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. We have continued to keep the public updated on our maintenance efforts for ICD-10-CM and ICD-10-PCS coding systems, as well as the General Equivalence Mappings that assist in conversion through the ICD-10 (previously ICD-9-CM) Coordination and Maintenance Committee. Information on these committee meetings can be found on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html.

During FY 2011, we developed and posted Version 28 of the ICD-10 MS-DRGs based on the FY 2011 MS-DRGs (Version 28) that we finalized in the FY 2011 IPPS/LTCH PPS final rule on the CMS Web site. This ICD-10 MS-DRGs Version 28 also included the CC Exclusion List and the ICD-10 version of the hospital-acquired conditions (HACs), which was not posted with Version 26. We also discussed this update at the September 15-16, 2010 and the March 9-10, 2011 meetings of the ICD-9-CM Coordination and Maintenance Committee. The minutes of these two meetings are posted on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html.

We reviewed public comments on the ICD-10 MS-DRGs Version 28 and made updates as a result of these comments. We called the updated version the ICD-10
MS-DRGs Version 28-R1. We posted a Definitions Manual of ICD-10 MS-DRGs Version 28-R1 on our ICD-10 MS-DRG Conversion Project Web site. To make the review of Version 28-R1 updates easier for the public, we also made available pilot software on a CD ROM that could be ordered through the National Technical Information Service (NTIS). A link to the NTIS ordering page was provided on the CMS ICD-10 MS-DRGs Web page. We stated that we believed that, by providing the ICD-10 MS-DRGs Version 28-R1 Pilot Software (distributed on CD ROM), the public would be able to more easily review and provide feedback on updates to the ICD-10 MS-DRGs.

We discussed the updated ICD-10 MS-DRGs Version 28-R1 at the September 14, 2011 ICD-9-CM Coordination and Maintenance Committee meeting. We encouraged the public to continue to review and provide comments on the ICD-10 MS-DRGs so that CMS could continue to update the system.

In FY 2012, we prepared the ICD-10 MS-DRGs Version 29, based on the FY 2012 MS-DRGs (Version 29) that we finalized in the FY 2012 IPPS/LTCH PPS final rule. We posted a Definitions Manual of ICD-10 MS-DRGs Version 29 on our ICD-10 MS-DRG Conversion Project Web site. We also prepared a document that describes changes made from Version 28 to Version 29 to facilitate a review. The ICD-10 MS-DRGs Version 29 was discussed at the ICD-9-CM Coordination and Maintenance Committee meeting on March 5, 2012. Information was provided on the types of updates made. Once again, the public was encouraged to review and comment on the most recent update to the ICD-10 MS-DRGs.
CMS prepared the ICD-10 MS-DRGs Version 30 based on the FY 2013 MS-DRGs (Version 30) that we finalized in the FY 2013 IPPS/LTCH PPS final rule. We posted a Definitions Manual of the ICD-10 MS-DRGs Version 30 on our ICD-10 MS-DRG Conversion Project Web site. We also prepared a document that describes changes made from Version 29 to Version 30 to facilitate a review. We produced mainframe and computer software for Version 30, which was made available to the public in February 2013. Information on ordering the mainframe and computer software through NTIS was posted on the ICD-10 MS-DRGs Conversion Project Web site. The ICD-10 MS-DRGs Version 30 computer software facilitated additional review of the ICD-10 MS-DRGs conversion.

We provided information on a study conducted on the impact of converting MS-DRGs to ICD-10. Information on this study is summarized in a paper entitled “Impact of the Transition to ICD-10 on Medicare Inpatient Hospital Payments.” This paper was posted on the CMS ICD-10 MS-DRGs Conversion Project Web site and was distributed and discussed at the September 15, 2010 ICD-9-CM Coordination and Maintenance Committee meeting. The paper described CMS’ approach to the conversion of the MS-DRGs from ICD-9-CM codes to ICD-10 codes. The study was undertaken using the ICD-9-CM MS-DRGs Version 27 (FY 2010), which was converted to the ICD-10 MS-DRGs Version 27. The study estimated the impact on aggregate payment to hospitals and the distribution of payments across hospitals. The impact of the conversion from ICD-9-CM to ICD-10 on Medicare MS-DRG hospital payments was estimated.
using FY 2009 Medicare claims data. The study found a hospital payment increase of 0.05 percent using the ICD-10 MS-DRGs Version 27.

CMS provided an overview of this hospital payment impact study at the March 5, 2012 ICD-9-CM Coordination and Maintenance Committee meeting. This presentation followed presentations on the creation of ICD-10 MS-DRGs Version 29. A summary report of this meeting can be found on the CMS Web site at: 

http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html. At the March 2012 meeting, CMS announced that it would produce an update on this impact study based on an updated version of the ICD-10 MS-DRGs. This update of the impact study was presented at the March 5, 2013 ICD-9-CM Coordination and Maintenance Committee meeting. The study found that moving from an ICD-9-CM-based system to an ICD-10 MS-DRG replicated system would lead to DRG reassignments on only 1 percent of the 10 million MedPAR sample records used in the study. Ninety-nine percent of the records did not shift to another MS-DRG when using an ICD-10 MS-DRG system. For the 1 percent of the records that shifted, 45 percent of the shifts were to a higher weighted MS-DRG, while 55 percent of the shifts were to lower weighted MS-DRGs. The net impact across all MS-DRGs was a reduction by 4/10000 or minus 4 pennies per $100. The updated paper is posted on the CMS Web site at:

http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html under the “Downloads” section. Information on the March 5, 2013 ICD-9-CM Coordination and Maintenance Committee meeting can be found on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/ICD-
9-CM-C-and-M-Meeting-Materials.html. This update of the impact paper and the ICD-10 MS-DRG Version 30 software provided additional information to the public who were evaluating the conversion of the MS-DRGs to ICD-10 MS-DRGs.

CMS prepared the ICD-10 MS-DRGs Version 31.0 based on the FY 2014 MS-DRGs (Version 31) that we finalized in the FY 2014 IPPS/LTCH PPS final rule. In November 2013, we posted a Definitions Manual of the ICD-10 MS-DRGs Version 31 on the ICD-10 MS-DRG Conversion Project Web site at:

http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. We also prepared a document that described changes made from Version 30 to Version 31 to facilitate a review. We produced mainframe and computer software for Version 31, which was made available to the public in December 2013. Information on ordering the mainframe and computer software through NTIS was posted on the CMS Web site at:

http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html under the “Related Links” section. This ICD-10 MS-DRGs Version 31 computer software facilitated additional review of the ICD-10 MS-DRGs conversion. We encouraged the public to submit to CMS any comments on areas where they believed the ICD-10 MS-DRGs did not accurately reflect grouping logic found in the ICD-9-CM MS-DRGs Version 31.

We reviewed public comments received and developed an update of ICD-10 MS-DRGs Version 31, which we called ICD-10 MS-DRGs Version 31.0-R. We made available a Definitions Manual of the ICD-10 MS-DRGs Version 31.0-R on the ICD-10 MS-DRG Conversion Project Web site at:
http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. We also prepared a document that describes changes made from Version 31 to Version 31-R to facilitate a review. We will continue to share ICD-10-MS-DRG conversion activities with the public through this Web site.

CMS prepared the ICD-10 MS-DRGs Version 32 based on the FY 2015 MS-DRGs (Version 32) that we finalized in the FY 2015 IPPS/LTCH PPS final rule. In November 2014, we made available a Definitions Manual of the ICD-10 MS DRGs Version 32 on the ICD-10 MS-DRG Conversion Project Web site at: http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. We also prepared a document that described changes made from Version 31-R to Version 32 to facilitate a review. We produced mainframe and computer software for Version 32, which was made available to the public in January 2015. Information on ordering the mainframe and computer software through NTIS was made available on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html under the “Related Links” section. This ICD-10 MS-DRGs Version 32 computer software facilitated additional review of the ICD-10 MS-DRGs conversion. We encouraged the public to submit to CMS any comments on areas where they believed the ICD-10 MS-DRGs did not accurately reflect grouping logic found in the ICD-9-CM MS-DRGs Version 32. We discuss five requests from the public to update the ICD-10 MS-DRGs Version 32 to better replicate the ICD-9-CM MS-DRGs in section II.G.3., 4., and 5. of the preamble of this FY 2016 IPPS/LTCH PPS final rule. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24351), we proposed to
implement the MS-DRG code logic in the ICD-10 MS-DRGs Version 32 along with any finalized updates to the ICD-10 MS-DRGs Version 32 for the final ICD-10 MS-DRGs Version 33. In the proposed rule, we proposed the ICD-10 MS-DRGs Version 33 as the replacement logic for the ICD-9-CM based MS-DRGs Version 32 as part of the proposed MS-DRG updates for FY 2016. We invited public comments on how well the ICD-10 MS-DRGs Version 32 replicates the logic of the MS-DRGs Version 32 based on ICD-9-CM codes.

Comment: One commenter addressed an ICD-10 MS-DRG replication issue regarding the procedure code designation and MS-DRG assignment of two ICD-10-PCS codes in the ICD-10 MS-DRGs Version 32 Definitions Manual under Appendix E - Operating Room Procedures and Procedure Code MS-DRG Index. The commenter agreed with CMS that the two ICD-10-PCS codes identified in the FY 2016 IPPS/LTCH PPS proposed rule, 02HQ30Z (Insertion of pressure sensor monitoring device into right pulmonary artery, percutaneous approach) and 02HR30Z (Insertion of pressure sensor monitoring device into left pulmonary artery, percutaneous approach), were appropriate translations for ICD-9-CM procedure code 38.26 (Insertion of implantable wireless pressure sensor without lead for intracardiac or great vessel hemodynamic monitoring), which identifies the CardioMEMSTM HF Monitoring System (80 FR 24426). However, the commenter noted that, under the ICD-9-CM based MS-DRGs Version 32 logic, procedure code 38.26 is designated as an operating room (O.R.) procedure for MS-DRG assignment and group to MS-DRG 264 (Other Circulatory O.R. Procedures), while under the ICD-10 based MS-DRGs Version 32 logic, the two ICD-10-PCS code translations are
not recognized as O.R. procedures for purposes of MS-DRG assignment. Therefore, the commenter requested that the two ICD-10-PCS codes be designated as O.R. procedures within Appendix E of the ICD-10 MS-DRG Definitions Manual and group to ICD-10 MS-DRG 264 to accurately replicate the ICD-9-CM MS-DRG Version 32 logic.

Response: We agree with the commenter that this is an ICD-10 MS-DRG replication error. ICD-10-PCS codes 02HQ30Z and 02HR30Z, along with the other ICD-10-PCS codes describing the insertion of a pressure sensor monitoring device that are also appropriate translations for ICD-9-CM procedure code 38.26, should be designated as O.R. procedures within Appendix E of the ICD-10 MS-DRG Definitions Manual and assigned to ICD-10 MS-DRG 264 to accurately replicate the ICD-9-CM MS-DRGs Version 32 logic. These other ICD-10-PCS codes describe the insertion of a pressure sensor monitoring device utilizing an open approach or a percutaneous endoscopic approach (for the right or left pulmonary artery). Therefore, to be consistent with the comparable ICD-10-PCS code translations describing a percutaneous approach and to accurately replicate the ICD-9-CM MS-DRGs Version 32 logic for ICD-9-CM procedure code 38.26, the ICD-10-PCS codes listed below that describe the insertion of a pressure sensor monitoring device utilizing an open approach or a percutaneous endoscopic approach (for the right or left pulmonary artery) should also be designated as O.R. procedures and assigned to ICD-10 MS-DRG 264.

After consideration of the public comments we received, as final policy for the FY 2016 ICD-10 MS-DRGs Version 33, we are designating the following ICD-10-PCS codes as O.R. procedures and assigning them to ICD-10 MS-DRG 264:
- 02HQ00Z (Insertion of pressure sensor monitoring device into right pulmonary artery, open approach);
- 02HQ30Z (Insertion of pressure sensor monitoring device into right pulmonary artery, percutaneous approach);
- 02HQ40Z (Insertion of pressure sensor monitoring device into right pulmonary artery, percutaneous endoscopic approach);
- 02HR00Z (Insertion of pressure sensor monitoring device into left pulmonary artery, open approach);
- 02HR30Z (Insertion of pressure sensor monitoring device into left pulmonary artery, percutaneous approach); and
- 02HR40Z (Insertion of pressure sensor monitoring device into left pulmonary artery, percutaneous endoscopic approach).

**Comment:** One commenter addressed an ICD-10 MS-DRG replication issue concerning excisional debridements of deep pressure ulcers of the ankle. The commenter recommended that the following two ICD-10-PCS codes be added to ICD-10 MS-DRG 581 (Other Skin, Subcutaneous Tissue and Breast Procedures without CC/MCC) to accurately replicate the ICD-9-CM MS-DRG logic: ICD-10-PCS procedure code 0LBT0ZZ (Excision of left ankle tendon, open approach) and ICD-10-PCS procedure code 0LBS0ZZ (Excision of right ankle tendon, open approach). The commenter stated that the ICD-9-CM procedure codes describing the excisional debridements of pressure ulcers that extend down into the ankle tendon are currently assigned to MS-DRG 581.
However, the ICD-10-PCS codes capturing these procedures are not in the ICD-10-PCS MS-DRG 581.

Response: We agree with the commenter that this is an ICD-10 MS-DRG replication error. ICD-9-CM code 83.39 (Excision of lesion of other soft tissue) captures this procedure and is assigned to ICD-9 MS-DRGs 579, 580, and 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC, and without CC/MCC, respectively). Therefore, ICD-10-PCS codes 0LBT0ZZ and 0LBS0ZZ also should be assigned to ICD-10 MS-DRGs 579, 580, and 581.

After consideration of the public comments received, we are assigning ICD-10-PCS procedure codes 0LBT0ZZ (Excision of left ankle tendon, open approach) and 0LBS0ZZ (Excision of right ankle tendon, open approach) to ICD-10 MS-DRGs 579, 580, and 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC, and without CC/MCC, respectively).

Comment: One commenter addressing an ICD-10 MS-DRG replication issue requested that CMS add the following four post-delivery procedure codes to the ICD-10 version of MS-DRGs 774 and 775 (Vaginal Delivery with and without Complicating Diagnoses, respectively) under the “Only Operating Room Procedures” section. The commenter stated that these codes are currently assigned to the ICD-9-CM version of MS-DRGs 774 and 775.

- 0HBJXZZ (Excision of left upper leg skin, external approach);
- 0DQR0ZZ (Repair anal sphincter, open approach (3rd degree obstetrical laceration repair));
● OUQJXZZ (Repair clitoris, external approach); and

● 0UBMXZZ (Excision of vulva, external approach).

The following table shows the equivalent ICD-9-CM codes provided by the requestor.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0UBMXZZ (Excision of vulva, external approach)</td>
<td>71.3 (Other local excision or destruction of vulva and perineum)</td>
</tr>
<tr>
<td>0DQR0ZZ (Repair anal sphincter, open approach (3rd degree obstetrical laceration repair)</td>
<td>75.61 (Repair of current obstetric laceration of rectum and sphincter ani)</td>
</tr>
<tr>
<td>0UQJXZZ (Repair clitoris, external approach)</td>
<td>75.69 (Repair of current obstetric laceration)</td>
</tr>
<tr>
<td>0HBJXZZ (Excision of left upper leg skin, external approach)</td>
<td>86.3 (Local excision/destruction of lesion/tissue of skin and subcutaneous tissues)</td>
</tr>
</tbody>
</table>

Response: We examined the list of post-delivery procedure codes in ICD-9 MS-DRGs 774 and 775 under the “Only Operating Room Procedures” section and found that ICD-9-CM procedure code 71.3 is included. Therefore, we agree with the commenter that this oversight is a replication error and that ICD-10-PCS procedure code 0UBMXZZ should be assigned to ICD-10 MS-DRGs 774 and 775 under the “Only Operating Room Procedures” section. However, with regard to ICD-9-CM procedure codes 75.61, 75.69, and 86.3, when we examined the list of post-delivery procedure codes in MS-DRGs 774 and 775 under the “Only Operating Room Procedures” section, we found that they were not included. Therefore, we disagree with adding ICD-10-PCS codes 0DQR0ZZ, 0UQJXZZ, and 0HBJXZZ to ICD-10 MS-DRGs 774 and 775 under the “Only operating room Procedures” section because these procedures are not currently
captured in ICD-9 MS-DRGs 774 and 775. The omission of these three ICD-10-PCS codes is not an ICD-10 MS-DRG replication error.

After consideration of the public comments received, we are assigning ICD-10-PCS code 0UBMXZZ (Excision of vulva, external approach) to ICD-10 MS-DRGs 774 and 775 (Vaginal Delivery with and without Complicating Diagnoses, respectively) under the “Only Operating Room Procedures” section.

b. Basis for FY 2016 MS-DRG Updates

CMS encourages input from our stakeholders concerning the annual IPPS updates when that input is made available to us by December 7 of the year prior to the next annual proposed rule update. For example, to be considered for any updates or changes in FY 2016, comments and suggestions should have been submitted by December 7, 2014. The comments that were submitted in a timely manner for FY 2016 are discussed below in this section.

Following are the changes we proposed to the MS-DRGs and our finalized policies for FY 2016. We invited public comments on each of the MS-DRG classification proposed changes described below, as well as our proposals to maintain certain existing MS-DRG classifications, which also are discussed below. In some cases, we proposed changes to the MS-DRG classifications based on our analysis of claims data. In other cases, we proposed to maintain the existing MS-DRG classification based on our analysis of claims data. For the FY 2016 proposed rule, our MS-DRG analysis was based on claims data from the December 2014 update of the FY 2014 MedPAR file, which contains hospital bills received through September 30, 2014, for discharges
occurring through September 30, 2014. In our discussion of the MS-DRG reclassification changes that follows, we refer to our analysis of claims data from the “December 2014 update of the FY 2014 MedPAR file.”

As explained in previous rulemaking (76 FR 51487), in deciding whether to propose and to make further modification to the MS-DRGs for particular circumstances brought to our attention, we consider whether the resource consumption and clinical characteristics of the patients with a given set of conditions are significantly different than the remaining patients in the MS-DRG. We evaluate patient care costs using average costs and lengths of stay and rely on the judgment of our clinical advisors to decide whether patients are clinically distinct or similar to other patients in the MS-DRG. In evaluating resource costs, we consider both the absolute and percentage differences in average costs between the cases we select for review and the remainder of cases in the MS-DRG. We also consider variation in costs within these groups; that is, whether observed average differences are consistent across patients or attributable to cases that are extreme in terms of costs or length of stay, or both. Furthermore, we consider the number of patients who will have a given set of characteristics and generally prefer not to create a new MS-DRG unless it would include a substantial number of cases.

In our examination of the claims data, we apply the following criteria established in FY 2008 (72 FR 47169) to determine if the creation of a new complication or comorbidity (CC) or major complication or comorbidity (MCC) subgroup within a base MS-DRG is warranted:

- A reduction in variance of costs of at least 3 percent.
● At least 5 percent of the patients in the MS-DRG fall within the CC or MCC subgroup.
● At least 500 cases are in the CC or MCC subgroup.
● There is at least a 20-percent difference in average costs between subgroups.
● There is a $2,000 difference in average costs between subgroups.

In order to warrant creation of a CC or MCC subgroup within a base MS-DRG, the subgroup must meet all five of the criteria.

2. MDC 1 (Diseases and Disorders of the Nervous System): Endovascular Embolization (Coiling) Procedures

We received a request again this year to change the MS-DRG assignment for endovascular embolization (coiling) procedures. This topic was discussed previously in the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28005 through 28006) and in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49883 through 49886). For FY 2015, we did not change the MS-DRG assignment for endovascular embolization (coiling) procedures.

After issuance of the FY 2015 IPPS/LTCH PPS final rule, we received a modified request from the commenter asking that CMS consider establishing four new MS-DRGs:

● Recommended MS-DRG XXX (Endovascular Intracranial Embolization Procedures with Principal Diagnosis of Hemorrhage);
● Recommended MS-DRG XXX (Endovascular Intracranial Embolization Procedures without Principal Diagnosis of Hemorrhage with MCC);
● Recommended MS-DRG XXX (Endovascular Intracranial Embolization Procedures without Principal Diagnosis of Hemorrhage with CC); and
Recommended MS-DRG XXX (Endovascular Intracranial Embolization Procedures without Principal Diagnosis of Hemorrhage without CC/MCC).

The requestor stated that establishing these new suggested MS-DRGs will promote clinical cohesiveness and resource comparability. The requestor stated that endovascular intracranial and endovascular embolization procedures are not similar to the open craniotomy procedures with which they are currently grouped. The requestor asserted that the differences in costs between endovascular intracranial procedures and open craniotomy procedures are significant, reflecting, for instance, the use of an operating suite versus an interventional vascular catheterization laboratory suite, intensive care and other costs.

In conjunction with the recommended new MS-DRGs, the requestor recommended that the following ICD-9-CM codes, which include endovascular embolization procedures and additional intracranial procedures, be removed from MS-DRG 020 (Intracranial Vascular Procedures with Principal Diagnosis of Hemorrhage with MCC); MS-DRG 021 (Intracranial Vascular Procedures with Principal Diagnosis of Hemorrhage with CC); MS-DRG 022 (Intracranial Vascular Procedures with Principal Diagnosis of Hemorrhage without CC/MCC); MS-DRG 023 (Craniotomy with Major Device Implant/Acute Complex CNS Principal Diagnosis with MCC or Chemo Implant); MS-DRG 024 (Craniotomy with Major Device Implant/Acute Complex CNS Principal Diagnosis without MCC); MS-DRG 025 (Craniotomy & Endovascular Intracranial Procedures with MCC); MS-DRG 026 (Craniotomy & Endovascular Intracranial
Procedures with CC); and MS-DRG 027 (Craniotomy & Endovascular Intracranial Procedures without CC/MCC):

- 00.62 (Percutaneous angioplasty of intracranial vessel);
- 39.72 (Endovascular (total) embolization or occlusion of head and neck vessels);
- 39.74 (Endovascular removal of obstruction from head and neck vessel(s));
- 39.75 (Endovascular embolization or occlusion of vessel(s) of head or neck using bare coils);
- 39.76 (Endovascular embolization or occlusion of vessel(s) of head or neck using bioactive coils); and
- 39.79 (Other endovascular procedures on other vessels).

The requestor asked that the four new requested MS-DRGs be created using these procedure codes. The requestor suggested that the first requested new MS-DRG would be MS-DRG XXX (Endovascular Intracranial Embolization Procedures with Principal Diagnosis of Hemorrhage). The principal diagnoses for hemorrhage would include the same hemorrhage codes in the current MS-DRGs 020, 021, and 022, which are as follows:

- 094.87 (Syphilitic ruptured cerebral aneurysm);
- 430 (Subarachnoid hemorrhage);
- 431 (Intracerebral hemorrhage);
- 432.0 (Nontraumatic extradural hemorrhage);
- 432.1 (Subdural hemorrhage); and
● 432.9 (Unspecified intracranial hemorrhage).

For this first new requested MS-DRG, the requestor suggested that only the following endovascular embolization procedure codes would be assigned:

● 39.72 (Endovascular (total) embolization or occlusion of head and neck vessels);

● 39.75 (Endovascular embolization or occlusion of vessel(s) of head or neck using bare coils); and

● 39.76 (Endovascular embolization or occlusion of vessel(s) of head or neck using bioactive coils).

The requestor recommended that the three additional new MS-DRGs would consist of a new base MS-DRG subdivided into three severity levels as follows:

● Recommended MS-DRG XXX (Endovascular Intracranial Embolization Procedures without Principal Diagnosis of Hemorrhage with MCC);

● Recommended MS-DRG XXX (Endovascular Intracranial Embolization Procedures without Principal Diagnosis of Hemorrhage with CC); and

● Recommended MS-DRG XXX (Endovascular Intracranial Embolization Procedures without Principal Diagnosis of Hemorrhage without CC/MCC).

The requestor suggested that these three new recommended MS-DRGs would have endovascular embolization procedures as well as additional percutaneous and endovascular procedures as listed below:

● 00.62 (Percutaneous angioplasty of intracranial vessel);
- 39.72 (Endovascular (total) embolization or occlusion of head and neck vessels);
- 39.74 (Endovascular removal of obstruction from head and neck vessel(s));
- 39.75 (Endovascular embolization or occlusion of vessel(s) of head or neck using bare coils);
- 39.76 (Endovascular embolization or occlusion of vessel(s) of head or neck using bioactive coils); and
- 39.79 (Other endovascular procedures on other vessels).

ICD-10-PCS provides the following more detailed codes for endovascular embolization, which are assigned to MS-DRGs 020, 021, 022, 023, 024, 025, 026, and 027 in the ICD-10 MS-DRGs Version 32:

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03LG3BZ</td>
<td>Occlusion of intracranial artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LG3DZ</td>
<td>Occlusion of intracranial artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LG4BZ</td>
<td>Occlusion of intracranial artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LG4DZ</td>
<td>Occlusion of intracranial artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LH3BZ</td>
<td>Occlusion of right common carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LH3DZ</td>
<td>Occlusion of right common carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LH4BZ</td>
<td>Occlusion of right common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LH4DZ</td>
<td>Occlusion of right common carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LJ3BZ</td>
<td>Occlusion of left common carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>03LJ3DZ</td>
<td>Occlusion of left common carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LJ4BZ</td>
<td>Occlusion of left common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LJ4DZ</td>
<td>Occlusion of left common carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LK3BZ</td>
<td>Occlusion of right internal carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LK3DZ</td>
<td>Occlusion of right internal carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LK4BZ</td>
<td>Occlusion of right internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LK4DZ</td>
<td>Occlusion of right internal carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LL3BZ</td>
<td>Occlusion of left internal carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LL3DZ</td>
<td>Occlusion of left internal carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LL4BZ</td>
<td>Occlusion of left internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LL4DZ</td>
<td>Occlusion of left internal carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LM3BZ</td>
<td>Occlusion of right external carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LM3DZ</td>
<td>Occlusion of right external carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LM4BZ</td>
<td>Occlusion of right external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LM4DZ</td>
<td>Occlusion of right external carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LN3BZ</td>
<td>Occlusion of left external carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LN3DZ</td>
<td>Occlusion of left external carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LN4BZ</td>
<td>Occlusion of left external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LN4DZ</td>
<td>Occlusion of left external carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LP3BZ</td>
<td>Occlusion of right vertebral artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Codes for Endovascular Embolization Assigned to MS-DRGs 020 through 027 in ICD-10 MS-DRGs Version 32

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03LP3DZ</td>
<td>Occlusion of right vertebral artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LP4BZ</td>
<td>Occlusion of right vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LP4DZ</td>
<td>Occlusion of right vertebral artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LQ3BZ</td>
<td>Occlusion of left vertebral artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LQ3DZ</td>
<td>Occlusion of left vertebral artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LQ4BZ</td>
<td>Occlusion of left vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LQ4DZ</td>
<td>Occlusion of left vertebral artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LR3DZ</td>
<td>Occlusion of face artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LR4DZ</td>
<td>Occlusion of face artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LS3DZ</td>
<td>Occlusion of right temporal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LS4DZ</td>
<td>Occlusion of right temporal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LT3DZ</td>
<td>Occlusion of left temporal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LT4DZ</td>
<td>Occlusion of left temporal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VG3BZ</td>
<td>Restriction of intracranial artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VG3DZ</td>
<td>Restriction of intracranial artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VG4BZ</td>
<td>Restriction of intracranial artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VG4DZ</td>
<td>Restriction of intracranial artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VH3BZ</td>
<td>Restriction of right common carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VH3DZ</td>
<td>Restriction of right common carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VH4BZ</td>
<td>Restriction of right common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
ICD-10-PCS Codes for Endovascular Embolization Assigned to MS-DRGs 020 through 027 in ICD-10 MS-DRGs Version 32

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03VH4DZ</td>
<td>Restriction of right common carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VJ3BZ</td>
<td>Restriction of left common carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VJ3DZ</td>
<td>Restriction of left common carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VJ4BZ</td>
<td>Restriction of left common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VJ4DZ</td>
<td>Restriction of left common carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VK3BZ</td>
<td>Restriction of right internal carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VK3DZ</td>
<td>Restriction of right internal carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VK4BZ</td>
<td>Restriction of right internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VK4DZ</td>
<td>Restriction of right internal carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VL3BZ</td>
<td>Restriction of left internal carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VL3DZ</td>
<td>Restriction of left internal carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VL4BZ</td>
<td>Restriction of left internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VL4DZ</td>
<td>Restriction of left internal carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VM3BZ</td>
<td>Restriction of right external carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VM3DZ</td>
<td>Restriction of right external carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VM4BZ</td>
<td>Restriction of right external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VM4DZ</td>
<td>Restriction of right external carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VN3BZ</td>
<td>Restriction of left external carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VN3DZ</td>
<td>Restriction of left external carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VN4BZ</td>
<td>Restriction of left external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Codes for Endovascular Embolization Assigned to MS-DRGs 020 through 027 in ICD-10 MS-DRGs Version 32

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03VN4DZ</td>
<td>Restriction of left external carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VP3BZ</td>
<td>Restriction of right vertebral artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VP3DZ</td>
<td>Restriction of right vertebral artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VP4BZ</td>
<td>Restriction of right vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VP4DZ</td>
<td>Restriction of right vertebral artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VQ3BZ</td>
<td>Restriction of left vertebral artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VQ3DZ</td>
<td>Restriction of left vertebral artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VQ4BZ</td>
<td>Restriction of left vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VQ4DZ</td>
<td>Restriction of left vertebral artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VR3DZ</td>
<td>Restriction of face artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VR4DZ</td>
<td>Restriction of face artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VS3DZ</td>
<td>Restriction of right temporal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VS4DZ</td>
<td>Restriction of right temporal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VT3DZ</td>
<td>Restriction of left temporal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VT4DZ</td>
<td>Restriction of left temporal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VU3DZ</td>
<td>Restriction of right thyroid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VU4DZ</td>
<td>Restriction of right thyroid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VV3DZ</td>
<td>Restriction of left thyroid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VV4DZ</td>
<td>Restriction of left thyroid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
For this request, as discussed in the FY 2016 IPPS/LTCH PPS proposed rule, we first examined claims data for all intracranial vascular procedure cases with a principal diagnosis of hemorrhage reported in MS-DRGs 020, 021, and 022 in the December 2014 update of the FY 2014 MedPAR file. The table below shows our findings. We found a total of 1,755 cases with an average length of stay ranging from 8.28 days to 16.84 days and average costs ranging from $36,998 to $71,665 in MS-DRGs 020, 021, and 022.

<table>
<thead>
<tr>
<th>Intracranial Vascular Procedures with Principal Diagnosis of Hemorrhage</th>
<th>Number of cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 020 (with MCC) – All cases</td>
<td>1,285</td>
<td>16.84</td>
<td>$71,655</td>
</tr>
<tr>
<td>MS-DRG 021 (with CC) – All cases</td>
<td>372</td>
<td>13.82</td>
<td>$52,143</td>
</tr>
<tr>
<td>MS-DRG 022 (without CC/MCC) – All cases</td>
<td>98</td>
<td>8.28</td>
<td>$36,998</td>
</tr>
</tbody>
</table>

Next, we examined claims data on the first part of the request, which was to create a new MS-DRG for endovascular intracranial embolization procedure cases with a principal diagnosis of hemorrhage that are currently assigned to MS-DRGs 020, 021, and 022. Our findings for the first part of this multi-part request are shown in the table below.

<table>
<thead>
<tr>
<th>Endovascular Intracranial Embolization Procedures with Principal Diagnosis of Hemorrhage</th>
<th>Number of cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Requested New Combined MS-DRG</td>
<td>1,275</td>
<td>15.6</td>
<td>$67,831</td>
</tr>
</tbody>
</table>

The requestor suggested that this new requested base MS-DRG would not be subdivided by severity levels. Using the requested code logic, cases with a principal
diagnosis of hemorrhage and procedure codes 39.72 (Endovascular (total) embolization or occlusion of head and neck vessels), 39.75 (Endovascular embolization or occlusion of vessel(s) of head or neck using bare coils), and 39.76 (Endovascular embolization or occlusion of vessel(s) of head or neck using bioactive coils) would be moved out of MS-DRGs 020, 021, and 022 and into a single new MS-DRG with no severity levels.

As can be seen in the table above, the average costs for the new requested combined MS-DRG would be $67,831. The average costs for current MS-DRGs 020, 021, and 022 were $71,655, $52,143, and $36,998, respectively. Based on these findings, if we established this requested new MS-DRG, payments for those cases at the highest severity level (MS-DRG 020, which had average costs of $71,655) would be reduced.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24351 through 24356), we stated that we believe that maintaining the current MS-DRG assignment for these types of procedures is appropriate. Our clinical advisors stated that the current grouping of procedures within MS-DRGs 020, 021, and 022 reflects patients who are unique in terms of utilization and complexity based on the three severity levels, which are specifically designed to capture clinical differences in these patients, and these factors support maintaining the current structure. Therefore, we did not propose to move cases with a principal diagnosis of hemorrhage and procedure codes 39.72, 39.75, and 39.76 out of MS-DRGs 020, 021, and 022 and create a new base MS-DRG. We invited public comments on this proposal.

As discussed earlier in this section, the requestor also recommended the creation of a new set of MS-DRGs for endovascular intracranial embolization procedures without
a principal diagnosis of hemorrhage with MCC, with CC, and without CC/MCC. For these requested new MS-DRGs, the requestor suggested assignment of endovascular embolization procedures as well as certain other percutaneous and endovascular procedures. The complete list of endovascular intracranial embolization procedures developed by the requestor is as follows:

- 00.62 (Percutaneous angioplasty of intracranial vessel);
- 39.72 (Endovascular (total) embolization or occlusion of head and neck vessels);
- 39.74 (Endovascular removal of obstruction from head and neck vessel(s));
- 39.75 (Endovascular embolization or occlusion of vessel(s) of head or neck using bare coils);
- 39.76 (Endovascular embolization or occlusion of vessel(s) of head or neck using bioactive coils); and
- 39.79 (Other endovascular procedures on other vessels)

The following table shows our findings from examination of claims data on endovascular intracranial procedures without a principal diagnosis of hemorrhage reported in MS-DRGs 023 through 027 from the December 2014 update of the FY 2014 MedPAR file.

<table>
<thead>
<tr>
<th>Endovascular Intracranial Procedures without Principal Diagnosis of Hemorrhage</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 023 – All cases</td>
<td>5,615</td>
<td>10.96</td>
<td>$37,784</td>
</tr>
<tr>
<td>MS-DRG 023 – Cases with endovascular intracranial procedure without diagnosis of hemorrhage</td>
<td>1,510</td>
<td>8.88</td>
<td>$39,666</td>
</tr>
<tr>
<td>MS-DRG 024 – All cases</td>
<td>1,848</td>
<td>5.93</td>
<td>$26,195</td>
</tr>
</tbody>
</table>
As can be seen from this table, if we created a new set of MS-DRGs recommended by the requester, most of the cases would have to be moved out of MS-DRGs 023 and 027. The 1,510 cases that would have to be moved out of MS-DRG 023 have average costs of $39,666 compared to average costs of $37,784 for all cases in MS-DRG 023. The average costs for these cases are not significantly different from the average costs for all cases in MS-DRG 023. The average length of stay for the cases with endovascular intracranial procedure without a diagnosis of hemorrhage in MS-DRG 023 is 8.88 compared to 10.96 days for all cases in MS-DRG 023. In the proposed rule, we stated that we believe that these data support the current MS-DRG assignment for MS-DRG 023. The 1,793 cases that would have to be moved out of MS-DRG 027 have average costs of $22,244 compared to the average costs of $16,613 for all cases in MS-DRG 027. While the average costs for these cases are higher than for all cases in MS-DRG 027, one would expect some procedures within an MS-DRG to have higher average costs and other procedures to have lower average costs than the overall average.
costs. Cases within the MS-DRGs describing endovascular intracranial procedures are grouped together based on similar clinical and resource criteria. Some cases will have average costs that are higher than the overall average costs for cases in the MS-DRG, while other cases will have lower average costs. These differences in average costs are found within all MS-DRGs. The average length of stay of MS-DRG 027 cases with endovascular intracranial procedure without a diagnosis of hemorrhage is 1.66 days as compared to 3.15 days for all cases in MS-DRG 027. Therefore, while the average costs are higher for the cases with endovascular intracranial procedure without a diagnosis of hemorrhage than for all cases in MS-DRG 027, the length of stay is shorter.

The 867 cases that would have to be moved out of MS-DRG 024 have average costs of $27,975 compared to average costs for all cases in MS-DRG 024 of $26,195. The average costs for these cases are not significantly different than the average costs for all cases in MS-DRG 024. The average length of stay for the 867 cases that would have to be moved out of MS-DRG 024 is 5.80 compared to 5.93 for all cases in MS-DRG 024. Therefore, the lengths of stay for the cases also are quite similar in MS-DRG 024. In the FY 2016 IPPS/LTCH PPS proposed rule, we stated that we determined that these data findings support maintaining the current MS-DRG assignment of these procedures in MS-DRG 024.

MS-DRGs 025 and 026 show the smallest number of cases that would have to be moved to the requested new MS-DRGs, but these cases have larger differences in average costs. The average costs of cases that would have to be moved out of MS-DRG 025 are $44,082 compared to $29,970 for all cases in MS-DRG 025. The average length of stay
for the MS-DRG 025 cases with endovascular intracranial procedure without a diagnosis of hemorrhage is 8.52 days as compared to 9.35 days for all cases in MS-DRG 025. Therefore, the lengths of stay are similar for cases in MS-DRG 025. The average costs of cases that would have to be moved out of MS-DRG 026 are $26,594 compared to $21,414 for all cases. The average length of stay for cases that would have to be moved out of MS-DRG 026 is 3.07 days compared to 6.09 days for all cases in MS-DRG 026, or almost half as long as for all cases in MS-DRG 026. As stated earlier, the average costs for cases that would be moved out of MS-DRGs 023, 024, 025, 026, and 027 under this request are higher than the average costs for all cases in these MS-DRGs, with most of the cases coming out of MS-DRGs 023 and 027. The average costs for these particular cases in MS-DRG 023 are not significantly different from the average costs for all cases in MS-DRG 023. In addition, while the average costs are higher for the cases with an endovascular intracranial procedure without a diagnosis of hemorrhage than for all cases in MS-DRG 027, the length of stay is shorter. We determined that the overall data do not support making the requested MS-DRG updates to MS-DRGs 023, 024, 025, 026, and 027 and creating three new MS-DRGs. Therefore, we did not propose to make changes to the current structure for MS-DRGs 023 through 027.

In summary, our clinical advisors reviewed each aspect of this multi-part request and advised us that the endovascular embolization procedures are appropriately assigned to MS-DRGs 020 through 027. They did not support removing the procedures (procedure codes 39.72, 39.75, and 39.76) from MS-DRGs 020, 021, and 022 and creating a single MS-DRG for endovascular intracranial embolization procedures with a
principal diagnosis of hemorrhage with no severity levels. Our clinical advisors stated that the current MS-DRG grouping of three severity levels captures differences in clinical severity, average costs, and length of stay for these patients appropriately. Our clinical advisors also recommended maintaining the current MS-DRG assignments for endovascular embolization and other percutaneous and endovascular procedures within MS-DRGs 023 through 027. They stated that these procedures are all clinically similar to others in these MS-DRGs. In addition, they stated that the surgical techniques are all designed to correct the same clinical problem, and they advised against moving a select number of those procedures out of MS-DRGs 023 through 027.

Based on the findings from our data analysis and the recommendations from our clinical advisors, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24356), we did not propose to create the four new MS-DRGs for endovascular intracranial embolization and other endovascular procedures recommended by the requestor. We proposed to maintain the current MS-DRG structure for MS-DRGs 020 through 027.

We invited public comments on these two proposals.

Comment: A number of commenters supported the proposal to maintain the current MS-DRG structure for MS-DRGs 020 through 027 and not to create four new MS-DRGs for endovascular intracranial embolization and other endovascular procedures. The commenters stated that the proposal was reasonable, given the data and information provided.

One commenter disagreed with the proposal. The commenter stated that the data demonstrate that the cost of endovascular coil cases consistently exceeds the overall
average cost of all cases within each of the MS-DRGs to which these procedures are currently assigned. Moreover, the commenter believed that it was inappropriate to minimize the clinical complexity of these procedures compared to other procedures in the current MS-DRGs.

Response: We appreciate the commenters’ support for our proposal to maintain the current MS-DRG structure for MS-DRGs 020 through 027 and not to create four new MS-DRGs for endovascular intracranial embolization and other endovascular procedures. In response to the commenter who disagreed with the proposal, as stated earlier in this section, while we recognize that the average costs of these cases are higher than the average costs of all cases in MS-DRGs 023 through 027, one would expect some procedures within an MS-DRG to have higher average costs and other procedures to have lower average costs than the overall average costs. Cases within the MS-DRGs describing endovascular intracranial procedures are grouped together based on similar clinical and resource criteria. Some cases will have average costs that are higher than the overall average costs for cases in the MS-DRG, while other cases will have lower average costs. Our clinical advisors recommended maintaining the current MS-DRG assignments for endovascular embolization and other percutaneous and endovascular procedures within MS-DRGs 023 through 027. They continue to believe that these procedures are all clinically similar to others in these MS-DRGs and that the surgical techniques are all designed to correct the same clinical problem, and continue to advise against moving a select number of those procedures out of MS-DRGs 020 through 027. Our clinical advisors stated that the endovascular intracranial embolizations and other
endovascular procedures address the same clinical problems as other procedures assigned to MS-DRGs 020 through 027. Therefore, the cases in MS-DRGs 020 through 027 are clinically similar.

After consideration of the public comments we received, we are finalizing our proposal to maintain the current MS-DRG structure for MS-DRGs 020 through 027 and not to create four new MS-DRGs for endovascular intracranial embolization and other endovascular procedures.

3. MDC 5 (Diseases and Disorders of the Circulatory System)

a. Adding Severity Levels to MS-DRGs 245 through 251

During the comment period for the FY 2015 IPPS/LTCH PPS proposed rule, we received a comment that recommended establishing severity levels for MS-DRG 245 (AICD Generator Procedures) and including additional severity levels for MS-DRG 246 (Percutaneous Cardiovascular Procedure with Drug-Eluting Stent with MCC or 4+ Vessels/Stents); MS-DRG 247 (Percutaneous Cardiovascular Procedure with Drug-Eluting Stent without MCC); MS-DRG 248 (Percutaneous Cardiovascular Procedure with Non-Drug-Eluting Stent with MCC or 4+ Vessels/Stents); MS-DRG 249 (Percutaneous Cardiovascular Procedure with Non-Drug-Eluting Stent without MCC); MS-DRG 250 (Percutaneous Cardiovascular Procedure without Coronary Artery Stent with MCC); and MS-DRG 251 (Percutaneous Cardiovascular Procedure without Coronary Artery Stent without MCC).

We considered this public comment to be outside of the scope of the FY 2015 IPPS/LTCH PPS proposed rule. Therefore, we did not address this comment in the
FY 2015 IPPS/LTCH PPS final rule. However, we indicated that we would consider the public comment for possible proposals in future rulemaking as part of our annual review process.

For the FY 2016 IPPS/LTCH PPS proposed rule, we received a separate, but related, request involving most of these same MS-DRGs. Therefore, for the FY 2016 IPPS/LTCH PPS proposed rule, we conducted a simultaneous analysis of claims data to address both the FY 2015 public comment request and the related FY 2016 request. We discuss both of these requests below.

b. Percutaneous Intracardiac Procedures

We received a request to remove the cardiac ablation and other specified cardiovascular procedures from the following MS-DRGs, and to create new MS-DRGs to classify these procedures:

- MS-DRG 246 (Percutaneous Cardiovascular Procedure with Drug-Eluting Stent with MCC or 4+ Vessels/Stents);
- MS-DRG 247 (Percutaneous Cardiovascular Procedure with Drug-Eluting Stent without MCC);
- MS-DRG 248 (Percutaneous Cardiovascular Procedure with Non-Drug-Eluting Stent with MCC or 4+ Vessels/Stents);
- MS-DRG 249 (Percutaneous Cardiovascular Procedure with Non-Drug-Eluting Stent without MCC);
- MS-DRG 250 (Percutaneous Cardiovascular Procedure without Coronary Artery Stent with MCC); and
- MS-DRG 251 (Percutaneous Cardiovascular Procedure without Coronary Artery Stent without MCC).

The commenter stated that, historically, the MS-DRGs listed above appropriately reflected the differential cost of percutaneous transluminal coronary angioplasty (PTCA) procedures with and without stents. The commenter noted that PTCA procedures with drug eluting stents were previously paid the highest, followed by PTCA procedures with bare metal stents and PTCA procedures with no stents, respectively. However, the commenter believed that, in recent years, the opposite has begun to occur and cases reporting a PTCA procedure without a stent are being paid more than cases reporting a PTCA procedure with a stent. The commenter further noted that cardiac ablation procedures and PTCA procedures without stents are currently assigned to the same MS-DRGs, notwithstanding that the procedures have different clinical objectives and patient diagnoses. The commenter indicated that cardiac ablation procedures are performed on patients with multiple distinct cardiac arrhythmias to alter electrical conduction systems of the heart, and PTCA procedures are performed on patients with coronary atherosclerosis to open blocked coronary arteries. The commenter also noted that cardiac ablation procedures are performed in the heart chambers by cardiac electrophysiologists, require significantly more resources, and require longer periods of time to complete. Conversely, PTCA procedures are performed in the coronary vessels by interventional cardiologists, require the use of less equipment, and require a shorter period of time to complete. Therefore, the commenter suggested that CMS create new MS-DRGs for percutaneous intracardiac procedures to help improve clinical
homogeneity by differentiating percutaneous intracardiac procedures (performed within the heart chambers) from percutaneous intracoronary procedures (performed within the coronary vessels). The commenter further believed that creating new MS-DRGs for these procedures would also better reflect the resource cost of specialized equipment used for more complex structures of electrical conduction systems when performing cardiac ablation procedures.

The following ICD-9-CM procedure codes identify and describe the cardiac ablation procedures and the other percutaneous intracardiac procedures that are currently classified under MS-DRGs 246 through 251 and that the commenter recommended that CMS assign to the newly created MS-DRGs:

- 35.52 (Repair of atrial septal defect with prosthesis, closed technique);
- 35.96 (Percutaneous balloon valvuloplasty);
- 35.97 (Percutaneous mitral valve repair with implant);
- 37.26 (Catheter based invasive electrophysiologic testing);
- 37.27 (Cardiac mapping);
- 37.34 (Excision or destruction of other lesion or tissue of heart, endovascular approach);
- 37.36 (Excision, destruction, or exclusion of left atrial appendage (LAA)); and
- 37.90 (Insertion of left atrial appendage device).

There are a number of ICD-10-PCS code translations that provide more detailed and specific information for each of the ICD-9-CM procedure codes listed above that also are currently classified under MS-DRGs 246 through 251 based on the GROUPER
Version 32 ICD-10 MS-DRGs. The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 35.52 are shown in the following table.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 35.52</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICD-10-PCS Code</strong></td>
</tr>
<tr>
<td>02U53JZ</td>
</tr>
<tr>
<td>02U54JZ</td>
</tr>
</tbody>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 35.96 are shown in the following table.

<table>
<thead>
<tr>
<th>ICD-10-PCS Translations for ICD-9-CM Procedure Code 35.96</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICD-10-PCS Code</strong></td>
</tr>
<tr>
<td>027F34Z</td>
</tr>
<tr>
<td>027F3DZ</td>
</tr>
<tr>
<td>027F3ZZ</td>
</tr>
<tr>
<td>027F44Z</td>
</tr>
<tr>
<td>027F4DZ</td>
</tr>
<tr>
<td>027F4ZZ</td>
</tr>
<tr>
<td>027G34Z</td>
</tr>
<tr>
<td>027G3DZ</td>
</tr>
<tr>
<td>027G3ZZ</td>
</tr>
<tr>
<td>027G44Z</td>
</tr>
<tr>
<td>027G4DZ</td>
</tr>
<tr>
<td>027G4ZZ</td>
</tr>
<tr>
<td>027H34Z</td>
</tr>
<tr>
<td>027H3DZ</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Translations for ICD-9-CM Procedure Code 35.96

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>027H3ZZ</td>
<td>Dilation of pulmonary valve, percutaneous approach</td>
</tr>
<tr>
<td>027H44Z</td>
<td>Dilation of pulmonary valve with drug-eluting intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>027H4DZ</td>
<td>Dilation of pulmonary valve with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>027H4ZZ</td>
<td>Dilation of pulmonary valve, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>027J34Z</td>
<td>Dilation of tricuspid valve with drug-eluting intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>027J3DZ</td>
<td>Dilation of tricuspid valve with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>027J3ZZ</td>
<td>Dilation of tricuspid valve, percutaneous approach</td>
</tr>
<tr>
<td>027J44Z</td>
<td>Dilation of tricuspid valve with drug-eluting intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>027J4DZ</td>
<td>Dilation of tricuspid valve with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>027J4ZZ</td>
<td>Dilation of tricuspid valve, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

The ICD-10-PCS code translation for ICD-9-CM procedure code 35.97 is 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach).

The ICD-10-PCS code translation for ICD-9-CM procedure code 37.26 is 4A023FZ (Measurement of cardiac rhythm, percutaneous approach).

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 37.27 are shown in the following table.

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.27

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02K83ZZ</td>
<td>Map conduction mechanism, percutaneous approach</td>
</tr>
<tr>
<td>02K84ZZ</td>
<td>Map conduction mechanism, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 37.34 are shown in the following table:

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02553ZZ</td>
<td>Destruction of atrial septum, percutaneous approach</td>
</tr>
<tr>
<td>02563ZZ</td>
<td>Destruction of right atrium, percutaneous approach</td>
</tr>
<tr>
<td>02573ZZ</td>
<td>Destruction of left atrium, percutaneous approach</td>
</tr>
<tr>
<td>02583ZZ</td>
<td>Destruction of conduction mechanism, percutaneous approach</td>
</tr>
<tr>
<td>02593ZZ</td>
<td>Destruction of chordae tendineae, percutaneous approach</td>
</tr>
<tr>
<td>025F3ZZ</td>
<td>Destruction of aortic valve, percutaneous approach</td>
</tr>
<tr>
<td>025G3ZZ</td>
<td>Destruction of mitral valve, percutaneous approach</td>
</tr>
<tr>
<td>025H3ZZ</td>
<td>Destruction of pulmonary valve, percutaneous approach</td>
</tr>
<tr>
<td>025J3ZZ</td>
<td>Destruction of tricuspid valve, percutaneous approach</td>
</tr>
<tr>
<td>025K3ZZ</td>
<td>Destruction of right ventricle, percutaneous approach</td>
</tr>
<tr>
<td>025L3ZZ</td>
<td>Destruction of left ventricle, percutaneous approach</td>
</tr>
<tr>
<td>025M3ZZ</td>
<td>Destruction of ventricular septum, percutaneous approach</td>
</tr>
<tr>
<td>02B53ZZ</td>
<td>Excision of atrial septum, percutaneous approach</td>
</tr>
<tr>
<td>02B63ZZ</td>
<td>Excision of right atrium, percutaneous approach</td>
</tr>
<tr>
<td>02B73ZZ</td>
<td>Excision of left atrium, percutaneous approach</td>
</tr>
<tr>
<td>02B83ZZ</td>
<td>Excision of conduction mechanism, percutaneous approach</td>
</tr>
<tr>
<td>02B93ZZ</td>
<td>Excision of chordae tendineae, percutaneous approach</td>
</tr>
<tr>
<td>02BF3ZZ</td>
<td>Excision of aortic valve, percutaneous approach</td>
</tr>
<tr>
<td>02BG3ZZ</td>
<td>Excision of mitral valve, percutaneous approach</td>
</tr>
<tr>
<td>02BH3ZZ</td>
<td>Excision of pulmonary valve, percutaneous approach</td>
</tr>
<tr>
<td>02BJ3ZZ</td>
<td>Excision of tricuspid valve, percutaneous approach</td>
</tr>
<tr>
<td>02BM3ZZ</td>
<td>Excision of ventricular septum, percutaneous approach</td>
</tr>
<tr>
<td>02T83ZZ</td>
<td>Resection of conduction mechanism, percutaneous approach</td>
</tr>
</tbody>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 37.36 are shown in the following table:

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02573ZK</td>
<td>Destruction of left atrial appendage, percutaneous approach</td>
</tr>
<tr>
<td>02574ZK</td>
<td>Destruction of left atrial appendage, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 37.90 are shown in the following table:

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02L73CK</td>
<td>Occlusion of left atrial appendage with extraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>02L73DK</td>
<td>Occlusion of left atrial appendage with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>02L74CK</td>
<td>Occlusion of left atrial appendage with extraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02L74DK</td>
<td>Occlusion of left atrial appendage with intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

The ICD-10-PCS code translations listed above, along with their respective MS-DRG assignments, can be found in the ICD-10 MS-DRGs Version 32 Definitions Manual posted on the CMS Web site at:


As mentioned earlier, we received a separate, but related, request to add severity levels to MS-DRGs 246 through 251. We address this request at the end of this section.
To address the first of these separate, but related, requests, we reviewed claims data for MS-DRGs 246 through 251 from the December 2014 update of the FY 2014 MedPAR file. Our findings are shown in the following table:

| Percutaneous Cardiovascular MS-DRGs with and without Stents |
|------------------|-----------------|-----------------|
| **MS-DRG**       | **Number of Cases** | **Average Length of Stay** | **Average Costs** |
| MS-DRG 246 – All cases | 30,617          | 5.52            | $23,855       |
| MS-DRG 246 – Cases with procedure codes 35.52, 35.96, 35.97, 37.26, 37.27, 37.34, 37.36, and 37.90 | 244            | 9.69            | $34,099       |
| MS-DRG 247 – All cases | 79,639          | 2.69            | $15,671       |
| MS-DRG 247 – Cases with procedure codes 35.52, 35.96, 35.97, 37.26, 37.27, 37.34, 37.36, and 37.90 | 260            | 5.20            | $25,797       |
| MS-DRG 248 – All cases | 9,310           | 6.37            | $22,504       |
| MS-DRG 248 – Cases with procedure codes 35.52, 35.96, 35.97, 37.26, 37.27, 37.34, 37.36, and 37.90 | 125            | 10.76           | $33,521       |
| MS-DRG 249 – All cases | 16,273          | 3.08            | $14,066       |
| MS-DRG 249 – Cases with procedure codes 35.52, 35.96, 35.97, 37.26, 37.27, 37.34, 37.36, and 37.90 | 81             | 5.12            | $23,710       |
| MS-DRG 250 – All cases | 9,275           | 7.07            | $22,902       |
| MS-DRG 250 – Cases with procedure codes 35.52, 35.96, 35.97, 37.26, 37.27, 37.34, 37.36, and 37.90 | 5,826          | 7.90            | $24,841       |
| MS-DRG 251 – All cases | 20,945          | 3.25            | $15,757       |
| MS-DRG 251 – Cases with procedure codes 35.52, 35.96, 35.97, 37.26, 37.27, 37.34, 37.36, and 37.90 | 14,436         | 3.39            | $17,290       |

As shown in the table above, there were a total of 30,617 cases in MS-DRG 246, with an average length of stay of 5.52 days and average costs of $23,855. For cases reporting a percutaneous intracardiac procedure in MS-DRG 246 (ICD-9-CM procedure
codes 35.52, 35.96, 35.97, 37.26, 37.27, 37.34, 37.36, and 37.90), there were a total of 244 cases, with an average length of stay of 9.69 days and average costs of $34,099. For MS-DRGs 247 through 251, a similar pattern was identified; the data reflected that the average costs are higher and the average length of stay is greater for cases reporting a percutaneous intracardiac procedure in comparison to the average costs and average length of stay for all of the cases in their respective MS-DRGs.

As reflected in the following table, a further analysis of the data showed that percutaneous intracardiac procedures represent a total of 20,972 cases in MS–DRGs 246 through 251, with a greater average length of stay (4.79 days versus 3.62 days) and higher average costs ($19,810 versus $17,532) in comparison to all of the remaining cases in MS–DRGs 246 through 251.

<table>
<thead>
<tr>
<th>Summary of Percutaneous Cardiovascular DRGs with and without Stents</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRGs 246 through 251 – Cases with procedure codes 35.52, 35.96, 35.97, 37.26, 37.27, 37.34, 37.36, and 37.90</td>
<td>20,972</td>
<td>4.79</td>
<td>$19,810</td>
</tr>
<tr>
<td>MS-DRGs 246 through 251 – Cases without procedure codes 35.52, 35.96, 35.97, 37.26, 37.27, 37.34, 37.36, and 37.90</td>
<td>145,087</td>
<td>3.62</td>
<td>$17,532</td>
</tr>
</tbody>
</table>

We stated in the FY 2016 IPPS/LTCH PPS proposed rule that the results of these data analyses support removing procedures performed within the heart chambers using intracardiac techniques from MS-DRGs 246 through 251, and assigning these procedures to separate MS-DRGs. The results of these data analyses also supported subdividing
these MS-DRGs using the “with MCC” and “without MCC” severity levels based on the application of the criteria established in the FY 2008 IPPS final rule (72 FR 47169), and described in section II.G.1.b. of the preamble of the proposed rule, that must be met to warrant the creation of a CC or an MCC subgroup within a base MS-DRG. Our clinical advisors also agreed that this differentiation would improve the clinical homogeneity of these MS-DRGs by separating percutaneous intracardiac procedures (performed within the heart chambers) from percutaneous intracoronary procedures (performed within the coronary vessels). In addition, we believe that creating these new MS-DRGs would better reflect the resource cost of specialized equipment used to perform more complex structures of electrical conduction systems during cardiac ablation procedures. Therefore, for FY 2016, we proposed to create two new MS-DRGs to classify percutaneous intracardiac procedures (80 FR24359). Specifically, we proposed to create MS-DRG 273, entitled “Percutaneous Intracardiac Procedures with MCC,” and MS-DRG 274, entitled “Percutaneous Intracardiac Procedures without MCC,” and to assign the procedures performed within the heart chambers using intracardiac techniques to the two proposed new MS-DRGs. We proposed that existing percutaneous intracoronary procedures with and without stents continue to be assigned to the other MS-DRGs to reflect that those procedures are performed within the coronary vessels and require fewer resources.

The table below represents the distribution of cases, average length of stay, and average costs for these proposed two new MS-DRGs.
Proposed New MS-DRGs for Percutaneous Intracardiac Procedures

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed MS-DRG 273 with MCC</td>
<td>6,195</td>
<td>8.03</td>
<td>$25,380</td>
</tr>
<tr>
<td>Proposed MS-DRG 274 without MCC</td>
<td>14,777</td>
<td>3.44</td>
<td>$17,475</td>
</tr>
</tbody>
</table>

We invited public comments on our proposal to create the two new MS-DRGs for percutaneous intracardiac procedures for FY 2016. In addition, we invited public comments on the ICD-10-PCS code translations that were presented earlier in this section and our proposal to assign these procedure codes to the proposed new MS-DRGs 273 and 274.

Comment: Several commenters supported the proposal to create proposed new MS-DRG 273 and MS-DRG 274 to improve clinical homogeneity and better reflect resource costs. The commenters stated that the proposal was reasonable, given the data and information provided. The commenters also agreed with the proposed ICD-10-PCS code translations and assignment of those codes to the proposed new MS-DRGs.

Several commenters commended CMS for conducting the analysis and continuing to make further refinements to the MS-DRGs. One commenter specifically expressed appreciation for CMS’ display of cost and length of stay data in the analysis, in addition to the clinical factors that support differentiation of intracardiac procedures from intracoronary procedures. This commenter recommended that, if the two proposed MS-DRGs are finalized, CMS continue to monitor them after ICD-10 implementation in an effort to mitigate potential unintended consequences. The commenter also suggested that, in the future, additional procedure codes may warrant assignment to the proposed
new MS-DRGs. Another commenter stated that adopting the proposal to create the new MS-DRGs will lead to more appropriate payment.

Response: We appreciate the commenters’ support. We agree that creating these new MS-DRGs will better reflect utilization of resources and clinical cohesiveness for intracardiac procedures in comparison to intracoronary procedures, as well as provide for appropriate payment for the procedures.

Comment: One commenter supported the proposal but also requested that CMS provide additional information on how the payment rate will be adjusted for the remaining existing MS-DRGs (246 through 251) following the creation of proposed new MS-DRGs 273 and 274.

Response: We thank the commenter for its support. For payment rate updates to all of the MS-DRGs for FY 2016, we refer readers to Table 5 associated with this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

After consideration of the public comments we received, we are finalizing our proposal to create MS-DRGs 273 (Percutaneous Intracardiac Procedures with MCC) and MS-DRG 274 (Percutaneous Intracardiac Procedures without MCC) for the FY 2016 ICD-10 MS-DRGs Version 33.

As mentioned earlier in this section, we received a similar request in response to the FY 2015 IPPS/LTCH PPS proposed rule to add severity levels to MS-DRGs 246 through 251. We considered this public comment to be outside of the scope of the
FY 2015 IPPS/LTCH PPS proposed rule. Therefore, we did not address this comment in the FY 2015 IPPS/LTCH PPS final rule. However, we indicated that we would consider the public comment for possible proposals in future rulemaking as part of our annual review process. Specifically, the commenter recommended including additional severity levels for MS-DRGs 246 through 251 and establishing severity levels for MS-DRG 245 (AICD Generator Procedures).

For our data analysis for this recommendation, we examined claims data from the December 2014 update of the FY 2014 MedPAR file to determine if including additional severity levels in MS-DRGs 246 through 251 was warranted. During our analysis, we applied the criteria established in the FY 2008 IPPS final rule (72 FR 47169), as described in section II.G.1.b. of the preamble of the proposed rule. As shown in the table below, we collapsed MS-DRGs 246 through 251 into base MS-DRGs (MS-DRGs 246, 248, and 250) by suggested severity level and applied the criteria.

<table>
<thead>
<tr>
<th>Percutaneous Cardiovascular MS-DRG with and without Stent Procedures by Suggested Severity Level</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suggested MS-DRG 246 with MCC</td>
<td>30,617</td>
<td>5.52</td>
<td>$23,855</td>
</tr>
<tr>
<td>Suggested MS-DRG 246 with CC</td>
<td>45,313</td>
<td>2.96</td>
<td>$16,233</td>
</tr>
<tr>
<td>Suggested MS-DRG 246 without CC/MCC</td>
<td>34,326</td>
<td>2.33</td>
<td>$14,928</td>
</tr>
<tr>
<td>Suggested MS-DRG 248 with MCC</td>
<td>9,310</td>
<td>6.37</td>
<td>$22,504</td>
</tr>
<tr>
<td>Suggested MS-DRG 248 with CC</td>
<td>9,510</td>
<td>3.49</td>
<td>$14,798</td>
</tr>
<tr>
<td>Suggested MS-DRG 248 without CC/MCC</td>
<td>6,763</td>
<td>2.51</td>
<td>$13,037</td>
</tr>
<tr>
<td>Suggested MS-DRG 250 with MCC</td>
<td>9,275</td>
<td>7.07</td>
<td>$22,903</td>
</tr>
<tr>
<td>Suggested MS-DRG 250 with CC</td>
<td>11,653</td>
<td>3.80</td>
<td>$16,113</td>
</tr>
<tr>
<td>Suggested MS-DRG 250 without CC/MCC</td>
<td>9,292</td>
<td>2.56</td>
<td>$15,310</td>
</tr>
</tbody>
</table>

We found that the criterion that there be a $2,000 difference in average costs between subgroups was not met. Specifically, between the “with CC” and “without
CC/MCC” subgroups for base MS-DRG 246, the difference in average costs was only $1,305; for base MS-DRG 248, the difference in average costs was only $1,761; and for base MS-DRG 250, the difference in average costs was only $803. The results of the data analysis of MS-DRGs 246 through 251 confirmed, and our clinical advisors agreed, that the existing 2-way severity level splits for these MS-DRGs (with MCC and without MCC) are appropriate, as displayed in the table below.
Therefore, we did not propose to further subdivide the severity levels for MS-DRGs 246 through 251. We invited public comments on our proposal not to create additional severity levels for MS-DRGs 246 through 251.

**Comment:** Several commenters supported the proposal not to create additional severity levels for MS-DRGs 246 through 251. The commenters stated that the proposal was reasonable, given the data and information provided.

**Response:** We appreciate the commenters’ support. Therefore, we are finalizing our proposal to not create additional severity levels for MS-DRGs 246-251 for the FY 2016 ICD-10 MS-DRGs Version 33.

Using the same MedPAR claims data for FY 2014, we separately examined cases in MS-DRG 245 to determine whether to subdivide this MS-DRG into severity levels. As displayed in the table below, the results of the FY 2014 data analysis showed there were a total of 1,699 cases, with an average length of stay of 5.49 days and average costs of $34,287, in MS-DRG 245.

<table>
<thead>
<tr>
<th>Percutaneous Cardiovascular MS-DRGs with and without Stents</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 246 – All cases</td>
<td>30,617</td>
<td>5.52</td>
<td>$23,855</td>
</tr>
<tr>
<td>MS-DRG 247 – All cases</td>
<td>79,639</td>
<td>2.69</td>
<td>$15,671</td>
</tr>
<tr>
<td>MS-DRG 248 – All cases</td>
<td>9,310</td>
<td>6.37</td>
<td>$22,504</td>
</tr>
<tr>
<td>MS-DRG 249 – All cases</td>
<td>16,273</td>
<td>3.08</td>
<td>$14,066</td>
</tr>
<tr>
<td>MS-DRG 250 – All cases</td>
<td>9,275</td>
<td>7.07</td>
<td>$22,903</td>
</tr>
<tr>
<td>MS-DRG 251 – All cases</td>
<td>20,945</td>
<td>3.25</td>
<td>$15,757</td>
</tr>
</tbody>
</table>
We applied the five criteria established in the FY 2008 IPPS final rule (72 FR 47169), as described in section II.G.1.b. of the preamble of the proposed rule, to determine if it was appropriate to subdivide MS-DRG 245 into severity levels. The table below illustrates our findings.

<table>
<thead>
<tr>
<th>AICD Generator Procedures by Suggested Severity Level</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suggested MS-DRG 245 with MCC</td>
<td>542</td>
<td>8.15</td>
<td>$40,004</td>
</tr>
<tr>
<td>Suggested MS-DRG 245 with CC</td>
<td>939</td>
<td>4.51</td>
<td>$32,237</td>
</tr>
<tr>
<td>Suggested MS-DRG 245 without CC/MCC</td>
<td>218</td>
<td>3.12</td>
<td>$28,907</td>
</tr>
</tbody>
</table>

Based on the analysis of the FY 2014 claims data for MS-DRG 245, the results supported creating a “with MCC” and a “without MCC” severity level split. However, our clinical advisors indicated that it would not be clinically appropriate to add severity levels based on an isolated year’s data fluctuation because this could lead to a lack of stability in MS-DRG payments. We agreed with our clinical advisors and noted that we annually conduct an analysis of base MS-DRGs to evaluate if additional severity levels are warranted. This analysis includes 2 years of MedPAR claims data to specifically compare data results from 1 year to the next to avoid making determinations about whether additional severity levels are warranted based on an isolated year’s data fluctuation. Generally, in past years, for our review of requests to add or establish
severity levels, in our analysis of the most recent claims data, there was at least one criterion that was not met. Therefore, it was not necessary to further analyze data beyond 1 year. However, the results of our analysis of claims data in the December 2014 update of the FY 2014 MedPAR file for this particular request involving MS-DRG 245 demonstrate that all five criteria to establish subgroups were met, and, therefore, it was necessary to also examine the FY 2013 MedPAR claims data file.

The results of our analysis from the December 2013 update of the FY 2013 claims data for MS-DRG 245 are shown in the table below.

<table>
<thead>
<tr>
<th>AICD Generator Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MS-DRG</strong></td>
</tr>
<tr>
<td>---------------------------</td>
</tr>
<tr>
<td>MS-DRG 245 – All cases</td>
</tr>
</tbody>
</table>

The FY 2013 claims data for MS-DRG 245 did not support creating any severity levels because the data did not meet one or more of the five required criteria for creating new severity levels. The data did not meet the requirement for a 3-way severity level split (with MCC, with CC, and without CC/MCC) or a 2-way severity level split (with MCC and without MCC) because there were not at least 500 cases in the MCC subgroup. While the data did meet this particular criterion for the 2-way severity level split of “with CC/MCC” and “without CC/MCC” because there were at least 500 cases in the CC subgroup, the data did not meet the criterion that there be at least a 20-percent difference in average costs between subgroups, as shown in the table below.

<table>
<thead>
<tr>
<th>AICD Generator Procedures</th>
</tr>
</thead>
</table>

The FY 2013 claims data for MS-DRG 245 did not support creating any severity levels because the data did not meet one or more of the five required criteria for creating new severity levels. The data did not meet the requirement for a 3-way severity level split (with MCC, with CC, and without CC/MCC) or a 2-way severity level split (with MCC and without MCC) because there were not at least 500 cases in the MCC subgroup. While the data did meet this particular criterion for the 2-way severity level split of “with CC/MCC” and “without CC/MCC” because there were at least 500 cases in the CC subgroup, the data did not meet the criterion that there be at least a 20-percent difference in average costs between subgroups, as shown in the table below.
<table>
<thead>
<tr>
<th>MS-DRG by Suggested Severity Level</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 245 with MCC</td>
<td>44</td>
<td>7.32</td>
<td>$39,536</td>
</tr>
<tr>
<td>MS-DRG 245 with CC</td>
<td>1,118</td>
<td>4.26</td>
<td>$31,786</td>
</tr>
<tr>
<td>MS-DRG 245 without CC/MCC</td>
<td>288</td>
<td>3.10</td>
<td>$29,383</td>
</tr>
</tbody>
</table>

As stated previously, we believe that 2 years of data showing that the requested CC or MCC subgroup meets all five of the established criteria for creating severity levels are needed in order to support a proposal to add severity levels for MS-DRG 245. Our clinical advisors also agreed that it would not be clinically appropriate to add severity levels based on an isolated year’s data fluctuation because this could lead to a lack of stability in payments. Therefore, we did not propose to add severity levels for MS-DRG 245 for FY 2016. We invited public comments on the results of our analysis and our proposal not to create severity levels for MS-DRG 245.

Comment: Several commenters supported the proposal not to create severity levels for MS-DRG 245. The commenters stated that the proposal was reasonable, given the data and information provided. One commenter specifically noted that it understood the rationale of CMS’ proposal based on analysis of the FY 2013 and FY 2014 data fluctuation. However, the commenter recommended that a followup analysis be conducted for the FY 2017 IPPS/LTCH PPS proposed rule.

Response: We appreciate the commenters’ support. We intend to conduct a followup analysis for MS-DRG 245 in the FY 2017 IPPS/LTCH PPS proposed rule as the commenter recommended.
After consideration of the public comments we received, we are finalizing our proposal not to create severity levels for MS-DRG 245 in FY 2016.

c. Zilver® PTX Drug-Eluting Peripheral Stent (Zilver® PTX®)

The Zilver® PTX Drug-Eluting Peripheral Stent (Zilver® PTX®) was approved for new technology add-on payments in FY 2014 (78 FR 50583 through 50585). Cases involving the Zilver® PTX® that are eligible for new technology add-on payments are identified by ICD-9-CM procedure code 00.60 (Insertion of drug-eluting stent(s) of superficial femoral artery).

We received a request from the manufacturer for an extension of new technology add-on payments for Zilver® PTX® in FY 2016. In the request, the manufacturer asked CMS to consider three options for procedure code 00.60 for FY 2016. The first option was to extend the new technology add-on payment through FY 2016. The request to extend the new technology add-on payment is addressed in section II.I.3.e. of the preamble of the proposed rule and this final rule. The second option was to establish a new family of MS-DRGs for procedures involving drug-eluting stents used in the peripheral (noncoronary) vasculature. The third option was to assign all Zilver® PTX® cases to MS-DRG 252 even if there is no MCC (which would necessitate revising the MS-DRG title to “Other Vascular Procedures”).

ICD-10-PCS provides the following more detailed procedure codes for the insertion of drug-eluting stents of superficial femoral artery:

- 047K04Z (Dilation of right femoral artery with drug-eluting intraluminal device, open approach);
● 047K34Z (Dilation of right femoral artery with drug-eluting intraluminal device, percutaneous approach);
● 047K44Z (Dilation of right femoral artery with drug-eluting intraluminal device, percutaneous endoscopic approach);
● 047L04Z (Dilation of left femoral artery with drug-eluting intraluminal device, open approach);
● 047L34Z (Dilation of left femoral artery with drug-eluting intraluminal device, percutaneous approach); and
● 047L44Z (Dilation of left femoral artery with drug-eluting intraluminal device, percutaneous endoscopic approach).

We examined claims data for cases involving the drug-eluting peripheral stent procedures reported in the December 2014 update of the FY 2014 MedPAR file for MS-DRGs 252, 253, and 254 (Other Vascular Procedures with MCC, with CC and without CC/MCC, respectively). The following table illustrates our findings.

<table>
<thead>
<tr>
<th>Drug-Eluting Peripheral Stent Procedures</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 252 – All cases</td>
<td>30,696</td>
<td>7.89</td>
<td>$23,935</td>
</tr>
<tr>
<td>MS-DRG 252 – Cases with procedure code 00.60</td>
<td>133</td>
<td>9.08</td>
<td>$32,623</td>
</tr>
<tr>
<td>MS-DRG 253 – All cases</td>
<td>34,746</td>
<td>5.68</td>
<td>$19,030</td>
</tr>
<tr>
<td>MS-DRG 253 – Cases with procedure code 00.60</td>
<td>353</td>
<td>4.99</td>
<td>$25,396</td>
</tr>
<tr>
<td>MS-DRG 254 – All cases</td>
<td>15,394</td>
<td>2.99</td>
<td>$12,629</td>
</tr>
<tr>
<td>MS-DRG 254 – Cases with procedure code 00.60</td>
<td>115</td>
<td>2.62</td>
<td>$21,461</td>
</tr>
</tbody>
</table>
Our findings showed that there were only 601 peripheral angioplasty cases with a drug-eluting stent reported. Of the 601 peripheral angioplasty cases with a drug-eluting stent, 133 cases were in MS-DRG 252, 353 cases were in MS-DRG 253, and 115 cases were in MS-DRG 254. The average costs for the drug-eluting stent cases in MS-DRGs 252, 253, and 254 were $32,623, $25,396, and $21,461, respectively. The average costs for all cases in MS-DRGs 252, 253, and 254 were $23,935, $19,030, and $12,629, respectively. The average costs for the drug-eluting stent cases in MS-DRG 253 ($25,396) were higher than the average costs for all cases in MS-DRG 252 ($23,935). However, the average costs for the drug-eluting stent cases in MS-DRG 254 ($21,461) were lower than the average costs for all cases in MS-DRG 252 ($23,935).

We determined that the small number of cases (601) did not provide justification to create a new set of MS-DRGs specifically for angioplasty of peripheral arteries using drug-eluting stents. In addition, the data did not support assigning all the drug-eluting stent cases to the highest severity level (MS-DRG 252), even when there is not an MCC, because the average costs for the drug-eluting stent cases in MS-DRG 254 ($21,461) were lower than the average costs for all cases in MS-DRG 252 ($23,935). The average length of stay for drug-eluting stent cases in MS-DRG 254 was 2.62 days compared to 7.89 days for all cases in MS-DRG 252. Cases are grouped together based on similar clinical and resource criteria.

Our clinical advisors recommended making no MS-DRG updates for peripheral angioplasty cases with a drug-eluting stent and considered the current MS-DRG assignment appropriate. Our clinical advisors agreed that the small number of peripheral
angioplasty cases with a drug-eluting stent does not support creating a new MS-DRG for this specific type of treatment. They stated that the cases are clinically similar to other cases within MS-DRGs 252, 253, and 254. Considering the data for peripheral angioplasty cases with a drug-eluting stent found reported in MS-DRGs 252, 253, and 254 and the input from our clinical advisors, in the FY 2016 IPPS/LTCH proposed rule (80 FR 24362), we did not propose to make any MS-DRG updates for peripheral angioplasty cases with a drug-eluting stent. We proposed to maintain the current MS-DRG assignments for these cases in MS-DRGs 252, 253, and 254. We invited public comments on our proposal.

Comment: A number of commenters supported the proposal to maintain the current MS-DRG assignments for peripheral angioplasty cases with a drug-eluting stent in MS-DRGs 252, 253, and 254. The commenters stated that the proposal was reasonable, given the data and information provided.

One commenter, the manufacturer, expressed concern with the proposal and asked CMS to reconsider its recommendation for denying the request that all Zilver® PTX® cases be assigned to MS-DRG 252 even if there were no MCC. The commenter stated that it is true that assignment of all drug-eluting cases to MS-DRG 252 would result in an overpayment for cases with a drug-eluting stent that currently are assigned to MS-DRG 254. However, the commenter stated that these cases represent only 19 percent of the drug-eluting stent cases, and that the overpayment of these cases would be modest because the average cost of drug-eluting stent cases in MS-DRG 254 is only $2,500 less than the average cost of all cases in MS-DRG 252. The commenter stated that there
would be an underpayment for all the drug-eluting stent cases if the cases continue to be assigned to MS-DRGs 252, 253, and 254. The commenter stated that implementing its original request would allow more adequate payment to hospitals using the Zilver® PTX® technology and thus remove a potential financial barrier to Medicare providers desiring to provide access of this technology to their patients.

Another commenter asserted that it understood CMS’ concern that the agency could be overpaying for uncomplicated cases by assigning all drug-eluting stent cases to MS-DRG 252, even if they did not have a MCC. However, the commenter stated that CMS is underpaying all drug-eluting stent cases by maintaining the current MS-DRG assignments for these procedures. The commenter expressed concern regarding patient access to this technology.

Response: We appreciate the commenters’ support for our proposal to maintain the current MS-DRG for drug-eluting stent cases in MS–DRGs 252, 253, and 254. Our clinical advisors have also reexamined this issue and continue to advise us that the cases reporting procedure code 00.60 are appropriately classified within MS–DRG 252, 253, or 254.

In regard to the commenters who disagreed with our proposal, as stated earlier, the data do not support assigning all the drug-eluting stent cases to the highest severity level (MS–DRG 252), even when there is not an MCC. We note that while the average costs for MS-DRG 254 (lowest severity level) may only represent 19 percent of the drug-eluting stent cases as shown in the table above, the MS-DRGs are comprised of a distinct structure with respect to the types of patients within each severity level. This
structure is based on an organizing principle that patients at the MCC level, the highest severity level, are those patients who are generally sicker, consume an increased utilization of resources, and require more complex services. Disregarding this structure solely for the purpose of increasing payment for patients who are not similar in terms of their severity of illness and resource utilization would be inconsistent with how the MS-DRGs are otherwise defined within the classification system.

In addition, as the requester pointed out in its own comments, “it is the nature of a MS-DRG system that there will be variations in cost between different hospitalizations that fall into the same MS-DRG or MS-DRGs – each MS-DRG will have some cases that are higher and some cases that are lower than the average costs for the entire MS-DRG.” We believe that the higher average costs for the drug-eluting stent cases can be attributed to the cost of the device and not necessarily because the patients receiving these stents are more severely ill.

With regard to the commenters’ concerns regarding patient access to the technology with the expiration of the new technology add-on payment, we would expect that hospitals that now have experience with the technology and have observed favorable clinical outcomes for their patients would nonetheless consider the technology to be worth the investment. Accordingly, we will continue to monitor cases with the Zilver® PTX® technology to determine if modifications are warranted to the MS-DRG structure in future rulemaking.
After consideration of the public comments we received, we are finalizing our proposal to maintain the current structure for MS–DRG assignments for procedures involving drug-eluting stents in MS-DRG 252, 253, or 254 for FY 2016.

d. Percutaneous Mitral Valve Repair System—Proposed Revision of ICD-10-PCS Version 32 Logic

We received a comment which brought to our attention that the ICD-10 MS-DRGs Version 32 assignment for ICD-10-PCS procedure code 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach) does not accurately replicate the ICD-9-CM MS-DRGs Version 32, which assigns this procedure code to the following MS-DRGs:

- MS-DRG 231 (Coronary Bypass with PTCA with MCC);
- MS-DRG 232 (Coronary Bypass with PTCA without MCC);
- MS-DRG 246 (Percutaneous Cardiovascular Procedure with Drug-Eluting Stent with MCC or 4+ Vessels/Stents);
- MS DRG 247 (Percutaneous Cardiovascular Procedure with Drug-Eluting Stent without MCC);
- MS-DRG 248 (Percutaneous Cardiovascular Procedure with Non-Drug-Eluting Stent with MCC or 4+ Vessels/Stents);
- MS DRG 249 (Percutaneous Cardiovascular Procedure with Non-Drug-Eluting Stent without MCC);
- MS-DRG 250 (Percutaneous Cardiovascular Procedure without Coronary Artery Stent with MCC); and
We agree with the commenter that the ICD-10 MS-DRGs logic should be consistent with the ICD-9 MS-DRGs logic; that is, the ICD-10 MS-DRGs Version 32 should replicate the ICD-9-CM MS-DRGs Version 32. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule, for the proposed FY 2016 ICD-10 MS-DRGs Version 33, we proposed to assign ICD-10-PCS procedure code 02UG3JZ to MS-DRGs 231 and 232 and MS-DRGs 246 through 251 (80 FR 24362). We invited public comments on this proposal.

**Comment:** Several commenters agreed with the proposal to assign ICD-10-PCS procedure code 02UG3JZ to ICD-10 MS-DRGs 231 and 232 and MS-DRGs 246 through 251 to accurately replicate the ICD-9-CM MS-DRGs Version 32 logic. The commenters also noted that, as discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24356 through 24359), for the FY 2016 ICD-10 MS-DRGs Version 33, CMS proposed to create two new ICD-10 MS-DRGs which include ICD-10-PCS procedure code 02UG3JZ. The commenters recognized that, if proposed new MS-DRGs 273 and 274 (Percutaneous Intracardiac Procedures with and without MCC, respectively) were finalized for FY 2016, ICD-10-PCS procedure code 02UG3JZ would then group to those new MS-DRGs. The commenters requested that CMS confirm the MS-DRG assignment.

**Response:** We appreciate the commenters’ support for our proposal to accurately replicate the assignment of ICD-10-PCS procedure code 02UG3JZ under the ICD-10 MS-DRGs. As discussed earlier in section III.G.3.a. of this final rule, we are finalizing
our proposal to create ICD-10 MS-DRGs 273 and 274 (Percutaneous Intracardiac Procedures with and without MCC, respectively). After consideration of the public comments we received, we are confirming as final policy for the FY 2016 ICD-10 MS-DRGs Version 33 that ICD-10-PCS procedure code 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach) is assigned to new ICD-10 MS-DRGs 273 and 274 and will continue to be assigned to MS-DRGs 231 and 232 (Coronary Bypass with PTC with MCC and without MCC, respectively).
e. Major Cardiovascular Procedures: Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Graft

New technology add-on payments for the Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Graft (Zenith® F. Graft) will end on September 30, 2015. Cases involving the Zenith® F. Graft are identified by ICD-9-CM procedure code 39.78 (Endovascular implantation of branching or fenestrated graft(s) in aorta) in MS-DRGs 237 and 238 (Major Cardiovascular Procedures with and without MCC, respectively). For additional information on the Zenith® F. Graft, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 49921 through 49922).

We received a request to reassign procedures described by ICD-9-CM procedure code 39.78 to the highest severity level in MS-DRGs 237 and 238, including in instances when there is not an MCC present, or to create a new MS-DRG that would contain all endovascular aneurysm repair procedures. We note that, in addition to ICD-9-CM procedure code 39.78, ICD-9-CM procedure code 39.71 (Endovascular implantation of other graft in abdominal aorta) also describes endovascular aneurysm repair procedures.
There are a number of ICD-10-PCS code translations that provide more detailed and specific information for each of ICD-9-CM codes 39.71 and 39.78 that also currently group to MS-DRGs 237 and 238 in the ICD-10 MS-DRGs Version 32. The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.71 and 39.78 are shown in the following tables:

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.71

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04U03JZ</td>
<td>Supplement abdominal aorta with synthetic substitute, percutaneous approach</td>
</tr>
<tr>
<td>04U04JZ</td>
<td>Supplement abdominal aorta with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04V03DZ</td>
<td>Restriction of abdominal aorta with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04V04DZ</td>
<td>Restriction of abdominal aorta with intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.78

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04V03DZ</td>
<td>Restriction of abdominal aorta with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04V04DZ</td>
<td>Restriction of abdominal aorta with intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

Note: As discussed later in this section, the FY 2016 IPPS/LTCH PPS proposed rule listed the dilation codes ICD-10-PCS 04793DZ through 04754DZ as possible translations for ICD-9-CM procedure code 39.78. For this final rule, we are only listing those codes that as “standalone” procedures are assigned to new MS-DRGs 268 and 269.

We analyzed claims data reporting ICD-9-CM procedure code 39.78 for cases assigned to MS-DRGs 237 and 238 in the December 2014 update of the FY 2014 MedPAR file. We found a total of 18,340 cases, with an average length of stay of 9.46 days and average costs of $36,355 in MS-DRG 237. We found 332 cases reporting ICD-9-CM procedure code 39.78, with an average length of stay of 8.46 days and...
average costs of $51,397 in MS-DRG 237. For MS-DRG 238, we found a total of 32,227 cases, with an average length of stay of 3.72 days and average costs of $25,087. We found 1,927 cases reporting ICD-9-CM procedure code 39.78, with an average length of stay of 2.52 days and average costs of $31,739 in MS-DRG 238.

<table>
<thead>
<tr>
<th>Zenith Fenestrated Graft Procedures</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 237 – All cases</td>
<td>18,340</td>
<td>9.46</td>
<td>$36,355</td>
</tr>
<tr>
<td>MS-DRG 237 – Cases with procedure code 39.78</td>
<td>332</td>
<td>8.46</td>
<td>$51,397</td>
</tr>
<tr>
<td>MS-DRG 238 – All cases</td>
<td>32,227</td>
<td>3.72</td>
<td>$25,087</td>
</tr>
<tr>
<td>MS-DRG 238 – Cases with procedure code 39.78</td>
<td>1,927</td>
<td>2.52</td>
<td>$31,739</td>
</tr>
</tbody>
</table>

As illustrated in the table above, the results of the data analysis indicate that the average costs for cases reporting procedure code 39.78 assigned to MS-DRG 238 were higher than the average costs for all cases in MS-DRG 238 ($31,739 compared to $25,087). In addition, the average costs for the 1,927 cases reporting procedure code 39.78 assigned to MS-DRG 238 were $4,616 less than the costs of all cases assigned to MS-DRG 237. We determined that moving cases reporting procedure code 39.78 from MS-DRG 238 to MS-DRG 237 would result in overpayments. We also noted that the average length of stay for the 1,927 cases reporting procedure code 39.78 in MS-DRG 238 was 2.52 days in comparison to the average length of stay for all cases in MS-DRG 237 of 9.46 days. Our clinical advisors did not agree with moving cases reporting procedure code 39.78 to a higher severity level (with MCC) MS-DRG.
We believe that the higher average costs could be attributed to the cost of the device. The Zenith® F. Graft is the only fenestrated graft device currently approved by the FDA. Therefore, this manufacturer is able to set its own costs in the market. We pointed out that the IPPS is not designed to pay solely for the cost of devices. More importantly, moving cases that greatly differ in their severity of illness and complexity of resources into a higher severity level MS-DRG, in the absence of an MCC, would conflict with the objective of the MS-DRGs, which is to maintain homogeneous subgroups that are different from one another in terms of utilization of resources, that have enough volume to be meaningful, and that improve our ability to explain variance in resource use (72 FR 47169). Therefore, we did not propose to reassign all cases reporting procedure code 39.78 from MS-DRG 238 to MS-DRG 237, as the commenter requested.

However, we recognized that the results of the data analysis also demonstrated that the average costs for cases reporting ICD-9-CM procedure code 39.78 are higher in both MS-DRG 237 and MS-DRG 238 in comparison to all cases in each respective MS-DRG. As these higher average costs could be attributable to the cost of the device, we noted the commenter’s concern that the end of the new technology add-on payment for Zenith® F. Graft, effective September 30, 2015, may result in reduced payment to hospitals and potentially lead to issues involving access to care for the subset of beneficiaries who would benefit from treatment with the Zenith® F. Graft. We continued to review the data to explore other alternatives as we analyzed additional claims data in
response to the second part of the request from the commenter; that is, to create a new MS-DRG that would contain all endovascular aneurysm repair procedures.

In our evaluation of the claims data in response to the request to create a new MS-DRG, we again reviewed claims data from the December 2014 update of the FY 2014 MedPAR file. We began our analysis by examining claims data for cases reporting ICD-9-CM procedure codes 39.71 and 39.78 assigned to MS-DRGs 237 and 238. Our findings are shown in the table below.

<table>
<thead>
<tr>
<th>Endovascular Abdominal Aorta Procedures</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 237 – All cases</td>
<td>18,340</td>
<td>9.46</td>
<td>$36,355</td>
</tr>
<tr>
<td>MS-DRG 237 – Cases with procedure codes 39.71 and 39.78</td>
<td>2,425</td>
<td>8.34</td>
<td>$47,363</td>
</tr>
<tr>
<td>MS-DRG 238 – All cases</td>
<td>32,227</td>
<td>3.72</td>
<td>$25,087</td>
</tr>
<tr>
<td>MS-DRG 238 – Cases with procedure codes 39.71 and 39.78</td>
<td>16,502</td>
<td>2.27</td>
<td>$28,998</td>
</tr>
</tbody>
</table>

As shown in the table above, the average costs for cases involving endovascular abdominal aorta aneurysm repair procedures assigned to MS-DRG 237 were higher than the average costs of all cases assigned to MS-DRGs 237. The average costs for cases reporting ICD-9-CM procedure codes 39.71 and 39.78 assigned to MS-DRG 237 were $47,363 compared to the average costs of $36,355 for all cases assigned to MS-DRG 237 and $25,087 for all cases assigned to MS-DRG 238. Similarly, the average costs for cases reporting ICD-9-CM procedure codes 39.71 and 39.78 assigned to MS-DRG 238 were higher than the average costs of all cases assigned to MS-DRG 238 ($28,998 compared to $25,087). The average length of stay for cases reporting ICD-9-CM
procedure codes 39.71 and 39.78 in MS-DRGs 237 and 238 were also shorter than the average length of stay for all cases in the respective MS-DRG.

Our clinical advisors did not support creating a new MS-DRG specifically for endovascular abdominal aortic aneurysm repair procedures only. Therefore, we reviewed other procedure codes currently assigned to MS-DRGs 237 and 238 and found that there were a number of procedures with varying resource requirements and clinical indications that could be analyzed further. We agreed with our clinical advisors that further analysis was warranted to determine how we could better recognize resource utilization, clinical complexity, and average costs by separating the more complex, more invasive, and more expensive procedures used to treat more severely ill individuals from the less complex, less invasive, and less expensive procedures currently grouped to these MS-DRGs.

Therefore, we evaluated all of the procedures currently assigned to MS-DRGs 237 and 238. In our evaluation, we found that MS-DRGs 237 and 238 contained two distinct groups of procedures. We found a high volume of less invasive procedures, such as pericardiotomies and pulsation balloon implants, that had substantially lower costs than the more invasive procedures, such as open and endovascular repairs of the aorta with replacement grafts. We found that the more invasive procedures were primarily associated with procedures on the aorta and heart assist procedures.

For this next phase of our analysis, the following procedure codes were designated as the more complex, more invasive procedures:

- 37.41 (Implantation of prosthetic cardiac support device around the heart);
- 37.49 (Other repair of heart and pericardium);
• 37.55 (Removal of internal biventricular heart replacement system);
• 37.64 (Removal of external heart assist system(s) or device(s));
• 38.04 (Incision of vessel, aorta);
• 38.14 (Endarterectomy, aorta);
• 38.34 (Resection of vessel with anastomosis, aorta);
• 38.44 (Resection of vessel with replacement, aorta, abdominal);
• 38.64 (Other excision of vessels, aorta, abdominal);
• 38.84 (Other surgical occlusion of vessels, aorta, abdominal);
• 39.24 (Aorta-renal bypass);
• 39.71 (Endovascular implantation of other graft in abdominal aorta); and
• 39.78 (Endovascular implantation of branching or fenestrated graft(s) in aorta).

There are a number of ICD-10-PCS code translations that provide more detailed and specific information for each of the ICD-9-CM codes listed above that also currently group to MS-DRGs 237 and 238 in the ICD-10 MS-DRGs Version 32. The comparable ICD-10-PCS code translations for these ICD-9-CM procedure codes are shown in the following table:

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02UA0JZ</td>
<td>Supplement heart with synthetic substitute, open approach</td>
</tr>
<tr>
<td>02UA3JZ</td>
<td>Supplement heart with synthetic substitute, percutaneous approach</td>
</tr>
<tr>
<td>02UA4JZ</td>
<td>Supplement heart with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
For the ICD-9-CM codes that result in greater than 50 ICD-10-PCS comparable code translations, we refer readers to Table 6P (ICD-10-PCS Code Translations for MS-DRG Changes) for this FY 2016 final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html). The table includes the MDC topic, the ICD-9-CM code, and the ICD-10-PCS code translations.

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.49

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02PA0QZ</td>
<td>Removal of implantable heart assist system from heart, open approach</td>
</tr>
<tr>
<td>02PA3QZ</td>
<td>Removal of implantable heart assist system from heart, percutaneous approach</td>
</tr>
<tr>
<td>02PA4QZ</td>
<td>Removal of implantable heart assist system from heart, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.55

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02PA0RZ</td>
<td>Removal of external heart assist system from heart, open approach</td>
</tr>
<tr>
<td>02PA3RZ</td>
<td>Removal of external heart assist system from heart, percutaneous approach</td>
</tr>
<tr>
<td>02PA4RZ</td>
<td>Removal of external heart assist system from heart, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.64

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02PA0RZ</td>
<td>Removal of external heart assist system from heart, open approach</td>
</tr>
<tr>
<td>02PA3RZ</td>
<td>Removal of external heart assist system from heart, percutaneous approach</td>
</tr>
<tr>
<td>02PA4RZ</td>
<td>Removal of external heart assist system from heart, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.04

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02CW0ZZ</td>
<td>Extirpation of matter from thoracic aorta, open approach</td>
</tr>
<tr>
<td>02CW3ZZ</td>
<td>Extirpation of matter from thoracic aorta, percutaneous approach</td>
</tr>
<tr>
<td>02CW4ZZ</td>
<td>Extirpation of matter from thoracic aorta, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C00ZZ</td>
<td>Extirpation of matter from abdominal aorta, open approach</td>
</tr>
<tr>
<td>04C03ZZ</td>
<td>Extirpation of matter from abdominal aorta, percutaneous approach</td>
</tr>
<tr>
<td>04C04ZZ</td>
<td>Extirpation of matter from abdominal aorta, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.14

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02CW0ZZ</td>
<td>Extirpation of matter from thoracic aorta, open approach</td>
</tr>
<tr>
<td>02CW3ZZ</td>
<td>Extirpation of matter from thoracic aorta, percutaneous approach</td>
</tr>
<tr>
<td>02CW4ZZ</td>
<td>Extirpation of matter from thoracic aorta, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C00ZZ</td>
<td>Extirpation of matter from abdominal aorta, open approach</td>
</tr>
<tr>
<td>04C03ZZ</td>
<td>Extirpation of matter from abdominal aorta, percutaneous approach</td>
</tr>
<tr>
<td>04C04ZZ</td>
<td>Extirpation of matter from abdominal aorta, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.34

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02BW0ZZ</td>
<td>Excision of thoracic aorta, open approach</td>
</tr>
<tr>
<td>02BW4ZZ</td>
<td>Excision of thoracic aorta, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04B00ZZ</td>
<td>Excision of abdominal aorta, open approach</td>
</tr>
<tr>
<td>04B04ZZ</td>
<td>Excision of abdominal aorta, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>04R007Z</td>
<td>Replacement of abdominal aorta with autologous tissue substitute, open approach</td>
</tr>
<tr>
<td>04R00JZ</td>
<td>Replacement of abdominal aorta with synthetic substitute, open approach</td>
</tr>
<tr>
<td>04R00KZ</td>
<td>Replacement of abdominal aorta with nonautologous tissue substitute, open approach</td>
</tr>
<tr>
<td>04R047Z</td>
<td>Replacement of abdominal aorta with autologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04R04JZ</td>
<td>Replacement of abdominal aorta with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04R04KZ</td>
<td>Replacement of abdominal aorta with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04500ZZ</td>
<td>Destruction of abdominal aorta, open approach</td>
</tr>
<tr>
<td>04503ZZ</td>
<td>Destruction of abdominal aorta, percutaneous approach</td>
</tr>
<tr>
<td>04504ZZ</td>
<td>Destruction of abdominal aorta, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04B00ZZ</td>
<td>Excision of abdominal aorta, open approach</td>
</tr>
<tr>
<td>04B03ZZ</td>
<td>Excision of abdominal aorta, percutaneous approach</td>
</tr>
<tr>
<td>04B04ZZ</td>
<td>Excision of abdominal aorta, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.84

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04L00CZ</td>
<td>Occlusion of abdominal aorta with extraluminal device, open approach</td>
</tr>
<tr>
<td>04L00DZ</td>
<td>Occlusion of abdominal aorta with intraluminal device, open approach</td>
</tr>
<tr>
<td>04L00ZZ</td>
<td>Occlusion of abdominal aorta, open approach</td>
</tr>
<tr>
<td>04L03CZ</td>
<td>Occlusion of abdominal aorta with extraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04L03DZ</td>
<td>Occlusion of abdominal aorta with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04L03ZZ</td>
<td>Occlusion of abdominal aorta, percutaneous approach</td>
</tr>
<tr>
<td>04L04CZ</td>
<td>Occlusion of abdominal aorta with extraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04L04DZ</td>
<td>Occlusion of abdominal aorta with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04L04ZZ</td>
<td>Occlusion of abdominal aorta, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0410093</td>
<td>Bypass abdominal aorta to right renal artery with autologous venous tissue, open approach</td>
</tr>
<tr>
<td>0410094</td>
<td>Bypass abdominal aorta to left renal artery with autologous venous tissue, open approach</td>
</tr>
<tr>
<td>0410095</td>
<td>Bypass abdominal aorta to bilateral renal artery with autologous venous tissue, open approach</td>
</tr>
<tr>
<td>04100A3</td>
<td>Bypass abdominal aorta to right renal artery with autologous arterial tissue, open approach</td>
</tr>
<tr>
<td>04100A4</td>
<td>Bypass abdominal aorta to left renal artery with autologous arterial tissue, open approach</td>
</tr>
<tr>
<td>04100A5</td>
<td>Bypass abdominal aorta to bilateral renal artery with autologous arterial tissue, open approach</td>
</tr>
<tr>
<td>04100J3</td>
<td>Bypass abdominal aorta to right renal artery with synthetic substitute, open approach</td>
</tr>
<tr>
<td>04100J4</td>
<td>Bypass abdominal aorta to left renal artery with synthetic substitute, open approach</td>
</tr>
<tr>
<td>04100J5</td>
<td>Bypass abdominal aorta to bilateral renal artery with synthetic substitute, open approach</td>
</tr>
<tr>
<td>04100K3</td>
<td>Bypass abdominal aorta to right renal artery with nonautologous tissue substitute, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>04100K4</td>
<td>Bypass abdominal aorta to left renal artery with nonautologous tissue substitute, open approach</td>
</tr>
<tr>
<td>04100K5</td>
<td>Bypass abdominal aorta to bilateral renal artery with nonautologous tissue substitute, open approach</td>
</tr>
<tr>
<td>04100Z3</td>
<td>Bypass abdominal aorta to right renal artery, open approach</td>
</tr>
<tr>
<td>04100Z4</td>
<td>Bypass abdominal aorta to left renal artery, open approach</td>
</tr>
<tr>
<td>04100Z5</td>
<td>Bypass abdominal aorta to bilateral renal artery, open approach</td>
</tr>
<tr>
<td>0410493</td>
<td>Bypass abdominal aorta to right renal artery with autologous venous tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0410494</td>
<td>Bypass abdominal aorta to left renal artery with autologous venous tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0410495</td>
<td>Bypass abdominal aorta to bilateral renal artery with autologous venous tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104A3</td>
<td>Bypass abdominal aorta to right renal artery with autologous arterial tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104A4</td>
<td>Bypass abdominal aorta to left renal artery with autologous arterial tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104A5</td>
<td>Bypass abdominal aorta to bilateral renal artery with autologous arterial tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104J3</td>
<td>Bypass abdominal aorta to right renal artery with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104J4</td>
<td>Bypass abdominal aorta to left renal artery with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104J5</td>
<td>Bypass abdominal aorta to bilateral renal artery with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104K3</td>
<td>Bypass abdominal aorta to right renal artery with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104K4</td>
<td>Bypass abdominal aorta to left renal artery with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104K5</td>
<td>Bypass abdominal aorta to bilateral renal artery with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104Z3</td>
<td>Bypass abdominal aorta to right renal artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104Z4</td>
<td>Bypass abdominal aorta to left renal artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04104Z5</td>
<td>Bypass abdominal aorta to bilateral renal artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>04U03JZ</td>
<td>Supplement abdominal aorta with synthetic substitute, percutaneous approach</td>
</tr>
<tr>
<td>04U04JZ</td>
<td>Supplement abdominal aorta with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04V03DZ</td>
<td>Restriction of abdominal aorta with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04V04DZ</td>
<td>Restriction of abdominal aorta with intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04793DZ</td>
<td>Dilation of right renal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04794DZ</td>
<td>Dilation of right renal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047A3DZ</td>
<td>Dilation of left renal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>047A4DZ</td>
<td>Dilation of left renal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04753DZ</td>
<td>Dilation of superior mesenteric artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04754DZ</td>
<td>Dilation of superior mesenteric artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04U03JZ</td>
<td>Supplement abdominal aorta with synthetic substitute, percutaneous approach</td>
</tr>
<tr>
<td>04U04JZ</td>
<td>Supplement abdominal aorta with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04V03DZ</td>
<td>Restriction of abdominal aorta with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04V04DZ</td>
<td>Restriction of abdominal aorta with intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

For the next phase of our analysis, the procedure codes shown in the following table were designated as the less complex, less invasive procedures.

<p>| ICD-9-CM Procedure Codes That Were Designated as the Less Complex, Less Invasive Procedures |</p>
<table>
<thead>
<tr>
<th>ICD-9-CM Procedure Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>35.00</td>
<td>Closed heart valvotomy, unspecified valve</td>
</tr>
<tr>
<td>35.01</td>
<td>Closed heart valvotomy, aortic valve</td>
</tr>
<tr>
<td>35.02</td>
<td>Closed heart valvotomy, mitral valve</td>
</tr>
<tr>
<td>35.03</td>
<td>Closed heart valvotomy, pulmonary valve</td>
</tr>
<tr>
<td>35.04</td>
<td>Closed heart valvotomy, tricuspid valve</td>
</tr>
<tr>
<td>37.12</td>
<td>Pericardiectomy</td>
</tr>
<tr>
<td>37.24</td>
<td>Biopsy of pericardium</td>
</tr>
<tr>
<td>37.31</td>
<td>Pericardiectomy</td>
</tr>
<tr>
<td>37.61</td>
<td>Implant of pulsation balloon</td>
</tr>
<tr>
<td>37.67</td>
<td>Implantation of cardiomyostimulation system</td>
</tr>
<tr>
<td>37.91</td>
<td>Open chest cardiac massage</td>
</tr>
<tr>
<td>37.99</td>
<td>Other operations on heart and pericardium</td>
</tr>
<tr>
<td>38.05</td>
<td>Incision of vessel, other thoracic vessels</td>
</tr>
<tr>
<td>38.06</td>
<td>Incision of vessel, abdominal arteries</td>
</tr>
<tr>
<td>38.07</td>
<td>Incision of vessel, abdominal veins</td>
</tr>
<tr>
<td>38.15</td>
<td>Endarterectomy, other thoracic vessels</td>
</tr>
<tr>
<td>38.16</td>
<td>Endarterectomy, abdominal arteries</td>
</tr>
<tr>
<td>38.35</td>
<td>Resection of vessel with anastomosis, other thoracic vessels</td>
</tr>
<tr>
<td>38.36</td>
<td>Resection of vessel with anastomosis, abdominal arteries</td>
</tr>
<tr>
<td>38.37</td>
<td>Resection of vessel with anastomosis, abdominal veins</td>
</tr>
<tr>
<td>38.46</td>
<td>Resection of vessel with replacement, abdominal arteries</td>
</tr>
<tr>
<td>38.47</td>
<td>Resection of vessel with replacement, abdominal veins</td>
</tr>
<tr>
<td>38.55</td>
<td>Ligation and stripping of varicose veins, other thoracic vessels</td>
</tr>
<tr>
<td>38.65</td>
<td>Other excision of vessels, thoracic vessels</td>
</tr>
<tr>
<td>38.66</td>
<td>Other excision of vessels, abdominal arteries</td>
</tr>
<tr>
<td>38.67</td>
<td>Other excision of vessels, abdominal veins</td>
</tr>
<tr>
<td>38.85</td>
<td>Other surgical occlusion of vessels, thoracic vessels</td>
</tr>
<tr>
<td>38.86</td>
<td>Other surgical occlusion of vessels, abdominal arteries</td>
</tr>
<tr>
<td>38.87</td>
<td>Other surgical occlusion of vessels, abdominal veins</td>
</tr>
<tr>
<td>39.0</td>
<td>Systemic to pulmonary artery shunt</td>
</tr>
<tr>
<td>39.1</td>
<td>Intra-abdominal venous shunt</td>
</tr>
<tr>
<td>39.21</td>
<td>Caval-pulmonary artery anastomosis</td>
</tr>
<tr>
<td>39.22</td>
<td>Aorta-subclavian-carotid bypass</td>
</tr>
<tr>
<td>39.23</td>
<td>Other intrathoracic vascular shunt or bypass</td>
</tr>
<tr>
<td>39.25</td>
<td>Aorta-iliac-femoral bypass</td>
</tr>
<tr>
<td>39.26</td>
<td>Other intra-abdominal vascular shunt or bypass</td>
</tr>
<tr>
<td>39.52</td>
<td>Other repair of aneurysm</td>
</tr>
<tr>
<td>39.54</td>
<td>Re-entry operation (aorta)</td>
</tr>
<tr>
<td>39.72</td>
<td>Endovascular (total) embolization or occlusion of head and neck vessels</td>
</tr>
<tr>
<td>39.75</td>
<td>Endovascular embolization or occlusion of vessel(s) of head or neck using</td>
</tr>
</tbody>
</table>
### ICD-9-CM Procedure Codes That Were Designated as the Less Complex, Less Invasive Procedures

<table>
<thead>
<tr>
<th>ICD-9-CM Procedure Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>bare coils</td>
<td></td>
</tr>
<tr>
<td>39.76</td>
<td>Endovascular embolization or occlusion of vessel(s) of head or neck using bioactive coils</td>
</tr>
<tr>
<td>39.79</td>
<td>Other endovascular procedures on other vessels</td>
</tr>
</tbody>
</table>

There are a number of ICD-10-PCS code translations that provide more detailed and specific information for each of the ICD-9-CM codes listed in the table immediately above that also currently group to MS-DRGs 237 and 238 in the ICD-10 MS-DRGs Version 32. The comparable ICD-10-PCS code translations for these ICD-9-CM procedure codes are shown in the following tables:

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 35.00

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02NF3ZZ</td>
<td>Release aortic valve, percutaneous approach</td>
</tr>
<tr>
<td>02NF4ZZ</td>
<td>Release aortic valve, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02NG3ZZ</td>
<td>Release mitral valve, percutaneous approach</td>
</tr>
<tr>
<td>02NG4ZZ</td>
<td>Release mitral valve, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02NH3ZZ</td>
<td>Release pulmonary valve, percutaneous approach</td>
</tr>
<tr>
<td>02NH4ZZ</td>
<td>Release pulmonary valve, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02NJ3ZZ</td>
<td>Release tricuspid valve, percutaneous approach</td>
</tr>
<tr>
<td>02NJ4ZZ</td>
<td>Release tricuspid valve, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 35.01

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02CF3ZZ</td>
<td>Extirpation of matter from aortic valve, percutaneous approach</td>
</tr>
<tr>
<td>02CF4ZZ</td>
<td>Extirpation of matter from aortic valve, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02NF3ZZ</td>
<td>Release aortic valve, percutaneous approach</td>
</tr>
<tr>
<td>02NF4ZZ</td>
<td>Release aortic valve, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translation for ICD-9-CM Procedure Code 35.02

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02CG3ZZ</td>
<td>Extirpation of matter from mitral valve, percutaneous approach</td>
</tr>
<tr>
<td>02CG4ZZ</td>
<td>Extirpation of matter from mitral valve, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02NG3ZZ</td>
<td>Release mitral valve, percutaneous approach</td>
</tr>
<tr>
<td>02NG4ZZ</td>
<td>Release mitral valve, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 35.03

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02CH3ZZ</td>
<td>Extirpation of matter from pulmonary valve, percutaneous approach</td>
</tr>
<tr>
<td>02CH4ZZ</td>
<td>Extirpation of matter from pulmonary valve, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02NH3ZZ</td>
<td>Release Pulmonary Valve, Percutaneous Approach</td>
</tr>
<tr>
<td>02NH4ZZ</td>
<td>Release Pulmonary Valve, Percutaneous Endoscopic Approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 35.04

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02CJ3ZZ</td>
<td>Extirpation of matter from tricuspid valve, percutaneous approach</td>
</tr>
<tr>
<td>02CJ4ZZ</td>
<td>Extirpation of matter from tricuspid valve, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02NJ3ZZ</td>
<td>Release tricuspid valve, percutaneous approach</td>
</tr>
<tr>
<td>02NJ4ZZ</td>
<td>Release tricuspid valve, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.12
<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02CN0ZZ</td>
<td>Extirpation of matter from pericardium, open approach</td>
</tr>
<tr>
<td>02CN3ZZ</td>
<td>Extirpation of matter from pericardium, percutaneous approach</td>
</tr>
<tr>
<td>02CN4ZZ</td>
<td>Extirpation of matter from pericardium, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02HN00Z</td>
<td>Insertion of pressure sensor monitoring device into pericardium, open approach</td>
</tr>
<tr>
<td>02HN02Z</td>
<td>Insertion of monitoring device into pericardium, open approach</td>
</tr>
<tr>
<td>02HN30Z</td>
<td>Insertion of pressure sensor monitoring device into pericardium, percutaneous approach</td>
</tr>
<tr>
<td>02HN32Z</td>
<td>Insertion of monitoring device into pericardium, percutaneous approach</td>
</tr>
<tr>
<td>02HN40Z</td>
<td>Insertion of pressure sensor monitoring device into pericardium, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02HN42Z</td>
<td>Insertion of monitoring device into pericardium, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02NN0ZZ</td>
<td>Release pericardium, open approach</td>
</tr>
<tr>
<td>02NN3ZZ</td>
<td>Release pericardium, percutaneous approach</td>
</tr>
<tr>
<td>02NN4ZZ</td>
<td>Release pericardium, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0W9D00Z</td>
<td>Drainage of pericardial cavity with drainage device, open approach</td>
</tr>
<tr>
<td>0W9D0ZX</td>
<td>Drainage of pericardial cavity, open approach, diagnostic</td>
</tr>
<tr>
<td>0W9D0ZZ</td>
<td>Drainage of pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WCD0ZZ</td>
<td>Extirpation of matter from pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WCD3ZZ</td>
<td>Extirpation of matter from pericardial cavity, percutaneous approach</td>
</tr>
<tr>
<td>0WCD4ZZ</td>
<td>Extirpation of matter from pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WH03Z</td>
<td>Insertion of infusion device into pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WH0YZ</td>
<td>Insertion of other device into pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WH33Z</td>
<td>Insertion of infusion device into pericardial cavity, percutaneous approach</td>
</tr>
<tr>
<td>0WH3YZ</td>
<td>Insertion of other device into pericardial cavity, percutaneous approach</td>
</tr>
<tr>
<td>0WH43Z</td>
<td>Insertion of infusion device into pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WH4YZ</td>
<td>Insertion of other device into pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WPD00Z</td>
<td>Removal of drainage device from pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WPD01Z</td>
<td>Removal of radioactive element from pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WPD03Z</td>
<td>Removal of infusion device from pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WPD0YZ</td>
<td>Removal of other device from pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WPD30Z</td>
<td>Removal of drainage device from pericardial cavity, percutaneous approach</td>
</tr>
<tr>
<td>0WPD31Z</td>
<td>Removal of radioactive element from pericardial cavity, percutaneous approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.12

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0WPD33Z</td>
<td>Removal of infusion device from pericardial cavity, percutaneous approach</td>
</tr>
<tr>
<td>0WPD3YZ</td>
<td>Removal of other device from pericardial cavity, percutaneous approach</td>
</tr>
<tr>
<td>0WPD40Z</td>
<td>Removal of drainage device from pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WPD41Z</td>
<td>Removal of radioactive element from pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WPD43Z</td>
<td>Removal of infusion device from pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WPD4YZ</td>
<td>Removal of other device from pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WWD00Z</td>
<td>Revision of drainage device in pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WWD01Z</td>
<td>Revision of radioactive element in pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WWD03Z</td>
<td>Revision of infusion device in pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WWD0YZ</td>
<td>Revision of other device in pericardial cavity, open approach</td>
</tr>
<tr>
<td>0WWD30Z</td>
<td>Revision of drainage device in pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WWD31Z</td>
<td>Revision of radioactive element in pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WWD33Z</td>
<td>Revision of infusion device in pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WWD3YZ</td>
<td>Revision of other device in pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WWD40Z</td>
<td>Revision of drainage device in pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WWD41Z</td>
<td>Revision of radioactive element in pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WWD43Z</td>
<td>Revision of infusion device in pericardial cavity, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>0WWD4YZ</td>
<td>Revision of other device in pericardial cavity, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.24

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02BN0ZX</td>
<td>Excision of pericardium, open approach, diagnostic</td>
</tr>
<tr>
<td>02BN3ZX</td>
<td>Excision of pericardium, percutaneous approach, diagnostic</td>
</tr>
<tr>
<td>02BN4ZX</td>
<td>Excision of pericardium, percutaneous endoscopic approach, diagnostic</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.31

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td>025N0ZZ</td>
<td>Destruction of pericardium, open approach</td>
</tr>
<tr>
<td>025N3ZZ</td>
<td>Destruction of pericardium, percutaneous approach</td>
</tr>
<tr>
<td>025N4ZZ</td>
<td>Destruction of pericardium, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02BN0ZZ</td>
<td>Excision of pericardium, open approach</td>
</tr>
<tr>
<td>02BN3ZZ</td>
<td>Excision of pericardium, percutaneous approach</td>
</tr>
<tr>
<td>02BN4ZZ</td>
<td>Excision of pericardium, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02TN0ZZ</td>
<td>Resection of pericardium, open approach</td>
</tr>
<tr>
<td>02TN3ZZ</td>
<td>Resection of pericardium, percutaneous approach</td>
</tr>
<tr>
<td>02TN4ZZ</td>
<td>Resection of pericardium, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.61</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10-PCS Code</td>
</tr>
<tr>
<td>5A02110</td>
</tr>
<tr>
<td>5A02210</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.67</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10-PCS Code</td>
</tr>
<tr>
<td>02QA0ZZ</td>
</tr>
<tr>
<td>02QA3ZZ</td>
</tr>
<tr>
<td>02QA4ZZ</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 37.91</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10-PCS Code</td>
</tr>
<tr>
<td>02QA0ZZ</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10-PCS Code</td>
</tr>
<tr>
<td>02880ZZ</td>
</tr>
<tr>
<td>02883ZZ</td>
</tr>
<tr>
<td>02884ZZ</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.05 are</td>
</tr>
</tbody>
</table>


shown in Table 6P.1b for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04C10ZZ</td>
<td>Extirpation of matter from celiac artery, open approach</td>
</tr>
<tr>
<td>04C13ZZ</td>
<td>Extirpation of matter from celiac artery, percutaneous approach</td>
</tr>
<tr>
<td>04C14ZZ</td>
<td>Extirpation of matter from celiac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C20ZZ</td>
<td>Extirpation of matter from gastric artery, open approach</td>
</tr>
<tr>
<td>04C23ZZ</td>
<td>Extirpation of matter from gastric artery, percutaneous approach</td>
</tr>
<tr>
<td>04C24ZZ</td>
<td>Extirpation of matter from gastric artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C30ZZ</td>
<td>Extirpation of matter from hepatic artery, open approach</td>
</tr>
<tr>
<td>04C33ZZ</td>
<td>Extirpation of matter from hepatic artery, percutaneous approach</td>
</tr>
<tr>
<td>04C34ZZ</td>
<td>Extirpation of matter from hepatic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C40ZZ</td>
<td>Extirpation of matter from splenic artery, open approach</td>
</tr>
<tr>
<td>04C43ZZ</td>
<td>Extirpation of matter from splenic artery, percutaneous approach</td>
</tr>
<tr>
<td>04C44ZZ</td>
<td>Extirpation of matter from splenic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C50ZZ</td>
<td>Extirpation of matter from superior mesenteric artery, open approach</td>
</tr>
<tr>
<td>04C53ZZ</td>
<td>Extirpation of matter from superior mesenteric artery, percutaneous approach</td>
</tr>
<tr>
<td>04C54ZZ</td>
<td>Extirpation of matter from superior mesenteric artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C60ZZ</td>
<td>Extirpation of matter from right colic artery, open approach</td>
</tr>
<tr>
<td>04C63ZZ</td>
<td>Extirpation of matter from right colic artery, percutaneous approach</td>
</tr>
<tr>
<td>04C64ZZ</td>
<td>Extirpation of matter from right colic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C70ZZ</td>
<td>Extirpation of matter from left colic artery, open approach</td>
</tr>
<tr>
<td>04C73ZZ</td>
<td>Extirpation of matter from left colic artery, percutaneous approach</td>
</tr>
<tr>
<td>04C74ZZ</td>
<td>Extirpation of matter from left colic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C80ZZ</td>
<td>Extirpation of matter from middle colic artery, open approach</td>
</tr>
<tr>
<td>04C83ZZ</td>
<td>Extirpation of matter from middle colic artery, percutaneous approach</td>
</tr>
<tr>
<td>04C84ZZ</td>
<td>Extirpation of matter from middle colic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04C90ZZ</td>
<td>Extirpation of matter from right renal artery, open approach</td>
</tr>
<tr>
<td>04C93ZZ</td>
<td>Extirpation of matter from right renal artery, percutaneous approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>04C94ZZ</td>
<td>Extirpation of matter from right renal artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04CA0ZZ</td>
<td>Extirpation of matter from left renal artery, open approach</td>
</tr>
<tr>
<td>04CA3ZZ</td>
<td>Extirpation of matter from left renal artery, percutaneous approach</td>
</tr>
<tr>
<td>04CA4ZZ</td>
<td>Extirpation of matter from left renal artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04CB0ZZ</td>
<td>Extirpation of matter from inferior mesenteric artery, open approach</td>
</tr>
<tr>
<td>04CB3ZZ</td>
<td>Extirpation of matter from inferior mesenteric artery, percutaneous approach</td>
</tr>
<tr>
<td>04CB4ZZ</td>
<td>Extirpation of matter from inferior mesenteric artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04CC0ZZ</td>
<td>Extirpation of matter from right common iliac artery, open approach</td>
</tr>
<tr>
<td>04CC3ZZ</td>
<td>Extirpation of matter from right common iliac artery, percutaneous approach</td>
</tr>
<tr>
<td>04CC4ZZ</td>
<td>Extirpation of matter from right common iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04CD0ZZ</td>
<td>Extirpation of matter from left common iliac artery, open approach</td>
</tr>
<tr>
<td>04CD3ZZ</td>
<td>Extirpation of matter from left common iliac artery, percutaneous approach</td>
</tr>
<tr>
<td>04CD4ZZ</td>
<td>Extirpation of matter from left common iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04CE0ZZ</td>
<td>Extirpation of matter from right internal iliac artery, open approach</td>
</tr>
<tr>
<td>04CE3ZZ</td>
<td>Extirpation of matter from right internal iliac artery, percutaneous approach</td>
</tr>
<tr>
<td>04CE4ZZ</td>
<td>Extirpation of matter from right internal iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04CF0ZZ</td>
<td>Extirpation of matter from left internal iliac artery, open approach</td>
</tr>
<tr>
<td>04CF3ZZ</td>
<td>Extirpation of matter from left internal iliac artery, percutaneous approach</td>
</tr>
<tr>
<td>04CF4ZZ</td>
<td>Extirpation of matter from left internal iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04CH0ZZ</td>
<td>Extirpation of matter from right external iliac artery, open approach</td>
</tr>
<tr>
<td>04CH3ZZ</td>
<td>Extirpation of matter from right external iliac artery, percutaneous approach</td>
</tr>
<tr>
<td>04CH4ZZ</td>
<td>Extirpation of matter from right external iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04CJ0ZZ</td>
<td>Extirpation of matter from left external iliac artery, open approach</td>
</tr>
<tr>
<td>04CJ3ZZ</td>
<td>Extirpation of matter from left external iliac artery, percutaneous approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>04CJ4ZZ</td>
<td>Extirpation of matter from left external iliac artery, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06C00ZZ</td>
<td>Extirpation of matter from inferior vena cava, open approach</td>
</tr>
<tr>
<td>06C03ZZ</td>
<td>Extirpation of matter from inferior vena cava, percutaneous approach</td>
</tr>
<tr>
<td>06C04ZZ</td>
<td>Extirpation of matter from inferior vena cava, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06C10ZZ</td>
<td>Extirpation of matter from splenic vein, open approach</td>
</tr>
<tr>
<td>06C13ZZ</td>
<td>Extirpation of matter from splenic vein, percutaneous approach</td>
</tr>
<tr>
<td>06C14ZZ</td>
<td>Extirpation of matter from splenic vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06C20ZZ</td>
<td>Extirpation of matter from gastric vein, open approach</td>
</tr>
<tr>
<td>06C23ZZ</td>
<td>Extirpation of matter from gastric vein, percutaneous approach</td>
</tr>
<tr>
<td>06C24ZZ</td>
<td>Extirpation of matter from gastric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06C40ZZ</td>
<td>Extirpation of matter from hepatic vein, open approach</td>
</tr>
<tr>
<td>06C43ZZ</td>
<td>Extirpation of matter from hepatic vein, percutaneous approach</td>
</tr>
<tr>
<td>06C44ZZ</td>
<td>Extirpation of matter from hepatic vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06C50ZZ</td>
<td>Extirpation of matter from superior mesenteric vein, open approach</td>
</tr>
<tr>
<td>06C53ZZ</td>
<td>Extirpation of matter from superior mesenteric vein, percutaneous approach</td>
</tr>
<tr>
<td>06C54ZZ</td>
<td>Extirpation of matter from superior mesenteric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06C60ZZ</td>
<td>Extirpation of matter from inferior mesenteric vein, open approach</td>
</tr>
<tr>
<td>06C63ZZ</td>
<td>Extirpation of matter from inferior mesenteric vein, percutaneous approach</td>
</tr>
<tr>
<td>06C64ZZ</td>
<td>Extirpation of matter from inferior mesenteric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06C70ZZ</td>
<td>Extirpation of matter from colic vein, open approach</td>
</tr>
<tr>
<td>06C73ZZ</td>
<td>Extirpation of matter from colic vein, percutaneous approach</td>
</tr>
<tr>
<td>06C74ZZ</td>
<td>Extirpation of matter from colic vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06C80ZZ</td>
<td>Extirpation of matter from portal vein, open approach</td>
</tr>
<tr>
<td>06C83ZZ</td>
<td>Extirpation of matter from portal vein, percutaneous approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>06C84ZZ</td>
<td>Extirpation of matter from portal vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06C90ZZ</td>
<td>Extirpation of matter from right renal vein, open approach</td>
</tr>
<tr>
<td>06C93ZZ</td>
<td>Extirpation of matter from right renal vein, percutaneous approach</td>
</tr>
<tr>
<td>06C94ZZ</td>
<td>Extirpation of matter from right renal vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06CB0ZZ</td>
<td>Extirpation of matter from left renal vein, open approach</td>
</tr>
<tr>
<td>06CB3ZZ</td>
<td>Extirpation of matter from left renal vein, percutaneous approach</td>
</tr>
<tr>
<td>06CB4ZZ</td>
<td>Extirpation of matter from left renal vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06CC0ZZ</td>
<td>Extirpation of matter from right common iliac vein, open approach</td>
</tr>
<tr>
<td>06CC3ZZ</td>
<td>Extirpation of matter from right common iliac vein, percutaneous approach</td>
</tr>
<tr>
<td>06CC4ZZ</td>
<td>Extirpation of matter from right common iliac vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06CD0ZZ</td>
<td>Extirpation of matter from left common iliac vein, open approach</td>
</tr>
<tr>
<td>06CD3ZZ</td>
<td>Extirpation of matter from left common iliac vein, percutaneous approach</td>
</tr>
<tr>
<td>06CD4ZZ</td>
<td>Extirpation of matter from left common iliac vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06CF0ZZ</td>
<td>Extirpation of matter from right external iliac vein, open approach</td>
</tr>
<tr>
<td>06CF3ZZ</td>
<td>Extirpation of matter from right external iliac vein, percutaneous approach</td>
</tr>
<tr>
<td>06CF4ZZ</td>
<td>Extirpation of matter from right external iliac vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06CG0ZZ</td>
<td>Extirpation of matter from left external iliac vein, open approach</td>
</tr>
<tr>
<td>06CG3ZZ</td>
<td>Extirpation of matter from left external iliac vein, percutaneous approach</td>
</tr>
<tr>
<td>06CG4ZZ</td>
<td>Extirpation of matter from left external iliac vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06CH0ZZ</td>
<td>Extirpation of matter from right hypogastric vein, open approach</td>
</tr>
<tr>
<td>06CH3ZZ</td>
<td>Extirpation of matter from right hypogastric vein, percutaneous approach</td>
</tr>
<tr>
<td>06CH4ZZ</td>
<td>Extirpation of matter from right hypogastric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06CJ0ZZ</td>
<td>Extirpation of matter from left hypogastric vein, open approach</td>
</tr>
<tr>
<td>06CJ3ZZ</td>
<td>Extirpation of matter from left hypogastric vein, percutaneous approach</td>
</tr>
<tr>
<td>06CJ4ZZ</td>
<td>Extirpation of matter from left hypogastric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>02CP0ZZ</td>
<td>Extirpation of matter from pulmonary trunk, open approach</td>
</tr>
<tr>
<td>02CP3ZZ</td>
<td>Extirpation of matter from pulmonary trunk, percutaneous approach</td>
</tr>
<tr>
<td>02CP4ZZ</td>
<td>Extirpation of matter from pulmonary trunk, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02CQ0ZZ</td>
<td>Extirpation of matter from right pulmonary artery, open approach</td>
</tr>
<tr>
<td>02CQ3ZZ</td>
<td>Extirpation of matter from right pulmonary artery, percutaneous approach</td>
</tr>
<tr>
<td>02CQ4ZZ</td>
<td>Extirpation of matter from right pulmonary artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02CR0ZZ</td>
<td>Extirpation of matter from left pulmonary artery, open approach</td>
</tr>
<tr>
<td>02CR3ZZ</td>
<td>Extirpation of matter from left pulmonary artery, percutaneous approach</td>
</tr>
<tr>
<td>02CR4ZZ</td>
<td>Extirpation of matter from left pulmonary artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02CS0ZZ</td>
<td>Extirpation of matter from right pulmonary vein, open approach</td>
</tr>
<tr>
<td>02CS3ZZ</td>
<td>Extirpation of matter from right pulmonary vein, percutaneous approach</td>
</tr>
<tr>
<td>02CS4ZZ</td>
<td>Extirpation of matter from right pulmonary vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02CT0ZZ</td>
<td>Extirpation of matter from left pulmonary vein, open approach</td>
</tr>
<tr>
<td>02CT3ZZ</td>
<td>Extirpation of matter from left pulmonary vein, percutaneous approach</td>
</tr>
<tr>
<td>02CT4ZZ</td>
<td>Extirpation of matter from left pulmonary vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02CV0ZZ</td>
<td>Extirpation of matter from superior vena cava, open approach</td>
</tr>
<tr>
<td>02CV3ZZ</td>
<td>Extirpation of matter from superior vena cava, percutaneous approach</td>
</tr>
<tr>
<td>02CV4ZZ</td>
<td>Extirpation of matter from superior vena cava, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03C00ZZ</td>
<td>Extirpation of matter from right internal mammary artery, open approach</td>
</tr>
<tr>
<td>03C03ZZ</td>
<td>Extirpation of matter from right internal mammary artery, percutaneous approach</td>
</tr>
<tr>
<td>03C04ZZ</td>
<td>Extirpation of matter from right internal mammary artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03C10ZZ</td>
<td>Extirpation of matter from left internal mammary artery, open approach</td>
</tr>
<tr>
<td>03C13ZZ</td>
<td>Extirpation of matter from left internal mammary artery, percutaneous approach</td>
</tr>
<tr>
<td>03C14ZZ</td>
<td>Extirpation of matter from left internal mammary artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03C20ZZ</td>
<td>Extirpation of matter from innominate artery, open approach</td>
</tr>
<tr>
<td>03C23ZZ</td>
<td>Extirpation of matter from innominate artery, percutaneous approach</td>
</tr>
<tr>
<td>03C24ZZ</td>
<td>Extirpation of matter from innominate artery, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.15

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03C30ZZ</td>
<td>Extirpation of matter from right subclavian artery, open approach</td>
</tr>
<tr>
<td>03C33ZZ</td>
<td>Extirpation of matter from right subclavian artery, percutaneous approach</td>
</tr>
<tr>
<td>03C34ZZ</td>
<td>Extirpation of matter from right subclavian artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03C40ZZ</td>
<td>Extirpation of matter from left subclavian artery, open approach</td>
</tr>
<tr>
<td>03C43ZZ</td>
<td>Extirpation of matter from left subclavian artery, percutaneous approach</td>
</tr>
<tr>
<td>03C44ZZ</td>
<td>Extirpation of matter from left subclavian artery, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.16

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.16 are shown in Table 6P.1c for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.35

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02BP0ZZ</td>
<td>Excision of pulmonary trunk, open approach</td>
</tr>
<tr>
<td>02BP4ZZ</td>
<td>Excision of pulmonary trunk, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02BQ0ZZ</td>
<td>Excision of right pulmonary artery, open approach</td>
</tr>
<tr>
<td>02BQ4ZZ</td>
<td>Excision of right pulmonary artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02BR0ZZ</td>
<td>Excision of left pulmonary artery, open approach</td>
</tr>
<tr>
<td>02BR4ZZ</td>
<td>Excision of left pulmonary artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02BS0ZZ</td>
<td>Excision of right pulmonary vein, open approach</td>
</tr>
<tr>
<td>02BS4ZZ</td>
<td>Excision of right pulmonary vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02BT0ZZ</td>
<td>Excision of left pulmonary vein, open approach</td>
</tr>
<tr>
<td>02BT4ZZ</td>
<td>Excision of left pulmonary vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>02BV0ZZ</td>
<td>Excision of superior vena cava, open approach</td>
</tr>
<tr>
<td>02BV4ZZ</td>
<td>Excision of superior vena cava, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03B00ZZ</td>
<td>Excision of right internal mammary artery, open approach</td>
</tr>
<tr>
<td>03B04ZZ</td>
<td>Excision of right internal mammary artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03B10ZZ</td>
<td>Excision of left internal mammary artery, open approach</td>
</tr>
</tbody>
</table>
## ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.35

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03B14ZZ</td>
<td>Excision of left internal mammary artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03B20ZZ</td>
<td>Excision of innominate artery, open approach</td>
</tr>
<tr>
<td>03B24ZZ</td>
<td>Excision of innominate artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03B30ZZ</td>
<td>Excision of right subclavian artery, open approach</td>
</tr>
<tr>
<td>03B34ZZ</td>
<td>Excision of right subclavian artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03B40ZZ</td>
<td>Excision of left subclavian artery, open approach</td>
</tr>
<tr>
<td>03B44ZZ</td>
<td>Excision of left subclavian artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>05B00ZZ</td>
<td>Excision of azygos vein, open approach</td>
</tr>
<tr>
<td>05B04ZZ</td>
<td>Excision of azygos vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>05B10ZZ</td>
<td>Excision of hemiazygos vein, open approach</td>
</tr>
<tr>
<td>05B14ZZ</td>
<td>Excision of hemiazygos vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>05B30ZZ</td>
<td>Excision of right innominate vein, open approach</td>
</tr>
<tr>
<td>05B34ZZ</td>
<td>Excision of right innominate vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>05B40ZZ</td>
<td>Excision of left innominate vein, open approach</td>
</tr>
<tr>
<td>05B44ZZ</td>
<td>Excision of left innominate vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>05B50ZZ</td>
<td>Excision of right subclavian vein, open approach</td>
</tr>
<tr>
<td>05B54ZZ</td>
<td>Excision of right subclavian vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>05B60ZZ</td>
<td>Excision of left subclavian vein, open approach</td>
</tr>
<tr>
<td>05B64ZZ</td>
<td>Excision of left subclavian vein, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

## ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.36

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04B10ZZ</td>
<td>Excision of celiac artery, open approach</td>
</tr>
<tr>
<td>04B14ZZ</td>
<td>Excision of celiac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04B20ZZ</td>
<td>Excision of gastric artery, open approach</td>
</tr>
<tr>
<td>04B24ZZ</td>
<td>Excision of gastric artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04B30ZZ</td>
<td>Excision of hepatic artery, open approach</td>
</tr>
<tr>
<td>04B34ZZ</td>
<td>Excision of hepatic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04B40ZZ</td>
<td>Excision of splenic artery, open approach</td>
</tr>
<tr>
<td>04B44ZZ</td>
<td>Excision of splenic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04B50ZZ</td>
<td>Excision of superior mesenteric artery, open approach</td>
</tr>
<tr>
<td>04B54ZZ</td>
<td>Excision of superior mesenteric artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04B60ZZ</td>
<td>Excision of right colic artery, open approach</td>
</tr>
<tr>
<td>04B64ZZ</td>
<td>Excision of right colic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>04B70ZZ</td>
<td>Excision of left colic artery, open approach</td>
</tr>
<tr>
<td>04B74ZZ</td>
<td>Excision of left colic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04B80ZZ</td>
<td>Excision of middle colic artery, open approach</td>
</tr>
<tr>
<td>04B84ZZ</td>
<td>Excision of middle colic artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04B90ZZ</td>
<td>Excision of right renal artery, open approach</td>
</tr>
<tr>
<td>04B94ZZ</td>
<td>Excision of right renal artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04BA0ZZ</td>
<td>Excision of left renal artery, open approach</td>
</tr>
<tr>
<td>04BA4ZZ</td>
<td>Excision of left renal artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04BB0ZZ</td>
<td>Excision of inferior mesenteric artery, open approach</td>
</tr>
<tr>
<td>04BB4ZZ</td>
<td>Excision of inferior mesenteric artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04BC0ZZ</td>
<td>Excision of right common iliac artery, open approach</td>
</tr>
<tr>
<td>04BC4ZZ</td>
<td>Excision of right common iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04BD0ZZ</td>
<td>Excision of left common iliac artery, open approach</td>
</tr>
<tr>
<td>04BD4ZZ</td>
<td>Excision of left common iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04BE0ZZ</td>
<td>Excision of right internal iliac artery, open approach</td>
</tr>
<tr>
<td>04BE4ZZ</td>
<td>Excision of right internal iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04BF0ZZ</td>
<td>Excision of left internal iliac artery, open approach</td>
</tr>
<tr>
<td>04BF4ZZ</td>
<td>Excision of left internal iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04BH0ZZ</td>
<td>Excision of right external iliac artery, open approach</td>
</tr>
<tr>
<td>04BH4ZZ</td>
<td>Excision of right external iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04BJ0ZZ</td>
<td>Excision of left external iliac artery, open approach</td>
</tr>
<tr>
<td>04BJ4ZZ</td>
<td>Excision of left external iliac artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>06B00ZZ</td>
<td>Excision of inferior vena cava, open approach</td>
</tr>
<tr>
<td>06B04ZZ</td>
<td>Excision of inferior vena cava, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06B10ZZ</td>
<td>Excision of splenic vein, open approach</td>
</tr>
<tr>
<td>06B14ZZ</td>
<td>Excision of splenic vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06B20ZZ</td>
<td>Excision of gastric vein, open approach</td>
</tr>
<tr>
<td>06B24ZZ</td>
<td>Excision of gastric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06B40ZZ</td>
<td>Excision of hepatic vein, open approach</td>
</tr>
<tr>
<td>06B44ZZ</td>
<td>Excision of hepatic vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06B50ZZ</td>
<td>Excision of superior mesenteric vein, open approach</td>
</tr>
<tr>
<td>06B54ZZ</td>
<td>Excision of superior mesenteric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06B60ZZ</td>
<td>Excision of inferior mesenteric vein, open approach</td>
</tr>
<tr>
<td>06B64ZZ</td>
<td>Excision of inferior mesenteric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06B70ZZ</td>
<td>Excision of colic vein, open approach</td>
</tr>
<tr>
<td>06B74ZZ</td>
<td>Excision of colic vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06B80ZZ</td>
<td>Excision of portal vein, open approach</td>
</tr>
<tr>
<td>06B84ZZ</td>
<td>Excision of portal vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06B90ZZ</td>
<td>Excision of right renal vein, open approach</td>
</tr>
<tr>
<td>06B94ZZ</td>
<td>Excision of right renal vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06BB0ZZ</td>
<td>Excision of left renal vein, open approach</td>
</tr>
<tr>
<td>06BB4ZZ</td>
<td>Excision of left renal vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06BC0ZZ</td>
<td>Excision of right common iliac vein, open approach</td>
</tr>
<tr>
<td>06BC4ZZ</td>
<td>Excision of right common iliac vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06BD0ZZ</td>
<td>Excision of left common iliac vein, open approach</td>
</tr>
<tr>
<td>06BD4ZZ</td>
<td>Excision of left common iliac vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06BF0ZZ</td>
<td>Excision of right external iliac vein, open approach</td>
</tr>
<tr>
<td>06BF4ZZ</td>
<td>Excision of right external iliac vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06BG0ZZ</td>
<td>Excision of left external iliac vein, open approach</td>
</tr>
<tr>
<td>06BG4ZZ</td>
<td>Excision of left external iliac vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06BH0ZZ</td>
<td>Excision of right hypogastric vein, open approach</td>
</tr>
<tr>
<td>06BH4ZZ</td>
<td>Excision of right hypogastric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>06BJ0ZZ</td>
<td>Excision of left hypogastric vein, open approach</td>
</tr>
<tr>
<td>06BJ4ZZ</td>
<td>Excision of left hypogastric vein, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.46</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>ICD-10-PCS Code</strong></td>
<td><strong>Code Description</strong></td>
</tr>
<tr>
<td>The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.46 are shown in Table 6P.1d for this final rule, which is available via the Internet on the CMS Web site at: <a href="http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html">http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html</a>.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.47</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICD-10-PCS Code</strong></td>
</tr>
<tr>
<td>The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.47 are shown in Table 6P.1e for this final rule, which is available via the Internet on the CMS Web site at: <a href="http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html">http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html</a>.</td>
</tr>
</tbody>
</table>

There is not an equivalent ICD-10-PCS code translation for ICD-9-CM procedure code 38.55.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.65</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICD-10-PCS Code</strong></td>
</tr>
<tr>
<td>The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.65 are shown in Table 6P.1f for this final rule, which is available via the Internet on the CMS Web site at: <a href="http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html">http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html</a>.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.66</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICD-10-PCS Code</strong></td>
</tr>
<tr>
<td>The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.66 are shown in Table 6P.1g for this final rule, which is available via the Internet on the CMS Web site at: <a href="http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html">http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html</a>.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.67</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICD-10-PCS Code</strong></td>
</tr>
<tr>
<td>The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.67 are shown in Table 6P.1h for this final rule, which is available via the Internet on the CMS Web site at: <a href="http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html">http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html</a>.</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.85

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.85 are shown in Table 6P.1i for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.86

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.86 are shown in Table 6P.1j for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 38.87

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 38.87 are shown in Table 6P.1k for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).
ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.0

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.0 are shown in Table 6P.1l for this final rule, which is available via the Internet on the CMS Web site at: <a href="http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html">http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html</a>.</td>
<td></td>
</tr>
</tbody>
</table>

ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.1

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.1 are shown in Table 6P.1m for this final rule, which is available via the Internet on the CMS Web site at: <a href="http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html">http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html</a>.</td>
<td></td>
</tr>
</tbody>
</table>

ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.21

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>021V09P</td>
<td>Bypass superior vena cava to pulmonary trunk with autologous venous tissue, open approach</td>
</tr>
<tr>
<td>021V09Q</td>
<td>Bypass superior vena cava to right pulmonary artery with autologous venous tissue, open approach</td>
</tr>
<tr>
<td>021V09R</td>
<td>Bypass superior vena cava to left pulmonary artery with autologous venous tissue, open approach</td>
</tr>
<tr>
<td>021V0AP</td>
<td>Bypass superior vena cava to pulmonary trunk with autologous arterial tissue, open approach</td>
</tr>
<tr>
<td>021V0AQ</td>
<td>Bypass superior vena cava to right pulmonary artery with autologous arterial tissue, open approach</td>
</tr>
<tr>
<td>021V0AR</td>
<td>Bypass superior vena cava to left pulmonary artery with autologous arterial tissue, open approach</td>
</tr>
<tr>
<td>021V0JP</td>
<td>Bypass superior vena cava to pulmonary trunk with synthetic substitute, open approach</td>
</tr>
<tr>
<td>021V0JQ</td>
<td>Bypass superior vena cava to right pulmonary artery with synthetic substitute, open approach</td>
</tr>
<tr>
<td>021V0JR</td>
<td>Bypass superior vena cava to left pulmonary artery with synthetic substitute, open approach</td>
</tr>
<tr>
<td>021V0KP</td>
<td>Bypass superior vena cava to pulmonary trunk with nonautologous tissue substitute, open approach</td>
</tr>
<tr>
<td>021V0KQ</td>
<td>Bypass superior vena cava to right pulmonary artery with nonautologous tissue substitute, open approach</td>
</tr>
<tr>
<td>021V0KR</td>
<td>Bypass superior vena cava to left pulmonary artery with nonautologous tissue substitute, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.21</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>ICD-10-PCS</strong> Code</td>
<td><strong>Code Description</strong></td>
</tr>
<tr>
<td>021V0ZP</td>
<td>Bypass superior vena cava to pulmonary trunk, open approach</td>
</tr>
<tr>
<td>021V0ZQ</td>
<td>Bypass superior vena cava to right pulmonary artery, open approach</td>
</tr>
<tr>
<td>021V0ZR</td>
<td>Bypass superior vena cava to left pulmonary artery, open approach</td>
</tr>
<tr>
<td>021V49P</td>
<td>Bypass superior vena cava to pulmonary trunk with autologous venous tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V49Q</td>
<td>Bypass superior vena cava to right pulmonary artery with autologous venous tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V49R</td>
<td>Bypass superior vena cava to left pulmonary artery with autologous venous tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4AP</td>
<td>Bypass superior vena cava to pulmonary trunk with autologous arterial tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4AQ</td>
<td>Bypass superior vena cava to right pulmonary artery with autologous arterial tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4AR</td>
<td>Bypass superior vena cava to left pulmonary artery with autologous arterial tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4JP</td>
<td>Bypass superior vena cava to pulmonary trunk with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4JQ</td>
<td>Bypass superior vena cava to right pulmonary artery with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4JR</td>
<td>Bypass superior vena cava to left pulmonary artery with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4KP</td>
<td>Bypass superior vena cava to pulmonary trunk with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4KQ</td>
<td>Bypass superior vena cava to right pulmonary artery with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4KR</td>
<td>Bypass superior vena cava to left pulmonary artery with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4ZP</td>
<td>Bypass superior vena cava to pulmonary trunk, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4ZQ</td>
<td>Bypass superior vena cava to right pulmonary artery, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021V4ZR</td>
<td>Bypass superior vena cava to left pulmonary artery, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.22

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>021W09B</td>
<td>Bypass thoracic aorta to subclavian with autologous venous tissue, open approach</td>
</tr>
<tr>
<td>021W09D</td>
<td>Bypass thoracic aorta to carotid with autologous venous tissue, open approach</td>
</tr>
<tr>
<td>021W0AB</td>
<td>Bypass thoracic aorta to subclavian with autologous arterial tissue, open approach</td>
</tr>
<tr>
<td>021W0AD</td>
<td>Bypass thoracic aorta to carotid with autologous arterial tissue, open approach</td>
</tr>
<tr>
<td>021W0JB</td>
<td>Bypass thoracic aorta to subclavian with synthetic substitute, open approach</td>
</tr>
<tr>
<td>021W0JD</td>
<td>Bypass thoracic aorta to carotid with synthetic substitute, open approach</td>
</tr>
<tr>
<td>021W0KB</td>
<td>Bypass thoracic aorta to subclavian with nonautologous tissue substitute, open approach</td>
</tr>
<tr>
<td>021W0KD</td>
<td>Bypass thoracic aorta to carotid with nonautologous tissue substitute, open approach</td>
</tr>
<tr>
<td>021W0ZB</td>
<td>Bypass thoracic aorta to subclavian, open approach</td>
</tr>
<tr>
<td>021W0ZD</td>
<td>Bypass thoracic aorta to carotid, open approach</td>
</tr>
<tr>
<td>021W49B</td>
<td>Bypass thoracic aorta to subclavian with autologous venous tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W49D</td>
<td>Bypass thoracic aorta to carotid with autologous venous tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4AB</td>
<td>Bypass thoracic aorta to subclavian with autologous arterial tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4AD</td>
<td>Bypass thoracic aorta to carotid with autologous arterial tissue, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4JB</td>
<td>Bypass thoracic aorta to subclavian with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4JD</td>
<td>Bypass thoracic aorta to carotid with synthetic substitute, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.22

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>021W4KB</td>
<td>Bypass thoracic aorta to subclavian with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4KD</td>
<td>Bypass thoracic aorta to carotid with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4ZB</td>
<td>Bypass thoracic aorta to subclavian, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4ZD</td>
<td>Bypass thoracic aorta to carotid, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.23 are shown in Table 6P.1n for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.25

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>021W4KB</td>
<td>Bypass thoracic aorta to subclavian with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4KD</td>
<td>Bypass thoracic aorta to carotid with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4ZB</td>
<td>Bypass thoracic aorta to subclavian, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4ZD</td>
<td>Bypass thoracic aorta to carotid, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.25 are shown in Table 6P.1o for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.26

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>021W4KB</td>
<td>Bypass thoracic aorta to subclavian with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4KD</td>
<td>Bypass thoracic aorta to carotid with nonautologous tissue substitute, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4ZB</td>
<td>Bypass thoracic aorta to subclavian, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>021W4ZD</td>
<td>Bypass thoracic aorta to carotid, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.26 are shown in Table 6P.1p for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).
ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.52

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.52 are shown in Table 6P.1q for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).
### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.54

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02QW0ZZ</td>
<td>Repair thoracic aorta, open approach</td>
</tr>
<tr>
<td>02QW3ZZ</td>
<td>Repair thoracic aorta, percutaneous approach</td>
</tr>
<tr>
<td>02QW4ZZ</td>
<td>Repair thoracic aorta, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.72

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03LR0DZ</td>
<td>Occlusion of face artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LR3DZ</td>
<td>Occlusion of face artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LR4DZ</td>
<td>Occlusion of face artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LS0DZ</td>
<td>Occlusion of right temporal artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LS3DZ</td>
<td>Occlusion of right temporal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LS4DZ</td>
<td>Occlusion of right temporal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LT0DZ</td>
<td>Occlusion of left temporal artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LT3DZ</td>
<td>Occlusion of left temporal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LT4DZ</td>
<td>Occlusion of left temporal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.75

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.75 are shown in Table 6P.1r for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.76

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.76 are
shown in Table 6P.1s for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

### ICD-10-PCS Code Translations for ICD-9-CM Procedure Code 39.79

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
</table>

The comparable ICD-10-PCS code translations for ICD-9-CM procedure code 39.79 are shown in Table 6P.1t for this final rule, which is available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html).

As previously stated, we separated the more complex, more invasive procedures from the less complex, less invasive procedures to continue our evaluation of the procedures assigned to MS-DRGs 237 and 238. Our data analysis showed that the distribution of cases, the average length of stay, and average costs of the more complex, more invasive aortic and heart assist procedures and the less complex, less invasive other cardiovascular procedures would be more appropriately reflected if we classified these distinguishing types of procedures under newly created MS-DRGs, as reflected in the table below.
Major Cardiovascular Procedures with and without MCC

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRGs 237 and 238 – Combined</td>
<td>50,567</td>
<td>5.8</td>
<td>$29,174</td>
</tr>
<tr>
<td>MS-DRGs 237 and 238 – Cases with more complex, more invasive procedure codes (37.41; 37.49; 37.55; 38.04; 38.14; 38.34; 38.44; 38.64; 38.84; 39.24; 39.71, and 39.78)</td>
<td>22,278</td>
<td>4.0</td>
<td>$31,729</td>
</tr>
<tr>
<td>MS-DRGs 237 and 238 - Cases with less complex, less invasive procedure codes (35.00; 35.01; 35.02; 35.03; 35.04; 37.12; 37.24; 37.31; 37.61; 37.67; 37.91; 37.99; 38.05; 38.06; 38.07; 38.15; 38.16; 38.35; 38.36; 38.37; 38.46; 38.47; 38.55; 38.65; 38.66; 38.67; 38.85; 38.86; 38.87; 39.0; 39.1; 39.21; 39.22; 39.23; 39.25; 39.26; 39.52; 39.54; 39.72; 39.75; 39.76; and 39.79)</td>
<td>28,289</td>
<td>7.1</td>
<td>$27,162</td>
</tr>
</tbody>
</table>

Our clinical advisors reviewed the results of the analysis and agreed that distinguishing the more complex, more invasive procedures from the less complex, less invasive procedures would result in improved clinical coherence for the various cardiovascular procedures currently assigned to MS-DRGs 237 and 238, as listed previously. Therefore, for FY 2016, we proposed to delete MS-DRGs 237 and 238. When we applied our established criteria to determine if the creation of a new CC or MCC subgroup within a base MS-DRG is warranted, we determined that a 2-way severity level split (with MCC and without MCC) was justified. Therefore, we proposed to create two new MS-DRGs that would contain the more complex, more invasive aortic
and heart assist procedures currently assigned to MS-DRGs 237 and 238, as listed previously. We proposed to create MS-DRG 268, entitled “Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC,” and MS-DRG 269, entitled “Aortic and Heart Assist Procedures Except Pulsation Balloon without MCC.” The table below shows the distribution of cases and the average length of stay and average costs of the more complex, more invasive procedures for aortic and heart assistance for the proposed new MS-DRGs 268 and 269.

<table>
<thead>
<tr>
<th>Proposed New MS-DRGs for Aortic and Heart Assist Procedures</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed New MS-DRG 268 with MCC</td>
<td>4,182</td>
<td>10.03</td>
<td>$45,996</td>
</tr>
<tr>
<td>Proposed New MS-DRG 269 without MCC</td>
<td>18,096</td>
<td>2.68</td>
<td>$28,431</td>
</tr>
</tbody>
</table>

We invited public comments on this proposal and the ICD-10-PCS code translations for these procedures shown earlier in this section, which we also proposed to assign to proposed new MS-DRGs 268 and 269.

In addition, when we further applied our established criteria to determine if the creation of a new CC or MCC subgroup for the remaining procedures was warranted, we determined that a 3-way severity level split (with MCC, with CC, and without CC/MCC) was justified. Therefore, we proposed to create three new MS-DRGs that would contain the remaining cardiovascular procedures that were designated as the less complex, less invasive procedures, as listed previously. For FY 2016, we proposed to create MS-DRG 270, entitled “Other Major Cardiovascular Procedures with MCC”; MS-DRG 271,
entitled “Other Major Cardiovascular Procedures with CC”; and MS-DRG 272, entitled “Other Major Cardiovascular Procedures without CC/MCC,” and to assign the less complex, less invasive cardiovascular procedures shown earlier in this section to these proposed new MS-DRGs. We believed that, as shown in the table below, the distribution of cases and average length of stay and average costs of these procedures would be more appropriately reflected when these types of procedures are classified under these proposed new MS-DRGs.

<table>
<thead>
<tr>
<th>Proposed New MS-DRGs for Other Major Cardiovascular Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>Proposed New MS-DRG 270 with MCC</td>
</tr>
<tr>
<td>Proposed New MS-DRG 271 with CC</td>
</tr>
<tr>
<td>Proposed New MS-DRG 272 without CC/MCC</td>
</tr>
</tbody>
</table>

We invited public comments on this proposal and the ICD-10-PCS code translations for the less complex, less invasive cardiovascular procedures shown earlier in this section, which we also proposed to assign to proposed new MS-DRGs 270, 271, and 272.

In summary, for FY 2016, we proposed to delete MS-DRGs 237 and 238, and to create the following five new MS-DRGs:

- Proposed new MS-DRG 268 (Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC);
- Proposed new MS-DRG 269 (Aortic and Heart Assist Procedures Except Pulsation Balloon without MCC);
• Proposed new MS-DRG 270 (Other Major Cardiovascular Procedures with MCC);
• Proposed new MS-DRG 271 (Other Major Cardiovascular Procedures with CC); and
• Proposed new MS-DRG 272 (Other Major Cardiovascular Procedures without CC/MCC).

We also proposed to assign the more complex, more invasive cardiovascular procedures identified in our analysis and the ICD-10-PCS code translations to proposed new MS-DRGs 268 and 269. In addition, we proposed to assign the less complex, less invasive cardiovascular procedures identified in our analysis and the ICD-10-PCS code translations to proposed new MS-DRGs 270, 271, and 272. We encouraged public comments on our proposal to create these proposed new MS-DRGs, as well as the ICD-10-PCS code translations that we proposed to assign to the corresponding proposed new MS-DRGs.

Comment: Several commenters supported the proposal to delete MS-DRGs 237 and 238 and to create five new proposed MS-DRGs 268, 269, 270, 271, and 272 to distinguish the more complex, more invasive procedures from the less complex, less invasive procedures resulting in improved clinical coherence for the various cardiovascular procedures currently assigned to MS-DRGs 237 and 238. Commenters stated that the proposal was reasonable, given the data and information provided.

One commenter who supported the creation of proposed new MS-DRGs 268 and 269 expressed additional support with regard to how these proposed new MS-DRGs
would incorporate selected high resource surgical aortic and visceral vessel procedures, as well as selected high resource extra-cardiac procedures. The commenter agreed that, in terms of resource utilization and clinical coherency, the procedures included would be classified appropriately to the proposed new MS-DRGs. However, this commenter requested clarification on some of the ICD-10-PCS code translations that were listed for ICD-9-CM procedure code 39.78 (Endovascular implantation of branching or fenestrated graft(s) in aorta). The commenter stated that, as displayed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24363), the dilation of right and left renal arteries and the superior mesenteric artery (procedures described by ICD-10-PCS codes 04793DZ through 04754DZ) also appear to be proposed for grouping to proposed MS-DRGs 268 and 269. The commenter believed that CMS did not intend to classify those dilation codes as “stand alone” procedures that would be assigned to proposed new MS-DRGs 268 and 269. The commenter stated that the ICD-10-PCS dilation codes should not be necessary as translations for ICD-9-CM procedure code 39.78.

Another commenter commended CMS on the timing of the proposal to establish proposed new MS-DRGs 268 and 269. The commenter stated that this proposal will allow patients requiring fenestrated grafts continued access to care in FY 2016, as the new-technology add-on payment for the Zenith Fenestrated Graft device is expiring September 30, 2015. The commenter also stated that, currently, there is not an appropriate mechanism to ensure access to these procedures, especially in rural hospitals, and that this proposal would change that.
Other commenters stated that the proposed new MS-DRGs would better recognize clinical homogeneity and resource requirements for the range of major cardiovascular procedures.

Response: We appreciate the commenters’ support of our proposal to delete MS-DRGs 237 and 238 and to create proposed new MS-DRGs 268 through 272.

In response to the comment requesting clarification on some of the ICD-10-PCS code translations that were listed for ICD-9-CM procedure code 39.78, the commenter is correct. It was not our intent to classify those dilation codes (ICD-10-PCS codes 04793DZ through 04754DZ) as “stand alone” procedures that would be assigned to proposed new MS-DRGs 268 and 269. Rather, we proposed those codes for consideration as supplemental codes to more fully describe the procedure performed. We agree with the commenter that these dilation codes are not necessary translations for ICD-9-CM procedure code 39.78 and as “stand alone” procedures they would be assigned to their own separate and clinically appropriate ICD-10 MS-DRG.

As we reviewed the translations for ICD-9-CM procedure code 39.78 in response to the commenter’s request, we reviewed all the comparable ICD-10-PCS code translations that we proposed to assign to proposed new MS-DRGs 268 through 272. Specifically, we reviewed the list of the more complex, more invasive procedures that we proposed to assign to proposed MS-DRGs 268 and 269 and the list of the less complex, less invasive procedures that we proposed to assign to proposed MS-DRGs 270 through 272. We determined that the ICD-10-PCS translations for ICD-9-CM procedure code 37.49 (Other repair of heart and pericardium) as displayed in Table 6P.1a of the proposed
rule were not complete. There was an inadvertent omission of an additional 78 ICD-10-PCS comparable code translations. Therefore, we are providing an updated Table 6P for this final rule, which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. We note that this list of ICD-10-PCS code translations for ICD-9-CM procedure code 37.49 is consistent with the list of possible code translations found in the General Equivalency Maps (GEMs) files provided for public use available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD10/index.html.

In conducting this review, our clinical advisors also determined that ICD-9-CM procedure code 37.49 and the corresponding ICD-10-PCS comparable code translations would be more appropriately classified under proposed new MS-DRGs 270 through 272 versus proposed new MS-DRGs 268 and 269. This decision is consistent with our proposal to assign less invasive procedures, such as pericardiotomies and pulsation balloon implants, to proposed new MS-DRGs 270 through 272. This procedure code captures procedures that are similar to the other procedures included in the proposal for MS-DRGs 270 through 272 involving the pericardium such as ICD-9-CM procedure codes 37.12 (Pericardiotomy), 37.24 (Biopsy of pericardium) and 37.61 (Pericardiectomy) and does not relate to the more complex, more invasive aortic and heart assist procedures that we proposed to assign to proposed MS-DRGs 268 and 269. According to our clinical advisors, the ICD-10-PCS code translations for ICD-9-CM procedure code 37.49 also do not constitute the level of complexity or resources similar
to the other procedures that we proposed to assign to proposed new MS-DRGs 268 and 269. In addition, our clinical advisors determined that ICD-9-CM procedure code 39.54 (Re-entry operation (aorta)) and the corresponding ICD-10-PCS comparable code translations would be more appropriately classified under proposed new MS-DRGs 268 through 269 versus proposed new MS-DRGs 270 through 272. This decision is consistent with our proposal to assign more invasive procedures, such as open and endovascular repairs of the aorta with replacement grafts, to proposed new MS-DRGs 268 and 269. According to our clinical advisors, the procedure described by ICD-9-CM procedure code 39.54 and the comparable ICD-10-PCS code translations are precisely indicated for the aorta, and, as such, the procedure code belongs under proposed new MS-DRGs 268 and 269 along with the other aorta and heart assist procedures.

Comment: One commenter requested clarification on certain ICD-10-PCS code translations for proposed new MS-DRGs 268 through 272 and how they relate to the General Equivalency Maps (GEMs) and ICD-10-PCS to ICD-9-CM Reimbursement Mappings files. The commenter noted that there were instances where more than one ICD-9-CM procedure code could be translated to an ICD-10-PCS code that was included in the proposed new MS-DRGs, as well as listed in the Reimbursement Mappings file. The commenter submitted an example where ICD-10-PCS code 04V00DZ (Restriction of abdominal aorta with intraluminal device, open approach) was listed as a comparable ICD-10-PCS translation for ICD-9-CM procedure code 39.52 (Other repair of aneurysm) in the proposal for proposed new MS-DRGs 270 through 272. However, the commenter stated that, in the FY 2015 Reimbursement Mappings file, this same ICD-10-PCS code
(04V00DZ) was shown to map to ICD-9-CM procedure code 39.71 (Endovascular implantation of other graft in abdominal aorta), which was included in the proposal for proposed new MS-DRGs 268 and 269. The commenter asked if the FY 2016 Reimbursement Mappings file would be updated to reflect that ICD-10-PCS code 04V00DZ maps back to ICD-9-CM procedure code 39.52.

Response: We acknowledge and appreciate the commenter’s request for clarification. We point out that the General Equivalence Mappings (GEMs) and Reimbursement Mappings files were developed as resources for the public and are updated separate from the IPPS rulemaking. The GEMs were developed to provide users with a code to code translation reference tool for both ICD-9-CM and ICD-10 codes sets and to offer acceptable translation alternatives where possible. The Reimbursement Mappings were created to provide a temporary mechanism for mapping records containing ICD-10 codes to “MS-DRG reimbursement minimum impact” ICD-9-CM codes and allow claims processing by legacy systems while systems were being converted to process ICD-10 claims directly. The GEMs have been updated on an annual basis as part of the ICD-10 Coordination and Maintenance Committee meetings process and will continue to be updated for approximately 3 years after ICD-10 is implemented. We refer readers to the ICD-10 Coordination and Maintenance Committee Meeting Materials for further information related to discussion of GEMs updates, which can be found on the CMS Web site at:

http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/ICD-9-CM-C-and-M-Meeting-Materials.html. The Reimbursement Mappings have been updated on an
annual basis in preparation for the transition to ICD-10 implementation. As stated on the CMS ICD-10 Coordination and Maintenance Committee Meeting Web page available on the CMS Web site at: [http://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-PCS-and-GEMs.html](http://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-PCS-and-GEMs.html), the FY 2016 Reimbursement Mappings files will be posted in August 2015.

**Comment:** One commenter who supported proposed new MS-DRGs 268 and 269 requested that CMS revise the titles to address concerns expressed by stakeholders. According to the commenter, the proposed titles have caused confusion among providers and consultants. The commenter suggested that CMS consider the following three modifications:

- Indicate that MS-DRGs 268 and 269 are aortic procedures, not aortic heart assist devices;
- Indicate that MS-DRGs 268 and 269 are assigned to heart assist removal or repair, and not the multitude of other heart assist insertion procedures not addressed in the proposed rule; and
- Remove the reference to pulsation balloon insertion, or add the reference to proposed new MS-DRGs 270 through 272 (Other Major Cardiovascular Procedures with MCC, with CC and without CC/MCC, respectively).

The commenter noted that the titles for proposed new MS-DRGs 268 and 269 contain the phrase “Heart Assist Procedures”. However, the commenter stated that not **all** heart assist procedures are proposed to be assigned to these MS-DRGs; essentially, it is only the removal of heart assist procedures codes that are included. The commenter
further noted that other heart assist procedures such as insertion of heart assist devices are identified in several other MS-DRGs, such as MS-DRGs 001 and 002 (Heart Transplant or Implant of Heart Assist System w MCC and without MCC, respectively) and that external heart assist devices are identified in MS-DRG 215 (Other Heart Assist System Implant), while heart assist devices inserted percutaneously with cardiac catheterization are identified in MS-DRGs 216 through 218 (Cardiac Valve & Other Major Cardiothoracic Procedures with Cardiac Catheterization with MCC, with CC and without CC/MCC, respectively).

The commenter also stated that the reference to “Except Pulsation Balloon” in the titles for proposed new MS-DRGs 268 and 269 indicates that all aortic and heart assist procedures would be included except pulsation balloon. The commenter asserted that the titles could cause confusion for stakeholders because there are other procedures that are nonpulsation balloon, heart assist procedures that correspond to the titles for proposed new MS-DRGs 268 and 269 and are assigned to other MS-DRGs. The commenter requested that CMS delete the terminology of pulsation balloon completely or remove it from proposed new MS-DRGs 268 and 269 and add it to proposed new MS-DRGs 270 through 272. The commenter maintained that incorporating the reference to pulsation balloon into proposed new MS-DRGs 270 through 272 would afford a clearer understanding of the procedures that are assigned for providers.

The commenter provided suggestions for the revision to the titles that CMS should take into consideration for proposed new MS-DRGs 268 through 272 as follows:
Suggested retitle of proposed new MS-DRG 268: “Aortic Procedures and Heart Assist Removal or Repair with MCC”;

Suggested retitle of proposed new MS-DRG 269: “Aortic Procedures and Heart Assist Removal or Repair without MCC”;

Suggested retitle of proposed new MS-DRG 270: “Pulsation Balloon and Other Major Cardiovascular Procedures with MCC”; 

Suggested retitle of proposed new MS-DRG 271: “Pulsation Balloon and Other Major Cardiovascular Procedures with CC”; and

Suggested retitle of proposed new MS-DRG 272: “Pulsation Balloon and Other Major Cardiovascular Procedures without CC/MCC”.

Response: We acknowledge the commenter’s request to consider revisions to the titles for proposed new MS-DRGs 268 through 272. However, we note that we did not receive any other comments from stakeholders expressing confusion with regard to the titles for these proposed new MS-DRGs or the assignment of heart assist procedures.

The commenter is correct that not all heart assist procedures are being proposed for assignment to proposed new MS-DRGs 268 and 269. As the commenter pointed out, there are other heart assist procedures that group to various MS-DRGs. The proposal was based on ICD-9-CM procedure codes that are currently assigned to MS-DRGs 237 and 238 and the corresponding ICD-10-PCS code translations for proposed new MS-DRGs 268 through 272. We believe that stakeholders understand that the MS-DRG system is a classification scheme consisting of clinically similar groups of patients with similar resource intensity, and that while the titles of the MS-DRGs reflect the category of
procedures which may or may not be assigned to a particular MS-DRG, they do not specifically identify the details of each applicable procedure code. We also believe that stakeholders do not rely solely on the MS-DRG titles to determine what procedures are assigned to a particular MS-DRG. Rather, they would consult the MS-DRG Definitions Manual. The MS-DRG Definitions Manual contains the complete documentation of the MS-DRG GROUPER logic and is available from 3M/HIS, which, under contract with CMS, is responsible for updating and maintaining the GROUPER program. As discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49905 through 49906), the MS-DRG Definitions Manual, Version 32, which includes the FY 2015 MS-DRG changes is available on a CD for $225. This manual may be obtained by writing 3M/HIS at the following address: 100 Barnes Road, Wallingford, CT 06492; or by calling (203) 949-0303; or by obtaining an order form at the Web site at:

http://www/3MHIS.com. In addition, as discussed in section II.G.1.a. of this final rule, in November 2014, CMS made available a Definitions Manual of the ICD-10 MS-DRGs Version 32 on the ICD-10 MS-DRG Conversion Project Web site at:

http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. Accordingly, we do not believe that the reference to “Heart Assist Procedures” in the title for proposed new MS-DRGs 268 and 269 would create confusion.

For this same reason, we also do not believe that including the reference to “except pulsation balloon” in the titles for proposed new MS-DRGs 268 and 269, to accurately reflect that the pulsation balloon procedure is not assigned to those MS-DRGs, necessarily indicates that all other aortic and heart assist procedures are included. We
would expect stakeholders to consult the MS-DRG Definitions Manual as described above to identify and determine whether a particular procedure is assigned to MS-DRG 268 or 269 or to another MS-DRG, rather than relying on the MS-DRGs title alone.

After consideration of the public comments received, we are adopting as final our proposal to delete ICD-9-CM MS-DRGs 237 and 238 and add the following five new MS-DRGs to ICD-10 MS-DRGs Version 33:

- MS-DRG 268 (Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC);
- MS-DRG 269 (Aortic and Heart Assist Procedures Except Pulsation Balloon without MCC);
- MS-DRG 270 (Other Major Cardiovascular Procedures with MCC);
- MS-DRG 271 (Other Major Cardiovascular Procedures with CC); and
- MS-DRG 272 (Other Major Cardiovascular Procedures without CC/MCC)

We agree that these modifications will more appropriately reflect payment while recognizing differences in complexity, resources and severity of illness for the various cardiovascular procedures. These finalized ICD-10 MS-DRGs will include the updated assignments discussed above related to the ICD-10-PCS code translations for ICD-9-CM codes 37.49 (Other repair of heart and pericardium) and 39.54 (Re-entry operation (aorta)). We also refer readers to the updated Table 6P for this final rule which is available via the Internet on the CMS Web site at:

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-
Lastly, we will consider if further modifications to the titles of these MS-DRGs are warranted in future rulemaking.
4. MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue)

a. Revision of Hip or Knee Replacements: Proposed Revision of ICD-10-PCS Version 32 Logic

We received two comments that the logic for ICD-10 MS-DRGs Version 32 does not work the same as it does for the ICD-9-CM based MS-DRGs Version 32 for procedures involving joint revisions. One of the commenters requested that CMS change the MS-DRG structure for procedures involving joint revisions within the ICD-10 MS-DRGs 466, 467, and 468 (Revision of Hip or Knee Replacement with MCC, with CC, and without CC/MCC, respectively) so that cases that have a spacer removed prior to the insertion of a new joint prosthesis are assigned to MS-DRG 466, 467, and 468, as is the case with the ICD-9-CM MS-DRGs. The other commenter asked that joint revision cases that involve knee revisions with cemented and uncemented qualifiers be assigned to these MS-DRGs. This commenter provided an example of a patient admitted for a knee revision and reported under ICD-10-PCS codes 0SPD0JZ (Removal of synthetic substitute from left knee joint, open approach) and 0SRU0JA (Replacement of left knee joint, femoral surface with synthetic substitute, uncemented, open approach), which should be assigned to MS-DRGs 466, 467, and 468. The requestor stated that joint revision cases reported with ICD-9-CM codes are assigned to MS-DRGs 466, 467, and 468, but similar cases reported with the corresponding ICD-10-PCS codes are not assigned to MS-DRGs 466, 467, and 468 in ICD-10-PCS MS-DRGs Version 32.
We agree that joint revision cases involving the removal of a spacer and subsequent insertion of a new joint prosthesis should be assigned to ICD-10 MS-DRGs 466, 467, and 468 as is the case currently with the ICD-9-CM based MS-DRGs Version 32. We also agree that knee revision cases that involve cemented and uncemented qualifiers should be assigned to ICD-10 MS-DRGs 466, 467, and 468. Knee revision cases currently reported with ICD-9-CM codes are assigned to MS-DRGs 466, 467, and 468 in the ICD-9-CM based MS-DRGs. We examined joint revision combination codes that are not currently assigned to MS-DRGs 466, 467, and 468 in ICD-10 MS-DRGs Version 32 and identified additional combinations that also should be included so that the joint revision ICD-10 MS-DRGs would have the same logic as the ICD-9-CM MS-DRGs. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24379 through 24395), we proposed to add code combinations listed in a table in the proposed rule that would capture the joint revisions to the Version 33 MS-DRG structure for ICD-10 MS-DRGs 466, 467, and 468 that we proposed to implement effective October 1, 2015. We invited public comments on our proposal to add the joint revision code combinations to MS-DRGs 466, 467, and 468 that were listed in the table in the proposed rule (80 FR 24379 through 24395).

**Comment:** A number of commenters supported the proposal to add the joint revision code combinations to MS-DRGs 466, 467, and 468. The commenters stated that the proposal was reasonable, given the data and information provided. One commenter commended CMS for its careful review of these code pairs for hip and knee revision cases and supported the proposed updates. Another commenter supported the proposed
MS-DRG assignment changes which the commenter believed would help to ensure that the ICD-10 MS-DRGs capture the appropriate ICD-10 procedure codes. One commenter stated that the proposed MS-DRG assignment changes improve alignment of these cases under the ICD-10 framework.

Response: We appreciate the commenters’ support for our proposal.

After consideration of the public comments we received, we are finalizing our proposal to add code combinations which capture the joint revision procedures set forth in the table below to the Version 33 MS-DRG structure for ICD-10 MS-DRGs 466, 467, and 468 that will be implemented effective October 1, 2015. We note that joint revision procedures are also included in the ICD-9-CM version of MS-DRGs 628, 629, and 630 (Other Endocrine, Nutritional, and Metabolic Operating Room Procedures with MCC, with CC, and without CC/MCC, respectively). Therefore, to ensure that the joint revision ICD-10 MS-DRGs would have the same logic as the ICD-9-CM MS-DRGs, any updates to the joint revision combinations would apply to MS-DRGs 466, 467, and 468 as well as MS-DRGs 628, 629, and 630 because both sets of MS-DRGs contain the same joint revision codes. These comparable joint revisions combinations updates also will be made to MS-DRGs 628, 629, and 630 in the Version 33 MS-DRG structure for ICD-10 to maintain consistency with the logic for the ICD-9-CM MS-DRGs, effective October 1, 2015. Therefore, the joint revision combination codes that we are finalizing in this final rule are the same for MS-DRGs 466, 467, 468, 628, 629, and 630 and are reflected in the updated table below.
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SR9019</td>
</tr>
<tr>
<td></td>
<td>Replacement of right hip joint with metal synthetic substitute, cemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SR901A</td>
</tr>
<tr>
<td></td>
<td>Replacement of right hip joint with metal synthetic substitute, uncemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SR901Z</td>
</tr>
<tr>
<td></td>
<td>Replacement of right hip joint with metal synthetic substitute, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SR9029</td>
</tr>
<tr>
<td></td>
<td>Replacement of right hip joint with metal on polyethylene synthetic substitute, cemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SR902A</td>
</tr>
<tr>
<td></td>
<td>Replacement of right hip joint with metal on polyethylene synthetic substitute, uncemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SR902Z</td>
</tr>
<tr>
<td></td>
<td>Replacement of right hip joint with metal on polyethylene synthetic substitute, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SR9039</td>
</tr>
<tr>
<td></td>
<td>Replacement of right hip joint with ceramic synthetic substitute, cemented, open approach</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSR903A Replacement of right hip joint with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSR903Z Replacement of right hip joint with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSR9049 Replacement of right hip joint with ceramic on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSR904A Replacement of right hip joint with ceramic on polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSR904Z Replacement of right hip joint with ceramic on polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSR904Z Replacement of right hip joint with ceramic on polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSR90J9 Replacement of right hip joint with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSR90JA Replacement of right hip joint with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------------------------------------------</td>
<td>-----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SR90JZ</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SRA009</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SRA00A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SRA00Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SRA019</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SRA01A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------------------</td>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint,</td>
<td>and</td>
<td>0SRA01Z</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td>0SRA039</td>
<td>Replacement of</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>right hip joint,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>acetabular</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>surface with</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>metal synthetic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>substitute,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>open approach</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint,</td>
<td>and</td>
<td>0SRA03A</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td>0SRA03Z</td>
<td>Replacement of</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>right hip joint,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>acetabular</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>surface with</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ceramic synthetic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>substitute,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>cemented, open</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint,</td>
<td>and</td>
<td>0SRA0J9</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td>0SRA0JA</td>
<td>Replacement of</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>right hip joint,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>acetabular</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>surface with</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>synthetic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>substitute,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>cemented, pen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint,</td>
<td>and</td>
<td>0SRA0JZ</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td>0SRA0JZ</td>
<td>Replacement of</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>right hip joint,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>acetabular</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>surface with</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>synthetic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>substitute,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>uncemented, open</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
</tbody>
</table>

**MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations**
<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSPR019</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSPR01A</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSPR01Z</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSPR039</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSPR03A</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSPR03Z</td>
</tr>
<tr>
<td>OSP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>OSPR0J9</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SRR0JA</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SRR0JZ</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SU909Z</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SU9A09Z</td>
</tr>
<tr>
<td>0SP908Z</td>
<td>Removal of spacer from right hip joint, open approach</td>
<td>and</td>
<td>0SUR09Z</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SR9019</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SR901A</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SR901Z</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------------------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR9029</td>
<td>Replacement of right hip joint with metal on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR902A</td>
<td>Replacement of right hip joint with metal on polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR902Z</td>
<td>Replacement of right hip joint with metal on polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR9039</td>
<td>Replacement of right hip joint with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR903A</td>
<td>Replacement of right hip joint with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR903Z</td>
<td>Replacement of right hip joint with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR9049</td>
<td>Replacement of right hip joint with ceramic on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------------------------------</td>
<td>----------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR904A</td>
<td>Replacement of right hip joint with ceramic on polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR904Z</td>
<td>Replacement of right hip joint with ceramic on polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR90JA</td>
<td>Replacement of right hip joint with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SR90JZ</td>
<td>Replacement of right hip joint with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and OSRA009</td>
<td>Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and OSRA00A</td>
<td>Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------------</td>
<td>----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open</td>
<td>and</td>
<td>0SRA00Z</td>
</tr>
<tr>
<td></td>
<td>approach</td>
<td></td>
<td>Replacement of right hip joint, acetabular surface</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>with polyethylene synthetic substitute, open</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open</td>
<td>and</td>
<td>0SRA019</td>
</tr>
<tr>
<td></td>
<td>approach</td>
<td></td>
<td>Replacement of right hip joint, acetabular surface</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>with metal synthetic substitute, cemented, open</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open</td>
<td>and</td>
<td>0SRA01A</td>
</tr>
<tr>
<td></td>
<td>approach</td>
<td></td>
<td>Replacement of right hip joint, acetabular surface</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>with metal synthetic substitute, uncemented, open</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open</td>
<td>and</td>
<td>0SRA01Z</td>
</tr>
<tr>
<td></td>
<td>approach</td>
<td></td>
<td>Replacement of right hip joint, acetabular surface</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open</td>
<td>and</td>
<td>0SRA039</td>
</tr>
<tr>
<td></td>
<td>approach</td>
<td></td>
<td>Replacement of right hip joint, acetabular surface</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>with ceramic synthetic substitute, cemented, open</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open</td>
<td>and</td>
<td>0SRA03A</td>
</tr>
<tr>
<td></td>
<td>approach</td>
<td></td>
<td>Replacement of right hip joint, acetabular surface</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>with ceramic synthetic substitute, uncemented, open</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRA03Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRA0J9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRA0JA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRA0JZ</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRR019</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, femoral surface with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRR01A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, femoral surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRR01Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, femoral surface with metal synthetic substitute, open approach</td>
</tr>
</tbody>
</table>
MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRR039</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRR03A</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRR03Z</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRR0J9</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRR0JA</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SRR0JZ</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and</td>
<td>0SU909Z</td>
</tr>
</tbody>
</table>
MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33
ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision
ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SUA09Z</td>
<td>Supplement right hip joint, acetabular surface with liner, open approach</td>
</tr>
<tr>
<td>0SP909Z</td>
<td>Removal of liner from right hip joint, open approach</td>
<td>and 0SUR09Z</td>
<td>Supplement right hip joint, femoral surface with liner, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and 0SR9019</td>
<td>Replacement of right hip joint with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and 0SR901A</td>
<td>Replacement of right hip joint with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and 0SR901Z</td>
<td>Replacement of right hip joint with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and 0SR9029</td>
<td>Replacement of right hip joint with metal on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and 0SR902A</td>
<td>Replacement of right hip joint with metal on polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and 0SR902Z</td>
<td>Replacement of right hip joint with metal on polyethylene synthetic substitute, open approach</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SR9039</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>OSP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SR903A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>OSP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SR903Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>OSP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SR9049</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint with ceramic on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>OSP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SR904A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint with ceramic on polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>OSP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SR904Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint with ceramic on polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>OSP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SR90J9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint with synthetic substitute, cemented, open approach</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33
### ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision
### ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SR90JA</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SR90JZ</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA009</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA00A</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA00Z</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA019</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA01A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA01Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA039</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA03A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA03Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA0J9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA0 JA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, uncemented, open approach</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRA0JZ</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRR019</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRR01A</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRR01Z</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRR039</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRR03A</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
<td>0SRR03Z</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP90BZ</td>
<td>Removal of resurfacing device from right hip joint, open approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP90JZ</td>
<td>Removal of synthetic substitute from right hip joint, open approach</td>
<td>and</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0SP90JZ</td>
<td>Removal of synthetic substitute from right hip joint, open approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP90JZ</td>
<td>Removal of synthetic substitute from right hip joint, open approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR902Z</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR9039</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR903A</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR903Z</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR9049</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR904A</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR904Z</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------</td>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SR90J9</td>
<td>Replacement of right hip joint with synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SR90JA</td>
<td>Replacement of right hip joint with synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SR90JZ</td>
<td>Replacement of right hip joint with synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA009</td>
<td>Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA00A</td>
<td>Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA00Z</td>
<td>Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA019</td>
<td>Replacement of right hip joint, acetabular surface with metal synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA01A</td>
<td>Replacement of right hip joint, acetabular Surface with metal synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA01Z</td>
<td>Replacement of right hip joint, acetabular surface with metal synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA039</td>
<td>Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA03A</td>
<td>Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA03Z</td>
<td>Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA0J9</td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA0JA</td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRA0JZ</td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRR019</td>
<td>Replacement of right hip joint, femoral surface with metal synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRR01A</td>
<td>Replacement of right hip joint, femoral surface with metal synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRR01Z</td>
<td>Replacement of right hip joint, femoral surface with metal synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRR039</td>
<td>Replacement of right hip joint, femoral surface with ceramic synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRR03A</td>
<td>Replacement of right hip joint, femoral surface with ceramic synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP948Z</td>
<td>Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRR03Z</td>
<td>Replacement of right hip joint, femoral surface with ceramic synthetic substitute, open approach</td>
<td></td>
</tr>
</tbody>
</table>
**ICD-10-PCS Code** | **Code Description** | **ICD-10-PCS Code** | **Code Description**
--- | --- | --- | ---
0SP948Z | Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRR0J9 | Replacement of right hip joint, femoral surface with synthetic substitute, cemented, open approach
0SP948Z | Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRR0JA | Replacement of right hip joint, femoral surface with synthetic substitute, uncemented, open approach
0SP948Z | Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SRR0JZ | Replacement of right hip joint, femoral surface with synthetic substitute, open approach
0SP948Z | Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SU909Z | Supplement right hip joint with liner, open approach
0SP948Z | Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SUA09Z | Supplement right hip joint, acetabular surface with liner, open approach
0SP948Z | Removal of spacer from right hip joint, percutaneous endoscopic approach and 0SUR09Z | Supplement right hip joint, femoral surface with liner, open approach
0SP94JZ | Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach and 0SR9019 | Replacement of right hip joint with metal synthetic substitute, cemented, open approach
0SP94JZ | Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach and 0SR901A | Replacement of right hip joint with metal synthetic substitute, uncemented, open approach
<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR901Z</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR9029</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR902A</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR902Z</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR9039</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR903A</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR903Z</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR9049</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR904A</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR904Z</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR90J9</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR90JA</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SR90JZ</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRA009</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRA00A Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRA00Z Replacement of right hip joint, acetabular surface with polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRA019 Replacement of right hip joint, acetabular surface with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRA01A Replacement of right hip joint, acetabular surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRA01Z Replacement of right hip joint, acetabular surface with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRA039 Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------</td>
<td>----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and 0SRA03A</td>
<td>Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and 0SRA03Z</td>
<td>Replacement of right hip joint, acetabular surface with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and 0SRA0J9</td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and 0SRA0JA</td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and 0SRA0JZ</td>
<td>Replacement of right hip joint, acetabular surface with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and 0SRR019</td>
<td>Replacement of right hip joint, femoral surface with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and 0SRR01A</td>
<td>Replacement of right hip joint, femoral surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33
#### ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision
#### ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>OSP94JZ</td>
</tr>
<tr>
<td>OSP94JZ</td>
<td>Replacement of right hip joint, femoral surface with metal synthetic substitute, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSP94JZ</td>
<td>Replacement of right hip joint, femoral surface with ceramic synthetic substitute, cemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSP94JZ</td>
<td>Replacement of right hip joint, femoral surface with ceramic synthetic substitute, uncemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSP94JZ</td>
<td>Replacement of right hip joint, femoral surface with ceramic synthetic substitute, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSP94JZ</td>
<td>Replacement of right hip joint, femoral surface with synthetic substitute, cemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSP94JZ</td>
<td>Replacement of right hip joint, femoral surface with synthetic substitute, uncemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSP94JZ</td>
<td>Replacement of right hip joint, femoral surface with synthetic substitute, open approach</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach and 0SU909Z</td>
<td>Supplement right hip joint with liner, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach and 0SUA09Z</td>
<td>Supplement right hip joint, acetabular surface with liner, open approach</td>
<td></td>
</tr>
<tr>
<td>0SP94JZ</td>
<td>Removal of synthetic substitute from right hip joint, percutaneous endoscopic approach and 0SUR09Z</td>
<td>Supplement right hip joint, femoral surface with liner, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRB019</td>
<td>Replacement of left hip joint with metal synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRB01A</td>
<td>Replacement of left hip joint with metal synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRB01Z</td>
<td>Replacement of left hip joint with metal synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRB029</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRB02A</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRB02Z</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRB039</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRB03A</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRB03Z</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRB049</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRB04A</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRB04Z</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------------------------------</td>
<td>----------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRB0J9</td>
<td>Replacement of left hip joint with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRB0JA</td>
<td>Replacement of left hip joint with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRB0JZ</td>
<td>Replacement of left hip joint with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE009</td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE00A</td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE00Z</td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE019</td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------------------</td>
<td>----------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE01A</td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE01Z</td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE039</td>
<td>Replacement of left hip joint, acetabular surface with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE03A</td>
<td>Replacement of left hip joint, acetabular surface with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE03Z</td>
<td>Replacement of left hip joint, acetabular surface with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE0J9</td>
<td>Replacement of left hip joint, acetabular surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and 0SRE0JA</td>
<td>Replacement of left hip joint, acetabular surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRE0JZ</td>
<td>Replacement of left hip joint, acetabular surface with synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRS019</td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRS01A</td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRS01Z</td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRS039</td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRS03A</td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach and 0SRS03Z</td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRS0J9</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRS0JA</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SRS0JZ</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SUB09Z</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SUE09Z</td>
</tr>
<tr>
<td>0SPB08Z</td>
<td>Removal of spacer from left hip joint, open approach</td>
<td>and</td>
<td>0SUS09Z</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRB019</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRB01A</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------------------------------------------</td>
<td>-----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRB01Z</td>
<td>Replacement of left hip joint with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRB029</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRB02A</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRB02Z</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRB039</td>
<td>Replacement of left hip joint with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRB03A</td>
<td>Replacement of left hip joint with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRB03Z</td>
<td>Replacement of left hip joint with ceramic synthetic substitute, open approach</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRB049</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRB04A</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRB04Z</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRB0J9</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRB0JA</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRB0JZ</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE009</td>
</tr>
</tbody>
</table>
**ICD-10-PCS Combinations**

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE00A</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE00Z</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE019</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE01A</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE01Z</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE039</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE03A</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE03Z</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE0J9</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE0JA</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRE0JZ</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRS019</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and</td>
<td>0SRS01A</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33
ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision
ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRS01Z</td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRS039</td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRS03A</td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRS03Z</td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRS0J9</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRS0JA</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SRS0JZ</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------------------</td>
<td>----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SUB09Z</td>
<td>Supplement left hip joint with liner, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SUE09Z</td>
<td>Supplement left hip joint, acetabular surface with liner, open approach</td>
</tr>
<tr>
<td>0SPB09Z</td>
<td>Removal of liner from left hip joint, open approach</td>
<td>and 0SUS09Z</td>
<td>Supplement left hip joint, femoral surface with liner, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRB019</td>
<td>Replacement of left hip joint with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRB01A</td>
<td>Replacement of left hip joint with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRB01Z</td>
<td>Replacement of left hip joint with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRB029</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRB02A</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------</td>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
</tr>
<tr>
<td></td>
<td>and 0SRB02Z</td>
<td></td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
</tr>
<tr>
<td></td>
<td>and 0SRB039</td>
<td></td>
<td>Replacement of left hip joint with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
</tr>
<tr>
<td></td>
<td>and 0SRB03A</td>
<td></td>
<td>Replacement of left hip joint with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
</tr>
<tr>
<td></td>
<td>and 0SRB03Z</td>
<td></td>
<td>Replacement of left hip joint with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
</tr>
<tr>
<td></td>
<td>and 0SRB049</td>
<td></td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
</tr>
<tr>
<td></td>
<td>and 0SRB04A</td>
<td></td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>OSPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
</tr>
<tr>
<td></td>
<td>and 0SRB04Z</td>
<td></td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, open approach</td>
</tr>
</tbody>
</table>
## MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRB0J9</td>
<td>Replacement of left hip joint with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRB0JA</td>
<td>Replacement of left hip joint with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRB0JZ</td>
<td>Replacement of left hip joint with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE009</td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE00A</td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE00Z</td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE019</td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, cemented, open approach</td>
</tr>
</tbody>
</table>
# MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33

ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision

### ICD-10-PCS Pairs Added

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE01A</td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE01Z</td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE039</td>
<td>Replacement of left hip joint, acetabular surface with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE03A</td>
<td>Replacement of left hip joint, acetabular surface with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE03Z</td>
<td>Replacement of left hip joint, acetabular surface with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE0J9</td>
<td>Replacement of left hip joint, acetabular surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRE0JA</td>
<td>Replacement of left hip joint, acetabular surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------</td>
<td>----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint,</td>
<td>and</td>
<td>Replacement of left hip joint,</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td>0SRE0JZ</td>
<td>acetabular surface with synthetic substitute, open</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint,</td>
<td>and 0SRS019</td>
<td>Replacement of left hip joint, femoral surface with</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td></td>
<td>metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint,</td>
<td>and 0SRS01A</td>
<td>Replacement of left hip joint, femoral surface with</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td></td>
<td>metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint,</td>
<td>and 0SRS01Z</td>
<td>Replacement of left hip joint, femoral surface with</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td></td>
<td>metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint,</td>
<td>and 0SRS039</td>
<td>Replacement of left hip joint, femoral surface with</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td></td>
<td>ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint,</td>
<td>and 0SRS03A</td>
<td>Replacement of left hip joint, femoral surface with</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td></td>
<td>ceramic synthetic substitute, uncemented, open</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint,</td>
<td>and 0SRS03Z</td>
<td>Replacement of left hip joint, femoral surface with</td>
</tr>
<tr>
<td></td>
<td>open approach</td>
<td></td>
<td>ceramic synthetic substitute, open approach</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33
### ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision
### ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRS0J9</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRS0JA</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SRS0JZ</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SUB09Z</td>
<td>Supplement left hip joint with liner, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SUE09Z</td>
<td>Supplement left hip joint, acetabular surface with liner, open approach</td>
</tr>
<tr>
<td>0SPB0BZ</td>
<td>Removal of resurfacing device from left hip joint, open approach</td>
<td>and 0SUS09Z</td>
<td>Supplement left hip joint, femoral surface with liner, open approach</td>
</tr>
<tr>
<td>0SPB0JZ</td>
<td>Removal of synthetic substitute from left hip joint, open approach</td>
<td>and 0SRB049</td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0SPB0JZ</td>
<td>Removal of synthetic substitute from left hip joint, open approach</td>
<td>and</td>
<td>0SRB04A</td>
</tr>
<tr>
<td>0SPB0JZ</td>
<td>Removal of synthetic substitute from left hip joint, open approach</td>
<td>and</td>
<td>0SRB04Z</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRB019</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRB01A</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRB01Z</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRB029</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRB02A</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach and 0SRB02Z</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach and 0SRB039</td>
<td>Replacement of left hip joint with ceramic synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach and 0SRB03A</td>
<td>Replacement of left hip joint with ceramic synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach and 0SRB03Z</td>
<td>Replacement of left hip joint with ceramic synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach and 0SRB049</td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach and 0SRB04A</td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach and 0SRB04Z</td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRB0J9</td>
</tr>
<tr>
<td></td>
<td>and</td>
<td></td>
<td>Replacement of left hip joint with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRB0JA</td>
</tr>
<tr>
<td></td>
<td>and</td>
<td></td>
<td>Replacement of left hip joint with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRB0JZ</td>
</tr>
<tr>
<td></td>
<td>and</td>
<td></td>
<td>Replacement of left hip joint with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE009</td>
</tr>
<tr>
<td></td>
<td>and</td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE00A</td>
</tr>
<tr>
<td></td>
<td>and</td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE00Z</td>
</tr>
<tr>
<td></td>
<td>and</td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE019</td>
</tr>
<tr>
<td></td>
<td>and</td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE01A</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE01Z</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE039</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE03A</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE03Z</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE0J9</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE0JA</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE0JZ</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRS019</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRS01A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRS01Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRS039</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRS03A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRS03Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, open approach</td>
</tr>
</tbody>
</table>
## MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33
### ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision
#### ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous</td>
<td>and</td>
<td>0SRS0J9</td>
</tr>
<tr>
<td></td>
<td>endoscopic approach</td>
<td>0SRS0JA</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>cemented, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous</td>
<td>and</td>
<td>0SRS0JZ</td>
</tr>
<tr>
<td></td>
<td>endoscopic approach</td>
<td>0SUB09Z</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous</td>
<td>and</td>
<td>0SUE09Z</td>
</tr>
<tr>
<td></td>
<td>endoscopic approach</td>
<td>0SUS09Z</td>
<td>Supplement left hip joint with acetabular surface with liner, open approach</td>
</tr>
<tr>
<td>0SPB48Z</td>
<td>Removal of spacer from left hip joint, percutaneous</td>
<td>and</td>
<td>0SRB019</td>
</tr>
<tr>
<td></td>
<td>endoscopic approach</td>
<td>0SRB01A</td>
<td>Replacement of left hip joint with metal synthetic substitute, cemented, open</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint,</td>
<td>and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>percutaneous endoscopic approach</td>
<td>0SRB01A</td>
<td>Replacement of left hip joint with metal synthetic substitute, uncemented, open</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approach</td>
</tr>
</tbody>
</table>

*Note: The table above lists code pairs for new hip revision procedures as part of the ICD-10-PCS code sets for MS-DRGs 466-468 and 628-630.*
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRB01Z</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, cemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Replacement of left hip joint with metal on polyethylene synthetic substitute, uncemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Replacement of left hip joint with ceramic synthetic substitute, cemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Replacement of left hip joint with ceramic synthetic substitute, uncemented, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Replacement of left hip joint with ceramic synthetic substitute, open approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and 0SRB049</td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and 0SRB04A</td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and 0SRB04Z</td>
<td>Replacement of left hip joint with ceramic on polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and 0SRB0J9</td>
<td>Replacement of left hip joint with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and 0SRB0JA</td>
<td>Replacement of left hip joint with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and 0SRB0JZ</td>
<td>Replacement of left hip joint with synthetic substitute, open approach</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and 0SRE009</td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE00A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE00Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with polyethylene synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE019</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE01A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE01Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with metal synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE039</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with ceramic synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE03A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with ceramic synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE03Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with ceramic synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE0J9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE0JA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRE0JZ</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, acetabular surface with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRS019</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRS01A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach and 0SRS01Z</td>
<td>Replacement of left hip joint, femoral surface with metal synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach and 0SRS039</td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach and 0SRS03A</td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach and 0SRS03Z</td>
<td>Replacement of left hip joint, femoral surface with ceramic synthetic substitute, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach and 0SRS0J9</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute, cemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach and 0SRS0JA</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute, uncemented, open approach</td>
<td></td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach and 0SRS0JZ</td>
<td>Replacement of left hip joint, femoral surface with synthetic substitute, open approach</td>
<td></td>
</tr>
</tbody>
</table>
## MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Hip Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SUB09Z</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SUE09Z</td>
</tr>
<tr>
<td>0SPB4JZ</td>
<td>Removal of synthetic substitute from left hip joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SUS09Z</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Descriptions</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0SPC09Z</td>
<td>Removal of liner from right knee joint, open approach</td>
<td>and 0SRC0J9</td>
<td>Replacement of right knee joint with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPC09Z</td>
<td>Removal of liner from right knee joint, open approach</td>
<td>and 0SRC0JA</td>
<td>Replacement of right knee joint with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPC09Z</td>
<td>Removal of liner from right knee joint, open approach</td>
<td>and 0SRC0JZ</td>
<td>Replacement of right knee joint with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPC09Z</td>
<td>Removal of liner from right knee joint, open approach</td>
<td>and 0SRT0J9</td>
<td>Replacement of right knee joint, femoral surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPC09Z</td>
<td>Removal of liner from right knee joint, open approach</td>
<td>and 0SRT0JA</td>
<td>Replacement of right knee joint, femoral surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPC09Z</td>
<td>Removal of liner from right knee joint, open approach</td>
<td>and 0SRT0JZ</td>
<td>Replacement of right knee joint, femoral surface with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPC09Z</td>
<td>Removal of liner from right knee joint, open approach</td>
<td>and 0SRV0J9</td>
<td>Replacement of right knee joint, tibial surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPC09Z</td>
<td>Removal of liner from right knee joint, open approach</td>
<td>and 0SRV0JA</td>
<td>Replacement of right knee joint, tibial surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Descriptions</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------</td>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>0SPC09Z</td>
<td>Removal of liner from right knee joint, open approach</td>
<td>and</td>
<td>0SRV0JZ</td>
</tr>
<tr>
<td>0SPC0JZ</td>
<td>Removal of synthetic substitute from right knee joint, open approach</td>
<td>and</td>
<td>0SRT0J9</td>
</tr>
<tr>
<td>0SPC0JZ</td>
<td>Removal of synthetic substitute from right knee joint, open approach</td>
<td>and</td>
<td>0SRT0JA</td>
</tr>
<tr>
<td>0SPC0JZ</td>
<td>Removal of synthetic substitute from right knee joint, open approach</td>
<td>and</td>
<td>0SRV0J9</td>
</tr>
<tr>
<td>0SPC0JZ</td>
<td>Removal of synthetic substitute from right knee joint, open approach</td>
<td>and</td>
<td>0SRV0JA</td>
</tr>
<tr>
<td>0SPC4JZ</td>
<td>Removal of synthetic substitute from right knee joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRT0J9</td>
</tr>
<tr>
<td>0SPC4JZ</td>
<td>Removal of synthetic substitute from right knee joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRT0JA</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Descriptions</td>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------</td>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0SPC4JZ</td>
<td>Removal of synthetic substitute from right knee joint, percutaneous endoscopic approach</td>
<td>and 0SRV0J9</td>
<td>Replacement of right knee joint, tibial surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPC4JZ</td>
<td>Removal of synthetic substitute from right knee joint, percutaneous endoscopic approach</td>
<td>and 0SRV0JA</td>
<td>Replacement of right knee joint, tibial surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPD09Z</td>
<td>Removal of liner from left knee joint, open approach</td>
<td>and 0SRD0J9</td>
<td>Replacement of left knee joint with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPD09Z</td>
<td>Removal of liner from left knee joint, open approach</td>
<td>and 0SRD0JA</td>
<td>Replacement of left knee joint with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPD09Z</td>
<td>Removal of liner from left knee joint, open approach</td>
<td>and 0SRD0JZ</td>
<td>Replacement of left knee joint with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPD09Z</td>
<td>Removal of liner from left knee joint, open approach</td>
<td>and 0SRU0J9</td>
<td>Replacement of left knee joint, femoral surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPD09Z</td>
<td>Removal of liner from left knee joint, open approach</td>
<td>and 0SRU0JA</td>
<td>Replacement of left knee joint, femoral surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPD09Z</td>
<td>Removal of liner from left knee joint, open approach</td>
<td>and 0SRU0JZ</td>
<td>Replacement of left knee joint, femoral surface with synthetic substitute, open approach</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Knee Revision

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Descriptions</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPD09Z</td>
<td>Removal of liner from left knee joint, open approach</td>
<td>and</td>
<td>0SRW0J9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left knee joint, tibial surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPD09Z</td>
<td>Removal of liner from left knee joint, open approach</td>
<td>and</td>
<td>0SRW0JA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left knee joint, tibial surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPD09Z</td>
<td>Removal of liner from left knee joint, open approach</td>
<td>and</td>
<td>0SRW0JZ</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left knee joint, tibial surface with synthetic substitute, open approach</td>
</tr>
<tr>
<td>0SPD0JZ</td>
<td>Removal of synthetic substitute from left knee joint, open approach</td>
<td>and</td>
<td>0SRU0J9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left knee joint, femoral surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPD0JZ</td>
<td>Removal of synthetic substitute from left knee joint, open approach</td>
<td>and</td>
<td>0SRU0JA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left knee joint, femoral surface with synthetic substitute, uncemented, open approach</td>
</tr>
<tr>
<td>0SPD0JZ</td>
<td>Removal of synthetic substitute from left knee joint, open approach</td>
<td>and</td>
<td>0SRW0J9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left knee joint, tibial surface with synthetic substitute, cemented, open approach</td>
</tr>
<tr>
<td>0SPD0JZ</td>
<td>Removal of synthetic substitute from left knee joint, open approach</td>
<td>and</td>
<td>0SRW0JA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Replacement of left knee joint, tibial surface with synthetic substitute, uncemented, open approach</td>
</tr>
</tbody>
</table>
### MS-DRGs 466-468 and 628-630 ICD-10-PCS Code Pairs Added to the Version 33 ICD-10 MS-DRGs 466, 467, 468, 628, 629, and 630: New Knee Revision ICD-10-PCS Combinations

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Descriptions</th>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPD0JZ</td>
<td>Removal of synthetic substitute from left knee joint, open approach</td>
<td>and</td>
<td>0SRW0JZ</td>
</tr>
<tr>
<td>0SPD4JZ</td>
<td>Removal of synthetic substitute from left knee joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRU0J9</td>
</tr>
<tr>
<td>0SPD4JZ</td>
<td>Removal of synthetic substitute from left knee joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRU0JA</td>
</tr>
<tr>
<td>0SPD4JZ</td>
<td>Removal of synthetic substitute from left knee joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRW0J9</td>
</tr>
<tr>
<td>0SPD4JZ</td>
<td>Removal of synthetic substitute from left knee joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRW0JA</td>
</tr>
<tr>
<td>0SPD4JZ</td>
<td>Removal of synthetic substitute from left knee joint, percutaneous endoscopic approach</td>
<td>and</td>
<td>0SRW0JZ</td>
</tr>
</tbody>
</table>

b. Spinal Fusion

We received a request to revise the titles of MS-DRGs 456, 457, and 458 (Spinal Fusion Except Cervical with Spinal Curvature/Malignancy/Infection or 9+ Fusion with MCC, with CC, and without CC/MCC, respectively) for the ICD-10 MS-DRGs so that
they more closely correspond to the terminology used to describe the ICD-10-PCS procedure codes without changing the ICD-10 MS-DRG logic. We agree with the requestor that revising the titles of these MS-DRGs would more appropriately identify the procedures classified under these groupings. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24395), we proposed new titles for these three MS-DRGs that would change the reference of “9+ Fusions” to “Extensive Fusions.”

We invited public comments on our proposal.

Comment: Several commenters supported the proposal to modify the titles for ICD-10 MS-DRGs 456 through 458. The commenters stated that the proposal was reasonable, given the data and information provided.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to modify the titles for ICD-10 MS-DRGs 456 through 458. The final title revisions to MS-DRGs 456, 457, and 458 for the FY 2016 ICD-10 MS-DRGs Version 33 are as follows:

- MS-DRG 456 (Spinal Fusion Except Cervical with Spinal Curvature/Malignancy/Infection or Extensive Fusion with MCC);
- MS-DRG 457 (Spinal Fusion Except Cervical with Spinal Curvature/Malignancy/Infection or Extensive Fusion with CC); and
- MS-DRG 458 (Spinal Fusion Except Cervical with Spinal Curvature/Malignancy/Infection or Extensive Fusion without CC/MCC).
5. MDC 14 (Pregnancy, Childbirth and the Puerperium): MS-DRG 775 (Vaginal Delivery Without Complicating Diagnosis)

We received a request to modify the logic for ICD-10 MS-DRG 775 (Vaginal Delivery without Complicating Diagnosis) so that the procedure code for the induction of labor with a cervical ripening gel would not group to the incorrect MS-DRG when a normal delivery has occurred. ICD-10-PCS procedure code 3E0P7GC (Introduction of other therapeutic substance into female reproductive, via natural or artificial opening) describes this procedure.

We reviewed how this procedure code is currently classified under the ICD-10 MS-DRGs Version 32 and noted that it is currently designated as an operating room (O.R.) procedure code that affects MS-DRG assignment. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24395), we agreed with the requestor that the current logic for ICD-10-PCS procedure code 3E0P7GC did not result in the appropriate MS-DRG assignment. The result of our analysis suggested that this code should not be designated as an O.R. code. Our clinical advisors agreed that this procedure did not require the intensity or complexity of service and resource utilization to merit an O.R. designation under ICD-10. Therefore, in the proposed rule, we proposed to make ICD-10-PCS procedure code 3E0P7GC a non-O.R. code so that cases reporting this procedure code will group to the appropriate MS-DRG assignment. We invited public comments on our proposal.

Comment: Several commenters supported the proposal to modify the logic for ICD-10 MS-DRG 775 so that procedure code 3E0P7GC would not group to the incorrect
MS-DRG when a normal delivery has occurred. The commenters stated that the proposal was reasonable, given the data and information provided.

Response: We appreciate the commenters’ support for our proposal.

After consideration of the public comments received, we are finalizing our proposal to modify the logic for ICD-10 MS-DRG 775 so that ICD-10-PCS procedure code 3E0P7GC will not group to the incorrect MS-DRG when a normal delivery has occurred.

Our analysis of ICD-10-PCS procedure code 3E0P7GC also prompted the review of additional, similar codes that describe the introduction of a substance. We evaluated the following ICD-10-PCS procedure codes:

- 3E0P76Z (Introduction of nutritional substance into female reproductive, via natural or artificial opening);
- 3E0P77Z (Introduction of electrolytic and water balance substance into female reproductive, via natural or artificial opening);
- 3E0P7SF (Introduction of other gas into female reproductive, via natural or artificial opening);
- 3E0P83Z (Introduction of anti-inflammatory into female reproductive, via natural or artificial opening endoscopic);
- 3E0P86Z (Introduction of nutritional substance into female reproductive, via natural or artificial opening endoscopic);
- 3E0P87Z (Introduction of electrolytic and water balance substance into female reproductive, via natural or artificial opening endoscopic);
● 3E0P8GC (Introduction of other therapeutic substance into female reproductive, via natural or artificial opening endoscopic); and

● 3E0P8SF (Introduction of other gas into female reproductive, via natural or artificial opening endoscopic).

From our analysis, we determined that these codes also are currently designated as O.R. codes which affect MS-DRG assignment. Our clinical advisors recommended that these codes should also be designated as non-O.R. because they do not require the intensity or complexity of service and resource utilization to merit an O.R. designation under the ICD-10 MS-DRGs. As a result of our analysis and based on our clinical advisors’ recommendation, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24395), we proposed to designate the above listed ICD-10-PCS procedure codes as non-O.R. procedure codes to ensure that these codes will group to the appropriate MS-DRG assignment.

We invited public comments on our proposal.

Comment: Several commenters agreed with the proposal to change the designation for the additional ICD-10-PCS codes listed in the proposed rule describing the introduction of a substance from O.R. to non-O.R. The commenters stated that the proposal was reasonable, given the data and information provided.

Response: We appreciate the commenters’ support.

After consideration of the public comments received, we are finalizing our proposal to designate the following ICD-10-PCS procedure codes as non-O.R. for the
FY 2016 ICD-10 MS-DRGs Version 33: 3E0P76Z; 3E0P77Z; 3E0P7SF; 3E0P83Z; 3E0P86Z; 3E0P87Z; 3E0P8GC; and 3E0P8SF.

6. MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs): CroFab Antivenin Drug

We received a request that CMS change the MS-DRG assignment for antivenom cases from MS-DRG 917 and 918 (Poisoning & Toxic Effects of Drugs with and without MCC, respectively). For the FY 2016 IPPS/LTCH PPS proposed rule, for these MS-DRGs, we examined claims data from the December 2014 update of the FY 2014 MedPAR file for cases reporting ICD-9-CM diagnosis codes of a principal diagnosis 989.5 (Toxic effect of venom), a secondary diagnosis ICD-9-CM E code of E905.0 (Venomous snakes and lizards), and the ICD-9-CM procedure code of 99.16 (Injection of antidote), which is a non-O.R. code and does not impact the MS-DRG assignment.

For the ICD-9-CM diagnosis code 989.5 (Toxic effect of venom), the ICD-10-CM provides more detailed diagnosis codes for these toxic effects of venom cases as shown in the following table:

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T63.001A</td>
<td>Toxic effect of unspecified snake venom, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.011A</td>
<td>Toxic effect of rattlesnake venom, accidental (unintentional) initial encounter</td>
</tr>
<tr>
<td>T63.021A</td>
<td>Toxic effect of coral snake venom, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.031A</td>
<td>Toxic effect of taipan venom, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.041A</td>
<td>Toxic effect of cobra venom, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>ICD-10-CM Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
</tr>
<tr>
<td>T63.061A</td>
<td>Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.71A</td>
<td>Toxic effect of venom of other Australian snake, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.081A</td>
<td>Toxic effect of venom of other African and Asian snake, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.091A</td>
<td>Toxic effect of venom of other snake, accidental (unintentional), initial encounter</td>
</tr>
</tbody>
</table>

For the ICD-9-CM Supplementary Classification of External Causes of Injury and Poisoning code E905.0 (Venomous snakes and lizards), ICD-10-CM provides more detailed diagnosis codes for these cases as shown in the following table:
We examined claims data for reported cases involving injections for snake bites in MS-DRGs 917 and 918 from the December 2014 update of the FY 2014 MedPAR file. Our findings are displayed in the table below.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T63.001A</td>
<td>Toxic effect of unspecified snake venom, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.011A</td>
<td>Toxic effect of rattlesnake venom, accidental (unintentional) initial encounter</td>
</tr>
<tr>
<td>T63.021A</td>
<td>Toxic effect of coral snake venom, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.031A</td>
<td>Toxic effect of taipan venom, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.041A</td>
<td>Toxic effect of cobra venom, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.061A</td>
<td>Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.071A</td>
<td>Toxic effect of venom of other Australian snake, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.081A</td>
<td>Toxic effect of venom of other African and Asian snake, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.091A</td>
<td>Toxic effect of venom of other snake, accidental (unintentional), initial encounter</td>
</tr>
</tbody>
</table>
Snake Bite with Injections

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 917 – All cases</td>
<td>26,393</td>
<td>4.77</td>
<td>$9,983</td>
</tr>
<tr>
<td>MS-DRG 917 – Cases with principal diagnosis code 989.5 and secondary diagnosis code E905.0 with procedure code 99.16 (non-OR)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>MS-DRG 918 – All cases</td>
<td>24,557</td>
<td>2.90</td>
<td>$4,953</td>
</tr>
<tr>
<td>MS-DRG 918 - Cases with principal diagnosis code 989.5 and secondary diagnosis code E905.0 with procedure code 99.16 (non-OR)</td>
<td>19</td>
<td>2.16</td>
<td>$12,014</td>
</tr>
</tbody>
</table>

As shown in the table above, we identified 19 cases involving injections for snake bites reported in MS-DRG 918 only. In the FY 2016 IPPS/LTCH PPS proposed rule, we pointed out that this small number of cases (19) does not provide justification to create a new MS-DRG. The cases are assigned to the same MS-DRG as are other types of poisonings and toxic effects. We were unable to identify another MS-DRG that would be a more appropriate MS-DRG assignment for these cases based on the clinical nature of this condition. The MS-DRGs are a classification system intended to group together diagnoses and procedures with similar clinical characteristics and utilization of resources. Basing a new MS-DRG on such a small number of cases (19) could lead to distortions in the relative payment weights for the MS-DRG because several expensive cases could impact the overall relative payment weight. Having larger clinical cohesive groups within an MS-DRG provides greater stability for annual updates to the relative payment weights.
Our clinical advisors reviewed the data, evaluated these conditions, and recommended that we not change the MS-DRG assignment for procedures involving the injection of the CroFab antivenom drug for snake bites because these cases are clinically similar to other poisoning cases currently assigned to MS-DRGs 917 and 918. Based on the findings in our data analysis and the recommendations of our clinical advisors, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24397), we did not propose to create a new MS-DRG for cases of CroFab antivenom drugs for snake bites. We proposed to maintain the current assignment of diagnosis codes in MS-DRGs 917 and 918. We invited public comments on our proposal.

Comment: A number of commenters supported the proposal to maintain the current MS-DRG assignment for procedures involving CroFab antivenom. The commenters stated that the proposal was reasonable, given the data and information provided.

Response: We appreciate the commenters’ support for our proposal.

After consideration of the public comments we received, we are finalizing our proposal to maintain the current MS-DRG assignment for procedures involving the CroFab antivenom drug for snakebites to MS-DRGs 917 and 918.

7. MDC 22 (Burns): Additional Severity of Illness Level for MS-DRG 927 (Extensive Burns or Full Thickness Burns with Mechanical Ventilation 96+ Hours with Skin Graft)

We received a request to add an additional severity level to MS-DRG 927 (Extensive Burns or Full Thickness Burns with Mechanical Ventilation 96+ Hours with Skin Graft). The requestor was concerned about payment for severe burn cases that used
dermal regenerative grafts. These grafts are captured by ICD-9-CM procedure code 86.67 (Dermal regenerative graft). The requestor stated that the total cost of these graft cases is significantly greater than the average total costs for all cases in MS-DRG 927. The requestor stated that the dermal regenerative grafts are used to cover large burns where donor skin is not available. The requestor stated that the grafts provide permanent covering of the wound and thus immediate closure of the wound. The requestor asserted that the grafts offer benefits such as the avoidance of infections. The requestor pointed out that MS-DRG 927 is not subdivided into severity of illness levels and recommended an additional severity level be added to address any payment issues for dermal regenerative grafts within MS-DRG 927.

ICD-10-PCS provides more detailed and specific codes for skin grafts. The ICD-10-PCS codes for skin grafts provide specific information on the part of the body receiving the skin graft, the type of graft, and the approach used to apply the graft. These codes can be found in the table labeled “OHR (Replacement of Skin)” in the ICD-10 MS-DRG Version 32 Definitions Manual available on the Internet at: http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. As stated earlier, for the ICD-9-CM codes that result in greater than 50 ICD-10-PCS comparable code translations, we referred readers to Table 6P (ICD-10-PCS Code Translations for Final MS-DRG Changes), which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. The table includes the MDC topic, the
ICD-9-CM code, and the ICD-10-PCS code translations. In Table 6P.2a, we show the comparable ICD-10-PCS codes for ICD-9-CM code 86.67 (Dermal regenerative graft).

We examined claims data for cases reported in MS-DRG 927 from the December 2014 update of the FY 2014 MedPAR file. The following table shows our findings.

<table>
<thead>
<tr>
<th>Extensive Burns or Full Thickness Burns with Mechanical Ventilation 96+ Hours with Skin Graft</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 927 – All cases</td>
<td>171</td>
<td>29.92</td>
<td>$113,844</td>
</tr>
<tr>
<td>MS-DRG 927 – Cases with procedure code 86.67</td>
<td>22</td>
<td>33.5</td>
<td>$146,903</td>
</tr>
<tr>
<td>MS-DRG 927 – Cases with procedure code 86.67 and 96.72 (Mechanical ventilation for 96+ hours)</td>
<td>14</td>
<td>38.6</td>
<td>$174,372</td>
</tr>
<tr>
<td>MS-DRG 927 – Cases with procedure code 86.67 and without 96.72 (Mechanical ventilation for 96+ hours)</td>
<td>8</td>
<td>24.6</td>
<td>$98,482</td>
</tr>
<tr>
<td>MS-DRG 927 – All cases with MCC</td>
<td>131</td>
<td>31.51</td>
<td>$121,519</td>
</tr>
<tr>
<td>MS-DRG 927 – All cases with CC</td>
<td>38</td>
<td>25.21</td>
<td>$91,910</td>
</tr>
<tr>
<td>MS-DRG 927 – All cases without CC/MCC</td>
<td>2</td>
<td>15.00</td>
<td>$27,872</td>
</tr>
</tbody>
</table>

As shown in the table above, we found a total of 171 cases in MS-DRG 927. Of these 171 cases, there were 131 cases with an MCC, 38 cases with a CC, and 2 cases without a CC or an MCC. We determined that the requested new severity level did not meet all of the criteria established in the FY 2008 IPPS final rule (72 FR 47169), and described in section II.G.1.b. of the preamble of the proposed rule, that must be met to warrant the creation of a CC or an MCC subgroup within a base MS-DRG. Specifically,
the requested new severity level did not meet the criterion that there are at least 500 cases in the CC or MCC subgroup.

We also pointed out that the long-term mechanical ventilation cases are driving the costs to a greater extent than the graft cases. We found that the 22 cases that received a graft had average costs of $146,903. The 14 cases that had both 96+ hours of mechanical ventilation and a graft had average costs of $174,372. The 8 cases that had a graft but did not receive 96+ hours of mechanical ventilation had average costs of $98,482.

Our clinical advisors reviewed this issue and recommended making no MS-DRG updates for MS-DRG 927. They advised us that the dermal regenerative graft cases are appropriately assigned to the MS-DRG 927 because they are clinically similar to other cases within MS-DRG 927. Our clinical advisors also agreed that the cases in MS-DRG 927 do not meet the established criterion for creating a new severity level.

Based on the findings of our data analysis, the fact that MS-DRG 927 did not meet the criterion for the creation of an additional severity level, and the recommendations of our clinical advisors, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24397), we did not propose to create a new severity level for MS-DRG 927. We proposed to maintain the current MS-DRG 927 structure without additional severity levels. We invited public comments on our proposal.

Comment: A number of commenters supported the proposal to maintain the current MS-DRG 927 structure without creating additional severity levels. The
commenters stated that the proposal was reasonable, given the data and information provided.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to maintain the current MS-DRG 927 structure without creating additional severity levels.

8. Medicare Code Editor (MCE) Changes

The Medicare Code Editor (MCE) is a software program that detects and reports errors in the coding of Medicare claims data. Patient diagnoses, procedure(s), and demographic information are entered into the Medicare claims processing systems and are subjected to a series of automated screens. The MCE screens are designed to identify cases that require further review before classification into an MS-DRG.

As discussed in section II.G.1.a. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule and this final rule, CMS prepared the ICD-10 MS-DRGs Version 32 based on the FY 2015 MS-DRGs (Version 32) that we finalized in the FY 2015 IPPS/LTCH PPS final rule. In November 2014, we made available a Definitions Manual of the ICD-10 MS-DRGs Version 32 and the MCE Version 32 on the ICD-10 MS-DRG Conversion Project Web site at: http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. We also prepared a document that described the changes made between Version 31-R to Version 32 to help facilitate a review of the ICD-10 MS-DRGs logic. We produced mainframe and computer software for ICD-10 MS-DRGs Version 32 and MCE Version 32, which was made available to the public in
January 2015. Information on ordering the mainframe and computer software through NTIS was made available on the CMS Web site at:

http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html under the “Related Links” section. We encouraged the public to submit to CMS any comments on areas where they believed the ICD-10 MS-DRG GROUPER and MCE did not accurately reflect the logic and edits found in the ICD-9-CM MS-DRG GROUPER and the MCE.

For FY 2016, in order to be consistent with the ICD-9-CM MS-DRG GROUPER and MCE Version 32, we proposed to add the ICD-10-CM codes listed in the table below to the ICD-10 MCE Version 33 of the “Manifestation codes not allowed as principal diagnosis” edit. Under the MCE, manifestation codes describe the “manifestation” of an underlying disease, not the disease itself. Because these codes do not describe the disease itself, they should not be used as principal diagnoses.
<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D75.81</td>
<td>Myelofibrosis</td>
</tr>
<tr>
<td>E08.00</td>
<td>Diabetes mellitus due to underlying condition with hyperosmolar without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)</td>
</tr>
<tr>
<td>E08.01</td>
<td>Diabetes mellitus due to underlying condition with hyperosmolarity with coma</td>
</tr>
<tr>
<td>E08.10</td>
<td>Diabetes mellitus due to underlying condition with ketoacidosis without coma</td>
</tr>
<tr>
<td>E08.11</td>
<td>Diabetes mellitus due to underlying condition with ketoacidosis with coma</td>
</tr>
<tr>
<td>E08.21</td>
<td>Diabetes mellitus due to underlying condition with diabetic nephropathy</td>
</tr>
<tr>
<td>E08.22</td>
<td>Diabetes mellitus due to underlying condition with diabetic chronic kidney disease</td>
</tr>
<tr>
<td>E08.29</td>
<td>Diabetes mellitus due to underlying condition with other diabetic kidney complication</td>
</tr>
<tr>
<td>E08.311</td>
<td>Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E08.319</td>
<td>Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema</td>
</tr>
<tr>
<td>E08.321</td>
<td>Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E08.329</td>
<td>Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema</td>
</tr>
<tr>
<td>E08.331</td>
<td>Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E08.339</td>
<td>Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema</td>
</tr>
<tr>
<td>E08.341</td>
<td>Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E08.349</td>
<td>Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema</td>
</tr>
<tr>
<td>E08.351</td>
<td>Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema</td>
</tr>
<tr>
<td>E08.359</td>
<td>Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema</td>
</tr>
<tr>
<td>E08.36</td>
<td>Diabetes mellitus due to underlying condition with diabetic cataract</td>
</tr>
<tr>
<td>E08.39</td>
<td>Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication</td>
</tr>
<tr>
<td>ICD-10-CM Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>E08.40</td>
<td>Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified</td>
</tr>
<tr>
<td>E08.41</td>
<td>Diabetes mellitus due to underlying condition with diabetic mononeuropathy</td>
</tr>
<tr>
<td>E08.42</td>
<td>Diabetes mellitus due to underlying condition with diabetic polyneuropathy</td>
</tr>
<tr>
<td>E08.43</td>
<td>Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy</td>
</tr>
<tr>
<td>E08.44</td>
<td>Diabetes mellitus due to underlying condition with diabetic amyotrophy</td>
</tr>
<tr>
<td>E08.49</td>
<td>Diabetes mellitus due to underlying condition with other diabetic neurological complication</td>
</tr>
<tr>
<td>E08.51</td>
<td>Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene</td>
</tr>
<tr>
<td>E08.52</td>
<td>Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene</td>
</tr>
<tr>
<td>E08.59</td>
<td>Diabetes mellitus due to underlying condition with other circulatory complications</td>
</tr>
<tr>
<td>E08.610</td>
<td>Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy</td>
</tr>
<tr>
<td>E08.618</td>
<td>Diabetes mellitus due to underlying condition with other diabetic arthropathy</td>
</tr>
<tr>
<td>E08.620</td>
<td>Diabetes mellitus due to underlying condition with diabetic dermatitis</td>
</tr>
<tr>
<td>E08.621</td>
<td>Diabetes mellitus due to underlying condition with foot ulcer</td>
</tr>
<tr>
<td>E08.622</td>
<td>Diabetes mellitus due to underlying condition with other skin ulcer</td>
</tr>
<tr>
<td>E08.628</td>
<td>Diabetes mellitus due to underlying condition with other skin complications</td>
</tr>
<tr>
<td>E08.630</td>
<td>Diabetes mellitus due to underlying condition with periodontal disease</td>
</tr>
<tr>
<td>E08.638</td>
<td>Diabetes mellitus due to underlying condition with other oral complications</td>
</tr>
<tr>
<td>E08.641</td>
<td>Diabetes mellitus due to underlying condition with hypoglycemia with coma</td>
</tr>
<tr>
<td>E08.649</td>
<td>Diabetes mellitus due to underlying condition with hypoglycemia without coma</td>
</tr>
<tr>
<td>E08.65</td>
<td>Diabetes mellitus due to underlying condition with hyperglycemia</td>
</tr>
<tr>
<td>E08.69</td>
<td>Diabetes mellitus due to underlying condition with other specified complication</td>
</tr>
<tr>
<td>E08.8</td>
<td>Diabetes mellitus due to underlying condition with unspecified complications</td>
</tr>
<tr>
<td>ICD-10-CM Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>E08.9</td>
<td>Diabetes mellitus due to underlying condition without complications</td>
</tr>
</tbody>
</table>

We invited public comment on our proposal to add the above list of ICD-10-CM diagnosis codes to the “Manifestation codes not allowed as principal diagnosis” edit in the FY 2016 ICD-10 MCE Version 33.

Comment: Several commenters supported the proposal to add the above listed ICD-10-CM diagnosis codes to the “Manifestation codes not allowed as principal diagnosis” edit in the FY 2016 ICD-10 MCE Version 33. The commenters stated that the proposed changes for the ICD-10 MCE seemed reasonable, given the data and information provided. However, one commenter asserted that the code description for ICD-10-CM diagnosis code D75.81, “Myelofibrosis”, as displayed in the table in the proposed rule was inaccurate and that the more accurate long description is “Secondary myelofibrosis”. The commenter stated that if the proposal for myelofibrosis under the “Manifestation codes not allowed as principal diagnosis” edit is restricted to “secondary myelofibrosis,” it would support the proposal. This commenter indicated that the disease of myelofibrosis is often the main reason for admission as it is a well-defined myeloproliferative neoplasm.

The commenter also noted it recently participated in proposals related to expanding coverage indications for hematopoietic stem cell transplant to include patients with a principal diagnosis of myelofibrosis. The commenter stated that primary or idiopathic myelofibrosis is coded with ICD-9-CM code 238.76 (Myelofibrosis with
myeloid metaplasia) and will be reported with ICD-10-PCS code D47.1 (Chronic myeloproliferative disease). The commenter expressed a desire for coding of this condition to not create confusion as implementation of ICD-10 approaches and pledged to work with its members to confirm understanding.

Response: We appreciate the commenters’ support of our proposal to add the listed ICD-10-CM diagnosis codes to the ICD-10 MCE Version 33 of the “Manifestation codes not allowed as principal diagnosis” edit. With regard to the commenter who asserted that the code description for ICD-10-CM diagnosis code D75.81 was inaccurate and that the more accurate long description is “Secondary myelofibrosis”, we point out that the official ICD-10-CM diagnosis code title description, as displayed in the 2015 Code Descriptions in Tabular Order file, which is available on the CMS ICD-10 Web site at [http://www.cms.gov/Medicare/Coding/ICD10/2015-ICD-10-CM-and-GEMs.html](http://www.cms.gov/Medicare/Coding/ICD10/2015-ICD-10-CM-and-GEMs.html) in the Downloads section, is as presented in the FY 2016 IPPS/LTCH PPS proposed rule, “Myelofibrosis”. In response to the commenter’s statement that if the proposal for myelofibrosis under the “Manifestation codes not allowed as principal diagnosis” edit is restricted to “secondary myelofibrosis,” the commenter would support it, we note that ICD-10-CM diagnosis code D75.81 (Myelofibrosis) has an inclusion term of “Secondary myelofibrosis NOS”. (Within ICD-10-CM, an inclusion term is defined as a term that is included under certain codes. The term represents a condition for which that code is to be used. The term may also be a synonym of the code title. We refer the reader to the ICD-10-CM Official Guidelines for Coding and Reporting for additional information related to inclusion terms.) As such, we believe the proposal to include ICD-10-CM
diagnosis code D75.81 (Myelofibrosis) on the list of “Manifestation codes not allowed as principal diagnosis” edit is not inconsistent with the commenter’s statement of support for a proposal restricted to “secondary myelofibrosis.” In response to the commenter indicating that the disease of myelofibrosis is often the main reason for admission as it is a well-defined myeloproliferative neoplasm, we note that, under both ICD-9-CM and ICD-10-CM, myelofibrosis is a manifestation code. As discussed previously, manifestation codes describe the manifestation of an underlying disease, not the disease itself, and therefore should not be used as a principal diagnosis. We also point out that a “code first” note appears at ICD-10-CM diagnosis code D75.81 (Myelofibrosis). The “code first” note is an etiology/manifestation coding convention (additional detail can be found in the ICD-10-CM Official Guidelines for Coding and Reporting), indicating that the condition has both an underlying etiology and manifestation due to the underlying etiology.

The commenter is correct that primary or idiopathic myelofibrosis is coded with ICD-9-CM code 238.76 (Myelofibrosis with myeloid metaplasia) and the comparable ICD-10-PCS procedure code translation is D47.1 (Chronic myeloproliferative disease). We also acknowledge and appreciate that the commenter stated its intent to work with its members to confirm understanding of coding as it relates to myelofibrosis as the transition to ICD-10 approaches. We encourage the commenter to review the ICD-10-CM Official Guidelines for Coding and Reporting to assist in that effort.

After consideration of the public comments we received, for FY 2016, we are finalizing our proposal to add the ICD-10-PCS codes listed earlier in this section to the
ICD-10 MCE Version 33 "Manifestation codes not allowed as principal diagnosis" edit, which will ensure consistency with the ICD-9-CM MS-DRG GROUPER and MCE Version 32.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24398 through 24399), we also proposed to revise the language describing the “Procedure inconsistent with LOS (Length of stay)” edit which lists ICD-10-PCS code 5A1955Z (Respiratory ventilation, greater than 96 consecutive hours), effective for the FY 2016 ICD-10 MCE Version 33. Currently, in Version 32 of the ICD-10 MCE, the language describing this “Procedure inconsistent with LOS (Length of stay)” edit states: “The following procedure should only be coded on claims with a length of stay of four days or greater.” Because the code description of the ICD-10-PCS code is for ventilation that occurs greater than 96 consecutive hours, we proposed to revise the language for the edit to read: “The following procedure code should only be coded on claims with a length of stay greater than 4 days.” This proposed revision would clarify the intent of this MCE edit. We invited public comments on our proposal.

**Comment**: Several commenters supported the proposal to revise the language describing the “Procedure inconsistent with LOS (Length of stay)” edit. The commenters stated that the proposed changes seem reasonable, given the data and information provided.

**Response**: We appreciate the commenters’ support.

Consistent with the proposal to revise the language for the “Procedure inconsistent with LOS (Length of stay)” edit because the code description for ICD-10-
PCS code 5A1955Z is for ventilation that occurs greater than 96 consecutive hours, we determined that it is also necessary to revise the language for the corresponding ICD-10 MS-DRG titles that currently reference the ICD-9-CM terminology for mechanical ventilation of “96 + hours” based on the ICD-9-CM procedure code 96.72 (Continuous invasive mechanical ventilation for 96 consecutive hours or more) to instead reflect the terminology for the ICD-10-PCS code translation. Consistent with the logic for the ICD-9-CM MS-DRGs Version 32, ICD-10-PCS code 5A1955Z is assigned to these same MS-DRGs under the ICD-10 MS-DRGs Version 33. Under ICD-9-CM, the following six MS-DRGs contain GROUPER and MCE logic based on procedure code 96.72:

- MS-DRG 003 (ECMO or Tracheostomy with Mechanical Ventilation 96+ Hours or Principal Diagnosis Except, Face Mouth and Neck with Major Operating Room Procedure);
- MS-DRG 004 (Tracheostomy with Mechanical Ventilation 96+ Hours or Principal Diagnosis Except, Face Mouth and Neck without Major Operating Room Procedure);
- MS-DRG 207 (Respiratory System Diagnosis with Ventilator Support 96+Hours);
- MS-DRG 870 (Septicemia or Severe Sepsis with Mechanical Ventilation 96+ Hours);
- MS-DRG 927 (Extensive Burns or Full Thickness Burns with Mechanical Ventilation 96+ Hours with Skin Graft); and
• MS-DRG 933 (Extensive Burns or Full Thickness Burns with Mechanical Ventilation 96+ Hours without Skin Graft).

The following two MS-DRGs do not include GROUPER and MCE logic based on procedure code 96.72. However, the titles currently include the terminology for without mechanical ventilation of “96 + hours”.

• MS-DRG 871 (Septicemia or Severe Sepsis without Mechanical Ventilation 96+ Hours with MCC) ; and

• MS-DRG 872 (Septicemia or Severe Sepsis without Mechanical Ventilation 96+ Hours with CC).

Therefore, we are revising the titles for the corresponding ICD-10 MS-DRGs as the GROUPER and MCE logic include ICD-10-PCS code 5A1955Z (Respiratory ventilation, greater than 96 consecutive hours) or the language in the title of the MS-DRG includes without mechanical ventilation of “96 + hours”. The revision to the titles is to add a “greater than” sign (>) before the 96 to reflect “> 96 consecutive hours” and to remove the “plus sign” (+) after the 96.

After consideration of the public comments received, we are finalizing our proposal to revise the language describing the “Procedure inconsistent with LOS (Length of stay)” edit which lists ICD-10-PCS code 5A1955Z (Respiratory ventilation, greater than 96 consecutive hours). Consistent with that proposal, we also are revising the ICD-10 MS-DRG Version 33 titles as follows, effective for FY 2016.
● MS-DRG 003: “(ECMO or Tracheostomy with Mechanical Ventilation >96 Hours or Principal Diagnosis Except, Face Mouth and Neck with Major Operating Room Procedure”;

● MS-DRG 004: “Tracheostomy with Mechanical Ventilation >96 Hours or Principal Diagnosis Except, Face Mouth and Neck without Major Operating Room Procedure”;

● MS-DRG 007: “Respiratory System Diagnosis with Ventilator Support >96 Hours”;

● MS-DRG 870: “Septicemia or Severe Sepsis with Mechanical Ventilation >96 Hours”;

● MS-DRG 871: “Septicemia or Severe Sepsis without Mechanical Ventilation >96 Hours with MCC”;

● MS-DRG 872: “Septicemia or Severe Sepsis without Mechanical Ventilation >96 Hours with CC”;

● MS-DRG 927: “Extensive Burns or Full Thickness Burns with Mechanical Ventilation >96 Hours with Skin Graft”; and

● MS-DRG 933: “Extensive Burns or Full Thickness Burns with Mechanical Ventilation >96 Hours without Skin Graft”.
9. Changes to Surgical Hierarchies

Some inpatient stays entail multiple surgical procedures, each one of which, occurring by itself, could result in assignment of the case to a different MS-DRG within the MDC to which the principal diagnosis is assigned. Therefore, it is necessary to have a decision rule within the GROUPER by which these cases are assigned to a single MS-DRG. The surgical hierarchy, an ordering of surgical classes from most resource-intensive to least resource-intensive, performs that function. Application of this hierarchy ensures that cases involving multiple surgical procedures are assigned to the MS-DRG associated with the most resource-intensive surgical class.

Because the relative resource intensity of surgical classes can shift as a function of MS-DRG reclassification and recalibrations, for FY 2016, we reviewed the surgical hierarchy of each MDC, as we have for previous reclassifications and recalibrations, to determine if the ordering of classes coincides with the intensity of resource utilization.

A surgical class can be composed of one or more MS-DRGs. For example, in MDC 11, the surgical class “kidney transplant” consists of a single MS-DRG (MS-DRG 652) and the class “major bladder procedures” consists of three MS-DRGs (MS-DRGs 653, 654, and 655). Consequently, in many cases, the surgical hierarchy has an impact on more than one MS-DRG. The methodology for determining the most resource-intensive surgical class involves weighting the average resources for each MS-DRG by frequency to determine the weighted average resources for each surgical class. For example, assume surgical class A includes MS-DRGs 001 and 002 and surgical class B includes MS-DRGs 003, 004, and 005. Assume also that the average
costs of MS-DRG 001 are higher than that of MS-DRG 003, but the average costs of MS-DRGs 004 and 005 are higher than the average costs of MS-DRG 002. To determine whether surgical class A should be higher or lower than surgical class B in the surgical hierarchy, we would weigh the average costs of each MS-DRG in the class by frequency (that is, by the number of cases in the MS-DRG) to determine average resource consumption for the surgical class. The surgical classes would then be ordered from the class with the highest average resource utilization to that with the lowest, with the exception of “other O.R. procedures” as discussed below.

This methodology may occasionally result in assignment of a case involving multiple procedures to the lower-weighted MS-DRG (in the highest, most resource-intensive surgical class) of the available alternatives. However, given that the logic underlying the surgical hierarchy provides that the GROUPER search for the procedure in the most resource-intensive surgical class, in cases involving multiple procedures, this result is sometimes unavoidable.

We note that, notwithstanding the foregoing discussion, there are a few instances when a surgical class with a lower average cost is ordered above a surgical class with a higher average cost. For example, the “other O.R. procedures” surgical class is uniformly ordered last in the surgical hierarchy of each MDC in which it occurs, regardless of the fact that the average costs for the MS-DRG or MS-DRGs in that surgical class may be higher than those for other surgical classes in the MDC. The “other O.R. procedures” class is a group of procedures that are only infrequently related to the diagnoses in the MDC, but are still occasionally performed on patients with cases
assigned to the MDC with these diagnoses. Therefore, assignment to these surgical classes should only occur if no other surgical class more closely related to the diagnoses in the MDC is appropriate.

A second example occurs when the difference between the average costs for two surgical classes is very small. We have found that small differences generally do not warrant reordering of the hierarchy because, as a result of reassigning cases on the basis of the hierarchy change, the average costs are likely to shift such that the higher-ordered surgical class has lower average costs than the class ordered below it.

Based on the changes that we proposed to make for FY 2016, as discussed in section II.G.3.e. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule, we proposed to revise the surgical hierarchy for MDC 5 (Diseases and Disorders of the Circulatory System) (80 FR 24399). Specifically, we proposed to delete MS-DRG 237 (Major Cardiovascular Procedures with MCC) and MS-DRG 238 (Major Cardiovascular Procedures without MCC) from the surgical hierarchy. We proposed to sequence proposed new MS-DRG 268 (Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC) and proposed new MS-DRG 269 (Aortic and Heart Assist Procedures Except Pulsation Balloon without MCC) above proposed new MS-DRG 270 (Other Major Cardiovascular Procedures with MCC), proposed new MS-DRG 271 (Other Major Cardiovascular Procedures with CC), and proposed new MS-DRG 272 (Other Major Cardiovascular Procedures without CC/MCC). We proposed to sequence proposed new MS-DRGs 270, 271, and 272 above MS-DRG 239 (Amputation for Circulatory System Disorders Except Upper Limb & Toe with MCC). In addition, we
proposed to sequence proposed new MS-DRG 273 (Percutaneous Intracardiac Procedures with MCC) and proposed new MS-DRG 274 (Percutaneous Intracardiac Procedures without MCC) above MS-DRG 246 (Percutaneous Cardiovascular Procedure with Drug-eluting Stent with MCC or 4+ Vessels/Stents).

We invited public comments on our proposals.

We did not receive any public comments on our proposals for the surgical hierarchy within MDC 5. Therefore, we are finalizing our proposals to delete ICD-9-CM MS-DRG 237 and ICD-9-CM MS-DRG 238 from the surgical hierarchy. We are adopting as final the sequencing of new ICD-10 MS-DRG 268 and new ICD-10 MS-DRG 269 above new ICD-10 MS-DRG 270, new ICD-10MS-DRG 271, and new ICD-10 MS-DRG 272. We also are finalizing our proposal to sequence new ICD-10 MS-DRGs 270, 271, and 272 above ICD-10 MS-DRG 239. Lastly, we are finalizing the sequencing of new ICD-10 MS-DRG 273 and new ICD-10 MS-DRG 274 above ICD-10 MS-DRG 246.

10. Changes to the MS-DRG Diagnosis Codes for FY 2016

a. Major Complications or Comorbidities (MCCs) and Complications or Comorbidities (CC) Severity Levels for FY 2016

A complete updated MCC, CC, and Non-CC Exclusion List is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html as follows:

- Table 6I (Complete MCC list);
- Table 6J (Complete CC list); and
b. Coronary Atherosclerosis Due to Calcified Coronary Lesion

We received a request that we change the severity levels for ICD–9–CM diagnosis codes 414.2 (Chronic total occlusion of coronary artery) and 414.4 (Coronary atherosclerosis due to calcified coronary lesion) from non-CCs to MCCs. The ICD-10-CM codes for these diagnoses are I25.82 (Chronic total occlusion of coronary artery) and I25.84 (Coronary atherosclerosis due to calcified coronary lesion), respectively, and both of these codes are currently classified as non-CCs.

This issue was previously discussed in the FY 2014 IPPS/LTCH PPS proposed rule and final rule (78 FR 27522 and 78 FR 50541 through 50542, respectively), and the FY 2015 IPPS/LTCH PPS proposed rule and final rule (79 FR 28018 and 28019 and 79 FR 49903 and 49904, respectively).

We examined claims data from the December 2014 update of the FY 2014 MedPAR file for ICD-9-CM diagnosis codes 414.2 and 414.4. The following table shows our findings.

<table>
<thead>
<tr>
<th>SDX</th>
<th>SDX Description</th>
<th>CC</th>
<th>Cnt 1</th>
<th>Cnt 1 Impact</th>
<th>Cnt 2</th>
<th>Cnt 2 Impact</th>
<th>Cnt 3</th>
<th>Cnt 3 Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>414.2</td>
<td>Chronic total occlusion of coronary artery</td>
<td>Non-CC</td>
<td>14,655</td>
<td>1.393</td>
<td>21,222</td>
<td>2.098</td>
<td>20,615</td>
<td>3.046</td>
</tr>
<tr>
<td>414.4</td>
<td>Coronary atherosclerosis due to calcified coronary lesion</td>
<td>Non-CC</td>
<td>1,752</td>
<td>1.412</td>
<td>3,238</td>
<td>2.148</td>
<td>3,244</td>
<td>3.053</td>
</tr>
</tbody>
</table>
We ran the data using the criteria described in the FY 2008 IPPS final rule with comment period (72 FR 47169) to determine severity levels for procedures in MS-DRGs. The C1 value reflects a patient with no other secondary diagnosis or with all other secondary diagnoses that are non-CCs. The C2 value reflects a patient with at least one other secondary diagnosis that is a CC, but none that is an MCC. The C3 value reflects a patient with at least one other secondary diagnosis that is an MCC.

The table above shows that the C1 finding is 1.393 for ICD-9-CM diagnosis code 414.2 and the C1 finding is 1.412 for ICD-9-CM diagnosis code 414.4. A value close to 1.0 in the C1 field suggests that the diagnosis produces the same expected value as a non-CC. A value close to 2.0 suggests the condition is more like a CC than a non-CC, but not as significant in resource usage as an MCC. A value close to 3.0 suggests that the condition is expected to consume resources more similar to an MCC than a CC or a non-CC. The C2 finding was 2.098 for ICD-9-CM diagnosis code 414.2, and the C2 finding was 2.148 for ICD-9-CM diagnosis code 414.4. A C2 value close to 2.0 suggests the condition is more like a CC than a non-CC, but not as significant in resource usage as an MCC when there is at least one other secondary diagnosis that is a CC but none that is an MCC. While the C1 value of 1.393 for ICD-9-CM diagnosis code 414.2 and the C1 value of 1.412 for ICD-9-CM diagnosis code 414.4 are above the 1.0 value for a non-CC, these values do not support the reclassification of diagnosis codes 414.2 and 414.4 to MCCs. As stated earlier, a value close to 3.0 suggests the condition is expected to consume resources more similar to an MCC than a CC or a non-CC. The C2 finding of 2.098 for ICD-9-CM
diagnosis code 414.2 and the C2 finding of 2.148 for ICD-9-CM diagnosis code 414.4 also do not support reclassifying these diagnosis codes to MCCs.

Our clinical advisors reviewed the data and evaluated these conditions. They recommended that we not change the severity level of diagnosis codes 414.2 and 414.4 from a non-CC to an MCC. Our clinical advisors did not believe that these diagnoses would increase the severity of illness level of patients. Considering the C1 and C2 ratings of both diagnosis codes 414.2 and 414.4 and the input from our clinical advisors, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24399 through 24400), we did not propose to reclassify conditions represented by diagnosis codes 414.2 and 414.4 to MCCs. We proposed to maintain both of these conditions as non-CCs. As stated earlier, the equivalent ICD-10-CM codes for these conditions are codes I25.82 and I25.84, respectively. Therefore, based on the data and clinical analysis, we proposed to maintain ICD-10-CM diagnosis codes I25.82 and I25.84 as non-CCs. We invited public comments on our proposals.

Comment: A number of commenters supported the proposals to maintain the designation of ICD-10-CM diagnosis codes I25.82 and I25.84 as non-CCs. The commenters stated that the proposals were reasonable, given the information that was provided.

One commenter disagreed with the proposal to maintain code I25.84 as a non-CC. The commenter indicated that it was not able to duplicate the results of C1 and C2 described in the narrative and the table presented in the proposed rule, despite contacting
CMS for assistance in running the data. The commenter disagreed with the CMS’ clinical advisors that the ICD-9-CM code 414.4 and ICD-10-CM code I25.84 represent conditions that are not at the MCC level. The commenter stated that patients with severe calcified lesions are more difficult to treat and, therefore, require greater resources. The commenter also expressed concerns that hospitals were underreporting cases of patients with calcified lesions.

Response: We appreciate the commenters’ support for our proposals. In response to the commenter who disagreed with our clinical advisors’ determination that ICD-9-CM code 414.4 and ICD-10-CM code I25.84 represent conditions that are not at the MCC level, we point out that ICD-9-CM code 414.4 captures patients who are diagnosed as having coronary atherosclerosis due to calcified coronary lesions. This diagnosis code includes patients with any range of calcified lesion, not just those with severe calcified lesions. Therefore, the use of ICD-9-CM code 414.4 is not restricted to those patients who have severe calcified lesions. Hospitals are correctly using this code to report all patients who are determined to have atherosclerosis due to calcified coronary lesions. The same is true for the use of ICD-10-CM code I25.84, which is not restricted to cases with severe calcified lesions. We based our analysis on claims data reported by hospitals. We cannot speculate on the underreporting of this condition on submitted claims. It also appears that the commenter did not follow the correct methodology in attempting to replicate the results for C1 and C2. The categorization of diagnoses as an MCC, CC, or non-CC was accomplished using an iterative approach in which each diagnosis was evaluated to determine the extent to which its presence as a secondary
diagnosis resulted in increased hospital resource use. We use the same cost calculations for computing the C1, C2, and C3 values that we use in calculating the relative weights. The cases for each “C” statistic are the cases with the secondary diagnosis codes for all the cases in that subset of non-CC cases, CC cases, or MCC cases. For example, the cases that are in the C3 statistic are those cases with one or more MCC secondary diagnosis codes in addition to the secondary diagnosis code under the specific review. Cases that are in the C2 statistic are those cases that do not have any MCC secondary diagnosis codes, but have one or more CC secondary diagnosis codes in addition to the secondary diagnosis code under review. The remaining cases are in the C1 statistic and have only non-CC secondary diagnosis codes along with the secondary diagnosis code under review. Numerical resource impact values were assigned for each diagnosis as follows:

<table>
<thead>
<tr>
<th>Value</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Significantly below expected value for the non CC subgroup</td>
</tr>
<tr>
<td>1</td>
<td>Approximately equal to expected value for the non CC subgroup</td>
</tr>
<tr>
<td>2</td>
<td>Approximately equal to expected value for the CC subgroup</td>
</tr>
<tr>
<td>3</td>
<td>Approximately equal to expected value for the major CC subgroup</td>
</tr>
<tr>
<td>4</td>
<td>Significantly above the expected value for the major CC subgroup</td>
</tr>
</tbody>
</table>

Each diagnosis for which Medicare data were available was evaluated to determine its impact on resource use and to determine the most appropriate CC subclass (non-CC, CC, or MCC) assignment. In order to make this determination, the average cost for each subset of cases was compared to the expected cost of cases in that subset. An expected average cost is computed across all cases in the data analysis for each base MS-DRG and severity level (1=MCC, 2=CC, and 3=Non-CC). Then, for each case in a
subset, the average expected cost is computed based on the base MS-DRG and severity level to which the cases are assigned. The following format was used to evaluate each diagnosis:

<table>
<thead>
<tr>
<th>Code</th>
<th>Diagnosis</th>
<th>Cnt1</th>
<th>C1</th>
<th>Cnt2</th>
<th>C2</th>
<th>Cnt3</th>
<th>C3</th>
</tr>
</thead>
</table>

Where count (Cnt) is the number of patients in each subset and C1, C2, and C3 are a measure of the impact on resource use of patients in each of the subsets. A C1 value of 1.412 for a secondary diagnosis code 414.4 (Coronary atherosclerosis due to calcified coronary lesion) means that, for the subset of patients who have the secondary diagnosis and have either no other secondary diagnosis present, or all the other secondary diagnoses present are non-CCs, the impact on resource use of the secondary diagnoses is greater than the expected value for a non-CC by an amount equal to 41.2 percent of the difference between the expected value of a CC and a non-CC (that is, the impact on resource use of the secondary diagnosis is closer to a CC than a non-CC).

After consideration of the public comments we received, the findings from our claims data, and the input from our clinical advisors noted above, we are finalizing our proposal to maintain ICD-10-CM diagnosis codes I25.82 and I25.84 as non-CCs.

c. Hydrenephrosis

Some ICD-10-CM diagnosis codes express conditions that are normally coded in ICD-9-CM using two or more ICD-9-CM diagnosis codes. CMS’ goal in developing the ICD-10 MS-DRGs was to ensure that a patient case is assigned to the same MS-DRG, regardless of whether the patient record were to be coded in ICD-9-CM or ICD-10-CM/PCS. When one of the ICD-10-CM combination codes is used as a principal
diagnosis, the cluster of ICD-9-CM codes that would be coded on an ICD-9-CM record was evaluated. If one of the ICD-9-CM codes in the cluster is a CC or an MCC, the single ICD-10-CM combination code used as a principal diagnosis also must imply that the CC or MCC is present. Appendix J of the ICD-10 MS-DRG Definitions Manual Version 32 includes two lists. Part 1 is the list of principal diagnosis codes where the ICD-10-CM code is its own MCC. Part 2 is the list of principal diagnosis codes where the ICD-10-CM code is its own CC. Appendix J of the ICD-10 MS-DRG Definitions Manual Version 32 is available via the CMS Web site at:


We received a request that the ICD-10-CM combination codes for hydronephrosis due to ureteral stricture and urinary stone (N13.1 and N13.2) be flagged as principal diagnoses that can act as their own CC for MS-DRG grouping purposes.

In ICD-9-CM, code 591 (Hydronephrosis) is classified as a CC. In ICD-10-CM, hydronephrosis is reported with a combination code if the hydronephrosis is due to a ureteral stricture or urinary stone obstruction of N13.1 (Hydronephrosis with ureteral stricture, not elsewhere classified) and N13.2 (Hydronephrosis with renal and ureteral calculous obstruction). In ICD-10-CM, these two codes (N13.1 and N13.2) are classified as CCs, but these codes are not recognized as principal diagnoses that act as their own CC (they are not included in the Appendix J of the ICD-10 MS-DRG Definitions Manual Version 32).
In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24400), we stated that we agreed with the requestor that ICD-10-CM diagnosis codes N13.1 and N13.2 should be flagged as principal diagnosis codes that can act as their own CC for MS-DRG grouping purposes. Therefore, we proposed that diagnosis codes N13.1 and N13.2 be added to the list of principal diagnoses that act as their own CC in Appendix J of the ICD-10 MS-DRG Definitions Manual Version 33. We invited public comments on our proposal.

**Comment:** A number of commenters supported the proposal. The commenters stated that the proposal was reasonable, given the data and information provided.

**Response:** We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to add diagnosis codes N13.1 and N13.2 to the list of principal diagnoses that can act as their own CC in Appendix J of the ICD-10 MS-DRG Definitions Manual Version 33.

11. Complications or Comorbidity (CC) Exclusions List for FY 2016

a. Background of the CC List and the CC Exclusions List

Under the IPPS MS-DRG classification system, we have developed a standard list of diagnoses that are considered CCs. Historically, we developed this list using physician panels that classified each diagnosis code based on whether the diagnosis, when present as a secondary condition, would be considered a substantial complication or comorbidity. A substantial complication or comorbidity was defined as a condition that, because of its presence with a specific principal diagnosis, would cause an increase in the length of stay by at least 1 day in at least 75 percent of the patients. However, depending on the
principal diagnosis of the patient, some diagnoses on the basic list of complications and comorbidities may be excluded if they are closely related to the principal diagnosis. In FY 2008, we evaluated each diagnosis code to determine its impact on resource use and to determine the most appropriate CC subclassification (non-CC, CC, or MCC) assignment. We refer readers to sections II.D.2. and 3. of the preamble of the FY 2008 IPPS final rule with comment period for a discussion of the refinement of CCs in relation to the MS-DRGs we adopted for FY 2008 (72 FR 47152 through 47171).

b. CC Exclusions List for FY 2016

In the September 1, 1987 final notice (52 FR 33143) concerning changes to the DRG classification system, we modified the GROUPER logic so that certain diagnoses included on the standard list of CCs would not be considered valid CCs in combination with a particular principal diagnosis. We created the CC Exclusions List for the following reasons: (1) to preclude coding of CCs for closely related conditions; (2) to preclude duplicative or inconsistent coding from being treated as CCs; and (3) to ensure that cases are appropriately classified between the complicated and uncomplicated DRGs in a pair. As we indicated above, we developed a list of diagnoses, using physician panels, to include those diagnoses that, when present as a secondary condition, would be considered a substantial complication or comorbidity. In previous years, we have made changes to the list of CCs, either by adding new CCs or deleting CCs already on the list.

In the May 19, 1987 proposed notice (52 FR 18877) and the September 1, 1987 final notice (52 FR 33154), we explained that the excluded secondary diagnoses were established using the following five principles:
Chronic and acute manifestations of the same condition should not be considered CCs for one another;

- Specific and nonspecific (that is, not otherwise specified (NOS)) diagnosis codes for the same condition should not be considered CCs for one another;

- Codes for the same condition that cannot coexist, such as partial/total, unilateral/bilateral, obstructed/unobstructed, and benign/malignant, should not be considered CCs for one another;

- Codes for the same condition in anatomically proximal sites should not be considered CCs for one another; and

- Closely related conditions should not be considered CCs for one another.

The creation of the CC Exclusions List was a major project involving hundreds of codes. We have continued to review the remaining CCs to identify additional exclusions and to remove diagnoses from the master list that have been shown not to meet the definition of a CC.\(^6\)

The ICD-10 MS-DRGs Version 32 CC Exclusion List is included as Appendix C in the Definitions Manual available via the Internet on the CMS Web site at:

---

\(^6\) We refer readers to the FY 1989 final rule (53 FR 38485, September 30, 1988) for the revision made for the discharges occurring in FY 1989; the FY 1990 final rule (54 FR 36552, September 1, 1989) for the FY 1990 revision; the FY 1991 final rule (55 FR 36126, September 4, 1990) for the FY 1991 revision; the FY 1992 final rule (56 FR 43209, August 30, 1991) for the FY 1992 revision; the FY 1993 final rule (57 FR 39753, September 1, 1992) for the FY 1993 revision; the FY 1994 final rule (58 FR 46278, September 1, 1993) for the FY 1994 revisions; the FY 1995 final rule (59 FR 45334, September 1, 1994) for the FY 1995 revisions; the FY 1996 final rule (60 FR 45782, September 1, 1995) for the FY 1996 revisions; the FY 1997 final rule (61 FR 46171, August 30, 1996) for the FY 1997 revisions; the FY 1998 final rule (62 FR 45966, August 29, 1997) for the FY 1998 revisions; the FY 1999 final rule (63 FR 40954, July 31, 1998) for the FY 1999 revisions; the FY 2000 final rule (64 FR 39851, August 1, 2001) for the FY 2000 revisions; the FY 2001 final rule (65 FR 47064, August 1, 2000) for the FY 2001 revisions; the FY 2002 final rule (66 FR 39851, August 1, 2001) for the FY 2002 revisions; the FY 2003 final rule (67 FR 49998, August 1, 2002) for the FY 2003 revisions; the FY 2004 final rule (68 FR 45364, August 1, 2003) for the FY 2004 revisions; the FY 2005 final rule (69 FR 49948, August 11, 2004) for the FY 2005 revisions; the FY 2006 final rule (70 FR 47873, August 12, 2005) for the FY 2006 revisions; the FY 2007 final rule (71 FR 47870, August 15, 2006) for the FY 2007 revisions; the FY 2008 final rule (72 FR 47130, August 14, 2007) for the FY 2008 revisions; the FY 2009 final rule (73 FR 48510, August 20, 2008) for the FY 2009 revisions; the FY 2010 final rule (74 FR 43799, August 31, 2009) for the FY 2010 revisions; the FY 2011 final rule (75 FR 50114, August 12, 2010) for the FY 2011 revisions; the FY 2012 final rule (76 FR 35142, August 17, 2011) for the FY 2012 revisions; the FY 2013 final rule (77 FR 53315, April 9, 2012) for the FY 2013 revisions; the FY 2014 final rule (78 FR 50541, July 30, 2013) for the FY 2014 revisions; and the FY 2015 final rule (79 FR 49905, July 30, 2014) for the FY 2015 revisions. In the FY 2000 final rule (64 FR 41490, July 30, 1999), we did not modify the CC Exclusions List because we did not make any changes to the ICD-9-CM codes for FY 2000.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24401), we did not propose any changes to the CC Exclusion List for FY 2016. Because we did not propose any changes to the ICD-10 MS-DRGs CC Exclusion List for FY 2016, we did not publish Table 6G (Additions to the CC Exclusion List) or Table 6H (Deletions from the CC Exclusion List). We developed Table 6K (Complete List of CC Exclusions), which is available only via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Because of the length of Table 6K, we did not publish it in the Addendum to the proposed rule.

As we did for the proposed rule, because we are not making any changes to the ICD-10 MS-DRGs CC Exclusion List for FY 2016, we are not publishing Table 6G (Additions to the CC Exclusion List) or Table 6H (Deletions from the CC Exclusion List). We developed Table 6K (Complete List of CC Exclusions), which is available only via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Because of the length of Table 6K, we are not publishing it in the Addendum to this final rule. Each of the secondary diagnosis codes for which there is an exclusion is listed in Part 1 of Table 6K. Each of these secondary diagnosis codes is indicated as a CC or an MCC. If the CC or MCC is allowed with all principal diagnoses, the phrase “NoExcl” (for no exclusions) follows the CC/MCC indicator. Otherwise, a link is given to a collection of diagnosis codes which, when used as the principal diagnosis, will cause the CC or MCC to be considered as only
a non-CC. Part 2 of Table 6K lists codes that are assigned as an MCC only for patients discharged alive. Otherwise, the codes are assigned as a non-CC.

A complete updated MCC, CC, and Non-CC Exclusions List is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

Because there are no new, revised, or deleted ICD-10-CM diagnosis codes for FY 2016, we have not developed Table 6A (New Diagnosis Codes), Table 6C (Invalid Diagnosis Codes), or Table 6E (Revised Diagnosis Code Titles), for this final rule and they are not published as part of this final rule. We have developed Table 6B (New Procedure Codes) for new ICD-10-PCS codes which will be implemented on October 1, 2015. Because there are no revised or deleted procedure codes for FY 2016, we have not developed Table 6D (Invalid Procedure Codes) or Table 6F (Revised Procedure Codes).

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24401), we did not propose any additions or deletions to the MS-DRG MCC List for FY 2016 nor any additions or deletions to the MS-DRG CC List for FY 2016. As we did for the proposed rule, for this final rule, we have not developed Tables 6I.1 (Additions to the MCC List), 6I.2 (Deletions to the MCC List), 6J.1 (Additions to the CC List), and 6J.2 (Deletions to the CC List), and they are not published as part of this final rule. We have developed Tables 6L (Principal Diagnosis Is Its Own MCC List) and 6M (Principal Diagnosis Is Its Own CC List). As stated in the Definitions Manual of the ICD-10 MS DRGs Version 32 on the ICD-10 MS-DRG Conversion Project Web site at:
http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html, a few ICD-10-CM diagnosis codes express conditions that are normally coded in ICD-9-CM using two or more ICD-9-CM diagnosis codes. In the interest of ensuring that the ICD-10 MS-DRGs place a patient in the same DRG, whenever one of these ICD-10-CM combination codes is used as principal diagnosis, the cluster of ICD-9-CM codes that would be coded on an ICD-9-CM record is considered. If one of the ICD-9-CM codes in the cluster is a CC or an MCC, the single ICD-10-CM combination code used as a principal diagnosis must also imply the CC or MCC that the ICD-9-CM cluster would have presented. The ICD-10-CM diagnoses for which this implication must be made are listed in these tables. We also have developed Table 6M.1 (Additions to Principal Diagnosis Is Its Own CC) to show the two additions to this list for the two principal diagnosis codes acting as their own CC.

The complete documentation of the ICD-10 MS-DRG Version 32 GROUPER logic, including the current CC Exclusions List, is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD10/ICD-10-MS-DRG-Conversion-Project.html. The complete documentation of the ICD-10 MS-DRG GROUPER logic also is available on the CMS Acute Inpatient PPS Web page at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.
12. Review of Procedure Codes in MS-DRGs 981 through 983, 984 through 986, and 987 through 989

Each year, we review cases assigned to former CMS DRG 468 (Extensive O.R. Procedure Unrelated to Principal Diagnosis), CMS DRG 476 (Prostatic O.R. Procedure Unrelated to Principal Diagnosis), and CMS DRG 477 (Nonextensive O.R. Procedure Unrelated to Principal Diagnosis) to determine whether it would be appropriate to change the procedures assigned among these CMS DRGs. Under the MS-DRGs that we adopted for FY 2008, CMS DRG 468 was split three ways and became MS-DRGs 981, 982, and 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively). CMS DRG 476 became MS-DRGs 984, 985, and 986 (Prostatic O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively). CMS DRG 477 became MS-DRGs 987, 988, and 989 (Nonextensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively).

MS-DRGs 981 through 983, 984 through 986, and 987 through 989 (formerly CMS DRGs 468, 476, and 477, respectively) are reserved for those cases in which none of the O.R. procedures performed are related to the principal diagnosis. These MS-DRGs are intended to capture atypical cases, that is, those cases not occurring with sufficient frequency to represent a distinct, recognizable clinical group. MS-DRGs 984 through 986 (previously CMS DRG 476) are assigned to those discharges in which one or more of the following prostatic procedures are performed and are unrelated to the principal diagnosis:
● 60.0 (Incision of prostate);
● 60.12 (Open biopsy of prostate);
● 60.15 (Biopsy of periprostatic tissue);
● 60.18 (Other diagnostic procedures on prostate and periprostatic tissue);
● 60.21 (Transurethral prostatectomy);
● 60.29 (Other transurethral prostatectomy);
● 60.61 (Local excision of lesion of prostate);
● 60.69 (Prostatectomy, not elsewhere classified);
● 60.81 (Incision of periprostatic tissue);
● 60.82 (Excision of periprostatic tissue);
● 60.93 (Repair of prostate);
● 60.94 (Control of (postoperative) hemorrhage of prostate);
● 60.95 (Transurethral balloon dilation of the prostatic urethra);
● 60.96 (Transurethral destruction of prostate tissue by microwave thermotherapy);
● 60.97 (Other transurethral destruction of prostate tissue by other thermotherapy); and
● 60.99 (Other operations on prostate).

All remaining O.R. procedures are assigned to MS-DRGs 981 through 983 and 987 through 989, with MS-DRGs 987 through 989 assigned to those discharges in which
the only procedures performed are nonextensive procedures that are unrelated to the principal diagnosis.\textsuperscript{7}

Our review of MedPAR claims data showed that there are no cases that merited movement or should logically be assigned to any of the other MDCs. Therefore, for FY 2016, we did not propose to change the procedures assigned among these MS-DRGs.

We invited public comments on our proposal.

We did not receive any public comments on our proposal and, therefore, are adopting it as final.

a. Moving Procedure Codes from MS-DRGs 981 through 983 or MS-DRGs 987 through 989 into MDCs

We annually conduct a review of procedures producing assignment to MS-DRGs 981 through 983 (Extensive O.R. procedure unrelated to principal diagnosis with MCC, with CC, and without CC/MCC, respectively) or MS-DRGs 987 through 989

\textsuperscript{7}The original list of the ICD-9-CM procedure codes for the procedures we consider nonextensive procedures, if performed with an unrelated principal diagnosis, was published in Table 6C in section IV. of the Addendum to the FY 1989 final rule (53 FR 38591). As part of the FY 1991 final rule (55 FR 36135), the FY 1992 final rule (56 FR 43212), the FY 1993 final rule (57 FR 23625), the FY 1994 final rule (58 FR 46279), the FY 1995 final rule (59 FR 45336), the FY 1996 final rule (60 FR 45783), the FY 1997 final rule (61 FR 46173), and the FY 1998 final rule (62 FR 45981), we moved several other procedures from DRG 468 to DRG 477, and some procedures from DRG 477 to DRG 468. No procedures were moved in FY 1999, as noted in the final rule (63 FR 40962), in the FY 2000 (64 FR 41496), in the FY 2001 (65 FR 47064), or in the FY 2002 (66 FR 39852). In the FY 2003 final rule (67 FR 49999), we did not move any procedures from DRG 477. However, we did move procedure codes from DRG 468 and placed them in more clinically coherent DRGs. In the FY 2004 final rule (68 FR 45365), we moved several procedures from DRG 468 to DRGs 476 and 477 because the procedures are nonextensive. In the FY 2005 final rule (69 FR 48950), we moved one procedure from DRG 468 to 477. In addition, we added several existing procedures to DRGs 476 and 477. In FY 2006 (70 FR 47317), we moved one procedure from DRG 468 and assigned it to DRG 477. In FY 2007, we moved one procedure from DRG 468 and assigned it to DRGs 479, 553, and 554. In FYs 2008, 2009, 2010, 2011, 2012, 2013, 2014, and 2015, no procedures were moved, as noted in the FY 2008 final rule with comment period (72 FR 46241), in the FY 2009 final rule (73 FR 48513), in the FY 2010 final rule (74 FR 43796), in the FY 2011 final rule (75 FR 50122), in the FY 2012 final rule (76 FR 51549), in the FY 2013 final rule (77 FR 53321), in the FY 2014 final rule (78 FR 50545); and in the FY 2015 final rule (79 FR 49906).
(Nonextensive O.R. procedure unrelated to principal diagnosis with MCC, with CC, and without CC/MCC, respectively) on the basis of volume, by procedure, to see if it would be appropriate to move procedure codes out of these MS-DRGs into one of the surgical MS-DRGs for the MDC into which the principal diagnosis falls. The data are arrayed in two ways for comparison purposes. We look at a frequency count of each major operative procedure code. We also compare procedures across MDCs by volume of procedure codes within each MDC.

We identify those procedures occurring in conjunction with certain principal diagnoses with sufficient frequency to justify adding them to one of the surgical MS-DRGs for the MDC in which the diagnosis falls. As noted above, there are no cases that merited movement or that should logically be assigned to any of the other MDCs. Therefore, for FY 2016, we did not propose to remove any procedures from MS-DRGs 981 through 983 or MS-DRGs 987 through 989 into one of the surgical MS-DRGs for the MDC into which the principal diagnosis is assigned. We invited public comments on our proposal.

We did not receive any public comments on our proposal and, therefore, are adopting it as final.

b. Reassignment of Procedures among MS-DRGs 981 through 983, 984 through 986, and 987 through 989

(1) Annual Review of Procedures

We also annually review the list of ICD-9-CM procedures that, when in combination with their principal diagnosis code, result in assignment to MS-DRGs 981
through 983, 984 through 986 (Prostatic O.R. procedure unrelated to principal diagnosis with MCC, with CC, or without CC/MCC, respectively), and 987 through 989, to ascertain whether any of those procedures should be reassigned from one of these three MS DRGs to another of the three MS-DRGs based on average costs and the length of stay. We look at the data for trends such as shifts in treatment practice or reporting practice that would make the resulting MS-DRG assignment illogical. If we find these shifts, we would propose to move cases to keep the MS-DRGs clinically similar or to provide payment for the cases in a similar manner. Generally, we move only those procedures for which we have an adequate number of discharges to analyze the data.

There are no cases representing shifts in treatment practice or reporting practice that would make the resulting MS-DRG assignment illogical, or that merited movement so that cases should logically be assigned to any of the other MDCs. Therefore, for FY 2016, we did not propose to move any procedure codes among these MS-DRGs.

We did not receive any public comments on our proposal and, therefore, are adopting it as final.

(2) Review of Cases with Endovascular Embolization Procedures for Epistaxis

During the comment period for the FY 2015 IPPS/LTCH PPS proposed rule, we received a public comment expressing concern regarding specific procedure codes that are assigned to MS-DRGs 981 through 983; 984 through 986; and 987 through 989 in relation to our discussion of the annual review of these MS-DRGs in section II.G.12. of that proposed rule (79 FR 28020). The commenter noted that the endovascular embolization of the arteries of the branches of the internal maxillary artery is frequently
performed for intractable posterior epistaxis (nosebleed). The commenter stated that, currently, diagnosis code 784.7 (Epistaxis) reported with procedure codes 39.75 (Endovascular embolization or occlusion of vessel(s) of head or neck using bare coils) and 39.76 (Endovascular embolization or occlusion of vessel(s) of head or neck using bioactive coils) groups to MS-DRGs 981, 982, and 983. The commenter indicated that it also found this grouping with the ICD-10 MS-DRGs Version 31 using ICD-10-CM diagnosis code R04.0 (Epistaxis) reported with artery occlusion procedure codes. The commenter requested that CMS review these groupings and consider the possibility of reassigning these epistaxis cases with endovascular embolization procedure codes into a more specific MS-DRG.

We considered this public comment to be outside of the scope of the FY 2015 IPPS/LTCH PPS proposed rule and, therefore, did not address it in the FY 2015 IPPS/LTCH PPS final rule. However, we indicated that we would consider this public comment for possible proposals in future rulemaking as part of our annual review process.

ICD-10-PCS provides more detailed codes for endovascular embolization or occlusion of vessel(s) of head or neck using bare coils and bioactive coils which are listed in the following table:
<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03LG0BZ</td>
<td>Occlusion of intracranial artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03LG0DZ</td>
<td>Occlusion of intracranial artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LG3BZ</td>
<td>Occlusion of intracranial artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LG3DZ</td>
<td>Occlusion of intracranial artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LG4BZ</td>
<td>Occlusion of intracranial artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LG4DZ</td>
<td>Occlusion of intracranial artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LH0BZ</td>
<td>Occlusion of right common carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03LH0DZ</td>
<td>Occlusion of right common carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LH3BZ</td>
<td>Occlusion of right common carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LH3DZ</td>
<td>Occlusion of right common carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LH4BZ</td>
<td>Occlusion of right common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LH4DZ</td>
<td>Occlusion of right common carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LJ0BZ</td>
<td>Occlusion of left common carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03LJ0DZ</td>
<td>Occlusion of left common carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LJ3BZ</td>
<td>Occlusion of left common carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LJ3DZ</td>
<td>Occlusion of left common carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LJ4BZ</td>
<td>Occlusion of left common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LJ4DZ</td>
<td>Occlusion of left common carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LK0BZ</td>
<td>Occlusion of right internal carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>03LK0DZ</td>
<td>Occlusion of right internal carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LK3BZ</td>
<td>Occlusion of right internal carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LK3DZ</td>
<td>Occlusion of right internal carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LK4BZ</td>
<td>Occlusion of right internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LK4DZ</td>
<td>Occlusion of right internal carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LL0BZ</td>
<td>Occlusion of left internal carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03LL0DZ</td>
<td>Occlusion of left internal carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LL3BZ</td>
<td>Occlusion of left internal carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LL3DZ</td>
<td>Occlusion of left internal carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LL4BZ</td>
<td>Occlusion of left internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LM0BZ</td>
<td>Occlusion of right external carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03LM0DZ</td>
<td>Occlusion of right external carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LM3BZ</td>
<td>Occlusion of right external carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LM3DZ</td>
<td>Occlusion of right external carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LM4BZ</td>
<td>Occlusion of right external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LM4DZ</td>
<td>Occlusion of right external carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LN0BZ</td>
<td>Occlusion of left external carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03LN0DZ</td>
<td>Occlusion of left external carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LN3BZ</td>
<td>Occlusion of left external carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
</tbody>
</table>
### ICD-10-PCS Codes for Endovascular Embolization or Occlusion of Vessel(s) of Head or Neck Using Bare Coils and Bioactive Coils

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03LN3DZ</td>
<td>Occlusion of left external carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LN4BZ</td>
<td>Occlusion of left external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LN4DZ</td>
<td>Occlusion of left external carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LP0BZ</td>
<td>Occlusion of right vertebral artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03LP0DZ</td>
<td>Occlusion of right vertebral artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LP3BZ</td>
<td>Occlusion of right vertebral artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LP3DZ</td>
<td>Occlusion of right vertebral artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LP4BZ</td>
<td>Occlusion of right vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LP4DZ</td>
<td>Occlusion of right vertebral artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LQ0BZ</td>
<td>Occlusion of left vertebral artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03LQ0DZ</td>
<td>Occlusion of left vertebral artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03LQ3BZ</td>
<td>Occlusion of left vertebral artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LQ3DZ</td>
<td>Occlusion of left vertebral artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03LQ4BZ</td>
<td>Occlusion of left vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03LQ4DZ</td>
<td>Occlusion of left vertebral artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VG0BZ</td>
<td>Restriction of intracranial artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03VG0DZ</td>
<td>Restriction of intracranial artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VG3BZ</td>
<td>Restriction of intracranial artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VG3DZ</td>
<td>Restriction of intracranial artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VG4BZ</td>
<td>Restriction of intracranial artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
# ICD-10-PCS Codes for Endovascular Embolization or Occlusion of Vessel(s) of Head or Neck Using Bare Coils and Bioactive Coils

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03VG4DZ</td>
<td>Restriction of intracranial artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VH0BZ</td>
<td>Restriction of right common carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03VH0DZ</td>
<td>Restriction of right common carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VH3BZ</td>
<td>Restriction of right common carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VH3DZ</td>
<td>Restriction of right common carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VH4BZ</td>
<td>Restriction of right common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VH4DZ</td>
<td>Restriction of right common carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VJ0BZ</td>
<td>Restriction of left common carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03VJ0DZ</td>
<td>Restriction of left common carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VJ3BZ</td>
<td>Restriction of left common carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VJ3DZ</td>
<td>Restriction of left common carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VJ4BZ</td>
<td>Restriction of left common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VJ4DZ</td>
<td>Restriction of left common carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VK0BZ</td>
<td>Restriction of right internal carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03VK0DZ</td>
<td>Restriction of right internal carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VK3BZ</td>
<td>Restriction of right internal carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VK3DZ</td>
<td>Restriction of right internal carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VK4BZ</td>
<td>Restriction of right internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VK4DZ</td>
<td>Restriction of right internal carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VL0BZ</td>
<td>Restriction of left internal carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>03VL0DZ</td>
<td>Restriction of left internal carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VL3BZ</td>
<td>Restriction of left internal carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VL3DZ</td>
<td>Restriction of left internal carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VL4BZ</td>
<td>Restriction of left internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VL4DZ</td>
<td>Restriction of left internal carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VM0BZ</td>
<td>Restriction of right external carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03VM0DZ</td>
<td>Restriction of right external carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VM3BZ</td>
<td>Restriction of right external carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VM3DZ</td>
<td>Restriction of right external carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VM4BZ</td>
<td>Restriction of right external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VM4DZ</td>
<td>Restriction of right external carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VN0BZ</td>
<td>Restriction of left external carotid artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03VN0DZ</td>
<td>Restriction of left external carotid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VN3BZ</td>
<td>Restriction of left external carotid artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VN3DZ</td>
<td>Restriction of left external carotid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VN4BZ</td>
<td>Restriction of left external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VN4DZ</td>
<td>Restriction of left external carotid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VP0BZ</td>
<td>Restriction of right vertebral artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03VP0DZ</td>
<td>Restriction of right vertebral artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VP3BZ</td>
<td>Restriction of right vertebral artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>03VP3DZ</td>
<td>Restriction of right vertebral artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VP4BZ</td>
<td>Restriction of right vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VP4DZ</td>
<td>Restriction of right vertebral artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VQ0BZ</td>
<td>Restriction of left vertebral artery with bioactive intraluminal device, open approach</td>
</tr>
<tr>
<td>03VQ0DZ</td>
<td>Restriction of left vertebral artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VQ3BZ</td>
<td>Restriction of left vertebral artery with bioactive intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VQ3DZ</td>
<td>Restriction of left vertebral artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VQ4BZ</td>
<td>Restriction of left vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VQ4DZ</td>
<td>Restriction of left vertebral artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VR0DZ</td>
<td>Restriction of face artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VR3DZ</td>
<td>Restriction of face artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VR4DZ</td>
<td>Restriction of face artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VS0DZ</td>
<td>Restriction of right temporal artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VS3DZ</td>
<td>Restriction of right temporal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VS4DZ</td>
<td>Restriction of right temporal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VT0DZ</td>
<td>Restriction of left temporal artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VT3DZ</td>
<td>Restriction of left temporal artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VT4DZ</td>
<td>Restriction of left temporal artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VU0DZ</td>
<td>Restriction of right thyroid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VU3DZ</td>
<td>Restriction of right thyroid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>03VU4DZ</td>
<td>Restriction of right thyroid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>03VV0DZ</td>
<td>Restriction of left thyroid artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>03VV3DZ</td>
<td>Restriction of left thyroid artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>03VV4DZ</td>
<td>Restriction of left thyroid artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

We examined claims data from the December 2014 update of the FY 2014 MedPAR file for cases with diagnosis code 784.7 reported with procedure codes 39.75 and 39.76 in MS-DRGs 981, 982, and 983. The following table shows our findings.
## Endovascular Embolization Procedures for Epistaxis

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 981 – All cases</td>
<td>21,118</td>
<td>12.38</td>
<td>$33,080</td>
</tr>
<tr>
<td>MS-DRG 981 – Epistaxis cases with principal diagnosis code 784.7 and procedure code 39.75</td>
<td>8</td>
<td>6.50</td>
<td>$34,655</td>
</tr>
<tr>
<td>MS-DRG 981 – Epistaxis cases with principal diagnosis code 784.7 and procedure code 39.76</td>
<td>2</td>
<td>12.50</td>
<td>$50,081</td>
</tr>
<tr>
<td>MS-DRG 982 – All cases</td>
<td>13,657</td>
<td>7.14</td>
<td>$19,392</td>
</tr>
<tr>
<td>MS-DRG 982 – Epistaxis cases with principal diagnosis code 784.7 and procedure code 39.75</td>
<td>22</td>
<td>3.14</td>
<td>$17,725</td>
</tr>
<tr>
<td>MS-DRG 982 – Epistaxis cases with principal diagnosis code 784.7 and procedure code 39.76</td>
<td>2</td>
<td>2.0</td>
<td>$11,010</td>
</tr>
<tr>
<td>MS-DRG 983 – All cases</td>
<td>2,989</td>
<td>3.60</td>
<td>$12,760</td>
</tr>
<tr>
<td>MS-DRG 983 – Epistaxis cases with principal diagnosis code 784.7 and procedure code 39.75</td>
<td>5</td>
<td>2.60</td>
<td>$10,532</td>
</tr>
<tr>
<td>MS-DRG 983 – Epistaxis cases with principal diagnosis code 784.7 and procedure code 39.76</td>
<td>4</td>
<td>1.50</td>
<td>$16,658</td>
</tr>
</tbody>
</table>

We found only 35 epistaxis cases with procedure code 39.75 reported and 8 cases with procedure code 39.76 reported among MS-DRGs 981, 982, and 983. The use of endovascular embolizations for epistaxis appears to be rare. The average costs for the cases with procedure code 39.75 in MS-DRGs 981, 982, and 983 are similar to the average costs for all cases in MS-DRGs 981, 982, and 983, respectively. The average costs for the cases with procedure code 39.75 in MS-DRGs 981, 982, and 983 were $34,655, $17,725, and $10,532, respectively, compared to $33,080, $19,392, and $12,760 for all cases in MS-DRGs 981, 982, and 983. The average costs for cases with procedure code 39.76 in MS-DRGs 981, 982, and 983 were $50,081, $11,010, and $16,658, respectively, and were significantly greater than all cases in MS-DRGs 981 and 983.
However, as stated earlier, there were only 8 cases reported with procedure code 39.76. As explained previously, MS-DRGs 981, 982, and 983 were created for operating room procedures that are unrelated to the principal diagnosis. Because there were so few cases reported, this does not appear to be a common procedure for epistaxis. There were not enough cases to base a change of MS-DRG assignment for these cases.

Our clinical advisors reviewed this issue and did not identify any new MS-DRG assignment that would be more appropriate for these rare cases. They advised us to maintain the current MS-DRG structure within MS-DRGs 981, 982, and 983.

Based on the results of the examination of the claims data and the recommendations from our clinical advisors, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24403 through 24405), we did not propose to create new MS-DRG assignments for epistaxis cases receiving endovascular embolization procedures. We proposed to maintain the current MS-DRG structure for epistaxis cases receiving endovascular embolization procedures and did not propose any updates to MS-DRGs 981, 982, and 983. We invited public comments on our proposal.

Comment: A number of commenters supported the proposal. The commenters stated that the proposal was reasonable, given the data and information provided.

Response: We appreciate the commenters’ support for our proposal.

After consideration of the public comments we received, we are finalizing our proposal to maintain the current MS-DRG structure for epistaxis cases receiving endovascular embolization procedures and not make any updates to MS-DRGs 981, 982, and 983.
c. Adding Diagnosis or Procedure Codes to MDCs

Based on the review of cases in the MDCs, as described above in sections II.G.2. through 7. of the preamble of this final rule, we did not propose to add any diagnosis or procedure codes to MDCs for FY 2016. We invited public comments on our proposal. We did not receive any public comments on our proposal and, therefore, are adopting it as final.

13. Changes to the ICD-9-CM System

a. ICD-10 Coordination and Maintenance Committee

In September 1985, the ICD-9-CM Coordination and Maintenance Committee was formed. This is a Federal interdepartmental committee, co-chaired by the National Center for Health Statistics (NCHS), the Centers for Disease Control and Prevention, and CMS, charged with maintaining and updating the ICD-9-CM system. The final update to ICD-9-CM codes was to be made on October 1, 2013. Thereafter, the name of the Committee was changed to the ICD-10 Coordination and Maintenance Committee, effective with the March 19-20, 2014 meeting. The ICD-10 Coordination and Maintenance Committee addresses updates to the ICD-10-CM, ICD-10-PCS, and ICD-9-CM coding systems. The Committee is jointly responsible for approving coding changes, and developing errata, addenda, and other modifications to the coding systems to reflect newly developed procedures and technologies and newly identified diseases. The Committee is also responsible for promoting the use of Federal and non-Federal educational programs and other communication techniques with a view toward standardizing coding applications and upgrading the quality of the classification system.
The official list of ICD-9-CM diagnosis and procedure codes by fiscal year can be found on the CMS Web site at:

http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/codes.html. The official list of ICD-10-CM and ICD-10-PCS codes can be found on the CMS Web site at:


The NCHS has lead responsibility for the ICD-10-CM and ICD-9-CM diagnosis codes included in the Tabular List and Alphabetic Index for Diseases, while CMS has lead responsibility for the ICD-10-PCS and ICD-9-CM procedure codes included in the Tabular List and Alphabetic Index for Procedures.

The Committee encourages participation in the above process by health-related organizations. In this regard, the Committee holds public meetings for discussion of educational issues and proposed coding changes. These meetings provide an opportunity for representatives of recognized organizations in the coding field, such as the American Health Information Management Association (AHIMA), the American Hospital Association (AHA), and various physician specialty groups, as well as individual physicians, health information management professionals, and other members of the public, to contribute ideas on coding matters. After considering the opinions expressed at the public meetings and in writing, the Committee formulates recommendations, which then must be approved by the agencies.

The Committee presented proposals for coding changes for implementation in FY 2016 at a public meeting held on September 23-24, 2014, and finalized the coding
changes after consideration of comments received at the meetings and in writing by November 15, 2014.

The Committee held its 2015 meeting on March 18-19, 2015. It was announced at this meeting that any new ICD-10-CM/PCS codes for which there was consensus of public support and for which complete tabular and indexing changes would be made by May 2015 would be included in the October 1, 2015 update to ICD-10-CM/ICD-10-PCS. For FY 2016, there are no new, revised, or deleted ICD-10-CM diagnosis codes. For FY 2016, there are new ICD-10-PCS procedure codes that are included in Table 6B (New Procedure Codes). However, there are no revised or deleted ICD-10-PCS procedure codes. There also are no new ICD-9-CM diagnosis or procedure codes because ICD-9-CM will be replaced by ICD-10-CM/ICD-10-PCS for services provided on or after October 1, 2015.

Copies of the agenda, handouts, and access to the live stream videos for the procedure codes discussions at the Committee’s September 23-24, 2014 meeting and March 18-19, 2015 meeting can be obtained from the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html?redirect=/icd9ProviderDiagnosticCodes/03_meetings.asp. The agenda, handouts and minutes of the diagnosis codes discussions at the September 23-24, 2014 meeting and March 18-19, 2015 meeting are found at: http://www.cdc.gov/nchs/icd/icd9cm-maintenance.html. These Web sites also provide detailed information about the Committee, including information on requesting a new code, attending a Committee meeting, timeline requirements and meeting dates.
We encourage commenters to address suggestions on coding issues involving diagnosis codes to: Donna Pickett, Co-Chairperson, ICD-10 Coordination and Maintenance Committee, NCHS, Room 2402, 3311 Toledo Road, Hyattsville, MD 20782. Comments may be sent by E-mail to: dfp4@cdc.gov.

Questions and comments concerning the procedure codes should be addressed to: Patricia Brooks, Co-Chairperson, ICD-10 Coordination and Maintenance Committee, CMS, Center for Medicare, Hospital and Ambulatory Policy Group, Division of Acute Care, C4-08-06, 7500 Security Boulevard, Baltimore, MD 21244-1850. Comments may be sent by E-mail to: patricia.brooks2@cms.hhs.gov.

In the September 7, 2001 final rule implementing the IPPS new technology add-on payments (66 FR 46906), we indicated we would attempt to include proposals for procedure codes that would describe new technology discussed and approved at the Spring meeting as part of the code revisions effective the following October.

Section 503(a) of Pub. L. 108-173 included a requirement for updating ICD-9-CM codes twice a year instead of a single update on October 1 of each year. This requirement was included as part of the amendments to the Act relating to recognition of new technology under the IPPS. Section 503(a) amended section 1886(d)(5)(K) of the Act by adding a clause (vii) which states that the Secretary shall provide for the addition of new diagnosis and procedure codes on April 1 of each year, but the addition of such codes shall not require the Secretary to adjust the payment (or diagnosis-related group classification) until the fiscal year that begins after such date. This requirement improves the recognition of new technologies under the IPPS system by providing information on
these new technologies at an earlier date. Data will be available 6 months earlier than would be possible with updates occurring only once a year on October 1.

While section 1886(d)(5)(K)(vii) of the Act states that the addition of new diagnosis and procedure codes on April 1 of each year shall not require the Secretary to adjust the payment, or DRG classification, under section 1886(d) of the Act until the fiscal year that begins after such date, we have to update the DRG software and other systems in order to recognize and accept the new codes. We also publicize the code changes and the need for a mid-year systems update by providers to identify the new codes. Hospitals also have to obtain the new code books and encoder updates, and make other system changes in order to identify and report the new codes.

The ICD-10 (previously the ICD-9-CM) Coordination and Maintenance Committee holds its meetings in the spring and fall in order to update the codes and the applicable payment and reporting systems by October 1 of each year. Items are placed on the agenda for the Committee meeting if the request is received at least 2 months prior to the meeting. This requirement allows time for staff to review and research the coding issues and prepare material for discussion at the meeting. It also allows time for the topic to be publicized in meeting announcements in the Federal Register as well as on the CMS Web site. The public decides whether or not to attend the meeting based on the topics listed on the agenda. Final decisions on code title revisions are currently made by March 1 so that these titles can be included in the IPPS proposed rule. A complete addendum describing details of all diagnosis and procedure coding changes, both tabular and index, is published on the CMS and NCHS Web sites in May of each year.
Publishers of coding books and software use this information to modify their products that are used by health care providers. This 5-month time period has proved to be necessary for hospitals and other providers to update their systems.

A discussion of this timeline and the need for changes are included in the December 4-5, 2005 ICD-9-CM Coordination and Maintenance Committee Meeting minutes. The public agreed that there was a need to hold the fall meetings earlier, in September or October, in order to meet the new implementation dates. The public provided comment that additional time would be needed to update hospital systems and obtain new code books and coding software. There was considerable concern expressed about the impact this new April update would have on providers.

In the FY 2005 IPPS final rule, we implemented section 1886(d)(5)(K)(vii) of the Act, as added by section 503(a) of Pub. L. 108-173, by developing a mechanism for approving, in time for the April update, diagnosis and procedure code revisions needed to describe new technologies and medical services for purposes of the new technology add-on payment process. We also established the following process for making these determinations. Topics considered during the Fall ICD-10 (previously ICD-9-CM) Coordination and Maintenance Committee meeting are considered for an April 1 update if a strong and convincing case is made by the requestor at the Committee’s public meeting. The request must identify the reason why a new code is needed in April for purposes of the new technology process. The participants at the meeting and those reviewing the Committee meeting summary report are provided the opportunity to comment on this expedited request. All other topics are considered for the October 1
update. Participants at the Committee meeting are encouraged to comment on all such requests. There were no requests approved for an expedited April 1, 2015 implementation of a code at the September 23-24, 2014 Committee meeting. Therefore, there were no new codes implemented on April 1, 2015.

ICD-9-CM addendum and code title information is published on the CMS Web site at:

http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html?redirect=/icd9ProviderDiagnosticCodes/01overview.asp#TopofPage. ICD-10-CM and ICD-10-PCS addendum and code title information is published on the CMS Web site at

http://www.cms.gov/Medicare/Coding/ICD10/index.html. Information on ICD-10-CM diagnosis codes, along with the Official ICD-10-CM Coding Guidelines, can also be found on the CDC Web site at: http://www.cdc.gov/nchs/index.html. Information on new, revised, and deleted ICD-10-CM/ICD-10-PCS codes is also provided to the AHA for publication in the Coding Clinic for ICD-10. AHA also distributes information to publishers and software vendors.

CMS also sends copies of all ICD-10-CM and ICD-10-PCS coding changes to its Medicare contractors for use in updating their systems and providing education to providers.

The code titles are adopted as part of the ICD-10 (previously ICD-9-CM) Coordination and Maintenance Committee process. Therefore, although we publish the code titles in the IPPS proposed and final rules, they are not subject to comment in the proposed or final rules.
b. Code Freeze

In the January 16, 2009 ICD-10-CM and ICD-10-PCS final rule (74 FR 3340), there was a discussion of the need for a partial or total freeze in the annual updates to both ICD-9-CM and ICD-10-CM and ICD-10-PCS codes. The public comment addressed in that final rule stated that the annual code set updates should cease 1 year prior to the implementation of ICD-10. The commenters stated that this freeze of code updates would allow for instructional and/or coding software programs to be designed and purchased early, without concern that an upgrade would take place immediately before the compliance date, necessitating additional updates and purchases.

HHS responded to comments in the ICD-10 final rule that the ICD-9-CM Coordination and Maintenance Committee has jurisdiction over any action impacting the ICD-9-CM and ICD-10 code sets. Therefore, HHS indicated that the issue of consideration of a moratorium on updates to the ICD-9-CM, ICD-10-CM, and ICD-10-PCS code sets in anticipation of the adoption of ICD-10-CM and ICD-10-PCS would be addressed through the Committee at a future public meeting.

The code freeze was discussed at multiple meetings of the ICD-9-CM Coordination and Maintenance Committee and public comment was actively solicited. The Committee evaluated all comments from participants attending the Committee meetings as well as written comments that were received. The Committee also considered the delay in implementation of ICD-10 until October 1, 2014. There was an announcement at the September 19, 2012 ICD-9-CM Coordination and Maintenance
Committee meeting that a partial freeze of both ICD-9-CM and ICD-10 codes will be implemented as follows:

- The last regular annual update to both ICD-9-CM and ICD-10 code sets was made on October 1, 2011.
- On October 1, 2012 and October 1, 2013, there were to be only limited code updates to both ICD-9-CM and ICD-10 code sets to capture new technology and new diseases.
- On October 1, 2014, there were to be only limited code updates to ICD-10 code sets to capture new technology and diagnoses as required by section 503(a) of Pub. L. 108-173. There were to be no updates to ICD-9-CM on October 1, 2014.
- On October 1, 2015, one year after the originally scheduled implementation of ICD-10, regular updates to ICD-10 were to begin.

On May 15, 2014, CMS posted an updated Partial Code Freeze schedule on the CMS Web site at: [http://www.cms.gov/Medicare/Coding/ICD10/ICD-9-CM-Coordination-and-Maintenance-Committee-Meetings.html](http://www.cms.gov/Medicare/Coding/ICD10/ICD-9-CM-Coordination-and-Maintenance-Committee-Meetings.html). This updated schedule provided information on the extension of the partial code freeze until 1 year after the implementation of ICD-10. As stated earlier, on April 1, 2014, the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-93) was enacted, which specified that the Secretary may not adopt ICD-10 prior to October 1, 2015. Accordingly, the U.S. Department of Health and Human Services released a final rule in the [Federal Register](https://www.federalregister.gov) on August 4, 2014 (79 FR 45128 through 45134) that included a new compliance date that requires the use of ICD-10 beginning October 1, 2015. The August 4, 2014 final rule
is available for viewing on the Internet at: http://www.gpo.gov/fdsys/pkg/FR-2014-08-04/pdf/2014-18347.pdf. That final rule also requires HIPAA covered entities to continue to use ICD-9-CM through September 30, 2015. Accordingly, the updated schedule for the partial code freeze is as follows:

- The last regular annual updates to both ICD-9-CM and ICD-10 code sets were made on October 1, 2011.

- On October 1, 2012, October 1, 2013, and October 1, 2014, there were only limited code updates to both the ICD-9-CM and ICD-10 code sets to capture new technologies and diseases as required by section 1886(d)(5)(K) of the Act.

- On October 1, 2015, there will be only limited code updates to ICD-10 code sets to capture new technologies and diagnoses as required by section 1886(d)(5)(K) of the Act. There will be no updates to ICD-9-CM, as it will no longer be used for reporting.

- On October 1, 2016 (1 year after implementation of ICD-10), regular updates to ICD-10 will begin.

The ICD-10 (previously ICD-9-CM) Coordination and Maintenance Committee announced that it would continue to meet twice a year during the freeze. At these meetings, the public will be encouraged to comment on whether or not requests for new diagnosis and procedure codes should be created based on the need to capture new technology and new diseases. Any code requests that do not meet the criteria will be evaluated for implementation within ICD-10 one year after the implementation of ICD-10, once the partial freeze is ended.
Complete information on the partial code freeze and discussions of the issues at the Committee meetings can be found on the ICD-10 Coordination and Maintenance Committee Web site at:

http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.html. A summary of the September 19, 2012 Committee meeting, along with both written and audio transcripts of this meeting, is posted on the Web site at:


This partial code freeze has dramatically decreased the number of codes created each year as shown by the following information.
<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>No.</th>
<th>Change</th>
<th>Fiscal Year</th>
<th>No.</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2009 (October 1, 2008)</td>
<td>Diagnoses</td>
<td>14,025</td>
<td>348</td>
<td>ICD-10-CM</td>
<td>68,069</td>
</tr>
<tr>
<td>FY 2009 (October 1, 2008)</td>
<td>Procedures</td>
<td>3,824</td>
<td>56</td>
<td>ICD-10-PCS</td>
<td>72,589</td>
</tr>
<tr>
<td>FY 2010 (October 1, 2009)</td>
<td>Diagnoses</td>
<td>14,315</td>
<td>290</td>
<td>ICD-10-CM</td>
<td>69,099</td>
</tr>
<tr>
<td>FY 2011 (October 1, 2010)</td>
<td>Diagnoses</td>
<td>14,432</td>
<td>117</td>
<td>ICD-10-CM</td>
<td>69,368</td>
</tr>
<tr>
<td>FY 2011 (October 1, 2010)</td>
<td>Procedures</td>
<td>3,859</td>
<td>21</td>
<td>ICD-10-PCS</td>
<td>72,081</td>
</tr>
<tr>
<td>FY 2012 (October 1, 2011)</td>
<td>Diagnoses</td>
<td>14,567</td>
<td>135</td>
<td>ICD-10-CM</td>
<td>69,833</td>
</tr>
<tr>
<td>FY 2012 (October 1, 2011)</td>
<td>Procedures</td>
<td>3,877</td>
<td>18</td>
<td>ICD-10-PCS</td>
<td>71,918</td>
</tr>
<tr>
<td>FY 2013 (October 1, 2012)</td>
<td>Diagnoses</td>
<td>14,567</td>
<td>0</td>
<td>ICD-10-CM</td>
<td>69,832</td>
</tr>
<tr>
<td>FY 2013 (October 1, 2012)</td>
<td>Procedures</td>
<td>3,878</td>
<td>1</td>
<td>ICD-10-PCS</td>
<td>71,920</td>
</tr>
<tr>
<td>FY 2014 (October 1, 2013)</td>
<td>Diagnoses</td>
<td>14,567</td>
<td>0</td>
<td>ICD-10-CM</td>
<td>69,823</td>
</tr>
<tr>
<td>FY 2014 (October 1, 2013)</td>
<td>Procedures</td>
<td>3,882</td>
<td>4</td>
<td>ICD-10-PCS</td>
<td>71,924</td>
</tr>
<tr>
<td>FY 2015 (October 1, 2014)</td>
<td>Diagnoses</td>
<td>14,567</td>
<td>0</td>
<td>ICD-10-CM</td>
<td>69,823</td>
</tr>
<tr>
<td>FY 2015 (October 1, 2014)</td>
<td>Procedures</td>
<td>3,882</td>
<td>0</td>
<td>ICD-10-PCS</td>
<td>71,924</td>
</tr>
<tr>
<td>FY 2016 (October 1, 2015)</td>
<td>Diagnoses</td>
<td>14,567</td>
<td>0</td>
<td>ICD-10-CM</td>
<td>69,823</td>
</tr>
<tr>
<td>FY 2016 (October 1, 2015)</td>
<td>Procedures</td>
<td>3,882</td>
<td>0</td>
<td>ICD-10-PCS</td>
<td>71,974</td>
</tr>
</tbody>
</table>
As mentioned earlier, the public is provided the opportunity to comment on any requests for new diagnosis or procedure codes discussed at the ICD-10 Coordination and Maintenance Committee meeting. The public has supported only a limited number of new codes during the partial code freeze, as can be seen by data shown above. We have gone from creating several hundred new codes each year to creating only a limited number of new ICD-9-CM and ICD-10 codes.

At the September 23-24, 2014 and March 18-19, 2015 Committee meetings, we discussed any requests we had received for new ICD-10-CM diagnosis and ICD-10-PCS procedure codes that were to be implemented on October 1, 2015. We did not discuss ICD-9-CM codes. The public was given the opportunity to comment on whether or not new ICD-10-CM and ICD-10-PCS codes should be created, based on the partial code freeze criteria. The public was to use the criteria as to whether codes were needed to capture new diagnoses or new technologies. If the codes do not meet those criteria for implementation during the partial code freeze, consideration was to be given as to whether the codes should be created after the partial code freeze ends 1 year after the implementation of ICD-10-CM/PCS. We invited public comments on any code requests discussed at the September 23-24, 2014 and March 18-19, 2015 Committee meetings for implementation as part of the October 1, 2015 update. The deadline for commenting on code proposals discussed at the September 23-24, 2014 Committee meeting was November 21, 2014. The deadline for commenting on code proposals discussed at the March 18-19, 2015 Committee meeting was April 17, 2015.

14. Other Policy Changes: Replaced Devices Offered without Cost or With a Credit
a. Background

In the FY 2008 IPPS final rule with comment period (72 FR 47246 through 47251), we discussed the topic of Medicare payment for devices that are replaced without cost or where credit for a replaced device is furnished to the hospital. We implemented a policy to reduce a hospital’s IPPS payment for certain MS-DRGs where the implantation of a device that has been recalled determined the base MS-DRG assignment. We specified that if a hospital received a credit for a recalled device equal to 50 percent or more of the cost of the device, we would reduce a hospital’s IPPS payment for those MS-DRGs.

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51556 and 51557), we clarified this policy to state that the policy applies if the hospital received a credit equal to 50 percent or more of the cost of the replacement device and issued instructions to hospitals accordingly.

b. Request for Clarification on Policy Relating to “Device-Dependent” MS-DRGs

After publication of the FY 2015 IPPS/LTCH PPS final rule, we received a request to clarify the list of “device-dependent” MS-DRGs subject to the policy for payment under the IPPS for replaced devices offered without cost or with a credit. Specifically, a requestor noted that ICD-9-CM procedure codes that previously grouped to MS-DRGs 216 through 221 (Cardiac Valve & Other Major Cardiothoracic Procedure with and without Cardiac Catheterization, with MCC, with CC, without CC/MCC, respectively) and were subject to the policy for payment under the IPPS as “device-dependent” MS-DRGs had been reassigned to new MS-DRGs 266 and 267.
(Endovascular Cardiac Valve Replacement with MCC and without MCC, respectively).
The requestor suggested that MS-DRGs 266 and 267 also should be considered “device-dependent” MS-DRGs and added to the list of MS-DRGs subject to the IPPS payment policy for replaced devices offered without cost or with a credit.

As noted by the requestor, as final policy for FY 2015, certain ICD-9-CM procedure codes that previously grouped to MS-DRGs 216 through 221, which are on the list of MS-DRGs subject to the policy for payment under the IPPS for replaced devices offered without cost or with a credit, were reassigned to MS-DRGs 266 and 267. We agree that MS-DRGs 266 and 267 should be included in the list of “device-dependent” MS-DRGs subject to the IPPS policy. We generally map new MS-DRGs onto the list when they are formed from procedures previously assigned to MS-DRGs that are already on the list. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24409), we proposed to add MS-DRGs 266 and 267 to the list of “device dependent” MS-DRGs subject to the policy for payment under the IPPS for replaced devices offered without cost or with a credit.

In addition, as discussed in section II.G.4.e. of the preamble of the proposed rule, for FY 2016, we proposed to delete MS-DRGs 237 and 238 (Major Cardiovascular Procedures with MCC and without MCC, respectively) and create new MS-DRGs 268 and 269 (Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC and without MCC, respectively), as well as new MS-DRGs 270, 271, and 272 (Other Major Cardiovascular Procedures with MCC, with CC, and without CC/MCC, respectively). Currently, MS-DRGs 237 and 238 are on the list of MS-DRGs subject to the policy for
payment under the IPPS for replaced devices offered without cost or with a credit. As stated previously, we generally map new MS-DRGs onto the list when they are formed from procedures previously assigned to MS-DRGs that are already on the list. Therefore, we indicated that if we finalized these proposed MS-DRG changes, we also would add proposed new MS-DRGs 268 through 272 to the list of MS-DRGs subject to the policy for payment under the IPPS for replaced devices offered without cost or with a credit.

We invited public comments on our proposed list of MS-DRGs to be subject to the IPPS policy for replaced devices offered without cost or with a credit for FY 2016 (80 FR 24409 through 24410).

Comment: Commenters supported the proposal to add MS-DRGs 266 and 267 to the list of MS-DRGs subject to the IPPS payment policy for replaced devices offered without cost or with a credit. We did not receive any public comments in response to our proposal to delete ICD-9-CM MS-DRGs 237 and 238 and add any of the finalized new ICD-10 MS-DRGs to the list.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are adding MS-DRGs 266 and 267 to the list of MS-DRGs subject to the policy for payment under the IPPS for replaced devices offered without cost or with a credit, and consistent with the applicable finalized MS-DRG changes, also removing existing MS-DRGs 237 and 238 and adding new MS-DRGs 268 through 272. The list of MS-DRGs that are subject to the IPPS policy for replaced devices offered without cost or with a credit for FY 2016
is displayed below. We also intend to issue this list to providers in the form of a Change Request (CR).

<table>
<thead>
<tr>
<th>MDC</th>
<th>MS-DRG</th>
<th>MS-DRG Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PreMDC</td>
<td>001</td>
<td>Heart Transplant or Implant of Heart Assist System with MCC</td>
</tr>
<tr>
<td>PreMDC</td>
<td>002</td>
<td>Heart Transplant or Implant of Heart Assist System without MCC</td>
</tr>
<tr>
<td>MDC 01</td>
<td>023</td>
<td>Craniotomy with Major Device Implant/Acute Complex CNS PDX with MCC or Chemo Implant</td>
</tr>
<tr>
<td>MDC 01</td>
<td>024</td>
<td>Craniotomy with Major Device Implant/Acute Complex CNS PDX without MCC</td>
</tr>
<tr>
<td>MDC 01</td>
<td>025</td>
<td>Craniotomy &amp; Endovascular Intracranial Procedures with MCC</td>
</tr>
<tr>
<td>MDC 01</td>
<td>026</td>
<td>Craniotomy &amp; Endovascular Intracranial Procedures with CC</td>
</tr>
<tr>
<td>MDC 01</td>
<td>027</td>
<td>Craniotomy &amp; Endovascular Intracranial Procedures without CC/MCC</td>
</tr>
<tr>
<td>MDC 01</td>
<td>040</td>
<td>Peripheral/Cranial Nerve &amp; Other Nervous System Procedures with MCC</td>
</tr>
<tr>
<td>MDC 01</td>
<td>041</td>
<td>Peripheral/Cranial Nerve &amp; Other Nervous System Procedures with CC or Peripheral Neurostimulation</td>
</tr>
<tr>
<td>MDC 01</td>
<td>042</td>
<td>Peripheral/Cranial Nerve &amp; Other Nervous System Procedures without CC/MCC</td>
</tr>
<tr>
<td>MDC 03</td>
<td>129</td>
<td>Major Head &amp; Neck Procedures with CC/MCC or Major Device</td>
</tr>
<tr>
<td>MDC 03</td>
<td>130</td>
<td>Major Head &amp; Neck Procedures without CC/MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>215</td>
<td>Other Heart Assist System Implant</td>
</tr>
<tr>
<td>MDC 05</td>
<td>216</td>
<td>Cardiac Valve &amp; Other Major Cardiothoracic Procedures with Cardiac Catheterization with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>217</td>
<td>Cardiac Valve &amp; Other Major Cardiothoracic Procedures with Cardiac Catheterization with CC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>218</td>
<td>Cardiac Valve &amp; Other Major Cardiothoracic Procedures with Cardiac Catheterization without CC/MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>219</td>
<td>Cardiac Valve &amp; Other Major Cardiothoracic Procedures without Cardiac Catheterization with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>220</td>
<td>Cardiac Valve &amp; Other Major Cardiothoracic Procedures without Cardiac Catheterization with CC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>221</td>
<td>Cardiac Valve &amp; Other Major Cardiothoracic Procedures without Cardiac Catheterization without CC/MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>222</td>
<td>Cardiac Defibrillator Implant with Cardiac Catheterization with AMI/HF/Shock with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>223</td>
<td>Cardiac Defibrillator Implant with Cardiac Catheterization with AMI/HF/Shock without MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>224</td>
<td>Cardiac Defibrillator Implant with Cardiac Catheterization</td>
</tr>
<tr>
<td>MDC</td>
<td>MS-DRG</td>
<td>MS-DRG Title</td>
</tr>
<tr>
<td>------</td>
<td>--------</td>
<td>--------------</td>
</tr>
<tr>
<td>MDC 05</td>
<td>225</td>
<td>Cardiac Defibrillator Implant with Cardiac Catheterization without AMI/HF/Shock without MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>226</td>
<td>Cardiac Defibrillator Implant without Cardiac Catheterization with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>227</td>
<td>Cardiac Defibrillator Implant without Cardiac Catheterization without MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>242</td>
<td>Permanent Cardiac Pacemaker Implant with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>243</td>
<td>Permanent Cardiac Pacemaker Implant without CC/MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>244</td>
<td>Permanent Cardiac Pacemaker Implant without CC/MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>245</td>
<td>AICD Generator Procedures</td>
</tr>
<tr>
<td>MDC 05</td>
<td>258</td>
<td>Cardiac Pacemaker Device Replacement with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>259</td>
<td>Cardiac Pacemaker Device Replacement without MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>260</td>
<td>Cardiac Pacemaker Revision Except Device Replacement with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>261</td>
<td>Cardiac Pacemaker Revision Except Device Replacement without CC/MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>262</td>
<td>Cardiac Pacemaker Revision Except Device Replacement without CC/MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>265</td>
<td>AICD Lead Procedures</td>
</tr>
<tr>
<td>MDC 05</td>
<td>266</td>
<td>Endovascular Cardiac Valve Replacement with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>267</td>
<td>Endovascular Cardiac Valve Replacement without MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>268</td>
<td>Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>269</td>
<td>Aortic and Heart Assist Procedures Except Pulsation Balloon without MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>270</td>
<td>Other Major Cardiovascular Procedures with MCC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>271</td>
<td>Other Major Cardiovascular Procedures with CC</td>
</tr>
<tr>
<td>MDC 05</td>
<td>272</td>
<td>Other Major Cardiovascular Procedures without CC/MCC</td>
</tr>
<tr>
<td>MDC 08</td>
<td>461</td>
<td>Bilateral or Multiple Major Joint Procedures of Lower Extremity with MCC</td>
</tr>
<tr>
<td>MDC 08</td>
<td>462</td>
<td>Bilateral or Multiple Major Joint Procedures of Lower Extremity without MCC</td>
</tr>
<tr>
<td>MDC 08</td>
<td>466</td>
<td>Revision of Hip or Knee Replacement with MCC</td>
</tr>
<tr>
<td>MDC 08</td>
<td>467</td>
<td>Revision of Hip or Knee Replacement without CC/MCC</td>
</tr>
<tr>
<td>MDC 08</td>
<td>468</td>
<td>Revision of Hip or Knee Replacement without CC/MCC</td>
</tr>
<tr>
<td>MDC 08</td>
<td>469</td>
<td>Major Joint Replacement or Reattachment of Lower Extremity with MCC</td>
</tr>
<tr>
<td>MDC 08</td>
<td>470</td>
<td>Major Joint Replacement or Reattachment of Lower Extremity</td>
</tr>
</tbody>
</table>
### List of MS-DRGs Subject to the IPPS Policy for Replaced Devices Offered without Cost or with a Credit

<table>
<thead>
<tr>
<th>MDC</th>
<th>MS-DRG</th>
<th>MS-DRG Title</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>without MCC</td>
</tr>
</tbody>
</table>

15. Out of Scope Public Comments

We received public comments regarding two MS-DRG issues that were outside of the scope of the proposals included in the FY 2016 IPPS/LTCH proposed rule. These comments were as follows:

- Several commenters requested the creation of a new MS-DRG for primary total ankle replacements and revisions of total ankle replacement procedures.
- Several commenters requested the creation of a new MS-DRG for hip fractures for individuals who receive total hip replacements.

However, because we consider these public comments to be outside of the scope of the proposed rule, we are not addressing them in this final rule. As stated in section II.G.1.b. of the preamble of this final rule, we encourage individuals with comments about MS-DRG classification to submit these comments no later than December 7 of each year so that they can be considered for possible inclusion in the annual proposed rule and, if included, may be subjected to public review and comment. We will consider these public comments for possible proposals in future rulemaking as part of our annual review process.
H. Recalibration of the FY 2016 MS-DRG Relative Weights

1. Data Sources for Developing the Relative Weights

In developing the FY 2016 system of weights, we used two data sources: claims data and cost report data. As in previous years, the claims data source is the MedPAR file. This file is based on fully coded diagnostic and procedure data for all Medicare inpatient hospital bills. The FY 2014 MedPAR data used in this final rule include discharges occurring on October 1, 2013, through September 30, 2014, based on bills received by CMS through March 31, 2015, from all hospitals subject to the IPPS and short-term, acute care hospitals in Maryland (which at that time were under a waiver from the IPPS). The FY 2014 MedPAR file used in calculating the relative weights includes data for approximately 9,682,319 Medicare discharges from IPPS providers. Discharges for Medicare beneficiaries enrolled in a Medicare Advantage managed care plan are excluded from this analysis. These discharges are excluded when the MedPAR “GHO Paid” indicator field on the claim record is equal to “1” or when the MedPAR DRG payment field, which represents the total payment for the claim, is equal to the MedPAR “Indirect Medical Education (IME)” payment field, indicating that the claim was an “IME only” claim submitted by a teaching hospital on behalf of a beneficiary enrolled in a Medicare Advantage managed care plan. In addition, the March 31, 2015 update of the FY 2014 MedPAR file complies with version 5010 of the X12 HIPAA Transaction and Code Set Standards, and includes a variable called “claim type.” Claim type “60” indicates that the claim was an inpatient claim paid as fee-for-service. Claim types “61,” “62,” “63,” and “64” relate to encounter claims, Medicare Advantage IME
claims, and HMO no-pay claims. Therefore, the calculation of the relative weights for FY 2016 also excludes claims with claim type values not equal to “60.” The data exclude CAHs, including hospitals that subsequently became CAHs after the period from which the data were taken. We note that the FY 2016 relative weights are based on the ICD-9-CM diagnoses and procedures codes from the MedPAR claims data, grouped through the ICD-9-CM version of the FY 2016 GROUPER (Version 33).

The second data source used in the cost-based relative weighting methodology is the Medicare cost report data files from the HCRIS. Normally, we use the HCRIS dataset that is 3 years prior to the IPPS fiscal year. Specifically, we used cost report data from the March 31, 2015 update of the FY 2013 HCRIS for calculating the FY 2016 cost-based relative weights.

2. Methodology for Calculation of the Relative Weights

As we explain in section I.I.E.2. of the preamble of this final rule, we calculated the FY 2016 relative weights based on 19 CCRs, as we did for FY 2015. The methodology we used to calculate the FY 2016 MS-DRG cost-based relative weights based on claims data in the FY 2014 MedPAR file and data from the FY 2013 Medicare cost reports is as follows:

- To the extent possible, all the claims were regrouped using the FY 2016 MS-DRG classifications discussed in sections II.B. and II.G. of the preamble of this final rule.

- The transplant cases that were used to establish the relative weights for heart and heart-lung, liver and/or intestinal, and lung transplants (MS-DRGs 001, 002, 005,
006, and 007, respectively) were limited to those Medicare-approved transplant centers
that have cases in the FY 2014 MedPAR file. (Medicare coverage for heart, heart-lung,
liver and/or intestinal, and lung transplants is limited to those facilities that have received
approval from CMS as transplant centers.)

- Organ acquisition costs for kidney, heart, heart-lung, liver, lung, pancreas, and
intestinal (or multivisceral organs) transplants continue to be paid on a reasonable cost
basis. Because these acquisition costs are paid separately from the prospective payment
rate, it is necessary to subtract the acquisition charges from the total charges on each
transplant bill that showed acquisition charges before computing the average cost for
each MS-DRG and before eliminating statistical outliers.

- Claims with total charges or total lengths of stay less than or equal to zero were
deleted. Claims that had an amount in the total charge field that differed by more than
$10.00 from the sum of the routine day charges, intensive care charges, pharmacy
charges, special equipment charges, therapy services charges, operating room charges,
cardiology charges, laboratory charges, radiology charges, other service charges, labor
and delivery charges, inhalation therapy charges, emergency room charges, blood
charges, and anesthesia charges were also deleted.

- At least 92.1 percent of the providers in the MedPAR file had charges for 14 of
the 19 cost centers. All claims of providers that did not have charges greater than zero
for at least 14 of the 19 cost centers were deleted. In other words, a provider must have
no more than five blank cost centers. If a provider did not have charges greater than zero
in more than five cost centers, the claims for the provider were deleted.
• Statistical outliers were eliminated by removing all cases that were beyond 3.0 standard deviations from the geometric mean of the log distribution of both the total charges per case and the total charges per day for each MS-DRG.

• Effective October 1, 2008, because hospital inpatient claims include a POA indicator field for each diagnosis present on the claim, only for purposes of relative weight-setting, the POA indicator field was reset to “Y” for “Yes” for all claims that otherwise have an “N” (No) or a “U” (documentation insufficient to determine if the condition was present at the time of inpatient admission) in the POA field.

Under current payment policy, the presence of specific HAC codes, as indicated by the POA field values, can generate a lower payment for the claim. Specifically, if the particular condition is present on admission (that is, a “Y” indicator is associated with the diagnosis on the claim), it is not a HAC, and the hospital is paid for the higher severity (and, therefore, the higher weighted MS-DRG). If the particular condition is not present on admission (that is, an “N” indicator is associated with the diagnosis on the claim) and there are no other complicating conditions, the DRG GROUPER assigns the claim to a lower severity (and, therefore, the lower weighted MS-DRG) as a penalty for allowing a Medicare inpatient to contract a HAC. While the POA reporting meets policy goals of encouraging quality care and generates program savings, it presents an issue for the relative weight-setting process. Because cases identified as HACs are likely to be more complex than similar cases that are not identified as HACs, the charges associated with HAC cases are likely to be higher as well. Therefore, if the higher charges of these HAC claims are grouped into lower severity MS-DRGs prior to the relative weight-setting
process, the relative weights of these particular MS-DRGs would become artificially inflated, potentially skewing the relative weights. In addition, we want to protect the integrity of the budget neutrality process by ensuring that, in estimating payments, no increase to the standardized amount occurs as a result of lower overall payments in a previous year that stem from using weights and case-mix that are based on lower severity MS-DRG assignments. If this would occur, the anticipated cost savings from the HAC policy would be lost.

To avoid these problems, we reset the POA indicator field to “Y” only for relative weight-setting purposes for all claims that otherwise have an “N” or a “U” in the POA field. This resetting “forced” the more costly HAC claims into the higher severity MS-DRGs as appropriate, and the relative weights calculated for each MS-DRG more closely reflect the true costs of those cases.

In addition, in the FY 2013 IPPS/LTCH PPS final rule, for FY 2013 and subsequent fiscal years, we finalized a policy to treat hospitals that participate in the Bundled Payments for Care Improvement (BPCI) initiative the same as prior fiscal years for the IPPS payment modeling and ratesetting process without regard to hospitals’ participation within these bundled payment models (that is, as if hospitals were not participating in those models under the BPCI initiative). The BPCI initiative, developed under the authority of section 3021 of the Affordable Care Act (codified at section 1115A of the Act), is comprised of four broadly defined models of care, which link payments for multiple services beneficiaries receive during an episode of care. Under the BPCI initiative, organizations enter into payment arrangements that include financial and
performance accountability for episodes of care. For FY 2016, as we proposed, we are continuing to include all applicable data from subsection (d) hospitals participating in BPCI Models 1, 2, and 4 in our IPPS payment modeling and ratesetting calculations. We refer readers to the FY 2013 IPPS/LTCH PPS final rule for a complete discussion on our final policy for the treatment of hospitals participating in the BPCI initiative in our ratesetting process. For additional information on the BPCI initiative, we refer readers to the CMS’ Center for Medicare and Medicaid Innovation’s Web site at: 


Once the MedPAR data were trimmed and the statistical outliers were removed, the charges for each of the 19 cost groups for each claim were standardized to remove the effects of differences in area wage levels, IME and DSH payments, and for hospitals located in Alaska and Hawaii, the applicable cost-of-living adjustment. Because hospital charges include charges for both operating and capital costs, we standardized total charges to remove the effects of differences in geographic adjustment factors, cost-of-living adjustments, and DSH payments under the capital IPPS as well. Charges were then summed by MS-DRG for each of the 19 cost groups so that each MS-DRG had 19 standardized charge totals. These charges were then adjusted to cost by applying the national average CCRs developed from the FY 2013 cost report data.
The 19 cost centers that we used in the relative weight calculation are shown in the following table. The table shows the lines on the cost report and the corresponding revenue codes that we used to create the 19 national cost center CCRs.
<table>
<thead>
<tr>
<th>Cost Center Group Name (19 total)</th>
<th>MedPAR Charge Field</th>
<th>Revenue Codes Contained in MedPAR Charge Field</th>
<th>Cost Report Line Description</th>
<th>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</th>
<th>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</th>
<th>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Days</td>
<td>Private Room Charges</td>
<td>011X and 014X</td>
<td>Adults &amp; Pediatrics (General Routine Care)</td>
<td>C_1_C5_30</td>
<td>C_1_C6_30</td>
<td>D3_HOS_C2_30</td>
</tr>
<tr>
<td>Semi-Private Room Charges</td>
<td></td>
<td>012X, 013X and 016X-019X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ward Charges</td>
<td></td>
<td>015X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intensive Days</td>
<td>Intensive Care Charges</td>
<td>020X</td>
<td>Intensive Care Unit</td>
<td>C_1_C5_31</td>
<td>C_1_C6_31</td>
<td>D3_HOS_C2_31</td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------</td>
<td>---------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Coronary Care Charges</td>
<td>021X</td>
<td>Coronary Care Unit</td>
<td>C_1_C5_32</td>
<td>C_1_C6_32</td>
<td>D3_HOS_C2_32</td>
<td></td>
</tr>
<tr>
<td>Burn Intensive Care Unit</td>
<td></td>
<td>Burn Intensive Care Unit</td>
<td>C_1_C5_33</td>
<td>C_1_C6_33</td>
<td>D3_HOS_C2_33</td>
<td></td>
</tr>
<tr>
<td>Surgical Intensive Care Unit</td>
<td></td>
<td>Surgical Intensive Care Unit</td>
<td>C_1_C5_34</td>
<td>C_1_C6_34</td>
<td>D3_HOS_C2_34</td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------</td>
<td>----------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other Special Care Unit</td>
<td>C_1_C5_35</td>
<td>C_1_C6_35</td>
<td>D3_HOS_C2_35</td>
</tr>
<tr>
<td>Drugs</td>
<td>Pharmacy Charges</td>
<td>025X, 026X and 063X</td>
<td>Intravenous Therapy</td>
<td>C_1_C5_64</td>
<td>C_1_C6_64</td>
<td>D3_HOS_C2_64</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Drugs Charged To Patient</td>
<td>C_1_C5_73</td>
<td>C_1_C6_73</td>
<td>D3_HOS_C2_73</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Supplies and Equipment</td>
<td>Medical/Surgical Supply Charges</td>
<td>0270, 0271, 0272, 0273, 0274, 0277, 0279, and 0621, 0622, 0623</td>
<td>Medical Supplies Charged to Patients</td>
<td>C_1_C5_71</td>
<td>C_1_C6_71</td>
<td>D3_HOS_C2_71</td>
</tr>
<tr>
<td>Durable Medical Equipment Charges</td>
<td>0290, 0291, 0292 and 0294-0299</td>
<td>DME-Rented</td>
<td>C_1_C5_96</td>
<td>C_1_C6_96</td>
<td>D3_HOS_C2_96</td>
<td></td>
</tr>
<tr>
<td>Used Durable Medical Charges</td>
<td>0293</td>
<td>DME-Sold</td>
<td>C_1_C5_97</td>
<td>C_1_C6_97</td>
<td>D3_HOS_C2_97</td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number)</td>
<td>Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number)</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------</td>
<td>-----------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>Implantable Devices</td>
<td></td>
<td>0275, 0276, 0278, 0624</td>
<td>C_1_C7_97</td>
<td></td>
<td></td>
<td>Adam_60201_07030_72</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C_1_C5_72</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C_1_C6_72</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>D3_HOS_C2_66</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C_1_C7_66</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapy Services</td>
<td>Physical Therapy Charges</td>
<td>042X</td>
<td>C_1_C5_66</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C_1_C6_66</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>D3_HOS_C2_66</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Occupational Therapy Charges</td>
<td>043X</td>
<td>Occupational Therapy</td>
<td>C_1_C5_67</td>
<td>C_1_C6_67</td>
<td>D3_HOS_C2_67</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speech Pathology Charges</td>
<td>044X and 047X</td>
<td>Speech Pathology</td>
<td>C_1_C5_68</td>
<td>C_1_C6_68</td>
<td>D3_HOS_C2_68</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhalation Therapy Charges</td>
<td>041X and 046X</td>
<td>Respiratory Therapy</td>
<td>C_1_C5_65</td>
<td>C_1_C6_65</td>
<td>D3_HOS_C2_65</td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Operating Room Charges</td>
<td>Operating Room</td>
<td>Operating Room</td>
<td>C_1_C5_50</td>
<td>C_1_C6_50</td>
<td>D3_HOS_C2_50</td>
<td>C_1_C7_50</td>
</tr>
<tr>
<td></td>
<td>036X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C_1_C5_50</td>
<td>C_1_C6_50</td>
<td>D3_HOS_C2_50</td>
<td></td>
</tr>
<tr>
<td></td>
<td>071X</td>
<td>Recovery Room</td>
<td>C_1_C5_51</td>
<td>C_1_C6_51</td>
<td>D3_HOS_C2_51</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C_1_C7_50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Labor &amp; Delivery Charges</td>
<td>Operating Room Charges</td>
<td>072X</td>
<td>Delivery Room and Labor Room</td>
<td>C_1_C5_52</td>
<td>C_1_C6_52</td>
<td>D3_HOS_C2_52</td>
</tr>
<tr>
<td>Anesthesia Charges</td>
<td>Anesthesia</td>
<td>037X</td>
<td>Anesthesiology</td>
<td>C_1_C5_53</td>
<td>C_1_C6_53</td>
<td>D3_HOS_C2_53</td>
</tr>
<tr>
<td>Cardiology Charges</td>
<td>Cardiology</td>
<td>048X and 073X</td>
<td>Electrocardiology</td>
<td>C_1_C5_69</td>
<td>C_1_C6_69</td>
<td>D3_HOS_C2_69</td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Cardiac Catheterization</td>
<td></td>
<td>0481</td>
<td>Cardiac Catheterization C_1_C5_59</td>
<td>C_1_C6_59</td>
<td>D3_HOS_C2_59</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C_1_C7_59</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory</td>
<td>Laboratory Charges</td>
<td>030X, 031X, and 075X</td>
<td>Laboratory</td>
<td>C_1_C5_60</td>
<td>C_1_C6_60</td>
<td>D3_HOS_C2_60</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other codes include:
- C_1_C5_61
- C_1_C6_61
- D3_HOS_C2_61
<table>
<thead>
<tr>
<th>Cost Center Group Name (19 total)</th>
<th>MedPAR Charge Field</th>
<th>Revenue Codes Contained in MedPAR Charge Field</th>
<th>Cost Report Line Description</th>
<th>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</th>
<th>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</th>
<th>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiology Radiology Charges</td>
<td>032X, 040X</td>
<td>Radiology – Diagnostic</td>
<td>C_1_C5_54</td>
<td>C_1_C6_54</td>
<td>D3_HOS_C2_54</td>
<td></td>
</tr>
<tr>
<td></td>
<td>028x, 0331, 0332, 0333, 0335, 0339</td>
<td>Radiology – Therapeutic</td>
<td>C_1_C5_55</td>
<td>C_1_C6_55</td>
<td>D3_HOS_C2_55</td>
<td></td>
</tr>
<tr>
<td></td>
<td>074X, 086X</td>
<td>Electroencephalography</td>
<td>C_1_C5_70</td>
<td>C_1_C6_70</td>
<td>D3_HOS_C2_70</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C_1_C7_70</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10
<table>
<thead>
<tr>
<th>Cost Center Group Name (19 total)</th>
<th>MedPAR Charge Field</th>
<th>Revenue Codes Contained in MedPAR Charge Field</th>
<th>Cost Report Line Description</th>
<th>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</th>
<th>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</th>
<th>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0342</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0343 and 344</td>
<td>Radioisotope</td>
<td>C_1_C5_56</td>
<td>C_1_C6_56</td>
<td>D3_HOS_C2_56</td>
</tr>
<tr>
<td>Computed Tomography (CT) Scan</td>
<td>CT Scan Charges</td>
<td>035X</td>
<td>Computed Tomography (CT) Scan</td>
<td>C_1_C5_57</td>
<td>C_1_C6_57</td>
<td>D3_HOS_C2_57</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnetic Resonance Imaging (MRI)</td>
<td>MRI Charges</td>
<td>061X</td>
<td>Magnetic Resonance Imaging (MRI)</td>
<td>C_1_C5_58</td>
<td>C_1_C6_58</td>
<td>D3_HOS_C2_58</td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Emergency Room Charges</td>
<td>Emergency Room</td>
<td>045x</td>
<td>Emergency</td>
<td>C_1_C5_91</td>
<td>C_1_C6_91</td>
<td>D3_HOS_C2_91</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood and Blood Products Charges</td>
<td>Blood</td>
<td>038x</td>
<td>Whole Blood &amp; Packed Red Blood Cells</td>
<td>C_1_C5_62</td>
<td>C_1_C6_62</td>
<td>D3_HOS_C2_62</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0819 (for acquisition)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>charges associated with MS-DRG 014 only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Storage / Processing</td>
<td>039x</td>
<td>Blood Storing, Processing, &amp; Transfusing</td>
<td>C_1_C5_63</td>
<td>C_1_C6_63</td>
<td>D3_HOS_C2_63</td>
<td></td>
</tr>
<tr>
<td>Other Services</td>
<td>Other Service Charge</td>
<td>0002-0099, 022X, 023X, 024X, 052X, 053X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Renal Dialysis</td>
<td>0800X</td>
<td>Renal Dialysis</td>
<td>C_1_C5_74</td>
<td>C_1_C6_74</td>
<td>D3_HOS_C2_74</td>
<td></td>
</tr>
<tr>
<td>ESRD Revenue Setting Charges</td>
<td>080X and 082X-088X</td>
<td></td>
<td></td>
<td>C_1_C7_74</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Outpatient Service Charges</td>
<td>049X</td>
<td>ASC (Non Distinct Part)</td>
<td>C_1_C5_75</td>
<td>C_1_C6_75</td>
<td>D3_HOS_C2_75</td>
<td></td>
</tr>
<tr>
<td>Lithotripsy Charge</td>
<td>079X</td>
<td>Other Ancillary</td>
<td>C_1_C5_76</td>
<td>C_1_C6_76</td>
<td>D3_HOS_C2_76</td>
<td></td>
</tr>
<tr>
<td>Clinic Visit Charges</td>
<td>051X</td>
<td>Clinic</td>
<td>C_1_C5_90</td>
<td>C_1_C6_90</td>
<td>D3_HOS_C2_90</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Observation beds</td>
<td>C_1_C5_92.01</td>
<td>C_1_C6_92.01</td>
<td>D3_HOS_C2_92.01</td>
<td></td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Professional Fees Charges</td>
<td>096X, 097X, and 098X</td>
<td>Other Outpatient Services</td>
<td>C_1_C7_92.01</td>
<td>C_1_C5_93</td>
<td>C_1_C6_93</td>
<td>D3_HOS_C2_93</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ambulance Charges</td>
<td>054X</td>
<td>Ambulance</td>
<td>C_1_C7_93</td>
<td>C_1_C5_95</td>
<td>C_1_C6_95</td>
<td>D3_HOS_C2_95</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rural Health Clinic</td>
<td></td>
<td></td>
<td>C_1_C7_88</td>
<td>C_1_C5_88</td>
<td>C_1_C6_88</td>
<td>D3_HOS_C2_88</td>
</tr>
<tr>
<td>Cost Center Group Name (19 total)</td>
<td>MedPAR Charge Field</td>
<td>Revenue Codes Contained in MedPAR Charge Field</td>
<td>Cost Report Line Description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and Line Number) Form CMS-2552-10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Columns 6 and 7 and Line Number) Form CMS-2552-10</td>
<td>Medicare Charges from HCRIS (Worksheet D-3, Column and Line Number) Form CMS-2552-10</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>FQHC</td>
<td></td>
<td></td>
<td>FQHC</td>
<td>C_1_C5_89</td>
<td>C_1_C6_89</td>
<td>D3_HOS_C2_89</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
We refer readers to the FY 2009 IPPS/LTCH PPS final rule (73 FR 48462) for a discussion on the revenue codes included in the Supplies and Equipment and Implantable Devices CCRs, respectively.

3. Development of National Average CCRs

We developed the national average CCRs as follows:

Using the FY 2013 cost report data, we removed CAHs, Indian Health Service hospitals, all-inclusive rate hospitals, and cost reports that represented time periods of less than 1 year (365 days). We included hospitals located in Maryland because we include their charges in our claims database. We then created CCRs for each provider for each cost center (see prior table for line items used in the calculations) and removed any CCRs that were greater than 10 or less than 0.01. We normalized the departmental CCRs by dividing the CCR for each department by the total CCR for the hospital for the purpose of trimming the data. We then took the logs of the normalized cost center CCRs and removed any cost center CCRs where the log of the cost center CCR was greater or less than the mean log plus/minus 3 times the standard deviation for the log of that cost center CCR. Once the cost report data were trimmed, we calculated a Medicare-specific CCR. The Medicare-specific CCR was determined by taking the Medicare charges for each line item from Worksheet D-3 and deriving the Medicare-specific costs by applying the hospital-specific departmental CCRs to the Medicare-specific charges for each line item from Worksheet D-3. Once each hospital’s Medicare-specific costs were established, we summed the total Medicare-specific costs and divided by the sum of the total Medicare-specific charges to produce national average, charge-weighted CCRs.
After we multiplied the total charges for each MS-DRG in each of the 19 cost centers by the corresponding national average CCR, we summed the 19 “costs” across each MS-DRG to produce a total standardized cost for the MS-DRG. The average standardized cost for each MS-DRG was then computed as the total standardized cost for the MS-DRG divided by the transfer-adjusted case count for the MS-DRG. The average cost for each MS-DRG was then divided by the national average standardized cost per case to determine the relative weight.

The FY 2016 cost-based relative weights were then normalized by an adjustment factor of 1.678947 so that the average case weight after recalibration was equal to the average case weight before recalibration. The normalization adjustment is intended to ensure that recalibration by itself neither increases nor decreases total payments under the IPPS, as required by section 1886(d)(4)(C)(iii) of the Act.

The 19 national average CCRs for FY 2016 are as follows:
<table>
<thead>
<tr>
<th>Group</th>
<th>CCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Days</td>
<td>0.480</td>
</tr>
<tr>
<td>Intensive Days</td>
<td>0.393</td>
</tr>
<tr>
<td>Drugs</td>
<td>0.191</td>
</tr>
<tr>
<td>Supplies &amp; Equipment</td>
<td>0.297</td>
</tr>
<tr>
<td>Implantable Devices</td>
<td>0.337</td>
</tr>
<tr>
<td>Therapy Services</td>
<td>0.332</td>
</tr>
<tr>
<td>Laboratory</td>
<td>0.125</td>
</tr>
<tr>
<td>Operating Room</td>
<td>0.199</td>
</tr>
<tr>
<td>Cardiology</td>
<td>0.118</td>
</tr>
<tr>
<td>Cardiac Catheterization</td>
<td>0.124</td>
</tr>
<tr>
<td>Radiology</td>
<td>0.159</td>
</tr>
<tr>
<td>MRIs</td>
<td>0.085</td>
</tr>
<tr>
<td>CT Scans</td>
<td>0.041</td>
</tr>
<tr>
<td>Emergency Room</td>
<td>0.183</td>
</tr>
<tr>
<td>Blood and Blood Products</td>
<td>0.336</td>
</tr>
<tr>
<td>Other Services</td>
<td>0.368</td>
</tr>
<tr>
<td>Labor &amp; Delivery</td>
<td>0.404</td>
</tr>
<tr>
<td>Inhalation Therapy</td>
<td>0.177</td>
</tr>
<tr>
<td>Anesthesia</td>
<td>0.106</td>
</tr>
</tbody>
</table>

Since FY 2009, the relative weights have been based on 100 percent cost weights based on our MS-DRG grouping system.

When we recalibrated the DRG weights for previous years, we set a threshold of 10 cases as the minimum number of cases required to compute a reasonable weight. In the FY 2016 IPPS/LTCH PPS proposed rule, we proposed to use that same case threshold in recalibrating the MS-DRG relative weights for FY 2016. In the FY 2016 IPPS/LTCH PPS proposed rule, we stated that, using data from the FY 2014 MedPAR file, there were 8 MS-DRGs that contain fewer than 10 cases (80 FR 24414). However, we mistakenly included MS-DRG 768 (Vaginal Delivery with O.R. Procedure Except Sterilization and/or D&C) as a low-volume MS-DRG, which, using data from the December 2014
update of the FY 2014 MedPAR file, had more than 10 cases. For this final rule, using
data from the March 2015 update of the FY 2014 MedPAR file, there continue to be 7
MS-DRGs that contain fewer than 10 cases, as reflected in the table below. Under the
MS-DRGs, we have fewer low-volume DRGs than under the CMS DRGs because we no
longer have separate MS-DRGs for patients aged 0 to 17 years. With the exception of
newborns, we previously separated some MS-DRGs based on whether the patient was
age 0 to 17 years or age 17 years and older. Other than the age split, cases grouping to
these MS-DRGs are identical. The MS-DRGs for patients aged 0 to 17 years generally
have very low volumes because children are typically ineligible for Medicare. In the
past, we have found that the low volume of cases for the pediatric MS-DRGs could lead
to significant year-to-year instability in their relative weights. Although we have always
encouraged non-Medicare payers to develop weights applicable to their own patient
populations, we have received frequent complaints from providers about the use of the
Medicare relative weights in the pediatric population. We believe that eliminating this
age split in the MS-DRGs will provide more stable payment for pediatric cases by
determining their payment using adult cases that are much higher in total volume.
Newborns are unique and require separate MS-DRGs that are not mirrored in the adult
population. Therefore, it remains necessary to retain separate MS-DRGs for newborns.
All of the low-volume MS-DRGs listed below are for newborns. For FY 2016, because
we do not have sufficient MedPAR data to set accurate and stable cost relative weights
for the following low-volume MS-DRGs, as we proposed, we computed relative weights
for the low-volume MS-DRGs by adjusting their final FY 2015 relative weights by the
percentage change in the average weight of the cases in other MS-DRGs. The crosswalk table is shown below:

<table>
<thead>
<tr>
<th>Low-Volume MS-DRG</th>
<th>MS-DRG Title</th>
<th>Crosswalk to MS-DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>789</td>
<td>Neonates, Died or Transferred to Another Acute Care Facility</td>
<td>Final FY 2015 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>790</td>
<td>Extreme Immaturity or Respiratory Distress Syndrome, Neonate</td>
<td>Final FY 2015 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>791</td>
<td>Prematurity with Major Problems</td>
<td>Final FY 2015 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>792</td>
<td>Prematurity without Major Problems</td>
<td>Final FY 2015 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>793</td>
<td>Full-Term Neonate with Major Problems</td>
<td>Final FY 2015 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>794</td>
<td>Neonate with Other Significant Problems</td>
<td>Final FY 2015 relative weight (adjusted by percent change in average weight of the cases in other MS DRGs)</td>
</tr>
<tr>
<td>795</td>
<td>Normal Newborn</td>
<td>Final FY 2015 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
</tbody>
</table>
Comment: One commenter stated that the relative weight for MS-DRG 014 (Allogeneic Bone Marrow Transplant) may be understated due to the omission of costs and charges associated with revenue code 0819 which was not included in column 3 of the table of cost report lines and revenue codes on pages 24412 and 24413 of the FY 2016 IPPS/LTCH PPS proposed rule. This commenter also noted that, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24411), CMS removes claims from the relative weight calculation that had an amount in the total charge field that differed by more than $10 from the sum of the routine day charges, intensive care charges, pharmacy charges, special equipment charges, therapy services charges, operating room charges, cardiology charges, laboratory charges, radiology charges, other service charges, labor and delivery charges, inhalation therapy charges, emergency room charges, blood charges, and anesthesia charges. The commenter asserted that if revenue code 0819 is not included in the mapped charges, a difference of greater than $10 would always result on any claim with revenue code 0819, causing the claims with revenue code 0819 to be deleted from the dataset, and the relative weight for MS-DRG 014 to be understated. Another commenter noted that, in response to its question in the past regarding the absence of revenue code 0819 from the cost centers crosswalk table, CMS had indicated that the national Blood and Blood Products CCR is what is used to reduce revenue code 0819 line item charges to costs on inpatient claims. The commenter believed this should be reflected in the table in the final rule so that hospitals are able to use this information to evaluate their internal cost reporting practices. The commenter also mentioned the variability in cost reporting among hospitals related to the Blood and Blood Products cost
centers, and noted that some hospitals report costs and charges related to stem cell transplantation on lines 62 or 63 of the Medicare cost report Form CMS-2552-10, while other hospitals report these costs and charges on line 112, “Other Organ Acquisition”. The commenter asserted that CMS’ use of a cost center group that may have no relation to where and how donor related charges and costs are actually being captured by providers could be one explanation for why the payment rate for MS-DRG 014 does not appropriately account for all donor related costs incurred by providers who perform stem cell transplantations. The commenter expressed hope that, as CMS reviews the use of nonstandard and subscripted cost centers, it also will undertake a review of where and how SCT charges and costs associated with donor related services reported through revenue code 0819 are being accounted for by hospitals in the cost reports. The commenter also was concerned there are no donor source codes in the ICD-10-PCS coding system and urged CMS to address this matter as soon as possible so that provider reporting of donor source codes is not interrupted with the implementation of ICD-10.

Response: Section 90.3.3.A.1 of Chapter 3 of the Medicare Claims Processing Manual states that payment for acquisition services associated with allogeneic stem cell transplants is included in the MS-DRG payment for the allogeneic stem cell transplant when the transplant occurs in the inpatient setting. The MAC will not make separate payment for these acquisition services because hospitals may bill and receive payment only for services provided to a Medicare beneficiary who is the recipient of the stem cell transplant and whose illness is being treated with the stem cell transplant. Unlike the acquisition costs of solid organs for transplant (for example, hearts and kidneys), which
are paid on a reasonable cost basis, acquisition costs for allogeneic stem cells are included in the prospective payment. We note that, in each proposed and final IPPS rule, in the description of the calculation of the MS-DRG relative weights, we state that organ acquisition costs are paid on a reasonable cost basis, and therefore, we deduct the acquisition charges from the total charges on each transplant bill that showed acquisition charges before computing the average cost for each MS-DRG. (We refer readers to the FY 2016 IPPS/LTCH PPS proposed rule 80 FR 24410 through 24411.) Under section 90.3.3.A.2 of the Medicare Claims Processing Manual, hospitals are to identify stem cell acquisition charges for allogeneic bone marrow/stem cell transplants separately by using revenue code 0819 (Other Organ Acquisition).

Accordingly, charges for allogeneic bone marrow transplants are, in fact, included in the MS-DRG relative weights calculation, in the “Blood and Blood Products” CCR. That is, for claims that group into MS-DRG 014, CMS includes the acquisition charges in the blood charges and uses the Blood and Blood Products CCR to adjust those charges to cost. Therefore, contrary to the concern expressed by the first commenter, the relative weight for MS-DRG 014 does reflect costs and charges associated with revenue code 0819, and claims containing revenue code 0819 are not systematically deleted from the dataset. In this final rule and for subsequent rules, we are modifying the crosswalk table for the entry of the Blood and Blood Products cost center group to include revenue code 0819, but we are specifying that only the charges associated with MS-DRG 014 are mapped to the Blood and Blood Products cost center. We are continuing to exclude other 081x revenue codes from the crosswalk table, as these codes are associated with Organ
Acquisition, which are otherwise excluded from the relative weights calculation because, as explained above, organ acquisition costs are paid on a reasonable cost basis and not under the prospective payment rate.

Regarding the comment which stated that some hospitals report costs and charges related to stem cell transplantation on lines 62 or 63 of the Medicare cost report Form CMS-2552-10, while other hospitals report these costs and charges on line 112, “Other Organ Acquisition,” we note that because the charges associated with revenue code 0819 are being mapped by CMS to the Blood and Blood Products cost centers from line 62 (Whole Blood and Packed Red Blood Cells) and line 63 (Blood Storing, Processing, and Transfusions), the appropriate cost centers for hospitals to report the attending costs of allogeneic bone marrow/stem cell transplants are lines 62 and 63 of CMS Form-2552-10. (The cost report instructions for Worksheet A in the Provider Reimbursement Manual (PRM), Part II (Pub. 15-2, Chapter 40, Section 4013, state that hospitals are to include on line 62 “the direct expenses incurred in obtaining blood directly from donors as well as obtaining whole blood, packed red blood cells, and blood derivatives,” and “the processing fee charged by suppliers.” We also note that line 112, along with the other organ transplant lines 105 through 111, are excluded from the calculation of the CCRs and the IPPS relative weights (and therefore are not listed on the crosswalk table). Consequently, any costs related to charges billed under revenue code 0819 that are reported on line 112 would not be captured in the MS-DRG relative weight calculations.

Regarding the commenter’s concern that donor related costs are not being
properly reported on the Medicare cost report, and that CMS should undertake a review of where and how donor related services reported through revenue code 0819 are being accounted for by hospitals on the cost reports, we believe this is related to overall inconsistencies in cost reporting, particularly with nonstandard cost centers, which we discuss in section II.E.2. of this final rule. As we state in response to comments received in that section, we appreciate the comments that stakeholders have submitted and will continue to explore ways in which CMS can improve the accuracy of the cost report data and the calculation of CCRs used in the cost estimation process. To the extent possible, we will continue to seek stakeholder input in an effort to limit the impact on hospitals.

Regarding the commenter’s concerns that there are no donor source codes under ICD-10-PCS, we note that the donor source is an integral part of all transplant and transfusion codes within ICD-10-PCS. Donor source information is captured in the seventh character qualifiers. For example, the root term “Transplantation” provides the following seventh character qualifier values as options to describe donor source: Syngeneic (live related); Allogeneic (live non-related); and Zooplasic (animal). We note that bone marrow transplant procedures are coded to the root operation “Transfusion” as stated in the ICD-10-PCS Reference Manual (which is available on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-PCS-and-GEMs.html). The root term “Transfusion” provides the seventh character qualifier values of Autologous and Nonautologous as options to describe donor source. For specific questions related to coding for transplants and transfusions, we refer readers to the American Hospital Association (AHA). The AHA Central Office™ is the national clearinghouse for medical
coding advice. Coding inquiries may be directed to the following AHA Web site:


Comment: One commenter pointed out that the proposed MS-DRG relative weight for MS-DRG 619 (O.R. Procedures for Obesity with MCC) is 2.8830, which is less than the MS-DRG relative weight for this MS-DRG for FY 2015 of 3.2890. The commenter stated that, while this category represents a small percentage of the total bariatric procedures performed on Medicare beneficiaries, patients with conditions described in this MS-DRG are at the greatest risk for readmission and require the greatest support and coordination of postoperative resources to ensure a safe and efficient recovery, and that providers will be unable to provide such support and resources if payment is so drastically reduced. The commenter asked CMS to reconsider the reduction, and consider an increase of 1.1 percent in the relative weight for MS-DRG 619 in keeping with Hospital IQR Program and meaningful electronic health record (EHR) user incentives. The commenter asked that, for hospitals not participating in the Hospital IQR Program or the EHR Incentive Program, CMS keep the relative weight for MS-DRG 619 neutral.

Response: We note that, while the proposed FY 2016 relative weight for MS-DRG 619 was 2.8830, the final FY 2016 relative weight for MS-DRG 619 is 2.9418 (as reflected in Table 5 associated with this final rule and available on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page.html). While we are sympathetic to the commenter’s concerns, we note that the reduction in the relative
weight from FY 2015 to FY 2016 is a function of the relative weight calculation, as described in section II.H. of the FY 2016 IPPS/LTCH PPS proposed rule and this final rule, which is comprised of hospitals’ billed charges for MS-DRG 619 and the costs reported on hospitals’ cost reports. The reduction in the relative weight may be attributed to the change in the number of cases and average charges for MS-DRG 619 used to develop the relative weight for FY 2015 and the final FY 2016 relative weight.

Specifically, we observed that FY 2015 cases were 896, and FY 2016 cases are 1,037, while FY 2015 average charges were $90,806, and FY 2016 average charges are $84,592.

We are finalizing the methodology for recalibration of the MS-DRG relative weights specified in this final rule for FY 2016 as proposed.

4. Discussion and Acknowledgement of Public Comments Received on Expanding the Bundled Payments for Care Improvement (BPCI) Initiative

a. Background

Since 2011, CMS has been working to develop and test models of bundling Medicare payments under the authority of section 1115A of the Act. Through these models, CMS plans to evaluate whether bundled payments result in higher quality and more coordinated care at a lower cost to Medicare. CMS is currently testing the Bundled Payments for Care Improvement (BPCI) initiative. Under this initiative, organizations enter into payment arrangements that include financial and performance accountability for episodes of care.

The BPCI initiative is comprised of four related payment models, which link payments for multiple services that Medicare beneficiaries receive during an episode of
care into a bundled payment. Episodes of care under the BPCI initiative begin with either (1) an inpatient hospital stay or (2) postacute care services following a qualifying inpatient hospital stay. More information on the four models under the BPCI initiative can be found on the CMS Center for Medicare and Medicaid Innovation’s Web site at: http://innovation.cms.gov/initiatives/bundled-payments/.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24414 through 24418), we presented a discussion of the models in the BPCI initiative and solicited public comments regarding policy and operational issues related to a potential expansion of the BPCI initiative in the future. Section 1115A(c) of the Act, as added by section 3021 of the Affordable Care Act, provides the Secretary with the authority to expand through rulemaking the duration and scope of a model that is being tested under section 1115A(b) of the Act, such as the BPCI initiative (including implementation on a nationwide basis), if the following findings are made, taking into account the evaluation of the model under section 1115A(b)(4) of the Act: (1) the Secretary determines that the expansion is expected to either reduce Medicare spending without reducing the quality of care or improve the quality of patient care without increasing spending; (2) the CMS Chief Actuary certifies that the expansion would reduce (or would not result in any increase in) net Medicare program spending; and (3) the Secretary determines that the expansion would not deny or limit the coverage or provision of Medicare benefits. The decision of whether or not to expand will be made by the Secretary in coordination with CMS and the Office of the Chief Actuary based on whether findings about the initiative meet the statutory criteria for expansion under section 1115A(c) of the Act. Given that further
evaluation of the BPCI initiative is needed to determine its impact on both Medicare cost and quality of care, we did not propose an expansion of any models within the initiative or any policy changes associated with it in the FY 2016 IPPS/LTCH PPS proposed rule.

Consistent with our continuing commitment to engaging stakeholders in CMS’ work, we sought public comments on a variety of issues to broaden and deepen our understanding of the important issues and challenges regarding bundled payments in the current health care marketplace. Among other subject-matter areas, we sought public comments on the scope of any expansion, episode definitions, bundled payment amounts, data needs, and the use of health information technology. In response to our solicitation, we received over 75 timely and informative public comments suggesting matters to consider in a potential future expansion of the BPCI initiative, including the evaluation of the BPCI models, further testing of the BPCI initiative, target pricing methodologies, data collection and reporting, quality measures, episode definitions, payment methodologies, and precedence rules. We appreciate the commenters’ views and recommendations. We will consider the public comments we received if the BPCI initiative is expanded in the future through rulemaking.
I. Add-On Payments for New Services and Technologies for FY 2016

1. Background

Sections 1886(d)(5)(K) and (L) of the Act establish a process of identifying and ensuring adequate payment for new medical services and technologies (sometimes collectively referred to in this section as “new technologies”) under the IPPS. Section 1886(d)(5)(K)(vi) of the Act specifies that a medical service or technology will be considered new if it meets criteria established by the Secretary after notice and opportunity for public comment. Section 1886(d)(5)(K)(ii)(I) of the Act specifies that a new medical service or technology may be considered for new technology add-on payment if, based on the estimated costs incurred with respect to discharges involving such service or technology, the DRG prospective payment rate otherwise applicable to such discharges under this subsection is inadequate. We note that, beginning with discharges occurring in FY 2008, CMS transitioned from CMS-DRGs to MS-DRGs.

The regulations at 42 CFR 412.87 implement these provisions and specify three criteria for a new medical service or technology to receive the additional payment: (1) the medical service or technology must be new; (2) the medical service or technology must be costly such that the DRG rate otherwise applicable to discharges involving the medical service or technology is determined to be inadequate; and (3) the service or technology must demonstrate a substantial clinical improvement over existing services or technologies. Below we highlight some of the major statutory and regulatory provisions relevant to the new technology add-on payment criteria as well as other information. For
a complete discussion on the new technology add-on payment criteria, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51572 through 51574).

Under the first criterion, as reflected in §412.87(b)(2), a specific medical service or technology will be considered “new” for purposes of new medical service or technology add-on payments until such time as Medicare data are available to fully reflect the cost of the technology in the MS-DRG weights through recalibration. We note that we do not consider a service or technology to be new if it is substantially similar to one or more existing technologies. That is, even if a technology receives a new FDA approval, it may not necessarily be considered “new” for purposes of new technology add-on payments if it is “substantially similar” to a technology that was approved by FDA and has been on the market for more than 2 to 3 years. In the FY 2006 IPPS final rule (70 FR 47351) and the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43813 and 43814), we explained our policy regarding substantial similarity in detail.

Under the second criterion, §412.87(b)(3) further provides that, to be eligible for the add-on payment for new medical services or technologies, the MS-DRG prospective payment rate otherwise applicable to the discharge involving the new medical services or technologies must be assessed for adequacy. Under the cost criterion, consistent with the formula specified in section 1886(d)(5)(K)(ii)(I) of the Act, to assess the adequacy of payment for a new technology paid under the applicable MS-DRG prospective payment rate, we evaluate whether the charges for cases involving the new technology exceed certain threshold amounts. We update the thresholds in Table 10 of each final rule that apply for the upcoming fiscal year. Table 10 that was released with the FY 2015
IPPS/LTCH PPS final rule contains the final thresholds that we used to evaluate applications for new medical service and new technology add-on payments for FY 2016.


In the September 7, 2001 final rule that established the new technology add-on payment regulations (66 FR 46917), we discussed the issue of whether the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule at 45 CFR Parts 160 and 164 applies to claims information that providers submit with applications for new medical service and new technology add-on payments. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51573) for complete information on this issue.

Under the third criterion, § 412.87(b)(1) of our existing regulations provides that a new technology is an appropriate candidate for an additional payment when it represents an advance that substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries. For example, a new technology represents a substantial clinical improvement when it reduces mortality, decreases the number of hospitalizations or physician visits, or reduces recovery time compared to the technologies previously available. (We refer readers to the September 7, 2001 final rule for a more detailed discussion of this criterion (66 FR 46902).)

The new medical service or technology add-on payment policy under the IPPS provides additional payments for cases with relatively high costs involving eligible new medical services or technologies while preserving some of the incentives inherent under
an average-based prospective payment system. The payment mechanism is based on the cost to hospitals for the new medical service or technology. Under § 412.88, if the costs of the discharge (determined by applying cost-to-charge ratios (CCRs) as described in § 412.84(h)) exceed the full DRG payment (including payments for IME and DSH, but excluding outlier payments), Medicare will make an add-on payment equal to the lesser of: (1) 50 percent of the estimated costs of the new technology or medical service (if the estimated costs for the case including the new technology or medical service exceed Medicare’s payment); or (2) 50 percent of the difference between the full DRG payment and the hospital’s estimated cost for the case. Unless the discharge qualifies for an outlier payment, the additional Medicare payment is limited to the full MS-DRG payment plus 50 percent of the estimated costs of the new technology or new medical service.

Section 503(d)(2) of Pub. L. 108-173 provides that there shall be no reduction or adjustment in aggregate payments under the IPPS due to add-on payments for new medical services and technologies. Therefore, in accordance with section 503(d)(2) of Pub. L. 108-173, add-on payments for new medical services or technologies for FY 2005 and later years have not been subjected to budget neutrality.

In the FY 2009 IPPS final rule (73 FR 48561 through 48563), we modified our regulations at § 412.87 to codify our longstanding practice of how CMS evaluates the eligibility criteria for new medical service or technology add-on payment applications. That is, we first determine whether a medical service or technology meets the newness criterion, and only if so, do we then make a determination as to whether the technology meets the cost threshold and represents a substantial clinical improvement over existing
medical services or technologies. We amended § 412.87(c) to specify that all applicants for new technology add-on payments must have FDA approval or clearance for their new medical service or technology by July 1 of each year prior to the beginning of the fiscal year that the application is being considered.

The Council on Technology and Innovation (CTI) at CMS oversees the agency’s cross-cutting priority on coordinating coverage, coding and payment processes for Medicare with respect to new technologies and procedures, including new drug therapies, as well as promoting the exchange of information on new technologies and medical services between CMS and other entities. The CTI, composed of senior CMS staff and clinicians, was established under section 942(a) of Pub. L. 108-173. The Council is co-chaired by the Director of the Center for Clinical Standards and Quality (CCSQ) and the Director of the Center for Medicare (CM), who is also designated as the CTI’s Executive Coordinator.

The specific processes for coverage, coding, and payment are implemented by CM, CCSQ, and the local claims-payment contractors (in the case of local coverage and payment decisions). The CTI supplements, rather than replaces, these processes by working to assure that all of these activities reflect the agency-wide priority to promote high-quality, innovative care. At the same time, the CTI also works to streamline, accelerate, and improve coordination of these processes to ensure that they remain up to date as new issues arise. To achieve its goals, the CTI works to streamline and create a more transparent coding and payment process, improve the quality of medical decisions, and speed patient access to effective new treatments. It is also dedicated to supporting
better decisions by patients and doctors in using Medicare-covered services through the promotion of better evidence development, which is critical for improving the quality of care for Medicare beneficiaries.

To improve the understanding of CMS’ processes for coverage, coding, and payment and how to access them, the CTI has developed an “Innovator’s Guide” to these processes. The intent is to consolidate this information, much of which is already available in a variety of CMS documents and in various places on the CMS Web site, in a user-friendly format. This guide was published in 2010 and is available on the CMS Web site at:


As we indicated in the FY 2009 IPPS final rule (73 FR 48554), we invite any product developers or manufacturers of new medical services or technologies to contact the agency early in the process of product development if they have questions or concerns about the evidence that would be needed later in the development process for the agency's coverage decisions for Medicare.

The CTI aims to provide useful information on its activities and initiatives to stakeholders, including Medicare beneficiaries, advocates, medical product manufacturers, providers, and health policy experts. Stakeholders with further questions about Medicare’s coverage, coding, and payment processes, or who want further guidance about how they can navigate these processes, can contact the CTI at CTI@cms.hhs.gov.
We note that applicants for add-on payments for new medical services or technologies for FY 2017 must submit a formal request, including a full description of the clinical applications of the medical service or technology and the results of any clinical evaluations demonstrating that the new medical service or technology represents a substantial clinical improvement, along with a significant sample of data to demonstrate that the medical service or technology meets the high-cost threshold. Complete application information, along with final deadlines for submitting a full application, will be posted as it becomes available on the CMS Web site at:

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-
Payment/AcuteInpatientPPS/newtech.html. To allow interested parties to identify the new medical services or technologies under review before the publication of the proposed rule for FY 2017, the CMS Web site also will post the tracking forms completed by each applicant.

2. Public Input Before Publication of a Notice of Proposed Rulemaking on Add-On Payments

Section 1886(d)(5)(K)(viii) of the Act, as amended by section 503(b)(2) of Pub. L. 108-173, provides for a mechanism for public input before publication of a notice of proposed rulemaking regarding whether a medical service or technology represents a substantial clinical improvement or advancement. The process for evaluating new medical service and technology applications requires the Secretary to--
● Provide, before publication of a proposed rule, for public input regarding whether a new service or technology represents an advance in medical technology that substantially improves the diagnosis or treatment of Medicare beneficiaries;

● Make public and periodically update a list of the services and technologies for which applications for add-on payments are pending;

● Accept comments, recommendations, and data from the public regarding whether a service or technology represents a substantial clinical improvement; and

● Provide, before publication of a proposed rule, for a meeting at which organizations representing hospitals, physicians, manufacturers, and any other interested party may present comments, recommendations, and data regarding whether a new medical service or technology represents a substantial clinical improvement to the clinical staff of CMS.

In order to provide an opportunity for public input regarding add-on payments for new medical services and technologies for FY 2016 prior to publication of the FY 2016 IPPS/LTCH PPS proposed rule, we published a notice in the Federal Register on November 21, 2014 (79 FR 69490), and held a town hall meeting at the CMS Headquarters Office in Baltimore, MD, on February 3, 2015. In the announcement notice for the meeting, we stated that the opinions and alternatives provided during the meeting would assist us in our evaluations of applications by allowing public discussion of the substantial clinical improvement criterion for each of the FY 2016 new medical service and technology add-on payment applications before the publication of the FY 2016 IPPS/LTCH PPS proposed rule.
Approximately 95 individuals registered to attend the town hall meeting in person, while additional individuals listened over an open telephone line. We also live-streamed the town hall meeting and posted the town hall on the CMS YouTube Web page at: https://www.youtube.com/watch?v=dn-R5KGQu-M. We considered each applicant’s presentation made at the town hall meeting, as well as written comments submitted on the applications that were received by the due date of January 19, 2015, in our evaluation of the new technology add-on payment applications for FY 2016 in the proposed rule.

In response to the published notice and the New Technology Town Hall meeting, we received written comments regarding the applications for FY 2016 new technology add-on payments. We summarized these comments in the preamble of the proposed rule or, if applicable, indicated that there were no comments received, at the end of each discussion of the individual applications in the proposed rule. We are not reprinting those summations in this final rule and refer readers to the FY 2016 IPPS/LTCH PPS proposed rule for this discussion.

We also received public comments in response to the proposed rule relating to topics such as marginal cost factors for new technology add-on payments, mapping new technologies to the appropriate MS-DRG, additional criteria for substantial clinical improvement, and changing the newness criterion. Because we did not request public comments nor propose to make any changes to any of the issues above, we are not summarizing these public comments nor responding to them in this final rule.
Comment: One commenter stated that it is not appropriate for CMS to continue to add requirements or to impose standards that exceed realistic requirements for clinical trials. The commenter cited the WATCHMAN® System as an example where CMS suggested that substantial clinical improvement should be based on a superiority trial rather than the noninferiority trial that was used.

Response: We received a similar public comment last year and responded to it in the FY 2015 IPPS/LTCH PPS final rule. We refer the readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 49925 through 49926) for a complete response to this issue.

3. Implementation of ICD-10-PCS Section “X” Codes for Certain New Medical Services and Technologies for FY 2016

As discussed in section II.G.1.a. of the preamble of this final rule, HIPAA covered entities are required, as of October 1, 2015, to use the ICD-10 coding system (ICD-10-PCS codes for procedures and ICD-10-CM codes for diagnosis), instead of the ICD-9-CM coding system, to report diagnoses and procedures for Medicare hospital inpatient services provided to Medicare beneficiaries as classified under the MS-DRG system and paid for under the IPPS. HIPAA covered entities must continue to use ICD-9-CM codes and coding guidelines through September 30, 2015. We refer readers to section II.G.1.a. of the preamble of this final rule for a complete discussion of the adoption of the ICD-10 coding system.

As part of the transition to the ICD-10-CM/PCS coding system, at the September 23-24, 2014 ICD-10 Coordination and Maintenance Committee meeting,
CMS received a request to create a new section within the ICD-10-PCS to capture new medical services and technologies that might not appropriately align with the current structure of the ICD-10-PCS codes. Examples of these types of new medical services and technologies included drugs, biologicals, and newer medical devices being tested in clinical trials that are not currently captured within the ICD-9-CM or the ICD-10-PCS. The requestor indicated that there may be a need to identify and report these technologies and inpatient services for purposes of approving new technology add-on payment applications and initiating subsequent new technology add-on payments based on approval or tracking and analyzing the use of these new technologies and services.

Although several commenters have opposed including these types of technologies and services within the current structure of the ICD-10-PCS codes during past ICD-10 Coordination and Maintenance Committee meetings, as well as in public comments, CMS has evaluated these suggestions and considered them to be valid. As a result, CMS has created a new component within the ICD-10-PCS codes, labeled Section “X” codes, to identify and describe these new technologies and services. The new Section “X” codes identify new medical services and technologies that are not usually captured by coders, or that do not usually have the desired specificity within the current ICD-10-PCS structure required to capture the use of these new services and technologies. As mentioned earlier, examples of these types of services and technologies include specific drugs, biologicals, and newer medical devices being tested in clinical trials. The new Section “X” codes within the ICD-10-PCS structure will be implemented on October 1, 2015, and will be used to identify new technologies and medical services approved under the new
technology add-on payment policy for payment purposes beginning October 1, 2015. The Section “X” codes also will be used to identify procedures or services that are not commonly captured within the definitions and descriptions included in most coding systems or procedures or services that require definitions and descriptions that contain greater detail or specificity, which may be needed for a variety of health care data needs.

An overview of Section “X” codes was provided at the March 18-19, 2015 ICD-10 Coordination and Maintenance Committee meeting. We also have posted an article on the CMS Web site that explains the creation and use of ICD-10-PCS Section “X” codes. This article can be found on the CMS 2016 ICD-10-PCS and GEMs Web site at http://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-PCS-and-GEMs.html.

Further information regarding the new Section “X” codes and their use within the ICD-10-PCS can be found on the CMS Web site at:


In addition, on June 18, 2015, CMS held a National ICD-10 Teleconference (Preparing for Implementation and New ICD-10-PCS Section “X” MLN Connects National Provider Call) to explain the Section “X” codes under the ICD-10. The agenda, slides, and audio from this teleconference are posted on the CMS Web site at:

As stated earlier, the ICD-10-PCS includes a new section containing the new Section “X” codes, which will be used beginning with discharges occurring on or after October 1, 2015. Decisions regarding changes to ICD-10-PCS Section “X” codes will be handled in the same manner as the decisions for all of the other ICD-10-PCS code changes. That is, proposals to create, delete, or revise Section “X” codes under the ICD-10-PCS structure will be referred to the ICD-10 Coordination and Maintenance Committee. In addition, several of the new medical services and technologies that have been, or may be, approved for new technology add-on payments may now, and in the future, be assigned a Section “X” code within the structure of the ICD-10-PCS. The FY 2016 ICD-10-PCS, which includes the new Section “X” codes, was posted in June 2015 via the Internet on the CMS Web site at:

http://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-PCS-and-GEMs.html. We also posted the FY 2016 ICD-10-PCS Guidelines on this CMS Web site that also includes guidelines for ICD-10-PCS “X” codes. We encourage providers to view the material provided on ICD-10-PCS Section “X” codes.

Comment: Several commenters supported the creation of the new ICD-10-PCS Section “X” codes as a means to more specifically identify new technologies or more precise information about certain services. The commenters recognized the challenges of maintaining a partial code freeze while at the same time finding a way to capture new procedures. One commenter who supported the creation of the new Section “X” codes to identify new medical services and technologies stated that it was important to have a
more robust coding system that will allow for recognition of more technologies, procedures, and variations in patients’ conditions.

Another commenter recognized the need to conserve code values within the regular ICD-10-PCS sections, as well as the exponential effect that adding a new value has on the large number of codes, and noted the importance of using Section “X” codes specifically for certain types of new technologies. The commenter stated that Section “X” codes are especially important to identify drugs and intraoperative supplies related to MS-DRG new technology add-on payments.

Response: We appreciate the commenters’ support.

Comment: Several commenters expressed concern that payers may mistakenly consider ICD-10-PCS Section “X” codes as interchangeable with CPT Category III codes. The commenters stated that, although CPT Category III codes also represent emerging technologies, the technologies lack substantive support in professional literature, and the codes used for these technologies often describe noncovered procedures that are experimental or investigational. In contrast, the commenter recognized that ICD-10-PCS Section “X” codes describe new technologies or services that frequently are FDA approved. However, the commenters asked that CMS clarify that ICD-10-PCS Section “X” codes will not be used to specifically identify experimental or unproven procedures.

Response: Section “X” codes were created to more specifically identify new technologies, procedures that have historically not been captured through ICD-9-CM codes, or to more precisely describe information on a specific procedure or technology
than is found with the other sections of ICD-10-PCS. Section “X” codes were not created, nor intended to be used, to identify experimental or investigational procedures.

Comment: Several commenters expressed concerns about the decision to create new codes during the partial code freeze, in particular the creation of the ICD-10-PCS Section “X” during the partial code freeze. The commenters believed that it would be more appropriate to delay the implementation of this section of the ICD-10-PCS and the use of Section “X” codes until after the ICD-10 coding system is implemented and the partial code freeze ends. The commenters also requested clarifications on how the new Section “X” codes would be used.

Response: We acknowledge that it has been a challenge for CMS to implement the ICD-10-PCS/CM coding system, particularly in light of the partial code freeze and several delays of the implementation of ICD-10. However, the partial code freeze has allowed sufficient time and the ability to capture new technologies or new medical services under the new coding system. Many participants at the ICD-10 Coordination and Maintenance Committee have voiced opposition to the creation of any new codes during the partial code freeze. Other participants have actively encouraged the creation of more code updates beyond those that capture new technologies or new medical services. We have given consideration to all of the public comments presented at the ICD-10 Coordination and Maintenance Committee meetings and have attempted to make updates to the ICD-10-CM/PCS in a manner that is most appropriate and results in less burden on the majority of users. Any updates to ICD-10-CM/PCS, including updates to the Section “X” codes, will be presented at future ICD-10 Coordination and Maintenance
Committee meetings for public comments. For those individuals who are interested in participating in future ICD-10 Coordination and Maintenance Committee meetings, information on the Committee can be found on the CMS Website at:
http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnos ticCodes/meetings.html.

We encourage public participation at these meetings either in person, by conference lines, or by the livestream provided by CMS. As discussed earlier, CMS has posted the FY 2016 ICD-10-PCS guidelines, which include guidelines on the use of Section “X” codes and an article explaining why ICD-10-PCS Section “X” codes were created and how to use them on the CMS Website. We believe that this detailed information will assist coders in using the new Section “X” codes.

4. FY 2016 Status of Technologies Approved for FY 2015 Add-On Payments

a. Glucarpidase (Voraxaze®)

BTG International, Inc. submitted an application for new technology add-on payments for Glucarpidase (Voraxaze®) for FY 2013. Glucarpidase is used in the treatment of patients who have been diagnosed with toxic methotrexate (MTX) concentrations as a result of renal impairment. The administration of Glucarpidase causes a rapid and sustained reduction of toxic MTX concentrations.

Voraxaze® was approved by the FDA on January 17, 2012. Beginning in 1993, certain patients could obtain expanded access for treatment use to Voraxaze® as an investigational drug. Since 2007, the applicant has been authorized to recover the costs of making Voraxaze® available through its expanded access program. We describe expanded access for treatment use of investigational drugs and authorization to recover
certain costs of investigational drugs in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53346 through 53350). Voraxaze® was available on the market in the United States as a commercial product to the larger population as of April 30, 2012. In the FY 2013 IPPS/LTCH PPS proposed rule (77 FR 27936 through 27939), we expressed concerns about whether Voraxaze® could be considered new for FY 2013. After consideration of all of the public comments received, in the FY 2013 IPPS/LTCH PPS final rule, we stated that we considered Voraxaze® to be “new” as of April 30, 2012, which is the date of U.S. market availability.

After evaluation of the newness, costs, and substantial clinical improvement criteria for new technology payments for Voraxaze® and consideration of the public comments we received in response to the FY 2013 IPPS/LTCH PPS proposed rule, we approved Voraxaze® for new technology add-on payments for FY 2013. Cases of Voraxaze® are identified with ICD-9-CM procedure code 00.95 (Injection or infusion of glucarpidase). As stated in the FY 2015 IPPS/LTCH PPS final rule correction notice (79 FR 59679), the cost of Voraxaze® is $23,625 per vial. The applicant stated that an average of four vials is used per Medicare beneficiary. Therefore, the average cost per case for Voraxaze® is $94,500 ($23,625 x 4). Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the technology or 50 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum new technology add-on payment for Voraxaze® is $47,250 per case.
As stated above, the new technology add-on payment regulations provide that a medical service or technology may be considered new within 2 or 3 years after the point at which data begin to become available reflecting the ICD-9-CM code assigned to the new service or technology (§ 412.87(b)(2)). Our practice has been to begin and end new technology add-on payments on the basis of a fiscal year, and we have generally followed a guideline that uses a 6-month window before and after the start of the fiscal year to determine whether to extend the new technology add-on payment for an additional fiscal year. In general, we extend add-on payments for an additional year only if the 3-year anniversary date of the product’s entry on the market occurs in the latter half of the fiscal year (70 FR 47362).

With regard to the newness criterion for Voraxaze®, we considered the beginning of the newness period to commence when Voraxaze® was first made available on the U.S. market on April 30, 2012. Because the 3-year anniversary date for Voraxaze® occurred in the latter half of FY 2015 (April 30, 2015), in the FY 2015 IPPS/LTCH PPS final rule, we continued new technology add-on payments for this technology for FY 2015 (79 FR 49918). However, for FY 2016, the 3-year anniversary date of the product’s entry on the U.S. market (April 30, 2015) occurred prior to the beginning of FY 2016. Therefore, we proposed to discontinue new technology add-on payments for Voraxaze® for FY 2016. We invited public comments on this proposal.

Comment: One commenter supported CMS’ proposal to discontinue new technology add-on payments for Voraxaze® for FY 2016.

Response: We appreciate the commenter’s support.
After consideration of the public comments we received, we are discontinuing new technology add-on payments for Voraxaze® for FY 2016. The 3-year anniversary date of the product’s entry onto the U.S. market occurred prior to the beginning of FY 2016 and, therefore, the technology will no longer be eligible for new technology add-on payments because the technology will no longer meet the “newness” criterion.

b. Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft

Cook® Medical submitted an application for new technology add-on payments for the Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft (Zenith® F. Graft) for FY 2013. The applicant stated that the current treatment for patients who have had an AAA is an endovascular graft. The applicant explained that the Zenith® F. Graft is an implantable device designed to treat patients who have an AAA and who are anatomically unsuitable for treatment with currently approved AAA endovascular grafts because of the length of the infrarenal aortic neck. The applicant noted that, currently, an AAA is treated through an open surgical repair or medical management for those patients not eligible for currently approved AAA endovascular grafts.

With respect to newness, the applicant stated that FDA approval for the use of the Zenith® F. Graft was granted on April 4, 2012. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53360 through 53365), we stated that because the Zenith® F. Graft was approved by the FDA on April 4, 2012, we believed that the Zenith® F. Graft met the newness criterion as of that date.
After evaluation of the newness, costs, and substantial clinical improvement criteria for new technology add-on payments for the Zenith® F. Graft and consideration of the public comments we received in response to the FY 2013 IPPS/LTCH PPS proposed rule, we approved the Zenith® F. Graft for new technology add-on payments for FY 2013. Cases involving the Zenith® F. Graft that are eligible for new technology add-on payments currently are identified by ICD-9-CM procedure code 39.78 (Endovascular implantation of branching or fenestrated graft(s) in aorta). In the application, the applicant provided a breakdown of the costs of the Zenith® F. Graft. The total cost of the Zenith® F. Graft utilizing bare metal (renal) alignment stents was $17,264. Of the $17,264 in costs for the Zenith® F. Graft, $921 is for components that are used in a standard Zenith AAA Endovascular Graft procedure. Because the costs for these components are already reflected within the MS-DRGs (and are no longer “new”), in the FY 2013 IPPS/LTCH PPS final rule, we stated that we did not believe it is appropriate to include these costs in our calculation of the maximum cost to determine the maximum add-on payment for the Zenith® F. Graft. Therefore, the total maximum cost for the Zenith® F. Graft is $16,343 ($17,264 - $921). Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum add-on payment for a case involving the Zenith® F. Graft is $8,171.50.

With regard to the newness criterion for the Zenith® F. Graft, we considered the beginning of the newness period to commence when the Zenith® F. Graft was approved
by the FDA on April 4, 2012. Because the 3-year anniversary date of the entry of the Zenith® F. Graft on the U.S. market occurred in the second half of FY 2015 (April 4, 2015), in the FY 2015 IPPS/LTCH PPS final rule, we continued new technology add-on payments for this technology for FY 2015 (79 FR 49922). However, for FY 2016, the 3-year anniversary date of the product’s entry on the U.S. market (April 4, 2015) occurred prior to the beginning of FY 2016. Therefore, we proposed to discontinue new technology add-on payments for the Zenith® F. Graft for FY 2016. We invited public comments on this proposal.

We did not receive any public comments on our proposal. Therefore, as we proposed, we are discontinuing new technology add-on payments for the Zenith® F. Graft technology for FY 2016. The 3-year anniversary of the product’s entry onto the U.S. market occurred prior to the beginning of FY 2016 and, therefore, the technology is not eligible for new technology add-on payments for FY 2016 because the technology will no longer meet “newness” criterion.

c. Kcentra™

CSL Behring submitted an application for new technology add-on payments for Kcentra™ for FY 2014. Kcentra™ is a replacement therapy for fresh frozen plasma (FFP) for patients with an acquired coagulation factor deficiency due to warfarin and who are experiencing a severe bleed. Kcentra™ contains the Vitamin K dependent coagulation factors II, VII, IX and X, together known as the prothrombin complex, and antithrombotic proteins C and S. Factor IX is the lead factor for the potency of the preparation. The product is a heat-treated, non-activated, virus filtered and lyophilized
plasma protein concentrate made from pooled human plasma. Kcentra™ is available as a lyophilized powder that needs to be reconstituted with sterile water prior to administration via intravenous infusion. The product is dosed based on Factor IX units. Concurrent Vitamin K treatment is recommended to maintain blood clotting factor levels once the effects of Kcentra™ have diminished.

Kcentra™ was approved by the FDA on April 29, 2013. In the FY 2014 IPPS/LTCH PPS final rule, we finalized new ICD-9-CM procedure code 00.96 (Infusion of 4-Factor Prothrombin Complex Concentrate) which uniquely identifies Kcentra™.

In the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27538), we noted that we were concerned that Kcentra™ may be substantially similar to FFP and/or Vitamin K therapy. In the FY 2014 IPPS/LTCH PPS final rule, in response to comments submitted by the manufacturer, we stated that we agree that Kcentra™ may be used in a patient population that is experiencing an acquired coagulation factor deficiency due to Warfarin and who are experiencing a severe bleed currently but are ineligible for FFP, particularly for use by IgA deficient patients and other patient populations that have no other treatment option to resolve severe bleeding in the context of an acquired Vitamin K deficiency. In addition, FFP is limited because it requires special storage conditions while Kcentra™ is stable for up to 36 months at room temperature thus allowing hospitals that otherwise would not have access to FFP (for example, small rural hospitals as discussed by the applicant in its comments) to keep a supply of Kcentra™ and treat patients who would possibly have no access to FFP. We noted that FFP is considered perishable and can be scarce by nature (due to production and other market limitations)
thus making some hospitals unable to store FFP, which limits access to certain patient populations in certain locations. Therefore, we stated that we believe that Kcentra™ provides a therapeutic option for a new patient population and is not substantially similar to FFP. Also, we gave credence to the information presented by the manufacturer that Kcentra™ provides a simple and rapid repletion relative to FFP and reduces the risk of a transfusion reaction relative to FFP because it does not contain ABO antibodies and does not require ABO typing. As a result, we concluded that Kcentra™ is not substantially similar to FFP, and that it meets the newness criterion.

After evaluation of the newness, cost, and substantial clinical improvement criteria for new technology add-on payments for Kcentra™ and consideration of the public comments we received in response to the FY 2014 IPPS/LTCH PPS proposed rule, we approved Kcentra™ for new technology add-on payments for FY 2014 (78 FR 50575 through 50580). Cases involving Kcentra™ that are eligible for new technology add-on payments currently are identified by ICD-9-CM procedure code 00.96. In the application, the applicant estimated that the average Medicare beneficiary would require an average dosage of 2500 International Units (IU). Vials contain 500 IU at a cost of $635 per vial. Therefore, cases of Kcentra™ would incur an average cost per case of $3,175 ($635 x 5). Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the technology or 50 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum add-on payment for a case of Kcentra™ was $1,587.50 for FY 2014.
In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50579), we stated that new technology add-on payments for Kcentra™ would not be available with respect to discharges for which the hospital received an add-on payment for a blood clotting factor administered to a Medicare beneficiary with hemophilia who is a hospital inpatient. Under section 1886(d)(1)(A)(iii) of the Act, the national adjusted DRG prospective payment rate is the amount of the payment with respect to the operating costs of inpatient hospital services (as defined in subsection (a)(4)) for discharges on or after April 1, 1988. Section 1886(a)(4) of the Act excludes from the term “operating costs of inpatient hospital services” the costs with respect to administering blood clotting factors to individuals with hemophilia. The costs of administering a blood clotting factor to a Medicare beneficiary who has hemophilia and is a hospital inpatient are paid separately from the IPPS. (For information on how the blood clotting factor add-on payment is made, we refer readers to Section 20.7.3, Chapter 3, of the Medicare Claims Processing Manual, which can be downloaded from the CMS Web site at: http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c03.pdf.) In addition, we stated that if Kcentra™ is approved by the FDA as a blood clotting factor, we believed that it may be eligible for blood clotting factor add-on payments when administered to Medicare beneficiaries with hemophilia. We make an add-on payment for Kcentra™ for such discharges in accordance with our policy for payment of a blood clotting factor, and the costs would be excluded from the operating costs of inpatient hospital services as set forth in section 1886(a)(4) of the Act.
Section 1886(d)(5)(K)(i) of the Act requires the Secretary to establish a mechanism to recognize the costs of new medical services and technologies under the payment system established under this subsection beginning with discharges on or after October 1, 2001. We believe that it is reasonable to interpret this requirement to mean that the payment mechanism established by the Secretary recognizes only costs for those items that would otherwise be paid based on the prospective payment system (that is, “the payment system established under this subsection”). As noted above, under section 1886(d)(1)(A)(iii) of the Act, the national adjusted DRG prospective payment rate is the amount of payment for the operating costs of inpatient hospital services, as defined in section 1886(a)(4) of the Act, for discharges on or after April 1, 1988. We understand this to mean that a new medical service or technology must be an operating cost of inpatient hospital services paid based on the prospective payment system, and not excluded from such costs, in order to be eligible for the new technology add-on payment. We pointed out that new technology add-on payments are based on the operating costs per case relative to the prospective payment rate as described in § 412.88. Therefore, we believe that new technology add-on payments are appropriate only when the new technology is an operating cost of inpatient hospital services and are not appropriate when the new technology is excluded from such costs.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50579), we stated that we believe that hospitals may only receive new technology add-on payments for discharges where Kcentra™ is an operating cost of inpatient hospital services. In other words, a hospital would not be eligible to receive the new technology add-on payment when it is
administering Kcentra™ in treating a Medicare beneficiary who has hemophilia. In those instances, Kcentra™ is specifically excluded from the operating costs of inpatient hospital services in accordance with section 1886(a)(4) of the Act and paid separately from the IPPS. However, when a hospital administers Kcentra™ to a Medicare beneficiary who does not have hemophilia, the hospital would be eligible for a new technology add-on payment because Kcentra™ would not be excluded from the operating costs of inpatient hospital services. Therefore, discharges where the hospital receives a blood clotting factor add-on payment are not eligible for a new technology add-on payment for the blood clotting factor. We refer readers to Section 20.7.3, Chapter 3, of the Medicare Claims Processing Manual for a complete discussion on when a blood clotting factor add-on payment is made. The manual can be downloaded from the CMS Web site at: http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c03.pdf.

With regard to the newness criterion for Kcentra™, we considered the beginning of the newness period to commence when Kcentra™ was approved by the FDA on April 29, 2013. Because the 3-year anniversary date of the entry of Kcentra™ on the U.S. market will occur in the second half of FY 2016 (April 29, 2016), we proposed to continue new technology add-on payments for this technology for FY 2016.

Because we are adopting the ICD-10 coding system effective October 1, 2015, for FY 2016, we proposed to identify and make new technology add-on payments for cases involving Kcentra™ with ICD 10 PCS procedure code 30283B1 (Transfusion of nonautologous 4-factor prothrombin complex concentrate into vein, percutaneous
We stated that the maximum new technology add-on payment for a case involving the Kcentra™ technology would remain at $1,587.50 for FY 2016.

We invited public comments on these proposals.

**Comment:** One commenter supported CMS’ proposal to continue new technology add-on payments for Kcentra™ for FY 2016.

**Response:** We appreciate the commenter’s support.

We did not receive any public comments on the coding and payment for Kcentra™ for FY 2016.

After consideration of the public comments we received, we are finalizing our proposal to continue new technology add-on payments for the Kcentra™ technology for FY 2016. Because we are adopting the ICD-10 coding system effective October 1, 2015, for FY 2016, as we proposed, we will identify and make new technology add-on payments for cases involving Kcentra™ with the presence of ICD-10-PCS procedure code 30283B1 (Transfusion of nonautologous 4-factor prothrombin complex concentrate into vein, percutaneous approach). New technology add-on payments for Kcentra™ will not be available with respect to discharges for which the hospital received an add-on payment for a blood clotting factor administered to a Medicare beneficiary with hemophilia who is a hospital inpatient. For information on how the blood clotting factor add-on payment is made (including a list of ICD-10 diagnosis codes that would negate the eligibility of a case for new technology add-on payments, if reported in combination with the ICD-10 procedure code used to identify cases involving the Kcentra™ technology), we refer readers to Section 20.7.3, Chapter 3, of the Medicare Claims
Processing Manual, which is available via the Internet on the CMS Web site at:

The maximum new technology add-on payment for a case involving the Kcentra™ technology will remain at $1,587.50 for FY 2016.

d. Argus® II Retinal Prosthesis System

Second Sight Medical Products, Inc. submitted an application for new technology add-on payments for the Argus® II Retinal Prosthesis System (Argus® II System) for FY 2014. The Argus® II System is an active implantable medical device that is intended to provide electrical stimulation of the retina to induce visual perception in patients who are profoundly blind due to retinitis pigmentosa (RP). These patients have bare or no light perception in both eyes. The system employs electrical signals to bypass dead photo-receptor cells and stimulate the overlying neurons according to a real-time video signal that is wirelessly transmitted from an externally worn video camera. The Argus® II implant is intended to be implanted in a single eye, typically the worse-seeing eye. Currently, bilateral implants are not intended for this technology. According to the applicant, the surgical implant procedure takes approximately 4 hours and is performed under general anesthesia.

The Argus® II System consists of three primary components: (1) an implant which is an epiretinal prosthesis that is fully implanted on and in the eye (that is, there are no percutaneous leads); (2) external components worn by the user; and (3) a “fitting” system for the clinician that is periodically used to perform diagnostic tests with the
system and to custom-program the external unit for use by the patient. We describe these components more fully below.

- **Implant**: The retinal prosthesis implant is responsible for receiving information from the external components of the system and electrically stimulating the retina to induce visual perception. The retinal implant consists of: (a) a receiving coil for receiving information and power from the external components of the Argus® II System; (b) electronics to drive stimulation of the electrodes; and (c) an electrode array. The receiving coil and electronics are secured to the outside of the eye using a standard scleral band and sutures, while the electrode array is secured to the surface of the retina inside the eye by a retinal tack. A cable, which passes through the eye wall, connects the electronics to the electrode array. A pericardial graft is placed over the extra-ocular portion on the outside of the eye.

- **External Components**: The implant receives power and data commands wirelessly from an external unit of components, which include the Argus II Glasses and Video Processing Unit (VPU). A small lightweight video camera and transmitting coil are mounted on the glasses. The telemetry coils and radio-frequency system are mounted on the temple arm of the glasses for transmitting data from the VPU to the implant. The glasses are connected to the VPU by a cable. This VPU is worn by the patient, typically on a belt or a strap, and is used to process the images from the video camera and convert the images into electrical stimulation commands, which are transmitted wirelessly to the implant.
"Fitting System": To be able to use the Argus® II System, a patient’s VPU needs to be custom-programmed. This process, which the applicant called “fitting”, occurs in the hospital/clinic shortly after the implant surgery and then periodically thereafter as needed. The clinician/physician also uses the “Fitting System” to run diagnostic tests (for example, to obtain electrode and impedance waveform measurements or to check the radio-frequency link between the implant and external unit). This “Fitting System” can also be connected to a “Psychophysical Test System” to evaluate patients’ performance with the Argus® II System on an ongoing basis.

These three components work together to stimulate the retina and allow a patient to perceive phosphenes (spots of light), which they then need to learn to interpret. While using the Argus® II System, the video camera on the patient-worn glasses captures a video image. The video camera signal is sent to the VPU, which processes the video camera image and transforms it into electrical stimulation patterns. The electrical stimulation data are then sent to a transmitter coil mounted on the glasses. The transmitter coil sends both data and power via radio-frequency (RF) telemetry to the implanted retinal prosthesis. The implant receives the RF commands and delivers stimulation to the retina via an array of electrodes that is secured to the retina with a retinal tack.

In patients with RP, the photoreceptor cells in the retina, which normally transduce incoming light into an electro-chemical signal, have lost most of their function. The stimulation pulses delivered to the retina via the electrode array of the Argus® II System are intended to mimic the function of these degenerated photoreceptors cells.
These pulses induce cellular responses in the remaining, viable retinal nerve cells that travel through the optic nerve to the visual cortex where they are perceived as phosphenes (spots of light). Patients learn to interpret the visual patterns produced by these phosphenes.

With respect to the newness criterion, according to the applicant, the FDA designated the Argus® II System a Humanitarian Use Device in May 2009 (HUD designation #09-0216). The applicant submitted a Humanitarian Device Exemption (HDE) application (#H110002) to the FDA in May 2011 to obtain market approval for the Argus® II System. The HDE was referred to the Ophthalmic Devices Panel of the FDA’s Medical Devices Advisory Committee for review and recommendation. At the Panel’s meeting held on September 28, 2012, the Panel voted 19 to 0 that the probable benefits of the Argus® II System outweigh the risks of the system for the proposed indication for use. The applicant received the HDE approval from the FDA on February 14, 2013. However, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49924 through 49925), we discussed comments we had received informing CMS that the Argus® II System was not available on the U.S. market until December 20, 2013. The applicant explained that, as part of the lengthy approval process, it was required to submit a request to the Federal Communications Commission (FCC) for a waiver of section 15.209(a) of the FCC rules that would allow the applicant to apply for FCC authorization to utilize this specific RF band. The FCC approved the applicant’s waiver request on November 30, 2011. After receiving the FCC waiver of the section 15.209(a) rules, the applicant requested and obtained a required Grant of Equipment Authorization to utilize
the specific RF band, which the FCC issued on December 20, 2013. Therefore, the applicant stated that the date the Argus® II System first became available for commercial sale in the United States was December 20, 2013. We agreed with the applicant that, due to the delay, the date of newness for the Argus® II System was December 20, 2013, instead of February 14, 2013.

Currently there are no other approved treatments for patients diagnosed with severe to profound RP. The Argus® II System has an IDE number of G050001 and is a Class III device. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50580 through 50583), we finalized new ICD-9-CM procedure code 14.81 (Implantation of epiretinal visual prosthesis), which uniquely identifies the Argus® II System. The other two codes finalized by CMS are for removal, revision, or replacement of the device.

After evaluation of the new technology add-on payment application and consideration of public comments received, we concluded that the Argus® II System met all of the new technology add-on payment policy criteria. Therefore, we approved the Argus® II System for new technology add-on payments in FY 2014 (78 FR 50580 through 50583). Cases involving the Argus® II System that are eligible for new technology add-on payments currently are identified by ICD-9-CM procedure code 14.81. We note that section 1886(d)(5)(K)(i) of the Act requires that the Secretary establish a mechanism to recognize the costs of new medical services or technologies under the payment system established under that subsection, which establishes the system for paying for the operating costs of inpatient hospital services. The system of payment for capital costs is established under section 1886(g) of the Act, which makes no mention
of any add-on payments for a new medical service or technology. Therefore, it is not appropriate to include capital costs in the add-on payments for a new medical service or technology. In the application, the applicant provided a breakdown of the costs of the Argus® II System. The total operating cost of the Argus® II System is $144,057.50. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum add-on payment for a case involving the Argus® II System for FY 2014 was $72,028.75.

With regard to the newness criterion for the Argus® II System, we considered the beginning of the newness period to commence when the Argus® II System became available on the U.S. market on December 20, 2013. Because the 3-year anniversary date of the entry of the Argus® II System on the U.S. market will occur in the first half of FY 2017 (December 23, 2016), we proposed to continue new technology add-on payments for this technology for FY 2016.

Because we are adopting the ICD-10 coding system beginning October 1, 2015, we proposed to identify and make new technology add-on payments for cases involving the Argus® II System when one of the following ICD-10-PCS procedure codes is reported: 08H005Z (Insertion of epiretinal visual prosthesis into right eye, open approach); or 08H105Z (Insertion of epiretinal visual prosthesis into left eye, open approach). We stated that the maximum new technology add-on payment for a case involving the Argus® II System would remain at $72,028.75 for FY 2016.

We invited public comments on our proposals.
We did not receive any public comments on our proposal to continue new technology add-on payments for the Argus® II System for FY 2016 or on the coding and payment of this technology. Therefore, we are finalizing our proposal to continue new technology add-on payments for the Argus® II System for FY 2016. Because we are adopting the ICD-10 coding system beginning October 1, 2015, we will identify and make new technology add-on payments for cases involving the Argus® II System when ICD-10-PCS procedure code 08H005Z or 08H105Z is reported. The maximum new technology add-on payment for a case involving the Argus® II System remains at $72,028.75 for FY 2016.

e. Zilver® PTX® Drug Eluting Peripheral Stent

Cook® Medical submitted an application for new technology add-on payments for the Zilver® PTX® Drug Eluting Peripheral Stent (Zilver® PTX®) for FY 2014. The Zilver® PTX® is intended for use in the treatment of peripheral artery disease (PAD) of the above-the-knee femoropopliteal arteries (superficial femoral arteries). According to the applicant, the stent is percutaneously inserted into the artery(s), usually by accessing the common femoral artery in the groin. The applicant stated that an introducer catheter is inserted over the wire guide and into the target vessel where the lesion will first be treated with an angioplasty balloon to prepare the vessel for stenting. The applicant indicated that the stent is self-expanding, made of nitinol (nickel titanium), and is coated with the drug Paclitaxel. Paclitaxel is a drug approved for use as an anticancer agent and for use with coronary stents to reduce the risk of renarrowing of the coronary arteries after stenting procedures.
The applicant received FDA approval on November 15, 2012, for the Zilver® PTX®. The applicant maintains that the Zilver® PTX® is the first drug-eluting stent used for superficial femoral arteries. The technology is currently described by ICD-9-CM procedure code 00.60 (Insertion of drug-eluting stent(s) of the superficial femoral artery).

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50583 through 50585), after evaluation of the new technology add-on payment application and consideration of the public comments received, we approved the Zilver® PTX® for new technology add-on payments in FY 2014. Cases involving the Zilver® PTX® that are eligible for new technology add-on payments are identified by ICD-9-CM procedure code 00.60. As explained in the FY 2014 IPPS/LTCH PPS final rule, to determine the amount of Zilver® PTX® stents per case, instead of using the amount of stents used per case based on the ICD-9-CM codes, the applicant used an average of 1.9 stents per case based on the Zilver® PTX® Global Registry Clinical Study. The applicant stated in its application that the anticipated cost per stent is approximately $1,795. Therefore, cases of the Zilver® PTX® would incur an average cost per case of $3,410.50 ($1,795 x 1.9). Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum add-on payment for a case of the Zilver® PTX® was $1,705.25 for FY 2014.

With regard to the newness criterion for the Zilver® PTX®, we considered the beginning of the newness period to commence when the Zilver® PTX® was approved by
the FDA on November 15, 2012. Because the 3-year anniversary date of the entry of the Zilver® PTX® on the U.S. market occurred after FY 2015 (November 15, 2015), in the FY 2015 IPPS/LTCH PPS final rule, we continued new technology add-on payments for this technology for FY 2015 (79 FR 49925). However, for FY 2016, the 3-year anniversary date of the product’s entry on the U.S. market (November 15, 2015) occurs in the first half of FY 2016. Therefore, we proposed to discontinue new technology add-on payments for the Zilver® PTX® for FY 2016. We invited public comments on this proposal.

Comment: One commenter requested that CMS extend the new technology add-on payment for the Zilver® PTX® for FY 2016.

Response: As stated previously, the new technology add-on payment regulations provide that a medical service or technology may be considered new within 2 or 3 years after the point at which data begin to become available reflecting the ICD-9-CM code assigned to the new service or technology (§ 412.87(b)(2)). Our practice has been to begin and end new technology add-on payments on the basis of a fiscal year, and we have generally followed a guideline that uses a 6-month window before and after the start of the fiscal year to determine whether to extend the new technology add-on payment for an additional fiscal year. In general, we extend add-on payments for an additional year only if the 3-year anniversary date of the product’s entry on the market occurs in the latter half of the fiscal year (70 FR 47362). Consistent with this practice, because the 3-year anniversary date of the product’s entry onto the U.S. market will occur
during the first half of FY 2016, we are not extending new technology add-on payments for FY 2016.

After consideration of the public comment we received, we are finalizing our proposal to discontinue new technology add-on payments for the Zilver® PTX® for FY 2016 because the technology will no longer be considered new.

f. CardioMEMSTM HF (Heart Failure) Monitoring System

CardioMEMS, Inc. submitted an application for new technology add-on payment for FY 2015 for the CardioMEMSTM HF (Heart Failure) Monitoring System, which is an implantable hemodynamic monitoring system comprised of an implantable sensor/monitor placed in the distal pulmonary artery. Pulmonary artery hemodynamic monitoring is used in the management of heart failure. The CardioMEMSTM HF Monitoring System measures multiple pulmonary artery pressure parameters for an ambulatory patient to measure and transmit data via a wireless sensor to a secure Web site.

The CardioMEMSTM HF Monitoring System utilizes radiofrequency (RF) energy to power the sensor and to measure pulmonary artery (PA) pressure and consists of three components: an Implantable Sensor with Delivery Catheter, an External Electronics Unit, and a Pulmonary Artery Pressure Database. The system provides the physician with the patient’s PA pressure waveform (including systolic, diastolic, and mean pressures) as well as heart rate. The sensor is permanently implanted in the distal pulmonary artery using transcatheter techniques in the catheterization laboratory where it is calibrated using a Swan-Ganz catheter. PA pressures are transmitted by the patient at
home in a supine position on a padded antenna, pushing one button which records an 18-second continuous waveform. The data also can be recorded from the hospital, physician’s office or clinic.

The hemodynamic data, including a detailed waveform, are transmitted to a secure Web site that serves as the Pulmonary Artery Pressure Database, so that information regarding PA pressure is available to the physician or nurse at any time via the Internet. Interpretation of trend data allows the clinician to make adjustments to therapy and can be used along with heart failure signs and symptoms to adjust medications.

The applicant believed that a large majority of patients receiving the sensor would be admitted as an inpatient to a hospital with a diagnosis of acute or chronic heart failure, which is typically described by ICD–9–CM diagnosis code 428.43 (Acute on chronic combined systolic and diastolic heart failure) and the sensor would be implanted during the inpatient stay. The applicant stated that for safety considerations, a small portion of these patients may be discharged and the sensor would be implanted at a future date in the hospital outpatient setting. In addition, there would likely be a group of patients diagnosed with chronic heart failure who are not currently hospitalized, but who have been hospitalized in the past few months for which the treating physician believes that regular pulmonary artery pressure readings are necessary to optimize patient management. Depending on the patient’s status, the applicant stated that these patients may have the sensor implanted in the hospital inpatient or outpatient setting.
The applicant received FDA approval on May 28, 2014. The CardioMEMSTM HF Monitoring System is currently described by ICD-9-CM procedure code 38.26 (Insertion of implantable pressure sensor without lead for intracardiac or great vessel hemodynamic monitoring).

After evaluation of the newness, costs, and substantial clinical improvement criteria for new technology payments for the CardioMEMSTM HF Monitoring System and consideration of the public comments we received in response to the FY 2015 IPPS/LTCN PPS proposed rule, we approved the CardioMEMSTM HF Monitoring System for new technology add-on payments for FY 2015 (79 FR 49940). Cases involving the CardioMEMSTM HF Monitoring System that are eligible for new technology add-on payments are identified by ICD-9-CM procedure code 38.26 (Insertion of implantable wireless pressure sensor for intracardiac or great vessel hemodynamic monitoring), which was effective October 1, 2011. With the new technology add-on payment application, the applicant stated that the total operating cost of the CardioMEMSTM HF Monitoring System is $17,750. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the CardioMEMSTM HF Monitoring System is $8,875.

With regard to the newness criterion for the CardioMEMSTM HF Monitoring System, we considered the beginning of the newness period to commence when the CardioMEMSTM HF Monitoring System was approved by the FDA on May 28, 2014.
Because the 3-year anniversary date of the entry of the CardioMEMSTM HF Monitoring System on the U.S. market will occur in FY 2017 (May 28, 2017), we proposed to continue new technology add-on payments for this technology for FY 2016.

Because we are adopting the ICD-10 coding system beginning October 1, 2015, for FY 2016, we proposed to identify and make new technology add-on payments for cases involving the CardioMEMSTM HF Monitoring System using either ICD-10-PCS procedure code 02HQ30Z (Insertion of pressure sensor monitoring device into right pulmonary artery, percutaneous approach) or ICD-10-PCS procedure code 02HR30Z (Insertion of pressure sensor monitoring device into left pulmonary artery, percutaneous approach). We stated that the maximum payment for a case involving the CardioMEMSTM HF Monitoring System would remain at $8,875 for FY 2016.

We invited public comments on our proposals.

Comment: Commenters supported CMS’ proposal to continue new technology add-on payments for the CardioMEMSTM HF Monitoring System for FY 2016. Commenters also supported CMS’ proposal to use ICD-10-PCS procedure codes 02HQ30Z and 02HR30Z when making new technology add-on payments for cases involving the CardioMEMSTM HF Monitoring System.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to continue new technology add-on payments for the CardioMEMSTM HF Monitoring System for FY 2016. Because we are adopting the ICD-10 coding system beginning October 1, 2015, for FY 2016, we will identify and make new technology
add-on payments for cases involving the CardioMEMSTM HF Monitoring System using either ICD-10-PCS procedure code 02HQ30Z (Insertion of pressure sensor monitoring device into right pulmonary artery, percutaneous approach) or ICD-10-PCS procedure code 02HR30Z (Insertion of pressure sensor monitoring device into left pulmonary artery, percutaneous approach). We note that as discussed in section II.G.3. of the preamble of this final rule, CMS determined that there are additional ICD-10-PCS codes describing the insertion of a pressure sensor monitoring that also are appropriate translations for ICD 9 CM procedure code 38.26. These other ICD-10-PCS codes describe the insertion of a pressure sensor monitoring device utilizing an open approach or a percutaneous endoscopic approach (for the right or left pulmonary artery). However, for purposes of new technology add-on payments for cases involving the CardioMEMSTM HF Monitoring System, as stated above, we will identify cases using either ICD-10-PCS procedure code 02HQ30Z (Insertion of pressure sensor monitoring device into right pulmonary artery, percutaneous approach) or ICD-10-PCS procedure code 02HR30Z (Insertion of pressure sensor monitoring device into left pulmonary artery, percutaneous approach). The maximum payment for a case involving the CardioMEMSTM HF Monitoring System will remain at $8,875 for FY 2016.

g. MitraClip® System

Abbott Vascular submitted an application for new technology add-on payments for the MitraClip® System for FY 2015. The MitraClip® System is a transcatheter mitral valve repair system that includes a MitraClip® device implant, a Steerable Guide Catheter, and a Clip Delivery System. It is designed to perform reconstruction of the
insufficient mitral valve for high-risk patients who are not candidates for conventional open mitral valve repair surgery.

Mitral regurgitation (MR), also referred to as mitral insufficiency or mitral incompetence, occurs when the mitral valve fails to close completely causing the blood to leak or flow backwards (regurgitate) into the left ventricle. If the amount of blood that leaks backwards into the left ventricle is minimal, then intervention is usually not necessary. However, if the amount of blood that is regurgitated becomes significant, this can cause the left ventricle to work harder to meet the body’s need for oxygenated blood. Severity levels of MR can range from grade 1+ through grade 4+. If left untreated, severe MR can lead to heart failure and death. The American College of Cardiology (ACC) and the American Heart Association (AHA) issued practice guidelines in 2006 that recommended intervention for moderate/severe or severe MR (grade 3+ to 4+). The applicant stated that the MitraClip® System is “indicated for percutaneous reduction of significant mitral regurgitation … in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease and in whom existing comorbidities would not preclude the expected benefit from correction of the mitral regurgitation.”

The MitraClip® System mitral valve repair procedure is based on the double-orifice surgical repair technique that has been used as a surgical technique in open chest, arrested-heart surgery for the treatment of MR since the early 1990s. According to the applicant, in utilizing “the double-orifice technique, a portion of the anterior leaflet is
sutured to the corresponding portion of the posterior leaflet using standard techniques and forceps and suture, creating a point of permanent cooptation ("approximation") of the two leaflets. When the suture is placed in the middle of the valve, the valve will have a functional double orifice during diastole.”

With regard to the newness criterion, the MitraClip® System received a premarket approval from the FDA on October 24, 2013. The MitraClip® System is indicated “for the percutaneous reduction of significant symptomatic mitral regurgitation (MR >= 3+) due to primary abnormality of the mitral apparatus (degenerative MR) in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.” The MitraClip® System became immediately available on the U.S. market following FDA approval. The MitraClip® System is a Class III device, and has an investigational device exemption (IDE) for the EVEREST study (Endovascular Valve Edge-to-Edge Repair Study) –IDE G030061, and for the COAPT study (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Health Failure Patients with Functional Mitral Regurgitation) – IDE G120024. Effective October 1, 2010, ICD-9-CM procedure code 35.97 (Percutaneous mitral valve repair with implant) was created to identify and describe the MitraClip® System technology.

On August 7, 2014, CMS issued a National Coverage Decision (NCD) concerning Transcatheter Mitral Valve Repair procedures. We refer readers to the CMS
After evaluation of the newness, costs, and substantial clinical improvement criteria for new technology payments for the MitraClip® System and consideration of the public comments we received in response to the FY 2015 IPPS/LTCH PPS proposed rule, we approved the MitraClip® System for new technology add-on payments for FY 2015 (79 FR 49946). As discussed in the FY 2015 IPPS/LTCH PPS final rule, this approval is on the basis of using the MitraClip® consistent with the NCD. Cases involving the MitraClip® System that are eligible for the new technology add-on payments are currently identified by ICD-9-CM procedure code 35.97. The average cost of the MitraClip® System is reported as $30,000. Under section 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the MitraClip® System is $15,000 for FY 2015.

With regard to the newness criterion for the MitraClip® System, we considered the beginning of the newness period to commence when the MitraClip® System was approved by the FDA on October 24, 2013. Because the 3-year anniversary date of the entry of the MitraClip® System on the U.S. market will occur in FY 2017 (October 24, 2016), we proposed to continue new technology add-on payments for this technology for FY 2016.
Because we are adopting the ICD-10 coding system beginning October 1, 2015, we proposed to identify and make new technology add-on payments for cases involving the MitraClip® System using ICD-10-PCS procedure code 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach). We stated that the maximum payment for a case involving the MitraClip® System would remain at $15,000 for FY 2016.

We invited public comments on our proposals.

**Comment:** Commenters supported CMS’ proposal to continue new technology add-on payments for the MitraClip® System for FY 2016. One commenter, the manufacturer, submitted a revised cost analysis. The commenter noted that the MitraClip® System maps to newly created MS-DRGs 273 and 274 (instead of MS-DRGs 250 and 251), the same MS-DRGs as the WATCHMAN® System (which is discussed in section II.I.5.f. of the preamble of this final rule). The commenter reported that it conducted an analysis using the supplemental thresholds that CMS discussed in the proposed rule for newly created MS-DRGs 273 and 274 and demonstrated that the MitraClip® System meets the cost criterion because the case-weighted average standardized charge per case exceeded the case-weighted threshold. Therefore, the commenter believed that the MitraClip® System continues to meet all three criteria for new technology add-on payments for FY 2016.

**Response:** We appreciate the commenters’ support. In the proposed rule, with regard to the cost criterion for the WATCHMAN® System, we discussed using supplemental thresholds for newly created MS-DRGs 273 and 274 and posted these
supplemental thresholds on the CMS Web site. We note that we are maintaining our current policy, which is to use the thresholds issued with each final rule for the upcoming fiscal year (that is, for FY 2017, we will use the thresholds for the updated MS-DRG assignments as reflected in Table 10 issued with this FY 2016 final rule) when making a determination to continue the add-on payment for those new technologies that were approved for the new technology add-on payment from the prior fiscal year.

We did not receive any public comments on the coding and payment of the MitraClip® System for FY 2016.

After consideration of the public comments we received, we are finalizing our proposal to continue new technology add-on payments for the MitraClip® System for FY 2016. Because we are adopting the ICD-10 coding system beginning October 1, 2015, we will identify and make new technology add-on payments for cases involving the MitraClip® System using ICD-10-PCS procedure code 02UG3JZ. The maximum payment for a case involving the MitraClip® System will remain at $15,000 for FY 2016.

h. Responsive Neurostimulator (RNS®) System

NeuroPace, Inc. submitted an application for new technology add-on payments for FY 2015 for the use of the RNS® System. (We note that the applicant submitted an application for new technology add-on payments for FY 2014, but failed to receive FDA approval prior to the July 1 deadline.) Seizures occur when brain function is disrupted by abnormal electrical activity. Epilepsy is a brain disorder characterized by recurrent, unprovoked seizures. According to the applicant, the RNS® System is the first
implantable medical device (developed by NeuroPace, Inc.) for treating persons diagnosed with epilepsy whose partial onset seizures have not been adequately controlled with antiepileptic medications. The applicant further stated that, the RNS® System is the first closed-loop, responsive system to treat partial onset seizures. Responsive electrical stimulation is delivered directly to the seizure focus in the brain when abnormal brain activity is detected. A cranially implanted programmable neurostimulator senses and records brain activity through one or two electrode-containing leads that are placed at the patient's seizure focus/foci. The neurostimulator detects electrographic patterns previously identified by the physician as abnormal, and then provides brief pulses of electrical stimulation through the leads to interrupt those patterns. Stimulation is delivered only when abnormal electrocorticographic activity is detected. The typical patient is treated with a total of 5 minutes of stimulation a day. The RNS® System incorporates remote monitoring, which allows patients to share information with their physicians remotely.

With respect to the newness criterion, the applicant stated that some patients diagnosed with partial onset seizures that cannot be controlled with antiepileptic medications may be candidates for the vagus nerve stimulator (VNS) or for surgical removal of the seizure focus. According to the applicant, these treatments are not appropriate for, or helpful to, all patients. Therefore, the applicant believed that there is an unmet clinical need for additional therapies for partial onset seizures. The applicant further stated that the RNS® System addresses this unmet clinical need by providing a
novel treatment option for treating persons diagnosed with medically intractable partial onset seizures. The applicant received FDA premarket approval on November 14, 2013.

After evaluation of the newness, costs, and substantial clinical improvement criteria for new technology payments for the RNS® System and consideration of the public comments we received in response to the FY 2015 IPPS/LTCH PPS proposed rule, we approved the RNS® System for new technology add-on payments for FY 2015 (79 FR 49950). Cases involving the RNS® System that are eligible for new technology add-on payments are currently identified using the following ICD-9-CM procedure codes: 01.20 (Cranial implantation or replacement of neurostimulator pulse generator) in combination with 02.93 (Implantation or replacement of intracranial neurostimulator lead(s)). According to the applicant, cases using the RNS® System would incur an anticipated cost per case of $36,950. Under § 412.88(a)(2) of the regulations, we limit new technology add-on payments to the lesser of 50 percent of the average costs of the device or 50 percent of the costs in excess of the MS-DRG payment rate for the case. As a result, the maximum new technology add-on payment for cases involving the RNS® System is $18,475.

With regard to the newness criterion for the RNS® System, we considered the beginning of the newness period to commence when the RNS® System was approved by the FDA on November 14, 2013. Because the 3-year anniversary date of the entry of the RNS® System on the U.S. market will occur in FY 2017 (November 14, 2016), we proposed to continue new technology add-on payments for this technology for FY 2016.
Because we are adopting the ICD-10 coding system beginning October 1, 2015, we proposed to identify and make new technology add-on payments for cases involving the RNS\textsuperscript{®} System using the following ICD-10-PCS procedure code combination: 0NH00NZ (Insertion of neurostimulator generator into skull, open approach) in combination with 00H00MZ (Insertion of neurostimulator lead into brain, open approach). We stated that the maximum payment for a case involving the RNS\textsuperscript{®} System would remain at $18,475 for FY 2016.

We invited public comments on our proposals.

\textbf{Comment:} Commenters supported CMS’ proposal to continue new technology add-on payments for the RNS\textsuperscript{®} System for FY 2016. One commenter noted that since FY 2015, additional evidence has been published further demonstrating the safety, effectiveness, and durability of the RNS\textsuperscript{®} System. The commenter cited in particular a peer-reviewed article that was published in February 2015 in \textit{Neurology}, the journal of the American Academy of Neurology. The commenter stated that this article provides interim results of safety and effectiveness from the 7-year, prospective, long-term, follow-up trial for the RNS System.\textsuperscript{8}

In addition, the commenter noted a recently published review and opinion in \textit{Nature Reviews Neurology} entitled “Epilepsy: Closing the loop for patients with epilepsy” (by two epilepsy specialists, Kristl Vonck, MD and Paul Boon, MD) that discusses the positive long-term results of responsive neurostimulation and the promise this therapy brings to a complex patient population with limited treatment options.

Response: We appreciate the commenters’ support and the citations of the additional supporting information.

We did not receive any public comments on the proposed coding and payment of the RNS® System for FY 2016.

After consideration of the public comments we received, we are finalizing our proposal to continue new technology add-on payments for the RNS® System for FY 2016. Because we are adopting the ICD-10 coding system beginning October 1, 2015, we will identify and make new technology add-on payments for cases involving the RNS® System using the following ICD-10-PCS procedure code combination: 0NH00NZ (Insertion of neurostimulator generator into skull, open approach) in combination with 00H00MZ (Insertion of neurostimulator lead into brain, open approach). The maximum payment for a case involving the RNS® System will remain at $18,475 for FY 2016.

5. FY 2016 Applications for New Technology Add-On Payments

We received nine applications for new technology add-on payments for FY 2016. However, two applications, the Angel Medical Guardian® Ischemia Monitoring Device and Ceftazidime Avibactam (AVYCAZ), were withdrawn from consideration for new technology add-on payments for FY 2016 prior to the publication of this final rule. In addition, in accordance with the regulations under § 412.87(c), applicants for new technology add-on payments must have FDA approval of the technology by July 1 of each year prior to the beginning of the fiscal year that the application is being considered. One applicant did not receive FDA approval for its technology, Idarucizumab, by
July 1, 2015, and, therefore, is ineligible for consideration for new technology add-on payments for FY 2016. We are not including the descriptions and discussions of these three applications that were included in the FY 2016 proposed rule in this final rule. We note that we did receive public comments on all three of these applications. However, because the applicant either withdrew its application or the technology is ineligible for new technology add-on payments for FY 2016 because the technology did not receive FDA approval by July 1, 2015, we also are not summarizing or responding to these public comments in this final rule. A discussion of the six remaining applications is presented below.

a. Blinatumomab (BLINCYTO™)

Amgen, Inc. submitted an application for new technology add-on payments for Blinatumomab (BLINCYTO™), a bi-specific T-cell engager (BiTE) used for the treatment of Philadelphia chromosome-negative (Ph-) relapsed or refractory (R/R) B-cell precursor acute-lymphoblastic leukemia (ALL), which is a rare aggressive cancer of the blood and bone marrow. Approximately 6,050 individuals are diagnosed with Ph- R/R B-cell precursor ALL in the United States each year, and approximately 2,400 individuals, representing 30 percent of all new cases, are adults. Ph- R/R B-cell precursor ALL occurs when there are malignant transformations of B-cell or T-cell progenitor cells, causing an accumulation of lymphoblasts in the blood, bone marrow, and occasionally throughout the body. As a bi-specific T-cell engager, the BLINCYTO™ technology attaches to a molecule on the surface of the tumorous cell, as well as to a molecule on the surface of normal T-cells, bringing the two into closer
proximity and allowing the normal T-cell to destroy the tumorous cell. Specifically, the BLINCYTO™ technology attaches to a cell identified as CD19, which is present on all of the cells of the malignant transformations that cause Ph- R/R B-cell precursor ALL and helps attract the cell into close proximity of the T-cell CD3 with the intent of getting close enough to allow the T-cell to inject toxins that destroy the cancerous cell. According to the applicant, the BLINCYTO™ technology is the first, and the only, bi-specific CD19-directed CD3 T-cell engager single-agent immunotherapy approved by the FDA.

BLINCYTO™ is administered as a continuous IV infusion delivered at a constant flow rate using an infusion pump. A single cycle of treatment consists of 28 days of continuous infusion, and each treatment cycle followed by 2 weeks without treatment prior to administering any further treatments. A course of treatment consists of two phases. Phase 1 consists of initial inductions or treatments intended to achieve remission followed by additional inductions and treatments to maintain consolidation; or treatments given after remission has been achieved to prolong the duration. During phase 1 of a single treatment course, up to two cycles of BLINCYTO® are administered, and up to three additional cycles are administered during consolidation. The recommended dosage of BLINCYTO™ administered during the first cycle of treatment is 9 mcg per day for the first 7 days of treatment. The dosage is then increased to 28 mcg per day for 3 weeks until completion. During phase 2 of the treatment course, all subsequent doses are administered as 28 mcg per day throughout the entire duration of the 28-day treatment period.
With respect to the newness criterion, the BLINCYTO™ technology received FDA approval on December 3, 2014, for the treatment of patients diagnosed with Ph- R/R B-cell precursor ALL, and the product gained entry onto the U.S. market on December 17, 2014. As stated in section II.G.1.a. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule and this final rule, effective October 1, 2015 (FY 2016), the ICD-10 coding system will be implemented. In the proposed rule, we noted that the applicant had applied for a new ICD-10-PCS procedure code at the March 18-19, 2015 ICD-10-CM/PCS Coordination and Maintenance Committee Meeting. In this final rule, we note that the new ICD-10-PCS procedure codes XW03351 (Introduction of Blinatumomab antineoplastic immunotherapy into peripheral vein, percutaneous approach, new technology group 1) and XW04351 (Introduction of Blinatumomab antineoplastic immunotherapy into central vein, percutaneous approach, new technology group 1) were established as shown in Table 6B (New Procedure Codes) and will uniquely identify procedures involving the BLINCYTO™ technology. More information on this request and the approval can be found on the CMS Web site at:


In the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43813 through 43814), we established criteria for evaluating whether a new technology is substantially similar to an existing technology, specifically: (1) whether a product uses the same or a
similar mechanism of action to achieve a therapeutic outcome; (2) whether a product is assigned to the same or a different MS-DRG; and (3) whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population. If a technology meets all three of these criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments. For a detailed discussion of the criteria for substantial similarity, we refer readers to the FY 2006 IPPS final rule (70 FR 47351 through 47352), and the FY 2010 IPPS/LTCH PPS final rule (74 FR 43813 through 43814).

With regard to the first criterion, whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome, we stated in the proposed rule our concern that the mechanism of action of the BLINCYTO™ technology does not appear to differ from those of other bi-specific T-cell engagers, which also attract the cancerous cell within close proximity of a normal T-cell with the intent of allowing the cell to get close enough to inject toxins to destroy the cancerous cell. There are several other BiTEs currently under investigation, including MT110 that are used for the treatment of patients diagnosed with gastrointestinal and lung cancers and are directed towards the EpCAM antigen, as well as MCSP-specific and CD33-specific BiTEs used for treating patients diagnosed with melanoma and acute myeloid leukemia, respectively. We believe that the feature that distinguishes the BLINCYTO™ technology from these other bi-specific T-cell engagers is that it specifically targets the CD19 cell. However, in the proposed rule, we stated that we are concerned that the specificity of the mechanism of action may
not be sufficient to distinguish the BLINCYTO™ technology from other bi-specific T-cell engagers and, therefore, the technology bears substantial similarity to these other BiTEs used as current treatment options for Medicare beneficiaries. Further, we stated that determining that the BLINCYTO™ technology meets the newness criterion based on the specificity of the mechanism of action would set a precedent that a drug employing the same mechanism of action could be considered “new” based on such specificity when evaluated under the substantial similarity criterion.

With respect to the second criterion, whether a product is assigned to the same or a different MS-DRG, the applicant maintained that ICD-9-CM diagnosis codes 204.00 (Acute lymphoid leukemia, without mention of having achieved remission) and 204.02 (Acute lymphoid leukemia in relapse) are used to identify patients who may potentially be eligible for treatment using the BLINCYTO™ technology. Using these diagnosis codes, the applicant researched claims data from the FY 2013 MedPAR file and found cases across a wide spectrum of MS-DRGs, not all of which are related to acute lymphoblastic leukemia. According to the applicant, 42.1 percent of all cases representing patients diagnosed with Ph- R/R B-cell precursor ALL were assigned to 238 MS-DRGs. Therefore, we believe that potential cases involving the BLINCYTO™ technology may be assigned to the same MS-DRG(s) as other cases involving bi-specific T-cell engagers used to treat patients with leukemia.

With respect to the third criterion, whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population, the applicant maintained in its application that the standard treatment for
patients diagnosed with Ph- R/R B-cell precursor ALL currently requires the use of multiple, intensive chemotherapy treatment drugs in combination to induce remission in order to allow the patient the opportunity to proceed to allogenic hematopoietic stem cell transplant (alloHSCT), which is the next stage in the course of treatment and the only known curative option. The applicant asserted that the BLINCYTO™ technology is not substantially similar to other treatment options because it does not involve the treatment of the same, or similar, type of diseases or the same, or similar, patient population. The applicant stated that, although chemotherapy is a successful treatment option to induce remission in patients diagnosed with Ph- R/R B-cell precursor ALL, many of these patients relapse or stop responding to this standard treatment and, therefore, are unable to proceed to alloHSCT, the next stage of treatment. Moreover, chemotherapy toxicities can be cumulative. Therefore, the commenter stated, patients who have received intensive treatments may not be eligible for further intensive chemotherapy treatments and, therefore, are unable to proceed to alloHSCT. The applicant asserted that the BLINCYTO™ technology is an anti-cancer immunotherapy that has shown to be effective in the treatment of a patient population in which chemotherapy has not been successful. Moreover, the applicant asserted that, as an anti-cancer immunotherapy, the BLINCYTO™ technology does not demonstrate the cumulative side-effects typically associated with chemotherapy treatments and, therefore, is a treatment option available to patients who are not eligible for further chemotherapy treatments based on the risks associated with cumulative toxicities. However, in the proposed rule, we stated our concern that this specific patient population is not necessarily distinguishable from the
overall patient population of individuals diagnosed with Ph- R/R B-cell precursor ALL, and we are unsure how to identify these patients using administrative claims data.

In summary, we stated in the proposed rule that the BLINCYTÔ™ technology may be similar to other approved technologies currently available to treat the same patient population and medical disorders and, therefore, may not meet the newness criterion. In addition, we stated that the specific patient population targeted by the applicant may not be sufficiently distinguishable from the overall patient population that may be eligible for treatment using options that are currently available for these types of medical disorders. We invited public comments on if, and how, the BLINCYTÔ™ technology meets the newness criterion.

**Comment:** The applicant submitted public comments that responded to CMS’ concerns presented in the proposed rule. With regard to CMS’ concern that the BLINCYTÔ™ technology’s mechanism of action does not appear to differ from other bi-specific T-cell engagers, the applicant emphasized that there are no other FDA-approved bi-specific T-cell engager constructs currently marketed and readily available to Medicare beneficiaries. Therefore, the applicant stated that there are no previously available technologies to use as comparators for determining whether BLINCYTÔ™ bears a substantial similarity to other bi-specific T-cell engagers. Furthermore, the applicant believed that the BLINCYTÔ™ technology’s mechanism of action is unique and distinguishable from all other FDA-approved therapies because it redirects the patient’s immune system toward the cancerous cells, which leads to the specifically targeted destruction of these cells. The applicant noted that no other
FDA-approved anti-cancer immunotherapy redirects the patient’s immune system in such a manner and, therefore, the novelty of the BLINCYTO™ technology’s bi-specific T-cell engager mechanism of action extends beyond the target antigen specificity. Therefore, the applicant disagreed with CMS that approving new technology add-on payments for this technology would set a precedent in which a drug employing the same mechanism of action could be considered new based on the specificity of its target antigen.

With regard to CMS’ concern that potentially eligible cases involving the BLINCYTO™ technology may be assigned to the same MS-DRG(s) as other cases involving target therapy used to treat patients diagnosed with leukemia, the applicant reiterated that there are currently no other FDA-approved bi-specific T-cell engager constructs available on the U.S. market to treat any patients, including Medicare beneficiaries, who have been diagnosed with Ph- R/R B-cell precursor ALL. As such, the applicant contended that potential cases eligible for the BLINCYTO™ would not be assigned to the same MS-DRG(s) as other cases involving other targeted therapies.

With regard to CMS’ concern that the specific population of patients identified by the applicant that may be eligible for treatment using the BLINCYTO™ technology (that is, patients who are ineligible for chemotherapy or for whom chemotherapy has not been successful) is not necessarily distinguishable from the overall patient population of individuals diagnosed with Ph-R/R B-cell precursor ALL, the applicant asserted that the approval of the new unique ICD-10-PCS procedure codes to be used to identify cases involving the BLINCYTO™ technology corroborates the recognizable distinction between the specific patient populations. The applicant believed that, if the
BLINCYTO™ technology is approved for new technology add-on payments, CMS would be able to use claims data reporting these new ICD-10-PCS procedure codes to distinguish the population of patients treated with the BLINCYTO™ technology from the broader population of patients diagnosed with Ph- R/R B-cell precursor ALL by using these specific new codes on inpatient hospital claims when the codes become effective October 1, 2015.

Response: We appreciate the details and input provided by the applicant in response to our concerns. We also acknowledge that new ICD-10-PCS procedure codes have been approved to uniquely identify procedures that involve the BLINCYTO™ technology, and that these procedure codes may ultimately be used to distinguish the specific patient population from the overall patient population of individuals diagnosed with Ph- R/R B-cell precursor ALL. After considering the additional information submitted by the applicant in response to our concerns, which supported the technology’s uniqueness and documented the lack of an equivalent treatment option for patients diagnosed with Ph- R/R B-cell precursor ALL, who may be ineligible for current treatment options, we agree with the applicant that the BLINCYTO™ technology is not substantially similar to other technologies currently available that also are used in the treatment of patients diagnosed with the same or similar types of conditions. We believe that the BLINCYTO™ technology uses a different mechanism of action than other similar technologies, eligible cases involving treatment using the BLINCYTO™ technology would be grouped to a different MS-DRG than those cases treated with similar technologies, and the BLINCYTO™ technology would be used in the treatment
of a different patient population than those currently treated with existing technologies. Therefore, we believe that the BLINCYTO™ technology meets the newness criterion.

Comment: Several commenters, including medical specialty societies, believed that the BLINCYTO™ technology meets the newness criterion. The commenters agreed with the applicant’s assertion that there are currently no other bi-specific T-cell engager constructs that are available on the U.S. market, and disagreed with CMS’ comparisons between the applicant’s technology and products currently approved or under investigation. One commenter stated that it is particularly notable that the BLINCYTO™ technology is the first FDA-approved drug to be used in immunotherapy for the treatment of cancer. The commenter noted that, while other bi-specific T-cell engager constructs are in the development stages, these products have not reached the advanced stages of development, whereas the BLINCYTO™ technology is currently FDA-approved and the subject of phase III clinical trials for the treatment of patients diagnosed with Ph- R/R B-cell precursor ALL. Some commenters believed that the relevant comparison analysis conducted for new technology add-on payment eligibility must be related to treatments that are currently available to Medicare beneficiaries. The commenters stated that it is inappropriate to rely upon comparison analysis that compares a candidate for new technology add-on payments, which requires the technology to have FDA approval as a condition, to technologies or treatments that may potentially become available in the future or that are currently under investigation, and sets an impossible standard to achieve that is also inconsistent with CMS’ regulations.
Response: We appreciate the commenters’ input. We agree with the commenters that new technology add-on payments are intended to recognize the cost of new items that are not reflected in the Medicare claims data used to set payment rates for MS-DRGs. The costs of treatment options that are currently under development and not available on the U.S. market or to Medicare beneficiaries would not be reflected in the Medicare claims data used to set the payment rates for MS-DRGs. Therefore, these treatment options are not an appropriate comparator for technologies being considered for approval under the new technology add-on payment policy. After considering the additional information submitted by the applicant and the input from other commenters, we have determined that the BLINCYTO™ technology meets the newness criterion.

As we discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24432), with respect to the cost criterion, the applicant researched claims data in the FY 2013 MedPAR file, which contained inpatient hospital discharges from October 1, 2012, to September 30, 2013, and identified cases reporting ICD-9-CM diagnosis codes 204.00 (Acute lymphoid leukemia, without mention of having achieved remission) and 204.02 (Acute lymphoid leukemia in relapse), which represent patients who may potentially be eligible for treatment using the BLINCYTO™ technology. The applicant found 2,649 cases across 246 MS-DRGs, including MS-DRGs 834 through 836 (Acute Leukemia without Major Operating Room Procedure, with MCC, with CC, and without CC/MCC, respectively) and MS-DRGs 837 through 839 (Chemotherapy with Acute Leukemia as Secondary Diagnosis, with MCC, with CC, and without CC/MCC, respectively), which represent approximately 48.1 percent of all cases with patients diagnosed with Ph- R/R
B-cell precursor ALL. The applicant also found that MS-DRG 809 (Major Hematological and Immunologic Diagnoses Except Sickle Cell Crisis and Coagulations Disorders with CC) and MS-DRG 871 (Septicemia or Severe Sepsis without Mechanical Ventilation 96+ Hours with CC) contained cases that further represent 9.8 percent of all cases representing patients diagnosed with Ph- R/R B-cell precursor ALL. The cases assigned to the remaining 238 MS-DRGs represent a combined 42.1 percent of all cases representing patients diagnosed with Ph- R/R B-cell precursor ALL, with no single MS-DRG containing cases representing more than 2.0 percent of all cases representing patients diagnosed with Ph- R/R B-cell precursor ALL. The applicant also noted that when identifying cases that may be eligible for the BLINCYTO™ technology, it excluded any claims for discharges paid by Medicare Advantage plans, as well as any claims submitted by Medicare PPS-exempt cancer hospitals.

Because the applicant was unable to provide a single estimate of the charges that would be avoided by using the BLINCYTO™ technology (that is, additional charges incurred during treatment using other technologies), the applicant conducted its own cost analysis using two scenarios for each group of MS-DRGs. The first scenario assumed that 50 percent of the charges for drugs would be eliminated by using the BLINCYTO™ technology, and the second scenario assumed that 75 percent of the charges for drugs would be eliminated. The applicant further conducted sensitivity analyses for each of the top eight MS-DRGs containing cases eligible for the BLINCYTO™ technology, as well as a sensitivity analysis for all of the other MS-DRGs outside of the top eight to which eligible cases mapped. The applicant then examined the average case-weighted
standardized charge per case and the average case-weighted threshold amount for all 2,649 cases identified during FY 2013 across all 246 MS-DRGs, and for 1,533 cases during FY 2013 across the top 8 MS-DRGs to demonstrate that the technology meets the cost criterion.

Under the analysis’ first scenario, 50 percent of the charges for drugs incurred by using other technologies were removed in order to exclude the charges associated with the use of these technologies. The applicant determined an average case-weighted threshold amount of $60,278 for the 2,649 Ph-R/R B-cell precursor ALL cases in the 246 MS-DRGs identified using the thresholds in Table 10 in the FY 2015 IPPS/LTCH PPS final rule. The applicant also determined an average case-weighted standardized charge per case of $245,006, or $184,728 above the average case-weighted threshold amount. For the subset of 1,533 cases that mapped to the top 8 MS-DRGs, the applicant determined an average case-weighted threshold amount of $65,478 using the threshold in Table 10 in the FY 2015 IPPS/LTCH PPS final rule. The applicant also determined an average case-weighted standardized charge per case of $249,354, or $183,876 above the average case-weighted threshold amount. Based on the applicant’s analyses, we believe that the BLINCYTO™ technology meets the cost criterion under the first scenario.

Under the second scenario, the applicant removed 75 percent of charges for drugs incurred by using other technologies in order to exclude the charges associated with the use of these technologies. The applicant determined an average case-weighted threshold amount of $60,278 for the 246 MS-DRGs identified using the thresholds from Table 10 in the FY 2015 IPPS/LTCH PPS final rule. The applicant determined an average
case-weighted standardized charge per case of $239,321, or $179,043 above the average case-weighted threshold amount. For the subset of 1,533 cases that mapped to the top 8 MS-DRGs, the applicant determined an average case-weighted threshold amount of $65,478 using the thresholds from Table 10 in the FY 2015 IPPS/LTCH PPS final rule. The applicant determined an average case-weighted standardized charge per case of $242,423, or $176,945 above the average case-weighted threshold amount. Based on the applicant’s analyses, we believe that the BLINCYTO™ meets the cost criterion under the second scenario.

In conducting the above analyses, the applicant summarized the charges from the claims it identified and standardized the charges using an unspecified data source. The applicant then inflated all charges from FY 2013 to FY 2015 using the 10.4427 percent inflation factor used by CMS to update the FY 2015 outlier threshold. In determining the costs for the technology per case, the applicant also assumed that the BLINCYTO™ technology would be administered for 28 days during each inpatient stay. The applicant also assumed a hospital markup of 2.0 percent, and applied this amount to its estimated charges per case.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24432 through 24433), we presented three concerns regarding the applicant’s methodology and assumptions used in its cost analyses. We stated that the applicant did not specify whether it used the FY 2015 IPPS final rule impact file or another data source to standardize the charges per case for this technology. We also stated our concern that the applicant did not provide a basis for the hospital markup assumed when conducting its cost analyses.
applicant provided this information, we stated that we are unable to determine whether the cost of the technology per case has been calculated appropriately. Moreover, we stated our concern that including charges representative of a full 28-day treatment cycle is not appropriate for the purpose of calculating the charges associated with the BLINCYTO™ technology in order to determine whether the technology meets the cost criterion. According to the applicant, clinical trial data demonstrate that there are large subsets of patients who require inpatient care for the full 28-day treatment cycle because of the extreme clinical conditions relating to patients diagnosed with Ph- R/R B-cell precursor ALL. However, the applicant also conceded that only 25 percent of patients enrolled in the U.S. clinical trial were hospitalized for the full 28-day treatment cycle, and only 38 percent of these patients were over the age of 65. This caused us concern regarding whether the methodology used by the applicant in its cost analysis is appropriate.

We invited public comments on if, and how, the BLINCYTO™ technology meets the cost criterion, specifically in regard to our concerns related to the applicant’s methodology.

Comment: The applicant submitted further information in response to CMS’ concerns. The applicant indicated that it used the FY 2015 IPPS final rule impact file and other instructions included in Technical Appendix B of the FY 2016 new technology add-on payment application to standardize the charges per case for potentially eligible cases for the BLINCYTO™ technology representing patients diagnosed with Ph- R/R B-cell precursor ALL under all of the scenarios. The applicant also provided more information...
regarding the basis of its markup values used when conducting sensitivity analyses to
demonstrate that the BLINCYTO™ technology meets the cost criterion. Specifically, the
applicant stated that it used a markup of 100 percent, which is a cost-to-charge ratio
(CCR) of 0.5, and further noted that the charges for the BLINCYTO™ technology would
be included in the pharmacy charge category on an inpatient hospital’s claim. The
applicant identified the national average cost-to-charge ratio of 0.192 for the pharmacy
charge category that was calculated in the FY 2015 IPPS/LTCH PPS final rule. The
applicant stated that this CCR indicated that charges in this category were 420 percent
higher than the costs. However, the applicant did not believe that a 420-percent markup
was appropriate for the purposes of new technology add-on payment MS-DRG
case-weighted threshold assessment for the cases eligible for the BLINCYTO™
technology. Therefore, the applicant indicated that it reverted to the use of a more
conservative markup of 100 percent in its analyses for eligibility for new technology
add-on payments to determine the average case-weighted standardized charges per case.
The applicant noted that, if it were to have used the national average markup for the
pharmacy charge center of 420 percent, the charges associated with the BLINCYTO™
technology would be significantly higher than that which is indicated in its analyses,
further exceeding the MS-DRG case-weighted threshold amount and demonstrating that
the BLINCYTO™ technology meets the cost criterion.

Furthermore, the applicant maintained that including charges representative of a
full 28-day treatment cycle is appropriate for the purpose of calculating the charges
associated with the BLINCYTO™ technology. However, the applicant indicated that it
conducted additional sensitivity analyses across both of the original scenarios used in the application in which it assumed no hospital markup on the charges associated with the BLINCYTO™ technology to demonstrate the standardized charges per case under different scenarios for the variable number of inpatient days; a scenario for standardized charges per case using the full 28 inpatient days, standardized charges per case using the mean total inpatient days for cycle 1 (21.2 days), and standardized charges per case using the mean total inpatient days per cycle across all cycles (16.2 days). Based on the results of these sensitivity analyses, the applicant continued to believe that the BLINCYTO™ technology meets the cost criterion, regardless of the number of assumed inpatient days and the associated charge markup. The applicant determined that, prior to the inclusion of any charges associated with the BLINCYTO™ technology, the case-weighted average standardized charge per case under all scenarios exceeds the average case-weighted threshold amounts for the respective MS-DRGs, further demonstrating that the target cases potentially eligible for the BLINCYTO™ technology have significantly higher costs to provide the standard of care.

Response: We appreciate the applicant’s submittal of the additional information and input. After reviewing the sensitivity analyses included in the original application and subsequent analyses included in the applicant’s public comment, we have determined that the BLINCYTO™ technology meets the cost criterion.

As discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24433 and 24434), with respect to the substantial clinical improvement criterion, the applicant asserted that the BLINCYTO™ technology represents a substantial clinical improvement
for the treatment of patients diagnosed with Ph- R/R B-cell precursor ALL because it offers a treatment option for patients who may be unresponsive to currently available options for treatment, decreases the rate of subsequent therapeutic interventions for patients who might not have otherwise achieved remission, and reduces mortality. The applicant provided data analysis results from four sources to demonstrate that the technology represents a substantial clinical improvement. These sources include a historical literature search, a model-based meta-analysis (Study 118427), a historical comparator data (Study 20120310), and a pivotal clinical trial (Study MT 103-211). We summarize the results from each of these sources below.

- The historical literature search revealed that superior regimens among currently used chemotherapeutic options result in a complete remission rate ranging from 18.0 percent to 38.6 percent, a median overall survival rate for patients experiencing early first relapse (<12 months) at 4.7 months, and a median overall survival rate for patients experiencing second or later relapse at 3 months. However, there are several limitations to using recent literature as a historical comparison for studies relating to patients diagnosed with Ph- R/R B-cell precursor ALL, including differences in patient populations or study design characteristics across published studies, which make it difficult to formulate absolute comparisons with regard to data obtained from the BLINCYTO™ pivotal clinical trial. Therefore, the applicant conducted a model-based meta analysis (Studies 118427 and 119384), and a historical comparator study (Study 20120310) to account for these differences.
In the model-based meta analysis (MBMA), the endpoints of complete remission (CR), duration of complete remission (DCR), and overall survival (OS) rate models were used to predict the efficacy of the BLINCYTO™ technology in cases representing patients diagnosed with Ph- R/R B-cell precursor ALL relative to patients treated using existing therapies. Simulations based on the MBMA for adult patients diagnosed with Ph- R/R B-cell precursor ALL projected a poor outcome with existing salvage therapies, and a significant increase in the proportion of CR, DCR, and OS rates in a population with the same summary prognostic factors as those enrolled in the BLINCYTO™ study MT103-211. For adult patients diagnosed with Ph- R/R B-cell precursor ALL who were treated with existing salvage therapies and having the same summary prognostic factors as those enrolled in the BLINCYTO™ study MT 103-211, the projected proportion of CR was 0.121 (95 percent CI: 0.041 to 0.341), the median DCR rate was 4.9 months (95 percent CI: 2.5 to 9.2 months), and the median OS rate was 3.9 months (95 percent CI: 3.0 to 4.7 months). For adult patients diagnosed with Ph- R/R B-cell precursor ALL having the same summary prognostic factors as those enrolled in the BLINCYTO™ study MT 103-211, treatment using the BLINCYTO™ technology when compared with existing salvage therapies is expected to have an odds ratio for proportion of CR of 3.50 (95 percent CI: 1.63 to 8.40), a hazard ratio for DCR of 0.53 (95 percent CI: 0.30 to 0.89), and a hazard ratio for OS of 0.60 (95 percent CI: 0.47 to 0.76). The applicant maintained that these results suggest that the BLINCYTO™ technology is associated with a reduced mortality rate and improved clinical outcomes when compared to standard chemotherapy treatment options.
A historical comparator study was also conducted to obtain patient-level data for standard of care treatment options for patients experiencing early first relapse, refractory relapse after HSCT, and second or greater relapse in the same patient population as targeted in the BLINCYTO™ pivotal clinical trial. Study 20120310 was a retrospective pooled analysis of historical data available from 1990 to 2014 on hematological remission and survival rates among patients diagnosed with Ph- R/R B-cell precursor ALL who were treated with standard of care therapies. The primary study endpoint was CR following relapse or salvage treatment; and secondary endpoints included estimates of OS rates, RFS rates, and the proportion of patients receiving alloHSCT. The weighted median OS rate for 1,112 patients based on available data was 3.3 months (95 percent CI: 2.8 to 3.6 months) and was calculated from the start of the last salvage treatment or the first relapse (if start of the last salvage date was unavailable) until the time of death. The weighted OS rate at 6 and 12 months was 30 percent (95 percent CI: 27 percent to 34 percent) and 15 percent (95 percent CI: 13 percent to 18 percent), respectively. Among the patients who achieved CR based on available data (108 patients), the weighted median RFS rate was 5.0 months (95 percent CI: 1.2 to 6.6 months). Among the 808 patients who received alloHSCT after salvage therapy based on available data, 18 percent (95 percent CI: 15 percent to 21 percent) received alloHSCT following the last line of salvage therapy, and among patients who achieved CR, 7 percent (95 percent CI: 5 percent to 9 percent) received alloHSCT. The applicant maintained that these results highlight the poor health care outcomes for patients treated...
with standard chemotherapy and that BLINCYTO™ represents a significant improvement.

- BLINCYTO™ study MT 103-211 is a pivotal clinical study providing efficacy data for the BLINCYTO™ technology used for the treatment of adult patients diagnosed with Ph- R/R B-cell precursor ALL. It is a phase 2, single-arm study that included a particularly difficult patient population to treat consisting of patients diagnosed with - Ph- R/R B-cell precursor ALL who experienced either: (1) R/R after remission during 12 months or less of the first salvage treatment; (2) R/R after the first salvage treatment; or (3) R/R within 12 months after receiving alloHSCT. The primary endpoint was the rate of CR plus CRh within the first 2 cycles of treatment using the BLINCYTO™ technology. The key secondary endpoints include best overall response within 2 cycles of treatment using the BLINCYTO™ technology, RFS, time of hematological relapse, OS rates, and the proportion of patients eligible for alloHSCT who underwent the procedure after receiving treatment using the BLINCYTO™ technology. An analysis of data from the pivotal trial showed that 40 percent of patients treated with the BLINCYTO™ technology who achieved CR or CRh were able to proceed to alloHSCT. A secondary analysis from the pivotal study found that in patients who achieved CR or CRh and had a minimal residual disease assessment during the first 2 cycles, the MRD response rate (little or no evidence of disease even at the molecular level) was 82.2 percent. The applicant asserted that this finding is significant because MRD is often a harbinger of relapse and a poor prognostic factor for patients diagnosed with Ph- R/R B-cell precursor ALL.
We stated in the proposed rule our concern that the data provided from the clinical studies are not sufficient to demonstrate that the BLINCYTO™ technology meets the substantial clinical improvement criterion. For example, the BLINCYTO™ study MT 103-211 was not randomized or blinded, and was comprised of a small sample group of 189 patients with a median age of 39 years. We further stated our concern that the sample group studied during the clinical trial is not appropriate to determine if the technology represents a substantial clinical improvement in treatment options available for the Medicare patient population. Moreover, we stated our concern that meaningful conclusions cannot be drawn from the results of this study because of the lack of a control group.

With regard to the applicant’s assertion that the BLINCYTO™ technology offers a treatment option for patients who may be unresponsive to currently available treatment modalities, the applicant specifically focused on how the BLINCYTO™ technology represents a treatment option for a patient population in which chemotherapy has proven to be unsuccessful, or for whom intensive chemotherapy treatment is not possible because of the risks associated with exposure to cumulative toxicities. The applicant believed that the MBMA, the historical comparator study, and the BLINCYTO™ study MT 103-211, which is a pivotal clinical trial sufficiently isolate this patient population in order to measure specific health care outcomes. We agreed with this assertion. However, we stated our concerns with the isolated patient population are that it is comprised of and represents a small sample group of patients whose age demographic is much younger than the age demographic of eligible Medicare beneficiaries.
The applicant also asserted that the BLINCYTO™ technology decreases the rate of subsequent therapeutic interventions for patients who might not have otherwise achieved remission. In other words, because treatment with the BLINCYTO™ technology appears to increase the possibility of some patients achieving remission, the applicant maintained that these patients would receive fewer therapeutic interventions and become eligible to receive alloHSCT. We stated that we believe that it is difficult to determine what services and therapeutic interventions these patients would have required if they had not achieved remission, and we are not convinced that treatment using the BLINCYTO™ technology leads to a decrease in additional therapeutic interventions. In the proposed rule, we also noted that patients who successfully achieve remission proceed to alloHSCT and, therefore, receive a different set of subsequent therapeutic interventions.

With regard to the applicant’s assertion that the BLINCYTO™ technology reduces mortality rates, we noted that the applicant did not directly capture mortality rates as an endpoint in the BLINCYTO™ pivotal study (MT 103-211), although mortality was analyzed during the other three studies that support the new technology add-on payment application. We noted that the data and the MBMA’s results included with the technology’s application used an OS odds ratio as a measure of mortality, and were developed from 18 studies published between January 1995 and December 2012. We stated our concern that relying on the results of data using a measure of mortality that is contingent upon studies completed in the 1990s presents a limitation in regard to the methodology used in the applicant’s analysis. Advances in overall oncology care over
the past 2 decades may invalidate the patient population represented in these studies as a comparison group. Therefore, we stated that we find it difficult to attribute the reduced mortality rate and improved clinical outcomes revealed by these studies to the efficacy of the BLINCYTO™ technology.

We invited public comments on if, and how, the BLINCYTO™ technology meets the substantial clinical improvement criterion, specifically in regard to our specified concerns.

Comment: The applicant submitted public comment in response to CMS’ concerns presented in the proposed rule which asserted that the sample size and lack of a control arm in the BLINCYTO™ study MT 103-211 is due to the rarity and fatality of Ph- R/R B-cell precursor ALL, which made it difficult to find patients to participate in the trials. Nevertheless, the applicant stated that the BLINCYTO™ study MT 103-211 is the largest Ph- R/R B-cell precursor ALL clinical trial reported to date, and was conducted within the limits of its capabilities because larger studies can only be conducted by national or international cooperative study groups. The applicant also maintained that the sample size is representative of the Medicare patient population who have been diagnosed with Ph- R/R B-cell precursor ALL in relapse in spite of the median age of 39 years, and patients who were Medicare beneficiaries due to disability.

Moreover, the applicant noted that MedPAR data demonstrate that 60 percent of the 479 inpatient stays for patients diagnosed with Ph- R/R B-cell precursor ALL in relapse in FY 2014 were Medicare patients under the age of 65. In addition, the applicant pointed out that single-arm trials are common in Phase II testing, especially when there is a
low-volume patient population with patients who have very poor prognosis, such as the patient population represented in the BLINCYTO™ study MT 103-211.

According to the applicant, the design of the pooled analysis of historic data provides a viable measure to determine that the BLINCYTO™ technology represents a substantial clinical improvement as compared to characteristically matched patients in a control arm that were treated with other currently available options that may not be appropriate or for which a patient’s status prohibits eligibility. The applicant also conducted propensity score analyses to further investigate and support historical data that was used as a comparator and found that the majority of patients in Study 20120310 were diagnosed and treated in the year 2000 or later. Moreover, the applicant believed that the results of the majority of propensity score analyses demonstrated an improvement in overall survival (OS) compared to standard of care chemotherapy. Further, the applicant defended the weighted value of outcome of OS rates in the BLINCYTO™ study MT103-211 as a commonly used endpoint in oncology trials, and a more clinically meaningful endpoint than mortality rates given the rapidly progressive and fatal nature of Ph- R/R B-cell precursor ALL diagnoses. The applicant asserted that CMS should not use, as a metric to determine if the BLINCYTO™ represents a significant clinical improvement, that additional therapeutic interventions associated with alloHSCT are available, given that alloHSCT is the only way to provide patients with a potential cure for diagnoses of Ph- R/R B-cell precursor ALL.

Response: We appreciate the applicant’s submittal of the additional information and the explanation of the study design and endpoints in light of the small and rare
population of patients diagnosed with Ph- R/R B-cell precursor ALL. We agree with the applicant that, in view of the MedPAR data and the difficulty in finding enough patients to include in a trial and a comparator arm, the sample group studied during the BLINCYTO™ MT 103-211 pivotal clinical trial sufficiently isolates the patient population that the BLINCYTO™ technology is intended to treat. We also agree with the applicant that, given the challenges of conducting a trial with a control arm and the use of historical comparator data, the BLINCYTO™ study MT 103-211 is a reasonable study to show substantial clinical improvement at this junction. However, if approved for new technology add-on payments, we would continue to monitor ongoing Phase III studies to determine if the substantial clinical improvement demonstrated in the BLINCYTO™ study MT 103-211 continues to exist.

Comment: Several commenters believed that the BLINCYTO™ technology demonstrates significant clinical improvement over existing therapies, and stated that patients who have not responded positively to other treatments have been able to benefit from treatment using the BLINCYTO™ technology and its use creates a bridge to alloHSCT, possibly recognized as a transplant procedure that proves to be a potentially curative treatment. While corroborating the applicant’s statements regarding the design of the BLINCYTO™ MT103-211 pivotal trial, one commenter pointed out that a response rate of 43 percent complete remission or complete remission with partial hematologic recovery (CR/CRh) as achieved in the BLINCYTO™ study MT103-211 is impressive using a population of patients diagnosed with relapsed Ph- R/R B-cell precursor ALL. Other commenters acknowledged that, while the BLINCYTO™ has its
own set of unique toxicities, such as cytokine release syndrome and neurotoxicity, these conditions are severe in only a small minority of patients. Another commenter stated that its experience with most patients has proven that the use of the BLINCYTO™ technology is well tolerated, and its effects positively contrast to the severe side effects associated with multi-agent chemotherapy salvage regiments that these patients would otherwise experience if access to treatment with the BLINCYTO™ technology were not available. The commenter further noted that, if patients treated using the BLINCYTO™ technology respond positively and it is well-tolerated, the patient has the option of becoming a candidate for alloHSCT. As a result, the commenter pointed out that positive response to treatment using the BLINCYTO™ lessens the need for patient’s excessive exposure to toxic multi-agent chemotherapy, which has a lower response rate and the potential to cause complications that can become a preventative for these patients from proceeding to alloHSCT.

Response: We appreciate the applicant’s additional information and the commenters’ input. As noted by one commenter, we recognize that a 43 percent complete or partial remission rate is impressive using a small sample size of a population of patients diagnosed with Ph- R/R B-cell precursor ALL. We also acknowledge that the treatment of patients using currently available combination chemotherapy, or the standard treatment for this disease, has an equivalent or lower rate of complete or partial remission, as well as excessively exposes patients to toxicities that may often be severe. Therefore, we believe that the BLINCYTO™ technology offers a treatment option for Medicare beneficiaries that represents a substantial clinical improvement over existing
treatment options for patients who are unresponsive to currently available treatment options and allows many patients the opportunity to access alternative less invasive options, and also provides a bridge to alloHSCT, the only potentially curative option for patients who have been diagnosed with Ph- R/R B-cell precursor ALL. We agree with the commenters that the BLINCYTO™ technology represents a substantial clinical improvement over existing technologies in a patient population diagnosed with Ph- R/R B-cell precursor ALL, or whose only other treatment option for bridging to alloHSCT has potentially worse outcomes and excessive exposure to toxicities.

After consideration of the public comments we received, we have determined that the BLINCYTO™ technology meets all of the criteria for approval of new technology add-on payments. Therefore, we are approving new technology add-on payments for the BLINCYTO™ technology for FY 2016. Cases involving the BLINCYTO™ technology that are eligible for new technology add-on payments will be identified by ICD-10-PCS procedure codes XW03351 or XW04351.

Comment: Although the applicant considered the cost and expected use based on a variable number of days for treatment in its costs analyses, the applicant recommended that CMS consider and use the cost of the full 28-day inpatient treatment cycle as the expected length of treatment when determining the maximum new technology add-on payment for cases involving the BLINCYTO™ rather than the average cost of lesser number of days used as other variables. The applicant noted that a single treatment cycle using the BLINCYTO™ consists of 28 days of continuous infusion, and each cycle of treatment is separated by a 2-week treatment-free interval. The applicant recommended
that the initial dose of BLINCYTO™ in the first cycle consist of 9 mcg/day for week 1 (first 7 days) of treatment and the dose is increased to 28 mcg/day starting at week 2 through week 4 of the first cycle. The applicant further stated that all subsequent cycles are recommended to be dosed at 28 mcg/day throughout the entire 28-day treatment period. As further explained by the applicant, for each cycle of therapy, a patient will receive one vial (35 mcg) of BLINCYTO™ per day over the entire 28-day treatment period.

According to the applicant, if the maximum new technology add-on payment for cases involving the BLINCYTO™ is capped at a level less than 50 percent of the estimated costs of the full 28-day inpatient treatment cycle, the actual add-on payment would be well below the cost of care for some patients. The applicant believed that if CMS set the maximum add-on payment amount based on the full 28-day treatment cycle, it would avoid the risk of underpaying or overpaying for cases involving the BLINCYTO™ or cases not performed in the inpatient setting and paid for under the IPPS that have fewer inpatient days. The applicant explained that during the treatment cycle using the BLINCYTO™, infusion bags are changed every 24 to 48 hours and hospitals would only be charged for the number of bags of BLINCYTO™ that are used during the inpatient stay under the IPPS and when the product is provided while the patient is admitted. Therefore, for those patients who have an inpatient length of stay that is shorter than the 28-day treatment cycle, the applicant stated that the add-on payment would be based only on the costs associated with the number of days that the patient received treatment using the BLINCYTO™ technology in the inpatient setting. The
applicant stated that CMS would not be paying the maximum add-on payment amount in those cases and pointed out that CMS would only pay the maximum add-on payment amount for cases that require the patient to remain in the inpatient setting in order to receive treatment using the BLINCYTO™ technology for the entire 28-day treatment cycle.

The applicant stated that it recognized that CMS may be concerned that it may not be able to differentiate which charges on claims should trigger eligibility for the new technology add-on payment. In addition, the applicant referenced section 1886(d)(5)(K)(ii)(III) of the Act, which refers to an additional payment in an amount that adequately reflects the estimated average cost of such service or technology, and CMS’s policy of limiting payment to 50 percent of the cost of the technology, as codified under § 412.88(a)(2)(i) of our regulations. However, the applicant believed that limiting new technology add-on payments for cases involving the BLINCYTO™ technology if the maximum payment amount is based on an expected average number of days of care may inappropriately limit the total payment for the case, which the applicant asserted is inconsistent with the statute. The applicant further stated that if the new technology maximum add-on payment is capped at a level less than 50 percent of the estimated costs of case based on the full 28-day cycle, it may negatively impact access to care for those patients who require a longer inpatient admission. The applicant explained that, in the case of the BLINCYTO™ technology, the cost of the technology is likely to be a significant driver in the overall cost of the admission and it is less likely that other charges unrelated to the use of the BLINCYTO™ technology would be the primary
driver for an increased new technology add-on payment amount. The applicant indicated that using a methodology that relies on the average cost of a case that is based on a number of treatment days that is less than the 28-day treatment cycle to establish the maximum add-on payment amount would disadvantage any hospital that treats Medicare beneficiaries who remain admitted to the hospital for longer than the mean total inpatient days per cycle observed in clinical trials. Therefore, the applicant encouraged CMS to set the maximum new technology add-on payment amount based on the full 28-day course of therapy.

Response: We disagree with the applicant that it would be most appropriate to determine the maximum new technology add-on payment amount for a case based on the recommended estimated 28-day treatment cycle. As the applicant acknowledged, in cases where there are different dosages administered on different days and different device sizes being used, it would be difficult for us to differentiate which charges on claims would trigger the case’s eligibility for the new technology add-on payment. It is historical practice for CMS to make the new technology add-on payment based on the average cost of the technology and not the maximum. For example, in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53358), we approved new technology add-on payments for DIFICID™ based on the average dosage of 6.2 days rather than the maximum 10 day dosage. In addition, as discussed below, based on the clinical trial data, the weighted average of cycle 1 and 2 treatment length is 17 days, as none of the five cycles typically reach 28 days. Just as some cases’ length of stay will be above the weighted mean and a hospital’s costs may exceed the payment for these cases, other
cases’ length of stay may be below the weighted mean and hospitals costs would be lower than what the hospital is paid. Therefore, because we are not able to differentiate which charges on claims would trigger the case’s eligibility for the new technology add-on payment if we based the maximum new technology add-on payment amount for a case on a 28-day treatment cycle, we believe that it is appropriate to use the average cost and the weighted mean of the first two cycles to establish the maximum new technology add-on payment for the BLINCYTO™ technology. However, the applicant is welcome to submit additional data for FY 2017 that demonstrates changes to the weighted mean of the first two cycles.

In order to establish the maximum new technology add-on payment amount for a case involving the BLINCYTO™ technology for FY 2016, we used the weighted average of the cycle 1 and cycle 2 observed treatment length. Specifically, in the Phase II trial, the most recent data available, 92 patients received cycle 1 for an average length of 21.2 days, and 52 patients received cycle 2 for an average length of 10.2 days. The weighted average of cycle 1 and 2 treatment length is 17 days. We note that a small number of patients also received 3 to 5 treatment cycles. However, based on the data provided, these cases do not appear to be typical at this point and we excluded them from this calculation. We note that, if we include all treatment cycles in this calculation, the weighted average number of days of treatment is much lower, 10 days. Using the clinical data provided by the applicant, we believe that setting the maximum new technology add-on payment amount for a case involving the BLINCYTO™ technology for FY 2016 based on a 17-day length of treatment cycle is representative of historical and current
practice. For FY 2107, if new data on length of treatment are available, we would consider any such data in evaluating the maximum new technology add-on payment amount.

In the application, the applicant estimated that the average Medicare beneficiary would require a dosage of 9mcg/day for the first 7 days under the first treatment cycle, followed by a dosage of 28mcg/day for the duration of the treatment cycle, as well as all days included in subsequent cycles. All vials contain 35mcg at a cost of $3,178.57 per vial. The applicant noted that all vials are single-use. Therefore, we have determined that cases involving the use of the BLINCYTO™ technology would incur an average cost per case of $54,035.69 (1 vial/day x 17 days x $3,178.57/vial). Under 42 CFR 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the technology or 50 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum new technology add-on payment amount for a case involving the use of the BLINCYTO™ is $27,017.85 for FY 2016.

b. DIAMONDBACK 360 Coronary Orbital Atherectomy System

Cardiovascular Systems, Inc. submitted an application for new technology add-on payments for the DIAMONDBACK 360® Coronary Orbital Atherectomy System (OAS) (DIAMONDBACK® Coronary OAS) for FY 2016. The DIAMONDBACK® Coronary OAS is a percutaneous orbital atherectomy system used to facilitate stent delivery in patients who have been diagnosed with coronary artery disease and severely calcified coronary artery lesions. The system uses an electrically driven, diamond-coated crown to
reduce calcified lesions in coronary blood vessels. The components of the DIAMONDBACK® Coronary OAS are: (1) the DIAMONBACK 360® Coronary Orbital Atherectomy Device (OAD); (2) the VIPERWIRE Advance Coronary Guide Wire; (3) the VIPERSLIDE Lubricant; and (4) the Orbital Atherectomy System Pump. The DIAMONBACK 360® OAD is designed to track exclusively over the VIPERWIRE, which, in turn, uses the VIPERSLIDE Lubricant to reduce the friction between the drive shaft of the DIAMONBACK 360® OAD and the VIPERWIRE. The Orbital Atherectomy System Pump provides the saline pumping mechanism and power to the DIAMONBACK 360® OAD. All DIAMONDBACK® Coronary OAS devices are single use and provide sterile application, except for the pump.

With respect to the newness criterion, the DIAMONDBACK® Coronary OAS received FDA pre-market approval as a Class III device on October 21, 2013. As stated in section II.G.1.a. of the preamble of the proposed rule and this final rule, effective October 1, 2015 (FY 2016), the ICD-10 coding system will be implemented. In the proposed rule, we indicated that the applicant had applied for a new ICD-10-PCS procedure code for consideration at the March 18-19, 2015 ICD-10-CM/PCS Coordination and Maintenance Committee Meeting. In this final rule, we note that the following new ICD-10-PCS procedure codes have been established to uniquely identify the procedures involving the DIAMONDBACK® Coronary OAS, effective October 1, 2015: X2C1361 (Extirpation of matter from coronary artery, one site using orbital atherectomy technology, percutaneous approach, new technology group 1); X2C1361 (Extirpation of matter from coronary artery, two sites using orbital atherectomy technology, percutaneous approach, new technology group 1).
technology, percutaneous approach, new technology group 1); X2C2361 (Extirpation of matter from coronary artery, three sites using orbital atherectomy technology, percutaneous approach, new technology group 1); and X2C3361 (Extirpation of matter from coronary artery, four or more sites using orbital atherectomy technology, percutaneous approach, new technology group 1). More information on this request and our approval can be found on the CMS Web site at:


According to the applicant, the DIAMONDBACK® Coronary OAS is the only atherectomy device that uses centrifugal force and orbital motion and, therefore, is not represented by the rotational, directional, or laser atherectomy device categories (as exemplified by Boston Scientific’s Rotablator system, the SilverHawk/Covidien devices, and the Spectranetics ELCA Coronary Laser, respectively). In addition, the applicant asserted that the DIAMONDBACK® Coronary OAS is the first and only device approved for use in the United States as a treatment for patients who have been diagnosed with severely calcified coronary artery lesions to facilitate stent delivery and optimal deployment. Therefore, the applicant believed that the DIAMONDBACK® Coronary OAS meets the newness criterion.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24439), we presented our concern that, in addition to patients who have been diagnosed with severely calcified coronary artery lesions, the applicant also indicated that the DIAMONDBACK® Coronary OAS may be used in the treatment of patients who do not have severely
calcified coronary artery lesions (for example, patients for whom the degree of calcification may not be severe) and that this technology may be substantially similar to the rotational, directional, and laser atherectomy devices that are already on the U.S. market for the treatment of such patients. In the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43813 through 43814), we established criteria for evaluating whether a new technology is substantially similar to an existing technology, specifically: (1) whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome; (2) whether a product is assigned to the same or a different MS-DRG; and (3) whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population. If a technology meets all three of these criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments.

With respect to the first criterion, whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome, the applicant maintained that the technology uses a differential sanding mechanism of action to remove plaque while potentially minimizing damage to the medial layer of the vessel. According to the applicant, this mechanism of action is the only one among atherectomy devices to use centrifugal force and orbital motion and, therefore, is not represented by the rotational, directional, or laser atherectomy device categories. We stated in the proposed rule that the applicant did not include with its application data to show the effectiveness of the orbital mechanism of the DIAMONDBACK® Coronary OAS compared to the
effectiveness of the rotational, directional, and laser mechanisms of similar devices used in treating patients with calcified coronary artery lesions. Therefore, we stated that we could not determine if the device’s mechanism of action is unique among atherectomy devices as the applicant claimed.

With respect to the second criterion, whether a product is assigned to the same or a different MS-DRG, the applicant determined that coronary atherectomy cases for which the DIAMONDBACK® Coronary OAS technology would be appropriate are assigned to MS-DRG 246 (Percutaneous Cardiovascular Procedure with Drug-Eluting Stent with MCC or 4+ Vessels/Stents); MS-DRG 247 (Percutaneous Cardiovascular Procedure with Drug-Eluting Stent without MCC); MS-DRG 248 (Percutaneous Cardiovascular Procedure with Non-Drug-Eluting Stent with MCC or 4+ Vessels/Stents); MS-DRG 249 (Percutaneous Cardiovascular Procedure with Non-Drug-Eluting Stent without MCC); MS-DRG 250 (Percutaneous Cardiovascular Procedure without Coronary Artery Stent with MCC), and MS-DRG 251 (Percutaneous Cardiovascular Procedure without Coronary Artery Stent without MCC). In the proposed rule, we stated our concern that potential cases involving the DIAMONDBACK® Coronary OAS would be assigned to the same MS-DRGs as other cases that use atherectomy devices currently available on the U.S. market.

With respect to the third criterion, whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population, the applicant maintained in its application that the DIAMONDBACK® Coronary OAS is the first and only device approved for use in the United States as a
treatment for severely calcified coronary lesions. According to the applicant, advances in current stent technology have allowed most patients with coronary lesions to be treated effectively with relatively favorable long-term outcomes. However, there remain subsets of the patient population that are still challenging to treat, including patients with severe coronary calcification. According to the applicant, the DIAMONDBACK® Coronary OAS is the only atherectomy device currently available to treat this patient population because it is the first and only device approved for use in the United States for severely calcified coronary lesions. However, in the proposed rule, we stated our concern that other devices currently available on the U.S. market may not necessarily be contraindicated for use in treating patients with severe coronary calcification. Specifically, we were not sure if patients with less than severe coronary calcification could be appropriately treated using the DIAMONDBACK® Coronary OAS or other atherectomy devices currently available on the U.S. market in order to determine if the DIAMONDBACK® Coronary OAS treats a different patient population as the applicant claimed.

We invited public comments on if, and how, the DIAMONDBACK® Coronary OAS meets the newness criterion.

Comment: In a public comment, the applicant asserted that the DIAMONDBACK® Coronary OAS is not substantially similar to the rotational, laser, or other atherectomy devices currently on the U.S. market. Further, with respect to our concern about the device’s mechanism of action, the applicant stated that the lack of data comparing the performance of the DIAMONDBACK® Coronary OAS to other
atherectomy devices is primarily a result of the FDA’s decision to not allow a controlled trial to be conducted that compared the efficacy and effects of FDA-approved technologies or devices and the efficacy and effects of another treatment that is not FDA-approved. Therefore, the applicant stated, a controlled trial was not conducted because currently there are no other technologies specifically approved for the treatment of severely calcified coronary lesions in the United States.

The applicant also believed the CMS has set a precedent, in the past, by approving devices for new technology add-on payments that treated conditions that were assigned to the same MS-DRGs as other devices, which were reported using the same ICD-9-CM procedure codes. The applicant noted as an example the recent approval of the Zilver® PTX Drug-Eluting Peripheral Stent, a drug-eluting stent used for the treatment of patients diagnosed with superficial femoral arteries, procedures that are assigned to MS-DRGs 252, 253, and 254, all of which contain other drug-eluting stents (78 FR 50583). As a result, the applicant believed that CMS’ concern and position in regard to contraindication would have precluded the Zilver® PTX technology from being approved for new technology add-on payments because there were other stents available on the U.S. market that also were not contraindicated to treat patients diagnosed with superficial femoral arteries, as well as other devices approved and available to treat patients diagnosed with superficial femoral arteries. The applicant noted that the current application for new technology add-on payments is for use of the DIAMONDBACK® Coronary OAS in the treatment of patients diagnosed with severely calcified lesions, which the applicant believed would be appropriately identified using the new ICD-10
codes it requested. Therefore, the applicant believed that isolating this patient population by using the ICD-10 codes to identify procedures involving the DIAMONDBACK® Coronary OAS also may prevent diffusion of the use of the device into inappropriate patient populations.

Response: We appreciate the applicant’s additional input. However, we remain concerned that the DIAMONDBACK® Coronary OAS is substantially similar to other atherectomy devices that are currently available on the U.S. market. Specifically, we are concerned that the orbital mechanism of action performs the same basic motion and has the same function as the current standard of care, rotational atherectomy devices. Although the applicant stated that FDA did not grant approval to conduct a trial comparing approved versus non-approved technologies, we note that the FDA does not prohibit manufacturers from performing other trials outside of the trials included under its approval process. Moreover, we are concerned that the patient population of cases that may be eligible for treatment using the DIAMONDBACK® Coronary OAS also currently has access to other atherectomy devices and similar technologies that are also used in the treatment of similar conditions. We acknowledge that the Zilver® PTX technology was approved for new technology add-on payments and that procedures involving this technology are assigned to MS-DRGs that contain other procedures involving stents. Also, we acknowledge that the Zilver® PTX was approved for new technology add-on payments when it had been assigned to the same MS-DRGs as other stents, and that the Zilver® PTX potentially could have been used to treat a similar or same patient population as other technologies used in procedures involving stents. However, the
Zilver\textsuperscript{®} PTX was also the first drug-eluting stent technology at the time we approved the application for new technology add-on payments and, therefore, its new mechanism of action set the basis and precedent for new technology add-on payment approval of similar technologies. Absent this, we would have had the same concerns about contraindication for the Zilver\textsuperscript{®} PTX technology as we currently have for the DIAMONDBACK\textsuperscript{®} Coronary OAS. After consideration of the public comments we received, we remain concerned if the DIAMONDBACK\textsuperscript{®} Coronary OAS meets the newness criteria.

With respect to the cost criterion, the applicant determined that cases representing patients who have been treated with transluminal coronary atherectomy for which the DIAMONDBACK\textsuperscript{®} Coronary OAS technology is appropriate map to MS-DRGs 246 through 251 as noted earlier in this section. The applicant searched the claims data in the FY 2013 MedPAR file for cases assigned to these six MS-DRGs (which contained claims for inpatient hospital discharges from October 1, 2012 to September 30, 2013) and identified 5,443 claims for cases reporting ICD-9-CM procedure code 17.55. The applicant indicated that it further examined the claims data for the cases that also reported ICD-9-CM diagnosis code 414.4, and identified 250 claims for cases with a diagnosis of calcified coronary lesion. The applicant stated that it applied the standard trims used by CMS when selecting cases for IPPS rate calibration. Therefore, it included cases from IPPS hospitals, including hospitals located in Maryland, and excluded cases paid by Medicare Advantage plans, statistical outlier cases, and cases from hospitals that did not submit charges in a sufficiently broad range of revenue centers.
The applicant reported that it conducted 16 sensitivity analyses based on four areas of uncertainty: whether to include all coronary atherectomy cases in the analysis or only those cases that reported calcified coronary artery lesions; whether to consider a lower value or higher value as the acquisition cost of a typical atherectomy catheter; whether to use the full cost of the DIAMONDBACK® Coronary OAS catheter and materials or only the cost of the catheter alone; and whether to include or exclude a factor to inflate costs to FY 2015 costs. Based on the result of the sensitivity analyses with all 16 combinations of the values that the applicant performed, the applicant reported that it determined that the average case-weighted standardized charge per case for the DIAMONDBACK® Coronary OAS would exceed the average case-weighted threshold amounts for MS-DRGs 246 through 251 in Table 10 of the FY 2015 IPPS/LTCH PPS final rule. According to the applicant, the average case-weighted standardized charge per case using the DIAMONDBACK® Coronary OAS device exceeds the average case-weighted threshold amounts for MS-DRGs 246 through 251 in Table 10 by approximately $6,000 to $15,000, depending on the results determined by using the combination of values of the four areas of uncertainty. As described below, the applicant believed that using the scenario that produced the lowest difference between the average case-weighted standardized charge per case determined by the applicant’s analyses and the average case-weighted threshold amounts for MS-DRGs 246 through 251 from Table 10 in the FY 2015 IPPS/LTCH PPS final rule still exceeded the Table 10 threshold amounts by $5,803.
Using the scenario that produced the lowest difference between the average case-weighted standardized charge per case determined by the applicant and the average case-weighted threshold amount in the FY 2015 IPPS/LTCH PPS final rule Table 10, the applicant included all cases reporting coronary atherectomy (specifically, the 5,443 cases reported with ICD-9-CM procedure code 17.55) in this analysis. The applicant removed the costs of the other specific technologies used during these procedures; that is, the applicant removed the higher of the two standard catheter costs, and added the full cost of the DIAMONDBACK® Coronary OAS catheter alone. To estimate the cost for the new technology, the applicant divided the projected cost per patient by the national average CCR for supplies (0.292) included in the FY 2015 IPPS/LTCH PPS final rule. This resulted in an average case-weighted average standardized charge per case of $86,080. The applicant stated that it did not apply an inflation factor to convert the FY 2013 costs to FY 2015 costs for this analysis. However, in other analyses, the applicant used the 2-year inflation factor of 10.44 percent taken from the FY 2015 IPPS/LTCH PPS final rule (79 FR 50379), which was the final inflation factor used in the CMS outlier threshold calculation for the applicable fiscal year. The applicant then determined that its average case-weighted standardized charge per case exceeded the average case-weighted threshold amounts for MS-DRGs 246 through 251 in Table 10 of the FY 2015 IPPS/LTCH PPS final rule by $5,803. The applicant maintained that all of the results of the analyses using this methodology that were included in its application likewise exceeded the Table 10 threshold amounts for these MS-DRGs and, therefore, demonstrated that the DIAMONDBACK® Coronary OAS meets the cost criterion.
Using the scenario that produced the lowest difference between its average case-weighted standardized charge per case and the average case-weighted threshold amounts for MS-DRGs 246 through 251 from the FY 2015 Table 10 for the analysis of the subgroup of cases representing patients who have severely calcified coronary artery lesions, the applicant reported that it included all of the cases that report coronary atherectomy that also reported diagnosis of calcified coronary lesions (250 cases reporting ICD-9-CM procedure code 414.4). As in the previous scenario, the applicant removed costs of the other specific technologies used during these other procedures; that is, the applicant removed the higher of the two standard catheter costs, and added the full cost of the DIAMONDBACK® Coronary OAS catheter alone. To estimate the costs for the new technology, the applicant divided the projected cost per patient by the national average CCR for supplies (0.292) in the FY 2015 IPPS/LTCH PPS final rule. This resulted in an average case-weighted standardized charge per case of $86,779. The applicant did not apply an inflation factor to convert the FY 2013 costs to FY 2015 costs for this analysis. The applicant then determined that the average case-weighted standardized charge per case exceeded the FY 2015 Table 10 threshold amount of $80,807 by $5,972. The applicant maintained that all of the results of the analyses using this methodology that were included in its application likewise exceeded the Table 10 threshold amounts for these MS-DRGs and, therefore, demonstrated that the DIAMONDBACK® Coronary OAS meets the cost criterion.

In the proposed rule, we questioned some of the assumptions underlying the four areas of uncertainty that were the basis for the applicant’s sensitivity analyses. We stated
that we would like to know the basis of the higher value that the applicant considered to be a possible acquisition cost of a typical atherectomy catheter. We also stated our concern that the applicant did not provide a basis for determining the two values it used to remove the costs associated with the other specific technologies that may have been used during the cases included in the analysis. We invited public comments on if, and how, the DIAMONDBACK® Coronary OAS meets the cost criterion.

Comment: The applicant (the manufacturer) addressed CMS’ concerns that were presented in the proposed rule by conducting another cost analysis. The applicant reported that it determined the cost of the existing technology by utilizing data from the Millennium Research Group, which publishes an annual report in the coronary market. The applicant referenced the average sales price in 2015 for rotational atherectomy, which is the standard device currently used in coronary atherectomy procedures. The applicant stated that the additional analysis included the cost for associated supplies and the average sales price of the rotational atherectomy catheter. The applicant maintained that, in both cost analyses, the DIAMONDBACK® Coronary OAS exceeded the cost threshold and, therefore, meets the cost criterion.

Response: We appreciate the applicant’s response and subsequent analyses, which we believe respond to the concerns we raised in the proposed rule.

After consideration of the applicant’s response, we have determined that the DIAMONDBACK® Coronary OAS meets the cost criterion.

As discussed in the proposed rule, in regard to substantial clinical improvement, the applicant maintained that the DIAMONDBACK® Coronary OAS offers a treatment
option for a patient population that has been diagnosed with severely calcified coronary arteries that are ineligible for currently available treatments and results in improved clinical outcomes for patients who have been diagnosed with complex coronary artery disease related to severely calcified coronary arteries. The applicant also stated that the DIAMONDBACK® Coronary OAS device significantly improves clinical outcomes for this patient population when compared to currently available treatment options, including reduced mortality, a reduced rate of device-related complications, a decreased rate of subsequent diagnostic or therapeutic interventions (for example, due to reduced rate of recurrence of the disease process), a decreased number of future hospitalizations or physician visits, more rapid beneficial resolution of the disease process treatment because of the use of the device, decreased pain, bleeding, or other quantifiable symptoms, and reduced recovery time.

The applicant included data from its ORBIT II study to demonstrate that the technology represents substantial clinical improvement over currently available treatment options, including improvement in mortality rates, major adverse cardiac event (MACE) rates, revascularization rates, and cost savings. According to the applicant, its ORBIT II study was a pivotal clinical study to evaluate the safety and effectiveness of the DIAMONDBACK® Coronary OAS in treating a subset of patients who have severely calcified coronary artery lesions. The applicant explained that the ORBIT II study was a prospective, multicenter, non-blinded clinical trial that enrolled 443 consecutive patients who have been diagnosed with severely calcified coronary lesions at 49 U.S. sites from May 25, 2010 to November 26, 2012, in which the DIAMONDBACK® Coronary OAS
was used to prepare patients who had severely calcified coronary lesions for stent placement. According to the applicant, the DIAMONDBACK® Coronary OAS produced clinical outcomes that exceeded its ORBIT II study’s two primary safety and efficacy endpoints within a patient population. The primary safety endpoint was 89.6 percent freedom from 30-day MACE, compared with the performance goal of 83 percent. The primary efficacy endpoint (residual stenosis <50 percent post-stent without in-hospital MACE) was 88.9 percent, compared with the performance goal of 82 percent. The applicant stated that, during the trial, stent delivery after use of the DIAMONDBACK® Coronary OAS occurred successfully in 97.7 percent of cases with <50 percent residual stenosis in 98.6 percent of the patients in the study. The applicant further stated that low rates of in-hospital Q-wave MI, cardiac death, and target vessel revascularization also were reported. The applicant believed that the results of its ORBIT II study met both the primary safety and efficacy endpoints by significant margins and not only helped to facilitate stent delivery, but also improved both acute care and 30-day clinical outcomes compared to historical controls.

The applicant also compared the results of its ORBIT II study with historical study data that measured the performance of other coronary atherectomy devices used in the treatment of patients who have moderate to severely calcified coronary lesions. According to the applicant, the death and revascularization rates reported in the ORBIT II study were much lower than those rates reported in the literature for patients who had severely calcified coronary lesions. For example, inpatient cardiac death rates were reported on one reported study in the literature (Mosseri, et al.) as 1.6 percent and in
another reported study (Abdel-Wahab, et al.) as 1.7 percent, while another study report (Clavijo, et al.) reported death at 30 days as 2.6 percent and 1.5 percent for RA + DES and DES, respectively.\(^9\)\(^{10}\)\(^{11}\) The applicant maintained that, compared to these historical study data, the data results of the ORBIT II study demonstrated much lower cardiac death rates of 0.2 percent in-hospital and 0.2 percent at 30 days. The applicant further reported that the results of its ORBIT II study showed lower mortality rates at 9 months and 1 year (3 percent and 4.4 percent, respectively) compared to previously reported rates (5.0 percent and 5.85 percent at 9 months and 6.3 percent at 1 year). The study report by Mosseri, et al. also reported a 1.6 percent in-hospital target lesion revascularization rate (TLR) in a patient population with more superficial calcification,\(^12\) whereas the study report by Clavijo, et al. reported a 1.3 percent 30-day TLR rate for the RA + DES group.\(^13\) In contrast, the applicant reported that the results of the ORBIT II study showed a lower TLR rate of 0.7 percent (both in-hospital and 30-day), even though more patients who had severely calcified coronary lesions were included in the study, and the patients were older and had more comorbidities. The applicant stated that, at 1-year, the results of the ORBIT II study showed a higher freedom from TVR/TLR rate (94.1 percent)


compared to previously reported rates (81.7 percent to 91.3 percent), even though patients who had more severely calcified coronary lesions were included in the ORBIT II study. According to the applicant, the MACE rate of 16.4 percent indicated in the results of the ORBIT II study was lower than the rate of the ROTAXUS (24.4 percent) and ACUITY/HORIZONS (19.9 percent) trials despite the use of a less stringent standard of severe calcification in the latter studies.\textsuperscript{14,15} Further, the applicant reported that patients in the ORBIT II study experienced a lower rate of device-related complications (such as dissection, abrupt closure, and perforation) compared to rates in the historical studies. Overall, the applicant asserted that a comparison of data from the ORBIT II study and the data from historical studies demonstrates that patients in the ORBIT II study had more severe calcium coronary lesions and potentially were more difficult to treat, although they experienced better outcomes.

In the proposed rule, we stated our concern that the ORBIT II study conducted by the applicant lacked a control arm. The applicant asserted in its original application that, although other FDA-approved coronary atherectomy products are available, none of them are indicated for the treatment of patients who have severely calcified coronary arteries and, therefore, could not be used as a control. The applicant believed that it accounted for this study limitation by comparing the results of the ORBIT II study to historical control subjects documented in published reports. However, we stated that we continue

to be concerned that meaningful conclusions cannot be drawn from a study that did not include a comparator group. Moreover, we questioned the reliability of comparing data from the ORBIT II study to historical study data because different definitions of severe calcification used in each study can make absolute comparisons difficult and/or invalid.

We invited public comments on if, and how, DIAMONDBACK® Coronary OAS meets the substantial clinical improvement criterion.

Comment: Several commenters believed that the DIAMONDBACK® Coronary OAS meets the substantial clinical improvement criterion and, therefore, recommended that CMS approve the application for new technology add-on payments for FY 2016. In particular, the applicant stated in its public comment that the single-arm ORBIT II trial and historical comparator data are sufficient to demonstrate substantial clinical improvement because the results show that the DIAMONDBACK® Coronary OAS performed better than other atherectomy devices on key safety and efficacy endpoints despite a more rigorous definition of severe calcification in the ORBIT II trial. The applicant also emphasized that the ORBIT II trial is one of the few FDA-approved single-arm coronary PCI trials in the last two decades, and that the lack of a comparator group does not negate the logic and scientific validity of the trial. Other commenters believed that there is adequate clinical and economic evidence to justify an approval of new technology add-on payments for the DIAMONDBACK® Coronary OAS due to the high-risk and resource intensive treatment that is typical for a patient diagnosed with severely calcified coronary lesions.
Response: We appreciate the commenters’ input. However, we do not believe the safety and efficacy endpoints used in the ORBIT II trial represent a substantial clinical improvement over existing atherectomy devices available and accessible to the Medicare population. While we recognize that the DIAMONDBACK® Coronary OAS has met the FDA’s standards for safety and effectiveness, the new technology add-on payment policy requires that the technology demonstrate a substantial clinical improvement, which is not inherent in FDA’s regulatory process. Moreover, while we agree with the commenters that patients with severely calcified coronary lesions require more resource intensive treatment and are at higher risk of responding poorly to currently available treatments, we also are not convinced that this patient population is not currently being treated with the use of a rotational, directional, or laser atherectomy device that achieves the same or similar therapeutic outcomes as the DIAMONDBACK® Coronary OAS. Because the applicant did not include data to compare the performance of currently available atherectomy devices used in treating patients diagnosed with severely calcified coronary lesions, we remain unable to make a determination as to whether use of the DIAMONDBACK® Coronary OAS results in a substantial clinical improvement over existing and currently available treatment options for the Medicare population.

After consideration of the public comments we received, we have determined that the DIAMONDBACK® Coronary OAS does not meet the criteria for approval of a new technology add-on payment. We remain concerned as to whether the DIAMONDBACK® Coronary OAS meets the newness criteria. Furthermore, we do not
believe that the device represents a substantial clinical improvement over existing and currently available treatment options. Therefore, we are not approving new technology add-on payments for this technology for FY 2016.

c. CRESEMBA® (Isavuconazonium)

Astellas Pharma US, Inc. (Astellas) submitted an application for new technology add-on payments for CRESEMBA® (isavuconazonium) for FY 2016. CRESEMBA® is an intravenous and oral broad-spectrum antifungal used for the treatment of adults who have severe invasive and life-threatening fungal infections, including invasive aspergillosis and mucormycosis (zygomycosis).

CRESEMBA® received FDA approval on March 6, 2015. The FDA indication for the use of this product is for the treatment of adults who have been diagnosed with invasive aspergillosis and mucormycosis. Isavuconazonium has two formulations: an intravenous (IV) solution and an oral capsule. The IV formulation of CRESEMBA® is administered at 200 mg while the oral formulation is administered at 100 mg. Dosing is not weight-based. According to the applicant, treatment of patients who have been diagnosed with these types of infection starts with up to 3 days of IV therapy in the inpatient hospital setting followed by daily oral therapy administered for the remainder of the inpatient stay and also the duration of treatment period, which is approximately 13.4 days.

As stated in section II.G.1.a. of the preamble of the proposed rule and this final rule, effective October 1, 2015 (FY 2016), the ICD-10 coding system will be implemented. In the proposed rule, we noted that the applicant had applied for a new
ICD-10-PCS procedure code for consideration at the March 18-19, 2015 ICD10-CM/PCS Coordination and Maintenance Committee Meeting. In this final rule, we note that the following two new ICD-10-PCS procedure codes have been established to uniquely identify procedures involving CRESEMBA®: XW03341 (Introduction of isavuconazole anti-infective into peripheral vein, percutaneous approach, new technology group 1); and XW04331 (Introduction of isavuconazole anti-infective into central vein, percutaneous approach, new technology group 1). More information on this request and the approval can be found on the CMS Web site at:


The applicant maintained that CRESEMBA® meets the newness criterion based on the March 6, 2015 FDA approval of the technology.

CRESEMBA® is part of the category of drugs known as azole antifungal drugs that inhibit the enzyme lanosterol 14 α-demethylase. Inhibiting this enzyme disrupts the process of converting lanosterol to ergosterol and, therefore, depletes the level of ergosterol in the fungal membrane and inhibits fungal growth. Azole antifungal drugs are used to treat patients with fungal infections such as aspergillosis, and other azole antifungal drugs also used for the treatment of these patients include voriconazole, posaconazole, and itroconazole. The CDC Web site at http://www.cdc.gov/fungal/diseases/aspergillosis/treatment.html states that voriconazole is used for the treatment of patients with invasive aspergillosis, but amphotericin B (Amp B) as well as other antifungal drugs can be used if patients cannot take voriconazole or the infection is not responsive to voriconazole. Amphotericin B is the first-line of
therapy and the only FDA-approved treatment of patients diagnosed with mucormycosis. Amphotericin B binds with ergosterol, a component of fungal cell membranes, and forms a transmembrane channel that leads to membrane leakage, which is the primary effect leading to fungal cell death. The third class of antifungal drugs is echinocandins; examples in this group are caspofungin, micafungin, and anidulafungin. Echinocandins noncompetitively inhibit beta-1, 3-D-glucan synthase enzyme complex in susceptible fungi to disturb fungal cell glucan synthesis. Beta-glucan destruction prevents resistance against osmotic forces, which leads to cell lysis (http://www.cdc.gov).

According to the applicant, echinocandins are effective against aspergillosis. Voriconazole is the recommended treatment for patients diagnosed with invasive aspergillosis. However, amphotericin B and other antifungal drugs may also be used if voriconazole cannot be administered because a patient is suffering from porphyria (a rare inherited blood disorder) or has had an allergic reaction to the drug or the infection is not responding to treatment using voriconazole. In addition, according to the applicant, the efficacy of azole antifungal drugs, such as posaconazole, in treating mucurmycosis is uncertain but has been described in certain situations.

The applicant stated that it is challenging to clinically distinguish the type of antifungal infection a patient may be experiencing. Therefore, the typical treatment of patients exhibiting symptoms of an invasive fungal infection includes both amphotericin B and voriconazole. According to the applicant, for the Medicare population, both drugs are usually administered in combination because it is difficult and time-consuming to delineate the specific type of fungal infections. The applicant noted that these patients
are often severely ill and immediate treatment of these symptoms is essential to the effective management of their condition.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24442), we stated we were concerned that CRESEMBA® may not meet the newness criterion because it may be substantially similar to other currently approved antifungal drugs. We refer readers to the FY 2010 LTCH PPS final rule (74 FR 43813 through 43814) for a discussion of our established criteria for evaluating whether a new technology is substantial similar to an existing technology, specifically: (1) whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome; (2) whether a product is assigned to the same or a different MS-DRG; and (3) whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population. If a technology meets all three of these criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments.

In evaluating this technology for substantial similarity, in the proposed rule, we stated that we believe that CRESEMBA® has a similar mechanism of action as the other groups of antifungal drugs available for the treatment of patients diagnosed with serious fungal infections, such as invasive aspergillosis and mucormycosis. As previously noted, voriconazole and itraconazole also are commonly usedazole antifungals used to treat patients diagnosed with aspergillosis. The applicant maintained that the availability of the drug in an oral formulation constitutes a different mechanism of action from the current azoles. In the proposed rule, we stated that we disagreed with the applicant’s
assertion because we believe a different method of administration does not necessarily
equate to a different mechanism of action. Although the applicant maintained that this
technology is not substantially similar because it is administered orally, the applicant did
not describe why it believed a different method of administration constitutes a different
mechanism of action. Because CRESEMBA® is part of the category of drugs currently
available known as azole antifungal drugs that inhibit the enzyme lanosterol 14
a-demethylase, it appears that the mechanism of action is not different, but that merely
the method of administration differs.

With respect to the second criterion for determining substantial similarity, we
stated in the proposed rule that we believe that the use of CRESEMBA® is inclusive of
the current treatment options available to Medicare beneficiaries and is also currently
described (although not specifically) by established procedure codes that identify similar
technologies, specifically other antifungal drugs that also are used in the treatment of
patients diagnosed with similar fungal infections. The use of antifungal drugs is
considered a nonoperating room procedure, which does not impact the MS-DRG
assignment of a patient case. Therefore, the use of CRESEMBA® would not impact the
MS-DRG assignment of a particular case. Furthermore, the FDA approval for the
technology is indicated for use in the treatment of the same or similar type of disease and
the same or similar patient population. According to the applicant, CRESEMBA® is used
in conjugation with other treatments, and this is reflected in its analysis for the new
technology cost criterion. In the proposed rule, we stated our concern that this
technology is administered with the other currently available treatments and, therefore,
cannot be considered an alternative treatment option. Therefore, we stated that we believe that CRESEMBA® may be considered substantially similar to other available treatments and could not be considered to be “new” for purposes of new technology add-on payments.

We invited public comments on if, and how, CRESEMBA® meets the newness criterion and our concerns regarding how it is similar to other treatments for serious fungal infections.

Comment: One commenter (the applicant and manufacturer of CRESEMBA®) submitted comments to further support its assertion and address our concerns that CRESEMBA® meets the newness criterion. The applicant stated that although the active moiety contained in CRESEMBA® has a similar mechanism of action as the other groups of antifungal drugs available for the treatment of patients diagnosed with serious fungal infections, such as invasive aspergillosis and mucormycosis, CRESEMBA® contains a water soluble prodrug specifically developed to facilitate the systemic delivery of the active moiety. The applicant pointed out that the technology allows intravenous administration without the need for nephrotoxic excipients, such as cyclodextrins, that are present in other antifungals, which are restricted from use in the treatment of patients diagnosed with renal impairment. The applicant further noted that CRESEMBA® administered intravenously can be used in patients diagnosed with renal impairment, and dose adjustments are not necessary or recommended for the treatment of elderly patients or patients diagnosed with renal impairments.

---

The applicant further stated that other existing treatments for invasive mold infections have limitations due either to the potential for toxicity, or restrictions on its use in the treatment of certain at-risk patient populations. The commenter noted that, although the liposomal preparation of amphotericin B has reduced the potential for nephrotoxicity, it does not eliminate it completely. According to the applicant, amphotericin B is nephrotoxic when administered with calcineurin inhibitors and also requires intravenous administration, which may complicate long-term administration. The applicant reiterated that cyclodextrins used in the intravenous preparation of posaconazole, itraconazole and voriconazole exhibit additional nephrotoxicity and, therefore, its uses in the treatment of patients diagnosed with renal impairment are restricted. Therefore, the applicant believed that there is an urgent need for potent and safe antifungal agents that can be administered both orally and intravenously without increased potential for nephrotoxicity.

The applicant also clarified that CRESEMBA® does not need to be administered in conjugation with other currently available treatments. The applicant stated that the results of its phase III studies demonstrated the efficacy of the CRESEMBA® technology as a singular treatment for invasive mold infections. In addition, the applicant stated that it recognized that CRESEMBA® has some attributes that are similar to other azoles antifungals. However, it believed that CRESEMBA® offers a needed alternative therapy for the treatment of patients diagnosed with invasive aspergillosis (IA) and mucormycosis (IM), given that currently approved therapies for the treatment of IA and IM are limited by: (1) pharmacokinetic challenges and toxicity, as noted with

\[17\] Ibid.
voriconazole; and (2) sub-optimal efficacy in high-risk patients, as noted with amphotericin B. The applicant stated that these two characteristics make these therapies often unusable in the treatment of patients most likely to later suffer from a diagnosis of IA and IM (for example, immunocompromised patients), and mortality rates remain high for both diseases. The applicant further stated that patients diagnosed with progressive IA or who are intolerant of voriconazole have few viable options, and there are currently no other approved primary treatments for patients diagnosed with IM except amphotericin B. The applicant believed that CRESEMBA® is an alternative treatment option because patients who cannot tolerate other existing therapies can be treated with CRESEMBA®; otherwise, no other treatment option would be available.

The applicant asserted that data from studies of both the oral and IV formulations have shown that CRESEMBA® has a more predictable pharmacokinetic/pharmacodynamic profile compared to voriconazole. The applicant further indicated that CRESEMBA® has moderate pharmacokinetic variability, which limits the risk of sub-therapeutic or supra-therapeutic exposure, while the variability of voriconazole pharmacokinetics is high. According to the applicant, the pharmacokinetics of CRESEMBA® include: linear and dose-proportional effects following both oral and IV administration; a long half-life enabling once daily maintenance dosing; oral bioavailability of 98 percent; the absence of food or gastric pH effects; and the option to be administered via both routes of administration under fed or fasting conditions irrespective of the use of drugs that increase gastric pH. Therefore, the applicant believed
that a more manageable drug-drug interaction profile was observed with respect to the CRESEMBA® technology compared to other mold-active azoles antifungals.

Response: We appreciate the applicant’s additional input and information in support of the application. We recognize that the CRESEMBA® prodrug was specifically developed to facilitate the systemic delivery of the active moiety and reduces the risk of nephrotoxicity relative to otherazole antifungals. However, despite the lack of presence of nephrotoxic cyclodextrins, we continue to believe that the CRESEMBA® uses the same mechanism of action as other azole antifungals because they both inhibit the enzyme lanosterol 14α-demethylase.

In addition, we continue to believe that the CRESEMBA® technology is substantially similar to the current treatment options available to Medicare beneficiaries that are also currently described (although not specifically) by established procedure codes that identify the use of these similar technologies, specifically other antifungal drugs that also are used in the treatment of patients diagnosed with similar fungal infections. As the applicant stated, while the use of amphotericin B may not be an ideal treatment option for some patients because it has many adverse side effects, we disagree with the applicant that CRESEMBA® offers an alternative treatment option instead of amphotericin B for patients who cannot tolerate other existing therapies and would otherwise have no other treatment option because amphotericin B and other antifungal drugs can also be effective and used as an option to treat patients diagnosed with IM. Therefore, we believe that, although CRESEMBA® can be effectively administered
without other antifungal drugs, the technology would be used to treat the same or similar type of disease and the same or similar patient population as other antifungal drugs.

After consideration of the public comment we received, we believe that the CRESEMBA® technology is substantially similar to other azole antifungal drugs because it meets all three of the criteria identified above and, therefore, does not meet the newness criterion.

As we discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24442 and 24443), to demonstrate that the technology meets the cost criterion, the applicant performed two analyses. The applicant searched claims in the FY 2013 MedPAR file (across all MS–DRGs) for any case reporting a principal or secondary diagnosis of aspergillosis (ICD-9-CM diagnosis code 117.3), zygomycosis [phycomycosis or mucormycosis] (ICD-9-CM diagnosis code 117.7), or pneumonia in aspergillosis (ICD-9-CM diagnosis code 484.6). The applicant excluded any case that was treated at a hospital that is not paid under the IPPS, as well as any case where Medicare fee-for-service was not the primary payer. The applicant calculated the standardized charge for each eligible case and then inflated the standardized charge by 10.4427 percent using the same inflation factor used by CMS to update the FY 2015 outlier threshold (79 FR 50379). The applicant assumed that the average length of stay for all eligible cases was 13.4 days based on its analysis. To determine the charges for the drug, the applicant assumed 13.4 days of therapy. According to the applicant, dosages of isavuconazole for a patient vary based on the day of therapy, but do not vary based on the patient’s weight. For the first and second day of therapy, the patient would be
administered a loading dose of 200 milligrams (mg) every 8 hours. For each subsequent day of therapy, the patient would be administered a maintenance dose of 200 mg per day.

For the first analysis, which was based on 100 percent of all MS-DRGs, the applicant identified a total of 5,984 cases with at least one of the three ICD-9-CM codes (aspergillosis (ICD-9-CM diagnosis code 117.3), zygomycosis [phycomycosis or mucormycosis] (ICD-9-CM diagnosis code 117.7), or pneumonia in aspergillosis (ICD-9-CM diagnosis code 484.6)) across a total of 333 MS-DRGs. The applicant’s rationale for using all the MS-DRGs was that it believed any patient diagnosed with either invasive aspergillosis or invasive mucormycosis (zygomycosis) could be eligible for treatment using isavuconazonium, regardless of the MS-DRG assignment. The applicant identified the average case-weighted threshold amounts for these 333 MS-DRGs as $72,186 using Table 10 from the FY 2015 IPPS/LTCH PPS final rule. The applicant did not remove charges for the other specific technologies from the average case-weighted standardized charge per case. The applicant’s rationale for not removing these charges was that the patients would be administrated isavuconazonium in combination with the other currently approved antifungal drugs as an effective treatment plan. The applicant computed a final inflated average case-weighted standardized charge per case of $151,450. Because this average case-weighted standardized charge per case exceeded the average case-weighted threshold amount from the FY 2015 Table 10, the applicant maintained that CRESEMBA® meets the cost criterion using this first analysis.

For its second analysis, the applicant analyzed 39 MS-DRGs that accounted for the top 75 cases of patients eligible for treatment using isavuconazonium; this was a
subset of 4,510 cases. Using a methodology similar to the one used in its first analysis, the applicant computed the final inflated average case-weighted standardized charge per case of $159,622. The applicant identified an average case-weighted threshold amount for the 39 MS-DRGs of $74,366 using Table 10 from the FY2015 IPPS/LTCH PPS final rule. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount in the FY 2015 Table 10, the applicant maintained that CRESEMBA® meets the cost criterion using this second analysis.

In the proposed rule, we stated we were concerned that the applicant did not remove any charges for the other antifungal drugs used during treatments (that is, the other component of the combination) because the applicant maintained that it would most likely be necessary for patients who are treated using CRESEMBA® to also continue treatment using the other antifungal drugs or medications in order to achieve successful treatment due to the severity of their symptoms. We believe that the applicant should have removed the charges for the other antifungal drugs used for treatments. We also noted that the applicant did not provide information to substantiate its assertion that the charges for these cases would not be reduced because of the severity of illness among the patients. The applicant inferred that patients treated using CRESEMBA® would be dependent upon the simultaneous and combined use of the other existing therapies to achieve successful treatment. Therefore, we stated our concern about the possibility of drug toxicity, poly pharmacy, and drug-to-drug interactions, especially among the Medicare population.
We invited public comment on whether CRESEMBA® meets the cost criterion, specifically with regard to our concerns regarding the applicant’s analyses and methodology.

**Comment:** To address CMS’ concerns stated in the proposed rule, the applicant submitted additional information that included the results from conducted sensitivity analyses to determine whether the cost of the cases included in its cost analysis presented in the proposed rule would have continued to exceed the cost threshold for the respective MS-DRGs after removing the submitted charges for other drugs. Using a methodology similar to the methodology used in the previous cost analyses as presented in the proposed rule, the applicant conducted three subsequent analyses that removed 18.3 percent, 41.0 percent, and 100 percent of charges associated with other drugs. The applicant reported that the average case-weighted threshold amount for the respective MS-DRGs remained at $72,186. Under each analysis, the average case-weighted standardized charges per cases were $145,260, $137,641, and $117,838 respectively. Because the average case-weighted standardized charge per case for each scenario exceeded the average case-weighted threshold amount for the respective MS-DRGs ($72,186), the applicant maintained that the CRESEMBA® meets the cost criterion based on the results of its new analysis.

**Response:** We appreciate the applicant’s additional input and information. After consideration of the subsequent analysis presented by the applicant and its results, we believe that the CRESEMBA® meets the cost criterion.
As we discussed in the proposed rule, with regard to substantial clinical improvement, the applicant stated that CRESEMBA® represents a substantial clinical improvement over existing therapies for patients diagnosed with invasive aspergillosis and mucormycosis based on its potentially improved efficacy profile, potentially improved safety profile, more favorable pharmacokinetic profile, and improved method of administration. The applicant discussed the unmet medical need for alternative treatment options for patients diagnosed with invasive aspergillosis and mucormycosis. Current treatments have limitations related to safety, side effects, and efficacy.\(^{18,19}\) The applicant provided information regarding its SECURE study, where the primary endpoint of all-cause mortality through day 42 showed that CRESEMBA® demonstrated noninferiority to voriconazole. The primary endpoint of all-cause mortality through day 42 in the intent-to-treat population (ITT, N=516) was 18.6 percent in the isavuconazonium treatment group and 20.2 percent in the voriconazole group. However, according to the applicant, the overall safety profile for CRESEMBA® demonstrated similar rates of mortality and nonfatal adverse events as the comparator, voriconazole. The applicant also shared information from other clinical trials. One of these clinical trials that studied the treatment of patients diagnosed with invasive aspergillosis showed treatment-emergent adverse reactions occurred in 96 percent and 99 percent of patients receiving the CRESEMBA® and voriconazole. In the proposed rule, we stated that the

---


adverse reactions associated with the use of CRESEMBA® and voriconazole appear to be similar.

Comment: In response to our concerns, the applicant noted that patients being treated with CRESEMBA® had a reduced number of treatment-related discontinuations over existing therapies. The applicant stated that the treatment-emergent adverse events (TEAEs) were reported in 96.1 percent of patients who received treatment using the CRESEMBA® technology and 98.5 percent of patients who received treatment using voriconazole. The applicant further stated that the five most common events that occurred in ≥5 percent of the patients in either group were nausea, vomiting, diarrhea, pyrexia, and hypokalemia, and the most frequent adverse events by system organ class were gastrointestinal disorders (67.7 percent for patients treated using CRESEMBA,® 69.5 percent for patients treated using voriconazole), and infections/infestations (59.1 percent for patients treated using CRESEMBA,® 61.0 percent for patients treated using voriconazole). The applicant also noted that the results indicated the following TEAEs were significantly less common with the group of patients treated using CRESEMBA® compared to the group of patients treated using voriconazole: skin and subcutaneous tissue disorders (33.5 percent for the group of patients treated with CRESEMBA,® 42.5 percent for the group of patients treated using voriconazole; p = 0.037), eye disorders (15.2 percent for the group of patients treated using CRESEMBA,® 26.6 percent for the group of the patients treated using voriconazole; p = 0.002), and hepatobiliary disorders (CRESEMBA® 8.9 percent, voriconazole 16.2 percent; p = 0.016). The applicant believed that the differences between the efficacy and effectiveness of the CRESEMBA®
compared to voriconazole as a result of the overall analysis of TEAEs and serious TEAEs were consistent with those of the subgroup analysis by age categories, gender, race, ethnicity, geographical region, receipt of allogeneic transplantation, active malignancy status, and neutropenia at baseline. The applicant stated that no clinically relevant trends were observed with other safety parameters, including laboratory parameters and ECG during the 84-day treatment period.

Response: We appreciate the additional information presented by the applicant in response to our concerns. While we recognize that CRESEMBA® meets FDA standards for safety and effectiveness, demonstration of a substantial clinical improvement over existing technologies available to Medicare beneficiaries is not necessarily inherent in the FDA’s regulatory requirement for the technology. We believe that the data presented by the applicant to support a substantial clinical improvement based on the demonstration of reduced TEAEs did not show results demonstrating significant differences regarding the analysis’ comparables. While we acknowledge that, in the setting of similar overall safety profiles, the discontinuation rates are reduced with the use of the CRESEMBA® technology when compared to use of voriconzole, we are unsure if the noted differences in the overall safety profiles demonstrate statistical significance.

In the proposed rule, we also stated that we were concerned that the applicant did not conduct the clinical trials evaluating head-to-head comparisons to alternative therapies such as amphotericin B. Currently, amphotericin B is the only FDA-approved drug for the treatment of mucormycosis, which also can be used to treat aspergillosis.
The applicant’s description of the technology was based on peer reviewed literature, which may be considered historical data.

**Comment:** The applicant also presented with its comments findings from the Fungiscope Registry database to demonstrate the results of head-to-head comparisons between the efficacy of effectiveness of the CRESEMBA® and other alternative therapies such as amphotericin B. The applicant stated that, in a matched-case control analysis, crude mortality through day 42 in patients who received treatment using CRESEMBA® as primary therapy was 33.3 percent relative to 39.4 percent in patients who received amphotericin-based treatment as primary therapy from matched controls, while the overall mortality rate (37.8 percent) for patients treated using CRESEMBA® was similar to the mortality rate for patients treated with amphotericin B as reported in the literature (37.8 percent).

**Response:** We appreciate the information included in the applicant’s comment in response to our concern. However, we believe that the crude mortality rates for both controls were similar, and the noted differences do not appear to be statistically significant.

With regard to improved efficacy, the applicant made several assertions in its application that we discussed in the proposed rule (80 FR 24443 through 24444). The applicant maintained that the use of CRESEMBA® can potentially decrease the rate of subsequent diagnostic or therapeutic interventions. According to the applicant, the technology lacks the adverse side effects of nephrotoxicity associated with
amphotericin B. However, in the proposed rule we stated that the results of the study reported by the applicant did not reflect this.

Specifically, the applicant believed that CRESEMBA® has positive activity against a broad range of fungi, including those resistant to other agents, thereby potentially decreasing subsequent therapeutic interventions. However, the applicant stated that the referenced literature indicates that further in-vivo studies are required in order to confirm the efficacy for treatment of severe infections caused by these fungi in immunocompromised patients. According to the applicant, CRESEMBA® is used to treat immunocompromised patients who are severely ill. The applicant also stated that CRESEMBA® can be used to treat patients diagnosed with invasive fungal infections before the pathogen has been identified, thereby potentially decreasing subsequent diagnostic and therapeutic interventions. The applicant maintained that the use of CRESEMBA® decreases the number of future hospitalizations or physician visits. We stated in the proposed rule (80 FR 24444) our concern that the applicant did not provide data to support this determination. One of the applicant’s studies, SECURE, which was a global, Phase 3, multicenter, randomized, double-blind, parallel group, noninferiority trial that evaluated CRESEMBA® versus voriconazole for the primary treatment of patients with invasive fungal disease (IFDs) caused by aspergillus spp. and other filamentous fungi was discussed by the applicant in its application. The results of the study were


presented in a paper stating that the length of stay for patients hospitalized with renal impairment was statistically significantly shorter in the treatment of patients in the CRESEMBA® arm (9 days) compared with patients treated with voriconazole in the control arm. According to the applicant, patients treated with CRESEMBA® showed shorter hospital length of stay compared to those treated with voriconazole in the overall study population. Subgroup analyses of patients who were aged 65 years and older and patients with a BMI equal to or greater than 30 kg/m² also had shorter, but not statistically significant, differences in length of stay when treated with isavuconazonole compared to voriconazole. The paper on the study revealed concerns about the small sample size in the subgroup (n=516) and that the differences were not statistically significant.23

With regard to improved safety and a more favorable pharmacokinetic profile, the applicant made several assertions which we discussed in the proposed rule (80 FR 24444). The applicant asserted that CRESEMBA® has the potential for simpler and more predictable dosing based on improved pharmacokinetics compared with other azole antifungal drugs, but the applicant did not provide data to substantiate this assertion.

Comment: The applicant provided the following information in its comment with regard to CRESEMBA’s pharmacokinetic profile and predictable dosing. According to the applicant, based on data from the development of CRESEMBA® and the prescribing information, CRESEMBA® does not require therapeutic drug monitoring (TDM)

23 Khandelwal N, Franks B, Shi F, Spalding J, Azie N. Health Economic Outcome Analysis of Patients Randomized in the SECURE Phase 3 Trial Comparing Isavuconazole to Voriconazole for Primary Treatment of Invasive fungal Disease Caused by Aspsergillus Species or Other Filamentous Fungi.
compared to voricanozole, which requires TDM due to liver disease, age and genetic polymorphism of the cytochrome CYP2C19. The applicant noted that, for CRESEMBA®, no dose adjustment is required for the following: age, gender, and race; mild, moderate, and severe renal impairment including patients with ESRD; mild to moderate hepatic impairment patients. The applicant included additional information from the Secure Phase III trial and other clinical studies 24,25 to substantiate that CRESEMBA® has the potential for simpler and more predictable dosing based on improved pharmacokinetics compared with other azole antifungal drugs.

Response: We appreciate the additional information provided by the applicant. We note that, with regard to the pharmacokinetic profile, based on the information provided by the applicant, CRESEMBA® appears to have a favorable profile, but the data relating to a comparison of rates for TEAEs between CRESEMBA® and voriconazole show that the rates are the same. In addition, while the applicant stated that CRESEMBA® does not require therapeutic drug monitoring (TDM) as compared to voricanozole, which does require TDM, we note that the FDA has indicated in the product labeling that serious hepatic reactions have been reported regarding the effects of the use of the CRESEMBA® and the FDA has recommended that treatment include the evaluation of liver related laboratory tests at the start and during the course of treatment using the CRESEMBA® therapy (similar to FDA indications for voricanozole).

As we discussed in the proposed rule, the applicant also asserted that CRESEMBA® has a lower drug-drug interaction potential than voriconazole or itraconazole, but did not provide data to substantiate this assertion. Furthermore, the applicant maintained that CRESEMBA® can be safely used in treating patients with renal impairment, whereas currently available treatments can harm the kidneys.\(^{26}\) In the paper accompanying the application, the applicant discussed aspergillosis and the various treatment options available and the advantages of voriconazole over deoxycholate amphotericin B (D-AMB) as primary treatment for patients with invasive aspergillosis.

In the proposed rule, we stated we were concerned that these results were not communicated in the resulting data provided by the applicant that were obtained from the trials (80 FR 24444).

**Comment:** The applicant stated in its comment that based on the Phase 3 trials, 79 of 403 patients had an estimated glomerular filtration rate (GFR) less than 60 mL/min/1.73 m2. The applicant also provided data from a phase one study, which evaluated the pharmacokinetics in patients diagnosed with mild, moderate, and severe renal dysfunction relative to the pharmacokinetics in healthy patients with normal renal function.\(^{27}\) The applicant noted that CRESEMBA® area under the curve 72 (AUC72) in ESRD patients is similar to the AUC72 in healthy controls due to the hemoconcentration because CRESEMBA® is highly protein bound (>99 percent) and not dialyzable.


The applicant presented the results from an analysis of a pooled subgroup from its previously stated studies (SECURE and VITAL), which evaluated the effectiveness of CRESEMBA® in patients diagnosed with and without renal impairment, as defined as eGFR < 60 mL/min/1.73 m². The end points measured were all cause mortality at day 42 and day 84 and DRC assessed overall response at end of treatment (EOT). At the end of day 42, the mortality rates for the patients diagnosed with renal impairment versus patient who do not suffer from renal impaired was 12.9 percent versus 18.8 percent. At the end of day 84, the mortality rates for the patients diagnosed with renal impairment versus patients who do not suffer renal impairment was 25.8 percent versus 28.6 percent. All-cause mortality on Day 42 and Day 84, and DRC-assessed overall response at EOT were comparable between patient groups (32 percent versus 36 percent). The applicant stated that the results of this pooled analysis demonstrated that CRESEMBA® was efficacious in patients diagnosed with renal impairment enrolled in the SECURE and VITAL trials and supports the Phase 1 trial findings that dose adjustments are not required for patients diagnosed with renal impairment treated using the CRESEMBA®.

Response: We appreciate the additional information provided in the applicant’s comment in response to our concerns, and we have considered these findings in our final review.

In the proposed rule, we also stated that we were concerned that the applicant did not provide a rationale for its assertion that the use of CRESEMBA® represents a substantial clinical improvement for Medicare beneficiaries because of “simpler and
more predictable dosing” nor did the applicant provide additional information and data regarding drug-to-drug interactions and nephrotoxicity (80 FR 24444).

In addition, the applicant maintained that the technology has an improved method of administration compared to current treatment alternatives. Specifically, the applicant asserted that the availability of this technology as an oral formulation is an improvement compared to other existing treatments, which are solely administered intravenously. In the proposed rule, we stated that we were concerned about the applicant’s assertion because other currently approved and available antifungal drugs, such as voriconazole (tablets, oral suspension, or intravenous administration), itraconazole (capsules, oral solution, or parenteral solution), and posaconazole (oral suspension or parenteral solution), also can be administered orally as well as parenteral for patients diagnosed with these types of fungal infections. In addition, we are aware that intravenous administration of antifungal drugs may be necessary because patients diagnosed with invasive aspergillosis and mucormycosis and treated as inpatients are often severely ill and may not be able to tolerate any food or medications orally.

Comment: The applicant responded to CMS’ concerns expressed in the proposed rule by presenting information that highlighted the following results based on data from the clinical studies: both the oral and IV formulations have shown that CRESEMBA® has a more predictable pharmacokinetic/pharmacodynamic profile when compared to voriconazole; CRESEMBA® has moderate pharmacokinetic variability, limiting the risk of sub-therapeutic or supra-therapeutic exposure, while the variability of voriconazole
pharmacokinetics is high; IV CRESEMBA® can be used in patients diagnosed with renal impairment as the IV formulation of CRESEMBA® does not include cyclodextrins.

The applicant further stated that the Pharmacokinetics (PK) study in patients diagnosed with renal impairment demonstrated exposures that support the label that no dose adjustments are recommended in patients who are elderly or renally impaired and no dose adjustment is needed in patients diagnosed with mild, moderate, or severe renal impairment, including those patients with ESRD. The applicant noted that outcomes in the renal impaired patients were comparable to the non-renal impaired.

According to the applicant, a more manageable drug-drug interaction profile was observed with CRESEMBA® than with other mold-active azoles. The applicant explained the following with regard to CRESEMBA®: it is a sensitive substrate of CYP3A (5-fold increase in isavuconazole AUC with concomitant ketoconazole) and a mild-to-moderate inhibitor of CYP3A4 (2-fold increase in midazolam AUC), while voriconazole is a strong inhibitor of CYP3A4 (10-fold increase in midazolam AUC); it is a mild inducer of CYP2B6 (42 percent decrease in bupropion); it does not inhibit or induce CYP1A2, CYP2C9, or CYP2C19 and does not inhibit CYP2A6 or CYP2D6; it is a mild inhibitor of P-gp, OCT1/OCT2 and MATE1; it has no inhibitory effects on sensitive substrates of BCRP, OAT1/OAT2, OATP1B1/OATP1B3, or MATE2-K, but does have mild indirect inhibitory effects on substrates of UGT.

The applicant also stated that CRESEMBA® demonstrated efficacy in the studies of patients diagnosed with IA and IM. The applicant asserted that CRESEMBA® demonstrated the following: noninferior efficacy compared to voriconazole for the
primary endpoint of all-cause mortality through day 42 in IA; comparable results for all-cause mortality were observed across sensitivity analyses, populations, time points and subgroups, further supporting the effectiveness of CRESEMBA®; and activity against several species of Mucorales, which are known to mimic Aspergillus infection and have been reported as a cause of breakthrough infection.

The applicant noted that CRESEMBA® had a similar treatment effect to that of amphotericin B compared to untreated controls from the literature for all-cause mortality. The applicant cited a matched-case analysis from a contemporary registry in which similar mortality rates were noted in patients treated with CRESEMBA® and matched control patients treated with amphotericin-based formulations. The applicant also noted that CRESEMBA® activity is supported by data from validated animal models of mucormycosis.

According to the applicant, CRESEMBA® demonstrated the following: a favorable safety profile compared to voriconazole; and fewer CRESEMBA® TEAEs compared to voriconazole such as skin, eye and hepatic adverse events. Finally, the applicant stated that CRESEMBA® is orally bioavailable and has no signal of nephrotoxic effects as associated with amphotericin B.

Response: We appreciate the applicant’s additional information submitted in response to our concerns regarding a lack of data for: (1) head-to-head comparative studies between CRESEMBA® and alternative therapies in the treatment of aspergillosis and invasive mucormycosis (IM); (2) safety in treating patients with renal impairment; and (3) predictable dosing based on improved pharmacokinetics compared with other
azole drugs for anti-fungal therapy. We note that in the matched-case control analysis, Study 0103 (Fungiscope Registry) specifically compared CRESEMBA® with amphotericin B in the treatment of IM, and that this study showed for IM patients treated with CRESEMBA® the mortality rate was 33.3 percent (7/21) and for IM patients treated with Amphotericin B the mortality rate was 39.4 percent (3/33). With regard to safety in treating patients with renal impairment, we agree with the applicant that relative to amphotericin B, CRESEMBA® can be a useful alternative for treating patients diagnosed with mucormycosis with regard to the nephrotoxic side effects associated with amphotericin B. While the applicant believed that CRESEMBA® has the potential for simpler and more predictable dosing based on improved pharmacokinetics compared with other azole drugs, we are concerned that the differences in rates for TEAEs between CRESEMBA® and voriconazole are not statistically significant and, therefore, the favorable pharmacokinetics profile of CRESEMBA® may not represent a substantial clinical improvement over currently available treatments using other azole antifungal drugs.

While amphotericin B has severe side effects, CRESEMBA® is associated with serious hepatic reactions, which requires the evaluation of liver related laboratory tests at the start and during the course of treatment using the CRESEMBA® therapy. In addition, in the Fungiscope Registry referenced by the applicant, we note that the crude mortality rates for CRESEMBA® and amphotericin B were similar.

While we acknowledge that CRESEMBA® reduces some side effects associated with the treatment of invasive antifungal infections, we believe that its outcomes are
markedly similar to those accomplished using other azole antifungal drugs currently available to Medicare beneficiaries and proven to be effective in the treatment of these types of diagnoses. Therefore, we do not believe that the CRESEMBA® represents a substantial clinical improvement over existing technologies.

**Comment:** One commenter did not believe that the CRESEMBA® technology represents substantial clinical improvement over existing technologies.

**Response:** We agree with the commenter that the technology does not represent a substantial clinical improvement over existing technologies.

After consideration of the public comments we received, for the reasons discussed earlier, we believe that the CRESEMBA® technology is substantially similar to other antifungal drugs used in the effective treatment of patients diagnosed with similar types of conditions that are currently available to Medicare beneficiaries and, therefore, does not meet the newness criterion. Moreover, we do not believe that the technology represents a substantial clinical improvement over existing technologies. Therefore, we are not approving the CRESEMBA® for new technology add-on payments for FY 2016.

d. LUTONIX® Drug-Coated Balloon (DCB) Percutaneous Transluminal Angioplasty (PTA) Catheter and IN.PACT™ Admiral™ Paclitaxel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

Two manufacturers, CR Bard Inc. and Medtronic, submitted applications for new technology add-on payments for FY 2016 for LUTONIX® Drug-Coated Balloon (DCB) Percutaneous Transluminal Angioplasty (PTA) Catheter (LUTONIX®) and IN.PACT™ Admiral™ Paclitaxel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
Catheter (IN.PACT™ Admiral™), respectively. Both of these technologies are drug-coated balloon angioplasty treatments for patients diagnosed with peripheral artery disease (PAD). Typical treatments for patients with PAD include angioplasty, stenting, atherectomy and vascular bypass surgery. PAD most commonly occurs in the femoropopliteal segment of the peripheral arteries, is associated with significant levels of morbidity and impairment in quality of life, and requires treatment to reduce symptoms and prevent or treat ischemic events. Treatment options for symptomatic PAD include noninvasive treatment such as medication and life-style modification (for example, exercise programs, diet, and smoking cessation) and invasive options which include endovascular treatment and surgical bypass. The 2013 American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the management of PAD recommend endovascular therapy as the first-line treatment for femoropopliteal artery lesions in patients suffering from claudication (Class I, Level A recommendation).

The applicants for LUTONIX® and IN.PACT™ Admiral™ stated that, in patients diagnosed with PAD, the femoropopliteal artery is characterized by difficult to treat lesions that can be long and diffuse, in a vessel that is considered the most mechanically stressed artery with a number of dynamic forces that impact the artery including shortening/elongation, torsion, compression and flexion. According to the applicants, the

unique challenges of treating disease in the femoropopliteal region in patients with PAD are related to limitations of current endovascular treatment options. PTA and stents have high restenosis rates. In the case of stents the region is often a no stent zone with concerns of stent fracture and limiting future treatment options with permanent implants. Coating of femoral and coronary stents with an antiproliferative drug, such as paclitaxel, is intended to reduce the development of restenosis in the stented segment of the artery.\textsuperscript{30,31}

The applicants stated that the drug-coated balloon catheter is a device-drug combination product comprised of a device component (an over-the-wire balloon catheter) and a drug component (a paclitaxel-urea coating in the case of IN.PACT\textsuperscript{TM} Admiral\textsuperscript{TM} and a paclitaxel-sorbitol for LUTONIX\textsuperscript{®}) on the balloon, intended for the treatment of patients with PAD, specifically superficial femoral artery (SFA) and popliteal artery disease. The device is engineered for two modes of action: the primary mode of action is attributable to the balloon’s mechanical dilatation of de novo or restenotic lesions in the vessel; and the secondary mode of action consists of drug delivery and application of paclitaxel to the vessel wall to inhibit the restenosis that is normally associated with the proliferative response to the PTA procedure. Following predilatation with a nondrug-coated PTA balloon, the interventionalist selects a drug-coated balloon with diameter of 100 percent of reference vessel diameter (RVD) and length sufficient to treat 5mm proximal and distal to the target lesion and predilated

\textsuperscript{30} Owens, CD.: Drug eluting balloon overview: technology and therapy. Presented at LINC 2011, Leipzig, Germany.
segment (including overlap of multiple balloons). The interventionalist inflates the drug-coated balloon for a minimum inflation time of 30 seconds for delivery of paclitaxel, and keeps the balloon inflated for as long as necessary to achieve a satisfactory procedural result, which is the standard of care for all balloon angioplasties.

According to both applicants, LUTONIX® and IN.PACT™ Admiral™ are the first drug coated balloons that can be used for treatment of patients who are diagnosed with PAD. As we stated in the proposed rule, because cases eligible for the two devices would group to the same MS-DRGs and we believe that these devices are substantially similar to each other (that is, they are intended to treat the same or similar disease in the same or similar patient population and are purposed to achieve the same therapeutic outcome using the same or similar mechanism of action), we believe that it is appropriate to evaluate both technologies as one application for new technology add-on payment under the IPPS. The applicants submitted separate cost and clinical data, and we reviewed and discuss each set of data separately. However, we are making one determination regarding new technology add-on payments that will apply to both devices. We believe that this is consistent with our policy statements in the past regarding substantial similarity. Specifically, we have noted that approval of new technology add-on payments would extend to all technologies that are substantially similar (66 FR 46915), and that we believe that continuing our current practice of extending a new technology add-on payment without a further application from the manufacturer of the competing product or a specific finding on cost and clinical improvement if we make
a finding of substantial similarity among two products is the better policy because we avoid—

- Creating manufacturer-specific codes for substantially similar products;
- Requiring different manufacturers of substantially similar products from having to submit separate new technology applications.
- Having to compare the merits of competing technologies on the basis of substantial clinical improvement; and
- Bestowing an advantage to the first applicant representing a particular new technology to receive approval (70 FR 47351).

If these substantially similar technologies had been submitted for review in different (and subsequent) years, rather than the same year, we would evaluate and make a determination on the first application and apply that same determination to the second application. However, because the technologies have been submitted for review in the same year, we believe it is appropriate to consider both sets of cost data and clinical data in making a determination because we do not believe that it is possible to choose one set of data over another set of data in an objective manner.


As stated in section II.G.1.a. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule and this final rule, effective October 1, 2015 (FY 2016), the ICD-10 coding
system will be implemented. In the proposed rule, we stated that the applicants applied for a new ICD-10-PCS procedure code for consideration at the March 18-19, 2015 ICD-10-CM/PCS Coordination and Maintenance Committee Meeting. In this final rule, we note that new ICD-10-PCS procedure codes (listed in the chart below) which uniquely identify procedures involving the LUTONIX® and Medtronic drug coated balloons have been established.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>047K041</td>
<td>Dilation of right femoral artery with drug-eluting intraluminal device using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047K0D1</td>
<td>Dilation of right femoral artery with intraluminal device using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047K0Z1</td>
<td>Dilation of right femoral artery using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047K341</td>
<td>Dilation of right femoral artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047K3D1</td>
<td>Dilation of right femoral artery with intraluminal device using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047K3Z1</td>
<td>Dilation of right femoral artery using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047K441</td>
<td>Dilation of right femoral artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047K4D1</td>
<td>Dilation of right femoral artery with intraluminal device using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047K4Z1</td>
<td>Dilation of right femoral artery using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047L041</td>
<td>Dilation of left femoral artery with drug-eluting intraluminal device using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047L0D1</td>
<td>Dilation of left femoral artery with intraluminal device using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047L0Z1</td>
<td>Dilation of left femoral artery using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047L341</td>
<td>Dilation of left femoral artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047L3D1</td>
<td>Dilation of left femoral artery with intraluminal device using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047L3Z1</td>
<td>Dilation of left femoral artery using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>ICD-10-PCS Code</td>
<td>Code Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>047L441</td>
<td>Dilation of left femoral artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047L4D1</td>
<td>Dilation of left femoral artery with intraluminal device using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047L4Z1</td>
<td>Dilation of left femoral artery using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047M041</td>
<td>Dilation of right popliteal artery with drug-eluting intraluminal device using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047M0D1</td>
<td>Dilation of right popliteal artery with intraluminal device using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047M0Z1</td>
<td>Dilation of right popliteal artery using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047M341</td>
<td>Dilation of right popliteal artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047M3D1</td>
<td>Dilation of right popliteal artery with intraluminal device using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047M3Z1</td>
<td>Dilation of right popliteal artery using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047M441</td>
<td>Dilation of right popliteal artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047M4D1</td>
<td>Dilation of right popliteal artery with intraluminal device using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047M4Z1</td>
<td>Dilation of right popliteal artery using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047N041</td>
<td>Dilation of left popliteal artery with drug-eluting intraluminal device using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047N0D1</td>
<td>Dilation of left popliteal artery with intraluminal device using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047N0Z1</td>
<td>Dilation of left popliteal artery using drug-coated balloon, open approach</td>
</tr>
<tr>
<td>047N341</td>
<td>Dilation of left popliteal artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047N3D1</td>
<td>Dilation of left popliteal artery with intraluminal device using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047N3Z1</td>
<td>Dilation of left popliteal artery using drug-coated balloon, percutaneous approach</td>
</tr>
<tr>
<td>047N441</td>
<td>Dilation of left popliteal artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047N4D1</td>
<td>Dilation of left popliteal artery with intraluminal device using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>047N4Z1</td>
<td>Dilation of left popliteal artery using drug-coated balloon, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>
More information on the request for and the approval of these codes can be found on the CMS Web site at:


As we discussed in the proposed rule, the approval of new technology add-on payments extends to all technologies that are substantially similar. Moreover, as discussed, we believe that applications for substantially similar technologies should be evaluated in a manner that avoids, among other things, having to compare the merits of competing technologies on the basis of substantial clinical improvement. If we receive applications for substantially similar technologies in different years, we would apply the first determination to any subsequent applications for substantially similar technologies. Because, in this case, two substantially similar technologies have applied for a new technology add-on payment for the same Federal fiscal year, we believe it is consistent with our policy to make one determination using all of the information submitted for the technologies rather than choosing one set of information to consider and not considering the other set of information.

In accordance with our policy, we stated in the proposed rule that we believe it is appropriate to use the earliest market availability date submitted as the beginning of the newness period. Accordingly, for both devices, we stated in the proposed rule that if
approved for new technology add-on payments, we believe that the beginning of the newness period would be October 10, 2014.

In the proposed rule we did not articulate any concerns regarding whether this technology meets the newness criterion, but we invited public comments on whether these two technologies meet the newness criterion. We did not receive any public comments concerning whether the technologies meet the newness criterion. Therefore, based on the information provided by the applicants, we believe that both LUTONIX® and IN.PACT™ Admiral™ DCBs meet the newness criterion.

As we stated above, each applicant submitted separate analyses regarding the cost criterion for each of their devices and both applicants maintained that their device meets the cost criterion. As we did in the proposed rule, we summarize each analysis below.

With regard to the LUTONIX®, to demonstrate that the technology meets the cost criterion, the applicant performed three different analyses. The applicant first searched the FY 2013 MedPAR data file that was used for the recalibration of the FY 2015 MS-DRG relative payment weights in the FY 2015 IPPS/LTCH PPS final rule. The applicant applied the standard trims that CMS used when selecting cases for IPPS rate recalibration as described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49911). In other words, the applicant included cases from IPPS hospitals and Maryland hospitals and excluded cases paid by Medicare Advantage plans, cases from hospitals that did not submit charges in a sufficiently broad range of revenue centers, and statistical outlier cases as described in the FY 2015 IPPS/LTCH PPS final rule. The applicant then searched for all claims reporting ICD-9-CM procedure code 39.50 (Angioplasty of other
non-coronary vessel(s)) and also reporting at least one of the following seven ICD-9-CM diagnosis codes (440.20 (Atherosclerosis of native arteries of the extremities, unspecified), 440.21 (Atherosclerosis of native arteries of the extremities with intermittent claudication), 440.22 (Atherosclerosis of native arteries of the extremities with rest pain), 440.23 (Atherosclerosis of native arteries of the extremities with ulceration), 440.24 (Atherosclerosis of native arteries of the extremities with gangrene), 440.29 (Other atherosclerosis of native arteries of the extremities), and 443.9 (Peripheral vascular disease, unspecified indicating peripheral artery disease). The applicant excluded all claims that reported any ICD-9-CM procedure codes involving a stent. A total of 23,157 cases reporting peripheral angioplasty were identified. Of these 23,157 cases, MS-DRGs 252, 253, and 254 (Other Vascular Procedures with MCC, with CC and without CC/MCC, respectively) accounted for 65 percent of cases; MS-DRGs 237 and 238 (Major Cardiovascular Procedures with MCC and without MCC, respectively), MS-DRGs 239 and 240 (Amputation for Circulatory System Disorders Except Upper Limb and Toe with MCC and with CC, respectively), and MS-DRG 853 (Infectious and Parasitic Diseases with Operating Room Procedure with MCC) accounted for 17 percent of cases (among these, peripheral angioplasty was secondary to some other circulation-related procedure: a major cardiovascular procedure (MS-DRGs 237 and 238), amputation due to poor circulation (MS-DRGs 239 and 240), or (typically) amputation with sepsis (MS-DRG 853)). The remaining 18 percent of cases were spread across a large number of other MS-DRGs. Next, the applicant obtained the average case-weighted charge per case based on the distribution of cases by MS-DRG and then
identified the average case-weighted threshold for the three MS-DRG groupings from the threshold amounts in Table 10 of the FY 2015 IPPS/LTCH PPS final rule. The applicant then calculated the unadjusted (unstandardized) average case-weighted charge per case for all MS-DRGs. According to the applicant, charges were not removed for any prior technology. To estimate the charge for the new technology, the applicant divided the projected cost per patient by the national average CCR for supplies (0.292) in the FY 2015 IPPS/LTCH PPS final rule, to arrive at the average case-weighted standardized charges per case. The average case-weighted standardized charges per case for the three primary MS-DRGs 252-254 group (65 percent), the five additional MS-DRGs 237-240 and MS-DRG 853 group (17 percent), and the other MS-DRGs (18 percent) were $69,243, $81,156, and $95,138, respectively. The applicant then inflated the average standardized case-weighted charges per case from FY 2013 to FY 2015 using the 2-year inflation factor of 10.44 percent specified in the FY 2015 IPPS/LTCH PPS final rule and added charges related to the new technology to the average case-weighted standardized charges per case, although the applicant indicated that it was not clear on the need to include an inflation factor. The final inflated average case-weighted standardized charges per case for the three primary MS-DRG groups (65 percent), the five additional MS-DRG groups (17 percent), and across other MS-DRGs (18 percent) were $85,386, $98,543, and $104,052, respectively. Because the final inflated average case-weighted standardized charge amounts exceed the corresponding average case-weighted threshold amounts of $69,594, $74,449, and $75,215, respectively, using the FY 2015 IPPS Table 10, the
applicant stated that LUTONIX® meets the cost criterion for new technology add-on payments.

With regard to the IN.PACT™ Admiral™, to demonstrate that the technology meets the cost criterion, the applicant performed two different analyses. The applicant believed that a case involving an angioplasty procedure that used the IN.PACT™ Admiral™ drug-coated balloon catheter would map to the same MS-DRGs as a case involving a plain balloon angioplasty procedure, MS-DRGs 252, 253, and 254 (Other Vascular Procedures with MCC, with CC, and without CC/MCC, respectively). The applicant first searched the FY 2013 MedPAR claims data that were used for the recalibration of the FY 2015 MS-DRG relative payment weights in the FY 2015 IPPS/LTCH PPS final rule. The data in this file included discharges occurring on October 1, 2012 through September 30, 2013. The applicant excluded claims for all discharges for Medicare beneficiaries enrolled in a Medicare Advantage plan. The applicant also limited claims to those hospitals that were included in the FY 2013 IPPS Final Rule Impact File. In addition, the applicant removed claims in accordance with the trims specified in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53326) that were used to recalibrate the MS-DRG relative payment weights. The applicant then searched for all claims reporting ICD-9-CM procedure code 39.50 (Angioplasty of other non-coronary vessel(s)) in combination with claims reporting at least one of the following seven ICD-9-CM diagnosis codes (440.20 through 440.24, 440.29, and 443.9) indicating peripheral artery disease. The applicant excluded all claims that reported any ICD-9-CM procedure codes for stent implantation. The applicant believed that excluding all cases
reporting stenting procedures would potentially underestimate the average charges for cases reporting peripheral angioplasty. A total of 23,157 cases involving peripheral angioplasty procedures were identified. Of these 23,157 cases, a majority (65 percent; 15,040 cases) mapped to one of the 3 primary MS-DRGs, MS-DRGs 252, 253, or 254. The remaining 35 percent of the cases (8,117) were assigned to a number of MS-DRGs other than the 3 primary MS-DRGs. Next, the applicant determined the distribution of cases by MS-DRG and the case-weighted threshold amounts from Table 10 in the FY 2015 IPPS/LTCH PPS final rule, for both the primary MS-DRG group and the total MS-DRG group. The applicant began by calculating the unadjusted (unstandardized) case-weighted average charge per case for all MS-DRGs. Following this computation, the applicant standardized the charges on each of the identified claims using the FY 2013 factors from the FY 2015 IPPS/LTCH PPS Final Rule Impact File, to match the year of the claims data used in this analysis (FY 2013 MedPAR file). According to the applicant, charges were not removed for any other specific technologies that may have been used because the applicant expected that a plain balloon will be utilized to predilate the vessel in a majority of drug-coated balloon angioplasty cases prior to the use of the drug-coated balloon (that is, the applicant did not believe it was necessary to remove charges associated with the other specific prior technology (a plain PTA balloon catheter in this case).) The applicant then inflated the average case-weighted standardized charges per case from FY 2013 to FY 2015 using the 2-year inflation factor of 10.44 percent specified in the FY 2015 IPPS/LTCH PPS final rule and added charges related to the new technology to the average charges per case. The final inflated average case-weighted
standardized charge per case both for the primary MS-DRGs group and the total MS-DRG group were $82,944 and $101,611, respectively. Because the final inflated average case-weighted standardized charge per case for the applicable MS-DRG exceeds the average case-weighted threshold amounts of $69,594 and $75,215, respectively, using the FY 2015 IPPS Table 10, the applicant stated that the IN.PACT™ Admiral™ technology meets the cost criterion for new technology add-on payments.

In the proposed rule, we stated that we were concerned that both applicants excluded cases of patients that received stent implantations from their analysis because the applicants believed that the technologies can be used instead of stenting procedures. We invited public comments on whether the LUTONIX® and the IN.PACT™ Admiral™ meet the cost criterion.

In their original cost analysis, both applicants included cases with diagnoses of PTA (identified by ICD-9-CM code 39.50) and cases with diagnoses of PAD (identified by diagnosis codes: 440.2x (Atherosclerosis of arteries of the extremities) or 443.9 (Peripheral vascular disease, unspecified)), but excluded cases with stent implantation. The applicants for the LUTONIX® and the IN.PACT™ Admiral™ submitted public comments that responded separately to our concern regarding the rationale for excluding cases involving stenting procedures for the cost analyses. We summarize these comments separately below.

Comment: One of the applicants (Medtronic, the manufacturer of the IN.PACT™ Admiral™ DCB) stated that in its original cost analysis it included cases with procedures of PTA (identified by ICD-9-CM code 39.50) and cases with diagnoses of PAD
(identified by diagnosis codes: 440.2x (Atherosclerosis of arteries of the extremities) or 443.9 (Peripheral vascular disease, unspecified)), but excluded cases with stent implantation because it viewed the patient population for PTA diagnoses as similar to the patient population eligible for DCB. The applicant also believed that the resulting analysis would be the clearest and simplest way to demonstrate that DCB meets the new technology add-on payment cost criterion. The applicant further stated that, upon further consideration, it believed that some patients who receive treatment involving stents could otherwise be indicated for and receive DCB therapy instead. In addition, the applicant believed that there may be a proportion of patients who are treated with provisional stenting procedures in addition to DCB therapy. Therefore, in addition to the patients diagnosed with only PTA included in its initial analysis, the applicant provided additional analyses taking into consideration patients treated with stenting procedures.

In its public comment specifically in response to CMS’ concern, to demonstrate that the IN.PACT™ Admiral™ technology meets the cost criterion taking into consideration cases involving stent procedures, the applicant performed additional cost analyses and identified all discharges with a diagnosis of peripheral artery disease reported using ICD-9-CM diagnosis code 440.2x (Atherosclerosis of arteries of the extremities) or discharges reporting ICD-9-CM diagnosis code 443.9 (Peripheral vascular disease, unspecified), with a percutaneous transluminal angioplasty (PTA) or stent procedure code using ICD-9-CM procedure code 39.50 (non-coronary angioplasty) or any one of the following ICD-9-CM codes for peripheral vascular stenting procedures: 39.90 (Insertion of non-drug-eluting peripheral (non-coronary) vessel stent(s)); 00.55
Based on the results of the subsequent analysis, the applicant stated that its assumptions about real-world use of DCBs, based on approximate estimates from internal market models, concluded that: the IN.PACT™ Admiral™ DCB technology could be used to augment the effective treatment of patients diagnosed only with PTA in approximately 42 percent of the cases identified; the IN.PACT™ Admiral™ DCB technology could be used in addition to stents in approximately 25 percent of the cases identified; and the IN.PACT™ Admiral™ DCB technology could replace the use of stents in approximately 33 percent of the cases identified. Using the distribution of potential cases eligible for treatment using the IN.PACT™ Admiral™ DCB technology obtained from internal market research estimates, 42 percent, 25 percent, and 33 percent respectively across the three sources of potential cases eligible for treatment using the IN.PACT™ Admiral™ DCB technology described above, the applicant ascertained an average case-weighted charge per case for “real-world” cases involving the IN.PACT™ Admiral™ DCB technology. The final average case-weighted standardized charges per “real-world” cases involving the IN.PACT™ Admiral™ DCB technology were $86,037 for the three primary MS-DRGs, and $103,887 for all MS-DRGs. Both of the average case-weighted standardized charges per case exceeded the respective average case-weighted threshold amounts for these sets of MS-DRGs, which are $68,643 for MS-DRGs 252, 253, and 254, and $74,799 for all MS DRGs, respectively. Therefore,
the applicant maintained that the IN.PACT™ Admiral™ technology meets the cost criterion for new technology add-on payments.

To address CMS’ concern regarding the exclusion of cases involving stent procedures, the applicant for the LUTONIX® technology conducted an additional costs analysis that accounted for cases involving angioplasty and stent procedures by simply adding the charges for both angioplasty and stent procedures to the charges determined in its original analysis. The applicant determined average case-weighted standardized charges per case for the three primary MS–DRGs (MS-DRGs 252, 253, and 254), the five additional MS–DRGs (MS-DRGs 237, 238, 239, 240 and MS–DRG 853) and the other MS–DRGs were $74,039, $83,650, and $90,170, respectively. The applicant determined that the final average case-weighted standardized charges per case for the three primary MS–DRG groups, the five additional MS–DRG groups and across other MS–DRGs were $90,683, $101,298, and $108,498, respectively. Because the final average case-weighted standardized charges per case for all three scenarios exceed the corresponding average case-weighted threshold amounts for the respective MS-DRGs of $68,712, $73,775, and $74,836, respectively, the applicant maintained that the LUTONIX® meets the cost criterion for new technology add-on payments based on the results of the subsequent cost analysis.

Response: We appreciate both of the applicants’ submission of additional information and responses. After review of the applicants’ subsequent analyses and consideration of the public comments we received, we believe that both technologies meet the cost criterion.
With regard to substantial clinical improvement for LUTONIX®, the applicant stated that LUTONIX® represents a substantial clinical improvement because it meets an unmet clinical need by providing access to “no stent zones” and because it can achieve greater patency; preserve the flexibility of future interventions; and address stent fractures and re-stenosis.\textsuperscript{32,33}

The applicant shared the findings from its LEVANT 1 and LEVANT 2 trials.

LEVANT 1: In the LEVANT 1 trial, 101 patients were randomized to a LUTONIX® drug-coated balloon treatment group or a control group that received percutaneous transluminal angioplasty (PTA) only. The primary endpoint of mean angiographic Late Lumen Loss at 6 months favored the LUTONIX® drug-coated balloon treatment group (0.46±1.13) compared to the control PTA group (1.09±1.07), with a p-value of 0.016.

LEVANT 2: The LEVANT 2 study is the applicant’s pivotal study that was conducted as a prospective, multicenter, single blind, 2:1 (test: control) randomized trial comparing the LUTONIX® drug-coated balloon angioplasty to standard balloon angioplasty used during the treatment of patients with femoropopliteal arteries. The applicant documented that the patient characteristics and lesions in both groups were well-matched; 43 percent of patients were diabetic; 35 percent were current smokers; 37 percent were female; and 8 percent had critical limb ischemia.

The study was conducted to show that drug-coated balloon angioplasty improves clinical outcomes for a patient population as compared to currently available treatments. All endpoints were adjudicated by a blinded Clinical Events Committee (CEC) and duplex ultrasound and angiographic core laboratories.

The applicant specified two primary endpoints that must both be met in order for the study to be successful. The first endpoint was primary patency at 12 months, defined as freedom from target lesion restenosis and target lesion revascularization (TLR). The results were the following: primary patency for LUTONIX® was 65.2 percent compared to primary patency of 52.6 percent for PTA. Kaplan-Meier analysis was 73.5 percent for LUTONIX® compared to 56.8 percent for PTA (p<0.001). The second primary efficacy endpoints were composite safety endpoints at 12 months, which included freedom from index-limb amputation; reintervention and related death. The results were 83.9 percent for LUTONIX® compared to 79.0 percent for PTA.

The secondary efficacy endpoints at 12 months for this trial were freedom from Target lesion revascularization (TLR), and the results were 89.7 percent for the LUTONIX® treatment group compared to 84.8 percent for the PTA control group, with p=0.17. Another end point was freedom from target vessel revascularization (TVR), where the result for the LUTONIX® treatment group was 76.2 percent compared to 66.6 percent in the control group with a p-value of 0.041. Clinical indicators, such as ankle brachial index (ABI), Rutherford scores (categorization of symptomology), quality of life (QOL), walking distance, and walking impairment WIQ, were significantly improved with a p-value of <0.001. The applicant assessed the primary safety endpoint using
Kaplan-Meier survival analysis and stated that there was no evidence of statistical difference.

Regarding the LEVANT 1 trial, in the proposed rule, we stated our concern that the results of the LEVANT 1 trial were not statistically significant with regard to the p-value documented. In addition, adverse events were similar for both groups and through 24 months; the percentage of patients with any death, amputation, or target vessel thrombosis was 8 percent in the treatment group compared to 12 percent in the control group.

Regarding the LEVANT 2 study, in the proposed rule we stated our concern that the patient population included in the study may not reflect the Medicare population. We also noted that only 37 percent of the studied patients were female. We stated that it could be beneficial to see additional subgroup analyses to test for statistical interaction between treatment and subgroups to ascertain that there is no imbalance in response to different subpopulations, such as males versus females.

We invited public comments on whether LUTONIX® (and IN.PACT™ Admiral™) meets the substantial clinical improvement criterion.

Comment: The applicant submitted public comments in response to CMS’ concerns regarding the statistical significance and adverse events documented in the LEVANT 1 trial. The applicant stated that the LEVANT 1 trial was a first-in-human study designed to provide a preliminary look at the efficacy of the LUTONIX® compared to standard PTA, along with a safety assessment of this novel technology in a human clinical study. The applicant reiterated that the primary endpoint for the LEVANT 1
study was angiographic Late Lumen Loss at 6 months. In conclusion, the applicant stated that the data did show a statistically significant benefit from the use of the LUTONIX® over the control PTA group (p-value = 0.016), and the study also assessed clinical endpoints such as target lesion revascularization (TLR) at several time points. The applicant further stated that although the study was not designed to show a statistical difference in TLR rates, there was a trend towards superiority for the LUTONIX® over standard PTA treatments.

**Response:** We appreciate the applicant’s submission of additional information in response to our concerns regarding the LEVANT 1 trial. While we do not believe that the results of this trial alone sufficiently demonstrate a substantial clinical improvement, we note that the applicant also submitted additional clinical data in support of its representation of a substantial clinical improvement.

**Comment:** In response to CMS’ concerns regarding the LEVANT 2 study, the applicant and manufacturer of the LUTONIX® technology submitted public comments in which it stated that the proportion of females in the LEVANT 2 study is consistent with other reported randomized superficial femoral artery (SFA) DCB and SFA stent studies, and noted that the percentage of females in the DCB and stent arms for these studies ranges from 29.1 percent to 41.0 percent, and the PTA arm ranges from 33.1 percent to 42 percent. The applicant stated that the LEVANT 2 study enrolled patients at 55 sites globally, including 42 sites across the U.S. to ensure inclusion of a diverse population of patients diagnosed with PAD. The applicant also presented enrollment data from other PAD trials such as the THUNDER, IN.PACT, and ZilverPTX and indicated that the
percentages of females enrolled were 35 percent, 35 percent, and 34.3 percent, respectively. The applicant conceded that the LEVANT 2 study was not designed to study subgroups (including females). Therefore, the applicant suggested that data analyses from such subgroups should be viewed with caution.

Response: We appreciate the applicant’s submission of additional information in response to our concerns regarding the LEVANT 2 trial. We acknowledge and have taken into consideration that there is a historical underrepresentation of women in PAD trials, and the epidemiology and the differential treatment rates between genders may also explain the lower rates of women enrolled in the trial. We note that, while the LUTONIX® LEVANT 2 study was not designed to study subgroups, Medtronic (the co-applicant) submitted a detailed subgroup analysis for the IN.PACT™ Admiral™ technology, which responded to our concerns and is discussed below.

With regard to substantial clinical improvement for the IN.PACT™ Admiral™, the applicant stated that evidence demonstrates that the technology significantly improves key clinical outcomes compared to previous technologies for patients with intermittent claudication. Examples of such key clinical outcomes included a decrease in recurrence of restenosis (disease process); a decrease in rates of repeat interventions (subsequent therapeutic interventions); a decrease in future hospitalizations; improved patient symptoms (decreased pain), and improvement in quality of life and function. To further demonstrate substantial clinical improvement, the applicant asserted that historical proof-of-concept research has demonstrated the utility of various drug-coated balloon
technologies in reducing restenosis and re-intervention compared with PTA.\textsuperscript{34,35} With this assertion, the applicant stated that there was no evidence of the promising primary patency and target lesion revascularization rates from large randomized controlled trials. This led the applicant to design the IN.PACT\textsuperscript{TM} SFA Trial. The IN.PACT\textsuperscript{TM} SFA Trial is a prospective, randomized-controlled, global, multicenter, single-blinded study conducted with independent, blinded adjudication of all key endpoints. The primary safety endpoint was freedom from device-related and procedure-related death through 30 days, and freedom from target limb major amputation and clinically-driven TVR through 12 months. The primary effectiveness endpoint was primary patency, a composite endpoint comprising an anatomic measure (binary restenosis as measured by duplex ultrasound or angiography) and a clinical measure (Clinically Driven Target Lesion Revascularization (CD-TLR)). The IN.PACT\textsuperscript{TM} SFA Trial was designed as a two-phase, global, multicenter trial in which 331 patients with symptoms of claudication or rest pain and with a positive diagnostic finding of de novo stenosis and/or non-stented restenotic lesions in the SFA and/or popliteal artery (PPA) were randomized in a 2:1 fashion to treatment with IN.PACT\textsuperscript{TM} Admiral \textsuperscript{TM} drug-coated balloon or uncoated balloon angioplasty. The trial was prospectively designed to be conducted in two phases: IN.PACT\textsuperscript{TM} SFA Phase I (conducted in Europe) and IN.PACT\textsuperscript{TM} SFA Phase II (conducted in the United States), jointly referred to as IN.PACT\textsuperscript{TM} SFA Trial. According


to the applicant, the patient demographics were well-matched, noting that 34 percent of the patients were women.

The applicant noted that, during the SFA Trial, both the study subjects and trial sponsor were blinded to the treatment assignments through completion of the 12-month primary endpoint evaluations. The applicant also stated that the independent Clinical Events Committee and the Core Laboratories were blinded to the treatment assignment and the duration of the follow-up of study participants. In addition, operators (implanting physicians and catheterization laboratory staff, including research coordinators) were not blinded to the treatment delivered due to macroscopic visual differences between IN.PACT™ Admiral™ drug-coated balloon and control technology.

The applicant reported the following: The primary endpoints were: improved primary patency rates in the IN.PACT™ Admiral™ drug-coated balloon arm compared to the control arm; and primary patency within 12 months is defined as freedom from clinically driven target lesion revascularization and freedom from restenosis as determined by duplex ultrasonography peak systolic velocity ratio ≤ 2.4 or ≤ 50 percent stenosis as assessed by angiography. Results showed that the 12-month primary patency rate was 82.2 percent in the IN.PACT™ Admiral™ drug-coated balloon arm versus 52.4 percent in the PTA arm (P <0.001). In addition, the 12-month freedom from binary restenosis (assessed by DUS/angiography) was 83.5 percent in the IN.PACT™ Admiral™ drug-coated balloon group compared to 66.3 percent in the PTA group (P=0.001). The second endpoint measured was Ankle-Brachial Index (ABI) showing 0.951 in the IN.PACT™ Admiral™ drug-coated balloon arm compared to 0.866 in the
control arm, P=0.002. The ABI is an objective hemodynamic measure used to predict the severity of PAD in the lower extremity. The test is done by comparing the systolic blood pressure at the ankle and the systolic blood pressure in the arm while a person is at rest. In general, higher values are better than lower values; a normal resting ankle-brachial index is from 1.0 to 1.4, an abnormal resting ankle-brachial index is 0.9 or lower and an ABI of 0.91 to 0.99 is considered borderline abnormal.\textsuperscript{36} Secondary endpoints were primary sustained clinical improvement, defined as freedom from target limb amputation, target vessel revascularization, and increase in Rutherford class; comparing IN.PACT\textsuperscript{TM} Admiral\textsuperscript{TM} with the control arm was 85.2 percent versus 68.9 percent; P <0.001. The rate of repeat target lesion revascularization (TLR), defined by the applicant as repeat revascularization of the target lesion by percutaneous endovascular treatment or bypass surgery, was 2.4 percent in the IN.PACT\textsuperscript{TM} Admiral\textsuperscript{TM} drug-coated balloon arm compared to 20.6 percent in the control arm. In addition, the target vessel revascularization (TVR) procedures (that is, any revascularization done to any segment of the entire target vessel that may reflect restenosis of a target lesion or disease progression causing a new lesion in the target artery)\textsuperscript{37} was 4.3 percent in the IN.PACT\textsuperscript{TM} Admiral\textsuperscript{TM} drug-coated balloon arm compared to 23.4 percent in the control arm with a p-value of <0.001).

Other secondary endpoints were conducted and the patients were followed at 1, 6, and 12 months to assess the following claudication symptoms: EQ-5D; Walking Impairment Questionnaire (WIQ); 6-minute walk test in a subset. Claudication symptoms were 7.3 percent in the IN.PACT™ Admiral™ drug-coated balloon arm compared to 20.7 percent in the control arm. For WIQ (defined as the ability of PAD patients to walk defined distances and speeds, plus climb stairs, thus evaluating claudication severity levels), the gains in improvement were similar in both groups. The 6-minute walk test, which is a measure of functional exercise capacity, was equivocal in both arms. Quality of life (QOL) was measured using five domains of the EQ-5D (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and was found to be equivocal. EQ-5D™ is a standardized instrument for use as a measure of health outcome.

The applicant also conducted extensive subgroup analyses of the primary safety end point, efficacy endpoint, and TLR rates to assess the response to IN.PACT™ Admiral™ in various subpopulations, including: Rutherford category (2, 3, and 4); diabetes; age (≥75); lesion length (< 5 cm, ≥ 5 cm to <10 cm, ≥10 cm to < 18 cm); total occlusion, and gender. According to the applicant, although the trial was not designed to power the subgroup analyses, in 9 of these 11 subgroups, patients in the IN.PACT™ Admiral™ treatment group were shown to have statistically significant better outcomes.

---


39 http://www.euroqol.org/
than patients in the PTA control group in the primary effectiveness and safety endpoints as well as clinically-driven TLR. This includes subgroups: Rutherford categories 2 & 3; diabetes; age (≥75); lesion length ≥ 5 cm to < 10 cm; lesion length ≥ 10 cm to < 18 cm; total occlusion; and gender (both male and female). In the two subgroups that did not meet statistical significance (Rutherford category 4 and lesion length < 5 cm), data for the primary effectiveness and safety endpoints as well as the clinically driven TLR trended in favor of IN.PACT™ Admiral™.

After reviewing the clinical data described above, in the proposed rule we raised a number of concerns related to the substantial clinical improvement criterion. Similar to the LUTONIX® LEVANT studies, in the proposed rule we stated that we were concerned that the IN.PACT™ SFA trial did not match the gender variable. Also, in the proposed rule we stated that we were concerned about the clinical meaningfulness of some of the endpoints measured by the IN.PACT SFA Trial conducted by Medtronic. For example, there were no changes in functional measures such as walking distances. The applicant indicated that this may be because patients in the control group had additional procedures to the point their symptoms were controlled to the same extent as those of the drug-coated balloon group. We stated that we believe that this assertion could be better supported with data. We also cited the higher ankle-brachial index in the drug-coated balloon catheter group as a related example of concern about the clinical meaningfulness of some of the endpoints measured by the IN.PACT SFA trials. While this is also consistent with an enduring physiologic effect of the drug-coated balloon device, we stated our concern that these ABI measurements appear to have been made by unblinded
study personnel. As a result, we stated that the IN.PACT™ Admiral™ technology may not be the optimal treatment for all patients diagnosed with peripheral arterial disease. The drug-coated balloon catheter has been compared only with a standard balloon, and no other alternatives, such as stents, surgery, or intensive exercise therapy. Therefore, it is unknown whether a drug-coated balloon strategy would yield the same, better, or worse outcomes than these alternatives. We also noted that while there appears to be broader anatomical applicability, not all of the studies provided definitively indicate that it is a clinical improvement over PTA.

We invited public comments on whether IN.PACT™ Admiral™ (and LUTONIX®) meets the substantial clinical improvement criterion.

Comment: The applicant submitted public comments in response to CMS’ concern regarding matching on the gender variable, in which the applicant stated that historically, the proportion of females enrolled in Peripheral Artery Disease (PAD) trials has been lower than that of males. The applicant provided data of lower percentages of women recruited for similar studies. In addition, the applicant noted that evidence suggests that women diagnosed with PAD may be less likely to undergo lower extremity revascularization than men. The applicant further stated that gender differences in the treatment of patients diagnosed with PAD, similar to that found with the treatment patients diagnosed with congestive heart disease (CHD), have been reported. Overall, multiple factors including differences in epidemiology, clinical presentation, and awareness of PAD may have contributed to differential selection for PAD treatment and, by extension, participation in a clinical trial. However, the applicant agreed that it is
important to ensure adequate representation of women in PAD trials and address barriers to treatment/trial enrollment.

The applicant further asserted that with respect to outcomes of women treated with IN.PACT™ Admiral™ DCB verses standard PTA options in the IN.PACT SFA Trial, detailed subgroup analyses were carried out to study treatment effects and interactions by gender and other variables. According to the applicant, results show that the use of DCB significantly improved outcomes compared to standard PTA options in both males and females. The primary effectiveness endpoint of primary patency at 12 months was statistically significant in favor of the IN.PACT™ Admiral™ DCB versus standard PTA options for both females and males. Similar findings were observed for the primary safety composite endpoint. In addition clinically-driven target lesion revascularization (TLR) rates were significantly lower in the IN.PACT™ Admiral™ DCB arm versus the PTA arm for both males and females. These gender specific analyses demonstrated no differences in treatment effects between men and women (that is, there was no gender by treatment interaction). The applicant stated that given the statistically significant results for the primary safety and effectiveness endpoints in both genders, it believed that a more balanced enrollment in the male and female subgroups would be expected to show the same results, with tighter confidence intervals.

Response: We appreciate the applicant’s response and, as noted above, we have taken into consideration that there is a historical underrepresentation of women in PAD trials in our determination of whether the technology represents a substantial clinical improvement.
Comment: The applicant submitted public comments in response to CMS’ concern regarding the clinical meaningfulness of some of the endpoints measured by the IN.PACT SFA Trial. The applicant stated that the IN.PACT™ Admiral™ SFA Trial was designed to assess the safety and efficacy of the IN.PACT™ Admiral™ DCB in treating femoropopliteal artery disease, with primary patency and safety composite as the primary endpoints at 12 months. However, the applicant noted that it also assessed important functional and quality of life outcomes as key secondary endpoints including the EQ-5D and walking impairment (WIQ). The applicant’s results showed that patients in the IN.PACT™ Admiral™ DCB arm had better EQ-5D results at 6 and 12 months relative to the baseline than patients in the PTA arm. At 6 months, there was a significantly greater decline in QoL in the PTA arm indicating early treatment failure. At 12 months, the applicant asserted that improvements continued to trend in favor of the IN.PACT™ Admiral™ DCB arm, approaching statistical significance in four of the five domains of the EQ-5D (all domains except anxiety/depression). The applicant noted that, although some of the functional outcome measures did not show statistically significant differences between treatment groups at 12 months, the PTA patients required 8.6 times more target vessel revascularizations to receive the same level of functional performance as IN.PACT™ Admiral™ DCB patients. The applicant asserted that clinically-driven target vessel revascularization (CD-TLR) is a key indicator for failed functional performance and both CD-TLR and primary sustained clinical improvement at 12 months demonstrated statistical significance (p<0.001) favoring the IN.PACT™ Admiral™ DCB group. The applicant concluded that patients treated with IN.PACT™ Admiral™ DCB
had significantly better primary patency and a marked reduction in the need for target lesion revascularization and associated costs.

**Response:** We appreciate the applicant’s clarification. We believe that our concerns are satisfied by the additional documentation, which indicates that the assessment of the EQ-5D (EQ 5 domains) and walking impairment surveys are sufficient quality of life outcomes that demonstrated trends that favored IN.PACT™ Admiral™ DCB over standard PTA.

**Comment:** The applicant submitted public comment regarding CMS’ concern on the clinical meaningfulness and measurement of the ankle branchial index (ABI) endpoint, in which the applicant stated that ABI is a simple noninvasive diagnostic test of choice when evaluating patients for PAD.\(^{40,41}\) The ABI is a result of a calculation based on an objective measurement of the pressures of the patient’s ankles/toes and arms. The nurse/technologist performs the ABI/TBI test according to the institutional policy/procedure, using Doppler flow detectors, and immediately records the pressure readings. Because the ABI is a ratio of the blood pressure at the ankle and the arm, the risk of subjectivity in the ABI value is minimal. The applicant further stated the sensitivity and specificity of ABI in diagnosing PAD has been validated using angiograms, and the test was found to have high sensitivity (95 percent) and specificity (100 percent) in diagnosing PAD.\(^{42}\)

---

\(^{40}\) Lange SF, Trampisch HJ, Pittrow D, Darius H, Mahn M, Allenberg JR. Profound influence of different methods for determination of the ankle brachial index on the prevalence estimate of peripheral arterial disease. BMC Public Health. 2007;7:147.

\(^{41}\) Shanmugasundaram M, Ram VK, Luft UC, Szerlip M, Alpert JS. Peripheral arterial disease—what do we need to know?. Clin Cardiol. Jun 29 2011;[Epub ahead of print].

Response: We appreciate the applicant’s expanded explanation and input.

Comment: In the applicant’s submitted public comment in response to CMS’ concern that the IN.PACT™ Admiral™ technology may not be the optimal treatment for all patients diagnosed with peripheral arterial disease, the applicant asserted that the IN.PACT™ Admiral™ DCB is not intended to be the optimal treatment for all patients with PAD and is not indicated for patients diagnosed with below-the-knee PAD. Rather, the applicant explained that the technology is indicated for treatment of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-7 mm (after pre-dilatation). The applicant further stated that current ACC/AHA Guidelines recommend the use of endovascular therapies for treatment of patients with vocational or lifestyle-limiting disability due to intermittent claudication only after inadequate response to exercise or medication, and when there is a favorable risk-benefit ratio. Patients diagnosed with intermittent claudication (IC) eligible for endovascular therapy based on guidelines may benefit from the IN.PACT™ Admiral™ DCB. The applicant believed that there will also be a portion of patients needing provisional stenting, or even surgery to achieve optimal outcomes that may benefit from the IN.PACT™ Admiral™.

Another commenter referenced an article that states that there remains a significant unmet clinical need in patients diagnosed with PAD, as well as a significant progress in the use of vascular procedures (both diagnostic and therapeutic) and
preventive care. The commenter recommended that CMS approve new technology add-on payments for the LUTONIX® IN.PACT™ Admiral™.

**Response:** We appreciate the applicant’s submission of the additional data on the specific unmet need that may be met by use of the LUTONIX® and IN.PACT™ Admiral™ technology. We believe that the information provided satisfies our concerns, and the totality of the data from the submitted studies demonstrates that the technologies meet the substantial clinical improvement criterion.

After consideration of the comments we received, we are approving the LUTONIX® and IN.PACT™ Admiral™ technologies for new technology add-on payments for FY 2016. Cases involving the use of LUTONIX® and IN.PACT™ Admiral™ DCBs that are eligible for new technology add-on payments will be identified by one of the ICD-10-PCS procedure codes identified in the table earlier in this section.

Each of the applicants submitted operating costs for its DCB. The manufacturer of the LUTONIX® stated that a mean of 1.37 drug-coated balloons was used during the LEVANT 2 clinical trial. The acquisition price for the hospital will be $1,900 per drug-coated balloon, or $2,603 per case (1.37 x $1,900). The applicant projects that approximately 8,875 cases will involve use of the LUTONIX® for FY 2016. The manufacturer for the IN.PACT™ Admiral™ stated that a mean of 1.4 drug-coated balloons was used during the IN.PACT™ Admiral™ DCB arm. The acquisition price for the hospital will be $1,350 per drug-coated balloon, or $1,890 per case (1.4 x $1,350).

---

The applicant projects that approximately 26,000 cases will involve use of the IN.PACT™ Admiral™ for FY 2016.

New technology add-on payments for cases involving these technologies will be based on the weighted average cost of the two DCBs described by the ICD-10-PCS procedure codes listed above (which are not manufacturer specific). Because ICD-10 codes are not manufacturer specific, we cannot set one new technology add-on payment amount for IN.PACT™ Admiral™ and a different new technology add-on payment amount for LUTONIX®, both technologies will be captured by using the same ICD-10-PCS procedure code. As such, we believe that the use of a weighted average of the cost of the standard DCBs based on the projected number of cases involving each technology to determine the maximum new technology add-on payment would be most appropriate.

To compute the weighted cost average, we summed the total number of projected cases for each of the applicants, which equaled 34,875 cases (26,000 plus 8,875). We then divided the number of projected cases for each of the applicants by the total number of cases, which resulted in the following case-weighted percentages: 25 percent for the LUTONIX® and 75 percent for the IN.PACT™ Admiral™. We then multiplied the cost per case for the manufacturer specific DCB by the case-weighted percentage (0.25 * $2,603 = $662.41 for LUTONIX® and 0.75 * $1,890 = $1,409.03 for the IN.PACT™ Admiral™). This resulted in a case-weighted average cost of $2,071.45 for DCBs.

Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS–
DRG payment for the case. As a result, the maximum payment for a case involving the LUTONIX® or IN.PACT™ Admiral™ DCBs is $1,035.72 for FY 2016.

e. VERASENSE™ Knee Balancer System (VKS)

OrthoSensor submitted an application for new technology add-on payments for the VERASENSE™ Knee Balancer System (VKS) for FY 2016. The VKS is a sterile, single patient use device to intraoperatively provide a means to dynamically balance the patient’s knee during total knee arthroplasty (TKA) surgery. The applicant stated that quantitative metrics, viewed on a monitor through real time wireless information, enable the surgeon to improve soft tissue stability and kinetics during TKA surgery. The VKS device includes a tibial trial insert composed of an array of responsive sensors that delivers quantified kinetic balance data during TKA surgery. Therefore, the applicant believed that the quantitative data provides a basis for the surgeon to make data-based decisions regarding tissue dissection during TKA surgeries, resulting in a more stable outcome.

According to the applicant, the VKS device combines dual sensor elements, coupled with micro-processing technology, to accurately depict intra-articular kinetics and contact point locations within the knee. The tibial trial insert is placed in the knee capsule. Proper placement of the insert does not require any force or infiltration of the bone or soft tissue in the knee. The applicant stated that the VKS device uses wireless communication protocols that overcome line-of-sight or other interference issues, therefore eliminating the need for line-of-sight or direct antenna-based tracking during the TKA surgery.
The first version of the VKS received FDA approval in 2009 for the OrthoRex Intra-Operative Load Sensor. The device was indicated for use as a tool to adjust the femoral knee implant to reduce instability from flexion gap asymmetry using a single patient use sterile force sensor. The applicant noted that the first version of the VKS was not available on the U.S. market at the time of FDA approval in 2009. The applicant stated that the 510K approval from the FDA allowed permission to continue to test the device and improve upon the specificity of the sensors. The applicant stated that the first version of the VKS did not enter on the U.S. market until late 2011. Further advancements were made to the VKS to more accurately refine the sensor specificity, which provides more accurate balance data unique to the contours of specific knee implant components. The applicant further explained that the tibial trial sensor was redesigned to respond quantitatively and specifically to the variations of the contours of specifically manufactured knee implants. The advanced sensor specificity, developed in conjunction with data gained from clinical trials, provides information regarding force and balance metrics that aid the surgeon’s understanding and measurement of knee balance. The applicant noted that without the advancements to the sensor specificity, which were perfected based on knowledge gained from the clinical trials, the sensor would not be as clinically useful as it is currently. According to the applicant, these advancements resulted in additional FDA clearances on June 13, 2013, and October 14, 2013, and the product’s description was updated on January 28, 2014.

The applicant maintained that the VKS meets the newness criterion for new technology add-on payments. In the FY 2016 IPPS/LTCH PPS proposed rule
(80 FR 24453), we stated that we believe that the beginning of the newness period for the VKS commenced when the product was first made available on the U.S. market in late 2011, and the 3-year anniversary date of the product’s availability on the U.S. market occurred in late 2014, which is prior to the beginning of FY 2016. We also stated that the advancements made to the VKS that resulted in the additional FDA approval clearances in 2013 may not be significant enough to distinguish the advanced technology from the first version of the VKS, which received FDA approval in 2009. Therefore, we did not believe that the VKS technology could be considered “new” for purposes of new technology add-on payments.

As discussed in the FY 2005 IPPS final rule (69 FR 49003), once data become available to reflect the cost of the technology in the relative weights, a technology can no longer be considered “new” and eligible to receive new technology add-on payments. Section 412.87(b)(2) states that a medical service or technology may be considered new within 2 or 3 years after the point at which data begin to become available reflecting the ICD-9-CM code assigned to the new service or technology (depending on when a new code is assigned and data on the new service or technology become available for DRG recalibration). After CMS has recalibrated the DRGs based on available data that reflects the costs of an otherwise new medical service or technology, the medical service or technology will no longer be considered “new” under this criterion. The applicant analyzed the relative weights from 2010 to 2014 for the MS-DRGs that may contain cases that would be eligible for treatment using the advanced VKS technology (MS-DRGs 461 through 470). As a result of its analysis, the applicant noted that there was no
increase in the calculation of the FY 2014 or FY 2015 relative weights for these MS-DRGs that would represent and include the additional cost of cases involving the advanced VKS technology. To the contrary, in the FY 2016 IPPS/LTCH PPS proposed rule, we stated that we believe that the costs of this technology are included in the charge data and the MS-DRGs have been recalibrated using that data. Therefore, we believe that the technology can no longer be considered “new” for the purposes of this provision, regardless of whether or not there was an increase in the MS-DRG relative weights during FYs 2014 and 2015, specifically because of the inclusion of the cost of the technology.

Specifically, as discussed in the proposed rule, in the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43813 through 43814) as part of the newness criterion, we established criteria for evaluating whether a new technology is substantially similar to an existing technology, specifically: (1) whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome; (2) whether a product is assigned to the same or a different MS-DRG; and (3) whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population. If a technology meets all three of the criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments.

In evaluating the VKS new technology add-on payment application under the substantial similarity criteria, in the FY 2016 IPPS/LTCH PPS proposed rule, we stated that we believe that the first version of the VKS and the advance version of the VKS use
the same mechanism of action to achieve the desired outcome by using a sterile device that is equipped with sensors used to adjust the femoral knee implant to reduce instability from flexion gap asymmetry. In addition, we believe that cases involving the first version of the VKS would be assigned to the same MS-DRG as the cases involving the advanced VKS. Moreover, it appeared that both the first version of the VKS and the advanced version of the VKS would treat the same or similar disease and the same or similar patient population. We concluded that, because the technology appeared to meet all three elements of the substantial similarity criteria, we believe that the beginning of the newness period for this technology would commence when it became available on the U.S. market in late 2011, and therefore the VKS may not be considered “new” for purposes of new technology add-on payments.

We invited public comments regarding whether or not the VKS technology is substantially similar to existing technologies, and whether or not the VKS technology meets the newness criterion.

Comment: The applicant submitted comments in response to our concerns regarding whether the anniversary date of entry onto the U.S. market for the VKS is within the 2 to 3 year limit in accordance with the newness criterion. According to the applicant, the technical evolution of the device received FDA 510k clearance in June 2013 based on a completely new operating principal and expanded functionality (tibia and overall limb alignment), which is representative of the advanced version of the device currently used. The applicant further stated that, in addition to the ability to measure both load and alignment of the knee (which are capabilities of the evolved use of
the device since the FDA clearance was granted in June 2013), there also has been effective use of the technology in a revision knee capacity, which is an added indication that is currently under review by FDA for clearance as an additional indication for the use of the technology. The applicant believed that improved TKA outcomes lead to greater mobility, reduced morbidity, and a reduced need for revision knee surgery as evidenced by experience demonstrating that the use of the TKS device leads to a more stable TKA and, subsequently, to a significantly reduced probability of the need for revision TKA procedures. The applicant added that the approval of new technology add-on payments for this technology would enable broader access to the benefits of the TKS’s capabilities and allow patients to experience statistically significantly improved TKA outcomes. The applicant also noted that new technology add-on payment newness criterion dictates eligibility by limiting the product’s “newness” classification within the statutory time of 2 to 3 years, and recognized that the intent of the limit is to ensure that there is no current data reflecting the cost of the new technology that would be used to recalibrate the MS-DRGs. However, the applicant explained that the charges and costs relating to the use of the advanced version of the new technology (which is the subject of the application) are not reflected in the most current claims data and have not been used to recalibrate MS-DRGs and, therefore, the MS-DRG payment rate otherwise applicable to the cost of procedures involving the use of the advanced version of the new technology would be inadequate.

Response: We appreciate the details included in the applicant’s response to distinguish the 2013 advanced version of the VKS that received FDA clearance from
prior versions of the technology, which also have received FDA approvals. However, after considering the information provided, we continue to believe that the advancements made to the VKS that resulted in the additional FDA approval clearances in 2013 are not significant enough to distinguish the advanced version of the technology from the first version of the VKS, which received FDA approval in 2009. In addition, in examining the FDA labeling included in the FDA approvals in 2009 and 2013, we recognize that the language from the labeling included in the 2013 FDA approval does not reflect the changes mentioned by the applicant with regard to its indications and use. Therefore, it appears that data of the current version of the VKS is already reflected within the MS-DRGs. We discuss the comments related to the substantial similarity components of the newness criterion, including MS-DRG assignment of cases involving this technology, in our responses to other comments below.

Comment: In response to CMS’ concerns whether the 2013 advanced version of the VKS device has a different mechanism of action than the previous version of the VKS device, the applicant explained in its comment that the mechanism of action for the 2013 FDA-cleared advanced version of the VKS uses novel proprietary changes to the electrical engineering principles in order to capture, measure, analyze, and report measures of load, balance, alignment and rotational congruency, which, when compared to the 2009 FDA-approved device, uses a different mechanism of action. The applicant noted that this development was a significant engineering change requiring reworking of the programs for the sensors, including modifying the internal design, placement, and programming to correctly capture and report measurements related to balance, load, and
alignment relative to rotational congruency across the tibial plateau. The applicant indicated that the advanced version of the VKS device that received FDA clearance in 2013 made note of the expanded capability, which added measurement of “alignment,” whereas the capability of the prior VKS device design could only measure load and balance.

The applicant further noted that, when comparing this advanced device to its predecessor, its use produces patient outcomes that are similar because both devices measured load relative to ligament balance, and outcomes were measured as a function of load. The applicant stated that the advanced device approved by the FDA in 2013 has the ability to uniquely report relative femoro-tibial rotation and has changed the variables regarding how the surgeon can use the device relative to the soft tissue (ligament) dissection and implant positioning, which allows the surgeon to better measure varus/valgus angles relative to load and balance, and allows for empirically-based decisions used in making angular cuts for both primary and revision TKA procedures. The applicant believed that the introduction of new engineering principles used in the 2013 FDA-cleared advanced version of the VKS device captures, measures, and reports more accurately intercompartmental load, overall limb alignment, and component rotation, which significantly distinguishes its capabilities from the prior version of the VKS device.

Response: We appreciate the information and details included in the applicant’s comment. However, we remain concerned that the 2013 FDA-cleared advanced version

---

44 Roche MW, Elson LC, Anderson CR. A Novel Technique Using Sensor-Based Technology to Evaluate Tibial Tray Rotation. Orthopedics. 2015 Mar 1;38(3).
of the VKS uses the same mechanism of action as the prior versions of the VKS that previously received FDA clearance in 2009 and 2011. We note that each technology previously approved for this device used similar mechanisms of action to balance a patient’s knee joint during TKA surgery. In addition, it is unclear whether the device’s current engineering changes, which include the added capability of measurement for knee joint load, balance, and limb alignment, resulted in improvements that go beyond what could be considered a software patch to make adjustments to refine the computation of kinetic knee joint stability and “balance.” Therefore, we do not believe there has been a change in the mechanism of action with the current VKS device.

Comment: In response to CMS’ concerns whether cases involving the advanced version of the VKS device would be assigned to the same MS-DRG as cases involving the previous versions of the VKS device, and whether each version of the VKS device could be used to treat the same or similar disease and the same or similar patient population, the applicant in its comment stated that it believed that cases representing patients requiring revision knee surgery, which map to MS-DRG 466, 467 and 468 (Revision of Hip or Knee replacement with MCC, with CC, and without CC/MCC, respectively), would now be eligible for evaluation as candidates eligible for treatment using the advanced version of the VKS device. The applicant believed that a new population of patients exists that could benefit from treatments in which intraoperative use of the VKS device can be further validated and improve upon the outcomes of these types of procedures. The applicant further explained that engineering advances extended the VKS’ capabilities that created a seamless surgical process supporting key
intraoperative challenges of revision knee surgery. The applicant stated that the ability to gain a seamless surgical flow during complex surgery, and having refined metrics including load and balance relative to the anatomy of a revision, enables surgeons to consider a new patient population. The applicant noted that the prior versions of the VKS device could not accommodate varus/valgus angles, and did not have the refined ability to provide information for angular bony cuts. The applicant stated that the advancements achieve outcomes based on a different mechanism of action that provides a higher degree of accuracy when reporting load, alignment, and balance, which enables accurate localization of load using metrics that convert to surgeon dissection specific to the patient’s knee. The applicant believed that these advancements also allow a new population of patients to be considered for these types of procedures that map to MS-DRGs 466, 467, 468.

Response: In examining the FDA labeling included in the FDA approvals and indications for the technology’s uses from 2009 and 2013, we do not recognize any language in the labeling included in the 2013 FDA approval of the advanced version of the VKS that reflects the changes in indication or recommend use, as mentioned by the applicant. Therefore, we are unable to determine if the advancements made to the 2013 FDA-cleared version of the VKS are significant enough that cases involving the advanced version would not be assigned to the same or different MS-DRGs or involve the treatment of the same or different patient population as would cases involving the previously FDA-cleared versions of the VKS.
As stated in section II.G.1.a. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule and this final rule, effective October 1, 2015 (FY 2016), the ICD-10 coding system will be implemented. In the proposed rule, we noted that the applicant had applied for a new ICD-10-PCS procedure code at the March 18-19, 2015 ICD-10-CM/PCS Coordination and Maintenance Committee Meeting. In this final rule, we note that the new ICD-10-PCS procedure codes XR2G021 (Monitoring of Right Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1) and XR2H021 (Monitoring of Left Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1), were established as shown in Table 6B (New Procedure Codes), which will uniquely identify procedures involving the VKS technology. More information on this request and the approval can be found on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/ICD-9-CM-C-and-M-Meeting-Materials.html and the FY 2016 New ICD-10-PCS Codes can be found at the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-PCS-and-GEMs.html.

With regard to the cost criterion, the applicant supplied three analyses to demonstrate that it meets the cost criterion. The applicant believed that cases that are eligible for the VKS technology map to MS-DRGs 461 and 462 (Bilateral or Multiple Major Joint Procedures of Lower Extremity with MCC and without MCC, respectively), MS-DRGs 466 through 468 (Revision of Hip or Knee replacement with MCC, with CC, and without CC/MCC, respectively), and MS-DRGs 469 and 470 (Major Joint Replacement or Reattachment of Lower Extremity with MCC and without MCC,
respectively). The first analysis used data from the 2012 National Inpatient Sample (NIS) from the Agency for Research and Quality (AHRQ). We note that the NIS includes Medicare, Medicaid, and commercial and uninsured claims data. However, the applicant limited its search to Medicare cases only.

The applicant searched for all Medicare cases assigned to MS-DRGs 461 and 462 and found 812 and 14,200 cases respectively (for a total of 15,012 cases). The applicant noted that the 15,012 cases assigned to MS-DRGs 461 and 462 also include cases representing hip revision procedures. Therefore, to determine the number of eligible cases reporting bilateral knee revisions assigned to MS-DRGs 461 and 462, based on clinical information, the applicant approximated that 4 percent of the cases assigned to MS-DRGs 461 and 462 represent Medicare beneficiaries who may be eligible for the VKS for a bilateral knee revision procedure. As a result, the applicant focused its analysis on 32 cases assigned to MS-DRG 461 (812 cases * .04), and 568 cases assigned to MS-DRG 462 (14,200 cases * .04). In the FY 2016 IPPS/LTCH PPS proposed rule, we stated we were concerned that the statistical data obtained from clinical information that the applicant used to determine the percentage of cases representing bilateral knee revisions still includes cases representing hip revision procedures. Specifically, the applicant did not uniquely identify cases representing bilateral knee revisions and only produced a percentage of all cases that still includes cases for hip revision procedures.

According to the applicant, eligible cases for the VKS technology include cases representing knee revision procedures that also map to MS-DRGs 466 through 468.

---

(which represent degrees of severity calculated for each MS-DRG). To determine the number of eligible cases reporting knee revision procedures assigned to MS-DRGs 466 through 468, the applicant first searched the NIS database for the total number of Medicare cases assigned to these MS-DRGs. This resulted in a total of 54,105 cases.

The applicant noted that MS-DRGs 466 through 468 also include cases for hip and knee revision procedures. Therefore, to determine the number of cases representing knee revision procedures in each of these three MS-DRGs, the applicant first divided the number of Medicare cases for each MS-DRG (5,195 for MS-DRG 466, 28,650 for MS-DRG 467, and 20,260 for MS-DRG 468) by the total number of Medicare cases assigned to MS-DRGs 466, 467, and 468 (54,105). The applicant then multiplied the percentage for each MS-DRG (9.6 percent for MS-DRG 466, 52.9 percent for MS-DRG 467, and 37.4 percent for MS-DRG 468) by the total amount of cases assigned to each MS-DRG. Based on this calculation, the applicant approximated the following number of cases representing knee revision procedures assigned to each of these three MS-DRGs: 3,054 cases in MS-DRG 466; 16,842 in MS-DRG 467; and 11,910 in MS-DRG 468. In the proposed rule we stated that the methodology the applicant used to determine the percentage of cases representing knee revision procedures still includes cases representing hip revision procedures. Specifically, in its methodology, the applicant did not use any source of statistical relevance to isolate cases representing knee revision procedures. Rather, the applicant used the percentage of Medicare cases assigned to each MS-DRG of the overall total cases for the three MS-DRGs, which includes knee and hip revisions, and multiplied by this percentage to further reduce the total number of cases.
We stated that we do not believe that this further reduction to the total number of Medicare cases has sufficiently isolated cases representing knee revision procedures.

According to the applicant, eligible cases for the VKS technology also include TKA procedures that map to MS-DRGs 469 and 470. To determine the number of eligible cases reporting TKA procedures assigned to MS-DRGs 469 and 470, the applicant first searched the NIS database for the total number of Medicare cases assigned to these MS-DRGs. This resulted in 35,740 cases in MS-DRG 469 and 547,955 cases in MS-DRG 470. The applicant noted that MS-DRGs 469 and 470 also include cases representing hip replacement and other joint replacement procedures. Therefore, in order to determine the number of TKA procedures within these MS-DRGs, the applicant searched the NIS database for cases reporting ICD-9-CM procedure codes that typically map to these MS-DRGs. The applicant first searched for cases representing TKA across all MS-DRGs that reported ICD-9-CM procedure code 81.54 (Total knee replacement) and found 336,050 cases. The applicant then searched the NIS database for cases representing hip and other joint replacement procedures across all MS-DRGs that reported ICD-9-CM procedure codes 81.51 (Total hip replacement), 81.52 (Partial hip replacement), 81.56 (Total ankle replacement), 81.57 (Replacement of joint of foot and toe), and 81.59 (Revision of joint replacement of lower extremity, not elsewhere classified) and found 238,050 cases. This resulted in a total of 574,100 cases representing knee, hip, and other joint replacement procedures.

The applicant then divided the number of cases representing TKA procedures by the total number of cases (336,050/574,100) and determined that 58.5 percent of all cases
assigned to MS-DRGs 469 and 470 are related to TKA procedures. The applicant then multiplied the percent of cases representing TKA procedures (58.5 percent) by the number of cases assigned to MS-DRGs 469 and 470, which resulted in 20,920 cases in MS-DRG 469 (35,740 * .585) and 320,746 cases in MS-DRG 470 (547,955 * .585). In the proposed rule we stated we were concerned that the methodology the applicant used to determine the percentage of cases representing TKA procedures still includes cases representing hip and other joint replacement procedures. Specifically, the applicant did not uniquely identify cases representing TKA procedures and only produced a percentage of all cases, which still includes cases representing hip and other joint replacement procedures.

Based on the analysis above, the applicant asserted that the total number of cases across MS-DRGs 461 and 462 and MS-DRGs 466 through 470 was 374,071. The applicant determined an average case-weighted charge per case of $57,341. The applicant then determined that it was necessary to remove charges related to the other computer-assisted devices/technologies used during these procedures and charges for operating room time because procedures involving the VKS do not require operating room time, and the charges for the VKS technology would inevitably be different. Therefore, the applicant removed approximately $146 from the average case-weighted charge per case for cases assigned to MS-DRGs 461 and 462, and $73 from the average case-weighted charge per case for cases assigned to MS-DRGs 466 through 470. The applicant noted that the $146 in charges removed from the average case-weighted charges per case for cases assigned to MS-DRGs 461 and 462 was slightly higher than the
charges removed from cases assigned to MS-DRGs 466 through 470 because these charges were for bilateral procedures which require additional operating room time.

Data from the NIS database is only available on a national level and not on a hospital-specific level. Therefore, in order to standardize the charges per case, the applicant used the FY 2012 IPPS Impact File and the mean value of all relevant standardization factors to standardize the charges per case. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24455), we stated that the analysis provided by the applicant did not use hospital-specific data and, therefore, the standardization process may be inaccurate because of the use of mean factors rather than hospital-specific factors. By using mean factors rather than hospital-specific factors, we stated that we believe that the standardization performed by the applicant does not sufficiently take into account hospital variations.

The applicant then inflated the charges using an inflation factor of 10.4227 percent based on the inflation factor in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50379), and added the charges related to the VKS technology to the adjusted average case-weighted standardized charge per case. This resulted in a final inflated average case-weighted standardized charge per case of $68,121. Using the FY 2015 IPPS Table 10 thresholds, the applicant determined that average case-weighted threshold amount for MS-DRGs 461 and 462 and MS-DRGs 466 through 470 is $57,341. Because the final inflated average case-weighted standardized charge per case for the applicable MS-DRGs exceeds the average case-weighted threshold amount, the applicant asserted that the technology meets the cost criterion.
The applicant’s second analysis used data from the 2013 American Hospital Discharge Data (AHD) based on 57 randomly selected hospitals. The applicant searched the data and did not find any cases assigned to MS-DRG 461. The applicant noted that it used a value of 10 cases for its analysis of cases assigned to MS-DRG 461 because data reflecting a zero value indicates that the hospital performed less than 10 procedures. The applicant found 533 cases assigned to MS-DRG 462. To determine the number of cases representing bilateral knee revision procedures in MS-DRG 462, similar to the first analysis, the applicant multiplied the total number of cases assigned to MS-DRG 462 by 4 percent, which resulted in 21 cases. Similar to our statement about the first analysis, in the proposed rule we were concerned that the applicant did not uniquely identify cases representing bilateral knee revision procedures and only produced a percentage of all cases, which still includes cases representing hip revision procedures.

To determine the number of eligible cases reporting knee revision procedures assigned to MS-DRGs 466 through 468, the applicant first searched the AHD database for the total number of cases assigned to these MS-DRGs. This resulted in a total of 2,969 cases. Because these MS-DRGs include cases representing hip and knee revision procedures, to determine the number of cases representing knee revision procedures in each of these three MS-DRGs, the applicant first divided the number of cases for each MS-DRG (122 for MS-DRG 466; 1,746 for MS-DRG 467; and 1,101 for MS-DRG 468) by the total number of cases in MS-DRGs 466 through 468 (2,969). The applicant then multiplied the percentage for each MS-DRG (4.1 percent for MS-DRG 466; 58.8 percent for MS-DRG 467; and 37.1 percent for MS-DRG 468) by the total number of cases in
each MS-DRG. Based on this calculation, the applicant approximated the following number of cases representing knee revision procedures in each of these three MS-DRGs: 1,307 cases in MS-DRG 466; 18,704 in MS-DRG 467; and 11,794 in MS-DRG 468. Similar to our concerns about the first analysis, in the proposed rule (80 FR 24455), we stated we were concerned that the methodology the applicant used to determine the percentage of cases of knee revision procedures still includes cases representing hip revision procedures. Specifically, in its methodology, the applicant did not use any source of statistical relevance to isolate cases representing knee revision procedures. The applicant simply used the percentage of Medicare cases for each MS-DRG of the overall total cases for the three MS-DRGs, which include knee and hip revision procedures, and multiplied by this percentage to further reduce the number of cases. We stated that we do not believe that this further reduction to the total number of Medicare cases has isolated cases representing knee revision procedures.

The applicant used the same methodology from the first analysis to determine the number of eligible cases representing TKA procedures assigned to MS-DRGs 469 and 470. The applicant searched the AHD database and found 1,217 cases assigned to MS-DRG 469 and 24,620 cases assigned to MS-DRG 470. To determine the number of cases representing TKA procedures within these MS-DRGs, the applicant multiplied the total number of cases within these MS-DRGs by the percentage of 58.5 percent from the NIS database, which represents the percentage of knee replacement procedure cases among the total number of cases representing knee, hip and joint replacement procedures. This resulted in 712 cases in MS-DRG 469 (1,217 * .585) and 14,411 cases in MS-DRG
470 (24,620 * .585). Similar to our concerns expressed earlier (and in the proposed rule), the methodology that the applicant used to determine the percentage of cases representing TKA procedures still includes cases representing hip replacement and other joint replacement procedures. Specifically, the applicant did not uniquely identify cases representing TKA procedures and only produced a percentage of all cases, which still includes cases representing hip and other joint replacement procedures.

Based on this analysis, the applicant asserted that the total number of cases across MS-DRGs 461 and 462 and MS-DRGs 466 and 470 was 46,960. The applicant determined an average case-weighted charge per case of $80,702. For the rest of the analysis, the applicant followed the same methodology as the first analysis. The applicant removed $146 from the average case-weighted charge per case for cases assigned to MS-DRGs 461 and 462 and $73 from the average case-weighted charge per case for cases assigned to MS-DRGs 466 through 470 for charges related to other computer-assisted devices/technologies used during these procedures and additional charges for the use of the operating room.

Similar to the first analysis, the applicant used the FY 2012 IPPS impact file and the mean value of all relevant standardization factors from all hospitals to standardize the charges per case. Similar to our concerns expressed earlier (and in the proposed rule), the analysis provided by the applicant did not use hospital-specific data and, therefore, the standardization process may be inaccurate because of the use of mean factors rather than hospital-specific factors. By using mean factors rather than hospital-specific factors, the
standardization performed by the applicant does not sufficiently take into account hospital variations.

The applicant then inflated the charges using an inflation factor of 10.4227 percent based on the inflation factor in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50379), and added the charges related to the VKS technology to the adjusted average case-weighted standardized charge per case. This resulted in a final inflated average case-weighted standardized charge per case of $90,515. Using the FY 2015 IPPS Table 10 thresholds, the applicant determined that the average case-weighted threshold amount for MS-DRGs 461 and 462 and MS-DRGs 466 through 470 is $80,699. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount for the applicable MS-DRGs, the applicant asserted that the VKS technology meets the cost criterion.

The applicant’s third analysis used data from the FY 2015 CMS Before Outliers Removed (BOR) file. The BOR file contained 469 cases in MS-DRG 461 and 9,396 cases in MS-DRG 462. To determine the number of cases representing bilateral knee revision procedures assigned to MS-DRGs 461 and 462, similar to the first analysis, the applicant used an assumption of 4 percent, which resulted in 19 cases in MS-DRG 461 and 376 cases in MS-DRG 462. Similar to our concerns stated earlier (and in the proposed rule (80 FR 24456)), the applicant did not uniquely identify cases representing bilateral knee revision procedures and only produced a percentage of all cases, which still includes cases representing hip revision procedures.
To determine the number of eligible cases reporting knee revision procedures assigned to MS-DRGs 466 through 468, the applicant again analyzed the BOR file which contained a total of 44,420 cases. Similar to first two analyses, because these MS-DRGs include cases representing hip and knee revision procedures, to determine the number of cases representing knee revision procedures in each of these three MS-DRGs, the applicant first divided the number of cases for each MS-DRG (4,202 for MS-DRG 466; 23,390 for MS-DRG 467; and 16,828 for MS-DRG 468) by the total number of cases in MS-DRGs 466 through 468 (44,420). The applicant then multiplied the percentage for each MS-DRG (9.5 percent for MS-DRG 466; 52.7 percent for MS-DRG 467; and 37.9 percent for MS-DRG 468) by the total number of cases in each MS-DRG. Based on this calculation, the applicant approximated the following number of cases representing knee revision procedures in each of these three MS-DRGs: 3,009 cases in MS-DRG 466; 16,747 in MS-DRG 467; and 12,049 in MS-DRG 468. Similar to our concerns stated earlier (and in the proposed rule), the methodology the applicant used to determine the percentage of cases representing knee revision procedures still includes cases representing hip revision procedures. Specifically, in its methodology, the applicant did not use any source of statistical relevance to isolate cases representing knee revision procedures. Rather, the applicant used the percentage of Medicare cases for each MS-DRG of the overall total number of cases for the three MS-DRGs, which includes cases representing knee and hip revision procedures, and multiplied by this percentage to further reduce the number of cases. We stated that we do not believe that this further
reduction to the total number of Medicare cases has isolated cases representing knee revision procedures.

The applicant used the same methodology from the first analysis to determine the number of eligible cases reporting TKA procedures assigned to MS-DRGs 469 and 470. The BOR file contained 27,737 cases in MS-DRG 469 and 437,649 cases in MS-DRG 470. To determine the number of cases representing TKA procedures within these MS-DRGs, the applicant multiplied the total number of cases within these MS-DRGs by the percentage of 58.5 percent obtained from the NIS database, which represents the percentage of knee replacement cases among the total number of cases representing knee, hip, and joint replacement procedures. This resulted in 16,236 cases in MS-DRG 469 (27,737 * .585) and 256,178 cases in MS-DRG 470 (437,649 * .585). Similar to our concerns stated earlier (and in the proposed rule), the methodology that the applicant used to determine the percentage of cases representing TKA procedures still includes cases representing hip and other joint replacement procedures. Specifically, the applicant did not uniquely identify cases representing TKA procedures and only produced a percentage of all cases, which still includes cases representing hip and other joint revision procedures.

Based on this analysis, the applicant asserted that the total number of cases across MS-DRGs 461 and 462 and MS-DRGs 466 through 470 was 304,614. The applicant determined an average case-weighted charge per case of $56,282. For the rest of the analysis, the applicant followed the same methodology as the first analysis. The applicant then removed $146 from the average case-weighted charge per case for cases
assigned to MS-DRGs 461 and 462 and $73 from the average case-weighted charge per case for cases assigned to MS-DRGs 466-470 for charges related to other computer-assisted devices/technologies used during these procedures and additional charges for the use of the operating room.

Similar to the first analysis, the applicant used the FY 2012 IPPS Impact File and the mean value of all relevant standardization factors from all hospitals to standardize the charges per case. Similar to our concerns stated earlier (and in the proposed rule), the analysis provided by the applicant did not use hospital-specific data and, therefore, the standardization process may be inaccurate because of the use of mean factors rather than hospital-specific factors. By using mean factors rather than hospital-specific factors, we stated that we believe that the standardization performed by the applicant did not sufficiently take into account hospital variations.

The applicant then inflated the charges using an inflation factor of 10.4227 percent based on the inflation factor in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50379), and added the charges related to the VKS technology to the adjusted average case-weighted standardized charge per case. This resulted in a final inflated average case-weighted standardized charge per case of $66,382. Using the FY 2015 IPPS Table 10 thresholds, the applicant determined that the average case-weighted threshold amount for MS-DRGs 461 and 462 and MS-DRGs 466 through 470 is $64,280. Because the final inflated average case-weighted standardized charge per case exceeds the average case-weighted threshold amount for the applicable MS-DRGs, the applicant asserted that the VKS technology meets the cost criterion.
Based on the information provided by the applicant, combined with the weight of our concerns, in the proposed rule we stated that we were unable to determine if and how the VKS technology meets the cost criterion. We invited public comments on whether or not the VKS technology meets the cost criterion, specifically with regard to the concerns raised.

Comment: The applicant submitted comments in response to CMS’ concerns that included an alternative analysis that the applicant conducted to demonstrate that the VKS technology meets the cost criterion. In its analysis, the applicant used the FY 2013 MedPAR file (which contained inpatient hospital claims data for discharges from October 1, 2012 to September 30, 2013) to search for cases involving TKA procedures that reported the following ICD-9-CM procedure codes: 00.80 (Revision of knee replacement, total (all components)); 00.81 (Revision of knee replacement, tibial component); 00.82 (Revision of knee replacement, femoral component); 00.83 (Revision of knee replacement, patellar component); 00.84 (Revision of total knee replacement, tibial insert (liner)); 81.54 (Total knee replacement); and 81.55 (Revision of knee replacement, not otherwise specified). The applicant focused its analysis on MS-DRGs 461 through 470 because these are the MS-DRGs that cases involving TKA procedures typically map to. The applicant noted that that analysis revealed that MS-DRGs 461 and 466 did not contain any cases because the MedPAR claims data do not include hospitals with less than 10 discharges. The applicant identified 283,123 claims (5,417 claims in MS-DRG 462; 2,918 claims in MS-DRG 467; 1,549 claims in MS-DRG 468; 1,673 claims in MS-DRG 469; 271,566 claims in MS-DRG 470). The applicant then
standardized the charges, applied an inflation factor of 1.10443 based on the 2-year charge inflation factor listed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50379), which resulted in an inflated average case-weighted standardized charge per case of $53,887. The applicant estimated device charges using the cost of the device and the national average CCR of 0.28, and additional charges for operating room time related to the device. The applicant combined these charges with the inflated average case-weighted standardized charges per case and determined a final inflated average case-weighted standardized charge per case of $65,571. The average case-weighted threshold amount in the FY 2015 IPPS Table 10 for these MS-DRGs was $61,870. Because the final inflated average case-weighted standardized charge per case exceeds the average case-weighted threshold amount of $61,870, the applicant maintained that the VKS meets the cost criterion using this analysis.

Response: We appreciate the applicant providing this alternative analysis under the cost criterion. After consideration of the additional information provided, we have determined that the VKS technology meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that the VKS technology represents a substantial clinical improvement. The applicant stated that the device offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments. The applicant explained that the use of the VKS technology has improved patient outcomes, including rapid recovery of patients diagnosed with comorbidities, the early return to normal activities, and increased levels of activity and functionality. The applicant noted that patients
treated using the VKS technology during TKA procedures did not experience readmission within 30 days, nor was it necessary for the treating physician (the surgeon) to complete a problem focused medical evaluation during the patient’s recovery. The applicant further noted that patients having a more favorable immediate outcome with a stable TKA were shown to return to normal function more rapidly than patients with unbalanced knees. Therefore, the applicant stated that patients with complex medical conditions would be able to respond to the early return of normal daily living.

The applicant also believed that the device offers the ability to diagnose a medical condition for a patient population experiencing medical conditions that are currently undetectable, or offers the ability to diagnose a medical condition earlier than that which is capable using currently available technologies. The applicant explained that the VKS technology provides an improved evaluation/diagnosis compared to an unbalanced TKA implant. Specifically, the applicant stated that the device enables the surgeon to obtain intraoperative measures enabling the surgeon to improve upon the placement of the TKA tibial and femoral components. In addition, the applicant stated that, intraoperatively, the device leads to an immediate diagnosis of an implant that can now be accurately positioned due to informed fine tissue dissection. The applicant further stated that the intraoperative technique has been demonstrated to result in increased implant stability and functional congruence. The applicant cited the following examples of outcomes that have been frequently documented and evaluated within clinical studies of medical devices:
Intended to address the leading causes of early implant failure in TKA: instability, malrotation and malalignment\textsuperscript{46};

Dynamic intercompartmental load data and Kinetic Tracking enables evidence based soft tissue releases to improve stability through full ROM \textsuperscript{47};

Provides intraoperative feedback on tibial–femoral component rotation, position of femoral Contact Points and femoral roll-back to facilitate optimal component position;

Enables reproducible, teachable surgical technique through quantifying surgeon “feel”; and

Captures intraoperative data for inclusion in patient EMR, registries or comparative effectiveness studies.

The applicant stated that use of the device significantly improves clinical outcomes for a patient population experiencing these types of medical procedures when compared to currently available treatments. The applicant explained that extensive research and development has resulted in the VKS technology demonstrating improved patient outcomes in multi-center studies. The applicant further explained that the VKS technology has intraoperatively provided a unique opportunity to observe the short-term clinical outcomes of patients with a quantifiably balanced knee versus those who have quantifiably unbalanced knees. According to the applicant, in a multi-center study, the use of the VKS technology has been shown to reduce post-operative pain and improve activity and patient satisfaction scores with statistical significance. Additionally, the


\textsuperscript{47} Roche MW, Elson LC, Anderson CR.: A Novel Technique Using Sensor-Based Technology to Evaluate Tibial Tray Rotation. Orthopedics. 2014 (In Press).
The applicant stated that 97 percent of patients whose knees were balanced using the VKS technology reported that they were “satisfied” to “very satisfied” at 1-year post-operative compared to 81 percent patient satisfaction after a TKA procedure without the use of the VKS technology. The applicant stated that the VKS technology provided a 16-percent improvement in patient satisfaction for VKS-balanced knees; the first significantly notable increase of patient-reported satisfaction in over 30 years.\(^{48}\)

According to the applicant, the use of the VKS technology avoided early implant failure. The applicant explained that considering the objective to ameliorate the present risks of revision in TKA procedures, the VKS technology has been advanced to address the need for improved knee balance through fine tissue dissection using information from the VKS technology intelligent tibial trial. While not disturbing the surgical flow of TKA procedures, the applicant stated that the VKS technology provides the surgeon with data on the dynamic intercompartmental load, and kinetic tracking enables evidence-based soft tissue releases to improve stability through full ROM.\(^{49}\) The applicant noted that the results of multi-center studies, using the VKS technology intraoperatively, have provided an opportunity to observe the short-term clinical outcomes of patients with a VKS-quantified balanced knee versus those who have VKS-quantified unbalanced knees.

The applicant further stated that the VKS technology provides intraoperative information on tibial–femoral component rotation, position of femoral contact points and


femoral roll-back to facilitate optimal component position. One clinical study reported 170 primary TKA procedures where the VKS technology corrected what would have resulted in unbalanced and malrotated implants in 53 percent of the patients. The applicant noted that when referencing the tibial tubercle to maximize tibiofemoral congruency, 53 percent of patients exhibited asymmetrical tibiofemoral congruency in extension. The applicant further stated that of those patients, 68 percent were shown to have excessive internal rotation of the tibial tray relative to the femur, while 32 percent exhibited excessive external rotation. Additionally, the average tibiofemoral incongruency deviated from a neutral position by 6°, ranging from 0.5° to 19.2. The applicant stated that when comparing the VKS with the convention of using the tibial tubercle to maximize tibiofemoral congruency to confirm the final rotation of the tibial tray, the VKS technology provided superior information. The applicant added that data from using the tibial tubercle to maximize tibiofemoral congruency to confirm the final rotation of the tibial tray are highly variable and inconsistent for confirming the final rotation of the tibial tray.

The applicant stated that the VKS technology has demonstrated and resulted in a “balanced knee” after TKA procedures with 6 month and 1 year outcome scores showing a significant improvement over conventional or computer-assisted TKA procedures. According to the applicant, by not disrupting the surgical flow the VKS technology has been viewed by surgeons to provide information enabling them to improve upon the balance of the knee, reduce the degree of rotation and only dissect the fine tissue as

---

needed sparing the release of the ligaments. The applicant further stated that the VKS technology has been shown to enable reproducible, teachable surgical technique through quantifying surgeon “feel.”

The applicant provided patient outcomes at 6 months and believed that this demonstrated a significant improvement for the “balanced knee” TKA procedures using the VKS technology. According to the applicant, multivariate binary logistic regression analyses were performed for both Knee Society Scores (KSS) and Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores at 6 months. Variables run in these analyses included: age at surgery, body mass index (BMI), gender, preoperative ROM, preoperative alignment, change in activity level (preoperative to 6 months), and joint state (balanced versus unbalanced). For KSS and WOMAC, both step-wise and backward multivariate logistic regression analyses were calculated to be best fit models with similar significance (P= 0.001). Ultimately, the step-wise model was used. The applicant stated that the binary model revealed that the variable exhibiting the most significant effect of improvement on KSS and WOMAC scores was balanced joint state (P = 0.001; P = 0.004). The applicant noted that joint state was the most highly significant variable; this demonstrated similar levels of significance throughout all possible combinations of variables included in the model (P = 0.001). The applicant added that joint state was also observed to be the sole significant factor in patient-reported outcome score improvement (P b 0.001).

The applicant added that analysis of the data revealed there was also a concurrent significance observed with activity level (P = 0.005). However, the applicant noted that
activity level was not significant on its own. The applicant concluded that a balanced joint state results in a higher activity level, which would make activity level more of a dependent variable, rather than a predictor. Therefore, to demonstrate activity level, the applicant used a regression analysis and evaluated KSS and WOMAC scores at 6 months, with odds ratios. According to the applicant, odds ratios were calculated based on meaningful clinical improvement in KSS scores, WOMAC scores, and activity levels at 6 months. In addition, the applicant pointed out that, based on literature review, “meaningful improvement” for KSS scores were anything greater than 50 points; WOMAC scores greater than 30 points; and gains in activity level greater than or equal to two lifestyle levels (from lowest score to highest: sedentary, semisedentary, light labor, moderate labor, heavy labor). Also, scores from the unbalanced group were used as the reference point. The applicant stated that odds ratio for balanced joint state and improved KSS score was 2.5, with a positive coefficient (95 percent CI). The applicant believed that this suggested a high probability of obtaining a meaningful improvement in KSS with a balanced knee joint, over those who do not have a balanced knee. According to the applicant, the odds ratio for balanced joint state and improved WOMAC score was 1.3, with a positive coefficient (95 percent CI). The applicant believed that this suggested a favorable probability that patients with a balanced joint state will achieve a meaningful improvement in WOMAC score, over those that do not have a balanced knee. According to the applicant, the odds ratio for balanced joint state and improved activity level was 1.8, with a positive coefficient (95 percent CI). The applicant believed that this

---

also suggested a favorable probability of meaningful gains in activity level in those with a balanced knee, versus those with an unbalanced knee.

The applicant further stated that 1 year clinical trial evidence supports the VKS technology protocol for TKA procedures. According to the applicant, of the 135 patients undergoing sensor-guided surgery, 13 percent remained unbalanced (by surgeon discretion). The applicant stated that “surgeon discretion,” in this analysis, indicates that the surgeon recognized and accepted the “unbalanced” intercompartmental load difference as presented by the VKS technology, but believed that the knee was in a clinically acceptable state. Pre-operatively, there was no statistical difference in any outcomes measures between the two cohorts, the averages of which were: total KSS = 105 ±24.6; total WOMAC = 47 ±14.8.

Additionally, according to the applicant, at 1 year, the average total KSS score of balanced patients exceeded that of unbalanced patients by 23.3 points (P<0.001); 179±17.2 and 156±23.4 for the balanced and unbalanced cohort, respectively. The balanced cohort average score for KSS pain and function, separately, were 96.4 and 82.4 respectively; the unbalanced cohort scored 87.8 and 68.3 points for pain and function. The applicant stated that the disparities between the balanced and unbalanced patients’ pain and function scores were also highly statistically significant (P<0.001, P=0.022).

For WOMAC, the applicant noted that that the balanced cohort improved their score by 8 points; 10±11.8 and 18±17 for balanced and unbalanced patients, respectively (WOMAC is scored with an inverse scale; lower scores indicate more improvement). The applicant further stated that while this difference did not prove to be statistically
significant by the standards set forth for this analysis (P=0.085), the authors believed that this is due, in part, to the large standard deviations associated with both cohorts.

According to the applicant, the balanced cohort’s average activity level score was 48.6, which corresponds with the light to moderate labor categories (tennis, light jogging, heavy yard work) and the unbalanced patient’s average activity level score was 26.7, which corresponds to the upper limits of the semi-sedentary range (light housework, walking for limited distances). The applicant believed that the difference between the average scores was statistically significant (P=0.015). The applicant noted that the most notable aspect of every outcome measure collected is that the unbalanced patient scores at 1 year still failed to achieve the level of improvement of the balanced patient scores at 6 months.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24458 and 24459), we presented a number of concerns regarding the applicant’s assertions regarding substantial clinical improvement. First, we stated that during the trials, after using the device, surgeons continued to make manual adjustments to the spacers to set the knee replacement. The applicant asserted that the VKS technology presents better accuracy for the surgeon when making adjustments to the spacers when implanting a knee replacement. However, we stated that the evidence does not delineate the degree of any improved outcomes or patient satisfaction associated with use of the VKS technology versus additional manual adjustments made by the surgeon. We also stated that most of the clinical evidence is based on patient satisfaction surveys. While the survey data appeared to demonstrate that patient satisfaction improved, we stated that we do not
believe the data presented are sufficient to determine if the VKS technology represents a substantial clinical improvement over manual adjustment. Furthermore, the use of historical literature controls might be useful during early clinical development, but there are possible biases and limitations of this research design. Specifically, there could be multiple differences in the pre-procedure clinical characteristics of patients with “unbalanced” knees and those with “balanced” knees that could affect outcomes, such as more severe initial disease, more pre-operative misalignment, more obesity, or more comorbidity. These and other potential confounders were not documented or adjusted for in the analyses of outcomes in the literature provided by the applicant. Additionally, as discussed above, the applicant released a first version of the VKS technology in 2011 and advancements were made to the VKS technology that resulted in additional FDA clearances in 2013. The applicant stated in its application that the first version is considered the first technology of its kind. Therefore, we stated in the proposed rule that we believe the VKS technology may no longer be considered new. The applicant submitted an application for the advanced version of the VKS technology from 2013. However, the applicant did not present clinical data to distinguish the improvements made to the advanced version from the first version. Therefore, in the proposed rule, we stated that we were unable to determine if the advanced version represents a substantial clinical improvement over existing technologies (that is, the first version of the VKS technology).

We invited public comments on whether the VKS technology meets the substantial clinical improvement criterion, specifically with regard to our concerns.
Comment: One commenter stated that recently published data shows improved short-term results for procedures using the VKS. The commenter further stated that sensor technology similar to that utilized with the VKS technology will become an important tool in achieving optimal clinical outcomes in knee replacement surgery, and encouraged CMS to approve new technology add-on payments to offset the added costs of this new technology and encouraged its expanded use to include a broader population of patients.

Another commenter questioned whether a knee defined as balanced by use of the VKS produced a significantly more favorable outcome than a knee defined as unbalanced by use of the VKS. The commenter stated that improved outcomes have not been demonstrated by the VKS that are significantly increased when compared to improved outcomes achieved with additional manual adjustments made by surgeons.

Response: We appreciate the commenters’ input. We considered these comments in our determination of whether the VKS represents a substantial clinical improvement over existing technologies.

Comment: The applicant submitted comments in response to CMS’ concerns as to whether the technology demonstrated a substantial clinical improvement. The applicant indicated that its objective has always been to improve the outcome of primary TKA procedures relative to instability, stiffness, pain, and patient immobility. The commenter noted that early findings inspired surgeons to propose measures of ligament balance as a function of load and balance. The applicant explained that the concept of ligament balance has always been a subjective surgical process due to the absence of an
objective means to measure variables such as load and alignment intraoperatively. The applicant stated that continued research and development identified ideal load, balance and kinematics as well as rotational alignment metrics now available with the 2013 devices.

According to the applicant, the devices FDA-cleared in June 2013 differ from those used in the early stages (2012) of the study. The applicant stated that engineering changes maintain the prior device measurements of balance as a function of load but the new approval added alignment within these measurements and improves upon the surgical flow, all features which are important to achieve a more stable TKA procedure result. The applicant noted that the device's expanded functionality (from June 2013 clearance) of the addition of alignment has spurred use in revision cases and is a new indication for use in the 510k currently under review.

The applicant also stated that outcome studies represent a series of patients enrolled and operated on by surgeons trained on the technique, using an early device and transitioning to the 2013 engineering changes. The applicant noted that participating surgeons adhered to the study design and surgical protocol and did not make additional manipulations of the knee after the surgeon captured the VKS metrics. The applicant further noted that, early on, some surgeons did not change their tissue dissection based upon the data from the VKS (the device was used merely to collect intercompartmental load data in these cases), as the data assessed from these earlier stage surgical cases were seen to have results indicating unbalanced knees. The applicant stated that early recognition of these “unbalanced” knees gave rise to the surgeon now modifying their
tissue dissection based on the VKS information and provided an “unbalanced” set of patients to compare outcomes.

The applicant also stated that highly statistically significant P-values of 0.0001 were reported using the KSS and WOMAC score. The applicant noted that KSS and WOMAC are validated scoring tools specifically designed to capture patient functional outcomes, including pain scores. The applicant also noted patient satisfaction measures were also collected which demonstrated that the VKS KSS and WOMAC scores were statistically higher than traditional scores for primary TKA or navigated TKA.  

The applicant stated that BMI of the VKS balanced cohort was compared to historical TKA controls. The applicant noted that historically patients tend to gain weight after TKA which contributes to poorer outcomes. Rather than gaining weight, as reported in the historical meta-analysis, the applicant further noted that average weight loss of the VKS cohort (over 65 years of age) was 10 lbs. at 1 year. The applicant stated that patients treated with the VERASENSE intraoperative technique

Zeni JA, Snyder-Mackler L. Most patients gain weight in the 2 years after total knee arthroplasty: comparison to a healthy control group (NIH Public Access Manuscript) Osteoarthritis Cartilage. 2010; 18(4); 510-514.
defining “balance and load” relative to intercompartmental congruency and alignment not only had positive KSS and WOMAC scores, but their improved functional status resulted in a loss of weight and BMI classification when compared to historical controls. The applicant further asserted that the VKS features in the 2013 FDA-cleared advanced version of the device resulted in statistically improved KSS and WOMAC scores as well as a 16-point increase in patient satisfaction measured over 2 years. The applicant concluded that the results offer further substantial clinical evidence that the VKS is a novel tool delivering improved intraoperative surgical skills to the orthopedic surgeon to quantitatively improve their operative technique and thereby give patients highly valued primary TKA outcomes.

**Response:** As stated above, most of the clinical evidence presented by the applicant is based on patient satisfaction surveys. While the survey data appeared to demonstrate that patient satisfaction improved, we still do not believe that the data presented are sufficient to determine if the VKS technology represents a substantial clinical improvement over existing technique. Specifically, the studies conducted were based on a limited study design, given that the applicant was in the process of establishing the definition of a balanced knee, lending to the possibility of confounding and bias. For example, there was no randomization of participants because physicians were given the discretion whether to use the device. We also noted that this study was a retrospective, observational study that was sufficient to assist in determining the evolving definition of a balanced knee, but not designed to determine if a balanced knee leads to substantial clinical improvement. Finally, as mentioned above, we were concerned that
there could be multiple differences in the pre-procedure clinical characteristics of patients with “unbalanced” knees and those with “balanced” knees that could affect outcomes, such as more severe initial disease, more pre-operative misalignment, more obesity, or more comorbidity. These and other potential confounders were not documented or adjusted for in the analyses of outcomes in the literature provided by the applicant. However, we note that the applicant is currently conducting randomized controlled studies measuring surgical technique and patient outcomes. Overall, based on the clinical evidence provided to date, we are not convinced that the VKS device leads to better outcomes over manual adjustments achieved by currently available treatment options. Therefore, after consideration of the public comments we received, we do not believe that the VKS technology represents a substantial clinical improvement over existing technologies, and we are not approving new technology add-on payments for the VKS technology for FY 2016.

Comment: One commenter stated that the VKS technology shows to be an effective, objective, and technically proficient advance in TKA procedures. The commenter believed that by using the new reengineered 2013 FDA-cleared advanced device, orthopedic surgeons can now quantitatively measure load, “balance,” and alignment to achieve optimal implant rotation and relative rotation between the tibial and femoral components, and soft tissue balancing. The commenter noted that tracking patient’s readmission rate with “balanced” knees did not require a 30-day readmission nor did they require a clinical visit with their surgeon. The commenter stated that the
VKS appears to be a valuable innovation that surgeons can implement and patients can derive benefit.

The commenter further stated that published findings provide evidence that the device significantly reduces the incidence of TKA failure due to stiffness and instability. The commenter added that the VKS technology should reduce the need for revision knee surgery and the morbidity patients learn to live with when their implant is not stable or incorrectly placed.

The commenter stated that estimates find Medicare spends over $1 billion annually just on facility and physician payment related to revision knee surgeries. The commenter noted that preventing complications and keeping patients out of acute and long term care facilities saves money and avoids added complications that can result in unintended consequences leading to excessive costs to the healthcare system and the patient. The commenter stated that hospitals have tight margins and recommended that CMS grant the VKS a new technology add-on payment for FY 2016.

The commenter also asserted that engineering advances of the 2013 FDA-cleared advanced device uses data gained from prior research and development consistent with the newness criterion and the demonstration of substantial clinical improvement. The commenter believed that payment for MS-DRGs 469 and 470 is inadequate, and with consideration of the 2013 FDA approval, payment for MS-DRGs 466, 467 and 468 payment would also be inadequate.

The commenter believed that the VKS technology meets all three criteria for new technology add-on payments. The commenter also believed that, in the absence of added
payment, surgeons would be denied the opportunity to quantitatively correct fine tissue dissection leading to a correctly “balanced” primary TKA and patients would be inappropriately served.

With regard to our first concern on substantial clinical improvement, the commenter stated that surgeons responded to the device metrics early on in the trial for collection only of “balance” information in order to establish a baseline for objectively defining what intraoperative balance meant (a definition that, prior to availability of the VKS technology, was not possible). The commenter further stated that upon establishment of a differential “window” between medial and lateral compartments of 15 pounds the sensor was then used as a tool to direct soft tissue dissection to achieve an intraoperative balance (within 15 pounds) result. The commenter explained that this cohort of patient results comprised the “balanced” population within the trial and, when compared with the “unbalanced” cohort (which were predominantly patients who received “manual adjustments”), showed improved outcomes and patient satisfaction associated with the use of VKS technology.

With regard to our second concern on substantial clinical improvement, the commenter stated that KSS and WOMAC scores are the most reported outcome tools for TKA procedures. The commenter asserted that patient satisfaction scores are equally validated outcome metrics. The commenter noted that the clinical outcomes at 6 months, and 2 years were recently published and reported that the VKS used by a trained surgeon delivers clinical outcomes much better than traditional primary TKA patients compared with the KSS and WOMAC scores. The commenter cited studies that showed patients
with balanced knees at 6 months had higher functional outcome scores than traditional patients at 2 years. The commenter stated that the scope of 2 to 3 years of the newness criterion makes it impossible to achieve more data, while also designing the best device to achieve the outcomes. The commenter believed that the studies were well-designed, had Institutional Review Board (IRB) approval, and were excellent protocol adherence with outcome data captured correctly.

Response: For the reasons previously stated, we do not believe that the VKS represents a substantial clinical improvement over existing technologies, and we are not approving new technology add-on payments for the VKS for FY2016.

f. WATCHMAN® Left Atrial Appendage (LAA) Closure Technology

Boston Scientific Corporation submitted an application for new technology add-on payments for FY 2016 for the WATCHMAN® Left Atrial Appendage (LAA) Closure Technology (WATCHMAN® System). (We note that, as discussed in detail later in this section, the applicant submitted an application for new technology add-on payments for FY 2015 for the WATCHMAN® System, but withdrew its application after we issued the FY 2015 IPPS/LTCH PPS proposed rule.) According to the applicant, when a patient has been diagnosed with atrial fibrillation (AF), the left atrium does not expand and contract normally. As a result, the left atrium is not capable of completely emptying itself of blood. Blood may pool, particularly in the part of the left atrium called the left atrial appendage. This pooled blood is prone to clotting, causing formation of a

---

thrombus. If a thrombus breaks off, it is called an embolism (or thromboembolism). An embolism can cause a stroke or other peripheral arterial blockage.

The applicant asserted that the WATCHMAN® System device is an implant that acts as a physical barrier, sealing the LAA to prevent thromboemboli from entering into the arterial circulation from the LAA, thereby reducing the risk of stroke and potentially eliminating the need for Warfarin therapy for patients diagnosed with nonvalvular AF who are eligible for Warfarin therapy but for whom the risks of long-term oral anticoagulation outweigh the benefits.

With regard to newness criterion, the applicant received FDA approval on March 15, 2015. According to the applicant, the WATCHMAN® System is the first LAA closure device approved by the FDA. Therefore, the applicant believes that the technology meets the newness criterion. Effective October 1, 2004 (FY 2005), ICD-9-CM procedure code 37.90 (Insertion of left atrial appendage device) was created to identify and describe procedures using the WATCHMAN® Left Atrial Appendage (LAA) Closure Technology. As stated in section II.G.1.a. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule and this final rule, effective October 1, 2015 (FY 2016), the ICD-10 coding system will be implemented. Under the ICD-10-PCS, procedure code 02L73DK (Occlusion of left atrial appendage with intraluminal device, percutaneous approach) is the comparable translation for ICD-9-CM procedure code 37.90.

In the FY 2016 IPPS/LTCH proposed rule (80 FR 24459), we did not state any concerns regarding whether the WATCHMAN® System meets the newness criterion. We
invited public comments on if, and how, the WATCHMAN® System meets the newness criterion.

Comment: One commenter, the applicant, reiterated that the WATCHMAN® System is not substantially similar to any FDA-approved technology currently on the market and satisfies the newness criteria.

Response: We thank the applicant for its additional comments. We agree that the WATCHMAN® System meets the newness criterion. We note that CMS received a formal National Coverage Decision (NCD) request from the manufacturer asking that CMS cover percutaneous, transcatheter, intraluminal LAA closure using an implanted device. We refer readers to the CMS Web site at: http://www.cms.gov/medicare-coverage-database/details/nca-details.aspx?NCAId=281 for information related to this ongoing NCD. The tracking sheet for this National Coverage Analysis (NCA) indicates an expected NCA completion date of February 19, 2016. The processes for evaluation and determination of an NCD and the processes for evaluation and approval of an application for new technology add-on payments are independent of each other. However, any payment made under the Medicare program for services provided to a beneficiary would be contingent on CMS’ coverage of the item, and any restrictions on the coverage would apply.

As discussed in the proposed rule (80 FR 24459), with regard to the cost criterion, the applicant used the FY 2013 MedPAR file (which contained inpatient hospital claims data for discharges from October 1, 2012 to September 30, 2013) to search for cases reporting ICD-9-CM procedure code 37.90. The applicant provided two analyses. The
first analysis includes all claims that reported ICD-9-CM procedure code 37.90, regardless of whether the code indicated a principal procedure that determined the MS-DRG assignment of the case. This analysis identified 507 cases across 29 MS-DRGs. The applicant noted that the MedPAR file contained claims that were returned to the provider that reported charges for actual cases from clinical trials that used the WATCHMAN® System that were well below post-FDA approval pricing. Therefore, the applicant removed the premarket device related charges. The applicant then standardized the charges, applied an inflation factor of 1.10443 based on the 2-year charge inflation factor listed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50379) and then added post-FDA approval charges for the WATCHMAN® System. Using the anticipated cost of the device after FDA approval and the National Average Implantable Device cost center CCR, the applicant estimated device charges post-FDA approval, combined those with the inflated average case-weighted standardized charges per case, and determined a final inflated average case-weighted standardized charge per case of $150,213. The average case-weighted threshold amount in the FY 2015 IPPS Table 10 for these MS-DRGs was $97,505. Because the final inflated average case-weighted standardized charge per case exceeds the average case-weighted threshold amount of $97,505, the applicant maintained that the WATCHMAN® System meets the cost criterion using this analysis.

In the applicant’s second analysis, cases eligible for the WATCHMAN® System were identified by claims reporting ICD-9-CM procedure code 37.90 assigned to MS-DRGs 250 and 251 (Percutaneous Cardiovascular Procedures without Coronary
Artery Stent with MCC and without MCC, respectively). The applicant believed that these are the MS-DRGs to which cases are typically assigned if the WATCHMAN® System is used in the principal procedure performed during the inpatient stay. The applicant applied the trims in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49910 through 49911), which resulted in 369 cases.

As with its first analysis, the applicant determined standardized nondevice charges for the applicable cases using claims data from the FY 2013 MedPAR file and applied an inflation factor. The applicant calculated average nondevice charges by subtracting what the applicant believed was the average total implantable device charges (calculated as the sum of the five individual device charge fields in the MedPAR file that constitute the Implantable Device cost center). Similar to its first analysis, the applicant then standardized the charges, applied an inflation factor of 1.10443, subtracted the device charges reported on the MedPAR claims (reflecting costs during the IDE study) and replaced them with the anticipated charges following FDA approval (converting the costs of the device to charges with a CCR of 0.349 based on the national average implantable device CCR from the FY 2015 IPPS/LTCH PPS final rule (79 FR 49914)), combined those with the inflated average case-weighted standardized charges per case, and determined a final inflated average case-weighted standardized charge per case of $117,663. The average case-weighted threshold amount for these MS-DRGs in the FY 2015 IPPS Table 10 was $72,804. Because the final inflated average case-weighted standardized charge per case exceeds the average case-weighted MS-DRG threshold amount of $72,804, the applicant maintained that the WATCHMAN® System meets the
cost criterion using this analysis. We note that the applicant searched for cases reporting ICD-9-CM procedure code 37.90. In section II.G.3.b. of the preamble of this final rule, we are finalizing a proposal regarding cardiac ablation and other specified cardiovascular procedures. Specifically, we proposed to assign the procedures performed within the heart chambers using intracardiac techniques, including those identified by ICD-9-CM procedure code 37.90, to two new MS-DRGs: MS-DRG 273 (Percutaneous Intracardiac Procedures with MCC) and MS-DRG 274 (Percutaneous Intracardiac Procedures without MCC). In the proposed rule, we stated that we believe that this could have implications for determining whether the applicant meets the cost criterion. There have been instances in the past where the coding associated with a new technology application is included in a finalized policy to change one or more MS-DRGs. For example, in the FY 2013 IPPS/LTCH PPS final rule, we describe the cost analysis for the Zenith® Fenestrated Abdominal Aortic Aneurysm Endovascular Graft which was identified by ICD-9-CM procedure code 39.78. In that same rule, we finalized a change to the assignment of that procedure code, reassigning it from MS-DRGs 252, 253, and 254 to MS-DRGs 237 and 238. Because of that change, we determined that, for FY 2013, in order for the Zenith® Fenestrated Abdominal Aortic Aneurysm Endovascular Graft to meet the cost criteria, it must demonstrate that the average case-weighted standardized charge per case exceeds the thresholds for MS-DRGs 237 and 238 (77 FR 53360). We note that, in that example, MS-DRGs 237 and 238 existed previously; therefore, thresholds that were 75 percent of one standard deviation beyond the geometric mean standardized charge for these DRGs were available to the public in Table 10 at the time the application was submitted. In the
FY 2016 IPPS/LTCH proposed rule, we stated that in this case, if MS-DRGs 273 and 274 were to be finalized for FY 2016, we recognize that thresholds that are 75 percent of one standard deviation beyond the geometric mean standardized charge would not have been available at the time the application was submitted. We stated that we believe that it could be appropriate for the applicant to demonstrate that the average case-weighted standardized charge per case exceeds these thresholds for MS-DRGs 273 and 274. Accordingly, we made available supplemental threshold values on the CMS website at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html that were calculated using the data used to generate the FY 2015 IPPS/LTCH PPS Table 10 and reassigned the procedure codes in accordance with the finalized policies discussed in section II.G.3.b. of the preamble of this final rule.

In the FY 2016 IPPS/LTCH proposed rule, we invited public comments on whether considering these supplemental threshold values as part of the cost criterion evaluation for this application is appropriate and also on how to address similar future situations in a broader policy context should they occur. We also invited public comments on the whether the WATCHMAN® System meets the cost criterion based on the applicant’s analysis.

**Comment:** Commenters disagreed that it would be appropriate to consider the supplemental thresholds as part of the cost analysis and recommended that CMS continue its current policy to evaluate the cost threshold provided by the applicant at the time an application is submitted. One commenter argued the following three reasons why CMS
should maintain the current policy: (1) an application with newly created MS-DRGs will be treated differently than an application associated with a procedure whose MS-DRGs are not newly created and, therefore, will be held to a higher standard, a standard that is beyond an applicant’s control; (2) applicants whose applications are associated with a procedure that CMS proposed to be reassigned to a newly created MS-DRG will have less time to review the supplemental thresholds; and (3) a short period of time makes it more difficult to review or verify CMS’ calculations of the supplemental thresholds.

Another commenter stated that the primary purpose of the final rule is to establish the processes and values that will be used during the next fiscal year. Therefore, the commenter asserted that CMS review should be conducted based on the same MS-DRGs and associated cost thresholds from the final rule and these thresholds should be the basis of CMS’ determination whether the applicant satisfies the cost criterion.

Commenters urged CMS to consider using the following sequence for new technology add-on payment applications that are associated with procedures that CMS proposes be reassigned to newly created MS-DRGs: First, CMS should evaluate the cost threshold in effect at the time the new technology add-on payment application is submitted to determine if an applicant exceeds the cost threshold. Second, CMS should determine if the application meets the new technology add-on payment criteria, including the cost threshold, in place at the time the new technology add-on payment was submitted. Third, CMS should reassign procedures associated with new technology add-on payments to a different MS-DRG after the new technology add-on payment decision is made. One commenter stated that such a sequence would be identical to the current
policy CMS uses when reassigning procedures already associated with a new technology add-on payment to new DRGs. The commenter further stated that in cases when CMS reassigns procedures already associated with a new technology add-on payment to a different set of DRGs than were originally used to determine if the applicant met the cost criterion, CMS does not require the new technology add-on payment to be reassessed using cost thresholds for the newly assigned MS-DRGs. The commenter noted that CMS did not reassess in the FY 2016 IPPS/LTCH PPS proposed rule whether the MitraClip® System (which was approved for FY 2015 new technology add-on payments) meets the cost criterion using the supplemental table values for the newly created DRGs 273 and 274 into which CMS proposed reassigning the procedure associated with MitraClip® System. The commenter stated that it believed CMS should follow the same process for the WATCHMAN® System this year and other applications in the future (should the need arise).

Response: We agree with the commenters that we should evaluate the cost threshold in effect at the time the new technology add-on payment application is submitted to determine if an applicant exceeds the cost threshold. We agree that this policy is most predictable for applicants. For the same reason, we are maintaining our current policy to use the thresholds issued with each final rule for the upcoming fiscal year (that is, for FY 2017 we will use Table 10 issued with this FY 2016 final rule, along with any updated MS-DRG assignments) when making a determination to continue add-on payments for those new technologies that were approved for new technology add-on payments from the prior fiscal year.
Comment: The applicant submitted a public comment using the methodology and analysis above to further demonstrate the WATCHMAN® System meet the cost criterion compared to the supplemental thresholds.

Response: We thank the applicant for providing this additional analysis. As discussed above, we are using the thresholds from FY 2015 to determine if the WATCHMAN® System meets the cost criterion. Based on the analysis described in the proposed rule, we have determined that the WATCHMAN® System meets the cost criterion.

Regarding the substantial clinical improvement criterion, we note that the applicant applied for new technology add-on payments for FY 2015 (as discussed in the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28043 through 28045)). However, prior to the publication of the FY 2015 IPPS/LTCH PPS final rule, the applicant withdrew the application. Before the withdrawal of the application, CMS stated its concerns with the application in the FY 2015 IPPS/LTCH PPS proposed rule. The applicant included responses to CMS’ previous concerns with the FY 2015 application in its FY 2016 application. Therefore, we addressed the applicant’s responses to the previous concerns specified in the FY 2015 IPPS/LTCH PPS proposed rule as well as our observations on the current FY 2016 application in the FY 2016 IPPS/LTCH PPS proposed rule, as we set forth below.

The applicant asserted that the WATCHMAN® System, a system that reduces the risk of thromboembolic stroke in patients diagnosed with high-risk nonvalvular AF who are eligible for Warfarin therapy, but in whom the potential risks of Warfarin therapy
outweigh the potential benefits, meets the substantial clinical improvement criterion because the WATCHMAN\textsuperscript{®} System is superior to currently available treatments. The applicant claimed that the WATCHMAN\textsuperscript{®} System is ideal for patients diagnosed with a prior hemorrhagic stroke while on Warfarin therapy, patients not adherent to Warfarin therapy, patients with difficulty achieving a therapeutic international normalized ratio (INR), and patients with an increased risk or history of falls. The applicant acknowledged that anticoagulation using Warfarin therapy or one of the novel oral anticoagulation agents (NOACs), such as dabigatran, rivaroxaban, or apixaban, is effective for preventing thromboembolism in patients who can tolerate such medication over the long term. However, these medications are associated with certain risks. The applicant stated that the most used and studied agent, Warfarin, requires dietary restrictions, has a high-risk of drug interactions, genetic variability in dose-response, and the need for frequent monitoring. According to the applicant, the average patient diagnosed with AF and treated with Warfarin therapy achieves a therapeutic INR for approximately one-half of the treatment time. The applicant further stated that these NOACs also have nonadherence risks, high discontinuation rates (up to 20 percent within 2 years), are difficult to monitor effectiveness, and in some cases have no readily available reversal strategy.

As discussed in the proposed rule (80 FR 24460), in support of its assertion that the WATCHMAN\textsuperscript{®} System is a substantial improvement, the applicant submitted data from two pivotal studies (PROTECT AF and the WATCHMAN\textsuperscript{®} Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy...
The data included results of a meta-analysis of the PROTECT AF and PREVAIL studies, an imputed placebo analysis, and a post hoc analysis of the bleeding risks associated with the WATCHMAN® System. According to the applicant, the clinical evidence from these trials and analyses establish the following: implantation of the WATCHMAN® System is safe; the WATCHMAN® System is superior to Warfarin when evaluated against a composite endpoint of all stroke, systemic embolism, and cardiovascular unexplained death in long-term follow-up; the WATCHMAN® System provides a greater reduction in major bleeding events after the conclusion of post procedure anti-thrombotic medication; and the WATCHMAN® System reduces the incidence of ischemic stroke when compared to patients diagnosed with AF who are not treated with Warfarin or other anticoagulation medication.

We note that, unlike in the FY 2015 application, the applicant did not include data from the ASAP study. In the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28043 through 28045), we expressed concerns that data from the ASAP study suggested that the device did not prevent strokes and was insufficient to demonstrate efficacy in the secondary patient population (patients diagnosed with AF who were ineligible for oral anticoagulation). We specifically stated that the ASAP Registry (5) enrolled 150 patients, at one of four centers, that had a contraindication to even short-term anticoagulation, mostly a history of prior bleeding, and there was no control group. Device implantation led to a serious adverse event in 13 patients (8.7 percent), including one case of device thrombus leading to ischemic stroke. Five other patients had a device-related thrombus that did not lead to stroke (4 of these patients were treated with
low molecular weight heparin), resulting in an overall 4.0 percent incidence (6 out of 150) of device-associated thrombus. In the PROTECT AF trial study, 20 of the 473 patients (4.2 percent) had device-associated thrombus, 3 of which led to an ischemic stroke. The rates of device-related thrombus are similar in the two studies (4.0 percent versus 4.2 percent), but the number of patients studied is smaller in the ASAP Registry (5) study compared to the PROTECT AF clinical trial study. In the 14-month follow-up data for the ASAP Registry (5) study, the rate of stroke or systemic embolism was 2.3 percent per year, which was said to be “lower than expected” based on prior data for patients diagnosed with AF who were not treated with warfarin (there was no concurrent control group). The data provided suggested efficacy in this patient population. However, we stated that we were concerned that there was not strong evidence that the device prevents stroke.

In the FY 2016 application, the applicant responded that, because the current intended use and indications for the WATCHMAN® System in the United States do not include patients who are ineligible for treatment using Warfarin therapy, the data from the ASAP study are irrelevant to the FY 2016 application. The applicant provided data from an imputed placebo analysis, a post-hoc analysis that compared the observed rate of ischemic strokes in patients treated with the WATCHMAN® System compared to no therapy, in order to address our concern that there was no strong evidence that the device prevented stroke.

Comment: One commenter, the manufacturer, stated that the ASAP data reflect patients who are intolerant to Warfarin. The commenter stated that it is not seeking
coverage for such patients and therefore does not believe that the ASAP data are relevant to the FY 2016 new technology add-on payment application for the WATCHMAN® System and, thus, it was omitted. The commenter noted that patients from the ASAP study are not part of the FDA approved indication. Therefore, the commenter stated that the ASAP registry should not be included in the evaluation for either efficacy or safety. The commenter added that patients eligible for the WATCHMAN® System, although deemed suitable for Warfarin, have a good clinical reason to seek an alternative. The commenter stated that the WATCHMAN® System is not intended as a first line alternative to oral anticoagulation but should be considered in patients for whom the risks of long-term oral anticoagulation outweigh the benefits. The commenter concluded that the appropriate patient population for this application is based on the WATCHMAN clinical trials (PROTECT AF, CAP, PREVAIL, and CAP2).

Response: We thank the commenter for its clarification concerning the appropriate patient population for the WATCHMAN® System.

According to the applicant, in the PROTECT AF trial, 463 patients were randomized to the WATCHMAN® System device and 244 patients to Warfarin therapy. Most patients randomized to the WATCHMAN® System device had it implanted (408=88 percent). Over the average 3.8 years of follow-up, more patients in the Warfarin therapy group withdrew (45 versus 15) or were lost to follow-up (11 versus 13) than in the WATCHMAN® System device group, leading to shorter mean follow-up (3.7 versus 3.9 years) in the Warfarin therapy group.
The applicant presented data shown in the following table and maintained that the results of the PROTECT study demonstrate primary efficacy and support that theWATCHMAN® System is noninferior and superior at 4 years.

<table>
<thead>
<tr>
<th>Patient Years</th>
<th>Years of mean follow-up</th>
<th>WATCHMAN® System observed rate per 100 patient years</th>
<th>Warfarin observed rate per 100 patient years</th>
<th>Percentage Reduction vs. Warfarin</th>
<th>*Posterior Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>1065</td>
<td>1.5</td>
<td>3</td>
<td>4.9</td>
<td>38%</td>
<td>&gt;99.9%</td>
</tr>
<tr>
<td>1588</td>
<td>2.3</td>
<td>3</td>
<td>4.3</td>
<td>29%</td>
<td>&gt;99.9%</td>
</tr>
<tr>
<td>2621</td>
<td>3.8</td>
<td>2.3</td>
<td>3.8</td>
<td>40%</td>
<td>&gt;99%</td>
</tr>
<tr>
<td>2717</td>
<td>4</td>
<td>2.2</td>
<td>3.7</td>
<td>39%</td>
<td>&gt;99.9%</td>
</tr>
</tbody>
</table>

* For Bayesian analysis, a posterior probability of 97.5 percent represents non-inferiority; ≥95 percent represents superiority.

In the FY 2015 IPPS/LTCH PPS proposed rule, we expressed concern that the evidence presented by the applicant demonstrating superiority compared to Warfarin therapy was insufficient. We expressed concern that the PROTECT AF trial was not designed to demonstrate superiority, and instead was designed to demonstrate noninferiority. We also expressed concern that the PREVAIL trial endpoint was not significantly improved in the conventional hypothesis testing statistical analysis at any time point. We stated that the longer term data showed improved efficacy and safety, but
still remain sparse. In the FY 2016 application, the applicant stated that, under a Bayesian analysis, the distributions of the posterior probabilities are not symmetrical. According to the applicant, posterior probabilities represent the appropriate way to determine statistical significance in Bayesian methodology. As predefined in the PROTECT AF trial, a posterior probability for noninferiority of equal to or more than 97.5 percent, and a prespecified level of at least 95 percent to support superiority were the criteria for statistical testing. According to the applicant, in both cases (noninferiority and superiority), the criteria were met for long-term follow-up as demonstrated in the results of the PROTECT AF trial. In the proposed rule, we stated that we agreed that the Bayesian methodology is a valid method of analysis. However, we were referencing the overall efficacy noninferiority in the PREVAIL trial.

In the FY 2016 proposed rule (80 FR 24461), we again presented our continued concern that the data results from the PROTECT AF study are insufficient to show superiority of the WATCHMAN® System over Warfarin therapy. We noted that the study was unblinded with a noninferiority design. We stated that we believe that the reduction in cardiovascular mortality shown in the results from the PROTECT AF study was unexpected and not well explained. Among the 57 patients in the WATCHMAN® System group who died, only 53 patient cases were assigned a cause of death and only 5 of the 9 “unexplained/other deaths” were included in the primary endpoint, although the protocol established that unexplained deaths were to be considered as cardiovascular mortalities. The total number of “cardiovascular or unexplained deaths” would have been 21, not 17. In the Warfarin therapy group, there was 1 “unexplained/other” death
that should have been included in the primary endpoint, resulting in a total of 23, not 22. We acknowledged that it may be difficult to calculate the impact of these additional events as the intention-to-treat analysis of the primary endpoint. However, we stated our concern that the inclusion of the additional deaths could have made the posterior probabilities for the device less favorable. Based on the data at face value, we stated that it appears that the WATCHMAN® System does not demonstrate statistically significant superiority over treatment with Warfarin therapy until 3.8 years has elapsed and the patient has been administered 6 months of oral anticoagulation and been exposed to the risk of the device-related complications. We stated that we were concerned that the applicant has not demonstrated substantially improved clinical outcomes.

In the prospective randomized evaluation of the PREVAIL study, the goal was to assess the safety and efficacy of LAA occlusion for stroke prevention in patients diagnosed with NVAF compared to long-term Warfarin therapy. The PREVAIL study was a confirmatory randomized trial designed to further assess the efficacy and safety of the WATCHMAN® System device. Patient selection and study design were similar to the PROTECT AF study. Two efficacy and 1 safety coprimary endpoints were assessed at 18 months. The rate of the first coprimary efficacy endpoint overall efficacy (composite of stroke, systemic embolism [SE], and cardiovascular/unexplained death) was 0.064 in the WATCHMAN® System device group versus 0.063 in the control group (rate ratio 1.07 [95 percent credible interval (CrI) 0.57 to 1.89]) and did not achieve the prespecified criteria of noninferiority (upper boundary of 95 percent CrI 1.75). The rate for the second coprimary efficacy endpoint (stroke or SE >7 days’ post-randomization) was
0.0253 versus 0.0200 (risk difference 0.0053 [95 percent CrI –0.0190 to 0.0273]), which achieved noninferiority. Early safety events were significantly lower than the results of the PROTECT AF study, which satisfies the prespecified safety performance goal. The PREVAIL study was designed to demonstrate noninferiority with wide efficacy margins. However, as previously stated, our concern was that the results of the study did not show the overall efficacy of the technology to be noninferior.

Comment: The applicant responded to our concerns and commented that it appreciates that CMS agrees that the Bayesian approach is valid for analyzing PROTECT AF and PREVAIL trials as both were powered based on those statistics. Although CMS agrees with this approach, the applicant asserted that it appears contradictory also to judge PREVAIL efficacy using a frequentist approach. The applicant stated that the primary objective of PREVAIL was to confirm procedural safety due to early complications from the first half of PROTECT AF. The applicant noted that, although the procedural complication rates were reduced by approximately 50 percent in the second half of PROTECT AF, and were maintained in the CAP registry, the FDA required the applicant to perform a second randomized trial to confirm this improvement in safety. The applicant stated that PREVAIL was the confirmatory trial that demonstrated the safety profile of the WATCHMAN® System and showed the device could be safely implanted by both experienced and new operators.

The applicant acknowledged that when the efficacy data are considered on their own, the WATCHMAN® arm in PREVAIL missed both co-primary efficacy endpoints (the 18-month rates of the composite of stroke (including hemorrhagic or ischemic),
systemic embolism, and cardiovascular or unexplained death and the 18-month rates of ischemic stroke or systemic embolism excluding the first 7 days post-randomization) in the October 2014 updated post hoc analyses. The applicant stated the reason why the stand-alone data in PREVAIL missed overall efficacy was due in large part to the over-performance of the Warfarin arm in PREVAIL. The applicant noted that when evaluating the Warfarin arm in PREVAIL, with respect to ischemic strokes, it outperformed historical Warfarin trials (and real-world experience) and the assumptions used for the design of the PREVAIL trial. Specifically, the applicant noted that the rate of ischemic strokes was three times less than any Warfarin control trial in the last decade, with an annual rate of 0.3 percent for ischemic stroke\textsuperscript{62} compared with 1.05 to 1.42 percent in other trials of oral-anticoagulant trials that included over 29,000 Warfarin patients.\textsuperscript{63, 64, 65, 66} In addition, the applicant stated the following: that although the PREVAIL ischemic stroke rate in the WATCHMAN\textsuperscript{®} arm was numerically higher than the Warfarin arm, it was consistent with the long-term follow up of all WATCHMAN\textsuperscript{®} patients in all other trials; the ischemic stroke rates for the WATCHMAN\textsuperscript{®} group are similar to those treated with anticoagulants as seen in PROTECT AF and the CAP registry when accounting for the higher CHA\textsubscript{2}DS\textsubscript{2}-VASc score. The applicant indicated that this implies the rates of ischemic stroke in the WATCHMAN\textsuperscript{®} arm of the PREVAIL

\textsuperscript{62}Holmes et al. Prospective randomized evaluation of the Watchman left atrial appendage Device in patients with atrial fibrillation versus long-term warfarin therapy; the PREVAIL trial. JACC, Vol. 4, No. 1, 2014, 1-11.


trial are comparable to those with treated with anticoagulants and shows a similar benefit as compared to Warfarin.67

The applicant further noted that although the PREVAIL efficacy endpoints were missed, the data was consistent with demonstrating non-inferiority (93 percent posterior probability of non-inferiority) of WATCHMAN® compared to Warfarin and came close to achieving statistical proof of non-inferiority (that is, posterior probability of 95.69 percent) with respect to the primary efficacy endpoint of composite stroke, systemic embolism and cardiovascular death.

The applicant also noted that in the primary December 2013 analysis specified by the protocol (using data locked in January 2013), the Bayesian estimate for the 18-month rate ratio was 1.07 with a 95 percent credible interval of 0.57 to 1.89. The applicant stated that the upper bound of 1.89 was not lower than the non-inferiority margin of 1.75 defined in the statistical analysis plan, the non-inferiority criterion was not met in the prespecified analysis (the posterior probability of non-inferiority was 95.69 percent). In the ad hoc October 2014 Bayesian analysis (using data locked in June 2014), the applicant noted that the 18-month rate was 0.065 for the Device group and 0.057 for the Control group. Also, the Bayesian estimate for the 18-month rate ratio was 1.21 with a 95 percent credible interval of 0.69 to 2.05. The applicant stated that because the upper bound of 2.05 was not lower than the non-inferiority margin of 1.75 defined in the statistical analysis plan, the non-inferiority criterion was still not met (the posterior probability of non-inferiority was 92.6 percent).

The applicant stated that the second primary endpoint evaluated the post-procedure difference between the WATCHMAN® System and Warfarin in terms of ischemic stroke and systemic embolism. The applicant noted the following: in the December 2013 data (using the January 2013 data lock), the pre-specified primary analysis time point, the 18 month rate difference was 0.0053, with a posterior probability of non-inferiority of 97.6 percent with the device meeting its endpoint; in October 2014, an updated analysis was performed on a data set locked in June 2014 where the rate difference increased to 0.0163 due to additional ischemic stroke events; the upper bound crossed the pre-specified boundary of 0.0275 resulting in the endpoint being missed with a posterior probability of non-inferiority of 89.2 percent. The applicant stated that the WATCHMAN® arm of PREVAIL was performing similarly to the other trials and the additional ischemic strokes aligned with the stroke risk over longer term follow up in the PROTECT trial.

The applicant noted that the PROTECT AF trial provided the informative prior for PREVAIL under the Bayesian analysis. The applicant stated that the total number of patients and duration of follow-up in PROTECT far exceeds that of PREVAIL as PROTECT AF represents over 75 percent of the randomized patient follow-up data, while PREVAIL accounts for less than a quarter.

For long-term performance of WATCHMAN®, the applicant stated that CMS should evaluate the primary efficacy data from PROTECT AF where patients have completed 2,717 patient years of follow up (compared to PREVAIL at 860 patient years) and have consistently demonstrated non-inferiority to Warfarin and shown superiority at
2,621 patient years. The applicant noted that, although PROTECT AF was not designed to show superiority of WATCHMAN® to Warfarin, as it was designed to be a non-inferiority trial, it was also designed to have the potential to demonstrate superiority. The applicant noted that while the protocol allowed for testing of superiority provided that non-inferiority was shown, the lack of power to show superiority means that the study was not likely to demonstrate superiority given the sample size and expected performance of WATCHMAN® vs. Warfarin.

The applicant also noted the following: although the 95 percent posterior probability of superiority does not cross the boundary until the 3.8 year time point, the data are consistent with superiority as early as the 1.3 year (900 patient year) analysis; the rate ratio is relatively constant thereafter, reflecting consistency of the benefit of WATCHMAN® versus Warfarin from that point onward.

The applicant also provided data from a patient level meta-analysis that combined the PROTECT AF and PREVAIL data to support the efficacy of the WATCHMAN® System and show the device was performing as expected when compared to the Warfarin control arm. The applicant stated the following major results from the meta-analysis of the PROTECT AF and PREVAIL randomized studies:

- Primary Efficacy Endpoint: The WATCHMAN® System was associated with a 21 percent reduction in the risk of a primary efficacy endpoint event, though not statistically significant (p=0.23).

- Stroke and Systemic Embolism: The WATCHMAN® System is similar to Warfarin in preventing all-cause stroke and systemic embolism (HR=1.02, p=0.93). It is
associated with a decrease in the relative risk of hemorrhagic stroke (88 percent, p=0.004); however, the device is not as effective as Warfarin in reducing the risk of ischemic stroke (HR=1.96, p=0.049). The applicant stated that in considering the total risks and benefits of the WATCHMAN® System, it is important to take into account more than the ischemic stroke event such as comparison of stroke severity (hemorrhagic versus ischemic), major bleeds, and mortality.

- Stroke Severity: Using the mRS instrument, those strokes occurring in the WATCHMAN® device arms were significantly less likely to be disabling (49 percent relative reduction in disabling strokes, p=0.044) than those occurring in the Warfarin groups.

- Major Bleeds: Warfarin can cause bleeding in anatomic locations other than the brain, such as the eye or spine. When considering all major bleeds unrelated to the implant procedure, Warfarin was associated with an approximately two-fold relative increase in the risk of a major bleed (p=0.002).

- Mortality: Use of the WATCHMAN® System is associated with a 27 percent relative reduction in the risk of all-cause mortality, though not statistically significant (p=0.074) and a 52 percent relative reduction in the risk of cardiovascular (CV)/unexplained mortality (p=0.006).

The applicant stated that the primary efficacy endpoint for each of the trials included cardiovascular (or unexplained) death, all strokes (both ischemic and hemorrhagic) and systemic embolism. Of the components of this endpoint, the commenter stated that death is the most devastating, followed in importance by
hemorrhagic strokes (which are generally catastrophic and typically result in greater
disability than ischemic strokes). Therefore, when interpreting the patient-level
meta-analyses, the applicant asserted that the overall conclusion is that the
WATCHMAN® System is a reasonable alternative to Warfarin. The applicant noted that
use of the WATCHMAN® System did not change the overall rate of all-cause stroke, but
it did alter the proportion of stroke subtypes: there was a reduction in hemorrhagic stroke
which was offset by less effective prevention of ischemic stroke. The applicant also
noted the following: although the overall rate of all-cause stroke was unchanged, patients
with the WATCHMAN® System were significantly less likely to have a disabling stroke;
when compared to Warfarin, the WATCHMAN® System yielded a significant relative
reduction in the risk of major bleeding by 51 percent as well as a significant relative
reduction in the risk of mortality due to CV or unknown causes by 52 percent; while the
rates of all-stroke in the meta-analysis were the same between groups (HR = 1.02,
p=0.94), the rate of ischemic strokes was less in the Warfarin arm (HR=1.95, p=0.05)
while the rate of hemorrhagic strokes was much less in the WATCHMAN® arm
(HR=0.22, p=0.004).

The applicant stated the following conclusions: while PREVAIL was never
intended nor powered to stand-alone for demonstrating overall efficacy, the primary
purpose was to demonstrate procedural safety; although the PREVAIL primary efficacy
endpoint was missed, CMS should not judge overall efficacy of the WATCHMAN®
System in the absence of the long-term follow-up data from PROTECT AF and the

68 Holmes DR, Jr., Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an Alternative to
meta-analysis which provides a more complete picture of the data showing that WATCHMAN® efficacy outcomes are similar to those of Warfarin in patients who do not take oral anticoagulants; the WATCHMAN® System performance was consistent across trials and the additional ischemic strokes seen over time in PREVAIL align appropriately with the higher stroke risk scores in this trial (that is, patients with mean CHADS₂ scores ranging from 2.2 to 2.7 in the consecutive trials, and CHA₂DS₂-VASc scores from 3.5 to 4.5, with the majority of patients in all trials considered high risk and anticoagulation recommended per AHA/ACC/HRS guidelines).

Response: We thank the applicant for the additional information and clarifications. We also appreciate the additional meta-analysis which we considered in our decision below. However, we continue to be concerned that the 95 percent posterior probability of superiority is not met for a number of years. In addition, there is no data establishing sustained effectiveness and superiority long term.

Comment: With regard to CMS’ interpretation of CV unexplained death, one commenter clarified that all four studies employed an independent Clinical Events Committee (CEC) to review and adjudicate site-reported adverse events and ascertain their seriousness, relationship of the event to the device or procedure, and relationship of study medications to the study endpoints. The commenter stated that the four deaths questioned by CMS were adjudicated by this independent committee and were assigned to the correct mortality categories. The commenter also noted that there are two mortality categories with the word “other”: “Cardiovascular - Unexplained/other” and

---

69 The Establishment and Operation of Clinical Trial Data Monitoring Committees for Clinical Trial Sponsors; Guidance for Clinical Trial Sponsors - Establishment and Operation of Clinical Trial Data Monitoring Committees, issued March 2006.
“Other (Non-Cardiovascular)”. The commenter explained that for determining the appropriate category, if a specific cause of death could not be determined, the death was assigned conservatively to the “Cardiovascular – Unexplained/other” category and it was factored into the PROTECT AF primary efficacy endpoint and if the cause of a death was known but not cardiovascular-related, such as suicide or motor vehicle accident, then the death was assigned to the “Other (Non-Cardiovascular)” category. The commenter stated that CMS is incorrectly implying that the four deaths assigned in the “Other (Non-Cardiovascular)” category should be included in the “Cardiovascular – Unexplained/other” category. The commenter explained that such an interpretation is incorrect because the causes of these deaths were known and determined not to be cardiovascular-related.

Response: We thank the commenter for clarifying and resolving our concern with regard to CV unexplained death and how these deaths were classified into either the “Cardiovascular - Unexplained/other” or “Other (Non-Cardiovascular)” category.

As discussed in the proposed rule (80 FR 24462), the applicant submitted data from a patient-level meta-analysis that combined the data from the PROTECT AF study with the data from the PREVAIL study. According to the applicant, this analysis supports the efficacy of the WATCHMAN® System and shows that the device was performing as expected compared to the Warfarin therapy control arm. The datasets were combined and weighted. According to the applicant, multiple outcomes of interest were examined, starting with the primary efficacy endpoint and then looking at individual outcomes: all stroke (ischemic and hemorrhagic) and associated disability; systemic
embolism; cardiovascular/unexplained death; and major bleeding. The overall incidence of all strokes (ischemic and hemorrhagic) was not statistically different between the WATCHMAN® System arm and the Warfarin therapy arm. However, the applicant stated that there were statistical differences identified when it analyzed the stroke subtypes. The applicant indicated that, initially, there were more ischemic strokes in the WATCHMAN® System arm. However, after accounting for early procedural complications, including strokes (within 7 days post procedure) in the PROTECT AF study, the difference for ischemic stroke between the two arms fell below statistical significance (p=0.21). According to the applicant, there were significantly more hemorrhagic strokes and cardiovascular deaths in the Warfarin therapy arm compared to the WATCHMAN® System arm, showing a 78 percent and 52 percent reduction in those events respectively (p=0.004 and p=0.006). To better assess the clinical impact of the different subtypes of strokes on patients, the applicant also performed statistical tests on disabilities resulting from stroke. The applicant indicated that, using a validated stroke severity assessment tool (Modified Rankin score), analyses show that there were significantly less disabling strokes with the WATCHMAN® System than Warfarin therapy. The applicant believed that this represents a substantial clinical improvement for the WATCHMAN® System device.

The applicant conducted an imputed placebo analysis to assess the benefit that untreated patients may expect with the WATCHMAN® System device. The applicant contended that many patients who are eligible for Warfarin therapy are not receiving any treatment and, therefore, are left unprotected from stroke. With annual ischemic stroke
rates ranging from 5.6 percent to 7.1 percent, the applicant maintained that the WATCHMAN® System device provides a substantive clinical benefit. In order to assess the benefit that untreated patients may be able to expect with the WATCHMAN® System, the sponsor performed the following exploratory analysis. The observed device ischemic strokes rates were compared against the estimated stroke risk of untreated nonvalvular AF patients. A placebo arm was then constructed using “well-established, validated literature” models based on both the CHADS2 and CHA2DS2-VASc scores. The applicant reported that this analysis showed the WATCHMAN® System device reduced stroke in the untreated patient population by 65 to 81 percent.

In the proposed rule, we noted that we previously expressed concern that there was a lack of strong evidence demonstrating that the WATCHMAN® System prevents stroke at all. The applicant responded that the imputed placebo analysis cited above addresses this concern. The applicant provided the table below as part of its FY 2016 application to show the relative risk reduction in Ischemic stroke rates using the WATCHMAN® System versus no therapy.

<table>
<thead>
<tr>
<th>Study</th>
<th>Average CHADS(2 footnote on acronym) Score</th>
<th>WATCHMAN® Patients</th>
<th>Observed WATCHMAN® Annual Ischemic Stroke Rate (95 Percent CI)</th>
<th>Imputed Untreated Annual Event Rate</th>
<th>Relative Risk Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
While the results of this analysis appear to suggest a large reduction in ischemic stroke rates in patients who did not receive any treatment, we continued to have some concerns regarding whether the WATCHMAN® System device prevents strokes. The indication for the treatment of the WATCHMAN® System device is for patients who are eligible for Warfarin therapy as opposed to patients who are ineligible for Warfarin therapy. We stated that our concern is that the results of the imputed placebo analysis are not sufficient to determine whether the WATCHMAN® System reduces the risk of stroke in patients who are eligible for Warfarin therapy. The applicant suggested that patients who are subtherapeutic or noncompliant with Warfarin therapy would have the same risk of stroke as patients who do not receive any therapy. However, the applicant did not offer any evidence that these two groups have the same risk of stroke. The WATCHMAN® System device is intended only for use in patients who are eligible for the anticoagulation, not for patients who have contraindications to oral anticoagulation. Because the device will not be labeled for use in those patients, we stated in the proposed rule that we believe that an analysis comparing stroke risk of untreated patients to those

<table>
<thead>
<tr>
<th></th>
<th>PROTECT AF</th>
<th>PREVAIL-only</th>
<th>CAP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.2</td>
<td>2.6</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>1.3 (0.9, 2.0)</td>
<td>2.3 (1.3, 4.0)</td>
<td>1.2 (0.8, 1.8)</td>
</tr>
<tr>
<td></td>
<td>5.6 to 5.7</td>
<td>6.6 to 6.7</td>
<td>6.4</td>
</tr>
<tr>
<td></td>
<td>77% (64%, 84%)</td>
<td>65% (39%, 80%)</td>
<td>81% (72%, 88%)</td>
</tr>
</tbody>
</table>
patients treated with the WATCHMAN® System is of limited value in assessing the technology’s benefit over existing therapy.

**Comment:** The applicant commented and explained that the imputed placebo analysis compares patients enrolled in the WATCHMAN® trials to similar patients from large real-word databases. The applicant noted that a placebo arm was constructed using well-established, validated literature models based on both the CHADS2 and CHA2DS2-VASc scores. The applicant stated that a benefit was then imputed, through analysis of the WATCHMAN® trials, for the WATCHMAN® System as compared to the imputed placebo patients, and a relative reduction in events was computed. The applicant clarified that this imputed placebo comparison is to “untreated” Warfarin-eligible non-valvular AF patients and not to patients contra-indicated or ineligible for Warfarin as the majority of these “untreated patients” are eligible for Warfarin and were not contraindicated for Warfarin. The applicant noted that when compared to untreated patients, each of the WATCHMAN® studies is associated with a substantial reduction in the risk of ischemic stroke, demonstrating a consistent and clinically meaningful response across each study. The applicant further noted that stroke risk reduction is between 65 and 81 percent when comparing the performance of the WATCHMAN® System to the groups used in the imputed placebo analyses.\(^{70}\) The applicant concluded that imputed placebo analyses show there is a strong expectation of a beneficial effect of WATCHMAN® when applied as intended to the patients who are eligible for Warfarin

for the short-term but who are unable or unwilling to take the drug for the long-term and who would otherwise go untreated.

Response: We thank the applicant for the additional input. We considered these comments in our decision below.

As discussed in the proposed rule (80 FR 24463), the applicant asserted that one of the primary goals of mechanical LAA closure is to provide an alternative treatment for patients other than long-term Warfarin therapy and exposure to the associated risk for bleeding. Although the primary efficacy endpoint of the PROTECT AF and PREVAIL studies considered hemorrhagic stroke, it did not encompass other types of major bleeding that may be associated with the use of Warfarin. The applicant indicated that it performed a supplemental analysis to determine the relative risks of all types of bleeding. The applicant divided the follow-up interval into four subsections (7 days, 45 days, 6 months, and 54 months). The applicant compared bleeding events in the WATCHMAN® System arm with the Warfarin therapy arm and concluded that, after 6 months (and discontinued use of Clopidogrel in the WATCHMAN® System group), the continued use of Warfarin was associated with a 3.4 fold increase in the risk of major bleeding.

According to the applicant, the significant reduction in bleeding after the procedural and concomitant medication therapy (6 months) with the cessation of long-term anticoagulants illustrates the substantial clinical benefit of the WATCHMAN® System. However, given the high burden endured (most notably, the higher risk of bleeding occurring in the first 7 days of an inpatient hospital stay) to achieve a reduction in bleeding in the long term, we stated in the proposed rule that we do not believe the
WATCHMAN® System meets the criteria for substantially improved clinical outcomes. In the proposed rule, we invited public comments on whether this technology meets the substantial clinical improvement criterion, particularly in light of the applicant’s response to our previous concerns and our current concern that there remains insufficient evidence that the WATCHMAN® System substantially improves clinical outcomes in patients diagnosed with nonvalvular AF and who are eligible for Warfarin therapy.

**Comment:** The applicant commented that despite WATCHMAN® System overall positive safety profile, CMS is choosing one specific event rate (that is, risk of peri-procedural bleeding) to conclude that WATCHMAN® System does not meet the criteria for substantial clinical improvement. The applicant argued that any device implant has some peri-procedural risks associated with the procedure (that is, pacemakers, defibrillators), but this should be balanced with the long-term risks of not having the therapy available (for example, death). The applicant stated that as long as the potential device safety profile is well established in well-designed clinical trials and the risks are within the norms of other established device-based therapies, FDA approved treatment options should be eligible for consideration as a substantial improvement over available alternatives; this is especially true when the long-term risks of those alternatives, in this case non-treatment with long term oral anticoagulation, are high. The applicant noted that, in this regard, incidence of safety events fell from 9.9 percent in the first half of PROTECT AF to 4.8 percent in the second half after changes were made in operator training and technical aspects of the procedure. The applicant also noted that the reduction in safety events was evident in the CAP Registry where the safety event was
4.1 percent; the PREVAIL trial where the event rate was 2.2 percent with a 95 percent credible interval bound of 2.65 percent, within the pre-specified performance goal of 2.67 percent and in the CAP2 registry where the safety event remained constant around 4.1 percent. The applicant noted that the WATCHMAN® procedural risks are on par with most left atrial cardiovascular medical device interventions (for example, ablation). 71

The applicant also noted the following: the one-time 7-day peri-procedural WATCHMAN® complication rate of 3.8 to 4.1 percent is similar to the yearly frequency of major bleeding or intracranial hemorrhage for patients on long-term Warfarin, which is 3.1 to 3.6 percent 72, 73, 74, 75; that any sequelae associated with the upfront bleeding risks associated with the implant procedure, unlike those that occur in patients on long-term Warfarin, should be more effectively managed because they occur in-hospital under medical supervision where immediate treatment is available.

The applicant also stated that CMS’ analysis does not consider that the bleeding rate with oral anticoagulation therapy is compounded yearly (that is, the risk goes up with longer exposure to Warfarin), dramatically increasing the likelihood of hemorrhagic stroke. The applicant asserted that, in contrast, WATCHMAN® patients are free of the burden of life-long treatment with Warfarin (99 percent Warfarin cessation at 12 months

71 Boston Scientific FDA Panel October 2014.
in PREVAIL and CAP2) and the bleeding risk is constant and reduced in years 1-9 post implant. The applicant stated that the reduced bleeding benefits associated with the WATCHMAN® System continue to diverge from Warfarin outcomes and the magnitude of benefit increases over time. Furthermore, the applicant asserted that for patients with CHA₂DS₂VASc score of 2 or greater, who are not on long-term oral anticoagulation and are unprotected against ischemic stroke, the annual risk of stroke ranges from 2 to 24 percent and over a 5-year period, the risk is between 10 to 75 percent that these patients may experience an ischemic stroke.

Response: While we agree with the commenter that one specific event rate (that is, risk of peri-procedural bleeding) should not preclude the WATCHMAN® System from meeting the criteria for substantial clinical improvement, we continue to be concerned that the 95 percent posterior probability of superiority is not met for a number of years. In addition, there is no data establishing sustained effectiveness and superiority long term. While the WATCHMAN® System can be an alternative to the subset of patients with nonvalvular atrial fibrillation who are unable to tolerate warfarin long term, we are concerned that the WATCHMAN® System is not as effective as Warfarin in reducing the risk of ischemic stroke.

Also, the clinical trials compared the WATCHMAN® System to Warfarin. Other anti-coagulants may be an effective treatment for this small population not eligible for Warfarin. Without additional clinical data, we are unable to determine if patients who respond to other anti-coagulants would require the WATCHMAN® System. Therefore,

---

76 Boston Scientific WATCHMAN FDA Panel Sponsor Presentation - October 2014.
based on the reasons stated above, we do not believe that the WATCHMAN® System meets the substantial clinical improvement criteria at this time and are not approving the WATCHMAN® System for new technology add on payment for FY 2016. We welcome the applicant to reapply next year as additional long-term data becomes available.

**Comment:** Many commenters supported the approval of the WATCHMAN® System for new technology add-on payment for FY 2016. Many of the commenters spoke about their experience with the device and reiterated many of the points expressed by the applicant in its comments.

**Response:** We thank the commenters for their comments. However, as mentioned above, we are not approving the WATCHMAN® System for new technology add-on payment for FY 2016.
III. Changes to the Hospital Wage Index for Acute Care Hospitals

A. Background

1. Legislative Authority

Section 1886(d)(3)(E) of the Act requires that, as part of the methodology for determining prospective payments to hospitals, the Secretary adjust the standardized amounts for area differences in hospital wage levels by a factor (established by the Secretary) reflecting the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level. We currently define hospital labor market areas based on the delineations of statistical areas established by the Office of Management and Budget (OMB). A discussion of the FY 2016 hospital wage index based on the statistical areas appears under sections III.A.2. and G. of the preamble of this final rule.

Section 1886(d)(3)(E) of the Act requires the Secretary to update the wage index annually and to base the update on a survey of wages and wage-related costs of short-term, acute care hospitals. This provision also requires that any updates or adjustments to the wage index be made in a manner that ensures that aggregate payments to hospitals are not affected by the change in the wage index. The adjustment for FY 2016 is discussed in section II.B. of the Addendum to this final rule.

As discussed in section III.J. of the preamble of this final rule, we also take into account the geographic reclassification of hospitals in accordance with sections 1886(d)(8)(B) and 1886(d)(10) of the Act when calculating IPPS payment amounts. Under section 1886(d)(8)(D) of the Act, the Secretary is required to adjust the
standardized amounts so as to ensure that aggregate payments under the IPPS after
implementation of the provisions of sections 1886(d)(8)(B), 1886(d)(8)(C), and
1886(d)(10) of the Act are equal to the aggregate prospective payments that would have
been made absent these provisions. The budget neutrality adjustment for FY 2016 is
discussed in section II.A.4.b. of the Addendum to this final rule.

Section 1886(d)(3)(E) of the Act also provides for the collection of data every
3 years on the occupational mix of employees for short-term, acute care hospitals
participating in the Medicare program, in order to construct an occupational mix
adjustment to the wage index. A discussion of the occupational mix adjustment that we
are applying, beginning October 1, 2015 (to the FY 2016 wage index), appears under
sections III.E.3. and F. of the preamble of this final rule.

2. Core-Based Statistical Areas (CBSAs) for the FY 2016 Final Rule

The wage index is calculated and assigned to hospitals on the basis of the labor
market area in which the hospital is located. Under section 1886(d)(3)(E) of the Act,
beginning with FY 2005, we delineate hospital labor market areas based on
OMB-established Core-Based Statistical Areas (CBSAs). The current statistical areas
(which were implemented beginning with FY 2015) are based on revised OMB
No. 13-01 established revised delineations for Metropolitan Statistical Areas,
Micropolitan Statistical Areas, and Combined Statistical Areas in the United States and
Puerto Rico, and provided guidance on the use of the delineations of these statistical
areas based on new standards published on June 28, 2010 in the Federal Register.
(75 FR 37246 through 37252) and the 2010 Census of Population and Housing data (we refer to these revised OMB delineations as the “new OMB delineations” in this final rule). A copy of this bulletin may be obtained at http://www.whitehouse.gov/sites/default/files/omb/bulletins/2013/b-13-01.pdf. We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951 through 49963) for a full discussion of our implementation of the new OMB labor market area delineations for the FY 2015 wage index. For FY 2016, we are continuing to use the new OMB delineations that we adopted beginning with FY 2015 to calculate the area wage indexes, including the transition wage indexes, which we discuss below.

B. Worksheet S-3 Wage Data for the FY 2016 Wage Index

The FY 2016 wage index values are based on the data collected from the Medicare cost reports submitted by hospitals for cost reporting periods beginning in FY 2012 (the FY 2015 wage indexes were based on data from cost reporting periods beginning during FY 2011).

1. Included Categories of Costs

The FY 2016 wage index includes the following categories of data associated with costs paid under the IPPS (as well as outpatient costs):

• Salaries and hours from short-term, acute care hospitals (including paid lunch hours and hours associated with military leave and jury duty);

• Home office costs and hours;

• Certain contract labor costs and hours (which includes direct patient care, certain top management, pharmacy, laboratory, and nonteaching physician Part A
services, and certain contract indirect patient care services (as discussed in the FY 2008 final rule with comment period (72 FR 47315 through 47318)); and

- Wage-related costs, including pension costs (based on policies adopted in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51586 through 51590)) and other deferred compensation costs.

2. Excluded Categories of Costs

   Consistent with the wage index methodology for FY 2015, the wage index for FY 2016 also excludes the direct and overhead salaries and hours for services not subject to IPPS payment, such as skilled nursing facility (SNF) services, home health services, costs related to GME (teaching physicians and residents) and certified registered nurse anesthetists (CRNAs), and other subprovider components that are not paid under the IPPS. The FY 2016 wage index also excludes the salaries, hours, and wage-related costs of hospital-based rural health clinics (RHCs), and Federally qualified health centers (FQHCs) because Medicare pays for these costs outside of the IPPS (68 FR 45395). In addition, salaries, hours, and wage-related costs of CAHs are excluded from the wage index for the reasons explained in the FY 2004 IPPS final rule (68 FR 45397 through 45398).

3. Use of Wage Index Data by Suppliers and Providers Other Than Acute Care Hospitals under the IPPS

   Data collected for the IPPS wage index also are currently used to calculate wage indexes applicable to suppliers and other providers, such as SNFs, home health agencies (HHAs), ambulatory surgical centers (ASCs), and hospices. In addition, they are used for
prospective payments to IRFs, IPFs, and LTCHs, and for hospital outpatient services. We note that, in the IPPS rules, we do not address comments pertaining to the wage indexes of any supplier or provider except IPPS providers and LTCHs. Such comments should be made in response to separate proposed rules for those suppliers and providers.

C. Verification of Worksheet S-3 Wage Data

The wage data for the FY 2016 wage index were obtained from Worksheet S-3, Parts II and III of the Medicare cost report (Form CMS-2552-10) for cost reporting periods beginning on or after October 1, 2011, and before October 1, 2012. For wage index purposes, we refer to cost reports during this period as the “FY 2012 cost report,” the “FY 2012 wage data,” or the “FY 2012 data.” Instructions for completing the wage index sections of Worksheet S-3 are included in the Provider Reimbursement Manual (PRM), Part 2 (Pub. No. 15-2), Chapter 40, Sections 4005.2 through 4005.4. The data file used to construct the FY 2016 wage index includes FY 2012 data submitted to us as of June 29, 2015. As in past years, we performed an extensive review of the wage data, mostly through the use of edits designed to identify aberrant data.

We asked our MACs to revise or verify data elements that result in specific edit failures. For the proposed FY 2016 wage index, we identified and excluded 93 providers with aberrant data that should not be included in the wage index. We stated in the FY 2016 IPPS/LTCH PPS proposed rule that if data elements for some of these providers with aberrant data are corrected, we intended to include data from those providers in the final FY 2016 wage index (80 FR 24464). We also adjusted certain aberrant data elements within a provider’s data and included these data in the proposed wage index.
For example, in situations where a hospital did not have documentable salaries, wages, and hours for contract housekeeping and dietary services, we imputed estimates, in accordance with established policies as discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49965 through 49967). We stated that we intended to resolve all unresolved data elements by the date the FY 2016 IPPS/LTCH PPS final rule is issued. The revised data are reflected in this FY 2016 IPPS/LTCH PPS final rule.

As a result of further review by the MACs and the April and June appeals processes, we received corrected data or improved documentation for 34 hospitals, and therefore, we are including these 34 hospitals in the final FY 2016 wage index. The hospitals that are excluded from the wage index remain excluded for a variety of reasons, such as, but not limited to, unresponsiveness to requests for documentation or insufficiently documented data, terminated hospitals’ failed edits for reasonableness, or low Medicare utilization.

In constructing the proposed FY 2016 wage index, we included the wage data for facilities that were IPPS hospitals in FY 2012, inclusive of those facilities that have since terminated their participation in the program as hospitals, as long as those data did not fail any of our edits for reasonableness. We believe that including the wage data for these hospitals is, in general, appropriate to reflect the economic conditions in the various labor market areas during the relevant past period and to ensure that the current wage index represents the labor market area’s current wages as compared to the national average of wages. However, we excluded the wage data for CAHs as discussed in the FY 2004 IPPS final rule (68 FR 45397 through 45398). For the FY 2016 IPPS/LTCH
PPS proposed rule, we removed 12 hospitals that converted to CAH status on or after February 13, 2014, the cut-off date for CAH exclusion from the FY 2015 wage index, and through and including February 5, 2015, the cut-off date for CAH exclusion from the FY 2016 wage index. After issuance of the proposed rule, we learned of one more hospital that converted to CAH status on or after February 13, 2014, and through and including February 5, 2015. Therefore, for this FY 2016 IPPS/LTCH PPS final rule, we removed a total of 13 CAHs that converted to CAH status on or after February 13, 2014, and through and including February 5, 2015. After removing hospitals with aberrant data and hospitals that converted to CAH status, we calculated the final FY 2016 wage index based on 3,362 hospitals.

For the final FY 2016 wage index, we allotted the wages and hours data for a multicampus hospital among the different labor market areas where its campuses are located in the same manner that we allotted such hospitals’ data in the FY 2015 wage index (79 FR 49964). Table 2, which contains the final FY 2016 wage index associated with this final rule (available via the Internet on the CMS Web site), includes separate wage data for the campuses of 8 multicampus hospitals. (We note that, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24464), we indicated that the proposed Table 2 includes separate wage data for the campuses of 7 multicampus hospitals. At the time of the development of the proposed rule, we were unaware of one additional multicampus hospital. We have included this eighth multicampus hospital in the FY 2016 final wage index.)
Comment: Commenters disagreed with the exclusion of certain hospitals’ data from the FY 2016 wage index public use files (PUFs) and requested that these hospitals be included in the FY 2016 final rule. The commenters asked for transparency and disclosure of criteria for these hospitals’ exclusion. They noted that the number of hospitals excluded from the wage index has risen over past years and that it is especially important for CMS to make decisions in a reasoned, consistent, and transparent manner because the entire CBSAs’ average hourly wages are impacted by deleting one hospital with a higher average hourly wage. The commenters noted that 93 hospitals were deleted from the FY 2016 proposed wage index, as compared to only 49 hospitals that were deleted from the FY 2015 proposed wage index. The commenters questioned CMS’ statutory authority to exclude data from hospitals with higher than average labor costs, and argued that section 1886(d)(3)(E) of the Act cannot be read to support the agency’s position that it has the discretion to delete certain hospitals from the PUF if they have extremely high labor costs. The commenters asserted that removal of these hospitals’ data is “arbitrary and capricious” and an “abuse of discretion.” The commenters also asserted that CMS should prove that a hospital’s costs are abnormal, and argued that, without giving hospitals advanced notice or guidance through a notice and public comment process as to what would make their costs qualify as “excessive” or “unusual,” hospitals cannot modify their practices to avoid such a determination. The commenters further reasoned that CMS’ decision to exclude certain hospitals’ data undermines the MAC desk review process, and therefore, it is inappropriate to ask hospitals to defend their data post-audit.
One commenter representing hospitals located in CBSA 46140, where a hospital was excluded due to having a very high average hourly wage relative to the CBSA, disagreed with the removal of the wage data of that hospital from the FY 2015 and FY 2016 wage indexes, and argued that “if CMS were to adopt a policy of excluding the hospital with the highest wage data from each CBSA, fairness would require that CMS also exclude the hospital with the lowest wage data from each CBSA.” The commenter stated that hospitals are aware of no such CMS policy.

Commenters asked for improved CMS communication with hospitals, including enlisting the MACs to notify hospitals in writing if the hospitals are excluded from the PUF, the criteria used to determine whether a hospital was excluded, and the procedures that a hospital may use to ask for reconsideration. The commenters also suggested that MACs be directed to notify State hospital associations not only when hospitals do not respond during the desk review, but also when there are efforts underway to correct hospitals’ aberrant data.

Response: Section 1886(d)(3)(E) of the Act requires the Secretary to adjust the proportion of hospitals’ costs attributable to wages and wage-related costs for area differences reflecting the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level. We believe that, under this section of the Act, we have discretion to exclude aberrant hospital data from the wage index PUFs to help ensure that the costs attributable to wages and wage-related costs in fact reflect the relative hospital wage level in the hospitals’ geographic area.
Since the origin of the IPPS, the wage index has been subject to its own annual review process, first by the MACs, and then by CMS. Hospitals are aware that both the MACs (via instructions issued by CMS) and CMS evaluate the accuracy and reasonableness of hospitals’ wage index data, and hospitals may appeal to CMS as part of the April and June appeals processes. As a standard practice, after each annual desk review, CMS reviews the results of the MACs’ desk reviews and focuses on items flagged during the desk review, requiring that the MACs and, if necessary, hospitals provide additional documentation, adjustments, or corrections to the data. Each year, in the IPPS proposed rules, we discuss the process wherein CMS asks the MACs to “revise or verify data elements that result in specific edit failures” (80 FR 24464). In the FY 2016 IPPS/LTCH PPS proposed rule, similar to the proposed rules of prior years, we stated that we included the wage data for facilities that were IPPS hospitals in FY 2012, inclusive of those facilities that have since terminated their participation in the program as hospitals, as long as those data did not fail any of our edits for reasonableness. We believe that including the wage data for these hospitals is appropriate, in general, to reflect the various labor market areas during the relevant past period and to ensure that the current wage index represents the labor market area’s current wages as compared to the national average of wages (80 FR 24464). That is, a hospital is included in the wage index if its data are reasonable, regardless of whether the hospital is open or whether it has terminated after the relevant past period, because the wage index is constructed to represent the relative average hourly wage for each labor market area in that past period. Thus, reasonableness and relativity to each area’s average hourly wages have been
longstanding tenets of the wage index development process that CMS has articulated in rulemaking.

We disagree with the commenters that removing hospitals from the FY 2016 wage index PUFs was arbitrary and undermined the MAC desk review process because, as discussed above, as a standard part of the refinement of the annual wage index, CMS evaluates the wage data for both accuracy and reasonableness to ensure that the wage index is a relative measure of the labor value provided to a typical hospital in a particular labor market area. As part of this evaluation process, it is CMS, not the MACs, that makes the decisions to include or exclude a hospital’s data from the wage index, and it would not be appropriate for CMS to make such decisions prior to a desk review being performed. The commenters seem to indicate that only hospitals with high average hourly wages were removed from the PUFs, noting that 93 hospitals were deleted from the FY 2016 proposed wage index, as compared to only 49 hospitals that were deleted from the FY 2015 proposed wage index. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24464), we stated that “For the proposed FY 2016 wage index, we identified and excluded 93 providers with aberrant data that should not be included in the proposed wage index. If data elements for some of these providers with aberrant data are corrected, we intended to include data from those providers in the final FY 2016 wage index” (emphasis added). We note that we never anticipated that the data of all 93 hospitals would be corrected; we only anticipated that the data of some of those hospitals would be corrected. This is because approximately 50 hospitals were deleted from the FY 2016 proposed wage index for reasons that would make their data unresolvable, such
as, but not limited to, termination (during or since the relevant past period), low/no Medicare utilization, being a CAH, or not reporting any wage data. Thus, “aberrant” hospitals are not limited to only hospitals that fail edits for reasonableness, but also include hospitals whose data are unresolvable. In fact, the number of hospitals deleted from the February or May 2015 PUFs due to having an extraordinarily high average hourly wage (and no other significant edit failures) was a small percentage of the 93 excluded hospitals (11.8 percent). Approximately 40 hospitals excluded from the February 2015 PUF had the potential to improve their data and be included in the May 2015 PUF and/or the final rule wage index. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49964), we stated that “For the proposed FY 2015 wage index, we stated that we identified and excluded 50 providers with aberrant data that should not be included in the wage index, although we stated that if data elements are corrected, we intended to include data from those providers in the final FY 2015 wage index (79 FR 28064). We have since determined that we had only removed 49, not 50, providers with aberrant data from the proposed wage index.” In an effort to avoid a similar miscounting of deleted hospitals for the FY 2016 proposed rule, we specified the total universe of deleted hospitals (93)--not just the number of hospitals with aberrant data which we anticipated would be able to be corrected as we had done for FY 2015. Essentially, the group of approximately 40 hospitals that were excluded during the development of the FY 2016 wage index and had the potential to improve their data is analogous to the 49 hospitals that were excluded from the FY 2015 proposed rule). As we stated earlier, we received corrected data or improved documentation for 34 hospitals. Therefore, we are including
these 34 hospitals in the final FY 2016 wage index. Furthermore, of those hospitals with high average hourly wages that did object to their exclusion from the proposed wage index by submitting an April appeal or a public comment letter, we have determined that only 5 hospitals would remain out of the final FY 2016 wage index. This demonstrates the effectiveness of our process--hospitals were included in final wage index because these hospitals were responsive to the MACs’ and CMS’ requests for sufficient documentation to improve their data. Consequently, the vast majority of hospitals whose data were excluded from the proposed wage index but had the potential to improve their data are included in the FY 2016 final wage index. We believe the final wage index is all the more accurate as a result.

Regarding the particular hospital in CBSA 46140 to which one commenter referred, while the hospital’s wage data were properly documented, the hospital does not merely have the highest average hourly wage in the CBSA; its average hourly wage is extremely and unusually high, significantly higher than the next highest average hourly wage in that CBSA and in the surrounding areas. We do not believe that the average hourly wage of this particular hospital accurately reflects the economic conditions in its labor market area during the FY 2012 cost reporting period. Therefore, its inclusion in the wage index would not ensure that the FY 2016 wage index represents the labor market area’s current wages as compared to the national average of wages. Rather, its inclusion would distort the average hourly wage of its labor market area. Accordingly, we have exercised our discretion to remove this hospital’s wage data from the FY 2016 wage index.
Furthermore, just as CMS has excluded certain hospitals from the wage index with extraordinarily high average hourly wages relative to their labor market areas, CMS also has excluded hospitals with extraordinarily low average hourly wages relative to their labor market areas. An objective comparison of the hospitals included in the FY 2016 preliminary PUF to the hospitals included in the February and May 2015 PUFs demonstrates CMS’ “fairness” in evaluating the appropriateness and relativity of the wage data of hospitals with both extraordinarily low and extraordinarily high average hourly wages. While 5 hospitals with high extraordinarily high average hourly wages remain excluded from the FY 2016 final wage index, 14 hospitals with extraordinarily low average hourly wages also remain excluded from the FY 2016 final wage index. Therefore, we disagree with commenters’ assertions that we have been “arbitrary and capricious” and have “abused” our discretion in excluding hospitals from the wage index.

Regarding the commenters’ requests for notification of exclusion from the PUFs, such a notification process already exists. Each time a PUF is posted, CMS instructs the MACs to send letters to each of their hospitals notifying and instructing them to review their wage index data that were just posted. Hospitals that review each PUF and observe that they are excluded may then submit an April appeal to CMS, and/or contact CMS and the MAC to discuss possible ways to revise or verify their data for inclusion in the wage index. We believe the established annual wage index timetable grants sufficient time for hospitals to review, appeal, and/or correct their data. We also welcome State hospital associations to be more proactive in the process of urging their constituents to be responsive to the MACs’ and CMS’ requests for documentation and to become more
involved in resolving issues related to aberrant data. We acknowledge the commenters’ suggestions for increased transparency, disclosure of criteria for hospitals’ exclusion, and improving awareness both at the State hospital association level and the hospital level. We note that it has never been CMS’ policy to disclose audit protocol. However, in the future, we may consider a limited proposal regarding criteria for excluding a hospital’s data from the wage index due to its overall average hourly wage being either too high or too low, as well as utilizing additional methods of communicating with stakeholders regarding the adequacy of their wage data.

D. Method for Computing the FY 2016 Unadjusted Wage Index

The method used to compute the FY 2016 wage index without an occupational mix adjustment follows the same methodology that we used to compute the FY 2012, FY 2013, FY 2014, and FY 2015 final wage indexes without an occupational mix adjustment (76 FR 51591 through 51593, 77 FR 53366 through 53367, 78 FR 50587 through 50588, and 79 FR 49967, respectively).

As discussed in the FY 2012 IPPS/LTCH PPS final rule, in “Step 5,” for each hospital, we adjust the total salaries plus wage-related costs to a common period to determine total adjusted salaries plus wage-related costs. To make the wage adjustment, we estimate the percentage change in the employment cost index (ECI) for compensation for each 30-day increment from October 14, 2011, through April 15, 2013, for private industry hospital workers from the BLS’ Compensation and Working Conditions. We have consistently used the ECI as the data source for our wages and salaries and other price proxies in the IPPS market basket, and as we discussed in the proposed rule
(80 FR 24464 through 24465), we are not making any changes to the usage for the FY 2016 wage index in this final rule. The factors used to adjust the hospital’s data were based on the midpoint of the cost reporting period, as indicated in the following table.

**MIDPOINT OF COST REPORTING PERIOD**

<table>
<thead>
<tr>
<th>After</th>
<th>Before</th>
<th>Adjustment Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/14/2011</td>
<td>11/15/2011</td>
<td>1.02167</td>
</tr>
<tr>
<td>11/14/2011</td>
<td>12/15/2011</td>
<td>1.02029</td>
</tr>
<tr>
<td>12/14/2011</td>
<td>01/15/2012</td>
<td>1.01893</td>
</tr>
<tr>
<td>01/14/2012</td>
<td>02/15/2012</td>
<td>1.01756</td>
</tr>
<tr>
<td>02/14/2012</td>
<td>03/15/2012</td>
<td>1.01620</td>
</tr>
<tr>
<td>03/14/2012</td>
<td>04/15/2012</td>
<td>1.01484</td>
</tr>
<tr>
<td>04/14/2012</td>
<td>05/15/2012</td>
<td>1.01348</td>
</tr>
<tr>
<td>05/14/2012</td>
<td>06/15/2012</td>
<td>1.01213</td>
</tr>
<tr>
<td>06/14/2012</td>
<td>07/15/2012</td>
<td>1.01080</td>
</tr>
<tr>
<td>07/14/2012</td>
<td>08/15/2012</td>
<td>1.00951</td>
</tr>
<tr>
<td>08/14/2012</td>
<td>09/15/2012</td>
<td>1.00825</td>
</tr>
<tr>
<td>09/14/2012</td>
<td>10/15/2012</td>
<td>1.00699</td>
</tr>
<tr>
<td>10/14/2012</td>
<td>11/15/2012</td>
<td>1.00568</td>
</tr>
<tr>
<td>11/14/2012</td>
<td>12/15/2012</td>
<td>1.00433</td>
</tr>
<tr>
<td>12/14/2012</td>
<td>01/15/2013</td>
<td>1.00292</td>
</tr>
<tr>
<td>01/14/2013</td>
<td>02/15/2013</td>
<td>1.00148</td>
</tr>
<tr>
<td>02/14/2013</td>
<td>03/15/2013</td>
<td>1.00000</td>
</tr>
<tr>
<td>03/14/2013</td>
<td>04/15/2013</td>
<td>0.98259</td>
</tr>
</tbody>
</table>

For example, the midpoint of a cost reporting period beginning January 1, 2012, and ending December 31, 2012, is June 30, 2012. An adjustment factor of 1.01080 would be applied to the wages of a hospital with such a cost reporting period.

Using the data as described above, the FY 2016 national average hourly wage (unadjusted for occupational mix) is $40.2911. The FY 2016 Puerto Rico overall average hourly wage (unadjusted for occupational mix) is $16.9153.
E. Occupational Mix Adjustment to the FY 2016 Wage Index

As stated earlier, section 1886(d)(3)(E) of the Act provides for the collection of data every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program, in order to construct an occupational mix adjustment to the wage index, for application beginning October 1, 2004 (the FY 2005 wage index). The purpose of the occupational mix adjustment is to control for the effect of hospitals’ employment choices on the wage index. For example, hospitals may choose to employ different combinations of registered nurses, licensed practical nurses, nursing aides, and medical assistants for the purpose of providing nursing care to their patients. The varying labor costs associated with these choices reflect hospital management decisions rather than geographic differences in the costs of labor.

1. Development of Data for the FY 2016 Occupational Mix Adjustment Based on the 2013 Medicare Wage Index Occupational Mix Survey

As provided for under section 1886(d)(3)(E) of the Act, we collect data every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program.

As discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49967 through 49968), the occupational mix adjustment to the FY 2015 wage index was based on data collected on the 2010 Occupational Mix Survey Hospital Reporting Form (CMS-10079 (2010)). For the FY 2016 wage index, we proposed to use the occupational mix data collected on the most recent 2013 occupational mix survey to compute the occupational
mix adjustment for FY 2016, as discussed in section II.B.2. of the preamble of this final rule.

We did not receive any public comments on this proposal. Therefore, we are finalizing our policy to use the occupational mix data collected on the 2013 survey to compute the occupational mix adjustment for FY 2016. We are including data for 3,135 hospitals that also have wage data included in the FY 2016 wage index.

2. Use of 2013 Occupational Mix Survey for the FY 2016 Wage Index

Section 304(c) of Pub. L. 106-554 amended section 1886(d)(3)(E) of the Act to require CMS to collect data every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program. We collected data in 2010 to compute the occupational mix adjustment for the FY 2013, FY 2014, and FY 2015 wage index. Therefore, we were required to collect data in 2013 and are using these data to compute the occupational mix adjustment for the FY 2016 wage index. We also plan to use the 2013 survey data for the FY 2017 and FY 2018 wage indexes. A new measurement of occupational mix will be required for FY 2019.

On December 7, 2012, we published in the Federal Register a notice soliciting comments on the proposed 2013 Medicare Wage Index Occupational Mix Survey (77 FR 73032 through 73033). The new 2013 survey (which we note was used for the proposed FY 2016 wage index) includes the same data elements and definitions as the 2010 survey and provides for the collection of hospital-specific wages and hours data for nursing employees for calendar year 2013 (that is, payroll periods ending between January 1, 2013 and December 31, 2013). The comment period for the notice ended on
February 5, 2013. After considering the public comments that we received on the December 2012 notice, we made a few minor editorial changes and published the 2013 survey in the Federal Register on February 28, 2013 (78 FR 13679 through 13680). This survey was approved by OMB on May 14, 2013, and is available on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Downloads/wage-index-occupational-mix-survey2013.pdf.

The 2013 Occupational Mix Survey Hospital Reporting Form CMS-10079 for the Wage Index Beginning FY 2016 (in Excel format) is available on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/Medicare-Wage-Index-Occupational-Mix-Survey2013.html. Hospitals were required to submit their completed 2013 surveys to their MACs by July 1, 2014. The preliminary, unaudited 2013 survey data were posted on the CMS Web site on July 11, 2014.

As with the Worksheet S-3, Parts II and III cost report wage data, we asked our MACs to revise or verify data elements in hospitals’ occupational mix surveys that result in certain edit failures. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24465), we stated that certain surveys with aberrant data elements were excluded from the proposed FY 2016 wage index, but any data elements resolved and revised in time to be included in the final wage index would be reflected in the FY 2016 IPPS/LTCH PPS final rule.
3. Calculation of the Occupational Mix Adjustment for FY 2016

For FY 2016, we proposed to calculate the occupational mix adjustment factor using the same methodology that we used for the FY 2012, FY 2013, FY 2014, and FY 2015 wage indexes (76 FR 51582 through 51586, 77 FR 53367 through 53368, 78 FR 50588 through 50589, and 79 FR 49968, respectively). Because the statute requires that the Secretary measure the earnings and paid hours of employment by occupational category not less than once every 3 years, all hospitals that are subject to payments under the IPPS, or any hospital that would be subject to the IPPS if not granted a waiver, must complete the occupational mix survey, unless the hospital has no associated cost report wage data that are included in the FY 2016 wage index. For the FY 2016 wage index, because we are using the Worksheet S-3, Parts II and III wage data of 3,362 hospitals, and we are using the occupational mix surveys of 3,135 hospitals for which we also have Worksheet S-3 wage data, that represents a “response” rate of 93.2 percent (3,135/3,362). In the FY 2016 wage index established in this final rule, we applied proxy data for noncompliant hospitals, new hospitals, or hospitals that submitted erroneous or aberrant data in the same manner that we applied proxy data for such hospitals in the FY 2012 wage index occupational mix adjustment (76 FR 51586).

In the FY 2011 IPPS/LTCH PPS proposed rule and final rule (75 FR 23943 and 75 FR 50167, respectively), we stated that, in order to gain a better understanding of why some hospitals are not submitting the occupational mix data, we will require hospitals that do not submit occupational mix data to provide an explanation for not complying. This requirement was effective for the 2013 occupational mix survey as well as the 2010
occupational mix survey. We instructed MACs to continue gathering this information as part of the FY 2016 wage index desk review process. We stated that we would review these data for future analysis and consideration of potential penalties for noncompliant hospitals.

**Comment:** One commenter stated that all hospitals should be obligated to submit the occupational mix survey because failure to complete the survey jeopardizes the accuracy of the wage index. The commenter added that a penalty should be instituted for nonsubmitters. The same commenter also requested that, pending CMS’ analysis of the Commuting Based Wage Index and given the Institute of Medicine’s study on geographic variation in hospital wage costs, CMS eliminate the occupational mix survey and the significant reporting burden it creates.

**Response:** We appreciate the commenter’s concern for the accuracy of the wage index. We have continually requested that all hospitals complete and submit the occupational mix surveys. We did not propose a particular penalty for hospitals that did not submit the 2013 occupational mix survey, but we are continuing to consider for future rulemaking various options for ensuring full compliance. Regarding the commenter’s request that CMS eliminate the survey due to the burden it creates, section 1886(d)(3)(E) of the Act requires us to measure the earnings and paid hours of employment by occupational category. As long as this statutory requirement remains in place, there may be some amount of administrative burden involved in reporting these data.

After consideration of public comments we received, we are calculating the occupational mix adjustment factor using the same methodology that we used for the
FY 2012, FY 2013, FY 2014, and FY 2015 wage indexes. As a result of applying this methodology, the FY 2016 occupational mix adjusted national average hourly wage is $40.2555. The FY 2016 occupational mix adjusted Puerto Rico-specific average hourly wage is $16.8711.

F. Analysis and Implementation of the Occupational Mix Adjustment and the FY 2016 Occupational Mix Adjusted Wage Index

As discussed in section III.E. of the preamble of this final rule, for FY 2016, we apply the occupational mix adjustment to 100 percent of the FY 2016 wage index. We calculated the occupational mix adjustment using data from the 2013 occupational mix survey data, using the methodology described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51582 through 51586).

Using the occupational mix survey data and applying the occupational mix adjustment to 100 percent of the FY 2016 wage index results in a national average hourly wage of $40.2555 and a Puerto Rico specific average hourly wage of $16.8711. After excluding data of hospitals that either submitted aberrant data that failed critical edits or that did not have FY 2012 Worksheet S-3, Parts II and III, cost report data for use in calculating the FY 2016 wage index, we calculated the FY 2016 wage index using the occupational mix survey data from 3,135 hospitals. For the FY 2016 wage index, we are using the Worksheet S-3, Parts II and III wage data of 3,362 hospitals, and we are using the occupational mix survey data of 3,135 hospitals for which we also have Worksheet S-3 wage data. The FY 2016 national average hourly wages for each occupational mix
nursing subcategory as calculated in Step 2 of the occupational mix calculation are as follows:

<table>
<thead>
<tr>
<th>Occupational Mix Nursing Subcategory</th>
<th>Average Hourly Wage</th>
</tr>
</thead>
<tbody>
<tr>
<td>National RN</td>
<td>38.823902202</td>
</tr>
<tr>
<td>National LPN and Surgical Technician</td>
<td>22.767361175</td>
</tr>
<tr>
<td>National Nurse Aide, Orderly, and Attendant</td>
<td>15.955866208</td>
</tr>
<tr>
<td>National Medical Assistant</td>
<td>18.006207097</td>
</tr>
<tr>
<td>National Nurse Category</td>
<td>32.875956041</td>
</tr>
</tbody>
</table>

The national average hourly wage for the entire nurse category as computed in Step 5 of the occupational mix calculation is $32.875956041. Hospitals with a nurse category average hourly wage (as calculated in Step 4 of the occupational mix calculation) of greater than the national nurse category average hourly wage receive an occupational mix adjustment factor (as calculated in Step 6 of the occupational mix calculation) of less than 1.0. Hospitals with a nurse category average hourly wage (as calculated in Step 4 of the occupational mix calculation) of less than the national nurse category average hourly wage receive an occupational mix adjustment factor (as calculated in Step 6 of the occupational mix calculation) of greater than 1.0.

Based on the 2013 occupational mix survey data, we determined (in Step 7 of the occupational mix calculation) that the national percentage of hospital employees in the nurse category is 42.62 percent, and the national percentage of hospital employees in the all other occupations category is 57.38 percent. At the CBSA level, the percentage of hospital employees in the nurse category ranged from a low of 25.65 percent in one CBSA to a high of 73.52 percent in another CBSA.
The FY 2016 Puerto Rico-specific average hourly wages for each occupational mix nursing subcategory as calculated in Step 2 of the occupational mix calculation are as follows:

<table>
<thead>
<tr>
<th>Occupational Mix Nursing Subcategory</th>
<th>Puerto Rico Average Hourly Wage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Puerto Rico RN</td>
<td>16.686558980</td>
</tr>
<tr>
<td>Puerto Rico LPN and Surgical Technician</td>
<td>10.308310116</td>
</tr>
<tr>
<td>Puerto Rico Nurse Aide, Orderly, and Attendant</td>
<td>9.695410146</td>
</tr>
<tr>
<td>Puerto Rico Medical Assistant</td>
<td>21.962356196</td>
</tr>
<tr>
<td>Puerto Rico Nurse Category</td>
<td>14.491916770</td>
</tr>
</tbody>
</table>

Based on the 2013 occupational mix survey data, we determined (in Step 7 of the occupational mix calculation) that the Puerto Rico percentage of hospital employees in the nurse category is 50.97 percent, and the Puerto Rico percentage of hospital employees in the all other occupations category is 49.03 percent.

We also compared the FY 2016 wage data adjusted for occupational mix from the 2013 survey to the FY 2016 wage data adjusted for occupational mix from the 2010 survey. This analysis illustrates the effect on area wage indexes of using the 2013 survey data compared to the 2010 survey data; that is, it shows whether hospitals’ wage indexes will increase or decrease under the 2013 survey data as compared to the prior 2010 survey data. Of the 407 urban CBSAs and 47 rural CBSAs, our analysis shows that the FY 2016 wage index values for 185 (45.5 percent) urban areas and 19 (40.4 percent) rural areas will increase. Forty-eight (11.8 percent) urban areas will increase by greater than or equal to 1 percent but less than 5 percent, and 5 (1.2 percent) urban areas will increase by 5 percent or more. Five (10.6 percent) rural areas will increase by greater than or equal
to 1 percent but less than 5 percent, and no rural areas will increase by 5 percent or more. However, the wage index values for 218 (53.6 percent) urban areas and 27 (57.4 percent) rural areas will decrease using the 2013 survey data. Seventy-four (18.2 percent) urban areas will decrease by greater than or equal to 1 percent but less than 5 percent, and one (0.2 percent) urban area will decrease by 5 percent or more. Eight (17.0 percent) rural areas will decrease by greater than or equal to 1 percent but less than 5 percent, and no rural areas will decrease by 5 percent or more. The largest positive impacts using the 2013 survey data compared to the 2010 survey data are 15.1 percent for an urban area and 3.8 percent for a rural area. The largest negative impacts are 5.0 percent for an urban area and 1.95 percent for two rural areas. Four urban areas and one rural area will be unaffected. These results indicate that the wage indexes of more CBSAs overall (54.0 percent) will decrease due to application of the 2013 occupational mix survey data as compared to the 2010 occupational mix survey data to the wage index. Further, a larger percentage of urban areas (45.5 percent) will benefit from the use of the 2013 occupational mix survey data as compared to the 2010 occupational mix survey data than will rural areas (40.4 percent).

We compared the FY 2016 occupational mix adjusted wage indexes for each CBSA to the unadjusted wage indexes for each CBSA. As a result of applying the occupational mix adjustment to the wage data, the wage index values for 219 (53.8 percent) urban areas and 24 (51.1 percent) rural areas will increase. One hundred three (25.3 percent) urban areas will increase by greater than or equal to 1 percent but less than 5 percent, and 6 (1.5 percent) urban areas will increase by 5 percent or more.
Nine (19.1 percent) rural areas will increase by greater than or equal to 1 percent but less than 5 percent, and no rural areas will increase by 5 percent or more. However, the wage index values for 187 (45.9 percent) urban areas and 23 (48.9 percent) rural areas will decrease. Ninety-one (22.4 percent) urban areas will decrease by greater than or equal to 1 percent but less than 5 percent, and no urban areas will decrease by 5 percent or more. Seven (14.9 percent) rural areas will decrease by greater than or equal to 1 percent but less than 5 percent, and no rural areas will decrease by 5 percent or more. The largest positive impacts will be 17.4 percent for an urban area and 2.7 percent for one rural area. The largest negative impacts will be 4.7 percent for an urban area and 2.1 percent for a rural area. One urban area will remain unchanged by application of the occupational mix adjustment, and no rural areas will remain unchanged by application of the occupational mix adjustment. These results indicate that a larger percentage of urban areas (53.8 percent) will benefit from application of the occupational mix adjustment than will rural areas (51.1 percent).

G. Transitional Wage Indexes

1. Background

As we stated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24467 through 24469), in the FY 2015 IPPS/LTCH PPS proposed rule and final rule (79 FR 28060 and 49957, respectively), we stated that, overall, we believed implementing the new OMB labor market area delineations would result in wage index values being more representative of the actual costs of labor in a given area. However, we recognized that some hospitals would experience decreases in wage index values as a
result of the implementation of these new OMB labor market area delineations. We also
realized that some hospitals would have higher wage index values due to the
implementation of the new OMB labor market area delineations.

The FY 2015 IPPS/LTCH PPS final rule (79 FR 49957) explained the
methodology utilized in implementing prior transition periods when adopting changes
that have significant payment implications, particularly large negative impacts.
Specifically, for FY 2005, in the FY 2005 IPPS final rule (69 FR 49032 through 49034),
we provided transitional wage indexes when the OMB definitions were implemented
after the 2000 Census. The FY 2015 IPPS/LTCH PPS final rule (79 FR 49957 through
49962) established similar transition methodologies to mitigate any negative payment
impacts experienced by hospitals due to our adoption of the new OMB labor market area
delineations for FY 2015.

As finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49957 through
49960) and as discussed below, for FY 2016, we are in the second year of two 3-year
transition periods for wage index: one for hospitals that, for FY 2014, were located in an
urban county that became rural under the new OMB delineations, and had no form of
wage index reclassification or redesignation in place for FY 2015 (that is, MGCRB
reclassifications under section 1886(d)(10) of the Act, redesignations under section
1886(d)(8)(B) of the Act, or rural reclassifications under section 1886(d)(8)(E) of the
Act); and one for hospitals deemed urban under section 1886(d)(8)(B) of the Act where
the urban area became rural under the new OMB delineations. In addition, the 1-year
transition that we applied in FY 2015 for hospitals that experienced a decrease in wage
index under the new OMB delineations expires at the end of FY 2015 and does not apply in FY 2016.

2. Transition for Hospitals in Urban Areas That Became Rural

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49957 through 49959), for hospitals that, for FY 2014, were located in an urban county that became rural under the new OMB delineations, and had no form of wage index reclassification or redesignation in place for FY 2015 (that is, MGCRB reclassifications under section 1886(d)(10) of the Act, redesignations under section 1886(d)(8)(B) of the Act, or rural reclassifications under section 1886(d)(8)(E) of the Act), we adopted a policy to assign them the urban wage index value of the CBSA in which they are physically located for FY 2014 for a period of 3 fiscal years (with the rural and imputed floors applied and with the rural floor budget neutrality adjustment applied to the area wage index). FY 2016 will represent the second year of this transition policy, and we did not propose any changes to this policy in the FY 2016 IPPS/LTCH PPS proposed rule. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49957), we stated our belief that it is appropriate to apply a 3-year transition period for hospitals located in urban counties that would become rural under the new OMB delineations, given the potentially significant payment impacts for these hospitals. We continue to believe that assigning the wage index of the hospitals’ FY 2014 area for a 3-year transition is the simplest and most effective method for mitigating negative payment impacts due to the adoption of the new OMB delineations.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR49959), we noted that there were situations where a hospital could not be assigned the wage index value of the CBSA
in which it geographically was located in FY 2014 because that CBSA split and no longer exists and some or all of the constituent counties were added to another urban labor market area under the new OMB delineations. If the hospital could not be assigned the wage index value of the CBSA in which it was geographically located in FY 2014 because that CBSA split apart and no longer exists, and some or all of its constituent counties were added to another urban labor market area under the new OMB delineations, we established that hospitals located in such counties that became rural under the new OMB delineations were assigned the wage index of the urban labor market area that contains the urban county in their FY 2014 CBSA to which they are closest (with the rural and imputed floors applied and with the rural floor budget neutrality adjustment applied). Any such assignment made in FY 2015 will continue for FYs 2016 and 2017, except as discussed below. We continue to believe this approach minimizes the negative effects of the change in the OMB delineations.

Under the policy adopted in the FY 2015 IPPS/LTCH PPS final rule, if a hospital for FY 2014 was located in an urban county that became rural for FY 2015 under the new OMB delineations and such hospital sought and was granted reclassification or redesignation for FY 2015 or such hospital seeks and is granted any reclassification or redesignation for FY 2016 or FY 2017, the hospital will permanently lose its 3-year transitional assigned wage index status, and will not be eligible to reinstate it. We established the transition policy to assist hospitals if they experience a negative payment impact specifically due to the adoption of the new OMB delineations in FY 2015. If a hospital chooses to forego this transition adjustment by obtaining some form of
reclassification or redesignation, we do not believe reinstatement of this transition adjustment would be appropriate. The purpose of the transition adjustment policy is to assist hospitals that may be negatively impacted by the new OMB delineations in transitioning to a wage index based on these delineations. By obtaining a reclassification or redesignation, we believe that the hospital has made the determination that the transition adjustment is not necessary because it has other viable options for mitigating the impact of the transition to the new OMB delineations.

As we did for FY 2015 (79 FR 49959), and as stated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24468), with respect to the wage index computation for FY 2016, we are following our existing policy regarding the inclusion of a hospital’s wage index data in the CBSA in which it is geographically located (we refer readers to Step 6 of the method for computing the unadjusted wage index in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51592)). Accordingly, as we began with FY 2015, for FY 2016, the wage data of all hospitals receiving this type of 3-year transition adjustment were included in the statewide rural area in which they are geographically located under the new OMB labor market area delineations. After the 3-year transition period, beginning in FY 2018, these formerly urban hospitals discussed above will receive their statewide rural wage index, absent any reclassification or redesignation.

In addition, we established in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49959) that the hospitals receiving this 3-year transition because they are in counties that were urban under the FY 2014 CBSA definitions, but are rural under the new OMB delineations, will not be considered urban hospitals. Rather, they will
maintain their status as rural hospitals for other payment considerations. This is because our application of a 3-year transitional wage index for these newly rural hospitals only applies for the purpose of calculating the wage index under our adoption of the new OMB delineations.

We did not receive any public comments on these provisions in the proposed rule.

3. Transition for Hospitals Deemed Urban under Section 1886(d)(8)(B) of the Act Where the Urban Area Became Rural under the New OMB Delineations

As stated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24468), and as discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49959 through 49960), there were some hospitals that, for FY 2014, were geographically located in rural areas but were deemed to be urban under section 1886(d)(8)(B) of the Act. For FY 2015, some of these hospitals redesignated under section 1886(d)(8)(B) of the Act were no longer eligible for deemed urban status under the new OMB delineations, as discussed in detail in section III.H.3. of the preamble of the FY 2015 IPPS/LTCH PPS final rule. Similar to the policy implemented in the FY 2005 IPPS final rule (69 FR 49059), and consistent with the FY 2015 policy we established for other hospitals in counties that were urban and became rural under the new OMB delineations, we finalized a policy to apply a 3-year transition to these hospitals redesignated to urban areas under section 1886(d)(8)(B) of the Act for FY 2014 that are no longer deemed urban under the new OMB delineations and revert to being rural.

For FY 2016, we did not propose any changes to this policy and are continuing to the second year of the implementation of our policy to provide a 3-year transition
adjustment to hospitals that are deemed urban under section 1886(d)(8)(B) of the Act under the FY 2014 labor market area delineations, but are considered rural under the new OMB delineations, assuming no other form of wage index reclassification or redesignation is granted. We assign these hospitals the area wage index value of hospitals reclassified to the urban CBSA (that is, the attaching wage index) to which they were redesignated in FY 2014 (with the rural and imputed floors applied and with the rural floor budget neutrality adjustment applied). If the hospital cannot be assigned the reclassified wage index value of the CBSA to which it was redesignated in FY 2014 because that CBSA was split apart and no longer exists, and some or all of its constituent counties were added to another urban labor market area under the new OMB delineations, such hospitals are assigned the wage index of the hospitals reclassified to the urban labor market area that contains the urban county in their FY 2014 redesignated CBSA to which they are closest. We assign these hospitals the area wage index of hospitals reclassified to a CBSA because hospitals deemed urban under section 1886(d)(8)(B) of the Act are treated as reclassified under current policy, under which such hospitals receive an area wage index that includes wage data of all hospitals reclassified to the area. This wage index assignment will be forfeited if the hospital obtains any form of wage index reclassification or redesignation.

We did not receive any public comments specific to either of the 3-year transition policies for hospitals that were located in an urban county that became rural under the new OMB delineations or for hospitals deemed urban under section 1886(d)(8)(B) of the Act where the urban area became rural under the new OMB delineations. Fiscal
year 2016 will be the second year of the 3-year transition period. We also remind hospitals that if any affected hospital is approved for any wage index reclassification or redesignation in FY 2016 or FY 2017, it will no longer be eligible for the remaining years of the transitional wage index.

4. Expiring Transition for Hospitals That Experience a Decrease in Wage Index under the New OMB Delineations

As we indicated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24468), in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49960 through 49962), we stated that, while we believe that instituting the latest OMB labor market area delineations would create a more accurate wage index system, we also recognized that implementing the latest OMB delineations may cause some short-term instability in hospital payments. Therefore, in addition to the 3-year transition adjustments for hospitals being transitioned from urban to rural status as discussed earlier, in the FY 2015 IPPS/LTCH PPS final rule, we established a 1-year blended wage index for all hospitals that would experience any decrease in their actual payment wage index. This 1-year blended wage index expires at the end of FY 2015. We did not propose any additional transition adjustment for hospitals that experienced a decrease in wage index values due to the adoption of the new OMB delineations for FY 2015 and, as discussed previously, will continue the 3-year transition adjustments for hospitals that changed from urban to rural status that we finalized in the FY 2015 IPPS/LTCH PPS final rule. We established a longer 3-year transition adjustment for hospitals losing urban status because there are significantly fewer affected urban-to-rural hospitals, and we believe the negative impacts to a hospital
shifting from urban to rural status are typically greater than other types of transitions. We stated our belief that a transition period longer than 1 year to address other impacts of the adoption of the new OMB delineations would reduce the accuracy of the overall labor market area wage index system because far more hospitals would be affected. As we stated in FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24468), the 1-year transition for all negatively affected hospitals in FY 2015 provided an opportunity for hospitals to evaluate potential reclassification options and mitigated initial negative impacts due to labor market assignment changes. We continue to believe that the adoption of the latest labor market delineations improve the accuracy and integrity of the hospital wage index system. Therefore, we believe it is necessary to allow this transition to expire.

Comment: The majority of commenters expressed appreciation to CMS for providing a transitional wage index to mitigate negative effects due to the application of the new OMB labor market delineations. They also supported CMS’ plan to discontinue the 1-year transition in FY 2016. One commenter requested that the transition period be extended for at least one additional fiscal year, with a suggested “75/25 percent” methodology to provide some support for hospitals that will continue to be negatively affected by the new OMB delineations.

Response: We appreciate the commenters’ support of the transition policies. We continue to believe that the 1-year transition for all negatively affected hospitals in FY 2015 provided an ample opportunity for hospitals to evaluate potential reclassification options, and mitigated initial negative impacts due to labor market assignment changes. Therefore, we do not believe that an extension of the transition
period is warranted. We continue to believe that the adoption of the latest labor market
delineations improves the accuracy and integrity of the hospital wage index system.

Thus, we are allowing the transition adjustment to expire at the end of FY 2015.

5. Budget Neutrality

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50372 through 50373), for
FY 2015, we applied the 3-year transition and 50/50 blended wage index adjustments in a
budget neutral manner. For FY 2016, in the FY 2016 IPPS/LTCH PPS proposed rule
(80 FR 24469), we proposed to apply the 3-year transition adjustments in a budget
neutral manner. We proposed to make an adjustment to the standardized amount to
ensure that the total payments, including the effect of the transition provisions, would
equal what payments would have been if we were not providing for any transitional wage
indexes under the new OMB delineations. For a complete discussion on the budget
neutrality adjustment for FY 2016, we refer readers to section II.A.4.b. of the Addendum
to this final rule, where we also address any public comments we received.

In this final rule, for FY 2016, we are applying the 3-year transition adjustments
in a budget neutral manner. We are making an adjustment to the standardized amount to
ensure that the total payments, including the effect of the transition provisions, will equal
what payments would have been if we were not providing for any transitional wage
indexes under the new OMB delineations

H. Application of the Rural, Imputed, and Frontier Floors

1. Rural Floor
Section 4410(a) of Pub. L. 105-33 provides that, for discharges on or after October 1, 1997, the area wage index applicable to any hospital that is located in an urban area of a State may not be less than the area wage index applicable to hospitals located in rural areas in that State. This provision is referred to as the “rural floor.” Section 3141 of Pub. L. 111-148 also requires that a national budget neutrality adjustment be applied in implementing the rural floor. Based on the final FY 2016 wage index associated with this final rule and available via the Internet on the CMS Web site, we estimated that 346 hospitals will receive an increase in their FY 2016 wage index due to the application of the rural floor.

Comment: Commenters thanked CMS for providing a State-specific analysis of the effects of nationwide budget neutrality of the rural floor required under section 3141 of the Affordable Care Act and requested additional long-term analysis of payment distortions produced by nationwide rural floor budget neutrality.

Response: We appreciate the commenters’ continued concern regarding rural floor budget neutrality. We are publishing State-specific rural floor impacts in Appendix A of this final rule and will consider additional analysis in future rulemaking.

2. Imputed Floor for FY 2016

In the FY 2005 IPPS final rule (69 FR 49109 through 49111), we adopted the “imputed floor” policy as a temporary 3-year regulatory measure to address concerns from hospitals in all-urban States that have argued that they are disadvantaged by the absence of rural hospitals to set a wage index floor for those States. Since its initial implementation, we have extended the imputed floor policy five times, the last of which
was adopted in the FY 2015 IPPS/LTCH PPS final rule and is set to expire on September 30, 2015. (We refer readers to further discussions of the imputed floor in the FY 2014 and FY 2015 IPPS/LTCH PPS final rules (78 FR 50589 through 50590 and 79 FR 49969 through 49970, respectively) and to the regulations at 42 CFR 412.64(h)(4.).) Currently, there are three all-urban States, Delaware, New Jersey, and Rhode Island, with a range of wage indexes assigned to hospitals in these States, including through reclassification or redesignation (we refer readers to discussions of geographic reclassifications and redesignations in section III.J. of the preamble of this final rule).

In computing the imputed floor for an all-urban State under the original methodology, which was established beginning in FY 2005, we calculated the ratio of the lowest-to-highest CBSA wage index for each all-urban State as well as the average of the ratios of lowest-to-highest CBSA wage indexes of those all-urban States. We then compared the State’s own ratio to the average ratio for all-urban States and whichever is higher is multiplied by the highest CBSA wage index value in the State--the product of which established the imputed floor for the State. As of FY 2012, there were only two all-urban States, New Jersey and Rhode Island, and only New Jersey benefitted under this methodology. Under the previous OMB labor market area delineations, Rhode Island had only one CBSA (Providence-New Bedford-Fall River, RI-MA) and New Jersey had 10 CBSAs. Therefore, under the original methodology, Rhode Island’s own ratio equaled 1.0, and its imputed floor was equal to its original CBSA wage index value. However, because the average ratio of New Jersey and Rhode Island was higher than
New Jersey’s own ratio, this methodology provided a benefit for New Jersey, but not for Rhode Island.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53368 through 53369), we retained the imputed floor calculated under the original methodology as discussed above, and established an alternative methodology for computing the imputed floor wage index to address the concern that the original imputed floor methodology guaranteed a benefit for one all-urban State with multiple wage indexes (New Jersey) but could not benefit the other all-urban State (Rhode Island). The alternative methodology for calculating the imputed floor was established using data from the application of the rural floor policy for FY 2013. Under the alternative methodology, we first determined the average percentage difference between the post-reclassified, pre-floor area wage index and the post-reclassified, rural floor wage index (without rural floor budget neutrality applied) for all CBSAs receiving the rural floor. (Table 2 (formerly Table 4D) associated with the FY 2013 IPPS/LTCH PPS final rule, which is available via the Internet on the CMS Web site, included the CBSAs receiving a State’s rural floor wage index.) The lowest post-reclassified wage index assigned to a hospital in an all-urban State having a range of such values then is increased by this factor, the result of which establishes the State’s alternative imputed floor. We amended § 412.64(h)(4) of the regulations to add new paragraphs to incorporate the finalized alternative methodology, and to make reference and date changes. In summary, for the FY 2013 wage index, we did not make any changes to the original imputed floor methodology at § 412.64(h)(4) and, therefore, made no changes to the New Jersey imputed floor computation for FY 2013. Instead, for
FY 2013, we adopted a second, alternative methodology for use in cases where an all-urban State has a range of wage indexes assigned to its hospitals, but the State cannot benefit under the original methodology.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50589 through 50590), we extended the imputed floor policy (both the original methodology and the alternative methodology) for 1 additional year, through September 30, 2014, while we continued to explore potential wage index reforms. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49969 through 49970), for FY 2015, we adopted a policy to extend the imputed floor policy (both the original methodology and alternative methodology) for another year, through September 30, 2015, as we continued to explore potential wage index reforms. In these final rules, we also revised the regulations at § 412.64(h)(4) and (h)(4)(vi) to reflect the extension of the imputed floor.

As discussed in section III.B. of the preamble of that FY 2015 final rule, we adopted the new OMB labor market area delineations beginning in FY 2015. Under the new OMB delineations, Delaware became an all-urban State, along with New Jersey and Rhode Island. Under the new OMB delineations, Delaware has three CBSAs, New Jersey has seven CBSAs, and Rhode Island continues to have only one CBSA (Providence-Warwick, RI-MA). We refer readers to a detailed discussion of our adoption of the new OMB labor market area delineations in section III.B. of the preamble of the FY 2015 IPPS/LTCH PPS final rule. Therefore, under the adopted new OMB delineations discussed in section III.B. of the preamble of the FY 2015 IPPS/LTCH PPS
For FY 2016, we proposed to extend the imputed floor policy (both the original methodology and the alternative methodology) for 1 additional year, through September 30, 2016, while we continue to explore potential wage index reforms (80 FR 24469 through 24470). We proposed to revise the regulations at § 412.64(h)(4) and (h)(4)(vi) to reflect this proposed additional 1-year extension. We invited public comments on the proposed additional 1-year extension of the imputed floor through September 30, 2016.

Comment: Several commenters supported the CMS proposal to extend the imputed floor for 1 year, stating that it establishes an approach to remedy the competitive disadvantage suffered by all-urban States due to several unique factors common to these areas. One commenter who supported the proposal recommended that CMS allow public input prior to finalizing any decisions regarding the imputed floor. Another commenter opposed the proposed 1-year extension, citing CMS’ previous assessment in the FY 2008 proposed rule that this type of floor should apply only when required by statute.

Response: We appreciate the commenters’ support for the proposal to extend the imputed floor for 1 year. As we have done every year since the initial proposal of the imputed floor, we provide and will continue to provide the industry with the opportunity to provide input on our proposals prior to finalizing any decisions regarding the imputed floor policy. We understand the concerns of the commenter who opposed the proposal, and will give further consideration to all comments as we continue to explore potential wage index reforms. As we stated in the FY 2005 IPPS final rule (69 FR 49110), we note
that the Secretary has broad authority under section 1886(d)(3)(E) of the Act to adjust the proportion (as estimated by the Secretary from time to time) of hospitals’ costs which are attributable to wage and wage-related cost of the DRG prospective payment rates for area differences in hospital wage levels by a factor (established by the Secretary). Therefore, we believe that we do have the discretion to adopt a policy that would adjust wage indexes in the stated manner. We adopted the imputed floor policy and subsequently extended it through notice-and-comment rulemaking to address concerns from hospitals in all-urban States.

After consideration of the public comments we received, we are finalizing our proposal without modification to extend the imputed floor policy under both the original methodology and the alternative methodology for an additional year, through September 30, 2016. We also are adopting as final the proposed revisions to §412.64(h)(4) and (h)(4)(vi) to reflect the 1-year extension of the imputed floor.

The wage index and impact tables associated with this FY 2016 IPPS/LTCH PPS final rule (which are available via the Internet on the CMS Web site) reflect the continued application of the imputed floor policy at § 412.64(h)(4) and a national budget neutrality adjustment for the imputed floor for FY 2016. There are 21 hospitals in New Jersey that will receive an increase in their FY 2016 wage index due to the continued application of the imputed floor policy under the original methodology and 4 hospitals in Rhode Island that will benefit under the alternative methodology. No hospitals in Delaware will benefit from the imputed floor under either methodology because all hospitals in the affected labor market areas will receive a higher wage index value due to reclassification.
3. State Frontier Floor

Section 10324 of Pub. L. 111-148 requires that hospitals in frontier States cannot be assigned a wage index of less than 1.0000 (we refer readers to regulations at 42 CFR 412.64(m) and to a discussion of the implementation of this provision in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50160 through 50161)). Forty-eight hospitals will receive the frontier floor value of 1.0000 for their FY 2016 wage index in this final rule. These hospitals are located in Montana, North Dakota, South Dakota, and Wyoming. Although Nevada also is defined as a frontier State, its FY 2016 rural floor value of 1.0194 is greater than 1.0000, and therefore, no Nevada hospitals will receive a frontier floor value for their FY 2016 wage index. We did not propose any changes to the frontier floor policy for FY 2016, and we did not receive any public comments on the issue.

The areas affected by the rural, imputed, and frontier floor policies for the FY 2016 wage index are identified in Table 2 (formerly Table 4D) associated with this final rule, which is available via the Internet on the CMS Web site.

I. FY 2016 Wage Index Tables

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24470), we proposed to streamline and consolidate the wage index tables associated with the IPPS proposed and final rules for FY 2016 and subsequent fiscal years. The wage index tables have consisted of 12 tables (Tables 2, 3A, 3B, 4A, 4B, 4C, 4D, 4E, 4F, 4J, 9A, and 9C) that are made available via the Internet on the CMS Web site. However, with the exception of Table 4E, we proposed to streamline and consolidate these 11 tables into 2 tables. We
refer readers to section VI. of the Addendum to this final rule for a discussion of the proposed and finalized revisions to the wage index tables.

J. Revisions to the Wage Index Based on Hospital Redesignations and Reclassifications

1. General Policies and Effects of Reclassification and Redesignation

Under section 1886(d)(10) of the Act, the MGCRB considers applications by hospitals for geographic reclassification for purposes of payment under the IPPS. Hospitals must apply to the MGCRB to reclassify not later than 13 months prior to the start of the fiscal year for which reclassification is sought (generally by September 1). Generally, hospitals must be proximate to the labor market area to which they are seeking reclassification and must demonstrate characteristics similar to hospitals located in that area. The MGCRB issues its decisions by the end of February for reclassifications that become effective for the following fiscal year (beginning October 1). The regulations applicable to reclassifications by the MGCRB are located in 42 CFR 412.230 through 412.280. (We refer readers to a discussion in the FY 2002 IPPS/LTCH PPS final rule (66 FR 39874 and 39875) regarding how the MGCRB defines mileage for purposes of the proximity requirements.) The general policies for reclassifications and redesignations that we proposed for FY 2016 and are finalizing in this final rule, and the policies for the effects of hospitals’ reclassifications and redesignations on the wage index, are the same as those discussed in the FY 2012 IPPS/LTCH PPS final rule for the FY 2012 final wage index (76 FR 51595 and 51596). In addition, in the FY 2012 IPPS/LTCH PPS final rule, we discussed the effects on the wage index of urban hospitals reclassifying to rural areas under 42 CFR 412.103. Hospitals that are geographically located in States without any
rural areas are ineligible to apply for rural reclassification in accordance with the provisions of 42 CFR 412.103.

Comment: A few commenters stated that, in cases where a countywide (group) reclassification had been previously approved by the MGCRB, a new hospital is not able to obtain the same reclassified wage index as the countywide group until the first year that individual hospital’s wage index data match one of the 3 years’ data used by the MGCRB and a new 3-year countywide reclassification is requested by the county’s hospitals (which can be a 4-year delay). The commenters were concerned that such a new hospital will have a wage index lower than the hospitals with which it competes for skilled labor. The commenters suggested that CMS change its policy to allow for a timelier competitive wage index for new hospitals. The commenters believed that there is a significant disincentive for stable hospitals to acquire other nearby facilities that are in financial distress because the “new” hospital would not be immediately eligible to participate in reclassification.

Other commenters suggested that the proximity rule for countywide reclassifications for hospitals in an urban county be modified to permit adjacent county reclassifications, regardless of whether they are in the same CSA or CBSA, or at a minimum, create an exception that would allow this in the event that half of the hospitals in the county are seeking to reclassify.

Response: We thank the commenters for their comments. We already have established criteria and processes for MGCRB reclassification, which are specified in 42 CFR 412.230 et. seq, and we did not propose any changes to these provisions for
Consequently, we are not making any changes to address the commenters’ concerns at this time. We are making a clarification in policy relating to the example cited by some commenters regarding hospitals that acquire other providers located in different labor market areas with current reclassifications, which is addressed in a response to a related comment under section III.J.2.a. of the preamble of this final rule.

2. FY 2016 MGCRB Reclassifications

a. FY 2016 Reclassification Requirements and Approvals

Under section 1886(d)(10) of the Act, the MGCRB considers applications by hospitals for geographic reclassification for purposes of payment under the IPPS. The specific procedures and rules that apply to the geographic reclassification process are specified in regulations under 42 CFR 412.230 through 412.280.

At the time this final rule was constructed, the MGCRB had completed its review of FY 2016 reclassification requests. Based on such reviews, there are 282 hospitals approved for wage index reclassifications by the MGCRB starting in FY 2016 that did not withdraw or terminate their reclassifications within 45 days of the publication of the FY 2016 proposed rule. Because MGCRB wage index reclassifications are effective for 3 years, for FY 2016, hospitals reclassified beginning in FY 2014 or FY 2015 are eligible to continue to be reclassified to a particular labor market area based on such prior reclassifications for the remainder of their 3-year period. There were 248 hospitals approved for wage index reclassifications in FY 2014 that continue for FY 2016, and 311 hospitals approved for wage index reclassifications in FY 2015 that continue for FY 2016. Of all the hospitals approved for reclassification for FY 2014, FY 2015, and
FY 2016, based upon the review at the time of this final rule, 841 hospitals are in a reclassification status for FY 2016. We note that the number of hospitals with active reclassifications changed between the proposed rule and the final rule because hospitals have the opportunity to withdraw or terminate their reclassification, or reinstate previously withdrawn reclassifications, within 45 days of the publication of the FY 2016 proposed rule.

Under the regulations at 42 CFR 412.273, hospitals are permitted to withdraw or terminate their MGCRB reclassification within 45 days of the publication of a proposed rule. For information about withdrawing, terminating, or canceling a previous withdrawal or termination of a 3-year reclassification for wage index purposes, we refer readers to 42 CFR 412.273, as well as the FY 2002 IPPS final rule (66 FR 39887 through 39888) and the FY 2003 IPPS final rule (67 FR 50065 through 50066). Additional discussion on withdrawals and terminations and clarifications regarding reinstating reclassifications and “fallback” reclassifications were included in the FY 2008 IPPS final rule (72 FR 47333).

Changes to the wage index that result from withdrawals of requests for reclassification, terminations, wage index corrections, appeals, and the Administrator’s review process for FY 2016 are incorporated into the wage index values published in this FY 2016 IPPS/LTCH PPS final rule. These changes affect not only the wage index value for specific geographic areas, but also the wage index value that redesignated/reclassified hospitals receive; that is, whether they receive the wage index that includes the data for both the hospitals already in the area and the redesignated/reclassified hospitals. Further,
the wage index value for the area from which the hospitals are redesignated/reclassified may be affected.

Comment: One commenter stated that CMS’ policy that hospitals must request to withdraw or terminate MGCRB reclassifications within 45 days of the proposed rule is problematic because a hospital could terminate a reclassification based on information in the proposed rule, and with the publication of the final rule, discover that its original reclassified status was more desirable. The commenter stated that hospitals cannot make informed decisions concerning their reclassification status based on values in a proposed rule that are likely to change and, therefore, recommended that CMS revise its existing policy to permit hospitals to withdraw or terminate their reclassification status within 45 days of the publication of the final rule.

Response: We did not make any proposals to change any of the reclassification processes or criteria for FY 2016. Any changes to the reclassification processes or criteria would need to be issued through notice-and-comment rulemaking. Consequently, we are not making any changes to address the commenter’s concerns at this time. We maintain that information provided in the proposed rule constitutes the best available data to assist hospitals in making reclassification decisions. The values published in the final rule represent the final wage index values reflective of reclassification decisions.

Comment: One commenter requested clarification of the reclassification status in the case of a Connecticut hospital that acquired another hospital in a different labor market area. According to the commenter, the acquired hospital would become a subordinate remote location of the acquiring hospital (that is, a “ multicampus” provider).
The commenter stated that the acquired hospital had individual reclassification applications approved to begin in FY 2014, 2015, and 2016, and the hospital had requested termination of the FY 2016 reclassification and reinstatement of the hospital’s FY 2015 reclassification.

Response: Our longstanding Medicare policy is to terminate reclassification status for a hospital whose CCN is no longer active because the MGCRB makes its reclassification decisions based on CCNs. We believe this policy results in more accurate reclassifications when compiling CBSA labor market wage data, as it is generally the case that hospitals that have terminated operations can no longer make timely and informed decisions regarding reclassification statuses, which could have ramifications for various wage index floors and labor market values. However, in this case, the acquiring hospital accepted the provider agreement of the acquired hospital located in a different market area, and the resulting merged hospital desires that the subordinate campus continue to receive previously approved reclassification benefits. While the original CCN for the acquired hospital would be considered “tied out” by CMS, we do believe that the acquiring hospital should be able to make determinations regarding the reclassification status of the subordinate campus located in a different labor market area if it accepted the provider agreement of that subordinate campus. Therefore, we are clarifying our wage index reclassification policy to address the specific situations where a hospital merges with or acquires another hospital located in a different labor market area, creating a “multicampus” hospital, and accepts the provider agreement of the acquired hospital. If the acquired campus (that is, the hospital whose CCN will no longer be
active) has remaining years left on a MGCRB reclassification, this reclassification status remains in effect for the subordinate campus located in a different market area. This clarification only applies to circumstances where the Medicare provider agreement is accepted by the acquiring hospital located in a different market area. We also wish to clarify that the acquiring hospital is authorized to make timely requests to terminate, withdraw, or reinstate any reclassification for the subordinate campus for any remaining years of the reclassification. We believe this policy results in more accurate labor market wage index values, and is consistent with current regulations regarding reclassification status of “multicampus” hospitals at § 412.230(d)(2)(v). Therefore, in response to the commenter, the hospital is eligible to terminate the reclassification approved to begin in FY 2016 and to reinstate a previously existing reclassification. CMS will make the appropriate adjustments to the payment systems to ensure the subordinate campus of the acquiring hospital is paid under the correct reclassification status.

b. Applications for Reclassifications for FY 2017

Applications for FY 2017 reclassifications are due to the MGCRB by September 1, 2015 (the first working day of September 2015). We note that this is also the deadline for canceling a previous wage index reclassification withdrawal or termination under 42 CFR 412.273(d). Applications and other information about MGCRB reclassifications may be obtained via the Internet on the CMS Web site at: http://cms.gov/Regulations-and-Guidance/Review-Boards/MGCRB/index.html, or by calling the MGCRB at (410) 786-1174. The mailing address of the MGCRB is: 2520 Lord Baltimore Drive, Suite L, Baltimore, MD 21244-2670.
3. Redesignation of Hospitals under Section 1886(d)(8)(B) of the Act

Section 1886(d)(8)(B)(i) of the Act requires the Secretary to treat a hospital located in a rural county adjacent to one or more urban areas as being located in the urban metropolitan statistical area to which the greatest number of workers in the county commute if certain adjacency and commuting criteria are met. The criteria utilize standards for designating Metropolitan Statistical Areas published in the *Federal Register* by the Director of the Office of Management and Budget (OMB) based on the most recently available decennial population data. Effective beginning FY 2015, we used the new OMB delineations based on the 2010 Decennial Census data to identify counties in which hospitals qualify under section 1886(d)(8)(B) of the Act to receive the wage index of the urban area. Hospitals located in these counties are referred to as “Lugar” hospitals and the counties themselves are often referred to as “Lugar” counties. The chart for this FY 2016 IPPS/LTCH PPS final rule which includes the listing of the rural counties containing the hospitals designated as urban under section 1886(d)(8)(B) of the Act is available via the Internet on the CMS Web site.

We did not receive any public comments on this listing that accompanied the FY 2016 IPPS/LTCH PPS proposed rule.
4. Waiving Lugar Redesignation for the Out-Migration Adjustment

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51599 through 51600), we adopted the policy that, beginning with FY 2012, an eligible hospital that waives its Lugar status in order to receive the out-migration adjustment has effectively waived its deemed urban status and, thus, is rural for all purposes under the IPPS, including being considered rural for the DSH payment adjustment, effective for the fiscal year in which the hospital receives the out-migration adjustment. (We refer readers to a discussion of DSH payment adjustment under section IV.D. of the preamble of this final rule.)

In addition, we adopted a minor procedural change in that rule that allows a Lugar hospital that qualifies for and accepts the out-migration adjustment (through written notification to CMS within 45 days from the publication of the proposed rule) to waive its urban status for the full 3-year period for which its out-migration adjustment is effective. By doing so, such a Lugar hospital would no longer be required during the second and third years of eligibility for the out-migration adjustment to advise us annually that it prefers to continue being treated as rural and receive the out-migration adjustment. Therefore, under the procedural change, a Lugar hospital that requests to waive its urban status in order to receive the rural wage index in addition to the out-migration adjustment would be deemed to have accepted the out-migration adjustment and agrees to be treated as rural for the duration of its 3-year eligibility period, unless, prior to its second or third year of eligibility, the hospital explicitly notifies CMS in writing, within the required period (generally 45 days from the publication of the proposed rule), that it instead elects to return to its deemed urban status.
and no longer wishes to accept the out-migration adjustment. If the hospital does notify CMS that it is electing to return to its deemed urban status, it would again be treated as urban for all IPPS payment purposes.

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51599 through 51600) for a detailed discussion of the policy and process for waiving Lugar status for the out-migration adjustment.

We did not receive any public comments on the discussion of this policy in the FY 2016 IPPS/LTCH PPS proposed rule.

K. Out-Migration Adjustment Based on Commuting Patterns of Hospital Employees

1. Background

In accordance with section 1886(d)(13) of the Act, as added by section 505 of Pub. L. 108-173, beginning with FY 2005, we established a process to make adjustments to the hospital wage index based on commuting patterns of hospital employees (the “out-migration” adjustment). The process, outlined in the FY 2005 IPPS final rule (69 FR 49061), provides for an increase in the wage index for hospitals located in certain counties that have a relatively high percentage of hospital employees who reside in the county but work in a different county (or counties) with a higher wage index.

2. New Data Source for the FY 2016 Out-Migration Adjustment

When the provision of section 1886(d)(13) of the Act was implemented for the FY 2005 wage index, we analyzed commuting data compiled by the U.S. Census Bureau which was derived from a special tabulation of the 2000 Census journey-to-work data for all industries (CMS extracted data applicable to hospitals). These data were compiled
from responses to the “long-form” survey, which the Census Bureau used at the time and which contained questions on where residents in each county worked (69 FR 49062). However, the 2010 Census was “short form” only; information on where residents in each county worked was not collected as part of the 2010 Census. The Census Bureau worked with CMS to provide an alternative dataset based on the latest available data on where residents in each county worked in 2010, for use in developing a new out-migration adjustment based on new commuting patterns using the 2010 Census data beginning with FY 2016. We reviewed and analyzed the alternative dataset from the Census Bureau and proposed new out-migration adjustments in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24471 through 24472), as discussed below (as we indicated we would in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49984 through 49985).

As stated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24471), to determine the new out-migration adjustments and applicable counties that we proposed for FY 2016, we analyzed commuting data compiled by the Census Bureau that were derived from a custom tabulation of the American Community Survey (ACS), an official Census Bureau survey, utilizing 2008 through 2012 (5-Year) Microdata. The data were compiled from responses to the ACS questions regarding the county where workers reside and the county to which workers commute. The tabulation was specific to hospital military and civilian employees (hospital sector Census code 8190/NAICS code 622) who worked in the 50 States, Washington, DC, and Puerto Rico and, therefore, provided information about commuting patterns of workers at the county level for residents of the 50 States, Washington, DC, and Puerto Rico. For the ACS, the Census Bureau selects a
random sample of addresses where workers reside to be included in the survey, and the sample is designed to ensure good geographic coverage. The ACS samples approximately 3.54 million resident addresses per year. The results of the ACS are used to formulate descriptive population estimates, and, as such, the sample on which the dataset is based represents the actual figures that would be obtained from a complete count.

We did not receive any public comments on the new data source for the FY 2016 out-migration adjustment discussed in the FY 2016 IPPS/LTCH PPS proposed rule.

3. FY 2016 Out-Migration Adjustment

Section 1886(d)(13)(B) of the Act requires the Secretary to use data the Secretary determines to be appropriate to establish the qualifying counties for the out-migration adjustment. For FY 2016 and subsequent years, until such time that CMS finalizes out-migration adjustments based on the next Census, we proposed that the out-migration adjustment be based on the data derived from the custom tabulation of the ACS described in section III.K.2. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24471 and 24472) and this final rule. As discussed above, we believe that these data are the most appropriate to establish qualifying counties because they are the most accurate and up-to-date data that are available to us. We proposed that the FY 2016 out-migration adjustments continue to be based on the same policies, procedures, and computation that were used for the FY 2012 out-migration adjustment. We have applied these same policies, procedures, and computations since FY 2012 and we believe they continue to be appropriate for FY 2016. (We refer readers to a full discussion of the
out-migration adjustment, including rules on deeming hospitals reclassified under section 1886(d)(8) or section 1886(d)(10) of the Act to have waived the out-migration adjustment, in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51601 through 51602).) Table 2 (formerly Table 4J) associated with this final rule (which is available via the Internet on the CMS Web site) lists the final out-migration adjustments for the FY 2016 wage index.

Comment: Several commenters supported the CMS proposed wage index updates for the out-migration adjustment for FY 2016.

Response: We appreciate the commenters’ support.

Therefore, we are finalizing the FY 2016 update to the out-migration data as proposed. The FY 2016 out-migration adjustment is based on the data derived from the custom tabulation of the ACS. The FY 2016 out-migration adjustments continue to be based on the same policies, procedures, and computation that were used for the FY 2012 out-migration adjustment.

4. Use of Out-Migration Adjustment Data Applied for FY 2014 or FY 2015 for 3 Years

Section 1886(d)(13)(F) of the Act states that a wage index increase under this paragraph shall be effective for a period of 3 fiscal years, except that the Secretary shall establish procedures under which a subsection (d) hospital may elect to waive the application of such wage index increase. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49984 through 49985), we stated that even if we proposed to adopt new out-migration adjustment data for FY 2016, hospitals that are already receiving an out-migration adjustment beginning with a fiscal year prior to FY 2016 would still
receive their out-migration adjustment based on the data used prior to FY 2016 for the years that remain of their 3-year qualification period in FY 2016 and after. Therefore, for FY 2016, hospitals that qualified in FY 2014 or FY 2015 to receive the out-migration adjustment based on the commuting data and the CBSA delineations used for FY 2014 will continue to receive the same out-migration adjustment for the remainder of their 3-year qualification period. For example, if a hospital qualified for the out-migration adjustment in FY 2014, but also will qualify in FY 2016 under the new commuting patterns and the new OMB labor market area delineations for FY 2016, this hospital will still receive the out-migration adjustment based on the commuting data and the CBSA delineations used for FY 2014, regardless of whether the FY 2016 adjustment is higher or lower than the adjustment based on FY 2014 data. If the hospital qualifies in FY 2017 (after the expiration of the 3-year qualifying period for the out-migration adjustment, which began in FY 2014) to receive the out-migration adjustment based on the new commuting data and OMB delineations in effect in FY 2017, it could receive the out-migration adjustment based on the new data for FYs 2017, 2018, and 2019. Conversely, for example, if a hospital qualified for the out-migration adjustment in FY 2014, but would not qualify in FY 2016 under the new commuting patterns and the new OMB delineations for FY 2016, this hospital will still receive the out-migration adjustment based on the commuting data and the CBSA delineations used for FY 2014.

Based on the new out-migration adjustment data used for this FY 2016 IPPS/LTCH final rule, 336 hospitals will receive the out-migration adjustment for FY 2016. Of hospitals that were eligible for the out-migration adjustment for FY 2015
but whose 3-year qualifying period for the out-migration adjustment expired, 6 hospitals are no longer eligible for the out-migration adjustment under the new data (3 hospitals in Alabama, 1 hospital in Missouri, and 2 hospital in Tennessee). Of the 336 hospitals, the out-migration adjustment of 248 hospitals will be unaffected, as these hospitals will receive the same out-migration adjustment because they are still within an existing 3-year eligibility period under the previous out-migration adjustment data. Of the 336 hospitals, 12 hospitals would have received a higher out-migration adjustment using the new data (1 hospital in Alabama; 2 hospitals in Massachusetts; 1 hospital in Michigan; 4 hospitals in Pennsylvania; 2 hospitals in Tennessee; and 2 hospitals in Wisconsin) and 4 hospitals would have received a lower out-migration adjustment using the new data (1 hospital in Idaho, 2 hospitals in Oregon, and 1 hospital in South Carolina). Seventy-five hospitals are newly eligible for the out-migration adjustment in FY 2016 using the new data. The following table shows the States and Territory in which the 75 affected hospitals are located:
<table>
<thead>
<tr>
<th>STATE</th>
<th>Number of Hospitals That Are Newly Eligible under the New Outmigration Data for FY 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALABAMA</td>
<td>2</td>
</tr>
<tr>
<td>ARKANSAS</td>
<td>3</td>
</tr>
<tr>
<td>CALIFORNIA</td>
<td>6</td>
</tr>
<tr>
<td>FLORIDA</td>
<td>4</td>
</tr>
<tr>
<td>GEORGIA</td>
<td>8</td>
</tr>
<tr>
<td>IDAHO</td>
<td>1</td>
</tr>
<tr>
<td>ILLINOIS</td>
<td>1</td>
</tr>
<tr>
<td>INDIANA</td>
<td>3</td>
</tr>
<tr>
<td>KANSAS</td>
<td>1</td>
</tr>
<tr>
<td>LOUISIANA</td>
<td>5</td>
</tr>
<tr>
<td>MAINE</td>
<td>1</td>
</tr>
<tr>
<td>MICHIGAN</td>
<td>2</td>
</tr>
<tr>
<td>MINNESOTA</td>
<td>1</td>
</tr>
<tr>
<td>MISSISSIPPI</td>
<td>3</td>
</tr>
<tr>
<td>MISSOURI</td>
<td>1</td>
</tr>
<tr>
<td>NORTH CAROLINA</td>
<td>4</td>
</tr>
<tr>
<td>OHIO</td>
<td>3</td>
</tr>
<tr>
<td>OKLAHOMA</td>
<td>2</td>
</tr>
<tr>
<td>PENNSYLVANIA</td>
<td>3</td>
</tr>
<tr>
<td>PUERTO RICO</td>
<td>5</td>
</tr>
<tr>
<td>SOUTH CAROLINA</td>
<td>1</td>
</tr>
<tr>
<td>TENNESSEE</td>
<td>3</td>
</tr>
<tr>
<td>TEXAS</td>
<td>6</td>
</tr>
<tr>
<td>VERMONT</td>
<td>1</td>
</tr>
<tr>
<td>WEST VIRGINIA</td>
<td>4</td>
</tr>
<tr>
<td>WISCONSIN</td>
<td>1</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>75</strong></td>
</tr>
</tbody>
</table>
L. Process for Requests for Wage Index Data Corrections

The preliminary, unaudited Worksheet S-3 wage data files for the proposed FY 2016 wage index were made available on May 23, 2014, and the preliminary CY 2013 occupational mix data files on July 11, 2014, through the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY-2016-Wage-Index-Home-Page.html.

In the interest of meeting the data needs of the public, beginning with the proposed FY 2009 wage index, we post an additional public use file on our Web site that reflects the actual data that are used in computing the proposed wage index. The release of this file does not alter the current wage index process or schedule. We notify the hospital community of the availability of these data as we do with the current public use wage data files through our Hospital Open Door Forum. We encourage hospitals to sign up for automatic notifications of information about hospital issues and about the dates of the Hospital Open Door Forums at the CMS Web site at: http://www.cms.gov/Outreach-and-Education/Outreach/OpenDoorForums/index.html.

In a memorandum dated April 7, 2014, we instructed all MACs to inform the IPPS hospitals they service of the availability of the wage index data files and the process and timeframe for requesting revisions (including the specific deadlines listed below). We also instructed the MACs to advise hospitals that these data were also made available directly through their representative hospital organizations.
If a hospital wished to request a change to its data as shown in the May 23, 2014 wage data files and July 11, 2014 occupational mix data files, the hospital was to submit corrections along with complete, detailed supporting documentation to its MAC by October 6, 2014. Hospitals were notified of this deadline and of all other deadlines and requirements, including the requirement to review and verify their data as posted in the preliminary wage index data files on the Internet, through the April 7, 2014 memorandum referenced above.

The MACs notified the hospitals by mid-February 2015 of any changes to the wage index data as a result of the desk reviews and the resolution of the hospitals’ early-October revision requests. The MACs also submitted the revised data to CMS by December 16, 2014. CMS published the proposed wage index public use files that included hospitals’ revised wage index data on February 13, 2015. Hospitals had until March 2, 2015, to submit requests to the MACs for reconsideration of adjustments made by the MACs as a result of the desk review, and to correct errors due to CMS’ or the MAC’s mishandling of the wage index data. Hospitals also were required to submit sufficient documentation to support their requests.

After reviewing requested changes submitted by hospitals, MACs were required to transmit to CMS any additional revisions resulting from the hospitals’ reconsideration requests by April 8, 2015. The deadline for a hospital to request CMS intervention in cases where the hospital disagreed with the MAC’s policy interpretations was April 15, 2015. We note that, as we did for the FY 2015 wage index, for the FY 2016 wage index, in accordance with the FY 2016 wage index timeline posted on the CMS
Web site at [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Downloads/FY2016-WI-Time-Table-Final.pdf](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Downloads/FY2016-WI-Time-Table-Final.pdf), the April appeals had to be sent via mail and email. We refer readers to the wage index timeline for complete details.

Hospitals were given the opportunity to examine Table 2, which was listed in section VI. of the Addendum to the proposed rule and available via the Internet on the CMS Web site at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY-2016-Wage-Index-Home-Page.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY-2016-Wage-Index-Home-Page.html). Table 2 associated with the proposed rule contained each hospital’s proposed adjusted average hourly wage used to construct the wage index values for the past 3 years, including the FY 2012 data used to construct the proposed FY 2016 wage index. We noted that the proposed hospital average hourly wages shown in Table 2 only reflect changes made to a hospital’s data that were transmitted to CMS by February 27, 2015.

We posted the final wage index data public use files on May 1, 2015 on the Internet at: [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY-2016-Wage-Index-Home-Page.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY-2016-Wage-Index-Home-Page.html). The May 2015 public use files were made available solely for the limited purpose of identifying any potential errors made by CMS or the MAC in the entry of the final wage index data that resulted from the correction process described above (revisions submitted to CMS by the MACs by April 8, 2015).

After the release of the May 2015 wage index data files, changes to the wage and occupational mix data could only be made in those very limited situations involving an
error by the MAC or CMS that the hospital could not have known about before its review of the final wage index data files. Specifically, neither the MAC nor CMS will approve the following types of requests:

- Requests for wage index data corrections that were submitted too late to be included in the data transmitted to CMS by the MACs on or before April 8, 2015.
- Requests for correction of errors that were not, but could have been, identified during the hospital’s review of the February 13, 2015 wage index public use files.
- Requests to revisit factual determinations or policy interpretations made by the MAC or CMS during the wage index data correction process.

If, after reviewing the May 2015 final public use files, a hospital believed that its wage or occupational mix data were incorrect due to a MAC or CMS error in the entry or tabulation of the final data, the hospital was given the opportunity to notify both its MAC and CMS regarding why the hospital believed an error exists and provide all supporting information, including relevant dates (for example, when it first became aware of the error). The hospital was required to send its request to CMS and to the MAC no later than June 1, 2015. Similar to the April appeals, beginning with the FY 2015 wage index, in accordance with the FY 2016 wage index timeline posted on the CMS Web site at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Downloads/FY2016-WI-Time-Table-Final.pdf, the June appeals were required to be sent via mail and email to CMS and the MACs. We refer readers to the wage index timeline for complete details.
Verified corrections to the wage index data received timely by CMS and the MACs (that is, by June 1, 2015) were incorporated into the final wage index in this FY 2016 IPPS/LTCH PPS final rule, which will be effective October 1, 2015.

We created the processes described above to resolve all substantive wage index data correction disputes before we finalize the wage and occupational mix data for the FY 2016 payment rates. Accordingly, hospitals that did not meet the procedural deadlines set forth above will not be afforded a later opportunity to submit wage index data corrections or to dispute the MAC’s decision with respect to requested changes. Specifically, our policy is that hospitals that do not meet the procedural deadlines set forth above will not be permitted to challenge later, before the PRRB, the failure of CMS to make a requested data revision. We refer readers also to the FY 2000 IPPS final rule (64 FR 41513) for a discussion of the parameters for appeals to the PRRB for wage index data corrections.

Again, we believe the wage index data correction process described above provides hospitals with sufficient opportunity to bring errors in their wage and occupational mix data to the MAC’s attention. Moreover, because hospitals had access to the final wage index data by May 1, 2015, they had the opportunity to detect any data entry or tabulation errors made by the MAC or CMS before the development and publication of the final FY 2016 wage index by August 2015, and the implementation of the FY 2016 wage index on October 1, 2015. Given these processes, the wage index implemented on October 1 should be accurate. Nevertheless, in the event that errors are
identified by hospitals and brought to our attention after June 1, 2015, we retain the right to make midyear changes to the wage index under very limited circumstances.

Specifically, in accordance with 42 CFR 412.64(k)(1) of our regulations, we make midyear corrections to the wage index for an area only if a hospital can show that: (1) the MAC or CMS made an error in tabulating its data; and (2) the requesting hospital could not have known about the error or did not have an opportunity to correct the error, before the beginning of the fiscal year. For purposes of this provision, “before the beginning of the fiscal year” means by the June deadline for making corrections to the wage data for the following fiscal year’s wage index (for example, June 1, 2015, for the FY 2016 wage index). This provision is not available to a hospital seeking to revise another hospital’s data that may be affecting the requesting hospital’s wage index for the labor market area.

As indicated earlier, because CMS makes the wage index data available to hospitals on the CMS Web site prior to publishing both the proposed and final IPPS rules, and the MACs notify hospitals directly of any wage index data changes after completing their desk reviews, we do not expect that midyear corrections will be necessary. However, under our current policy, if the correction of a data error changes the wage index value for an area, the revised wage index value will be effective prospectively from the date the correction is made.

In the FY 2006 IPPS final rule (70 FR 47385 through 47387 and 47485), we revised 42 CFR 412.64(k)(2) to specify that, effective on October 1, 2005, that is, beginning with the FY 2006 wage index, a change to the wage index can be made retroactive to the beginning of the Federal fiscal year only when CMS determines all of
the following: (1) the MAC or CMS made an error in tabulating data used for the wage index calculation; (2) the hospital knew about the error and requested that the MAC and CMS correct the error using the established process and within the established schedule for requesting corrections to the wage index data, before the beginning of the fiscal year for the applicable IPPS update (that is, by the June 1, 2015 deadline for the FY 2016 wage index); and (3) CMS agreed before October 1 that the MAC or CMS made an error in tabulating the hospital’s wage index data and the wage index should be corrected.

In those circumstances where a hospital requested a correction to its wage index data before CMS calculated the final wage index (that is, by the June 1, 2015 deadline for the FY 2016 wage index), and CMS acknowledges that the error in the hospital’s wage index data was caused by CMS’ or the MAC’s mishandling of the data, we believe that the hospital should not be penalized by our delay in publishing or implementing the correction. As with our current policy, we indicated that the provision is not available to a hospital seeking to revise another hospital’s data. In addition, the provision cannot be used to correct prior years’ wage index data; and it can only be used for the current Federal fiscal year. In situations where our policies would allow midyear corrections other than those specified in 42 CFR 412.64(k)(2)(ii), we continue to believe that it is appropriate to make prospective-only corrections to the wage index.

We note that, as with prospective changes to the wage index, the final retroactive correction will be made irrespective of whether the change increases or decreases a hospital’s payment rate. In addition, we note that the policy of retroactive adjustment
will still apply in those instances where a final judicial decision reverses a CMS denial of a hospital’s wage index data revision request.

M. Labor-Related Share for the FY 2016 Wage Index

Section 1886(d)(3)(E) of the Act directs the Secretary to adjust the proportion of the national prospective payment system base payment rates that are attributable to wages and wage-related costs by a factor that reflects the relative differences in labor costs among geographic areas. It also directs the Secretary to estimate from time to time the proportion of hospital costs that are labor-related and to adjust the proportion (as estimated by the Secretary from time to time) of hospitals’ costs which are attributable to wages and wage-related costs of the DRG prospective payment rates. We refer to the portion of hospital costs attributable to wages and wage-related costs as the labor-related share. The labor-related share of the prospective payment rate is adjusted by an index of relative labor costs, which is referred to as the wage index.

Section 403 of Pub. L. 108-173 amended section 1886(d)(3)(E) of the Act to provide that the Secretary must employ 62 percent as the labor-related share unless this would result in lower payments to a hospital than would otherwise be made. However, this provision of Pub. L. 108-173 did not change the legal requirement that the Secretary estimate from time to time the proportion of hospitals’ costs that are attributable to wages and wage-related costs. Thus, hospitals receive payment based on either a 62-percent labor-related share, or the labor-related share estimated from time to time by the Secretary, depending on which labor-related share resulted in a higher payment.
In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50596 through 50607), we rebased and revised the hospital market basket. We established a FY 2010-based IPPS hospital market basket to replace the FY 2006-based IPPS hospital market basket, effective October 1, 2013. In that final rule, we presented our analysis and conclusions regarding the frequency and methodology for updating the labor-related share for FY 2014. Using the FY 2010-based IPPS market basket, we finalized a labor-related share for FY 2014 and for FY 2015 of 69.6 percent. In addition, we implemented this revised and rebased labor-related share in a budget neutral manner. However, consistent with section 1886(d)(3)(E) of the Act, we did not take into account the additional payments that would be made as a result of hospitals with a wage index less than or equal to 1.0000 being paid using a labor-related share lower than the labor-related share of hospitals with a wage index greater than 1.0000.

The labor-related share is used to determine the proportion of the national IPPS base payment rate to which the area wage index is applied. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24474 through 24475), for FY 2016, we did not propose to make any further changes to the national average proportion of operating costs that are attributable to wages and salaries, employee benefits, contract labor, the labor-related portion of professional fees, administrative and facilities support services, and all other labor-related services. Therefore, for FY 2016, we proposed to continue to use a labor-related share of 69.6 percent for discharges occurring on or after October 1, 2015.

Tables 1A and 1B, which were published in section VI. of the Addendum to the FY 2016 IPPS/LTCH PPS proposed rule and available via the Internet on the CMS Web
site, reflected the proposed labor-related share. For FY 2016, for all IPPS hospitals whose wage indexes are less than or equal to 1.0000, we proposed to apply the wage index to a labor-related share of 62 percent of the national standardized amount. For all IPPS hospitals whose wage indexes are greater than 1.000, for FY 2016, we proposed to apply the wage index to a proposed labor-related share of 69.6 percent of the national standardized amount. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24474 through 24475), we noted that, for Puerto Rico hospitals, the national labor-related share is 62 percent because the national wage index for all Puerto Rico hospitals is less than 1.0000.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50601 through 50603), we also rebased and revised the labor-related share for the Puerto Rico-specific standardized amounts using FY 2010 as a base year. We finalized a labor-related share for the Puerto Rico-specific standardized amounts for FY 2014 of 63.2 percent. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49990), for FY 2015, we did not make any further changes to the Puerto Rico-specific average proportion of operating costs that are attributable to wages and salaries, employee benefits, contract labor, the labor-related portion of professional fees, administrative and facilities support services, and all other labor-related services. For FY 2015, we continued to use a labor-related share for the Puerto Rico-specific standardized amounts of 63.2 percent for discharges occurring on or after October 1, 2014.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24475), for FY 2016, we proposed to continue to use a labor-related share for the Puerto Rico-specific
standardized amounts of 63.2 percent for discharges occurring on or after October 1, 2015. Puerto Rico hospitals are paid based on 75 percent of the national standardized amounts and 25 percent of the Puerto Rico-specific standardized amounts. For FY 2016, we proposed that the labor-related share of a hospital’s Puerto Rico-specific rate would be either the Puerto Rico-specific labor-related share of 63.2 percent or 62 percent, depending on which results in higher payments to the hospital. If the hospital has a Puerto Rico-specific wage index greater than 1.000 for FY 2016, we proposed to set the hospital’s rates using a labor-related share of 63.2 percent for the 25 percent portion of the hospital’s payment determined by the Puerto Rico standardized amounts because this amount would result in higher payments. Conversely, a hospital with a Puerto Rico-specific wage index of less than or equal to 1.000 for FY 2016 would be paid using the Puerto Rico-specific labor-related share of 62 percent of the Puerto Rico-specific rates because the lower labor-related share would result in higher payments.

**Comment:** One commenter recommended that CMS compute an alternative labor and nonlabor-related share percentage under the national standardized amount for hospitals in Puerto Rico. The commenter explained that the current labor-related share percentage of 62 percent under the national standardized amounts meets the statutory definition in section 1886(d)(3)(E) of the Act, resulting in lower payments for providers in Puerto Rico. Therefore, the commenter believed that CMS should calculate an alternative national labor-related share percentage for hospitals in Puerto Rico that is lower than 62 percent. The commenter further stated that CMS does not have empirical
data that demonstrate why a lower labor share is justified. The commenter also provided the following data that shows nonlabor costs are higher in Puerto Rico. Based on data from the Council for Community and Economic Research (available on the internet at http://www.coli.org), the composite cost-of-living index for the MSA of San Juan, Puerto Rico out of 200 MSAs is 112.9 (where 100 is the average composite index). The commenter also noted that the measure for nonlabor items in Puerto Rico such as utilities and supermarket were 185.1 and 122.7, respectively.

Response: As we responded in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49990 through 49991), current law requires that the labor-related share for the national standardized amount be set at 62 percent for hospitals with a wage index less than or equal to 1.0000. Specifically, as discussed above, section 403 of Pub. L. 108-173 amended section 1886(d)(3)(E) of the Act to provide that the Secretary must employ 62 percent as the labor-related share unless this would result in lower payments to a hospital than would otherwise be made.

In addition, sections 1886(d)(9)(A) and (d)(9)(E)(iv) of the Act require that Puerto Rico hospitals are paid a blended rate for their inpatient operating costs based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. Therefore, for the portion of payment determined under the national standardized amount, Puerto Rico hospitals must follow section 1886(d)(3)(E) of the Act which requires the Secretary to use 62 percent as the labor-related share unless this would result in lower payments to a hospital than would otherwise be made. For Puerto Rico, the national labor-related share is 62 percent because the national wage
index for all Puerto Rico hospitals is less than 1.0000. Therefore, we are unable to change the labor-related share of 62 percent.

After consideration of public comments received, we are finalizing our proposals without modification. For FY 2016, we are continuing to use a labor-related share for the national standardized amount of 69.6 percent for discharges occurring on or after October 1, 2015. Tables 1A and 1B, which are published in section VI. of the Addendum to this FY 2016 IPPS/LTCH PPS final rule and available via the Internet on the CMS Web site, reflect this labor-related share. For FY 2016, for all IPPS hospitals whose wage indexes are less than or equal to 1.0000, we are applying the wage index to a labor-related share of 62 percent of the national standardized amount. For all IPPS hospitals whose wage indexes are greater than 1.0000, for FY 2016, we are applying the wage index to a labor-related share of 69.6 percent of the national standardized amount.

Puerto Rico hospitals are paid based on 75 percent of the national standardized amounts and 25 percent of the Puerto Rico-specific standardized amounts. For Puerto Rico hospitals, the national labor-related share is 62 percent because the national wage index for all Puerto Rico hospitals is less than 1.0000. For FY 2016, we are continuing to use a labor-related share for Puerto Rico-specific standardized amounts of 63.2 percent for discharges occurring on or after October 1, 2015. We also are finalizing our proposal that the labor-related share of a hospital’s Puerto Rico-specific rate for FY 2016 is either the Puerto Rico-specific labor-related share of 63.2 percent or 62 percent, depending on which results in higher payments to the hospital. The final FY 2016 Puerto Rico specific labor-related share of 63.2 percent or 62 percent is reflected in Table 1C, which is
published in section VI. of the Addendum to this FY 2016 IPPS/LTCH PPS final rule and available via the Internet on the CMS Web site.

N. Changes to 3-Year Average Pension Policy and Changes to the Wage Index

Timetable Regarding Pension Costs for FY 2017 and Subsequent Years

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51586 through 51590), we revised our policy for reporting costs of qualified defined benefit pension plans for the Medicare wage index. Under that revised policy, the pension costs that are to be included in the wage index equal a hospital’s average cash contributions deposited to its defined benefit pension plan over a 3-year period or, if less than a 3-year period, the number of years that the hospital has sponsored a defined benefit plan. The 3-year average is centered on the base cost reporting period for the wage index. For example, the FY 2016 wage index is based on Medicare cost reporting periods beginning during Federal FY 2012, and reflects the average pension contributions made in a hospital’s cost reporting period that began during Federal FYs 2011, 2012, and 2013. As stated in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51587), we centered the 3-year average on the base cost reporting period for the wage index in order to ensure that the average annual pension cost reflected in the wage index is consistent with the cost reporting period applicable to all other costs included in the index. We also stated that we did not anticipate that the use of contributions made in the period immediately following the base cost reporting period (for example, using Federal FY 2013 as one of the 3-year periods for FY 2016) would create an administrative burden because by the time the MAC would be reviewing a hospital’s base cost reporting period wage data for inclusion in the
subsequent year’s wage index, trust account statements and general ledger reports to support the contributions should be readily available. We refer readers to the FY 2012 IPPS/LTCH PPS final rule for a complete discussion of this policy.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49987 through 49990), we finalized changes to the FY 2017 wage index timeline. We stated that we believed the timeline changes would not only improve the accuracy of the February public use file (PUF), but also would reduce the number of hospital appeals based on the February PUF. Among these changes to the wage index timeline for FY 2017 is a requirement that hospitals must request revisions to the preliminary PUF by the first week of September 2015. In response to our FY 2015 proposal to change the wage index timeline for FY 2017, a public commenter stated that the proposed FY 2017 deadline of early August 2015 did not provide enough time for hospitals to incorporate their pension data into the desk review process because the Internal Revenue Service (IRS) Form 5500 (used as the basis for reporting pension contributions for defined benefit plans) is due 7 months after the end of the plan year (July 31), with possible extensions through mid-September. In response to that comment, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49989), we provided for a general deadline of early September to submit revisions to the wage index data posted in the May 2015 preliminary PUF, but provided a limited exception for submission of pension data for certain hospitals. Specifically, starting with the FY 2017 wage index, we will allow an extension for a hospital with a fiscal year begin date on or after August 15 of a year to submit its initial pension data by mid-October 2015, which would revise the preliminary PUF. We stated that we believed
the majority of hospitals, which do have fiscal year begin dates prior to August 15 of a year, would be able to submit their pension data, along with the remainder of their wage index documentation, to their MACs by the beginning of September of each year, in time for the beginning of the annual wage index desk review process. We also stated that, in future rulemaking, we may consider revisions to the 3-year average pension policy that would allow all hospitals to submit their pension data at the same time. We refer readers to the FY 2015 IPPS/LTCH PPS final rule for a complete discussion of the changes to the FY 2017 wage index timeline (79 FR 49987 through 49990).

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24475), we stated that we have now reconsidered the changes made to the FY 2017 wage index timeline in light of our experience to date with the administrative aspects of the 3-year average pension policy as explained above and in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51586 through 51590). Based on our findings, we believe that a revision of the 3-year average pension policy is warranted, beginning with the FY 2017 wage index.

Specifically, in the FY 2016 IPPS/LTCH PPS proposed rule, instead of the 3-year average being centered on the base cost reporting period for the wage index, we proposed that, for the FY 2017 wage index and all subsequent fiscal year wage indexes, the 3-year average would be based on pension contributions made during the base cost reporting period plus the prior 2 cost reporting years. For example, the FY 2017 wage index would be based on Medicare cost reporting periods beginning during Federal FY 2013. Therefore, the FY 2017 wage index would reflect the average pension contributions made in hospitals’ cost reporting periods beginning during Federal FYs 2011, 2012, and 2013.
(rather than Federal FYs 2012, 2013, and 2014 under the FY 2015 policy). Our proposed change in the 3-year averaging period would produce a 1-year lag in reporting pension costs relative to reporting all other costs included in the wage index and, for most hospitals, would result in the same 3-year average pension costs for both the FY 2016 and FY 2017 wage index. That is, for FY 2016, the 3-year average consists of Federal FYs 2011, 2012, and 2013, and under our proposal, the 3-year average for FY 2017 also would consist of Federal FYs 2011, 2012, and 2013. Under our proposal, the 3-year average for FY 2018 would consist of Federal FYs 2012, 2013, and 2014.

**Comment:** Several commenters supported the proposed change in the 3-year averaging period for pension costs.

**Response:** We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal without modification that, instead of the 3-year average being centered on the base cost reporting period for the wage index, for the FY 2017 wage index and all subsequent fiscal year wage indexes, the 3-year average will be based on pension contributions made during the base cost reporting period plus the prior 2 cost reporting years.

For FY 2017 only, we proposed that all hospitals submit requests to revise their previously submitted pension data by early October to mid-October (instead of the first week of September, as stated in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49989)). We had anticipated proposing an early September deadline for all hospitals to submit revisions on all data in the preliminary PUF, including pension data. However, we
realized that such a deadline would involve requiring hospitals to submit all of the revisions to pension data prior to the effective date of the final rule. Therefore, we proposed this deadline change of early October to mid-October so that all hospitals would submit revisions to their pension data by the same deadline, which should simplify the deadline for submitting those data as well as provide more time to most hospitals to submit these data. Because the pension data for FY 2017 would be the same pension data already used in FY 2016 (as mentioned above), we would expect minimal revisions to the pension data for FY 2017. Because we proposed an extension until early to mid-October for all hospitals to revise their pension data for FY 2017, we proposed to eliminate the limited exception and extension for hospitals with a fiscal year begin date of on or after August 15, as set forth in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49989). The exception is no longer necessary, given the proposed use of data from older cost reports for the 3-year averaging of pension costs and the proposed extension of time for submission of revisions of pension data for all hospitals for FY 2017. For FY 2018 and subsequent fiscal years, we proposed to require that all hospitals request revisions to the preliminary PUF for all wage index issues, including submission and/or revisions of pension data, by the first week of September. The September deadline for FY 2018 and subsequent fiscal years is consistent with the deadline established in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49989) for the FY 2017 wage index data. Specifically, in that final rule, in response to commenters, we established the early September deadline as a feasible deadline for hospitals to request revisions to their preliminary wage and occupational mix data. In addition, we also stated that a deadline
in early September would be manageable for hospitals, while also providing the MACs with the most amount of time possible to complete their desk reviews.

This proposal also would allow for a single deadline for all hospitals to submit revisions to their wage data, including their pension costs (as stated above). A single deadline is preferable because it would result in less confusion and would be easier to administer for all hospitals. In addition, the limited exception for hospitals with a fiscal year begin date of on or after August 15 would have provided administrative relief only to a minority of hospitals. Furthermore, in many cases, hospitals that participate in a systemwide pension plan or State-run retirement system have been unable to obtain timely documentation to support their allocated share of total plan contributions. We believe that a shift in the 3-year average to the base cost reporting period plus the prior 2 cost reporting years would provide all hospitals sufficient time to collect and submit their pension data by the proposed September deadline, and allow MACs to complete their desk reviews on schedule, thereby improving the accuracy of the February PUF.

The chart below includes the FY 2017 wage index timetable published in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49989), except for the mid-October deadline under the limited exception and extension for submitting pension data to the MACs for hospitals with fiscal year begin dates on or after August 15, which we are eliminating in this final rule. It also includes our final policy for FY 2017 for all hospitals to request revisions to their pension data by mid-October 2015 (rather than early October as published in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49989)).

<p>| FY 2017 WAGE INDEX TIMETABLE WITH DEADLINE FOR PENSION REVISIONS |</p>
<table>
<thead>
<tr>
<th>Actions</th>
<th>Deadlines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posting of Preliminary PUF on CMS Web site</td>
<td>Mid-May 2015</td>
</tr>
<tr>
<td>Deadline for Hospitals to Request Revisions to Preliminary PUF</td>
<td>First week of September 2015</td>
</tr>
<tr>
<td>Deadline for Hospitals to Request Revisions to Pension Data</td>
<td>Early October 2015 to Mid-October 2015</td>
</tr>
<tr>
<td>Deadline for MACs to Complete Desk Reviews</td>
<td>Mid-November 2015</td>
</tr>
<tr>
<td>Posting of January PUF on CMS Web site (formerly “February” PUF)</td>
<td>Late January 2016</td>
</tr>
<tr>
<td>Deadline Following Posting of January PUF for Hospitals to Request Revisions</td>
<td>Mid-February 2016</td>
</tr>
<tr>
<td>Completion of Appeals by MACs and Transmission of Final Wage Data to CMS</td>
<td>Mid to Late March 2016</td>
</tr>
<tr>
<td>Deadline for Hospitals to Appeal in April</td>
<td>Early April 2016</td>
</tr>
<tr>
<td>Posting of Final PUF</td>
<td>Late April 2016</td>
</tr>
<tr>
<td>Deadline for Hospitals to Appeal in May</td>
<td>Late May 2016</td>
</tr>
<tr>
<td>Expected Issuance of IPPS Final Rule</td>
<td>August 1, 2016</td>
</tr>
</tbody>
</table>

For FY 2018 and subsequent fiscal years, we proposed the same timetable as in FY 2017 (adjusted for the years), except there would no longer be a separate deadline in October for submitting and/or revising pension data. Rather, all requests to submit and/or revise pension data (as well as any other requests for revisions to the preliminary PUF) for FY 2018 and subsequent fiscal years would be required to be submitted by hospitals to MACs in the first week of September each year.
Comment: Several commenters generally supported the proposed modification of the wage index timetable. Some commenters specifically supported a single deadline for revisions to preliminary wage index data, although these commenters disagreed with the September deadline for requesting revisions to the preliminary May PUF. These commenters preferred an October deadline to allow hospitals more time to review their data.

Response: We appreciate the commenters’ general support for the wage index timetable. For only FY 2017, we proposed that all hospitals submit requests to revise their previously submitted pension data by early to mid-October 2015, instead of the previous early September 2015 deadline for pension revisions finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49989). This deadline of mid-October 2015 for hospitals to submit pension data revisions will simplify the deadline for submitting those data as well as provide more time to most hospitals to submit those data. We note that, on May 15, 2015, when we posted the FY 2017 preliminary PUF on the CMS Web site, we included a tentative FY 2017 timetable which included a tentative deadline of October 15, 2015, for all hospitals to request revisions to pension data and to provide documentation to support the request. This tentative FY 2017 Wage Index Development Timetable stated the following: October 15, 2015 – “Per the proposed pension policy in the FY 2016 IPPS/LTCH proposed rule, deadline for all hospitals to request revisions to pension data and to provide documentation to support the request. MACs must receive the revision requests and supporting documentation by this date. In addition, this date of October 15, 2015 only applies to pension plans that are classified as defined benefit
pension plans. Requests to revise data of all other types of pension plans (such as defined
contribution plans) must be received by the MACs no later than September 2, 2015.” We refer readers to the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-
Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY2017-Wage-Index-
Home-Page.html.

Furthermore, because we proposed an extension until early to mid-October for all hospitals to revise their pension data for FY 2017, we proposed to eliminate the limited exception and extension for hospitals with a fiscal year begin date of on or after August 15, as set forth in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49989). The exception is no longer necessary, given the use of data from older cost reports for the 3-year averaging of pension costs and the proposed extension of time for submission of revisions of pension data for all hospitals for FY 2017. Therefore, we are finalizing a mid-October 2015 deadline by which, for FY 2017 only, hospitals must request revisions to their pension data for pension plans that are classified as defined benefit pension plans. Requests to revise data of all other types of pension plans (such as defined contribution plans) must be received by the MACs no later than the first week of September 2015. The final FY 2017 Wage Index Development Timetable will be posted on the following CMS Web site after issuance of this FY 2016 final rule:

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-
Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY2017-Wage-Index-Home-
Page.html.
In addition, we proposed that, for FY 2018 and subsequent fiscal years, all hospitals are required to request revisions to the preliminary PUF for all wage index issues, including submission and/or revisions of pension data, by the first week of September. We further proposed that the remainder of the timetable for FY 2017 would apply for FY 2018 and subsequent fiscal years (adjusted for the years). The September deadline, consistent with the deadline established in the FY 2015 IPPS/LTCH PPS final rule for the FY 2017 and subsequent year’s wage index data (79 FR 49989), is the earliest feasible deadline for hospitals to request revisions to their preliminary wage and occupational mix data. This deadline in early September is manageable for hospitals, while it also provides the MACs with the most amount of time possible to complete their desk reviews. As such, we are finalizing that, for FY 2018 and subsequent fiscal years, all hospitals are required to request revisions to the preliminary PUF for all wage index issues, including submission and/or revisions of pension data, by the first week of September. Further, we are finalizing that the remainder of the timetable for FY 2017 will apply for FY 2018 and subsequent fiscal years (adjusted for the years).

After consideration of the public comments we received, for FY 2017 only, we are finalizing our proposals without modification that all hospitals submit requests to revise their previously submitted defined benefit pension data by early October to mid-October and eliminating the limited exception and extension for hospitals with a fiscal year begin date of on or after August 15 to submit their pension data by mid-October. We also are finalizing our proposals without modification to require that all hospitals request revisions to the preliminary PUF for all wage index issues, including
submission and/or revisions of pension data, by the first week of September for FY 2018 and subsequent fiscal years, and to apply the remainder of the timetable for FY 2017 to FY 2018 and subsequent fiscal years (adjusted for the years).

The chart below summarizes the wage index timetables for FY 2018 and subsequent fiscal years.

<table>
<thead>
<tr>
<th>WAGE INDEX TIMETABLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actions</td>
</tr>
<tr>
<td>Posting of Preliminary PUF on CMS Web site</td>
</tr>
<tr>
<td>Deadline for Hospitals to Request Revisions to Preliminary PUF (including revision requests for all pension data)</td>
</tr>
<tr>
<td>Deadline for MACs to Complete Desk Reviews</td>
</tr>
<tr>
<td>Posting of January PUF on CMS Web site (formerly “February” PUF)</td>
</tr>
<tr>
<td>Deadline Following Posting of January PUF for Hospitals to Request Revisions</td>
</tr>
<tr>
<td>Completion of Appeals by MACs and Transmission of Final Wage Data to CMS</td>
</tr>
<tr>
<td>Deadline for Hospitals to Appeal in April</td>
</tr>
<tr>
<td>Posting of Final PUF</td>
</tr>
<tr>
<td>Deadline for Hospitals to Appeal in May</td>
</tr>
<tr>
<td>Expected Issuance of IPPS Final Rule</td>
</tr>
<tr>
<td>Effective date of the wage index</td>
</tr>
</tbody>
</table>

O. Clarification of Allocation of Pension Costs for the Wage Index
As discussed in section III.N. of the preamble of this final rule, the pension cost to be included in the Medicare wage index equals a hospital’s average cash contributions deposited to its defined benefit pension plan over a 3-year period. Since implementing this policy, we have become aware of some confusion with respect to how hospitals are to compute the 3-year average when allocating their pension costs on the Medicare cost report if a hospital participates in a pension plan or retirement system that also covers other entities. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24477), we clarified that if a hospital participates in a pension plan or retirement system that also covers other entities, the hospital must report its respective 3-year average pension cost (or prefunding balance) reflecting only the hospital’s allocated share of total plan contributions, and not including any share of pension costs of other entities. For each hospital, this is accomplished by first determining the hospital’s allocated portion of pension contribution for each year of the 3-year average, and then computing the 3-year average for that hospital based only on that hospital’s respective allocated pension contributions. This is consistent with the regulations at 42 CFR 413.24(a), which state, in pertinent part, that providers must provide adequate cost data based on their financial and statistical records. Therefore, a provider may not claim as an allowable cost the costs of services associated with another entity. It is not appropriate to compute the 3-year average (or prefunding balance) based on the total contributions made to the plan by all participating entities and then determine a hospital’s allocated portion of the 3-year average cost (or prefunding balance) because there are instances in which the 3-year average could be skewed because a hospital may be including pension costs from another
entity in its 3-year average. Specifically, if the allocated percentage of total plan contributions for one or more of the participating entities changes during the 3-year average, the average will be skewed. The allocated percentage to each entity can change due to mergers, changes in plan coverage, or other factors. We also note that the allocation of contributions between the various entities participating in a pension plan or pension system should agree with the methodology used for plan reporting purposes and/or financial statement purposes, and the methodology used should be applied consistently over time. Furthermore, if wage index reporting is required for two or more hospitals covered under the same pension plan or retirement system, those hospitals should ensure that the allocation of plan contributions for each reporting period is determined on a consistent basis to avoid duplicate reporting of costs.

We did not receive any public comments on this clarification that was included the FY 2016 IPPS/LTCH PPS proposed rule.
IV. Other Decisions and Changes to the IPPS for Operating Costs and Indirect Medical Education (IME) Costs

A. Changes in the Inpatient Hospital Update for FY 2016 (§ 412.64(d))

1. FY 2016 Inpatient Hospital Update

   In accordance with section 1886(b)(3)(B)(i) of the Act, each year we update the national standardized amount for inpatient operating costs by a factor called the “applicable percentage increase.” For FY 2016, we are setting the applicable percentage increase by applying the adjustments listed below in the same sequence as we did for FY 2015. Specifically, consistent with section 1886(b)(3)(B) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act, we are setting the applicable percentage increase by applying the following adjustments in the following sequence.

   The applicable percentage increase under the IPPS is equal to the rate-of-increase in the hospital market basket for IPPS hospitals in all areas, subject to (1) a reduction of one-quarter of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals that fail to submit quality information under rules established by the Secretary in accordance with section 1886(b)(3)(B)(viii) of the Act; (2) a 66 2/3 percent reduction to three-quarters of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals not considered to be meaningful EHR users in accordance with section 1886(b)(3)(B)(ix) of the Act; (3) an adjustment based on changes in economy-wide productivity (the multifactor productivity
(MFP) adjustment); and (4) an additional reduction of 0.2 percentage point as required by section 1886(b)(3)(B)(xii) of the Act. Sections 1886(b)(3)(B)(xi) and (b)(3)(B)(xii) of the Act, as added by section 3401(a) of the Affordable Care Act, state that application of the MFP adjustment and the additional FY 2016 adjustment of 0.2 percentage point may result in the applicable percentage increase being less than zero. Under section 1886(b)(3)(B)(ix) of the Act, the reduction to three-quarters of the applicable percentage increase for those hospitals that are not meaningful EHR users will increase to 100 percent for FY 2017 and subsequent fiscal years.

We note that, in compliance with section 404 of the MMA, in the FY 2014 IPPS/LTCH PPS final rule, we replaced the FY 2006-based IPPS operating and capital market baskets with the revised and rebased FY 2010-based IPPS operating and capital market baskets for FY 2014. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49993 through 49996), we continued to use the FY 2010-based IPPS operating and capital market baskets for FY 2015 and the labor-related share of 69.6 percent, which is based on the FY 2010-based IPPS market basket. For FY 2016, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24477), we proposed to continue using the FY 2010-based IPPS operating and capital market baskets and the labor-related share of 69.6 percent, which is based on the FY 2010-based IPPS market basket. We did not receive any public comments on this proposal and, therefore, for FY 2016, will continue to use the FY 2010-based IPPS operating and capital market baskets and the labor-related share of 69.6 percent.
Based on the most recent data available for the FY 2016 proposed rule, in accordance with section 1886(b)(3)(B) of the Act, we proposed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24477) to base the FY 2016 market basket update used to determine the applicable percentage increase for the IPPS on IHS Global Insight, Inc.’s (IGI’s) first quarter 2015 forecast of the FY 2010-based IPPS market basket rate-of-increase with historical data through fourth quarter 2014, which was estimated to be 2.7 percent. We proposed that if more recent data became subsequently available (for example, a more recent estimate of the market basket and the MFP adjustment), we would use such data, if appropriate, to determine the FY 2016 market basket update and the MFP adjustment in this final rule.

Based on updated data for this FY 2016 IPPS/LTCH PPS final rule, that is, the IGI’s second quarter 2015 forecast of the FY 2010-based IPPS market basket rate-of-increase with historical data through first quarter 2015, we estimate that the FY 2016 market basket update used to determine the applicable percentage increase for the IPPS is 2.4 percent.

For FY 2016, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act (hereafter referred to as a hospital that submits quality data) and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act (hereafter referred to as a hospital that is a meaningful EHR user), we discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24477 through 24478) that there are four possible applicable percentage increases that can be applied to the standardized amount. Based on more recent data described
above, we determined final applicable percentage increases to the standardized amount for FY 2016, as specified in the table below.

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51689 through 51692), we finalized our methodology for calculating and applying the MFP adjustment. As we explained in that rule, section 1886(b)(3)(B)(xi)(II) of the Act, as added by section 3401(a) of the Affordable Care Act, defines this productivity adjustment as equal to the 10-year moving average of changes in annual economy-wide, private nonfarm business MFP (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, calendar year, cost reporting period, or other annual period). The Bureau of Labor Statistics (BLS) publishes the official measure of private nonfarm business MFP. We refer readers to the BLS Web site at http://www.bls.gov/mfp for the BLS historical published MFP data.

MFP is derived by subtracting the contribution of labor and capital input growth from output growth. The projections of the components of MFP are currently produced by IGI, a nationally recognized economic forecasting firm with which CMS contracts to forecast the components of the market baskets and MFP. As described in the FY 2012 IPPS/LTCH PPS final rule, in order to generate a forecast of MFP, IGI replicated the MFP measure calculated by the BLS using a series of proxy variables derived from IGI’s U.S. macroeconomic models. In the FY 2012 IPPS/LTCH PPS final rule, we identified each of the major MFP component series employed by the BLS to measure MFP as well as provided the corresponding concepts determined to be the best available proxies for the BLS series.
Beginning with the FY 2016 rulemaking cycle, as discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24478), the MFP adjustment is calculated using a revised series developed by IGI to proxy the aggregate capital inputs. Specifically, IGI has replaced the Real Effective Capital Stock used for Full Employment GDP with a forecast of BLS aggregate capital inputs recently developed by IGI using a regression model. This series provides a better fit to the BLS capital inputs, as measured by the differences between the actual BLS capital input growth rates and the estimated model growth rates over the historical time period. Therefore, we are using IGI’s most recent forecast of the BLS capital inputs series in the MFP calculations beginning with the FY 2016 rulemaking cycle. A complete description of the MFP projection methodology is available on our Web site at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats/MarketBasketResearch.html. Although we discuss the IGI changes to the MFP proxy series in the FY 2016 IPPS/LTCH PPS proposed rule and in this final rule, in the future, when IGI makes changes to the MFP methodology, we will announce them on our Web site rather than in the annual rulemaking.

For FY 2016, we proposed an MFP adjustment of 0.6 percentage point (80 FR 24478). Similar to the market basket update, for the proposed rule, we used the most recent data available to compute the MFP adjustment. As noted above, we proposed that if more recent data became subsequently available, we would use such data, if appropriate, to determine the FY 2016 market basket update and MFP adjustment in this FY 2016 IPPS/LTCH PPS final rule.
Based on the most recent data available for this final rule, which is IGI’s second quarter 2015 forecast (with historical data through first quarter 2015), the MFP adjustment is 0.5 percentage point for FY 2016.

**Comment:** One commenter supported the proposed FY 2016 IPPS market basket increase of 1.1 percent, after applicable adjustments, to update the IPPS payments for FY 2016 based upon the most current data available. The commenter urged CMS to conduct regular payment impact analysis to ensure appropriate payment levels for inpatient services.

**Response:** We appreciate the commenter’s support of the FY 2016 market basket update under the IPPS. As noted, for this final rule, we are using updated data to estimate the FY 2016 market basket update and MFP adjustment used to determine the applicable percentage increase for the IPPS. We also note that, in each proposed and final rule, we include a payment impact analysis.

**Comment:** One commenter recognized that some of the proposed adjustments of the annual Medicare inpatient rate update are statutory requirements but, nevertheless, expressed disappointment in the small proposed increase of 0.3 percent after the various adjustments. The commenter further stated that, from the perspective of providers, Medicare is continually asking them to do more, such as report more data, provide care in different ways, and invest in more health care information technology. The commenter believed the continual small increases in Medicare payments suggest that Medicare is not interested in helping to pay for any of these improvements. The commenter stated that urban safety-net hospitals are continually stepping up to meet these challenges and urged...
CMS to join them in stepping up by showing a greater willingness to share the cost of doing so.

Response: We acknowledge the commenter’s concern regarding the increased reporting requirements coupled with the MFP adjustment under section 1886(b)(3)(B)(xi) of the Act and the 0.2 percentage point statutory adjustment under section 1886(b)(3)(B)(xii) of the Act. However, as the commenter mentioned, we are required to determine the applicable percentage increase based on the statutory requirements discussed above.

Comment: One commenter stated that the increase to the operating inpatient rates of 1.1 percent omits the 2-percent automatic reductions or sequester required by the Budget Control Act of 2011 (Pub. L. 112-25). The commenter stated the real payment update to acute care hospitals when all of the quality adjustments are considered is approximately –1.0 percent. The commenter further stated that hospitals will be receiving less for the same services in FY 2016 when compared to payment rates in FY 2015. The commenter recommended that the 2-percent sequester reduction be included in the calculation of the annual percentage update because it is a real line item reduction to hospital IPPS payments. The commenter believed that the inclusion of the sequestration would lead to an accurate portrayal of the annual Medicare payment update to hospitals.

Response: We appreciate the commenter’s concerns. However, the sequestration reduction is not a statutory reduction to the applicable percentage increase (it is a
2-percent reduction to overall payments) and, therefore, is not included in the calculation of the applicable percentage increase.

As stated in the proposed rule, we proposed to use more recently available data to determine the final market basket update and the multifactor productivity adjustment. We did not receive any public comments on this proposal. Therefore, for this final rule, we are finalizing a market basket update of 2.4 percent and an MFP adjustment of 0.5 percentage point based on more recently available data.

Based on the most recent data available for this final rule as described above, we have determined four final applicable percentage increases to the standardized amount for FY 2016, as specified in the table below.
### FINAL FY 2016 APPLICABLE PERCENTAGE INCREASES FOR THE IPPS

<table>
<thead>
<tr>
<th>FY 2016</th>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Basket Rate-of-Increase</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Adjustment for Failure to Submit Quality Data under Section 1886(b)(3)(B)(viii) of the Act</td>
<td>0.0</td>
<td>0.0</td>
<td>-0.6</td>
<td>-0.6</td>
</tr>
<tr>
<td>Adjustment for Failure to be a Meaningful EHR User under Section 1886(b)(3)(B)(ix) of the Act</td>
<td>0.0</td>
<td>-1.2</td>
<td>0.0</td>
<td>-1.2</td>
</tr>
<tr>
<td>MFP Adjustment under Section 1886(b)(3)(B)(xi) of the Act</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
</tr>
<tr>
<td>Statutory Adjustment under Section 1886(b)(3)(B)(xii) of the Act</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
</tr>
<tr>
<td>Final Applicable Percentage Increase Applied to Standardized Amount</td>
<td>1.7</td>
<td>0.5</td>
<td>1.1</td>
<td>-0.1</td>
</tr>
</tbody>
</table>

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24478), we proposed to revise the existing regulations at 42 CFR 412.64(d) to reflect the current law for the FY 2016 update. Specifically, in accordance with section 1886(b)(3)(B) of the Act, we proposed to modify paragraph (vi) of § 412.64(d)(1) to include the applicable percentage increase to the FY 2016 operating standardized amount. We did not receive any public
comments on this proposal. Therefore, we are finalizing our proposed revisions to the regulations at § 412.64(d).

Section 1886(b)(3)(B)(iv) of the Act provides that the applicable percentage increase to the hospital-specific rates for SCHs and MDHs equals the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS). Therefore, the update to the hospital-specific rates for SCHs and MDHs also is subject to section 1886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act. We note that section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114-10, enacted on April 16, 2015) extended the MDH program (which, under previous law, was to be in effect for discharges on or before March 31, 2015 only) for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017).

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24478), for FY 2016, we proposed the following updates to the hospital-specific rates applicable to SCHs: an update of 1.9 percent for a hospital that submits quality data and is a meaningful EHR user; an update of 1.225 percent for a hospital that fails to submit quality data and is a meaningful EHR user; an update of 0.55 percent for a hospital that submits quality data and is not a meaningful EHR user; and an update of -0.125 percent for a hospital that fails to submit quality data and is not a meaningful EHR user. We note that at the time of the development of the FY 2016 IPPS/LTCH PPS proposed rule, the MACRA had yet to be signed into law and therefore we did not explicitly address the update of the
hospital-specific rates for FY 2016 for MDHs. However, as noted, under section 1886(b)(3)(B)(iv) of the Act, the update to the hospital-specific rates is the same for both MDHs and SCHs and is equal to the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS). As mentioned above, for the FY 2016 proposed rule, we used IGI’s first quarter 2015 forecast (with historical data through fourth quarter 2014) of the FY 2010-based IPPS market basket update. Similarly, we used IGI’s first quarter 2015 forecast of the MFP adjustment. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24478), we proposed that if more recent data became subsequently available (for example, a more recent estimate of the market basket and the MFP adjustment), we would use such data, if appropriate, to determine the update for SCHs in this final rule.

We did not receive any public comments with regard to this proposal and, therefore, are finalizing the proposal to determine the update to the hospital-specific rates for SCHs and MDHs in this final rule using the most recent data available.

As discussed above, based on more recent data for IGI’s second quarter 2015 forecast of the FY 2010-based IPPS market basket update with historical data through first quarter 2015, we estimate that the FY 2016 market basket update used to determine the update factor for this final rule for the hospital-specific rates of SCHs and MDHs is 2.4 percent. Similarly, for this final rule, we used IGI’s second quarter 2015 forecast of the MFP adjustment, which is estimated at 0.5 percentage point for FY 2016. Accordingly, we are finalizing the following updates to the hospital-specific rates applicable to SCHs and MDHs: an update of 1.7 percent for a hospital that submits
quality data and is a meaningful EHR user; an update of 1.1 percent for a hospital that fails to submit quality data and is a meaningful EHR user; an update of 0.5 percent for a hospital that submits quality data and is not a meaningful EHR user; and an update of -0.1 percent for a hospital that fails to submit quality data and is not a meaningful EHR user.

2. FY 2016 Puerto Rico Hospital Update

Puerto Rico hospitals are paid a blended rate for their inpatient operating costs based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. Section 1886(d)(9)(C)(i) of the Act is the basis for determining the applicable percentage increase applied to the Puerto Rico-specific standardized amount. Section 401(c) of Pub. L. 108-173 amended section 1886(d)(9)(C)(i) of the Act, which states that, for discharges occurring in a fiscal year (beginning with FY 2004), the Secretary shall compute an average standardized amount for hospitals located in any area of Puerto Rico that is equal to the average standardized amount computed under subclause (I) for fiscal year 2003 for hospitals in a large urban area (or, beginning with FY 2005, for all hospitals in the previous fiscal year) increased by the applicable percentage increase under subsection (b)(3)(B) for the fiscal year involved. Therefore, the update to the Puerto Rico-specific operating standardized amount equals the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act (that is, the same update factor as for all other hospitals subject to the IPPS). Accordingly, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24479), we proposed an applicable
percentage increase to the Puerto Rico-specific operating standardized amount of 1.9 percent for FY 2016. For the proposed rule, we used the first quarter 2015 forecast of the FY 2010-based IPPS market basket update with historical data through fourth quarter 2014. We proposed that if more recent data became subsequently available, we would use such data, if appropriate, to determine the final FY 2016 applicable percentage increase for this final rule. We note that the provisions of section 1886(b)(3)(B)(viii) of the Act, which specify the adjustments to the applicable percentage increase for “subsection (d)” hospitals that do not submit quality data under the rules established by the Secretary, and the provisions of section 1886(b)(3)(B)(ix) of the Act, which specify the adjustments to the applicable percentage increase for “subsection (d)” hospitals that are not meaningful EHR users, are not applicable to hospitals located in Puerto Rico.

Similarly, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24479), we used IGI’s first quarter 2015 forecast of the MFP adjustment. We proposed that if more recent data became subsequently available, we would use such data, if appropriate, to determine the MFP adjustment for the final rule.

We did not receive any public comments concerning our proposal. Therefore, using the most recent data available, for FY 2016, we are finalizing an applicable percentage increase to the Puerto Rico-specific operating amount of 1.7 percent (which reflects a FY 2016 estimate of the FY 2010-based IPPS market basket rate-of-increase of 2.4 percent, less an MFP adjustment of 0.5 percentage point and less an additional reduction of 0.2 percentage point as required by section 1886(b)(3)(B)(xii) of the Act). As we noted above, for the proposed rule, we used the first quarter 2015 forecast of the
FY 2010-based IPPS market basket update and MFP with historical data through fourth quarter 2014. For this final rule, we used the most recent data available, which is IGI’s second quarter 2015 forecast (with historical data through first quarter 2015).

B. Rural Referral Centers (RRCs): Annual Updates to Case-Mix Index and Discharge Criteria (§ 412.96)

Under the authority of section 1886(d)(5)(C)(i) of the Act, the regulations at § 412.96 set forth the criteria that a hospital must meet in order to qualify under the IPPS as a rural referral center (RRC). RRCs receive some special treatment under both the DSH payment adjustment and the criteria for geographic reclassification.

Section 402 of Pub. L. 108-173 raised the DSH payment adjustment for RRCs such that they are not subject to the 12-percent cap on DSH payments that is applicable to other rural hospitals. RRCs also are not subject to the proximity criteria when applying for geographic reclassification. In addition, they do not have to meet the requirement that a hospital’s average hourly wage must exceed, by a certain percentage, the average hourly wage of the labor market area in which the hospital is located.

Section 4202(b) of Pub. L. 105-33 states, in part, that any hospital classified as an RRC by the Secretary for FY 1991 shall be classified as such an RRC for FY 1998 and each subsequent fiscal year. In the August 29, 1997 IPPS final rule with comment period (62 FR 45999), CMS reinstated RRC status for all hospitals that lost that status due to triennial review or MGCRB reclassification. However, CMS did not reinstate the status of hospitals that lost RRC status because they were now urban for all purposes because of the OMB designation of their geographic area as urban. Subsequently, in the
August 1, 2000 IPPS final rule (65 FR 47089), we indicated that we were revisiting that decision. Specifically, we stated that we would permit hospitals that previously qualified as an RRC and lost their status due to OMB redesignation of the county in which they are located from rural to urban, to be reinstated as an RRC. Otherwise, a hospital seeking RRC status must satisfy all of the other applicable criteria. We use the definitions of “urban” and “rural” specified in Subpart D of 42 CFR Part 412. One of the criteria under which a hospital may qualify as an RRC is to have 275 or more beds available for use (§412.96(b)(1)(ii)). A rural hospital that does not meet the bed size requirement can qualify as an RRC if the hospital meets two mandatory prerequisites (a minimum case-mix index (CMI) and a minimum number of discharges), and at least one of three optional criteria (relating to specialty composition of medical staff, source of inpatients, or referral volume). (We refer readers to §412.96(c)(1) through (c)(5) and the September 30, 1988 Federal Register (53 FR 38513) for additional discussion.) With respect to the two mandatory prerequisites, a hospital may be classified as an RRC if--

- The hospital’s CMI is at least equal to the lower of the median CMI for urban hospitals in its census region, excluding hospitals with approved teaching programs, or the median CMI for all urban hospitals nationally; and

- The hospital’s number of discharges is at least 5,000 per year, or, if fewer, the median number of discharges for urban hospitals in the census region in which the hospital is located. The number of discharges criterion for an osteopathic hospital is at least 3,000 discharges per year, as specified in section 1886(d)(5)(C)(i) of the Act.

1. Case-Mix Index (CMI)
Section 412.96(c)(1) provides that CMS establish updated national and regional CMI values in each year’s annual notice of prospective payment rates for purposes of determining RRC status. The methodology we used to determine the national and regional CMI values is set forth in the regulations at § 412.96(c)(1)(ii). The national median CMI value for FY 2016 is based on the CMI values of all urban hospitals nationwide, and the regional median CMI values for FY 2016 are based on the CMI values of all urban hospitals within each census region, excluding those hospitals with approved teaching programs (that is, those hospitals that train residents in an approved GME program as provided in § 413.75). These values are based on discharges occurring during FY 2014 (October 1, 2013 through September 30, 2014), and include bills posted to CMS’ records through March 2015.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24479), we proposed that, in addition to meeting other criteria, if rural hospitals with fewer than 275 beds are to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2015, they must have a CMI value for FY 2014 that is at least--

- 1.6075; or

- The median CMI value (not transfer-adjusted) for urban hospitals (excluding hospitals with approved teaching programs as identified in § 413.75) calculated by CMS for the census region in which the hospital is located. (We refer readers to the table set forth in the FY 2016 IPPS/LTCH PPS proposed rule at 80 FR 24480.)

The final CMI values for FY 2016 are based on the latest available data (FY 2014 bills received through March 2015). In addition to meeting other criteria, if rural
hospitals with fewer than 275 beds are to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2015, they must have a CMI value for FY 2014 that is at least—

- 1.6082; or
- The median CMI value (not transfer-adjusted) for urban hospitals (excluding hospitals with approved teaching programs as identified in § 413.75) calculated by CMS for the census region in which the hospital is located.

The final median CMI values by region are set forth in the following table.

<table>
<thead>
<tr>
<th>Region</th>
<th>Case-Mix Index Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. New England (CT, ME, MA, NH, RI, VT)</td>
<td>1.3737</td>
</tr>
<tr>
<td>2. Middle Atlantic (PA, NJ, NY)</td>
<td>1.4500</td>
</tr>
<tr>
<td>3. South Atlantic (DE, DC, FL, GA, MD, NC, SC, VA, WV)</td>
<td>1.5035</td>
</tr>
<tr>
<td>4. East North Central (IL, IN, MI, OH, WI)</td>
<td>1.5104</td>
</tr>
<tr>
<td>5. East South Central (AL, KY, MS, TN)</td>
<td>1.4184</td>
</tr>
<tr>
<td>6. West North Central (IA, KS, MN, MO, NE, ND, SD)</td>
<td>1.5855</td>
</tr>
<tr>
<td>7. West South Central (AR, LA, OK, TX)</td>
<td>1.6276</td>
</tr>
<tr>
<td>8. Mountain (AZ, CO, ID, MT, NV, NM, UT, WY)</td>
<td>1.7075</td>
</tr>
<tr>
<td>9. Pacific (AK, CA, HI, OR, WA)</td>
<td>1.6168</td>
</tr>
</tbody>
</table>

A hospital seeking to qualify as an RRC should obtain its hospital-specific CMI value (not transfer-adjusted) from its MAC. Data are available on the Provider Statistical and Reimbursement (PS&R) System. In keeping with our policy on discharges, the CMI values are computed based on all Medicare patient discharges subject to the IPPS MS-DRG-based payment.

2. Discharges
Section 412.96(c)(2)(i) provides that CMS set forth the national and regional numbers of discharges criteria in each year’s annual notice of prospective payment rates for purposes of determining RRC status. As specified in section 1886(d)(5)(C)(ii) of the Act, the national standard is set at 5,000 discharges. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24480), for FY 2016, we proposed to update the regional standards based on discharges for urban hospitals’ cost reporting periods that began during FY 2013 (that is, October 1, 2012 through September 30, 2013), which are the latest cost report data available at the time the proposed rule was developed.

We proposed that, in addition to meeting other criteria, a hospital, if it is to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2015, must have, as the number of discharges for its cost reporting period that began during FY 2013, at least--

- 5,000 (3,000 for an osteopathic hospital); or
- The median number of discharges for urban hospitals in the census region in which the hospital is located. (We refer readers to the table set forth in the FY 2016 IPPS/LTCH PPS proposed rule at 80 FR 24480.)

Based on the latest discharge data available at this time (that is, based on FY 2013 cost report data), the final median number of discharges for urban hospitals by census region are set forth in the following table.
<table>
<thead>
<tr>
<th>Region</th>
<th>Number of Discharges</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. New England (CT, ME, MA, NH, RI, VT)</td>
<td>7,462</td>
</tr>
<tr>
<td>2. Middle Atlantic (PA, NJ, NY)</td>
<td>10,594</td>
</tr>
<tr>
<td>3. South Atlantic (DE, DC, FL, GA, MD, NC, SC, VA, WV)</td>
<td>10,233</td>
</tr>
<tr>
<td>4. East North Central (IL, IN, MI, OH, WI)</td>
<td>7,992</td>
</tr>
<tr>
<td>5. East South Central (AL, KY, MS, TN)</td>
<td>7,672</td>
</tr>
<tr>
<td>6. West North Central (IA, KS, MN, MO, NE, ND, SD)</td>
<td>7,857</td>
</tr>
<tr>
<td>7. West South Central (AR, LA, OK, TX)</td>
<td>5,490</td>
</tr>
<tr>
<td>8. Mountain (AZ, CO, ID, MT, NV, NM, UT, WY)</td>
<td>8,046</td>
</tr>
<tr>
<td>9. Pacific (AK, CA, HI, OR, WA)</td>
<td>8,797</td>
</tr>
</tbody>
</table>

We note that the median number of discharges for hospitals in each census region is greater than the national standard of 5,000 discharges. Therefore, under this final rule, 5,000 discharges is the minimum criterion for all hospitals, except for osteopathic hospitals for which the minimum criterion is 3,000 discharges.

C. Indirect Medical Education (IME) Payment Adjustment Factor for FY 2016 (§ 412.105)

Under the IPPS, an additional payment amount is made to hospitals with residents in an approved graduate medical education (GME) program in order to reflect the higher indirect patient care costs of teaching hospitals relative to nonteaching hospitals. The payment amount is determined by use of a statutorily specified adjustment factor. The regulations regarding the calculation of this additional payment, known as the IME adjustment, are located at § 412.105. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51680) for a full discussion of the IME adjustment and IME adjustment factor. Section 1886(d)(5)(B)(ii)(XII) of the Act provides that, for discharges occurring
during FY 2008 and fiscal years thereafter, the IME formula multiplier is 1.35. Accordingly, for discharges occurring during FY 2016, the formula multiplier is 1.35. We estimate that application of this formula multiplier for the FY 2016 IME adjustment will result in an increase in IPPS payment of 5.5 percent for every approximately 10 percent increase in the hospital’s resident to bed ratio.

We did not receive any public comments on this provision. As noted above, the IME formula multiplier is specified in statute and is 1.35 for FY 2016.
D. FY 2016 Payment Adjustment for Medicare Disproportionate Share Hospitals (DSHs) (§ 412.106)

1. Background

Section 1886(d)(5)(F) of the Act provides for additional Medicare payments to subsection (d) hospitals that serve a significantly disproportionate number of low-income patients. The Act specifies two methods by which a hospital may qualify for the Medicare disproportionate share hospital (DSH) adjustment. Under the first method, hospitals that are located in an urban area and have 100 or more beds may receive a Medicare DSH payment adjustment if the hospital can demonstrate that, during its cost reporting period, more than 30 percent of its net inpatient care revenues are derived from State and local government payments for care furnished to needy patients with low incomes. This method is commonly referred to as the “Pickle method.” The second method for qualifying for the DSH payment adjustment, which is the most common, is based on a complex statutory formula under which the DSH payment adjustment is based on the hospital’s geographic designation, the number of beds in the hospital, and the level of the hospital’s disproportionate patient percentage (DPP). A hospital’s DPP is the sum of two fractions: the “Medicare fraction” and the “Medicaid fraction.” The Medicare fraction (also known as the “SSI fraction” or “SSI ratio”) is computed by dividing the number of the hospital’s inpatient days that are furnished to patients who were entitled to both Medicare Part A and Supplemental Security Income (SSI) benefits by the hospital’s total number of patient days furnished to patients entitled to benefits under Medicare Part A. The Medicaid fraction is computed by dividing the hospital’s number of inpatient
days furnished to patients who, for such days, were eligible for Medicaid, but were not entitled to benefits under Medicare Part A, by the hospital’s total number of inpatient days in the same period.

Because the DSH payment adjustment is part of the IPPS, the DSH statutory references (under section 1886(d)(5)(F) of the Act) to “days” apply only to hospital acute care inpatient days. Regulations located at § 412.106 govern the Medicare DSH payment adjustment and specify how the DPP is calculated as well as how beds and patient days are counted in determining the Medicare DSH payment adjustment. Under § 412.106(a)(1)(i), the number of beds for the Medicare DSH payment adjustment is determined in accordance with bed counting rules for the IME adjustment under § 412.105(b).

2. Impact on Medicare DSH Payment Adjustment of the Continued Implementation of New OMB Labor Market Area Delineations

As discussed in section III.G. of the preamble of this final rule, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951) we implemented the revised OMB labor market area delineations (which are based on 2010 Decennial Census data) for the FY 2015 wage index. (In this final rule, we refer to these revised OMB labor market area delineations as the “new OMB delineations.”) We stated that this implementation would have an impact on the calculation of Medicare DSH payments to certain hospitals. Hospitals that are designated as rural with less than 500 beds and that are not rural referral centers (RRCs) are subject to a maximum DSH payment adjustment of 12 percent. Accordingly, hospitals with less than 500 beds that were in urban counties
that became rural when we adopted the new OMB delineations, and that did not become
RRCs, are subject to a maximum DSH payment adjustment of 12 percent. (We note that
urban hospitals are only subject to a maximum DSH payment adjustment of 12 percent if
they have less than 100 beds.)

Under the regulation at 42 CFR 412.102, a hospital located in an area that is
reclassified from urban to rural, as defined in the regulations, may receive an adjustment
to its rural Federal payment amount for operating costs for 2 successive fiscal years.
Specifically, the regulations state that, in the first year after a hospital loses urban status,
the hospital will receive an additional payment that equals two-thirds of the difference
between the DSH payments as applicable to the hospital before its redesignation from
urban to rural and the DSH payments applicable to the hospital subsequent to its
redesignation from urban to rural. In the second year after a hospital loses urban status,
the hospital will receive an additional payment that equals one-third of the difference
between the DSH payments applicable to the hospital before its redesignation from urban
to rural and the DSH payments otherwise applicable to the hospital subsequent to its
redesignation from urban to rural.

For the purposes of ratesetting, calculating budget neutrality, and modeling
payment impacts for this FY 2016 final rule, for any hospital that was previously urban
but changed to rural status in FY 2015 as a result of the adoption of the new OMB labor
market area delineations, in the FY 2016 IPPS/LTCH PPS proposed rule, we proposed to
model its DSH payments such that the payment equals the amount of the rural DSH
payments plus one-third of the difference between the urban DSH payments and the rural DSH payments.

We did not receive any public comments on our proposal.

3. Payment Adjustment Methodology for Medicare Disproportionate Share Hospitals (DSHs) under Section 3133 of the Affordable Care Act

a. General Discussion

Section 3133 of the Patient Protection and Affordable Care Act, as amended by section 10316 of the same Act and section 1104 of the Health Care and Education Reconciliation Act (Pub. L. 111-152), added a new section 1886(r) to the Act that modifies the methodology for computing the Medicare DSH payment adjustment beginning in FY 2014. For purposes of this final rule, we refer to these provisions collectively as section 3133 of the Affordable Care Act.

Medicare DSH payments are calculated under a statutory formula that considers the hospital’s Medicare utilization attributable to beneficiaries who also receive Supplemental Security Income (SSI) benefits, and the hospital’s Medicaid utilization. Beginning with discharges in FY 2014, hospitals that qualify for Medicare DSH payments under section 1886(d)(5)(F) of the Act receive 25 percent of the amount they previously would have received under the statutory formula for Medicare DSH payments. This provision applies equally to hospitals that qualify for DSH payments under section 1886(d)(5)(F)(i)(I) of the Act and those hospitals that qualify under the Pickle method under section 1886(d)(5)(F)(i)(II) of the Act.
The remaining amount, equal to an estimate of 75 percent of what otherwise would have been paid as Medicare DSH payments, reduced to reflect changes in the percentage of individuals under age 65 who are uninsured, is available to make additional payments to each hospital that qualifies for Medicare DSH payments and that has uncompensated care. The payments to each hospital for a fiscal year are based on the hospital’s amount of uncompensated care for a given time period relative to the total amount of uncompensated care for that same time period reported by all hospitals that receive Medicare DSH payments for that fiscal year.

As provided by section 3133 of the Affordable Care Act, section 1886(r) of the Act requires that, for FY 2014 and each subsequent fiscal year, a subsection (d) hospital that would otherwise receive a disproportionate share hospital payment made under section 1886(d)(5)(F) of the Act receives two separately calculated payments. Specifically, section 1886(r)(1) of the Act provides that the Secretary shall pay to such a subsection (d) hospital (including a Pickle hospital) 25 percent of the amount the hospital would have received under section 1886(d)(5)(F) of the Act for DSH payments, which represents the empirically justified amount for such payment, as determined by the Medicare Payment Advisory Commission in its March 2007 Report to the Congress. We refer to this payment as the “empirically justified Medicare DSH payment.”

In addition to this empirically justified Medicare DSH payment, section 1886(r)(2) of the Act provides that, for FY 2014 and each subsequent fiscal year, the Secretary shall pay to such subsection (d) hospital an additional amount equal to the product of three factors. The first factor is the difference between the aggregate amount
of payments that would be made to subsection (d) hospitals under section 1886(d)(5)(F) of the Act if subsection (r) did not apply and the aggregate amount of payments that are made to subsection (d) hospitals under section 1886(r)(1) of the Act for each fiscal year. Therefore, this factor amounts to 75 percent of the payments that would otherwise be made under section 1886(d)(5)(F) of the Act.

The second factor is, for FYs 2014 through 2017, 1 minus the percent change in the percent of individuals under the age of 65 who are uninsured, determined by comparing the percent of such individuals who are uninsured in 2013, the last year before coverage expansion under the Affordable Care Act (as calculated by the Secretary based on the most recent estimates available from the Director of the Congressional Budget Office before a vote in either House on the Health Care and Education Reconciliation Act of 2010 that, if determined in the affirmative, would clear such Act for enrollment), minus 0.1 percentage point for FY 2014, and minus 0.2 percentage point for FYs 2015 through 2017. For FYs 2014 through 2017, the baseline for the estimate of the change in uninsurance is fixed by the most recent estimate of the Congressional Budget Office before the final vote on the Health Care and Education Reconciliation Act of 2010, which is contained in a March 20, 2010 letter from the Director of the Congressional Budget Office to the Speaker of the House. (The March 20, 2010 letter is available for viewing on the following Web site:

For FY 2018 and subsequent years, the second factor is 1 minus the percent change in the percent of individuals who are uninsured, as determined by comparing the percent of individuals who are uninsured in 2013 (as estimated by the Secretary, based on data from the Census Bureau or other sources the Secretary determines appropriate, and certified by the Chief Actuary of CMS), and the percent of individuals who are uninsured in the most recent period for which data are available (as so estimated and certified), minus 0.2 percentage point for FYs 2018 and 2019. Therefore, for FY 2018 and subsequent years, the statute provides some greater flexibility in the choice of the data sources to be used for the estimate of the change in the percent of uninsured individuals.

The third factor is a percent that, for each subsection (d) hospital, represents the quotient of the amount of uncompensated care for such hospital for a period selected by the Secretary (as estimated by the Secretary, based on appropriate data), including the use of alternative data where the Secretary determines that alternative data is available which is a better proxy for the costs of subsection (d) hospitals for treating the uninsured, and the aggregate amount of uncompensated care for all subsection (d) hospitals that receive a payment under section 1886(r) of the Act. Therefore, this third factor represents a hospital’s uncompensated care amount for a given time period relative to the uncompensated care amount for that same time period for all hospitals that receive Medicare DSH payments in that fiscal year, expressed as a percent.
For each hospital, the product of these three factors represents its additional payment for uncompensated care for the applicable fiscal year. We refer to the additional payment determined by these factors as the “uncompensated care payment.”

Section 1886(r) of the Act applies to FY 2014 and each subsequent fiscal year. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50620 through 50647) and the FY 2014 IPPS interim final rule with comment period (78 FR 61191 through 61197), we set forth our policies for implementing the required changes to the DSH payment methodology made by section 3133 of the Affordable Care Act for FY 2014. In those rules, we noted that, because section 1886(r) of the Act modifies the payment required under section 1886(d)(5)(F) of the Act, it affects only the DSH payment under the operating IPPS. It does not revise or replace the capital IPPS DSH payment provided under the regulations at 42 CFR Part 412, Subpart M, which were established through the exercise of the Secretary’s discretion in implementing the capital IPPS under section 1886(g)(1)(A) of the Act.

Finally, section 1886(r)(3) of the Act provides that there shall be no administrative or judicial review under section 1869, section 1878, or otherwise of any estimate of the Secretary for purposes of determining the factors described in section 1886(r)(2) of the Act or of any period selected by the Secretary for the purpose of determining those factors. Therefore, there is no administrative or judicial review of the estimates developed for purposes of applying the three factors used to determine uncompensated care payments, or the periods selected in order to develop such estimates.
b. Eligibility for Empirically Justified Medicare DSH Payments and Uncompensated Care Payments

As indicated earlier, the payment methodology under section 3133 of the Affordable Care Act applies to “subsection (d) hospitals” that would otherwise receive a DSH payment made under section 1886(d)(5)(F) of the Act. Therefore, hospitals must receive empirically justified Medicare DSH payments in a fiscal year in order to receive an additional Medicare uncompensated care payment for that year. Specifically, section 1886(r)(2) of the Act states that, in addition to the payment made to a subsection (d) hospital under section 1886(r)(1) of the Act, the Secretary shall pay to such subsection (d) hospitals an additional amount. Because section 1886(r)(1) of the Act refers to empirically justified Medicare DSH payments, the additional payment under section 1886(r)(2) of the Act is limited to hospitals that receive empirically justified Medicare DSH payments in accordance with section 1886(r)(1) of the Act for the applicable fiscal year.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50622) and the FY 2014 IPPS interim final rule with comment period (78 FR 61193), we provided that hospitals that are not eligible to receive empirically justified Medicare DSH payments in a fiscal year will not receive uncompensated care payments for that year. We also specified that we would make a determination concerning eligibility for interim uncompensated care payments based on each hospital’s estimated DSH status for the applicable fiscal year (using the most recent data that are available). We indicated that our final determination on the
hospital's eligibility for uncompensated care payments would be based on the hospital's actual DSH status at cost report settlement for that payment year.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50622) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50006), we specified our policies for several specific classes of hospitals within the scope of section 1886(r) of the Act. We refer readers to those two final rules for a detailed discussion of our policies. In summary, we specified the following:

- **Subsection (d) Puerto Rico hospitals** that are eligible for DSH payments also are eligible to receive empirically justified Medicare DSH payments and uncompensated care payments under the new payment methodology (78 FR 50623 and 79 FR 50006).

- **Maryland hospitals** are not eligible to receive empirically justified Medicare DSH payments and uncompensated care payments under the payment methodology of section 1886(r) of the Act because they are not paid under the IPPS. As discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50007), effective January 1, 2014, the State of Maryland elected to no longer have Medicare pay Maryland hospitals in accordance with section 1814(b)(3) of the Act and entered into an agreement with CMS that Maryland hospitals will be paid under the Maryland All-Payer Model. However, under the Maryland All-Payer Model, Maryland hospitals still are not paid under the IPPS. Therefore, they remain ineligible to receive empirically justified Medicare DSH payments or uncompensated care payments under section 1886(r) of the Act.

- **SCHs** that are paid under their hospital-specified rate are not eligible for Medicare DSH payments. SCHs that are paid under the IPPS Federal rate receive interim
payments based on what we estimate and project their DSH status to be prior to the beginning of the Federal fiscal year (based on the best available data at that time) subject to settlement through the cost report, and if they receive interim empirically justified Medicare DSH payments in a fiscal year, they also will receive interim uncompensated care payments for that fiscal year on a per discharge basis, subject as well to settlement through the cost report. Final eligibility determinations will be made at the end of the cost reporting period at settlement, and both interim empirically justified Medicare DSH payments and uncompensated care payments will be adjusted accordingly (78 FR 50624 and 79 FR 50007).

- **MDHs** are paid based on the IPPS Federal rate or, if higher, the IPPS Federal rate plus 75 percent of the amount by which the Federal rate is exceeded by the updated hospital-specific rate from certain specified base years (76 FR 51684). The IPPS Federal rate used in the MDH payment methodology is the same IPPS Federal rate that is used in the SCH payment methodology. We note that at the time of the development of the FY 2016 IPPS/LTCH PPS proposed rule, the MDH Program was to be in effect for discharges on or before March 31, 2015, only. Section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Pub. L. 114-10, enacted April 16, 2015, extended the MDH program for discharges on or after April 1, 2015, through September 30, 2017. (We refer readers to the interim final rule with comment period at section IV.L.3. of the preamble of this document for a full discussion of the extension of the MDH Program.) Because MDHs are paid based on the IPPS Federal rate, for FY 2016, MDHs will continue to be eligible to receive Medicare DSH payments and
uncompensated care payments if their disproportionate patient percentage is at least 15 percent. We will apply the same process to determine MDH eligibility for Medicare DSH and uncompensated care payments, as we do for all other IPPS hospitals, through September 30, 2017. Moreover, we will continue to make a determination concerning eligibility for interim uncompensated care payments based on each hospital’s estimated DSH status for the applicable fiscal year (using the most recent data that are available). Our final determination on the hospital’s eligibility for uncompensated care payments will be based on the hospital’s actual DSH status at cost report settlement for that payment year. In addition, as we do for all IPPS hospitals, we calculate a numerator for Factor 3 for all MDHs, regardless of whether they are projected to be eligible for Medicare DSH payments during the fiscal year, but the denominator for Factor 3 will be based on the uncompensated care data from the hospitals that we have projected to be eligible for Medicare DSH payments during the fiscal year.

- **IPPS hospitals that have elected to participate in the Bundled Payments for Care Improvement initiative** continue to be paid under the IPPS (77 FR 53342) and, therefore, are eligible to receive empirically justified Medicare DSH payments and uncompensated care payments (78 FR 50625 and 79 FR 50008).

- **Hospitals participating in the Rural Community Hospital Demonstration Program** under section 410A of the Medicare Modernization Act do not receive DSH payments and, therefore, are excluded from receiving empirically justified Medicare DSH payments and uncompensated care payments under the new DSH payment methodology.
(78 FR 50625 and 79 FR 50008). There are 17 hospitals currently participating in the demonstration.

c. Empirically Justified Medicare DSH Payments

As we have discussed earlier, section 1886(r)(1) of the Act requires the Secretary to pay 25 percent of the amount of the DSH payment that would otherwise be made under section 1886(d)(5)(F) of the Act to a subsection (d) hospital. Because section 1886(r)(1) of the Act merely requires the program to pay a designated percentage of these payments, without revising the criteria governing eligibility for DSH payments or the underlying payment methodology, we stated in the FY 2014 IPPS/LTCH PPS final rule that we did not believe that it was necessary to develop any new operational mechanisms for making such payments. Therefore, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50626), we implemented this provision by advising MACs to simply adjust the interim claim payments to the requisite 25 percent of what would have otherwise been paid. We also made corresponding changes to the hospital cost report so that these empirically justified Medicare DSH payments can be settled at the appropriate level at the time of cost report settlement. We provided more detailed operational instructions and cost report instructions following issuance of the FY 2014 IPPS/LTCH PPS final rule that are available on the CMS Web site at: http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2014-Transmittals-Items/R5P240.html.

d. Uncompensated Care Payments

As we have discussed earlier, section 1886(r)(2) of the Act provides that, for each eligible hospital in FY 2014 and subsequent years, the uncompensated care payment is
the product of three factors. These three factors represent our estimate of 75 percent of the amount of Medicare DSH payments that would otherwise have been paid, an adjustment to this amount for the percent change in the national rate of uninsurance compared to the rate of uninsurance in 2013, and each eligible hospital’s estimated uncompensated care amount relative to the estimated uncompensated care amount for all eligible hospitals. Below we discuss the data sources and methodologies for computing each of these factors, our final policies for FY 2014 and FY 2015, and our proposed and final policies for FY 2016.

(1) Calculation of Factor 1 for FY 2016

Section 1886(r)(2)(A) of the Act establishes Factor 1 in the calculation of the uncompensated care payment. Section 1886(r)(2)(A) of the Act states that it is a factor equal to the difference between (i) the aggregate amount of payments that would be made to subsection (d) hospitals under section 1886(d)(5)(F) if this section did not apply for such fiscal year (as estimated by the Secretary); and (ii) the aggregate amount of payments that are made to subsection (d) hospitals under section 1886(r)(1) of the Act for such fiscal year (as so estimated). Therefore, section 1886(r)(2)(A)(i) of the Act represents the estimated Medicare DSH payment that would have been made under section 1886(d)(5)(F) of the Act if section 1886(r) of the Act did not apply for such fiscal year. Under a prospective payment system, we would not know the precise aggregate Medicare DSH payment amount that would be paid for a Federal fiscal year until cost report settlement for all IPPS hospitals is completed, which occurs several years after the end of the Federal fiscal year. Therefore, section 1886(r)(2)(A)(i) of the Act provides
authority to estimate this amount, by specifying that, for each fiscal year to which the provision applies, such amount is to be “estimated by the Secretary.” Similarly, section 1886(r)(2)(A)(ii) of the Act represents the estimated empirically justified Medicare DSH payments to be made in a fiscal year, as prescribed under section 1886(r)(1) of the Act. Again, section 1886(r)(2)(A)(ii) of the Act provides authority to estimate this amount.

Therefore, Factor 1 is the difference between our estimates of: (1) the amount that would have been paid in Medicare DSH payments for the fiscal year, in the absence of the new payment provision; and (2) the amount of empirically justified Medicare DSH payments that are made for the fiscal year, which takes into account the requirement to pay 25 percent of what would have otherwise been paid under section 1886(d)(5)(F) of the Act. In other words, this factor represents our estimate of 75 percent (100 percent minus 25 percent) of our estimate of Medicare DSH payments that would otherwise be made, in the absence of section 1886(r) of the Act, for the fiscal year.

As we did for FY 2015, in order to determine Factor 1 in the uncompensated care payment formula for FY 2016, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24484), we proposed to continue the policy established in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50628 through 50630) and in the FY 2014 IPPS interim final rule with comment period (78 FR 61194). Under this policy, Factor 1 is determined by developing estimates of both the aggregate amount of Medicare DSH payments that would be made in the absence of section 1886(r)(1) of the Act and the aggregate amount of empirically justified Medicare DSH payments to hospitals under
section 1886(r)(1) of the Act through rulemaking. These estimates will not be revised or updated after we know the final Medicare DSH payments for FY 2016.

Therefore, in order to determine the two elements of Factor I (Medicare DSH payments prior to the application of section 1886(r)(1) of the Act, and empirically justified Medicare DSH payments after application of section 1886(r)(1) of the Act), in FYs 2014 and 2015, we used the most recently available projections of Medicare DSH payments for the applicable fiscal year, as calculated by CMS’ Office of the Actuary using the most recently filed Medicare hospital cost report with Medicare DSH payment information and the most recent Medicare DSH patient percentages and Medicare DSH payment adjustments provided in the IPPS Impact File.

For purposes of calculating Factor I and modeling the impact of this provision for the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24484), we used the Office of the Actuary’s February 2015 Medicare DSH estimates, which are based on data from the December 2014 update of the Medicare Hospital Cost Report Information System (HCRIS), 2012 cost report data provided to CMS by IHS hospitals, and the FY 2015 IPPS/LTCH PPS final rule IPPS Impact File, published in conjunction with the publication of the FY 2015 IPPS/LTCH PPS final rule. Because SCHs that are projected to be paid under their hospital-specific rate are not subject to the provisions of section 1886(r) of the Act, these hospitals were excluded from the February 2015 Medicare DSH estimates. Furthermore, because section 1886(r) of the Act specifies that the uncompensated care payment is in addition to the empirically justified DSH payment (or 25 percent of DSH payments that would be made without regard to section 1886(r)),
Maryland hospitals participating in the Maryland All-Payer Model and hospitals participating in the Rural Community Hospital Demonstration that do not receive DSH payments also are excluded from the Office of the Actuary’s Medicare DSH estimates.

Using the data sources discussed above, the Office of the Actuary applies inflation updates and assumptions for future changes in utilization and case-mix to estimate Medicare DSH payments for the upcoming fiscal year. The February 2015 Office of the Actuary estimate for proposed Medicare DSH payments for FY 2016, without regard to the application of section 1886(r)(1) of the Act, was approximately $13.338 billion. Therefore, based on the February 2015 estimate, the estimate for empirically justified Medicare DSH payments for FY 2016, with the application of section 1886(r)(1) of the Act, was $3.335 billion (25 percent of the total amount estimated). Under § 412.106(g)(1)(i) of the regulations, Factor 1 is the difference between these two estimates of the Office of the Actuary. Therefore, in the proposed rule, we proposed that Factor 1 for FY 2016 would be $10,003,425,327.39 ($13,337,900,436.52 minus $3,334,475,109.13). We invited public comments on our proposed calculation of Factor 1 for FY 2016.

Comment: A number of commenters supported CMS’ methodology for determining Factor 1 and the proposed Factor 1 for FY 2016.

Response: We appreciate the commenters’ support.

Comment: A number of commenters asked for greater transparency around the methodology used by the Office of the Actuary to estimate aggregate DSH payments that would have been paid absent implementation of the Affordable Care Act, particularly
transparency in the calculation of estimated DSH payments for purposes of Factor 1. The commenters urged CMS to clarify the methodology used to make these projections and to provide additional information related to them. The commenters also requested that this information be provided in advance of publication of the IPPS final rule and, in the future, in proposed rules each year. The commenters stated that hospitals do not have sufficient information to understand or replicate the relevant projections and estimates for Factor 1.

Many commenters highlighted that one of the assumptions (the assumption shown in “Other” column) used in determining the proposed Factor 1 for FY 2016 has a substantial negative effect on hospitals, and requested more explanation for that assumption as well as a reassessment of the assumption. They pointed out that this assumption had previously, according to CMS, included the impact of only IPPS discharges and the impact of DSH payments increasing or decreasing at a different rate than other IPPS payments. The commenters expressed concern that the “Other” column changed from 1.0355 in the FY 2015 IPPS/LTCH PPS final rule to 0.9993 in the FY 2016 IPPS/LTCH PPS proposed rule. The commenters noted that the explanation offered in the FY 2015 IPPS/LTCH PPS final rule discussed Medicaid enrollment and utilization patterns and that this did not appear to explain the change in the variable in the FY 2016 IPPS/LTCH PPS proposed rule. Some commenters pointed out that, to some extent, the “Other” assumption is affected by the “Discharge” assumption, and that they believed discharges are decreasing faster than what was taken into consideration in the FY 2015 IPPS/LTCH PPS final rule. In other words, they believed that the trend
information used to determine the “Discharge” assumption may be resulting in a lower number for the “Other” assumption. One commenter stated that CMS does not disclose how discharge data are adjusted by a completion factor. One commenter also pointed out that the values for the assumptions regarding discharges and case-mix across FY 2014, FY 2015, and FY 2016 are relatively similar, while the value for the “Other” assumption has changed. The commenters requested that CMS also share detailed calculations of the discharge and case-mix values.

Several commenters believed that the “Other” assumption should reflect the changes in DSH payments that would result from the Medicaid and CHIP expansion. Other commenters asked CMS to explain how the Medicaid and CHIP expansion is accounted for in the Factor 1 estimate. The commenters stated that the additional Medicaid and CHIP enrollment estimated for 2014 through 2016 by CBO in a February 2014 report represents a 32-percent increase in this population. The commenters stated that they had reviewed other data, including the ASPE Issue Brief entitled “Impact of Insurance Expansion on Hospital Uncompensated Care Costs in 2014,” that indicate that Medicaid enrollment and utilization have increased. The commenters believed that Factor 1 is too low because it does not take this increase into consideration appropriately. They noted that CMS has responded to similar comments in prior rulemaking by stating that “the increase due to Medicaid expansion is not as large as commenters contended due to the actuarial assumption that the new enrollees are healthier than the average Medicaid recipient, and, therefore, use fewer hospital services.” However, the commenters asserted that CMS provided no support for this contention and that CMS
should have enrollment and/or utilization information from Medicaid expansion programs. Furthermore, the commenters stated that they believed CMS did not take into consideration any one-time increase in utilization resulting from the new Medicaid enrollment and the previously unmet health care needs of that population. These commenters believed that, in the early years of Medicaid expansion, such an increase in utilization would be more logical than CMS' assertion that new Medicaid enrollees would use fewer hospital services.

Several commenters believed that it would be appropriate to adjust the “Other” assumption in a manner that supports safety-net hospitals in order to reflect the growing number of hospitals that are becoming eligible for DSH. Based on this belief, the commenters expressed concern about the sustainability of continued reductions to aggregate uncompensated care payments. The commenters noted that, as insurance coverage increases, the aggregate amount available for uncompensated care payments will decline and thus reduce the amount of payments to be distributed to help cover the cost of uncompensated care. The commenters further noted that hospitals in States that have not expanded Medicaid are not experiencing a decrease in uncompensated care costs and that reductions in Medicare DSH payments are detrimental to these hospitals. Some commenters noted the reductions in payments they would experience due to CMS’ uncompensated care proposal in totality.

Several commenters believed there was incomplete information in the FY 2016 IPPS/LTCH PPS proposed rule regarding the “completion factor” and requested further detail. One commenter believed that the growth rates in DSH payments are higher than
the current data indicate because the completion factor for the cost reports in HCRIS for
2012 and 2013 is low. Specifically, the commenter shared an analysis that showed that
approximately one-half of the 2012 cost reports contained adjusted Medicaid days data
and approximately one-fifth of the 2013 cost reports contained adjusted Medicaid days
data. The commenter showed the results of a longitudinal analysis between December
2012 and March 2015 using HCRIS data that demonstrated that Medicaid days increased
between when 2010, 2011, and 2012 cost reports were filed and March 2015, regardless
of the status of the cost report settlement process (for example, amended, reopened,
settled without audit, or settled with audit). The range of increase shown by the
commenter’s analysis was between 0.3 percent and 3.7 percent. The commenter stated
that in its longitudinal analysis of HCRIS data between December 2012 and March 2015,
it further examined DSH payments reported in HCRIS and found that payments increased
on average 1.1 percent over the 2-year period.

One commenter requested that CMS use the most recent 2012 cost report data in
its estimate of Factor 1. The commenter stated that problems in obtaining accurate data
for Medicaid days can lead to underreporting in the initial submission of the Medicare
cost report and that this delay can also affect the DSH payment calculated in the cost
report. Therefore, the commenter requested that CMS revise its estimate of the 2012
DSH payments in the final rule using the latest available update of the 2012 Medicare
cost report data.

Commenters wanted to better understand the changes in the estimate of aggregate
DSH payments that would have been paid absent implementation of the Affordable Care
Act over time and wanted to be able to replicate the figures. The commenters believed that transparency is critical because the statute precludes judicial review of the estimates for purposes of determining the three factors used in computing uncompensated care payments and because they understand that these estimates will not be revised or updated after the final rule.

Response: Factor 1 is not estimated in isolation. The Factor 1 estimates for proposed rules are generally consistent with the economic assumptions and actuarial analysis used to develop the President’s Budget estimates under current law, and the Factor 1 estimates for the final rule are generally consistent with those used for the Mid-Session Review of the President’s Budget. For additional information on the development of the President’s Budget, we refer readers to the Office of Management and Budget Web site at: https://www.whitehouse.gov/omb/budget. For additional information on the specific economic assumptions used in the Midsession Review of the President’s FY 2016 Budget, we refer readers to the “Midsession Review of the President’s FY 2016 Budget” available on the Office of Management and Budget Web site at: https://www.whitehouse.gov/sites/default/files/omb/budget/fy2016/assets/16msr.pdf, under “Economic Assumptions”. For a general overview of the principal steps involved in projecting future inpatient costs and utilization, we refer readers to the “2014 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds” available on the CMS Web site at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-
As we did in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50010), later in this section we provide additional information regarding the data sources, methods, and assumptions employed by the actuaries in determining the Office of the Actuary’s updated estimate of Factor 1 for FY 2016. We believe that this discussion addresses the methodological concerns raised by commenters regarding the various assumptions used in the estimate, including the “Other” and “Discharges” assumptions and also provides additional information regarding how we address the Medicaid and CHIP expansion. However, we note that, with regard to the commenters’ questions and concerns on the completion factor for 2012 and 2013 cost reports in HCRIS, the Office of the Actuary assumed a discharge completion factor of 99 percent for FY 2013 and 98 percent for FY 2014. Similarly, the Office of the Actuary assumed that case-mix was stabilized at the time of the estimate and no additional completion factor adjustment was needed. These assumptions are consistent with historical patterns. Regarding the commenters’ assertion that Medicaid expansion is not adequately accounted for in the “Other” column, we note that the Office of the Actuary assumed per capita spending for Medicaid beneficiaries who enrolled due to the expansion is 50 percent of the average per capita of the pre-expansion Medicaid beneficiary due to the better health of these beneficiaries. We have found this assumption to be consistent with recent internal estimates of Medicaid per capita spending pre-expansion and post-expansion.
In response to the commenters who requested that we adjust the “Other” assumption to reflect the growing number of DSH hospitals in a manner that supports safety-net hospitals, particularly in States that do not have a Medicaid or CHIP expansion, we note that our proposed methodology includes assumptions regarding how DSH payments will increase in aggregate, regardless of how many hospitals qualify for DSH payments. Furthermore, we believe that, while the statute provides the Secretary with discretion to make an estimate, the statute is clear that the computation of Factor 1 begins with an aggregate amount of payments that would be made to subsection (d) hospitals under section 1886(d)(5)(F) if this section did not apply for such fiscal year. In our view, the most appropriate way to do so is to project to the best of our abilities how payments will actually change in aggregate, based on the programs and policies that will be in effect during the fiscal year.

We agree with the commenters that CMS should use the most recent update of the 2012 Medicare cost report data available to us and note that the Office of the Actuary has done so in using the March 2015 extract of 2012 cost reports in HCRIS for this final rule.

Comment: Some commenters requested that, in light of their concerns about the data sources and methods used to estimate Factor 1, CMS adopt a process of reconciling the initial estimates of Factor 1 with actual data for the payment year in conjunction with the final settlement of hospital cost reports for the applicable year. Specifically, the commenters asserted that later data that become available after the end of a Federal fiscal year but before final DSH payment determinations are made in notices
of program reimbursement would result in Factor 1 estimates that are more accurate than estimates made before the start of a Federal fiscal year. The commenters believed that a “true-up approach” would resolve most of what they characterize as “discrepancies between estimates and reality.” The commenters stated that generalized concerns about administrative ease and finality are not justifications for the use of advance estimates that are inaccurate due to “inherent uncertainties” in making projections of DSH payments in an “early, post-ACA environment.” As an example of a way by which this “true-up” could occur, one commenter requested the CMS update the calculation of the discharge factor used to calculate Factor 1 in an interim final rule.

Response: We continue to believe that applying our best estimates prospectively is most conducive to administrative efficiency, finality, and predictability in payments (78 FR 50628; 79 FR 50010). As we noted in the FY 2014 IPPS/LTCH PPS final rule, we do not know the aggregate Medicare DSH payment amount that would be paid for each Federal fiscal year until the time of cost report settlements, which occur several years after the end of the fiscal year. Furthermore, the statute provides that Factor 1 shall be determined based on estimates of the aggregate amount of DSH payments that would be made in the absence of section 1886(r) of the Act and the aggregate amount of empirically justified DSH payments that are made under section 1886(r)(1) of the Act. We believe that, in affording the Secretary the discretion to estimate the amount of these payments and by including a prohibition against administrative and judicial review of those estimates in section 1886(r)(3) of the Act, Congress recognized the importance of finality and predictability in payments and sought to avoid a situation in which the
uncompensated care payments would be subject to change over a period of a number of years. Accordingly, we do not agree with the commenters that we should establish a process for reconciling our estimates of Factor 1. We note that, in reviewing the Office of the Actuary’s prior estimates for DSH payments compared to actual experience, from FY 2005 to FY 2016, the original estimates have been higher than actual experience for 8 of the 12 years and lower than actual experience in only 4 years.

**Comment:** Some commenters indicated that the estimated DSH payments do not account for the impact of the decision in *Allina v. Sebelius*, by excluding Medicare Advantage days from the SSI ratio and including dual eligible Medicare Advantage days in the Medicaid fraction, thus understating the estimate of Factor 1.

**Response:** We do not believe the *Allina* decision has any bearing on our estimate of Factor 1 for FY 2016. The holding in *Allina* addresses traditional DSH payments made to a group of providers between 2004 and 2010. Moreover, the decision did not address the FY 2014 IPPS/LTCH PPS final rule (78 FR 50614 through 50620) in which we readopted the policy of counting Medicare Advantage days in the SSI ratio for FY 2014 and all subsequent fiscal years. In its estimate of Factor 1 for FY 2016 for the FY 2016 IPPS/LTCH PPS proposed rule, the Office of the Actuary was making an estimate of difference between the aggregate amount of DSH payments that would be made under section 1886(d)(5)(F) of the Act in FY 2016 if section 1886(r) of the Act did not apply and the aggregate amount of empirically justified DSH payments that will be made to hospitals in FY 2016 under section 1886(r)(1) of the Act. Thus, although the Office of the Actuary used 2012 cost report data in making this estimate, it also applied
inflation adjustments and assumptions in order to estimate Medicare DSH payments for FY 2016. Accordingly, consistent with §412.106(b)(2), as readopted in the FY 2014 IPPS/LTCH PPS final rule, in estimating DSH payments for FY 2016, the Office of the Actuary did not remove patients enrolled in Medicare Advantage plans from SSI ratios or make any other adjustments to the hospital cost report data for 2012 included in the HCRIS database. We believe this methodology is consistent with the statute and regulations.

After consideration of the public comments we received, we are finalizing, as proposed, the methodology for calculating Factor 1 for FY 2016. Using this methodology, below we discuss the resulting Factor 1 amount for FY 2016.

To determine Factor 1 and to model the impact of this provision for FY 2016, we used the Office of the Actuary’s July 2015 Medicare DSH estimates based on data from the March 2015 update of 2012 cost report data included in HCRIS, 2012 cost report data provided to CMS by IHS hospitals, and the FY 2015 IPPS/LTCH PPS final rule IPPS Impact File, published in conjunction with the publication of the FY 2015 IPPS/LTCH PPS final rule. Because SCHs that are projected to be paid under their hospital-specific rate are not subject to the provisions of section 1886(r) of the Act, these hospitals were excluded from the July 2015 Medicare DSH estimates. Furthermore, because section 1886(r) of the Act specifies that the uncompensated care payment is in addition to the empirically justified DSH payment (or 25 percent of DSH payments that would be made without regard to section 1886(r)), Maryland hospitals participating in the Maryland All-Payer Model and hospitals participating in the Rural Community Hospital
Demonstration that do not receive DSH payments also are excluded from the Office of the Actuary’s Medicare DSH estimates.

Using the data sources discussed above, the Office of the Actuary applied inflation updates and assumptions for future changes in utilization and case-mix to estimate Medicare DSH payments for the upcoming fiscal year. The July 2015 Medicare DSH estimate for FY 2016, without regard to the application of section 1886(r)(1) of the Act, is $13,411,096,528.05. Based on this estimate, the estimate for empirically justified Medicare DSH payments for FY 2016, with the application of section 1886(r)(1) of the Act, is $3,352,774,132.01 (25 percent of the total amount estimated). Under § 412.106(g)(1)(i) of the regulations, Factor 1 is the difference between these two estimates of the Office of the Actuary. Therefore, for this final rule, Factor 1 for FY 2016 is $10,058,322,396.04 ($13,411,096,528.05 minus $3,352,774,132.01). Below we provide additional detail regarding the development of this estimate.

The Office of the Actuary’s estimates for FY 2016 begin with a baseline of $11.637 billion in Medicare DSH expenditures for FY 2012. The following table shows the factors applied to update this baseline through the current estimate for FY 2016.
Factors Applied for FY 2013 through FY 2016 to Estimate Medicare DSH Expenditures Using FY 2012 Baseline

<table>
<thead>
<tr>
<th>FY</th>
<th>Update</th>
<th>Discharge</th>
<th>Case-Mix</th>
<th>Other</th>
<th>Total</th>
<th>Estimated DSH Payments (in billion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>1.028</td>
<td>0.9844</td>
<td>1.014</td>
<td>1.0137</td>
<td>1.040189</td>
<td>$12.105</td>
</tr>
<tr>
<td>2014</td>
<td>1.009</td>
<td>0.9634</td>
<td>1.015</td>
<td>0.9993</td>
<td>0.985961</td>
<td>$11.935</td>
</tr>
<tr>
<td>2015</td>
<td>1.014</td>
<td>0.9893</td>
<td>1.005</td>
<td>1.0512</td>
<td>1.059784</td>
<td>$12.648</td>
</tr>
<tr>
<td>2016</td>
<td>1.009</td>
<td>1.0006</td>
<td>1.005</td>
<td>1.045</td>
<td>1.060313</td>
<td>$13.411</td>
</tr>
</tbody>
</table>

In this table, the discharge column shows the increase in the number of Medicare fee-for-service (FFS) inpatient hospital discharges. The figures for FYs 2013 and 2014 are based on Medicare claims data that have been adjusted by a completion factor. The discharge figure for FY 2015 is based on preliminary data for 2015. The discharge figure for FY 2016 is an assumption based on recent trends recovering back to the long-term trend and assumptions related to how many beneficiaries will be enrolled in Medicare FFS and also MA plans. The case-mix column shows the increase in case-mix for IPPS hospitals. The case-mix figures for FYs 2013 and 2014 are based on actual data adjusted by a completion factor. The FY 2015 and FY 2016 increases are based on the recommendation of the 2010-2011 Medicare Technical Review Panel. The “Other” column shows the increase in other factors that contribute to the Medicare DSH estimates. These factors include the difference between the total inpatient hospital discharges and the IPPS discharges, various adjustments to the payment rates that have been included over the years but are not reflected in the other columns (such as the increase in rates for the Cape Cod litigation and the reduction in rates for the 2-midnight
stay policy). In addition, the “Other” column includes a factor for the Medicaid expansion due to the Affordable Care Act.

The table below shows the factors that are included in the “Update” column of the above table.

<table>
<thead>
<tr>
<th>FY</th>
<th>Market Basket Percentage</th>
<th>Affordable Care Act Payment Reductions</th>
<th>Multifactor Productivity Adjustment</th>
<th>Documentation and Coding Percentage Adjustment</th>
<th>Total Update Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>2.6</td>
<td>-0.1</td>
<td>-0.7</td>
<td>+1.0</td>
<td>2.8</td>
</tr>
<tr>
<td>2014</td>
<td>2.5</td>
<td>-0.3</td>
<td>-0.5</td>
<td>-0.8</td>
<td>0.9</td>
</tr>
<tr>
<td>2015</td>
<td>2.9</td>
<td>-0.2</td>
<td>-0.5</td>
<td>-0.8</td>
<td>1.4</td>
</tr>
<tr>
<td>2016</td>
<td>2.4</td>
<td>-0.2</td>
<td>-0.5</td>
<td>-0.8</td>
<td>0.9</td>
</tr>
</tbody>
</table>

Note: All numbers are based on the Midsession Review of FY 2016 Budget projections.

(2) Calculation of Factor 2 for FY 2016

Section 1886(r)(2)(B) of the Act establishes Factor 2 in the calculation of the uncompensated care payment. Specifically, section 1886(r)(2)(B)(i) of the Act provides that, for each of FYs 2014, 2015, 2016, and 2017, a factor equal to 1 minus the percent change in the percent of individuals under the age of 65 who are uninsured, as determined by comparing the percent of such individuals (I) who are uninsured in 2013, the last year before coverage expansion under the Affordable Care Act (as calculated by the Secretary based on the most recent estimates available from the Director of the Congressional Budget Office before a vote in either House on the Health Care and Education Reconciliation Act of 2010 that, if determined in the affirmative, would clear such Act for enrollment); and (II) who are uninsured in the most recent period for which data are
available (as so calculated), minus 0.1 percentage point for FY 2014 and minus 0.2 percentage point for each of FYs 2015, 2016, and 2017.

Section 1886(r)(2)(B)(i)(I) of the Act further indicates that the percent of individuals under 65 without insurance in 2013 must be the percent of such individuals who are uninsured in 2013, the last year before coverage expansion under the Affordable Care Act (as calculated by the Secretary based on the most recent estimates available from the Director of the Congressional Budget Office before a vote in either House on the Health Care and Education Reconciliation Act of 2010 that, if determined in the affirmative, would clear such Act for enrollment). The Health Care and Education Reconciliation Act (Pub. L. 111-152) was enacted on March 30, 2010. It was passed in the House of Representatives on March 21, 2010, and by the Senate on March 25, 2010. Because the House of Representatives was the first House to vote on the Health Care and Education Reconciliation Act of 2010 on March 21, 2010, we have determined that the most recent estimate available from the Director of the Congressional Budget Office “before a vote in either House on the Health Care and Education Reconciliation Act of 2010…” (emphasis added) appeared in a March 20, 2010 letter from the director of the CBO to the Speaker of the House. Therefore, we believe that only the estimates in this March 20, 2010 letter meet the statutory requirement under section 1886(r)(2)(B)(i)(I) of the Act. (To view the March 20, 2010 letter, we refer readers to the Web site at:

In its March 20, 2010 letter to the Speaker of the House of Representatives, the CBO provided two estimates of the “post-policy uninsured population.” The first estimate is of the “Insured Share of the Nonelderly Population Including All Residents” (82 percent) and the second estimate is of the “Insured Share of the Nonelderly Population Excluding Unauthorized Immigrants” (83 percent). Starting in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50631), we used the first estimate that includes all residents, including unauthorized immigrants. We stated that we believe this estimate is most consistent with the statute, which requires us to measure “the percent of individuals under the age of 65 who are uninsured” and provides no exclusions except for individuals over the age of 65. In addition, we stated that we believe that this estimate more fully reflects the levels of uninsurance in the United States that influence uncompensated care for hospitals than the estimate that reflects only legal residents. The March 20, 2010 CBO letter reports these figures as the estimated percentage of individuals with insurance. However, because section 1886(r)(2)(B)(i) of the Act requires that we compare the percent of individuals who are uninsured in the applicable year with the percent of individuals who were uninsured in 2013, in the FY 2014 and FY 2015 IPPS/LTCH PPS final rules (78 FR 50631 and 79 FR 50014), we used the CBO insurance rate figure and subtracted that amount from 100 percent (that is, the total population without regard to insurance status) to estimate the 2013 baseline percent of individuals without insurance. Therefore, for FYs 2014 through 2017, per statute, our estimate of the uninsurance percentage for 2013 is 18 percent.
Section 1886(r)(2)(B)(i) of the Act requires that we compare the baseline uninsurance rate to the percent of such individuals who are uninsured in the most recent period for which data are available. In the FY 2014 and FY 2015 IPPS/LTCH PPS final rules (78 FR 50634 and 79 FR 50014), we used the same data source, the most recent available CBO estimates, to calculate this percent of individuals without insurance. In response to public comments, we also agreed that we should normalize the CBO estimates, which are based on the calendar year, for the Federal fiscal years for which each calculation of Factor 2 is made (78 FR 50633).

Consistent with the data used in FY 2014 and FY 2015, in the FY 2016 IPPS/LTCH PPS proposed rule, we used the CBO’s January 2015 estimates of the effects of the Affordable Care Act on health insurance coverage (which are available at http://www.cbo.gov/sites/default/files/cbofiles/attachments/43900-2014-04-ACAtables2.pdf), normalized to the Federal fiscal year, to calculate the percent of individuals without insurance (80 FR 24486). The CBO’s January 2015 estimate of individuals under the age of 65 with insurance in CY 2015 was 87 percent. Therefore, the CBO’s most recent estimate of the rate of uninsurance in CY 2015 at the time of development of the FY 2016 IPPS/LTCH PPS proposed rule was 13 percent (that is, 100 percent minus 87 percent). Similarly, the CBO’s January 2015 estimate of individuals under the age of 65 with insurance in CY 2016 was 89 percent. Therefore, the CBO’s most recent estimate of the rate of uninsurance in CY 2016 available for the FY 2016 IPPS/LTCH PPS proposed rule was 11 percent (that is, 100 percent minus 89 percent).
The proposed calculation of Factor 2 for FY 2016 included in the FY 2016 IPPS/LTCH proposed rule was as follows:

- CY 2015 rate of insurance coverage (January 2015 CBO estimate): 87 percent.
- CY 2016 rate of insurance coverage (January 2015 CBO estimate): 89 percent.
- FY 2016 rate of insurance coverage: \((87 \text{ percent} \times 0.25) + (89 \text{ percent} \times 0.75) = 88.5 \text{ percent.}\)
- Percent of individuals without insurance for 2013 (March 2010 CBO estimate): 18 percent
- Percent of individuals without insurance for FY 2016 (weighted average): 11.5 percent

\[
1 - \frac{(0.115 - 0.18)}{0.18} = 1 - 0.3611 = 0.6389 \text{ (63.89 percent)} \text{ (We note that, in the proposed rule, this calculation should have read: } 1 - \left[ \frac{(0.115 - 0.18)}{0.18} \right] = 1 - 0.3611 = 0.6389 \text{ (63.89 percent).)}
\]

0.6389 (63.89 percent) - .002 (0.2 percentage points for FY 2016 under section 1886(r)(2)(B)(i) of the Act) = 0.6369 or 63.69 percent

0.6369 = Factor 2

Therefore, we proposed that Factor 2 for FY 2016 would be 63.69 percent. We indicated that our proposal for Factor 2 was subject to change if more recent CBO estimates of the insurance rate became available at the time of the preparation of the final rule. We invited public comments on our proposed calculation of Factor 2 for FY 2016.
In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24486), we stated that the FY 2016 Proposed Uncompensated Care Amount was $10,003,425,327.39 x 0.6369 = $6,371,181,591.01.

Comment: A number of commenters objected to CMS’ proposed calculation of Factor 2. The commenters questioned the accuracy of CBO’s estimates and requested additional information on how the CBO calculates its insurance estimates, including the assumptions used in its estimates. For example, some commenters questioned the accuracy of the CBO’s assumptions regarding “unauthorized immigrants” and provided information from other data sources, such as the Census Bureau, Department of Homeland Security Office of Immigration Statistics, and the Pew Research Center, to suggest that the total uninsured percentage in FY 2016 should be 13 percent rather than 11 percent as proposed. One commenter requested an explanation of why CBO changed its baseline formula for pre-Affordable Care Act coverage and how CBO is tracking actual insured and uninsured populations. Some commenters believed that the CBO insurance estimates do not take into account States that have not expanded their Medicaid programs. Other commenters questioned whether CBO accounted for factors that ultimately affect the insured population, such as individuals who will disenroll from coverage due to their inability to pay premiums or insured individuals who are unable to pay for hospital services they receive due to high deductibles and coinsurance in employer-sponsored and exchange-sponsored plans.

Response: We note that, in the FY 2014 IPPS/LTCH PPS final rule, we finalized a policy to employ the most recent available CBO estimates of the rates of uninsurance in
the calculation of Factor 2 for FY 2014 and subsequent years. As discussed in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50632), section 1886(r)(2)(B)(i)(I) of the Act refers to the percent of uninsured in 2013 as calculated by the Secretary based on the CBO data. Similarly, section 1886(r)(2)(B)(i)(II) of the Act immediately afterwards refers to the percent of uninsured “in the most recent period for which data is available (as so calculated).” The phrase “as so calculated” in the latter section can be reasonably interpreted to require the calculation to similarly be based on CBO estimates.

Furthermore, we continue to believe that the CBO projections of insurance coverage are the most reliable and consistent basis on which to calculate Factor 2, and that it is preferable from a statistical point of view to calculate a percent change in insurance over time using a consistent data source.

We note that CBO’s coverage projections for CY 2015 and CY 2016 reflect changes in the rate of uninsurance arising from participation in the health insurance exchanges, Medicaid and CHIP enrollment, and changes in employer-sponsored, nongroup, and other insurance coverage. Unauthorized immigrants who are not eligible for Medicaid and exchange coverage and low-income residents of States not participating in the Medicaid expansion are included in the uninsured population. In addition, the estimate reflects other individuals who choose to remain uninsured, despite being eligible for Medicaid or having access through an employer, the exchange, or from an insurer. Therefore, the CBO estimates do take into account some uncertainties and risks under the Affordable Care Act, including the probabilities of different outcomes of Medicaid expansions and changes in insurance coverage status over time. More detailed
explanations of the methodology and assumptions used by CBO can be accessed on the CBO Web site and particularly in the Appendix of the March 2015 Updated Budget Projections: 2015-2025 (which are available at http://www.cbo.gov/sites/default/files/cbofiles/attachments/49973-UpdatedBudgetProjections.pdf).

Comment: Commenters requested that CMS update the Factor 2 estimates with later data, such as through an additional interim final rule or by establishing a reconciliation process that uses actual data regarding the rate of uninsurance at the time of cost report settlements. The commenters indicated that they understood that estimates must be used for interim payments, but stated that they believed more accurate numbers based on actual experience should be available for purposes of determining final payments at the time of cost report settlement. One commenter pointed out that CBO continually revises its own projected enrollment numbers for changes in insurance coverage and thus reconciliation is appropriate because otherwise providers would “absorb the full impact of these errors.” Another commenter objected to the view that Factor 2 should be based solely upon estimates as opposed to actual data. The commenter pointed out that the DSH statute does not use the word “estimate” in connection with the computation of the second prong of Factor 2. The commenter viewed the omission of the term “estimate” as deliberate for the period FY 2014 through FY 2017, noting that the statute employs the term “estimate” elsewhere, such as in the second prong of Factor 2 for FY 2018 and beyond. This commenter asserted that the
statute requires that the initial estimates of the percentage of uninsured individuals for FY 2016 and FY 2017 be reconciled with actual data when those data become available.

Many commenters believed that the information shared by CMS in the FY 2016 IPPS/LTCH PPS proposed rule would be outdated and need to be revised in light of the *King v. Burwell* case. The commenters noted that, as of June, no decision had been issued by the Supreme Court and that an adverse ruling for the Secretary would lead to a smaller reduction in the rate of uninsurance. Some commenters provided information regarding two studies that estimated increases in the number of uninsured individuals if the Supreme Court were to set aside the subsidies in States without State-operated exchanges. The commenters stated that, based on their understanding of these studies, there could be approximately 8.2 million to 9.8 million more individuals uninsured in CY 2016 than previously estimated, which would result in a national uninsured rate of 15.1 percent to 18.3 percent. Based on this analysis, the commenters estimated that Factor 2 should be 0.8036 or 80.36 percent, much higher than the 0.6369 or 63.69 percent proposed by CMS. The commenters stated that, all else being equal, this change to Factor 2 would result in an amount to be available for uncompensated care payments of approximately $8.0 million compared to the approximately $6.4 million proposed by CMS. The commenters stated that CMS could update this estimate in the final rule or through an interim final rule. Commenters stated that updating Factor 2 for the results of the decision in *King v. Burwell* would reflect CMS policy to use updated data on the rate of uninsurance. One commenter requested that CMS use updated enrollment data from the exchanges to lower its estimate of the number of insured individuals for FY 2016.
Response: In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50632), we finalized a policy to employ the most recent available CBO estimates of the rate of uninsurance in the calculation of Factor 2 for FY 2014 and subsequent years, and did not adopt any policy for reconciling those estimates. In the FY 2014 IPPS/LTCH PPS final rule, we stated that we believe that employing actual data to reconcile the projections employed to determine Factor 2 would impose an unacceptable delay in the final determination of uncompensated care payments. Actual data on the rates of insurance and uninsurance do not become available until several years after the payment year, and the initial data for a year will continue to be adjusted for several years after that as further data become available. We continue to believe that determining Factor 2 prospectively by applying the best estimate of the projected level of uninsurance for the applicable fiscal year is most conducive to administrative efficiency, finality, and predictability in payments.

With respect to the commenter’s concerns about language used in section 1886(r)(2)(B)(i)(II) of the Act, we acknowledge the commenter’s point that the statute does not explicitly include the word “estimate” in describing the percent of individuals who are uninsured in the most recent period for which data are available. However, we note that the statute does describe this figure “as so calculated.” We continue to believe that this reference is intended to instruct the Secretary to perform the calculation in the same manner as the calculation under section 1886(r)(2)(B)(i)(I) of the Act. Section 1886(r)(2)(B)(i)(I) of the Act expressly instructs the Secretary to calculate the percent of individuals who are uninsured in 2013 “based on the most recent estimates available from
the Director of the Congressional Budget Office . . .” (Emphasis added.) Accordingly, we interpret the term “calculated” in section 1886(r)(2)(B)(i)(II) of the Act to mean calculated based on CBO estimates and disagree that the statute requires that we reconcile this figure with actual data.

With respect to the commenters’ concerns regarding the accuracy of the Factor 2 estimate in light of the *King v. Burwell* case, we note that the Supreme Court’s ruling in the case affirmed that individuals who purchase their health insurance on exchanges established by the Federal government are eligible for tax subsidies. As a result, we do not expect the decision to have any effect on the estimate of the percent of individuals that are uninsured in FY 2016. Moreover, we note that, because we finalized a policy in the FY 2014 IPPS/LTCH PPS final rule to use the most recent available CBO projections of insurance coverage in our calculation of Factor 2, any update to the uninsurance data used in the computation of Factor 2 must also originate from the CBO. The most recent available CBO projection of uninsurance is the March 2015 baseline available on the Web site at: [https://www.cbo.gov/sites/default/files/cbofiles/attachments/43900-2015-03-ACAtables.pdf](https://www.cbo.gov/sites/default/files/cbofiles/attachments/43900-2015-03-ACAtables.pdf), and consistent with our policy, we are using this estimate in the calculation of Factor 2 for this FY 2016 IPPS/LTCH PPS final rule.

**Comment:** Some commenters requested that CMS work with Congress to take steps to mitigate the effect of the reduction in Factor 2 on the overall amount available to make uncompensated care payments for FY 2016. Several commenters requested that CMS delay the implementation of Factor 2 until all or substantially all of the States implement health insurance exchanges and until the level of Medicaid expansion is
known on a State-by-State basis. The commenters expected that, once these events occur, more reliable information sources would be available to determine the reduction in the rate of uninsurance. Another commenter suggested that, at a minimum, CMS maintain the percentage of uninsured it applied in the FY 2015 calculation until a more accurate projection can be made. One commenter specifically mentioned using the documentation and coding adjustments as a model for phasing in reductions to the amount available for uncompensated care payments. Another commenter asked CMS to ensure the payment methodology does not harm access to care in rural areas.

Response: We thank the commenters for their alternative suggestions. We do not believe there is a statutory basis to delay the implementation of Factor 2 or to phase in reductions because the statute requires us to implement the uncompensated care payment methodology in its entirety for FY 2014 and each subsequent fiscal year. The statute also does not provide us with a basis to use the percentage of uninsured we applied for FY 2015 because the statute requires us to use the data on the percent of individuals who are uninsured in the most recent period for which data are available, and such data are available for FY 2016. Finally, although we understand the commenters’ concerns regarding access to care in rural areas, the statute does not include any exception in the payment methodology for hospitals by geographic location or geographic classification. Therefore, hospitals in rural areas are subject to the same reductions as hospitals elsewhere in the country.

After consideration of the public comments we received, we are finalizing, as proposed, the calculation of Factor 2 for FY 2016. Using this methodology, below we
discuss the resulting Factor 2 amount for FY 2016 and the total uncompensated care amount for FY 2016.

To determine Factor 2 for FY 2016, we used the CBO’s March 2015 estimates of the effects of the Affordable Care Act on health insurance coverage (which are available at http://www.cbo.gov/sites/default/files/cbofiles/attachments/43900-2015-03-ACAtables.pdf). The CBO’s March 2015 estimate of individuals under the age of 65 with insurance in CY 2015 is 87 percent. Therefore, the CBO’s most recent estimate of the rate of uninsurance in CY 2015 is 13 percent (that is, 100 percent minus 87 percent). Similarly, the CBO’s March 2015 estimate of individuals under the age of 65 with insurance in CY 2016 is 89 percent. Therefore, the CBO’s most recent estimate of the rate of uninsurance in CY 2016 available for this final rule is 11 percent (that is, 100 percent minus 89 percent).

The calculation of the final Factor 2 for FY 2016, employing a weighted average of the CBO projections for CY 2015 and CY 2016, is as follows:

- CY 2015 rate of insurance coverage (March 2015 CBO estimate): 87 percent.
- CY 2016 rate of insurance coverage (March 2015 CBO estimate): 89 percent.
- FY 2016 rate of insurance coverage: (87 percent * .25) + (89 percent * .75) = 88.5 percent.
- Percent of individuals without insurance for 2013 (March 2010 CBO estimate): 18 percent.
- Percent of individuals without insurance for FY 2016 (weighted average): 11.5 percent.
1-\((0.115-0.18)/0.18\) = 1-0.3611 = 0.6389 (63.89 percent)

0.6389 (63.89 percent) - .002 (0.2 percentage points for FY 2016 under section 1886(r)(2)(B)(i) of the Act) = 0.6369 or 63.69 percent

0.6369 = Factor 2

Therefore, the final Factor 2 for FY 2016 is 63.69 percent.

The FY 2016 Final Uncompensated Care Amount is: \(\$10,058,322,396.04 \times 0.6369 = \$6,406,145,534.04\).

| FY 2016 Final Uncompensated Care Total Available | $6,406,145,534.04. |

(3) Calculation of Factor 3 for FY 2016

Section 1886(r)(2)(C) of the Act defines Factor 3 in the calculation of the uncompensated care payment. As we have discussed earlier, section 1886(r)(2)(C) of the Act states that Factor 3 is equal to the percent, for each subsection (d) hospital, that represents the quotient of (i) the amount of uncompensated care for such hospital for a period selected by the Secretary (as estimated by the Secretary, based on appropriate data (including, in the case where the Secretary determines alternative data are available that are a better proxy for the costs of subsection (d) hospitals for treating the uninsured, the use of such alternative data)); and (ii) the aggregate amount of uncompensated care for all subsection (d) hospitals that receive a payment under section 1886(r) of the Act for such period (as so estimated, based on such data).

Therefore, Factor 3 is a hospital-specific value that expresses the proportion of the estimated uncompensated care amount for each subsection (d) hospital and each
subsection (d) Puerto Rico hospital with the potential to receive Medicare DSH payments relative to the estimated uncompensated care amount for all hospitals estimated to receive Medicare DSH payments in the fiscal year for which the uncompensated care payment is to be made. Factor 3 is applied to the product of Factor 1 and Factor 2 to determine the amount of the uncompensated care payment that each eligible hospital will receive for FY 2014 and subsequent fiscal years. In order to implement the statutory requirements for this factor of the uncompensated care payment formula, it was necessary to determine: (1) the definition of uncompensated care or, in other words, the specific items that are to be included in the numerator (that is, the estimated uncompensated care amount for an individual hospital) and the denominator (that is, the estimated uncompensated care amount for all hospitals estimated to receive Medicare DSH payments in the applicable fiscal year); (2) the data source(s) for the estimated uncompensated care amount; and (3) the timing and manner of computing the quotient for each hospital estimated to receive Medicare DSH payments. The statute instructs the Secretary to estimate the amounts of uncompensated care for a period based on appropriate data. In addition, we note that the statute permits the Secretary to use alternative data in the case where the Secretary determines that such alternative data are available that are a better proxy for the costs of subsection (d) hospitals for treating individuals who are uninsured.

In the course of considering how to determine Factor 3 during the rulemaking process for FY 2014, we considered defining the amount of uncompensated care for a hospital as the uncompensated care costs of each hospital and determined that
Worksheet S-10 of the Medicare cost report potentially provides the most complete data regarding uncompensated care costs for Medicare hospitals. However, because of concerns regarding variations in the data reported on the Worksheet S-10 and the completeness of these data, we did not propose to use data from the Worksheet S-10 to determine the amount of uncompensated care for FY 2014, the first year this provision was in effect, or for FY 2015. We instead employed the utilization of insured low-income patients, defined as inpatient days of Medicaid patients plus inpatient days of Medicare SSI patients as defined in 42 CFR 412.106(b)(4) and 412.106(b)(2)(i), respectively, to determine Factor 3. We believed that these alternative data, which are currently reported on the Medicare cost report, would be a better proxy for the amount of uncompensated care provided by hospitals. We also indicated that we were expecting reporting on the Worksheet S-10 to improve over time and remained convinced that the Worksheet S-10 could ultimately serve as an appropriate source of more direct data regarding uncompensated care costs for purposes of determining Factor 3.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24487), we stated that we believe it remains premature to propose the use of Worksheet S-10 for purposes of determining Factor 3 for FY 2016 and, therefore, proposed to continue to employ the utilization of insured low-income patients (defined as inpatient days of Medicaid patients plus inpatient days of Medicare SSI patients as defined in § 412.106(b)(4) and § 412.106(b)(2)(i), respectively) to determine Factor 3. We indicated that we believe that continuing to use this methodology would give hospitals more time to learn how to submit accurate and consistent data through Worksheet S-10, as well as give CMS more
time to continue to work with the hospital community and others to develop the appropriate clarifications and revisions to Worksheet S-10 to ensure standardized and consistent reporting of all data elements. Accordingly, we proposed that, for FY 2016, CMS would base its estimates of the amount of hospital uncompensated care on utilization data for Medicaid and Medicare SSI patients, as determined by CMS in accordance with §§ 412.106(b)(2)(i) and (b)(4). We stated that we still intend to propose through future rulemaking the use of the Worksheet S-10 data for purposes of determining Factor 3. We invited public comments on this proposal to continue to use insured low-income days to determine Factor 3 for FY 2016.

Comment: Most commenters believed that the Worksheet S-10 data are not yet sufficiently consistent and reliable to be employed for purposes of determining each hospital’s share of uncompensated care payments. Many commenters supported the proposal to continue employing Medicare SSI days and Medicaid days to determine Factor 3 for FY 2016.

Some commenters noted that the proxy is appropriate until the Worksheet S-10 data become more reliable and accurate for collecting uncompensated care costs. One commenter indicated that it had performed analyses exploring the relationship between uncompensated care costs and Medicaid expansion. Among other results, the commenter indicated that its analysis showed that the proportion of Medicaid volumes has increased while the proportion of self-pay and charity has decreased in States that have expanded their Medicaid programs. The commenter concluded that Medicaid and uncompensated care are now inversely related in States that have expanded their programs and stated that
the validity of the insured low-income days proxy will soon be in question as newer data becomes available.

Commenters who continued to support use of the proxy for FY 2016 in order to allow for improved data collection on Worksheet S-10 focused on two areas: changes to Worksheet S-10 and the process to audit Worksheet S-10. With regard to changes to Worksheet S-10, the commenters stated that the Worksheet S-10 form and instructions should be changed in order to improve consistency in reporting across providers and overall accuracy. They stated that the current instructions are imprecise and lack meaningful guidance from CMS. The commenters stated that often stakeholders provide specific recommendations for changes to Worksheet S-10 that CMS should consider, and encouraged CMS to work expeditiously with a broad range of stakeholders to improve Worksheet S-10. Many commenters provided detailed suggestions related to reporting requirements for specific lines of Worksheet S-10. Summaries that illustrate the breadth of the commenters’ suggestions as they pertain, in general, to the reporting of uncompensated care, charity care, bad debt, and Medicaid costs are presented below.

- Commenters requested clarification of whether charity care charges should be reported for inpatient hospital services, outpatient hospital services, or both. They requested the ability to report these charges on separate lines and to apply separate CCRs to these separate sets of costs.

- Commenters noted that because Worksheet S-10 is derived from data reported on the Medicare cost report, charges and payments for physician services are currently excluded. However, the commenters stated that hospitals provide physician services to
patients with little or no access to private physicians. They noted that safety-net hospitals in low-income communities particularly provide these services. The commenters believed that providers should be encouraged to provide these services and that one means to do so is to revise Worksheet S-10 to include reporting of uncompensated care related to employed physician services and to establish an uncompensated care cost methodology that takes these services into account.

- One commenter pointed out that it would be appropriate to add a self-pay category to Worksheet S-10 to distinguish this uninsured population from others who have some form of third party coverage.

- Commenters requested that the CCR used on Worksheet S-10 to convert charges to costs be changed so that it includes direct GME payments because the charges include direct GME payments. To determine costs, that CCR is multiplied by the charges reported in column 8 charges, which include overhead charges that reflect direct GME. The commenters noted that the current source of the CCR on Worksheet S-10 is Worksheet C, and therefore the CCR does not include the cost of direct GME.

- Commenters requested that Worksheet S-10, which currently collects charity care costs based on dates of service, be changed to allow for the reporting of charity care costs based on the date the hospital writes off the charity care. The commenters stated that, under the current requirement, hospitals must spend significant additional time to document charity care write-offs. The commenters also stated that they do not believe the current approach is accurate because hospitals will not have identified and resolved all of their charity care accounts by the time they file their cost reports, which is no later
than 5 months after the close of a hospital’s fiscal year. The commenters stated that charity care determinations involve complexities, such as changes in specific patient circumstances and time involved in obtaining necessary documentation.

- Commenters noted that the current reporting instructions, particularly in PRM II, Section 4012, exclude discounts to patients from reporting as uncompensated care. They then noted that some States mandate such discounts, and that many hospitals provide discounts to any uninsured patient. In their view, these instructions could create a situation where hospitals are precluded from reporting these costs as charity when, in their view, this is uncompensated care.

- Some commenters believed that CMS should be clearer with regard to how charges related to indigent care programs are reported. The commenters believed that charges for services provided to this patient care population should not be considered uncompensated care costs. Other commenters disagreed and provided specific examples of the types of programs that should be included.

- Commenters requested that CMS define the use of presumptive eligibility tools as an acceptable method to identify and document charity care charges. The commenters believed that the current CMS practice of disallowing charity care based on the finding of presumptive eligibility tools is inappropriate because the current reporting instructions relate to when Medicare beneficiaries should be determined to be indigent and not the application of hospitals’ charity care policies to other patient populations and these instructions were developed before presumptive eligibility tools were widely used by hospitals.
Commenters believed that hospitals should not be required to report expected payments in addition to received payments for charity care accounts. The commenters noted that the difficulty is that the amounts expected from patients for whom there have been partial write-offs in accordance with a hospital’s charity care policy are often not paid in full.

Commenters believed that Worksheet S-10 understates charity care costs for patients who participate in high deductible plans. The commenters also believed that charity care for noncontracted insurance payers is overstated.

One commenter suggested that bad debt be reported in three categories: uninsured bad debt from charity patients; uninsured bad debt from noncharity patients; and cost-sharing bad debts. The commenter suggested that CCRs not be applied to bad debt charges related to cost-sharing. The commenter believed this disaggregation would yield data that are comparable to the charity care data reported on Worksheet S-10.

Commenters requested that CMS be clear with regard to the time period for which bad debt expense should be reported. Specifically, the commenters asked that CMS clearly state that the instructions mean that a hospital should report bad debt expense as reflected on its financial statement. Furthermore, the commenters requested that CMS amend the cost reporting instructions to require hospitals to report amounts based on Generally Accepted Accounting Principles.

Commenters advised requiring Medicaid DSH payments and Medicaid supplemental payment information to be reported on separate lines and to offset these payments against Medicaid costs reported on Worksheet S-10.
Some commenters suggested that CMS capture data on the number of patients in various government programs so that any future formula based on Worksheet S-10 could provide differential weighting to hospitals based on their proportion of total inpatient and outpatient utilization by patients in these programs or payments from governmental payors such as Medicare and Medicaid. The commenters suggested collecting patient share information for non-dually eligible FFS Medicare beneficiaries, non-dually eligible Medicare Advantage beneficiaries, dual-eligible FFS beneficiaries, dual-eligible Medicare Advantage beneficiaries, and beneficiaries in the Fully Integrated Dulls Advantage demonstration.

Many commenters requested that CMS consider an auditing process, ensure that its contractors administer such a process consistently, and make the instructions for such an audit public. The commenters did not believe that hospitals were purposefully reporting erroneous information on their costs reports. However, many of the commenters were concerned that unclear reporting instructions on the Worksheet S-10 would result in inconsistent and inaccurate reporting of data. They suggested that CMS look to the process used to audit and review the data used for the Medicare wage index annually. Specifically, the commenters requested that CMS develop timetables for the cut-off of submissions or changes to the data, that MACs be engaged to audit these data to ensure validity, consistency and accuracy across hospitals, and that CMS develop a public use file that would include Worksheet S-10 data to be used in that rulemaking cycle and the calculated uncompensated care payment distribution to each eligible hospital. The commenters also suggested that CMS institute a fatal edit in the cost report
audit process for negative or zero uncompensated care costs. Relatedly, commenters requested that CMS provide hospitals a means to appeal adjustments to the Worksheet S-10.

Many commenters shared observations regarding concerns and anomalies they identified in data from Worksheet S-10. A number of commenters shared analysis, including analyses that looked at the proportion of hospitals that did not report bad debt expenses, that reported a higher amount for gross charges on Worksheet S-10 than Worksheet C, or reported CCRs that seemed inappropriately high (such as for all-inclusive rate facilities). In addition, one commenter questioned imputed values for CAHs. Other commenters noted that the current requirements result in negative uncompensated care values for some hospitals.

These commenters, as well as commenters who opposed the continuation of the proxy, also requested that CMS provide a tentative timeline and implementation process for when and how the Worksheet S-10 would be used for determining Medicare uncompensated care payments. Some commenters suggested that CMS delay the use Worksheet S-10 until an audit process is established, and suggested a delay of at least 4 years. Some commenters requested a transition from using a Factor 3 based on insured low income days to a Factor 3 based on uncompensated care costs from another source such as Worksheet S-10. These commenters suggested a variety of methods for such a transition, including blending or combining the Factor 3 values, and also a variety of lengths for such a transition, such as 3 years or 10 years. Some commenters requested that CMS implement caps on redistribution, such as a maximum cap of 10 percent on any
redistribution of uncompensated care payments for 5 years, in the absence of a transition. These commenters expressed concern regarding sudden destabilizing losses due a change in their uncompensated care payments, noting that providing for a transition would prevent financial shocks to hospitals and create an incentive for them to more accurately report uncompensated care on Worksheet S-10.

Some commenters suggested how CMS should define uncompensated care using information from Worksheet S-10 and additional information that they believed should be collected in order to determine uncompensated care. For example, the commenters believed that bad debts and charity care should be included in the definition of uncompensated care. Some commenters specifically indicated that they believe that CMS should treat the uncompensated portion of state or local indigent care programs as charity care. The commenters also believed that costs not covered by Medicaid payments should be included in the definition of uncompensated care because they are not compensated. The commenters also noted that this approach would improve consistency across hospitals for comparison purposes because some hospitals treat some of these costs as charity care costs based on their charity care policies. Commenters provided different views with regard to publicly funded indigent care programs. Some commenters believed that charges for services provided to these patient populations should not be included. Other commenters believed that these charges should be included and that neither private nor public grant monies should be subtracted from them.

Response: We appreciate the commenters’ support for the use of data on low-income insured days as a proxy for uncompensated care in calculating
uncompensated care payments until Worksheet S-10 data become more reliable. We expect reporting on Worksheet S-10 to improve over time, both in accuracy and consistency, particularly in the area of charity care, which is already being used and audited for payment determinations related to the EHR Incentive Program. Since the publication of the FY 2014 IPPS/LTCH PPS final rule, we have continued to evaluate and assess the comments we have received from stakeholders about Worksheet S-10 as well as to consider what changes might need to be made to the instructions to improve the data submitted by hospitals. Although we have not decided upon revisions to the Worksheet S-10 instructions at this time, we remain committed to making improvements to Worksheet S-10 if we find they are warranted. We appreciate the specific recommendations from commenters for changing the Worksheet S-10 form and instructions and will take them into consideration as we continue to evaluate reporting on Worksheet S-10.

We have noted that we expect to proceed with a proposal to use data on the Worksheet S-10 to determine uncompensated care costs in the future and also have indicated that we will take steps such as revising and clarifying cost report instructions, as appropriate. We have stated that it is our intention to propose introducing the use of the Worksheet S-10 data for purposes of determining Factor 3 within a reasonable amount of time. At this time, we are considering a possible timeline for using Worksheet S-10 data to calculate Factor 3, and we intend to discuss this further in the FY 2017 IPPS proposed rule, which is typically released in April of the preceding fiscal year.
Comment: Several commenters objected to the proposal to calculate Factor 3 based on a hospital’s share of total Medicaid days and Medicare SSI days as a proxy for measuring a hospital’s share of uncompensated care. Many of these commenters believed that continued use of the proxy rewards providers in States where Medicaid has expanded. The commenters asserted that CMS should not finalize its proposal to use low-income insured days as a proxy for uncompensated care costs as proposed and instead supported the use of Worksheet S-10 data to determine uncompensated care costs for FY 2016. In particular, MedPAC disagreed with CMS’ statement that the data on utilization for insured low-income patients can serve as a reasonable proxy for the treatment costs of uninsured patients. MedPAC specifically cited its 2007 analysis of data from the GAO and data from the American Hospital Association (AHA), which suggests that Medicaid days and low-income Medicare days are not a good proxy for uncompensated care costs. MedPAC also provided additional analyses that found that current Worksheet S-10 data, compared to Medicaid/Medicare SSI days, are a better proxy for predicting audited uncompensated care costs. Specifically, MedPAC included an analysis testing whether data from the Worksheet S-10 or Medicaid and Medicare SSI days are a better indicator of costs associated with caring for the uninsured. The analysis compared 2011 data from Worksheet S-10 and 2011 Medicaid and Medicare SSI days with 2009 audited data obtained from the Medicaid and CHIP Payment and Access Commission (MACPAC). The analysis found that the correlation between audited uncompensated care data and data from the Worksheet S-10 was over 0.80, whereas the correlation between audited uncompensated care data and Medicaid and Medicare SSI
days was only about 0.50. Moreover, the analysis found that the 2011 S-10 data explained over 60 percent of the variance in audited uncompensated care costs whereas Medicaid days and Medicare SSI days only explain about 25 percent of the variance. Therefore, MedPAC believed that using Medicare SSI/Medicaid days as a proxy for uncompensated care does not appropriately target hospitals with the highest burden of uncompensated care costs and supported Worksheet S-10 in the Medicare cost report as an appropriate measure of uncompensated care that could begin to replace the reliance on Medicaid and Medicare SSI day shares. In response to concerns about whether the quality of the data reported on Worksheet S-10 is adequate for use in distributing uncompensated care payments, MedPAC argued that these data are already better than using Medicaid and Medicare SSI days as a proxy for uncompensated care costs, and that the data on Worksheet S-10 will improve over time as the data are actually used in making payments.

Response: As we stated in the FY 2014 and FY 2015 IPPS/LTCH PPS final rules, we believe that data on utilization for insured low-income patients can be a reasonable proxy for the treatment costs of uninsured patients. Moreover, due to the concerns that continue to be expressed by commenters regarding the accuracy and consistency of the data reported on the Worksheet S-10, we continue to believe that Medicaid and Medicare SSI days remain a better proxy at this time for the amount of uncompensated care provided by hospitals. However, we remain convinced that Worksheet S-10 can ultimately serve as an appropriate source of more direct data regarding uncompensated care costs for purposes of determining Factor 3. Worksheet
S-10 was developed specifically to collect information on uncompensated care costs in response to interest by MedPAC and other stakeholders regarding the topic (for example, MedPAC’s March 2007 Report to Congress), and it is not unreasonable to expect information on the cost report to be used for payment purposes. We are continuing to review available data on the suitability of the Worksheet S-10 data, and are encouraged by MedPAC’s analysis showing a high correlation between Medicaid audited uncompensated care data and data reported on Worksheet S-10. We also are refining our benchmarking analyses in order to compare available Worksheet S-10 data to other data sources on uncompensated care, such as uncompensated care costs reported to the Internal Revenue Service on Form 990 by not-for-profit hospitals.

As discussed in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50639), in using Medicaid and Medicare SSI days as a proxy for uncompensated care, we recognize it would be possible for hospitals in States that choose to expand Medicaid to receive higher uncompensated care payments because they may have more Medicaid patient days than hospitals in a State that does not choose to expand Medicaid. Regardless, for the reasons discussed above, we believe that data on insured low-income days remain the best proxy for uncompensated care costs currently available to determine Factor 3.

Comment: One commenter believed that the current methodology utilizing low-income insured days as a proxy for uncompensated care does not differentiate between the types of inpatient days or consider the degree of acuity for patients with advanced medical conditions. The commenter suggested that CMS apply a wage and case-mix adjustment to the Medicaid and Medicare SSI days using the hospital area wage
index and hospital-specific case-mix index. The commenter believed that this adjustment was appropriate in order to measure cost variation among hospitals.

Response: We appreciate the commenter’s expression of the need to wage and case-mix adjust the Medicaid and SSI days, but we continue to believe it is not appropriate to apply a wage index or case-mix adjustment to low-income days to calculate Factor 3 for FY 2016. Although wage index information is readily available, for the reasons discussed in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50639) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50017), we continue to believe that it is not an accurate measure of the intensity of uncompensated care costs and would not serve as an appropriate basis for making adjustments to Factor 3. As for case-mix information, as stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50636), these data continue to be unavailable to us.

Comment: One commenter requested that CMS consider the possibility of using a proxy for SSI days in the calculation of Factor 3 and for other purposes related to DSH for Puerto Rico. The commenter noted that U.S. citizens residing in Puerto Rico are not entitled to SSI benefits, and that the reliance upon SSI enrollment in calculating Factor 3 results in uncompensated care payments that are unintentionally and unfairly lower for providers in Puerto Rico.

Response: As discussed earlier, we are currently using the utilization of insured low-income patients, defined as inpatient days of Medicaid patients plus inpatient days of Medicare SSI patients, as a proxy to estimate a hospital’s uncompensated care. When we adopted this methodology for distributing uncompensated care payments for FY 2014, we
estimated Puerto Rico hospitals would receive a 41.3 percent increase in Medicare DSH and uncompensated care payments (78 FR 51009). While this increase was moderated with a reduction of 7.7 percent in FY 2015 (79 FR 50412), the methodology used to determine uncompensated care payments significantly benefitted Puerto Rico hospitals relative to the methodology used to determine DSH payments under section 1886(d)(5)(F) of the Act. Further, as previously discussed, it is our intention to propose introducing the use of Worksheet S–10 of the Medicare cost report for purposes of distributing the uncompensated care payments within a reasonable amount of time. We note that eligibility for SSI days will not be an issue in determining uncompensated care payments after the move to Worksheet S-10 because Medicare SSI days will no longer be used in the distribution methodology. We have encouraged Puerto Rico hospitals to report uncompensated care costs on Worksheet S-10 of the Medicare cost report completely and accurately so that when we transition to the use of the Worksheet S-10, they can continue to receive the share of the uncompensated care payments to which they are entitled. If Puerto Rico hospitals do not properly report uncompensated care costs on Worksheet S-10, they risk a substantial reduction in future payments.

In the interim, until we are ready to move to use of Worksheet S-10 for distributing the uncompensated care payments, we acknowledge that use of SSI Medicare inpatient days in the distribution of uncompensated care payments may disadvantage Puerto Rico hospitals. However, as there was no proposal to modify the methodology for distributing uncompensated care payments to Puerto Rico hospitals in the FY 2016 IPPS/LTCH PPS proposed rule, we do not believe that there would be logical outgrowth to adopt such a
change in this FY 2016 IPPS/LTCH PPS final rule. Any change to the proxy used to determine uncompensated care for Puerto Rico hospitals would need to be adopted through notice-and-comment rulemaking. We plan to address this issue for inclusion in the FY 2017 IPPS/LTCH PPS proposed rule if we also propose to continue using inpatient days of Medicare SSI patients as a proxy for uncompensated care in FY 2017.

Comment: Some commenters asserted that the FY 2016 IPPS/LTCH PPS proposed rule failed to address the impact of Allina v. Sebelius on the Medicare DSH and uncompensated care formulas. The commenters asserted that, with regard to Medicaid and Medicare SSI days used in the calculation of Factor 3, the FY 2011/2012 cost reports do not appropriately reflect dual eligible MA days in conjunction with the court’s ruling in Allina. In addition, one commenter stated that the 2013 SSI ratios, which were released by CMS in May 2015, appear to include MA days, which is inconsistent with the court’s ruling in the Allina case.

Response: We do not believe the Allina decision has any bearing on our estimate of Factor 3 for FY 2016. The decision in Allina did not address the issue of how patient days should be counted for purposes of estimating uncompensated care. Moreover, section 1886(r)(2)(C) of the Act provides discretion for the Secretary to determine how to estimate uncompensated care costs. We continue to believe that, for purposes of determining uncompensated care payments, Medicare SSI days should include both MA and FFS SSI days.

After consideration of the public comments we received, we continue to believe that using low-income insured days as a proxy for uncompensated care costs provides a
reasonable basis to determine Factor 3 as we work to improve Worksheet S-10 to accurately and consistently capture uncompensated care costs. Accordingly, in this final rule, we are finalizing for FY 2016 the policy that we originally adopted in the FY 2014 IPPS/LTCH PPS final rule, of employing the utilization of insured low-income patients, defined as inpatient days of Medicaid patients plus inpatient days of Medicare SSI patients as defined in 42 CFR 412.106(b)(4) and 412.106(b)(2)(i), respectively, to determine Factor 3 for FY 2016. Details on the calculation of Factor 3 for FY 2016 follow.

As we did for the FY 2014 and FY 2015 IPPS/LTCH PPS proposed rules, for the FY 2016 IPPS/LTCH PPS proposed rule, we published on the CMS Web site a table listing Factor 3 for all hospitals that we estimated would receive empirically justified Medicare DSH payments in FY 2016 (that is, hospitals that we projected would receive interim uncompensated care payments during the fiscal year), and for the remaining subsection (d) hospitals and subsection (d) Puerto Rico hospitals that have the potential of receiving a DSH payment in the event that they receive an empirically justified Medicare DSH payment for the fiscal year as determined at cost report settlement. Hospitals had 60 days from the date of public display of the FY 2016 IPPS/LTCH PPS proposed rule to review these tables and notify CMS in writing of a change in a hospital’s subsection (d) hospital status, such as if a hospital closed or converted to a CAH.

After the publication of this FY 2016 IPPS/LTCH final rule, hospitals will have until August 31, 2015, to review and submit comments on the accuracy of these tables. Comments can be submitted to the CMS inbox at Section3133DSH@cms.hhs.gov
through August 31, 2015, and any changes to Factor 3 will be posted on the CMS Web site prior to October 1, 2015.

The statute also allows the Secretary the discretion to determine the time periods from which we will derive the data to estimate the numerator and the denominator of the Factor 3 quotient. Specifically, section 1886(r)(2)(C)(i) of the Act defines the numerator of the quotient as the amount of uncompensated care for such hospital for a period selected by the Secretary. Section 1886(r)(2)(C)(ii) of the Act defines the denominator as the aggregate amount of uncompensated care for all subsection (d) hospitals that receive a payment under section 1886(r) of the Act for such period. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50638), we adopted a process of making interim payments with final cost report settlement for both the empirically justified Medicare DSH payments and the uncompensated care payments required by section 3133 of the Affordable Care Act. Consistent with that process, we also determined the time period from which to calculate the numerator and denominator of the Factor 3 quotient in a way that would be consistent with making interim and final payments. Specifically, we must have Factor 3 values available for hospitals that we estimate will qualify for Medicare DSH payments and for those hospitals that we do not estimate will qualify for Medicare DSH payments but that may ultimately qualify for Medicare DSH payments at the time of cost report settlement.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50018), we finalized a policy to use the most recently available full year of Medicare cost report data for determining Medicaid days and the most recently available SSI ratios. This is consistent with the policy we adopted in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50638) of
calculating the numerator and the denominator of Factor 3 for hospitals based on the most recently available full year of Medicare cost report data (including the most recently available data that may be used to update the SSI ratios) with respect to a Federal fiscal year. In other words, we used data from the most recently available full year cost report for the Medicaid days, the most recent cost report data submitted to CMS by IHS hospitals, and the most recently available SSI ratios (that is, latest available SSI ratios before the beginning of the Federal fiscal year) for the Medicare SSI days. Therefore, to estimate Factor 3 for FY 2015, we used data from the most recently available full year cost report and the most recent cost report data submitted to CMS by IHS hospitals for the Medicaid days and the most recently available SSI ratios, which for FY 2015 were data obtained from the 2011/2012 cost reports and the 2010 cost report data submitted by IHS hospitals for the Medicaid days, and the FY 2012 SSI ratios for the Medicare SSI days.

Since the publication of the FY 2015 IPPS/LTCH PPS final rule, we have been informed by the hospital community that they are experiencing difficulties with submitting accurate data for Medicaid days within the timeframes noted in the Provider Reimbursement Manual, Part 2, for a variety of reasons, such as their ability to receive eligibility data from State Medicaid agencies. (As outlined in Section 104, Chapter 1, of the Provider Reimbursement Manual, Part 2, a hospital generally has 5 months after the close of its cost reporting period to file its cost report.) In addition, we have been informed that there is variation in the ability of hospitals and MACs, respectively, to submit and accept amended cost report data in time for the computation of Factor 3.
While we continue to believe that it is important to use data that are as recent as possible, we recognize that, from time to time, the balance between recency and accuracy may require refinement. In the case of Factor 3, because we make prospective determinations of the uncompensated care payment without reconciliation, we believe that it would increase the accuracy of the data used to determine Factor 3, and accordingly, each eligible hospital's allocation of the overall uncompensated care amount, if we provided hospitals with more time to submit these data and MACs with more time to consider these submitted data before they are used in the computation of Factor 3. As we described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50018), it is not possible for us to wait for a later database update of the cost report data to calculate the final Factor 3 amount for the final rule because this could cause delay in the publication of the final rule. Therefore, we are unable to provide hospitals additional time to submit supplemental data, or for their MACs to consider and accept those data as applicable and appropriate. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24488), we noted that one alternative would be to use slightly older data within the most recent extract of the hospital cost report data in the HCRIS database. We stated that we believe this would allow hospitals more time to submit data and MACs more time to consider and accept such data as applicable and appropriate.

Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24488), for the computation of Factor 3 for FY 2016, we proposed to hold constant the cost report years used to calculate Factor 3 and to use data from the 12-month 2012 or 2011 cost reports and, in the case of IHS hospitals, the 2012 cost report data submitted to CMS by IHS
hospitals. However, because a more recent HCRIS database was available at the time of the development of the FY 2016 proposed rule, we proposed that we would continue to use the most recent HCRIS database extract available to us at the time of the annual rulemaking cycle. We noted that, as in prior years, if the more recent of the two cost reporting periods does not reflect data for a 12-month period, we would use data from the earlier of the two periods so long as that earlier period reflects data for a period of 12 months. If neither of the two periods reflects 12 months, we would use the period that reflects a longer amount of time. We proposed to codify this change for FY 2016 by amending the regulations at § 412.106(g)(1)(iii)(C). We invited public comments on this proposal, which we describe more fully below.

For the FY 2015 IPPS/LTCH PPS final rule, we used the more recent of the full year 2012 or full year 2011 data from the March 2014 update of the hospital cost report data in the HCRIS database and 2010 cost report data submitted to CMS by IHS hospitals as of March 2014 to obtain the Medicaid days to calculate Factor 3. In addition, we used the FY 2012 SSI ratios published on the following CMS Web site to calculate Factor 3: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/dsh.html. In contrast, under our proposal for FY 2016, we indicated we would use the more recent of the full year 2012 or full year 2011 data from the March 2015 update of the hospital cost report data in the HCRIS database and the 2012 cost report data submitted to CMS by IHS hospitals to obtain the Medicaid days to calculate Factor 3. In addition, to calculate Factor 3 for FY 2016, we anticipated that, under our proposal, we would use the FY 2013 SSI ratios that we expected to be
published on the CMS Web site but were not yet available before the public display of the proposed rule. For illustration purposes, in Table 18 associated with the FY 2016 proposed rule (which is available via the Internet on the CMS Web site at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Proposed-Rule-Home-Page-Items/FY2016-IPPS-Proposed-Rule-Tables.html), we computed Factor 3 using the more recent of the full year 2012 or 2011 data from the December 2014 update of the hospital cost report data in the HCRIS database to obtain the Medicaid days and the FY 2012 SSI ratios published on the CMS Web site. We anticipated using the more recent of the full year 2012 or 2011 data from the March 2015 update of the hospital cost report data in the HCRIS database to obtain the Medicaid days and the FY 2013 SSI ratios to determine the final Factor 3 for FY 2016.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24488), we stated that for subsequent years, if we propose and finalize a policy of using insured low-income days in computing Factor 3, we intend to continue to use the most recent HCRIS database extract at the time of the annual rulemaking cycle, and to use the subsequent year of cost reports, as applicable, using the methodology described above (that is, to advance the 12-month cost reports by 1 year). We noted that, starting with the 2013 cost reports, data for IHS hospitals will be included in the HCRIS. Therefore, if an IHS hospital has a 12-month 2013 cost reporting period in the HCRIS database, we will not need to use the 2012 data separately submitted to CMS by the IHS hospital. For example, if we finalize for FY 2017, a policy under which Factor 3 is determined on the basis of insured low-income
days, this approach would result in the use of the more recent of the 12-month 2013 or 2012 cost reports in the most recent HCRIS database extract available at the time of rulemaking. In addition, for any subsequent years in which we finalize a policy to use insured low-income days to compute Factor 3, our intention would be to continue to use the most recently available SSI ratio data to calculate Factor 3 at the time of annual rulemaking. As we indicated in the FY 2016 IPPS/LTCH PPS proposed rule, we believe that it is appropriate to state our intentions regarding the specific data we would use in the event Factor 3 is determined on the basis of low-income insured days for subsequent years to provide hospitals with as much guidance as possible so they may best consider how and when to submit cost report information in the future. We note that we will make proposals with regard to our methodology for calculating Factor 3 for subsequent years through notice-and-comment rulemaking.

Comment: Several commenters supported the proposal to use more recent of the full year 2012 or 2011 data from the March 2015 update of the hospital cost report data in the HCRIS database to obtain the Medicaid days and the FY 2013 SSI ratios to determine the final Factor 3 for FY 2016. Other commenters stated that they did not oppose the proposal.

Response: We appreciate the commenters’ support for or lack of opposition to this proposal.

Comment: Several commenters questioned the data used to calculate the hospitals’ Factor 3 and requested clarifications on various aspects of the proposed policy. For example, several commenters stated that their Medicaid days were understated, and
other commenters stated that their Medicaid days were based on a 6-month cost report and they should be based on a 12-month cost report either by combining cost reports or annualizing the data. Several commenters requested that CMS clarify whether the 12-month 2012 cost report would have to fall within the Federal fiscal year, or if CMS intends to use the full year cost report from previous years if there are no full year cost reports during the period. One commenter suggested that, for a new hospital for which the applicable historical cost reporting data represent less than 12 months, CMS use the full 12-month cost reporting data that are closest to the cost reporting period selected for determining Factor 3 in the FY 2016 IPPS/LTCH PPS final rule even if these cost reporting data are more recent than the selected period. The commenter also recommended, as an alternative, that CMS allow a new hospital to settle its uncompensated care payment on its filed cost report for the applicable fiscal year until the cost reporting period data that are applicable for computing Factor 3 include a full 12-month cost reporting period. One commenter asked for clarification on which SSI ratios will be used to settle the FY 2015 and FY 2016 cost reports, as well as which SSI ratios will be used for what purpose. A number of commenters provided information regarding their Medicaid days and requested changes based on that information.

**Response:** We appreciate the commenters raising these data concerns and areas of needed clarification. We are finalizing our proposal to calculate Factor 3 using SSI days from the FY 2013 SSI ratios and Medicaid days from 2012 cost report data submitted to CMS by IHS hospitals and the more recent of hospital-specific full year 2012 cost reports (unless that cost report is unavailable or reflects less than a full
12-month year, in which case we will use the cost report from 2012 or 2011 that is closest to being a full 12-month cost report) from the March 2015 update of the hospital cost report data in the HCRIS database. We also are finalizing our proposed revisions to the regulation at § 412.106(g)(1)(iii)(C), which codifies the cost reporting periods selected for purposes of determining Factor 3 of the uncompensated care payment methodology for FY 2016. We note that since we issued the FY 2016 IPPS/LTCH PPS proposed rule, the FY 2013 SSI ratios have become available on the CMS Web site at:
http://www.cms.gov/Medicare/Medicare-Fee-for-Service-
Payment/AcuteInpatientPPS/dsh.html. We also clarify that the 12-month cost report does not need to coincide with the Federal fiscal year.

With regard to the comments from hospitals that found their Factor 3 was calculated using a cost report that was less than 12 months, we are finalizing our proposal to use the 2012 cost report, unless that cost report is unavailable or reflects less than a full 12-month year. In the event the 2012 cost report is for less than 12 months, we will use the cost report from 2012 or 2011 that is closest to being a full 12-month cost report. In the case where a less than 12-month cost report is used to calculate a hospital’s Factor 3, this would indicate that both the 2012 and 2011 cost reports were less than 12 months. In such a case, we will use the longer of the two cost reports to calculate a hospital’s Factor 3. We note that section 1886(r)(2)(C) of the Act specifies that Factor 3 is equal to the percent that represents the amount of uncompensated care for such hospital for a period selected by the Secretary (as estimated by the Secretary, based on appropriate data divided by the aggregate amount of uncompensated care for all subsection (d) hospitals
that receive a payment for such period (as so estimated). In implementing this provision, as we did through rulemaking in the FY 2014 IPPS/LTCH PPS final rule, we noted that we believed it was appropriate to first select the period—in that case, the period for which we had the most recently available data—and then to select the data from a cost report that aligns best with that period. Based upon our experience with implementing the provision for FY 2014 and FY 2015, we have determined that it is more appropriate to use the most recent extract of hospital cost report data for a slightly earlier period in order to give hospitals more time to submit data and MACs more time to consider and accept that data. As we have discussed, we believe this policy will improve the accuracy of the data used to calculate Factor 3. However, we acknowledge that the situations presented by commenters, where a hospital remains in operation in both Federal fiscal years for which we analyze cost report data but submits cost reports for both Federal fiscal years that reflect substantially less than a full year of data, pose unique challenges in the context of estimating Factor 3. We did not make a proposal to annualize or combine cost reports to calculate Factor 3. As a result, this is an issue that we intend to consider further and may address in future rulemaking.

As stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50643), for new hospitals, which for Medicare DSH purposes include hospitals with a CCN established after 2012, we do not have data currently available to determine if the new hospital is eligible for empirically justified Medicare DSH payments and, therefore, eligible to receive an uncompensated care payment for FY 2016, nor do we have the data necessary to calculate a Factor 3 amount. Accordingly, we will treat new hospitals in the same
manner as hospitals that are not found to be eligible to receive empirically justified Medicare DSH payments based upon the most recent available cost report from 2012 or 2011, such that the hospital may not receive either interim empirically justified Medicare DSH payments or interim uncompensated care payments. However, if the hospital is later determined to be eligible to receive empirically justified Medicare DSH payments based on its FY 2016 cost report, the hospital also will receive an uncompensated care payment based on the sum of Medicaid days and Medicare SSI days reported on its FY 2016 cost report.

In response to the commenters’ concerns about which SSI ratios will be used for what purpose, we note that, consistent with our methodology in FY 2014 and FY 2015, the most recently available SSI ratios, in conjunction with the Medicaid fraction listed in the most recent update of the Provider Specific File, are used to identify which hospitals are projected to receive empirically justified DSH payments for FY 2016, and thus are eligible to receive interim uncompensated care payments for FY 2016. For this FY 2016 IPPS/LTCH PPS final rule, the 2013 SSI ratios are the most recently available SSI ratios and the March 2015 update is the most recent update of the Provider Specific File. The final determination as to whether a hospital is eligible to receive empirically justified DSH payments and therefore eligible to receive an uncompensated care payment is made at cost report settlement using the SSI ratio and Medicaid fraction reported on the provider’s FY 2016 cost report. Therefore, for FY 2016, the 2013 SSI ratios are used to project eligibility to receive interim empirically justified DSH payments and interim uncompensated care payments, and the 2016 SSI ratios are used to determine, at cost
report settlement, whether the hospital is ultimately eligible for empirically justified DSH payments and the uncompensated care payment. Furthermore, as stated elsewhere in this final rule, the SSI days from the 2013 SSI ratios are used in computing Factor 3. The calculation of Factor 3 in this final rule is a final determination that is not subject to review and will not be revised at cost report settlement to reflect updated information regarding the eligibility of individual hospitals for empirically justified DSH payments and uncompensated care payments.

Comment: Several commenters requested additional time after the publication of the final rule to review the data used to calculate Factor 3 and submit corrections. Some commenters asked questions regarding whether or not Medicaid days from more recent cost reports than the cost reporting periods we proposed to use could be included for their hospitals in determining Factor 3 for FY 2016. Some of these commenters included specific information and copies of documentation related to these days.

Response: We thank the commenters for their submissions. Regarding the data used to calculate Factor 3, we believe that the SSI days from the FY 2013 SSI ratios and Medicaid days from the more recent of hospitals’ 2012 or 2011 cost report (that encompasses a period closest to 12 months) from the March 2015 HCRIS extract, as well as Medicaid days from 2012 cost report data submitted to CMS by IHS hospitals, should be used to determine Factor 3. As we stated above, we believe using 2011/2012 cost report data will allow hospitals more time to submit their cost report data and MACs more time to consider and accept such data as applicable and appropriate, thus balancing recency and accuracy. We cannot allow for further updates and revisions to the data used
to determine Factor 3 because they would cause an unacceptable delay in the publication of this final rule and prevent changes and updates to payments under the IPPS from taking effect on October 1, the first day of the fiscal year. Furthermore, the statute provides the Secretary with the authority and discretion to estimate the amount of uncompensated care for a hospital and also provides the Secretary with the authority and discretion to select the time period for which this uncompensated care amount is estimated.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24488), we proposed to continue the policies that were finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50020) to address several specific issues concerning the process and data to be employed in determining Factor 3 in the case of hospital mergers for FY 2016 and subsequent fiscal years. In order to confirm mergers and ensure the accuracy of the data used to determine each merged hospital’s uncompensated care payment, we stated that we would publish a table on the CMS Web site, in conjunction with the issuance of each Federal fiscal year’s IPPS/LTCH PPS proposed and final rules, that contains a list of the mergers that we are aware of and the computed uncompensated care payment for each merged hospital. Hospitals have 60 days from the date of public display of each year’s IPPS/LTCH PPS proposed rule to review these tables and notify CMS in writing of any inaccuracies. After the publication of the IPPS/LTCH PPS final rule, hospitals will have until August 31 of that year (for FY 2016, the deadline is August 31, 2015) to review and submit comments on the accuracy of the table for the applicable fiscal year. Comments can be submitted to our inbox at Section3133DSH@cms.hhs.gov through August 31, and
any changes to Factor 3 will be posted on the CMS Web site prior to the start of the applicable fiscal year on October 1. We invited public comments on our proposal to continue these policies concerning the process and data to be employed in determining Factor 3 in the case of hospital mergers, as described above.

Comment: Some commenters provided detailed information regarding specific merger situations involving their hospitals and requested that CMS consider these mergers in determining Factor 3 for FY 2016. One commenter expressed concern that if a hospital is not identified as having undergone a merger prior to the public display of the final rule, a recalculation would be performed on the surviving hospital’s Factor 3 at the end of the applicable fiscal year in which the merger has taken place. The commenter was concerned that this process may result in an extended delay before a hospital’s uncompensated care payment is corrected and may result in understated interim uncompensated care payments. The commenter recommended an alternate approach for the recalculation of a hospital’s Factor 3 that utilizes the tentative settlement process currently used by the MACs for the purpose of updating the hospital’s payment rate prior to final settlement.

Response: We appreciate the commenters’ input. As in FY 2015, we published a table on the CMS Web site in conjunction with the issuance of the proposed rule containing a list of the mergers that we are aware of and the computed uncompensated care payment for each merged hospital. The affected hospitals had the opportunity to comment during the public comment period on the accuracy of this information. We have updated our list of mergers based on information submitted by the MACs as of
June 2015. In addition, we have reviewed the commenters’ submissions of mergers not previously identified in the proposed rule and have updated our list accordingly.

While we continue to believe that recalculation of a surviving hospital’s Factor 3 at cost report settlement is the most conducive to administrative efficiency and predictability for both providers and MACs, we may explore the possibility of an alternative approach in which recalculation occurs during the tentative settlement process in future notice-and-comment rulemaking. In addition, we remind the commenters that, in the event that a merger is not identified by the MACs, we allow opportunity for comment on the accuracy of the mergers that we have identified during the comment period for the proposed rule and after the publication of the final rule. Hospitals have until August 31, 2015 to review and submit comments on the accuracy of the list of mergers that we have identified in this final rule.
E. Hospital Readmissions Reduction Program: Changes for FY 2016 Through FY 2017 (§§ 412.150 through 412.154)

1. Statutory Basis for the Hospital Readmissions Reduction Program

Section 3025 of the Affordable Care Act, as amended by section 10309 of the Affordable Care Act, added a new section 1886(q) to the Act. Section 1886(q) of the Act establishes the “Hospital Readmissions Reduction Program,” effective for discharges from an “applicable hospital” beginning on or after October 1, 2012, under which payments to those applicable hospitals may be reduced to account for certain excess readmissions.

Section 1886(q)(1) of the Act sets forth the methodology by which payments to “applicable hospitals” will be adjusted to account for excess readmissions. In accordance with section 1886(q)(1) of the Act, payments for discharges from an “applicable hospital” will be an amount equal to the product of the “base operating DRG payment amount” and the adjustment factor for the hospital for the fiscal year. That is, “base operating DRG payments” are reduced by a hospital-specific adjustment factor that accounts for the hospital’s excess readmissions. Section 1886(q)(2) of the Act defines the base operating DRG payment amount as the payment amount that would otherwise be made under section 1886(d) of the Act (determined without regard to section 1886(o) of the Act [the Hospital VBP Program]) for a discharge if this subsection did not apply; reduced by any portion of such payment amount that is attributable to payments under paragraphs (5)(A), (5)(B), (5)(F), and (12) of section 1886(d) of the Act. Paragraphs (5)(A), (5)(B), (5)(F),
and (12) of section 1886(d) of the Act refer to outlier payments, IME payments, DSH adjustment payments, and add-on payments for low-volume hospitals, respectively.

Furthermore, section 1886(q)(2)(B) of the Act specifies special rules for defining the payment amount that would otherwise be made under section 1886(d) of the Act for certain hospitals, including policies for SCHs and for MDHs for FY 2013. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53374), we finalized policies to implement the statutory provisions related to the definition of “base operating DRG payment amount” with respect to those hospitals.

Section 1886(q)(3)(A) of the Act defines the “adjustment factor” for an applicable hospital for a fiscal year as equal to the greater of (i) the ratio described in subparagraph (B) for the hospital for the applicable period (as defined in paragraph (5)(D)) for such fiscal year; or (ii) the floor adjustment factor specified in subparagraph (C).

Section 1886(q)(3)(B) of the Act, in turn, describes the ratio used to calculate the adjustment factor. It states that the ratio is equal to 1 minus the ratio of – (i) the aggregate payments for excess readmissions and (ii) the aggregate payments for all discharges. Section 1886(q)(3)(C) of the Act establishes the floor adjustment factor, which is set at 0.97 for FY 2015 and subsequent fiscal years.

Section 1886(q)(4) of the Act defines the terms “aggregate payments for excess readmissions” and “aggregate payments for all discharges” for an applicable hospital for the applicable period. The term “aggregate payments for excess readmissions” is defined in section 1886(q)(4)(A) of the Act as the sum, for applicable conditions of the product, for each applicable condition, of (i) the base operating DRG payment amount for such
hospital for such applicable period for such condition; (ii) the number of admissions for such condition for such hospital for such applicable period; and (iii) the excess readmissions ratio for such hospital for such applicable period minus 1. The “excess readmissions ratio” is a hospital-specific ratio based on each applicable condition.

Specifically, section 1886(q)(4)(C) of the Act defines the excess readmissions ratio as the ratio of actual-over-expected readmissions; specifically, the ratio of “risk-adjusted readmissions based on actual readmissions” for an applicable hospital for each applicable condition, to the “risk-adjusted expected readmissions” for the applicable hospital for the applicable condition.

Section 1886(q)(5) of the Act provides definitions of “applicable condition,” “expansion of applicable conditions,” “applicable hospital,” “applicable period,” and “readmission.” The term “applicable condition” (which is addressed in detail in section IV.C.3.a. of the FY 2012 IPPS/LTCH PPS final rule (76 FR 51665 through 51666)) is defined as a condition or procedure selected by the Secretary among conditions and procedures for which: (i) readmissions represent conditions or procedures that are high volume or high expenditures and (ii) measures of such readmissions have been endorsed by the entity with a contract under section 1890(a) of the Act and such endorsed measures have exclusions for readmissions that are unrelated to the prior discharge (such as a planned readmission or transfer to another applicable hospital).

Section 1886(q)(5)(B) of the Act also requires the Secretary, beginning in FY 2015, to the extent practicable, to expand the applicable conditions beyond the three conditions for which measures have been endorsed to the additional four conditions that have been
identified by the MedPAC in its report to Congress in June 2007 and to other conditions and procedures as determined appropriate by the Secretary.

Section 1886(q)(5)(C) of the Act defines “applicable hospital,” that is, a hospital subject to the Hospital Readmissions Reduction Program, as a subsection (d) hospital or a hospital that is paid under section 1814(b)(3) of the Act, as the case may be. The term “applicable period,” as defined under section 1886(q)(5)(D) of the Act, means, with respect to a fiscal year, such period as the Secretary shall specify. As explained in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51671), the “applicable period” is the period during which data are collected in order to calculate various ratios and payment adjustments under the Hospital Readmissions Reduction Program.

Section 1886(q)(6) of the Act sets forth the public reporting requirements for hospital-specific readmission rates. Section 1886(q)(7) of the Act limits administrative and judicial review of certain determinations made pursuant to section 1886(q) of the Act. Finally, section 1886(q)(8) of the Act requires the Secretary to collect data on readmission rates for all hospital inpatients (not just Medicare patients) for a broad range of both subsection (d) and nonsubsection (d) hospitals in order to calculate the hospital-specific readmission rates for all such hospital inpatients and to publicly report these “all-patient” readmission rates.

2. Regulatory Background

The payment adjustment factor set forth in section 1886(q) of the Act did not apply to discharges until FY 2013. In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51660 through 51676), we addressed the issues of the selection of readmission
measures and the calculation of the excess readmissions ratio, which will be used, in part, to calculate the readmissions adjustment factor. Specifically, in that final rule, we finalized policies that relate to the portions of section 1886(q) of the Act that address the selection of and measures for the applicable conditions, the definitions of “readmission” and “applicable period,” and the methodology for calculating the excess readmissions ratio. We also established policies with respect to measures for readmissions for the applicable conditions and our methodology for calculating the excess readmissions ratio.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53374 through 53401), we finalized policies that relate to the portions of section 1886(q) of the Act that address the calculation of the hospital readmissions payment adjustment factor and the process by which hospitals can review and correct their data. Specifically, in that final rule, we addressed the base operating DRG payment amount, aggregate payments for excess readmissions and aggregate payments for all discharges, the adjustment factor, applicable hospital, limitations on review, and reporting of hospital-specific information, including the process for hospitals to review readmission information and submit corrections. We also established a new Subpart I under 42 CFR Part 412 (§§ 412.150 through 412.154) to codify rules for implementing the Hospital Readmissions Reduction Program.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50649 through 50676), we finalized our policies that relate to refinement of the readmissions measures and related methodology for the current applicable conditions, expansion of the “applicable conditions” for FY 2015 and subsequent fiscal years, and clarification of the process for reporting hospital-specific information, including the opportunity to review and submit
corrections. We also established policies related to the calculation of the adjustment factor for FY 2014.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50024 through 50048), we made refinements to the readmissions measures and related methodology for applicable conditions for FY 2015 and subsequent fiscal years, expanded the “applicable conditions” for FY 2017 and subsequent fiscal years, discussed the maintenance of technical specifications for quality measures, and described a waiver from the Hospital Readmissions Reduction Program for hospitals formerly paid under section 1814(b)(3) of the Act (§ 412.154(d)). We also specified the applicable period for FY 2015 and made changes to the calculation of the aggregate payments for excess readmissions to include two additional applicable conditions for the FY 2015 payment determination.

3. Overview of Policies for the FY 2016 and FY 2017 Hospital Readmissions Reduction Program

In this final rule, for the FY 2016 Hospital Readmissions Reduction Program, we are—

- Specifying the adjustment factor floor for FY 2016 (section IV.E.6. of the preamble of this final rule);
- Specifying the applicable period for FY 2016 (section IV.E.7. of the preamble of this final rule);
- Specifying the calculation of aggregate payments for excess readmissions for FY 2016 (section IV.E.8. of the preamble of this final rule); and
- Adopting an extraordinary circumstance exception policy to address hospitals that experience a disaster or other extraordinary circumstance beginning in FY 2016 and for subsequent years (section IV.E.9. of the preamble of this final rule).

In addition, in this final rule, for the FY 2017 Hospital Readmissions Reduction Program, we are making a refinement to the pneumonia readmissions measure, which would expand the measure cohort, for the FY 2017 payment determination and subsequent years (section IV.E.4. of the preamble of this final rule).

We note that, during the comment period for the FY 2016 IPPS/LTCH PPS proposed rule, we received public comments that were not related to our specific proposals for the Hospital Readmissions Reduction Program and therefore considered out of the scope of the proposed rule. Some of the out-of-scope comments were related to a wide range of aspects of the Hospital Readmissions Reduction Program and its readmissions measures. For example, there were recommendations for statutory changes to the program payment structure and previously finalized program definitions, changes to the program goals, and the frequency of assessing and reporting performance on measures. Notably, there were many public comments on risk adjustment for sociodemographic status (SDS) at the patient-level and hospital-level. While we appreciate the commenters’ feedback, we consider these topics to be out of scope of the proposed rule. Therefore, we are not addressing most of them in this final rule. However, we are addressing topic of the risk-adjustment for SDS in this final rule because of the volume of public comments and the importance of this topic for outcome
measures in payment programs. We are also addressing the impact of declining admissions on the Hospital Readmissions Reduction Program.

All other out-of-scope topics will be taken into consideration when developing policies and program requirements for future years.

**Comment:** Several commenters suggested that all readmissions measures in the Hospital Readmissions Reduction Program should be risk-adjusted to reflect the hospital’s inpatient population and account for sociodemographic factors, including income, education level, and poverty rate. The commenters suggested that, without an SDS adjustment, large hospitals, major teaching hospitals, and hospitals with a higher DSH proportion (indicating higher levels of care for more vulnerable patients) are more likely to be penalized for community factors outside of a hospital’s control (for example, availability of primary care, physical therapy, rehabilitative services, and family support).

**Response:** While we appreciate these comments and the importance of the role that sociodemographic status plays in the care of patients, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of low sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures. To date, we have found that hospitals that care for large proportions of patients of low sociodemographic status are capable of performing well on our measures (we refer readers to the 2014 Chartbook, pages 48-57, 70-73, and 78, at:

http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-
NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate for each measure. For 2 years, NQF will conduct a trial of a temporary policy change that will allow inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will determine whether to make this policy change permanent. Measure developers must submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of sociodemographic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

Comment: A number of commenters recommended that CMS examine the effect of declining hospital admissions on readmission penalties, and consider whether future revisions to the readmission measure formulas are needed.

Response: We thank the commenters for their recommendation. We note that the basic readmissions formulas for the Hospital Readmissions Reduction Program are
specified in the statute. We will continue to monitor admissions rates and the effects of changes in admission rates on measures performance in our quality reporting and incentive programs.

4. Refinement of the Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization Measure Cohort for the FY 2017 Payment Determination and Subsequent Years

a. Background

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24490 through 24492), for the FY 2017 payment determination and subsequent years, we proposed a refinement of the currently NQF-endorsed CMS Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization measure (NQF #0506) (hereafter referred to as the CMS 30-Day Pneumonia Readmission Measure (NQF #0506)), which would have expanded the measure cohort. For the purposes of describing the refinement of this measure, we noted that “cohort” is defined as the hospitalizations, or “index admissions,” that are included in the measure. This cohort is the set of hospitalizations that meet all of the inclusion and exclusion criteria, and we proposed an expansion to this set of hospitalizations. The previously adopted CMS 30-Day Pneumonia Readmission Measure (NQF #0506) included hospitalizations for patients with a principal discharge diagnosis of pneumonia indicating viral or bacterial pneumonia. For measure cohort details of the prior version of the measure, we refer readers to the measure methodology report and measure risk adjustment statistical model.
The proposed measure refinement would have expanded the measure cohort to include hospitalizations for patients with a principal discharge diagnosis of aspiration pneumonia and for patients with a principal discharge diagnosis of either sepsis or respiratory failure who also have a secondary diagnosis of pneumonia present on admission. We suggested that including such patients would better represent the complete population of a hospital’s patients who are receiving clinical management and treatment for pneumonia, and ensure the measure includes more complete and comparable populations across hospitals. In addition, use of comparable populations would reduce measurement bias resulting from different coding practices seen across hospitals. We stated our belief that measure results derived from refinement of the measure cohort in the manner we proposed would improve the measure’s assessment of avoidable readmissions and more accurately reflect quality and outcome for pneumonia patients. The determination to refine the measure cohort was based on our evaluation of both the frequency and variation in utilization of these diagnosis codes, and as such coding practices have been described in recently published studies. The rationale for expanding the measure cohort for the CMS 30-Day Pneumonia Readmission Measure (NQF #0506) was further described in section VIII.A.6.b. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24564 through 24566) under our discussion of proposed refinements for the Hospital IQR Program.
b. Overview of the Measure Cohort Change

The proposed measure refinement would have expanded the cohort to include hospitalizations for patients with a principal discharge diagnosis of aspiration pneumonia and for patients with a principal discharge diagnosis of either sepsis or respiratory failure who also have a secondary diagnosis of pneumonia that is coded as present on admission. The data sources, exclusion criteria, and assessment of the outcome of readmission remained unchanged.

The proposed refinement of the CMS 30-Day Pneumonia Readmission Measure (NQF #0506) with this expanded measure cohort was reviewed by the Measure Applications Partnership (MAP), which conditionally supported use of the measure update for the Hospital Readmissions Reduction Program pending NQF review of the measure update and appropriate consideration under the NQF SDS pilot, if required, as detailed in its Pre-Rulemaking 2015 MAP Recommendations Report available at: https://www.qualityforum.org/Setting_Priorities/Partnership/MAP_Final_Reports.aspx.

We note that during the MAP Hospital Workgroup and MAP Coordinating Committee in-person meetings, some members discussed the benefit of a phased approach that would first allow for public reporting of the refined measure before implementing it in a pay-for-performance program in order to allow providers to gain experience with the measure refinement, while other members expressed concern that this would delay implementation of an improved measure and also cause alignment issues and potential confusion among providers. The MAP supported the use of the measure refinement without stipulating prior public reporting as a condition of support. However,
we acknowledge the importance of this consideration and took it into account when determining to propose implementation of the measure refinement in the Hospital Readmissions Reduction Program beginning with the FY 2017 payment determination.

We considered other options in proposing when to implement the refinement of the CMS 30-Day Pneumonia Readmission Measure (NQF #0506) in the Hospital Readmissions Reduction Program, including the option to implement the measure refinement beginning with the FY 2018 payment determination. Delaying implementation of the measure refinement until FY 2018 would allow hospitals to gain more experience with the impact of the measure refinement on their measure results and excess readmissions ratios. However, it also would mean delaying use of an improved measure that we believe would better represent the complete population of a hospital’s pneumonia patients and better reflect comparable pneumonia patients across hospitals. Delaying implementation of the measure refinement for the Hospital Readmissions Reduction Program could also potentially increase confusion among hospitals as well as raise alignment issues with other CMS hospital inpatient quality reporting and payment programs that use the same measure.

After considering these options, we proposed to begin with the FY 2017 payment determination to implement the refinement of the CMS 30-Day Pneumonia Readmission Measure (NQF#0506) in the Hospital Readmissions Reduction Program. We believed that after weighing the considerations, the proposed measure refinement should be incorporated into the Hospital Readmissions Reduction Program as soon as statutorily and operationally feasible, primarily because improving the measure in the manner we
proposed would greatly improve the measure’s assessment of quality and outcome for pneumonia patients and, therefore, its implementation should not be unnecessarily delayed.

c. Risk Adjustment

The risk adjustment and statistical modeling approach as well as the measure calculation for the proposed measure remained unchanged from the previously adopted measure. However, we did confirm the use of current risk-adjustment variables in the expanded measure cohort by confirming their association with the outcome. We also examined additional risk variables leading to the addition of a few additional risk variables in the measure.

d. Calculating the Excess Readmissions Ratio

The proposed refinement of the measure cohort for the CMS 30-Day Pneumonia Readmission Measure (NQF #0506) would have used the same methodology and statistical modeling approach as the previously adopted in the CMS 30-Day Pneumonia Readmission Measure (NQF #0506) for the Hospital Readmissions Reduction Program, as well as the other Hospital Readmissions Reduction Program measures. We published a detailed description of how the readmission measures estimate the excess readmissions ratios in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53380 through 53381).

We noted that the set of hospitals for which this refined measure would be calculated for the Hospital Readmissions Reduction Program would differ from those used in calculations for the Hospital IQR Program. The Hospital Readmissions Reduction Program includes only subsection (d) hospitals as defined in section
1886(d)(1)(B) of the Act (and, if not waived from participating, those hospitals paid under section 1814(b)(3) of the Act), while the Hospital IQR Program calculations include non-IPPS hospitals, such as CAHs, cancer hospitals, and hospitals located in the Territories of the United States. However, we believed that adoption of the refinement to the measure cohort for the CMS 30-Day Pneumonia Readmission Measure (NQF #0506) would be appropriate for both programs.

In summary, we proposed a refinement of the NQF-endorsed CMS 30-Day Pneumonia Readmission Measure (NQF #0506), which would expand the measure cohort, in the Hospital Readmissions Reduction Program for the FY 2017 payment determination and subsequent years.

We invited public comment on this proposal.

**Comment:** Many commenters supported CMS’ proposed refinement of the NQF-endorsed CMS 30-Day Pneumonia Readmission Measure (NQF #0506), stating that the revised cohort would more completely cover the inpatient hospital patient population.

**Response:** We appreciate the commenters’ support.

**Comment:** Many commenters expressed concern that patients with acute respiratory failure present higher acuity than average community acquired pneumonia patients, as they often arrive at the hospital intubated or in immediate need of ventilator support and frequently have pre-existing lung disease and pathology, severe influenza, or viral pneumonia. Several commenters also stated that the proposed inclusion of patients with respiratory failure may result in the double counting of cases in two different readmission measures (pneumonia and chronic obstructive pulmonary disease (COPD)).
as both the proposed revised pneumonia measure and the COPD measure could include the same cases when respiratory failure is the primary diagnosis and COPD and pneumonia are listed as the secondary diagnoses. One commenter was particularly concerned about the inclusion of sepsis patients with other infectious diseases in addition to pneumonia, severe illness consistent with severe sepsis, or prolonged intubation.

**Response:** We thank the commenters for their recommendations, and appreciate their concerns regarding the extent of the cohort expansion particularly with regard to inclusion of patients with a primary diagnosis of respiratory failure and severe sepsis. Upon further evaluation and analysis of the impact of the proposed measure, and in response to the public comments, we are finalizing a modified version of the expanded pneumonia cohort from what we had specified in the proposed rule. The modified version includes patients with a principal discharge diagnosis of pneumonia or aspiration pneumonia, and patients with a principal discharge diagnosis of sepsis with a secondary diagnosis of pneumonia coded as present on admission. However, we are not including patients with a principal discharge diagnosis of respiratory failure or patients with a principal discharge diagnosis of sepsis if they are coded as having severe sepsis as we had previously proposed.

As we stated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24490 through 24492), the purpose of expanding the cohort of the current pneumonia readmission measure is to include a broader spectrum of pneumonia patients and respond to changes in coding practices that were potentially biasing estimates of the performance of hospitals. Additional analyses were conducted after the proposed rule was published
as part of the measure reevaluation and re-specification process. These analyses revealed challenges to the risk adjustment methodology with respect to patients with severe sepsis and respiratory failure, and revealed that the proposed cohort expansion would exacerbate the bias in the existing measure that it was intended to mitigate. Specifically, hospital coding frequency was found to be even more strongly, and inversely, associated with performance. Therefore, we modified the refined cohorts to address this bias.

The decision to finalize the modified version is also consistent with clinical practice, as these sickest patients often receive care in an intensive care unit and other specialized interventions (such as ventilator support) that is clinically distinct from the care provided to patients with less severe forms of pneumonia. The modified version has also been determined to be statistically robust, such that risk-standardization accounted for case-mix differences across hospitals, without being confounded by hospital coding patterns. These changes also are consistent with public comments received in response to the FY 2016 IPPS/LTCH PPS proposed rule. For details on the rationale for the cohort expansion, the analyses supporting the re-specified cohort we are finalizing instead of the specifications previously proposed, and the full specification and results of the measure as adopted in this final rule, we refer readers to the measure methodology report for the finalized measure in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

This additional analysis indicates that the modified version of the expansion of the cohort we are finalizing responds to potential bias in the current measure, and that risk
adjustment is adequate. We believe this revised cohort expansion produces a measure that does not favor or disadvantage hospitals on the basis of their coding practices. We also believe the revised cohort we are adopting still effectively broadens the cohort of patients included in the measure to be more clinically comprehensive (bringing in sepsis and aspiration pneumonia patients) in relation to what we previously proposed. Finally, we believe that we also are being responsive to commenters’ concerns by not including those patients that are most severely ill on arrival (those with severe sepsis and respiratory failure, as included in the previously proposed version), because these patients’ increased risk is challenging to appropriately account for across hospitals.

We note that because patients with a principal discharge diagnosis of respiratory failure are no longer included in the modified version of the cohort, there is no opportunity for readmissions to be counted in both the pneumonia and COPD readmission measures.

Comment: A number of commenters argued that patients with a diagnosis of sepsis and secondary diagnosis of pneumonia have a higher predicted mortality and readmission risk, and often have multiple comorbidity conditions, which are prone to exacerbation during the index admission. One commenter argued the inclusion of sepsis in the pneumonia readmission measures creates the possibility of duplicate penalties. Another commenter argued that additional conditions needed to be added to the risk adjustment for sepsis patients. Another commenter was particularly concerned about the inclusion of sepsis patients with severe sepsis.
Response: We thank the commenters for their comments. As we discussed, we have conducted additional analysis regarding the impact of the modified cohort, and in response to public comments and the results of this analysis, we are finalizing the modified version of the expanded pneumonia cohort from what we had specified in the proposed rule. The modified version of the expanded pneumonia cohort includes patients with a principal discharge diagnosis of pneumonia or aspiration pneumonia, and patients with a principal discharge diagnosis of sepsis with a secondary diagnosis of pneumonia coded as present on admission, but does not include patients with a principal discharge diagnosis of respiratory failure or patients coded as having severe sepsis. Based on the testing and analysis we conducted, we believe that the risk adjustment we are finalizing adequately accounts for the varying severity and comorbidities of patients across the finalized cohort, and that hospitals will not be unfairly penalized for treating sicker patients. Based on our additional evaluation, we confirmed that the approach to risk-adjustment for the modified measure was effective, as hospital coding frequency was not associated with performance on the readmission measure.

We had previously proposed including the presence of sepsis or respiratory failure in the index admission as covariates, or risk-adjusters, in the model. However, analyses conducted subsequent to publication of the FY 2016 IPPS/LTCH PPS proposed rule revealed that this approach would exacerbate the bias in the existing measure that it was intended to mitigate as such patients’ increased risk was challenging to appropriately account for across hospitals. Therefore, in the modified measure, the risk adjustment factors used in the publicly reported version of the readmission measure were retained
and one new risk-adjustment variable (respiratory dependence/tracheostomy (CC77)) was added. No additional risk adjustment variables were added for the patients included in the expanded cohort (that is, aspiration pneumonia and sepsis patients).

We conducted additional analyses and found that limiting the measure expansion to aspiration pneumonia patients and sepsis patients without including risk adjustment for these alternate principal diagnoses of respiratory failure and severe sepsis was the most feasible approach that brought in a large portion of patients currently excluded from the measure but mitigated the biases introduced by hospital coding patterns. Specifically, our analysis indicated that under the revisions we are adopting, hospital performance among hospitals with higher rates of patients with sepsis or aspiration pneumonia is similar to those with fewer such patients, suggesting that the finalized risk adjustment methodology adequately accounts for the differences in risk among the subgroups of patients. For details on the finalized risk adjustment model, we refer readers to the measure methodology report for the finalized measure in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on the CMS Web site at:


Comment: Several commenters objected to the addition of aspiration pneumonia to the revised cohort. A number of commenters suggested that adding aspiration pneumonia to the current measure denominator would result in a 26.4 percent increase in the patient cohort for major teaching hospitals, compared to a 20.6 percent increase for
nonteaching hospitals, raising concerns that the modification would adversely affect teaching hospital measure performance.

Response: We appreciate the commenters’ concerns regarding the inclusion of aspiration pneumonia in the finalized cohort. We believe that inclusion of aspiration pneumonia patients in the expanded cohort we are adopting in this final rule is appropriate to broaden the portion of patients otherwise excluded from the measure. While the pathological causes of aspiration pneumonia are slightly different from the causes of community acquired pneumonia, in routine clinical practice it can be very challenging for physicians to differentiate aspiration syndromes, including pneumonitis and pneumonia, from other types of pneumonia included in the measure. This is reflected in tremendous variation across hospitals in the use of aspiration pneumonia diagnosis codes. This variation suggests that hospitals are not consistently distinguishing between these conditions as distinct subtypes. Moreover, the treatment of patients hospitalized for pneumonia or aspiration pneumonia or sepsis due to pneumonia is very similar and involves antibiotics, IV fluids, and symptom management. In addition, although some patients with aspiration pneumonia have a higher predicted mortality or readmission risk, many of the associated comorbidities are captured in the finalized measure’s risk adjustment methodology, including clinical history of stroke, neuromuscular disease, and dementia.

We find that hospital performance among hospitals with higher rates of patients with aspiration pneumonia is similar to those with fewer such patients, suggesting that the finalized risk adjustment methodology adequately accounts for the differences in risk
among the subgroups of patients. Although major teaching hospitals may have larger increases in the size of their cohorts due to this modification, that should not impose additional burden on these hospitals (as this is a claims-based measure and does not require data collection), nor should it lead to worse performance on the measure by major teaching hospitals due to adequate risk-adjustment for the aspiration pneumonia patients.

The analyses of this measure indicated that an approximately equal numbers of hospitals, and, specifically, equal numbers of teaching hospitals, improved or worsened their categorical performance under the modified version of the measure we are adopting in this final rule. We did not see evidence that teaching hospitals will be differentially burdened or adversely affected on the basis of this modification to the measure. We believe that while some variation in case-mix is to be expected, the risk adjustment methodology we have adopted takes into account many of the risk factors for aspiration pneumonia (including age, neurologic disease, and dementia), and adequately controls for these differences. We found minimal association between aspiration coding patterns and risk-standardized readmission rates. For details on the measure as finalized, we refer readers to the measure methodology report for the finalized measure in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on the CMS Web site at:


Comment: A number of commenters expressed concern that the revised measure only received conditional support from the MAP for use in the Hospital Readmissions Reduction Program pending NQF review of the measure update and appropriate
consideration under the NQF sociodemographic status pilot. The commenters noted that NQF review and consideration of the measure under the sociodemographic status pilot have not yet occurred, and recommended postponing implementation of the measure refinement until these conditions have been met. Several commenters also suggested that the revisions to the measure cohort were significant enough that the revised measure was in many respects a new, rather than a revised, measure. Some commenters expressed concern that consumers may be confused or unaware of the differences between the revised measure we are adopting in this final rule and the previously adopted version of the measure.

Response: We thank the commenters for their thoughts regarding the MAP review and NQF endorsement. We note that NQF endorsement is not a formal requirement for the refinement of Hospital Readmissions Reduction Program measures. We plan to submit the modified version of the measure that we are adopting in this final rule to the NQF for endorsement maintenance as part of the Pulmonary Project when the project has its call for measures later this year. In addition, the modified version of this measure will be included in the NQF SDS pilot as part of the endorsement maintenance process. While we believe both of these processes will provide valuable input on this measure, one of the most important goals of the Hospital Readmissions Reduction Program is to more completely cover the inpatient hospital patient population, and we have performed extensive additional analyses to evaluate the impact of the revised measure. We did not want to delay the implementation of this important revision until after the completion of the NQF endorsement process, as we believe that improving the
measure in the form we are finalizing will greatly improve the measure’s assessment of quality and outcome for pneumonia patients, and further the goals of the Hospital Readmissions Reduction Program. Therefore, we believe that it is appropriate to implement the measure in the finalized timeframe.

Although the modified version of the cohort expansion for this measure that we are finalizing will increase the number of patients included in the measure and change the national readmission rate, we do not believe this constitutes a new measure. The intent of the measure has not changed since initial development and NQF endorsement. The finalized readmission measure cohort will be approximately 15 percent smaller than originally proposed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24491). In addition, section 1886(q)(5)(B) of the Act allows the use of a feasible and practical measure that has not been NQF-endorsed as long as due consideration has been given to the measure. After extensive consideration, we believe adoption of the modified version of this measure beginning with the FY 2017 payment determination is feasible, practical, and important for improving the assessment of quality and outcome for pneumonia patients such that implementation should not be unnecessarily delayed. For details of the finalized measure that we are adopting in this final rule, we refer readers to the measure methodology report and measure risk adjustment statistical model in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on the CMS Web site at:

http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. We will note which
version of the measure is displayed on *Hospital Compare* to minimize any potential confusion for consumers.

**Comment:** Several commenters objected to studies CMS cited in the proposed rule regarding the impact of coding differences across hospitals on the 30-Day Pneumonia Readmission Measure (NQF#0506), arguing that these studies examine in-hospital mortality rates, but not 30-day readmission rates. The commenters further argued that these studies do not examine the cause of the coding differences, and that additional study on the effect of the revised measure is needed prior to implementation in the Hospital Readmissions Reduction Program.

**Response:** We thank the commenters for their responses. We note that, although the original medical research prompting the expansion of the measure cohort used only inpatient mortality as the outcome, we evaluated the concerns about potential bias due to differences in coding practice among hospitals using the 30-day readmission and mortality measures and found patterns as described in the literature. This subsequent evaluation lead us to undergo the measure reevaluation work that resulted in the proposed change to the cohort as described in the FY 2016 IPPS/LTCH PPS proposed rule and the modified version that we are adopting in this final rule. Furthermore, a more recent publication has confirmed similar risks using 30-day readmission and mortality rates in Medicare beneficiaries. For details of this publication and the modified version of the expanded measure cohort that we are adopting in this final rule, we refer readers to the measure methodology report and measure risk adjustment statistical model in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on CMS Web site at:
Comment: A number of commenters requested that CMS postpone implementation of the revised measure in order to allow hospitals more time to prepare for the impact of any changes to their rates and to develop or evaluate interventions for the expanded cohort. Many commenters also asked CMS to provide dry run data on Hospital Compare for hospitals to review prior to implementation, with some requesting a year of public reporting prior to implementation. Other commenters noted that the performance period for the FY 2017 payment year will have ended by the time this final rule is published, which will limit the ability of hospitals to improve performance prior to payment impact.

Several commenters also requested delayed implementation of the revised measure in order to provide time to assess the impact of the upcoming transition to ICD-10 on the revised pneumonia readmission measure, and suggested that CMS not make any changes to the current pneumonia measure until any impact can be evaluated. The commenters asked that CMS provide data on the revised measure, including ICD-9 and ICD-10 detailed codes, to allow hospitals to assess impact prior to implementation.

Response: We thank the commenters for their comments and acknowledge their concerns urging delayed implementation of the measure. However, we believe that it is important to expand the portion of the hospital inpatient population covered by the Hospital Readmissions Reduction Program at this time. Most hospitals have been working on addressing the key topics associated with readmissions, including
coordination of care and care transitions, for some time, and we do not believe delayed implementation will be of benefit to patients.

With respect to the upcoming ICD-10 transition, we are aware of stakeholder concerns about the potential impacts to hospital performance on quality measures when ICD-10 is implemented on October 1, 2015, as well as their calls for more extensive testing to understand the impacts before any payments or penalties are implicated. As part of ICD-10 transition planning that has taken place over the past several years, we have performed testing and analyses across the agency with respect to system readiness and claims reimbursement, and we have provided extensive education and outreach to providers, vendors, and other payers. Our systems for quality programs have been tested and will continue to be tested as ICD-10 data are submitted in order to ensure the accuracy of measure calculations and to monitor and assess the translation of measure specifications to ICD-10, potential coding variation, and impacts on measure performance and payment incentive programs. We will continue to work with stakeholders during the ICD-10 transition to monitor and assess impacts and to address any potential issues that may occur.

With respect to the modified version of the expanded measure cohort that we are adopting in this final rule, we refer commenters to the measure methodology report for the details of the measure in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on CMS Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.
Based on further analyses and testing of this measure and after consideration of the public comments we received, we are finalizing a modified version of the expanded pneumonia cohort from the version we specified in the FY 2016 IPPS/LTCH PPS proposed rule. The modified version of the expanded pneumonia cohort includes patients with a principal discharge diagnosis of pneumonia or aspiration pneumonia, and patients with a principal discharge diagnosis of sepsis with a secondary diagnosis of pneumonia coded as POA, but does not include patients with a principal discharge diagnosis of respiratory failure or patients with a principal discharge diagnosis of sepsis if they are coded as having severe sepsis.

5. Maintenance of Technical Specifications for Quality Measures

We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50039) for a discussion of the maintenance of technical specifications for quality measures for the Hospital Readmissions Reduction Program. Technical specifications of the readmission measures are provided on our Web site in the Measure Methodology Reports at:

http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. Additional resources about the Hospital Readmissions Reduction Program and measure technical specifications are on the QualityNet Web site on the Resources page at:

6. Floor Adjustment Factor for FY 2016 (§ 412.154(c)(2))

Section 1886(q)(3)(A) of the Act defines the “adjustment factor” for an applicable hospital for a fiscal year as equal to the greater of (i) the ratio described in subparagraph (B) for the hospital for the applicable period (as defined in paragraph (5)(D)) for such fiscal year; or (ii) the floor adjustment factor specified in subparagraph (C). Section 1886(q)(3)(B) of the Act, in turn, describes the ratio used to calculate the adjustment factor. Specifically, it states that the ratio is equal to 1 minus the ratio of – (i) the aggregate payments for excess readmissions and (ii) the aggregate payments for all discharges. The calculation of this ratio is codified at § 412.154(c)(1) of the regulations. Section 1886(q)(3)(C) of the Act specifies the floor adjustment factor, which is set at 0.97 for FY 2015 and subsequent fiscal years. We codified the floor adjustment factor at § 412.154(c)(2) of the regulations (77 FR 53386).

Consistent with section 1886(q)(3) of the Act, codified at § 412.154(c)(2), the adjustment factor is either the greater of the ratio or, for FY 2015 and subsequent fiscal years, a floor adjustment factor of 0.97. Under our established policy, the ratio is rounded to the fourth decimal place. In other words, for FY 2015 and subsequent fiscal years, a hospital subject to the Hospital Readmissions Reduction Program will have an adjustment factor that is between 1.0 (no reduction) and 0.9700 (greatest possible reduction).

7. Applicable Period for FY 2016

Under section 1886(q)(5)(D) of the Act, the Secretary has the authority to specify the applicable period with respect to a fiscal year under the Hospital Readmissions
Reduction Program. In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51671), we finalized our policy to use 3 years of claims data to calculate the readmission measures.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53675), we codified the definition of “applicable period” in the regulations at 42 CFR 412.152 as the 3-year period from which data are collected in order to calculate excess readmissions ratios and adjustments for the fiscal year, which includes aggregate payments for excess readmissions and aggregate payments for all discharges used in the calculation of the payment adjustment.

Consistent with the definition specified at § 412.152, we established that the applicable period for FY 2014 under the Hospital Readmissions Reduction Program is the 3-year period from July 1, 2009, to June 30, 2012. That is, we determined the excess readmissions ratios and calculate the payment adjustment (including aggregate payments for excess readmissions and aggregate payments for all discharges) for FY 2014 using data from the 3-year time period of July 1, 2009 through June 30, 2012, as this was the most recent available 3-year period of data upon which to base these calculations (78 FR 50669).

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 40 through 50041), for FY 2015, consistent with the definition specified at § 412.152, we finalized an “applicable period” for the Hospital Readmissions Reduction Program to be the 3-year period from July 1, 2010 through June 30, 2013. That is, we determined the excess readmissions ratios and the payment adjustment (including aggregate payments for excess readmissions and aggregate payments for all discharges) for FY 2015 using data from the 3-year time period of July 1, 2010 through June 30, 2013.
In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24492), for FY 2016, consistent with the definition specified at § 412.152, we proposed an “applicable period” for the Hospital Readmissions Reduction Program to be the 3-year period from July 1, 2011 through June 30, 2014. In other words, we proposed that the excess readmissions ratios and the payment adjustment (including aggregate payments for excess readmissions and aggregate payments for all discharges) for FY 2016 using data from the 3-year time period of July 1, 2011 through June 30, 2014.

Comment: Some commenters requested that CMS revise the applicable time period to only include a shorter time period such as the most recent year.

Response: We note that we addressed this concern in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53380), and that we use a 3-year period of index admissions to increase the number of cases per hospital used for measure calculation, which improves the precision of each hospital’s readmission estimate. Although this approach utilizes older data, it also identifies more variation in hospital performance and still allows for improvement from one year of reporting to the next.

After consideration of the public comments we received, we are finalizing as proposed the applicable period of the 3-year time period of July 1, 2011 to June 30, 2014 to calculate the excess readmission ratios and the readmission payment adjustment factors for FY 2016.

a. Background

Section 1886(q)(3)(B) of the Act specifies the ratio used to calculate the adjustment factor under the Hospital Readmissions Reduction Program. It states that the ratio is equal to 1 minus the ratio of – (i) the aggregate payments for excess readmissions and (ii) the aggregate payments for all discharges. The definition of “aggregate payments for excess readmissions” and “aggregate payments for all discharges,” as well as a methodology for calculating the numerator of the ratio (aggregate payments for excess readmissions) and the denominator of the ratio (aggregate payments for all discharges) are codified at § 412.154(c)(2) of the regulations (77 FR 53387).

Section 1886(q)(4) of the Act sets forth the definitions of “aggregate payments for excess readmissions” and “aggregate payments for all discharges” for an applicable hospital for the applicable period. The term “aggregate payments for excess readmissions” is defined in section 1886(q)(4)(A) of the Act as for a hospital for an applicable period, the sum, for applicable conditions of the product, for each applicable condition, of (i) the base operating DRG payment amount for such hospital for such applicable period for such condition; (ii) the number of admissions for such condition for such hospital for such applicable period; and (iii) the excess readmissions ratio for such hospital for such applicable period minus 1. We codified this definition of “aggregate payments for excess readmissions” under the regulations at § 412.152 as the product, for each applicable condition, of: (1) the base operating DRG payment amount for the hospital for the applicable period for such condition; (2) the number of admissions for
such condition for the hospital for the applicable period; and (3) the excess readmissions ratio for the hospital for the applicable period minus 1 (77 FR 53675).

The excess readmissions ratio is a hospital-specific ratio calculated for each applicable condition. Specifically, section 1886(q)(4)(C) of the Act defines the excess readmissions ratio as the ratio of “risk-adjusted readmissions based on actual readmissions” for an applicable hospital for each applicable condition, to the “risk-adjusted expected readmissions” for the applicable hospital for the applicable condition. The methodology for the calculation of the excess readmissions ratio was finalized in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51673). “Aggregate payments for excess readmissions” is the numerator of the ratio used to calculate the adjustment factor under the Hospital Readmissions Reduction Program (as described in further detail later in this section).

The term “aggregate payments for all discharges” is defined at section 1886(q)(4)(B) of the Act as for a hospital for an applicable period, the sum of the base operating DRG payment amounts for all discharges for all conditions from such hospital for such applicable period. “Aggregate payments for all discharges” is the denominator of the ratio used to calculate the adjustment factor under the Hospital Readmissions Reduction Program. We codified this definition of “aggregate payments for all discharges” under the regulations at § 412.152 (77 FR 53387).

We finalized the inclusion of one additional applicable condition, Patients Readmitted Following Coronary Artery Bypass Graft (CABG) Surgery, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50033 through 50039) effective for FY 2017. We will
address the inclusion of this additional measure in the calculation of the readmissions payment adjustment for FY 2017 in the FY 2017 rulemaking.

b. Calculation of Aggregate Payments

As discussed above, when calculating the numerator (aggregate payments for excess readmissions), we determine the base operating DRG payments for the applicable period. “Aggregate payments for excess readmissions” (the numerator) is defined as the sum, for applicable conditions of the product, for each applicable condition, of (i) the base operating DRG payment amount for such hospital for such applicable period for such condition; (ii) the number of admissions for such condition for such hospital for such applicable period; and (iii) the excess readmissions ratio for such hospital for such applicable period minus 1.

When determining the base operating DRG payment amount for an individual hospital for such applicable period for such condition, we use Medicare inpatient claims from the MedPAR file with discharge dates that are within the same applicable period to calculate the excess readmissions ratio. We use MedPAR claims data as our data source for determining aggregate payments for excess readmissions and aggregate payments for all discharges, as this data source is consistent with the claims data source used in IPPS rulemaking to determine IPPS rates.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24493 through 24496), for FY 2016, we proposed to use MedPAR claims with discharge dates that are on or after July 1, 2011, and no later than June 30, 2014. Under our established methodology, we use the update of the MedPAR file for each Federal fiscal year, which is updated
6 months after the end of each Federal fiscal year within the applicable period, as our data source (that is, the March updates of the respective Federal fiscal year MedPAR files) for the final rules.

The FY 2011 through FY 2014 MedPAR data files can be purchased from CMS. Use of these files allows the public to verify the readmissions adjustment factors. Interested individuals may order these files through the CMS Web site at: http://www.cms.hhs.gov/LimitedDataSets/ by clicking on MedPAR Limited Data Set (LDS)-Hospital (National). This Web page describes the files and provides directions and detailed instructions for how to order the data sets. Persons placing an order must send the following: a Letter of Request, the LDS Data Use Agreement and Research Protocol (refer to the Web site for further instructions), the LDS Form, and a check for $3,655 to:

- If using the U.S. Postal Service: Centers for Medicare and Medicaid Services, RDDC Account, Accounting Division, P.O. Box 7520, Baltimore, MD 21207-0520.
- If using express mail: Centers for Medicare and Medicaid Services, OFM/Division of Accounting- RDDC, Mailstop C#-07-11, 7500 Security Boulevard, Baltimore, MD 21244-1850.

In the FY 2016 IPPS/LTCH PPS proposed rule, we proposed to determine aggregate payments for excess readmissions and aggregate payments for all discharges using data from MedPAR claims with discharge dates that are on or after July 1, 2011, and no later than June 30, 2014. However, we noted that, for the purpose of modeling the proposed FY 2016 readmissions payment adjustment factors for the FY 2016
IPPS/LTCH PPS proposed rule, we used excess readmissions ratios for applicable hospitals from the FY 2015 Hospital Readmissions Reduction Program applicable period. For this FY 2016 IPPS/LTCH PPS final rule, applicable hospitals will have had the opportunity to review and correct data from the proposed FY 2016 applicable period of July 1, 2011 to June 30, 2014, before they are made public under our policy regarding the reporting of hospital-specific information, which we discussed in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53374 through 53401).

In the FY 2016 IPPS/LTCH PPS proposed rule, for FY 2016, we proposed to use MedPAR data from July 1, 2011 through June 30, 2014. Specifically, in the FY 2016 IPPS/LTCH PPS proposed rule, we used the March 2012 update of the FY 2011 MedPAR file to identify claims within FY 2011 with discharge dates that are on or after July 1, 2011, the March 2013 update of the FY 2012 MedPAR file to identify claims within FY 2012, the March 2014 update of the FY 2013 MedPAR file to identify claims within FY 2013, and the December 2014 update of the FY 2014 MedPAR file to identify claims within FY 2014 with discharge dates no later than June 30, 2014. For this final rule, we proposed to use the same MedPAR files as listed above for claims within FY 2011, FY 2012 and FY 2013. For claims within FY 2014, we proposed to use in the final rule the March 2015 update of the FY 2014 MedPAR file.

In order to identify the admissions for each condition, to calculate the aggregate payments for excess readmissions for an individual hospital, for FY 2016, we proposed to identify each applicable condition using the ICD-9-CM codes used to identify applicable conditions to calculate the excess readmissions ratios. (Although the compliance date for
the ICD-10-CM and ICD10-PCS code sets is October 1, 2015 (79 FR 45128 through 45134), these proposed policies apply to data periods prior to this compliance date.)

Under our existing policy, we identify eligible hospitalizations and readmissions of Medicare patients discharged from an applicable hospital having a principal diagnosis for the measured condition in an applicable period (76 FR 51669). The discharge diagnoses for each applicable condition are based on a list of specific ICD-9-CM codes for that condition. These codes are posted on the QualityNet Web site at:


We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50041 through 50048) for a discussion of how we identify the applicable conditions to calculate the aggregate payments for excess readmissions for FY 2015. For FY 2016, we proposed to follow this same approach.

In the FY 2016 IPPS/LTCH PPS proposed rule, for FY 2016, we proposed to continue to apply the same exclusions to the claims in the MedPAR file as we applied for FY 2015 for the current applicable conditions. For FY 2016, in order to have the same types of admissions to calculate aggregate payments for excess readmissions as is used to calculate the excess readmissions ratio, we proposed to identify admissions for the AMI, HF, PN, THA/TKA, COPD applicable conditions, for the purposes of calculating aggregate payments for excess readmissions as follows:
● We would exclude admissions that are identified as an applicable condition if the patient died in the hospital, as identified by the discharge status code on the MedPAR claim.

● We would exclude admissions identified as an applicable condition for which the patient was transferred to another provider that provides acute care hospital services (that is, a CAH or an IPPS hospital), as identified through examination of contiguous stays in MedPAR at other hospitals.

● We would exclude admissions identified as an applicable condition for patients who are under the age of 65, as identified by linking the claim information to the information provided in the Medicare Enrollment Database.

● For conditions identified as AMI, we would exclude claims that are same day discharges, as identified by the admission date and discharge date on the MedPAR claim.

● We would exclude admissions for patients who did not have Medicare Parts A and B FFS enrollment in the 12 months prior to the index admission, based on the information provided in the Medicare Enrollment Database.

● We would exclude admissions for patients without at least 30 days post-discharge enrollment in Medicare Parts A and B FFS, based on the information provided in the Medicare Enrollment Database.

● We would exclude all multiple admissions within 30 days of a prior index admission’s discharge date, as identified in the MedPAR file, consistent with how multiple admissions within 30 days of an index admission are excluded from the calculation of the excess readmissions ratio.
These exclusions are consistent with our current methodology, which was established in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50048).

Furthermore, we would only identify Medicare FFS claims that meet the criteria (that is, claims paid for under Medicare Part C (Medicare Advantage) would not be included in this calculation), consistent with the methodology to calculate excess readmissions ratios based solely on admissions and readmissions for Medicare FFS patients. Therefore, consistent with our established methodology, for FY 2016, we would exclude admissions for patients enrolled in Medicare Advantage as identified in the Medicare Enrollment Database. This policy is consistent with how admissions for Medicare Advantage patients are identified in the calculation of the excess readmissions ratios under our established methodology. The tables below list the ICD-9-CM codes we proposed to use to identify each applicable condition to calculate the aggregate payments for the excess readmissions proposal for FY 2016. These ICD-9-CM codes also would be used to identify the applicable conditions to calculate the excess readmissions ratios, consistent with our established policy (76 FR 51673 through 51676).
ICD-9-CM CODES TO IDENTIFY PNEUMONIA (PN) CASES

<table>
<thead>
<tr>
<th>ICD-9-CM Code</th>
<th>Description of Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>480.0</td>
<td>Pneumonia due to adenovirus</td>
</tr>
<tr>
<td>480.1</td>
<td>Pneumonia due to respiratory syncytial virus</td>
</tr>
<tr>
<td>480.2</td>
<td>Pneumonia due to parainfluenza virus</td>
</tr>
<tr>
<td>480.3</td>
<td>Pneumonia due to SARS-associated coronavirus</td>
</tr>
<tr>
<td>480.8</td>
<td>Viral pneumonia: pneumonia due to other virus not elsewhere classified</td>
</tr>
<tr>
<td>480.9</td>
<td>Viral pneumonia unspecified</td>
</tr>
<tr>
<td>481</td>
<td>Pneumococcal pneumonia [streptococcus pneumoniae pneumonia]</td>
</tr>
<tr>
<td>482.0</td>
<td>Pneumonia due to klebsiella pneumoniae</td>
</tr>
<tr>
<td>482.1</td>
<td>Pneumonia due to pseudomonas</td>
</tr>
<tr>
<td>482.2</td>
<td>Pneumonia due to hemophilus influenzae [h. influenzae]</td>
</tr>
<tr>
<td>482.30</td>
<td>Pneumonia due to streptococcus unspecified</td>
</tr>
<tr>
<td>482.31</td>
<td>Pneumonia due to streptococcus group a</td>
</tr>
<tr>
<td>482.32</td>
<td>Pneumonia due to streptococcus group b</td>
</tr>
<tr>
<td>482.39</td>
<td>Pneumonia due to other streptococcus</td>
</tr>
<tr>
<td>482.40</td>
<td>Pneumonia due to staphylococcus unspecified</td>
</tr>
<tr>
<td>482.41</td>
<td>Pneumonia due to staphylococcus aureus</td>
</tr>
<tr>
<td>482.42</td>
<td>Methicillin Resistant Pneumonia due to Staphylococcus Aureus</td>
</tr>
<tr>
<td>482.49</td>
<td>Other staphylococcus pneumonia</td>
</tr>
<tr>
<td>482.81</td>
<td>Pneumonia due to anaerobes</td>
</tr>
<tr>
<td>482.82</td>
<td>Pneumonia due to escherichia coli [e.coli]</td>
</tr>
<tr>
<td>482.83</td>
<td>Pneumonia due to other gram-negative bacteria</td>
</tr>
<tr>
<td>482.84</td>
<td>Pneumonia due to legionnaires' disease</td>
</tr>
<tr>
<td>482.89</td>
<td>Pneumonia due to other specified bacteria</td>
</tr>
<tr>
<td>482.9</td>
<td>Bacterial pneumonia unspecified</td>
</tr>
<tr>
<td>483.0</td>
<td>Pneumonia due to mycoplasma pneumoniae</td>
</tr>
<tr>
<td>483.1</td>
<td>Pneumonia due to chlamydia</td>
</tr>
<tr>
<td>483.8</td>
<td>Pneumonia due to other specified organism</td>
</tr>
<tr>
<td>485</td>
<td>Bronchopneumonia organism unspecified</td>
</tr>
<tr>
<td>486</td>
<td>Pneumonia organism unspecified</td>
</tr>
<tr>
<td>487.0</td>
<td>Influenza with pneumonia</td>
</tr>
<tr>
<td>488.11</td>
<td>Influenza due to identified novel H1N1 influenza virus with pneumonia</td>
</tr>
</tbody>
</table>
ICD-9-CM CODES TO IDENTIFY HEART FAILURE (HF) CASES

<table>
<thead>
<tr>
<th>ICD-9-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>402.01</td>
<td>Hypertensive heart disease, malignant, with heart failure</td>
</tr>
<tr>
<td>402.11</td>
<td>Hypertensive heart disease, benign, with heart failure</td>
</tr>
<tr>
<td>402.91</td>
<td>Hypertensive heart disease, unspecified, with heart failure</td>
</tr>
<tr>
<td>404.01</td>
<td>Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified</td>
</tr>
<tr>
<td>404.03</td>
<td>Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease</td>
</tr>
<tr>
<td>404.11</td>
<td>Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified</td>
</tr>
<tr>
<td>404.13</td>
<td>Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified and chronic kidney disease stage V or end stage renal disease</td>
</tr>
<tr>
<td>404.91</td>
<td>Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease heart failure and with chronic kidney disease stage I through stage IV, or unspecified</td>
</tr>
<tr>
<td>404.93</td>
<td>Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease</td>
</tr>
<tr>
<td>428.xx</td>
<td>Heart Failure</td>
</tr>
</tbody>
</table>
ICD-9-CM CODES TO IDENTIFY ACUTE MYOCARDIAL INFARCTION (AMI) CASES

<table>
<thead>
<tr>
<th>ICD-9-CM Code</th>
<th>Description of Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>410.00</td>
<td>AMI (anterolateral wall) – episode of care unspecified</td>
</tr>
<tr>
<td>410.01</td>
<td>AMI (anterolateral wall) – initial episode of care</td>
</tr>
<tr>
<td>410.10</td>
<td>AMI (other anterior wall) – episode of care unspecified</td>
</tr>
<tr>
<td>410.11</td>
<td>AMI (other anterior wall) – initial episode of care</td>
</tr>
<tr>
<td>410.20</td>
<td>AMI (inferolateral wall) – episode of care unspecified</td>
</tr>
<tr>
<td>410.21</td>
<td>AMI (inferolateral wall) – initial episode of care</td>
</tr>
<tr>
<td>410.30</td>
<td>AMI (inferoposterior wall) – episode of care unspecified</td>
</tr>
<tr>
<td>410.31</td>
<td>AMI (inferoposterior wall) – initial episode of care</td>
</tr>
<tr>
<td>410.40</td>
<td>AMI (other inferior wall) – episode of care unspecified</td>
</tr>
<tr>
<td>410.41</td>
<td>AMI (other inferior wall) – initial episode of care</td>
</tr>
<tr>
<td>410.50</td>
<td>AMI (other lateral wall) – episode of care unspecified</td>
</tr>
<tr>
<td>410.51</td>
<td>AMI (other lateral wall) – initial episode of care</td>
</tr>
<tr>
<td>410.60</td>
<td>AMI (true posterior wall) – episode of care unspecified</td>
</tr>
<tr>
<td>410.61</td>
<td>AMI (true posterior wall) – initial episode of care</td>
</tr>
<tr>
<td>410.70</td>
<td>AMI (subendocardial) – episode of care unspecified</td>
</tr>
<tr>
<td>410.71</td>
<td>AMI (subendocardial) – initial episode of care</td>
</tr>
<tr>
<td>410.80</td>
<td>AMI (other specified site) – episode of care unspecified</td>
</tr>
<tr>
<td>410.81</td>
<td>AMI (other specified site) – initial episode of care</td>
</tr>
<tr>
<td>410.90</td>
<td>AMI (unspecified site) – episode of care unspecified</td>
</tr>
<tr>
<td>410.91</td>
<td>AMI (unspecified site) – initial episode of care</td>
</tr>
</tbody>
</table>
**ICD-9-CM Codes to Identify Chronic Obstructive Pulmonary Disease (COPD) Cases**

<table>
<thead>
<tr>
<th>ICD-9-CM Code</th>
<th>Description of Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>491.21</td>
<td>Obstructive chronic bronchitis; With (acute) exacerbation; acute exacerbation of COPD, decompensated COPD, decompensated COPD with exacerbation</td>
</tr>
<tr>
<td>491.22</td>
<td>Obstructive chronic bronchitis; with acute bronchitis</td>
</tr>
<tr>
<td>491.8</td>
<td>Other chronic bronchitis. Chronic: tracheitis, tracheobronchitis.</td>
</tr>
<tr>
<td>491.9</td>
<td>Unspecified chronic bronchitis</td>
</tr>
<tr>
<td>492.8</td>
<td>Other emphysema; emphysema (lung or pulmonary): NOS, centriacinar, centrilobular, obstructive, panacinar, panlobular, unilateral, vesicular. MacLeod's syndrome; Swyer-James syndrome; unilateral hyperlucent lung</td>
</tr>
<tr>
<td>493.20</td>
<td>Chronic obstructive asthma; asthma with COPD, chronic asthmatic bronchitis, unspecified</td>
</tr>
<tr>
<td>493.21</td>
<td>Chronic obstructive asthma; asthma with COPD, chronic asthmatic bronchitis, with status asthmaticus</td>
</tr>
<tr>
<td>493.22</td>
<td>Chronic obstructive asthma; asthma with COPD, chronic asthmatic bronchitis, with (acute) exacerbation</td>
</tr>
<tr>
<td>496</td>
<td>Chronic: nonspecific lung disease, obstructive lung disease, obstructive pulmonary disease (COPD) NOS. NOTE: This code is not to be used with any code from categories 491-493.</td>
</tr>
<tr>
<td>518.81*</td>
<td>Other diseases of lung; acute respiratory failure; respiratory failure NOS</td>
</tr>
<tr>
<td>518.82*</td>
<td>Other diseases of lung; acute respiratory failure; other pulmonary insufficiency, acute respiratory distress</td>
</tr>
<tr>
<td>518.84*</td>
<td>Other diseases of lung; acute respiratory failure; acute and chronic respiratory failure</td>
</tr>
<tr>
<td>799.1*</td>
<td>Other ill-defined and unknown causes of morbidity and mortality; respiratory arrest, cardiorespiratory failure</td>
</tr>
</tbody>
</table>

*Principal diagnosis when combined with a secondary diagnosis of AECOPD (491.21, 491.22, 493.21, or 493.22).
ICD-9-CM CODES TO IDENTIFY TOTAL HIP ARTHROPLASTY/TOTAL KNEE ARTHROPLASTY (THA/TKA) CASES

<table>
<thead>
<tr>
<th>ICD-9-CM Code</th>
<th>Description of Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>81.51</td>
<td>Total hip arthroplasty</td>
</tr>
<tr>
<td>81.54</td>
<td>Total knee arthroplasty</td>
</tr>
</tbody>
</table>

For FY 2016, we proposed to calculate aggregate payments for excess readmissions, using MedPAR claims from July 1, 2011 to June 30, 2014, to identify applicable conditions based on the same ICD-9-CM codes used to identify the conditions for the readmissions measures, and to apply the proposed exclusions for the types of admissions discussed above. To calculate aggregate payments for excess readmissions, we proposed to calculate the base operating DRG payment amounts for all claims in the 3-year applicable period for each applicable condition (AMI, HF, PN, COPD and THA/TKA) based on the claims we have identified as described above. Once we have calculated the base operating DRG amounts for all the claims for the five applicable conditions, we proposed to sum the base operating DRG payments amounts by each condition, resulting in five summed amounts, one amount for each of the five applicable conditions. We proposed to then multiply the amount for each condition by the respective excess readmissions ratio minus 1 when that excess readmissions ratio is greater than 1, which indicates that a hospital has performed, with respect to readmissions for that applicable condition, worse than the average hospital with similar patients. Each product in this computation represents the payments for excess readmissions for that condition. We proposed to then sum the resulting products which represent a hospital’s proposed “aggregate payments for excess readmissions” (the numerator of the ratio).
Because this calculation is performed separately for each of the five conditions, a hospital’s excess readmissions ratio must be less than or equal to 1 on each measure to avoid CMS’ determination that there were payments made by CMS for excess readmissions (resulting in a payment reduction under the Hospital Readmissions Reduction Program). In other words, in order to avoid a payment reduction a hospital’s excess readmissions ratio must be less than or equal to 1 on each measure. We note that we did not propose any changes to our existing methodology to calculate “aggregate payments for all discharges” (the denominator of the ratio).

We proposed the following methodology for FY 2016 as displayed in the chart below.
FORMULAS TO CALCULATE THE READMISSIONS ADJUSTMENT FACTOR FOR FY 2016

Aggregate payments for excess readmissions $= \left[ \text{sum of base operating DRG payments for AMI} \times (\text{Excess Readmissions Ratio for AMI} - 1) \right] + \left[ \text{sum of base operating DRG payments for HF} \times (\text{Excess Readmissions Ratio for HF} - 1) \right] + \left[ \text{sum of base operating DRG payments for PN} \times (\text{Excess Readmissions Ratio for PN} - 1) \right] + \left[ \text{sum of base operating DRG payments for COPD} \times (\text{Excess Readmissions Ratio for COPD} - 1) \right] + \left[ \text{sum of base operating DRG payments for THA/TKA} \times (\text{Excess Readmissions Ratio for THA/TKA} - 1) \right]$.  

*We note that if a hospital’s excess readmissions ratio for a condition is less than/equal to 1, there are no aggregate payments for excess readmissions for that condition included in this calculation.

Aggregate payments for all discharges $= \text{sum of base operating DRG payments for all discharges}$.  

$\text{Ratio} = 1 - \left( \frac{\text{Aggregate payments for excess readmissions}}{\text{Aggregate payments for all discharges}} \right)$.  

Proposed Readmissions Adjustment Factor for FY 2016 is the higher of the ratio or 0.9700.  

*Based on claims data from July 1, 2011 to June 30, 2014 for FY 2016.

We invited public comment on these proposals.

Comment: Several commenters recommended changes to the methodology to calculate the readmission payment adjustment factors, many of these similar to comments received in prior rulemaking. MedPAC reiterated several comments regarding the Hospital Readmissions Reduction Program related to the calculation of the readmissions payment adjustment factor, including that the readmission penalty formula is flawed because aggregate penalties remain constant even as national readmission rates decline; the condition-specific penalty per excess readmission is higher for conditions with low readmission rates; and the penalty should roughly equal the cost of excess readmissions.
over a fixed target level of readmissions. Other commenters also echoed MedPAC’s point that the calculation of the readmission payment adjustment factor creates excessive payment reductions that exceed the cost to the Medicare program of the readmission. Other perceived flaws noted by commenters included that the payment adjustment factor should be adjusted to account for socioeconomic factors and that the calculation does not recognize improvement by a hospital in reducing readmissions.

While some commenters asserted that CMS has the authority through rulemaking to modify the calculation of the payment adjustment factor to address these issues, other commenters indicated that these revisions would require a change in statute.

Response: We received similar types of comments in previous rulemaking and we continue to believe that the statute is prescriptive with respect to the calculation of aggregate payments for excess readmissions because it specifies that the "aggregate payments for excess readmissions" is the sum for each condition of the product of the operating DRG payment amount for such hospital for such applicable period for such condition and the number of admissions for such condition and the excess readmission ratio minus one. We believe that section 1886(q)(4)(A) of the Act requires us to include all admissions for a condition in the calculation of aggregate payments for excess readmissions. Therefore, we agree with the commenters who indicated that the statutory calculation of the penalty creates a result that the commenters believe to be prescriptive. The commenters who believe we have the discretionary authority to implement an alternative penalty calculation to address their issues did not suggest an adequate
statutory basis for such an approach. We continue to believe that we are implementing the provision as required by law.

As noted above, ASPE is conducting research on the issue of risk adjustment for sociodemographic status as directed by the IMPACT Act, and expects to issue a report to Congress, including recommendations for improvements to the Hospital Readmissions Reduction Program based on that research.

Comment: Some commenters continue to believe that, by including admissions denied by the CMS RACs, a hospital would be penalized twice for the same admission--once by the RAC denial and a second time by having the admission included in the readmission payment penalty.

Response: As we have explained in prior rulemaking, given the timing of the RAC audits and the updates of the SAF and MedPAR files used to calculate the readmissions measures and readmissions payment adjustment factors, we are not certain that all denied claims will be reflected in our claims files at the time of our calculations under the Hospital Readmissions Reduction Program. However, we continue to believe that using these updates of the MedPAR and SAF files is consistent with IPPS ratesetting and allows for transparency for the public to obtain this dataset for replication. Furthermore, inpatient stays that are denied payment under Medicare Part A typically remain classified as inpatient stays, and can be billed to Medicare Part B as an Medicare Part B inpatient stay. These inpatient stays that are denied payment under Medicare Part A will typically continue to count as a qualifying inpatient stay for other payment purposes such as qualifying for SNF benefits and Medicare DSH patient days. Therefore,
we continue to believe that it is appropriate to include these admissions in the Hospital Readmissions Reduction Program.

We did not receive any public comments generally objecting to the other proposed aspects of the calculation of aggregate payments for excess readmissions for FY 2016, such as the specific ICD-9 codes used in the calculation and the data sources for calculation.

After considering the public comments we received, we are finalizing our proposed calculation of aggregate payments for excess readmissions without modification.

9. Extraordinary Circumstance Exception Policy for the Hospital Readmissions Reduction Program Beginning in FY 2016 and for Subsequent Years

a. Background

In the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28117), we welcomed public comment on our proposal to adopt an extraordinary circumstance exception policy for the Hospital Readmissions Reduction Program. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50048), we indicated that we received many comments in support of CMS establishing a formal extraordinary circumstance exception policy for the Hospital Readmissions Reduction Program. We also previously indicated that any specific proposals related to the implementation of an extraordinary circumstance exception policy would be proposed through rulemaking with an opportunity for public comment.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24497), we agreed with commenters that there may be periods of time during which a hospital is not able to
submit all claims (from which readmission measures data are derived) in an accurate or timely fashion due to an extraordinary circumstance beyond its control. Section 1886(q)(5)(D) of the Act permits the Secretary to determine the “applicable period” for readmissions data collection, and we believe that the statute allows us to determine that the period not include times when hospitals may encounter extraordinary circumstances.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24497), we proposed adopting an extraordinary circumstance exception policy for the Hospital Readmissions Reduction Program beginning in FY 2016 and for subsequent years. This policy was similar to the extraordinary circumstance exception policy for the Hospital IQR Program, as finalized in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51651), modified in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50836) (designation of a non-CEO hospital contact), and further modified in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50277) (amended § 412.140(c)(2) to refer to “extension or exemption” instead of the former “extension or waiver”). We also considered how best to align an extraordinary circumstance exception policy for the Hospital Readmissions Reduction Program with existing extraordinary circumstance exception policies for other IPPS quality reporting and payment programs, such as the Hospital VBP Program, to the extent feasible.

In the proposed rule (80 FR 24497), we also considered the feasibility and implications of excluding data for certain readmission measures for a limited period of time from the calculations for a hospital’s excess readmissions ratios for the applicable performance period. By minimizing the data excluded from the program, this approach would enable affected hospitals to continue to participate in the Hospital Readmissions
Reduction Program for a given fiscal year if they otherwise continue to meet applicable measure minimum threshold requirements. We believe that this approach could help alleviate the reporting burden for a hospital that is adversely impacted by a natural disaster or other extraordinary circumstance beyond its control, while enabling the hospital to continue to participate in the Hospital Readmissions Reduction Program.

b. Requests for an Extraordinary Circumstance Exception

As we stated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24497), based upon our prior experience with the Hospital IQR Program and the Hospital VBP Program, we anticipate the need to provide exceptions to only a small number of hospitals affected by a natural disaster or other extraordinary circumstance. During the review of a hospital’s request for an extraordinary circumstance exception, we will maintain the general principle that providing high quality of care and ensuring patient safety is of paramount importance, especially in difficult circumstances. We do not intend to allow a hospital to use this proposed policy and the request process to seek exclusion from the Hospital Readmissions Reduction Program in its entirety for a given fiscal year(s) solely because of experiencing an extraordinary circumstance. Rather, we intend to provide relief for a hospital whose ability to accurately or timely submit all of its claims (from which readmission measures data are derived) has been negatively impacted as a direct result of experiencing a significant disaster or other extraordinary circumstance beyond the control of the hospital.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24497 through 24498) we proposed that the request process for an extraordinary circumstance exception begin with
the submission of an extraordinary circumstance exception request form by a hospital within 90 calendar days of the natural disaster or other extraordinary circumstance. We believe that the 90-calendar day timeframe is an appropriate period of time for a hospital to determine whether to submit an extraordinary circumstance exception request. It is also the same length of time as the current time period allowed under the Hospital VBP Program. Under this policy, a hospital will be able to request a Hospital Readmissions Reduction Program extraordinary circumstance exception at the same time it may request similar exceptions under the Hospital IQR Program (§ 412.140(c)(2)), the Hospital VBP Program (78 FR 50704 through 50706), and the HAC Reduction Program (which we are finalizing in section IV.G.8.b. of the preamble to this final rule). The extraordinary circumstance exception request form will be made available on the QualityNet Web site.

The following minimum set of information will be required to submit the request:

- Hospital CCN;
- Hospital name;
- Hospital Chief Executive Officer (CEO) and any other designated personnel contact information, including name, email address, telephone number, and mailing address (must include a physical address; a post office box address is not acceptable);
- Hospital's reason for requesting an exception, including:
  ++ CMS program name (the Hospital Readmissions Reduction Program);
  ++ The measure(s) and submission quarters affected by the extraordinary circumstance that the hospital is seeking an exception for should be accompanied with the specific reasons why the exception is being sought; and
++ How the extraordinary circumstance negatively impacted performance on the measure(s) for which an exception is being sought;

- Evidence of the impact of the extraordinary circumstances, including but not limited to, photographs, newspaper, and other media articles; and

- The request form must be signed by the hospital’s CEO or designated non-CEO contact and submitted to CMS.

The same set of information is currently required under the Hospital IQR Program and the Hospital VBP Program on the request form from a hospital seeking an extraordinary circumstance exception with respect to these programs. The specific list of required information is subject to change from time to time at the discretion of CMS.

Following receipt of the request form, CMS will: (1) provide a written acknowledgement of receipt of the request using the contact information provided in the request form to the CEO and any additional designated hospital personnel; and (2) provide a formal response to the CEO and any additional designated hospital personnel using the contact information provided in the request notifying them of our decision. Under this policy, we will review each request for an extraordinary circumstance exception on a case-by-case basis at our discretion. To the extent feasible, we also will review requests in conjunction with any similar requests made under other IPPS quality reporting and payment programs, such as the Hospital IQR Program and the Hospital VBP Program.

This policy would not preclude CMS from granting extraordinary circumstance exceptions to hospitals that do not request them if we determine at our discretion that a
disaster or other extraordinary circumstance has affected an entire region or locale. If CMS makes such a determination to grant an extraordinary circumstance exception to hospitals in an affected region or locale, we will convey this decision through routine communication channels to hospitals, vendors, and QIOs, including, but not limited to, issuing memos, emails, and notices on the QualityNet Web site. This provision also aligns with the Hospital IQR Program’s extraordinary circumstances extensions or exemptions policy.

We invited public comment on this proposal.

Comment: Many commenters supported the proposal to establish a request process for extraordinary circumstance exceptions for the Hospital Readmissions Reduction Program. The commenters noted that it was in alignment with other CMS hospital quality reporting programs and would provide relief to hospitals affected by a natural disaster or other extraordinary circumstances. Several commenters recommended that CMS develop a single extraordinary circumstance exception request form for all hospital quality reporting programs. Several commenters also supported the proposed hospital extraordinary circumstances waiver process, but requested additional information on the expected timeline for review of the submission and determination.

Response: We thank the commenters for their support, and note that we are expecting to update the extraordinary circumstances exception form currently in use by the other CMS quality reporting programs to include the Hospital Readmissions Reduction Program. The timeline for review and determination regarding requests for an extraordinary circumstance exception request can vary depending on a number of factors
including the nature of the event, the exception requested, and the number of programs affected. We will work closely with hospitals who submit an extraordinary circumstance exception request to ensure that they receive a timely response.

Comment: Several commenters expressed concern that, because of the overlap in performance years, multiple payment years could be affected by the same loss of measure data. The commenters requested additional guidance regarding how a hospital should apply for an exemption if the period of affected data is used in performance periods for multiple payment years.

Response: We note that the extraordinary circumstance exception request form allows hospitals to list the quarter(s) that were affected by the extraordinary circumstance, and we are aware that the overlapping measure performance periods mean that extraordinary circumstance exception requests may impact multiple program years. We will work closely with an affected hospital to address these concerns.

Comment: Several commenters suggested that there are situations that do not prevent a hospital from submitting claims or other measure data in a timely fashion, but do cause performance to drop significantly for reasons outside of a hospital's control. The commenters suggested that circumstances outside the hospital's control may disrupt community services and hospital programs needed to continue readmission prevention efforts during natural disasters, which may result in higher readmission rates, and requested that the exceptions process be modified to recognize these situations. The commenters requested that CMS consider extraordinary circumstances on a case-by-case
basis even when data submission is not inhibited, and that CMS allow for an appeals process governing extraordinary circumstance decisions.

Response: We thank the commenters for their recommendations. As we discussed in the proposed rule (80 FR 24497), based on our experience with the Hospital VBP Program and the Hospital IQR Program, we anticipate a need to provide exemptions only to a small number of hospitals where the ability to accurately or timely submits claims has been directly impacted. We will continue to monitor extraordinary circumstance exception requests to ensure that the process we are adopting in this final rule supports the goals of the Hospital Readmissions Reduction Program. However, we do not intend to modify the criteria for an extraordinary circumstance exception at this time. We do not anticipate a need to establish an appeals process for extraordinary circumstance exception determinations.

After consideration of the public comments we received, we are adopting the extraordinary circumstances exception policy as proposed.
F. Hospital Value-Based Purchasing (VBP) Program: Policy Changes for the FY 2018 Program Year and Subsequent Years

1. Background

a. Statutory Background and Overview of Past Program Years

Section 1886(o) of the Act, as added by section 3001(a)(1) of the Affordable Care Act, requires the Secretary to establish a hospital value-based purchasing program (the Hospital VBP Program) under which value-based incentive payments are made in a fiscal year to hospitals that meet performance standards established for a performance period for such fiscal year. Both the performance standards and the performance period for a fiscal year are to be established by the Secretary.

For more of the statutory background and descriptions of our current policies for the Hospital VBP Program, we refer readers to the Hospital Inpatient VBP Program final rule (76 FR 26490 through 26547); the FY 2012 IPPS/LTCH PPS final rule (76 FR 51653 through 51660); the CY 2012 OPPS/ASC final rule with comment period (76 FR 74527 through 74547); the FY 2013 IPPS/LTCH PPS final rule (77 FR 53567 through 53614); the FY 2014 IPPS/LTCH PPS final rule (78 FR 50676 through 50707); the CY 2014 OPPS/ASC final rule with comment period (78 FR 75120 through 75121); and the FY 2015 IPPS/LTCH PPS final rule with comment period (79 FR 50048 through 50087).

We have also codified certain requirements for the Hospital VBP Program at 42 CFR 412.160 through 412.167.
b. FY 2016 Program Year Payment Details

Section 1886(o)(7)(B) of the Act instructs the Secretary to reduce the base operating DRG payment amount for a hospital for each discharge in a fiscal year by an applicable percent. Under section 1886(o)(7)(A) of the Act, the sum total of these reductions in a fiscal year must equal the total amount available for value-based incentive payments for all eligible hospitals for the fiscal year, as estimated by the Secretary. We finalized details on how we would implement these provisions in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53571 through 53573) and refer readers to that rule for further details.

Under section 1886(o)(7)(C)(iv) of the Act, the applicable percent for the FY 2016 program year is 1.75 percent. Using the methodology we adopted in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53571 through 53573), we estimate that the total amount available for value-based incentive payments for FY 2016 is $1,499,107,502, based on the December 2014 update of the FY 2014 MedPAR file. We intend to update this estimate for the FY 2016 IPPS/LTCH PPS final rule, using the March 2015 update of the FY 2014 MedPAR file.

As finalized in the FY 2013 IPPS/LTCH PPS final rule, we will utilize a linear exchange function to translate this estimated amount available into a value-based incentive payment percentage for each hospital, based on its Total Performance Score (TPS) (77 FR 53573 through 53576). We will then calculate a value-based incentive payment adjustment factor that will be applied to the base operating DRG payment amount for each discharge occurring in FY 2016, on a per-claim basis. We published
proxy value-based incentive payment adjustment factors in Table 16 of the FY 2016 IPPS/LTCH PPS proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Proposed-Rule-Home-Page-Items/FY2016-IPPS-Proposed-Rule-Tables.html). The proxy factors are based on the TPSs from the FY 2015 program year. These FY 2015 performance scores are the most recently available performance scores that hospitals have been given the opportunity to review and correct.

The slope of the linear exchange function used to calculate those proxy value-based incentive payment adjustment factors is 2.5797595162. This slope, along with the estimated amount available for value-based incentive payments, is also published in Table 16.

We stated that we intended to update this table as Table 16A in this FY 2016 IPPS/LTCH PPS final rule (which will be available via the Internet on the CMS Web site) to reflect changes based on the March 2015 update to the FY 2014 MedPAR file. We also stated that we intended to update the slope of the linear exchange function used to calculate those updated proxy value-based incentive payment adjustment factors. The updated proxy value-based incentive payment adjustment factors for FY 2016 will continue to be based on historic FY 2015 program year TPSs because hospitals will not have been given the opportunity to review and correct their actual TPSs for the FY 2016 program year until after this FY 2016 IPPS/LTCH PPS final rule is published. After hospitals have been given an opportunity to review and correct their actual TPSs for FY 2016, we will add Table 16B (which will be available via the Internet on the CMS
Web site) to display the actual value-based incentive payment adjustment factors, exchange function slope, and estimated amount available for the FY 2016 program year. We expect that Table 16B will be posted on the CMS Web site in October 2015.

Comment: Several commenters urged CMS to make every effort to release the final VBP adjustment factors for FY 2016 as close to October 1, 2015 as possible. The commenters also requested that CMS review our timeline for reviewing these factors and make the necessary changes to ensure the final factors are released in a timely manner. In addition, the commenters expressed disappointment that CMS made no attempt to calculate FY 2016 proxy factors using the updated measures and domain weights finalized in last year’s rule and believed that we should include an analysis of the FY 2016 impact in the proposed rule files that better aligns with the ever-changing program specifics and most recent data available.

Response: We appreciate the importance of timely release of the final adjustment factors for FY 2016, and while we are unable to guarantee an exact release date for the final factors, we will make every effort to release these factors in a timely fashion.

With regard to the FY 2016 proxy factors, while we understand commenters’ concerns, we make these calculations using the most recently available performance data that hospitals have had the opportunity to review, which at the time of the final rule’s publication does not include the scoring data for the next fiscal year. We do not believe it would be useful to publish proxy factors using domain weights finalized for the next fiscal year without the corresponding performance scoring data from the same program year because that action would mix policies between fiscal years, which is why we
adopted the practice of calculating proxy factors from the previous year. We believe that these calculations represent the most accurate data available at the time of the final rule’s publication and appropriately reflect policies for a single program year.

We also received a number of general comments on the Hospital VBP Program:

Comment: Several commenters expressed continued support for value-based payment models. Other commenters noted that the incentive structure could provide greater inducement for providers to work collaboratively to improve performance. One commenter applauded the Hospital VBP Program for assessing multiple aspects of care as well as recognizing providers for both achievement versus national benchmarks and improvement versus baseline performance.

Response: We thank the commenters for their support.

Comment: Several commenters supported CMS’ move away from clinical process measures and toward the use of outcome measures.

Response: We thank the commenters for their support.

Comment: One commenter commended CMS for providing advance notice of its policy proposals for the Hospital VBP Program structure and measures from FY 2017 to FY 2021.

Response: We thank the commenter for this support.

Comment: Several commenters appreciated CMS’ continued attempts to better align with the Hospital IQR Program, Hospital Readmissions Reduction Program, the HAC Reduction Program, the Physician Value-Based Payment Modifier Program, and The Joint Commission to avoid redundancy and excessive resource burdens.
Response: We thank the commenters for their support.

Comment: One commenter supported the Hospital IQR Program as a mechanism for measure release and initial publication prior to inclusion into the Hospital VBP Program. The commenter believed this process allows the public and providers a “preview year” to better analyze and understand the methodology and impact of the measures as well as ensure accuracy of measurement and comparisons.

Response: We thank the commenter for this support.

Comment: Several commenters suggested specific means through which CMS could mitigate perceived biases within the Hospital VBP Program, including the addition of a measure that adjusts for small sample size, adjustments for provider penalties based on the sociodemographic status of their patient population, and the development of sociodemographic stratification measures built on factors used in analysis by key stakeholders.

Several commenters also suggested that CMS ensure the measures are appropriately validated and risk-adjusted by limiting performance-based payment programs to measures that have been endorsed by NQF and approved for specific program use by the MAP, a public-private partnership convened by the NQF for the purpose of providing input to the Secretary on the selection of certain quality and efficiency measures.

Response: While we appreciate these comments and the importance of the role that sociodemographic status plays in the care of patients, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of low
sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures. To date, we have found that hospitals that care for large proportions of patients of low sociodemographic status are capable of performing well on our measures (we refer readers to the 2014 Chartbook pages 48-57, 70-73, and 78 at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Downloads/Medicare-Hospital-Quality-Chartbook-2014.pdf).

NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate for each measure. For 2 years, NQF will conduct a trial of a temporary policy change that will allow inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will determine whether to make this policy change permanent. Measure developers must submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of socioeconomic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of these reports and related
Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

Comment: One commenter recommended that CMS provide measure developers with direction about expectations regarding reporting periods, volume of procedure thresholds, and other critical elements of a measure to avoid compromising the integrity of the carefully designed and tested measures. This commenter believed that modified specifications subsequent to the testing process jeopardize the value of measure testing.

Response: We thank the commenter for this recommendation. Upon completion of measure testing, developers provide recommendations on reporting periods and minimum volume threshold based on reliability. We do not believe that we change measure specifications after testing in a way that would affect the validity of a measure.

Comment: One commenter raised concerns that the incentives and penalties are too insignificant to drive real change in quality and cost containment.

Response: As required by section 1886(o)(7)(B) of the Act, incentive payments will be funded for FY 2016 through a reduction to the FY 2016 base operating DRG payment for each discharge of 1.75 percent. The applicable percentage for FY 2017 and subsequent years is capped at 2 percent. This is the amount that we are statutorily authorized to withhold at this time.

Comment: Some commenters encouraged CMS to align objectives, measures, and reporting format for physician and hospital quality programs such as the Physician Value-Based Payment Modifier, EHR Incentive, and Hospital IQR Programs as well as
the PQRS, and adopt a more streamlined and coordinated approach that will reduce what the commenters believed is unnecessary data collection and submission burden.

**Response:** As we stated in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51626), we agree that alignment of incentives is an important goal, and we strive to align quality measurement and value-based purchasing efforts with the National Quality Strategy and across our programs, to the extent possible, given differences in payment system maturity and statutory authorities. We will continue to seek to align aspects of all of our quality initiatives to promote high quality care and continued innovation, as well as minimize burden on providers.

**Comment:** One commenter suggested that CMS ensure the measures hospitals are evaluated on are proven to actually improve patient outcomes and increase the quality of care for all patients.

**Response:** We agree with the commenter’s suggestion and continue to work with stakeholders to define evidenced-based measures of quality that assess clinical care, patient experiences with care, and outcomes. We believe that the selected measures in the Hospital VBP Program are closely linked with improvements in quality of care and outcomes for all patients.

**Comment:** One commenter recommended that CMS develop a plan for incrementally phasing out improvement scoring for specific measures, which have been included in the Hospital VBP Program for several consecutive years, as a means of emphasizing comparative achievement performance. The commenter added that such a plan would facilitate the development of properly structured incentives to drive the
appropriate developments in healthcare delivery systems, resulting in better care for patients at a lower cost for payers.

Response: While we appreciate the commenter’s goal of driving appropriate development in healthcare delivery systems, section 1886(o)(3)(B) of the Act requires that the performance standards with respect to measures adopted in the Hospital VBP Program include levels of achievement and improvement. As we have stated in the past (76 FR 26514), we believe improvement scores are an important incentive for many hospitals that participate in the Hospital VBP Program because improvement scores award points for showing improvement on measures, not solely for outperforming other hospitals.

Comment: One commenter expressed serious concerns regarding what the commenter believed to be the disproportionate effect of the Hospital VBP Program on teaching and large hospitals due to insufficient risk adjustment. The commenter noted that CMS has an obligation to ensure that measurement and comparisons are as accurate as possible.

Response: We are committed to accurate and fair hospital quality measurement comparison. We are currently analyzing how various hospitals are affected by the measures in the program. There is a statutorily required Hospital VBP Program monitoring and evaluation report to Congress due January 1, 2016, in which we expect to present our analysis of the Hospital VBP Program’s impact on teaching and large hospitals.
Comment: One commenter recommended that CMS place a priority on ascertaining appropriate quality measures and encouraged CMS to include stakeholders that have relevant expertise in the measure development process.

Response: We are committed to defining appropriate, evidenced-based measures of quality. To the extent practicable, we continue to work with stakeholders, including those with relevant experience, and technical experts in the measure development process.

Comment: Several commenters expressed concern that CMS has not articulated a plan for calculating the Hospital VBP Program scores that will be affected by the transition from ICD-9-CM to ICD-10-CM/PCS codes and how such a transition could affect program measures and benchmarks, as well as the proposed baseline and performance periods. The commenters advised greater transparency and convening with stakeholders as a means of both soliciting feedback and addressing potential unintended consequences with respect to the transition. A few commenters requested that CMS elaborate on whether and how CMS will begin to re-specify claims-based measures in ICD-10-CM/PCS codes, given CMS’ intent to use claims-based measures in future program years and in other quality measurement programs. Finally, one commenter urged CMS to oppose any Congressional efforts to further delay the scheduled implementation of ICD-10.

Response: We are aware of stakeholder concerns about the potential impacts to hospital performance on quality measures when ICD-10 is implemented on October 1, 2015, as well as calls for more extensive testing to understand the impacts
before any payments or penalties are implicated. We are fully prepared to accept ICD-10-based claims data beginning October 1 for use in quality programs and ready to calculate measure results on schedule in accordance with established program timelines. We encourage stakeholders to subscribe to our listserv titled “Hospital Inpatient Value-Based Purchasing (HVBP) and Improvement” to receive notification of scheduled events. Stakeholders may join at https://www.qualitynet.org/dcs/ContentServer?pagename=QnetPublic/ListServe/Register.

Comment: One commenter noted that while CMS has updated the specifications for its chart-abstracted measures, CMS has not published any re-specification for the claims-based measures, specifically PSI-90.

Response: As with our chart abstracted measures, many claims-based measures have updated ICD-10 codes contained in the Measure Information Forms (MIFs) on the NQF Web site.77 AHRQ’s proposed changes for ICD–10–CM/PCS conversion of its quality indicators are available at: http://www.qualityindicators.ahrq.gov/icd10/default.aspx.

Comment: A few commenters requested that CMS convene a number of national provider calls to share how the ICD-10-CM/PCS transition may affect the measures, benchmarks, and performance standards and to solicit stakeholder feedback in preparation for FY 2017 rulemaking.

Response: We plan to convene national provider calls to share future plans for the ICD-10-CM/PCS transition. We encourage stakeholders to subscribe to our listserv titled “Hospital Inpatient Value-Based Purchasing (HVBP) and Improvement” to receive notification of scheduled events. Stakeholders may join at https://www.qualitynet.org/dcs/ContentServer?pagename=QnetPublic/ListServe/Register.

Comment: Several commenters expressed concern about the overlap of measures between the Hospital VBP Program and the HAC Reduction Program, given the different constructions and goals of each. These commenters urged CMS to use the measures in either the Hospital VBP Program or the HAC Reduction Program, but not both, to ensure the programs do not provide hospitals with conflicting signals or multiple payment penalties. One commenter expressed its preference that CMS remove the overlapping measures from the Hospital VBP Program, while another commenter recommended that CMS remove the overlapping measures from the HAC Reduction Program. One commenter added that CMS could explore a maximum penalty for a single measure across all pertinent programs.

Response: As we stated in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50056) in response to similar comments, we acknowledge that there is overlap in quality measures between the Hospital VBP Program and the HAC Reduction Program. While we are aware that commenters object to the possibility of scoring hospitals on certain measures under both programs, we note that these measures cover topics of critical importance to quality improvement in the inpatient hospital setting and to patient safety. We selected these quality measures because we believe that hospital acquired
condition measures comprise some of the most critical patient safety areas, therefore justifying the use of the measures in more than one program. These measures track infections that could cause significant health risks to Medicare patients, and we believe it is appropriate to provide incentives for hospitals to avoid them under more than one program.

We further stress that the HAC Reduction Program and the Hospital VBP Program are separate programs with different purposes and policy goals. The HAC Reduction Program reduces payments to hospitals for excess HACs to increase patient safety in hospitals. On the other hand, the Hospital VBP Program is an incentive program that redistributes a portion of the Medicare payments made to hospitals based on their performance on various measures. Therefore, although the measures exist in more than one program, the measures are used and calculated for very distinct purposes. Accordingly, we believe that the critical importance of these measures to patient safety warrants their inclusion in both programs.

2. Retention, Removal, Expansion, and Updating of Quality Measures for the FY 2018 Program Year

a. Retention of Previously Adopted Hospital VBP Program Measures for the FY 2018 Program Year

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53592), we finalized our proposal to readopt measures from the prior program year for each successive program year, unless proposed and finalized otherwise (for example, if we propose and finalize the removal of a measure). We stated our belief that this policy would facilitate measure
adoption for the Hospital VBP Program for future program years, as well as align the Hospital VBP Program with the Hospital IQR Program (77 FR 53592). In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24498), we did not propose to change our current policy of readopting measures from the prior program year for each successive program year.

We received several comments on measures we readopted into the FY 2018 program year:

Comment: One commenter noted its support for the policy CMS finalized in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53592) to readopt measures from prior program years each year unless otherwise indicated.

Response: We appreciate the commenter’s support.

Comment: One commenter expressed support for the readoption of PSI-90 because it represents important patient safety outcomes for consumers and purchasers.

Response: We appreciate the commenter’s support.

Comment: One commenter requested that CMS publish the PSI-90 methodology to be more transparent and reproducible.

Response: The methodology used to calculate the PSI-90 measure is detailed in the original technical report by the ARHQ Composite Workgroup:


Comment: One commenter expressed concern about the inclusion of the PSI-90 composite measure because it relies on claims-based data, which has limited clinical
information, making it difficult for a claims-based measure to address nuances of comorbidities, severity, and complications and the ability to perform adequate risk-adjustment.

Response: While we acknowledge commenters’ concerns about the use of claims-based data for the PSI-90 composite measure, we note that there are previously conducted validity studies that assess the relationship between administrative claim data and clinical information provided by medical records.\textsuperscript{78} We also note that NQF reviewed the risk-adjustment methodology of the component indicators during its last cycle of NQF endorsement, and endorsed the PSI-90 composite measure as a valid and reliable.

Comment: One commenter did not support AHRQ’s proposal as part of its NQF measure maintenance process to include PSI-10 in the PSI-composite given that the denominator is broad and a better indicator would require more than one measure.

Response: We appreciate commenter’s concern and are aware that NQF is reviewing the PSI-90 composite with three additional components (PSI-9, PSI-10, and PSI-11), as part of the routine measure maintenance process. We will take NQF’s decision on continuing endorsement into consideration for proposal in future program years under the Hospital VBP Program.

Comment: Several commenters did not support the inclusion of the PSI-12 component of the PSI-90 composite that is being readopted for the FY 2018 program year.

because it does not exclude trauma patients, given the high rates of Perioperative Pulmonary Embolism (PE)/Deep Vein Thrombosis (DVT) Rate in trauma patients. Without the trauma exclusion, commenters explained that facilities that treat a large amount of spinal cord injury patients and other traumatic cases will automatically be adversely affected and will not be able to compete with non-trauma facilities. Thus, commenters believe trauma centers are unfairly penalized by PSI-12. Some commenters suggested that the PSI-12 component also exclude patients with a diagnosis of cancer or brain tumors because these patients represent a very high-risk group due to their underlying medical condition.

Further, commenters suggested that PSI-12 relies on risk adjustment criteria that could lead to potential unintended consequences (for example, the measure could tag every LE thrombophlebitis, whether or not it is clinically significant, which could lead to useless data that will have little impact on quality). Finally, commenters noted that the PSI-12 component includes not otherwise specified (NOS) codes, including superficial thrombosis, which commenters did not believe is appropriate to measure because there are predictors of DVT that are outside of the control of the facility.

Response: We acknowledge commenters’ concerns, but note that NQF reviewed the measure and took into account concerns about exclusions. NQF endorsed PSI-12 as a valid and reliable measure (NQF #0450) and as part of the PSI-90 composite measure during its last cycle of NQF endorsement (NQF #0531).

Comment: Several commenters expressed concern with the PSI-15 component of the PSI-90 composite measure that is being readopted for the FY 2018 program year
because coding for accidental puncture is still non-uniform due to lack of clarity as to what constitutes an “accident” despite CMS’ reference to the American Hospital Association Coding Clinical Guidance in the FY 2014 IPPS/LTCH PPS final rule. The commenters stated that punctures or lacerations are often incorrectly coded as “accidental” when the puncture or laceration was part of the surgery. Commenters requested that CMS provide more precise guidance regarding the correct coding of the PSI-15 component of the PSI-90 measure to minimize confusion and improve the accuracy of the measure.

Response: We acknowledge commenters’ specific concerns regarding coding of the PSI-15 component of the PSI-90 composite. We continue to believe that the American Hospital Association Coding Clinical Guidance provides sufficient guidance regarding the correct coding of “accidental” punctures and lacerations that are not “intrinsic” or “inherent” in a major procedure. We believe that hospitals should continue to provide education to their staff on correct coding of PSI-15. The AHRQ Quality Improvement Toolkit may also provide additional guidance to facilitate improvements to documentation and coding:


Comment: One commenter recommended that CMS separate public safety measures, such as PSI-03 Pressure Ulcer Rate and PSI-15 Accidental Puncture or Laceration to increase transparency for consumers and providers.
Response: We thank the commenter for this suggestion and we will take it into consideration in future rulemaking.

Comment: One commenter expressed continued concern about including PSI-9, PSI-10, and PSI-11 in the PSI-90 composite because of concerns with the measures’ validity. The commenter believed that improvements in PSI performance reflect “gaming” of the system and not necessarily safer care for patients. The commenter recommended that CMS implement key steps to improve the validity of these claims-based measures and referred to similar comments which it made in the context of the Hospital IQR Program in section VIII.A.1.b. of the preamble of this final rule.

Response: We appreciate the commenter’s concern and are aware that NQF is reviewing the PSI-90 composite with three additional components (PSI-9, PSI-10, and PSI-11), as part of the routine measure maintenance process. We will take NQF’s decision on continuing endorsement into consideration when evaluating whether the measure remains appropriate for the Hospital VBP Program. Regarding the commenter’s concerns regarding the validity of the PSI-90 composite, we note that NQF has previously endorsed the PSI-90 composite as a valid measure (NQF #0531). We continue to believe the PSI-90 composite is an important measure of patient safety.

Comment: One commenter noted that since PSI-7 and NHSN CLABSI are both in the Hospital VBP Program, central line infections are counted twice (first as part of PSI-90 and then again as a NHSN CLABSI outcome measure) with different data sources. Commenter recommended the use of the NHSN CLABSI measure because it draws from clinical data and continues to have concerns with the PSI-90 measure.
Response: While we acknowledge that there is the potential for overlap between the two measures, the source of the data is different. PSI-7 is based on coding of physician documentation and does not account for vascular catheter exposure, whereas the CLABSI measure relies on microbiologic laboratory confirmation and does account for vascular catheter exposure (catheter days). Despite the potential for some overlap in these measures, we continue to believe that both measures are important to reducing central line associated blood stream infections.

Comment: A few commenters expressed concern with readopting the MSPB-1 measure because it measures volume of spending without considering quality or appropriateness of care. The commenters noted that it might create incentives for hospitals to reduce utilization of appropriate and necessary diagnostic technologies and therapeutic options. The commenters believed the measure lacks sufficient granularity and relies on poor risk-adjustment and attribution methodologies.

Response: We finalized the MSPB-1 measure for inclusion in the Hospital VBP Program in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53592), where we addressed a number of concerns related to the measure. With regard to linking MSPB-1 to quality of care, we have emphasized that within the Hospital VBP program, MSPB-1 is combined with other quality measures in order to calculate the TPS (77 FR 53586). We continue to believe that the method of calculating a hospital's TPS, which ensures that the MSPB-1 is only a portion of the TPS, incentivizes hospitals to continue to provide high quality care. We further note that the measure is risk-adjusted using a methodology that is consistent with the risk-adjustment model used for several CMS initiatives.
Comment: One commenter recommended that in order to most accurately and reliably report meaningful colon and abdominal hysterectomy SSI rates, exenterations be excluded from the measure. The commenter believed that CMS disproportionately skews and penalizes large tertiary centers that perform exenterations, especially for recurrent cancers.

Response: We agree that not all surgical procedures confer the same risk for SSI, and some surgical patients are at greater risk for infection because their functional status is compromised by disease conditions or other patient-specific factors. CDC is collecting additional SSI risk factors that will enable new risk modeling using the 2015 SSI data. While these new risk models can take into account additional factors that place patients at risk for infection, not all SSI risk differences associated with procedural and patient differences can be included because of the data collection burden that would be imposed on NHSN users.

Comment: One commenter did not support the THA/TKA measure CMS finalized for the FY 2019 program year because of validity and appropriateness concerns. The commenter questioned the accuracy of the administrative data sets for both procedures. The commenter also noted that despite NQF’s endorsement of sociodemographic risk adjustment refinements, this measure is not risk-adjusted for sociodemographic factors, which have significant correlation with variability of outcomes. The commenter also noted the current composition of the measure could result in problems with access to total joint surgery for certain classes of patients (for
example, obese, lupus patients and transplant patients) given that they carry a higher risk for complications.

Response: We acknowledge the commenter’s concerns regarding the use of administrative data for the THA/TKA measure, but note that there are previously conducted validation studies that validate the use of administrative claims data to provide sufficient clinical information. We believe that the current composition of the THA/TKA measure will not result in decreased patient access to THA/TKA procedures, as the measure incorporates an appropriately comprehensive risk-adjustment methodology for patient case-mix and comorbidity.

As we discussed more fully above, while we appreciate these comments and the importance of the role that sociodemographic status plays in the care of patients, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of low sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures. To date, we have found that hospitals that care for large proportions of patients of low sociodemographic status are capable of performing well on our measures (we refer readers to the 2014 Chartbook pages 48-57, 70-73, and 78 at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

---

Comment: One commenter did not support CMS’ inclusion of the PC-01 measure because it is Web-based and there has not been any chart validation for accuracy and consistency of data collection across hospitals. Further, the commenter believed the benchmark of 0 percent is unrealistic because The Joint Commission has stated that not all justifications for an elective delivery are included on the ICD-9-CM Justification Table.

Response: We acknowledge commenter’s concern regarding the PC-01 measure, but note that PC-01 is NQF-endorsed (NQF # 0469) as clinically valid. Moreover, we disagree with the assertion that the benchmark of 0 percent is unrealistic because not all justifications for an elective delivery are included in the ICD-9-CM Justification Table. As we have previously noted, the benchmark is intended to represent a level of excellent performance to which hospitals generally should aspire. While no measure can account for every possible situation, the measure specifications (available at: https://manual.jointcommission.org/releases/TJC2015A1/MIF0166.html) provide a large number of ICD-9-CM Principal Diagnosis Code or Other Diagnosis Codes for conditions possibly justifying elective delivery prior to 39 weeks gestation. Furthermore, the 0 percent benchmark for PC-01 was calculated from the mean of the top 10 percent for all hospitals during the baseline period. We continue to believe that hospitals should aspire to prevent elective deliveries from being performed before the gestational age of 39 weeks without a medical indication.
Comment: One commenter recommended that CMS retire measures when the evidentiary basis for a measure has changed, the cost of collection and measurement burden outweighs the utility of the measure, or the measure has demonstrated minimal impact on health outcomes and status.

Response: We thank the commenter for these suggestions and we will take these comments into consideration in future rulemaking.

Comment: One commenter asked that CMS suspend use of HCAHPS measures addressing pain management until the revised questions are reexamined to determine whether they are contributing to overprescribing due to the pressures HCAHPS scores place on providers.

Response: We understand and share the commenter’s concerns about inappropriate prescribing of prescription opioids and its link to prescription opioid dependence, abuse, and addiction. We believe that the rising level of opioid dependence, abuse, addiction, and overdose is a public health emergency in the United States. Although we are not aware of scientific research that establishes a causal connection between HCAHPS scores and provider prescription practices, we recognize that there have been anecdotal reports suggesting a link and that many providers believe such a link exists. However, there is no evidence of which we are aware that finds failing to prescribe unneeded pain medications lowers a hospital’s HCAHPS scores.

There are three questions on the HCAHPS survey which directly address the issue of pain control during a patient’s hospital stay. Recent studies have shown a positive
relationship between patients being satisfied with their pain relief while in the hospital (that is, giving high scores on pain control questions) and decreased chronic opioid use.  

There is evidence that good physician and nurse communication are the strongest predictors of better patient experience survey scores, including HCAHPS scores. Finally, the 2018 HCAHPS questions will include the Care Transition Management measure which will place additional focus on educating patients about their outpatient care plan. We believe that this additional measure will further highlight patient safety and outpatient care coordination.

Comment: One commenter suggested that CMS evaluate an adjustment to the HCAHPS survey based on a secondary psychiatric diagnosis because these patients report significantly lower scores on the Communication with Nurses, Communication with Doctors, and Pain Management HCAHPS survey dimensions. The commenter suggested that the investigation could address hospital concerns related to pain management and opioid abuse and could identify the percentage of patients a hospital is treating who suffer from opioid addiction and adjust the data accordingly without adding substantial administrative burden to hospitals.

Response: Currently, we do not collect or investigate secondary psychiatric diagnoses for HCAHPS. We do collect and measure self-rated mental health which is

---


81 Elliott MN, Kanouse DE, et al., “Components of Care Vary in Importance for Overall Patient Reported Experience by Type of Hospitalization.” Medical Care, 2009.
correlated with such diagnoses.\textsuperscript{82} Findings have shown that self-rated mental health is not strongly associated with HCAHPS scores after controlling for the full set of current HCAHPS patient-mix adjustment (PMA) variables. It is unlikely that secondary psychiatric diagnoses would be an important addition to HCAHPS PMA, even if there is a bivariate association with HCAHPS scores.

With respect to opioid abuse, recent studies have shown a positive relationship between patients being satisfied with their pain relief in the hospital and decreased chronic opioid use.\textsuperscript{83} There is evidence that, in general, good physician and nurse communication are the strongest predictors of better patient experience survey scores, including HCAHPS scores.\textsuperscript{84}

**Comment:** One commenter suggested that CMS separate the Hospital Cleanliness & Quietness dimension from the rest of the HCAHPS Survey because these two elements are separated in the HCAHPS data that is reported in *Hospital Compare* and it would be useful for consumers to know which element is driving the performance and improvement within these quality areas. The commenter noted that hospital cleanliness is especially important to hospital environmental services members. Another commenter recommended that Hospital Cleanliness be weighted more heavily than Hospital Quietness for the dimension score because hospital cleanliness has a direct impact on the prevention of hospital-acquired conditions.


\textsuperscript{84} Elliott et al., Medical Care, 2009.
Response: On Hospital Compare, we provide separate scores for hospital cleanliness and hospital quietness. These separate scores are available to consumers to use in choosing a hospital. In presenting a composite clean/quiet dimension score in the Hospital VBP Program, there is no objective rationale for giving undue weight to one or the other dimension since both hospital cleanliness and quietness are observed to impact patient recovery.

Comment: Several commenters expressed concern for the sufficiency of the risk adjustment of the HCAHPS composite measures and believe that the methods for delivering the survey are outdated given the shift to Web-based activities and suggested that CMS conduct research to improve the delivery methods of the HCAHPS survey.

Response: While Web-based surveys are increasing in use and have much value in other contexts, a recent Randomized Control Trial (RCT) study found Web-based approaches currently result in lower response rates and poorer representativeness than any of the four approved HCAHPS modes in the HCAHPS population.\textsuperscript{85} We will continue to explore this option as hospital email address information on patients becomes more complete and daily Internet access becomes more complete in the HCAHPS target population.

Comment: Two commenters stated that patient satisfaction does not lead to better health outcomes and therefore using HCAHPS as a measure may not be driving positive

outcomes. One commenter urged CMS to work with AHRQ to assess patient satisfaction’s impact on health outcomes.

Response: HCAHPS measures patient experience, a dimension of quality care that is distinct from clinical measures of quality and of inherent value. Improving all aspects of quality of care, including patient experience, is a CMS and HHS policy priority. Recent reviews have found that the vast majority of studies have found positive associations between patient experience and clinical process measures of quality, outcomes, and efficiency, particularly in the inpatient setting. The most widely cited article that found negative associations, by Fenton et al., has been identified as being methodologically flawed in a recent reanalysis of its data.

b. Removal of Two Measures

One consideration in determining whether a measure should be retained or removed from the program is based on an analysis of whether the measure is “topped-out.” We have adopted two criteria for determining the “topped-out” status of Hospital VBP measures:

- Statistically indistinguishable performance at the 75th and 90th percentiles; and
- Truncated coefficient of variation ≤ 0.10.


In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24498 through 24500), we proposed to remove the IMM-2: Influenza Immunization and AMI-7a: Fibrinolytic Therapy Received within 30 Minutes of Hospital Arrival measures, effective for the FY 2018 program year. We believe that removing these measures will continue to ensure that we make valid statistical comparisons through our finalized scoring methodology, while reducing the reporting burden on participating hospitals.

(1) Removal of IMM-2: Influenza Immunization Measure

Based on our evaluation of the most recently available data, we believe that IMM-2 is “topped-out.” As we have discussed in prior rulemaking, measuring hospital performance on “topped-out” measures will have no meaningful effect on a hospital’s TPS, given that performance on “topped-out” measures is generally so high and unvarying that meaningful distinctions and improvements in performance can no longer be made.

As discussed further in section VIII.A.3.b. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24557 through 24558) and this final rule, we believe that this measure should continue to be part of the Hospital IQR Program measure set because it is the only measure that addresses the Best Practices to Enable Healthy Living goal in the CMS Quality Strategy and priority of the same name in the National Quality Strategy.

We invited public comment on this proposal.

Comment: Most commenters supported the proposal to remove the IMM-2 measure because it is “topped-out.”
Response: We thank the commenters for their support.

Comment: A few commenters did not support the proposal to remove IMM-2 from the Hospital VBP Program despite its “topped-out” status. One commenter believed that the measure will ensure that providers continue to administer this vaccine, and given that adult immunization rates remain low, the commenter noted that quality measures are an important tool to increase vaccination rates. Another commenter did not believe that CMS’ measure removal criteria are patient-centered. This commenter noted that a measure might meet the criteria for removal but a large number of patients may still fail to receive the appropriate standard of care.

Response: We disagree with the commenter that the measure removal criteria for IMM-2 are not patient-centered. We continue to believe that influenza immunization is important; hence, we have opted to retain the measure in the Hospital IQR Program.

However, as discussed in prior rulemaking, measuring hospital performance on “topped-out” measures has no meaningful effect on a hospital’s TPS, given that meaningful distinctions in performance between hospitals cannot be made. As we have stated in the past (76 FR 26500), we believe that if a measure is “topped-out,” then there is no room for improvement for the vast majority of hospitals.

After consideration of the public comments we received, we are finalizing the proposal to remove IMM-2 from the FY 2018 program year and subsequent years.
(2) Removal of AMI-7a: Fibrinolytic Therapy Received within 30 Minutes of Hospital Arrival Measure

Our evaluation of the most recently available data shows that AMI-7a is not widely reported by hospitals, and that many hospitals have less than the minimum number of cases required for reporting because most acute myocardial infarction patients receive percutaneous coronary intervention instead of fibrinolytic therapy. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24499), we proposed to remove AMI-7a because collection of the measure data is burdensome to hospitals and measure data are infrequently reported. Therefore, we do not believe that its continued adoption under the Hospital VBP Program will advance our quality improvement goals. As discussed in section VIII.A.3.b. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24558 through 24559), we also proposed to remove the chart-abstracted version of AMI–7a, but to retain the electronic version for the CY 2016/FY 2018 payment determination and subsequent years under the Hospital IQR Program.

We invited public comment on this proposal.

Comment: Most commenters supported the proposal to remove the AMI-7a measure. Some commenters noted that the measure will not advance quality improvement goals, that data collection is burdensome, and that it no longer reflects current clinical guidelines and standards of care. Some commenters also agreed that many hospitals would have a difficult time achieving the minimum number of cases needed to report this measure.
Response: We thank the commenters for their support of removal. While we acknowledge that primary percutaneous coronary intervention (PCI) remains the recommended method of reperfusion when it can be performed in a timely fashion by experienced practitioners, we do not agree that this measure no longer reflects current clinical guidelines.

Comment: One commenter recommended that CMS establish a system to periodically monitor performance on retired measures to ensure that quality gains are sustained.

Response: At this time, we do not have a formal mechanism in place to monitor whether measures that have been “topped-out” remain “topped-out.” However, we monitor the performance of removed measures to ensure that performance does not decline significantly and will continue to do so. We must balance the costs of continued monitoring of a successful measure with high levels of performance with the adoption of other measures where there are opportunities for improvement in clinical quality. We will take the recommendation into consideration in the future. For now, we continue to believe that if a measure is “topped-out,” there is no room for improvement for the vast majority of hospitals, and that measuring hospital performance on that measure will not have a meaningful effect on a hospital’s TPS.

Comment: One commenter did not support the removal of the AMI-7a measure because the commenter did not believe the measure removal criteria are patient-centered. The commenter noted that a measure might meet the criteria for removal but a large number of patients may still fail to receive the appropriate standard of care.
Response: We disagree with the commenter that our measure removal criteria are not patient-centered. Currently, most acute myocardial infarction patients receive percutaneous coronary intervention instead of fibrinolytic therapy. While we acknowledge commenter’s concern, our evaluation data shows that AMI-7a is infrequently reported, and in consequence, does not result in better patient outcomes for the AMI population. Furthermore, we have no reason to believe that removal of the measure will decrease the use of fibrinolytic therapy for those who need it.

After consideration of the public comments we received, we are finalizing the proposal to remove AMI-7a from the Hospital VBP Program for the FY 2018 program year and subsequent years.

c. New Measure for the FY 2018 Program Year: 3-Item Care Transition Measure (CTM-3) (NQF #0228)


The 3-Item Care Transition Measure (CTM-3) is an NQF-endorsed measure. We adopted this measure in the Hospital IQR Program in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53513 through 53516). Initial measure data were posted on Hospital Compare in December 2014 and the full measure specifications are available at:

The CTM-3 measure adds three questions to the HCAHPS Survey, as follows:

- During this hospital stay, staff took my preferences and those of my family or caregiver into account in deciding what my health care needs would be when I left.
  - □ Strongly disagree
  - □ Disagree
  - □ Agree
  - □ Strongly agree

- When I left the hospital, I had a good understanding of the things I was responsible for in managing my health.
  - □ Strongly disagree
  - □ Disagree
  - □ Agree
  - □ Strongly agree

- When I left the hospital, I clearly understood the purpose for taking each of my medications.
  - □ Strongly disagree
  - □ Disagree
  - □ Agree
□ Strongly agree

□ I was not given any medication when I left the hospital

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50065 through 50066), we stated that we were considering proposing to add the CTM-3 measure from the HCAHPS Survey to the Patient and Caregiver Centered Experience of Care/Care Coordination (PCCEC/CC) domain of the FY 2018 program year, and we sought public comments on this topic. We specifically sought public comments on how the new CTM-3 dimension should be included in the scoring methodology that we have adopted for the PCCEC/CC domain.

Based on other public comments last year, we agreed to release additional information about the validity, reliability, and statistical properties of the CTM-3 measure when we proposed the measure (79 FR 50066). We made this information publicly available in 2014 through the NQF re-endorsement process of the HCAHPS Survey (NQF #0166), available at:


We note that the MAP supported the inclusion of the CTM-3 measure in the Hospital VBP Program in its MAP Pre-Rulemaking Report: 2013 Recommendations on Measures Under Consideration by HHS, available at:

http://www.qualityforum.org/Publications/2013/02/MAP_Pre-Rulemaking_Report_-_February_2013.aspx. The MAP noted that the addition of the CTM-3 measure will fill a gap in measuring care transitions.
In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24499), we proposed this measure for the Hospital VBP Program based on the MAP recommendation, our adoption of the measure in the Hospital IQR Program and our posting of measure data on Hospital Compare for at least 1 year before the beginning of the performance period for that measure. We believe that the proposed addition of the CTM-3 measure to the Hospital VBP Program meets the statutory requirements for inclusion in the FY 2018 program year. Finally, we also believe that this measure, in conjunction with the HCAHPS survey, assesses an important component of quality in the acute care inpatient hospital setting. However, we emphasize that HCAHPS scores are designed and intended for use at the hospital level. We do not endorse the use of HCAHPS scores for comparisons within hospitals, such as comparison of HCAHPS scores associated with a particular ward, floor, provider, or nursing staff. Further, the pain domain questions are intended to evaluate patients’ experience of their pain management. HCAHPS pain domain results are not designed to judge, or compare, appropriate versus inappropriate provider prescribing behavior.

We invited public comment on this proposal.

Comment: Several commenters supported the proposed adoption of the CTM-3 measure as a good measure of hospital communication and care, citing that the inclusion of the measure would not only address all aspects of a defined episode of care but it would also affect the appropriate administration of prescribed antimicrobials, contribute to the early recognition of post-discharge infections, and incentivize hospitals to improve their coordination of patient transitions to outpatient care settings. These commenters
noted that CTM-3 also features the necessary components to assess the quality of care received by patients at discharge, patient-caregiver comprehension of assigned health management plans, and the distribution of appropriate treatment, collectively mitigating the current rates of hospital readmissions and mortality among Medicare recipients.

Response: We thank the commenters for their support.

Comment: One commenter expressed appreciation for CMS’ continued review of the HCAHPS patient-mix adjustment, and applauded CMS’ more granular approach to adjust based on the language spoken by the patient.

Response: We thank the commenter for this support.

Comment: Several commenters expressed support for the measure, but noted concern with regard to its potential effect on the PCCEC/CC domain, the length and burdensome nature of the HCAHPS survey, as well as potential issues with patient comprehension of the language used in the questions. The commenters questioned the validity of the HCAHPS tool, given that this voluntary survey already has a low response rate.

Some commenters suggested that CMS should consider using a threshold (such as percentiles) rather than a consistency score to ensure that this new measure does not adversely affect the HCAHPS domain. Several commenters recommended CMS decrease the HCAHPS consistency score to 10 percent and weight the HCAHPS measure total score with the CTM-3 measure at 90 percent. Another commenter recommended revising the methodology of the consistency score to more accurately measure consistent performance and retaining the 20 percent score. Instead, this commenter suggested using
the HCAHPS floor values as the minimum range for consistency, and that CMS could use the 25th percentile value. The commenter stated that, in this way, consistency points would only be rewarding hospitals that maintain a reasonable level of performance in each HCAHPS measure.

Response: The CTM-3 measure is an established and validated measure of patient experience with care transitions that has been incorporated into the HCAHPS measure. The measure was developed by Eric Coleman, MD, MPH, Professor of Medicine and Health at the Division of Health and Policy Research at the University of Colorado Anschutz Medical Campus. Dr. Coleman is the founder and director of The Care Transitions Program (www.caretransitions.org). The three Care Transition Measure questions are under copyright of The Care Transitions Program. We conducted additional analyses for HCAHPS and released additional information about the validity, reliability, and statistical properties of the CTM-3 measure when we proposed the measure (79 FR 50066). We made this information publicly available in 2014 through the NQF re-endorsement process of the HCAHPS Survey (NQF #0166), available at: http://www.qualityforum.org/ProjectMeasures.aspx?projectID=73867.

With respect to response rates and burden of the HCAHPS survey, available evidence suggests the addition of 3 items has no measurable effect on response rates. National HCAHPS response rates are unchanged to the nearest percentage point over the last four years. A 2008 meta-analysis found response rates are only weakly associated
with non-response bias in probability sample surveys similar to HCAHPS, surveys that also adhere to high process standards of survey methodology.\textsuperscript{88}

As indicated by the formula, consistency points only reward performance that is consistently good across the HCAHPS dimensions. Consistently poor performance does not earn consistency points. Consistency points provide additional incentives beyond achievement and improvement points to improve a hospital’s lowest-performing dimension. Adding the CTM measure to the HCAHPS performance score should not adversely affect consistency point scoring. In particular, the score for this measure for the purposes of consistency points is compared to all other hospitals in the baseline period. A hospital will be awarded the maximum 20 consistency points when its performance on each HCAHPS dimension during the performance period equals or exceeds each dimension’s achievement threshold. Otherwise, if any dimension rate is less than the achievement threshold, consistency points are awarded based on the lowest dimension’s location relative to the worst performing hospital on that dimension. Evaluations have found that consistency points have good psychometric properties and positively correlate with overall HCAHPS performance.

**Comment:** One commenter suggested that CMS should provide further discussion and instruction to hospitals regarding the implementation of the proposed 3-Item Care Transition Measure and whether this new measure will align with the existing measures in the HCAHPS survey. Another commenter did not support the inclusion of the CTM-3 measure because the commenter believed the survey results are

subjective, the results inaccurately reflect the effectiveness of hospitals’ care transitions, and the survey does not assess post-discharge planning efforts via Web-based patient portals and outcomes.

Response: The HCAHPS survey and its administrative protocols are designed to produce standardized information about patient’s perspectives of care that allow objective and meaningful comparisons of hospitals on topics that are important to consumers. All survey vendors as well as hospitals which self-administer the HCAHPS survey receive annual training and oversight on HCAHPS survey implementation. The CTM-3 measure added 3 questions to the HCAHPS questionnaire in 2013. Survey vendors and self-administering hospitals have had two years of experience collecting data for the three HCAHPS questions (listed above) which comprise the CTM-3 measure. We have conducted additional analyses for HCAHPS, with results available as part of the HCAHPS NQF submission, confirming this measures’ reliability and validity in the HCAHPS population (http://www.qualityforum.org/ProjectMeasures.aspx?projectID=73867).

Comment: One commenter expressed concern that the CTM-3 measure does not fully ensure medication therapy in the continuity of care for patients with acute coronary syndrome (ACS) and chronic obstructive pulmonary disease (COPD) in particular. The commenter suggested that CMS take additional steps to close these gaps via proper medication management, adding a question asking patients to assess their ease of obtaining prescription immediately after discharge, and updating the medication-related
question to: “When I left the hospital, I clearly understood the purpose for taking each of my medications and how long I should take each of my medications.”

Response: The HCAHPS Survey is a standardized survey instrument and data collection methodology for measuring patients’ experience of hospital care. The HCAHPS survey produces comparable nation-wide data which allow consumers to make objective and meaningful comparisons of hospitals thus supporting consumer choice of hospital. The emphasis is on the patients’ experience of care while in the inpatient setting. Any modification of the HCAHPS Survey needs to focus on care provided by the hospital. We will share the commenter’s question suggestions to the CTM-3 measure developers. Further, HCAHPS survey results are publicly reported to create incentives for hospitals to improve the quality of care they provide in their facilities.

Comment: One commenter recommended that CMS consider alternative approaches to documenting the CTM-3 measure, including the use of emails and Web-based portals, which, the commenter believed, would make data collection and aggregation less costly and therefore allow hospitals to gather a larger sample size of data.

Response: While Web-based surveys are increasing in use and have much value in other contexts, a recent Randomized Control Trial (RCT) study found Web-based approaches currently result in lower response rates and poorer representativeness than any of the four approved HCAHPS modes in the HCAHPS population.\textsuperscript{89} We will

continue to explore Web-based approaches as hospital email address information on patients becomes more complete and as daily internet access becomes more complete in the HCAHPS target population.

Comment: Several commenters requested that CMS implement the CTM-3 measure sooner than the FY 2018 program year.

Response: We are unable to implement the measure sooner than the FY 2018 program year. First, in accordance with section 1886(o)(2)(C)(i) of the Act, we post data on measures on Hospital Compare for at least one year before we select them for the Hospital VBP Program. CTM-3 initial measure data was posted on Hospital Compare in December 2014. Further, under section 1886(o)(3)(C) of the Act, we establish and announce the performance standards for all measures in the Hospital VBP Program at least 60 days before the beginning of the performance period. As discussed below, we are finalizing the baseline period for the CTM-3 measure as January 1, 2014 – December 31, 2014 and the performance period as January 1, 2016 – December 31, 2016.

After consideration of the public comments we received, we are finalizing the proposal to add CTM-3 to the FY 2018 program year and subsequent years.

d. Removal of Clinical Care—Process Subdomain for the FY 2018 Program Year and Subsequent Years

We have previously adopted three measures for the Clinical Care—Process subdomain for the FY 2017 program year (for example, 79 FR 50062 (Table on Previously Adopted and New Measures for the FY 2017 program year)). However, as proposed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24499), we are
finalizing our proposal to remove the AMI-7a and IMM-2 measures from the Hospital VBP Program, and we did not propose to adopt any additional measures for the Clinical Care—Process subdomain. Because only one measure, PC-01 Elective Delivery, which measures the incidence of elective births prior to 39 weeks gestation, would remain in the Clinical Care—Process subdomain for the FY 2018 program year, we proposed to move PC-01 to the Safety domain and to remove the Clinical Care—Process subdomain beginning with the FY 2018 program year.

As we have stated over the past several years (for example, 79 FR 50084), we desire the Hospital VBP Program to be as inclusive as possible while maintaining and ensuring the reliability of the domains. We believe that the PC-01 Elective Delivery measure continues to be appropriate for the Hospital VBP Program because, in 2012, nearly one million Medicare beneficiaries were women age 45 and under. Further, in 2011, Medicare paid for roughly 14,000 births (79 FR 50060). However, not all hospitals provide maternity services, which would leave these hospitals with no Clinical Care-Process subdomain measures to report in FY 2018 if PC-01 remains the only measure in that subdomain.

We believe that the PC-01 Elective Delivery measure, currently in the Clinical Care—Process subdomain, can appropriately be recategorized as a Safety domain measure. PC-01 addresses a process designed to reduce risk to both the neonate and the mother, thereby making care safer. Guidelines from the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics state elective

---

deliveries should not be performed at <39 weeks gestation unless medically indicated. Evidence has shown that early-term deliveries result in significant short-term neonatal mortality and result in more cesarean deliveries, and longer maternal length of stay. Furthermore, the MAP Hospital Workgroup has included PC-01 as an “obstetrical adverse event” measure in its Safety family of measures. As we continue to align our measure categorizations more closely with the CMS Quality Strategy, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24500), we proposed to recategorize PC-01 as a Safety measure in the Safety domain, and for the reasons discussed above, to remove the Clinical Care—Process subdomain beginning with the FY 2018 program year.

Finally, we proposed that if we finalize our proposal to remove the Clinical Care—Process subdomain, we would rename the Clinical Care—Outcomes subdomain as simply the Clinical Care domain. We also proposed to reweight the domains to reflect our proposals, which we detail in section IV.G.8.a. (erroneously referenced as section IV.G.7.a. in the preamble of the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24508 through 24509).

We invited public comments on these proposals.

---


93 MAP Families of Measures: Safety, Care Coordination, Cardiovascular Conditions, Diabetes Final Report, October 2012, p. 46.
Comment: Several commenters supported the proposal to remove the Clinical Care—Process subdomain and move the PC-01 measure to the Safety domain beginning with the FY 2018 program year.

Response: We thank the commenters for their support.

Comment: Several commenters expressed confusion regarding the inclusion of process measures in future program years. These commenters recommended that CMS retain the Clinical Care—Process subdomain at a weight of zero and work to repopulate this domain with appropriate process of care measures for future years when the domain weight could be adjusted. One commenter explained that many hospitals would only qualify for the Hospital VBP Program because they meet case minimums for process measures. Another commenter credited the Hospital VBP Program with facilitating improvements in processes throughout hospitals. One commenter noted that it might support the proposal to remove process measures as a domain; however, it did not believe that process measures should be removed completely from the Hospital VBP Program. One commenter expressed concern that new process measures that may be developed in the future would be given the same weight as future outcome measures grouped in the same domain.

A few commenters noted that the four current Hospital VBP Program domains could accommodate process of care measures in the future, if needed.

Response: We did not intend to signal that we would no longer consider process measures in future program years. Rather, we agree with some commenters who noted that the four Hospital VBP Program domains, Safety, Clinical Care, Efficiency and Cost
Reduction, and PCCEC/CC, are able to accommodate process of care measures in the future, if needed. Further, removing the distinction between process measures and outcome measures is in line with our stated policy of favoring outcome measures over process measures. We would consider adding more process measures if they will further the Hospital VBP Program’s objectives.

**Comment:** One commenter did not support the proposed renaming of the Clinical Care—Outcomes subdomain.

**Response:** We believe renaming Clinical Care Outcomes subdomain to the Clinical Care domain gives us the flexibility to add process measures to that domain when appropriate in future program years.

**Comment:** One commenter requested that CMS clarify whether hospitals that elect to report six months of data for the PC-01 Elective Delivery measure as an eCQM for the Hospital IQR Program would also need to submit PC-01 Elective Delivery measure data using chart abstraction for the full year to have it included in the Hospital VBP Program scoring determination.

**Response:** Hospitals must submit PC-01 measure data based on chart abstraction for the Hospital IQR Program.

**Comment:** Several commenters supported the proposed recategorization of the PC-01 Elective Delivery measure as a Safety domain measure, as well as the proposed weight distribution in FY 2018.

**Response:** We thank the commenters for their support.
After consideration of the public comments we received, we are finalizing the proposal to move PC-01 to the Safety domain, remove the Clinical Care—Process subdomain, and rename the Clinical Care—Outcomes subdomain as the Clinical Care domain for the FY 2018 program year and subsequent years.

e. NHSN Measures Standard Population Data

The NHSN measures are calculated by CDC, and currently include the CAUTI, CLABSI, MRSA bacteremia, CDI, and Colon and Abdominal Hysterectomy SSI measures in the FY 2017 program year and subsequent program years. They measure the occurrence of these HAIs in hospitals participating in the Hospital VBP Program. In order to calculate the NHSN measures for use in both the Hospital IQR Program and the Hospital VBP Program, CDC must go through several steps. First, CDC determines each NHSN measure’s number of predicted infections. CDC determines the number of predicted infections using both specific patient care location characteristics (for example, number of days in which a patient in an ICU has a central line) and infection rates that occurred among a standard population (sometimes referred to by CDC as “national baseline” but referred to here as “standard population data”). Finally, for each NHSN measure, CDC calculates the Standardized Infection Ratio (SIR) by comparing a hospital’s observed number of HAIs with the number of HAIs predicted for the hospital, adjusting for several risk factors. For more information about the way NHSN measures are calculated, we refer readers to QualityNet’s Web page on HAI measures, which may be found at:

94 Available at: http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html.
95 Available at: http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html.
96 Available at: http://www.cdc.gov/nhsn/PDFs/Newsletters/NHSN_NL_OCT_2010SE_final.pdf.
As part of routine measure maintenance, CDC is updating the “standard population data” to ensure the NHSN measures’ number of predicted infections reflect the current state of HAIs in the United States.\(^{97}\) Currently, CDC calculates the “standard population data” for the CAUTI measure based on data it collected in CY 2009.\(^{98}\) CDC calculates the “standard population data” for the CLABSI and Colon and Abdominal Hysterectomy SSI measures based on data it collected in 2006 to 2008.\(^{99}\) CDC calculates the “standard population data” for the MRSA bacteremia and CDI measures based on data it collected in 2010 to 2011.\(^{100}\) Beginning in 2015, CDC will collect data in order to update the standard population data for all of these NHSN measures (the CY 2015 standard population data for HAI measures will hereinafter be referred to as “new standard population data”).

Because the Hospital VBP Program calculates improvement points using comparisons between data collected from hospitals in a baseline period and data collected in a performance period, the Hospital VBP Program must treat CDC’s standard population data update differently than other quality programs. We have determined that we cannot equally compare CDC’s “new standard population data” to the “current standard population data” in order to calculate improvement points. If we do not address the CDC’s measure update, we will be unable to compare the baseline and performance

\(^{98}\) Available at: [http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html#b6](http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html#b6).
\(^{99}\) Available at: [http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html#b6](http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html#b6).
\(^{100}\) Available at: [http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html#b6](http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html#b6).
periods for NHSN measures in the FY 2017 and FY 2018 program years. To address the problem, we intend to use the “current standard population data” to calculate performance standards and calculate and publicly report measure scores until the FY 2019 program year, as depicted in the table below. For the FY 2019 program year and subsequent years, the Hospital VBP Program will use the “new standard population data” to calculate performance standards and calculate and publicly report measure scores.

<table>
<thead>
<tr>
<th>CDC’s Standard Population Data in the Hospital VBP Program</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NHSN Measures Baseline Periods</strong></td>
</tr>
<tr>
<td>FY 2017 Program Year*</td>
</tr>
<tr>
<td>Current standard population data</td>
</tr>
<tr>
<td>FY 2018 Program Year*</td>
</tr>
<tr>
<td>Current standard population data</td>
</tr>
<tr>
<td>FY 2019 Program Year**</td>
</tr>
<tr>
<td>New standard population data</td>
</tr>
<tr>
<td>FY 2020 Program Year**</td>
</tr>
<tr>
<td>New standard population data</td>
</tr>
<tr>
<td><strong>NHSN Measures Performance Periods</strong></td>
</tr>
<tr>
<td>Current standard population data</td>
</tr>
<tr>
<td>Current standard population data</td>
</tr>
<tr>
<td>New standard population data</td>
</tr>
<tr>
<td>New standard population data</td>
</tr>
</tbody>
</table>

* CDC will use “current standard population data” to calculate measure data that we will translate into scores on the measures.
** CDC will use “new standard population data” (CY 2015) to calculate measure data that we will translate into scores on the measures.

For a discussion addressing the “new standard population data” in the Hospital IQR Program, we refer readers to sections VIII.A.4.b. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24562) and this final rule.

**Comment:** Several commenters supported CMS’ continuing use of the “current standard population data” to calculate performance standards until the FY 2019 program year because the strategy allows for accurate measurement between baseline and
performance periods without readjusting the data to align with the “new standard population data.” One commenter noted this would help hospitals without an ICU capture more cases and better align with the HAC Reduction Program.

**Response:** We thank the commenters for their support.

**Comment:** One commenter supported the development of a plan to address CDC’s NHSN new standard population data because they believe that the update will reflect significant progress toward elimination of HAIs especially for CLABSI. The commenter also believed that the update of the standard population data will assist in resetting the baseline for CAUTI, which they believe, has been challenging.

**Response:** We thank the commenter for its support.

**Comment:** One commenter supported the proposal to use new standard population data to calculate performance in both the baseline and performance periods, and urges CMS to consider the timing of this change to coincide with similar changes to these measures in the Hospital VBP Program.

**Response:** We thank the commenter for its support.

**Comment:** One commenter disagreed with the policy of using “new standard population data” beginning in the FY 2019 program year because the commenter believed that CMS should assess the impact of CDC’s CY 2015 CAUTI “standard population data” based on substantive changes to surveillance criteria for the CAUTI measure.

Several commenters recommended that if assessment identifies potential problems, then CDC should use CY 2016 as the “standard population data” because it
will be more stable. One commenter requested that CDC publish the differences from year-to-year collection.

**Response:** We appreciate the commenters’ thoughts on stability of the 2015 data. CDC’s new CAUTI definition was developed as a result of a subject matter expert working group comprised of CDC and non-CDC participants who systematically assessed each definitional component. The end result is a new CAUTI definition that is simplified from previous iterations and allows for less subjectivity while optimizing clinical credibility. An assessment of the impact of the definition change on CAUTI incidence was completed as part of the definition development. In addition, the NHSN application provides a technical infrastructure and built in controls on data entry that serve as safeguards against reporting of events that do not meet the new CAUTI definition. For these reasons, CDC is confident that the CAUTI data reported in 2015 will be appropriate to use for a new standard population.

f. Summary of Previously Adopted and Newly Adopted Measures for the FY 2018 Program Year

In summary, for the FY 2018 program, we are adopting the following measure set:

<table>
<thead>
<tr>
<th><strong>FY 2018 Previously Adopted and Newly Adopted Measures</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient and Caregiver-Centered Experience of Care/Care Coordination Domain</strong></td>
</tr>
<tr>
<td>HCAHPS</td>
</tr>
<tr>
<td>CTM-3*</td>
</tr>
<tr>
<td><strong>Clinical Care Domain</strong></td>
</tr>
<tr>
<td>MORT-30-AMI</td>
</tr>
<tr>
<td>MORT-30-HF</td>
</tr>
<tr>
<td>FY 2018 Previously Adopted and Newly Adopted Measures</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>MORT-30-PN</td>
</tr>
<tr>
<td><strong>Safety Domain</strong></td>
</tr>
<tr>
<td>CAUTI</td>
</tr>
<tr>
<td>CLABSI</td>
</tr>
</tbody>
</table>
| Colon and Abdominal Hysterectomy SSI                  | Centers for Disease Control and Prevention Harmonized Procedure Specific Surgical Site Infection Outcome Measure  
  - Colon  
  - Abdominal Hysterectomy |
| MRSA bacteremia                                       | National Healthcare Safety Network Facility-Wide Inpatient Hospital-Onset Methicillin-Resistant *Staphylococcus aureus* Bacteremia Outcome Measure |
| CDI                                                  | National Healthcare Safety Network Facility-Wide Inpatient Hospital-Onset *Clostridium difficile* Infection Outcome Measure |
| PSI-90                                                | Patient Safety for Selected Indicators (Composite) |
| PC-01**                                               | Elective Delivery |
| **Efficiency and Cost Reduction Domain**              |                                        |
| MSPB-1                                                | Payment-Standardized Medicare Spending Per Beneficiary |

*Finalized new measure.
**Finalized to be moved from the Clinical Care—Process subdomain to the Safety domain.

3. Previously Adopted and Newly Adopted Measures for the FY 2019, FY 2021, and Subsequent Program Years

Due to the time necessary to adopt measures, we often adopt policies for the Hospital VBP Program well in advance of the program year for which they will be applicable (for example, 76 FR 26490 through 26547; 76 FR 51653 through 51660; 76 FR 74527 through 74547; 77 FR 53567 through 53614; 78 FR 50676 through 50707; 78 FR 75120 through 75121; 79 FR 50048 through 50087). In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24501 through 24503), we signaled our intent to include
additional data in certain NHSN measures beginning with the FY 2019 program year, proposed to adopt a new measure beginning with the FY 2021 program year, and summarized all previously adopted and newly proposed measures.

a. Intent to Propose in Future Rulemaking to Include Selected Ward (Non-Intensive Care Unit (ICU)) Locations in Certain NHSN Measures Beginning with the FY 2019 Program Year

The Hospital VBP Program uses adult, pediatric, and neonatal intensive care unit (ICU) data to calculate performance standards and measure scores for the CAUTI and CLABSI measures for the FY 2017 and FY 2018 program years (79 FR 50061). In the FY 2014 IPPS/LTCH PPS proposed rule, we proposed under the Hospital IQR Program to expand the collection of CAUTI and CLABSI measures to include several selected ward (non-ICU) locations beginning with events occurring on or after January 1, 2014 (78 FR 27684). In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50787), after consideration of the public comments received, we deferred the implementation date of the CAUTI and CLABSI measure expansion to selected ward (non-ICU) settings for the Hospital IQR Program from January 1, 2014 to January 1, 2015 (78 FR 50787). Selected ward (non-ICU) locations are defined as adult or pediatric medical, surgical, and medical/surgical wards (79 FR 50061; 78 FR 50787).

In the FY 2015 IPPS/LTCH PPS final rule, we signaled our intent to consider using data from selected ward (non-ICU) locations for the Hospital VBP Program, beginning in the FY 2019 program year for purposes of calculating performance standards for the CAUTI and CLABSI measures (79 FR 50061). In the FY 2016
IPPS/LTCH PPS proposed rule (80 FR 24501 through 24502), we stated our intent to propose to include the selected ward (non-ICU) locations in the CAUTI and CLABSI measures beginning with the FY 2019 program year in future rulemaking. We intend to propose to adopt a baseline period of January 1, 2015 through December 31, 2015, and a performance period of January 1, 2017 through December 31, 2017, for the CAUTI and CLABSI measures. This expansion of the CAUTI and CLABSI measures would be consistent with the NQF re-endorsement update to these measures, which allows application of the measures beyond ICUs (78 FR 50787). We believe this expansion of the measures will allow hospitals that do not have ICU locations to use the tools and resources of the NHSN for quality improvement and public reporting efforts (78 FR 50787).

We invited public comment on this plan to accommodate these measures’ expansions in the Hospital VBP Program future rulemaking.

Comment: Several commenters supported CMS’ proposal to include performance data from non-ICU locations in the CLABSI and CAUTI measures starting in FY 2019, including the proposal to use FY 2019 as the first year for the newly revised measures. Several commenters noted that CLABSI and CAUTI measures are important targets for dedicated surveillance and prevention efforts outside the ICU setting. One commenter noted that the inclusion of the selected ward (non-ICU) locations in the Hospital VBP Program would represent a more robust reflection of organizational performance. Another commenter believes this proposal will allow hospitals that do not have ICU locations to use the tools and resources of the NHSN for their quality improvement
efforts. Finally, one commenter noted that more hospitals will be able to submit data and be scored given the expansion. The commenter also commended CMS for waiting to integrate these measures into the Hospital VBP Program until there is a baseline and performance period using the same measure definition to allow for an achievement and improvement score.

Response: We thank the commenters for their support.

Comment: One commenter requested that CMS consider providing selected ward (non-ICU) locations with the mechanisms in the FY 2016 IPPS/LTCH PPS final rule to begin voluntarily collecting data related to the CAUTI and CLABSI measures for purposes of calculating performance standards.

Response: We note that data collection began under the Hospital IQR Program on January 1, 2015 and the first submission deadline to NHSN does not occur until after publication of the FY 2016 IPPS/LTCH PPS final rule. We intend to include performance standards in the FY 2017 IPPS/LTCH PPS proposed and final rules.

Comment: Several commenters urged CMS to carefully review the data submitted to determine its appropriateness for inclusion in the program.

Response: We thank the commenters for their suggestion, and we will take the comments and suggestions into consideration in future rulemaking. We review all the Hospital VBP Program data provided from NHSN, and, in concert with CDC, will conduct appropriate analyses on the data provided.

Comment: One commenter supported CMS’ proposal to include performance data from non-ICU locations in the CLABSI and CAUTI measures, but the commenter
objected to the proposal to postpone the adoption of these NQF-endorsed measures until 2019 feeling that this is too delayed given the extent of morbidity and mortality associated with these infections.

**Response:** We thank the commenter for the suggestion, but note that we cannot adopt the measures earlier than the FY 2019 program year because of statutory and other restrictions on measures entering the program.

**Comment:** One commenter did not support the expansion of CAUTI data collection to non-ICU wards because a subset of patients, for example, spinal cord injury/dysfunction patients, may be in danger of receiving improper care unless they are excluded from the measure. These patients are often hospitalized after trauma and may experience over distension of the bladder and dysenergic uropathy if their bladder management is not performed appropriately. The commenter noted that some hospitals remove the catheter prematurely as a result of the CAUTI measure, often without recognizing spinal cord injury patients as an at-risk population, which can result in improper and unsafe bladder management.

**Response:** We agree that patients with spinal cord injury/dysfunction require careful evaluation for bladder dysfunction and proper emptying practices. However, we do not believe that this is a reason to exclude patients from CAUTI surveillance. Patients with spinal cord injury/dysfunction are at risk of CAUTI, and frequent use of indwelling urinary catheters on a long-term basis places a premium on proper insertion and maintenance practices.
Comment: Some commenters supported CMS’ inclusion of the expanded scope of surveillance and recommended that CMS add detail on how the SIR metric for CAUTI and CLABSI will be calculated and used for public reporting, given that there has been little experience or use of a blend of types of locations into an overall SIR. One commenter recommended that CMS work with CDC’s NHSN subject matter experts to better understand the impact of the expanded scope prior to adoption. One commenter also suggested that CMS improve the risk adjustment for the CLABSI, CAUTI, and CDI.

Response: The SIR is a risk-adjusted summary measure that takes into account the variability of HAI incidence among different patient populations (for example, ICU vs. non-ICU patients). CDC will perform in-depth analyses of the 2015 data to determine an appropriate baseline for the inclusion of non-ICU data in future CLABSI and CAUTI SIRs.

We thank the commenters for their views on our intent to propose to include the selected ward (non-ICU) locations in the CAUTI and CLABSI measures beginning with the FY 2019 program year in future rulemaking.

b. New Measure for the FY 2021 Program Year: Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization (NQF #1893)

Hospital 30-Day, All-Cause, RSMR following COPD Hospitalization (NQF #1893) (MORT-30-COPD) is a risk-adjusted, NQF-endorsed mortality measure monitoring mortality rates following COPD hospitalizations. We adopted this measure in the Hospital IQR Program in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50792).
Initial measure data were posted on Hospital Compare in December 2014 and the full measure specifications are available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

Chronic lower respiratory disease (including COPD) is the third leading cause of death in the United States.\textsuperscript{101} Between 1998 and 2008, the number of patients hospitalized annually for acute exacerbations of COPD increased by approximately 18 percent.\textsuperscript{102, 103, 104} Moreover, COPD is one of the top 20 conditions contributing to Medicare costs.\textsuperscript{105} The median 30-day RSMR following admissions for COPD between July 2010 and June 2013 was 7.8 percent with variation in mortality rates ranging from 5.5 percent to 12.4 percent across over 2,700 hospitals.\textsuperscript{106}

The MAP supported the inclusion of the MORT-30-COPD measure in the Hospital VBP Program as detailed in the “Spreadsheet of MAP 2015 Final Recommendations.”\textsuperscript{107} The MAP noted that the addition of the MORT-30-COPD


\textsuperscript{107} National Quality Forum “Spreadsheet of MAP 2015 Final Recommendations” available at: http://www.qualityforum.org/map/ and “Process and Approach for MAP Pre-Rulemaking Deliberations 2015” found at:
measure would be appropriate as 30-day mortality rate measures for AMI, HF, and PN are already part of the Hospital VBP Program measure set.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24502), we proposed this measure for the Hospital VBP Program based on the MAP recommendation, our adoption of the measure in the Hospital IQR Program and our posting of measure data on Hospital Compare for at least 1 year prior to the start of the performance period. In addition, the MORT-30-COPD measure is appropriate for the Hospital VBP Program because it addresses a high volume, high cost condition, and chronic lower respiratory disease (including COPD) is the third leading cause of mortality in the United States. The measure aligns with the CMS Quality Strategy Goal of Effective Prevention and Treatment. Based on the continued high risk of mortality after COPD hospitalizations, we proposed to add it to the Clinical Care domain for the FY 2021 program year.

We invited public comment on this proposal.

Comment: Several commenters supported the adoption of the MORT-30-COPD measure for the FY 2021 program year because this measure will advance the treatment, management, and care coordination required for COPD hospitalizations, resulting in better outcomes for patients and a reduction in overall costs. One commenter believed this measure will increase incentives for hospitals to better manage COPD for patients after discharge.

Response: We thank the commenters for their support.
Comment: Several commenters requested that CMS consider an earlier adoption of the MORT-30-COPD measure for the FY 2019 program year, with data collection beginning in FY 2017 to align with the Hospital Readmissions Reduction Program requirements.

Response: We are unable to implement the measure in the Hospital VBP Program sooner than the FY 2021 program year because, as we discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24505), we proposed to adopt the measure for a future program year in order to ensure that we can adopt baseline and performance periods of sufficient length for performance scoring purposes. As we stated in the proposed rule (80 FR 24504), we believe a 36-month baseline and performance period is appropriate for the mortality measures when possible. Adopting the MORT-30-COPD measure for the FY 2021 program year also aligns the measurement periods for all the 30-day mortality measures in the program.

Comment: Many commenters did not support CMS’ proposal to adopt the MORT-30-COPD measure. The commenters urged CMS to adjust for sociodemographic status because COPD is a condition sensitive to environmental factors and exacerbations of the condition can be related to the patient’s sociodemographic status.

Commenters expressed concern with the measure’s reliability. The commenters noted that testing results showed only moderate reliability. These commenters recommended that CMS develop a plan to improve or replace the claims-based mortality measures used in the Hospital VBP Program.
One commenter suggested that MORT-30-COPD is not a good measure of a hospital’s evidence-based quality practices for COPD. Another commenter suggested that hospitals will be penalized twice in two different programs. Finally, one commenter noted that the current form of the measure does not address end of life or palliative care, which greatly affects hospitals that specialize in these areas of service.

Response: As we have explained above, while we appreciate these comments and the importance of the role that sociodemographic status plays in the care of patients, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of low sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures. To date, we have found that hospitals that care for large proportions of patients of low sociodemographic status are capable of performing well on our measures (we refer readers to the 2014 Chartbook pages 48-57, 70-73, and 78 at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Downloads/Medicare-Hospital-Quality-Chartbook-2014.pdf).

NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate for each measure. For 2 years, NQF will conduct a trial of a temporary policy change that will allow inclusion of sociodemographic factors in the risk-adjustment approach for some performance
measures. At the conclusion of the trial, NQF will determine whether to make this policy change permanent. Measure developers must submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of socioeconomic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of these reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

While we acknowledge the commenters’ concerns regarding the measure’s reliability, we note that we use the same statistical approach to reliability for the COPD mortality measure that we have established for our other hospital risk-adjusted outcome measures. Reliability is related to sample-size, and we adopted a risk-adjustment modeling methodology that takes into account sample size. Moreover, as stated in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53591) and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50693), we believe that the mortality measures capture important quality data for purposes of the Hospital VBP Program. We believe that the claims-based mortality measures are sufficiently reliable for inclusion in the Hospital VBP Program, and they are NQF-endorsed.

We disagree with the commenter that the COPD mortality measure is not a good measure of evidenced-based quality practices, as high quality care is necessary to achieve
low mortality rates. In regard to the commenter’s concern that the measure does not address end-of-life or palliative care, we note that patients enrolled in hospice any time in the 12 months prior to the index admission, including the first day of the index admission, are excluded from the measure because mortality is not necessarily an adverse outcome or indicator of poor quality care in this population. However, the measure does not exclude patients who transition to hospice or palliative care because such transitions may be the result of quality failures that have led to poor clinical outcomes.

Comment: One commenter noted that the mortality rate is high for patients with COPD, and the commenter encouraged CMS to monitor hospitals to ensure that they do not discourage admission of COPD patients in order to score better on the measure.

Response: We acknowledge the commenter’s concern and recognize that any performance-based payment program may create the potential for unintended consequences. However, we remain committed to monitoring and assessing unintended consequences, such as changes in utilization, and adjusting the program as needed. In order to assess trends in measure performance and healthcare utilization, we continuously analyze our measures, including the MORT-30-COPD measure, and publish our findings annually in the “Medicare Hospital Quality Chartbook” at:


Comment: One commenter urged CMS to use the years between now and FY 2021 to ensure the validity of the proposed measure and ensure that information
attained from using this measure will improve the quality of care for patients prior to moving forward with implementation plans for FY 2021.

Response: We appreciate the commenter’s suggestion, but note that the measure has been tested and validated for the acute inpatient setting. We also note that NQF has endorsed the measure as valid and reliable (NQF # 1893).

After consideration of the public comments we received, we are finalizing the proposal to add MORT-30-COPD to the FY 2021 program year and subsequent years.

c. Summary of Previously Adopted and Newly Adopted Measures for the FY 2019 and FY 2021 and Subsequent Program Years

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50063), we finalized our proposal to adopt the Hospital-Level Risk-Standardized Complication Rate Following Elective Primary THA/TKA measures for the FY 2019 program year and subsequent years. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50063 through 50065), we also finalized our proposal to adopt the PSI-90 measure for the FY 2019 program year and subsequent years.
**FY 2019 Previously Adopted Measures**

<table>
<thead>
<tr>
<th>Clinical Care Domain</th>
<th>Safety Domain</th>
</tr>
</thead>
<tbody>
<tr>
<td>THA/TKA</td>
<td>PSI-90</td>
</tr>
</tbody>
</table>

- **THA/TKA**
  - Hospital-Level Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty/Total Knee Arthroplasty

- **PSI-90**
  - Patient Safety For Selected Indicators (Composite)

In this final rule, we are finalizing our proposal to adopt the MORT-30-COPD measure for the FY 2021 program year and subsequent years.

**FY 2021 Newly Adopted Measure**

<table>
<thead>
<tr>
<th>Clinical Care Domain</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT-30-COPD</td>
</tr>
</tbody>
</table>

- **MORT-30-COPD**
  - Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Chronic Obstructive Pulmonary Disease Hospitalization

4. Possible Measure Topics for Future Program Years

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50066 through 50070), we responded to comments on measures that could potentially be used to expand the Efficiency and Cost Reduction domain in the future. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24503), we again sought public comments on this issue. We indicated that we were interested in expanding the Efficiency and Cost Reduction domain to include a more robust measure set, which may include measures that supplement the MSPB measure with more condition and/or treatment specific episode measures. In the FY 2016 IPPS/LTCH PPS proposed rule, we also encouraged comment on Efficiency and Cost Reduction measures already included in the Hospital IQR Program as well as measures we proposed in section VIII.A.7. of the preamble of the FY 2016 IPPS/LTCH
PPS proposed rule (80 FR 24566 through 24581) for inclusion in the Hospital IQR Program beginning with the FY 2018 payment determination.

**Comment:** We received a number of comments related specifically to the proposed clinical episode-based payment measures themselves.

**Response:** We thank the commenters for their input regarding the four clinical episode-based measures we proposed for the Hospital IQR Program. We have addressed these comments in section VIII.A.7.b. of the preamble of this final rule. We note that we are finalizing three of the four proposed measures: (1) Kidney/UTI Clinical Episode-Based Payment Measure (claims-based); (2) Cellulitis Clinical Episode-Based Payment Measure (claims-based); and (3) Gastrointestinal Hemorrhage Clinical Episode-Based Payment Measure (claims-based) for the Hospital IQR Program, but not beginning with the FY 2018 payment determination as proposed. Instead, we are finalizing these measures beginning with the FY 2019 payment determination and will provide data to hospitals on these measures in confidential hospital-specific reports before the measures are included in the Hospital IQR Program. We refer readers to section VIII.A.7.b. of the preamble of this final rule for further details. In order to include these measures in the Hospital VBP Program in the future, we would have to propose and finalize related policies through future notice and comment rulemaking.

We also received several comments related to the potential future inclusion of the clinical episode-based payment measures in the Hospital VBP Program. We summarize and respond to those comments below.
Comment: Several commenters supported a more granular episode-based payment measure in place of, rather than in addition to, the MSPB-1 measure.

Response: We thank the commenters for their support of the episode-based payment measures. We continue to believe that the MSPB measure provides valuable information about Medicare spending. We would propose any changes to the efficiency domain measure set through future rulemaking.

Comment: One commenter recommended that instead of adding duplicative, condition-specific Efficiency and Cost Reduction measures, CMS should improve the “predictive power” of the existing MSPB-1 measure through stronger risk-adjustment.

Response: We do not believe that the clinical episode-based pending measures are duplicative of the existing MSPB-1 measure. Rather, the measures provide a more complete picture of Medicare spending, in order to allow hospitals to better understand and target their efficiency efforts. The MSPB-1 measure has been endorsed by the NQF. It is considered to be a valid, reliable measure of Medicare spending.

Comment: One commenter did not support CMS’ possible addition of episode-based efficiency measures if it is possible that certain hospitals may be penalized twice if the hospitals have both high procedure costs and a high MSPB-1 rate unless we can ensure that hospitals with a high volume of patients—especially those with complex patients for an episode condition or surgery—are not inappropriately penalized, rewarded, or otherwise scrutinized as a result of performance on overlapping measures. The commenter asked that CMS specify the combination of diagnosis codes and
procedures needed to define clinically relevant services for this episode-based efficiency measure.

**Response:** As we note in section VIII.A.7.b. of the preamble of this final rule, we developed these measures in response to public comment requesting that we develop a more robust efficiency measure set and that we include measures that are inclusive of clinically-related services. While performance on the overall Medicare spending measure may correlate with performance on the clinical episode-based measures, we believe that they will provide valuable additional information.

**Comment:** A few commenters urged CMS to continue exploring additional measures of cost and efficiency for the program, arguing that the value of care provided is a function of both quality and cost, where both elements carry equal weight. One commenter urged us to establish a policy goal and specific plan to incrementally increase the efficiency domain to 50 percent of the TPS as more efficiency measures are developed and added to the program.

**Response:** We thank commenters for their input and we will take it into consideration in future rulemaking.

**Comment:** Commenters suggested reducing the weight of the Efficiency domain during future initial implementation of new episode-based measures until we have adequate experience using the new measures.

**Response:** We thank the commenters for their input regarding the four clinical episode-based measures we proposed for the Hospital IQR Program. We note that we are finalizing three of the four proposed measures: (1) Kidney/UTI Clinical Episode-Based
Payment Measure (claims-based); (2) Cellulitis Clinical Episode-Based Payment Measure (claims-based); and (3) Gastrointestinal Hemorrhage Clinical Episode-Based Payment Measure (claims-based) for the Hospital IQR Program, but not beginning with the FY 2018 payment determination as proposed. Instead, we are finalizing them beginning with the FY 2019 payment determination and will provide data to hospitals on these measures in confidential hospital-specific reports before the measures are included in the Hospital IQR Program. We refer readers to section VIII.A.7.b. of the preamble of this final rule for further details.

Comment: One commenter recommended that CMS explore utilization measures that reflect the appropriateness of service use and intensity in hospitals for inclusion in the Efficiency and Cost Reduction domain.

Response: We thank commenter for this input regarding Efficiency and Cost Reduction domain.

Comment: One commenter supported efficiency measures that are linked closely to hospital services.

Response: We thank commenter for this input regarding the Efficiency and Cost Reduction domain.

Comment: One commenter requested that CMS disaggregate by clinical service line and that CMS provide the number of episodes per service line for certain files on Hospital Compare, including data that shows the breakdown of spending per episode on physician, inpatient, outpatient, durable medical equipment, home care, and nursing home services during admission and post-discharge. The commenter noted that this
information is already provided to individual hospitals, but it would be more useful if hospitals and their agents could compare results among hospitals.

Response: A “Medicare Hospital Spending by Claim” table is currently available on Hospital Compare at: [http://www.medicare.gov/hospitalcompare/Data/spending-per-hospital-patient.html](http://www.medicare.gov/hospitalcompare/Data/spending-per-hospital-patient.html). The table divides each hospital’s average episode spending levels into three time periods: (1) during the 3 days prior to the index admission; (2) during the index admission; and (3) during the 30 days after hospital discharge. Within the time periods, the average episode spending levels are further broken down into seven service types (for example, inpatient or outpatient).

We also received several comments providing thoughts on other new measures for us to add in future program years:

Comment: Several commenters encouraged CMS to develop a measure that captures information about patient transitions to outpatient care, arguing that as hospitals are taking on a greater role in post-acute care coordination, understanding how well efforts to connect patients with external providers and social support systems will contribute to a critical gap.

Response: We thank the commenters for their suggestions, and we will take them into consideration in future rulemaking.

Comment: One commenter encouraged CMS to develop a measure that incorporates healthcare workers in home and community-based services.

Response: We thank the commenter for this suggestion, and we will take it into consideration in future rulemaking.
Comment: One commenter recommended that CMS explore implementing measures of advance care planning because proper end-of-life planning discussions reduce related costs of care. The commenter suggested an advanced care plan in an electronic medical record as a measure.

Response: We thank the commenter for these suggestions, and we will take them into consideration in future rulemaking.

Comment: One commenter suggested that CMS consider CABG and/or Stroke mortality measures.

Response: We thank the commenter for these suggestions, and we will take them into consideration in future rulemaking.

Comment: One commenter recommended that CMS consider including the cost of anesthesia delivery models as a future measure in the Efficiency and Cost Reduction domain because peer-reviewed literature indicates that Certified Registered Nurse Anesthetists (CRNAs) acting as the sole anesthesia provider are the most cost-effective model for anesthesia delivery without any measurable difference in quality of care. This commenter also suggested that CMS consider the costs incurred by (1) an anesthesiologist being “present at induction” and (2) an anesthesiologist being “present at emergence” from anesthesia. The commenter noted that waiting costs due to delayed starts to surgery lead to postponing the surgery schedule, overtime for staff, delaying surgeon’s rounds that affect patient care and discharge of the patient, opportunity costs, and diversion of resources from other patient care. The commenter noted that the literature shows that anesthesiologists fail to comply with federal requirements and noted
lapses in anesthesiologist supervision is common which adds hospital costs while the patient remains anesthetized.

Response: We thank the commenter for these suggestions, and we will take them into consideration in future rulemaking.

Comment: One commenter suggested adding the cost of anesthesia subsidies per anesthetizing location as part of the Efficiency and Cost Reduction domain because a new measure on spending on subsidies information could support hospitals in determining and adopting the most efficient model of anesthesia care based on their needs.

Response: We thank the commenter for this suggestion and we will take it into consideration in future rulemaking.

Comment: One commenter suggested that CMS adopt the STK-04 measure because strokes leave many with new disabilities and increased health risks, and the commenter believed we should prioritize outcome measures related to stroke.

Response: We thank the commenter for this suggestion, and we will take it into consideration in future rulemaking.

Comment: One commenter suggested that CMS prioritize adding NQF #0500, the Severe Sepsis and Septic Shock Management Bundle, to the Hospital VBP Program and noted that it has been added to the Hospital IQR Program for FY 2017.

Response: We thank the commenter for this suggestion, and we will take it into consideration in future rulemaking.
Comment: A few commenters recommended that CMS prioritize implementation of a nutrition or malnutrition-related quality measure set as soon as feasible because malnutrition is a patient safety risk and an independent predictor of negative patient outcomes including mortality, length of hospital stay, readmissions, and hospitalization cost. The commenters noted that malnutrition gap areas include lack of systematic: (1) screening, assessment, and nutrition intervention; (2) execution of nutrition care plans upon admission through discharge; and (3) care coordination to home or other post-acute care sites.

Response: We thank the commenters for their suggestions, and we will take these comments into consideration in future rulemaking.

Comment: A few commenters suggested that CMS adopt the PSI–4: Death among surgical inpatients with serious treatable complications measure and the AMI Payment per Episode measure.

Response: We thank the commenters for their suggestions, and we will take these comments into consideration in future rulemaking.

Comment: One commenter suggested that CMS fill measurement gaps so that a broader perspective of the quality of care rendered can be assessed. Specifically, the commenter suggested that CMS include outcome measures related to medication errors, mental and behavioral health, arthritis, diabetes, chronic kidney disease, depression, Alzheimer’s disease, ischemic heart disease, stroke/transient ischemic attack, breast cancer, colorectal cancer, hip/pelvic fracture, cataract, osteoporosis, glaucoma, and endometrial cancer. The commenter noted that many outcome measures for those
conditions may not yet exist, but the commenter suggested that the recently enacted Medicare Access and CHIP Reauthorization Act provided for measurement development funding, which could be directed toward developing measures to fill in these gaps.

**Response:** We thank the commenter for these suggestions, and we will take these comments into consideration in future rulemaking. We note that the funding for measurement development provided in section 1848(s) of the Act, as added by section 102 of the Medicare Access and CHIP Reauthorization Act of 2015, can only be used to develop measures for use by physicians and other eligible professionals. The statute states that the funding must be used to carry out section 1848(s) of the Act, including, but not limited to, the development, improvement, updating, or expansion of measures in accordance with the final measure development plan that the Secretary is required to post by May 1, 2016. The measures that are developed with this funding must be specifically targeted for application under the quality performance category of the Merit-Based Incentive Payment System under section 1848(q)(2)(B)(i) of the Act or under the qualifying alternative payment model participant provisions under section 1833(z)(2)(C) of the Act.

**Comment:** One commenter recommended that CMS adopt the patient falls with injury or patient falls rate for future program years.

**Response:** We thank the commenter for this suggestion, and we will take these comments into consideration in future rulemaking.

**Comment:** One commenter contended that chart-abstracted process of care measures should not be replaced by parallel eCQM ones in the Hospital VBP Program
until all hospitals are reporting the same measures electronically and an appropriate data validation process is in place.

Response: We thank the commenter for this suggestion, and we will take these comments into consideration in future rulemaking.

Comment: One commenter encouraged the continued harmonization of COPD measures across all programs and supported the development of measures addressing care gaps, specifically management of poorly controlled COPD, so that patients utilize the right therapies and predict risk for exacerbation.

Response: We thank the commenter for these suggestions, and we will take these comments into consideration in future rulemaking.

Comment: One commenter noted that the excess acute care days after hospitalization are explicitly prohibited from inclusion in the Hospital VBP Program because the composite measures for AMI and HF contain a measure of readmissions.

Response: We thank the commenter for this interpretation, and we will take it into consideration in future rulemaking.

Comment: Several commenters did not support adding excess day measures until there is additional analysis. The commenters believed these measures need to be NQF reviewed to ensure they are valid, reliable and feasible as well as appropriate for review in the NQF sociodemographic trial period. The commenters also recommended, rather than adding new measures, CMS should review our multiple bundling initiatives and ensure these measures are aligned.
Response: We thank the commenters for their thoughts, and we will take these comments into consideration in future rulemaking.

5. Previously Adopted and Newly Adopted Baseline and Performance Periods for the FY 2018 Program Year

a. Background

Section 1886(o)(4) of the Act requires the Secretary to establish a performance period for the Hospital VBP Program that begins and ends prior to the beginning of such fiscal year. We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50048 through 50087) for the baseline and performance periods for the Clinical Care—Process, PCCEC/CC, Clinical Care—Outcomes, and Efficiency and Cost Reduction domains that we have adopted for the FY 2017 program year.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50692 through 50694), we adopted baseline and performance periods for the 30-day mortality measures for FY 2017, FY 2018, and FY 2019, and for the PSI-90 measure for FY 2017 and FY 2018 (78 FR 50692 through 50694, 50698 through 50699).

b. Baseline and Performance Periods for the Patient and Caregiver-Centered Experience of Care/Care Coordination Domain for the FY 2018 Program Year

Since the FY 2015 program year, we have adopted a 12-month baseline period and 12-month performance period for measures in the PCCEC/CC domain (77 FR 53598; 78 FR 50692; 79 FR 50072). We continue to believe that a 12-month performance period for the HCAHPS Survey and proposed CTM-3 measure provides us sufficient data on which to score hospital performance, which is an important goal for both us and
stakeholders. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24503), for the FY 2018 program year, we proposed to adopt a 12-month performance period of January 1, 2016 through December 31, 2016 for the PCCEC/CC domain. We also proposed to adopt a corresponding 12-month baseline period of January 1, 2014 through December 31, 2014 for purposes of calculating improvement points and calculating performance standards.

We invited public comment on these proposals.

We did not receive any public comments on these proposals, and we are finalizing the baseline and performance period as proposed.

c. Baseline and Performance Periods for NHSN Measures and PC-01 in the Safety Domain for the FY 2018 Program Year

Since the FY 2016 program year, we have adopted a 12-month baseline period and 12-month performance period for NHSN measures (78 FR 75121; 79 FR 50071). In addition, we adopted the PC-01 measure for the FY 2017 program year with a 12-month baseline period and 12-month performance period (79 FR 50072). We continue to believe that a 12-month performance period provides us with sufficient data on which to score hospital performance on the NHSN measures, as well as the PC-01 measure, in the Safety domain. We also note that 12-month baseline and performance periods are consistent with the reporting periods used for these measures under the Hospital IQR Program. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24503), for the FY 2018 program year, we proposed to adopt a performance period of January 1, 2016 through December 31, 2016 for the NHSN measures and the PC-01
measure in the Safety domain. We also proposed to adopt a corresponding baseline period of January 1, 2014 through December 31, 2014 for purposes of calculating improvement points and calculating performance standards.

We invited public comment on these proposals.

Comment: One commenter supported the proposal to use 12-month baseline and performance periods for the CAUTI, CLABSI, Colon and Abdominal Hysterectomy SSI, CDI, and MRSA bacteremia measures.

Response: We thank the commenter for its support.

After consideration of the public comment we received, we are finalizing the baseline and performance periods as proposed.

d. Baseline and Performance Periods for the Efficiency and Cost Reduction Domain for the FY 2018 Program Year

Since the FY 2016 program year, we have adopted a 12-month baseline period and 12-month performance period for the MSPB-1 measure in the Efficiency and Cost Reduction domain (79 FR 50072; 78 FR 50692). These baseline and performance periods enable us to collect sufficient measure data, while allowing time to calculate and incorporate MSPB-1 measure data into the Hospital VBP Program scores in a timely manner. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24503), for the FY 2018 program year, we proposed to adopt a 12-month performance period of January 1, 2016 through December 31, 2016 for the MSPB-1 measure in the Efficiency and Cost Reduction domain. We also proposed to adopt a corresponding baseline period of January 1, 2014 through December 31, 2014. We note that these proposed baseline
and performance periods align with the baseline and performance periods for the PCCEC/CC domain and all measures in the Safety domain with the exception of PSI-90.

We invited public comment on these proposals.

We did not receive any public comments on these proposals, and we are finalizing the baseline and performance period as proposed.
The table below summarizes the baseline and performance periods for the FY 2018 program year (with previously adopted baseline and performance periods for the mortality and PSI composite (PSI-90) measures noted). We note that we are finalizing our proposal, discussed above, to remove the Clinical Care—Process subdomain from the Hospital VBP Program beginning with the FY 2018 program year. We note further that these baseline and performance periods would continue to align with the PCCEC/CC domain and the Efficiency and Cost Reduction domain, as well as the periods proposed for certain measures in the Safety domain.

<table>
<thead>
<tr>
<th>Domain</th>
<th>Baseline Period</th>
<th>Performance Period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PCCEC/CC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>● CTM-3</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Safety</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Efficiency and Cost Reduction</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Previously adopted baseline and performance periods.
6. Previously Adopted and Newly Adopted Baseline and Performance Periods for Future Program Years

a. Previously Adopted Baseline and Performance Periods for the FY 2019 Program Year

The table below summarizes the previously adopted baseline and performance periods for the Clinical Care domain and PSI-90 measures for the FY 2019 program year.

<table>
<thead>
<tr>
<th>Domain</th>
<th>Baseline Period</th>
<th>Performance Period</th>
</tr>
</thead>
</table>
| Clinical Care         | ● Mortality (MORT-30-AMI, MORT-30-HF, MORT-30-PN)  
● THA/TKA             | ● July 1, 2009 – June 30, 2012  
● January 1, 2015 – June 30, 2017* |

* The table in FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24505) inadvertently stated that this performance period is January 1, 2015 – June 30, 2017. However, as adopted in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50073), this performance period is January 1, 2015 – June 30, 2017.

b. Baseline and Performance Periods for the PSI-90 Measure in the Safety Domain in the FY 2020 Program Year

The table below summarizes the previously adopted and proposed baseline and performance periods for the FY 2020 program year that we proposed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24504). In the FY 2020 program year, we proposed to adopt a performance period of July 1, 2016 to June 30, 2018 for the PSI-90 measure. We proposed a corresponding baseline period of July 1, 2012 to June 30, 2014. This will allow us to collect 24-months of data from hospitals on the PSI-90 measure.
Previously Adopted and Newly Proposed Baseline and Performance Periods for the FY 2020 Program Year

<table>
<thead>
<tr>
<th>Domain</th>
<th>Baseline Period</th>
<th>Performance Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>● Mortality (MORT-30-AMI,</td>
<td>July 1, 2010 – June 30,</td>
<td>July 1, 2015 – June 30,</td>
</tr>
<tr>
<td>MORT-30-HF, MORT-30-PN)*</td>
<td>2013</td>
<td>2018</td>
</tr>
<tr>
<td>● THA/TKA*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSI (PSI-90) Measure</td>
<td>July 1, 2012 – June 30,</td>
<td>July 1, 2016 – June 30,</td>
</tr>
<tr>
<td></td>
<td>2014</td>
<td>2018</td>
</tr>
</tbody>
</table>

* Previously adopted baseline and performance periods

We invited comment on these proposals.

We did not receive any public comments on these proposals, and we are finalizing the baseline and performance period as proposed.

c. Baseline and Performance Periods for the Clinical Care Domain for the FY 2021 Program Year

The table below summarizes the proposed baseline and performance periods for the FY 2021 program year that we proposed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24504 through 24505). In the FY 2014 IPPS/LTCH PPS and FY 2015 IPPS/LTCH PPS final rules (78 FR 50692 through 50694; 79 FR 50072 through 50073), we adopted baseline and performance periods for the three 30-day mortality measures for the FY 2017, FY 2018, FY 2019, and FY 2020 program years. We adopted baseline and performance periods for the THA/TKA measure for the FY 2019 and FY 2020 program years (79 FR 50073). We adopted this policy in light of the length of the performance period that is needed to collect enough measure data for reliable performance scoring.
We continue to believe that we should adopt 36-month baseline and performance periods for the mortality measures when possible to accommodate those durations.

We believe that a similar rationale applies to the new MORT-30-COPD measure that we proposed to adopt for the Clinical Care domain for the FY 2021 program year. Furthermore, we are attempting to align measurement periods under the Hospital VBP Program with measurement periods under the Hospital IQR Program for the 30-day mortality measures. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24504 through 24505), for the FY 2021 program year, we proposed to adopt a 36-month performance period of July 1, 2016 through June 30, 2019 for all mortality measures (the three previously adopted mortality measures, as well as the proposed MORT-30-COPD measure) in the Clinical Care domain. We also proposed to adopt a corresponding baseline period of July 1, 2011 through June 30, 2014. We note that the proposed performance periods will align with the reporting periods for the mortality measures in the Hospital IQR Program for the first time.

For the THA/TKA measure in the FY 2021 program year, we proposed to adopt a 36-month performance period of April 1, 2016 through March 31, 2019. We also proposed to adopt a corresponding baseline period of April 1, 2011 through March 31, 2014. This baseline and performance period will align with the THA/TKA measure reporting period for the Hospital IQR Program and will make reporting more seamless for hospitals.

We invited public comment on these proposals.
We did not receive any public comments on these proposals, and we are finalizing the baseline and performance period as proposed.

7. Performance Standards for the Hospital VBP Program

a. Background

Section 1886(o)(3)(A) of the Act requires the Secretary to establish performance standards for the measures selected under the Hospital VBP Program for a performance period for the applicable fiscal year. The performance standards must include levels of achievement and improvement, as required by section 1886(o)(3)(B) of the Act, and must be established not later than 60 days before the beginning of the performance period for the fiscal year involved, as required by section 1886(o)(3)(C) of the Act. We refer readers to the Hospital Inpatient VBP Program final rule (76 FR 26511 through 26513) for further discussion of achievement and improvement standards under the Hospital VBP Program.

In addition, when establishing the performance standards, section 1886(o)(3)(D) of the Act requires the Secretary to consider appropriate factors, such as: (1) practical experience with the measures, including whether a significant proportion of hospitals failed to meet the performance standard during previous performance periods;
(2) historical performance standards; (3) improvement rates; and (4) the opportunity for continued improvement.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53599 through 53604), we adopted performance standards for the FY 2015 program year and certain FY 2016 program year measures. We also finalized our policy to update performance standards for future program years via notice on the CMS Web site or another publicly available Web site. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50694 through 50698), we revised our regulatory definitions of “achievement threshold” and “benchmark” at 42 CFR 412.160 and adopted performance standards for additional FY 2016 program year measures. We also adopted an interpretation of “achievement threshold” and “benchmark” under 42 CFR 412.160 to exclude the numerical values that result when the performance standards are calculated. We have further adopted a policy under which we may update a measure’s performance standards for a fiscal year once if we identify data issues, calculation errors, or other problems that would significantly affect the displayed performance standards (79 FR 50079). We refer readers to the FY 2014 IPPS/LTCH PPS final rule for the complete set of FY 2016 performance standards (78 FR 50697 through 50698).

b. Technical Updates

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50077 through 50079), we adopted a policy under which we may adopt technical updates to performance standards under the Hospital VBP Program. We adopted this policy by amending the definition of “performance standards” under 42 CFR 412.160 of our regulations to enable us to update
performance standards’ numerical values to incorporate nonsubstantive technical updates made to Hospital VBP Program measures between the time that they are adopted for a particular program year and the time that we actually calculate hospital performance on those measures after the performance period for the program year has concluded. We stated our intent to continue to use rulemaking to adopt substantive updates to measures adopted for the Hospital VBP Program. We stated that examples of changes that we might consider to be substantive include those in which the changes are so significant that the measure is no longer the same measure or when a standard of performance assessed by a measure becomes more stringent. However, we stated our intent to determine what constitutes substantive versus nonsubstantive changes on a case-by-case basis, although we affirmed our intent to be as transparent as possible with stakeholders about any such updates we might adopt.

On January 29, 2015, we announced a technical update to the performance standards that we have adopted for the PSI-90 measure for the FY 2017 program year. The announcement was published on QualityNet and can be viewed at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic percent2FPPage percent2FQnetBasic&cid=1228774624610. The update resulted from a more recent AHRQ Quality Indicator software version becoming available. The FY 2017 performance standards were initially calculated using Version 4.4 of the AHRQ software, and the update allowed us to use Version 4.5a for both the performance standards and hospital results.
For more detailed information on the updates implemented in Version 4.5a, we refer readers to the Log of Coding Updates and revisions, posted on QualityNet, available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic percent2FPage percent2FQnetTier4&cid=1228695355425. For more information on differences between Version 4.5a and previous versions of the software, we refer readers to the AHRQ Web site, available at: http://qualityindicators.ahrq.gov or to the AHRQ help desk directly, available at: QIsupport@ahrq.hhs.gov or (307) 427-1949.

c. Performance Standards for the FY 2018 Program Year

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24506 through 24507), in accordance with our finalized methodology for calculating performance standards (discussed more fully in the Hospital Inpatient VBP Program final rule (76 FR 26511 through 26513)), we proposed to adopt the following additional performance standards for the FY 2018 program year. We noted that the numerical values for the performance standards displayed below represent estimates based on the most recently available data, and we stated that we intended to update the numerical values in the FY 2016 IPPS/LTCH PPS final rule. We note further that the MSPB-1 measure’s performance standards are based on performance period data; therefore, we are unable to provide numerical equivalents for the standards at this time.

We note further that the performance standards for the NHSN measures, the PSI-90 measure, and the MSPB-1 measure are calculated with lower values representing better performance. This distinction is made in contrast to other measures for which higher values indicate better performance. As discussed further in the FY 2014
IPPS/LTCH PPS final rule, the performance standards for the Colon and Abdominal Hysterectomy SSI are computed separately for each procedure stratum, and we will first award achievement and improvement points to each stratum separately, then compute a weighted average of the points awarded to each stratum by predicted infections (78 FR 50684).

We note that the achievement threshold and benchmarks for the PSI-90, MORT-30-AMI, MORT-30-HF, and MORT-30-PN measures have not been updated from the FY 2016 IPPS/LTCH PPS proposed rule because those performance standards were based on the most recent data available. All other measures have been updated to reflect new data in the chart below.

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAUTI*</td>
<td>National Healthcare Safety Network Catheter-associated Urinary Tract Infection Outcome Measure</td>
<td>0.906</td>
<td>0.000</td>
</tr>
<tr>
<td>CLABSI*</td>
<td>National Healthcare Safety Network Central line-associated Bloodstream Infection Outcome Measure</td>
<td>0.369</td>
<td>0.000</td>
</tr>
<tr>
<td>CDI*</td>
<td>National Healthcare Safety Network Facility-wide Inpatient Hospital-onset <em>Clostridium difficile</em> Infection Outcome Measure</td>
<td>0.794</td>
<td>0.002</td>
</tr>
<tr>
<td>MRSA bacteremia*</td>
<td>National Healthcare Safety Network Facility-wide Inpatient Hospital-onset Methicillin-resistant <em>Staphylococcus aureus</em> Bacteremia Outcome Measure</td>
<td>0.767</td>
<td>0.000</td>
</tr>
<tr>
<td>Measure ID</td>
<td>Description</td>
<td>Achievement Threshold</td>
<td>Benchmark</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>PSI-90±*</td>
<td>Patient safety for selected indicators (composite)</td>
<td>0.577321</td>
<td>0.397051</td>
</tr>
</tbody>
</table>
| Colon and Abdominal Hysterectomy SSI* | American College of Surgeons – Centers for Disease Control and Prevention Harmonized Procedure Specific Surgical Site Infection Outcome Measure  
  ● Colon  
  ● Abdominal Hysterectomy  | ● 0.824  
  ● 0.710  | ● 0.000  
  ● 0.000  |
| PC-01     | Elective Delivery                                                           | 0.020408               | 0.000     |

**Clinical Care Measures**

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT-30-AMI±</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Acute Myocardial Infarction Hospitalization *</td>
<td>0.851458*</td>
<td>0.871669*</td>
</tr>
<tr>
<td>MORT-30-HF±</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Heart Failure *</td>
<td>0.881794*</td>
<td>0.903985*</td>
</tr>
<tr>
<td>MORT-30-PN±</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Pneumonia Hospitalization *</td>
<td>0.882986*</td>
<td>0.908124*</td>
</tr>
</tbody>
</table>

**Efficiency and Cost Reduction Measure**

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Median Medicare Spending per Beneficiary ratio across all hospitals during the performance period</th>
<th>Mean of the lowest decile Medicare Spending per Beneficiary ratios across all hospitals during the performance period</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSPB-1*</td>
<td>Payment-Standardized Medicare Spending Per Beneficiary</td>
<td>Median Medicare Spending per Beneficiary ratio across all hospitals during the performance period</td>
<td>Mean of the lowest decile Medicare Spending per Beneficiary ratios across all hospitals during the performance period</td>
</tr>
</tbody>
</table>

* Lower values represent better performance.
* Previously adopted performance standards.

**Comment**: Several commenters noted that hospitals need timelier, more comprehensive and more coordinated data support from CMS, especially for claims.
measures, to better understand measure performance and how performance affects payments (for example, to model payment impacts). These commenters recommended that CMS release quarterly data sets that have sufficient information for hospitals to be able to track their performance on the Hospital VBP Program and understand the details of the program.

Response: We thank the commenters for the suggestions and will take this under advisement as we seek to make our measures more transparent. We currently release data annually, and we offer educational sessions for hospitals to learn more about policies and ask questions. Hospitals can learn more about such events by visiting:

http://www.qualityreportingcenter.com/inpatient/iqr/events/.

Based on public comments in the FY 2015 IPPS/LTCCH PPS final rule, we proposed to adopt the “normalization” approach to scoring the PCCEC/CC domain, which will introduce only minor changes to the original scoring formula, as follows. For purposes of the HCAHPS Base Score, the new CTM-3 dimensions would be calculated in the same manner as the eight existing HCAHPS dimensions. For each of the nine dimensions, Achievement Points (0–10 points) and Improvement Points (0–9 points) would be calculated, the larger of which would be summed across the nine dimensions to create a prenormalized HCAHPS Base Score (0–90 points, as compared to 0–80 points when only eight dimensions were included). The prenormalized HCAHPS Base Score would then be multiplied by 8/9 (0.88888) and rounded according to standard rules (values of 0.5 and higher are rounded up, values below 0.5 are rounded down) to create the normalized HCAHPS Base Score. Each of the nine dimensions would be of equal
weight, so that, as before, the normalized HCAHPS Base Score would range from 0 to 80 points. HCAHPS Consistency Points would then be calculated in the same manner as before and would continue to range from 0 to 20 points. The Consistency Points would now consider scores across all nine of the PCCEC/CC dimensions. The final element of the scoring formula would be the sum of the HCAHPS Base Score and the HCAHPS Consistency Points and will range from 0 to 100 points, as before.

<table>
<thead>
<tr>
<th>Proposed Performance Standards for the FY 2018 Program Year Patient and Caregiver-Centered Experience of Care/Care Coordination Domain</th>
<th>HCAHPS Survey Dimension</th>
<th>Floor (percent)</th>
<th>Achievement Threshold (percent)</th>
<th>Benchmark (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communication with Nurses</td>
<td>55.27</td>
<td>78.52</td>
<td>86.68</td>
<td></td>
</tr>
<tr>
<td>Communication with Doctors</td>
<td>57.39</td>
<td>80.44</td>
<td>88.51</td>
<td></td>
</tr>
<tr>
<td>Responsiveness of Hospital Staff</td>
<td>38.40</td>
<td>65.08</td>
<td>80.35</td>
<td></td>
</tr>
<tr>
<td>Pain Management</td>
<td>52.19</td>
<td>70.20</td>
<td>78.46</td>
<td></td>
</tr>
<tr>
<td>Communication about Medicines</td>
<td>43.43</td>
<td>63.37</td>
<td>73.66</td>
<td></td>
</tr>
<tr>
<td>Hospital Cleanliness &amp; Quietness</td>
<td>40.05</td>
<td>65.60</td>
<td>79.00</td>
<td></td>
</tr>
<tr>
<td>Discharge Information</td>
<td>62.25</td>
<td>86.60</td>
<td>91.63</td>
<td></td>
</tr>
<tr>
<td>3-Item Care Transition*</td>
<td>25.21</td>
<td>51.45</td>
<td>62.44</td>
<td></td>
</tr>
<tr>
<td>Overall Rating of Hospital</td>
<td>37.67</td>
<td>70.23</td>
<td>84.58</td>
<td></td>
</tr>
</tbody>
</table>

* Newly proposed measure

We invited public comments on these proposed performance standards.

Comment: One commenter supported the proposal to adjust the scoring of the HCAHPS measure to reflect the addition of a ninth dimension.

Response: We thank the commenter for its support.
Comment: One commenter expressed concern with how consistency points are calculated for the HCAHPS since such scores can reward both good and bad performance (for example, consistently good or consistently bad). The commenter recommended that CMS consider using a threshold such as 25th percentile, rather than a consistency score.

Response: As previously discussed, consistency points only reward performance that is consistently good across the HCAHPS dimensions. Consistently poor performance does not earn consistency points. Consistency points provide additional incentives beyond achievement and improvement points to improve a hospital’s lowest-performing dimension.

After consideration of the public comments we received, we are finalizing the performance standards for the FY 2018 program year as proposed.

d. Previously Adopted Performance Standards for Certain Measures for the FY 2019 Program Year

As discussed above, we have adopted certain Safety and Clinical Care domain measures for future program years in order to ensure that we can adopt baseline and performance periods of sufficient length for performance scoring purposes. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50062 through 50065), we adopted the PSI-90 measure in the Safety domain and the THA/TKA measure in the Clinical Care domain for the FY 2019 program year. As with the PSI-90, MSPB-1, and NHSN measures described above, the THA/TKA measure is calculated with lower values representing better performance. Therefore, in the FY 2015 IPPS/LTCH PPS final rule
we adopted the following performance standards for the FY 2019 program year

(79 FR 50077):

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI-90*</td>
<td>Patient Safety for Selected Indicators (Composite)</td>
<td>0.853715</td>
<td>0.589462</td>
</tr>
<tr>
<td>MORT-30-AMI</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Acute Myocardial Infarction Hospitalization</td>
<td>0.850671</td>
<td>0.873263</td>
</tr>
<tr>
<td>MORT-30-HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Heart Failure Hospitalization</td>
<td>0.883472</td>
<td>0.908094</td>
</tr>
<tr>
<td>MORT-30-PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Pneumonia Hospitalization</td>
<td>0.882334</td>
<td>0.909460</td>
</tr>
<tr>
<td>THA/TKA*</td>
<td>Hospital-Level Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty and/or Total Knee Arthroplasty</td>
<td>0.032229</td>
<td>0.023178</td>
</tr>
</tbody>
</table>

* Lower values represent better performance.

e. Previously Adopted and Newly Adopted Performance Standards for Certain Measures for the FY 2020 Program Year

As discussed above, we have adopted certain Safety and Clinical Care domain measures for future program years in order to ensure that we can adopt baseline and performance periods of sufficient length for performance scoring purposes. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50063 through 50065), we adopted the
PSI-90 measure in the Safety domain and the THA/TKA measure in the Clinical Care domain for the FY 2019 program year and subsequent years. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50077), we also adopted the following performance standards for the MORT-30-AMI, MORT-30-HF, MORT-30-PN, and THA/TKA measures for the FY 2020 program year. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24507 through 24508), we proposed performance standards for the PSI-90 measure for the FY 2020 program year as set forth below:

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety Domain</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSI-90*</td>
<td>Patient Safety for Selected Indicators (Composite)</td>
<td>0.778761</td>
<td>0.545903</td>
</tr>
<tr>
<td><strong>Clinical Care Domain</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORT-30-AMI*</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Acute Myocardial Infarction Hospitalization</td>
<td>0.853715</td>
<td>0.875869</td>
</tr>
<tr>
<td>MORT-30-HF*</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Heart Failure Hospitalization</td>
<td>0.881090</td>
<td>0.906068</td>
</tr>
<tr>
<td>MORT-30-PN*</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Pneumonia Hospitalization</td>
<td>0.882266</td>
<td>0.909532</td>
</tr>
<tr>
<td>THA/TKA**</td>
<td>Hospital-Level Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty and/or Total Knee Arthroplasty</td>
<td>0.032229</td>
<td>0.023178</td>
</tr>
</tbody>
</table>

* Lower values represent better performance

* Previously adopted performance standards.
We did not receive any public comments on this proposal, and we are finalizing the performance standards as proposed.

f. Performance Standards for Certain Measures for the FY 2021 Program Year

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24508), we proposed the following performance standards for the FY 2021 program year for the Clinical Care domain measures (THA/TKA, MORT-30-HF, MORT-30-AMI, MORT-30-PN, and the proposed MORT-30-COPD):

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT-30-AMI</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Acute Myocardial Hospitalization</td>
<td>0.860355</td>
<td>0.879714</td>
</tr>
<tr>
<td>MORT-30-HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Heart Failure Hospitalization</td>
<td>0.883803</td>
<td>0.906144</td>
</tr>
<tr>
<td>MORT-30-PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Pneumonia Hospitalization</td>
<td>0.886443</td>
<td>0.91067</td>
</tr>
<tr>
<td>MORT-30-COPD</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Chronic Obstructive Pulmonary Disease Hospitalization</td>
<td>0.860355</td>
<td>0.879714</td>
</tr>
<tr>
<td>THA/TKA*</td>
<td>Hospital-Level Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty/ Total Knee Arthroplasty</td>
<td>0.03089</td>
<td>0.022304</td>
</tr>
</tbody>
</table>

* Lower values represent better performance.
We did not receive any public comments on this proposal, and we are finalizing the performance standards as proposed.

8. FY 2018 Program Year Scoring Methodology

a. Domain Weighting for the FY 2018 Program Year for Hospitals That Receive a Score on All Domains

In the FY 2015 IPPS/LTCH PPS final rule, we adopted the following domains and domain weights for the FY 2017 program year for hospitals that receive a score in all newly aligned domains:

<table>
<thead>
<tr>
<th>Domain</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td>20 percent</td>
</tr>
<tr>
<td>Clinical Care</td>
<td>30 percent</td>
</tr>
<tr>
<td>• Clinical Care—Outcomes</td>
<td>25 percent</td>
</tr>
<tr>
<td>• Clinical Care—Process</td>
<td>5 percent</td>
</tr>
<tr>
<td>Efficiency and Cost Reduction</td>
<td>25 percent</td>
</tr>
<tr>
<td>Patient and Caregiver-Centered Experience of Care/Care Coordination</td>
<td>25 percent</td>
</tr>
</tbody>
</table>

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24498 through 24499), for the FY 2018 program year, we proposed to remove two “topped-out” measures from the Clinical Care—Process subdomain. In addition, we proposed to move one measure (PC-01) from the Clinical Care—Process subdomain to the Safety domain and to remove the Clinical Care—Process subdomain (80 FR 24500).

We stated that if these proposals are adopted, the Safety domain will include seven measures for the FY 2018 program year, including PC-01, which would be new to
that domain. Because we proposed to move one measure to the Safety domain, and because we continue to believe that hospitals should be provided strong incentives to perform well on measures of patient safety, we proposed to increase the Safety domain’s weight by 5 percentage points. We proposed to adopt the following FY 2018 program year domain weighting for hospitals receiving a score on all newly-aligned domains:

| Proposed Domain Weights for the FY 2018 Program Year for Hospitals Receiving a Score on All Domains |
|---------------------------------------------------------------|----------|
| Domain                                                        | Weight   |
| Safety                                                        | 25 percent |
| Clinical Care                                                 | 25 percent |
| Efficiency and Cost Reduction                                 | 25 percent |
| Patient and Caregiver-Centered Experience of Care/Care Coordination | 25 percent |

We invited public comments on the proposed domain weights.

**Comment:** Several commenters supported CMS’ proposal to reweight the four measure domains so that each accounts for 25 percent of a hospital’s TPS. One commenter noted that the proposed equal weighting aligns with the CMS Quality Strategy and highlights the importance of each of the domains to understanding the value provided by a hospital caring for a patient.

**Response:** We thank the commenters for their support.

**Comment:** One commenter supported the proposal to increase the Safety domain’s weight by five percent because of the addition of the PC-01 measure and our goal of providing strong incentives to hospitals to perform well on measures of patient safety.

**Response:** We thank the commenter for the support.
Comment: Several commenters supported the proposed updates to the scoring methodology, including the consolidation of the Clinical Care domain because the commenter noted that with our focus on clinical outcomes, it is less necessary for us to differentiate domain weights for outcome versus process measures.

Response: We thank the commenters for their support.

Comment: One commenter recommended that, in order to accurately score hospitals on their performance, CMS consider temporarily reducing the weight assigned to the Clinical Care measurement domain absent a plan to improve or replace the mortality measures due to concerns about their reliability. The commenter also recommended that CMS increase the weight of the Safety domain given that it is comprised of more reliable HAI measures.

Response: The mortality measures in the Hospital VBP Program have been tested for validity and reliability. While we agree that the Hospital VBP Program should encourage providers to improve patient outcomes, we believe that equally weighting the four domains is appropriate for the FY 2018 program year based on the distribution of the measures we are finalizing in this final rule. For the FY 2018 program year, we finalized seven measures for the Safety domain. We finalized three measures for the Clinical Care domain. We finalized one measure for the PCCEC/CC domain. We finalized one measure for the Efficiency and Cost Reduction domain.

Comment: A few commenters proposed that CMS weight the Safety and Clinical Care domains more heavily and give less weight to Efficiency and Cost Reduction and PCCEC/CC domains because hospitals have the greatest ability to effect change in the
Safety and Clinical Care domains. One commenter recommended that the weights for the four domains be set at 20 percent for PCCEC/CC and Efficiency and Cost Reduction and at 30 percent for Safety and Clinical Care.

Response: We believe that hospitals can effect change through the measures in each of the four domains in the Hospital VBP Program. We believe that equally weighting the four domains is appropriate for the FY 2018 program year based on the distribution of the measures we are finalizing in this rule. For the FY 2018 program year, we finalized seven measures for the Safety domain. We finalized three measures for the Clinical Care domain. We finalized one measure for the PCCEC/CC domain. We finalized one measure for the Efficiency and Cost Reduction domain.

Comment: One commenter suggested that CMS raise the proposed weight of the Clinical Care domain to ensure that the focus of the Hospital VBP Program is on improved patient outcomes.

Response: While we agree that the Hospital VBP Program should encourage providers to improve patient outcomes, we believe that equally weighting the four domains is appropriate for the FY 2018 program year based on the distribution of the measures we are finalizing in this final rule. For the FY 2018 program year, we finalized seven measures for the Safety domain. We finalized three measures for the Clinical Care domain. We finalized one measure for the PCCEC/CC domain. We finalized one measure for the Efficiency and Cost Reduction domain.

Comment: Several commenters recommended other scoring options such as scoring statistical outliers differently compared to those that are clustered around the
mean or lowering the achievement threshold so that hospitals have greater potential to attain achievement points. One commenter proposed that CMS acknowledge that maximum achievement points are not possible for all outcome measures and that CMS should review how these measures are scored in the future.

Response: We thank commenters for their recommendation with regard to the statistical outliers, and we will take it into consideration for future rulemaking. We disagree with the commenter’s assertion that maximum achievement points are not possible for all outcome measures. We refer the commenter to the Hospital Inpatient VBP Program final rule (76 FR 26514) where we adopted a methodology for scoring outcome measures. We note that if a hospital’s performance on an outcome measure during a performance period is greater than or equal to the benchmark, the hospital receives the maximum 10 achievement points. While we acknowledge the commenter’s concerns regarding the potential to achieve maximum achievement points, we also note that the benchmark is intended to represent a level of excellent performance to which hospitals generally should aspire.

Comment: A few commenters expressed concern that the scoring methodology could allow hospitals that achieve low cost care at low quality to also receive incentive payments, or at least not be penalized, because there is no penalty component to providing poor quality care. One commenter suggested that CMS assist poor performing hospitals by helping them identify how to make appropriate changes for positive results. The commenter also urged CMS to ensure that hospitals are unable to mask poor care for some patient populations while providing high quality care to others.
Response: We acknowledge the commenters’ concerns and encourage all hospitals unsure of how to improve their performance, on any measure finalized for the Hospital VBP Program, to utilize the quality improvement resources that CMS, AHRQ, and CDC have made available to assist hospitals with improvement (QIOs, QI toolkits, PSOs, and NHSN State-based prevention initiatives). We also offer an improvement Webinar series where hospitals with high levels of achievement share their path to improvement. We encourage stakeholders to subscribe to our listserv titled “Hospital Inpatient Value-Based Purchasing (HVBP) and Improvement” to receive notification of scheduled events. 

https://www.qualitynet.org/dcs/ContentServer?pagename=QnetPublic/ListServe/Register

Comment: A few commenters did not support the weight given to the Efficiency and Cost Reduction domain, which consists of just the MSPB-1 measure because they believed that this weight was disproportionately heavy. One commenter noted that hospitals are unable to monitor their own performance. Another commenter believed that measuring Medicare payments will not lead to quality improvements.

Response: As we stated in the FY 2014 IPPS/LTCH PPS final rule (79 FR 50048 through 50087), we believe we have appropriately balanced our desire to provide strong incentives for hospitals to consider the cost and the quality of the care that they provide to Medicare beneficiaries and to all patients by assigning the Efficiency and Cost Reduction domain to 25 percent of the TPS. We continue to believe it merits significant domain weighting in order to ensure that hospitals monitor the costs of the care they provide to Medicare beneficiaries during the inpatient hospitalization and are involved in the
coordination of beneficiaries’ care immediately prior to a hospitalization and post-discharge.

With regard to the concern that the domain is comprised of only one measure, we acknowledge the potential for building a more robust efficiency measure set, as we stated in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53585 through 53586) and FY 2014 IPPS/LTCH PPS final rule (79 FR 50048 through 50087). In the FY 2015 IPPS/LTCH PPS rulemaking (79 FR 28122 through 28224; 79 FR 50066 through 50070), we sought comment on measures that could potentially be used to expand the Efficiency and Cost Reduction domain in the future. We also again solicited and received public comments on how we might pursue that goal in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24503). In the interim, we continue to believe that increased emphasis on efficiency is an important goal for the Hospital VBP Program, and that the efficiency domain weight should remain at 25 percent accordingly. However, we thank the commenters for their thoughts and intend to continue examining domain weighting and will consider revisiting this issue in the future.

Comment: Some commenters did not support CMS’ proposal to adopt equal weighting across all four domains because of the overlap of measures in the Hospital VBP Program and other reporting programs.

Response: While we acknowledge that there is some overlap in quality measures between the Hospital VBP Program and the HAC Reduction Program, we note that these measures cover topics of critical importance to quality improvement and patient safety in the inpatient hospital setting. We selected these quality measures because we believe that
HAC measures comprise some of the most critical patient safety areas. These measures track infections that could cause significant health risks to Medicare beneficiaries, and we believe it is appropriate to provide incentives for hospitals to avoid them under more than one program.

We further stress that the HAC Reduction Program and the Hospital VBP Program are separate programs with different purposes and policy goals. The HAC Reduction Program reduces payments to hospitals for excess hospital acquired conditions to increase patient safety in hospitals. On the other hand, the Hospital VBP Program is an incentive program that redistributes a portion of the Medicare payments made to hospitals based on their performance on various measures. Therefore, although the measures exist in more than one program, the measures are used and calculated for very distinct purposes. Accordingly, we believe that the critical importance of these measures to patient safety warrants their inclusion in both programs. We will, in the future, continue to monitor the HAC Reduction Program and Hospital VBP Program and analyze the impact of our measures selection, including any unintended consequences with having a measure in more than one program, and will revise the measure set in one or both programs if needed.

After consideration of the public comments we received, we are finalizing the domain weights as proposed.
b. Domain Weighting for the FY 2018 Program Year for Hospitals Receiving Scores on Fewer than Four Domains

In prior program years, we finalized a policy that hospitals must have received domain scores on all finalized domains in order to receive a TPS. However, because the Hospital VBP Program has evolved from its initial two domains to an expanded measure set with additional domains, we considered whether it was appropriate to continue this policy.

Therefore, in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53606 through 53607), we finalized our proposal that, for the FY 2015 program year and subsequent years, hospitals with sufficient data to receive at least two out of the four domain scores that existed for the FY 2015 program year (that is, sufficient cases and measures to receive a domain score on at least two domains) will receive a TPS. We also finalized our proposal that, for hospitals with at least two domain scores, TPSs would be reweighted proportionately to the scored domains to ensure that the TPS is still scored out of a possible 100 points and that the relative weights for the scored domains remain equivalent to the weighting which occurs when there are scores in all four domains. We believe that this approach allows us to include relatively more hospitals in the Hospital VBP Program while continuing to focus on reliably scoring hospitals on their quality measure performance.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50701 through 50702), we continued this approach for the FY 2016 program year and subsequent program years for purposes of eligibility for the program.
In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50084 through 50085), we adopted a policy that, for the FY 2017 program year and subsequent years, hospitals must receive domain scores on at least three quality domains in order to receive a TPS. We stated our belief that, by adopting this policy, we will continue to allow as many hospitals as possible to participate in the program while ensuring that reliable TPSs result. We also finalized a policy that hospitals with sufficient data on at least three of four domains for FY 2017 will have their TPSs proportionately reweighted. Finally, in the FY 2015 IPPS/LTCH PPS final rule, we adopted case minimums for the FY 2016 program year and subsequent years (79 FR 50085 through 50086).

Under these policies, in order to receive a TPS for the FY 2018 program year:

- Hospitals must meet the requirements to receive an HCAHPS Survey measure score in order to receive a PCCEC/CC domain score. Hospitals must report a minimum number of 100 HCAHPS surveys for a hospital to receive a PCCEC/CC domain score (76 FR 26530).

- Hospitals must meet the requirements to receive a MSPB-1 measure score in order to receive an Efficiency and Cost Reduction domain score. Hospitals must report a minimum number of 25 cases for the MSPB-1 measure (77 FR 53609 through 53610).

- Hospitals must receive a minimum of two measure scores within the Clinical Care domain. Hospitals must report a minimum number of 25 cases for each of the mortality measures (77 FR 53609 through 53610).

- Hospitals must receive a minimum of three measure scores within the Safety domain.
Hospitals must report a minimum of three cases for any underlying indicator for the PSI-90 measure based on AHRQ’s measure methodology (77 FR 53608 through 53609).

Hospitals must report a minimum of one predicted infection for NHSN-based surveillance measures based on CDC’s minimum case criteria (77 FR 53608 through 53609).

Hospitals must report a minimum of 10 cases for the PC-01 measure (76 FR 26530).

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24509), we did not propose any changes to the minimum numbers of cases and measures that we have adopted above. However, because we proposed to remove the Clinical Care—Process subdomain from the Hospital VBP Program effective with the FY 2018 program year, we considered whether we should revisit our finalized requirement that hospitals must receive scores on at least three domains in order to receive a TPS. However, we continue to believe that this requirement appropriately balances our desire to enable as many hospitals as possible to participate in the Hospital VBP Program and the need for TPSs to be sufficiently reliable to provide meaningful distinctions between hospitals’ performance on quality measures. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24509), we did not propose to change this requirement at that time. We welcomed public comments on whether we should consider adopting a different policy on this topic. We indicated that we will continue to proportionately reweight hospitals’ TPSs when they have sufficient data on only three domains.
We did not receive any public comments on this issue.
G. Changes to the Hospital-Acquired Condition (HAC) Reduction Program

1. Background

We refer readers to section V.I.1.a. of the FY 2014 IPPS/LTCH PPS final rule (78 FR 50707 through 50708) for a general overview of the HAC Reduction Program.

2. Statutory Basis for the HAC Reduction Program

Section 3008 of the Affordable Care Act added section 1886(p) to the Act to provide an incentive for certain hospitals to reduce the incidence of HACs. Section 1886(p) of the Act requires the Secretary to make an adjustment to payments to “applicable hospitals” effective beginning on October 1, 2014, and for subsequent program years. Section 1886(p)(1) of the Act sets forth the requirements by which payments to “applicable hospitals” will be adjusted to account for HACs with respect to discharges occurring during FY 2015 or later. For hospitals with HAC scores in the top quartile relative to other applicable hospitals for a given fiscal year, the amount of Medicare payment is reduced to 99 percent of the amount of payment that would otherwise apply to discharges under section 1886(d) or 1814(b)(3) of the Act, as applicable. Section 1886(p)(2)(A) of the Act defines “applicable hospitals” as subsection (d) hospitals that meet certain criteria. Section 1886(p)(2)(B)(i) of the Act defines these criteria and specifies that the payment adjustment would apply to an applicable hospital that ranks in the top quartile (25 percent) of all subsection (d) hospitals, relative to the national average, of conditions acquired during the applicable period, as determined by the Secretary. Section 1886(p)(2)(B)(ii) of the Act requires the Secretary to establish and apply a risk-adjustment methodology in calculating HAC scores for each hospital.
Sections 1886(p)(3) and (p)(4) of the Act define “hospital-acquired conditions” and “applicable period,” respectively. The term “hospital-acquired condition” means “a condition identified in subsection 1886(d)(4)(D)(iv) of the Act and any other condition determined appropriate by the Secretary that an individual acquires during a stay in an applicable hospital, as determined by the Secretary.” The term “applicable period” means, with respect to a fiscal year, a period specified by the Secretary.

Section 1886(p)(5) of the Act requires that, prior to FY 2015 and each subsequent fiscal year, the Secretary provide confidential reports to each applicable hospital with respect to the HAC Reduction Program scores for the applicable period, to give the hospitals an opportunity to review and correct the data. Section 1886(p)(6)(A) of the Act sets forth the reporting requirements by which the Secretary would make information available to the public regarding HACs for each applicable hospital. Section 1886(p)(6)(B) of the Act requires the Secretary to ensure that an applicable hospital has the opportunity to review, submit corrections, and for the information to be made public with respect to the HAC scores of the applicable hospital prior to such information being made public. Section 1886(p)(6)(C) of the Act requires that, once corrected, the HAC scores be posted on the Hospital Compare Web site (http://www.medicare.gov/hospitalcompare/search.html) in an easily understandable format.

Section 1886(p)(7) of the Act limits administrative and judicial review of certain determinations made pursuant to section 1886(p) of the Act. These determinations include: what qualifies as an applicable hospital; the specifications of a HAC; the
Secretary’s determination of the “applicable period”; the provision of confidential reports submitted to the applicable hospital; and the information publicly reported on the Hospital Compare Web site.

3. Overview of Previous HAC Reduction Program Rulemaking

For further description of our policies for the HAC Reduction Program, we refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50707 through 50729) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50087 through 50104). These policies describe the general framework for implementation of the HAC Reduction Program, including: (a) the relevant definitions applicable to the program; (b) the payment adjustment under the program; (c) the measure selection and conditions for the program, including a risk-adjustment and scoring methodology; (d) performance scoring; (e) the process for making hospital-specific performance information available to the public, including the opportunity for a hospital to review the information and submit corrections; and (f) limitation of administrative and judicial review.

We have also codified certain requirements of the HAC Reduction Program at 42 CFR 412.170 through 412.172.

4. Implementation of the HAC Reduction Program for FY 2016

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24509 through 24514), we did not propose any changes to the above described policies for the implementation of the HAC Reduction Program for FY 2016. However, we remind readers that, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50101 through 50102), we finalized the following measures for use in the FY 2016 program: AHRQ PSI-90 Composite and CDC Central
Line-Associated Bloodstream Infection (CLABSI), Catheter-Associated Urinary Tract Infection (CAUTI), and Colon and Abdominal Hysterectomy Surgical Site Infection (SSI). In the FY 2016 IPPS/LTCH PPS proposed rule, we did not propose to add or remove any measures for FY 2016.

We provided an update on NQF proceedings for three of the measures previously finalized for the FY 2016 program: PSI–90 Composite; CLABSI; and CAUTI. For FY 2016, we are retaining the AHRQ PSI-90 Composite measure (in Domain 1) that we adopted in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50717). As we noted in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50090), the AHRQ PSI-90 Composite measure is undergoing NQF maintenance review. At the time of development of this final rule, the PSI-90 Composite measure consists of eight component indicators: PSI-3 Pressure ulcer rate; PSI-6 Iatrogenic pneumothorax rate; PSI-7 Central venous catheter related blood stream infections rate; PSI-8 Postoperative hip fracture rate; PSI-12 Perioperative pulmonary embolism or Deep vein thrombosis rate; PSI-13 Postoperative sepsis rate; PSI-14 Postoperative wound dehiscence rate; and PSI-15 Accidental puncture or laceration rate.

As part of the NQF maintenance review process, AHRQ is considering revisions to the composite weighting system as well as the addition of PSI-9 Perioperative hemorrhage rate, PSI-10 Postoperative physiologic and metabolic derangement rate, and PSI-11 Postoperative respiratory failure rate measures, or a combination of these three measures, to the PSI-90 Composite measure. We consider the potential inclusion of additional component measures in the PSI-90 Composite measure to be a significant
change to the measure and, if that occurs, we would engage in notice-and-comment rulemaking prior to requiring the reporting of the revised composite for the HAC Reduction Program. At the time of development of this final rule, the AHRQ PSI-90 Composite measure is continuing to undergo NQF maintenance review. No changes have been finalized. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24510), we did not propose any changes to this measure.

Similarly, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50090), we noted that the CDC NHSN CAUTI and CLABSI measures in Domain 2 that we adopted in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50717) for inclusion in FYs 2015, 2016, and 2017 were undergoing NQF maintenance review. We stated in the FY 2015 IPPS/LTCH PPS final rule that if there are significant changes to these measures, we would engage in notice-and-comment rulemaking prior to requiring the reporting of the revised measures. These measures have now completed the NQF maintenance review process, and modified versions of the measures were reendorsed by NQF on November 10, 2014.\textsuperscript{108} We note that reendorsed versions of the CDC NHSN CLABSI and CAUTI measures included a new statistical option for calculating the measure result, the Adjusted Ranking Metric (ARM), in addition to the standardized infection ratio (SIR) statistical option. For FY 2016, we will continue use of the CDC NHSN CLABSI and CAUTI measures as previously finalized for the program with use of the SIR. We will be working with CDC in the future to determine if the newly available ARM would be appropriate for use in the HAC Reduction Program. If we determine at a later time that the ARM is appropriate for

\textsuperscript{108}National Quality Forum. Measures search. Available at: \url{http://www.qualityforum.org/QPS/MeasureDetails.aspx?standardID=1122&print=0&entityTypeID=1} and \url{http://www.qualityforum.org/QPS/MeasureDetails.aspx?standardID=1121&print=0&entityTypeID=1}.
use in the HAC Reduction Program and provides an advantage to the existing measure result (the SIR), we would propose this change in notice-and-comment rulemaking.

We noted in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24511) that we anticipated providing hospitals with their confidential hospital-specific reports and discharge level information used in the calculation of their FY 2016 Total HAC Score in late summer 2015 via the *QualityNet Secure Portal*. In order to have access to their hospital-specific reports, hospitals must register for a *QualityNet Secure Portal* account. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24511), we did not propose to make any changes to the review and correction policies for FY 2016. Hospitals have a period of 30 days after the information is posted to the *QualityNet Secure Portal* to review and submit corrections for the calculation of their HAC Reduction Program measure scores, domain scores, and Total HAC Score for the fiscal year.

**Comment:** Some commenters supported the HAC Reduction Program because they believe it serves as a mechanism against preventable and adverse events and effectively promotes improvement in hospitals.

**Response:** We appreciate the commenters’ support. We are committed to the reduction of HACs, which are important markers of quality of care and whose reduction can possibly influence patient outcomes and the cost of care.

**Comment:** Some commenters expressed concerns about the threshold levels for penalties and argued that the program overwhelmingly and disproportionately penalizes the nation’s major teaching hospitals. The commenters stated that hospitals are identified

---

as poor performers due to limitations in the scoring methodology, data collection, risk adjustment, and size of teaching facilities, rather than to true differences in the quality of care. These commenters noted that hospitals that have instituted rigorous programs to identify and treat infections are at a disadvantage when compared to those with less comprehensive quality programs. The commenters suggested that CMS explore measure performance within specific hospital peer cohorts to allow hospitals to be compared based on similar characteristics and risk profiles.

Response: We acknowledge the commenters’ concerns. We note that the intent of the HAC Reduction Program is to encourage all hospitals to reduce the incidence of HACs, and that there is room for improvement in the incidence of HACs, regardless of the institution or hospital. The measures adopted in the HAC Reduction Program, which are risk-adjusted to ensure that hospitals serving a large proportion of sicker patients will not be penalized unfairly, target important quality improvement areas. Endorsement by the NQF and support by the NQF MAP also are taken into account in deciding which measures to adopt. All of the measures finalized for inclusion in the HAC Reduction Program are NQF-endorsed and were recommended for inclusion in the program by the NQF MAP. We believe that the HAC Reduction Program encourages improvement in patient safety over the long term for all hospitals. We will continue to monitor the HAC Reduction Program and take the commenters’ concerns under consideration as we strive to improve the program.

Comment: Some commenters urged CMS to use administrative authority under section 1886(d)(5)(I)(i) of the Act to limit the HAC penalty to the base operating DRG
payment only, which they believed would be consistent with Congressional intent and with the Hospital VBP Program and the Hospital Readmissions Reduction Program. The commenters noted that, by restricting the penalty to the base operating DRG payment only, CMS could ensure consistency across our value-based purchasing programs and reduce provider confusion.

Response: We did not propose to change the application of the payment adjustment that we finalized in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50711). As we discussed in that rule, the statutory requirements for the HAC Reduction Program payment adjustment differ from those for the Hospital VBP Program and the Hospital Readmissions Reduction Program. In accordance with sections 1886(o)(7)(A) and 1886(o)(7)(B) of the Act, the Hospital VBP Program applies adjustments to the base operating DRG payment amount, which is defined at section 1886(o)(7)(D) of the Act to exclude certain payments under subsection (d). Similarly, in accordance with section 1886(q)(1) of the Act, the Hospital Readmissions Reduction Program adjustment is applied to the base operating DRG payment amount, which is defined at section 1886(q)(2) of the Act to exclude certain payments under subsection (d).

For the HAC Reduction Program, no such statutory exclusion exists and section 1886(p)(1) of the Act states that the payment for applicable hospitals shall be equal to 99 percent of the amount of payment that would otherwise apply. Therefore, the HAC Reduction Program payment adjustment will continue to be applied after the application of the other program adjustments, including add-on payments consisting of outliers, DSH, uncompensated care, and IME. We refer readers to the FY 2015 IPPS/LTCH PPS
final rule (78 FR 50088) for additional information on the HAC Reduction Program’s payment adjustment.

Comment: Some commenters suggested that CMS use the Adjusted Ranking Metric (ARM) option for calculating the measure results for the CDC NHSN CLABSI and CAUTI measures. The ARM is a summary measure calculation used to rank facilities and accounts for differences in the amount of exposure volume (that is, patient months, patient days, or device days) or opportunity for healthcare-associated infection among a group of patients in a given facility, as well as unmeasured variation across facilities. The commenters stated this would allow for an equal weighting between hospitals with low exposure volumes and hospitals with high exposure volumes.

Response: We thank commenters for this suggestion. We will be working with CDC in the future to determine if the newly available ARM would be appropriate for use in the HAC Reduction Program. If we determine at a later time that the ARM is appropriate for use in the HAC Reduction Program and provides an advantage to the existing measure result (the SIR), we would propose this change in notice-and-comment rulemaking.

Comment: Some commenters suggested that CMS institute appropriate sociodemographic status (SDS) adjustments for hospitals serving vulnerable patient populations.

Response: While we appreciate these comments and the importance of the role that sociodemographic status plays in the care of patients, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of low
sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures.

NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate for each measure. For 2 years, NQF will conduct a trial of a temporary policy change that will allow inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will determine whether to make this policy change permanent. Measure developers must submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk-adjustment model.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of socioeconomic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of these ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

Comment: Numerous commenters expressed concerns about overlap in quality measures between the Hospital VBP Program and the HAC Reduction Program. The commenters argued that this overlap creates the possibility of double penalties for some
hospitals, while assessing disparate scores on the same measures for other hospitals. The commenters suggested that CMS eliminate the measure overlap between the programs.

Response: As we stated in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50056), we acknowledge that there is some overlap in quality measures between the Hospital VBP Program and the HAC Reduction Program. While we are aware that commenters object to scoring hospitals on certain measures under both programs, we note that these measures cover topics of critical importance to quality improvement in the inpatient hospital setting and to patient safety. We selected these quality measures because we believe that HAC measures comprise some of the most critical patient safety areas. These measures track infections that could cause significant health risks to Medicare beneficiaries, and we believe it is appropriate to provide incentives for hospitals to avoid them under more than one program. Patient safety is a CMS priority and we believe justifies the use of the measures in both programs.

We further note that the HAC Reduction Program and the Hospital VBP Program are separate programs with different purposes and policy goals. The HAC Reduction Program is a program that reduces payments to hospitals for excess HACs to increase patient safety in hospitals. On the other hand, the Hospital VBP Program is an incentive program that redistributes a portion of the Medicare payments made to hospitals based on their performance on various measures. Therefore, although the measures exist in more than one program, the measures are used and calculated for very distinct purposes. Accordingly, we believe that the critical importance of these measures to patient safety warrants their inclusion in both programs. We will, in the future, monitor the HAC
Reduction Program and the Hospital VBP Program and analyze the impact of our measures selection, including any unintended consequences with having a measure in more than one program, and will revise the measure set in one or both programs if warranted.

Comment: Numerous commenters raised concerns about the current inclusion of the PSI-90 Composite measure in the HAC Reduction Program. The commenters argued that a number of the measures in the PSI-90 Composite are rare events and do not meet the high-volume requirement for measures in the HAC Reduction Program. The commenters suggested that CMS only include measures that accurately gauge quality and are not inherently skewed against teaching hospitals, large hospitals, and hospitals that provide care to vulnerable populations. The commenters suggested that CMS review alternatives to the PSI-90 Composite, given the concerns raised by the NQF committee and the resulting nonendorsement of the measure during the maintenance review process last year. The commenters noted that this is a composite measure and it would be more informative for consumers to utilize separate public safety measures.

Response: We would like to clarify the status of the PSI–90 Composite measure with regard to NQF endorsement; the PSI-90 Composite measure has not lost NQF endorsement but still remains under maintenance review. As part of the routine NQF measure maintenance process, the Patient Safety Committee expressed concerns about the weighting of the PSI–90 measure components and requested to see additional measure information related to reweighting of the PSI–90 Composite measure with the three additional components (PSI–9, PSI 10, and PSI–11) before deciding if it would
recommend continued endorsement of the measure. AHRQ has submitted the requested data for the NQF Patient Safety Committee’s consideration. In regard to commenters’ concerns regarding the validity of the PSI-90 Composite measure, we note that NQF has previously endorsed the PSI-90 Composite as a valid measure (NQF #0531). We continue to believe the PSI-90 Composite is an important measure of patient safety. Experts agree that this measure is scientifically rigorous. In regard to the administrative data elements of the PSI-90 Composite measure, we note that there are previously conducted validation studies that validate the relationship between administrative claims data and medical records. We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50091) for a further discussion of the validation of the relationship between administrative claims data and medical records.

Comment: One commenter argued the current PSI-90 Composite measure components have been demonstrated to have low measure validity and rely heavily on administrative data elements. The commenter noted that some codes, like sepsis, have a wide variation in the documentation and assignment of the diagnosis and that, by manipulating the diagnosis, it is possible to change the performance rates of this measure without actually affecting the care of the patient. The commenter recommended that CMS implement a policy to improve the validity of these claim-based measures. Specifically, the commenter proposed that the policy should:

- Require hospitals to make an annual attestation that they are explicitly following specific coding and documentation practices, as outlined by professional organizations such as the Association for Clinical Documentation Improvement
Specialists (ACDIS) and American Health Information Management Association (AHIMA);

- Release joint consensus statements in collaboration with AHIMA, ACDIS, and Coding Clinics to provide clarity to hospitals around codes that will include or exclude a case from claims-based measures;
- Require that hospitals maintain a record of codes that are changed as a result of internal coding reviews to provide a record for coding and documentation audits; and
- Conduct random and routine audits of these documentation and coding practices at the hospital level.

Response: We have previously addressed the commenters’ specific concerns regarding validity and coding issues of the PSI–90 Composite measure, and we refer readers to our responses to these comments in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50715). We acknowledge the commenters’ continuing concerns and will continue to monitor the use of this measure in the HAC Reduction Program.

Comment: Some commenters supported the addition of the PSI-11, Postoperative Respiratory Failure Rate measure component, pending testing. The commenters noted that postoperative respiratory failure is a condition for which actionable guidelines exist, with evidence-based screening criteria to determine what individuals are at risk. However, the commenters disagreed with the inclusion of both PSI-9, Perioperative Hemorrhage Rate and PSI-10, Postoperative Physiologic and Metabolic Derangement Rate. One commenter noted its experience with high false positive rates for both
measures. This commenter cited complaints from physicians due to unclear coding criteria, resulting in the code being used too frequently and inconsistently.

**Response:** We appreciate commenters’ input and acknowledge their concerns. We are aware that NQF is reviewing the PSI-90 Composite measure with three additional components (PSI-9, PSI-10, and PSI-11), as part of the routine measure maintenance process. We will take NQF’s decision on continuing endorsement into consideration when evaluating whether the measure remains appropriate for the HAC Reduction Program. In regard to commenters’ concerns regarding the validity of the PSI-90 Composite measure, we note that NQF has previously endorsed the PSI-90 Composite as a valid measure (NQF #0531). We continue to believe the PSI-90 Composite is an important measure of patient safety.

**Comment:** Several commenters noted that perioperative hemorrhage is a high-volume condition and that up to 5 percent of patients who undergo cardiac surgery require additional surgery to control bleeding. The commenters also noted that postoperative respiratory failure is also a high-cost condition. The commenters stated that perioperative hemorrhage and postoperative respiratory failure are preventable conditions by the use of evidence-based guidelines. The commenters suggested that, pending NQF endorsement of the addition of these measures, CMS expeditiously incorporate these measures through rulemaking. The commenters also supported CMS’ commitment to pursue the changes to the HAC Reduction Program through rulemaking.

**Response:** We appreciate the commenters’ input and will take this feedback into consideration in future measure selection and rulemaking. We emphasize that improving
patient safety is our primary objective for the HAC Reduction Program. AHRQ’s Quality Indicator program continually updates and refines measures to provide the best possible quality indicators to the public. All of the AHRQ quality indicators go through a rigorous testing process prior to changes being made to the indicators. We note that NQF policy and guidance generally has favored risk adjustment approaches over exclusion of high-risk patients, when possible, to optimize the generalizability and value of quality measures. Suggestions regarding potential PSI measure revisions can be made directly to QIsupport@ahrq.hhs.gov.

Comment: One commenter expressed concerns with the unintended consequence of the CDC Surgical Site Infection (SSI) measure. The commenter noted that this measure is disproportionately skewing and penalizing SSI rates in large tertiary centers that perform exenterations, especially for recurrent cancers. The commenter noted that exenterations are rare, complex multi-organ system resections and are performed for one of three reasons: colorectal cancer, a genitourinary (GU) cancer, or a gynecologic cancer. The commenter stated that the few institutions that perform these rare operations might be disproportionately affected by misclassification of SSIs in cases of recurrent cancer when the colon has previously been removed and only the small bowel is included as the gastrointestinal component of the exenteration. The commenter suggested that the unintended consequence could be remedied by a new CPT code for exenteration for recurrent cancer including small bowel sans colon, or exclusion of exenteration from NQF #0753.
Response: We are using the SSI measure in the HAC Reduction Program as specified by the measure steward, the CDC. Comments and suggestions regarding inclusion and exclusion criteria should be addressed to NHSN@cdc.gov. We appreciate and are concerned about unintended consequences and will continue to monitor the HAC Reduction Program and take the commenters’ concerns under consideration.

Comment: One commenter suggested that CMS identify untreated malnutrition, including disease-related malnutrition (acute and chronic) as a HAC. The commenter noted that including untreated malnutrition would encourage hospitals to implement policies and procedures that promote systematic nutrition screening, assessment, and appropriate nutrition intervention. The commenter stated that it is widely recognized that nutritional status plays a significant role in health outcomes and healthcare costs. The commenter cited that malnourished patients are more likely to experience complications such as pneumonia, pressure ulcers, nosocomial infections, and death. The commenter also cited that malnourished patients have significantly longer hospitalizations. The commenter stated the inclusion of untreated malnutrition would create the necessary accountability to minimize the health and economic impact of disease-malnutrition.

Response: We thank the commenter for this suggestion and will consider new measures in the program through future rulemaking.

5. Changes for Implementation of the HAC Reduction Program for FY 2017

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50717), we finalized the following measures for use in the FY 2017 program: AHRQ PSI-90 Composite and CDC NHSN CLABSI, CAUTI, Colon and Abdominal Hysterectomy SSI, Methicillin-Resistant
Staphylococcus aureus (MRSA) Bacteremia, and Clostridium difficile (CDI). In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24511), we did not propose any changes to this measure set for FY 2017. We also did not propose to make any changes to the measures from how they were finalized for use in the FY 2016 program (CAUTI, CLABSI, and Colon and Abdominal Hysterectomy SSI) or FY 2017 program (the addition of MRSA Bacteremia and CDI).

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24511 through 24512), for FY 2017, we proposed three changes to existing program policies: (1) the dates of the time period used to calculate hospital performance; (2) the addition of a narrative rule used in the methodology to calculate the Domain 2 score; and (3) the relative contribution of Domain 1 (patient safety) and Domain 2 (infection) to the Total HAC Score. Each proposal is described in more detail below.

a. Applicable Time Period for the FY 2017 HAC Reduction Program

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50717), we finalized and codified policy at 42 CFR 412.170 that provided that there will be a 2-year applicable time period to collect data used to calculate the Total HAC Score.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24511), for FY 2017, we proposed to continue similar 2-year time periods for the calculation of HAC Reduction Program measure results. For the Domain 1 measure (AHRQ PSI-90 Composite measure), we proposed to use the 24-month period from July 1, 2013 through June 30, 2015. The claims for all Medicare FFS beneficiaries discharged during this period would be included in the calculations of measure results for FY 2017. For the
CDC NHSN measures, previously finalized for use in the FY 2017 HAC Reduction Program (CLABSI, CAUTI, Colon and Abdominal Hysterectomy SSI, MRSA Bacteremia, and CDI), we proposed to use data from CYs 2014 and 2015.

We sought public comment on the proposal to use these updated time periods for calculation of measure results for the FY 2017 program.

Comment: One commenter supported the proposed time periods for the calculation of HAC Reduction Program measure results. The commenter noted that this proposed change places an emphasis on outcome based measures, allowing for focus on influencing preventable events and improvement on quality of care.

Response: We appreciate the commenter’s support.

After consideration of the public comments we received, we are finalizing the proposed applicable time periods discussed above for the FY 2017 HAC Reduction Program without modification.

b. Narrative Rule Used in Calculation of the Domain 2 Score for the FY 2017 HAC Reduction Program

We noted in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50723) that there will be instances in which applicable hospitals may not have data on all Domain 1 and 2 measures, and, therefore, a set of narrative rules were finalized to determine how to score each Domain. The scoring rules were finalized in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50723 through 50725) and clarified in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50096 through 50098). For FY 2017, we will follow the rules as previously finalized. As described below, in the FY 2016 IPPS/LTCH PPS proposed rule
(80 FR 24511 through 24512), we also proposed an additional narrative rule for use beginning in the FY 2017 program year. This additional narrative rule would be applicable to calculation of the Domain 2 score and would treat each Domain 2 measure independently when determining if a score of 10 (maximal score) should be assigned to the measure for nonsubmission of data without a waiver (if applicable).

We note that the current narrative rules for Domain 2 assign a score for each Domain 2 measure and the measure scores are averaged to provide a Domain 2 Score. For the FY 2015 and FY 2016 HAC Reduction Program, if a hospital reports data for at least one of the Domain 2 measures, its Domain 2 Score is based solely on the measure(s) the hospital reported and the hospital is not assigned the maximum number of points for any nonreported measure(s). This approach was employed for the FY 2015 and FY 2016 HAC Reduction Program because the applicable periods for the Domain 2 measures for those program years (the FY 2015 period was January 1, 2012 through December 31, 2013, and the FY 2016 period was January 1, 2013 through December 31, 2014) occurred, at least in part, prior to the announcement of the HAC Reduction Program with the publication of the FY 2014 IPPS/LTCH PPS final rule (78 FR 50707 through 50729) in August 2013. The proposed applicable period for Domain 2 measures in the FY 2017 program (CYs 2014 and 2015) occurs in its entirety after the HAC Reduction Program was announced. In the FY 2016 IPPS/LTCH PPS proposed rule, we informed hospitals of the impact that not reporting these data would have on their FY 2017 Total HAC Score. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24511 through 24512), we proposed, for FY 2017 and subsequent program years,
that each Domain 2 measure be treated independently when determining if a score of 10 (maximal score) should be assigned to the measure for nonsubmission of data without a waiver (if applicable). For instance, if a hospital does not submit data for the Colon and Abdominal Hysterectomy SSI measure and does not have a valid waiver for nonreporting, the measure would receive a score of 10. This score of 10 would then be combined with the measure scores the hospital received for data reported on the other FY 2017 Domain 2 measures (CLABSI and CAUTI) to calculate the hospital’s total Domain 2 score. The rationale for this proposed change in methodology is to encourage hospitals to submit all available data on all measures in the program and to further encourage hospitals to reduce all HACs included in the program.

We invited public comments on our proposal to implement the score calculations discussed above in FY 2017 and subsequent years, as well as our proposal for an additional narrative rule that would treat each Domain 2 measure independently when determining if a score of 10 (maximal score) should be assigned to the measure for nonsubmission of data without a waiver (if applicable).

Comment: Many commenters supported the proposed changes to the narrative rule used in the calculation of Domain 2 scores. The commenters noted that these proposed changes support greater transparency by encouraging hospitals to submit all available data required for reporting to NHSN on the different measures captured in the Domain 2 score. One commenter noted that, in December 2014, the technical expert panel (TEP) convened by CMS to reevaluate scoring methodology recommended treating Domain 2 measures independently for purposes of determining a Domain 2 score. Some
commenters also suggested that, in addition to exempting those with waivers, CMS continue the practice of not calculating a score when data have been submitted but there is not enough data to calculate the standardized infection ratio (SIR). These commenters suggested that CMS clarify in the final rule that it will continue this practice.

Response: We appreciate the commenters’ support. To provide clarification in this final rule, in the event the SIRs for each Domain 2 measure cannot be calculated because the facility has less than 1.0 predicted infection for each measure, a Domain 2 score cannot be calculated and so we will use solely the Domain 1 score to calculate a hospital’s Total HAC Score. In other words, we will exclude from the Total HAC Score calculation any measure for which a SIR cannot be calculated.

Comment: Some commenters suggested that CMS amend the program to include only hospitals with enough data to report at least one of the infection measures in Domain 2. The commenters suggested that CMS consider an alternative scoring methodology for hospitals that do not have adequate data for Domain 2. The commenters also suggested that hospitals for which CMS is unable to calculate a Domain 2 score be excluded from the pool of hospitals that determine the penalty quartile.

Response: We acknowledge the commenters’ concern and appreciate the suggestions. However, we note that section 1886(p)(2) of the Act requires all subsection (d) hospitals under the Act to be included in the HAC Reduction Program. In addition, the intention of the scoring methodology for calculating a Total HAC Score is to make use of all available data for each hospital and to encourage hospitals to report HAI data to CDC NHSN, even if they do not have enough data to reliably calculate a SIR for the
CDC NHSN HAI measures in Domain 2. CDC indicated that it continuously evaluate the data reported to NHSN and consider the best measures for monitoring and comparative purposes.

After consideration of the public comments we received, we are finalizing the narrative rules used in the calculation of the Domain 2 Score discussed above as proposed.

c. Domain 1 and Domain 2 Weights for the FY 2017 HAC Reduction Program

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50102), we finalized for FY 2016 a methodology for calculating a Total HAC Score for each hospital by determining a score for each domain, then multiplying each domain score by a weight (Domain 1 – AHRQ Patient Safety Indicators, 25 percent; Domain 2 – CDC NHSN measures, 75 percent), and adding together the weighted domain scores to determine the Total HAC Score (§ 412.172(e)(3)).

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24512), for FY 2017, we proposed to adjust the weighting of Domains 1 and 2 so that the weight of Domain 1 would be 15 percent and the weight of Domain 2 would be 85 percent. We proposed to decrease the Domain 1 weight for two reasons. First, with the implementation of the CDC MRSA Bacteremia and CDI measures in the FY 2017 program, we believe the weighting of both domains needs to be adjusted to reflect the addition of the fifth and sixth measures in Domain 2. Second, among the public comments on the FY 2014 and FY 2015 IPPS/LTCH PPS final rules that were considered, MedPAC and other stakeholders recommended that Domain 2 should be weighted more than Domain 1.
because they believed the CDC NHSN chart-abstracted measures in Domain 2 were more reliable and actionable than claims-based measures. We invited public comments on this proposal to decrease the Domain 1 weight from 25 percent to 15 percent and increase the Domain 2 weight from 75 percent to 85 percent for FY 2017.

Comment: Many commenters supported the proposed adjustment to the relative weightings of Domains 1 and 2 for FY 2017. The commenters stated that the proposed change gives more weight to the CDC NHSN chart-abstracted measures, which utilize standardized definitions that capture both data on Medicare as well as non-Medicare patients, rather than measures obtained from claims-based data on Medicare patients only. The commenters supported MedPAC’s and other stakeholder’s assertions that CDC NHSN chart-abstracted measures in Domain 2 are more reliable and actionable than the claims-based measures in Domain 1.

Response: We agree that an increase in the Domain 2 weight is warranted, given that the number of measures is increasing to include addition of the CDC NHSN Surgical Site Infection (SSI) measure for FY 2016 and the addition of the CDC NHSN Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia and C. difficile measures for FY 2017. We agree that both patient safety events and infections are important components of the HAC Reduction Program. We refer readers to the FY 2014 IPPS/LTCH PPS proposed rule (79 FR 28143 through 29144) for additional information for assigning a higher weight to Domain 2.

Comment: Some commenters objected to the proposed reduction of the weight of Domain 1 to 15 percent in FY 2017. The commenters believed that this approach
promotes an overly narrow definition of HACs that places too much emphasis on infections alone. The commenters asserted that, while infections are important patient outcomes, patients are exposed to risks from many of the outcomes in the PSI-90 Composite, such as pressure ulcers, postoperative hemorrhage, or accidental puncture/laceration. The commenters suggested that CMS take a more balanced approach to weighting the existing domains in order to place a high bar for hospitals to avoid preventable infections and harmful complications.

Response: We acknowledge the commenters’ concerns. We maintain that the AHRQ PSI–90 measure plays a vital role in patient safety and it continues to comprise an integral part of the HAC Reduction Program with a weight of 15 percent of the Total HAC Score.

Comment: Commenters expressed concerns over the pace of the change in relative weightings and encouraged CMS to use the same domain weighting in both FY 2016 and FY 2017. The commenters stated that changes to the weighing of measurement domains in FY 2017, for which the performance period is already underway, should not be made.

Response: We acknowledge the commenters’ concerns. We note that the proposed change in relative weightings, for the FY 2017 program, was based on recommendations from MedPAC and other stakeholders that believe the CDC NHSN chart-abstracted measures in Domain 2 are more reliable and actionable than claims-based measures. We also note that the relative weightings were proposed to be adjusted to account for the additions of the CDC NHSN Methicillin-Resistant
Staphylococcus aureus (MRSA) Bacteremia and C. difficile measures for FY 2017 in Domain 2.

Comment: Commenters expressed apprehension about modifying the relative weighting of the domains before hospital systems have fully understood the effects of the transition from the ICD-9 coding system to the ICD-10 coding system.

Response: We are aware of stakeholder concerns about the potential impacts to hospital performance on quality measures when the ICD-10 coding system is implemented on October 1, 2015, as well as their calls for more extensive testing to understand the impacts before any payments or penalties are implicated. As part of ICD-10 transition planning that has taken place over the past several years, we have performed testing and analyses across the agency with respect to system readiness and claims payments, in addition to extensive education and outreach to providers, vendors, and other payers. CMS’ systems for quality programs have been tested and will continue to be tested as ICD-10 data are submitted in order to ensure the accuracy of measure calculations and to monitor and assess the translation of measure specifications to ICD-10, potential coding variation, and impacts on measure performance and payment incentive programs. We will continue to work with stakeholders during the ICD-10 transition to monitor and assess impacts and to address any potential issues that may occur.

Comment: Commenters expressed concerns that the change to the relative weightings may have a disproportionate impact on States that mandate reporting of infections by hospitals and other providers through NHSN. The commenters suggested
that CMS undertake a State-by-State review of reporting to determine if there may be a correlation between State-mandated reporting requirements and higher infection rates reported by hospitals and to consider those findings for future program improvements.

Response: We appreciate commenters’ concern that the relative weightings may have an impact on states that mandate reporting. However, hospitals can voluntarily report to NHSN, and are highly encouraged to do so, because their HAC scores are dependent on it. We will take the commenters’ feedback into future consideration as we strive to improve the HAC Reduction Program.

After consideration of the public comments we received, we are finalizing the Domain 1 and 2 weightings for FY 2017 as proposed.

6. Measure Refinements for the FY 2018 HAC Reduction Program

a. Inclusion of Select Ward (Non-Intensive Care Unit (ICU)) Locations in Certain CDC NHSN Measures Beginning in the FY 2018 Program Year

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24512 through 24513), we proposed measure refinements to the CDC NHSN CLABSI and CAUTI measures that were previously adopted for the HAC Reduction Program to include select ward (non-ICU) locations beginning in the FY 2018 program. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50712 through 50719), we adopted the CLABSI and CAUTI measures inclusive of pediatric and adult patients in ICUs for the HAC Reduction Program beginning with FY 2015. We noted at that time that the Hospital IQR Program finalized data collection for these measures for adult and pediatric patients in medical, surgical, and medical/surgical wards (also referred to as select ward locations), in
addition to ICU locations, effective beginning January 1, 2015, and that we would propose the additional locations for the HAC Reduction Program in the future.

The refined CAUTI and CLABSI measures that include select ward locations in addition to ICU locations were endorsed by the NQF in 2012. The MAP 2015 final recommendations indicated that the CLABSI and CAUTI measures with ICU and select ward locations be included in the HAC Reduction Program.\textsuperscript{110} We note that during the MAP Hospital Workgroup meeting (December 9-10, 2014) and the MAP Coordinating Committee meeting (January 26-27, 2015), some members discussed the benefit of reporting the modified measures publicly before including them in a payment program in order to allow providers and CMS to gain experience with the modified measures. Other members expressed concern that this could delay implementation of an improved measure.\textsuperscript{111} The MAP supported the use of the refined measures without stipulating prior public reporting as a condition of support. However, we acknowledge the importance of this consideration and took it into account when considering the timing of implementing the expanded measure in the HAC Reduction Program.

As described in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24512), we considered a number of options for when to begin using the refined measures in the HAC Reduction Program. The CDC NHSN measure data used in the HAC Reduction Program are obtained from data that hospitals report as part of their participation in the Hospital IQR Program. Therefore, due to the timing of the Hospital IQR Program including select ward locations (beginning January 1, 2015), the FY 2017 HAC Reduction Program, using

\textsuperscript{110} Available at: http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=78853.

\textsuperscript{111} Ibid.
the applicable period of CYs 2014 and 2015 for the CDC NHSN measures, is the first
time data from select ward locations could be included in the program. However, using
select ward location data in the FY 2017 program would result in hospitals with ICU
locations having the opportunity to contribute 2 years of data, while hospitals without
ICU locations would have the opportunity to contribute 1 year of data for measure result
calculation. We believe this systematically unequal distribution of data could introduce
bias in the program and should be avoided. If the introduction of select ward location
data for the CLABSI and CAUTI measures is delayed until the FY 2018 HAC Reduction
Program (applicable period would likely be CYs 2015 and 2016), all hospitals, regardless
of whether or not they have ICUs, would have the opportunity to contribute 2 years of
data for measure result calculations.

In addition, delaying implementation until FY 2018 would allow CMS and
providers to gain some experience with the impact that the inclusion of these data would
have on a hospital’s HAC Reduction Program scores. We also considered the possibility
of further delaying implementation of the refined measures until the FY 2019 program
(applicable period would likely be CYs 2016 and 2017) in order to not include the first
year of reporting (CY 2015) in a payment program measure calculation.

After considering these three options, in the FY 2016 IPPS/LTCH PPS proposed
rule (80 FR 24512), we proposed to include data from pediatric and adult medical ward,
surgical ward, and medical/surgical ward locations in addition to data from adult and
pediatric ICU locations for the CDC NHSN CLABSI and CAUTI measures beginning
with the FY 2018 HAC Reduction Program. This option balances our belief that the
refinement of the CLABSI and CAUTI measures to include select ward locations results in an improved measure that more accurately captures hospital-wide performance regarding these HACs with the need to provide hospitals with the opportunity to submit data for the full period of performance and the desire to gain experience with the refined measures before incorporating them into the HAC Reduction Program. We also believe this measure refinement will allow hospitals that do not have ICU locations to use the tools and resources of the NHSN for quality improvement and public reporting efforts (78 FR 50787).

We invited public comment on our proposal.

Comment: Many commenters supported the proposed measure refinements to include select ward (non-ICU) locations for FY 2018. The commenters stated that the CDC NHSN CLABSI and CAUTI measures are important targets for dedicated surveillance and prevention efforts outside the ICU setting and their inclusion in the program represents a more robust reflection of overall organizational performance. The commenters noted that this proposed change appropriately recognizes the importance of controlling hospital-acquired infections outside of the ICU. Some commenters stated that the proposal would allow hospitals without ICU locations to have a greater opportunity to participate in public reporting and quality improvement. The commenters suggested that CMS, in collaboration with CDC, determine how the standardized infection ratio (SIR) for CAUTI and CLABSI for these two location types will be calculated and displayed, noting that the SIR tends to vary significantly between ICU and select ward locations.
Response: We appreciate the commenters’ support. We will consider the recommendation regarding public reporting of hospital SIRs for the future.

Comment: Commenters commended CMS for the thorough assessment undertaken to determine the most appropriate time to implement the CDC NHSN CAUTI and CLABSI measures. One commenter noted that there are significant volumes of incident rates of CLASBI and CAUTI that occur in non-ICU locations. One commenter suggested, in the interim, that CMS provide selected ward (non-ICU) locations with the mechanisms to begin voluntary data collection related to the measures for purposes of calculating performance standards. This commenter noted that these measures are an important tool in measuring efficiency within hospitals in order to reduce costly hospital-acquired infections that can have detrimental effects on the patients who develop them.

Response: We appreciate the commenters’ support. The intent of the HAC Reduction Program is to reduce the number of hospital-acquired infections in all areas of the hospital. We believe that including non-ICU ward locations allows us to work toward achieving that aim.

Comment: Many commenters suggested that CMS consider delaying the inclusion of select ward (non-ICU) locations until FY 2019. The commenters suggested CY 2017 to serve as the first performance period, to align with the Hospital VBP Program. The commenters suggested that CMS be consistent in its reporting and payment policies, especially given the overlap of measures between the pay-for-performance programs. Some commenters expressed concerns that clinical laboratories will need training to implement the proposed changes, noting that hospitals
would need at least part of 2015 to use as a learning period to implement any finalized infection agent changes.

Commenters suggested that CMS refrain from using CY 2015 as part of the performance period for the refined CDC NHSN CAUTI and CLABSI measures. In the alternative, the commenters suggested that CMS utilize CY 2016 as the 1-year performance period if it insisted on incorporating the refined measures in FY 2018, or using a 12-month performance-reporting period. Some commenters suggested that CMS consider providing additional details about the NHSN locations that are included and excluded.

Response: We appreciate the commenters’ concern and suggestions. We note that implementation of the modified CLABSI and CAUTI measures that include expansion outside the ICU were discussed in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50787). We further note that the modified CLABSI and CAUTI measures that include expansion outside the ICU were included on the 2014 Measures Under Consideration list and were discussed and generally supported by the MAP Hospital Workgroup at its December 2014 meeting. We believe that implementation of the expanded measures in FY 2018 will allow more hospitals to have their performance monitored during FY 2018 by including hospitals without ICUs that were previously not included, or small hospitals with ICUs that previously lacked enough data to calculate a standardized infection ratio (SIR).

Allowing FY 2017 to serve as the first program year would permit hospitals with ICU locations to contribute 2 years of data, while hospitals without ICU locations would
only have 1 year of data to contribute for measure result calculations. We believe this unequal distribution of data could introduce bias in the program and should be avoided. We note that implementation in FY 2018 would allow all hospitals, regardless of whether or not they have ICUs, to have the opportunity to contribute 2 years of data for measure result calculations. This option balances our belief that the refinement of the CLABSI and CAUTI measures to include select ward locations results in an improved measure that more accurately captures hospital-wide performance.

To address the commenters’ specific point to delay implementation to align the HAC Reduction Program with the Hospital VBP Program, we continue to stress that the HAC Reduction Program and the Hospital VBP Program are separate programs with different purposes and policy goals. The HAC Reduction Program incentivizes the improvement of patient safety in hospitals by reducing payments to hospitals for excess HACs, while the Hospital VBP Program is an incentive program that redistributes a portion of the Medicare payments made to hospitals based on their performance on various measures. We also note that the Hospital VBP Program has a specific statutory requirement at section 1886(o)(2)(C)(i) of the Act that measures selected under the program must have had measure data posted on Hospital Compare for 1 year prior to the performance period; the HAC Reduction Program has no such analogous requirement.

Comment: One commenter requested to know when the CDC NHSN CAUTI and CLABSI results, reflecting the expanded population, would be reported on Hospital Compare.
Response: FY 2018 HAC Reduction Program results will be publicly reported on Hospital Compare around December 2017. As previously finalized in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50725), we will publicly report the following on the Hospital Compare Web site: (1) hospital scores with respect to each measure; (2) each hospital’s domain specific score; and (3) the hospital’s Total HAC Score.

Comment: One Commenter suggested that CMS provide an analysis of the impact of the expansion of the CDC NHSN measures on the program. The commenter noted that this is a relatively recent expansion and additional information regarding its impact should be made available to stakeholders prior to implementation.

Response: We appreciate the commenter’s suggestion. We will determine the feasibility of conducting an impact analysis of the CDC NHSN measures on the HAC Reduction Program.

Comment: One commenter expressed concerns that expanding the CDC NHSN CAUTI data collection to non-ICU wards may endanger patients with spinal cord injury/dysfunction (SCI), unless they are excluded from the measure. The commenter noted that, in response to the CDC NHSN CAUTI measure, a number of hospitals and hospital systems have encouraged removal of indwelling catheters, often without recognizing spinal cord injury patients as an at-risk population. The commenter stated that premature catheter removal has resulted in improper and unsafe bladder management in the acute care and subacute care settings.

Response: We appreciate the commenter’s suggestion on excluding SCI patients from CAUTI reporting. Patient exclusions are determined by the measure steward, which
is the CDC. We are currently using the CAUTI measure as specified by the CDC in the HAC Reduction Program, which includes SCI patients. Questions concerning CDC NHSN measures should be addressed to NHSN@cdc.gov.

After consideration of the public comments we received, we are finalizing the inclusion of data from pediatric and adult medical ward, surgical ward, and medical/surgical ward locations, in addition to data from adult and pediatric ICU locations for the CDC NHSN CLABSI and CAUTI measures, beginning in FY 2018, as proposed.

b. Update to CDC NHSN Measures Standard Population Data

In this section, we provide information regarding upcoming changes to the standard population data that are used to calculate the SIR for the CDC NHSN measures. These changes are occurring as part of routine measure maintenance.

The CDC NHSN measures are used to monitor hospital performance on prevention of healthcare-associated infections (HAIs). For each NHSN measure, CDC calculates the SIR, which compares a hospital’s observed number of HAIs to the number of infections predicted for the hospital, adjusting for several risk factors. The predicted number of infections is determined using patient care location characteristics (for example, the number of central line days) and infection rates that occurred among a standard population during a specified time period (sometimes referred to by CDC as “national baseline” but referred to here as “standard population data”). For example, CDC currently uses data collected in CY 2009 for the CAUTI measure to determine the

---

standard population data.\(^{113}\) For more information about the method by which NHSN measures are calculated, we refer readers to QualityNet’s Web page on HAI measures, which may be found at:


As part of routine measure maintenance, CDC will be updating the standard population data to ensure the NHSN measures’ number of predicted infections reflects the current state of HAIs in the United States.\(^{114}\) Beginning January 1, 2015, CDC started collecting data to use in updating the standard population data for HAI measures. (The CY 2015 standard population data for HAI measures will hereinafter be referred to as “new standard population data.”) Measure results using infections reported in CY 2016 will reflect the use of the new standard population data. It is anticipated that the new standard population data will affect the HAC Reduction Program beginning in FY 2018 when the applicable period for the CDC NHSN measures included in the program is likely to include CY 2015 and CY 2016.

**Comment:** Many commenters supported the adoption of updated standard population data in the calculation of SIRs for the CDC NHSN measures to ensure that the predicted number of infections used in the measures are based on the most recent data.

**Response:** We appreciate the commenters’ recognition of the importance to update the baselines used to calculate HAI performance to ensure use of the most recent data.

\(^{113}\)Available at: [http://www.cdc.gov/nhsn/pdfs/pscManual/7pscCAUTIcurrent.pdf](http://www.cdc.gov/nhsn/pdfs/pscManual/7pscCAUTIcurrent.pdf); and [http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html](http://www.cdc.gov/HAI/surveillance/QA_stateSummary.html).

Comment: Many commenters objected to how CMS will incorporate the updated standard population data. The commenters noted that only measure results reported in CY 2016 would utilize the new standard population data, resulting in the FY 2018 penalty determinations being based upon data from different standard populations for the 2 reporting years. The commenters suggested that, for reliability purposes, CMS explore other options to implement the standard population data change to ensure that 2 years of performance data are calculated under the same methodology. The commenters suggested that the incorporation of the updated standard population data be accomplished in a way that allows hospitals ample time to be able to review, understand, and explain the changes in performance that may occur before the changes affect payment. The commenters also suggested that CMS engage in further conversations with CDC and hospital stakeholders to evaluate different approaches for implementation prior to a final decision.

Response: We acknowledge the commenters’ concerns and appreciate their suggestions. To provide clarification regarding use of the updated standard population data, the FY 2018 program will use SIRs for CY 2015 and CY 2016 that will be calculated using the new standard population data that are based on CY 2015 data reported to NHSN. There will not be two different standard populations used to determine FY 2018 measure results or scores; only the new standard population will be used. The CDC will use CY 2015 data to obtain the national rate and then will use this new national rate to calculate the SIRs for CY 2015 and CY 2016 in connection with the FY 2018 HAC Reduction Program.
Comment: Commenters expressed concerns that using the rebased and expanded measures in FY 2018 would result in the HAC Reduction Program implementing these measures a full year earlier than in the Hospital VBP Program. The commenters noted that there is value in implementing the rebased measures in FY 2019 for both programs. The commenters noted that standardizing CDC data collection for these two programs leads to less confusion during data reporting. The commenters suggested delaying the implementation of the newly rebased and expanded measures until FY 2019.

Response: We appreciate commenters’ concern. CDC’s new CAUTI definition was developed by a subject-matter expert working group comprised of CDC and non-CDC participants who systematically assessed each definitional component. The result is a new CAUTI definition that is simplified from previous iterations and allows for less subjectivity while optimizing clinical credibility. An assessment of the impact of the definition change on CAUTI incidence was completed as part of the definition development. In addition, the NHSN application provides a technical infrastructure and built-in controls on data entry that serve as safeguards against the reporting of events that do not meet the new CAUTI definition. For these reasons, CDC is confident that the CAUTI data reported in CY 2015 will be appropriate to use for a new standard population.

To address commenters’ concerns about program overlap, we note that the Hospital VBP Program has a specific statutory requirement at section 1886(o)(2)(C)(i) of the Act that measures selected under the program must have had measure data posted on Hospital Compare for 1 year prior to the performance period; the HAC Reduction
Program has no such analogous requirement. We will continue to look at ways to better align the two programs in the future.

Comment: One commenter suggested that CMS revise the SIR methodology or exclude hospitals with low-volumes that may lack sufficient cases to establish an expected infection calculation. The commenter noted that when the Expected Infection Value is less than one, CMS deems the ratio invalid, and eliminates the Infection Prevention Component (Domain 2) from the overall performance roll-up. The commenter noted that this results in all of the weighting criteria shifting to the patient safety domain (Domain 1).

Response: We appreciate the commenter’s suggestions and will take them under advisement as we seek to make our measures more transparent. We conferred with CDC, which indicated that they continuously evaluate the data reported to NHSN and consider the best measures for monitoring and comparative purposes. Currently the SIR is the best measure to allow for risk adjustment and production of a facility-level and/or CCN-level metric that can be used for comparison across similar facility types. This provides the opportunity to most accurately represent a facility’s success. CDC continues to review the data and evaluate options for metric development, including situations where facilities have low denominator volume and/or few infections.

7. Maintenance of Technical Specifications for Quality Measures

Technical specifications for AHRQ’s PSI-90 Composite measure in Domain 1 can be found at AHRQ’s Web site at:

for the CDC NHSN HAI measures in Domain 2 can be found at CDC’s NHSN Web site at: http://www.cdc.gov/nhsn/acute-care-hospital/index.html. Both Web sites provide measure updates and other information necessary to guide hospitals participating in the collection of HAC Reduction Program data.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50100), we described a policy under which we use a subregulatory process to make nonsubstantive updates to measures used for the HAC Reduction Program. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24513), we did not propose any changes to this policy.

8. Extraordinary Circumstance Exception Policy for the HAC Reduction Program Beginning in FY 2016 and for Subsequent Years
a. Background

In the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28142), we welcomed public comment on whether a potential waiver or exception policy for hospitals located in areas that experience disasters or other extraordinary circumstances should be implemented, and the policy and operational considerations of such an extraordinary circumstance exception policy for the HAC Reduction Program. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50101), we indicated that we received many comments in support of CMS establishing a formal extraordinary circumstance exception policy under the HAC Reduction Program. We also previously indicated that any specific proposals related to the implementation of an extraordinary circumstance exception policy would be proposed through notice-and-comment rulemaking. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24513 through 24514), we proposed to
establish an extraordinary circumstance exception policy for the HAC Reduction Program beginning in FY 2016 and for subsequent years.

In developing this proposed extraordinary circumstance exception policy for the HAC Reduction Program beginning in FY 2016 and for subsequent years, we considered a policy and process similar to that for the Hospital IQR Program, as finalized in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51651), modified by the FY 2014 IPPS/LTCH PPS final rule (78 FR 50836) (designation of a non-CEO hospital contact), and further modified in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50277) (amended § 412.40(c)(2)) to refer to “extension or exemption” instead of the former “extension or waiver”). We also considered how best to align an extraordinary circumstance exception policy for the HAC Reduction Program with existing extraordinary circumstance exception policies for other IPPS quality reporting and payment programs, such as the Hospital VBP Program, to the extent feasible.

We considered the feasibility and implications of excluding data for certain measures for a limited period of time from the calculations for a hospital’s measure results or Total HAC Score for the applicable performance period. By minimizing the data excluded from the program, the proposed policy would enable affected hospitals to continue to participate in the HAC Reduction Program for a given fiscal year if they otherwise continue to meet applicable measure minimum threshold requirements. We believe that this approach could help alleviate the reporting burden for a hospital that is adversely impacted by a natural disaster or other extraordinary circumstance beyond its
control, while enabling the hospital to continue to participate in the HAC Reduction Program.

b. Requests for an Extraordinary Circumstance Exception

Based upon our prior experience with the Hospital IQR Program and the Hospital VBP Program, we anticipate the need to provide exceptions to only a small number of hospitals affected by a natural disaster or other extraordinary circumstance. During the review of a hospital’s request for an extraordinary circumstance exception, we will maintain the general principle that providing high quality of care and ensuring patient safety is of paramount importance. We do not intend to allow a hospital to use this proposed policy and the request process to seek exclusion from the HAC Reduction Program in its entirety for a given fiscal year(s) solely because of experiencing an extraordinary circumstance. Rather, we intend to provide relief for a hospital whose ability to accurately collect quality measure data and/or to report those data in a timely manner has been negatively impacted as a direct result of experiencing a significant disaster or other extraordinary circumstance beyond the control of the hospital. Section 1886(p)(4) of the Act permits the Secretary to determine the “applicable period” for HAC data collection, and we believe that the statute allows us to determine that the period not include times when hospitals may encounter extraordinary circumstances.

We proposed that the request process for an extraordinary circumstance exception begin with the submission of an extraordinary circumstance exception request form by a hospital within 90 calendar days of the natural disaster or other extraordinary circumstance. We believe that the 90-calendar day timeframe is an appropriate period of
time for a hospital to determine whether to submit an extraordinary circumstance exception request. It is also the same length of time as the current time period allowed under the Hospital VBP Program. Under this proposed policy, a hospital would be able to request a HAC Reduction Program extraordinary circumstance exception at the same time it may request a similar exception under the Hospital IQR Program, the Hospital VBP Program, and the Hospital Readmissions Reduction Program (if an extraordinary circumstance exception policy is adopted for the Hospital Readmissions Reduction Program as described in section IV.E.9. of the preamble of FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24497 through 24498)). The extraordinary circumstance exception request form would be made available on the QualityNet Web site (https://www.qualitynet.org/).

The following minimum set of information would be required to submit the request:

- Hospital CCN;
- Hospital name;
- Hospital Chief Executive Officer (CEO) and any other designated personnel contact information, including name, email address, telephone number, and mailing address (must include a physical address; a post office box address is not acceptable);
- Hospital's reason for requesting an exception, including:

  ++ CMS program name (for example, the HAC Reduction Program, the Hospital VBP Program, or the Hospital IQR Program);
++ The measure(s) and submission quarters affected by the extraordinary circumstance that the hospital is seeking an exception for should be accompanied with the specific reasons why the exception is being sought; and

++ How the extraordinary circumstance negatively impacted performance on the measure(s) for which an exception is being sought;

- Evidence of the impact of the extraordinary circumstances, including but not limited to, photographs, newspaper articles, and other media articles; and

- The request form must be signed by the hospital’s CEO or designated non-CEO contact and submitted to CMS.

The same set of information is currently required under the Hospital IQR Program and the Hospital VBP Program on the request form from a hospital seeking an extraordinary circumstance exception with respect to these programs. The specific list of required information would be subject to change from time to time at the discretion of CMS.

Following receipt of the request form, CMS would: (1) provide a written acknowledgement of receipt of the request using the contact information provided in the request form to the CEO and any additional designated hospital personnel; and (2) provide a formal response to the CEO and any additional designated hospital personnel using the contact information provided in the request notifying them of the CMS decision. Under the proposed policy, we would review each request for an extraordinary circumstance exception on a case-by-case basis at CMS’ discretion. To the extent feasible, we also would review such a request in conjunction with any similar
requests made under other IPPS quality reporting and payment programs, such as the Hospital IQR Program and the Hospital VBP Program.

The proposed policy would not preclude CMS from granting extraordinary circumstance exceptions to hospitals that do not request them if we determine at our discretion that a disaster or other extraordinary circumstance has affected an entire region or locale. If CMS makes such a determination to grant an extraordinary circumstance exception to hospitals in an affected region or locale, we would convey this decision through routine communication channels to hospitals, vendors, and QIOs, including, but not limited, to issuing memos, emails, and notices on the QualityNet Web site at: https://www.qualitynet.org/. This provision also would align with the Hospital IQR Program’s extraordinary circumstances extension or exemption policy, as set forth in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51651).

We invited public comment on this proposal.

Comment: Many commenters supported the proposal to establish an extraordinary circumstance exception policy. The commenters appreciated that CMS previously implemented similar policies for other quality reporting programs and agreed that policies should be consistent across programs. The commenters appreciated that penalties will not be imposed for failure to meet goals related to natural or manmade disasters, overwhelming epidemics, or catastrophic failures of infrastructure. The commenters recommended that CMS develop a single request form, encompassing all quality reporting programs from which a hospital might request an exception. The commenters noted that the request form could list all of the various quality reporting
programs and require a hospital to check off the programs for which it has encountered difficulty collecting data.

Response: We appreciate the commenters’ support for the adoption of an extraordinary circumstance exception policy for the HAC Reduction Program. We also appreciate the recommendations from the commenters and will take into consideration these recommendations as we implement operational processes.

Comment: One commenter suggested that CMS adopt an extraordinary circumstance exception that allows for at least a 1-year exemption from the HAC Reduction Program. The commenter stated that an exception policy of at least 1 year would allow hospitals to focus on and address their immediate needs during a time of crisis and to recover from physical damage and data lags. The commenter noted that hospitals struggling with an extraordinary circumstance may face a truncated reporting period and may have a low volume of data to report, resulting in inconsistent and unreliable outcomes.

Response: We appreciate the commenter’s suggestion. Each request for an extraordinary circumstance exception will be reviewed on a case-by-case basis. Determinations will be based on the information a hospital submits in connection with the reason for the request, such as: the measure(s) and submission quarters affected by the extraordinary circumstance; how the extraordinary circumstance negatively impacted performance on the measure(s); and evidence of the impact.

Comment: One commenter suggested that CMS consider a range of extenuating circumstances that could adversely affect a hospital’s ability to submit data in a timely
fashion. The commenter also suggested that CMS allow an appeals process to govern extraordinary circumstance exception decisions.

Response: We appreciate the commenter’s recommendations. As we discussed in the proposed rule (80 FR 24497), based on our experience with the Hospital Value-Based Purchasing Program and the Hospital Inpatient Quality Reporting Program, we anticipate a need to provide exemptions only to a small number of hospitals where the ability to accurately or timely submits claims has been directly impacted. We will continue to monitor extraordinary circumstance exception requests to ensure that the process we are adopting in this final rule supports the goals of the HAC Reduction Program. However, we do not intend to modify the criteria for an extraordinary circumstance exception at this time. We do not anticipate a need to establish an appeals process for extraordinary circumstance exception determinations.

Comment: One commenter asked if an exception for FY 2015 will be granted if an extraordinary circumstance occurred prior to implementation of the final rule.

Response: We are finalizing the extraordinary circumstance exception policy beginning in FY 2016, as was proposed. Therefore, exceptions may only be granted for circumstances occurring on or after October 1, 2015.

After consideration of the public comments we received, we are finalizing the extraordinary circumstance exception policy as proposed.
H. Simplified Cost Allocation Methodology for Hospitals (§ 412.302)

1. Background

The Medicare hospital cost report employs a cost-finding methodology to allocate direct and indirect costs using statistics appropriate to each department within a hospital. The costs of nonrevenue-producing cost centers (general service or overhead cost centers) are allocated to each other and to the revenue-producing cost centers using statistical bases and related statistics that measure the amount of service furnished by each cost center to the other cost centers (42 CFR 413.24(b) and (d)). In this regard, cost-finding is the process of recasting the data derived from the accounts ordinarily kept by a hospital to ascertain costs of the various types of services furnished (42 CFR 413.24(b)(1)).

In the FY 1997 IPPS final rule (61 FR 46214 through 46215), CMS implemented the simplified cost allocation methodology at 42 CFR 412.302(d)(4) for hospitals as an alternative to the standard cost-finding methodology. The simplified cost allocation methodology reduces the number of statistical bases that a hospital must maintain. Under the simplified cost allocation methodology, a hospital must use a prescribed list of statistical bases, without deviation, as set forth in the Provider Reimbursement Manual (PRM), Part II (CMS Pub. 15-2), Chapter 40, Section 4020, Form CMS-2552. The simplified cost allocation methodology was devised in response to concerns expressed by the hospital industry over 20 years ago regarding the high costs of the recordkeeping required under the cost reporting rules. Since implementation of the simplified cost allocation methodology, there have been advances in technology of recordkeeping for
hospitals, resulting in less arduous and costly recordkeeping. It was expected that, although use of the simplified cost allocation methodology by hospitals would result in reduced recordkeeping costs, it also would likely result in reduced Medicare payments to hospitals.

In the FY 2011 IPPS/LTCH PPS final rule (75 FR 50075 through 50080), we created standard cost centers for Magnetic Resonance Imaging (MRI) and computed tomography (CT) scans, and required that hospitals report the costs and charges for these services under new cost centers on the Medicare cost report Form CMS-2552-10. The new standard cost centers for MRIs and CT scans were effective for cost reporting periods beginning on or after May 1, 2010.

Beginning in FY 2014, we started to calculate the MS-DRG relative weights using 19 CCRs, including distinct CCRs for MRIs and CT scans. In addition, beginning in the CY 2014 OPPS, we started to calculate the OPPS relative payment weights using distinct CCRs for MRIs and CT scans. Some stakeholders expressed concern that CMS was not appropriately determining the cost of advanced imaging for inpatient and outpatient hospital services because, when the costs of hospitals that use the simplified cost allocation methodology are included in cost determinations, less precise CCRs are generated. This is because the simplified cost allocation methodology requires a hospital to use square footage instead of dollar value for capital-related moveable equipment. In response to public comments on the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27486) and the CY 2014 OPPS/ASC proposed rule (78 FR 43547), in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50521 through 50523) and in the CY 2014
OPPS/ASC final rule with comment period (78 FR 74843 through 74847), we encouraged hospitals to use the statistical basis of “dollar value” for the costs of capital-related movable equipment, especially for costly MRI and CT imaging equipment, to support a more precise cost allocation and, therefore, more precise CCRs. However, a hospital that obtained approval from their MAC, under Section 2313 of the Provider Reimbursement Manual (PRM), Part I (CMS Pub. 15-1), to use the simplified cost allocation methodology set forth in Section 4020 of CMS Pub. 15-2 was restricted by the required statistical basis of “square footage” for costs of capital-related movable equipment. We recommended that hospitals use the statistical basis of the dollar value or use the “Direct Assignment of General Service Cost” method by requesting MAC approval in accordance with Section 2307 of CMS Pub. 15-1.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24514 through 24515), we proposed to eliminate the simplified cost allocation methodology because, as discussed above, the allocation of the costs of capital-related movable equipment using the required basis (square footage) under the simplified cost allocation methodology, instead of the recommended basis (dollar value) yields less precise calculated CCRs. We stated in the proposed rule that, currently, less than 1 percent of hospitals have elected to use the simplified cost allocation methodology. Based on FY 2013 HCRIS data, we stated that only 9 of 1,269 CAHs and 23 of 4,389 hospitals other than CAHs used the simplified cost allocation methodology. Furthermore, we stated that we believe that advances in technology have reduced the cost of recordkeeping, allowing hospitals to maintain
2. Proposed Regulatory Change

The regulations applicable to the election of the simplified cost allocation methodology are located in 42 CFR 412.302. For the reasons set forth in section IV.H.1. of the preamble of the FY 2016 IPPS/LTCH proposed rule (80 FR 24514 through 24515), we proposed to amend §412.302 by revising paragraph (d)(4) to eliminate a hospital's ability to elect the simplified cost allocation methodology under the terms and conditions provided in the instructions for CMS Form 2552 for cost reporting periods beginning on or after October 1, 2015.

3. Summary of Public Comments, Our Responses, and Final Changes

We set forth below summaries of the public comments that we received and our responses to those public comments.

Comment: Commenters questioned the accuracy of CMS’ data as cited in the proposed rule with regard to the number of hospitals that use the simplified cost allocation methodology. The commenters stated that if the data included hospitals that answered “Yes” to the question on Worksheet S-2, line 149 of the Medicare cost report, “Was there a change to the simplified cost-finding method?”, the CMS’ data were incorrect. Commenters pointed out that hospitals that answered “Yes” to this question are only those hospitals that changed their cost-finding method to the simplified cost allocation methodology. A few commenters suggested that the number of hospitals using the simplified cost allocation methodology was closer to 2,000 if the number captures
those hospitals that used the square footage statistic for both the “building and fixtures” and “movable equipment” cost centers.

Response: We appreciate the commenters’ concerns regarding the accuracy of the data cited in the proposed rule regarding the number of hospitals that currently use the simplified cost allocation methodology. In response to the commenters, we reassessed the data for the 5,658 hospitals reported in the FY 2013 HCRIS, based on the statistical basis reported for each general services cost center, and found that there are less than 100 hospitals using the simplified cost allocation methodology. We agree with the commenters’ conclusions that capturing hospitals who answered “Yes” to the question on Worksheet S-2, line 149 of the Medicare cost report will not represent the number of hospitals who use the simplified cost allocation methodology. We believe the commenters’ concerns regarding the accuracy of the data result from a misconception of what it means to use the simplified cost allocation methodology. The simplified cost allocation methodology is only indicated by hospitals that use the entire list of the statistical bases as required by Section 4020 of CMS Pub. 15-2. We based the data cited in the proposed rule on the FY 2013 HCRIS data and selected only those hospitals that used the entire list of statistical bases as required by and set forth in Section 4020 of CMS Pub. 15-2. Hospitals that used one or more, but not all, of the statistical bases are not using the simplified cost allocation methodology and were not included in our data analysis in the proposed rule because the simplified cost allocation methodology is only denoted by hospitals that use each and every statistical basis on the prescribed list in Section 4020 of CMS Pub. 15-2. For example, hospitals that use square footage as a
statistical basis for both the “building and fixtures” and “movable equipment” cost centers, but deviate from any one of the other statistical bases required from the list of 19 cost centers under the simplified cost allocation methodology, are not using the simplified cost allocation methodology.

Using the FY 2013 HCRIS data, we applied filters using the 19 statistical bases required by the simplified cost allocation methodology and determined that less than 100 hospitals used the simplified cost allocation methodology. We began with a total hospital population of 5,658 from the FY 2013 HCRIS. First, we applied a filter to the 5,658 hospitals for the “buildings and fixtures” and “movable equipment” cost centers using square footage as the statistical basis for the simplified cost allocation methodology and determined that 3,337 hospitals used this basis. In so doing, we were able to eliminate 2,321 hospitals that were not using the simplified cost allocation methodology’s basis of square footage for these cost centers. We then applied a second filter to the 3,337 hospitals for the “laundry and linen” cost center using patient days as the statistical basis for the simplified cost allocation methodology and determined that 1,008 hospitals used patient days. After applying the second filter, we were able to eliminate an additional 2,329 hospitals that may have used square footage but were not using the simplified cost allocation methodology’s basis of patient days for this cost center; in most cases, hospitals used pounds of laundry or an alternative basis not within the simplified cost allocation methodology. We next applied a third filter to the resulting 1,008 hospitals for the “dietary” cost center using patient days as the statistical basis for the simplified cost allocation methodology and determined that 687 hospitals used patient days. After
applying the third filter, we were able to eliminate an additional 321 hospitals that were not using the simplified cost allocation methodology’s basis of patient days for this cost center. With the resulting 687 hospitals, we next applied a fourth filter for the “nursing administration” cost center using nursing salaries as the statistical basis for the simplified cost allocation methodology and determined that 523 hospitals used nursing salaries. In this manner, we continued filtering through the simplified cost allocation methodology’s remaining costs centers and corresponding statistical bases and ended with a result of less than 100 hospitals using the simplified cost allocation methodology.

In our original data analysis set forth in the proposed rule, we excluded hospitals with cost centers that were listed in the HCRIS report as blank because we assumed that if a cost center was blank, a hospital was not using the simplified cost allocation methodology. However, upon revisiting the data following the receipt of public comments, we determined that if a cost center was blank, it did not necessarily mean the hospital was not using the simplified cost allocation methodology. In this regard, we broadened the filters to include hospitals with the blank cost centers which broadened the population. Within this larger population, we concluded that there were more hospitals using the simplified cost allocation methodology than originally cited in the proposed rule. Although this second data analysis was more conservative and included a larger population, we still found that less than 100 hospitals are using the simplified cost allocation methodology.

Comment: Some commenters stated that CMS should explore alternatives to eliminating the simplified cost allocation methodology rather than disrupting the cost
reporting practices of a large number of hospitals that do not use “dollar value” to allocate capital-related moveable equipment.

Response: We appreciate the commenters’ concerns and believe that it is important to minimize disruption of hospital cost reporting practices, while at the same time allowing hospitals to use a more precise statistical allocation basis of dollar value. Therefore, in response to comments, in this final rule, rather than eliminating the simplified cost allocation methodology as we proposed, we are modifying the simplified cost allocation methodology to permit the use of either dollar value or square footage as the statistical basis for capital-related moveable equipment. With this modification, we believe there will be no disruption of cost reporting practices for hospitals, regardless of whether or not they use the simplified cost allocation methodology. While hospitals currently using the standard cost-finding method of allocation may also use an approved alternative statistical basis of square footage for capital-related moveable equipment and can request approval to change back to the recommended and more precise statistical allocation basis of dollar value, hospitals using the simplified cost allocation methodology are not afforded this same flexibility to change to dollar value as a statistical basis for capital-related moveable equipment. Currently, under the simplified cost allocation methodology, there can be no deviation from the prescribed statistical bases for any of the cost centers as set forth in the PRM (CMS Pub. 15-2, Chapter 40, Section 4020, Form CMS-2552-10). Under our modified policy, hospitals that use the simplified cost allocation methodology (that is, hospitals that use each and every statistical basis within the list of cost centers under the simplified cost allocation
methodology) may continue their use of these statistical bases, with the added flexibility to request approval to use the dollar value statistical basis for capital-related moveable equipment. In this regard, hospitals using the simplified cost allocation methodology will no longer be required to use the square footage statistical basis for capital-related moveable equipment but will be provided greater flexibility to request approval to use the statistical basis of dollar value which may be better suited to their cost allocation needs. We note that hospitals currently using one or more, but not all, of the statistical bases under the simplified cost allocation methodology are not considered to be using the simplified cost allocation methodology. Rather, they are considered to be using the standard cost-finding methodology with approved alternative statistical bases. These hospitals may continue to use these previously approved statistical bases. As discussed above and in the proposed rule, we believe that advances in recordkeeping information technology since the simplified cost allocation methodology was devised almost 20 years ago have afforded hospitals the ability to more accurately track data and costs with relative ease and to more quickly recall such data than in the past. Thus, we believe that hospitals should use the cost allocation methodology that results in the most precise cost allocation.

Comment: A few commenters suggested that CMS provide data to support its belief that using dollar value as a statistic for capital-related moveable equipment will result in more precise CCRs and will outweigh the additional reporting burden to hospitals.
Response: We appreciate the commenters’ concerns surrounding the perceived burden to hospitals and the use of dollar value as a statistic for capital-related moveable equipment to support more precise CCRs. As noted in the proposed rule, beginning in FY 2014, we started to calculate the MS-DRG relative weights using 19 CCRs, including distinct CCRs for MRIs and CT scans. In addition, beginning in the CY 2014 OPPS, we started to calculate the OPPS relative payment weights using distinct CCRs for MRIs and CT scans. In public comments, some stakeholders, including the hospital industry, expressed concern that CMS was not appropriately determining the cost of advanced imaging for inpatient and outpatient hospital services because, when the costs of hospitals that use the simplified cost allocation methodology, or square footage as a statistical basis for capital-related moveable equipment, are included in cost determinations, less precise CCRs are generated. In the FY 2011 IPPS/LTCH PPS final rule (75 FR 50077), we notified hospitals of the need and importance of properly reporting the capital costs of moveable equipment on the Medicare cost report and recommended that hospitals use the statistical allocation method of “dollar value” for costs on Worksheet A, Column 2 for Capital-Related Costs – Moveable Equipment, or by requesting contractor approval in accordance with Section 2307 of CMS Pub. 15-1 to use the “direct assignment” allocation method. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53283), we reiterated this recommendation so that when distinct CCRs for MRI and CT scan would be proposed, the CCRs would fairly and accurately represent the cost of these costly imaging equipment. We encouraged hospitals to use the statistical basis of “dollar value”
for the costs of capital-related movable equipment, especially for costly MRI and CT imaging equipment.

Dollar value is the statistical basis that uses the actual cost of the asset being depreciated and more accurately allocates costs among the cost centers using those assets. In the CY 2014 OPPS/ASC final rule with comment period, we indicated that commenters had expressed concern that the use of square footage as the statistical basis of allocation “results in CCRs that lack face validity” (78 FR 74843 through 74847). It has been CMS’ longstanding policy that hospitals use dollar value as the recommended default statistical basis for capital-related moveable equipment. As discussed above, currently under the simplified cost allocation methodology, hospitals are required to use square footage as the statistical basis for capital-related moveable equipment. Thus, we are finalizing a policy that affords hospitals using the simplified cost allocation methodology the flexibility to use either square footage or dollar value as a statistical basis for capital-related moveable equipment. However, we encourage all hospitals, regardless of their cost-finding methodology, to use dollar value as a statistical basis for the capital-related moveable equipment cost center because we believe it results in more precise CCRs.

Comment: Some commenters believed that, despite advances in technology and recordkeeping for hospitals, the elimination of the simplified cost allocation methodology would create a significant administrative burden.

Response: We appreciate the commenters’ concern regarding the additional burden to hospitals with the elimination of the simplified cost allocation methodology.
As discussed earlier, we are not finalizing our proposal to eliminate the simplified cost allocation methodology. Instead, we are modifying the simplified cost allocation methodology to give hospitals greater flexibility to request approval from their MACs to use the statistical basis of dollar value for capital-related moveable equipment. In this regard, we do not foresee any burden to any hospitals. Instead, we believe greater flexibility is being afforded.

In summary, after consideration of the public comments we received, we are not finalizing our proposal to eliminate the simplified cost allocation methodology. Instead, we are modifying the simplified cost allocation methodology set forth in CMS Pub. 15-2, Chapter 40, Section 4020, to provide additional flexibility to hospitals that use the simplified cost allocation methodology by allowing them to obtain approval from their MACs to use an alternative statistical basis of dollar value for capital-related moveable equipment. In this regard, hospitals using the simplified cost allocation methodology will no longer be restricted to using square footage as a statistical basis for capital-related moveable equipment. Instead, hospitals using the simplified cost allocation methodology may obtain MAC approval in accordance with the instructions set forth in Section 2313 of CMS Pub. 15-1 to use either square footage or dollar value as the statistical basis for capital-related moveable equipment. However, we encourage all hospitals, regardless of their cost-finding methodology, to use dollar value as a statistical basis for the capital-related moveable equipment cost center because we believe it results in more precise CCRs.
Hospitals that are not currently using the simplified cost allocation methodology but desire to do so will need to obtain approval from their MACs, consistent with our current policy set forth at Section 2313 of CMS Pub. 15-1. MACs will approve new requests to use the simplified cost allocation methodology if the hospital demonstrates that the maintenance of the new statistics is less costly and the use does not result in inappropriately shifting costs.

Hospitals that are not using the simplified cost allocation methodology but are using one or more, but not all, of the statistical bases from the cost center list under the simplified cost allocation methodology in Section 4020, Chapter 40 of CMS Pub. 15-2 and have been permitted to do so by their MACs, will continue to be permitted to request such usage from their MACs.

I. Rural Community Hospital Demonstration Program

1. Background

Section 410A(a) of Pub. L. 108-173 required the Secretary to establish a demonstration program to test the feasibility and advisability of establishing “rural community” hospitals to furnish covered inpatient hospital services to Medicare beneficiaries. The demonstration pays rural community hospitals under a reasonable cost-based methodology for Medicare payment purposes for covered inpatient hospital services furnished to Medicare beneficiaries. A rural community hospital, as defined in section 410A(f)(1), is a hospital that--

- Is located in a rural area (as defined in section 1886(d)(2)(D) of the Act) or is treated as being located in a rural area under section 1886(d)(8)(E) of the Act;
CMS-1632-F & IFC

- Has fewer than 51 beds (excluding beds in a distinct part psychiatric or rehabilitation unit) as reported in its most recent cost report;
- Provides 24-hour emergency care services; and
- Is not designated or eligible for designation as a CAH under section 1820 of the Act.

Section 410A(a)(4) of Pub. L. 108-173 specified that the Secretary was to select for participation no more than 15 rural community hospitals in rural areas of States that the Secretary identified as having low population densities. Using 2002 data from the U.S. Census Bureau, we identified the 10 States with the lowest population density in which rural community hospitals were to be located in order to participate in the demonstration: Alaska, Idaho, Montana, Nebraska, Nevada, New Mexico, North Dakota, South Dakota, Utah, and Wyoming (source: U.S. Census Bureau, Statistical Abstract of the United States: 2003).

CMS originally solicited applicants for the demonstration in May 2004; 13 hospitals began participation with cost reporting periods beginning on or after October 1, 2004. In 2005, 4 of these 13 hospitals withdrew from the program and converted to CAH status. This left nine hospitals participating at that time. In 2008, we announced a solicitation for up to six additional hospitals to participate in the demonstration program. Four additional hospitals were selected to participate under this solicitation. These four additional hospitals began under the demonstration payment methodology with the hospital’s first cost reporting period starting on or after July 1, 2008. At that time, 13 hospitals were participating in the demonstration.
Five hospitals (3 of the hospitals that were original participants in the demonstration program and 2 of the hospitals were among the 4 hospitals that began the demonstration program in 2008) withdrew from the demonstration program during CYs 2009 and 2010. (Three of these hospitals indicated that they would be paid more for Medicare inpatient hospital services under the rebasing option allowed under the SCH methodology provided for under section 122 of the Medicare Improvements for Patients and Providers Act of 2008 (Pub. L. 110-275). One hospital restructured to become a CAH, and one hospital closed.) In CY 2011, one hospital that was among the original set of hospitals that participated in the demonstration withdrew from the demonstration. These actions left seven of the originally participating hospitals (that is, hospitals that were selected to participate in either 2004 or 2008) participating in the demonstration program as of June 1, 2011.

Sections 3123 and 10313 of the Affordable Care Act (Pub. L. 111-148) amended section 410A of Pub. L. 108-173, changing the rural community hospital demonstration program in several ways. First, the Secretary is required to conduct the demonstration program for an additional 5-year period, to begin on the date immediately following the last day of the initial 5-year period. Furthermore, in the case of a rural community hospital that is participating in the demonstration program as of the last day of the initial 5-year period, the Affordable Care Act requires the Secretary to provide for the continued participation of such rural hospital in the demonstration program during the 5-year extension period, unless the hospital makes an election to discontinue participation.
In addition, the Affordable Care Act provides that, during the 5-year extension period, the Secretary shall expand the number of States with low population densities determined by the Secretary to 20. Furthermore, the Secretary is required to use the same criteria and data that the Secretary used to determine the States for the initial 5-year period. The Affordable Care Act also allows not more than 30 rural community hospitals in such States to participate in the demonstration program during the 5-year extension period.

We published a solicitation for applications for additional participants in the rural community hospital demonstration program in the Federal Register on August 30, 2010 (75 FR 52960). Applications were due on October 14, 2010. The 20 States with the lowest population density that were eligible for the demonstration program are: Alaska, Arizona, Arkansas, Colorado, Idaho, Iowa, Kansas, Maine, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Mexico, North Dakota, Oklahoma, Oregon, South Dakota, Utah, and Wyoming (source: U.S. Census Bureau, Statistical Abstract of the United States: 2003). We approved 19 new hospitals for participation in the demonstration program. We determined that each of these new hospitals would begin participating in the demonstration with its first cost reporting period beginning on or after April 1, 2011.

Three of these 19 hospitals declined participation prior to the start of the cost reporting periods for which they would have begun the demonstration. In addition to the 7 hospitals that were selected in either 2004 or 2008, the new selection led to a total of 23 hospitals in the demonstration. During CY 2013, one additional hospital among the
set selected in 2011 withdrew from the demonstration, similarly citing a relative financial advantage to returning to the customary SCH payment methodology, which left 22 hospitals participating in the demonstration.

In addition, section 410A(c)(2) of Pub. L. 108-173 required that, in conducting the demonstration program under this section, the Secretary must ensure that the aggregate payments made by the Secretary do not exceed the amount which the Secretary would have paid if the demonstration program under this section was not implemented. This requirement is commonly referred to as “budget neutrality.” Generally, when we implement a demonstration program on a budget neutral basis, the demonstration program is budget neutral in its own terms; in other words, the aggregate payments to the participating hospitals do not exceed the amount that would be paid to those same hospitals in the absence of the demonstration program. Typically, this form of budget neutrality is viable when, by changing payments or aligning incentives to improve overall efficiency, or both, a demonstration program may reduce the use of some services or eliminate the need for others, resulting in reduced expenditures for the demonstration program’s participants. These reduced expenditures offset increased payments elsewhere under the demonstration program, thus ensuring that the demonstration program as a whole is budget neutral or yields savings. However, the small scale of this demonstration program, in conjunction with the payment methodology, makes it extremely unlikely that this demonstration program could be viable under the usual form of budget neutrality.

Specifically, cost-based payments to participating small rural hospitals are likely to increase Medicare outlays without producing any offsetting reduction in Medicare
expenditures elsewhere. Therefore, a rural community hospital’s participation in this demonstration program is unlikely to yield benefits to the participant if budget neutrality were to be implemented by reducing other payments for these same hospitals.

In the past 11 IPPS final rules, spanning the period for which the demonstration program has been implemented, we have adjusted the national inpatient PPS rates by an amount sufficient to account for the added costs of this demonstration program, thus applying budget neutrality across the payment system as a whole rather than merely across the participants in the demonstration program. As we discussed in the FYs 2005 through 2015 IPPS final rules (69 FR 49183; 70 FR 47462; 71 FR 48100; 72 FR 47392; 73 FR 48670; 74 FR 43922, 75 FR 50343, 76 FR 51698, 77 FR 53449, 78 FR 50740, and 79 FR 50141, respectively), we believe that the language of the statutory budget neutrality requirements permits the agency to implement the budget neutrality provision in this manner.

In general terms, in each of these previous years, we used available cost reports for the participating hospitals to derive an estimate of the additional costs attributable for the demonstration. Prior to FY 2013, we used finalized, or settled, cost reports, as available, and “as submitted” cost reports for hospitals for which finalized cost reports were not available. Annual market basket percentage increase amounts provided by the CMS Office of the Actuary reflecting the growth in the prices of inputs for inpatient hospitals were applied to these cost amounts. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53452), we used “as submitted” cost reports (for cost reporting periods ending in CY 2010) for each hospital participating in the demonstration in estimating the costs of
the demonstration. In addition, in FY 2013, we incorporated different update factors (the market basket percentage increase and the applicable percentage increase, as applicable, to several years of data as opposed to solely using the market basket percentage increase) for the calculation of the budget neutrality offset amount. Finally, in each of the previous years, an annual update factor provided by the CMS Office of the Actuary reflecting growth in the volume of inpatient operating services also was applied. For the budget neutrality calculations in the IPPS final rules for FYs 2005 through 2011, the annual volume adjustment applied was 2 percent; for the IPPS final rules for FYs 2012, 2013, 2014, and 2015, it was 3 percent. For a detailed discussion of our budget neutrality offset calculations, we refer readers to the IPPS final rule applicable to the fiscal year involved.

In general, for FYs 2005 through 2009, we based the budget neutrality offset estimate on the estimated cost of the demonstration in an earlier given year. For these periods, we derived that estimated cost by subtracting the estimated amount that would otherwise be paid without the demonstration in an earlier given year from the estimated amount for the same year that would be paid under the demonstration under the reasonable cost-based methodology authorized by section 410A of Pub. L. 108-173. The reasonable cost-based methodology authorized by section 410A of Pub. L. 108-173, as amended, is hereafter referred to as the “reasonable cost methodology.” (We ascertained the estimated amount that would be paid in an earlier given year under the reasonable cost methodology and the estimated amount that would otherwise be paid without the demonstration in an earlier given year from “as submitted” cost reports that were submitted by the hospitals prior to the inception of the demonstration.) We then updated
the estimated cost described above to the current year by multiplying it by the market basket percentage increases applicable to the years involved and the applicable annual volume adjustment. For the FY 2010 IPPS/RY 2010 LTCH PPS final rule, data from finalized cost reports reflecting the participating hospitals’ experience under the demonstration were available. Specifically, the finalized cost reports for the first 2 years of the demonstration, that is, cost reports for cost reporting years beginning in FYs 2005 and 2006 (CYs 2004, 2005, and 2006) were available. These data showed that the actual costs of the demonstration for these years exceeded the amounts originally estimated in the respective final rules for the budget neutrality adjustment. In the FY 2010 IPPS/RY 2010 LTCH PPS final rule, we included in the budget neutrality offset amount an amount in addition to the estimate of the demonstration costs in that fiscal year. This additional amount was based on the amount that the costs of the demonstration for FYs 2005 and 2006 exceeded the budget neutrality offset amounts finalized in the IPPS rules applicable for those years.

Following upon the FY 2010 IPPS/RY 2010 LTCH PPS final rule, we continued to propose a methodology for calculating the budget neutrality offset amount to account for both the estimated demonstration costs in the upcoming fiscal year and an amount by which the actual demonstration costs corresponding to an earlier, given year (which would be known once finalized cost reports became available for that year) exceeded the budget neutrality offset amount finalized in the corresponding year’s IPPS final rule. However, we noted in the FYs 2011, 2012, and 2013 IPPS final rules that, because of a delay affecting the settlement process for cost reports for IPPS hospitals occurring on a
larger scale than merely for the demonstration, we were unable to finalize this component of the budget neutrality offset amount accounting for the amount by which the actual demonstration costs in a given year exceeded the budget neutrality offset amount finalized in the corresponding year’s IPPS final rule for cost reports of demonstration hospitals dating to those beginning in FY 2007.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53449 through 53453), we adopted changes to the methodology for calculating the budget neutrality offset amount in an effort to further improve and refine the methodology. We noted that the revised methodology varied, in part, from the methodology finalized in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51698 through 51705). We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53449 through 53453) for a detailed discussion of the methodology we used for FY 2013. We noted that, although we made changes to certain aspects of the budget neutrality offset amount calculation for FY 2013, several core components of the methodology remained unchanged. For example, we continued to include in the budget neutrality offset amount the estimate of the demonstration costs for the upcoming fiscal year and the amount by which the actual demonstration costs corresponding to an earlier year (which would be determined once we have finalized cost reports for that year) exceeded the budget neutrality offset amount finalized in the corresponding year’s IPPS final rule.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50739 through 50744), we determined the final budget neutrality offset amount to be applied to the FY 2014 IPPS rates to be $52,589,741. This amount was comprised of two distinct components: (1) the
final resulting difference between the total estimated FY 2014 reasonable cost amount to be paid under the demonstration to the 22 participating hospitals for covered inpatient hospital services, and the total estimated amount that would otherwise be paid to such hospitals in FY 2014 without the demonstration (this amount was $46,549,861); and (2) the amount by which the actual costs of the demonstration for FY 2007 (as shown in the finalized cost reports for cost reporting periods beginning in FY 2007 for the 9 hospitals that participated in the demonstration during FY 2007) exceeded the budget neutrality offset amount that was finalized in the FY 2007 IPPS final rule (this amount was $6,039,880).

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50141 through 50145), we determined the final budget neutrality offset amount to be applied to the FY 2015 IPPS rates to be $64,566,915. This amount was comprised of two distinct components: (1) the final resulting difference between the total estimated FY 2015 reasonable cost amount to be paid under the demonstration to the 22 participating hospitals for covered inpatient hospital services, and the total estimated amount that would otherwise be paid to such hospitals in FY 2015 without the demonstration (this amount was $54,177,144); and (2) the amount by which the actual costs of the demonstration for FY 2008 (as shown in the finalized cost reports for cost reporting periods beginning in FY 2008 for the hospitals that participated in the demonstration during FY 2008) exceeded the budget neutrality offset amount that was finalized in the FY 2008 IPPS final rule (this amount was $10,389,771).

2. FY 2016 Budget Neutrality Offset Amount
In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24518), in general, we proposed to use the established methodology used in FY 2015 (79 FR 50141 through 50145), with some modifications as discussed below, for determining the budget neutrality offset amount to be applied to the FY 2016 national IPPS rates to reflect the costs of the demonstration. We proposed to use “as submitted” cost reports ending in CY 2013 as the basis for estimating the reasonable cost amounts for covered services under the demonstration, as well as the amounts that would be paid absent the demonstration. As in previous years’ IPPS rules, we believe that because these are the most recent available cost reports, they will be an accurate predictor of these amounts.

As discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24518), although the proposed methodology for FY 2016 is similar to that for the past several rules, we note that the demonstration will have begun to phase out by the beginning of FY 2016, and because of this, we believe additional calculations would be appropriate. The 7 “originally participating hospitals,” that is, those hospitals that began the demonstration between 2005 and 2009, will have ended their participation in the 5-year extension period authorized by the Affordable Care Act prior to the start of FY 2016. Therefore, we proposed that the financial experience of these hospitals would not factor into the estimated reasonable cost amount and the estimated amounts that would otherwise be paid without the demonstration for FY 2016.

The participation period for the 15 hospitals that entered the demonstration in 2011 and 2012 through the solicitation that followed the Affordable Care Act amendments expanding the demonstration program and that are still participating in the
demonstration will end on a rolling basis according to the end dates of the hospitals’ cost report periods, respectively, from April 30, 2016, through December 31, 2016. As further discussed below, our proposed methodology for estimating the reasonable cost amounts for covered inpatient hospital services under the demonstration, as well as the amounts that would otherwise be paid without the demonstration, would reflect the fact that some of the hospitals within this cohort will participate in the demonstration for only a fraction of the 12 months in FY 2016. Of the 15 hospitals that entered the demonstration in 2011 and 2012 under the Affordable Care Act expansion, 11 hospitals are scheduled to end the demonstration on or before September 30, 2016; 8 of these 11 hospitals are scheduled to end the demonstration prior to September 30, 2016.

For each of these 8 hospitals, we proposed that the FY 2016 estimated reasonable cost amount and the estimated amount that would otherwise be paid without the demonstration derived from the “as submitted” cost reports for cost reporting periods ending in CY 2013 be prorated according to the ratio of the number of months between October 1, 2015 and the end of the hospital’s cost reporting period in relation to the entire 12-month period. (For example, if a hospital’s cost reporting period end date is June 30, 2016, the factor to be multiplied by the estimated reasonable cost amount and the estimated amount that would otherwise be paid without the demonstration from the calendar year end 2013 cost report is 0.75.) For the 7 hospitals that would end the demonstration on either September 30, 2016 or December 31, 2016, estimates of these amounts would correspond to the amounts indicated in the calendar year end 2013 cost reports.
We note that the 7 hospitals that started the demonstration between FYs 2005 and 2009 also will have ended their participation on a rolling basis during FY 2015. In the FY 2015 IPPS/LTCH PPS final rule, in accordance with the policy we finalized in the FY 2015 IPPS/LTCH PPS final rule, we based the estimate of the cost of the demonstration for FY 2015 on the financial experience as indicated on these hospitals’ CY 2012 “as submitted” cost reports (as discussed earlier) without making any adjustment to reflect the fact that hospitals would be ending at different points during FY 2015. We believe this methodology was reasonable because only 5 hospitals are ending their participation in the demonstration before September 30, 2015, out of the 22 hospitals on which the estimate of the cost of the demonstration for that year was based. Furthermore, as discussed previously, the methodology stated in this and previous rules for determining the costs of the demonstration in a given fiscal year entails the comparison of the actual costs of the demonstration as determined from finalized cost reports for that fiscal year (when they are available) to the estimated amount identified for that fiscal year in the corresponding fiscal year’s final rule. Consistent with this policy, this second step will be used to reconcile any differences between the estimated and actual demonstration costs for FY 2015 once finalized cost reports for cost reporting periods beginning in FY 2015 are available. Although we believe that our methodology for estimating costs for FY 2015 was reasonable, for FY 2016, we proposed a more refined methodology to estimate the costs of the demonstration; that is, one that entails prorating, as discussed above, the estimated reasonable cost amount and the estimated amounts that would otherwise be paid without the demonstration as indicated on the “as
submitted” cost reports for cost reporting periods ending in CY 2013 based on the number of months that each hospital will have participated in the demonstration during FY 2016.

Similar to previous years, we proposed the methodology for calculating the budget neutrality offset amount to proceed in several steps, as follows:

*Step 1:* For each of the 15 hospitals that will be participating in the demonstration during FY 2016, we proposed to identify the general reasonable cost amount calculated under the reasonable cost methodology for covered inpatient hospital services for the period of participation during FY 2016 based on “as submitted” cost reports ending in CY 2013. As discussed above, we proposed that the basis of this estimate for each hospital scheduled to participate for part of FY 2016 would be the fraction of the number of months that the hospital will be participating out of the 12 months within FY 2016 multiplied by the reasonable cost amount for covered inpatient hospital services indicated on the “as submitted” cost report ending in CY 2013.

Given that 8 hospitals will be participating in the demonstration for only part of FY 2016, we believe that such a methodology of prorating represents an appropriate refinement to the methodology established in previous rules for estimating the reasonable cost amount paid under the demonstration because each hospital’s relevant cost experience, respectively, which this estimated amount reflects, would apply for the specific number of months for which it is participating in the demonstration in FY 2016. We believe that applying the relevant fraction, representing the number of months that
the hospital will have participated during FY 2016 out of the 12 months in the fiscal year, will lead to more precise estimates.

Because section 410A of Pub. L. 108-173 stipulates that swing-bed services are to be included among the covered inpatient hospital services for which the demonstration payment methodology applies, we proposed to include the cost of these services, as reported on the “as submitted” cost reports ending in CY 2013 for the hospitals that provided swing-bed services in CY 2013, similarly prorated by the fraction of the number of months that the hospital will be participating out of the total number of months within FY 2016.

Similar to the methodology applied in FY 2015, we proposed to sum the two above-referenced amounts to calculate the general total estimated FY 2013 reasonable cost amount for covered inpatient hospital services for all participating hospitals. Next, we proposed to multiply the derived sum by the FY 2014, FY 2015, and FY 2016 IPPS market basket percentage increases, which are formulated by the CMS Office of the Actuary. We proposed to use the final FY 2016 IPPS market basket percentage increase in this final rule. We proposed to multiply this product of the prorated reasonable cost amount for all 15 hospitals (based on CY 2013 “as submitted” cost reports) and the market basket percentage increases applicable to the years involved by a 3-percent annual volume adjustment for FYs 2014, 2015, and 2016. The result was the proposed total estimated FY 2016 reasonable cost amount for covered inpatient hospital services for all hospitals participating in FY 2016.
We propose to apply the IPPS market basket percentage increases applicable for FYs 2014 through 2016 to the reasonable cost amount derived from CY 2013 cost reports described earlier to model the estimated FY 2016 reasonable cost amount under the demonstration. We proposed to use the IPPS market basket percentage increases because we believe that these update factors appropriately indicate the trend of increase in inpatient hospital operating costs under the reasonable cost methodology involved. The 3-percent annual volume adjustment was stipulated by the CMS Office of the Actuary and is being used because it is intended to reflect the tendency of hospitals’ inpatient caseloads to increase. Because inpatient caseloads for small hospitals may fluctuate, we proposed to incorporate into the estimate of demonstration costs a factor to allow for a potential increase in inpatient hospital services.

Step 2: For each of the 15 hospitals that will be participating in FY 2016, we proposed to identify the general estimated amount that would otherwise be paid in FY 2016 under applicable payment methodologies for covered inpatient hospital services (as indicated on the “as submitted” cost report for cost reporting periods ending in CY 2013) if the demonstration was not implemented. Similar to Step 1, we proposed that the basis of this estimate for each hospital participating for part of FY 2016 would be the fraction of the number of months that the hospital will be participating out of the 12 months within FY 2016 multiplied by the estimated amount that would otherwise be paid for these services as indicated on the “as submitted” cost report ending in CY 2013. We believe that such a methodology of prorating represents an appropriate refinement to the methodology established in previous rules for estimating the amount that otherwise
would be paid without the demonstration because each hospital’s relevant costs and claims experiences, respectively, which this estimated amount reflects, would apply for the specific number of months for which it is participating in the demonstration in FY 2016. As we stated in Step 1, we believe that applying the relevant fraction, representing the number of months that the hospital will have participated during FY 2016 out of the 12 months in the fiscal year, will lead to more precise estimates.

Similarly, as in Step 1, for the hospitals that provide swing-bed services, we proposed to include the amount that would otherwise be paid for these services without the demonstration, as reported on the “as submitted” cost reports ending in CY 2013 for the hospitals that provided swing-bed services in CY 2013. We proposed to prorate, as appropriate, the estimated amount that would otherwise be paid for these services (as indicated on the “as submitted” cost report for cost reporting periods ending in CY 2013) by the fraction of the number of months that the hospital will be participating in FY 2016 out of the total number of months within FY 2016, and include this amount in the total FY 2013 general estimated amount that would otherwise be paid for covered inpatient hospital services without the demonstration.

Similar to the methodology applied in FY 2015, we proposed to sum these two amounts and multiply the derived sum by the FYs 2014, 2015, and 2016 IPPS applicable percentage increases. We proposed to use the final FY 2016 applicable percentage increase in this final rule. This methodology differs from Step 1, in which we proposed to apply the IPPS market basket percentage increases to the sum of the hospitals’ general total FY 2013 estimated reasonable cost amount for covered inpatient hospital services.
We believe that the IPPS applicable percentage increases are appropriate update factors to estimate the amounts that would generally otherwise be paid without the demonstration. This is because IPPS payments would constitute the majority of payments that would otherwise be made without the demonstration and the applicable percentage increase is the factor used under the IPPS to update the inpatient hospital payment rates. We proposed then to multiply this product by a 3-percent annual volume adjustment for FYs 2014, 2015, and 2016. The result represents the proposed general total estimated FY 2016 amount that would otherwise be paid for covered inpatient hospital services without the demonstration to the hospitals that would be participating in FY 2016.

Step 3: We proposed to subtract the amount derived in Step 2 (representing the sum of estimated amounts that generally would otherwise be paid to the participating hospitals for covered inpatient hospital services for FY 2016 if the demonstration had not been implemented) from the amount derived in Step 1 (representing the sum of the estimated reasonable cost amount that generally would be paid under the demonstration to all participating hospitals for covered inpatient hospital services for FY 2016). We proposed that the resulting difference would represent one component of the estimated amount for which an adjustment to the FY 2016 national IPPS rates would be calculated (as further discussed below).

For the FY 2016 proposed rule, the resulting difference was $26,195,949 (80 FR 24520). This estimated amount was based on the specific assumptions identified regarding the data sources used, that is, “as submitted” recently available cost reports.
We stated in the proposed rule that if updated data became available prior to the FY 2016 IPPS/LTCH PPS final rule, we would use them to the extent appropriate to estimate the costs for the demonstration program in FY 2016. Therefore, we indicated that the estimated budget neutrality offset amount may change in the final rule, depending on the availability of updated data.

_Step 4:_ We proposed to include in the budget neutrality offset amount the amount by which the actual demonstration costs corresponding to an earlier given year (which would be determined once we have finalized cost reports for that year) differs from the budget neutrality offset amount finalized in the corresponding year’s IPPS final rule. (In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50145), we calculated the amount by which the actual costs of the demonstration in FY 2008 exceeded the budget neutrality offset amount that was finalized in the FY 2008 IPPS final rule. The corresponding differences for FYs 2005, 2006, and 2007 were identified and included in the budget neutrality offset amounts in previous years’ IPPS final rules.) At the time of development of the FY 2016 IPPS/LTCH PPS proposed rule, finalized cost reports for cost reporting periods beginning in FY 2009 were available for the 10 hospitals that completed a cost report period starting in FY 2009. These cost reports have been issued by the MACs as finalized, and they have been subjected to review processes specific to the calculations for cost-based payment as determined by the payment methodology for the demonstration. We note that CMS has issued a notice of reopening for several of these cost reports pertaining to an issue that affects hospitals nationwide. However, we stated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24520) that it was not yet
known if, or to what extent, the calculations for budget neutrality under the
demonstration would be affected in the event of a reopening of these cost reports. Until
such a determination is made, we indicated we believe that it would be appropriate to use
these cost reports for our calculations under Step 4 for FY 2016 in order to take into
account the actual costs of the demonstration for FY 2009 as soon as possible and to
enhance the accuracy of the budget neutrality offset calculation (80 FR 24520).

Therefore, in the proposed rule, we identified the difference between the actual
cost of the demonstration as indicated on these finalized FY 2009 cost reports and the
budget neutrality offset amount that was identified in the FY 2009 IPPS final rule
(73 FR 48670 through 48671), and we proposed to adjust the current year’s budget
neutrality offset amount by that difference. We stated that if there is a reopening that
necessitates a recalculation for any of these reports, we would conduct another
calculation once the affected cost reports are revised and finalized to determine the
difference between the cost of the demonstration as reflected on the revised and finalized
cost reports and the amount that was included in the budget neutrality offset amount for
FY 2009 as identified in the FY 2009 IPPS final rule (taking into account any amount
already included in the finalized budget neutrality offset amount in this FY 2016
IPPS/LTCH PPS final rule that reflects an adjustment based on FY 2009 cost reports).

We indicated that if finalized cost reports for demonstration hospitals that participated in
FY 2010 or FY 2011 are available prior to this FY 2016 IPPS/LTCH PPS final rule, we
intended to adjust the budget neutrality offset amount for FY 2016 for any amounts by
which the finalized costs of the demonstration for the year (FY 2010 or FY 2011) differ
from the amounts included in the budget neutrality offset finalized in the respective year’s IPPS final rule that indicate the estimated cost of the demonstration for that fiscal year.

As further discussed below, we noted in the proposed rule that Step 4 would result in the amount indicating the actual cost of the demonstration for FY 2009 (determined from the current finalized FY 2009 cost reports described in Step 4) being less than the amount that was originally identified in the FY 2009 IPPS final rule as the estimated cost of the demonstration. Therefore, we proposed to include that component as a negative adjustment to the budget neutrality offset amount for FY 2016 (as explained below).

Step 5: The total budget neutrality offset amount that we proposed to apply in determining the budget neutrality adjustment to the FY 2016 IPPS rates used the sum of the amounts derived in Steps 3 and 4. Each of these amounts represents a discrete calculation, reflecting the two-stage process of ensuring budget neutrality for the demonstration: (1) estimating the costs of the demonstration prospectively for the upcoming fiscal year from historical “as submitted” cost reports (Step 3), and (2) then retrospectively reconciling the difference between this estimate for a prior fiscal year and the actual costs as recorded on finalized cost reports for the specific fiscal year (Step 4).

Therefore, for the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24521), we proposed to incorporate the following components into the calculation of the total budget neutrality offset:

(a) The amount, derived from Step 3, representing the difference between the sum of the estimated reasonable cost amounts that would be paid under the demonstration
to participating hospitals for covered inpatient hospital services for FY 2016 and the sum of the estimated amounts that would generally be paid if the demonstration had not been implemented. This amount would be based on “as submitted” cost reports for cost reporting periods ending in CY 2013, and would be prorated according to the number of months that each hospital will have participated in the demonstration in FY 2016 out of the 12-month fiscal year period. This amount was $26,195,949.

(b) The amount, as derived from Step 4, by which the actual costs of the demonstration for FY 2009 (as shown in the finalized cost reports for the 10 hospitals that completed a cost reporting period beginning in FY 2009) differ from the budget neutrality offset amount that was finalized in the FY 2009 IPPS final rule. Analysis of this set of cost reports shows that the budget neutrality offset amount that was finalized in the FY 2009 IPPS final rule exceeds the actual cost of the demonstration by $8,457,452.

For FY 2016, the total budget neutrality offset amount that we proposed to apply was the amount determined under item (a) of Step 5 ($26,195,949) minus the amount determined under item (b) of Step 5 ($8,457,452), or $17,738,497. We proposed to subtract the amount under item (b) from that under item (a) because the amount under item (b) represents the amount by which the budget neutrality offset finalized in the FY 2009 IPPS final rule exceeded the actual costs of the demonstration for FY 2009. Accordingly, we proposed to reduce the budget neutrality offset amount for FY 2016 by that amount (80 FR 24521).

We stated in the proposed rule that if updated data became available prior to this FY 2016 IPPS/LTCH PPS final rule, we would use them to the extent appropriate to
determine the budget neutrality offset amount for FY 2016. Therefore, we indicated that
the amount of the budget neutrality offset may change in this FY 2016 IPPS/LTCH PPS
final rule based on the availability of updated data. In addition, similar to previous years,
we proposed that if finalized cost reports for all of the demonstration hospitals that
classified in an applicable year (FY 2010 or FY 2011) are available prior to the
FY 2016 IPPS/LTCH PPS final rule, we would adjust the budget neutrality offset amount
to reflect the difference between the actual cost of the demonstration for the year
(FY 2010 or FY 2011) and the budget neutrality offset amount applicable to such year as
finalized in the respective year’s final rule, as explained in Step 4. The resulting total
would be the amount for which an adjustment to the national IPPS rates would be made.

We did not receive any public comments on our proposed budget neutrality offset
methodology, as discussed above. Therefore, we are finalizing the FY 2016 budget
neutrality offset methodology as proposed, with the modifications discussed below, that
will be used to derive the respective components that comprise the budget neutrality
offset amount for which the adjustment to the national IPPS rates is calculated for
FY 2016

Step 1: In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24521), we stated
that if updated data became available prior to the FY 2016 IPPS/LTCH PPS final rule, we
would use them to the extent appropriate to determine the budget neutrality offset amount
for FY 2016. We also stated that the budget neutrality offset amount may change in the
final rule, based on the availability of updated data. In addition, in the FY 2016
IPPS/LTCH PPS proposed rule (80 FR 24519 through 24520), we proposed to use the
final FY 2016 IPPS market basket percentage and the final FY 2016 applicable percentage increase in our calculation of the demonstration costs for FY 2016.

Therefore, in order to derive the estimate of the demonstration costs for the 15 hospitals that will be participating in the demonstration during FY 2016 (that is, the difference between the estimate of the reasonable cost amount and the estimated amount that would otherwise be paid without the demonstration), we will use the final FY 2016 IPPS market basket percentage and applicable percentage increase provided by the CMS Office of the Actuary. These update factors are specified in section IV.A. of the preamble of this final rule. Accordingly, with this modification, the resulting estimate of costs of the demonstration for FY 2016 for the 15 hospitals participating in the demonstration in FY 2016 is $26,044,620, representing one component of the amount for which the adjustment to the national IPPS rates is calculated.

Step 2: We are identifying the difference between the actual cost of the demonstration for FY 2009 as indicated in the finalized cost reports for hospitals that participated in FY 2009 and that had cost reporting periods beginning in FY 2009 (this amount is $14,332,936), and the budget neutrality offset amount that was identified in the FY 2009 IPPS final rule (this amount is $22,790,388) (73 FR 48671). We are including that difference ($8,457,452) in the FY 2016 budget neutrality offset amount, as further explained below. As stated in the proposed rule, if there is a reopening that necessitates a recalculation for any of these reports, we will conduct another calculation once the affected reports are revised and finalized to determine the difference between the costs of the demonstration as reflected in the revised and finalized cost reports and the amount
that was included in the budget neutrality offset amount for FY 2009 as identified in the FY 2009 IPPS final rule (taking into account any amount already included in the finalized budget neutrality offset amount in the FY 2016 IPPS/LTCH PPS final rule that reflects an adjustment based on FY 2009 cost reports).

Step 3: In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24520 through 24521), we proposed that if finalized cost reports for demonstration hospitals that participated in FY 2010 or FY 2011 are available prior to the FY 2016 IPPS/LTCH PPS final rule, we would adjust the budget neutrality offset amount for FY 2016 to reflect the difference between the actual cost of the demonstration for the year (FY 2010 or FY 2011) and the amount included in the budget neutrality offset finalized in the respective year’s IPPS final rule that indicates the estimated cost of the demonstration for that fiscal year. We have obtained finalized cost reports for cost reporting periods beginning in FY 2010 for the 9 hospitals whose cost reporting periods began in FY 2010, and thus are including in the budget neutrality offset amount for FY 2016 the difference between the actual cost of the demonstration in FY 2010 as indicated in these finalized cost reports, and the budget neutrality offset amount finalized for FY 2010 in the applicable IPPS final rule indicating the estimated cost of the demonstration for FY 2010. We discuss below several particular elements of the IPPS final rules for FYs 2010 and 2011 (74 FR 43922 through 43924 and 75 FR 50344 through 50345) that are relevant to conducting this analysis:

(a) The budget neutrality offset amount as set forth in the FY 2010 IPPS final rule (74 FR 43923 through 43924) included two different components. First, it included
the estimate of the costs of the demonstration for FY 2010 for the 11 hospitals that were scheduled to participate in the demonstration as of the date the FY 2010 IPPS final rule was issued (this amount was $15,081,251). Second, the amounts by which the actual costs of the demonstration program in FYs 2005 and 2006, respectively, exceeded the budget neutrality offset amounts identified in the IPPS final rules for those years were incorporated as additional, discrete amounts into the budget neutrality offset amount for FY 2010 (we note that, because these amounts do not reflect the estimated demonstration costs for FY 2010, they are not included in our calculation under this Step 3).

(b) Given that when the FY 2010 IPPS final rule was published, the demonstration was expected to end in FY 2010, the estimate of the costs of the demonstration for FY 2010 for the 11 hospitals that were scheduled to participate in FY 2010 was calculated in the FY 2010 IPPS final rule using a prorating methodology similar to that described above for the estimate for FY 2016. Thus, the fraction of the number of months that the hospital was scheduled to participate in the demonstration during FY 2010 out of the 12-month fiscal year period served as the basis for estimating the reasonable cost amount that would be paid under the demonstration and the amount that would have been paid without the demonstration in FY 2010.

(c) Following upon the extension of the demonstration in 2010, as required by the Affordable Care Act, the FY 2011 IPPS final rule (75 FR 50344 through 50345) incorporated into the budget neutrality offset amount the estimated costs of the demonstration for FY 2010 that were not accounted for in the FY 2010 IPPS final rule because, in that final rule, we calculated the cost for FY 2010 assuming that for a subset
of hospitals the demonstration would end before the end of that fiscal year. (This amount was $6,488,221.)

Therefore, the estimated costs of the demonstration for FY 2010 (and the budget neutrality offset amount relating to these costs) were finalized in the FYs 2010 and 2011 IPPS final rules, as discussed above. Accordingly, we are summing these two amounts, specified in the FYs 2010 and 2011 IPPS final rules ($15,081,251 and $6,488,221 respectively). This summed amount is $21,569,472. In this final rule, we are determining the difference between this amount and the actual costs of the demonstration in FY 2010. The actual cost of the demonstration in FY 2010 is determined from finalized cost reports for the hospitals that participated in the demonstration and that had cost reporting periods beginning in FY 2010; that amount is $16,817,922. Therefore, the estimated costs of the demonstration identified in the applicable final rules ($21,569,472) exceeded the actual costs of the demonstration ($16,817,922) by $4,751,550 for FY 2010.

Step 4: The amounts determined respectively in Steps 1, 2, and 3, each represent a discrete calculation, reflecting the following two-stage process of ensuring budget neutrality for the demonstration: (1) estimating the costs of the demonstration prospectively for the upcoming fiscal year from historical cost reports (Step 1); and (2) then retrospectively reconciling the difference between this estimate for a prior fiscal year and the actual costs as recorded on finalized cost reports for the specific fiscal year (Steps 2 and 3). Therefore, for this FY 2016 IPPS/LTCH PPS final rule, we are incorporating the following components into the calculation of the total budget neutrality offset:
(a) The amount, derived from Step 1, representing the difference between the sum of the estimated reasonable cost amounts to be paid under the demonstration to participating hospitals for covered inpatient hospital services for FY 2016 and the sum of the estimated amounts that would generally be paid in FY 2016 if the demonstration had not been implemented. This amount is based on “as submitted” cost reports for cost reporting periods ending in CY 2013, and is prorated according to the number of months that each hospital will have participated in the demonstration in FY 2016 out of the 12-month fiscal year period. This amount is $26,044,620.

(b) The amount, as derived from Step 2, by which the actual costs of the demonstration for FY 2009 (as shown in the finalized cost reports for the 10 hospitals that completed a cost reporting period beginning in FY 2009) differ from the budget neutrality offset amount that was finalized in the FY 2009 IPPS final rule. Analysis of this set of cost reports shows that the budget neutrality offset amount that was finalized in the FY 2009 IPPS final rule exceeds the actual cost of the demonstration by $8,457,452 for FY 2009.

(c) The amount, as derived from Step 3, by which the actual costs of the demonstration for FY 2010 (as shown in the finalized cost reports for the 9 hospitals that completed a cost reporting period beginning in FY 2010) differ from the amount that was finalized as the costs of the demonstration for FY 2010 in the FYs 2010 and 2011 IPPS final rules. Analysis of this set of cost reports shows that the budget neutrality offset amount that was finalized to account for the demonstration costs in FY 2010 (as set forth
in the FYs 2010 and 2011 IPPS final rules as discussed above) exceeds the actual cost of the demonstration for FY 2010 by $4,751,550.

For FY 2016, the total budget neutrality offset amount that we are applying to the national IPPS rates is: the amount determined under item (a) of Step 4 ($26,044,620) minus the amount determined under item (b) of Step 4 ($8,457,452) minus the amount determined under item (c) of Step 4 ($4,751,550). We are subtracting the amounts under items (b) and (c) from that under item (a) because the amounts under items (b) and (c) represent the amount by which the budget neutrality offset finalized in the applicable IPPS final rules (FYs 2009, 2010, and 2011) exceeded the actual costs of the demonstration for FYs 2009 and 2010, respectively. Accordingly, we are reducing the budget neutrality offset amount under (a) of Step 4 by the amounts in (b) and (c) of Step 4, for a total FY 2016 budget neutrality offset amount of $12,835,618. This is the final budget neutrality offset amount for which the adjustment to the national IPPS rates for FY 2016 is calculated. (We discuss the final payment rate adjustment that is required to ensure budget neutrality of the demonstration program for FY 2016 (the budget neutrality adjustment factor) in section II.A.4.f. of the Addendum to this final rule.)

Finally, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24521), we indicated that we were considering whether to propose in future rulemaking that the calculation of the final costs of the demonstration for a fiscal year reflect that some of the participating hospitals would otherwise have been eligible for the payment adjustment for low-volume hospitals in that fiscal year if they had not participated in the demonstration. Our policy under the demonstration is that hospitals participating in the demonstration are
not able to receive the low-volume payment adjustment in addition to the reasonable
cost-based payment authorized by section 410A of Pub. L. 108-173. We refer readers to
Change Request 7505, dated July 22, 2011, available on the CMS Web site at:
http://www.cms.gov. Section 1886(d)(12) of the Act provides for a payment adjustment
to account for the higher costs per discharge for low-volume hospitals under the IPPS,
effective FY 2005 (69 FR 49099 through 49102). We note that sections 3125 and 10314
of the Affordable Care Act provided for temporary changes in the qualifying criteria and
payment adjustment for low-volume hospitals for FYs 2011 and 2012, which have been
extended by subsequent legislation: through FY 2013, by the American Taxpayer Relief
Act of 2012 (ATRA) (Pub. L. 112-240) (78 FR 50610 through 50613); through
March 31, 2014, by the Pathway for SGR Reform Act (Pub L. 113-67) (79 FR 15022
through 15025); through March 31, 2015, by the Protecting Access to Medicare Act of
2014 (Pub. L. 113-93) (79 FR 49998 through 50001); and most recently through
September 30, 2017, by section 204 of the Medicare Access and CHIP Reauthorization
Act of 2015 (Pub. L. 114-10). The extension under section 204 of Pub. L. 114-10 is
discussed in section IV.L. of the preamble of this final rule. These temporary changes
have increased the number of hospitals that are eligible to receive the low-volume
hospital payment adjustment.

To the extent a hospital would have received a low-volume hospital payment
adjustment if it had not participated in the demonstration, we believe it would be
reasonable to take this into account in future rulemaking in determining what the hospital
would have otherwise been paid in an applicable year without the demonstration.
Because this payment adjustment has not been factored into the estimation of payments that otherwise would have been paid under the demonstration, such a proposal would require detailed consideration of the data sources and methodology that would be used to determine which among the demonstration hospitals would have otherwise been eligible for the low-volume payment adjustment and to estimate the amount of the adjustment. We invited public comments on this issue.

We did not receive any public comments on this issue. We will continue to examine this issue and consider which data sources and methodology would be appropriate for determining which among the demonstration hospitals would have otherwise been eligible for the low-volume payment adjustment and for estimating the amount of that adjustment. We may address this issue again in the FY 2017 IPPS/LTCH PPS proposed rule.

We also intend to discuss in the FY 2017 IPPS/LTCH PPS proposed rule how we propose to reconcile the budget neutrality offset amounts identified in the IPPS final rules for FYs 2011 through 2016 with the actual costs of the demonstration for those years, considering the fact that the demonstration will end December 31, 2016.

J. Changes to MS-DRGs Subject to the Postacute Care Transfer Policy (§ 412.4)

1. Background

Existing regulations at § 412.4(a) define discharges under the IPPS as situations in which a patient is formally released from an acute care hospital or dies in the hospital. Section 412.4(b) defines acute care transfers, and § 412.4(c) defines postacute care transfers. Our policy set forth in § 412.4(f) provides that when a patient is transferred
and his or her length of stay is less than the geometric mean length of stay for the
MS-DRG to which the case is assigned, the transferring hospital is generally paid based
on a graduated per diem rate for each day of stay, not to exceed the full MS-DRG
payment that would have been made if the patient had been discharged without being
transferred.

The per diem rate paid to a transferring hospital is calculated by dividing the full
MS-DRG payment by the geometric mean length of stay for the MS-DRG. Based on an
analysis that showed that the first day of hospitalization is the most expensive
(60 FR 45804), our policy generally provides for payment that is twice the per diem
amount for the first day, with each subsequent day paid at the per diem amount up to the
full MS-DRG payment (§ 412.4(f)(1)). Transfer cases also are eligible for outlier
payments. In general, the outlier threshold for transfer cases, as described in § 412.80(b),
is equal to the fixed-loss outlier threshold for nontransfer cases (adjusted for geographic
variations in costs), divided by the geometric mean length of stay for the MS-DRG, and
multiplied by the length of stay for the case, plus 1 day.

We established the criteria set forth in § 412.4(d) for determining which DRGs
qualify for postacute care transfer payments in the FY 2006 IPPS final rule (70 FR 47419
through 47420). The determination of whether a DRG is subject to the postacute care
transfer policy was initially based on the Medicare Version 23.0 GROUPER (FY 2006)
and data from the FY 2004 MedPAR file. However, if a DRG did not exist in Version
23.0 or a DRG included in Version 23.0 is revised, we use the current version of the
Medicare GROUPER and the most recent complete year of MedPAR data to determine if
the DRG is subject to the postacute care transfer policy. Specifically, if the MS-DRG’s
total number of discharges to postacute care equals or exceeds the 55th percentile for all
MS-DRGs and the proportion of short-stay discharges to postacute care to total
discharges in the MS-DRG exceeds the 55th percentile for all MS-DRGs, CMS will apply
the postacute care transfer policy to that MS-DRG and to any other MS-DRG that shares
the same base MS-DRG. In the preamble to the FY 2006 IPPS final rule (70 FR 47419),
we stated that we will not revise the list of DRGs subject to the postacute care transfer
policy annually unless we are making a change to a specific DRG.

To account for MS-DRGs subject to the postacute care policy that exhibit
exceptionally higher shares of costs very early in the hospital stay, § 412.4(f) also
includes a special payment methodology. For these MS-DRGs, hospitals receive
50 percent of the full MS-DRG payment, plus the single per diem payment, for the first
day of the stay, as well as a per diem payment for subsequent days (up to the full
MS-DRG payment (§ 412.4(f)(6)). For an MS-DRG to qualify for the special payment
methodology, the geometric mean length of stay must be greater than 4 days, and the
average charges of 1-day discharge cases in the MS-DRG must be at least 50 percent of
the average charges for all cases within the MS-DRG. MS-DRGs that are part of an
MS-DRG severity level group will qualify under the MS-DRG special payment
methodology policy if any one of the MS-DRGs that share that same base MS-DRG
qualifies (§ 412.4(f)(6)).

2. Changes to the Postacute Care Transfer MS-DRGs for FY 2016
In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24522), we discussed that, based on our annual review of MS-DRGs, we had identified two proposed new MS-DRGs that we proposed to include on the list of MS-DRGs subject to the postacute care transfer policy. As we discussed in section II.G. of the preamble of the proposed rule (80 FR 24349 through 24410), in response to public comments and based on our analysis of FY 2014 MedPAR claims data, we proposed to make changes to MS-DRGs, effective for FY 2016.

As discussed in section II.G.3.b. of the preamble of the proposed rule (80 FR 24356 through 24361), we proposed to modify the MS-DRG assignment of certain cardiovascular procedures currently assigned to MS-DRGs 246 (Percutaneous Cardiovascular Procedures with Drug-Eluting Stent with MCC or 4+ Vessels/Stents), 247 (Percutaneous Cardiovascular Procedures with Drug-Eluting Stent without MCC), 248 (Percutaneous Cardiovascular Procedures with Non-Drug Eluting Stent with MCC or 4+ Vessels/Stents), 249 (Percutaneous Cardiovascular Procedures with Non-Drug Eluting Stent without MCC), 250 (Percutaneous Cardiovascular Procedures without Coronary Artery Stent with MCC), and 251 (Percutaneous Cardiovascular Procedures without Coronary Artery Stent without MCC) to improve the clinical homogeneity of these MS-DRGs and reflect the resource cost of specialized equipment. We proposed to create new MS-DRGs 273 and 274 (Percutaneous Intracardiac Procedures with and without MCC, respectively) and to reassign the procedures performed within the heart chambers using intracardiac techniques from their existing assignment in MS-DRGs 246 through 251 to the two proposed new MS-DRGs.
To improve clinical coherence for the various cardiovascular procedures assigned to MS-DRGs 237 and 238 (Major Cardiovascular Procedures with and without MCC, respectively), as discussed in section II.G.3.e. of the preamble of the proposed rule (80 FR 24362 through 24379), we also proposed to delete MS-DRGs 237 and 238 and to create five new proposed MS-DRGs. Proposed new MS-DRGs 268 and 269 (Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC and without MCC, respectively) would contain the more complex, more invasive aortic and heart assist procedures assigned to MS-DRGs 237 and 238. Proposed new MS-DRGs 270 (Other Major Cardiovascular Procedures with MCC), 271 (Other Major Cardiovascular Procedures with CC), and 272 (Other Major Cardiovascular Procedures without CC/MCC) would include the less complex, less invasive cardiovascular procedures assigned to MS-DRGs 237 and 238.

In light of these proposed changes to the MS-DRGs for FY 2016, according to the regulations under § 412.4(c), we evaluated these proposed MS-DRGs against the general postacute care transfer policy criteria using the FY 2014 MedPAR data. If an MS-DRG qualified for the postacute care transfer policy, we also evaluated that MS-DRG under the special payment methodology criteria according to regulations at § 412.4(f)(6). We continue to believe it is appropriate to reassess MS-DRGs when proposing reassignment of procedures and/or diagnostic codes that would result in material changes to an MS-DRG. As a result of our review, we proposed to update the list of MS-DRGs that are subject to the postacute care transfer policy to include the proposed new MS-DRGs 273 and 274. We determined that existing MS-DRGs 246 through 251 do not qualify for the
postacute care transfer policy and would not meet the review criteria for FY 2016.

Proposed new MS-DRGs 268 through 272 also would not qualify for postacute care transfer policy status.

We did not receive any public comments on our proposals. Therefore, we are finalizing our proposals to update the list of MS-DRGs that are subject to the postacute care transfer policy to include new MS-DRGs 273 and 274. We omitted data for MS-DRGs 246 through 251 from the table published in the proposed rule (80 FR 24522 through 24523) and stated they did not meet review criteria. However, because we proposed changes to MS-DRGs 246 through 251 due to the reassignment of procedures to new MS-DRGs 273 and 274, we are including data for MS-DRGs 246 through 251 in the table in this final rule that show that MS-DRGs 246 through 251 do not qualify for the postacute care transfer policy for FY 2016. New MS-DRGs 268 through 272 also do not qualify for postacute care transfer policy status for FY 2016. The table below lists the MS-DRGs that are subject to the postacute care transfer policies for FY 2016.
<table>
<thead>
<tr>
<th>New MS-DRG</th>
<th>MS-DRG Title</th>
<th>Total Cases</th>
<th>Postacute Care Transfers (55th percentile: 1,395)</th>
<th>Short-Stay Postacute Care Transfers</th>
<th>Percent of Short-Stay Postacute Care Transfers to all Cases (55th percentile: 7.8005%)</th>
<th>Postacute Care Transfer Policy Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>246</td>
<td>Percutaneous Cardiovascular Procedures with Drug-Eluting Stent with MCC or 4+ Vessels/Stents</td>
<td>32,542</td>
<td>9,305</td>
<td>1,490</td>
<td>4.5787%*</td>
<td>NO</td>
</tr>
<tr>
<td>247</td>
<td>Percutaneous Cardiovascular Procedures with Drug-Eluting Stent without MCC</td>
<td>85,648</td>
<td>8,054</td>
<td>669</td>
<td>0.7811%*</td>
<td>NO</td>
</tr>
<tr>
<td>248</td>
<td>Percutaneous Cardiovascular Procedures with Non-Drug Eluting Stent with MCC or 4+ Vessels/Stents</td>
<td>9,727</td>
<td>3,486</td>
<td>455</td>
<td>4.6777%*</td>
<td>NO</td>
</tr>
<tr>
<td>249</td>
<td>Percutaneous Cardiovascular Procedures with Non-Drug Eluting Stent without MCC</td>
<td>17,331</td>
<td>2,817</td>
<td>169</td>
<td>0.9751%*</td>
<td>NO</td>
</tr>
<tr>
<td>250</td>
<td>Percutaneous Cardiovascular Procedures without Coronary Artery Stent with MCC</td>
<td>3,720</td>
<td>1,094*</td>
<td>183</td>
<td>4.9194%*</td>
<td>NO</td>
</tr>
<tr>
<td>251</td>
<td>Percutaneous Cardiovascular Procedures without Coronary Artery Stent without MCC</td>
<td>6,974</td>
<td>799*</td>
<td>51</td>
<td>0.7313%*</td>
<td>NO</td>
</tr>
<tr>
<td>268</td>
<td>Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC</td>
<td>4,464</td>
<td>2,178</td>
<td>268</td>
<td>6.0036%*</td>
<td>NO</td>
</tr>
<tr>
<td>269</td>
<td>Aortic and Heart Assist Procedures Except Pulsation Balloon without MCC</td>
<td>19,382</td>
<td>3,617</td>
<td>0</td>
<td>0%*</td>
<td>NO</td>
</tr>
<tr>
<td>270</td>
<td>Other Major Cardiovascular Procedures with MCC</td>
<td>15,141</td>
<td>5,964</td>
<td>719</td>
<td>4.7487%*</td>
<td>NO</td>
</tr>
<tr>
<td>271</td>
<td>Other Major Cardiovascular Procedures with CC</td>
<td>10,368</td>
<td>4,027</td>
<td>532</td>
<td>5.1312%*</td>
<td>NO</td>
</tr>
<tr>
<td>272</td>
<td>Other Major Cardiovascular Procedures without CC/MCC</td>
<td>4,785</td>
<td>880*</td>
<td>54</td>
<td>1.1285%*</td>
<td>NO</td>
</tr>
<tr>
<td>273</td>
<td>Percutaneous Intracardiac Procedures with MCC</td>
<td>6,602</td>
<td>2,654</td>
<td>646</td>
<td>9.7849%*</td>
<td>YES</td>
</tr>
<tr>
<td>274</td>
<td>Percutaneous Intracardiac Procedures without MCC</td>
<td>15,812</td>
<td>2,445</td>
<td>140</td>
<td>0.8854%*</td>
<td>YES**</td>
</tr>
</tbody>
</table>

* Indicates a current postacute care transfer policy criterion that the MS-DRG did not meet.
** As described in the policy at 42 CFR 412.4(d)(3)(ii)(D), MS-DRGs that share the same base MS-DRG will all qualify under the postacute care transfer policy if any one of the MS-DRGs that share that same base MS-DRG qualifies.

In addition, in the FY 2016 IPPS/LTCH PPS proposed rule, we determined that proposed new MS-DRGs 273 and 274 also would meet the criteria for the special payment methodology. Therefore, we proposed that the two proposed new MS-DRGs would be subject to the MS-DRG special payment methodology, effective FY 2016.

We did not receive any public comments on our proposal. Therefore, we are finalizing our proposal that new MS-DRGs 273 and 274 will be subject to the MS-DRG special payment methodology, effective FY 2016. The table below lists the MS-DRGs that are subject to the special payment policy for FY 2016.

<table>
<thead>
<tr>
<th>New MS-DRG</th>
<th>MS-DRG Title</th>
<th>Geometric Mean Length of Stay</th>
<th>Average Charges of 1-Day Discharges</th>
<th>50 Percent of Average Charges for all Cases within MS-DRG</th>
<th>Special Payment Policy Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>273</td>
<td>Percutaneous Intracardiac Procedures with MCC</td>
<td>6.1</td>
<td>$67,126</td>
<td>$60,588</td>
<td>YES</td>
</tr>
<tr>
<td>274</td>
<td>Percutaneous Intracardiac Procedures without MCC</td>
<td>2.6</td>
<td>$0</td>
<td>$0</td>
<td>YES*</td>
</tr>
</tbody>
</table>

*As described in the policy at 42 CFR 412.4(d)(6)(iv), MS-DRGs that share the same base MS-DRG will all qualify under the MS-DRG special payment policy if any one of the MS-DRGs that share that same base MS-DRG qualifies.

The postacute care transfer status and special payment policy status of these MS-DRGs are reflected in Table 5 associated with this final rule, which is listed in
section VI. of the Addendum to this final rule and available via the Internet on the CMS Web site.

K. Short Inpatient Hospital Stays

We noted in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24523) that hospitals and physicians continue to voice their concern with parts of the 2-midnight rule finalized in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50943 through 50954). We indicated that we were considering this feedback carefully, as well as recent MedPAC recommendations, and expected to include a further discussion of the broader set of issues related to short inpatient hospital stays, long outpatient stays with observation services, and the related -0.2 percent IPPS payment adjustment in the CY 2016 hospital outpatient prospective payment system proposed rule. We refer readers to the proposal and related discussion of these issues that were included in the CY 2016 OPPS/ASC proposed rule that appeared in the Federal Register on July 8, 2015 (80 FR 39348). We will respond to public comments received on these issues in response to the CY 2016 OPPS/ASC proposed rule in the CY 2016 OPPS/ASC final rule with comment period (which is expected to be issued in November 2015). To be assured consideration, public comments must be submitted in response to the CY 2016 OPPS/ASC proposed rule, and received no later than 5 p.m. EST on August 31, 2015. The CY 2016 OPPS/ASC proposed rule contains further instructions on submitting public comments (80 FR 39200).
L. Interim Final Rule with Comment Period Implementing Legislative Extensions

Relating to the Payment Adjustment for Low-Volume Hospitals and the Medicare-Dependent, Small Rural Hospital (MDH) Program

1. Recent Legislation

The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Pub. L. 114-10, enacted on April 16, 2015, extended the Medicare-dependent, small rural hospital (MDH) program as well as certain provisions relating to payment to low-volume hospitals under the IPPS. Section 204 of the MACRA extended the temporary changes to the low-volume hospital qualifying criteria and payment adjustment under the IPPS, originally provided for by the Affordable Care Act, for discharges occurring on or after April 1, 2015 through FY 2017 (September 30, 2017). Section 205 of the MACRA extended the MDH program for hospital discharges occurring on or after April 1, 2015 through FY 2017 (September 30, 2017). Due to the timing of the development of the FY 2016 IPPS/LTCH PPS proposed rule and the enactment of the MACRA, we were unable to address these legislative extensions in that proposed rule.

2. Payment Adjustment for Low-Volume Hospitals (§ 412.101)

a. Background

Section 1886(d)(12) of the Act provides for an additional payment to each qualifying low-volume hospital that is paid under IPPS beginning in FY 2005, and the low-volume hospital payment policy is set forth in the regulations at 42 CFR 412.101. Sections 3125 and 10314 of the Affordable Care Act provided for a temporary change in the low-volume hospital payment policy for FYs 2011 and 2012. Specifically, the
provisions of the Affordable Care Act amended the qualifying criteria for low-volume hospitals to specify, for FYs 2011 and 2012, that a hospital qualifies as a low-volume hospital if it is more than 15 road miles from another subsection (d) hospital and has less than 1,600 discharges of individuals entitled to, or enrolled for, benefits under Medicare Part A during the fiscal year. In addition, the statute as amended by the Affordable Care Act, provides that the low-volume hospital payment adjustment (that is, the percentage increase) is to be determined using a continuous linear sliding scale ranging from 25 percent for low-volume hospitals with 200 or fewer discharges of individuals entitled to, or enrolled for, benefits under Medicare Part A in the fiscal year to 0 percent for low-volume hospitals with greater than 1,600 discharges of such individuals in the fiscal year. We revised the regulations governing the low-volume hospital policy at § 412.101 to reflect the changes to the qualifying criteria and the payment adjustment for low-volume hospitals according to the provisions of the Affordable Care Act in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50238 through 50275 and 50414).

The temporary changes to the low-volume hospital qualifying criteria and payment adjustment originally provided for by the Affordable Care Act have been extended by subsequent legislation as follows: through FY 2013 by the American Taxpayer Relief Act of 2012 (ATRA), Pub. L. 112-240; through March 31, 2014, by the Pathway for SGR Reform Act of 2013, Pub. L. 113-167; through March 31, 2015, by the Protecting Access to Medicare Act of 2014 (PAMA), Pub. L. 113-93; and most recently through FY 2017 by section 204 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Pub. L. 114-10. The extension provided by section 204 of the
MACRA is discussed in greater detail in section IV.L.2.b. of the preamble of this interim final rule with comment period. For additional details on the implementation of the previous extensions, through March 31, 2015, of the temporary changes to the low-volume hospital qualifying criteria and payment adjustment originally provided for by the Affordable Care Act, we refer readers to the following Federal Register documents: the FY 2013 IPPS notice (78 FR 14689 through 14691); the FY 2014 IPPS/LTCH PPS final rule (78 FR 50611 through 50612); the FY 2014 IPPS interim final rule with comment period (79 FR 15022 through 15025); the FY 2014 IPPS notice (79 FR 34444 through 34446); and the FY 2015 IPPS/LTCH PPS final rule (79 FR 49998 through 50001).

b. Implementation of Provisions of the MACRA for FY 2015

Section 204 of the MACRA provided for an extension of the temporary changes to the low-volume hospital qualifying criteria and payment adjustment for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017). We addressed the extension of the temporary changes to the low-volume hospital payment policy for the last half of FY 2015, that is, for discharges occurring on or after April 1, 2015, through September 30, 2015, in instructions issued in Change Request 9197, Transmittals 3263 and 3281. (We note that Change Request 9197 was originally issued on May 22, 2015 as Transmittal 3263, and reissued on June 5, 2015 as Transmittal 3281 to correct a date in Attachment 3, draft Notification to Provider letter. All other information remained the same.) Generally, hospitals that were receiving the low-volume hospital payment adjustment for FY 2015
as of March 31, 2015 would continue to have low-volume hospital status for the second half of FY 2015, as long as the hospital continued to meet the applicable qualifying low-volume hospital criteria.

In the instructions issued in Change Request 9197, for discharges occurring on or after April 1, 2015, through September 30, 2015, consistent with the existing regulations at § 412.101(b)(2)(ii), we state that the same discharge data used for the low-volume adjustment for discharges occurring during the first half of FY 2015 will continue to be used for discharges occurring during the last half of FY 2015, as these data were the most recent available data at the time of the development of the FY 2015 payment rates. Specifically, for FY 2015 discharges occurring on or after April 1, 2015, through September 30, 2015, the low-volume hospital qualifying criteria and payment adjustment (percentage increase) is determined using FY 2013 Medicare discharge data from the March 2014 update of the MedPAR files. These discharge data can be found in Table 14 of the Addendum to the FY 2015 IPPS/LTCH PPS final rule, which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2015-IPPS-Final-Rule-Home-Page-Items/FY2015-Final-Rule-Tables.html. We note that, consistent with past practice, Table 14 is a list of IPPS hospitals with fewer than 1,600 Medicare discharges and is not a listing of the hospitals that qualify for the low-volume adjustment for FY 2015; it does not reflect whether or not the hospital meets the mileage criterion (that is, the hospital must also be located more than 15 road miles from any other IPPS hospital). In order to receive the applicable low-volume hospital payment adjustment (percentage increase) for
FY 2015 discharges, a hospital must meet both the discharge and mileage criteria. We discuss the conforming changes to the regulations at § 412.101 consistent with the extension of the temporary changes to the low-volume hospital definition and payment adjustment provided by section 204 of the MACRA in section IV.L.2.c. of the preamble of this interim final rule with comment period.

c. Low-Volume Hospital Definition and Payment Adjustment for FY 2016

As discussed above, under section 1886(d)(12) of the Act, as amended by section 204 of the MACRA, the temporary changes in the low-volume hospital payment policy originally provided by the Affordable Care Act and extended through subsequent legislation, are effective through FY 2017. Under the prior extension, in accordance with section 105 of PAMA, those temporary changes in the low-volume hospital payment policy were to be in effect for discharges on or before March 31, 2015 only. Due to the timing of the development of the FY 2016 IPPS/LTCH PPS proposed rule and the enactment of the MACRA, we were unable to address the extension of the changes in the low-volume hospital payment policy for FY 2016 (or the last half of FY 2015, as discussed in section IV.L.2.b. of the preamble of this interim final rule with comment period) in that proposed rule. In this interim final rule with comment period, we are revising the regulations at § 412.101 to conform to the provisions of section 204 of the MACRA.

To implement the low-volume hospital payment adjustment for FY 2016 consistent with provisions of the MACRA, in accordance with existing § 412.101(b)(2)(ii) and consistent with our historical approach, we are updating the
discharge data source used to identify qualifying low-volume hospitals and calculate the payment adjustment (percentage increase). Under existing § 412.101(b)(2)(ii), for the applicable fiscal years, a hospital’s Medicare discharges from the most recently available MedPAR data, as determined by CMS, are used to determine if the hospital meets the discharge criteria to receive the low-volume payment adjustment in the current year. The applicable low-volume percentage increase, as originally provided for by the Affordable Care Act, is determined using a continuous linear sliding scale equation that results in a low-volume hospital payment adjustment ranging from an additional 25 percent for hospitals with 200 or fewer Medicare discharges to a zero percent additional payment adjustment for hospitals with 1,600 or more Medicare discharges. For FY 2016, consistent with our historical policy, qualifying low-volume hospitals and their payment adjustment will be determined using the most recently available Medicare discharge data from the March 2015 update of the FY 2014 MedPAR file, as these data are the most recent data available. Table 14 listed in the Addendum of the FY 2016 IPPS/LTCH PPS final rule (which is available via the Internet on the CMS Web site at: http://www.cms.hhs.gov/Acute InpatientPPS/01_overview.asp) lists the “subsection (d)” hospitals with fewer than 1,600 Medicare discharges based on the claims data from this FY 2014 MedPAR file and their potential low-volume payment adjustment for FY 2016. Consistent with past practice, we note that this list of hospitals with fewer than 1,600 Medicare discharges in Table 14 does not reflect whether or not the hospital meets the mileage criterion. Eligibility for the low-volume hospital payment adjustment for FY 2016 also will be dependent upon meeting the mileage criterion specified at
§ 412.101(b)(2)(ii); that is, the hospital must be located more than 15 road miles from any other IPPS hospital. In other words, eligibility for the low-volume hospital payment adjustment for FY 2016 also is dependent upon meeting (in the case of a hospital that did not qualify for the low-volume hospital payment adjustment in FY 2015) or continuing to meet (in the case of a hospital that did qualify for the low-volume hospital payment adjustment in FY 2015) the mileage criterion specified at revised § 412.101(b)(2)(ii) (that is, the hospital is located more than 15 road miles from any other subsection (d) hospital).

In order to receive a low-volume hospital payment adjustment under § 412.101 for FY 2016, consistent with our previously established procedure, a hospital must notify and provide documentation to its MAC that it meets the discharge and distance requirements under § 412.101(b)(2)(ii), as revised. Specifically, for FY 2016, a hospital must make a written request for low-volume hospital status that is received by its MAC no later than September 1, 2015, in order for the applicable low-volume hospital payment adjustment to be applied to payments for its FY 2016 discharges occurring on or after October 1, 2015. Under this procedure, a hospital that qualified for the low-volume payment adjustment in FY 2015 may continue to receive a low-volume payment adjustment for FY 2016 without reapplying if it continues to meet the Medicare discharge criterion established for FY 2016 and the mileage criterion. However, the hospital must send written verification that is received by its MAC no later than September 1, 2015, stating that it continues to be more than 15 miles from any other “subsection (d)” hospital. This written verification could be a brief letter to the MAC stating that the hospital continues to meet the low-volume hospital distance criterion as documented in a
prior low-volume hospital status request. If a hospital’s written request for low-volume hospital status for FY 2016 is received after September 1, 2015, and if the MAC determines that the hospital meets the criteria to qualify as a low-volume hospital, the MAC will apply the applicable low-volume hospital payment adjustment to determine the payment for the hospital’s FY 2016 discharges, effective prospectively within 30 days of the date of its low-volume hospital status determination, consistent with past practice. (For additional details on our established process for the low-volume hospital payment adjustment, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53408) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50000 through 50001).

In this interim final rule with comment period, we are making conforming changes to the existing regulations text at § 412.101 to reflect the extension of the changes to the qualifying criteria and the payment adjustment methodology for low-volume hospitals through FY 2017 (that is, through September 30, 2017) in accordance with section 204 of the MACRA. In general, these conforming changes consist of replacing the phrase “through FY 2014, and the portion of FY 2015 before April 1, 2015” with “through FY 2017” each place it appears, and replacing the phrase “the portion of FY 2015 beginning on April 1, 2015, and subsequent fiscal years” with the phrase “FY 2018 and subsequent fiscal years” each place it appears. Specifically, we are revising paragraphs (b)(2)(i), (b)(2)(ii), (c)(1), (c)(2), and (d) of § 412.101. Under these revisions to § 412.101, beginning with FY 2018, consistent with section 1886(d)(12) of the Act, as amended, the low-volume hospital qualifying criteria and payment adjustment methodology will revert to that which was in effect prior to the
amendments made by the Affordable Care Act and subsequent legislation (that is, the low-volume hospital payment adjustment policy in effect for FYs 2005 through 2010).

3. Medicare-Dependent, Small Rural Hospital (MDH) Program (§ 412.108)
   a. Background for MDH Program

   Section 1886(d)(5)(G) of the Act provides special payment protections, under the IPPS, to a Medicare-dependent, small rural hospital (MDH). (For additional information on the MDH program and the payment methodology, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51683 through 51684).)

   Since the extension of the MDH program through FY 2012 provided by section 3124 of the Affordable Care Act, the MDH program has been extended by subsequent legislation as follows: First, section 606 of the ATRA (Pub. L. 112–240) extended the MDH program through FY 2013 (that is, for discharges occurring before October 1, 2013). Second, section 1106 of the Pathway for SGR Reform Act of 2013 (Pub. L. 113–67) extended the MDH program through the first half of FY 2014 (that is, for discharges occurring before April 1, 2014). Third, section 106 of the PAMA (Pub. L. 113–93) extended the MDH program through the first half of FY 2015 (that is, for discharges occurring before April 1, 2015). Most recently, section 205 of the MACRA (Pub. L. 114–10) extended the MDH program though FY 2017 (that is, for discharges occurring before October 1, 2017). For additional information on the extensions of the MDH program after FY 2012, we refer readers to the following Federal Register documents: the FY 2013 IPPS/LTCH PPS final rule (77 FR 53404 through 53405 and 53413 through 53414); the FY 2013 IPPS notice (78 FR 14689); the FY 2014
a. IPPS/LTCH PPS final rule (78 FR 50647 through 50649); the FY 2014 interim final rule with comment period (79 FR 15025 through 15027); the FY 2014 notice (79 FR 34446 through 34449); and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50022 through 50024).

b. MACRA Provisions for Extension of the MDH Program

Section 205 of the MACRA provided for an extension of the MDH program for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017). Specifically, section 205 of the MACRA amended sections 1886(d)(5)(G)(i) and 1886(d)(5)(G)(ii)(II) of the Act by striking “April 1, 2015” and inserting “October 1, 2017”. Section 205 of the MACRA also made conforming amendments to sections 1886(b)(3)(D)(i) and 1886(b)(3)(D)(iv) of the Act.

In this interim final rule with comment period, we are making conforming changes to the regulations at § 412.108(a)(1) and (c)(2)(iii) to reflect the extension of the MDH program provided for by the MACRA. Due to the timing of the development of the FY 2016 IPPS/LTCH PPS proposed rule and the enactment of the MACRA, we were unable to address the extension of the MDH program for FY 2016 (or the last half of FY 2015) in that proposed rule. After the MACRA was enacted, we addressed the extension of the MDH program for the last half of FY 2015 (that is, for discharges occurring on or after April 1, 2015, through September 30, 2015) in instructions issued in Change Request 9197, Transmittals 3263 and 3281. (We note that Change Request 9197 was originally issued May 22, 2015 as Transmittal 3263, and reissued June 5, 2015 as
Transmittal 3281 to correct a date in Attachment 3, draft Notification to Provider letter. All other information remained the same.

As explained in Change Request 9197, consistent with the previous extensions of the MDH program and the regulations at § 412.108, generally, a provider that was classified as an MDH as of March 31, 2015, was reinstated as an MDH effective April 1, 2015, with no need to reapply for MDH classification. However, if the MDH had classified as an SCH or cancelled its rural classification under § 412.103(g) effective on or after April 1, 2015, the effective date of MDH status may not be retroactive to April 1, 2015. For more details regarding MDH status for the second half of FY 2015, we refer the reader to Change Request 9197.

4. Responses to Comments

Because of the large number of public comments we normally receive on Federal Register documents, we are not able to acknowledge and respond to them individually. We will consider all comments we receive by the date and time specified in the DATES section of this document, and, when we proceed with a subsequent document, we will respond to the comments in the preamble of that document.

5. Waiver of Notice of Proposed Rulemaking and Delay in Effective Date

We ordinarily publish a notice of proposed rulemaking in the Federal Register and invite public comment prior to a rule taking effect in accordance with section 553(b) of the Administrative Procedure Act (APA) and section 1871 of the Act. In addition, in accordance with section 553(d) of the APA and section 1871(e)(1)(B)(i) of the Act, we ordinarily provide a delay in the effective date of a substantive rule. For substantive rules
that constitute major rules, in accordance with 5 U.S.C. 801, we ordinarily provide a 60-day delay in the effective date. None of the processes or effective date requirements apply, however, when the rule in question is interpretive, a general statement of policy, or a rule of agency organization, procedure, or practice. They also do not apply when the statute establishes rules to be applied, leaving no discretion or gaps for an agency to fill in through rulemaking. In addition, an agency may waive notice-and-comment rulemaking, as well as any delay in effective date, when the agency for good cause finds that notice and public comment on the rule as well the effective date delay are impracticable, unnecessary, or contrary to the public interest. In cases where an agency finds good cause, the agency must incorporate a statement of this finding and its reasons in the rule issued.

Sections 204 and 205 of the MACRA require the agency to make the changes to the payment adjustment for low-volume hospitals and the MDH program set forth in sections IV.B. and C. of the preamble of this interim final rule with comment period, effective April 1, 2015 through September 30, 2017. We are conforming our regulations at § 412.101 and § 412.108 to specific statutory requirements contained in sections 204 and 205 of the MACRA or that directly result from those statutory requirements and informing the public of the procedures and practices the agency will follow to ensure compliance with those statutory provisions. To the extent that notice-and-comment rulemaking or a delay in effective date, or both, would otherwise apply, we believe that there is good cause to waive such requirements and to implement the requirements of section 204 and 205 of the MACRA through an interim final rule with comment period.
Specifically, we find it unnecessary to undertake notice-and-comment rulemaking in this instance because this interim final rule with comment period sets forth the requirements for the extension of the temporary changes to the payment adjustment for low-volume hospitals and the extension of the MDH program as prescribed by the MACRA, as well as procedures and practices that directly result from those statutory requirements. As changes related to requirements of section 204 and 205 of the MACRA outlined in this interim final rule with comment period have already taken effect, it also would be impracticable to undertake notice-and-comment rulemaking.

For the reasons outlined, we find good cause to waive the notice of proposed rulemaking for the requirements for the extension of the temporary changes to the payment adjustment for low-volume hospitals and the extension of the MDH program as prescribed by the sections 204 and 205 of the MACRA and implement these provisions on an interim final basis. Even though we are waiving notice of proposed rulemaking requirements and are issuing these provisions on an interim basis, we are providing a 60-day public comment period. For these reasons, we also find that a waiver of any delay in effective date, if it were otherwise applicable, is necessary to comply with the requirements of section 204 and 205 of the MACRA. Therefore, we find good cause to waive notice-and-comment procedures as well as any delay in the effective dates for these MACRA requirements.

6. Collection of Information Requirements

This interim final rule with comment period does not impose information collection and recordkeeping requirements. Consequently, it need not be reviewed by the

7. Impact of Legislative Extensions

a. Effects of the Payment Adjustment for Low-Volume Hospitals for FY 2016

Based on the latest available data, we estimate that approximately 593 hospitals will qualify as a low-volume hospital in FY 2016. We project that the extension for FY 2016 of the temporary changes to the low-volume hospital definition and the payment adjustment methodology provided for by the MACRA will result in an increase in payments of approximately $322 million in FY 2016 as compared to payments to qualifying hospitals without the extension of the temporary changes to the low-volume hospital definition and the payment adjustment methodology.

b. Effects of the Extension of the MDH Program for FY 2016

As discussed above, in this interim final rule with comment period, we are making conforming changes to the regulations at § 412.108(a)(1) and (c)(2)(iii) to reflect the extension of the MDH program provided for by the MACRA. Hospitals that qualify as MDHs receive the higher of operating IPPS payments made under the Federal standardized amount or the payments made under the Federal standardized amount plus 75 percent of the amount by which the hospital-specific rate (a hospital-specific cost-based rate) exceeds the Federal standardized amount. Based on the latest available data we have for 163 MDHs, we project that 90 MDHs will receive the blended payment (that is, the Federal standardized amount plus 75 percent of the amount by which the hospital-specific rate exceeds the Federal standardized amount) for FY 2016. We
estimate that those hospitals will experience an overall increase in payments of approximately $96 million as compared to payments they would have received had the MDH program not been extended for FY 2016.
V. Changes to the IPPS for Capital-Related Costs

A. Overview

Section 1886(g) of the Act requires the Secretary to pay for the capital-related costs of inpatient acute hospital services in accordance with a prospective payment system established by the Secretary. Under the statute, the Secretary has broad authority in establishing and implementing the IPPS for acute care hospital inpatient capital-related costs. The IPPS for capital-related costs was initially implemented in the Federal fiscal year (FY) 1992 IPPS final rule (56 FR 43358), in which we established a 10-year transition period to change the payment methodology for Medicare hospital inpatient capital-related costs from a reasonable cost-based methodology to a prospective methodology (based fully on the Federal rate).

FY 2001 was the last year of the 10-year transition period established to phase in the IPPS for hospital inpatient capital-related costs. For cost reporting periods beginning in FY 2002, capital IPPS payments are based solely on the Federal rate for almost all acute care hospitals (other than hospitals receiving certain exception payments and certain new hospitals). (We refer readers to the FY 2002 IPPS final rule (66 FR 39910 through 39914) for additional information on the methodology used to determine capital IPPS payments to hospitals both during and after the transition period.)

The basic methodology for determining capital prospective payments using the Federal rate is set forth in § 412.312 of the regulations. For the purpose of calculating capital payments for each discharge, the standard Federal rate is adjusted as follows:
(Standard Federal Rate) x (DRG Weight) x (Geographic Adjustment Factor (GAF)) x (COLA for hospitals located in Alaska and Hawaii) x (1 + Capital DSH Adjustment Factor + Capital IME Adjustment Factor, if applicable).

In addition, under § 412.312(c), hospitals also may receive outlier payments under the capital IPPS for extraordinarily high-cost cases that qualify under the thresholds established for each fiscal year.

B. Additional Provisions

1. Exception Payments

The regulations at § 412.348 provide for certain exception payments under the capital IPPS. The regular exception payments provided under §§ 412.348(b) through (e) were available only during the 10-year transition period. For a certain period after the transition period, eligible hospitals may have received additional payments under the special exceptions provisions at § 412.348(g). However, FY 2012 was the final year hospitals could receive special exceptions payments. For additional details regarding these exceptions policies, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51725).

Under § 412.348(f), a hospital may request an additional payment if the hospital incurs unanticipated capital expenditures in excess of $5 million due to extraordinary circumstances beyond the hospital’s control. Additional information on the exception payment for extraordinary circumstances in § 412.348(f) can be found in the FY 2005 IPPS final rule (69 FR 49185 and 49186).
2. New Hospitals

Under the capital IPPS, § 412.300(b) of the regulations defines a new hospital as a hospital that has operated (under previous or current ownership) for less than 2 years and lists examples of hospitals that are not considered new hospitals. In accordance with § 412.304(c)(2), under the capital IPPS a new hospital is paid 85 percent of its allowable Medicare inpatient hospital capital-related costs through its first 2 years of operation, unless the new hospital elects to receive full prospective payment based on 100 percent of the Federal rate. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51725) for additional information on payments to new hospitals under the capital IPPS.

3. Hospitals Located in Puerto Rico

Section 412.374 of the regulations provides for the use of a blended payment amount for prospective payments for capital-related costs to hospitals located in Puerto Rico. Accordingly, under the capital IPPS, we compute a separate payment rate specific to Puerto Rico hospitals using the same methodology used to compute the national Federal rate for capital-related costs. In general, hospitals located in Puerto Rico are paid a blend of the applicable capital IPPS Puerto Rico rate and the applicable capital IPPS Federal rate. Capital IPPS payments to hospitals located in Puerto Rico are computed based on a blend of 25 percent of the capital IPPS Puerto Rico rate and 75 percent of the capital IPPS Federal rate. For additional details on capital IPPS payments to hospitals located in Puerto Rico, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51725).
C. Annual Update for FY 2016

The annual update to the capital PPS Federal and Puerto Rico-specific rates, as provided for at § 412.308(c), for FY 2016 is discussed in section III. of the Addendum to this final rule.

We note that, in section II.D. of the preamble of this final rule, we present a discussion of the MS-DRG documentation and coding adjustment, including previously finalized policies and historical adjustments, as well as the recoupment adjustment to the standardized amounts under section 1886(d) of the Act that we are finalizing for FY 2016 in accordance with the amendments made to section 7(b)(1)(B) of Pub. L. 110-90 by section 631 of the ATRA. Because section 631 of the ATRA requires CMS to make a recoupment adjustment only to the operating IPPS standardized amount, we are not making a similar adjustment to the national or Puerto Rico capital IPPS rates (or to the operating IPPS hospital-specific rates or the Puerto Rico-specific standardized amount). This approach is consistent with our historical approach regarding the application of the recoupment adjustment authorized by section 7(b)(1)(B) of Pub. L. 110-90.
VI. Changes for Hospitals Excluded from the IPPS

A. Rate-of-Increase in Payments to Excluded Hospitals for FY 2016

Certain hospitals excluded from a prospective payment system, including children’s hospitals, 11 cancer hospitals, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa) receive payment for inpatient hospital services they furnish on the basis of reasonable costs, subject to a rate-of-increase ceiling. A per discharge limit (the target amount as defined in § 413.40(a) of the regulations) is set for each hospital based on the hospital’s own cost experience in its base year, and updated annually by a rate-of-increase percentage. For each cost reporting period, the updated target amount is multiplied by total Medicare discharges during that period and applies as an aggregate upper limit (the ceiling as defined in § 413.40(a)) of Medicare payments for total inpatient operating costs for a hospital’s cost reporting period. In accordance with § 403.752(a) of the regulations, RNHCIs also are subject to the rate-of-increase limits established under § 413.40 of the regulations discussed above.

As explained in the FY 2006 IPPS final rule (70 FR 47396 through 47398), beginning with FY 2006, we have used the percentage increase in the IPPS operating market basket to update the target amounts for children’s hospitals, cancer hospitals, and RNHCIs. Consistent with §§ 412.23(g), 413.40(a)(2)(ii)(A), and 413.40(c)(3)(viii), we also have used the percentage increase in the IPPS operating market basket to update the target amounts for short-term acute care hospitals located in the U.S. Virgin Islands,
Guam, the Northern Mariana Islands, and American Samoa. As we finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50156 through 50157), we will continue to use the percentage increase in the FY 2010-based IPPS operating market basket to update the target amounts for children’s hospitals, cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa for FY 2016 and subsequent fiscal years. Accordingly, for FY 2016, the rate-of-increase percentage to be applied to the target amount for these children’s hospitals, cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa is the FY 2016 percentage increase in the FY 2010-based IPPS operating market basket.

For the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24525), based on IHS Global Insight, Inc.’s 2015 first quarter forecast, we estimated that the FY 2010-based IPPS operating market basket update for FY 2016 was 2.7 percent (that is, the estimate of the market basket rate-of-increase). We indicated in the proposed rule that if more recent data became available for the final rule, we would use them to calculate the IPPS operating market basket update for FY 2016. For this FY 2016 IPPS/LTCH PPS final rule, based on IHS Global Insight, Inc.’s 2015 second quarter forecast (which is the most recent data available), we calculated the FY 2010-based IPPS operating market basket update for FY 2016 to be 2.4 percent. Therefore, the FY 2016 rate-of-increase percentage that is applied to the FY 2015 target amounts in order to calculate the FY 2016 target amounts for children’s hospitals, cancer hospitals, RNHCIs, and
short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa is 2.4 percent, in accordance with the applicable regulations at 42 CFR 413.40.

B. Report on Adjustment (Exceptions) Payments

Section 4419(b) of Pub. L. 105-33 requires the Secretary to publish annually in the Federal Register a report describing the total amount of adjustment payments made to excluded hospitals and hospital units by reason of section 1886(b)(4) of the Act during the previous fiscal year.

The process of requesting, adjusting, and awarding an adjustment payment is likely to occur over a 2-year period or longer. First, generally, an excluded hospital must file its cost report for the fiscal year in accordance with § 413.24(f)(2) of the regulations. The MAC reviews the cost report and issues a notice of provider reimbursement (NPR). Once the hospital receives the NPR, if its operating costs are in excess of the ceiling, the hospital may file a request for an adjustment payment. After the MAC receives the hospital’s request in accordance with applicable regulations, the MAC or CMS, depending on the type of adjustment requested, reviews the request and determines if an adjustment payment is warranted. This determination is sometimes not made until more than 180 days after the date the request is filed because there are times when the request applications are incomplete and additional information must be requested in order to have a completed request application. However, in an attempt to provide interested parties with data on the most recent adjustment payments for which we have data, we are
publishing data on adjustment payments that were processed by the MAC or CMS during FY 2014.

The table below includes the most recent data available from the MACs and CMS on adjustment payments that were adjudicated during FY 2014. As indicated above, the adjustments made during FY 2014 only pertain to cost reporting periods ending in years prior to FY 2013. Total adjustment payments given to excluded hospitals during FY 2014 are $1,515,104. The table depicts for each class of hospitals, in the aggregate, the number of adjustment requests adjudicated, the excess operating costs over the ceiling, and the amount of the adjustment payments.

<table>
<thead>
<tr>
<th>Class of Hospital</th>
<th>Number</th>
<th>Excess Cost Over Ceiling</th>
<th>Adjustment Payments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children’s</td>
<td>1</td>
<td>$1,140,682</td>
<td>$829,567</td>
</tr>
<tr>
<td>Cancer</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Religious Nonmedical Health Care Institution (RNHCI)</td>
<td>2</td>
<td>$729,557</td>
<td>$685,537</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
<td>$1,870,239</td>
<td>$1,515,104</td>
</tr>
</tbody>
</table>

C. Out of Scope Comments Relating to Critical Access Hospitals (CAHs) Inpatient Services

In response to the FY 2016 IPPS/LTCH PPS proposed rule, we received the following public comment relating to conditions for payment for inpatient services furnished in critical access hospitals (CAHs), which we consider to be outside of the scope of the FY 2016 proposed rule.

One commenter specifically addressed the requirement that, for inpatient CAH services to be payable under Medicare Part A, a physician must certify that the individual may reasonably be expected to be discharged or transferred to a hospital within 96 hours
after admission to the CAH (section 1814(a)(8) of the Act; 42 CFR 424.15). The commenter stated that this certification is inconsistent with the congressional intent of the CAH program and should be eliminated. The commenter stated that CAHs provide high quality and cost-efficient care, which allows Medicare beneficiaries living in rural areas to receive this care close to home. The commenter noted that some CAHs have established general surgery programs, which allow senior citizens to receive surgical services in a nearby and familiar location. However, the commenter believed that the 96-hour certification requirement for payment of inpatient services furnished in a CAH prohibits CAHs from receiving payment for providing these surgical services.

We acknowledge the commenter’s concerns. However, because we did not specifically propose any changes related to the 96-hour certification requirement for CAH inpatient services, we consider this comment to be outside the scope of the proposed rule and are not addressing the comment at this time. We note that the 96-hour certification requirement was last addressed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50163 through 50165).
VII. Changes to the Long-Term Care Hospital Prospective Payment System (LTCH PPS) for FY 2016

A. Background of the LTCH PPS

1. Legislative and Regulatory Authority

   Section 123 of the Medicare, Medicaid, and SCHIP (State Children’s Health Insurance Program) Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106-113) as amended by section 307(b) of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106-554) provides for payment for both the operating and capital-related costs of hospital inpatient stays in long-term care hospitals (LTCHs) under Medicare Part A based on prospectively set rates. The Medicare prospective payment system (PPS) for LTCHs applies to hospitals that are described in section 1886(d)(1)(B)(iv) of the Act, effective for cost reporting periods beginning on or after October 1, 2002.

   Section 1886(d)(1)(B)(iv)(I) of the Act defines an LTCH as a hospital which has an average inpatient length of stay (as determined by the Secretary) of greater than 25 days. Section 1886(d)(1)(B)(iv)(II) of the Act also provides an alternative definition of LTCHs: specifically, a hospital that first received payment under section 1886(d) of the Act in 1986 and has an average inpatient length of stay (as determined by the Secretary of Health and Human Services (the Secretary)) of greater than 20 days and has 80 percent or more of its annual Medicare inpatient discharges with a principal diagnosis that reflects a finding of neoplastic disease in the 12-month cost reporting period ending in FY 1997.
Section 123 of the BBRA requires the PPS for LTCHs to be a “per discharge” system with a diagnosis-related group (DRG) based patient classification system that reflects the differences in patient resources and costs in LTCHs.

Section 307(b)(1) of the BIPA, among other things, mandates that the Secretary shall examine, and may provide for, adjustments to payments under the LTCH PPS, including adjustments to DRG weights, area wage adjustments, geographic reclassification, outliers, updates, and a disproportionate share adjustment.

In the August 30, 2002 Federal Register, we issued a final rule that implemented the LTCH PPS authorized under the BBRA and BIPA (67 FR 55954). For the initial implementation of the LTCH PPS (FYs 2003 through FY 2007), the system used information from LTCH patient records to classify patients into distinct long-term care diagnosis-related groups (LTC-DRGs) based on clinical characteristics and expected resource needs. Beginning in FY 2008, we adopted the Medicare severity long-term care diagnosis-related groups (MS-LTC-DRGs) as the patient classification system used under the LTCH PPS. Payments are calculated for each MS-LTC-DRG and provisions are made for appropriate payment adjustments. Payment rates under the LTCH PPS are updated annually and published in the Federal Register.

The LTCH PPS replaced the reasonable cost-based payment system under the Tax Equity and Fiscal Responsibility Act of 1982 (TEFRA) (Pub. L. 97-248) for payments for inpatient services provided by an LTCH with a cost reporting period beginning on or after October 1, 2002. (The regulations implementing the TEFRA reasonable cost-based payment provisions are located at 42 CFR Part 413.) With the implementation of the PPS
for acute care hospitals authorized by the Social Security Amendments of 1983 (Pub. L. 98-21), which added section 1886(d) to the Act, certain hospitals, including LTCHs, were excluded from the PPS for acute care hospitals and were paid their reasonable costs for inpatient services subject to a per discharge limitation or target amount under the TEFRA system. For each cost reporting period, a hospital-specific ceiling on payments was determined by multiplying the hospital's updated target amount by the number of total current year Medicare discharges. (Generally, in this section VII. of the preamble of this final rule, when we refer to discharges, we describe Medicare discharges.) The August 30, 2002 final rule further details the payment policy under the TEFRA system (67 FR 55954).

In the August 30, 2002 final rule, we provided for a 5-year transition period from payments under the TEFRA system to payments under the LTCH PPS. During this 5-year transition period, an LTCH’s total payment under the PPS was based on an increasing percentage of the Federal rate with a corresponding decrease in the percentage of the LTCH PPS payment that is based on reasonable cost concepts, unless an LTCH made a one-time election to be paid based on 100 percent of the Federal rate. Beginning with LTCHs’ cost reporting periods beginning on or after October 1, 2006, total LTCH PPS payments are based on 100 percent of the Federal rate.

In addition, in the August 30, 2002 final rule, we presented an in-depth discussion of the LTCH PPS, including the patient classification system, relative weights, payment rates, additional payments, and the budget neutrality requirements mandated by section 123 of the BBRA. The same final rule that established regulations for the LTCH PPS
under 42 CFR Part 412, Subpart O, also contained LTCH provisions related to covered inpatient services, limitation on charges to beneficiaries, medical review requirements, furnishing of inpatient hospital services directly or under arrangement, and reporting and recordkeeping requirements. We refer readers to the August 30, 2002 final rule for a comprehensive discussion of the research and data that supported the establishment of the LTCH PPS (67 FR 55954).

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51733 through 51743) for a chronological summary of the main legislative and regulatory developments affecting the LTCH PPS through the annual update cycles prior to the FY 2014 rulemaking cycle. In addition, in this rule, we discuss the provisions of the Pathway for SGR Reform Act of 2013 (Pub. L. 113-67), enacted on December 26, 2013, and the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-97), enacted on March 27, 2014, both of which affect the LTCH PPS. In section VII.B. of the preamble of this final rule, we discuss our finalized policies to implement the provisions of section 1206(a) of Pub. L. 113-67, which amended section 1886(m) of the Act by adding paragraph (6) and established, among other things, patient-level criteria for payments under the LTCH PPS for implementation beginning with FY 2016, and our changes to the calculation of the greater than 25-day average length of stay criteria, consistent with the statute, in section VII.F. of the preamble of this final rule. In section VII.E. of the preamble of this final rule, as discussed in the preamble, we are finalizing several technical clarifications relating to our implementation of the new statutory moratoria on the establishment of new LTCHs and LTCH satellite facilities (subject to certain defined
exceptions) and the new statutory moratorium on bed increases in existing LTCHs under section 1206(b)(2) of Pub. L. 113-67, as amended.

2. Criteria for Classification as an LTCH

a. Classification as an LTCH

Under the regulations at § 412.23(e)(1), to qualify to be paid under the LTCH PPS, a hospital must have a provider agreement with Medicare. Furthermore, § 412.23(e)(2)(i), which implements section 1886(d)(1)(B)(iv)(I) of the Act, requires that a hospital have an average Medicare inpatient length of stay of greater than 25 days to be paid under the LTCH PPS. Alternatively, § 412.23(e)(2)(ii) states that, for cost reporting periods beginning on or after August 5, 1997, a hospital that was first excluded from the PPS in 1986 and can demonstrate that at least 80 percent of its annual Medicare inpatient discharges in the 12-month cost reporting period ending in FY 1997 have a principal diagnosis that reflects a finding of neoplastic disease must have an average inpatient length of stay for all patients, including both Medicare and non-Medicare inpatients, of greater than 20 days.

b. Hospitals Excluded from the LTCH PPS

The following hospitals are paid under special payment provisions, as described in § 412.22(c) and, therefore, are not subject to the LTCH PPS rules:

- Veterans Administration hospitals.
- Hospitals that are reimbursed under State cost control systems approved under 42 CFR Part 403.
- Hospitals that are reimbursed in accordance with demonstration projects authorized under section 402(a) of the Social Security Amendments of 1967.
(Pub. L. 90-248) (42 U.S.C. 1395b-1) or section 222(a) of the Social Security Amendments of 1972 (Pub. L. 92-603) (42 U.S.C. 1395b-1 (note)) (Statewide all-payer systems, subject to the rate-of-increase test at section 1814(b) of the Act).

- Nonparticipating hospitals furnishing emergency services to Medicare beneficiaries.

3. Limitation on Charges to Beneficiaries

In the August 30, 2002 final rule, we presented an in-depth discussion of beneficiary liability under the LTCH PPS (67 FR 55974 through 55975). This discussion was further clarified in the RY 2005 LTCH PPS final rule (69 FR 25676). In keeping with those discussions, if the Medicare payment to the LTCH is the full LTC-DRG payment amount, consistent with other established hospital prospective payment systems, § 412.507 currently provides that an LTCH may not bill a Medicare beneficiary for more than the deductible and coinsurance amounts as specified under §§ 409.82, 409.83, and 409.87 and for items and services specified under § 489.30(a). However, under the LTCH PPS, Medicare will only pay for days for which the beneficiary has coverage until the short-stay outlier (SSO) threshold is exceeded. If the Medicare payment was for a SSO case (§ 412.529), and that payment was less than the full LTC-DRG payment amount because the beneficiary had insufficient remaining Medicare days, the LTCH is currently also permitted to charge the beneficiary for services delivered on those uncovered days (§ 412.507). In light of our finalized policies to implement section 1206(a) of Pub. L. 113-67, we also need to address beneficiary charges in the context of the new site neutral payment rate. Therefore, in section VII.B.7.c. of the preamble of this
final rule, we are finalizing proposals to amend the existing regulations relating to the limitation on charges to address beneficiary charges under the new LTCH PPS payment rate.

4. Administrative Simplification Compliance Act (ASCA) and Health Insurance Portability and Accountability Act (HIPAA) Compliance

Claims submitted to Medicare must comply with both the Administrative Simplification Compliance Act (ASCA) (Pub. L. 107-105), and the Health Insurance Portability and Accountability Act of 1996 (HIPAA) (Pub. L. 104-191). Section 3 of the ASCA requires that the Medicare Program deny payment under Part A or Part B for any expenses incurred for items or services for which a claim is submitted other than in an electronic form specified by the Secretary. Section 1862(h) of the Act (as added by section 3(a) of the ASCA) provides that the Secretary shall waive such denial in two specific types of cases and may also waive such denial in such unusual cases as the Secretary finds appropriate (68 FR 48805). Section 3 of the ASCA operates in the context of the HIPAA regulations, which include, among other provisions, the transactions and code sets standards requirements codified under 45 CFR Parts 160 and 162 (generally known as the Transactions Rule). The Transactions Rule requires covered entities, including covered health care providers, to conduct certain electronic health care transactions according to the applicable transactions and code sets standards.

The Department of Health and Human Services (HHS) has a number of initiatives designed to encourage and support the adoption of health information technology and promote nationwide health information exchange to improve health care. The Office of
the National Coordinator for Health Information Technology (ONC) leads these efforts in collaboration with other agencies, including CMS and the Office of the Assistant Secretary for Planning and Evaluation (ASPE). Through a number of activities, including several open government initiatives, HHS is promoting the adoption of electronic health record (EHR) technology certified under the ONC Health Information Technology (HIT) Certification Program developed to support secure, interoperable, health information exchange. The HIT Policy Committee (a Federal Advisory Committee) has recommended areas in which HIT certification under the ONC HIT Certification Program would help support providers that are eligible for the Medicare and Medicaid EHR Incentive Programs, such as long-term care and postacute care hospitals and behavioral health care providers. We believe that the use of certified EHRs by LTCHs (and other types of providers that are ineligible for the Medicare and Medicaid EHR Incentive Programs) can effectively and efficiently help providers improve internal care delivery practices, support the exchange of important information across care partners and during transitions of care, and could enable the reporting of electronically specified clinical quality measures (eCQMs) (as described elsewhere in this rule). More information on the ONC HIT Certification Program and efforts to develop standards applicable to LTCHs can be found by accessing the following Web sites and resources:

- [http://www.healthit.gov/facas/FACAS/health-it-policy-committee/hitpc-workgroups/certificationadoption](http://www.healthit.gov/facas/FACAS/health-it-policy-committee/hitpc-workgroups/certificationadoption);
- [http://wiki.siframework.org/LCC+LTPAC+Care+Transition+SWG](http://wiki.siframework.org/LCC+LTPAC+Care+Transition+SWG); and
B. Application of the Site Neutral Payment Rate (New § 412.522)

1. Overview

Section 1206 of Pub. L. 113-67 mandates significant changes to the payment system for LTCHs beginning with LTCH discharges occurring in cost reporting periods beginning on or after October 1, 2015. Under the current LTCH PPS, all discharges are paid under the LTCH PPS standard Federal payment rate (that is, payments calculated under the existing regulations, including adjustments, in Subpart O of 42 CFR Part 412). Section 1206 requires the establishment of an alternate “site neutral” payment rate for Medicare inpatient discharges from an LTCH that fail to meet certain statutorily defined criteria. Discharges that meet the criteria will continue to be paid the LTCH PPS standard Federal payment rate. Discharges that do not meet the statutory criteria will be paid at a new site neutral payment rate, as described below. We note that, for the remainder of this section, the phrase “LTCH PPS standard Federal payment rate case” refers to an LTCH PPS case that meets the criteria for exclusion from the site neutral payment rate under section 1886(m)(6)(A)(ii) of the Act as discussed in section VII.B.3. of the preamble of this final rule, and the phrase “site neutral payment rate case” refers to an LTCH PPS case that does not meet the statutory patient-level criteria and, therefore, is paid the applicable site neutral payment rate in accordance with section 1886(m)(6)(A)(i) of the Act, as discussed in section VII.B.4. of the preamble of this final rule.

Under section 1886(m)(6)(A) of the Act as added by section 1206(a) of Pub. L. 113-67, beginning in cost reporting periods starting on or after October 1, 2015,
all LTCH discharges are paid according to the site neutral payment rate unless certain criteria are met. For LTCH cases that meet the criteria for exclusion, the site neutral payment rate does not apply and payment is made without regard to the provisions of section 1886(m)(6) of the Act. For cases that meet the criteria for exclusion from the site neutral payment rate, payment will continue to be based on the LTCH PPS standard Federal payment rate as determined in § 412.523. As discussed in section VII.B.3. of the preamble of this final rule, under section 1886(m)(6)(A)(ii) of the Act, the criteria for exclusion from the site neutral payment rate are: (1) the discharge from the LTCH does not have a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation; (2) admission to the LTCH was immediately preceded by discharge from a subsection (d) hospital; and (3) the immediately preceding stay in a subsection (d) hospital included at least 3 days in an intensive care unit (ICU) (referred to in this final rule as the ICU criterion) or the discharge from the LTCH is assigned to a MS-LTC-DRG based on the patient’s receipt of ventilator services of at least 96 hours (referred to in this final rule as the ventilator criterion).

In this section of the final rule, we discuss our proposed and finalized policies to implement the required changes to the LTCH PPS payment rate, as well as other related finalized policy provisions in accordance with section 1206(a) of Pub. L. 113-67 under the broad authority of section 123(a)(1) of the BBRA, as amended by section 307(b) of the BIPA.

2. Application of the Site Neutral Payment Rate under the LTCH PPS
For FY 2016, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24527), we proposed to add a new section to the regulations under 42 CFR Part 412 Subpart O (new § 412.522) to establish the site neutral payment rate required by section 1886(m)(6) of the Act as added by section 1206(a)(1) of Pub. L. 113-67. Specifically, section 1886(m)(6) of the Act requires that, beginning in cost reporting periods occurring on or after October 1, 2015, all LTCH discharges are paid under the site neutral payment rate unless certain criteria are met. All LTCH discharges that meet the criteria for exclusion from the site neutral payment rate will continue to be paid the LTCH PPS standard Federal payment rate. Accordingly, in this final rule, under the broad authority of section 123(a)(1) of the BBRA, as amended by section 307(b) of the BIPA and in accordance with section 1206(a) of Pub. L. 113-67, we are establishing policies to implement the statutory criteria for excluding cases from the site neutral payment rate under new § 412.522(b), as well as establish the requirements for determining the site neutral payment rate for a given LTCH discharge under new § 412.522(c) (as discussed in detail below).

In addition, we proposed certain changes to § 412.521 in light of our implementation of the site neutral payment rate under new §412.522 (80 FR 24527). We did not receive any public comments on our proposed changes to § 412.521, and are adopting these proposals as final, without modification. Specifically, we are finalizing conforming changes to paragraph (a)(2) of § 412.521 to include the new site neutral payment rate established in accordance with new § 412.522 as a method of payment under the LTCH PPS. We also are finalizing a technical change to the language in
§ 412.521(a)(2) that currently refers to the Federal payment rate by changing the term from “Federal payment rate” to “standard Federal payment rate” in order to provide consistent terminology when referring to such a payment.

Comment: Many commenters objected to the application of the new site neutral payment rate. Some commenters expressed concern that wound care is not categorically excluded from the application of the new site neutral payment rate and requested that CMS create such a categorical exclusion. Some of these commenters also requested that a study of the relative outcomes of wound care in LTCHs and other settings be conducted. Other commenters requested that CMS pay differently for site neutral payment rate cases treated in rural LTCHs, and recommended paying these hospitals for services performed on a cost basis similar to critical access hospitals (CAHs), or comparably to inpatient rehabilitation facilities (IRFs).

Response: While we acknowledge that the new site neutral payment rate will be lower than the historic standard Federal payment rate for certain LTCH discharges, we do not have the authority to establish regulatory payment policy exceptions to pay rural LTCHs at any rate other than what is provided under the new dual payment rate structure under the LTCH PPS. Further, under the LTCH PPS we do not have the authority to pay anything other than the site neutral payment rate for any LTCH discharge that does not meet the exclusion criteria. The statute explicitly established the dual payment rate structure, which expressly provides that payment for all LTCH discharges will be calculated based on the new site neutral payment rate, unless the LTCH discharge meets the statutorily defined exclusion criteria to be paid based on the LTCH PPS.
standard Federal payment rate. Because the new site neutral payment rate and the exclusions apply to all LTCH discharges, further legislation would be required if we were to pay any rate other than the site neutral payment rate, or, where the exceptions to that rate apply, the LTCH PPS standard Federal payment rate. Furthermore, Congress did not provide any authority within the statute to delay implementation of the new dual rate LTCH PPS payment structure to allow time for a study to assess the relative outcomes of wound care in LTCHs compared to other settings. We note that CMS is currently engaged in many quality assessment initiatives, including in LTCHs and other postacute settings. In light of that ongoing work, we do not have current plans to conduct a separate study limited to outcomes for wound care cases in different settings. Further information on our quality initiatives is available on the CMS Web site at:


Comment: Several commenters expressed concerns that exclusion from the lower site neutral payment rate may be dependent upon events that may be outside of the LTCH’s control. For example, the commenters stated that an LTCH would have no control over when a subsection (d) hospital submitted its claim for the immediately preceding subsection (d) hospital discharge, or whether an immediately preceding subsection (d) hospital discharge claim would contain a coding error such that the claim would fail to indicate that the patient received ICU services for at least 3 days. Given this lack of control, commenters expressed concern about our setting the LTCH PPS payment rates based in part upon the content of the subsection (d) hospital’s claim.
Response: We expect LTCHs and their referring hospitals to be closely engaged with each other in coordination of care efforts with regard to their referred patients. As part of these working relationships, we encourage each party to effectively communicate and exchange information to help ensure that LTCH claims are paid appropriately. We acknowledge the commenters’ concerns. The new dual payment rate structure is, by statute, premised on events which occurred prior to the admission to the LTCH. We must look at what happens or did not happen in the immediately preceding subsection (d) hospital inpatient stay, and we believe that the IPPS claim is the best existing source of accurate and complete information for events which occurred during the IPPS hospital inpatient stay.

In fact, we have considered the issues raised by the commenters in our development of the claims processing systems changes needed to implement the new dual rate LTCH PPS payment structure. We believe that these claims processing systems changes will appropriately identify all LTCH discharges, consistent with the statutory requirements under the new dual rate LTCH PPS payment structure, based on the best available data at the time the LTCH discharge claim is processed. Furthermore, our operational design of the claims processing system requirements under this new dual rate LTCH PPS payment structure also includes automatic prompts to appropriately adjust the LTCH PPS payment for an LTCH case if there is a change in either the subsection (d) hospital’s claim information or the LTCH’s claim information that would result in any change in payment (that is, from the site neutral payment rate to the LTCH PPS standard Federal payment rate or vice versa), consistent with the statutory criteria.
However, we acknowledge that, as this is a new payment structure, it may not work flawlessly in each and every instance. In those rare instances where an obvious error occurs in the determination of the LTCH PPS payment amount for a particular case, LTCHs can contact their MACs and we will reevaluate our available information to ensure that the correct payment is made under current policies. We appreciate ongoing feedback from hospitals concerning ways to make these processes more efficient and cost effective, while continuing to ensure that LTCH claims are paid appropriately. As we gain experience under the revised LTCH PPS, we may modify some of our operational approaches.

Comment: One commenter requested that CMS provide additional payment under the LTCH PPS for end-stage renal disease (ESRD) patients under the same circumstances as under the IPPS, noting that section 1881(b) of the Act does not limit the adjustment to subsection (d) hospitals. The commenter believed that information included in its comment and an analysis previously provided to CMS supported its request for this additional payment amount.

Response: Although we consider this comment to be outside the scope of the proposed rule, we note that we responded to the same suggestion in a detailed response in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50767). As discussed in that final rule, based on our analysis of FY 2012 LTCH PPS claims data, the costs of treating ESRD patients in LTCHs are adequately reflected in data used to determine the MS-LTC–DRG relative weights for nondialysis MS-LTC–DRGs, and that the additional resources associated with renal dialysis treatments are included in the LTCH PPS payments.
Because the commenters failed to present any new evidence to contradict those conclusions, we continue to believe that the standard Federal payment rate accounts for these costs. Furthermore, as we discuss in section VII.B.7.b. of the preamble of this final rule, until we gain experience with the effects and implementation of the new site neutral payment rate and the types of cases paid at this rate, we believe that it is premature to consider whether additional payments are either necessary or appropriate. We may revisit this issue in the future, if data demonstrate such a change is warranted for either LTCH PPS standard Federal payment rate cases or site neutral payment rate cases.

Comment: A few commenters expressed appreciation for the information added to the publically available FY 2014 LTCH MedPAR File for the proposed rule which identifies whether the LTCH discharge in the historical data is site neutral payment rate case or standard payment rate case (that is, meets the criteria for exclusion from the site neutral payment rate) had the new statutory patient criteria been in effect at the time of the discharge. Some commenters also requested additional information be added to the publically available IPPS & LTCH PPS MedPAR files, such as encrypted patient identifiers, and encrypted admission and discharge dates, along with the number of days the patient spent in the ICU in the immediately preceding IPPS hospital stay prior to admission to the LTCH. These commenters believe that such additional information is needed to determine which historical discharges were immediately preceded by a qualifying IPPS hospital stay and could be used to verify the payment rate designation (that is, site neural or standard) CMS has included in the publically available LTCH MedPAR file.
Response: We understand that for commenters that would like to replicate the proposed LTCH PPS rates, factors and payment estimates presented in the proposed rule, it is necessary to be able to identify the LTCH discharges in the historical data that would be standard payment rate cases and the ones that would be site neutral payment rate cases (had the statutory criteria been in effect at the time of the discharge). We are also aware that currently the publically available IPPS and LTCH PPS MedPAR files do not contain any specified direct patient identifiers consistent with CMS’s privacy and security standards and as outlined in the HIPAA Privacy Rule. (For additional information on CMS’ privacy and security standards under the HIPAA Privacy Rule, we refer readers to the CMSWeb site at: http://www.cms.gov/Regulations-and-Guidance/HIPAA-Administrative-Simplification/HIPAAGenInfo/PrivacyandSecurityStandards.html, and for additional information on CMS’ publically available Limited Data Set (LDS) files, we refer readers to the CMS Web site at: http://cms.hhs.gov/Research-Statistics-Data-and-Systems/Files-for-Order/LimitedDataSets/index.html.) It is for these reasons that, as noted by commenters, we added an identifier to the publically available FY 2014 LTCH MedPAR File to identify the historical LTCH discharges in that file as standard payment rate cases or site neutral payment rate cases (had the statutory dual rate LTCH PPS payment structure been in effect at the time of the discharge). These are the same payment rate identifiers we used to develop the FY 2016 proposed rates, factors and payment estimates as described in the proposed rule. We believe that the addition of this payment rate identifier to the publically available LTCH MedPAR file provides sufficient information for commenters to replicate and evaluate the proposed rates, factors and
payment estimates in the proposed rule. We considered adding the encrypted information requested by commenters to the publically available IPPS and LTCH PPS MedPAR files; however, we are not able to do so at this time because to add such specific direct patient identifiers would need to be done in conformance with CMS’s privacy and security standards, including any requirements outlined in the HIPAA Privacy Rule. We are, however, adding the information on the number of days the patient spent in the ICU in an immediately preceding IPPS hospital stay prior to admission to the LTCH, as requested by commenters, since this aggregated count of days conforms with CMS’s privacy and security standards because it does not result in the identification of specific beneficiaries. We believe including the count of days in the ICU from the immediately preceding IPPS hospital stay to the publically available MedPAR file will allow the public to adequately corroborate the indicator of the historical LTCH discharges as a standard payment rate case or a site neutral payment rate cases (had the statutory criteria been in effect at the time of the discharge).

3. Criteria for Exclusion from the Site Neutral Payment Rate


As stated earlier, section 1206(a) of Pub. L. 113-67 amended section 1886(m) of the Act by adding paragraph (6), which specifies that beginning in cost reporting periods starting on or after October 1, 2015, all LTCH PPS discharges will be paid based on the site neutral payment rate unless certain criteria are met. In general, under section 1886(m)(6)(A)(ii) of the Act, the criteria for exclusion from the site neutral payment rate are: the discharge from the LTCH does not have a principal diagnosis relating to a
psychiatric diagnosis or to rehabilitation, the admission to the LTCH was immediately preceded by discharge from a subsection (d) hospital, and that immediately preceding stay in a subsection (d) hospital included at least 3 days in an intensive care unit (ICU) (referred to in this final rule as the ICU criterion) or the discharge from the LTCH is assigned to an MS-LTC-DRG based on the patient’s receipt of at least 96 hours of ventilator services during the LTCH stay (referred to in this final rule as the ventilator criterion). Below we summarize our proposals and the public comments received, and provide our responses to those comments and the finalized policies to implement the statutory criteria for exclusion from the site neutral payment rate.

b. Implementation of the Criterion for a Principal Diagnosis Relating to a Psychiatric Diagnosis or to Rehabilitation

Section 1886(m)(6)(A)(ii)(II) of the Act specifies that in order for an LTCH discharge to be excluded from payment under the site neutral payment rate, the LTCH discharge cannot have a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation. To implement this criterion, under the broad authority of section 123(a)(1) of the BBRA, as amended by section 307(b) of the BIPA and in accordance with section 1206(a) of Pub. L. 113-67, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24528 through 24529), we proposed to identify cases with a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation that would be assigned to specific MS-LTC-DRG groupings that we believe indicate such principal diagnoses using the most recent version of the MS-LTC-DRGs. We invited public comments on our proposed approach and our proposed list of applicable MS-LTC-DRGs.
Comment: Several commenters supported our proposal to identify discharges with a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation using the specific MS-LTC-DRGs included in our proposal.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing without change our proposal to identify discharges with a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation that are assigned to the specific MS-LTC-DRG groupings included in our proposal using the most recent version of the MS-LTC-DRGs. (For additional information on the version of the MS-DRGs, and by extension the MS-LTC-DRGs, that is Version 33, we refer readers to section II.G. of the preamble of this final rule.)

Accordingly, as we proposed, we are establishing that an LTCH discharge assigned to one of the following ICD-10 MS-LTC-DRG groupings in the most recent version of the MS-LTC-DRGs (that is, Version 33 for FY 2016) will be identified as a case with a principal diagnosis relating to a psychiatric diagnosis:

- MS-LTC-DRG 876 (O.R. Procedure with Principal Diagnosis of Mental Illness);
- MS-LTC-DRG 880 (Acute Adjustment Reaction & Psychosocial Dysfunction);
- MS-LTC-DRG 881 (Depressive Neuroses);
- MS-LTC-DRG 882 (Neuroses except Depressive);
- MS-LTC-DRG 883 (Disorders of Personality & Impulse Control);
- MS-LTC-DRG 884 (Organic Disturbances & Mental Retardation);
● MS-LTC-DRG 885 (Psychoses);
● MS-LTC-DRG 886 (Behavioral & Developmental Disorders);
● MS-LTC-DRG 887 (Other Mental Disorder Diagnoses);
● MS-LTC-DRG 894 (Alcohol/Drug Abuse or Dependence, Left Ama);
● MS-LTC-DRG 895 (Alcohol/Drug Abuse or Dependence, with Rehabilitation Therapy);
● MS-LTC-DRG 896 (Alcohol/Drug Abuse or Dependence, without Rehabilitation Therapy with MCC); and
● MS-LTC-DRG 897 (Alcohol/Drug Abuse or Dependence, without Rehabilitation Therapy without MCC).

Furthermore, as we proposed, we also are establishing that an LTCH discharge assigned to one of the following ICD-10 MS-LTC-DRG groupings in the most recent version of the MS-LTC-DRGs (that is, Version 33 for FY 2016) will be identified as an LTCH discharge with a principal diagnosis relating to rehabilitation:

● MS-LTC-DRG 945 (Rehabilitation with CC/MCC); and
● MS-LTC-DRG 946 (Rehabilitation without CC/MCC).

Under this finalized policy, as we proposed, an LTCH discharge grouped to any of the MS-LTC-DRG groupings listed above will not meet the criteria under new § 412.522(b)(1)(i) to be excluded from the site neutral payment rate.

c. Addition of Definition of a “Subsection (d) Hospital” to LTCH Regulations

The site neutral payment rate established in section 1206(a) of Pub. L. 113-67 includes several references to “subsection (d) hospitals.” The term “subsection (d)
hospital” is defined in section 1886(d)(1)(B) of the Act as a hospital that is located in 1 of the 50 States or the District of Columbia that is not a psychiatric hospital, a rehabilitation hospital, a children’s hospital, an LTCH, or a cancer hospital. However, section 1886(m)(6)(D) of the Act, as added by section 1206(a)(1) of Pub. L. 113-67, added that, for LTCH PPS purposes, any reference to a “subsection (d) hospital” is deemed to include a “subsection (d) Puerto Rico hospital,” which is defined by section 1886(d)(9)(A) of the Act (providing that the term “subsection (d) Puerto Rico hospital” means a hospital that is located in Puerto Rico and that would be considered a subsection (d) hospital (as defined in paragraph (d)(1)(B)) if it were located in 1 of the 50 States).

Given these statutory provisions, as part of our implementation of section 1206(a) of Pub. L. 113-67, and under the broad authority under section 123(a)(1) of the BBRA, as amended by section 307(b) of the BIPA, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24529), we proposed to add a definition of the term “subsection (d) hospital” to § 412.503 (defined as any hospital qualifying as a subsection (d) hospital under section 1886(d)(1)(B) of the Act and any hospital located in Puerto Rico that would be qualified as a subsection (d) hospital under section 1886(d)(1)(B) of the Act if it were located in 1 of the 50 States).

Comment: Several commenters supported the proposed definition of a “subsection (d) hospital” under the LTCH PPS.

Response: We appreciate the commenters’ support.
After consideration of the public comments received, we are finalizing our proposal to add the proposed definition for a “subsection (d) hospital” under § 412.503, without change.

d. Interpretation of “Immediately Preceded” by a Subsection (d) Hospital Discharge

Section 1886(m)(6)(A)(ii)(II) of the Act specifies that, in order to be excluded from payment under the site neutral payment rate, the LTCH discharge must meet the ICU criterion at section 1866(m)(6)(A)(iii) of the Act or the ventilator criterion at section 1866(m)(6)(A)(iv) of the Act. Both the ICU criterion and the ventilator criterion require that the LTCH admission be “immediately preceded” by a discharge from a subsection (d) hospital. Therefore, under the broad authority under section 123(a)(1) of the BBRA, as amended by section 307(b) of the BIPA, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24529 through 24530), we proposed to define the phrase “immediately preceded” in the context of a discharge from a subsection (d) hospital. Specifically, we proposed that the discharged Medicare patient would have to depart the subsection (d) hospital and arrive for admission to the LTCH without having returned home or being admitted to any other inpatient setting, including an IRF, an IPF, or a SNF. As required by the statute, we proposed that any LTCH admission that did not qualify under this definition as having been “immediately preceded” by a discharge from a subsection (d) hospital would not be eligible to qualify for exclusion from the site neutral payment rate based on the ICU or the ventilator criterion. We proposed to codify these proposals at new § 412.522(b)(1)(ii).
To implement these policies, we proposed to look at the Medicare patient’s discharge date on the subsection (d) hospital’s claim, and compare it to the admission date on the LTCH’s Medicare claim for the patient. In doing so, we proposed that the discharge date had to have occurred on the same date as the LTCH admission (or, for those rare circumstances where a patient is discharged from a subsection (d) hospital before the midnight census, but was not admitted to the LTCH until after the midnight census of that date of discharge, the day before the calendar date of the LTCH admission) if a patient’s discharge were to qualify as being immediately preceded by a discharge from a subsection (d) hospital.

We also proposed to condition eligibility for exclusion from the site neutral payment rate on the immediately preceding subsection (d) hospital’s claim using of certain codes, namely Patient Discharge Status Code 63, which signifies a patient was discharged or transferred to an LTCH, or Patient Discharge Status Code 91, which signifies a patient was discharged/transferred to a Medicare-certified LTCH with a planned acute care hospital inpatient readmission.

In making these proposals, we also noted that our proposed interpretation of “immediately preceded” by a subsection (d) hospital would work in tandem with our existing interrupted stay policy at § 412.531. An interruption of stay occurs when, during the course of an LTCH hospitalization, the patient is discharged to an inpatient acute care hospital, an IRF, or a SNF for treatment for a service that is not available at the LTCH for a specified period followed by readmittance within a specified number of days to the same LTCH. In such cases, the care following readmission is considered a continuation
of the care interrupted by the first discharge, so both “halves” of the LTCH episode of care are bundled, and Medicare makes a single payment based on the second date of discharge. As the two halves constitute a single episode of care, the discharge that is relevant to determining if that episode of care was immediately preceded by the required subsection (d) hospital stay is the care provided prior to the first admission to the LTCH. Using these concepts, any interruption of stay defined under § 412.531 would not invalidate the immediately preceded status for the single episode of care--only the care provided prior to the first LTCH admission would be relevant.

Comment: Some commenters generally supported CMS’ proposal to define the phrase “immediately preceded” in the context of the subsection (d) hospital discharge occurring on the same calendar date as the LTCH admission (or, in certain rare circumstances, the calendar date before the date of the LTCH admission). However, many commenters expressed concern with CMS’ proposal to require specific patient discharge status codes on the subsection (d) hospital claim. These commenters believed that reliance on these status codes was unnecessary, given the high percentage of LTCH admissions that occur on the same date as preceding subsection (d) hospital discharges, and noted that there is inconsistency in the use of discharge status codes by subsection (d) hospitals. The commenters also believed that it would be difficult and burdensome for LTCHs to get information from the referring hospital regarding the discharge status code. Some of these commenters suggested that CMS determine whether the immediately preceding requirement for LTCH discharges paid at the LTCH PPS standard Federal
payment rate is met solely from information provided by the LTCH, such as through some form of self-attestation.

**Response:** After considering the comments we received, we believe that reliance on the discharge and admission dates may adequately address our concerns and, therefore, we agree that requiring the presence of specific discharge status code(s) on the preceding subsection (d) hospital claim as a condition of qualifying for the exclusions from the site neutral payment rate may not be necessary at this time. We considered continuing to require the discharge status codes when LTCH admission occurred the day after the subsection (d) hospital discharge, which would allow additional time for intervening services to be received by the patient. However, the commenters’ analyses showed that between 95 percent and 99 percent of LTCH admissions that occur within 1 day of a subsection (d) hospital discharge occur on the same date as the subsection (d) hospital discharge and provides adequate protection against inappropriate payments at this time. Based on this assessment, we are not finalizing the discharge status code requirements at this time. However, we may revisit this issue in future rulemaking, and may propose changes to this policy if reliance on the discharge and admission dates prove inadequate to determine appropriate payment. We also are taking this opportunity to remind all hospitals of their responsibility to bill accurately, including the use of the appropriate patient discharge status codes. Regarding the specific suggestions that we determine immediately preceding discharges based solely on LTCH claims, we do not believe such an approach would serve as adequate protection against misuses and inappropriate payments under the new dual rate LTCH PPS payment structure. We
believe that claims data, which hospitals submit for Medicare payment, should be a reliable data source upon which to base a determination of whether an immediately preceding subsection (d) hospital stay occurred. When such reliable primary source data are available, we see little reason to rely on a secondary source, such as an LTCH conveying assurances of an immediately preceding discharge. We do not believe that it would be appropriate to rely upon, either presumptively or otherwise, an attestation or assertion about what the LTCH’s may believe occurred in the previous subsection (d) hospital admission, when more reliable data are available directly from the subsection (d) hospital that delivered that preceding care rather than in our claims processing systems.

After consideration of the public comments we received, we are finalizing our proposed policy that conditions eligibility for exclusion from the site neutral payment rate on the LTCH admission having been “immediately preceded” by a subsection (d) hospital stay, as evidenced by the admission to the LTCH occurring either on the date of or, in certain rare circumstances, the calendar date after the discharge from the preceding subsection (d) hospital. As discussed above, we are not finalizing our proposals regarding the discharge status codes as reported on the preceding subsection (d) hospital’s claim. As finalized at new § 412.522(b)(1)(ii), an LTCH discharge will be considered to have been immediately preceded by a discharge from a subsection (d) hospital if there was a direct admission from such a hospital, as evidenced by the dates of discharge and admission, to the LTCH.

e. Implementation of the Intensive Care Unit (ICU) Criterion

Section 1886(m)(6)(A)(iii)(I) of the Act specifies that in order to be excluded from payment under the site neutral payment rate under the ICU criterion, the LTCH
admission must be immediately preceded by a discharge from a subsection (d) hospital that included at least 3 days in an intensive care unit (ICU), as determined by the Secretary. In doing so, section 1886(m)(6)(A)(iii)(II) of the Act requires the use of data from revenue center codes 020X or 021X (or such successor codes as the Secretary may establish). As discussed in the proposed rule (80 FR 24530), revenue center codes are reported on the hospital claim with revenue center code 020X (indicating intensive care), and the revenue center code 021X (indicating coronary care). Both of these revenue center codes are used to bill Medicare for services provided by “intensive care units (ICUs)” as defined under our existing definition at § 413.53(d) of the regulations, and, as indicated by the “X” in the revenue code descriptions both are further divided into subcategories that form a revenue center code series.

As described in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24530), we proposed to implement the ICU criterion under new § 412.522(b)(2). In that section, we proposed that the claim from the subsection (d) hospital that immediately preceded the admission to the LTCH had to indicate receipt of at least 3 days of care in an ICU using revenue center codes 020X or 021X (or such successor code as the Secretary may establish), the use of which must be consistent with our definition of an ICU under § 413.53(d), in order to fulfill the ICU criterion for exclusion from the site neutral payment rate. We refer readers to the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24530) for more information on the development of our proposal for the implementation of the ICU criterion under section 1886(m)(6)(A)(iii) of the Act, including our explanation as to why we believe that our proposed implementation of the
ICU criterion will work in tandem with our existing LTCH policies governing interrupted stays. As we noted in the context of our “immediately preceded” policy discussion above, because the two halves of an interrupted stay constitute a single episode of care (as shown by the issuance of a single payment), the discharge that is relevant to determining if that episode of care was immediately preceded by a subsection (d) hospital stay that included 3 days in the ICU is the first admission to the LTCH.

Comment: Some commenters generally supported CMS’ proposal to use the presence or absence of revenue center codes 020X or 021X on the preceding subsection (d) hospital claim as the basis for concluding that an LTCH admission was or was not preceded by a subsection (d) hospital stay including at least 3 days in the ICU, and, based on that finding, whether the LTCH admission was eligible for exclusion from the site neutral payment rate. Some commenters opined that CMS lacks the authority to exclude certain subsets of these codes. Other commenters disagreed with the proposal to rely on the subsection (d) hospital’s reporting of these revenue center codes because doing so would increase administrative burdens imposed upon subsection (d) hospitals and LTCHs. Some commenters recommended that CMS adopt a policy by which compliance would be determined based solely on the information an LTCH submitted on its claims, others suggested reliance on self-attestation. Others suggested specific focus on, and the adoption of indicators based on, the severity of a patient’s illness rather than relying on the use of revenue center codes. Some commenters also disagreed with CMS’ proposal to define an ICU stay in a manner that required the subsection (d) hospital’s adherence to § 413.53(d), asserting that there was no statutory basis for such a requirement.
Response: We appreciate the commenters’ suggestions, but we disagree with the commenters who asserted we lacked the authority to exclude certain subsets of revenue center codes. The statute merely requires us to use data from the sequences of revenue center codes, not every code within the sequences. We also disagree with commenters who asserted that there is no legal obligation to require consistency between the use of revenue center codes 020X or 021X for purposes of determining LTCH PPS payment rates and the subsection (d) hospital’s coding of its claim in a manner that complies with our definition of ICU services under § 413.53(d). Hospitals must comply with all applicable requirements when they submit a claim for Medicare reimbursement. Section 1886(m)(6)(A)(iii) of the Act does not exempt subsection (d) hospitals from any of the requirements that govern their delivery of services, or their billing for those services. As such, the requirements governing their use of revenue center codes 020X or 021X on their claims are unchanged by our policy to use those codes as the basis for determining exclusion of an LTCH discharge from the site neutral payment rate. Furthermore, we also disagree with the commenters who suggested it would be appropriate to determine compliance with the ICU criterion based solely on data obtained from an LTCH’s claim. Congress expressly mandated that the ICU criterion was to be based on events that occurred prior to the LTCH admission. The best source of data for what happened in a subsection (d) hospital is that subsection (d) hospital, and the information needed to determine ICU exclusion eligibility should be readily available on any properly billed subsection (d) hospital claim. Furthermore, given the potential for audit, and the penalties for filing false claims, we believe that claims data should be a reliable data
source upon which to make a determination for exclusion from the site neutral payment rate under the ICU criteria. When such reliable primary source data is available, we see little reason to rely on a secondary source such as an LTCH conveying its understanding of the services received at the preceding subsection (d) hospital at the time of patient transfer. We do not believe that it would be appropriate to rely upon, presumptively or otherwise, assertions about the LTCH’s understanding about the previous medical care received by the patient, when more reliable data is available directly from the subsection (d) hospital that provided that care in our claims processing systems. Again, as discussed above, we recognize the commenters’ concerns and have in fact considered these issues in our development of claims processing systems changes to implement the new system. We believe that these systems changes will allow for appropriate payment for all LTCH discharges under the new dual rate LTCH PPS payment structure. As part of the relationship between referring IPPS hospitals and LTCHs, we encourage each party to communicate and exchange information to help ensure that LTCH claims are paid appropriately. While final payment of the LTCH claim will be based in part on information from preceding subsection (d) hospital’s IPPS claim, we would encourage LTCHs to ask questions of the referring hospitals in order to ascertain all necessary information prior to admitting a patient. We may revisit these issues as we gain more experience under the revised LTCH PPS particularly if we observe an unusual change in hospital ICU coding behavior or if we become aware of data which demonstrates that use of particular codes within the 020X or 021X are inappropriate bases for meeting the ICU criterion. We do, however, acknowledge that as this is a new payment structure, it may
not work flawlessly in each and every instance. In those rare instances where obvious
errors occur in the determination of the LTCH PPS payment amount for a particular case,
LTCHs can contact their MACs and we will recheck our available information to ensure
that correct payments are made under our policies.

Comment: One commenter requested clarification of how the proposals to
implement the ICU criterion would interact with CMS' existing interrupted stay policy.

Response: As we previously noted in our discussion of our policies regarding the
“immediately preceded” requirement, our dual rate LTCH PPS payment structure policies
were designed to complement our existing interrupted stay policies. Both halves of an
interrupted stay constitute a single episode of care (as demonstrated by the issuance of a
single payment). As such interrupted stays have historically been treated as a single
episode of care, we established in this final rule that the relevant subsection (d) hospital
discharge for purposes of the payment of interrupted stays under the dual rate LTCH PPS
payment structure is the first subsection (d) discharge. Under this policy, any time spent
in a subsection (d) hospital’s ICU during an interrupted LTCH stay would not be
considered in the evaluation of whether the interrupted LTCH stay met the ICU criterion
because such care would not have immediately preceded the initial admission to the
LTCH. Conversely, if the subsection (d) hospital discharge that immediately preceded
the initial LTCH admission meets the ICU criterion (that is, includes at least 3 ICU days),
and the period of time relating to an intervening interrupted stay does not include any
days in a subsection (d) hospital’s ICU, the ICU criterion would still be met because the
initial LTCH admission fulfilled the ICU criterion for exclusion from the site neutral
payment rate. However, we note that if the intervening stay in the acute care hospital is 10 days or longer (such that our interrupted stay policy would be inapplicable with respect to the readmission to the LTCH), in order for the second admission to meet the ICU criterion to be excluded from the site neutral payment rate, the acute care hospital stay would have to include at least 3 days in an ICU.

After consideration of the public comments we received, we are finalizing without modification our proposal that at least 3 days of ICU services must be reported on the preceding subsection (d) hospital claim using revenue center codes 020X or 021X, and that such coding must be consistent with our policies governing ICU services under §413.53(d) in order for an LTCH discharge to fulfill the requirements of the ICU criterion for exclusion from the site neutral payment rate. As we proposed, we are codifying this policy under new §412.522(b)(2).

f. Implementation of the Ventilator Criterion

Section 1886(m)(6)(A)(vi) of the Act specifies that in order to be excluded from payment under the site neutral payment rate under the ventilator criterion, the LTCH admission must be immediately preceded by a discharge from a subsection (d) hospital (as discussed in section VII.B.3.d. of the preamble of this final rule), and the LTCH discharge must be assigned to an MS-LTC-DRG based on the beneficiary’s receipt of at least 96 hours of ventilator services in the LTCH. As we discussed in the preamble of the proposed rule (80 FR 24531), we proposed that, for the purposes of a discharge being excluded from the site neutral payment rate based on the ventilator criterion, the discharge must use the applicable procedure code to indicate that at least 96 hours of
ventilator services were received during the LTCH stay. Currently, under the ICD-9-CM coding system, procedure code 96.72 (Continuous invasive mechanical ventilation for 96 consecutive hours or more) is used to describe such long-term mechanical ventilator services. As discussed in sections II.G.1.a. and VII.C. of the preamble of this final rule, the use of the ICD-10-CM/PCS coding system is required beginning October 1, 2015. Under the ICD-10-PCS coding system, procedure code 5A1955Z (Respiratory ventilation, greater than 96 consecutive hours) describes such long-term mechanical ventilator services. Therefore, we further proposed, effective with discharges in cost reporting periods beginning on or after October 1, 2015, to determine if a discharge meets the requirements of the ventilator criterion in order to be eligible for exclusion from the site neutral payment rate based on whether the LTCH reports procedure code 5A1955Z on its hospital claim. If finalized, we proposed to place these requirements under new § 412.522(b)(3).

Under this proposal, any LTCH claims that do not report this procedure code would not meet the requirements of the ventilator criterion in order to be eligible for exclusion from the site neutral payment rate. For more detail regarding the ventilator criterion proposals and the alternatives that we had considered in developing those proposals (including the use of MS-LTC-DRGs in lieu of this procedure code), we refer readers to the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24531).

Comment: Commenters generally supported CMS’ proposal to determine whether an LTCH discharge meets the ventilator criterion based on the use of ICD-10-PCS procedure code 5A1955Z. However, some commenters expressed concern
that CMS’ proposal failed to identify and include cases that receive \textit{exactly} 96 hours of ventilator services. The commenters pointed out that, under the statutory language, cases representing patients receiving \textit{exactly} 96 hours of ventilation should also be paid the LTCH PPS standard Federal payment rate, assuming the other relevant criteria are met. Some commenters suggested that discharges identified by ICD-10-PCS procedure code 5A1945Z (Continuous invasive mechanical ventilation, 24 – 96 consecutive hours) and were grouped into one of the six long-term mechanical ventilator MS-LTC-DRGs (that is, MS-LTC-DRGs 003, 004, 207, 870, 927, 933) should also be used as an additional procedure code to identify discharges meeting the ventilator criterion. Doing so, they believed, would ensure proper payment of cases that received \textit{exactly} 96 hours of ventilator services. Other commenters noted their belief that the statute does not require consecutive hours on ventilator services and, therefore, were concerned that the use of ICD-10-PCS procedure code 5A1945Z, which they believed specified more than 96 hours of \textit{continuous} ventilation, would not recognize discharges that receive 96 hours or more of \textit{noncontinuous} of ventilator services. For example, the commenters indicated that ICD-10-PCS procedure code 5A1945Z may not appropriately account for hours used during ventilator weaning, which could discourage LTCHs from weaning patients off of ventilator services within less than 96 hours, if the number of hours provide during the weaning process would result in less than 96 hours of services being provided.

Response: The commenters are correct in noting that the range of consecutive hours for mechanical ventilation services under the ICD-10-PCS differs from the ICD-9-CM, with the primary difference being the handling of the 96\textsuperscript{th} hour. The ICD-9-CM
system provides three unique procedure codes for mechanical ventilator services based on the number of consecutive hours: ICD-9-CM procedure code 96.70 for an unspecified duration of service, ICD-9-CM procedure code 96.71 for services less than 96 consecutive hours in duration, and ICD-9-CM procedure code 96.72 for services consisting of 96 consecutive hours or more. Whereas, the ICD-10-PCS provides three unique codes for mechanical ventilator services based on the number of consecutive hours with the following ranges: services consisting of less than 24 consecutive hours (ICD-10-PCS procedure code 5A1935Z); services consisting of 24 to 96 consecutive hours (ICD-10-PCS procedure code 5A1945Z); and services consisting of greater than 96 consecutive hours (ICD-10-PCS procedure code 5A1955Z). Consequently, under the ICD-10-PCS, mechanical ventilation services in duration of exactly 96 hours are no longer grouped in the same range as services consisting of more than 96 hours, as it is under ICD-9-CM system.

We have considered the commenters’ suggestions. While we agree that our proposed use of procedure code 5A1945Z would not identify a case where the patient received exactly 96 hours of ventilator services and that such a case should be paid the LTCH PPS standard Federal payment rate. Despite that, for the reasons noted below, we continue to believe that the most appropriate means of implementing the ventilator criterion is by the use of ICD-10-PCS procedure code 5A1955Z.

We first considered the commenters’ suggested alternative method, but determined that it was not a viable option because, under the ICD-10 coding guidelines and Version 33.0 MS-DRGs (discussed in section II.G.1.a. of this preamble) and by
extension the MS-LTC-DRGs, discharges with ICD-10-PCS procedure code 5A1945Z (Respiratory ventilation, 24-96 consecutive hours), but not ICD-10-PCS procedure code 5A1955Z (Respiratory ventilation, greater than 96 consecutive hours), will not be grouped into any of the MS-LTC-DRGs suggested by the commenters. That is, the commenters’ suggested alternative is not possible because the GROUPER logic for those MS-LTC-DRGs only includes ICD-10-PCS procedure code 5A1955Z. Furthermore, based on existing claims elements and ICD-10-PCS procedure codes’ descriptions, we were unable to identify any feasible alternative procedure code to identify a case where the patient received exactly 96 hours of ventilator services, and the commenters did not provide any data or anecdotal evidence of such situations regularly occurring. We do not believe that many patients receive exactly 96 hours of ventilator services, and we expect that this problem will rarely, if ever, arise. However, if these rare instances occur, the LTCH should contact its MAC to have the appropriate LTCH PPS payment amount under the new dual rate LTCH PPS payment structure determined for any such claims (which should be coded with the appropriate use of ICD-10-PCS procedure code 5A1945Z).

With respect to the commenters’ concerns regarding counting the number of hours in which a patient is being weaned from mechanical ventilator services, the AHA Coding Clinic (4th Quarter 2014) instructs coders that, in general, “[w]hen the patient is being weaned from mechanical ventilation, the entire duration of the weaning process is counted to determine the correct code assignment.” We also refer readers to the AHA Coding Clinic guidelines, which provide guidance on determining the duration of
mechanical ventilation services, including any weaning period. Therefore, we do not believe that the use of ICD-10-PCS procedure code 5A1955Z, which specifies more than 96 hours of continuous ventilation, would discourage LTCHs from weaning patients of a ventilator in less than 96 hours because the use of this procedure code accounts for hours spent during the ventilator weaning process. However, we remind providers that providing medically unnecessary services to patients (including additional time on a ventilator in order to meet the requirements for exclusion from the site neutral payment rate) and reporting charges for such services constitutes fraudulent behavior for which we will monitor. We also intend to continue to monitor the appropriateness of the use of ICD-10-PCS procedure code 5A1955Z, and may propose alternative implementation measures for the ventilator criterion to the extent experience under the revised LTCH PPS demonstrates such action is necessary.

After consideration of the public comments we received, we are finalizing our proposal, without modification, and codifying our ventilator criterion under new § 412.522.
4. Determination of the Site Neutral Payment Rate (New § 412.522(c))

a. General

Section 1206(a) of Pub. L. 113-67 amended section 1886(m) of the Act by adding paragraph (6), which specifies that beginning with cost reporting periods starting on or after October 1, 2015, all LTCH PPS discharges are paid according to the site neutral payment rate unless certain criteria are met. In general, section 1886(m)(6)(B)(ii) of the Act specifies that the site neutral payment rate is the lower of the IPPS comparable per diem amount under § 412.529(d)(4), including any applicable outlier payments under § 412.525(a), or 100 percent of the estimated cost of the case. Consistent with the requirements of section 1886(m)(6)(B)(ii) of the Act, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24531 through 24532), we proposed under new § 412.522(c)(1) that the site neutral payment rate is the lower of the IPPS comparable per diem amount determined under § 412.529(d)(4), including any applicable outlier payments under § 412.525(a), or 100 percent of the estimated cost of the case determined under § 412.529(d)(2).

Under our proposed calculation of the site neutral payment rate, new § 412.522(c)(1)(i) provides that the IPPS comparable per diem amount would be calculated using the same method used to determine an amount comparable to the hospital IPPS per diem amount as set forth in the existing regulations at § 412.529(d)(4), consistent with section 1886(m)(6)(B)(ii)(I) of the Act. Specifically, in the RY 2007 LTCH PPS final rule (71 FR 27852 through 27853), we established a method to determine an amount payable under 42 CFR Part 412, Subpart O, that is comparable to
what would otherwise be paid under the IPPS for the costs of inpatient operating services, which is commonly referred to as the “the IPPS comparable per diem amount.” Accordingly, consistent with § 412.529(d)(4), we proposed to determine the IPPS comparable per diem amount based on the standardized amount determined under § 412.64(c), adjusted by the applicable DRG weighting factors determined under § 412.60 as specified at § 412.64(g). We also proposed to further adjust this amount to account for differences in area wage levels based on geographic location using the applicable IPPS labor-related share and the IPPS wage index for nonreclassified hospitals published in the annual IPPS final rule in accordance with § 412.525(c). For LTCHs located in Alaska and Hawaii, we proposed that this amount would be further adjusted by the applicable COLA factors established annually during the rulemaking cycle. We also proposed that the IPPS comparable per diem amount include an adjustment for treating a disproportionate share of low-income patients, consistent with the DSH payment adjustment under § 412.106, as applicable, which would include a proxy adjustment for the uncompensated care payment (78 FR 50765 through 50767). In the case of an LTCH that is a teaching hospital, we proposed that the IPPS comparable per diem amount include an IME payment adjustment, consistent with the formula set forth under § 412.105, where the LTCH’s IME cap (that is, the limit on the number of full-time equivalent (FTE) residents that may be counted for IME) would be imputed from the LTCH’s direct GME cap as set forth at § 413.79(c)(2). In addition, we proposed that the IPPS comparable per diem amount also include payment for inpatient capital-related costs, based on the capital IPPS Federal rate determined in accordance with § 412.308(c),
adjusted by the applicable IPPS DRG weighting factors. We proposed to further adjust the capital IPPS Federal rate by the applicable geographic adjustment factors based on the geographic location of the LTCH and the COLA factors for LTCHs located Alaska and Hawaii, consistent with § 412.316. In addition, we proposed to include in this amount the adjustments to the capital IPPS Federal rate for DSH payments in accordance with § 412.320 and IME payments in accordance with § 412.322. Consistent with §§ 412.529(d)(4)(i)(B) and (C), we proposed to determine the IPPS comparable per diem amount by dividing the IPPS comparable payment amount described above by the geometric average length of stay of the specific MS-DRG under the IPPS and multiplying that amount by the covered days of the LTCH stay. We proposed that the IPPS comparable per diem amount is limited to the full comparable amount to what would otherwise be paid under the IPPS.

Comment: Several commenters expressed concern regarding CMS’ proposal to establish that the new LTCH site neutral payment rate as the lesser of the IPPS comparable per diem amount, or 100 percent of the estimated cost of the case. Specifically, the commenters stated that an LTCH would receive a lower payment than an IPPS hospital for treating the same type of case. Therefore, the commenters recommended that CMS pay LTCH site neutral payment rate cases the exact amount that would be paid for the case under the IPPS.

Response: We acknowledge the commenters’ concerns. However, section 1886(m)(6)(B)(ii) of the Act specifies that the site neutral payment rate is the lower of the IPPS comparable per diem amount under § 412.529(d)(4), including any applicable
outlier payments under § 412.525(a), or 100 percent of the estimated cost of the case. Without the enactment of further legislation, we do not have the authority to make any further adjustments to the calculation of the site neutral payment rate that would guarantee that payment for such a case would equal the exact amount paid for an identical discharge from an IPPS hospital.

After consideration of the public comments we received, we are finalizing, without modification, our proposal to establish that the site neutral payment rate is the lesser of the IPPS comparable per diem amount, or 100 percent of the estimated cost of the case.

The IPPS comparable per diem amount described under § 412.529(d)(4) does not include additional payments for extraordinarily high-cost cases under the IPPS outlier policy. Therefore, consistent with the requirements of section 1886(m)(6)(B)(ii)(I) of the Act, under our proposed calculation of the site neutral payment rate under new § 412.522(c)(1), we proposed to add any high-cost outlier (HCO) payment that may be payable under § 412.525(a) to the IPPS comparable per diem amount. To do so, we also proposed to revise the HCO policy under existing § 412.525(a) to provide for high-cost outlier payments under the site neutral payment rate calculated under proposed new § 412.522(c) (as discussed in greater detail in section VII.B.7.b. of the preamble of this final rule). We proposed that site neutral payment rate cases receive an additional payment for HCOs that would be equal to 80 percent of the difference between the estimated cost of the case and the HCO threshold, which we are proposing would be the sum of site neutral payment rate for the case and the IPPS fixed-loss amount. We also
proposed that HCO payments for site neutral payment rate cases would be budget neutral and proposed to apply a budget neutrality factor to the LTCH PPS payments for those cases to maintain budget neutrality. (For additional information on our revised HCO policy in regard to site neutral payment rate cases under § 412.525(a), we refer readers to section VII.B.7.b. of the preamble of this final rule.)

Comment: Commenters supported the proposal to under new § 412.522(c)(1) to include any applicable HCO payments specified in § 412.525(a) in the IPPS comparable per diem amount determined under § 412.529(d)(4) when determining the payment for site neutral payment rate cases. We also received comments on our proposed revisions to the HCO policy under existing § 412.525(a) to determine high-cost outlier payments under the site neutral payment rate, which are discussed in section VII.B.7.b. of the preamble of this final rule.

Response: We appreciate the commenters’ support. We are adopting this proposal, without modification. As noted above, we refer readers to section VII.B.7.b. of the preamble of this final rule for a discussion of our revisions to the HCO policy under existing § 412.525(a) to determine high-cost outlier payments under the site neutral payment rate, and summations of the public comments we received, including our responses to those comments, and a statement of our final policy.

Furthermore, under our proposed calculation of the site neutral payment rate, under proposed new § 412.522(c)(1)(ii), we proposed to calculate 100 percent of the estimated cost of a case by multiplying the LTCH’s hospital-specific cost-to-charge ratio (CCR) by the Medicare allowable charges for the LTCH case, which is the same method
we use to determine SSO payments under § 412.529(d)(2), as well as HCO payments under the HCO policy under § 412.525(a). Consistent with our existing policies for computing CCRs under the LTCH PPS, we also proposed to apply the payment policies described under §§ 412.529(f)(4)(i) through (f)(4)(iii) to the calculation of the estimated cost of the case for site neutral payment rate cases under proposed new § 412.522(c)(1)(ii). Under this proposal, the CCR applied at the time a claim is processed would generally be based on either the most recent settled cost report or the most recent tentatively settled cost report, whichever is from the latest cost reporting period. CMS may specify an alternative to the CCR otherwise applicable if we believe that the CCR being applied is inaccurate, in accordance with section 150.24 of Chapter 3 of the Medicare Claims Processing Manual (Pub. 100-4), or an LTCH may request an alternate (higher or lower) CCR based on its presentation of substantial evidence in support of that alternate. The CMS Regional Office must approve the request, and the MAC notifies the LTCH whenever a change is made to its CCR. The applicable MAC may also use the statewide average CCR that is established annually by CMS if it is unable to determine an accurate CCR for an LTCH under one of the circumstances specified at existing § 412.529(f)(4)(iii) (that is, in general, for a new LTCH, when the LTCH’s CCR exceeds 3 standard deviations from the corresponding national geometric mean CCR, and for an LTCH for which data to calculate a CCR are otherwise not available). These same CCR policies also are applicable under the LTCH PPS HCO policy (§§ 412.525(a)(4)(iv)(B) and (a)(4)(iv)(C)).
We did not receive any public comments on our proposal to calculate 100 percent of the estimated cost of a site neutral payment rate case by multiplying the LTCH's hospital-specific CCR by the Medicare allowable charges for the LTCH case, and to codify this policy under new § 412.522(c)(1)(ii). Therefore, we are adopting that proposal, without modification.

In the FY 2016 IPPS/LTCH PPS (80 FR 24532), we proposed to include a reconciliation adjustment to site neutral payment rate cases. Currently, under the LTCH PPS, payments for HCO and SSO cases may be subject to reconciliation at cost report settlement under § 412.525(a)(4)(iv)(D) and § 412.529(f)(4)(iv), respectively. Under these policies, reconciliation is based on the CCR calculated using the CCR computed from the settled cost report that coincides with the discharge. Under our existing criteria, reconciliation occurs in instances where an LTCH's actual CCR for the cost reporting period fluctuates plus or minus 10 percentage points compared to the interim CCR used to calculate payments when a claim is processed. We adopted this reconciliation policy for the LTCH PPS HCO and SSO cases because CCRs based on settled cost reports are not available when claims are processed unless significant delays are imposed on the payment of claims. (For additional information, we refer readers to the June 9, 2003 IPPS/LTCH PPS high-cost outlier final rule (68 FR 34507) and sections 150.26 through 150.28 of the Medicare Claims Processing Manual (Pub. 100-4).) Given the use of LTCH CCRs to calculate the estimated cost of cases under the proposed site neutral payment rate, we stated in the proposed rule that we believe that it would be equally appropriate to apply the current CCR reconciliation policy principles to site neutral
payment rate payments. Therefore, we proposed under new § 412.522(c)(4) to reconcile site neutral payment rate payments based on the CCR calculated using the settled cost report that coincides with the discharge. We also proposed that, at the time of any such reconciliation of site neutral payment rate payments, such payments be adjusted to account for the time value of any underpayments or overpayments. Any adjustment would be based upon a widely available index to be established in advance by the Secretary and will be applied from the midpoint of the cost reporting period to the date of reconciliation. The index that would be used to calculate the time value of money is the monthly rate of return that the Medicare Trust Fund earns, which can be found at:

http://www.ssa.gov/OACT/ProgData/newIssueRates.html, consistent with our current reconciliation policy described in section 150.27 of Chapter 3 of the Medicare Claims Processing Manual (Pub. 100-4). Furthermore, we proposed that our existing policies governing CCRs for both HCO (under §§ 412.525(a)(4)(iv)(A) through (C)) and SSO payments (under §§ 412.529(f)(4)(i) through (iii)) would apply to the CCRs used to determine the estimated cost of a case under proposed new § 412.522(c)(4).

Comment: Several commenters disagreed with CMS’ proposal to apply our existing reconciliation policy to payments made for site neutral payment rate cases. The commenters stated that such a policy is unprecedented and contrary to the predictability of a PPS. They believed that applying a reconciliation policy to payments for site neutral payment rate cases would result in an adjustment to all LTCH site neutral payment rate cases for every LTCH at the conclusion of every cost reporting period.
Response: We disagree with the commenters. Consistent with the current reconciliation policy, payments for site neutral payment rate cases would be subject to reconciliation only when certain criteria are met. As noted above and referenced by several commenters, the current criteria for reconciliation are presented in sections 150.26 through 150.28 of the Medicare Claims Processing Manual (Pub. 100 4), and include the criterion that the LTCH’s actual CCR must be plus or minus 10 percentage points from the CCR used during that cost reporting period to trigger outlier payments.

The purpose of the policy was not intended to automatically require that all payments for site neutral payment rate cases in every LTCH’s cost reporting period be reconciled. Nevertheless, we understand the commenters’ concerns regarding the need for predictability and stability in LTCH PPS payments. Therefore, we believe that it would be appropriate to generally postpone the implementation of a reconciliation policy for site neutral payments until we have gained more experience under the revised LTCH PPS.

This approach would allow CMS the opportunity to review the existing reconciliation criteria, and revise, if appropriate, that criteria to identify the circumstances under which it would be appropriate to reconcile the entire site neutral payment rate payment amount, should it be determined that such a policy is warranted. However, we continue to believe that it is appropriate to include any HCO payments made to site neutral payment rate cases in our existing reconciliation policy. Such a policy provides for a consistent application of the reconciliation policy to both site neutral payment rate cases and LTCH PPS standard Federal payment rate cases, while we monitor whether it may be
appropriate to apply a reconciliation policy to the entire site neutral payment rate as we gain experience under the revised LTCH PPS.

Therefore, we are not finalizing the proposal to apply, under new §412.522(c)(4), a reconciliation policy to payments made for site neutral payment rate cases. However, we are finalizing the proposal to include any HCO payments made for site neutral payment rate cases under the existing reconciliation policy at § 412.525(a)(4)(iv)(D). (As noted previously, our HCO policy for site neutral payment rate cases is discussed in detail in section VII.B.7.b. of the preamble of this final rule.)

b. Blended Payment Rate for FY 2016 and FY 2017

Section 1886(m)(6)(B) of the Act establishes a transitional payment method for cases that will be paid the site neutral payment rate for LTCH discharges occurring in cost reporting periods beginning during FY 2016 or FY 2017. For those discharges, the applicable site neutral payment rate is to be the blended payment rate specified in section 1886(m)(6)(B)(iii) of the Act. For LTCH discharges occurring in cost reporting periods beginning during FY 2018 or later, the applicable site neutral payment rate will be the site neutral payment rate as defined in section 1886(m)(6)(B)(ii) of the Act.

Section 1886(m)(6)(B)(iii) of the Act specifies that the blended payment rate is comprised of 50 percent of the site neutral payment rate for the discharge under section 1886(m)(6)(B)(ii) of the Act and 50 percent of the LTCH PPS standard Federal payment rate that would have applied to the discharge if paragraph (6) of section 1886(m) of the Act had not been enacted. As previously discussed, we proposed to codify the site neutral payment rate specified under section 1886(m)(6)(B)(ii) of the Act under proposed
new § 412.522(c)(1), as adjusted under proposed new § 412.522(c)(2). Under proposed new § 412.522(c)(1), the site neutral payment rate is the lower of the IPPS comparable per diem amount determined under § 412.529(d)(4), including any applicable outlier payments under § 412.525(a), or 100 percent of the estimated cost of the case determined under § 412.529(d)(2). For purposes of the blended payment rate, we proposed that the payment rate that would otherwise be applicable if section 1886(m)(6) of the Act had not been enacted would be the LTCH PPS standard Federal payment; which, in light of other proposals presented in the proposed rule, would be the LTCH PPS standard Federal payment rate that is applicable to discharges that meet the criteria for exclusion from the site neutral payment rate under proposed new § 412.522(a)(2). That rate is the LTCH PPS standard Federal payment rate determined under § 412.523. Therefore, consistent with the requirements of section 1886(m)(6)(B)(ii) of the Act, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24533), we proposed under proposed new § 412.522(c)(3), for LTCH discharges occurring in cost reporting periods beginning on or after October 1, 2015, and on or before September 30, 2017 (that is, discharges occurring in cost reporting periods beginning during FYs 2016 and 2017), that the payment amount for site neutral payment rate cases would be a blended payment rate, which would be calculated as 50 percent of the applicable site neutral payment rate amount for the discharge as determined under proposed new § 412.522(c)(1) and 50 percent of the applicable LTCH PPS standard Federal payment rate determined under § 412.523. Under this proposal, the payment amounts determined under proposed new § 412.522(c)(1) (the site neutral payment rate) and under § 412.523 (the LTCH PPS standard Federal rate)
would include any applicable adjustments, such as HCO payments, as applicable, consistent with the requirements under § 412.523(d). For example, the portion of the blended payment for the discharge that is based on proposed new § 412.522(c)(3) would include 50 percent of any applicable site neutral payment rate HCO payment under our revised HCO payment policy (discussed in detail in section VII.B.7.b. of the preamble of this final rule), consistent with proposed new § 412.522(c)(1)(i), which provides for HCO payments under § 412.525(a). Similarly, the portion of the blended payment for the discharge that is based on the LTCH PPS standard Federal payment rate would include any applicable HCO payment under existing § 412.525(a).

Comment: Some commenters requested that CMS establish a longer transitional period for LTCHs to receive blended payments because of the concern that reduced payments to LTCHs under the revised LTCH PPS would create a negative impact on these providers.

Response: We acknowledge the commenters' concerns. However, the blended payment rate provided under the statute is only applicable to LTCH discharges occurring during FY 2016 and FY 2017, and does not extend applicability to discharges occurring during cost reporting periods beginning in FY 2018 and subsequent fiscal years.

After consideration of the public comments we received, we are finalizing our proposed policy, without modification.

c. LTCH PPS Standard Federal Payment Rate

Section 1206(a) of Pub. L. 113-67 amended section 1886(m) of the Act by adding paragraph (6), which specifies that beginning with cost reporting periods starting on or
after October 1, 2015, all LTCH PPS discharges are paid according to the site neutral payment rate, unless certain criteria are met. For detailed discussion of our proposed and finalized policies regarding the criteria for exclusion from the site neutral payment rate, we refer readers to section VII.B.3. of the preamble of this final rule. For LTCH cases that meet the criteria for exclusion from the site neutral payment rate, section 1886(m)(6)(A)(ii) of the Act specifies that the site neutral payment rate will not apply and payment will be made without regard to requirements of section 1886(m)(6)(A)(ii) of the Act. Consistent with these statutory requirements, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24533), we proposed under new § 412.522(a)(2) that for LTCH discharges that meet the criteria for exclusion from site neutral payment rate under new § 412.522(b), payment will be based on the LTCH PPS standard Federal payment rate as determined in § 412.523. That is, under new § 412.522(a)(2), LTCH PPS standard Federal payment rate cases would continue to be paid based on the LTCH PPS standard Federal payment rate. Under this policy, all of the existing payment adjustments under § 412.525(d), that is, the adjustments for SSO cases under § 412.529, the adjustments for interrupted stays under § 412.531, and the 25-percent threshold policy under § 412.534 and § 412.536, would still apply if appropriate. In addition, as discussed in greater detail in section VII.B.7.b. of the preamble of the proposed rule and this final rule, we proposed that our existing HCO policy would apply to LTCH PPS standard Federal payment rate cases, except that the 8 percent HCO target would be established using only data from LTCH PPS standard Federal payment rate cases.
We did not receive any public comments on our proposal to pay for LTCH discharges that meet the criteria for exclusion from the site neutral payment rate under new § 412.522(a)(2) based on the LTCH PPS standard Federal payment rate. We are adopting this policy as final, without modification. We note that we proposed changes to the MS-LTC-DRG relative weight calculations and HCO policy for LTCH PPS standard Federal payment rate cases, which are discussed in section VII.B.7. of the preamble of this final rule and include summations of the public comments we received and our responses.

5. Application of Certain Existing LTCH PPS Payment Adjustments to Payments Made under the Site Neutral Payment Rate

Consistent with current LTCH PPS payment policies for adjusting Federal prospective payments, under the broad authority under section 123(a)(1) of the BBRA, as amended by section 307(b) of the BIPA, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24533 through 24534), we proposed that certain existing payment adjustments under the special payment provisions set forth at existing § 412.525(d), with the exception of the SSO adjustment described under § 412.525(d)(1) would apply to site neutral payment rate cases. These adjustments include the interrupted stay policy and the 25-percent threshold policy. The current payment adjustment under the interrupted stay policy at § 412.531 was developed and implemented prior to the statutory LTCH PPS dual rate payment structure and contains terms specific to payment based on the LTCH PPS standard Federal payment rate (such as LTC-DRG payment and Federal LTC-DRG prospective payment). Under our proposal, the site neutral payment rate would not be
calculated based on the LTCH PPS standard Federal payment rate because the payment would generally be the lower of the IPPS comparable per diem amount (including any applicable outlier payments), or 100 percent of the estimated cost of the case. Consequently, in order to apply the provisions of the existing interrupted stay policy at § 412.531 to site neutral payment rate cases, under proposed new § 412.522(c)(2)(ii), we proposed to specify that, for purposes of the application of the provisions of § 412.531 to LTCH discharges described under § 412.522(a)(1), the LTCH PPS standard payment-related terms, such as “LTC-DRG payment”, “full Federal LTC-DRG prospective payment”, and “Federal prospective payment,” mean the site neutral payment rate calculated under proposed new § 412.522(c).

We stated in the proposed rule that we believe that it is appropriate to apply these adjustments to the site neutral payment rate cases because the site neutral payment rate merely establishes an alternate payment amount under the LTCH PPS, as opposed to creating an exception from the LTCH PPS. Additionally, we believe that the policy concerns upon which these policies are based apply equally to payments made under the LTCH PPS site neutral payment rates and the standard Federal payment rates.

We established the interrupted stay policy to address instances in which a patient is discharged from an LTCH and later readmitted to that LTCH within a certain amount of time. This kind of readmission to the LTCH represents a continuation or resumption of the initial, interrupted treatment, rather than a new episode of care. (For a discussion of our implementation of the interrupted stay policy, we refer readers to the RY 2003 LTCH PPS final rule (67 FR 56002).) We continue to believe that the interrupted stay
policy serves as an effective instrument to protect the Medicare Trust Fund from significant and inappropriate expenditures (78 FR 50768), and we do not believe that the site neutral payment rate will address these concerns unless the interrupted stay policy is applied to site neutral payment rate cases in the same manner as it is applied to standard Federal payment rate cases.

The 25-percent threshold payment adjustment policy was implemented based on analyses of Medicare discharge data that indicated that patterns of patient shifting appeared to be occurring more for provider financial advantage than for patient benefit. In order to discourage such activity, a payment adjustment was applied to LTCH discharges of patients who were admitted to the LTCH from the same referring hospital in excess of an applicable percentage threshold (79 FR 50185). We refer readers to the detailed discussions of the 25-percent threshold payment adjustment policy for LTCH hospital-within-hospitals (HwHs) and LTCH satellite facilities in the FY 2005 IPPS/LTCH final rule (69 FR 49191 through 49214) and its application to all other LTCHs in the FY 2008 LTCH PPS final rule (72 FR 26919 through 26944), as well as our discussion in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50185 through 50187), for additional details on the 25-percent threshold payment adjustment. We do not believe that the site neutral payment rate will address these patient shifting concerns unless the 25-percent threshold payment adjustment is applied to site neutral payment rate cases in the same manner as it is applied to LTCH PPS standard Federal payment rate cases.

In considering the potential policy proposals, we recognized that there is a current statutory moratorium on the full implementation of the 25-percent threshold payment
adjustment policy under section 1206(b)(1)(A) of Pub. L. 113-67 that is scheduled to expire in FY 2016. (For a discussion of our implementation of the current statutory moratorium on the full implementation of the 25-percent threshold payment adjustment policy, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50185 through 50187).) In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24533 through 24534), we proposed to apply all of the payment adjustments to site neutral payment rates in the same manner as they are currently applied (and will continue to be applied for the foreseeable future) to LTCH PPS standard Federal payment rates—including, as applicable, the moratorium on implementing the 25-percent threshold payment adjustment.

We did not propose to apply the SSO payment adjustment to the site neutral payment rate at this time because, while the policy goal of ensuring patients in an LTCH receive a full course of treatment remains, under our current method of paying for SSOs as described under § 412.529, we pay for SSOs based on the lowest of several payment options, one of which is the LTCH’s estimated cost of the case. As described above, site neutral payment rate cases are paid the lower of the IPPS comparable per diem amount, or 100 percent of the estimated cost of the case. Because the estimated cost option is used in determining both SSO payments and site neutral payment rates and both methods make payment based on the lowest of their respective payment options, in most cases, applying our current SSO payment adjustment to site neutral payment rate cases would not affect the resulting LTCH PPS payment made for the discharge. We may consider proposing the application of an alternative SSO payment adjustment in the future if we
find evidence that Medicare beneficiaries are not regularly receiving the full course of treatment when such treatment is paid for at the site neutral payment rate.

Comment: MedPAC supported the CMS proposal to apply the interrupted stay policy and the 25-percent threshold policy to site neutral payment rate cases. However, other commenters disagreed with the proposal and indicated that one or both of these policies should be eliminated entirely because the concerns that led to these policies are addressed with the statutory revisions to the payment rates under the LTCH PPS. The commenters stated that if the policies are not eliminated entirely that, at a minimum, the provisions should not apply to site neutral payment rate cases because payments for site neutral payment rate cases are similar to the payments under the IPPS for these types of cases, and the lengths of stay for site neutral payment rate cases should be similar to the lengths of stay for similar cases paid under the IPPS. Some commenters suggested that CMS establish an IRF-like interrupted stay policy as an alternative to the LTCH interrupted stay policy. Some commenters noted that CMS indicated in prior rulemakings that the revised LTCH PPS would render the 25-percent threshold policy unnecessary. Other commenters suggested that CMS apply the 25-percent threshold policy to site neutral payment rate cases prior to applying the policy to LTCH PPS standard Federal payment rate cases as an alternative to excluding site neutral payment rate cases from the 25-percent threshold policy altogether.

Response: We appreciate MedPAC’s support. In response to the commenters who disagreed with the proposals, we believe that it is premature to determine if modifications should be made to these policies, including their applicability to site neutral
payment rate cases, without the benefit of experience gained under the revised LTCH PPS; especially given that the higher blended payment rate will apply to LTCH discharges that do not meet the criteria for exclusion from the site neutral payment rate until cost reporting periods beginning on or after October 1, 2017. In addition, we did not indicate in prior rulemakings that these policies were unnecessary. We stated that, at that time, the policies may no longer be necessary in light of the intended changes to the LTCH PPS. We believe that it would be prudent to maintain these policies as they currently exist, including their applicability to site neutral payment rate cases, while we gain more experience. However, we will keep this suggestion in mind when contemplating whether the current policy should be modified. In the event that we determine that policy modifications are warranted, we will address them through future rulemaking.

Comment: One commenter requested clarification about our proposed application of the 25-percent threshold policy to site neutral payment rate cases.

Response: The 25-percent threshold policy would apply to site neutral payment rate cases in the same manner as it would apply to LTCH PPS standard Federal payment cases; all LTCH discharges (site neutral payment rate cases or LTCH PPS standard Federal payment rate cases) that are beyond an LTCH’s applicable threshold from a single referring hospital would be subjected to an adjustment in accordance with the 25-percent threshold policy.
Comment: Several commenters expressed support for our proposal not to apply the SSO policy to site neutral payment rate cases. Other commenters believed that the SSO policy should be modified in consideration of site neutral payment rate cases.

Response: We appreciate the commenters’ support. We will consider the commenters’ suggestions to revise the SSO policy, and may consider additional policy proposals to address this issue in future rulemaking.

After consideration of public comments we received, we are finalizing, without modification, our proposals to apply the interrupted stay policy and the 25-percent threshold policy to site neutral payment rate cases, and not to apply the SSO policy to site neutral payment rate cases at this time.

6. Policies Relating to the LTCH Discharge Payment Percentage

Section 1886(m)(6)(C) of the Act, as added by section 1206 of Pub. L. 113-67, imposes several requirements related to an LTCH’s discharge payment percentage. As defined by section 1886(m)(6)(C)(iv) of the Act, the term “LTCH discharge payment percentage” is a ratio, expressed as a percentage, of Medicare discharges not paid the site neutral payment rate to total number of Medicare discharges occurring during the cost reporting period. In other words, an LTCH’s discharge payment percentage would be the ratio of an LTCH’s Medicare discharges that meet the criteria for exclusion from the site neutral payment rate (as described under new § 412.522(a)(2)) to an LTCH’s total number of Medicare discharges paid under the LTCH PPS (that is, both Medicare discharges paid under the site neutral payment rate and those that meet the criteria for exclusion from the site neutral payment rate, as described under new §§ 412.522(a)(1)
and (2), respectively) during the cost reporting period. Therefore, consistent with the statutory requirement at section 1886(m)(6)(C)(iv) of the Act and under the broad authority under section 123(a)(1) of the BBRA, as amended by section 307(b) of the BIPA, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24534) under proposed new § 412.522(d)(1), we proposed to define an LTCH’s discharge payment percentage as a ratio, expressed as a percentage, of Medicare discharges excluded from the site neutral payment rate as described under proposed new § 412.522(a)(2) to total Medicare discharges paid under the LTCH PPS (in accordance with 42 CFR Part 412, Subpart O) during the cost reporting period.

Comment: One commenter requested clarification about whether our proposed definition of the discharge payment percentage included Medicare Advantage beneficiaries, and noted that the statute expressly excludes these beneficiaries from the percentage.

Response: We agree with the commenter that the exclusion of Medicare Advantage beneficiaries is consistent with the statute. We believe that our proposed use of the phrase “Medicare discharges paid under the LTCH PPS (in accordance with 42 CFR Part 412, Subpart O)” was a clear statement concerning the exclusion of Medicare Advantage beneficiaries from the discharge patient percentage (80 FR 24534). However in the interest of clarity, we are taking this opportunity to reiterate that the LTCH’s discharge payment percentage under new § 412.522(d)(1) would not include Medicare Advantage patients in either the numerator or denominator of that ratio.
Comment: One commenter requested we develop a procedure by which LTCHs who demonstrate “highly compliant” discharge payment percentages would receive payment for all discharges at the LTCH PPS standard Federal payment rate.

Response: As explained more fully previously in this preamble, we do not have the authority to pay any rate other than the site neutral payment rate for discharges that do not meet the exclusion statutory criteria.

After consideration of the public comments we received, we are finalizing our proposed definition of the discharge patient percentage under new § 412.522(d)(1), including the technical correction of the typographical error in the phrase “paid under this Subpart O” that we are correcting to read as “paid under this subpart” for clarity.

In addition, section 1886(m)(6)(C)(i) of the Act requires that we provide notice to each LTCH of the LTCH’s discharge payment percentage (as defined in section 1886(m)(6)(C)(iv) of the Act) for LTCH cost reporting periods beginning during or after FY 2016. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24534 through 24535), we proposed to codify this statutory requirement at proposed new § 412.522(d)(2). Under this proposal, for cost reporting periods beginning on or after October 1, 2015, as required by the statute, we would inform each LTCH of their discharge payment percentage as defined under proposed new § 412.522(d)(1). We stated that we plan to develop such a notification process through subregulatory guidance. We also note that, under section 1886(m)(6)(C)(ii) of the Act, for cost reporting periods beginning on or after October 1, 2020, the statute requires that any LTCH whose discharge payment percentage for the period is not at least 50 percent will
be informed of such a fact and all of the LTCH’s discharges in each successive cost reporting period will be paid the payment amount that would apply under subsection (d) for the discharge if the hospital were a subsection (d) hospital, subject to the process for reinstatement provided for by section 1886(m)(6)(C)(iii) of the Act.

Because this statutory requirement is not effective until cost reporting periods beginning on or after October 1, 2020, we did not propose to make any changes related to the limitation requirement or the process for reinstatement at this time. However, we invited public comments on the development and implementation of the process for reinstatement under section 1886(m)(6)(C)(iii) of the Act.

Comment: Several commenters requested that CMS develop internal procedures and instructional mechanisms that explain how LTCHs will be notified of their discharge patient percentage through rulemaking.

Response: We appreciate the commenters’ input regarding the limitation requirements or the process for reinstatement as a result of the discharge patient percentage policy, including suggestions for “cure periods” for LTCHs whose discharge patient percentages fall below 50 percent. We will consider these comments as we develop proposals in these areas for discharges occurring in cost reporting periods beginning on or after October 1, 2020. However, we note that the development of operational guidance consistent with the law and our regulations does not require rulemaking. We will continue to engage with stakeholders as we develop operational guidance for our contractors.
After consideration of the public comments we received, we are finalizing, without modification, our proposals to codify the statutory requirement under new § 412.522(d)(2) that we provide notice to each LTCH of its discharge payment percentage for each cost reporting period beginning on or after October 1, 2015.

7. Additional LTCH PPS Policies Related to the Implementation of the Site Neutral Payment Rate Required by Section 1206(a) of Pub. L. 113-67

As discussed earlier in this section, section 1206(a) of Pub. L. 113–67 amended section 1886(m) of the Act by adding paragraph (6), which establishes patient-level criteria for payments made under the LTCH PPS for LTCH discharges occurring during cost reporting periods beginning on or after October 1, 2015 (FY 2016). In the FY 2015 IPPS/LTCH PPS proposed and final rules, we stated our intent to implement the requirements established by section 1206(a) of Pub. L. 113–67 through notice and comment rulemaking during the FY 2016 IPPS/LTCH PPS rulemaking cycle. In the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28205 through 28206), we discussed several significant issues arising from the statutory changes to the LTCH PPS required by section 1206(a) of Pub. L.113–67, which establishes two distinct payment groups for LTCH discharges under the revised system: discharges meeting specified patient-level criteria that will be paid under the LTCH PPS standard Federal payment rate and all other patient discharges that will be paid under the site neutral payment rate. In that same proposed rule, we expressed our interest in receiving feedback from LTCH stakeholders on our plans to evaluate whether it would be appropriate to modify any of our historical policies or methodologies as we began to develop proposals to implement the statutory
changes to the LTCH PPS. In particular, we solicited public feedback on the policies relating to the MS-LTC-DRG relative payment weights and high-cost outlier payments in preparation of developing proposals to implement the statutory changes to the LTCH PPS beginning in FY 2016. We explained that in setting the payment rates and factors under the LTCH PPS in accordance with requirements of section 1206(a) of Pub. L. 113–67, for certain LTCH PPS payment adjustments we planned to evaluate whether it would be appropriate to modify our historical methodology to account for the establishment of the two distinct payment rates for LTCH discharges. In particular, we stated our intent to examine whether, beginning in FY 2016, it would continue to be appropriate to include data for all LTCH PPS cases, including site neutral payment rate cases, in the methodology used to set the MS-LTC-DRGs relative payment weights. We also stated our intent to explore the possibility of changes to the current LTCH PPS high-cost outlier payment policy. Given the fact that, for a number of LTCH discharges, payment would be made based on the lower site neutral payment rate (that is, the lesser of an “IPPS comparable” per diem payment amount or 100 percent of the estimated cost of the case), we believed that it would be appropriate to evaluate whether a single high-cost outlier threshold could be applied to all LTCH PPS cases (both LTCH PPS standard Federal payment rate and site neutral payment rate cases), or whether it may be more appropriate to have separate high-cost outlier thresholds for each of the two payment rates under the statutory revisions to the LTCH PPS.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50197 through 50198), we summarized the comments we received in response to our request for input from LTCH
stakeholders. As we stated in that same final rule, we appreciated the commenters' thoughtful and detailed feedback, particularly those comments regarding the MS-LTC-DRG relative payment weights and the high-cost outlier policy under the new LTCH PPS dual rate payment structure established by section 1206(a) of Pub. L. 113–67.

In developing the proposals presented in the FY 2016 IPPS/LTCH PPS proposed rule, we considered the recommendations and information provided by those commenters. Below we discuss our proposed and finalized policies related to the MS-LTC-DRG payment relative weights and high-cost outlier policy in regard to our implementation policies under the LTCH PPS dual rate payment structure required by section 1206(a) of Pub. L. 113-67.

a. MS-LTC-DRG Relative Payment Weights

Under the LTCH PPS, relative payment weights for each MS-LTC-DRG are a primary element used to account for the variations in cost per discharge and resource utilization between the diagnosis-related groups (§ 412.515). Each year, based on the latest available LTCH claims data, we calculate a relative payment weight for each MS-LTC-DRG that represents the resources used for an average inpatient LTCH case assigned to that MS-LTC-DRG to ensure that Medicare patients with conditions or illnesses classified under each MS-LTC-DRG have access to an appropriate level of services and to encourage efficiency (79 FR 50170). CMS adjusts the classifications and weighting factors annually to reflect changes in factors affecting the relative use of hospital resources, such as treatment patterns, technology, and the number of discharges (§ 412.517).
Under the new dual rate LTCH PPS payment structure, section 1206(a) of Pub. L.113–67 establishes two distinct payment rates for LTCH discharges: discharges meeting specified patient-level criteria that will be excluded from the site neutral payment rate and all other patient discharges that will be paid under the site neutral payment rate. As discussed in greater detail in section VII.B.4.c. of the preamble of our proposed rule and this final rule, under new § 412.522(a)(2), we are establishing that LTCH discharges that meet the criteria for exclusion from site neutral payment rate will be paid using the LTCH PPS standard Federal payment rate described under § 412.523, as adjusted. In general, the LTCH PPS standard Federal payment rate is calculated by adjusting the standard Federal rate (determined under § 412.523(c)(3)) by the applicable MS-LTC-DRG relative payment weight for that Medicare cases. Under new § 412.522(c) (as discussed in greater detail in section VII.B.4.a. of the preamble of this final rule), consistent with section 1886(m)(6)((B)(ii) of the Act, we are establishing that the site neutral payment rate is the lower of the IPPS comparable per diem amount (including any applicable outlier payments), or 100 percent of the estimated cost of the case. Under this policy, the IPPS comparable per diem amount is determined using the same method to determine adjusted payments under the SSO policy at § 412.529(d)(4), and the estimated cost of the case is determined using the same method to determine estimated costs under the SSO policy at § 412.529(d)(2). We also note that the methodology we are adopting to determine payments for site neutral payment rate cases does not use the LTCH PPS standard Federal payment rate or the applicable MS-LTC-DRG relative payment weights.
As discussed above, in preparation for the proposed rule, we considered LTCH stakeholder input and evaluated whether it would be appropriate to modify our historical MS-LTC-DRG relative payment weight methodology to account for the establishment of the two distinct payment rates for LTCH discharges under the statutory changes to the LTCH PPS. Specifically, we examined whether our historical methodology, which uses data from all LTCH PPS discharges, should be continued when we calculate the MS-LTC-DRG relative payment weights under the new LTCH PPS dual rate payment structure, or whether it would be more appropriate to limit the data used to calculate relative payment weights to that obtained from discharges paid based on the LTCH PPS standard Federal payment rate (that is, discharges that would have met the criteria to be excluded from the site neutral payment rate had those criteria been in effect at the time of the discharge). Our existing methodology for developing the MS-LTC-DRG relative payment weights includes established policies related to the data used to calculate the relative payment weights, the hospital-specific relative value methodology, the treatment of severity levels in the MS-LTC-DRGs, the low-volume and no-volume MS-LTC-DRGs, adjustments for nonmonotonicity, and the calculation of the MS-LTC-DRG relative payment weights with a budget neutrality factor (79 FR 50171). Our most recent discussion of the existing methodology for calculating the MS-LTC-DRG relative payment weights can be found in the FY 2015 IPPS/LTCH final rule (79 FR 50168 through 50176). For FY 2016, our finalized methodology for calculating the FY 2016 MS-LTC-DRG relative payment weights (including the policy we are finalizing below to use only data from cases that would have been LTCH PPS
standard Federal payment rate cases had the new LTCH PPS payment structure been in effect at the time of the discharge) is discussed in section VII.C.3. of the preamble of this final rule.

In response to our solicitation for stakeholder input during the FY 2015 rulemaking cycle, we received numerous comments that addressed the calculation of the MS-LTC-DRG relative payment weights under the new statutory LTCH PPS structure. In its comment, MedPAC urged CMS to establish “. . . new relative payment weights for each MS-LTC-DRG based solely on the most recent available standardized data associated with discharges meeting the specified patient-level criteria” because those discharges under the new law would represent cases treating the most severely ill, incurring higher resource costs that warrant higher LTCH payments. MedPAC also stated that the change in methodology should not result in increased aggregate payments for the cases paid under the LTCH PPS standard Federal payment rate under the new statutory LTCH PPS structure. Most of the other commenters agreed with MedPAC’s recommendation that the MS-LTC-DRG relative payment weights under the new statutory structure should be calculated using only the data from cases that meet the statutory patient-level criteria for exclusion from the site neutral payment rate (or cases that would have qualified for exclusion had the new LTCH PPS payment structure been in effect at the time of discharge) A few commenters conducted their own analyses and found that both relative payment weight approaches (that is, using data from all LTCH PPS cases as compared to using only data from standard Federal payment rate cases) produce MS-LTC-DRG relative payment weights that are similar. In addition, some of
the commenters urged CMS to focus on keeping payments for LTCH PPS standard Federal payment rate cases at the same level that would have been in the absence of the statutory changes, or otherwise consider employing a methodology that promotes stability and predictability in the MS-LTC-DRG relative payment weights. Therefore, the overwhelming majority of the preliminary stakeholder feedback we received did not support using data from all LTCH PPS cases to determine the MS-LTC-DRG relative payment weights for the LTCH PPS standard Federal payment rate cases (80 FR 24536).

In the FY 2016 IPPS/LTCH PPS proposed rule, we expressed our appreciation for the commenters’ detailed feedback and took into consideration their concerns and recommendations in our evaluation the issue of the MS-LTC-DRG relative payment weights under the new LTCH PPS structure required by section 1206(a) of Pub. L. 113-67 in preparation for that proposed rule. As part of our evaluation, as we discussed in the proposed rule (80 FR 24536), we examined the FY 2013 LTCH claims data used to determine the FY 2015 MS-LTC-DRG relative weights and found that approximately 54 percent of LTCH cases would meet the criteria for exclusion from the site neutral payment rate (that is, those cases would be paid the LTCH PPS standard Federal payment rate had the new criteria been in effect at the time of the discharge) and approximately 46 percent of LTCH cases would be paid the site neutral payment rate (had the new criteria been in effect at the time of the discharge). We then compared the MS-LTC-DRG relative payment weights computed using data from all LTCH PPS cases to the MS-LTC-DRG relative payment weights computed using only data from the LTCH PPS standard Federal payment rate cases (had those criteria been in effect at the time of the discharge).
Specifically, using the FY 2013 LTCH claims data (the same LTCH claims data used in the FY 2015 IPPS/LTCH PPS final rule), we calculated FY 2015 MS-LTC-DRG relative payment weights using only data from the 54 percent of LTCH PPS cases that would be paid the LTCH PPS standard Federal payment rate, and compared them to the FY 2015 MS-LTC-DRG relative payment weights established in Table 11 of the FY 2015 IPPS/LTCH PPS final rule, which were calculated using data from all LTCH cases (that is, both case that would have been LTCH PPS standard Federal payment rate cases and would have been site neutral payment rate cases had those criteria been in place at the time of the discharge). Similar to results found by industry stakeholders, we found that both approaches produced comparable MS-LTC-DRG payments for LTCH PPS standard Federal payment rate cases. For example, our analysis of the average MS-LTC-DRG relative payment weight (that is, the case-mix) of LTCH PPS cases that would be paid the LTCH PPS standard Federal payment rate showed that the average case-mix using relative payment weights determined from using only data from LTCH PPS standard Federal payment rate cases differed by only approximately 0.01 percentage point from the average case-mix of those same cases using relative weights determined from data from all LTCH PPS cases.

However, we also discussed our belief that the costs and resource use for cases paid at the site neutral payment rate in the future may be lower on average than the costs and resource use for LTCH cases in our historical data that would have been paid at the site neutral payment rate if the statutory changes were in place when the discharges occurred. We believe that this is likely, even if the proportion of site neutral payment
rate cases in future data remains similar to the historical data (that is, 46 percent). (We discuss our assumptions about cases paid at the site neutral payment rate in the future in more detail in section VII.B.7.b. of the preamble of this final rule, where we present our proposed and final policies regarding outlier payments for site neutral payment rate cases.) Therefore, even though the analysis described shows that including or excluding what would have been site neutral payment rate cases if the new statutory requirements were applied to the historical discharges would not have much impact on the relative payment weight calculation for FY 2016, over time we believe that the relative payment weights could become distorted if future site neutral payment rate cases involve less intensive resource use and lower costs, which we believe is a plausible response to the lower site neutral payment rates under the statutory LTCH PPS changes. This also could lead to less stability in the MS-LTC-DRG relative payment weights because these cases become incorporated into data used to calculate the relative payment weights.

Taking all of this information into account and given the feedback we received on this issue in the FY 2015 rulemaking cycle, we believe that computing the MS-LTC-DRG relative payment weights using only data from LTCH PPS cases that will be (or, in the future, are) paid the LTCH PPS standard Federal payment rate (that is, cases that meet the criteria for exclusion from the site neutral payment rate) will result in the most appropriate payments under the new statutory structure. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24537), we proposed that, beginning with FY 2016, the annual recalibration of the MS-LTC-DRG relative payment weighting factors would be determined using only data from LTCH discharges that meet the criteria
for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases). Accordingly, we proposed to codify this proposal by adding paragraph (c) to § 412.517 to specify that, beginning in FY 2016, the annual recalibration of the MS-LTC-DRG relative weighting factors are determined using data from LTCH discharges described under new § 412.522(a)(2), or that would have been described by that section had the new dual rate LTCH PPS payment structure been in effect at the time of discharge.

In addition, we proposed to continue to apply the existing budget neutrality requirement for the annual changes to the MS-LTC-DRG classifications and relative payment weights at § 412.517(b), which specifies that any such changes must be made in a budget neutral manner such that estimated aggregate LTCH PPS payments are not affected. We explained that we believe that a budget neutrality requirement is appropriate for the MS-LTC-DRG relative payment weights that would be used to determine LTCH PPS payments for LTCH PPS standard Federal payment rate cases for the same reasons discussed when the policy was originally adopted in the FY 2008 LTCH PPS final rule (72 FR 26880 through 26884). Therefore, we did not propose to make any changes to the budget neutrality requirement at § 412.517(b).

Comment: Several commenters, including the MedPAC, supported CMS’ proposal, in general, to compute the MS-LTC-DRG relative payment weights using only data from LTCH PPS cases that meet the criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases). The commenters stated that this policy would result in appropriate LTCH PPS standard Federal payment
rate payments under the new dual rate LTCH PPS because the discharges meeting the LTCH PPS standard Federal payment rate criteria are “considered under the law to warrant the LTCH higher payments.” Some of these commenters supported adopting this approach beginning in FY 2016, to correspond with the commencement of the new dual rate LTCH PPS payment structure. However, other commenters believed that, for FY 2016, the calculation of MS-LTC-DRG weights should be based on all LTCH cases in the available data, and then in subsequent years, the MS-LTC-DRG weights should be based on only LTCH cases meeting the new LTCH PPS standard Federal payment rate criteria. These commenters asserted that CMS’ proposal was based upon the incorrect assumption that all LTCH discharges are immediately subject to the new dual rate LTCH PPS payment system after October 1, 2015, rather than LTCH discharges becoming subject to the new dual rate LTCH PPS payment structure based on the LTCH’s cost reporting periods beginning on or after October 1, 2015. The commenters believed that because some LTCH discharges will be subject to the new dual rate LTCH PPS payment structure after October 1, 2015, CMS should set payment weights for those discharges using all LTCH claims in the available data because there should be no difference in the MS-LTC-DRG weighting methodology for the LTCH discharges that will not be subject to the new dual rate LTCH PPS payment structure until after October 1, 2015 (that is, LTCH discharges in cost reporting periods beginning before October 1, 2015). Some of these commenters requested that CMS establish two sets of MS-LTC-DRG relative weights for FY 2016—one set of relative weights computed using only data from LTCH PPS cases that would meet the criteria for exclusion from the site neutral payment rate as
CMS proposed, which would apply to discharges in LTCH cost reporting periods that begin on or after October 1, 2015, and a second set of weights computed using all LTCH cases, regardless of whether they would meet the new patient criteria, which would apply to discharges in LTCH cost reporting periods that begin before October 1, 2015. Some commenters acknowledged the result of CMS’ analyses included in the proposed rule that indicate that the MS-LTC-DRG relative weights overall are similar when using all LTCH cases or only those that meet the new criteria. However, these commenters stated that there could be notable variation for specific MS-LTC-DRGs. In addition, several commenters recommended that CMS explore options for improving the year-to-year stability of the MS-LTC-DRG weights and reducing any year-to-year variation that could result from smaller sample sizes, as they recommended previously when providing feedback during the FY 2015 rulemaking cycle.

Some commenters agreed with CMS’ proposal to continue to make the annual changes to the MS-LTC-DRG classifications and relative payment weights in a budget neutral manner such that estimated aggregate LTCH PPS payments are not affected. One commenter believed that the budget neutrality requirement should not be included until the new payment system is in place, consistent the original implementation of the budget neutrality requirement, which was introduced a few years after the initial implementation of the LTCH PPS.

Response: We appreciate the commenters’ support. However, we believe that the commenters are mistaken that, under this proposal, we did not consider the statutory phase-in and that we assumed that all LTCH discharges are immediately subject to the
new dual rate payment structure after October 1, 2015. As explained in the proposed rule and reiterated above, we believe that this policy would result in appropriate LTCH PPS standard Federal payment rate payments under the new dual rate LTCH PPS, which becomes effective beginning on October 1, 2015. We also believe that this approach will promote stability and predictability in the MS-LTC-DRG relative weights under the revised LTCH PPS, which was a statement made by many commenters in the feedback they provided during the FY 2015 rulemaking cycle.

Furthermore, using only data from LTCH PPS cases that meet the criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) to compute the MS-LTC-DRG relative payment weights for FY 2016 is consistent with the HCO policy calculations we are finalizing in this final rule after consideration of public comments, which are discussed in section VII.B.7.b. of the preamble of this final rule. While we appreciate the commenters’ recognition that using all of the cases in the historical data or only using cases that would have met the criteria for exclusion for the site neutral payment rate (had those criteria been in effect at the time of the discharge) would not have substantial impact on the relative weight calculation for FY 2016, we are aware that variation for specific MS-LTC-DRGs would occur as noted by commenters. However, such a variation can occur with the annual update of the relative weights based on the latest available LTCH PPS data under existing § 412.517, and, in general, appropriately adjusts the relative weights to reflect the resource use of LTCHs based on the best available data. For these reasons, we are not adopting the commenters’ suggestions to calculate the FY 2016 MS-LTC-DRG relative weights based
on all of the cases in the historical data or to calculate two sets of relative weights for FY 2016. As suggested by commenters, we intend to monitor the year-to-year changes in the MS-LTC-DRG relative weights, and to the extent issues such as stability or inappropriate variation are encountered, we would explore possible options to address those issues once we have more experience under the changes to the LTCH PPS.

We appreciate the comments we received in support of our proposal to continue to make the annual changes to the MS LTC DRG classifications and relative payment weights in a budget neutral manner such that estimated aggregate LTCH PPS payments are not affected. In addition to resulting in appropriate payments, we believe that this adjustment will continue to help to provide stability in LTCH PPS payments that are computed using the MS-LTC-DRG weights because the purpose of the budget neutrality adjustment is to ensure that estimated aggregate LTCH PPS payments do not increase or decrease as a result of the annual update of the MS-LTC-DRG classifications and relative weights. We do not believe that this change in Medicare payments to LTCHs is parallel to the change in Medicare payments to LTCHs under the initial implementation of the LTCH PPS in a way that would make it necessary to delay the continued application of the MS-LTC-DRG budget neutrality requirement. The period under which there was no MS-LTC-DRG budget neutrality requirement allowed LTCHs to adjust to a complete change in the structure of Medicare reimbursement; that is, from reasonable cost-based payments to a DRG-based prospective payment system, in which one of the primary elements for the basis of payments the coding of the diagnosis and procedure codes that are used to determine DRG assignment. As we explained when the policy was originally
adopted, there had been fluctuations in the MS-LTC-DRG relative weights during the first 4 years of the LTCH PPS that were, in part, due to actual improvements in coding so that cases are appropriately assigned to MS-LTC-DRGs. We believed it was appropriate to establish the MS-LTC-DRG budget neutrality adjustment in the 5th year of the LTCH PPS when our annual case-mix index analysis indicated that changes in LTCH coding practices, which we believe were a primary contributor to fluctuations in the MS-LTC-DRG relative weights in the past, had appeared to be stabilizing as LTCHs became more familiar with a DRG-based system (72 FR 26880). While the new dual rate LTCH PPS payment structure is arguably the most extensive change since the implementation of the LTCH PPS, it is not a complete change in the structure of Medicare payments to LTCHs, as was the case when LTCHs moved from cost-based payments to prospective payments. Therefore, we disagree with the commenter that it would be appropriate to delay the application of the MS-LTC-DRG budget neutrality requirement until LTCHs gain experience under the revised LTCH PPS.

After consideration of public commenters we received, for the reasons discussed above, we are finalizing, without modification, our proposal to compute the MS-LTC-DRG relative payment weights using only data from LTCH PPS cases that met the criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases), or that would have met the criteria had the new dual rate LTCH PPS payment structure been in effect at the time of discharge, and to continue to apply the existing budget neutrality requirement for the annual changes to the MS-LTC-DRG classifications and relative payment weights. Furthermore, we are
clarifying the language we proposed to codify this policy under new paragraph (c) of § 412.517, to specify that beginning in FY 2016, the annual recalibration of the MS-LTC-DRG relative weights is determined using LTCH PPS discharges described in § 412.522(a)(2) (or that would have been described in such section had the application of site neutral payment rate been in effect at the time of the discharge).

b. High-Cost Outliers

Under the LTCH PPS, the existing regulations at § 412.525(a) provide for an additional adjustment to LTCH PPS payments to account for outlier cases that have extraordinarily high costs relative to the costs of most discharges (referred to as high-cost outliers (HCOs).) Providing such adjustments for HCOs strongly improves the accuracy of the LTCH PPS in determining resource costs at the patient and hospital level. In addition, HCO payments reduce the financial losses that would otherwise be incurred by hospitals when treating patients who require more costly care and, therefore, reduce the incentives to underserve these patients. Currently, we set the HCO threshold before the beginning of the payment year so that total estimated HCO payments are projected to equal 8 percent of estimated total payments under the LTCH PPS. Under our current HCO policy, an LTCH would receive an additional payment if the estimated cost of a case exceeds the adjusted LTCH PPS payment plus a fixed-loss amount. In such cases, the additional HCO payment amount is equal to 80 percent of the difference between the estimated cost of the case and the HCO threshold, which is the sum of the adjusted Federal MS-LTC-DRG prospective payment amount for the case and the fixed-loss amount. The fixed-loss amount is the amount used to limit the loss that an LTCH would
incur under the HCO policy for a case with unusually high costs. This results in Medicare and the LTCH sharing financial risk in the treatment of extraordinarily costly cases. Under the HCO policy, the fixed-loss amount is the maximum loss that an LTCH can incur for a case with unusually high costs before receiving an additional payment amount. The additional payment amount under the LTCH PPS HCO policy is determined using a marginal cost factor, which is a fixed percentage of costs above the HCO threshold. The marginal cost factor under the LTCH PPS HCO policy is 80 percent.

Under the current HCO policy, we annually determine a fixed-loss amount, that is, the maximum loss that an LTCH can incur under the LTCH PPS for a case with unusually high costs before an adjustment is made to the payment for the case. We do so by using the best available data to estimate aggregate LTCH PPS payments with and without a HCO policy, and, based on those estimates, set the fixed-loss amount at an amount that result in estimated total HCO payments being equal to 8 percent of estimated total LTCH PPS payments. Additional information on the LTCH PPS HCO methodology can be found in the FY 2003 LTCH PPS final rule (67 FR 56022 through 56027) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50398 through 50400).

As discussed in the previous section, under the new statutory LTCH PPS structure, section 1206(a) of Pub. L.113–67 establishes two distinct payment rates for LTCH discharges beginning in FY 2016. To implement this statutory change, in the FY 2016 IPPS/LTCH PPS proposed rule, under proposed new § 412.522(a)(2), we proposed to pay for LTCH discharges that meet the criteria for exclusion from site neutral
payment rate based on the LTCH PPS standard Federal payment rate, which includes HCO payments. Under proposed new § 412.522(c), consistent with the statute, we proposed that the site neutral payment rate is the lower of the IPPS comparable per diem amount as determined under existing § 412.529(d)(4) (including any applicable adjustments, such as outlier payments), or 100 percent of the estimated cost of the case as determined under existing § 412.529(d)(2). Below we discuss our proposed and finalized policies for determining HCO payments under the new statutory LTCH PPS payment structure.

In response to our solicitation for stakeholder input included in the FY 2015 IPPS/LTCH PPS proposed rule, we received numerous comments that addressed the HCO policy under the new statutory LTCH PPS structure. In its comment, MedPAC recommended that both LTCH PPS standard Federal payment rate cases and site neutral payment rate cases receive HCO payments, and that estimated total HCO payments under the LTCH PPS continue to be projected to be equal to 8 percent of estimated total LTCH PPS payments for all cases (that is, both the LTCH PPS standard Federal payment rate cases and the site neutral payment rate cases). In contrast, most of the other commenters recommended that separate HCO fixed-loss amounts and separate HCO payment “targets” (that is, the projected percentage that estimated HCO payments are of estimated total payments) be determined for LTCH PPS standard Federal payment rate cases and site neutral payment rate cases. Specifically, these commenters recommended that we calculate a fixed-loss amount under the current HCO policy for LTCH PPS standard Federal payment rate cases using only data (and estimated payments) from what would
have been or are LTCH PPS standard Federal payment rate cases, without including data (and estimated payments) from cases that would have been or are paid the site neutral payment rate. In addition, some of the commenters recommended initially applying the existing HCO policy separately to both LTCH PPS standard Federal payment rate cases and site neutral payment rate cases; that is, determining separate HCO fixed-loss amounts so that estimated HCO payments would be equal to 8 percent of estimated total payments for each of the two LTCH PPS payment types (the LTCH PPS standard Federal payment rate cases and site neutral payment rate cases), respectively, and then adjusting the HCO targets as more data under the statutory revisions to the LTCH PPS become available. In other words, commenters suggested that it may be more appropriate to have different HCO targets for the two LTCH PPS payment types rather than two HCO targets of 8 percent. When making recommendations regarding the HCO policy under the statutory LTCH PPS changes, several commenters urged CMS to focus on maintaining LTCH PPS payments for LTCH PPS standard Federal payment rate cases at the same payment level as they are currently under the LTCH PPS, including the level of HCO payments, and to mitigate any instability in the HCO fixed-loss amount for LTCH PPS standard Federal payment rate cases.

Several commenters conducted independent analyses that looked at separate HCO fixed-loss amounts for LTCH PPS standard Federal payment rate cases and site neutral payment rate cases. Upon review of their analyses, these commenters specifically recommended that separate HCO fixed-loss amounts be used for the two LTCH PPS payment types. A few of the commenters’ analyses included assumptions about LTCH
behavioral response to statutory changes to the LTCH PPS (such as changes in patient volume and costs). A few commenters indicated that using historical data would not reflect the anticipated behavioral response as a result of the new statutory payment structure and, therefore, may lead to an overestimation of costs and HCO payments (particularly with regard to payments for site neutral payment rate cases), resulting in a fixed-loss amount that is set too high relative to the HCO target. If this were to occur, these commenters expressed concern that LTCHs would be “underpaid” because HCO payments are budget neutral and actual HCO payments would fall below the HCO payments target.

In the FY 2016 IPPS/LTCH PPS proposed rule, we stated our appreciation for the commenters’ detailed feedback and indicated that we had taken their concerns and recommendations into consideration while framing our proposed HCO policy under the new statutory LTCH PPS structure. As we always have for the LTCH PPS, we designed our proposed HCO policy under the new statutory structure to achieve a balance of the following goals: to reduce financial risk, reduce incentives to underserve costly beneficiaries, and improve the overall fairness of the PPS (67 FR 56023). With these goals in mind, we evaluated whether it would be appropriate to modify our current HCO policy to account for the establishment of the new dual rate LTCH PPS payment structure. This included examining whether our current HCO target, under which we set a single fixed-loss amount so that estimated total HCO payments are projected to equal 8 percent of estimated total LTCH PPS payments, should continue to be used upon implementation of the statutory LTCH PPS payment changes, or whether it would be
more appropriate to have two separate HCO targets (one for LTCH PPS standard Federal payment rate cases and one for site neutral payment rate cases).

In examining this issue, we considered how LTCH discharges based on historical claims data would have been classified under the new dual rate LTCH PPS payment structure and the CMS’ Office of the Actuary (OACT) projections regarding how LTCHs would likely respond to our proposed implementation of policies resulting from the statutory payment changes. For FY 2016, our actuaries currently project that the proportion of cases that would qualify as LTCH PPS standard Federal payment rate cases versus site neutral payment rate cases under the new statutory provisions would remain consistent with what is reflected in the historical LTCH PPS claims data. (As previously noted, based on FY 2013 LTCH claims data, we found that approximately 54 percent of LTCH cases would have been paid the LTCH PPS standard Federal payment rate and approximately 46 percent of LTCH cases would have been paid the site neutral payment rate if those rates had been in effect at that time.) While our actuaries do not project an immediate change in these proportions, they do project cost and resource changes to take into account the lower payment rates. Our actuaries also project that the costs and resource use for cases paid at the site neutral payment rate would likely be lower, on average, than the costs and resource use for cases paid at the LTCH PPS standard Federal payment rate and would likely mirror the costs and resource use for IPPS cases assigned to the same MS-DRG, regardless of whether the proportion of site neutral payment rate cases in the future remains similar to what is found based on the historical data. This actuarial assumption is based on our expectation that site neutral payment rate cases
would generally be paid based on an IPPS comparable per diem amount under the statutory LTCH PPS payment changes, which, in the majority of cases, is much lower than the payment that would have been paid if these statutory changes were not enacted. These assumptions are consistent with statements from several commenters who noted that the type of site neutral payment rate cases may change in cost and severity over time in response to the new statutory payment structure because the payment for those cases would generally be lower than the current payment made under the LTCH PPS for these types of cases (80 FR 24538).

In light of these projections and expectations, we stated in the proposed rule that we believe that the use of a single fixed-loss amount and HCO target for all LTCH PPS cases would be problematic. Currently, the FY 2015 LTCH PPS fixed-loss amount is $14,972, which was determined using FY 2013 LTCH claims data (79 FR 50400). The FY 2015 IPPS fixed-loss amount is $25,799 (79 FR 50374). A single fixed-loss amount and target under the LTCH PPS would allow LTCH cases paid at the site neutral payment rate to qualify for HCO payments much more easily than comparable IPPS cases assigned to the same MS-DRG. This would occur because the HCO threshold (which is generally the sum of the adjusted Federal PPS payment for the case and the fixed-loss amount) under the IPPS would be higher than the HCO threshold under the LTCH PPS for a case assigned to the same MS-DRG (which would be expected to have a comparable adjusted Federal PPS payment, costs and resource use to a case paid as a LTCH PPS site neutral payment rate case). We also stated in the proposed rule that while we recognize that differing statutory requirements between the two payment systems
result in comparable LTCH PPS site neutral payment rate cases and IPPS cases not being paid exactly the same amount, we did not believe that it would be appropriate for comparable LTCH PPS site neutral payment rate cases to receive dramatically different HCO payments from those cases that would be paid under the IPPS. Based on the FY 2015 figures, an IPPS hospital would have to absorb approximately $11,000 more in additional estimated costs than the LTCH treating a comparable case based on the difference between the IPPS fixed-loss amount of $25,799 and the LTCH PPS fixed-loss amount of $14,792 before it would begin to receive HCO payments. We believe that the most appropriate fixed-loss amount for site neutral payment rate cases under the LTCH PPS for a given fiscal year beginning with FY 2016 would be the IPPS fixed-loss amount for that fiscal year. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24538 through 24539), for FY 2016, we proposed a fixed-loss amount for site neutral payment rate cases of $24,485, which was the same proposed FY 2016 IPPS fixed-loss amount discussed in section II.A.4.g.(1) of the Addendum to the proposed rule and this final rule. We believe that this policy will reduce differences between HCO payments for similar cases under the IPPS and site neutral payment rate cases under the LTCH PPS and promote fairness between the two systems. We also proposed to make a payment adjustment for HCOs paid under the site neutral payment rate at a rate equal to 80 percent of the difference between the estimated cost of the case and the proposed IPPS HCO threshold, which is consistent with the current LTCH PPS HCO policy. The proposed IPPS HCO threshold for site neutral payment rate cases would be the sum of the LTCH PPS payment for such cases and the proposed IPPS fixed-loss amount of
$24,485. As stated above, we believe that this policy will reduce differences between HCO payments for similar cases under the IPPS and site neutral payment rate cases under the LTCH PPS and promote fairness between the two systems. We also proposed to codify these proposals by making revisions to the existing HCO policy at §412.525(a). In light of these proposals, we noted that any site neutral payment rate case that is paid 100 percent of the estimated cost of the case because that amount is lower than the IPPS comparable per diem amount will never be eligible to receive a HCO payment because, by definition, the estimated costs of such cases will never exceed the IPPS comparable per diem amount by any threshold.

Comment: Commenters supported the proposed HCO policy under the new statutory LTCH PPS structure, under which there would be separate HCO fixed-loss amounts and separate HCO payment targets for LTCH PPS standard Federal payment rate cases and site neutral payment rate cases. Commenters also expressed support for the proposals concerning the methodology for determining the HCO payment amount for site neutral payment rate cases, including the use of the IPPS FLT for FY 2016. While commenters generally agreed with our assumptions that the costs and resource use for site neutral payment rate cases would likely mirror the costs and resource use for IPPS cases assigned to the same MS-DRG, some commenters also noted their belief that the type of site neutral payment rate cases may change in cost and severity over time in response to the new dual rate LTCH PPS payment structure. These commenters requested that CMS revisit the use of the IPPS fixed-loss amount once we have actual experience under the revised LTCH PPS, and possibly develop a HCO fixed-loss amount
for site neutral payment rate cases that is independent of the IPPS’s amount in the future. (Commenters also provided comments regarding the proposed budget neutrality adjustment for HCO payments to site neutral payment rate cases, which are discussed later in this section.)

Response: We appreciate the commenters’ support of these proposals. As we indicated in the proposed rule, we believe having a single HCO policy for both standard Federal payment rate cases and site neutral payment rate cases under the revised LTCH PPS would be problematic in light of our projections and expectations of LTCHs’ behavioral response to statutory changes to the LTCH PPS. We also explained that, given the expectation that cases paid at the site neutral payment rate would likely be similar to IPPS cases assigned to the same MS-DRG, the most appropriate fixed-loss amount for site neutral payment rate cases would be the IPPS fixed-loss amount for that fiscal year. To the extent experience under the revised LTCH PPS indicates site neutral payment rate cases differ sufficiently from these expectations, we agree it would be appropriate to revisit in future rulemaking the most appropriate fixed-loss amount used to determine HCO payments for site neutral payment rate cases.

After consideration of public comments we received, we are finalizing without modification our proposals to have separate HCO policies under the new dual rate LTCH PPS payment structure and our proposed methodology for calculating site neutral payment rate case the HCO payments, including the use of the IPPS FLT. We also are finalizing proposed revisions to the existing HCO policy at §412.525(a) to codify these policies, as discussed below in this section.
Therefore, in this final rule, we are establishing a fixed-loss amount for site neutral payment rate cases for FY 2016 of $22,544, which was the same FY 2016 IPPS fixed-loss amount discussed in section II.A.4.g.(1) of the Addendum to this final rule. As stated above, we believe that this policy will reduce differences between HCO payments for similar cases under the IPPS and site neutral payment rate cases under the LTCH PPS and promote fairness between the two systems.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24539), after having established the IPPS fixed-loss amount as an appropriate threshold to propose for HCOs paid under the site neutral payment rate, we next examined how to establish an appropriate fixed-loss amount and HCO target for LTCH PPS standard Federal payment rate cases. Therefore, we agreed with the commenters who recommended in response to our solicitation for input during the FY 2015 rulemaking cycle that we establish a fixed-loss amount and target for LTCH PPS standard Federal payment rate cases using the current LTCH PPS HCO policy, but limiting the data used under that policy to was and/or what would have been LTCH PPS standard Federal payment rate cases if the new dual rate LTCH PPS payment structure was/had been in effect at the time of those discharges. We also agreed with the commenters from the FY 2015 rulemaking cycle that believed this policy would result in increased stability over time with respect to HCO payments for the LTCH PPS standard Federal payment rate cases. We also believed that this approach would meet the goals cited for our revised and current HCO policy; that is, reducing financial risk, reducing incentives to underserve costly beneficiaries, and improving the overall fairness of the LTCH PPS (67 FR 56023). Therefore, in the
FY 2016 IPPS/LTCH PPS proposed rule, we did not propose to make any modifications to the HCO methodology as it applies to LTCH PPS standard Federal payment rate cases, other than determining a fixed-loss amount using only data from LTCH PPS standard Federal payment rate cases. Specifically, under our proposal, LTCH PPS standard Federal payment rate cases as described under proposed new § 412.522(a)(2) would receive an additional payment for an HCO case that is equal to 80 percent of the difference between the estimated cost of the case and the HCO threshold, which would be the sum of the LTCH PPS payment for the LTCH PPS standard Federal payment rate case and the fixed-loss amount for such cases. The fixed-loss amount for LTCH PPS standard Federal payment rate cases would continue to be determined so that estimated HCO payments would be projected to be equal to 8 percent of estimated total LTCH PPS payments for LTCH PPS standard Federal payment rate cases.

In the FY 2016 IPPS/LTCH PPS proposed rule, to codify our proposed changes to the HCO policy to account for the new dual rate LTCH PPS payment structure, we proposed to revise paragraphs (a)(1), (a)(2), and (a)(3), and add a new paragraph (a)(4) to existing § 412.525. In existing § 412.525 (a)(1), (a)(2), and (a)(3), we proposed to make technical changes to the existing language to make it clear that the provisions in those paragraphs apply to LTCH discharges under both LTCH PPS payment rates (that is, site neutral payment rate cases as described at new § 412.522(a)(1) and the standard Federal payment rate cases as described at new § 412.522(a)(2)). Under the proposed new paragraph (a)(4) to § 412.525, we also proposed to specify what the terms “applicable LTCH PPS prospective payment” and “applicable fixed-loss amount” mean for purposes
of this paragraph. Specifically, we proposed that, for purposes of § 412.525(a), “applicable LTCH PPS prospective payment” means either the site neutral payment rate under new § 412.522(c) for LTCH discharges described under new § 412.522(a)(1) or the standard Federal prospective payment rates under § 412.523 for LTCH discharges described under new § 412.522(a)(2). Similarly, we proposed that, for purposes of § 412.525(a), “applicable fixed-loss amount” means either, for LTCH described under new § 412.522(a)(1), the fixed-loss amount established for such cases, or, for LTCH discharges described under new § 412.522(a)(2), the fixed-loss amount established for such cases. In addition, we proposed to add language to paragraph (a) of § 412.525 to clarify that the fixed-loss is the maximum loss that a LTCH can incur under the LTCH PPS for a case with unusually high costs “before receiving an additional payment,” and is not the maximum loss an LTCH can incur. We proposed to make this clarification to highlight that the additional payment under the revised HCO policy is 80 percent (not 100 percent) of the estimated costs above the outlier threshold (that is, the sum of the applicable LTCH PPS prospective payment and the applicable fixed-loss amount).

Comment: Commenters supported the proposals to apply the existing HCO policy to LTCH PPS standard Federal payment rate cases, including the 8 percent HCO payment percentage target. However, some commenters requested that, when calculating the fixed-loss amount for cases that will be paid using the LTCH PPS standard Federal payment rate in FY 2016, CMS include all of the cases in the historical data that would have been paid using the LTCH PPS standard Federal payment rate had the revised FY 2016 LTCH PPS been in effect at the time of the discharge, not just the historical data.
for cases meeting the criteria for exclusion from the site neutral payment rate. These commenters believed that CMS’ use of only the historical cases meeting the criteria for exclusion from the site neutral payment rate in the calculation of the fixed-loss amount for FY 2016 is inaccurate. They also stated that the proposed approach results in estimated aggregate FY 2016 high-cost outlier payments for cases paid using the LTCH PPS standard Federal payment rate that are less than 8 percent of estimated aggregate FY 2016 payments for such cases (that is, paid using the LTCH PPS standard Federal payment rate during FY 2016). These commenters also requested that CMS modify the proposed conforming changes to the existing HCO policy at § 412.525(a) to reflect their requested changes to the fixed-loss amount.

Response: We appreciate the commenters’ support of our proposals to determine HCO for LTCH PPS standard Federal payment rate cases using our existing HCO policies, including the 8 percent HCO payment percentage target. We proposed that the fixed-loss amount for LTCH PPS standard Federal payment rate cases would continue to be determined so that estimated HCO payments would be projected to be “equal to 8 percent of estimated total LTCH PPS payments for LTCH PPS standard Federal payment rate cases” (80 FR 24539). In the proposed rule, we clearly indicated that the phrase “LTCH PPS standard Federal payment rate case” refers to a LTCH PPS case that meets the criteria for exclusion from the site neutral payment rate under section 1886(m)(6)(A)(ii) of the Act (80 FR 24527). The commenters’ concern regarding the calculation of the fixed-loss amount for FY 2016 comes from the distinction between “cases paid using the LTCH PPS standard Federal payment rate in FY 2016” and “LTCH
PPS standard Federal payment rate cases in FY 2016.” Under the statutory phase-in of
the LTCH PPS for FY 2016, cases in an LTCH with a cost reporting period starting
before October 1, 2015, that do not meet the criteria for exclusion from the site neutral
payment rate will nevertheless be “paid using the LTCH PPS standard Federal payment
rate” until the start of that LTCH’s first cost reporting period beginning in FY 2016.
These cases are the historical cases that the commenters requested be included in the
calculation of the FY 2016 fixed-loss amount for “LTCH PPS standard Federal payment
rate cases” even though those cases would not meet the criteria to be excluded from the
site neutral payment rate had the revised LTCH PPS been in effect at the time of the
discharge.

For the calculation of the fixed-loss amount in the second year of the revised
LTCH PPS (that is, FY 2017), there is no difference between the historical cases that
would have been paid using the LTCH PPS standard Federal payment rate and the
historical cases that would meet the criteria for exclusion from the site neutral payment
rate (that is, LTCH PPS standard Federal payment rate cases) had the revised FY 2017
LTCH PPS been in effect at the time of the discharge. The distinction between them
under the revised FY 2016 LTCH PPS (explained above) no longer exists--they are the
same cases. It is only in the first year of the revised LTCH PPS (FY 2016) that there is a
difference. As explained above, this difference is due to the statutory phase-in of the
revised LTCH PPS in FY 2016: cases in an LTCH with a cost reporting period starting
before October 1, 2015, that do not meet the criteria for exclusion from the site neutral
payment rate will continue to be paid at the higher LTCH PPS standard Federal payment rate until the start of that hospital’s first cost reporting period in FY 2016.

We considered the approach requested by commenters of using the historical cases that would have been paid using the LTCH PPS standard Federal payment rate had the revised FY 2016 PPS been in effect at the time of the discharge to calculate the fixed-loss amount for FY 2016. However, we believe that approach would lead to less stability in the fixed-loss amount between FY 2016 and FY 2017 because cases not meeting the criteria for exclusion from the site neutral payment rate (had those criteria been in effect) would be included in the calculation of the fixed-loss amount for FY 2016 and then not included in the calculation for FY 2017. As we stated in the proposed rule, we believe our proposal would result in increased stability over time with respect to HCO payments for the LTCH PPS standard Federal payment rate cases (80 FR 24539). In addition, as noted earlier, there is uncertainty surrounding the site neutral payment rate case population under the new dual rate LTCH PPS payment structure. For the portion of the site neutral payment rate case population that will continue to be paid at the LTCH PPS standard Federal payment rate for a portion of FY 2016 (that is, those FY 2016 cases that would not meet the criteria for exclusion and would be paid the site neutral payment rate were those cases in LTCH cost reporting periods subject to those criteria at the time of the discharge), there is even greater uncertainty as to what the costs of those cases will be during that time. Therefore, we disagree that our proposed methodology is inaccurate. However, we acknowledge that these two approaches result in different estimated aggregate FY 2016 payments for cases paid using the LTCH PPS standard Federal
payment rate, but that is due to the transitory effect of the statutory phase-in of the revised LTCH PPS. In FY 2017, the two approaches would result in the same estimated aggregate FY 2017 LTCH PPS expenditures.

After consideration of the public comments we received, for the reasons discussed, we are finalizing our policy as proposed without modification. In this final rule, we are calculating the fixed-loss amount for FY 2016 so that estimated aggregate FY 2016 HCO payments for cases that meet the criteria for exclusion from the site neutral payment rate are estimated to be equal to 8 percent of estimated aggregate FY 2016 payments for cases that meet the criteria for exclusion from the site neutral payment rate, rather than calculating the fixed-loss amount so that estimated aggregate FY 2016 HCO payments for cases paid using the LTCH PPS standard Federal payment rate are estimated to be equal to 8 percent of estimated aggregate FY 2016 payments for cases paid using the LTCH PPS standard Federal payment rate. We also are finalizing our proposals, without modification, to codify the changes to the HCO policy to account for the new dual rate LTCH PPS payment structure in existing § 412.525.

The current LTCH PPS HCO policy has a budget neutrality requirement in which the LTCH PPS standard Federal payment rate is reduced by an adjustment factor to account for the estimated proportion of HCO payments to total estimated LTCH PPS payments, that is, 8 percent. (We refer readers to § 412.523(d)(1) of the regulations.) This budget neutrality requirement is intended to ensure that the HCO policy would not result in any change in estimated aggregate LTCH PPS payments. Under our proposal to continue to apply the current HCO methodology as it relates to LTCH PPS standard
Federal payment rate cases (other than determining a fixed-loss amount using only data from LTCH PPS standard Federal payment rate cases (had the new statutory patient criteria been in effect at the time of the discharge), we also would continue to apply the current budget neutrality requirement (described above). In accordance with the current LTCH PPS HCO policy budget neutrality requirement, we believe that the HCO policy for site neutral payment rate cases should also be budget neutral, meaning that the proposed site neutral payment rate HCO payments should not result in any change in estimated aggregate LTCH PPS payments. In order to achieve this, under new § 412.522(c)(2)(i), we proposed to apply a budget neutrality factor to the payment for all site neutral payment rate cases described under proposed new § 412.522(a)(1), which would also be established on an estimated basis. This approach was consistent with the HCO policy proposed LTCH PPS standard Federal payment rate cases HCO policy, which is budget neutral within the universe of LTCH PPS standard Federal payment rate cases (had the new statutory patient criteria been in effect at the time of the discharge). We invited public comments on this approach and the alternative approach of applying a single budget neutrality factor to all LTCH PPS cases, irrespective of the site neutral payment rate.

In order to estimate the magnitude a proposed budget neutrality adjustment under our proposed HCO payment budget neutrality requirement for site neutral payment rate cases, we again relied on the assumption by our actuaries that site neutral payment rate cases would have lengths of stay and costs comparable to IPPS cases assigned to the same MS-DRG. Under the IPPS, the fixed-loss amount is estimated based on a 5.1
percent target (79 FR 50378). In accordance with section 1886(d)(5)(A)(iv) of the Act, estimated operating IPPS HCO payments for any year are projected to be at least 5 percent, but no more than 6 percent of estimated total operating DRG payments, which does not include IME and DSH payments plus HCO payments. When setting the HCO threshold, we historically compute a 5.1 percent target by dividing the total operating IPPS HCO payments by the total operating IPPS DRG payments plus operating IPPS HCO payments (79 FR 50374). We believe that it is reasonable to set the site neutral payment rate case HCO target at the IPPS HCO target because these cases are expected to have lengths of stay and costs comparable to IPPS cases assigned to the same MS-DRG. Furthermore, using the IPPS fixed-loss threshold for the site neutral payment rate cases would be expected to result in HCO payments for site neutral payment rate cases that are similar in proportion as is seen in IPPS cases assigned to the same MS-DRG; that is, 5.1 percent. We recognize that, given the uncertainty surrounding the site neutral payment rate case population under the revised LTCH PPS and differences between the relative utilization of the MS-DRGs and MS-LTC-DRGs between the two systems, this prediction may not take effect. However, we must begin somewhere, and we believed that this proposed policy seems to be the best budget neutrality option at this time based on the information available to ensure LTCH PPS spending does not inappropriately increase under our proposal for site neutral payment rate HCO cases. As with all of our finalized policies, we will continue to monitor HCOs payments under the LTCH PPS and, as necessary, propose modifications to the proposed method as needed based on what is observed during the implementation process.
Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24540 through 24541), under proposed new § 412.522(c)(2)(i), we proposed to adjust payments to site neutral payment rate cases (that is, LTCH PPS discharges described under proposed new § 412.522(a)(1)) by a budget neutrality factor so that the estimated HCO payments payable to site neutral payment rate cases do not result any increase in aggregate LTCH PPS payments. As discussed in greater detail in section V.D.4. of the Addendum to the proposed rule and this final rule, in estimating total LTCH PPS payments in Federal FY 2016, we proposed to apply an adjustment to account for the varying effective dates of the statutory LTCH PPS payment changes required by section 1886(m)(6) of the Act, as amended by section 1206 of Pub. L. 113-67, which are effective for discharges occurring in cost reporting periods beginning on or after October 1, 2015.

Comment: Commenters objected to the proposed site neutral payment rate HCO budget neutrality adjustment, claiming that it would result in savings instead of being budget neutral. The commenters’ primary objection was based on their belief that, because the IPPS base rates used in the IPPS comparable per diem amount calculation of the site neutral payment rate include a budget neutrality adjustment for IPPS HCO payments (for example, a 5.1 percent adjustment on the operating IPPS standardized amount), an “additional” budget neutrality factor is not necessary and is, in fact, duplicative. Based on their belief that the proposed site neutral payment rate HCO budget neutrality adjustment is duplicative, some commenters recommended that if CMS continues with the application of that budget neutrality adjustment, the calculation of the IPPS comparable per diem amount should be revised to use the IPPS operating
standardized amount prior to the application of the IPPS HCO budget neutrality adjustment. The commenters also disagreed with CMS’ proposed approach for determining the proposed site neutral payment rate HCO budget neutrality factor, and also noted some technical changes to the calculation should CMS finalize this proposal.

Response: We disagree with the commenters that a budget neutrality adjustment for site neutral payment rate HCO payments is unnecessary or duplicative. While the commenters are correct that the IPPS base rates that are used in site neutral payment rate calculation include a budget neutrality adjustment for IPPS HCO payments, that adjustment is merely a part of the calculation of one of the inputs (that is, the IPPS base rates) that are used in the LTCH PPS computation of site neutral payment rate. The HCO budget neutrality factor that is applied in determining the IPPS base rates is intended to fund estimated HCO payment made under the IPPS, and is therefore determined based on estimated payments made under the IPPS. As such, the HCO budget neutrality factor that is applied to the IPPS base rates does not account for the additional HCO payments that would be made to site neutral payment rate cases under the LTCH PPS. Without a budget neutrality adjustment when determining payment for a case under the LTCH PPS, any HCO payment payable to site neutral payment rate cases would increase aggregate LTCH PPS payments above the level of expenditure if there were no HCO payments for site neutral payment rate cases. Therefore, our proposed approach appropriately results in LTCH PPS payments to site neutral payment rate cases that are budget neutral relative to a policy with no HCO payments to site neutral payment rate cases. For these reasons, we are not adopting the commenters’ recommendation to change the calculation of the
IPPS comparable per diem amount to adjust the IPPS operating standardized amount used in that calculation to account for the application of the IPPS HCO budget neutrality adjustment.

After consideration of the public comments we received, for the reasons discussed above, we are adopting our proposal to adjust payments to site neutral payment rate cases by a budget neutrality factor so that the estimated HCO payments payable to site neutral payment rate cases do not result any increase in aggregate LTCH PPS payments (relative to LTCH PPS payments without HCO payments to site neutral payment rate cases), without modification. In doing so, we note that we present and respond to the comments on CMS’ proposed approach for determining the proposed site neutral payment rate budget neutrality factor, including the technical changes recommended by some commenters, in section V.D.4. of the Addendum to this final rule.

In addition to the proposed changes to the existing HCO policy under § 412.525(a) and the budget neutrality adjustment to account for site neutral payment rate HCO payments under proposed § 412.522(c)(2)(i), we proposed to make conforming changes to existing § 412.523 under paragraph (d)(1) to specify that the HCO target of 8 percent in that provision only applies to HCO payments under § 412.525(a) as they relate to LTCH PPS standard Federal payment rate cases; that is, HCO payments made for discharges described under proposed new § 412.522(a)(2) and not all HCO payments described under proposed new § 412.525(a).
We did not receive any public comments on the proposed conforming changes to existing § 412.523(d)(1). Therefore, we are adopting these changes as final without modification.

In summary, in this final rule, we are finalizing the policy to have separate HCO fixed-loss amounts and HCO targets (and corresponding budget neutrality adjustments) for site neutral payment rate cases and LTCH PPS standard Federal payment rate cases, respectively, under the new dual rate LTCH PPS payment structure. For the reasons discussed above, we believe that separate and independent HCO fixed-loss amounts for each of the two types of LTCH PPS cases will result in the most appropriate payments under the LTCH PPS and achieve the stated goals of our HCO policy. In accordance with our revised HCO policy for LTCH PPS standard Federal payment rate cases and site neutral payment rate cases, we are establishing that, beginning with FY 2016, our current HCO policy will apply to LTCH PPS standard Federal payment rate cases, such that LTCH PPS standard Federal payment rate cases will receive an additional payment for an HCO case that is equal to 80 percent of the difference between the estimated cost of the case and the LTCH PPS standard Federal payment HCO threshold (which is the sum of the LTCH PPS standard Federal payment rate for the case and the fixed-loss amount for such cases). The fixed-loss amount for LTCH PPS standard Federal payment rate cases will be determined so that estimated HCO payments will be projected to equal 8 percent of estimated total LTCH PPS payments for LTCH PPS standard Federal payment rate cases. To maintain budget neutrality, the LTCH PPS standard Federal payment rate will continue to be adjusted by 8 percent to account for the estimated HCO payments to
LTCH PPS standard Federal payment rate cases. Similarly, we are establishing that site neutral payment rate cases will receive an additional payment for an HCO case that is equal to 80 percent of the difference between the estimated cost of the case and the site neutral payment rate HCO threshold, which is the sum of site neutral payment rate for the case and the fixed-loss amount for such cases. For site neutral payment rate cases, we are finalizing the proposal to use the fixed-loss amount determined annually under the IPPS HCO policy, and we estimate that this will result in an estimated proportion of HCO payments to total LTCH PPS payments for site neutral payment rate cases of 5.1 percent.

We are establishing that HCO payments to site neutral payment rate cases will be budget neutral, consistent with the current LTCH PPS HCO policy. To maintain budget neutrality, we are finalizing the proposal to apply a budget neutrality factor to the LTCH PPS payments for site neutral payment rate cases. (The details of the determination of the site neutral payment rate HCO budget neutrality factor are discussed in section V.D.4. of the Addendum to this final rule.) To codify the policies discussed in this section, we are making changes to the existing HCO policy under § 412.525(a) and conforming changes to existing § 412.523(d)(1), as well as a budget neutrality requirement for HCO payments to site neutral payment rate cases under new § 412.522(c)(2)(i).

c. Limitation on Charges to Beneficiaries

In accordance with existing regulations and for the consistency with other established hospital prospective payment systems polices, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24541), we proposed to revise § 412.507 to establish allowable charges to Medicare beneficiaries whose discharge from the LTCH is paid under the site
neutral payment rate (as described in section VII.B.4. of the preamble of the proposed rule and this final rule). Section 1206(a)(1) of Pub. L. 113-67 requires that, beginning with cost reporting periods occurring on or after October 1, 2015, all LTCH discharges be paid at the applicable site neutral payment rate unless certain criteria are met. In general, the site neutral rate payment is based on the lesser of 100 percent of the estimated cost of the case or the IPPS comparable per diem amount (as discussed more detail in section VII.B.4.a. of the preamble of this final rule). We believe that, in general, the LTCH PPS payment an LTCH receives at the site neutral payment rate represents a full payment for purposes of determining allowable beneficiary charges for covered services. As such, using the broad authority conferred upon the Secretary under section 123(a)(1) of the BBRA, as amended by section 307(b) of the BIPA, in the proposed rule, we proposed to revise §412.507 to limit allowable charges to beneficiaries. Specifically, we proposed that, if Medicare has paid the full site neutral payment rate for a discharge, an LTCH may only charge the beneficiary applicable deductibles and copay amounts until the high-cost outlier threshold is met. In addition, we proposed to revise the terminology used under §412.507 to differentiate between cases paid under the site neutral payment rate and those paid under the LTCH PPS standard Federal payment rate. We noted that, under this proposed revision, for a case paid under the site neutral payment rate, that payment applies to the LTCH’s costs for services furnished until the high-cost outlier threshold is met, and LTCHs may charge the beneficiary for noncovered services in the same manner as if the case were paid under the LTCH PPS standard Federal payment rate, as specified under existing §412.507. We did not propose to make any additional changes to our
current provisions limiting charges to beneficiaries for discharges paid as SSO cases because, as explained in section VII.B.5. of the preamble of the proposed rule and this final rule, we did not propose to adopt any SSO payment adjustment policies for discharges paid under the site neutral payment rate at this time. We stated that we believe that these proposals concerning the limitation on charges to beneficiaries are in accordance with existing regulations and consistent with other established hospital payment systems policies.

We did not receive any public comments concerning our proposed changes to the regulations limiting charges to beneficiaries. Therefore, we are finalizing, without modification, our proposals to limit charges to beneficiaries.
C. Medicare Severity Long-Term Care Diagnosis-Related Group (MS-LTC-DRG) Classifications and Relative Weights for FY 2016

1. Background

Section 123 of the BBRA required that the Secretary implement a PPS for LTCHs to replace the cost-based payment system under TEFRA. Section 307(b)(1) of the BIPA modified the requirements of section 123 of the BBRA by requiring that the Secretary examine the feasibility and the impact of basing payment under the LTCH PPS on the use of existing (or refined) hospital DRGs that have been modified to account for different resource use of LTCH patients.

When the LTCH PPS was implemented for cost reporting periods beginning on or after October 1, 2002, we adopted the same DRG patient classification system utilized at that time under the IPPS. As a component of the LTCH PPS, we refer to this patient classification system as the “long-term care diagnosis-related groups (LTC-DRGs).” Although the patient classification system used under both the LTCH PPS and the IPPS are the same, the relative weights are different. The established relative weight methodology and data used under the LTCH PPS result in relative weights under the LTCH PPS that reflect the differences in patient resource use of LTCH patients, consistent with section 123(a)(1) of the BBRA (Pub. L. 106-113).

As part of our efforts to better recognize severity of illness among patients, in the FY 2008 IPPS final rule with comment period (72 FR 47130), the MS-DRGs and the Medicare severity long-term care diagnosis-related groups (MS-LTC-DRGs) were adopted under the IPPS and the LTCH PPS, respectively, effective beginning
October 1, 2007 (FY 2008). For a full description of the development, implementation, and rationale for the use of the MS-DRGs and MS-LTC-DRGs, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47141 through 47175 and 47277 through 47299). (We note that, in that same final rule, we revised the regulations at § 412.503 to specify that for LTCH discharges occurring on or after October 1, 2007, when applying the provisions of 42 CFR Part 412, Subpart O applicable to LTCHs for policy descriptions and payment calculations, all references to LTC-DRGs would be considered a reference to MS-LTC-DRGs. For the remainder of this section, we present the discussion in terms of the current MS-LTC-DRG patient classification system unless specifically referring to the previous LTC-DRG patient classification system that was in effect before October 1, 2007.)

The MS-DRGs adopted in FY 2008 represent an increase in the number of DRGs by 207 (that is, from 538 to 745) (72 FR 47171). The MS-DRG classifications are updated annually. There are currently 753 MS-DRG groupings. For FY 2016, there are 758 MS-DRG groupings that we are finalizing in conjunction with all of the changes discussed in section II.G. of the preamble of this final rule. Consistent with section 123 of the BBRA, as amended by section 307(b)(1) of the BIPA, and § 412.515 of the regulations, we use information derived from LTCH PPS patient records to classify LTCH discharges into distinct MS-LTC-DRGs based on clinical characteristics and estimated resource needs. We then assign an appropriate weight to the MS-LTC-DRGs to account for the difference in resource use by patients exhibiting the case complexity and multiple medical problems characteristic of LTCHs. Below we provide a general
summary of our existing methodology for determining the FY 2016 MS-LTC-DRG relative weights under the LTCH PPS.

In this final rule, in general, for FY 2016, we are using our existing methodology to determine the MS-LTC-DRG relative weights (as discussed in greater detail in section VII.C.3. of the preamble of this final rule). However, under the new dual rate LTCH PPS payment structure, we are establishing that, beginning with FY 2016, the annual recalibration of the MS-LTC-DRG relative weights will be determined (1) using only data from available LTCH PPS claims that would have qualified for payment under the new LTCH PPS standard Federal payment rate if that rate were in effect when claims data from time periods before the new dual rate LTCH PPS payment structure applies were used to calculate the relative weights, and (2) using only data from available LTCH PPS claims that qualify for payment under the new LTCH PPS standard Federal payment rate when claims data from time periods after the dual rate LTCH PPS payment structure applies are used to calculate the relative weights. For the remainder of this discussion, we use the phrase “applicable LTCH cases” or “applicable LTCH data” when referring to the resulting claims data set used to calculate the relative weights (as described in greater detail in section VII.C.3.c. of the preamble of this final rule). In addition, we are continuing to exclude the data from all-inclusive rate providers and LTCHs paid in accordance with demonstration projects, as well as any Medicare Advantage claims from the MS-LTC-DRG relative weight calculations for the reasons discussed in section VII.C.3.c. of the preamble of this final rule.
Under our finalized policies, the MS-LTC-DRG relative weights will not be used to determine the LTCH PPS payment for cases paid at the site neutral payment rate and data from cases paid at the site neutral payment rate or that would have been paid at the site neutral payment if the dual rate LTCH PPS payment structure had been in effect will not be used to develop the relative weights. (For details on our finalized policies regarding the application of the site neutral payment rate, we refer readers to section VII.B. of the preamble of this final rule. For additional information on our finalized policy to use data from applicable LTCH cases to determine the MS-LTC-DRG relative weights under the new dual rate LTCH PPS payment structure, we refer readers to section VII.B.7.a. of the preamble of this final rule.)

Furthermore, for FY 2016, in using data from applicable LTCH cases to establish MS-LTC-DRG relative weights, we will continue to establish low-volume MS-LTC-DRGs (that is, MS-LTC-DRGs with less than 25 cases) using our quintile methodology in determining the MS-LTC-DRG relative weights because LTCHs do not typically treat the full range of diagnoses as do acute care hospitals. Therefore, for purposes of determining the relative weights for the large number of low-volume MS-LTC-DRGs, we group all of the low-volume MS-LTC-DRGs into five quintiles based on average charges per discharge. Then, under our existing methodology, we account for adjustments made to LTCH PPS standard Federal payment rate payments for short-stay outlier (SSO) cases (that is, cases where the covered length of stay at the LTCH is less than or equal to five-sixths of the geometric average length of stay for the MS-LTC-DRG), and we make adjustments to account for nonmonotonically increasing
weights, when necessary. The methodology is premised on more severe cases under the MS-LTC-DRG system requiring greater expenditure of medical care resources and higher average charges such that, in the severity levels within a base MS-LTC-DRG, the relative weights should increase monotonically with severity from the lowest to highest severity level. (We discuss each of these components of our MS-LTC-DRG relative weight methodology in greater detail in section VII.C.3.g. of the preamble of this final rule.)

2. Patient Classifications into MS-LTC-DRGs
   a. Background

      The MS-DRGs (used under the IPPS) and the MS-LTC-DRGs (used under the LTCH PPS) are based on the CMS DRG structure. As noted above in this section, we refer to the DRGs under the LTCH PPS as MS-LTC-DRGs although they are structurally identical to the MS-DRGs used under the IPPS.

      The MS-DRGs are organized into 25 major diagnostic categories (MDCs), most of which are based on a particular organ system of the body; the remainder involve multiple organ systems (such as MDC 22, Burns). Within most MDCs, cases are then divided into surgical DRGs and medical DRGs. Surgical DRGs are assigned based on a surgical hierarchy that orders operating room (O.R.) procedures or groups of O.R. procedures by resource intensity. The GROUPER software program does not recognize all ICD-9-CM procedure codes as procedures affecting DRG assignment. That is, procedures that are not surgical (for example, EKGs), or minor surgical procedures (for example, a biopsy of skin and subcutaneous tissue (procedure code 86.11)) do not affect the MS-LTC-DRG assignment based on their presence on the claim.
Generally, under the LTCH PPS, a Medicare payment is made at a predetermined specific rate for each discharge and that payment varies by the MS-LTC-DRG to which a beneficiary’s stay is assigned. Cases are classified into MS-LTC-DRGs for payment based on the following six data elements:

- Principal diagnosis;
- Additional or secondary diagnoses;
- Surgical procedures;
- Age;
- Sex; and
- Discharge status of the patient.

Currently, for claims submitted on the 5010 format, up to 25 diagnosis codes and 25 procedure codes are considered for an MS-DRG assignment. This includes one principal diagnosis and up to 24 secondary diagnoses for severity of illness determinations. (For additional information on the processing of up to 25 diagnosis codes and 25 procedure codes on hospital inpatient claims, we refer readers to section II.G.11.c. of the preamble of the FY 2011 IPPS/LTCH PPS final rule (75 FR 50127).)

Under HIPAA transactions and code sets regulations at 45 CFR Parts 160 and 162, covered entities must comply with the adopted transaction standards and operating rules specified in Subparts I through S of Part 162. Among other requirements, by January 1, 2012, covered entities were required to use the ASC X12 Standards for Electronic Data Interchange Technical Report Type 3--Health Care Claim: Institutional (837), May 2006, ASC X12N/005010X223, and Type 1 Errata to Health Care Claim:
HIPAA requires covered entities to use the applicable medical data code set requirements when conducting HIPAA transactions (45 CFR 162.1000). Currently, upon the discharge of the patient, the LTCH must assign appropriate diagnosis and procedure codes from the most current version of the Internal Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). For additional information on the ICD-9-CM coding system, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47241 through 47243 and 47277 through 47281). We also refer readers to the detailed discussion on correct coding practices in the August 30, 2002 LTCH PPS final rule (67 FR 55981 through 55983).

Currently, providers use the code sets under the ICD-9-CM coding system to report diagnoses and procedures for Medicare hospital inpatient services under the MS-DRG system. We have been discussing the conversion to the ICD-10 coding system for many years. Hospitals, including LTCHs, are required to use the ICD-10 coding system effective October 1, 2015. Consequently, providers will begin using the code sets under the ICD-10 coding system to report diagnoses (ICD-10-CM codes) and procedures (ICD-10-PCS codes) for Medicare hospital inpatient services under the MS-DRG system (and by extension the MS-LTC-DRG system) beginning October 1, 2015. For additional information on the implementation of the ICD-10 coding system, we refer readers to
section II.G.1. of the preamble of this final rule. Additional coding instructions and examples are published in the AHA’s Coding Clinic for ICD-10-CM/PCS.

To create the MS-DRGs (and by extension, the MS-LTC-DRGs), base DRGs were subdivided according to the presence of specific secondary diagnoses designated as complications or comorbidities (CCs) into one, two, or three levels of severity, depending on the impact of the CCs on resources used for those cases. Specifically, there are sets of MS–DRGs that are split into 2 or 3 subgroups based on the presence or absence of a CC or a major complication or comorbidity (MCC). We refer readers to section II.D. of the FY 2008 IPPS final rule with comment period for a detailed discussion about the creation of MS-DRGs based on severity of illness levels (72 FR 47141 through 47175).

MACs enter the clinical and demographic information submitted by LTCHs into their claims processing systems and subject this information to a series of automated screening processes called the Medicare Code Editor (MCE). These screens are designed to identify cases that require further review before assignment into a MS-LTC-DRG can be made. During this process, certain cases are selected for further development (74 FR 43949).

After screening through the MCE, each claim is classified into the appropriate MS-LTC-DRG by the Medicare LTCH GROUPER software on the basis of diagnosis and procedure codes and other demographic information (age, sex, and discharge status). The GROUPER software used under the LTCH PPS is the same GROUPER software program used under the IPPS. Following the MS-LTC-DRG assignment, the Medicare contractor determines the prospective payment amount by using the Medicare PRICER
program, which accounts for hospital-specific adjustments. Under the LTCH PPS, we provide an opportunity for LTCHs to review the MS-LTC-DRG assignments made by the Medicare contractor and to submit additional information within a specified timeframe as provided in § 412.513(c).

The GROUPER software is used both to classify past cases to measure relative hospital resource consumption to establish the MS-LTC-DRG relative weights and to classify current cases for purposes of determining payment. The records for all Medicare hospital inpatient discharges are maintained in the MedPAR file. The data in this file are used to evaluate possible MS-DRG and MS-LTC-DRG classification changes and to recalibrate the MS-DRG and MS-LTC-DRG relative weights during our annual update under both the IPPS (§ 412.60(e)) and the LTCH PPS (§ 412.517), respectively.

b. Changes to the MS-LTC-DRGs for FY 2016

As specified by our regulations at § 412.517(a), which require that the MS-LTC-DRG classifications and relative weights be updated annually, and consistent with our historical practice of using the same patient classification system under the LTCH PPS as is used under the IPPS, we are updating the MS-LTC-DRG classifications effective October 1, 2015, through September 30, 2016 (FY 2016) consistent with the changes to specific MS-DRG classifications presented in section II.G of the preamble of this final rule. Therefore, the MS-LTC-DRGs for FY 2016 presented in this final rule are the same as the MS-DRGs that are being used under the IPPS for FY 2016. Specifically, as discussed in section II.G.1.b. of this preamble of this final rule, we are using the ICD-10 MS-DRGs Version 33 as the replacement logic for the ICD-9-CM based
MS-DRGs Version 32 as part of the MS-DRG updates (and by extension the MS-LTC-DRG) updates for FY 2016. The GROUPER Version 33 is based on ICD-10-CM/PCS diagnoses and procedure codes, consistent with the requirement to use ICD-10 beginning October 1, 2015, as noted above and discussed in greater detail section II.G.1. of the preamble of this final rule.

In the proposed rule, we invited public comments on how well the ICD-10 MS-DRGs Version 33 (and by extension the ICD-10 MS-LTC-DRGs Version 33) replicates the logic of the ICD-9 MS-DRGs Version 32 (and by extension ICD-9 MS-LTC-DRGs Version 32). These comments and our responses are discussed in section II.G.1.a. of the preamble of this final rule. (We note that, when referencing MS-LTC-DRGs Version 33 in the remainder of this section, we are referring to the ICD-10-based MS-LTC-DRGs Version 33 unless otherwise stated. Similarly, when referencing MS-LTC-DRGs Version 32 for the remainder of this section, we are referring to the ICD-9-based MS-LTC-DRGs Version 32 unless otherwise stated.) In addition, because the MS-LTC-DRGs for FY 2016 are the same as the MS-DRGs for FY 2016, the other changes that affect MS-DRG (and by extension MS-LTC-DRG) assignments under GROUPER Version 33, as discussed in section II.G. of the preamble of this final rule, including the changes to the MCE software and the ICD-10 coding system, will also be applicable under the LTCH PPS for FY 2016.
3. Development of the FY 2016 MS-LTC-DRG Relative Weights

a. General Overview of the Development of the MS-LTC-DRG Relative Weights

One of the primary goals for the implementation of the LTCH PPS is to pay each LTCH an appropriate amount for the efficient delivery of medical care to Medicare patients. The system must be able to account adequately for each LTCH’s case-mix in order to ensure both fair distribution of Medicare payments and access to adequate care for those Medicare patients whose care is more costly (67 FR 55984). To accomplish these goals, we have annually adjusted the LTCH PPS standard Federal prospective payment system rate by the applicable relative weight in determining payment to LTCHs for each case. In order to make these annual adjustments under the new dual rate LTCH PPS payment structure, as previously discussed in section VII.B.7.a. of the preamble of this final rule, we are finalizing the policy, beginning with FY 2016, to recalibrate the MS-LTC-DRG relative weighting factors annually using data from applicable LTCH cases. Under this policy, the resulting MS-LTC-DRG relative weights will continue to be used to adjust the LTCH PPS standard Federal rate when calculating the payment for LTCH PPS standard Federal payment rate cases. However, the MS-LTC-DRG relative weights will not be used to determine the LTCH PPS payment for cases paid under the site neutral payment rate. (For details on our finalized policies regarding application of the site neutral payment rate, we refer readers to section VII.B. of the preamble of this final rule.)

The established methodology to develop the MS-LTC-DRG relative weights is consistent with the methodology established when the LTCH PPS was implemented in
the August 30, 2002 LTCH PPS final rule (67 FR 55989 through 55991), with the exception of some modifications of our historical procedures for assigning relative weights in cases of zero volume and/or nonmonotonicity resulting from the adoption of the MS-LTC-DRGs. (For details on these modifications to our historical procedures for assigning relative weights in cases of zero volume and/or nonmonotonicity, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47289 through 47295) and the FY 2009 IPPS final rule (73 FR 48542 through 48550).) Under the LTCH PPS, relative weights for each MS-LTC-DRG are a primary element used to account for the variations in cost per discharge and resource utilization among the payment groups (§ 412.515). To ensure that Medicare patients classified to each MS-LTC-DRG have access to an appropriate level of services and to encourage efficiency, we calculate a relative weight for each MS-LTC-DRG that represents the resources needed by an average inpatient LTCH case in that MS-LTC-DRG. For example, cases in a MS-LTC-DRG with a relative weight of 2 will, on average, cost twice as much to treat as cases in a MS-LTC-DRG with a relative weight of 1.

b. Development of the MS-LTC-DRG Relative Weights for FY 2016

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50170 through 50176), we presented our policies for the development of the MS-LTC-DRG relative weights for FY 2015.

In this final rule, as proposed, we are continuing to use our existing methodology to determine the MS-LTC-DRG relative weights for FY 2016, including the application of established policies related to, the hospital-specific relative value methodology, the
treatment of severity levels in the MS-LTC-DRGs, low-volume and no-volume MS-LTC-DRGs, adjustments for nonmonotonicity, and the steps for calculating the MS-LTC-DRG relative weights with a budget neutrality factor. However, as previously noted and discussed in greater detail in section VII.B.7.a. of the preamble of this final rule, under the new dual rate LTCH PPS payment structure, after consideration of public comments, as we proposed, we are establishing that the FY 2016 MS-LTC DRG relative weights will be determined based only on data from applicable LTCH cases (which includes our finalized policy of using only cases that would meet the criteria for exclusion from the site neutral payment rate (had those criteria been in effect at the time of the discharge)).

We discuss the effects of our finalized policies concerning the data used to determine the FY 2016 MS-LTC-DRG relative weights on the various components of our existing methodology in the discussion that follows.

Furthermore, as we have done since the FY 2008 update, and as we proposed, we are applying a two-step budget neutrality adjustment to the annual update to the MS-LTC-DRG classifications and relative weights at § 412.517(b) (in conjunction with § 412.503), such that estimated aggregate LTCH PPS payments would be unaffected, that is, would be neither greater than nor less than the estimated aggregate LTCH PPS payments that would have been made without the classification and relative weight changes (72 FR 26882 through 26884). For additional information on the established two-step budget neutrality methodology, we refer readers to the FY 2008 IPPS final rule (72 FR 47295 through 47296). Below we present our proposed methodology for determining the proposed MS-LTC-DRG relative weights for FY 2016 LTCH PPS
standard Federal payment rate payments, which is generally consistent with our existing methodology, except for the proposed use of applicable LTCH data.

c. Applicable LTCH Data

For this final rule, to calculate the MS-LTC-DRG relative weights for FY 2016 LTCH PPS standard Federal payment rate payments, we obtained total charges from FY 2014 Medicare LTCH claims data from the March 2015 update of the FY 2014 MedPAR file, which are the best available data at this time, and the finalized Version 33 of the GROUPER to classify LTCH cases. Consistent with our historical practice and as we proposed, we are using those data and the finalized Version 33 of the GROUPER in establishing the FY 2016 MS-LTC-DRG relative weights in this final rule. To calculate the FY 2016 MS-LTC-DRG relative weights under the new dual rate LTCH PPS payment structure that will be effective beginning October 1, 2015, beginning with the annual recalibration of the MS-LTC-DRG relative weights for FY 2016, we are using applicable LTCH data, which, as previously discussed in section VII.B.7.a. of this preamble of, includes our finalized policy of using only cases that meet the criteria for exclusion from the site neutral payment rate (or would meet the criteria had they been in effect at the time of the discharge). Accordingly, as we proposed, we began by first evaluating the LTCH claims data in the March 2015 update of the FY 2014 MedPAR file to determine which LTCH cases would have met the criteria for exclusion from the site neutral payment rate under § 412.522(b) (as discussed in greater detail in section VII.B.3. of the preamble of this final rule) had the new dual rate LTCH PPS payment structure been in effect at the time of discharge. We identified the FY 2014 LTCH cases that were
not assigned to MS-LTC-DRGs 876, 880, 881, 882, 883, 884, 885, 886, 887, 894, 895, 896, 897, 945 and 946, which, under our finalized policies, will identify LTCH cases that do not have a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation (as discussed in section VII.B.3.b. of the preamble of this final rule); and that either—

- The admission to the LTCH was “immediately preceded” by discharge from a subsection (d) hospital and the immediately preceding stay in that subsection (d) hospital included at least 3 days in an ICU, as we define under the ICU criterion (discussed in section VII.B.3.e. of the preamble of this final rule); or

- The admission to the LTCH was “immediately preceded” by discharge from a subsection (d) hospital and the claim for the LTCH discharge includes the applicable procedure code that indicates at least 96 hours of ventilator services were provided during the LTCH stay, as we define under the ventilator criterion (discussed in section VII.B.3.f. of the preamble of this final rule). Claims data from the March 2015 update of the FY 2014 MedPAR file that reported ICD-9-CM procedure code 96.72 were used to identify cases involving at least 96 hours of ventilator services in accordance with the ventilator criterion. (We note that the corresponding ICD-10-PCS code for cases involving at least 94 hours of ventilation services is 5A1955Z, effective as of October 1, 2015.)

Then, consistent with our historical methodology and as we proposed, we excluded any claims in the resulting data set that were submitted by LTCHs that are all-inclusive rate providers and LTCHs that are reimbursed in accordance with demonstration projects authorized under section 402(a) of Pub. L. 90-248 or
section 222(a) of Pub. L. 92-603. In addition, consistent with our historical practice and as we proposed, we excluded the Medicare Advantage (Part C) claims that were in the resulting data set based on the presence of a GHO Paid indicator value of “1” in the MedPAR files. The claims that remained after these three trims (that is, the applicable LTCH data) were then used to calculate the relative weights for the LTCH PPS standard Federal payment rate payments for FY 2016.

In summary, in identifying the claims data for the development of the FY 2016 MS-LTC-DRG relative weights in this final rule, we are using claims data after we trim the claims data of 10 all-inclusive rate providers reported in the March 2015 update of the FY 2014 MedPAR file, as well as any Medicare Advantage claims data for cases that would have met the criteria for exclusion from the site neutral payment rate under § 412.522(b) if the new dual rate LTCH PPS payment structure were in effect at the time of discharge. (We note, there were no data from any LTCHs that are paid in accordance with a demonstration project reported in the March 2015 update of the FY 2014 MedPAR file. However, had there been we would we trim the claims data from those LTCHs as well, in accordance with our established policy.) We are using the remaining data (that is, the applicable LTCH data) to calculate the relative weights for the LTCH PPS standard Federal payment rate payments for FY 2016. We note, the public comments we received, our responses to those comments, and our finalized policy of using only cases that would meet the criteria for exclusion from the site neutral payment rate (had those criteria been in effect at the time of the discharge) for the annual recalibration of the MS-LTC-DRG relative weights beginning for FY 2016 is presented in section VII.B.7.a.
of this preamble of this final rule. We did not receive any public comments on the other parts of our proposals on the applicable LTCH data used to determine the relative weights for MS-LTC-DRGs for FY 2016, and are adopting those proposals as final without change.

After consideration of the public comments we received, we are finalizing our proposals on the applicable LTCH data used to determine the relative weights for MS-LTC-DRGs for FY 2016 without change.

d. Hospital-Specific Relative Value (HSRV) Methodology

By nature, LTCHs often specialize in certain areas, such as ventilator-dependent patients. Some case types (MS-LTC-DRGs) may be treated, to a large extent, in hospitals that have, from a perspective of charges, relatively high (or low) charges. This nonrandom distribution of cases with relatively high (or low) charges in specific MS-LTC-DRGs has the potential to inappropriately distort the measure of average charges. To account for the fact that cases may not be randomly distributed across LTCHs, consistent with the methodology we have used since the implementation of the LTCH PPS, as proposed, we are continuing to use a hospital-specific relative value (HSRV) methodology to calculate the MS-LTC-DRG relative weights for FY 2016 LTCH PPS standard Federal payment rate payments. We believe this method removes this hospital-specific source of bias in measuring LTCH average charges (67 FR 55985). Specifically, under this methodology, we are reducing the impact of the variation in charges across providers on any particular MS-LTC-DRG relative weight by converting
each LTCH’s charge for an applicable LTCH case to a relative value based on that LTCH’s average charge for such cases.

Under the HSRV methodology, we standardize charges for each LTCH by converting its charges for each applicable LTCH case to hospital-specific relative charge values and then adjusting those values for the LTCH’s case-mix. The adjustment for case-mix is needed to rescale the hospital-specific relative charge values (which, by definition, average 1.0 for each LTCH). The average relative weight for a LTCH is its case-mix; therefore, it is reasonable to scale each LTCH’s average relative charge value by its case-mix. In this way, each LTCH’s relative charge value is adjusted by its case-mix to an average that reflects the complexity of the applicable LTCH cases it treats relative to the complexity of the applicable LTCH cases treated by all other LTCHs (the average LTCH PPS case-mix of all applicable LTCH cases across all LTCHs).

In accordance with our established methodology, for FY 2016, we standardized charges for each applicable LTCH case by first dividing the adjusted charge for the case (adjusted for SSOs under § 412.529 as described in section VII.C.3.g. (Step 3) of the preamble of this final rule) by the average adjusted charge for all applicable LTCH cases at the LTCH in which the case was treated. SSO cases are cases with a length of stay that is less than or equal to five-sixths the average length of stay of the MS-LTC-DRG ($ 412.529$ and $ 412.503$). The average adjusted charge reflects the average intensity of the health care services delivered by a particular LTCH and the average cost level of that LTCH. The resulting ratio was multiplied by that LTCH’s case-mix index to determine the standardized charge for the case (67 FR 55989).
Multiplying the resulting ratio by the LTCH's case-mix index accounts for the fact that the same relative charges are given greater weight at a LTCH with higher average costs than they would at a LTCH with low average costs, which is needed to adjust each LTCH's relative charge value to reflect its case-mix relative to the average case-mix for all LTCHs. Because we standardized charges in this manner, we count charges for a Medicare patient at a LTCH with high average charges as less resource intensive than they would be at a LTCH with low average charges. For example, a $10,000 charge for a case at a LTCH with an average adjusted charge of $17,500 reflects a higher level of relative resource use than a $10,000 charge for a case at a LTCH with the same case-mix, but an average adjusted charge of $35,000. We believe that the adjusted charge of an individual case more accurately reflects actual resource use for an individual LTCH because the variation in charges due to systematic differences in the markup of charges among LTCHs is taken into account.

We did not receive any public comments concerning our proposal to continue to use HSRV methodology to determine the MS-LTC-DRG relative weights for FY 2016, and therefore, we are finalizing this proposed policy, without modification.

e. Treatment of Severity Levels in Developing the MS-LTC-DRG Relative Weights

For purposes of determining the MS-LTC-DRG relative weights, under our historical methodology, there are three different categories of MS-DRGs based on volume of cases within specific MS-LTC-DRGs: (1) MS-LTC-DRGs with at least 25 applicable LTCH cases in the data used to calculate the relative weight, which are each assigned a unique relative weight; (2) low-volume MS-LTC-DRGs (that is,
MS-LTC-DRGs that contain between 1 and 24 applicable LTCH cases that are grouped into quintiles (as described below) and assigned the relative weight of the quintile; and (3) no-volume MS-LTC-DRGs that are cross-walked to other MS-LTC-DRGs based on the clinical similarities and assigned the relative weight of the cross-walked MS-LTC-DRG (as described in greater detail below). For FY 2016, we are using applicable LTCH cases to establish the same volume-based categories to calculate the FY 2016 relative weights for LTCH PPS standard Federal payment rate payments. This approach is consistent with our policies regarding the continued use of our existing methodology related to the treatment of severity levels as presented in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50172).

We provide in-depth discussions of our finalized policy regarding weight-setting for low-volume MS-LTC-DRGs in section VII.C.3.f. of the preamble of this final rule and for no-volume MS-LTC-DRGs, under Step 5 in section VII.C.3.g. of the preamble of this final rule.) Furthermore, in determining the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments, when necessary, as proposed, we made adjustments to account for nonmonotonicity, as discussed in greater detail below in Step 6 of section VII.C.3.g. of the preamble of this final rule. We refer readers to the discussion in the FY 2010 IPPS/RY 2010 LTCH PPS final rule for our rationale for including an adjustment for nonmonotonicity (74 FR 43953 through 43954).

f. Low-Volume MS-LTC-DRGs

In order to account for MS-LTC-DRGs for LTCH PPS Standard Federal payment rate cases with low-volume (that is, with fewer than 25 applicable LTCH cases),
consistent with our existing methodology for purposes of determining the FY 2015
MS-LTC-DRG relative weights, as proposed, we are employing the quintile methodology
for low-volume MS-LTC-DRGs, such that we grouped the “low-volume MS-
LTC-DRGs” (that is, MS-LTC-DRGs that contained between 1 and 24 applicable LTCH
cases into one of five categories (quintiles) based on average charges (67 FR 55984
through 55995 and 72 FR 47283 through 47288). In cases where the initial assignment of
a low-volume MS-LTC-DRG to a quintile resulted in nonmonotonicity within a
base-DRG, as proposed, we made adjustments to the resulting low-volume MS-LTC-
DRGs to preserve monotonicity, as discussed in detail below in section VII.C.3.g.
(Step 6) of the preamble of this final rule.

In the proposed rule, using the most current available data at that time, we noted
our identification of 250 MS-LTC-DRGs that contained between 1 and 24 applicable
LTCH cases. Based on the best available data for this final rule (that is, the March 2015
update of the FY 2014 MedPAR files, we now identified 251 MS-LTC-DRGs that
contained between 1 and 24 applicable LTCH cases. This list of MS-LTC-DRGs was
then divided into one of the 5 low-volume quintiles, each containing 50 MS-LTC-DRGs
(251/5 = 50, with a remainder of 1). We assigned the low-volume MS-LTC-DRGs to
specific low-volume quintiles by sorting the low-volume MS-LTC-DRGs in ascending
order by average charge in accordance with our established methodology. Based on the
data available for the proposed rule, the number of MS-LTC-DRGs with less than 25
applicable LTCH cases was evenly divisible by 5. Therefore, it was not necessary to
employ our historical methodology for determining which of the low-volume quintiles
contain an additional low-volume MS-LTC-DRG. However, for this final rule, based on
the most current data available at this time, because the number of MS-LTC-DRGs with
less than 25 applicable LTCH cases has shifted to 251 (which does not divide evenly), as
proposed, we used our historical methodology for determining which quintiles would
contain the additional MS-LTC-DRGs. Specifically for this final rule, after organizing
the MS-LTC-DRGs by ascending order by average charge, we assigned the first fifth (1st
through 50th) of low-volume MS-LTC-DRGs (with the lowest average charge) into
Quintile 1. The 50 MS-LTC-DRGs with the highest average charge cases were assigned
into Quintile 5. Because the average charge of the 151st low-volume MS-LTC-DRG in
the sorted list was closer to the average charge of the 150th low-volume MS-LTC-DRG
(assigned to Quintile 3) than to the average charge of the 152nd low-volume
MS-LTC-DRG (assigned to Quintile 4), we are assigning it to Quintile 3 (such that
Quintile 3 contains 51 low-volume MS-LTC-DRGs before any adjustments for
nonmonotonicity, as discussed below). This results in 4 of the 5 low-volume quintiles
containing 50 MS-LTC-DRGs (Quintiles 1, 2, 4 and 5) and one low-volume quintile
containing 51 MS-LTC-DRGs (Quintile 3). Table 13A, listed in section VI. of the
Addendum to this final rule and available via the Internet, lists the composition of the
low-volume quintiles for MS-LTC-DRGs for FY 2016.

Accordingly, in order to determine the FY 2016 relative weights for the
MS-LTC-DRGs with low-volume, as proposed, we are using the five low-volume
quintiles described above. We determined a relative weight and (geometric) average
length of stay for each of the five low-volume quintiles using the methodology described
in section VII.C.3.g. of the preamble of this final rule. As we proposed, we assigned the same relative weight and average length of stay to each of the low-volume MS-LTC-DRGs that make up an individual low-volume quintile. We note that, as this system is dynamic, it is possible that the number and specific type of MS-LTC-DRGs with a low-volume of applicable LTCH cases will vary in the future. Furthermore, we note that we will continue to monitor the volume (that is, the number of applicable LTCH cases) in the low-volume quintiles to ensure that our quintile assignments used in determining the MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments result in appropriate payment for LTCH cases that will be grouped to low-volume MS-LTC-DRGs and do not result in an unintended financial incentive for LTCHs to inappropriately admit these types of cases.

We did not receive any public comments concerning our proposals related to low-volume MS-LTC-DRGs. Therefore, we are finalizing, without modification, these proposals.

### g. Steps for Determining the FY 2016 MS-LTC-DRG Relative Weights

In this final rule, as proposed, we are generally using our existing methodology to determine the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments. However, in doing so, we are using only applicable LTCH cases and data to determine the FY 2016 MS-LTC-DRG relative weights (including our finalized policy of using only cases that met or would have met the criteria for exclusion from the site neutral payment rate (had those criteria been in effect at the time of the discharge as discussed in section VII.B.7.a. of the preamble of this final rule).
Comment: Based on their analysis of the proposed FY 2016 MS-LTC-DRG weights, some commenters stated that there may be reversal in the description of the steps of the CMS methodology for calculating the MS-LTC-DRG relative weights. Commenters also noted that the data trimming in the step to remove statistical outliers appears to only address the removal of statistical outliers based on total charges and not the total charges per day requirement.

Response: We reexamined the description of the methodology for calculating the MS-LTC-DRG relative weights and found an inadvertent error in the order in which we have been presenting steps 1 and 2 of our methodology. Under our longstanding historical methodology to calculate the MS-LTC-DRG relative weights, we first remove cases with a length of stay of 7 days or less (which has been mistakenly described at step 2 in our methodology) and then remove statistical outliers (which has been mistakenly described at step 1 in our methodology). Cases with a length of stay of 7 days or less are removed in the initial step because leaving them in would distort the relative weights of the MS-LTC-DRGs. It is essential to remove such cases prior to trimming for statistical outliers in order to appropriately identify aberrant data when removing statistical outliers that would distort the measure of average resource use reflected in the MS-LTC-DRG relative weights. We thank commenters for pointing out this error in the description of the methodology. We note that the differences between applying steps 2 and 1 in the correct order (as we have always calculated these values) as opposed to the reversed order described in the proposed rule have heretofore been negligible (in fact, our understanding is that certain outside parties have replicated and/or performed analyses of
the MS-LTC-DRG relative weights in prior years). However, under our finalized policy to use only cases that would meet the criteria for exclusion from the site neutral payment rate (had those criteria been in effect at the time of the discharge), the new dual rate LTCH PPS payment structure has reduced the number of cases we are using to calculate MS-LTC-DRG relative weights, making the description/order of the steps more significant. We appreciate the commenters bringing this to our attention and regret any confusion caused by our misstatement regarding the order of the steps one must take to calculate relative weights. We assure the industry that since the advent of the LTCH PPS we have been calculating these values by first removing the cases with an average length of stay of 7 days or less, and then removing statistical outliers. In addition, we agree with commenters that, for the FY 2016 proposed rule, we made a technical error in our application of the data trimming to remove statistical outliers. We appreciate commenters bringing this to our attention and the MS-LTC-DRG relative weights calculated for this final rule reflect the correct application of the data trimming. That is, we have ensured that to identify statistical outliers, we have applied the trim based on both charges per case and the charges per day (see step 2 below), consistent with our longstanding methodology.

After consideration of the public comments we received, we are finalizing our proposal to continue to use our existing methodology to calculation the MS-LTC-DRG relative weights for FY 2016, including calculating the values in the ordered steps we have employed in this calculation from the onset of the LTCH PPS. To reflect this, in this final rule, we are correcting the order of steps described in this preamble to reflect
the order in which they have been, and will continue to be applied in the application of our existing policy.

In summary, to determine the FY 2016 MS-LTC-DRG relative weights, we grouped applicable LTCH cases to the appropriate MS-LTC-DRG, while taking into account the low-volume quintiles (as described above) and cross-walked no-volume MS-LTC-DRGs as described below. After establishing the appropriate MS-LTC-DRG (or low-volume quintile), we calculated the FY 2016 relative weights for LTCH PPS standard Federal payment rate payments by first removing cases with a length of stay of 7 days or less and statistical outliers (Steps 1 and 2 below). Next, we adjusted the number of applicable LTCH cases in each MS-LTC-DRG (or low-volume quintile) for the effect of SSO cases (Step 3 below). After removing applicable LTCH cases with a length of stay of 7 days or less (Step 1 below) and statistical outliers (Step 2 below) and, which are the SSO-adjusted applicable LTCH cases and corresponding charges (step 3 below), we calculated “relative adjusted weights” for each MS-LTC-DRG (or low-volume quintile) using the HSRV method. Below we discuss in detail the steps for calculating the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments.

Step 1--Remove cases with a length of stay of 7 days or less.

The first step in our calculation of the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments is to remove cases with a length of stay of 7 days or less. The MS-LTC-DRG relative weights reflect the average of resources used on representative cases of a specific type. Generally, cases with a length
of stay of 7 days or less do not belong in a LTCH because these stays do not fully receive or benefit from treatment that is typical in a LTCH stay, and full resources are often not used in the earlier stages of admission to a LTCH. If we were to include stays of 7 days or less in the computation of the FY 2016 MS-LTC-DRG relative weights, the value of many relative weights would decrease and, therefore, payments would decrease to a level that may no longer be appropriate. We do not believe that it would be appropriate to compromise the integrity of the payment determination for those LTCH cases that actually benefit from and receive a full course of treatment at a LTCH by including data from these very short stays. Therefore, consistent with our existing relative weight methodology, in determining the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments, we removed LTCH cases with a length of stay of 7 days or less from applicable LTCH cases. (For additional information on what would be removed in this step of the relative weight methodology, we refer readers to 67 FR 55989 and 74 FR 43959.)

**Step 2--Remove statistical outliers.**

The next step in our calculation of the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments is to remove statistical outlier cases from the LTCH cases with a length of stay of at least 8 days. Consistent with our existing relative weight methodology, as proposed, we are continuing to define statistical outliers as cases that are outside of 3.0 standard deviations from the mean of the log distribution of both charges per case and the charges per day for each MS-LTC-DRG. These statistical outliers are removed prior to calculating the relative weights because we
believe that they may represent aberrations in the data that distort the measure of average resource use. Including those LTCH cases in the calculation of the relative weights for LTCH PPS standard Federal payment rate payments could result in an inaccurate relative weight that does not truly reflect relative resource use among those MS-LTC-DRGs. (For additional information on what would be removed in this step of the relative weight methodology, we refer readers to 67 FR 55989 and 74 FR 43959.) After removing cases with a length of stay of 7 days or less and statistical outliers, we are left with applicable LTCH cases that have a length of stay greater than or equal to 8 days. In this final rule, we refer to these cases as “trimmed applicable LTCH cases.”

**Step 3—Adjust charges for the effects of SSOs.**

As the next step in the calculation of the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments, consistent with our historical approach, we adjusted each LTCH’s charges per discharge for those remaining cases (that is, trimmed applicable LTCH cases) for the effects of SSOs (as defined in § 412.529(a) in conjunction with § 412.503). Specifically, we made this adjustment by counting an SSO case as a fraction of a discharge based on the ratio of the length of stay of the case to the average length of stay for the MS-LTC-DRG for non-SSO cases. This has the effect of proportionately reducing the impact of the lower charges for the SSO cases in calculating the average charge for the MS-LTC-DRG. This process produces the same result as if the actual charges per discharge of an SSO case were adjusted to what they would have been had the patient’s length of stay been equal to the average length of stay of the MS-LTC-DRG.
Counting SSO cases as full LTCH cases with no adjustment in determining the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments will lower the FY 2016 MS-LTC-DRG relative weight for affected MS-LTC-DRGs because the relatively lower charges of the SSO cases will bring down the average charge for all cases within a MS-LTC-DRG. This will result in an “underpayment” for non-SSO cases and an “overpayment” for SSO cases. Therefore, as proposed, we are continuing to adjust for SSO cases under § 412.529 in this manner because it results in more appropriate payments for all LTCH PPS standard Federal payment rate cases. (For additional information on this step of the relative weight methodology, we refer readers to 67 FR 55989 and 74 FR 43959.)

Step 4--Calculate the FY 2016 MS-LTC-DRG relative weights on an iterative basis.

Consistent with our historical relative weight methodology, we then calculated the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments using the HSRV methodology, which is an iterative process. First, for each SSO-adjusted trimmed applicable LTCH case, we calculated a hospital-specific relative charge value by dividing the charge per discharge after adjusting for SSOs of the LTCH case (from Step 3) by the average charge per SSO-adjusted discharge for the LTCH in which the case occurred. The resulting ratio was then multiplied by the LTCH’s case-mix index to produce an adjusted hospital-specific relative charge value for the case. An initial case-mix index value of 1.0 was used for each LTCH.
For each MS-LTC-DRG, we calculated the FY 2016 relative weight by dividing the SSO-adjusted average of the hospital-specific relative charge values for applicable LTCH cases (that is, the sum of the hospital-specific relative charge value from above divided by the sum of equivalent cases from step 3 for each MS-LTC-DRG) for the MS-LTC-DRG by the overall SSO-adjusted average hospital-specific relative charge value across all applicable LTCH cases for all LTCHs (that is, the sum of the hospital-specific relative charge value from above divided by the sum of equivalent applicable LTCH cases from step 3 for each MS-LTC-DRG). Using these recalculated MS-LTC-DRG relative weights, each LTCH’s average relative weight for all of its SSO-adjusted trimmed applicable LTCH cases (that is, its case-mix) was calculated by dividing the sum of all the LTCH’s MS-LTC-DRG relative weights by its total number of SSO-adjusted trimmed applicable LTCH cases. The LTCHs’ hospital-specific relative charge values (from above) were then multiplied by the hospital-specific case-mix indexes. The hospital-specific case-mix adjusted relative charge values were then used to calculate a new set of MS-LTC-DRG relative weights across all LTCHs. This iterative process was continued until there was convergence between the relative weights produced at adjacent steps, for example, when the maximum difference was less than 0.0001. (We note that, although we are not making any changes to this step of our relative weight methodology in this final rule, we have made some minor changes to the description of this step to clarify the application of our existing policy.)

Step 5--Determine a FY 2016 relative weight for MS-LTC-DRGs with no applicable LTCH cases.
Using the trimmed applicable LTCH cases, we identified the MS-LTC-DRGs for which there were no claims in the March 2015 update of the FY 2014 MedPAR file and, therefore, for which no charge data was available for these MS-LTC-DRGs. Because patients with a number of the diagnoses under these MS-LTC-DRGs may be treated at LTCHs, consistent with our historical methodology, we are generally assigning a relative weight to each of the no-volume MS-LTC-DRGs for LTCH PPS standard Federal payment rate cases based on clinical similarity and relative costliness (with the exception of “transplant” MS-LTC-DRGs, “error” MS-LTC-DRGs, and MS-LTC-DRGs that indicate a principal diagnosis related to a psychiatric diagnosis or rehabilitation (referred to as the “psychiatric or rehabilitation” MS-LTC-DRGs), as discussed below). (For additional information on this step of the relative weight methodology, we refer readers to 67 FR 55991 and 74 FR 43959 through 43960.)

As proposed, we are cross-walking each no-volume MS-LTC-DRG to another MS-LTC-DRG for which we calculated a relative weight (determined in accordance with the methodology described above). Then, the “no-volume” MS-LTC-DRG was assigned the same relative weight (and average length of stay) of the MS-LTC-DRG to which it was cross-walked (as described in greater detail below).

Of the 758 MS-LTC-DRGs for FY 2016, we identified 367 MS-LTC-DRGs for which there are no trimmed applicable LTCH cases (the number identified includes no trimmed applicable LTCH cases in the 8 “transplant” MS-LTC-DRGs, the 2 “error” MS-LTC-DRGs, and the 15 “psychiatric or rehabilitation” MS-LTC-DRGs, which are discussed below). As proposed, we are assigning relative weights to each of the 342
no-volume MS-LTC-DRGs that contained trimmed applicable LTCH cases based on clinical similarity and relative costliness to one of the remaining 391 (758 - 367= 391) MS-LTC-DRGs for which we were able to calculate relative weights based on the trimmed applicable LTCH cases in the FY 2014 MedPAR file data using the steps described above. (For the remainder of this discussion, we refer to the “cross-walked” MS-LTC-DRGs as the MS-LTC-DRGs to which we cross-walked one of the 342 “no volume” MS-LTC-DRGs.) Then, we generally assigned the 342 no-volume MS-LTC-DRG the relative weight of the cross-walked MS-LTC-DRG. (As explained below in Step 6, when necessary, we made adjustments to account for nonmonotonicity.)

As proposed, we cross-walked the no-volume MS-LTC-DRG to a MS-LTC-DRG for which we were able to calculate relative weights based on the March 2015 update of the FY 2014 MedPAR file, and to which it is similar clinically in intensity of use of resources and relative costliness as determined by criteria such as care provided during the period of time surrounding surgery, surgical approach (if applicable), length of time of surgical procedure, postoperative care, and length of stay. (For more details on our process for evaluating relative costliness, we refer readers to the FY 2010 IPPS/R Y 2010 LTCH PPS Final rule (73 FR 48543).) We believe in the rare event that there would be a few LTCH cases grouped to one of the no-volume MS-LTC-DRGs in FY 2015, the relative weights assigned based on the cross-walked MS-LTC-DRGs would result in an appropriate LTCH PPS payment because the crosswalks, which are based on clinical similarity and relative costliness, would be expected to generally require equivalent relative resource use.
We then assigned the relative weight of the cross-walked MS-LTC-DRG as the relative weight for the no-volume MS-LTC-DRG such that both of these MS-LTC-DRGs (that is, the no-volume MS-LTC-DRG and the cross-walked MS-LTC-DRG) have the same relative weight (and average length of stay) for FY 2016. We note that, if the cross-walked MS-LTC-DRG had 25 applicable LTCH cases or more, its relative weight (calculated using the methodology described in Steps 1 through 4 above) was assigned to the no-volume MS-LTC-DRG as well. Similarly, if the MS-LTC-DRG to which the no-volume MS-LTC-DRG was cross-walked had 24 or less cases and, therefore, was designated to one of the low-volume quintiles for purposes of determining the relative weights, we assigned the relative weight of the applicable low-volume quintile to the no-volume MS-LTC-DRG such that both of these MS-LTC-DRGs (that is, the no-volume MS-LTC-DRG and the cross-walked MS-LTC-DRG) have the same relative weight for FY 2016. (As we noted above, in the infrequent case where nonmonotonicity involving a no-volume MS-LTC-DRG resulted, additional adjustments as described in Step 6 were required in order to maintain monotonically increasing relative weights.)

For this final rule, a list of the no-volume MS-LTC-DRGs and the MS-LTC-DRGs to which each was cross-walked (that is, the cross-walked MS-LTC-DRGs) for FY 2016 is shown in Table 13B, which is listed in section VI. of the Addendum to this final rule and is available via the Internet on the CMS Web site.

To illustrate this methodology for determining the relative weights for the FY 2016 MS-LTC-DRGs with no applicable LTCH cases, we are providing the
following example, which refers to the no-volume MS-LTC-DRGs crosswalk information for FY 2016 provided in Table 13B.

Example: There were no trimmed applicable LTCH cases in the FY 2014 MedPAR file that we are using for this final rule for MS-LTC-DRG 61 (Acute Ischemic Stroke with Use of Thrombolytic Agent with MCC). We determined that MS-LTC-DRG 70 (Nonspecific Cerebrovascular Disorders with MCC) is similar clinically and based on resource use to MS-LTC-DRG 61. Therefore, we assigned the same relative weight (and average length of stay) of MS-LTC-DRG 70 of 0.9070 for FY 2016 to MS-LTC-DRG 61 (we refer readers to Table 11, which is listed in section VI. of the Addendum to this final rule and is available via the Internet on the CMS Web site).

Again, we note that, as this system is dynamic, it is entirely possible that the number of MS-LTC-DRGs with no volume will vary in the future. As proposed, we are using the most recent available claims data to identify the trimmed applicable LTCH cases from which we determined the relative weights in this final rule.

For FY 2016, consistent with our historical relative weight methodology, as we proposed, we are establishing a relative weight of 0.0000 for the following transplant MS-LTC-DRGs: Heart Transplant or Implant of Heart Assist System with MCC (MS-LTC-DRG 1); Heart Transplant or Implant of Heart Assist System without MCC (MS-LTC-DRG 2); Liver Transplant with MCC or Intestinal Transplant (MS-LTC-DRG 5); Liver Transplant without MCC (MS-LTC-DRG 6); Lung Transplant (MS-LTC-DRG 7); Simultaneous Pancreas/Kidney Transplant (MS-LTC-DRG 8); Pancreas Transplant (MS-LTC-DRG 10); and Kidney Transplant (MS-LTC-DRG 652). This is because
Medicare will only cover these procedures if they are performed at a hospital that has been certified for the specific procedures by Medicare and presently no LTCH has been so certified. At the present time, we include these eight transplant MS-LTC-DRGs in the GROUPER program for administrative purposes only. Because we use the same GROUPER program for LTCHs as is used under the IPPS, removing these MS-LTC-DRGs would be administratively burdensome. (For additional information regarding our treatment of transplant MS-LTC-DRGs, we refer readers to the RY 2010 LTCH PPS final rule (74 FR 43964).) In addition, consistent with our historical policy and as we proposed, we are establishing a relative weight of 0.0000 for the 2 “error” MS-LTC-DRGs (that is, MS-LTC-DRG 998 (Principal Diagnosis Invalid as Discharge Diagnosis) and MS-LTC-DRG 999 (Ungroupable)) because applicable LTCH cases grouped to these MS-LTC-DRGs cannot be properly assigned to an MS-LTC-DRG according to the grouping logic.

In the proposed rule, for FY 2016, we proposed to establish a relative weight equal to the respective FY 2015 relative weight of the MS-LTC-DRGs for the following “psychiatric or rehabilitation” MS-LTC-DRGs: MS-LTC-DRG 876 (O.R. Procedure with Principal Diagnoses of Mental Illness); MS-LTC-DRG 880 (Acute Adjustment Reaction & Psychosocial Dysfunction); MS-LTC-DRG 881 (Depressive Neuroses); MS-LTC-DRG 882 (Neuroses Except Depressive); MS-LTC-DRG 883 (Disorders of Personality & Impulse Control); MS-LTC-DRG 884 (Organic Disturbances & Mental Retardation); MS-LTC-DRG 885 (Psychoses); MS-LTC-DRG 886 (Behavioral & Developmental Disorders); MS-LTC-DRG 887 (Other Mental Disorder Diagnoses); MS-
LTC-DRG 894 (Alcohol/Drug Abuse or Dependence, Left Ama); MS-LTC-DRG 895 (Alcohol/Drug Abuse or Dependence, with Rehabilitation Therapy); MS-LTC-DRG 896 (Alcohol/Drug Abuse or Dependence, without Rehabilitation Therapy with MCC); MS-LTC-DRG 897 (Alcohol/Drug Abuse or Dependence, without Rehabilitation Therapy without MCC); MS-LTC-DRG 945 (Rehabilitation with CC/MCC); and MS-LTC-DRG 946 (Rehabilitation without CC/MCC). Under our proposed implementation of the new dual rate LTCH PPS payment structure, LTCH discharges that are grouped to these 15 “psychiatric and rehabilitation” MS-LTC-DRGs would not meet the criteria for exclusion from the site neutral payment rate. As such, under our proposed implementation of the criterion for a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation (which we are finalizing, as discussed in section VII.B.3.b. of the preamble of this final rule), there are no applicable LTCH cases to use in calculating a relative weight for the “psychiatric and rehabilitation” MS-LTC-DRGs. In other words, any LTCH PPS discharges grouped to any of the 15 “psychiatric and rehabilitation” MS-LTC-DRGs will always be paid at the site neutral payment rate, and, therefore, those MS-LTC-DRGs will never include any LTCH cases that meet the criteria for exclusion from the site neutral payment rate. However, section 1886(m)(6)(B) of the Act establishes a transitional payment method for cases that will be paid at the site neutral payment rate for LTCH discharges occurring in cost reporting periods beginning during FY 2016 or FY 2017. Under the transitional payment method for cases for site neutral payment rate cases discussed in detail in section VII.B.4.b. of the preamble of this final rule, for LTCH discharges occurring in cost reporting periods beginning on or after October 1, 2015, and
on or before September 30, 2017 (that is, discharges occurring in cost reporting periods beginning during FYs 2016 and 2017), site neutral payment rate cases will be paid a blended payment rate, calculated as 50 percent of the applicable site neutral payment rate amount for the discharge and 50 percent of the applicable LTCH PPS standard Federal payment rate. Because the LTCH PPS standard Federal payment rate is based on the relative weight of the MS-LTC-DRG, in order to determine the transitional blended payment for site neutral payment rate cases grouped to one of the “psychiatric or rehabilitation” MS-LTC-DRGs in FY 2016, in the proposed rule, we proposed to assign a relative weight to these MS-LTC-DRGs for FY 2016, that would be the same as the FY 2015 relative weight. We believe that using the respective FY 2015 relative weight for each of the “psychiatric or rehabilitation” MS-LTC-DRGs would result in appropriate payments for LTCH cases that will be paid at the site neutral payment rate under the transition policy provided by the statute because there are no clinically similar MS-LTC-DRGs for which we were able to determine relative weights based on applicable LTCH cases in the FY 2014 MedPAR file data using the steps described above. Furthermore, we believe that it would be administratively burdensome and introduce unnecessary complexity to the MS-LTC-DRG relative weight calculation to use the LTCH discharges in the MedPAR file data to calculate a relative weight for those 15 “psychiatric and rehabilitation” MS-LTC-DRGs to be used for the sole purpose of determining half of the transitional blended payment for site neutral payment rate cases during the transition period. (80 FR 24548 through 24549)
Comment: Some commenters requested that CMS provide more detail about how the GROUPER software will account for CCs and MCCs in grouping cases into one of the 15 “psychiatric or rehabilitation” MS-LTC-DRGs.

Response: When we proposed to adopt the severity-adjusted MS-DRGs (and by extension the MS-LTC-DRGs) as a replacement patient classification to the CMS DRG (and by extension the LTC-DRG) system, we present a detailed discussion on the development of the MCC, CC, and non-CC severity levels in the MS-DRGs and MS-LTC-DRGs (refer to the FY 2008 IPPS proposed rule (72 FR 24697 through 24706 and 24756 through 24757)). We also wish to point out that only two of the 15 “psychiatric or rehabilitation” MS-LTC-DRGs are grouped based on severity level. These are MS-LTC-DRG 945 (Rehabilitation with CC/MCC) and MS-LTC-DRG 946 (Rehabilitation without CC/MCC). The grouping of LTCH cases into these MS-LTC-DRGs will be in accordance with our established method for grouping discharges into MS-LTC-DRGs when those MS-LTC-DRGs are subdivided based on severity level; that is, cases with at least one code that is on the CC or MCC list are assigned to the “with CC/MCC” MS-LTC-DRG (MS-LTC-DRG 945) by the GROUPER software and LTCH cases without a CC or an MCC are assigned to the “without CC/MCC” MS-LTC-DRG (MS-LTC-DRG 946) by the GROUPER software. Because the other 13 “psychiatric or rehabilitation” MS-LTC-DRGs (that is, MS-LTC-DRGs 876, 880, 881, 882, 883, 884, 885, 886, 887, 894, 895, 896, and 897), by definition, are not subdivided based on severity level under our established method for grouping discharges into MS-LTC-DRGs, the presence of code that is on the CC or MCC list will not impact
the MS-LTC-DRG grouping for such cases. For a full discussion of our method of grouping under the MS-DRGs (and by extension, the MS-LTC-DRGs) based on severity level, we refer readers to the discussion of the development of the severity-adjust MS-DRGs in the FY 2008 IPPS proposed rule (72 FR 24697-24706).

**Comment:** Commenters generally supported the proposal to adopt the FY 2015 relative weights for the “psychiatric or rehabilitation” MS-LTC-DRGs. However, some commenters pointed out a technical error in Table 11 of the proposed rule. The commenters noted that although CMS stated in the preamble that for the 15 MS-LTC-DRGs CMS identified as “psychiatric or rehabilitation,” CMS proposed to adopt the FY 2015 relative weights (and average length of stay thresholds) for FY 2016 to pay for cases grouped to those MS-LTC-DRGs from LTCHs whose FY 2016 cost reporting periods had not yet begun and under the transitional blended payment rate. However, they added, the proposed FY 2016 relative weights (and proposed average length of stay thresholds) listed in Table 11 of the proposed rule were not the FY 2015 relative weights for those MS-LTC-DRGs established in the FY 2015 IPPS/LTCH PPS final rule.

**Response:** We appreciate the commenters’ support of our proposal to adopt the FY 2015 relative weights for the “psychiatric or rehabilitation” MS-LTC-DRGs for FY 2016. The commenters correctly pointed out that Table 11 of the proposed rule contained an inadvertent technical error in the proposed FY 2016 relative weights (and average length of stay thresholds in that table) for the “psychiatric or rehabilitation” MS-LTC-DRGs. We are correcting that technical error in Table 11 of this final rule, and
after consideration of public comments we are adopting our proposal to assign the
FY 2016 MS-LTC-DRG relative weights (and average length of stay thresholds) for the
15 “psychiatric or rehabilitation” MS-LTC-DRGs the FY 2015 relative weights for those
respective MS-LTC-DRGs without further change.

In summary, in this final rule, for FY 2016, as we proposed, we are establishing a
relative weight (and average length of stay thresholds) equal to the respective FY 2015
relative weight of the MS-LTC-DRGs for the 15 “psychiatric or rehabilitation”
MS-LTC-DRGs listed above (that is, MS-LTC-DRGs 876, 880, 881, 882, 883, 884, 885,
886, 887, 894, 895, 896, 897, 945, and 946). Table 11, which is listed in section VI. of
the Addendum to this final rule and is available via the Internet on the CMS Web site,
reflects the correction of the technical error discussed above.

Step 6--Adjust the FY 2016 MS-LTC-DRG relative weights to account for
nonmonotonically increasing relative weights.

As discussed earlier in this section, the MS-DRGs contain base DRGs that have
been subdivided into one, two, or three severity of illness levels. Where there are three
severity levels, the most severe level has at least one secondary diagnosis code that is
referred to as an MCC (that is, major complication or comorbidity). The next lower
severity level contains cases with at least one secondary diagnosis code that is a CC (that
is, complication or comorbidity). Those cases without an MCC or a CC are referred to as
“without CC/MCC.” When data do not support the creation of three severity levels, the
base MS-DRG is subdivided into either two levels or the base MS-DRG is not
subdivided. The two-level subdivisions could consist of the MS-DRG with CC/MCC and
the MS-DRG without CC/MCC. Alternatively, the other type of two-level subdivision may consist of the MS-DRG with MCC and the MS-DRG without MCC.

In those base MS-LTC-DRGs that are split into either two or three severity levels, cases classified into the “without CC/MCC” MS-LTC-DRG are expected to have a lower resource use (and lower costs) than the “with CC/MCC” MS-LTC-DRG (in the case of a two-level split) or both the “with CC” and the “with MCC” MS-LTC-DRGs (in the case of a three-level split). That is, theoretically, cases that are more severe typically require greater expenditure of medical care resources and will result in higher average charges. Therefore, in the three severity levels, relative weights should increase by severity, from lowest to highest. If the relative weights decrease as severity increases (that is, if within a base MS-LTC-DRG, an MS-LTC-DRG with CC has a higher relative weight than one with MCC, or the MS-LTC-DRG “without CC/MCC” has a higher relative weight than either of the others), they are nonmonotonic. We continue to believe that utilizing nonmonotonic relative weights to adjust Medicare payments would result in inappropriate payments because the payment for the cases in the higher severity level in a base MS-LTC-DRG (which are generally expected to have higher resource use and costs) would be lower than the payment for cases in a lower severity level within the same base MS-LTC-DRG (which are generally expected to have lower resource use and costs).

Therefore, in determining the FY 2016 MS-LTC-DRG relative weights for LTCH PPS standard Federal payment rate payments in this final rule, consistent with our historical methodology, as proposed, we combined MS-LTC-DRG severity levels within a base MS-LTC-DRG for the purpose of computing a relative weight when necessary to ensure
that monotonicity is maintained. For a comprehensive description of our existing methodology to adjust for nonmonotonicity, we refer readers to the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43964 through 43966). Any adjustments for nonmonotonicity that were made in determining the FY 2016 MS-LTC-DRG relative weights in this rule by applying this methodology are denoted in Table 11, which is listed in section VI. of the Addendum to this final rule and is available via the Internet on the CMS Web site.

**Step 7**--Calculate the FY 2016 MS-LTC-DRG reclassification and recalibration budget neutrality factor.

In accordance with the regulations at §412.517(b) (in conjunction with §412.503), the annual update to the MS-LTC-DRG classifications and relative weights is done in a budget neutral manner such that estimated aggregate LTCH PPS payments would be unaffected, that is, would be neither greater than nor less than the estimated aggregate LTCH PPS payments that would have been made without the MS-LTC-DRG classification and relative weight changes. (For a detailed discussion on the establishment of the budget neutrality requirement for the annual update of the MS-LTC-DRG classifications and relative weights, we refer readers to the RY 2008 LTCH PPS final rule (72 FR 26881 and 26882).)

The MS-LTC-DRG classifications and relative weights are updated annually based on the most recent available LTCH claims data to reflect changes in relative LTCH resource use (§412.517(a) in conjunction with §412.503). Under the budget neutrality requirement at §412.517(b), for each annual update, the MS-LTC-DRG relative weights
are uniformly adjusted to ensure that estimated aggregate payments under the LTCH PPS would not be affected (that is, decreased or increased). Consistent with that provision, we are updating the FY 2016 MS-LTC-DRG classifications and relative weights for LTCH PPS standard Federal payment rate payments based on the most recent available LTCH data for applicable LTCH cases, and applying a budget neutrality adjustment in determining the FY 2016 MS-LTC-DRG relative weights.

To ensure budget neutrality in the update to the MS-LTC-DRG classifications and relative weights under § 412.517(b), as proposed, we are continuing to use our established two-step budget neutrality methodology. As discussed previously in this section, this approach is consistent with our general policies regarding the continued use of our existing methodologies, as presented in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50175 through 50176).

In this final rule, in the first step of our MS-LTC-DRG budget neutrality methodology, for FY 2016, we calculated and applied a normalization factor to the recalibrated relative weights (the result of Steps 1 through 6 above) to ensure that estimated payments were not affected by changes in the composition of case types or the changes to the classification system. That is, the normalization adjustment is intended to ensure that the recalibration of the MS-LTC-DRG relative weights (that is, the process itself) neither increases nor decreases the average case-mix index.

To calculate the normalization factor for FY 2016 (the first step of our budget neutrality methodology), we used the following three steps: (1.a.) we used the most recent available applicable LTCH cases from the most recent available data (that is,
LTCH discharges from the FY 2014 MedPAR file) and grouped them using the FY 2016 GROUPER (that is, Version 33 for FY 2016) and the recalibrated FY 2016 MS-LTC-DRG relative weights (determined in Steps 1 through 6 above) to calculate the average case-mix index; (1.b.) we grouped the same applicable LTCH cases (as are used in Step 1.a.) using the FY 2015 GROUPER (Version 32) and FY 2015 MS-LTC-DRG relative weights and calculated the average case-mix index; and (1.c.) we computed the ratio of these average case-mix indexes by dividing the average CMI for FY 2015 (determined in Step 1.b.) by the average case-mix index for FY 2016 (determined in Step 1.a.). As a result, in determining the MS-LTC-DRG relative weights for FY 2016, each recalibrated MS-LTC-DRG relative weight was multiplied by 1.27929 (determined in Step 1.c.) in the first step of the budget neutrality methodology, which produces “normalized relative weights.”

In the second step of our MS-LTC-DRG budget neutrality methodology, we calculated a second budget neutrality factor consisting of the ratio of estimated aggregate FY 2016 LTCH PPS standard Federal payment rate payments for applicable LTCH cases (the sum of all calculations under Step 1.a. above) after reclassification and recalibration to estimated aggregate payments for FY 2015 LTCH PPS standard Federal payment rate payments for applicable LTCH cases before reclassification and recalibration (that is, the sum of all calculations under Step 1.b. above).

That is, for this final rule, for FY 2016, under the second step of the budget neutrality methodology, we determined the budget neutrality adjustment factor using the following three steps: (2.a.) we simulated estimated total FY 2016 LTCH PPS standard
Federal payment rate payments for applicable LTCH cases using the normalized relative weights for FY 2016 and GROUPER Version 33 (as described above); (2.b.) we simulated estimated total FY 2015 LTCH PPS standard Federal payment rate payments for applicable LTCH cases using the FY 2015 GROUPER (Version 32) and the FY 2015 MS-LTC-DRG relative weights in Table 11 of the FY 2015 IPPS/LTCH PPS final rule available on the Internet, as described in section VI. of the Addendum of that final rule (79 FR 5040 through 50402); and (2.c.) we calculated the ratio of these estimated total payments by dividing the value determined in Step 2.b. by the value determined in Step 2.a. In determining the FY 2016 MS-LTC-DRG relative weights, each normalized relative weight was then multiplied by a budget neutrality factor of 1.0033952 (the value determined in Step 2.c.) in the second step of the budget neutrality methodology to determine the budget neutral FY 2016 relative weight for each MS-LTC-DRG.

Accordingly, in determining the FY 2016 MS-LTC-DRG relative weights in this final rule, consistent with our existing methodology, we applied a normalization factor of 1.27929 and a budget neutrality factor of 1.0033952 (computed as described above). Table 11, which is listed in section VI. of the Addendum to this rule and is available via the Internet on the CMS Web site, lists the MS-LTC-DRGs and their respective relative weights, geometric mean length of stay, five-sixths of the geometric mean length of stay (used to identify SSO cases under § 412.529(a)), and the “IPPS Comparable Thresholds” (used in determining SSO payments under § 412.529(c)(3)), for FY 2016 (and reflect both the normalization factor of 1.27929 and the budget neutrality factor of 1.0033952).
We did not receive any public comments on our proposed methodology for calculating the FY 2016 MS-LTC-DRG reclassification and recalibration budget neutrality factor, and we are adopting it as final without modification. We note that the public comments we received, our responses to those comments, and our finalized policy of applying a budget neutrality requirement as part of the annual recalibration of the MS-LTC-DRG relative weights for FY 2016 are presented in section VII.B.7.a. of this preamble of this final rule.

D. Changes to the LTCH PPS Standard Federal Payment Rates for FY 2016

1. Overview of Development of the LTCH PPS Standard Federal Payment Rates

The basic methodology for determining LTCH PPS standard Federal prospective payment rates is set forth at § 412.515 through § 412.536. In this section, we discuss the factors that we used to update the LTCH PPS standard Federal payment rate for FY 2016, that is, effective for LTCH discharges occurring on or after October 1, 2015 through September 30, 2016. As previously discussed, under the dual rate LTCH PPS payment structure required by statute, we are establishing that, beginning with FY 2016, only LTCH discharges that meet the criteria for exclusion from the site neutral payment rate will be paid based on the LTCH PPS standard Federal payment rate specified at § 412.523. (For additional details on our finalized policies related to the dual rate LTCH PPS payment structure required by statute, we refer readers to section VII.C. of the preamble of this final rule.)

For details on the development of the initial FY 2003 standard Federal rate, we refer readers to the August 30, 2002 LTCH PPS final rule (67 FR 56027 through 56037).
For subsequent updates to the LTCH PPS standard Federal rate as implemented under § 412.523(c)(3), we refer readers to the following final rules: RY 2004 LTCH PPS final rule (68 FR 34134 through 34140); RY 2005 LTCH PPS final rule (68 FR 25682 through 25684); RY 2006 LTCH PPS final rule (70 FR 24179 through 24180); RY 2007 LTCH PPS final rule (71 FR 27819 through 27827); RY 2008 LTCH PPS final rule (72 FR 26870 through 27029); RY 2009 LTCH PPS final rule (73 FR 26800 through 26804); FY 2010 IPPS/R supervised health care facility LTCH PPS final rule (74 FR 44021 through 44030); FY 2011 IPPS/LTCH PPS final rule (75 FR 50443 through 50444); FY 2012 IPPS/LTCH PPS final rule (76 FR 51769 through 51773); FY 2013 IPPS/LTCH PPS final rule (77 FR 53479 through 53481); FY 2014 IPPS/LTCH PPS final rule (78 FR 50760 through 50765); and FY 2015 IPPS/LTCH PPS final rule (79 FR 50176 through 50180).

In this FY 2016 final rule, we present our finalized policies related to the annual update to the LTCH PPS standard Federal payment rate for FY 2016, which includes the annual market basket update. Consistent with our historical practice of using the best data available, as proposed, we also used more recent data to determine the FY 2016 annual market basket update to the LTCH PPS standard Federal payment rate in this final rule.

The application of the update to the LTCH PPS standard Federal payment rate for FY 2016 is presented in section V.A. of the Addendum to this final rule. The components of the annual market basket update to the LTCH PPS standard Federal payment rate for FY 2016 are discussed below, including the reduction to the annual update for LTCHs that fail to submit quality reporting data for fiscal year FY 2016 as
required by the statute (as discussed in section VII.D.2.c. of the preamble of this final rule). In addition, as discussed in section V.A. of the Addendum of this final rule, we made an adjustment to the LTCH PPS standard Federal payment rate to account for the estimated effect of the changes to the area wage level adjustment for FY 2016 on estimated aggregate LTCH PPS payments, in accordance with § 412.523(d)(4).

2. FY 2016 LTCH PPS Annual Market Basket Update

a. Overview

Historically, the Medicare program has used a market basket to account for price increases in the services furnished by providers. The market basket used for the LTCH PPS includes both operating and capital-related costs of LTCHs because the LTCH PPS uses a single payment rate for both operating and capital-related costs. As discussed in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53468 through 53476), we adopted the newly created FY 2009-based LTCH-specific market basket for use under the LTCH PPS beginning in FY 2013. For additional details on the historical development of the market basket used under the LTCH PPS, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53467 through 53468).

Section 3401(c) of the Affordable Care Act provides for certain adjustments to any annual update to the LTCH PPS standard Federal payment rate and refers to the timeframes associated with such adjustments as a “rate year” (which are discussed in more detail in section VII.C.2.b. of the preamble of this final rule.) We note that because the annual update to the LTCH PPS policies, rates, and factors now occurs on October 1, we adopted the term “fiscal year” (FY) rather than “rate year” (RY) under the
LTCH PPS beginning October 1, 2010, to conform with the standard definition of the Federal fiscal year (October 1 through September 30) used by other PPSs, such as the IPPS (75 FR 50396 through 50397). Although the language of sections 3004(a) 3401(c), 10319, and 1105(b) of the Affordable Care Act refers to years 2010 and thereafter under the LTCH PPS as “rate year,” consistent with our change in the terminology used under the LTCH PPS from “rate year” to “fiscal year,” for purposes of clarity, when discussing the annual update for the LTCH PPS standard Federal payment rate, including the provisions of the Affordable Care Act, we use “fiscal year” rather than “rate year” for 2011 and subsequent years.

b. Revision of Certain Market Basket Updates as Required by the Affordable Care Act

Section 1886(m)(3)(A) of the Act, as added by section 3401(c) of the Affordable Care Act, specifies that, for rate year 2010 and each subsequent rate year through 2019, any annual update to the LTCH PPS standard Federal payment rate shall be reduced:

- For rate year 2010 through 2019, by the “other adjustment” specified in sections 1886(m)(3)(A)(ii) and (m)(4) of the Act; and
- For rate year 2012 and each subsequent year, by the productivity adjustment (which we refer to as “the multifactor productivity (MFP) adjustment”) described in section 1886(b)(3)(B)(xi)(II) of the Act.

Section 1886(m)(3)(B) of the Act provides that the application of paragraph (3) of section 1886(m) of the Act may result in the annual update being less than zero for a rate year, and may result in payment rates for a rate year being less than such payment rates for the preceding rate year.
Section 1886(b)(3)(B)(xi)(II) of the Act defines the MFP adjustment as equal to the 10-year moving average of changes in annual economy-wide, private nonfarm business multifactor productivity (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, calendar year, cost reporting period, or other annual period). Under our methodology, the end of the 10-year moving average of changes in the MFP coincides with the end of the appropriate FY update period. In addition, the MFP adjustment that is applied in determining any annual update to the LTCH PPS standard Federal payment rate is the same adjustment that is required to be applied in determining the applicable percentage increase under the IPPS under section 1886(b)(3)(B)(i) of the Act as they are both based on a fiscal year. We refer readers to section IV.A.1. of the preamble of this final rule for more information on the FY 2016 MFP adjustment.

c. Adjustment to the Annual Update to the LTCH PPS Standard Federal Payment Rate under the Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

In accordance with section 1886(m)(5) of the Act, as added by section 3004(a) of the Affordable Care Act, the Secretary established the Long-Term Care Hospital Quality Reporting Program (LTCH QRP). The reduction in the annual update to the LTCH PPS standard Federal payment rate for failure to report quality data under the LTCH QRP for FY 2014 and subsequent fiscal years is codified under § 412.523(c)(4) of the regulations. (As previously noted, although the language of section 3004(a) of the Affordable Care Act refers to years 2011 and thereafter under the LTCH PPS as “rate year,” consistent with our change in the terminology used under the LTCH PPS from “rate year” to “fiscal
year,” for purposes of clarity, when discussing the annual update for the LTCH PPS, including the provisions of the Affordable Care Act, we use “fiscal year” rather than “rate year” for 2011 and subsequent years.) The LTCH QRP, as required for FY 2014 and beyond by section 1886(m)(5)(A)(i) of the Act, applies a 2.0 percentage point reduction to any update under § 412.523(c)(3) for an LTCH that does not submit quality reporting data to the Secretary in accordance with section 1886(m)(5)(C) of the Act with respect to such a year (that is, in the form and manner and at the time specified by the Secretary under the LTCH QRP) (§ 412.523(c)(4)(i)). Section 1886(m)(5)(A)(ii) of the Act provides that the application of the 2.0 percentage points reduction may result in an annual update that is less than 0.0 for a year, and may result in LTCH PPS payment rates for a year being less than such LTCH PPS payment rates for the preceding year (§ 412.523(c)(4)(iii)). Furthermore, section 1886(m)(5)(B) of the Act specifies that the 2.0 percentage points reduction is applied in a noncumulative manner, such that any reduction made under section 1886(m)(5)(A) of the Act shall apply only with respect to the year involved, and shall not be taken into account in computing the LTCH PPS payment amount for a subsequent year (§ 412.523(c)(4)(iii)). We discuss the application of the 2.0 percentage point reduction under § 412.523(c)(4)(i) in our discussion of the annual market basket update to the LTCH PPS standard Federal payment rate for FY 2016 in section VII.D.2.e. of the preamble of this final rule. (For additional information on the history of the LTCH QRP, including the statutory authority and the selected measures, we refer readers to section VII.C. of the preamble of this final rule.)
d. Market Basket under the LTCH PPS for FY 2016

Under the authority of section 123 of the BBRA as amended by section 307(b) of the BIPA, we adopted a newly created FY 2009-based LTCH-specific market basket for use under the LTCH PPS beginning in FY 2013. The FY 2009-based LTCH-specific market basket is based solely on the Medicare cost report data submitted by LTCHs and, therefore, specifically reflects the cost structures of only LTCHs. For additional details on the development of the FY 2009-based LTCH-specific market basket, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53467 through 53476).

For FY 2016, as proposed, we are continuing to use the FY 2009-based LTCH-specific market basket to update the LTCH PPS for FY 2016. We continue to believe that the FY 2009-based LTCH-specific market basket appropriately reflects the cost structure of LTCHs for the reasons discussed when we adopted the FY 2009-based LTCH-specific market basket for use under the LTCH PPS in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53467 through 53476).

Comment: One commenter stated our proposal to use the FY 2009-based market basket update for FY 2016 is contradictory to our statements about the statutory change in the LTCH PPS payment structure, and the proposed rule contains language that states the FY 2009 LTCH-specific market basket is being used as the basis for FY 2016 update. The commenter referred our statement in the proposed rule that “[w]e continue to believe that the FY 2009-based LTCH-specific market basket appropriately reflects the cost structure of LTCHs for the reasons discussed when we adopted the FY 2009-based LTCH-specific market basket for use under the LTCH PPS…” (80 FR 24552). The
commenter believed the market basket should reflect the most currently available data to update the LTCH PPS standard Federal payment rate that will be used to pay LTCH cases that meet the criteria for exclusion from the site neutral payment rate.

Response: The proposed LTCH market basket update reflects the most recent forecast of the 2009-based LTCH-specific market basket for FY 2016. Specifically, the update reflects the projected growth in the relative input prices LTCHs are expected to encounter for the period of October 1, 2015 through September 30, 2016. The Medicare Cost Report used to determine the base year weights for the FY 2009-based LTCH-specific market basket was the most up-to-date data available at the time of the rebasing in FY 2013. We have performed sensitivity analysis for various market baskets and found that the cost share weights do not change substantially from year to year. For this reason, it has been our historical practice to rebase the market baskets about every 4 years. As such, we disagree with the commenter’s assertion that the FY 2009-based LTCH-specific market basket does not reflect the most currently available data to update the annual payment rates. Rather the FY 2009-based LTCH-specific market basket reflects IGI’s latest forecast on price inflation at this time, and for these reasons we believe that it is appropriate to continue to use the FY 2009-based LTCH-specific market basket to update the LTCH PPS standard Federal payment rate for FY 2016.

After consideration of the public comments we received, we are finalizing our proposal to continue to use the FY 2009-based LTCH-specific market basket to update the LTCH PPS standard Federal payment rate for FY 2016.
e. Annual Market Basket Update for LTCHs for FY 2016

Consistent with our historical practice and our proposal, we estimate the market basket update and the MFP adjustment based on IGI’s forecast using the most recent available data. Based on IGI’s second quarter 2015 forecast, the FY 2016 full market basket estimate for the LTCH PPS using the FY 2009-based LTCH-specific market basket is 2.4 percent. The current estimate of the MFP adjustment for FY 2016 based on IGI’s second quarter 2015 forecast is 0.5 percent, as discussed in section IV.A. of the preamble of this final rule. In addition, consistent with our historical practice, we are using a more recent estimate of the market basket and the MFP adjustment to determine the FY 2016 market basket update and the MFP adjustment in this final rule.

For FY 2016, section 1886(m)(3)(A)(i) of the Act requires that any annual update to the LTCH PPS standard Federal payment rate be reduced by the productivity adjustment (“the MFP adjustment”) described in section 1886(b)(3)(B)(xi)(II) of the Act. Consistent with the statute, we are reducing the full FY 2016 market basket update by the FY 2016 MFP adjustment. To determine the market basket update for LTCHs for FY 2016, as reduced by the MFP adjustment, consistent with our established methodology, we subtracted the FY 2016 MFP adjustment from the FY 2016 market basket update. Furthermore, sections 1886(m)(3)(A)(ii) and 1886(m)(4)(E) of the Act requires that any annual update to the LTCH PPS standard Federal payment rate for FY 2016 be reduced by the “other adjustment” described in paragraph (4), which is 0.2 percentage point for FY 2016. Therefore, following application of the productivity adjustment, as proposed, we are further reducing the adjusted market basket update (that
is, the full market basket increase less the MFP adjustment) by the “other adjustment” specified by sections 1886(m)(3)(A)(ii) and 1886(m)(4) of the Act. (For additional details on our established methodology for adjusting the market basket increase by the MFP and the “other adjustment” required by the statute, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51771).)

For FY 2016, section 1886(m)(5) of the Act requires that for LTCHs that do not submit quality reporting data as required under the LTCHQR Program, any annual update to an LTCH PPS standard Federal payment rate, after application of the adjustments required by section 1886(m)(3) of the Act, shall be further reduced by 2.0 percentage points. Therefore, the update to the LTCH PPS standard Federal payment rate for FY 2016 for LTCHs that fail to submit quality reporting data under the LTCH QRP, the full LTCH PPS market basket increase estimate, subject to an adjustment based on changes in economy-wide productivity (“the MFP adjustment”) as required under section 1886(m)(3)(A)(i) of the Act and an additional reduction required by sections 1886(m)(3)(A)(ii) and 1886(m)(4) of the Act, will also be further reduced by 2.0 percentage points.

In this final rule, in accordance with the statute, consistent with our proposal, we are reducing the FY 2016 full market basket estimate of 2.4 percent (based on IGI’s second quarter 2015 forecast of the FY 2009-based LTCH-specific market basket) by the FY 2016 MFP adjustment of 0.5 percentage point (based on IGI’s second quarter 2015 forecast). Following application of the productivity adjustment, the adjusted market basket update of 1.9 percent (2.4 percent minus 0.5 percentage point) was then reduced
by 0.2 percentage point, as required by sections 1886(m)(3)(A)(ii) and 1886(m)(4)(E) of the Act. Therefore, in this final rule, under the authority of section 123 of the BBRA as amended by section 307(b) of the BIPA, we are establishing an annual market basket update under to the LTCH PPS standard Federal payment rate for FY 2016 of 1.7 percent (that is, the most recent estimate of the LTCH PPS market basket update of 2.4 percent, less the MFP adjustment of 0.5 percentage point, and less the 0.2 percentage point required under section 1886(m)(4)(E) of the Act). Accordingly, consistent with our finalized policy, we are revising § 412.523(c)(3) by adding a new paragraph (xii), which specifies that the LTCH PPS standard Federal payment rate for FY 2016 is the LTCH PPS standard Federal payment rate for the previous LTCH PPS year updated by 1.7 percent, and as further adjusted, as appropriate, as described in § 412.523(d). For LTCHs that fail to submit quality reporting data under the LTCH QRP, under § 412.523(c)(3)(xi) in conjunction with § 412.523(c)(4), we are further reducing the annual update to the LTCH PPS standard Federal payment rate by 2.0 percentage points in accordance with section 1886(m)(5) of the Act. Accordingly, consistent with our finalized policy, we are establishing an annual update to the LTCH PPS standard Federal payment rate of -0.3 percent (that is, 1.7 percent minus 2.0 percentage points) for FY 2016 for LTCHs that fail to submit quality reporting data as required under the LTCH QRP. As stated above, consistent with our historical practice, as proposed, we are using a more recent estimate of the market basket and the MFP adjustment to establish an annual update to the LTCH PPS standard Federal payment rate for FY 2016 under § 412.523(c)(3)(xii) in this final rule. (We note that we also are adjusting the FY 2016
LTCH PPS standard Federal payment rate by an area wage level budget neutrality factor in accordance with § 412.523(d)(4) (as discussed in section V.B.5. of the Addendum of this final rule.)

**Comment:** Based on its assessment of the adequacy of Medicare payments to LTCHs, which was presented in its March 2015 Report to the Congress, MedPAC concluded that no update to the LTCH PPS standard Federal payment rate for FY 2016 is warranted. MedPAC further stated that Medicare’s current level of payments appears more than adequate to accommodate cost growth, even before any update, citing that Medicare margin for LTCHs for the past several years have exceeded five percent. For these reasons, MedPAC reiterated its recommendation that the Secretary eliminate the market basket update to the LTCH PPS standard Federal payment rate for FY 2016.

**Response:** We appreciate MedPAC’s concerns about the necessity of a market basket update to the LTCH PPS standard Federal payment rate for FY 2016. However, as noted earlier, there is uncertainty surrounding the LTCH patient universe under the new dual rate LTCH PPS payment structure, in particular the uncertainty as to what the costs of those cases will be during the transition to that revised system. Given this uncertainty, we do not believe that it is appropriate or prudent to eliminate the market basket update to the LTCH PPS standard Federal payment rate for FY 2016 at this time. For the reasons discussed above, we believe it is appropriate that the market basket update less the multi-factor productivity adjustment (and the “other” statutory adjustment) be applied in determining the LTCH PPS standard Federal payment rate for FY 2016 in order to keep pace with expected input price inflation. However, we will
keep this recommendation in mind in developing policies once we gain experience under the new system.

Comment: Some commenters requested that CMS clarify that the annual update established for IPPS excluded hospitals (that is, hospitals paid under the reasonable cost-based TEFRA payment system) for FY 2016, discussed in section VI of the Addendum to the proposed rule, is applicable to the target amount used to determine the LTCH PPS payment adjustment for “subclause (II) LTCHs” under existing § 412.526, and make any modifications to the regulations if needed.

Response: When we established the LTCH PPS payment adjustment for “subclause (II) LTCHs” at § 412.526, we established that for cost reporting periods beginning during FYs after FY 2015, the target amount (used to determine the adjusted payment for Medicare inpatient operating costs under reasonable cost-based reimbursement rules) will equal the hospital’s target amount for the previous cost reporting period updated by the applicable annual rate-of-increase percentage specified in § 413.40(c)(3) for the subject cost reporting period (79 FR 50197). This provision is codified at § 412.526(c)(1)(ii) of the regulations, and, therefore, no modifications are needed to the existing regulations. However, in response to the commenters’ request for clarification, we are taking the opportunity to specify that, for cost reporting periods beginning during FY 2016, the target amount for the payment adjustment for “subclause (II) LTCHs” is updated, consistent with the existing requirements of § 412.526(c)(1)(ii).

As discussed in section IV. of the preamble of the proposed rule and the Addendum, the FY 2016 rate-of-increase percentage for updating the target amounts is equal to the
estimated percentage increase in the FY 2016 IPPS operating market basket, in accordance with applicable regulations at § 413.40. Based on IHS Global Insight, Inc.’s 2015 second quarter forecast, with historical data through the 2015 first quarter, we estimate that the FY 2010-based IPPS operating market basket update for FY 2016 is 2.4 percent (that is, the estimate of the market basket rate of increase). Therefore, the rate-of-increase percentage that will be applied to the FY 2015 target amounts in order to determine the FY 2016 target amounts for “subclause (II) LTCHs” under § 412.526(c)(1)(i) is 2.4 percent.

Comment: One commenter requested we rebase the LTCH PPS standard Federal payment rate (that is, recalculate the LTCH PPS standard Federal payment rate based on more recent cost report data). The commenter argued that LTCH cases that will receive an LTCH PPS standard Federal payment rate payment will be more resource intensive and thus warrant a higher base payment.

Response: While we consider this comment outside the scope of this proposed rule as we did not make any proposals to make such a recalculation of the LTCH PPS standard Federal rate beyond the annual market basked update (including any statutory adjustments), we do not believe that it is necessary or appropriate to rebase at this time. As we state several times throughout this preamble section, there is a good deal of uncertainty about the behavioral response of LTCHs to the new dual rate LTCH PPS payment structure as well as the nature of the future patient population in LTCHs. Furthermore, as we discuss in section VII.B.7.a. of this preamble, beginning with FY 2016, the annual update of the MS-LTC-DRG relative weights will be determined
using only data from LTCH discharges that meet the criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases), which will appropriately reflect the relative costliness and resource use of LTCH PPS standard Federal payment rate cases. For these reasons, we do not believe that rebasing is warranted at this time.

After consideration of the public comments we received, we are finalizing our proposal to update the LTCH PPS standard Federal payment rate using the market basket update and the MFP adjustment based on IGI’s forecast using the most recent available data (and the ‘other’ adjustments required by the statute). Accordingly, as stated above, consistent with our finalized policy, we are specifying at § 412.523(c)(3)(xii) that the LTCH PPS standard Federal payment rate for FY 2016 is the LTCH PPS standard Federal payment rate for the previous LTCH PPS year updated by 1.7 percent, and as further adjusted, as appropriate, as described in § 412.523(d).
E. Moratoria on the Establishment of LTCHs and LTCH Satellite Facilities and on the Increase in the Number of Beds in Existing LTCHs and LTCH Satellite Facilities

Section 1206(b)(2) of Pub. L. 113-67, as amended by section 112(b) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-93), established “new” statutory moratoria on the establishment of new LTCHs and LTCH satellite facilities and on the increase in the number of hospital beds in existing LTCHs and LTCH satellite facilities. For a discussion on our implementation of these moratoria, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50189 through 50193). Since the implementation of these LTCH PPS policy moratoria, we have been informed that some confusion may exist regarding the exceptions to the moratorium on the establishment of new LTCH and LTCH satellite facilities, as well as the application of the moratorium on an increase in the number of beds in existing LTCH and LTCH satellite facilities.

Under existing regulations at 42 CFR 412.23(e)(6), we specify that, to qualify for an exception under the moratorium to establish a new LTCH or LTCH satellite facility during the timeframe between April 1, 2014, and September 30, 2017, a hospital or entity must meet the following criteria:

- The hospital or entity must have begun its qualifying period for payment as an LTCH in accordance with § 412.23(e).
- The hospital or entity must have a binding written agreement with an outside, unrelated party for the actual construction, renovation, lease, or demolition for an LTCH, and must have expended before April 1, 2014, at least 10 percent of the estimated cost of the project or, if less, $2,500,000.
• The hospital or entity must have obtained an approved certificate of need in a State where one is required.

As we stated in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24553), we believe that the existing regulation text regarding the moratorium on the establishment and classification of new LTCHs and LTCH satellite facilities could be misread as requiring fulfillment of all three conditions in order to qualify for an exception to the moratorium on the establishment of new LTCH and LTCH satellite facilities. This was not our intent, and we acknowledge that implementing the moratorium in that manner would have been directly contradictory to the statutory requirement. Technically, while we did not explicitly specify in the regulations text under § 412.23(e)(6) that only one of the listed criteria had to be met in order to qualify for an exception to the moratorium on the establishment of new LTCHs and LTCH satellite facilities (the language text states “as applicable”), we clearly stated it in the preamble of the FY 2015 IPPS/LTCH PPS final rule. (We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50189 through 50193).) In addition, the requirement that one of the three exceptions had to be met in order to qualify for an exception to the moratorium was also indicated in our proposal to implement the initial application of the moratorium during the FY 2009 rulemaking cycle. (We refer readers to the FY 2009 IPPS/LTCH PPS final rule (73 FR 29705).)

As we stated in the preamble of the FY 2015 IPPS/LTCH PPS final rule, the provisions in the new moratorium are nearly identical to the language in the prior “expired” moratorium under section 114(d) of MMSEA (Pub. L. 110-173). As also
noted, the mechanics of exceptions to the new and expired moratoria on the establishment of new LTCHs and LTCH satellite facilities are analogous. Therefore, except as noted, to the extent that the new and expired moratoria were consistent, we proposed and adopted the identical implementation mechanisms. To minimize the confusion that may exist as a result of the existing regulations text, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24553), we proposed to revise the regulations under § 412.23(e)(6)(ii) to more clearly convey the established policy that only one of the statutory conditions needs to be met in order to qualify for the exception to the new moratorium on the establishment of new LTCH and LTCH satellite facilities.

We also have become aware of some confusion concerning what constitutes the “estimated cost of the project” with regard to the second exception. To alleviate confusion, we are further clarifying our longstanding policy on what constitutes the “estimated cost of the project.” In discussing this exception in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50189 through 50193), we noted that the “cost of the project” included the activities (plural) that were enumerated in the first prong of the exception. Those enumerated activities included “the actual construction, renovation, lease, or demolition for a long-term care hospital.” That is, our policy is that the sum total of any costs associated with any of the enumerated activities that comprised the project as a whole (with the project being the establishment of a new LTCH or a new LTCH satellite facility) would be considered in determining whether the facility met the amount specified in the statute. In using an “or” in this list of activities, we intended to acknowledge that any one project may or may not include every element listed (for
example, new construction may not include any demolition), but if it does include an element, our policy is that the cost of that element and the costs of any other of the listed elements in the project are to be summed to determine the total cost of the project. Therefore, under our longstanding policy, when determining whether 10 percent of the estimated cost of the project had been expended prior to the start of the moratorium, the “project” is the establishment of a new LTCH or LTCH satellite facility, not any one element that, when combined with other elements listed in the first prong, would lead to the establishment of the LTCH or LTCH satellite facility. For example, if an entity has expended 10 percent of the costs of demolition, but that amount is less than both 10 percent of the estimated cost of the project, and less than the $2,500,000.00 ceiling amount, the entity would not qualify for this exception to the moratorium.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24554), we also noted that we were taking that opportunity to provide additional clarification on our policy concerning the moratorium on increases in the number of beds in existing LTCH and LTCH satellite facilities. As we noted in the FY 2015 IPPS/LTCH PPS final rule, while the expired moratorium specifically included an exception to the moratorium on the increase in the number of beds in existing LTCHs and LTCH satellite facilities, the new moratorium under section 1206(b)(2)(B) of Pub. L. 113-67 expressly noted that the exceptions to the expired moratoria would not apply under the “new” moratoria. Further amendments made by section 112(b) of Pub. L. 113-93, created certain exceptions, but did not retract the prior statement regarding the express omission of any exceptions (79 FR 50189 through 50193). As the further amendments only provided exception to
the moratorium on establishing new satellites, the express omission of any exceptions to the new moratorium on increasing the number of beds in an existing LTCH or LTCH satellite facility remained in place. As such, an LTCH may not increase the total number of Medicare certified beds beyond the number that existed prior to April 1, 2014, including when an existing LTCH meets one of the exceptions to the moratorium on the establishment of a new LTCH satellite facility. An LTCH satellite facility’s beds historically have been, and continue to be, counted as the LTCH’s beds. Therefore, under our existing regulation at §412.23(e)(7)(iii), an existing LTCH cannot, through meeting the criteria for an exception to the new moratorium on the establishment of a new LTCH satellite facility, increase its total number of Medicare certified beds by establishing any number beds at the new LTCH satellite facility that would result in the total number of Medicare certified beds in that LTCH exceeding what existed prior to April 1, 2014. That is, if an existing LTCH meets one of the statutory exceptions for new satellite facilities and opens a new LTCH satellite facility during the moratorium, that new LTCH satellite facility’s beds must come from the movement of beds in existence prior to April 1, 2014, from other locations of the existing LTCH to the new LTCH satellite facility. This requirement also applies to any remote locations that may be established by an existing LTCH during the moratorium on new beds.

Comment: Several commenters expressed concern with CMS’ articulation of the existing policy. The commenters believed that CMS was proposing to change policy, rather than clarifying existing policy. The commenters urged CMS to adopt a final policy expressly inverse to its clarification.
Response: We disagree with any assertion that the clarification in the proposed rule represents a change in policy. When we implemented the current moratorium in the FY 2015 IPPS/LTCH PPS final rule, we stated that an existing LTCH may not increase the number of its hospital beds. This policy was not subject to any exceptions (79 FR 50190). We discussed in that final rule, in response to several comments received that urged us to create a regulatory exception to the bed moratorium, that we did not believe an exception was warranted and, therefore, did not establish one. We believe that our clear statement in the FY 2015 final rule, our decision not to provide for exceptions to the bed moratorium, and our longstanding policy to count a satellite facility’s beds as an LTCH’s beds were clear articulations of our policy. Nonetheless, as we were later informed that there was confusion regarding the moratorium, in the FY 2016 IPPS/LTCH PPS proposed rule, we reiterated our existing policy to alleviate that confusion.

In summary, without exception, an LTCH may not increase the total number of Medicare certified beds beyond the number that existed prior to April 1, 2014. The number of Medicare certified beds in an LTCH includes beds in all locations, including, as applicable, satellite facilities.

F. Changes to Average Length of Stay Criterion under Pub. L. 113-67 (§412.23)

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24554), we proposed to revise §412.23 to bring it into conformance with the self-implementing statutory changes under section 1206(a)(3) of Pub. L. 113-67 regarding how the average length of stay for an LTCH is to be calculated. As required by section 1861(ccc) of the Act, in order for a hospital to be classified as an LTCH, it must maintain an average length of stay of greater than 25 days as calculated by the Secretary (or meet the requirements of clause (II) of
section 1886(d)(1)(B)(iv) of the Act). Prior to the statutory change in Pub. L. 113-67, the Medicare average length of stay was calculated, in accordance with § 412.23(e)(3) of the regulations, by dividing the total number of covered and noncovered Medicare inpatient days by the total number of Medicare discharges. This calculation included Medicare inpatient days and discharges that were paid under a Medicare Advantage (MA) plan. (For a full discussion of the inclusion of MA days in the average length of stay calculation, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51774).)

Section 1206(a)(3)(A) of Pub. L. 113-67 specified that, in general, for discharges occurring in cost reporting periods beginning on or after October 1, 2015, applicable total Medicare inpatient days and discharges that are paid at the site neutral payment rate (discussed in section VII.B. of the preamble of the proposed rule and this final rule with comment period), or for which payments are made under an MA plan, are to be excluded from the calculation of an LTCH’s average length of stay. Section 1206(a)(3)(B) of Pub. L. 113-67 further required that this exclusion of site neutral and MA days would not apply to an LTCH that was classified as a “subsection (d) hospital” as of December 10, 2013. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule, we proposed to amend § 423.23 to conform with this self-implementing statutory exclusion and the self-implementing statutory exception to the exclusion, by revising paragraphs (e)(3)(ii) through (e)(3)(v), adding a new paragraph (e)(3)(vi), and revising the introductory text of paragraph (e)(6)(ii).

We did not receive any public comments on our proposals. However, upon further consideration, we realized that section 112(c)(2) of Pub. L. 113-93 altered the
“subsection (d) hospital” language established by section 1206(a)(3)(B) of Pub. L. 113-67 to “long-term care hospital.” That is, section 112(c)(2) of Pub. L. 113-93 removed the phrase “subsection (d) hospital” in the provision regarding entities “classified as a subsection (d) hospital as of December 10, 2013” and in its place inserted “long-term care hospital”, resulting in the combined statutory mandates providing “classified as a long-term care hospital as of December 10, 2013”. While we initially mistakenly thought of this legislative language change as a technical change, we now recognize its substantive effect. As the change is statutorily mandated and self-implementing, we are making conforming changes to what we proposed in paragraph (e)(3)(vi) of § 412.23 (which specified that the provisions do not apply to a hospital classified as a “subsection (d) hospital” as of December 10, 2013). As the statute does not set forth any discretion on this provision, and as commenters did not object to the other content of our proposed text for § 412.23, using the authority noted below, we are waiving notice-and-comment rulemaking for this change (replacing “subsection (d) hospital” with “long-term care hospital”) in our proposed rule’s text, finalizing that change, and otherwise finalizing the remaining proposed regulation text changes in § 412.23 without modification.

We ordinarily publish a notice of proposed rulemaking in the Federal Register to provide a period for public comment before the provisions of a rule take effect. We can waive this procedure, however, if we find good cause that notice-and-comment procedures are impracticable, unnecessary, or contrary to the public interest and we incorporate a statement of finding and its reasons in the rule (5 U.S.C. 553(b)(B)). To
that end, we find that it is unnecessary to undertake notice-and-comment rulemaking for the changes to the average length of stay calculation at 42 CFR 412.23(e)(3)(vi) (governing the exclusion of site neutral stays and MA days from the calculation) because those changes are statutorily required modifications to how the average length of stay is to be calculated. We find that notice-and-comment rulemaking is unnecessary to implement these statutory changes to the average length of stay calculation because they are self-implmenting provisions of law, not requiring the exercise of any discretion on the part of the Secretary. As such, the changes in this final rule to the average length of stay calculation in § 412.23(e)(3)(vi) need not be published in a proposed rule prior to publication in this final rule, as such publication is unnecessary in the absence of any discretion regarding this aspect of the average length of stay calculation. Therefore, we find good cause to waive notice-and-comment procedures concerning the average length of stay calculation at § 412.23(e)(3)(vi).
VIII. Quality Data Reporting Requirements for Specific Providers and Suppliers

We seek to promote higher quality and more efficient healthcare for Medicare beneficiaries. This effort is supported by the adoption of widely agreed-upon quality measures. We have worked with relevant stakeholders to define quality measures for most settings and to measure various aspects of care for most Medicare beneficiaries. These measures assess structural aspects of care, clinical processes, patient experiences with care, care coordination, and improving patient outcomes.

We have implemented quality reporting programs for multiple care settings, including:

- Hospital inpatient services under the Hospital Inpatient Quality Reporting (IQR) Program (formerly referred to as the Reporting Hospital Quality Data for Annual Payment Update (RHQDAPU) Program);
- Hospital outpatient services under the Hospital Outpatient Quality Reporting (OQR) Program (formerly referred to as the Hospital Outpatient Quality Data Reporting Program (HOP QDRP));
- Care furnished by physicians and other eligible professionals under the Physician Quality Reporting System (PQRS, formerly referred to as the Physician Quality Reporting Program Initiative (PQRI));
- Inpatient rehabilitation facilities under the Inpatient Rehabilitation Facility Quality Reporting Program (IRF QRP);
- Long-term care hospitals under the Long-Term Care Hospital Quality Reporting Program (LTCH QRP) (also referred to as the LTCHQR Program);
• PPS-exempt cancer hospitals under the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program;

• Ambulatory surgical centers under the Ambulatory Surgical Center Quality Reporting (ASCQR) Program;

• Inpatient psychiatric facilities under the Inpatient Psychiatric Facilities Quality Reporting (IPFQR) Program;

• Home health agencies under the home health quality reporting program (HH QRP); and,

• Hospice facilities under the Hospice Quality Reporting Program.

We have also implemented the End-Stage Renal Disease Quality Incentive Program and Hospital VBP Program (described further below) that link payment to performance.

In implementing the Hospital IQR Program and other quality reporting programs, we have focused on measures that have high impact and support CMS and HHS priorities for improved quality and efficiency of care for Medicare beneficiaries. Our goal for the future is to align the clinical quality measure requirements of the Hospital IQR Program with various other Medicare and Medicaid programs, including those authorized by the Health Information Technology for Economic and Clinical Health (HITECH) Act, so that the reporting burden on providers will be reduced. As appropriate, we will consider the adoption of clinical quality measures with electronic specifications so that the electronic collection of performance information is a seamless component of care delivery. Establishing such a system will require interoperability between EHRs and CMS data
collection systems, additional infrastructure development on the part of hospitals and CMS, and adoption of standards for capturing, formatting, and transmitting the data elements that make up the measures. However, once these activities are accomplished, adoption of measures that rely on data obtained directly from EHRs will enable us to expand the Hospital IQR Program measure set with less cost and reporting burden to hospitals. We believe that in the near future, collection and reporting of data elements through EHRs will greatly simplify and streamline reporting for various CMS quality reporting programs, and that hospitals will be able to switch primarily to EHR-based data reporting for many measures that are currently manually chart-abstracted and submitted to CMS for the Hospital IQR Program.

We also have implemented a Hospital VBP Program under section 1886(o) of the Act, described in the Hospital Inpatient VBP Program final rule (76 FR 26490 through 26547). We most recently adopted additional policies for the Hospital VBP Program in section IV.I. of the FY 2015 IPPS/LTCH PPS final rule (79 FR 50048 through 50087). Under the Hospital VBP Program, hospitals receive value-based incentive payments based on their performance with respect to performance standards for a performance period for the fiscal year involved. The measures under the Hospital VBP Program must be selected from the measures (other than readmission measures) specified under the Hospital IQR Program as required by section 1886(o)(2)(A) of the Act.

In selecting measures for the Hospital IQR Program, we are mindful of the conceptual framework we have developed for the Hospital VBP Program. Because measures adopted for the Hospital VBP Program must first have been specified under the
Hospital IQR Program, these two programs are linked and the reporting infrastructure for the programs overlap. We view the Hospital VBP Program as the next step in promoting higher quality care for Medicare beneficiaries by transforming Medicare from a passive payer of claims into an active purchaser of quality healthcare for its beneficiaries.

Value-based purchasing is an important step to revamping how care and services are paid for, moving increasingly toward rewarding better value, outcomes, and innovations.

We also view the Hospital-Acquired Condition (HAC) payment adjustment program authorized by section 1886(p) of the Act, as added by section 3008 of the Affordable Care Act, and the Hospital VBP Program, as related but separate efforts to reduce HACs. The Hospital VBP Program is an incentive program that awards payments to hospitals based on quality performance on a wide variety of measures, while the HAC Reduction Program creates a payment adjustment resulting in payment reductions for poorly performing hospitals based on their rates of HACs.

In the preamble of the FY 2016 IPPS/LTCH PPS proposed rule, we proposed changes to the following Medicare quality reporting systems:

- In section VIII.A. (80 FR 24555 through 24590), the Hospital IQR Program.
- In section VIII.B. (80 FR 24590 through 24595), the PCHQR Program.
- In section VIII.C. (80 FR 24595 through 24611), the LTCH QRP.

In addition, in section VIII.D. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24611 through 24615), we proposed changes to the Medicare EHR Incentive Program for eligible hospitals and CAHs.
A. Hospital Inpatient Quality Reporting (IQR) Program

1. Background

a. History of the Hospital IQR Program

We refer readers to the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43860 through 43861) and the FY 2011 IPPS/LTCH PPS final rule (75 FR 50180 through 50181) for detailed discussions of the history of the Hospital IQR Program, including the statutory history, and to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50217 through 50249) for the measures we have adopted for the Hospital IQR measure set through the FY 2017 payment determination and subsequent years.

b. Maintenance of Technical Specifications for Quality Measures

The technical specifications for the Hospital IQR Program measures, or links to Web sites hosting technical specifications, are contained in the CMS/The Joint Commission (TJC) Specifications Manual for National Hospital Quality Measures (Specifications Manual). This Specifications Manual is posted on the QualityNet Web site at http://www.qualitynet.org/. We generally update the Specifications Manual on a semiannual basis and include in the updates detailed instructions and calculation algorithms for hospitals to use when collecting and submitting data on required measures. These semiannual updates are accompanied by notifications to users, providing sufficient time between the change and the effective date in order to allow users to incorporate changes and updates to the specifications into data collection systems.

The technical specifications for the HCAHPS patient experience of care survey are contained in the current HCAHPS Quality Assurance Guidelines manual available at
the HCAHPS Web site, [http://www.hcahpsonline.org](http://www.hcahpsonline.org). We maintain the HCAHPS technical specifications by updating the HCAHPS *Quality Assurance Guidelines* manual annually, and include detailed instructions on survey implementation, data collection, data submission and other relevant topics. As necessary, HCAHPS Bulletins are issued to provide notice of changes and updates to technical specifications in HCAHPS data collection systems.

Many of the quality measures used in different Medicare and Medicaid reporting programs are endorsed by the National Quality Forum (NQF). As part of its regular maintenance process for endorsed performance measures, the NQF requires measure stewards to submit annual measure maintenance updates and undergo maintenance of endorsement review every three years. We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50202 through 50203) for additional detail on the measure maintenance process.

We believe that it is important to have in place a subregulatory process to incorporate non-substantive updates to the measure specifications for measures we have adopted for the Hospital IQR Program so that these measures remain up-to-date. We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53504 through 53505) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203) for our policy for using the subregulatory process to make non-substantive updates to measures used for the Hospital IQR Program. We recognize that some changes made to NQF-endorsed measures undergoing maintenance review are substantive in nature and might not be appropriate
for adoption using a subregulatory process. We will continue to use rulemaking to adopt substantive updates made to measures we have adopted for the Hospital IQR Program.

c. Public Display of Quality Measures

Section 1886(b)(3)(B)(viii)(VII) of the Act was amended by the Deficit Reduction Act (DRA) of 2005. Section 5001(a) of the DRA requires that the Secretary establish procedures for making information regarding measures submitted available to the public after ensuring that a hospital has the opportunity to review its data before they are made public. We refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50776 through 50778) for a more detailed discussion about public display of quality measures. We did not propose to change our current policy of reporting data from the Hospital IQR Program as soon as it is feasible on CMS Web sites such as the Hospital Compare Web site http://www.medicare.gov/hospitalcompare and/or the interactive https://data.medicare.gov Web site, after a preview period.

The Hospital Compare Web site is an interactive Web tool that assists beneficiaries by providing information on hospital quality of care to those who need to select a hospital. For more information on measures reported to Hospital Compare, we refer readers to the Web site at: http://www.medicare.gov/hospitalcompare. Other information not reported to Hospital Compare may be made available on other CMS Web sites such as http://www.cms.hhs.gov/HospitalQualityInitiatives/ or https://data.medicare.gov.
2. Process for Retaining Previously Adopted Hospital IQR Program Measures for Subsequent Payment Determinations

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53512 through 53513), for our finalized measure retention policy. When we adopt measures for the Hospital IQR Program beginning with a particular payment determination, these measures are automatically adopted for all subsequent payment determinations unless we propose to remove, suspend, or replace the measures.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24556), we did not propose any changes to our policy for retaining previously adopted measures for subsequent payment determinations.

3. Removal and Suspension of Hospital IQR Program Measures

a. Considerations in Removing Quality Measures from the Hospital IQR Program

As discussed above, we generally retain measures from the previous year’s Hospital IQR Program measure set for subsequent years’ measure sets except when we specifically propose to remove, suspend, or replace a measure. We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50185) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203 through 50204) for more information on the criteria we consider for removing quality measures. We also take into account the views of the Measure Applications Partnership (MAP) when determining when a measure should be removed, and we strive to eliminate redundancy of similar measures (77 FR 53505 through 53506).

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203 through 50204), we also finalized our proposal to clarify the criteria for determining when a measure is “topped
out.” In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24556), we did not propose any changes to the two criteria that we use to determine whether or not a measure is “topped out.”

We use these previously adopted measure removal criteria to help evaluate when we should propose a measure for removal. However, we continue to believe that there are circumstances in which a measure that meets criteria for removal should be retained regardless, because the drawbacks of removing a measure could be outweighed by other benefits to retaining the measure. Therefore, because of the continued need to balance benefits and drawbacks as well as our desire to increase transparency, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24556 through 24557), we proposed additional factors to consider for measure removal and also include factors to consider in order to retain measures.

Specifically, we proposed to take into consideration the following additional factor in determining whether a measure should be removed:

- Feasibility to implement the measure specifications.

In addition, we proposed to remove one of the factors (“Availability of alternative measures with a stronger relationship to patient outcomes”) we take into consideration when determining whether to remove measures, because it is duplicates another factor (“The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic”).

We also proposed to take into consideration the following factors in determining whether a measure should be retained:
• Measure aligns with National Quality Strategy or CMS Quality Strategy goals;
• Measure aligns with other CMS programs, including other quality reporting programs, or the EHR Incentive Program; and
• Measure supports efforts to move facilities towards reporting electronic measures

For example, we may consider retaining a measure that is statistically “topped-out” in order to align with the Medicare EHR Incentive Program. Below is a table of newly proposed and previously adopted factors that we would take into consideration in removing or retaining measures:

<table>
<thead>
<tr>
<th>Factors CMS Considers in Removing or Retaining Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measure Removal Factors</td>
</tr>
<tr>
<td>1. Measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped-out” measures)</td>
</tr>
<tr>
<td>2. A measure does not align with current clinical guidelines or practice</td>
</tr>
<tr>
<td>3. The availability of a more broadly applicable measure (across settings, populations, or the availability of a measure that is more proximal in time to desired patient outcomes for the particular topic)</td>
</tr>
<tr>
<td>4. Performance or improvement on a measure does not result in better patient outcomes</td>
</tr>
<tr>
<td>5. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic</td>
</tr>
<tr>
<td>6. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm</td>
</tr>
<tr>
<td>7. It is not feasible to implement the measure specifications*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>“Topped-Out” Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Statistically indistinguishable performance at the 75th and 90th percentiles; and</td>
</tr>
<tr>
<td>2. Truncated coefficient of variation ≤ 0.10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure Retention Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Measure aligns with other CMS and HHS policy goals*</td>
</tr>
<tr>
<td>2. Measure aligns with other CMS programs, including other quality reporting programs, or the EHR Incentive Program; and</td>
</tr>
</tbody>
</table>


3. Measure supports efforts to move facilities towards reporting electronic measures

* Consideration proposed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24556 through 24557).

We note that these removal/retention factors continue to be considerations taken into account when deciding whether or not to remove measures; but they are not firm requirements.

We invited public comments on our proposal.

Comment: Several commenters supported the considerations in removing/retaining quality measures and noted their appreciation for our efforts to align with other programs as well as the National Quality Strategy or CMS Quality Strategy goals, and to consider the feasibility of data collection and reporting. Several commenters specifically noted their support for CMS’ efforts to transition to electronic clinical quality measures.

Response: We thank the commenters for their support.

Comment: Several commenters supported the addition of a measure retention criterion stating “Measure supports efforts to move facilities towards reporting electronic measures.”

Response: We thank the commenters for their support.

Comment: Some commenters requested more detail on the measure removal criterion: “feasibility to implement the measure specifications.” A few commenters recommended that this measure removal criterion should include considerations of the difficulty of collection experienced by providers. The commenters also recommended
that the assessment should evaluate the impact on clinical workflow, the degree of completeness, and the ease of related data collection requirements assumed to be derived from clinical workflow.

Response: In considering the “feasibility to implement the measure specifications” as proposed, we consider both our ability to receive the necessary data, as well as hospitals’ ability to collect the measure data. Accordingly, when considering this measure removal criterion, we account for data collection challenges, including, but not limited to clinical workflow, the degree of completeness, and the ease of related data collection requirements, experienced by hospitals and providers.

Comment: One commenter encouraged CMS to consider approaches to improve hospital performance on measures that are slow to meet the "topped-out" criteria. Specifically, the commenter indicated that there is a need to put additional focus on the process measures that are tied to high quality data within IQR in order to support improvement of hospital quality and patient outcomes.

Response: We thank the commenter for its suggestion and note that we generally retain measures until they either become “topped-out” or meet one of the other measure removal criteria. We believe that the inclusion of these measures, whether they are process or outcomes measures, in the Hospital IQR Program will drive hospitals to improve performance. However, we will take the commenter’s suggestion to put additional focus on process measures tied to high quality data under advisement for our plans for education and outreach on the Hospital IQR Program.
Comment: A few commenters opposed the proposed criterion “measure aligns with other CMS and HHS policy goals” as a factor to be considered for measure retention, noting that there may be reasons to remove a measure from one program, even though it is still appropriate in another.

Response: We would like to clarify that when we consider whether or not a “measure aligns with other CMS and HHS policy goals,” we evaluate whether a measure supports the CMS Quality Strategy goals or the National Quality Strategy, instead of alignment with other quality reporting programs. We are however, finalizing another criterion that allows retention of a measure that aligns with other quality reporting programs, such as the EHR Incentive Program, in order to enable hospitals to rely on the same measures to meet the requirements of multiple programs.

Comment: A few commenters opposed the addition of the measure removal criterion “measure supports efforts to move facilities towards reporting electronic measures.” Some commenters suggested that a measure-by-measure approach to accelerating/encouraging electronic reporting is not adequate.

Response: We clarify that we have added this criterion in acknowledgement that there may be instances when we may consider retaining an electronic version of a measure that is statistically “topped out” in its chart-abstracted mode specifically to align with the EHR Incentive Program. Accordingly, we make every effort to ensure an aligned set of electronic clinical quality measures across the Hospital IQR Program and the EHR Incentive Program.
Comment: One commenter supported the removal of topped out measures, noting that they provide little room for improvement, but recommended the creation of a system to monitor performance on retired measures to ensure that quality gains are sustained.

Response: We thank the commenter for its support and will take its suggestion under consideration.

After consideration of the public comments we received, we are finalizing factors that we would take into consideration in removing or retaining measures as proposed. Specifically, we are finalizing: (1) the addition of the removal factor “feasibility to implement the measure specifications;” (2) the removal of the factor “availability of alternative measures with a stronger relationship to patient outcomes;” and (3) the addition of the retention factors “measure aligns with National Quality Strategy or CMS Quality Strategy goals,” “measure aligns with other CMS programs, including other quality reporting programs, or the EHR Incentive Program,” and “measure supports efforts to move facilities towards reporting electronic measures.”

b. Removal of Hospital IQR Program Measures for the FY 2018 Payment Determination and Subsequent Years

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24557 through 24560), we proposed to remove the following nine measures, either in their entirety or just the chart abstracted form, from the Hospital IQR Program measure set for the FY 2018 payment determination and subsequent years: STK-01: Venous Thromboembolism (VTE) Prophylaxis (NQF #0434), STK-06: Discharged on Statin Medication (NQF #0439), STK-08: Stroke Education (NQF endorsement removed), VTE-1: Venous
Thromboembolism Prophylaxis (NQF #0371), VTE-2: Intensive Care Unit Venous Thromboembolism Prophylaxis (NQF #0372), VTE-3: Venous Thromboembolism Patients with Anticoagulation Overlap Therapy (NQF #0373), IMM-1: Pneumococcal Immunization (NQF #1653), AMI-7a: Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival (NQF #0164), and SCIP-Inf-4: Cardiac Surgery Patients with Controlled Postoperative Blood Glucose (NQF #0300).

(1) STK-01, STK-06, STK-08, VTE-1, VTE-2, and VTE-3

We proposed to remove the chart-abstracted versions of STK-01, STK-06, STK-08, VTE-1, VTE-2, and VTE-3 because these measures are “topped-out.” However, we proposed to retain STK-06, STK-08, VTE-1, VTE-2, and VTE-3 as electronic clinical quality measures for the FY 2018 payment determination and subsequent years. As we state in section VIII.A.3.a. of the preamble of this final rule, in our discussion of factors we consider in removing or retaining a measure, “topped-out” status is only one of many factors, which we consider.

In balancing the benefits and disadvantages of removing or retaining a measure, we believe that the benefits of retaining the electronic versions of these measures outweigh the possible disadvantages. Specifically, we believe that while these measures are statistically “topped-out,” retaining the electronic versions of the measures is beneficial because they align the Hospital IQR Program with the Medicare EHR Incentive Program. In addition, retaining the electronic version of the measures would allow us to monitor the effectiveness of measure reporting by EHRs and help to
familiarize hospitals with reporting electronically specified measures to CMS under the Hospital IQR Program.

Our data show that the electronically specified versions of these measures are reported with non-zero values by as many as 2,864 hospitals attesting under 2014 Meaningful Use and that hospitals report on the full range of available electronic clinical quality measures. Accordingly, we know that EHRs are certified to these measures, and that hospitals do indeed report them. The available data suggest that retaining STK-06, STK-08, VTE-1, VTE-2, and VTE-3 as electronic clinical quality measures furthers CMS' high priority goal to enable the electronic reporting of quality data and to align the Hospital IQR and EHR Incentive Programs.

We also believe that reporting electronic clinical quality measures presents minimal burden on hospitals as compared to their chart-abstracted equivalents and that retaining the electronically specified versions of these measures is appropriate until we fully understand the differences between the chart-abstracted and electronic versions of quality measures. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50808) we stated that we do not believe that the measures, in their electronically specified form, are substantively different than their chart-abstracted form, although we recognized that the EHR-based extraction methodology is different from the chart-abstraction data collection methodology.

However, CMS now recognizes that although the intent of a measure is the same whether it is reported via chart-abstraction or electronically, the submission modes are not the same and measure rates may be different.
As described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we have only heard anecdotal comments about actual performance level differences between the two modes of collection. We do not have sufficient data to be able to confirm these comments, but in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50273), we finalized a proposal to conduct a validation pilot test for electronically specified measures, which we intend to complete in 2015. The results of this pilot are not yet available. As we have stated in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53555), determining the equivalence of electronic clinical quality measures and chart-abstracted measures would require extensive testing given that the data for the Hospital IQR Program supports public reporting for both the Hospital IQR and Hospital VBP Programs. Due to the reasons described above, we believe it is appropriate to retain the electronically specified version of these five measures at this time.

We invited public comment on our proposals.

Comment: Several commenters supported the proposal to remove the chart-abstracted versions of the nine indicated measures in the Hospital IQR Program and retaining them as electronic clinical quality measures. The commenters noted that the removal of these measures reduces administrative burdens on hospitals.

Response: We thank the commenters for their support.

Comment: Several commenters supported the proposal to remove the six “topped-out” measures and to retain five of the measures as electronic clinical quality measures, noting their support of the transition from manually abstracted measures to the electronic versions.
Response: We thank the commenters for their support.

Comment: One commenter supported the proposed removal of STK-1 in its entirety and the removal of the chart abstracted versions of STK-06, STK-08, VTE-1, VTE-2, and VTE-3. However, the commenter suggested that a future policy should be adopted for coordinating measure removal and the maintenance of the National Hospital Inpatient Quality Measures (NHIQM) specifications such that vendors have adequate time to accommodate the changes.\textsuperscript{115}

Response: We thank the commenter for its support. We also note that we consider a number of guidelines and considerations, outlined above, when determining whether to remove or retain measures from the Hospital IQR Program measure set. Considerations include the NHIQM specifications,\textsuperscript{116} which represent the result of efforts by CMS and The Joint Commission to achieve consistency among common national hospital performance measures and to share a single set of common documentation. In addition, we note that the retention of the electronic versions of STK-06, STK-08, VTE-1, VTE-2, and VTE-3 does not introduce new specifications for vendors to accommodate, as these measures have been in the Hospital IQR Program in previous years, thus negating the concern of vendors needing adequate time to accommodate changes.


Comment: One commenter noted that it is currently developing guidelines for VTE that can inform the development of future measures.

Response: We thank the commenter for sharing that they are working in this area and look forward to the insight the guidelines can provide for the development of VTE measures.

Comment: One commenter expressed concern that the proposed removal of the chart-abstracted version of measures will reduce quality standards and recommends that no chart-abstracted measures be replaced until such time that electronic clinical quality measures can be submitted and reported with high fidelity, accuracy and quality threshold requirements. The commenter also expressed concern that as chart-abstracted measures are removed from the Hospital IQR Program, abstraction and submission vendors may remove functionality from quality measurement submission software, impeding performance tracking, limiting hospitals’ ability to track both the chart-abstracted and electronic version of such measures in parallel, and reducing the number of measurements that can be used to implement new payment models within the private sector.

Some commenters recommended that the chart-abstracted versions of “topped-out” measures be retained and requested that both electronic clinical quality measure and chart-abstracted measure data be published, to enable comparisons.

Response: We note that the five measures that we proposed for removal in their chart-abstracted form but retained the electronic versions of met our “topped-out” criteria as specified in FY 2013 IPPS/LTCH PPS final rule (77 FR 53512 through 53513) where
the formulas are discussed. Accordingly, we believe that the removal of these measures is appropriate and that the removal of the functionality to capture the chart-abstracted versions of these measures will not negatively affect quality.

In addition, we believe that retaining the electronic versions of six measures (STK-06, STK-08, VTE-1, VTE-2, VTE-3, and AMI-7a) is appropriate because they align the Hospital IQR Program with the Medicare EHR Incentive Program, allow us to monitor the effectiveness of measure reporting by EHRs, and help to familiarize hospitals with reporting electronically specified measures to CMS. We also note that a validation pilot test for electronically specified measures is being completed in 2015 in order to ensure that electronic measures can be submitted and reported with high fidelity, accuracy and quality threshold requirements. Finally, we note that the Hospital IQR Program measure set includes six measures (ED-1, ED-2, STK-04, VTE-5, VTE-6, and PC-01) which have the capability to be reported both via chart-abstraction and electronically. We refer readers to section VIII.8.b. of the preamble of this final rule below in which we discuss our modified policies finalized, including that these measures are required via chart-abstraction and data will be posted to Hospital Compare. Hospitals may submit these measures via both methods. This information may allow us to compare the chart-abstracted and electronic versions of measure data, in order to confirm variability between data sources.

**Comment:** Several commenters expressed continuing concern regarding the removal of measures that are deemed “topped-out,” noting their belief that the removal of these measures could result in unintended adverse consequences, as well as signal a
general disinterest in this aspect of care on the part of CMS. The commenters recommended that CMS ensure that the proposed removal would not cause any gaps in care. A few commenters recommended that sample “topped-out” measures be audited periodically to ensure satisfactory performance, noting that periodic auditing could detect reductions on quality of care.

Response: We believe that removing measures meeting the “topped-out” criteria will not negatively affect quality, because by definition, performance on these measures is adequately high. In addition, we believe that the addition of measure retention criteria, described above, signals our intent to retain measures that address high priority aspects of care, even if those measures are “topped-out.” Finally, we want to thank the commenters for their suggestion that we consider auditing “topped-out” measures.

Comment: One commenter supported the proposed removal of the STK measures. However, the commenter was concerned that the remaining STK-04 measure will be ineffectual, as it is a measure with low volume.

Response: We thank the commenter for its support of the proposed removal of the STK measures in their chart-abstracted forms. We believe that STK-04 should remain in the program in its chart-abstracted form, because based on our calculations in accordance with our “topped out” policy, it does not fall under this category. Due to this, we believe there is room for improvement in performance. Over 900 hospitals submitted data on this measure in CY 2014 for the FY 2016 payment determination, however, we will re-evaluate the measure for next year’s proposed rule.
Comment: Several commenters supported the removal of the “topped-out” measures, but questioned the value of retaining the electronic versions of those measures. Specifically, the commenters expressed concern that the retention of the electronic versions of these measures, which were developed for chart abstraction and translated to electronic measures, will delay movement to measures that were developed using EHRs. One commenter also noted concern that this policy requires inappropriate use of resources and has no impact on quality.

Response: We do not believe that these measures, in their electronically specified form, are substantively different than their chart-abstracted form, despite our recognition that: (1) the EHR-based extraction methodology is different from the chart abstraction data collection methodology, and (2) measure rates may vary depending on methodology. We believe that retaining the electronic versions of these measures is beneficial, because it allows us to align the Hospital IQR Program with the Medicare EHR Incentive Program. We refer readers to section VIII.8.b. of the preamble of this final rule where we discuss our finalized modified policy. We are retaining a variety of electronic clinical quality measures in order to ensure that hospitals have flexibility and choice in determining which electronic measures to report. In addition, retaining the electronic versions of measures does not detract from developing new measures based on data elements readily available in EHRs.

In regards to the comment that electronic clinical quality measure reporting requires an inappropriate use of resources, we disagree, and note that a movement towards the use of electronic data is a national priority, as evidenced by the HITECH act
and Meaningful Use program requirements. We believe that the collection of electronic clinical quality measure data will enable hospitals to efficiently capture and calculate quality data that can be used to address quality at the point of care and track improvements over time.

We will make note of the issues raised in the comments received for next year's proposed rule, when we may consider removing additional electronic clinical quality measures from the Hospital IQR Program, possibly including:

- VTE-3 VTE Patients with Anticoagulation Overlap Therapy (NQF #0373);
- VTE-4 VTE Patients Receiving Unfractionated Heparin (UFH) with Dosages/Platelet Count Monitoring by Protocol (or Nomogram) (NQF N/A);
- VTE-5 VTE Discharge Instructions (NQF N/A);
- VTE-6 Incidence of Potentially Preventable VTE (NQF N/A);
- PN-6 Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients (NQF #0147);
- Healthy Term Newborn (NQF #0716);
- AMI-7a Fibrinolytic Therapy Received Within 30 minutes of Hospital Arrival (NQF #0164);
- SCIP-INF-9 Urinary Catheter Removed on Postoperative Day 1 (POD1) or Postoperative Day 2 (POD2) with Day of Surgery Being Day Zero (NQF N/A);
- CAC-3 Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver (NQF N/A);
- AMI-2-Aspirin Prescribed at Discharge for AMI (NQF N/A);
• AMI-10 Statin Prescribed at Discharge (NQF N/A);

• SCIP-INF-1a Prophylactic Antibiotic Received within 1 Hour Prior to Surgical Incision (NQF #0527); and,

• SCIP-INF-2 Prophylactic Antibiotic Selection for Surgical Patients.

After consideration of the public comments we received, we are finalizing our proposal to remove the chart-abstracted versions of STK-01, STK-06, STK-08, VTE-1, VTE-2, and VTE-3, but also retain STK-06, STK-08, VTE-1, VTE-2, and VTE-3 as electronic clinical quality measures for the FY 2018 payment determination and subsequent years as proposed.

(2) IMM-2 Influenza Immunization (NQF #1659)

One additional measure, IMM-2, has been determined to be statistically “topped-out;” however, after considering the benefits and disadvantages of removing or retaining this measure, we are retaining this measure in the Hospital IQR Program measure set for the FY 2018 payment determination and subsequent years, because the benefits outweigh the disadvantages. One of the factors that we consider when determining whether to remove or retain a measure is whether a measure aligns with National Quality Strategy (NQS) or CMS Quality Strategy goals. Currently, IMM-2 is the only Hospital IQR Program measure to address the Best Practices to Enable Healthy Living NQS Priority and CMS Quality Strategy goal. In addition, IMM-2 supports the NQS priorities and CMS Quality Strategy goals to promote effective interventions to prevent and reduce the leading causes of mortality.117

Comment: Several commenters supported the retention of the IMM-2 Influenza Immunization measure in the Hospital IQR Program, noting that the measure plays a critical role in CMS’ Best Practices to Enable Healthy Living NQS Priority and CMS Quality Strategy goal.

Response: We thank the commenters for their support.

Comment: A few commenters opposed CMS’ proposal to retain IMM-2 despite its “topped-out” status, citing the burden associated with reporting the measure and the little benefit and value they believe retention will add.

Response: While we recognize that the IMM-2 measure has been statistically deemed “topped-out,” it is the only Hospital IQR Program measure to address the Best Practices to Enable Healthy Living NQS Priority and CMS Quality Strategy goal. In addition, IMM-2 supports other NQS priorities and CMS Quality Strategy goals to promote effective interventions to prevent and reduce the leading causes of mortality. In accordance with the measure removal and retention criteria discussed in section VIII.8.b of the preamble of this rule, we believe that the value of retaining this measure outweighs the burden associated with collection as well as the “topped-out” status. Accordingly, we believe that the measure is valuable in promoting quality and that this measure adds value to the Hospital IQR Program measure set.

After consideration of the public comments we received, we are finalizing our policy to retain IMM-2 Influenza Immunization (NQF #1659) as proposed.
(3) Removal of Immunization 1 (IMM-1) Pneumococcal Immunization (NQF #1653)

We adopted the IMM-1 Pneumococcal Immunization measure (NQF #1653) for the FY 2014 payment determination and subsequent years with data collection beginning with January 1, 2012 discharges (75 FR 50211). In October 2012, subsequent to the beginning of IMM-1 data collection on January 1, 2012, the Advisory Committee on Immunization Practices (ACIP) published new guidelines on pneumococcal vaccination. With the publication of the new ACIP guidelines, IMM-1, as specified in the Hospital IQR Program, was no longer compliant with current clinical guidelines.

As part of our efforts to re-specify IMM-1 to account for the many potential scenarios that must be considered when determining if pneumococcal vaccination is appropriate, we determined that it was not feasible to implement the measure specifications that incorporated the new guidelines given their complexity.

Specifically, the October 2012 ACIP guidelines recommended the routine use of 13-valent pneumococcal conjugate (PCV13) vaccine for adults aged ≥19 years with certain comorbid conditions, and that PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) that was currently recommended for these groups of adults. The timing of vaccination with PCV13 and PPSV23 is dependent upon if and when an individual has received the other vaccine.

In order to implement the measure consistent with these new guidelines, providers would need reliable, detailed data on: (1) whether or not a pneumococcal vaccine was

---

previously administered; (2) which type of pneumococcal vaccine (PCV13 vs. PPSV23) was administered; and (3) when it was administered. When considering possible clinical scenarios of screening and vaccinating for pneumonia, current chart and electronic data do not consistently allow for successful abstraction of these varied and detailed historical facts, all of which are needed to appropriately administer a pneumococcal vaccine.

We believe that the measure, as updated by ACIP guidelines, would burden hospitals with data abstraction and yield results with only questionable meaningfulness and reliability. We outlined these pneumococcal vaccination implementation issues in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50780 through 50781), and suspended data collection for IMM-1 until further notice.

Since the suspension of IMM-1, ACIP again updated its 2012 guidelines in September 2014. In reviewing the updated 2014 guidelines, we held discussions with other HHS agencies to identify implementation strategies for these updated guidelines. However, we were still unable to identify a consistent data source, such as a national immunization registry, that is available to hospitals which would provide sufficient patient-level clinical information to ensure that hospitals would be able to accurately and reliably determine whether they were following the guidelines. There continues to be a lack of detailed and reliable patient level data on prior pneumococcal vaccination that is readily available to all hospitals. Without detailed, reliable, and readily available data for hospitals, it will be difficult to determine if the pneumococcal vaccinations are appropriately administered.

In determining whether to remove the IMM-1 measure, we considered the factors stated above in section VIII.A.3.a. of the preamble of this final rule, in our discussion of considerations for the removal and retention of quality measures from the Hospital IQR Program. Based on the continued lack of ready access to comprehensive patient-level immunization data by hospital staff and the continued infeasibility to implement or align this measure with current clinical guidelines or practice, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24558) we proposed to remove this measure from the Hospital IQR Program. We emphasize that, despite the proposed removal of the IMM-1 measure from the Hospital IQR Program, we understand and value the role pneumococcal vaccines play in preventing pneumococcal disease\textsuperscript{120} and we expect hospitals to continue to provide pneumococcal vaccinations for their hospital populations as appropriate.

We invited public comments on this proposal to remove IMM-1 from the Hospital IQR Program beginning in CY 2016 for the FY 2018 payment determination and subsequent years.

**Comment:** Several commenters supported the removal of the IMM-1 Pneumococcal Immunization measure, while expressing an appreciation for the review and analysis efforts which might have contributed to the decision to remove the measure.

**Response:** We thank the commenters for their support.

**Comment:** Several commenters encouraged CMS to reconsider the removal of the pneumococcal immunization measure (IMM-1) and cited the importance of this measure to appropriate patient vaccination. The commenters recommended that CMS

refine the measure to better align with the recommendations of the ACIP. One commenter also noted that IMM-1 aligns with CMS and HHS policy goals, and that its removal is in conflict with the stated measure retention criteria. A few commenters noted concern that the proposed removal of IMM-1 is in contrast to the scope of work outlined in CMS' Quality Improvement Network Quality Improvement Organization (QIN-QIO).

Response: We believe that pneumococcal immunization is extremely important in preventing pneumococcal disease. We disagree that removal is in conflict with our removal and retention policy. As discussed above in section VIII.2.a. of the preamble of this final rule, the retention factor “measure aligns with other CMS and HHS policy goals” is only one factor we consider in removing or retaining measures. We must also balance other factors and considerations. While a pneumococcal immunization measure aligns with CMS and HHS policy goals, we believe that this measure is infeasible to implement without comprehensive patient-level immunization data, which is not readily available to hospital staff. As indicated, the continued lack of ready access to comprehensive patient-level immunization data by hospital staff and the continued infeasibility to implement or align this measure with current clinical guidelines or practice, are driving factors that support the proposal to remove this measure from the Hospital IQR Program. We emphasize that, despite the proposed removal of the IMM–1 measure from the Hospital IQR Program, we understand and value the role pneumococcal vaccines play in preventing pneumococcal disease. In instances where hospitals have adequate access to a patient’s pneumococcal immunization history, we would expect hospitals to provide a pneumococcal vaccination if it were indicated. We
also refer hospitals to the ACIP guidelines for additional information on pneumococcal immunization in hospitals [http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html](http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html).

In addition, this measure was not required for the Hospital IQR Program beginning with January 1, 2014 discharges, and was suspended from the program in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50780 through 50781). Furthermore, while we recognize that CMS awarded QIOs a four-year contract to improve immunization rates and reduce immunization disparities, we note that QIO performance is not dependent upon vaccination in the hospital setting.121

**Comment:** One commenter expressed concern that CMS has not provided data to support its assertion that hospitals will continue to vaccinate as appropriate.

**Response:** In instances where hospitals have adequate access to a patient’s pneumococcal immunization history, we would expect hospitals to provide a pneumococcal vaccination if it were indicated. The ACIP guidelines ([http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html](http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html)) recommended the routine use of 13-valent pneumococcal conjugate (PCV13) vaccine for adults aged ≥19 years with certain comorbid conditions, and that PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) that was currently recommended for these groups of adults.

---

Comment: One commenter recommends that CMS develop a flow chart that provides hospitals with guidance on whether patients need a pneumococcal vaccination, and which type, based on the patient's vaccination history.

Response: We thank the commenter for its suggestion regarding additional guidance on appropriate vaccination, and will take this recommendation under consideration. We also note that the ACIP guidelines serve as a resource for additional information on pneumococcal immunization in hospitals (http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html).

After consideration of the public comments we received, we are finalizing our policy to remove Immunization 1 (IMM-1) Pneumococcal Immunization (NQF #1653) for the FY 2018 payment determination and subsequent years as proposed.

(4) Removal of AMI-7a Fibrinolytic Therapy Received within 30 Minutes of Hospital Arrival Measure (NQF #0164)

Our evaluation of the most recently available data shows that AMI-7a is not widely reported by hospitals, and according to the most recent data available, hospitals reporting this measure have less than the required number of cases to be publicly reported. In determining whether to remove AMI-7a as a chart-abstracted measure, we considered the factors stated in above in section VIII.A.3.a. of the preamble of this final rule in our discussion of considerations for the removal and retention of quality measures from the Hospital IQR Program. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24558 through 24559), we proposed to remove AMI-7a as a chart-abstracted measure beginning in CY 2016 for the FY 2018 payment determination and subsequent
years because performance on this measure does not result in better patient outcomes. Specifically, measure data are infrequently reported, as most acute myocardial infarction patients receive percutaneous coronary intervention instead of fibrinolytic therapy. In addition, we believe that the burden of requiring all hospitals to report data on this measure, when only a minority of facilities report enough cases to be publicly reported, outweighs the benefits of retaining the chart-abstracted version of this measure.

However, we proposed to retain AMI-7a as an electronic clinical quality measure. We believe that once electronic capture of the measure is possible, the time and resources for electronic reporting should be significantly less as compared to manual abstraction. In addition, as discussed above in section VIII.A.3.a. of the preamble of this final rule, retaining the electronically specified version of a measure allows us to support the alignment of the Hospital IQR Program and the Medicare EHR Incentive Program. In addition, retaining this measure will both allow us to monitor the effectiveness of measure reporting by EHRs and help familiarize hospitals with reporting electronically specified measures under the Hospital IQR Program.

We invited public comments on our proposal to remove the chart-abstracted version of AMI-7a but retain the electronic version for the CY 2016/FY 2018 payment determination and subsequent years.

**Comment:** Several commenters supported the proposal to remove AMI-7a.

**Response:** We thank the commenters for their support.

**Comment:** One commenter requested clarification on whether the chart-abstracted version of AMI-7a is being removed from the Hospital IQR Program, or
if the measure is being removed in its entirety, as is the case under the Hospital VBP Program.

**Response:** We would like to clarify that we are finalizing our proposals to remove the chart-abstracted version of AMI-7a from both the Hospital IQR Program and Hospital VBP Program (see section IV.F.2.b.(2) of the preamble of this final rule). However, we are retaining AMI-7a in its electronic form under the Hospital IQR Program as a measure that may be selected to meet the electronic clinical quality measure requirement for the FY 2018 payment determination.

**Comment:** Several commenters recommended that both the chart-abstracted and the electronic versions of the AMI-7a Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival measure be removed, and noted that the chart-abstracted version of the measure is being removed because it meets the removal criteria “Performance or improvement on a measure does not result in better patient outcomes.”

**Response:** In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24558), we proposed to remove the AMI-7a measure in its chart-abstracted form. We also proposed to retain the measure as an electronic clinical quality measure for the FY 2018 payment determination, despite the reasons cited for removing the chart-abstracted version, in order to support the alignment of the Hospital IQR Program with the Medicare EHR Incentive Program. This would allow us to monitor the effectiveness of measure reporting by EHRs and help familiarize hospitals with reporting electronically. However, we will take this comment into consideration in next year’s proposed rule when, as noted
above, we may consider removing some electronic clinical quality measures from the Hospital IQR Program.

After consideration of the public comments we received, we are finalizing our policy to remove the chart-abstracted version of AMI-7a Fibrinolytic Therapy Received within 30 Minutes of Hospital Arrival Measure (NQF #0164), but retain the electronic version for the CY 2016/FY 2018 payment determination and subsequent years as proposed.

(5) Removal of SCIP-Inf-4 Cardiac Surgery Patients with Controlled Postoperative Blood Glucose (NQF #0300)

In the CY 2008 OPPS/ASC final rule with comment period (72 FR 66876), we finalized SCIP-Inf-4 Cardiac Surgery Patients with Controlled Postoperative Blood Glucose (NQF #0300) for the Hospital IQR Program for FY 2009 and subsequent years. We also stated that hospitals were required to begin submitting data for SCIP-Inf-4 beginning with January 1, 2008 discharges.

Since the finalization of SCIP-Inf-4 for the Hospital IQR Program, the measure underwent routine NQF maintenance endorsement proceedings in 2012. During the NQF maintenance proceedings, the NQF Steering Committee discussed and recommended that the measure assess a lower blood glucose level target and lengthen the timeframe for achieving the lower blood glucose level target. As part of the maintenance endorsement renewal process, SCIP-Inf-4 was modified with the goal of achieving post-operative blood glucose levels of 180 mg/dl at 18-24 hours after surgery (previously, the timeframe was to achieve 200 mg/dl by 6 AM on post-operative days 1 and 2). We finalized the
adoption of these measure refinements (see revised measure specifications at http://www.qualityforum.org/QPS/0300), in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50788) with data collection beginning with January 1, 2014 discharges. We also stated then that we would consider whether additional refinements should be made to better define the 18-24 hour timeframe for the measure.

Since finalizing the refinements to SCIP-Inf-4, we have been contacted by stakeholders and experts in the field of endocrinology regarding the newly refined goal of 180 mg/dl within an 18-24 hour timeframe. Specifically, there are concerns about the following aspects of the measure: (1) defining “optimal glycemic control;” (2) measuring the correlation between optimal glycemic goals and better outcomes;\textsuperscript{122} and (3) using an arbitrary 18-24 hour timeframe that does not cover a physiologically meaningful period of time.

Experts in the endocrinology field have shared that providers’ enthusiasm to meet the measure blood glucose goals in the specified timeframe may lead to the following unintended consequences: (1) providers delaying patients’ meals until the 24-hour timeframe has passed; (2) providers keeping diabetic patients in intensive care units on insulin drips until the 24-hour timeframe has passed; (3) providers ensuring patients’ postprandial glucose levels are kept below 180 mg/dl by concurrent use of intravenous and subcutaneous insulin administration; and (4) undetected hypoglycemic events caused by using multiple forms of insulin administration since the measure does not assess blood

\textsuperscript{122} Optimal glycemic research for 6 AM blood glucose control shows a weak correlation between optimal glycemic goals and better outcomes related to morbidity, mortality and length of stay, suggesting that this type of metric may not be valid. LaPar FJ, Isbell JM, Kern JA, Ailawadi G, Kron IL. Surgical Care Improvement Project measure for postoperative glucose control should not be used as a measure of quality after cardiac surgery. J Thorac Cardiovasc Surg 2014;147:1041-8.
glucose levels past 24 hours. Multiple stakeholders also indicate that the Society of Thoracic Surgeons’ guidelines\footnote{Lazar HL, McDonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR et al. The Society of Thoracic Surgeons Practice Guideline Series: Blood Glucose Management During Adult Cardiac Surgery. \textit{Ann Thorac Surg} 2009; 87: 663-9.} on preoperative through postoperative cardiac surgery glucose control, which helped inform CMS in maintenance of this measure, are currently being reviewed. Newer guidelines will address methods to monitor glycemic control in the post-cardiac surgical patient population. However, these guidelines are not currently available to guide further refinements of SCIP-Inf-4.

In view of stakeholder concerns, the seriousness of the potential negative unintended consequences, and recent analysis that shows the refined measure is “topped-out,” on January 9, 2015, we formally suspended the collection of data for SCIP-Inf-4 beginning with July 1, 2014 discharges. We refer readers to https://www.qualitynet.org/dcs/BlobServer?blobkey=id&blobnocache=true&blobwhere=1228890406532&blobheader=multipart%2Foctet-stream&blobheadername1=Content-Disposition&blobheadervalue1=attachment%3Bfilename%3D2015-02-IP.pdf&blobcol=urldata&blobtable=MungoBlobs for more information about the suspension.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24559), we proposed to remove SCIP-Inf-4 from the Hospital IQR Program effective beginning with CY 2016 discharges for the FY 2018 payment determination and subsequent years. We believe removal of this measure, rather than continued suspension, is appropriate for several reasons. First, performance on this measure does not result in better patient outcomes. Recent literature has highlighted that not meeting optimal glycemic control for a narrow
Second, the measure does not align with current clinical guidelines or practice. As previously stated, stakeholders and experts in the field of endocrinology have voiced their concerns in these areas, especially with using an arbitrary 18-24 hour timeframe that does not cover a physiologically meaningful period of time, as current practice guidelines aim for overall glycemic control. Third, public reporting of a measure leads to negative unintended consequences other than patient harm. As mentioned above, these negative unintended consequences include potentially delaying patient meals or transition from the intensive care unit while keeping patients on insulin drips. For more information on the factors we consider for removing or retaining quality measures, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203 through 50204) and section VIII.A.3.a. of the preamble of this final rule. The measure will remain suspended until CY 2016 discharges begin. Despite our proposed removal of SCIP-Inf-4, we continue to believe glycemic control is important, and we hope to include measures focusing on glycemic control in the Hospital IQR Program in the near future.

We invited public comments on our proposal to remove SCIP-Inf-4 from the Hospital IQR Program for the FY 2018 payment determination and subsequent years.

---


Comment: Several commenters supported the removal of the SCIP-4 measure, noting that unintended consequences have occurred due to providers' enthusiasm to meet the measure and acknowledging that SCIP-Inf-4 does not align with current practice guidelines. One commenter noted that the measure is being removed in accordance with the measure removal/retention policy described.

Response: We thank the commenters for their support.

Comment: A few commenters recommended that we await the results of the guideline updates put forward by the Society of Thoracic Surgeons before considering the incorporation of metrics of postoperative glucose control in cardiac surgery patients into the Hospital IQR Program. One commenter encouraged CMS to focus on the creation of a better measure that could capture glucose control over time for cardiac surgery patients.

Response: Current practice guidelines, and to our knowledge, future guidelines, will aim for overall glycemic control. SCIP-Inf-4 is specified to evaluate a particular point in time and not overall glycemic control during the postoperative period. If we were to refine the measure to look at overall glycemic control instead of one point in time, this would require many steps, including an environmental scan and literature review to ensure that this is still a gap area that would warrant respecification and testing, as well as MAP input and proposal through rulemaking. These steps would require significant CMS resources, and at this time, we are not considering respecifying this measure. A measure looking at overall postoperative glycemic control would best be developed as an electronic clinical quality measure and tested in this manner. We let our new measure environmental scan and literature review, among other factors, inform our
selection of new measures for development. We also target new measures based on many other factors and refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53510 through 53512) for a discussion of the considerations we use to expand and update quality measure set under the Hospital IQR Program.

Comment: Several commenters supported the proposals to remove the chart-abstracted versions of the nine indicated measures in the Hospital IQR Program and retain them as electronic clinical quality measures. Commenters noted that the removal of these measures reduces administrative burdens on hospitals.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing our proposal to remove SCIP-Inf-4 Cardiac Surgery Patients with Controlled Postoperative Blood Glucose (NQF #0300) for the FY 2018 payment determination and subsequent years as proposed.

The table below lists the measures we are finalizing for removal for the FY 2018 payment determination and subsequent years.

<table>
<thead>
<tr>
<th>Measures Removed for the FY 2018 Payment Determination and Subsequent Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Topped-out” Measures</td>
</tr>
<tr>
<td>● STK-01: Venous Thromboembolism (VTE) Prophylaxis (NQF #0434)</td>
</tr>
<tr>
<td>● STK-06: Discharged on Statin Medication* (NQF #0439)</td>
</tr>
<tr>
<td>● STK-08: Stroke Education* (NQF endorsement removed)</td>
</tr>
<tr>
<td>● VTE-1: Venous Thromboembolism Prophylaxis* (NQF #0371)</td>
</tr>
<tr>
<td>● VTE-2: Intensive Care Unit Venous Thromboembolism Prophylaxis* (NQF #0372)</td>
</tr>
<tr>
<td>● VTE-3: Venous Thromboembolism Patients with Anticoagulation Overlap Therapy* (NQF #0373)</td>
</tr>
</tbody>
</table>
### Measures Removed for the FY 2018 Payment Determination and Subsequent Years

#### Other Measures

- IMM-1 Pneumococcal Immunization (NQF #1653)
- SCIP-Inf-4 Cardiac Surgery Patients with Controlled Postoperative Blood Glucose (NQF #0300)
- AMI-7a Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival* (NQF #0164)

* Retained as electronic clinical quality measures for the Hospital IQR Program FY 2018 payment determination and subsequent years.

### 4. Previously Adopted Hospital IQR Program Measures for the FY 2017 Payment Determination and Subsequent Years

#### a. Background

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50246), we described that the Hospital IQR Program measure set for the FY 2017 payment determination and subsequent years includes a total of 64 measures:

- 6 NHSN measures
- 29 electronic clinical quality measures (voluntary; 12 of these have the option of being reported as chart-abstracted measures)
- 16 chart-abstracted measures (12 of these have the option of being reported as electronic clinical quality measures)
- 21 claims-based measures
- 1 survey measure
- 3 structural measures

In the FY 2015 IPPS/LTCH PPS final rule, we described that of the 63 measures making up the Hospital IQR Program measure set for the FY 2017 payment...
determination and subsequent years, 42 were previously finalized measures, 11 were measures newly adopted in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49865) and 10 were measures that were determined to be “topped-out” but were retained in the Hospital IQR Program as voluntary electronic clinical quality measures (79 FR 50208).

The following table shows measures previously adopted for the Hospital IQR Program FY 2017 payment determination and subsequent years. For a detailed list of the Hospital IQR Program FY 2018 payment determination and subsequent years measure set, we refer readers to section VIII.A.7.f. of the preamble of this final rule.

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHSN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLABSI</td>
<td>National Healthcare Safety Network (NHSN) Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure</td>
<td>0139</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI</td>
<td>American College of Surgeons – Centers for Disease Control and Prevention (ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure</td>
<td>0753</td>
</tr>
<tr>
<td>CAUTI</td>
<td>National Healthcare Safety Network (NHSN) Catheter-associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
<td>0138</td>
</tr>
<tr>
<td>MRSA Bacteremia</td>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia Outcome Measure</td>
<td>1716</td>
</tr>
<tr>
<td>CDI</td>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure</td>
<td>1717</td>
</tr>
<tr>
<td>HCP</td>
<td>Influenza Vaccination Coverage Among Healthcare Personnel</td>
<td>0431</td>
</tr>
<tr>
<td>Chart-abstracted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMI-7a*</td>
<td>Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival</td>
<td>0164</td>
</tr>
</tbody>
</table>
## Previously Adopted Hospital IQR Program Measures for the FY 2017 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED-1*</td>
<td>Median Time from ED Arrival to ED Departure for patients Admitted ED Patients</td>
<td>0495</td>
</tr>
<tr>
<td>ED-2*</td>
<td>Admit Decision Time to ED Departure Time for Admitted Patients</td>
<td>0497</td>
</tr>
<tr>
<td>Imm-2</td>
<td>Influenza Immunization</td>
<td>1659</td>
</tr>
<tr>
<td>PC-01*</td>
<td>Elective Delivery (Collected in aggregate, submitted via Web-based tool or electronic clinical quality measure)</td>
<td>0469</td>
</tr>
<tr>
<td>SCIP-Inf-4</td>
<td>Cardiac Surgery Patients with Controlled Postoperative Blood Glucose</td>
<td>0300</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Severe Sepsis and Septic Shock: Management Bundle (Composite Measure)</td>
<td>0500</td>
</tr>
<tr>
<td>STK-01</td>
<td>Venous Thromboembolism (VTE) Prophylaxis</td>
<td>0434</td>
</tr>
<tr>
<td>STK-04*</td>
<td>Thrombolytic Therapy</td>
<td>0437</td>
</tr>
<tr>
<td>STK-06*</td>
<td>Discharged on Statin Medication</td>
<td>0439</td>
</tr>
<tr>
<td>STK-08*</td>
<td>Stroke Education</td>
<td>N/A</td>
</tr>
<tr>
<td>VTE-1*</td>
<td>Venous Thromboembolism Prophylaxis</td>
<td>0371</td>
</tr>
<tr>
<td>VTE-2*</td>
<td>Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
<tr>
<td>VTE-5*</td>
<td>Venous Thromboembolism Discharge Instructions</td>
<td>N/A</td>
</tr>
<tr>
<td>VTE-6*</td>
<td>Incidence of Potentially Preventable Venous Thromboembolism</td>
<td>N/A</td>
</tr>
<tr>
<td>MORT-30-AMI</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Myocardial Infarction (AMI) Hospitalization for Patients 18 and Older</td>
<td>0230</td>
</tr>
<tr>
<td>MORT-30-HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Heart Failure (HF) Hospitalization for Patients 18 and Older</td>
<td>0229</td>
</tr>
<tr>
<td>MORT-30-PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization</td>
<td>0468</td>
</tr>
<tr>
<td>MORT-30-COPD</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization</td>
<td>1893</td>
</tr>
<tr>
<td>STK Mortality</td>
<td>Stroke 30-day Mortality Rate</td>
<td>N/A</td>
</tr>
<tr>
<td>CABG Mortality</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Coronary Artery Bypass Graft (CABG) Surgery</td>
<td>2558</td>
</tr>
<tr>
<td>Short Name</td>
<td>Measure Name</td>
<td>NQF #</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>READM-30-AMI</td>
<td>Hospital 30-Day All-Cause Risk-Standardized Readmission Rate (RSRR) Following Acute Myocardial Infarction (AMI) Hospitalization</td>
<td>0505</td>
</tr>
<tr>
<td>READM-30-HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Heart Failure (HF) Hospitalization</td>
<td>0330</td>
</tr>
<tr>
<td>READM-30-PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization</td>
<td>0506</td>
</tr>
<tr>
<td>READM-30-THA/TKA</td>
<td>Hospital-Level 30-Day, All-Cause Risk-Standardized Readmission Rate (RSRR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)</td>
<td>1551</td>
</tr>
<tr>
<td>READM-30-HWR</td>
<td>Hospital-Wide All-Cause Unplanned Readmission Measure (HWR)</td>
<td>1789</td>
</tr>
<tr>
<td>COPD READMIT</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization</td>
<td>1891</td>
</tr>
<tr>
<td>STK READMIT</td>
<td>30-Day Risk Standardized Readmission Rate Following Stroke Hospitalization</td>
<td>N/A</td>
</tr>
<tr>
<td>CABG READMIT</td>
<td>Hospital 30-Day, All-Cause, Unplanned, Risk-Standardized Readmission Rate (RSRR) Following Coronary Artery Bypass Graft (CABG) Surgery</td>
<td>2515</td>
</tr>
<tr>
<td>MSPB</td>
<td>Payment-Standardized Medicare Spending Per Beneficiary (MSPB)</td>
<td>2158</td>
</tr>
<tr>
<td>AMI payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI)</td>
<td>2431</td>
</tr>
<tr>
<td>HF Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care For Heart Failure (HF)</td>
<td>2436</td>
</tr>
<tr>
<td>PN Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For Pneumonia</td>
<td>2579</td>
</tr>
<tr>
<td>Hip/knee complications</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)</td>
<td>1550</td>
</tr>
<tr>
<td>PSI 4 (PSI/NSI)</td>
<td>Death among Surgical Inpatients with Serious, Treatable Complications</td>
<td>0351</td>
</tr>
<tr>
<td>Short Name</td>
<td>Measure Name</td>
<td>NQF #</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>PSI 90</td>
<td>Patient Safety for Selected Indicators (Composite Measure)</td>
<td>0531</td>
</tr>
<tr>
<td></td>
<td><strong>Electronic Clinical Quality Measures</strong></td>
<td></td>
</tr>
<tr>
<td>AMI-2</td>
<td>Aspirin Prescribed at Discharge for AMI</td>
<td>N/A</td>
</tr>
<tr>
<td>AMI-7a*</td>
<td>Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival</td>
<td>0164</td>
</tr>
<tr>
<td>AMI-8a</td>
<td>Primary PCI Received Within 90 Minutes of Hospital Arrival</td>
<td>0163</td>
</tr>
<tr>
<td>AMI-10</td>
<td>Statin Prescribed at Discharge</td>
<td>N/A</td>
</tr>
<tr>
<td>CAC-3</td>
<td>Home Management Plan of Care Document Given to Patient/Caregiver</td>
<td>N/A</td>
</tr>
<tr>
<td>EHDI-1a</td>
<td>Hearing Screening Prior to Hospital Discharge</td>
<td>1354</td>
</tr>
<tr>
<td>ED-1*</td>
<td>Median Time from ED Arrival to ED Departure for Admitted ED Patients</td>
<td>0495</td>
</tr>
<tr>
<td>ED-2*</td>
<td>Admit Decision Time to ED Departure Time for Admitted Patients</td>
<td>0497</td>
</tr>
<tr>
<td>HTN</td>
<td>Healthy Term Newborn</td>
<td>0716</td>
</tr>
<tr>
<td>PC-01*</td>
<td>Elective Delivery (Collected in aggregate, submitted via Web-based tool or electronic clinical quality measure)</td>
<td>0469</td>
</tr>
<tr>
<td>PC-05</td>
<td>Exclusive Breast Milk Feeding and the Subset Measure PC-05a Exclusive Breast Milk Feeding Considering Mother’s Choice</td>
<td>0480</td>
</tr>
<tr>
<td>PN-6</td>
<td>Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients</td>
<td>0147</td>
</tr>
<tr>
<td>SCIP-Inf-1a</td>
<td>Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision</td>
<td>0527</td>
</tr>
<tr>
<td>SCIP-Inf-2a</td>
<td>Prophylactic Antibiotic Selection for Surgical Patients</td>
<td>0528</td>
</tr>
<tr>
<td>SCIP-Inf-9</td>
<td>Urinary Catheter Removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with Day of Surgery Being Day Zero</td>
<td>N/A</td>
</tr>
<tr>
<td>STK-02</td>
<td>Discharged on Antithrombotic Therapy</td>
<td>0435</td>
</tr>
<tr>
<td>STK-03</td>
<td>Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>0436</td>
</tr>
<tr>
<td>STK-04*</td>
<td>Thrombolytic Therapy</td>
<td>0437</td>
</tr>
<tr>
<td>STK-05</td>
<td>Antithrombotic Therapy by the End of Hospital Day Two</td>
<td>0438</td>
</tr>
<tr>
<td>STK-06*</td>
<td>Discharged on Statin Medication</td>
<td>0439</td>
</tr>
<tr>
<td>STK-08*</td>
<td>Stroke Education</td>
<td>N/A</td>
</tr>
<tr>
<td>Short Name</td>
<td>Measure Name</td>
<td>NQF #</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>-------</td>
</tr>
<tr>
<td>STK-10</td>
<td>Assessed for Rehabilitation</td>
<td>0441</td>
</tr>
<tr>
<td>VTE-1*</td>
<td>Venous Thromboembolism Prophylaxis</td>
<td>0371</td>
</tr>
<tr>
<td>VTE-2*</td>
<td>Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
<tr>
<td>VTE-3</td>
<td>Venous Thromboembolism Patients with Anticoagulation Overlap Therapy</td>
<td>0373</td>
</tr>
<tr>
<td>VTE-4</td>
<td>Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram</td>
<td>N/A</td>
</tr>
<tr>
<td>VTE-5*</td>
<td>Venous Thromboembolism Discharge Instructions</td>
<td>N/A</td>
</tr>
<tr>
<td>VTE-6*</td>
<td>Incidence of Potentially Preventable Venous Thromboembolism</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Patient Survey**

<table>
<thead>
<tr>
<th></th>
<th>Measure Name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCAHPS</td>
<td>HCAHPS + 3-Item Care Transition Measure (CTM-3)</td>
<td>0166</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0228</td>
</tr>
</tbody>
</table>

**Structural**

<table>
<thead>
<tr>
<th>Registry for Nursing Sensitive Care</th>
<th>Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registry for General Surgery</td>
<td>Participation in a Systematic Clinical Database Registry for General Surgery</td>
<td>N/A</td>
</tr>
<tr>
<td>Safe Surgery Checklist</td>
<td>Safe Surgery Checklist Use</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* Measure is listed twice, as both chart-abstracted and electronic clinical quality measure.

**Comment:** One commenter requested clarification on whether or not the Sepsis Bundle measure is currently suspended. The commenter had concerns with the sepsis measure as it is currently specified. Specifically, the commenter noted that the measure is abstract, untested, and that elements of the bundle that apply to physical reassessment of patients with persistent hypotension do not have strong evidence supporting a process-outcome link. The commenter recommended the suspension or removal of the measure from the program until the listed concerns are addressed.
Response: We are clarifying here that the Severe Sepsis and Septic Shock: Management Bundle measure (NQF #0500) was suspended in August of 2014,127 while the measure steward worked with NQF and other stakeholders to incorporate the results of recent studies into NQF #0500’s “element F.” “Element F” included measuring central venous pressure and central venous oxygen saturation; the measure steward was working with NQF and stakeholders on whether this part of “element F” should be retained or removed from the measure. On March 26, 2015128 we issued a notification announcing that hospitals are required to submit data on the Sepsis Bundle measure for the Hospital IQR Program beginning with October 1, 2015 discharges for the FY 2017 payment determination and subsequent years based on updates to the measure and subsequent NQF re-endorsement.129

Since publication of the FY 2015 IPPS/LTCH PPS final rule (79 FR 50236), where we discuss the original finalized version of the measure, changes to the specifications have been undertaken by the steward and endorsed by NQF in response to newly published evidence. Changes have centered on one of the composite elements, referred to as “Element F.” These changes do not reflect variations to the measurement strategy. The measure has seven elements. “Element F” reassesses the patient for volume status (that is, does the patient have enough fluid in circulation?) and perfusion status (that is, is that fluid circulated appropriately?).

128 Reference ID 2015-29-IP; Dated March 26, 2015. Available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier3&cid=1228774625060.
In 2014, the measure was updated so that it reassessed volume and perfusion (Element F) using a complicated and invasive approach to patient care. It called for assessment of central venous pressure (CVP) and percent of oxygen saturation in blood returning to the heart (ScVO2). This assessment required providers to place a long catheter in the patient’s neck or chest in a position that approximated the location of the heart. Blood and pressure readings were obtained from this catheter.

The measure has since been updated,\textsuperscript{130} again so that the measure reassesses volume and perfusion (Element F) giving providers the opportunity to simply re-examine their patients with a physical exam. Rather than placing an invasive catheter into a patient, requiring consent to do so, and risking complications to patients and hospitals, providers may now simply return to the bedside to manually re-examine their patient. The simple, focused physical exam replaces what was an onerous requirement, and one of the most cited objections to the measure by commenters. Element F now allows a provider choice and does not mandate the use of invasive strategies.

These changes to the requirement to reassess volume and perfusion (Element F) were made after three clinical research studies were published. In March 2014, the Protocolized Care for Early Septic Shock (ProCESS)\textsuperscript{131} trial demonstrated that an invasive approach was not required. This trial was followed in October 2014 by the Australian Resuscitation in Sepsis Evaluation Randomized Controlled Trial (ARISE),\textsuperscript{132} which arrived at the same conclusion. In March 2015, the Protocolised Management in

\begin{itemize}
\item \textsuperscript{130} \url{http://www.qualityforum.org/ProjectMeasures.aspx?projectID=73701}.
\end{itemize}
Sepsis Trial (ProMISe)\textsuperscript{133} also reached the same conclusion. NQF and the measure developers acted on the basis of the first trial, ProCESS4, and liberalized the requirement to reassess volume and perfusion (Element F).

The revised Element F only makes compliance with the previously posted measure easier. The revision retains the same strategy, but makes it easier for hospitals and clinicians to be compliant. The measure is based on the International Guidelines for Management of Severe Sepsis and Septic Shock (2012). Accordingly, the measure has been tested for its reliability and validity and evaluated to determine the importance of collecting measure data.

b. NHSN Measures Standard Population Data

The previously adopted NHSN measures include the CAUTI, CLABSI, MRSA Bacteremia, CDI, colon and abdominal hysterectomy SSI measures, and HCP for the FY 2017 payment determination and subsequent years. We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50200 through 50202) and the FY 2012 IPPS/LTCH PPS final rule (76 FR 51616 through 51618; 76 FR 51629 through 51633) for more information about these measures. These NHSN measures measure the incidence of HAIs in hospitals participating in the Hospital IQR Program. In order to calculate the NHSN measures for use in the Hospital IQR Program, CDC must go through several steps.

First, CDC determines each NHSN measure’s number of predicted infections. CDC determines this number using both specific hospital characteristics (for example,

number of central line days for CLABSI) and infection rates that occurred among a standard population (sometimes referred to by CDC as “national baseline” but referred to here as “standard population data”). CDC currently uses data it collected in calendar year (CY) 2009 for the CAUTI measure’s standard population data.

In addition, for each NHSN measure, CDC calculates the Standardized Infection Ratio (SIR) by comparing a hospital’s reported number of HAIs with the standard population data. For more information about the way NHSN measures are calculated, we refer readers to the QualityNet Web page on HAI measures at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1228760487021.

We are notifying the public that CDC will update the standard population data to ensure the NHSN measures’ number of predicted infections reflect the current state of HAIs in the United States. The standard referent population that CDC uses to calculate the Standardized Infection Ratios (SIRs) is comprised of healthcare-associated infection data that CDC’s NHSN collects from healthcare facilities throughout the United States for infection events that occurred in a specified baseline time period. Beginning in CY 2016, CDC will use data collected for infection events that occurred in 2015 as the new standard referent population. To do so, CDC will collect HAI data that healthcare facilities are reporting for events that have or will occur in CY 2015 to use in updating the standard population data for HAI measures. This new CY 2015 standard population data for HAI measures will hereinafter be referred to as “new standard population data.”
While this is not a Hospital IQR Program proposal, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24562), we still invited public input on the CDC’s plans to update the standard population data for HAI measures.

**Comment:** Several commenters supported the plan to use data collected for infection events in 2015 as the new standard referent population, stating that updated population data could help facilitate more accurate comparisons of infection rates.

**Response:** We thank the commenters for their support.

**Comment:** A few commenters supported the planned updates to the standard population data for the NHSN measures, but requested that CMS further assess the use of CY 2015 data for CAUTI, noting that due to changes in measure definitions, CY 2015 CAUTI data may not be reflective of actual infection rates.

**Response:** We appreciate the commenters’ views on the stability of the 2015 data. CDC’s new CAUTI definition was developed by a subject matter expert working group comprised of CDC and non-CDC participants who systematically assessed each definitional component. The end result is a new CAUTI definition that is simplified from previous iterations and allows for less subjectivity while optimizing clinical credibility. An assessment of the impact of the definition change on CAUTI incidence was completed as part of the definition development. In addition, the NHSN application provides a technical infrastructure and built-in controls on data entry that serve as safeguards against the reporting of events that do not meet the new CAUTI definition. For these reasons, the CDC has informed us of its confidence that the CAUTI data
reported in 2015 will be reflective of actual infection rates and appropriate to use for a new standard population.

Comment: A few commenters expressed confusion regarding when CAUTI and CLABSI results would reflect the expanded population reported. In addition, one commenter asked for clarification on when SIR rates will reflect the use of the updated standard population data. That commenter also requested information on when these updates will be reported on Hospital Compare for the Hospital IQR Program. In addition, commenters urged CMS to coordinate with CDC to communicate the changes to the public.

Response: As noted above, data collected for infection events occurring in 2015 will be used as the new standard referent population to determine the predicted number of infections beginning for CY 2016/FY 2018 payment determination for CAUTI and CLABSI results as well as SIR rates. For additional clarifications on public display of quality measures, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203) or the FY 2012 IPPS/LTCH PPS final rule (76 FR 51608), where we explain that we report data on Hospital Compare as soon as is feasible. In addition, we note that CMS continues to coordinate with CDC in regards to communicating with the public.

Comment: One commenter opposed the proposed updates to the standard population of the NHSN measure. Specifically, the commenter expressed concern that the intent of the claims data is to pay bills and not to measure quality. In addition, the
commenter noted that the proposed method of HAI data retrieval may not be the most accurate or reliable.

Response: We believe this method of receiving data from the CDC is accurate, reliable and otherwise appropriate, because NHSN users are trained to identify HAIs and report HAI data to NHSN in accordance with standard surveillance protocols, all of which specify the clinical findings and laboratory results that are to be used when reporting to NHSN. In all instances, these protocols avoid use of claims data to make determinations of whether a clinical event should be reported as an HAI to NHSN.

While this was not a Hospital IQR Program proposal, we appreciated public input on the CDC’s plans to update the standard population data for HAI measures.

5. Expansion and Updating of Quality Measures

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53510 through 53512) for a discussion of the considerations we use to expand and update quality measures under the Hospital IQR Program. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24562), we did not propose any changes to these considerations.

6. Refinements to Existing Measures in the Hospital IQR Program

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24562 through 24566) we proposed refinements to the measure cohorts for: (1) the Hospital 30-day, All-cause, Risk-Standardized Mortality Rate (RSMR) following Pneumonia Hospitalization (NQF #0468) measure; and (2) the Hospital 30-day, All-Cause, Risk-Standardized Readmission Rate following Pneumonia Hospitalization (NQF #0506) measure. The proposed refined measures were included on a publicly available document entitled “List of Measures

Under Consideration for December 1, 2014” in compliance with section 1890A(a)(2) of the Act, and they were reviewed by the MAP as discussed in its MAP Pre-Rulemaking Report. These measure refinements are discussed in greater detail below.

a. Refinement of Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) following Pneumonia Hospitalization (NQF #0468) Measure Cohort

(1) Background

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24562 through 24564), we proposed a refinement to the previously adopted Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization (NQF #0468) measure (hereinafter referred to as the CMS 30-day Pneumonia Mortality Measure), which expands the measure cohort. For the purposes of describing the refinement of this measure, we note that “cohort” is defined as the hospitalizations, or “index admissions,” that are included in the measure and evaluated to ascertain whether the patient subsequently died within 30 days of the index admission. This cohort is the set of hospitalizations that meet all of the inclusion and exclusion criteria, and we proposed an expansion to this set of hospitalizations.

The previously adopted CMS 30-day Pneumonia Mortality Measure (72 FR 47351) includes hospitalizations for patients with a principal discharge diagnosis of pneumonia indicating viral or bacterial pneumonia. For more cohort details on the measure as currently implemented, we refer readers to the measure methodology report


The proposed measure refinement would have expanded the measure cohort to include hospitalizations for patients with a principal discharge diagnosis of aspiration pneumonia and for patients with a principal discharge diagnosis of either sepsis or respiratory failure who also have a secondary diagnosis of pneumonia present on admission.

This refinement to the CMS 30-Day Pneumonia Mortality Measure was proposed for several reasons. First, recent evidence has shown an increase in the use of sepsis and respiratory failure as principal diagnosis codes among patients hospitalized with pneumonia. Pneumonia patients with these principal diagnosis codes are not currently included in the measure cohort, and including them would better capture the complete patient population of a hospital with patients receiving clinical management and treatment for pneumonia.

Second, because patients with a principal diagnosis of sepsis and respiratory failure are not included in the current CMS 30-Day Pneumonia Mortality Measure specifications, efforts to evaluate changes over time in pneumonia outcomes could be biased as coding practices change.

Finally, another published study\textsuperscript{137} has also demonstrated wide variation in the use of sepsis and respiratory failure codes as principal discharge diagnoses for pneumonia patients across hospitals, potentially biasing efforts to compare hospital performance on 30-day mortality. These published studies and CMS analyses show that hospitals that use sepsis and respiratory failure codes for the principal diagnosis frequently have better performance on the CMS 30-Day Pneumonia Mortality Measure. This coding practice improves performance on the measure because patients with greatest severity of illness (for example, those with sepsis) are systematically excluded from the measure under current measure specifications, leaving only patients with less severity of illness in the cohort.

In response to these emerging data, we examined coding patterns across hospitals caring for Medicare patients and sought to forecast the impact of enhancing or broadening the measure cohort to include the complete patient population, at each hospital, who are receiving clinical management and treatment for pneumonia. Our findings were consistent with a published study.\textsuperscript{138} That is, our results suggested that there is: (1) an increasing use of respiratory failure and sepsis as principal discharge diagnoses for pneumonia patients; and (2) wide variation across hospitals in the use of these codes.


In addition to assessing the use of the principal diagnosis codes of sepsis and respiratory failure, we also analyzed coding patterns and the impact of expanding the pneumonia measure to include patients with the principal diagnosis of aspiration pneumonia. We noted after our analyses that aspiration pneumonia: (1) is a common reason for pneumonia hospitalization, particularly among the elderly; (2) is currently not included in the CMS hospital outcome measure specifications for pneumonia patients; and (3) appears to be similarly subject to variation in diagnosis, documentation, and coding. These findings suggest that a measure with an enhanced or broader cohort for the current CMS 30-Day Pneumonia Mortality Measure will ensure that the measure includes more complete and comparable populations across hospitals. Use of comparable populations would reduce measurement bias resulting from different coding practices across hospitals.

The proposed 30-Day Pneumonia Mortality Measure with this expanded measure cohort was included on a publicly available document entitled “List of Measures Under Consideration for December 1, 2014” with identification number E0468 and has been reviewed by the MAP. The revised measure was conditionally supported pending NQF endorsement of the measure update, as detailed in the “Spreadsheet of MAP 2015 Final Recommendations” available at: http://www.qualityforum.org/map/. The refined pneumonia mortality measure will be submitted to NQF for re-endorsement when the appropriate measure endorsement project has a call for measures this year. We will work to minimize potential confusion when publicly reporting the updated measure.
(2) Overview of Measure Cohort Change

The proposed measure refinement expands the cohort to include hospitalizations for patients with a principal discharge diagnosis of aspiration pneumonia and for patients with a principal discharge diagnosis of sepsis or respiratory failure who also have a secondary diagnosis of pneumonia that is coded as present on admission. The data sources, exclusion criteria, assessment of the outcome of mortality, and 3 year data evaluation period all remained unchanged.

(3) Risk Adjustment

The statistical modeling approach as well as the measure calculation remained unchanged from the previously adopted measure. The risk adjustment approach also remains unchanged; however, we included additional risk variables to account for the discharge diagnoses added as part of the expanded cohort. For the full measure specifications of the proposed change to the measure, we referred readers to the AMI, HF, PN, COPD, and Stroke Readmission Update zip file on our Web site at:


(4) Effect of Refinement of Hospital 30-day, All-Cause, Risk-Standardized Mortality Rate (RSMR) following Pneumonia Hospitalization Measure Cohort

Using administrative claims data for FY 2015 (that is, discharges between July 2010 - June 2013), we analyzed and simulated the effect of the proposed cohort refinements on the CMS 30-day Pneumonia Mortality Measure as if these changes had been applied for FY 2015. We note that these statistics are for illustrative purposes only,
and we did not propose to revise the measure calculations for the FY 2015 payment determination.

Expanding the measure cohort to include a broader population of patients as proposed would have added a large number of patients, as well as additional hospitals (which would now meet the minimum threshold of 25 eligible cases), to the CMS 30-day Pneumonia Mortality Measure. In the FY 2010 IPPS/LTCH PPS final rule (74 FR 43881), we established that if a hospital has fewer than 25 eligible cases combined over a measure’s reporting period, we would replace the hospital’s data with a footnote indicating that the number of cases is too small to reliably determine how well the hospital is performing. These cases are still used to calculate the measure; however, for hospitals with fewer than 25 eligible cases, the hospital’s mortality rates and interval estimates are not publicly reported for the measure. For more information about this minimum case threshold for public reporting, we refer readers to section VIII.A.13. of the preamble of this final rule. The increase in the size of the measure cohort proposed in the FY 2016 IPPS/LTCH PPS proposed rule would have changed results for many hospitals and would change the number of hospitals that have greater than 25 cases.

The previously adopted pneumonia mortality measure cohort includes 976,590 patients and 4,418 hospitals for the FY 2015 payment determination. We noted the following effects for the CMS 30-Day Pneumonia Mortality Measure if the proposed expanded cohort had been applied for FY 2015: (1) the expansion of the cohort would include an additional 686,605 patients (creating a total measure cohort size of 1,663,195 patients); (2) an additional 86 hospitals would meet the minimum 25 patient cases
volume threshold over the 3-year measure period and would be publicly reported for the measure; (3) 41 percent of the refined measure cohort would consist of patients with a principal discharge diagnosis of aspiration pneumonia and patients with a principal discharge diagnosis of sepsis or respiratory failure who also have a secondary diagnosis of pneumonia present on admission; and (4) there would be an increase in the number of hospitals considered outliers and a shift in some hospitals’ outlier status classification, for example from “better than the national rate” to “no different than the national rate” or from “worse than the national rate” to “no different than the national rate.”

A detailed description of the refinements to the CMS 30-Day Pneumonia Mortality Measure and the effects of the change are available in the AMI, HF, PN, COPD, and Stroke Readmission Update zip file on our Web site at:

http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. We note that this file contains information for both Mortality and Readmission.

We invited public comment on our proposal to refine the previously adopted Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization (NQF #0468) measure, expanding the measure cohort.

Because comments for this proposal also overlap with those for the next section (VIII.A.6.b. of the preamble of this final rule (Refinement of Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization (NQF #0506) Measure Cohort)), we address comments related to both proposals after the next section.
b. Refinement of Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization (NQF #0506) Measure Cohort

(1) Background

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24564 through 24566), we proposed a refinement of the previously adopted measure, Hospital 30-day all-cause, risk-standardized readmission rate following pneumonia hospitalization (NQF #0506) (hereinafter referred to as the CMS 30-Day Pneumonia Readmission Measure) which expands the measure cohort. For the purposes of describing the refinement of this measure, we note that “cohort” is defined as the hospitalizations, or “index admissions,” that are included in the measure and evaluated to ascertain whether the patient was subsequently readmitted to the hospital within 30 days of the index admission. This cohort is the set of hospitalizations that meets all of the inclusion and exclusion criteria and we proposed an expansion to this set of hospitalizations.

The previously adopted CMS 30-Day Pneumonia Readmission Measure, as specified in the FY 2009 IPPS PPS proposed rule (73 FR 23648) and adopted in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68780 through 68781), includes hospitalizations for patients with a principal discharge diagnosis of pneumonia indicating viral or bacterial pneumonia. For measure cohort details of the currently implemented measure, we refer readers to the measure methodology report and measure risk adjustment statistical model in the AMI, HF, PN, COPD, and Stroke Readmissions Update zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.
This proposed measure refinement would have expanded the measure cohort to include hospitalizations for patients with a principal discharge diagnosis of aspiration pneumonia and for patients with a principal discharge diagnosis of either sepsis or respiratory failure who also have a secondary diagnosis of pneumonia present on admission. The determination to refine the measure cohort was based on our evaluation of both the frequency and variation in utilization of these diagnosis codes, as such coding practices have been described in recently published studies.

This refinement to the CMS 30-Day Pneumonia Readmission Measure was being proposed in response to recent evidence showing increasing use of the principal diagnosis codes of sepsis and respiratory failure among patients hospitalized with pneumonia. Including such patients could better represent the complete population of a hospital’s patients who are receiving clinical management and treatment for pneumonia. In addition, because patients with a principal diagnosis of sepsis and respiratory failure are not included in the current CMS 30-Day Pneumonia Readmission Measure specifications, efforts to evaluate changes over time in pneumonia outcomes could be biased as coding practices change.

Wide variation exists in the use of sepsis and respiratory failure codes across hospitals, potentially biasing efforts to compare hospital performance on 30-day readmission rates.\(^{139}\) While the referenced study\(^{140}\) evaluated the effect of coding


practices on mortality measure performance, the rationale is applicable to readmission measure performance as well. The increased use of sepsis and respiratory failure diagnosis codes improves performance because the patients with greatest severity of illness (for example, those with sepsis or respiratory failure) are currently systematically excluded from the measure, leaving only patients with lesser severity of illness in the measure cohort.

In response to this emerging data, we examined coding patterns across hospitals caring for Medicare patients and sought to forecast the impact of broadening the measure cohort to include the complete population of patients at each hospital who are receiving clinical management and treatment for pneumonia. Our findings were consistent with a published study\textsuperscript{141} for mortality; that is, our results suggested that there is an increasing use of respiratory failure and sepsis as principal discharge diagnoses for pneumonia patients, as well as showed wide variation across hospitals in the use of these codes. In addition to assessing the use of the principal diagnosis codes of sepsis and respiratory failure, we also analyzed coding patterns and the impact of expanding the pneumonia measure to include patients with the principal diagnosis of aspiration pneumonia. We noted after our analyses that aspiration pneumonia: (1) is a common reason for pneumonia hospitalization, particularly among the elderly; (2) is currently not included in the CMS hospital outcome measure specifications for pneumonia patients; and (3) appears to be similarly subject to variation in diagnosis, documentation, and coding. These findings suggest that expanding the measure cohort for the current CMS 30-Day

Pneumonia Readmission Measure will ensure the measure includes more complete and comparable populations across hospitals. Use of comparable populations would reduce measurement bias resulting from different coding practices seen across hospitals. We believe that measure results derived from refinement of the measure cohort in the manner we proposed, which will include additional pneumonia patients that are not being included under the current measure specifications, will improve the fidelity of the measure’s assessment of quality and outcome for pneumonia.

The proposed refined measure was included on a publicly available document entitled “List of Measures Under Consideration for December 1, 2014” with identification number E0506, has been reviewed by the MAP, and was conditionally supported pending NQF review of the measure update. In particular, MAP members noted that the measure should be considered for sociodemographic status (SDS) adjustment in the upcoming NQF trial period, reviewed for the empirical and conceptual relationship between SDS factors and risk-standardized readmission rates, and endorsed with appropriate consideration of SDS factors as determined by NQF standing committees. We refer readers to the “Spreadsheet of MAP 2015 Final Recommendations” available at: http://www.qualityforum.org/map/ for more information. When the appropriate measure endorsement project has a call for measures in 2015, this measure will be submitted to the NQF for reendorsement with special consideration of the potential impact of SDS adjustment on the measure.
(2) Overview of Measure Cohort Change

The proposed measure refinement would have expanded the measure cohort to include hospitalizations for patients with a principal discharge diagnosis of aspiration pneumonia and for patients with a principal discharge diagnosis of sepsis or respiratory failure who also have a secondary diagnosis of pneumonia that is coded as present on admission. The data sources, exclusion criteria, assessment of the outcome of readmission, and previous 3 years data evaluation period remained unchanged.

(3) Risk Adjustment

The statistical modeling approach as well as the measure calculation remained unchanged from the previously adopted measure. The risk adjustment approach also remains unchanged; however, we included additional risk variables to account for the discharge diagnoses added as part of the expanded cohort. For the full measure specifications of the proposed changes to the measure, we referred readers to the AMI, HF, PN, COPD, and Stroke Readmissions Update zip file on our Web site at:


(4) Effect of Refinement of Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization Measure Cohort

Using administrative claims data for FY 2015 (that is, discharges between July 2010 - June 2013); we analyzed and simulated the effect of the proposed measure cohort refinements on the CMS 30-Day Pneumonia Readmission Measure as if these changes had been applied for FY 2015. We note that these statistics are for illustrative
purposes only, and we did not propose to revise the measure calculations for the FY 2015 payment determination. We anticipate that this measure will first be publicly reported with the proposed cohort change in CY 2016.

Based on our analysis, we anticipate that expanding the measure cohort to include a broader population of patients as proposed would have added a large number of patients, as well as additional hospitals (which would now meet the minimum threshold of 25 eligible cases), to the CMS 30-Day Pneumonia Readmission Measure. In the FY 2010 IPPS/LTCH PPS final rule (74 FR 43881), CMS established that if a hospital has fewer than 25 eligible cases combined over a measure’s reporting period, we would replace the hospital’s data with a footnote indicating that the number of cases is too small to reliably tell how well the hospital is performing. These cases are still used to calculate the measure; however, for hospitals with fewer than 25 eligible cases, the hospital’s readmission rates and interval estimates are not publicly reported for the measure. For more information about this minimum case threshold for public reporting, we refer readers to section VIII.A.13 of the preamble of this final rule. The increase in the size of the measure cohort proposed in FY 2016 IPPS/LTCH PPS proposed rule for this measure cohort would have changed results for many hospitals and would change the number of hospitals that have greater than 25 cases.

The previously adopted pneumonia readmission measure cohort includes 1,094,959 patients and 4,451 hospitals for FY 2015 payment determination. We noted the following effects for the CMS 30-Day Pneumonia Readmission Measure if the proposed expanded cohort had been applied for FY 2015: (1) the expansion of the CMS
30-Day Pneumonia Readmission Measure cohort would include an additional 670,491 patients (creating a total measure cohort of 1,765,450 patients); (2) there would be an additional 67 hospitals that meet the minimum 25 patient cases volume threshold over the 3-year applicable period and would be publicly reported for the measure; (3) patients with a principal discharge diagnosis of aspiration pneumonia and patients with a principal discharge diagnosis of sepsis or respiratory failure who also have a secondary diagnosis of pneumonia present on admission would represent 38 percent of the total expanded measure cohort; and (4) there would be an increase in the number of hospitals considered outliers and a shift in some hospitals’ outlier status classification, for example from “better than the national rate” to “no different than the national rate” or from “worse than the national rate” to “no different than the national rate.”

A detailed description of the refinements to the CMS 30-Day Pneumonia Readmission Measure and the effects of the change are available in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on our Web site at:


We invited public comment on our proposals to refine the previously adopted Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization (NQF #0506) measure, and the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) following Pneumonia Hospitalization (NQF #0468) measure which expands the measure cohort.
Comment: Several commenters supported CMS' proposal to expand the cohort for identifying Pneumonia patients for the two PN measures, and noted that the expanded cohort would address the concern of coding variation. One commenter encouraged CMS to expand this cohort to also apply to the Payment Episode for PN. Another commenter noted the refinement would better reflect the population of patients who are managing and being treated for pneumonia. One commenter supported the proposed refinement to the Hospital 30-day, All-Cause, Risk-Standardization Readmission Rate following Pneumonia Hospitalization (NQF #0506) measure, indicating that the expanded cohort would address the concern of coding variation. Another commenter supported the proposed cohort expansions for the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Pneumonia Hospitalization and Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate Following Pneumonia Hospitalization measures.

Response: We thank the commenters for their support and are considering updating other measures that contain the same pneumonia cohort, such as the Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode of Care for Pneumonia measure, which uses the same cohort as the currently reported Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Pneumonia Hospitalization measure.

Comment: One commenter commended CMS’ proposal and associated rationale for incorporating the refinements to the patient populations for the pneumonia mortality and readmission measures. The commenter agreed with CMS that, without modification, the current specifications may result in significant variation in the number of pneumonia
cases captured due to differences in hospital coding and that, by refining the population for these measures, CMS will ensure better collection of more complete and comparable data across hospitals.

Response: We thank the commenter for its support.

Comment: Many commenters expressed concern that the proposed Refinements of the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Pneumonia Hospitalization and the Hospital 30-Day, All-Cause, Risk-Standardized Readmissions Rate Following Pneumonia Hospitalization measure cohorts, stating that the proposed expansions of the measures were not revisions, but a wholesale expansion which could have unintended consequences. The commenters also noted concern that these changes could inappropriately expand the measure to a population of patients with greater severity of illness and higher costs. One commenter acknowledged that although some risk-adjustment processes were proposed, the adequacy of the revised risk adjustment for handling the expanded population is unknown. Finally, some commenters noted concern that the measures do not appropriately account for variation in patient acuity and that hospitals treating the sickest patients will appear to perform poorly. One commenter also suggested that the expansion could artificially increase readmission rates unless the measures are risk-adjusted.

Response: We appreciate the commenters’ concerns about the extent of the expansion of these measures and the inclusion of patients with greater illness severity.

In the proposed rule, we described an expanded measure cohort that included patients with: (1) a principal discharge diagnosis of bacterial/viral pneumonia; (2) a
principal discharge diagnosis of aspiration pneumonia; (3) a principal discharge diagnosis of sepsis if pneumonia was POA; (4) a principal discharge diagnosis of severe sepsis (including septic shock) if pneumonia was POA; and (5) principal discharge diagnosis of respiratory failure if pneumonia was POA. We also proposed including the presence of sepsis or respiratory failure in the index admission as covariates, or risk-adjusters, in the model.

However, analyses conducted after publication of the proposed rule as part of the measure reevaluation and respecification process revealed challenges to risk adjustment with respect to patients with severe sepsis and respiratory failure, and suggested that this proposed cohort expansion could exacerbate the bias in the existing measure that it was intended to mitigate. Specifically, hospital coding frequency was found to be even more strongly, and inversely, associated with performance; hospitals with the greatest proportion of patients receiving a principal diagnosis of sepsis or respiratory failure had the lowest risk-adjusted mortality and were more likely to be ‘better-performing’ outliers. This finding was concerning, because clinically, we do not expect differences in coding practices to be related to performance on the measure. Our aim was to expand the cohort to adequately capture the wide range of pneumonia patients across hospitals, regardless of coding patterns, but that would adequately account for different degrees of illness among the hospitals’ population.

The reevaluation and respecification of the proposed expansions resulted in measure cohorts that are a broader clinical representation than the currently reported measures cohorts and that account for the wider spectrum of clinical severity of
pneumonia among Medicare beneficiaries receiving acute care at IPPS U.S. hospitals. During this subsequent analysis, the measures were then modified so that the cohorts were expanded to only include: (1) patients with a principal discharge diagnosis of pneumonia (current reported cohort), (2) patients with a principal discharge diagnosis of aspiration pneumonia, and (3) patients with a principal discharge diagnosis of sepsis (excluding severe sepsis) with a secondary diagnosis of pneumonia that was POA. Patients with: (4) a principal discharge diagnosis of severe sepsis (including septic shock) if pneumonia was POA; and (5) principal discharge diagnosis of respiratory failure if pneumonia was POA were not included. The finalized measures, with the modified expanded cohort, also do not include additional risk variables for the presence of sepsis or respiratory failure in index admission as part of the measures’ risk-adjustment since the patients with respiratory failure or severe sepsis will not be included in the finalized measures. This respecification was determined to be statistically robust, such that in the finalized measures, with the modified expanded cohort, risk-standardization adequately accounted for case-mix differences across hospitals, without being confounded by hospital coding patterns. Furthermore, this respecification is also consistent with clinical patterns of care, as the very sickest patients (those with principal discharge diagnosis of severe sepsis or respiratory failure) often require care in an intensive care unit (ICU) and other specialized interventions (such as ventilator support) that is clinically distinct from the care provided to patients with less severe forms of pneumonia.
These analyses led to our decision to not include the sickest patients in the refinements of the Hospital 30-day, All-Cause, Risk Standardized Mortality Rate (RSMR) following Pneumonia Hospitalization (NQF #0468) measure and the Hospital 30-day, All-Cause, Risk Standardized Readmission Rate following Pneumonia Hospitalization (NQF #0506) measure. Upon this further analysis and in response to public comment, we are modifying our proposal and finalizing a modified version of the expanded pneumonia cohort. Instead of including all five proposed diagnosis categories as described above, we are finalizing only three: (1) patients with a principal discharge diagnosis of pneumonia (the current reported cohort); (2) patients with a principal discharge diagnosis of aspiration pneumonia; and (3) patients with a principal discharge diagnosis of sepsis (excluding severe sepsis) with a secondary diagnosis of pneumonia POA. We are not including patients with the most severe illness, which are represented in the two patient groups we are not finalizing: (4) patients with a principal discharge diagnosis of respiratory failure; and (5) patients with a principal discharge diagnosis of severe sepsis (including septic shock). As a result, we are also not finalizing our proposal to risk adjust with respect to these two conditions being present during the index admission.

We find that this modified cohort expansion produces a measure that does not favor or disadvantage hospitals on the basis of their coding practices. Although the modified expansion of the cohort for these measures will increase the number of included patients and change the national readmission and mortality rates, we do not believe this constitutes a new measure; the intent of the measure has not changed since initial
development and NQF endorsement. The modified measures will not expand the population by as much or change the national rate as much as noted in the proposed rule. The modified mortality measure cohort will be approximately 18 percent smaller than what was proposed and the modified readmission measure cohort will be approximately 15 percent smaller than what was proposed.

We believe the modified versions of the measure refinements being finalized effectively broadens the cohort of patients included to be more clinically comprehensive than that of the current reported measures (bringing in sepsis and aspiration pneumonia patients), but avoids including patients that are most severely ill on arrival (those with severe sepsis and respiratory failure). Those patients’ increased risk was challenging to appropriately account for across hospitals. By limiting measure expansion without including risk-adjustment for these alternate principal diagnoses (that is, severe sepsis and respiratory failure), we brought in a large portion of patients currently excluded from the measures, but mitigated the biases introduced by hospital coding patterns.

Based on our additional evaluation, we confirmed that after removing the risk variables for sepsis and respiratory failure during the index admission from the previously proposed approach, risk-adjustment was effective for the modified refinements to the measures, as hospital coding frequency was no longer associated with performance on either the mortality or readmission measures. As was previously proposed, the risk adjustment factors used in the current publicly reported versions of the mortality and readmission measures\textsuperscript{142,143} were retained, with the addition of 5 new

\textsuperscript{142} For more cohort details on the measure as currently implemented, we refer readers to the measure methodology report and measure risk adjustment statistical model in the AMI, HF, PN, COPD, and Stroke
risk-adjustment variables (Septicemia/sepsis (CC2), Disorders of fluid/electrolyte/acid-base (CC23), Delirium and encephalopathy (CC48), Respiratory dependence/tracheostomy (CC77), Decubitus ulcer of skin (CC148)) and two modified risk-adjustment variables (addition of Pleural effusion/pneumothorax (CC114) and respiratory arrest (CC78) to existing risk-adjustment variables) for the mortality measure and 1 new risk-adjustment variable (respiratory dependence/tracheostomy (CC77)) for the readmission measure. No additional risk adjustment variables were added for the patients included in the modified expanded cohort (that is, aspiration pneumonia and sepsis patients). The previously proposed risk adjustment approach (now excluding variables for sepsis, and respiratory failure present during the index admission) adequately accounts for the varying severity and comorbidities of patients across the finalized, modified cohort; therefore, hospitals will not be unfairly penalized for treating sicker patients. Specifically, hospital performance among those with higher rates of patients with sepsis or aspiration pneumonia is similar to those with fewer such patients, suggesting that the risk-adjustment methodology adequately accounts for the differences in risk among the subgroups of patients. For details of the modified refinements of the measures we are finalizing, including risk-adjustment and impact on hospitals, we refer readers to the measure methodology report and measure risk adjustment statistical model in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on our Web site at:

Comment: Many commenters opposed the expansion of the patient cohorts for the Refinement of PN Mortality Cohort: 30-Day, All-Cause, Risk-Standardized Mortality Rate and the Refinement of PN Readmission Cohort: 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) measures until the proposed changes have been reviewed by the National Quality Forum. One commenter stated that the preliminary information provided in the proposed rule and to the MAP in December was not sufficient for evaluation, and that additional information regarding the measures’ reliability, validity and appropriateness must be fully considered. Specifically, the commenter was not convinced that CMS has provided enough evidence to support such a significant expansion of these measures at this time, with the commenter’s own analysis indicating that cohort size could increase 67 percent. Several commenters also expressed concern that the conditions proposed by the MAP were not addressed with regard to NQF endorsement.

Response: As noted in both measure refinement discussions above, the MAP conditionally supported these refined measures during the 2014 MAP Hospital Workgroup Meeting and conditionally supported them pending NQF review of the updates. We do not agree that the information presented to the MAP was insufficient, because while the MAP provides a recommendation on whether measures are appropriate for a program, it does not provide an in-depth review of evidence and testing. The NQF
review, on the other hand, provides stakeholders an opportunity for in-depth review of such aspects.

In addition, we believe the finalized measures’ (with the modified expanded cohort) reliability, validity and appropriateness are sufficient. CMS’ reliability testing demonstrated moderate reliability that is comparable to other CMS claims-based outcome measures. The finalized measures, with the modified expanded cohort, have both clinical and face validity. The inclusion of additional patient groups is based on research findings and an aim to maintain clinically comparable cohorts across hospitals. The validity of the measures is further based on prior findings demonstrating the adequacy of claims-based risk-adjustment outcome measures. Furthermore, the finalized measures’ validity is based on the demonstration that they mitigate biases introduced by hospital coding patterns. For more details on the measures, including predictive ability, reliability, and validity, we refer readers to the measure methodology reports in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on our Web site at:
http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. This data was presented to the MAP and will also be included in the NQF applications.

When the appropriate measure endorsement project has a call for measures in 2015, the finalized measures, with the modified expanded cohorts, will be submitted to the NQF for reendorsement. The original 30-day, All-Cause, Risk-Standardized Readmission Rate following Pneumonia Hospitalization and 30-day, All-Cause, Risk-Standardized Mortality Rate following Pneumonia Hospitalization measures were
previously NQF-endorsed, and we do not believe the intent of the measures have changed.

**Comment:** Some commenters did not support the inclusion of aspiration pneumonia in the cohort for the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization (NQF #0468) and the Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization (NQF #0506) measures. One commenter noted that these diagnoses have different causes and associated risks and that patients with these diagnoses may have higher acuity, higher mortality and readmission rates, and more comorbidities than patients with community acquired pneumonia. Another commenter noted concern that the majority of patients with aspiration pneumonia are medically frail patients with comorbidities that predispose them to recurrent aspiration events and another was concerned that stroke patients can be at higher risk for re-aspiration and therefore pneumonia readmission. This commenter further suggested that the measure could inappropriately become a catch all for neuro-muscular diseases, CVA, head injury, advanced dementia, among other diagnoses, which would not measure true pneumonia readmissions.

**Response:** The purpose of expanding the cohort of the current pneumonia readmission measure is to include a broader spectrum of pneumonia patients and respond to changes in coding practices that were potentially biasing estimates of the performance of hospitals. We believe the modified expanded cohorts for the finalized measures effectively broaden the patients included in the measure to be more clinically
comprehensive (bringing in sepsis and aspiration pneumonia patients) but avoids including those patients that are most severely ill on arrival (those with severe sepsis and respiratory failure).

We appreciate the commenters concerns that community acquired pneumonia and aspiration pneumonia have different causes and associated risks (for example, recurrent aspiration due to other comorbidities). While the pathological causes of aspiration pneumonia are slightly different from the causes of community acquired pneumonia, in routine clinical practice, evidence shows it can be very challenging for physicians to differentiate aspiration syndromes including pneumonitis and pneumonia, from other types of pneumonia included in the measure. This is reflected in the tremendous variation across hospitals in the use of aspiration pneumonia diagnosis codes. This variation suggests that hospitals are not consistently distinguishing between these conditions as distinct subtypes regardless of patients’ comorbid conditions.

Moreover, the treatment of patients hospitalized for pneumonia, aspiration pneumonia, or sepsis due to pneumonia is very similar and involves treatment with antibiotics, IV fluids, and symptom management. In addition, although some patients with aspiration pneumonia, such as medically frail patients or those who have suffered a stroke as noted by the commenter, have a higher predicted mortality or readmission risk, many of the associated comorbidities, are captured in the measures’ risk-adjustment methodology. For example, the risk models include clinical history of stroke, as well as conditions associated with frailty, such as neuromuscular disease, and dementia. Therefore, we do not believe that the measure would inappropriately become a catch-all
for neuro-muscular diseases, cerebrovascular accident (CVA), head injury, advanced dementia, among other diagnoses, which would not measure true pneumonia readmissions. Our analyses, as described above and in the measure methodology reports (available in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html), show that hospital performance among hospitals with higher rates of patients with aspiration pneumonia is similar to those with fewer such patients, confirming that the risk-adjustment methodology adequately accounts for the differences in risk among the subgroups of patients.

Comment: One commenter suggested that CMS should consider stratifying the measures, and evaluate the impact of the proposed change on hospital performance, as it is currently unknown.

Response: We appreciate the suggestion to consider stratification of the measure. Stratification can be used as a means to account for differences among subgroups of patients within a measure. It can be used to report outcomes separately for different groups, unadjusted by a risk model. For example, a measure may specify stratification of results within a major clinical category (for example, diabetes) by severity or other clinical differences, as well as by race or age category. However, we did not find that stratification was required in the modified expanded cohort that is being finalized for these measures because risk adjustment adequately accounts for the varying severity and
comorbidities of patients across the finalized cohort. Therefore, hospitals will not be unfairly penalized for treating sicker patients.

Specifically, our analyses found that hospital performance among hospitals with higher rates of patients with sepsis or aspiration pneumonia hospital performance is similar to those with fewer such patients, suggesting that the risk adjustment methodology adequately accounts for the differences in risk among the subgroups of patients; further information can be found in the subsequent link provided. Details regarding the number of hospitals that would change performance categories and how their performance is related to their coding practices is detailed in the measure specifications report for the measure as finalized are provided in the measure methodology report and measure risk adjustment statistical model in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

**Comment:** Some commenters advised CMS to articulate its public reporting approach for both the old and new versions of the measures so that the observed changes are not perceived as changes in care by consumers. In addition, one commenter noted that previous pneumonia mortality and readmission data and benchmarks did not include patients with this expanded set of diagnoses, so the change may erroneously show worsening hospital performance on these measures. One commenter recommended that CMS develop a communication strategy regarding the changes to the measures and the impact of those changes on public reporting.
Response: We note that consumers typically view the main Hospital Compare Web site: http://www.medicare.gov/hospitalcompare/search.html, which does not include information about how hospitals performed in the past, only how they are currently performing as compared to the national rate. Archived hospital performance data is instead available at: https://data.medicare.gov/data/archives/hospital-compare. While hospitals may shift performance categories (for example, from worse than to better than the national rate) between the current publically reported and finalized measures (with modified expanded cohorts), we do not believe measure rates over time will be abundantly evident to consumers. Nonetheless, we will ensure that adequate information be available to the public regarding which version of the measures are displayed on Hospital Compare to reduce any potential confusion for consumers.

Comment: Some commenters recommended that CMS conduct a study to validate the expanded measures and one recommended a review by outside experts.

Response: We will submit the finalized measures with the modified expanded cohort to the NQF for review when the appropriate project is called. The NQF will assess the modified, refined measures for validity. As discussed above, we determined the finalized readmission and mortality measures with the modified expanded cohorts to have both clinical and face validity. Prior studies have demonstrated that using comorbidity information from administrative claims is a valid approach to risk adjustment and adequately assesses the difference in case mix among hospitals. Furthermore, the finalized measures have greater validity than the current publically reported measures, because they mitigate biases introduced by hospital coding patterns.
A detailed description of the refinements to the CMS 30-Day Pneumonia Readmission and Mortality Measures and the effects of the changes are available in the AMI, HF, PN, COPD, and Stroke Readmission Updates zip file on our Web site at:

http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html

Comment: One commenter noted that hospitals have not had the opportunity to develop and evaluate interventions for the proposed expanded cohort. The commenter suggested that hospitals be given an entire performance period of cohort expansion knowledge, and requested that CMS delay the proposed expansion until FY 2021.

Response: These measure refinements focus on coordination-of-care and care-transitions interventions to reduce mortality and readmissions. These practices, such as ensuring appropriate follow-up post-discharge and medication reconciliation, should already be in place for patients in hospitals and would not differ greatly for the modified expanded cohort of patients included in the measure refinements being finalized. Therefore, we do not agree with delaying the implementation of these measures, especially because the publicly reported versions of the measures are subject to bias resulting from differences in coding patterns among hospitals, which the refined measures address. We believe that this refinement provides a less biased and more comprehensive look at pneumonia patients.

Comment: One commenter agreed with the addition of respiratory failure and sepsis with a secondary diagnosis of pneumonia, as their inclusion will provide a better account of pneumonia readmissions.
Response: As discussed above, after extensive evaluation and analysis of the results of the proposed refinement of these measures, we are finalizing, with modifications, the refinements to both measures without the inclusion of patients with a principal diagnosis of respiratory failure or severe sepsis in the expanded cohort. We refer readers to our responses above.

Comment: One commenter expressed concern that one of the cited studies noted their risk adjustment approach was insufficient and could penalize hospitals treating sicker patients, and that the CMS approach was similar.

Response: We refer readers to our earlier responses to comments for a more detailed discussion on the rationale for finalizing the modified expanded cohort and not the proposed expanded cohort. We believe the modified version of the measure refinements being finalized effectively broadens the cohort of patients included in the measures to be more clinically comprehensive (bringing in sepsis and aspiration pneumonia patients), but avoids including those patients in the proposed expanded cohort that are most severely ill on arrival (those with severe sepsis and respiratory failure). After removal of the most severely ill, the modified risk adjustment model being finalized adequately accounts for the varying severity and comorbidities of patients across the modified cohort; therefore, we believe that hospitals will not be unfairly penalized for treating sicker patients. As described in more detail above, our analyses demonstrated that hospital performance among hospitals with higher rates of patients with sepsis or aspiration pneumonia is similar to those with fewer such patients, suggesting that the risk
adjustment methodology adequately accounts for the differences in risk among the subgroups of patients.

After consideration of the public comments we received and extensive evaluation and analysis of the results of the refined measures, we are finalizing a modified version of the measure refinements (expanded pneumonia cohort) proposed for the FY 2017 payment determination and subsequent years for both the Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization (NQF #0506) measure and the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) following Pneumonia Hospitalization (NQF #0468) measure. Instead of including all five proposed diagnosis categories, we are finalizing only three: (1) patients with a principal discharge diagnosis of pneumonia (the current reported cohort); (2) patients with a principal discharge diagnosis of aspiration pneumonia; and (3) patients with a principal discharge diagnosis of sepsis (excluding severe sepsis) with a secondary diagnosis of pneumonia coded as present on admission (POA). We are not including patients with the most severe illness, which are represented in the 2 diagnosis categories we are not finalizing: (1) patients with a principal discharge diagnosis of respiratory failure with a secondary diagnosis of pneumonia present on admission; and (2) patients with a principal discharge diagnosis of sepsis (including septic shock) with a secondary diagnosis of pneumonia present on admission. As a result, we are also not finalizing our proposal to risk adjust with respect to these two conditions.
7. Additional Hospital IQR Program Measures for the FY 2018 and FY 2019 Payment Determinations and Subsequent Years

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24566 through 24581), we proposed to add eight new measures to the Hospital IQR Program for the FY 2018 payment determination and subsequent years. We proposed to adopt seven new claims-based measures and one new structural measure: (1) Hospital Survey on Patient Safety Culture (structural); (2) Kidney/UTI Clinical Episode-Based Payment measure (claims-based); (3) Cellulitis Clinical Episode-Based Payment measure (claims-based); (4) Gastrointestinal Hemorrhage Clinical Episode-Based Payment measure (claims-based); (5) Lumbar Spine Fusion/Re-Fusion Clinical Episode-Based Payment measure (claims-based); (6) Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for Primary Elective THA/TKA (claims-based); (7) Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction (claims-based); and (8) Excess Days in Acute Care after Hospitalization for Heart Failure (claims-based).

The proposed measures were included on a publicly available document entitled “List of Measures Under Consideration for December 1, 2014”\textsuperscript{144} in compliance with section 1890A(a)(2) of the Act, and they were reviewed by the MAP as discussed in its MAP Pre-Rulemaking Report and Spreadsheet of MAP 2015 Final Recommendations.\textsuperscript{145}

\textsuperscript{144} Measure Applications Partnership: List of Measures Under Consideration (MUC) for December 1, 2014. Available at: \url{http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=78318}.

For purposes of the Hospital IQR Program, section 1886(b)(3)(B)(IX)(aa) of the Act requires that any measure specified by the Secretary must have been endorsed by the entity with a contract under section 1890(a) of the Act. The NQF currently holds this contract. However, section 1886(b)(3)(B)(IX)(bb) of the Act provides an exception that, in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary.

We invited public comment on each of the proposed measures listed above. We address general comments received on all proposed measures here and discuss more specific comments in subsequent sections below.

Comment: One commenter expressed concern regarding the continued use of claims data for some measure reporting, noting that there is variation in coding practices across hospitals, and that unlike chart-abstracted data, internal validation practices may not occur. The commenter recommended that CMS regularly perform audits of hospital coding practices and require hospitals to annually attest that they are following specific coding practices.

Response: We thank the commenter for their suggestion and note that we rely on accurate claims data for both billing and quality reporting purposes. We believe that claims-based measures are valuable forms of data that do not add to hospital burden. In addition, we disagree with the commenter’s suggestion that we should require hospitals
to attest that they are following specific coding practices, as we believe this would pose an unnecessary burden on hospitals. We continue to rely on the Medicare Claims Review Programs,\(^\text{146}\) (a collection of initiatives enacted to prevent or identify and recover improper payments before CMS processes a claim, and to identify and recover improper payments after processing a claim) to conduct audits of hospital coding practices, if appropriate.

**Comment:** Many commenters opposed the proposal to include eight new measures in the Hospital IQR Program; indicating that the lack of NQF endorsement poses questions about their reliability, validity, and feasibility. The commenters also noted that the measures do not address any national priority area or goal for improving care, or concerns over institutional behavior.

**Response:** We acknowledge the credibility of NQF endorsement, however, section 1886(b)(3)(B)(IX)(bb) of the Act provides an exception that, in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We also reviewed the NQF-endorsed measures and were unable to identify any other NQF-endorsed measures that addressed excess days in acute care or the clinical episode-based payment conditions. Regardless, as discussed previously and below, all measures being finalized in this rule will be

submitted for NQF endorsement when the next call for measures opens except the Hospital Survey on Patient Safety Culture measure. This measure may be a time-limited measure that will assist us in assessing the feasibility of implementing a single survey on patient safety culture in the future.

In addition, all of the proposed measures were reviewed by the MAP, as discussed in its MAP Pre-Rulemaking Report and Spreadsheet of MAP 2015 Final Recommendations, indicating that they have been determined to be appropriate for the Hospital IQR Program. We note that measure developers conduct reliability and validity testing and that the MAP considers whether the measure under consideration is appropriate for a program.\textsuperscript{147} Aside from the structural measure (Hospital Survey on Patient Safety Culture), the development and testing (including validity and reliability) results of the finalized measures has undergone review by physicians from a variety of specialties and more details concerning testing results of these measures are detailed in the methodology reports that are mentioned under each measure section. Furthermore, feasibility is not an issue of concern since the claims-based measures are calculated by CMS using administrative claims data.

Finally, we note that we specifically select and propose measures that address goals for improving care and that the measures being finalized in this final rule all address NQS or CMS Quality Strategy Goals, which include\textsuperscript{148} making care safer by

\textsuperscript{147} MAP’s “Process and Approach for MAP Pre-Rulemaking Deliberations 2015” January 2015 http://www.qualityforum.org/Setting_Priorities/Partnership/MAP_Final_Reports.aspx.

reducing harm strengthening person & family engagement as partners in care, promoting effective communication & coordination of care, promoting effective prevention & treatment of chronic diseases, community coordination to promote “best practices” of healthy living, and making care affordable.

The factors we take into account in implementing and expanding the Hospital IQR Program are described in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53510).

Comment: A few commenters recommended that CMS consider adopting the recommendations outlined in the Institute of Medicine’s (IOM) Vital Signs report for streamlining and focusing national quality measurement efforts.

Response: We refer readers to http://iom.nationalacademies.org/~/media/Files/Report%20Files/2015/Vital_Signs/VitalSigns_RB.pdf for recommendations outlined in the Institute of Medicine’s (IOM) Vital Signs report. We thank the commenters for this suggestion and will take this under consideration.

Comment: One commenter encouraged CMS to study the effects of SDS factors and incorporate appropriate risk-adjustments on all proposed measures in the Hospital IQR Program in order for results to accurately reflect the differences in patients treated in hospitals. The commenter also specifically requested that the following measures be assessed for the impact of SDS factors: Kidney/UTI Clinical Episode-Based Payment measure; Cellulitis Clinical Episode-Based Payment measure; Gastrointestinal Hemorrhage Clinical Episode-Based Payment measure; Lumbar Spine Fusion/Re-Fusion Clinical Episode-Based Payment measure; Hospital-Level, Risk-Standardized Payment
Associated with an Episode-of-Care for Primary Elective THA/TKA; Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction; Excess Days in Acute Care after Hospitalization for Heart Failure; Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization Measure, and the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization Measure.

Response: While we appreciate these comments and the importance of the role that sociodemographic status plays in the care of patients, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of low sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures. To date, we have found that hospitals that care for large proportions of patients of low sociodemographic status are capable of performing well on our measures (we refer readers to the 2014 Chartbook pages 48-57, 70-73, and 78 at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Downloads/Medicare-Hospital-Quality-Chartbook-2014.pdf).

NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate for each measure. For 2 years, NQF will conduct a trial of a temporary policy change that will allow inclusion of
sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will determine whether to make this policy change permanent. Measure developers must submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model.

Furthermore, the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of socioeconomic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of these reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

We discuss specific comments and our finalized policies for each of the proposed measures below.

a. Hospital Survey on Patient Safety Culture

(1) Background

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24566 through 24567), for the FY 2018 payment determination and subsequent years, we proposed to adopt the Hospital Survey on Patient Safety Culture. This proposed structural measure assesses whether a hospital administers a patient safety culture survey. Improving the safety of patient care is a priority and a quality improvement goal for CMS. We believe this structural measure will allow us to gain an understanding of whether hospitals are using a survey of patient safety culture in their hospitals. Because the number of questions in this
measure is limited to five and can be completed using a Web-based tool, we believe this structural measure will not add undue reporting burden to hospitals.

We note that patient safety culture surveys are useful tools for measuring organizational conditions that can lead to adverse events and other incidences that can cause harm to patients in health care organizations. Patient safety culture surveys can be used to: (1) raise staff awareness about patient safety; (2) assess the current status of patient safety culture; (3) identify strengths and areas for improvement; and (4) examine trends in patient safety culture over time.

There are multiple surveys that are currently used by the healthcare industry to assess patient safety culture including: the Pascal Metrics’ Safety Attitudes Questionnaire (SAQ); the Agency for Healthcare Research and Quality (AHRQ) Hospital Survey on Patient Safety Culture (HSOPSC); the Patient Safety Climate in Healthcare Organizations (PSCHO); and the Manchester Patient Safety Framework. However, it is not clear which patient safety culture survey is used most frequently, or how many hospitals consistently assess their performance on these surveys. One

---

example of use of a patient safety culture survey is the HSOPSC, which is nonproprietary and available to hospitals at no cost. AHRQ developed the survey, with CMS input, released it in 2004, and subsequently displayed results from 653 hospitals in 2014.\textsuperscript{155} Use of the HSOPSC, as well as reporting results to AHRQ, was and continues to be voluntary. Among the reporting hospitals, there was variation in frequency of survey use, format of administration (Web versus paper) and staff sampling scheme.\textsuperscript{156}

Through the proposed Hospital Survey on Patient Safety Culture Measure, we will begin to understand how hospitals are using surveys, like the examples cited above, in improving their patient safety culture. This proposed measure will allow CMS to collect data on whether a hospital conducts a patient safety culture survey, and if so, which tool they use, how frequently the tool is administered, and the response rate. This structural measure will help inform CMS of whether a measure targeting the culture of patient safety using a specific survey is feasible.

Finally, we note that the MAP supports this measure and specifically highlighted that a patient safety culture survey is an important tool for hospitals to use to build a system of quality improvement within health care facilities.\textsuperscript{157} While this measure is not currently NQF-endorsed, we proposed this measure in the Hospital IQR Program under the exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act as previously


\textsuperscript{157} National Quality Forum Measure Application Partnership. “Spreadsheet of MAP 2015 Final Recommendations.” Available at: \url{http://www.qualityforum.org/map/}.
discussed in section VIII.A.7. of the preamble of this final rule. We considered other existing measures related to patient safety that have been endorsed by the NQF and we were unable to identify any NQF-endorsed measures that assess a patient safety culture, and found no other feasible and practical measures on this topic. We also are not aware of any other measures that assess whether a hospital administers a survey on patient safety.

(2) Overview of Measure

Reporting on a patient safety culture survey involves providing answers to the following questions listed below. Hospitals would submit answers via a Web-based tool on the QualityNet Web site:

(A) Does your facility administer a detailed assessment of patient safety culture using a standardized collection protocol and structured instrument?
(B) What is the name of the survey that is administered?
(C) How frequently is the survey administered?
(D) Does your facility report survey results to a centralized location? (Optional response options include the following: national data repository; state-based data repository; health system repository; other; and do not report the data outside the facility.)
(E) During the most recent assessment:
   (a) How many staff members were requested to complete the survey?
   (b) How many completed surveys were received?
(These questions can allow calculation of a response rate.)
(3) Data Sources

For FY 2018 payment determination and subsequent years, we proposed that data collection for this structural measure for hospitals occur from January 1 through December 31 of each calendar year, with data submission occurring the following year. For the first year, data collection would be from January 1, 2016 through December 31, 2016. These data will be collected via a Web-based tool available on the QualityNet Web site.

We invited public comment on our proposal to adopt the Hospital Survey on Patient Safety Culture measure for the FY 2018 payment determination and subsequent years.

Comment: Several commenters supported the adoption of the Hospital Survey on Patient Safety Culture within the Hospital IQR Program, stating their approval of a tool that could improve a culture of safety in hospitals. One commenter recommended that CMS leverage the findings from this measure to identify a consistent tool for measuring this attribute in future proposals. One commenter noted that a safety culture survey allows hospitals to identify gaps in patient safety, build awareness of critical issues, and examine trends in patient safety trends over time.

Response: We thank the commenters for their support. The purpose of this measure is to obtain comprehensive information on which surveys are being utilized from all hospitals eligible to report under the Hospital IQR Program. We hope to obtain valuable information from the structural measure that can assist us in assessing the feasibility of implementing a single survey on patient safety culture in the future. We
note that patient safety culture surveys are useful tools for measuring organizational conditions that can lead to adverse events and other incidences that can cause harm to patients in health care organizations. Improving the safety of patient care is a priority and a quality improvement goal for CMS.

Comment: Several commenters noted that they are not confident that the measure will add value to the Hospital IQR Program because it assesses whether hospitals utilize a patient safety culture survey but does not actually assess a hospital’s culture. The commenters recommended that CMS focus on development measures for patient safety outcomes.

Response: The purpose of this measure is to obtain comprehensive information on which surveys are being utilized from all hospitals eligible to report under the Hospital IQR Program. While we agree with the commenters that this particular measure does not assess the safety cultures of hospitals, this measure will provide us with more information on whether there is widespread use of a single survey on patient safety culture and inform future measure development activities.

Comment: One commenter expressed concern that the use of this measure will burden hospitals by increasing administrative costs associated with survey implementation and evaluation.

Response: We are clarifying that the adoption of this structural measure is not mandating the use of a specific patient safety culture survey or one at all; the purpose is to obtain comprehensive information on which, if any, surveys are being utilized from all hospitals eligible to report under the Hospital IQR Program. For hospitals that do not
currently have a survey in place, they would simply respond that they do not administer a
detailed assessment of patient safety culture using a standardized collection protocol or
structured instrument (the first question in the Overview of Measure section), and leave
the rest of the questionnaire blank.

Comment: Some commenters recommended that CMS refrain from making the
Patient Safety Culture survey data immediately publicly available. The commenters
expressed concern that because it is not established which survey is associated with
higher quality, displaying data on this measure may be misleading to beneficiaries.

Response: We disagree with commenters that posting data about this measure
should be delayed on the Hospital Compare Web site. Beneficiaries would not be misled
by the posted information. Data displayed on Hospital Compare for this measure would
not link the use of a specific survey with higher quality. The purpose of this measure is
to obtain comprehensive information on whether hospitals are using a survey and which
surveys are being utilized.

Comment: Some commenters opposed the Hospital Survey on Patient Safety
Culture measure, and recommended that CMS should obtain this information from other
sources, such as Partnership for Patients. The commenters also believed that this survey
does not provide CMS with data on a particular patient safety culture survey that CMS
could require in the future.

Response: The purpose of this measure is to obtain comprehensive information
on whether hospitals are using surveys and which surveys are being utilized from all
hospitals eligible to report under the Hospital IQR Program. The goal is to assess the
landscape of which surveys are currently used. The Partnership for Patients’ Organizational Assessment Tool (OAT)\textsuperscript{158} does not collect information on specific surveys utilized by hospitals or particularly those participating in the Hospital IQR Program, which is our main purpose for adopting this measure.

\textbf{Comment}: Some commenters expressed concern that the Patient Safety Culture Measure is not NQF-endorsed.

\textbf{Response}: As stated above in our measure discussion, we note that the MAP supports this measure and specifically highlighted that a patient safety culture survey is an important tool for hospitals to use to build a system of quality improvement within health care facilities.\textsuperscript{159} While this measure is not NQF-endorsed, we proposed this measure in the Hospital IQR Program under the exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act as previously discussed in section VIII.A.7. of the preamble of this final rule. We considered other existing measures related to patient safety that have been endorsed by the NQF and we were unable to identify any NQF-endorsed measures that assess a patient safety culture, and found no other feasible and practical measures on this topic. We also are not aware of any other measures that assess whether a hospital administers a survey on patient safety.

This structural measure will allow us to assess whether hospitals are using surveys, which surveys are being utilized, and the frequency of their use. This


\textsuperscript{159} National Quality Forum Measure Application Partnership. “Spreadsheet of MAP 2015 Final Recommendations.” Available at: http://www.qualityforum.org/map/.
information will assist us in assessing the feasibility of implementing a single survey on patient safety culture in the future.

Comment: One commenter recommended that CMS consider a metric in which hospital survey scores are indicated and noted that a climate survey measure may be more appropriate than a culture survey measure.

Response: We thank the commenter for its recommendations. This structural measure will allow us to assess whether and which patient safety culture surveys are being utilized by hospitals and the frequency of their use. This is a necessary first step in determining whether a single survey could be implemented in the future, such as one in which hospital survey scores are indicated. Furthermore, the terms “climate survey” and “culture survey” tend to be used interchangeably, thus, making it difficult to assess which climate surveys are not already considered culture surveys. In addition, we were unable to identify any NQF-endorsed measures that assess a patient safety climate.

Comment: One commenter recommended that CMS focus on patient safety measures addressing falls as well as nurse staffing and skill mix.

Response: We disagree that we should only focus on patient safety measures that address falls and nurse staffing and skill mix. This structural measure will allow us to assess whether and which patient safety culture surveys are being utilized by hospitals and the frequency of their use. We note that some surveys, such as the AHRQ Hospital Survey on Patient Safety Culture, include a staffing assessment.
Comment: One commenter expressed concern that structural measures do not provide meaningful differences in the quality of care for patients and urged CMS to provide hospitals more information on the time period for conducting such a survey.

Response: Structural measures may be perceived as not providing meaningful differences in quality of care since, many times, these types of measures request information on whether a hospital is participating in or utilizing a registry or checklist, which is then displayed on Hospital Compare as a “yes” or “no.” However, we believe registries can provide meaningful feedback to hospitals to improve their practices, and a safe surgery checklist is considered a best practice. At this time, we have not determined how many years we will keep this measure in the Hospital IQR Program.

After consideration of the public comments we received, we are finalizing the adoption of the Hospital Survey on Patient Safety Culture measure for the FY 2018 payment determination and subsequent years as proposed.

b. Clinical Episode-Based Payment Measures

(1) Background

Clinical Episode-Based Payment measures are clinically coherent groupings of healthcare services that can be used to assess providers’ resource use. Combined with other clinical quality measures, they contribute to the overall picture of providers’ clinical effectiveness and efficiency. Episode-based performance measurement allows meaningful comparisons between providers based on resource use for certain clinical


conditions or procedures, as noted in the NQF report for the “Episode Grouper Evaluation Criteria” project available at:
http://www.qualityforum.org/Publications/2014/09/Evaluating_Episode_Groupers__A_Report_from_the_National_Quality_Forum.aspx and in various peer-reviewed articles.\textsuperscript{161} Episode-based measurement further supports CMS’ efforts in response to the mandate in section 3003 of the Affordable Care Act that the Secretary develop an episode grouper to improve care efficiency and quality.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24567 through 24572), we proposed four Clinical Episode-Based Payment measures for inclusion in the Hospital IQR Program beginning with the FY 2018 payment determination: the Kidney/Urinary Tract Infection Clinical Episode-Based Payment measure, the Cellulitis Clinical Episode-Based Payment measure, the Gastrointestinal Hemorrhage Clinical Episode-Based Payment measure, and the Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure. The proposed measures evaluate the difference between observed and expected episode cost at the episode level before comparing at the provider level.

The MAP conditionally supported these measures pending NQF endorsement.\textsuperscript{162} Once the call for measures for the Cost and Resource Use project at NQF is announced, these measures will be submitted for endorsement.

\textsuperscript{162} National Quality Forum. The report is available at:
http://www.qualityforum.org/Publications/2015/01/Process_and_Approach_for_MAP_Pre-Rulemaking_Deliberations_2015.aspx and the “Spreadsheet of
The measures we proposed are described below, and detailed specifications can be found in the “Measure Methodology” report for proposed episodic payment measures, available at: http://www.qualitynet.org > Hospital-Inpatient > Claims-Based Measures > Proposed episodic payment measures > Measure Methodology. The measures follow the general construction of the previously adopted, NQF-endorsed, Hospital IQR Program measure, Payment-Standardized Medicare Spending per Beneficiary (MSPB), described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51626) and include standardized payments for Medicare Part A and Part B services. Similar to the MSPB measure, the episodes are risk adjusted for individual patient characteristics and other factors (for example, attributes of inpatient stays). Unlike the MSPB measure however, these clinical episode-based measures include only Medicare Part A and B services that are clinically related to the triggering diagnosis or procedure.

Mathematically, the methodology described below first computes the provider’s Episode Amount (calculated as the average of the ratios of each episode’s observed costs to its expected costs multiplied by the national average observed episode cost) and then divides the provider’s Episode Amount by the episode-weighted median of all providers’ Episode Amounts (as shown in equation (A) below).

---

(A) Episode Measure\(j\) = \(\frac{\text{Episode Amount}_{ij}}{\text{Episode-Weighted Median of All Providers' Episode Amounts}}\) = \(\frac{\sum_{i \in I} O_{ij}}{\text{Episode-Weighted Median of All Providers' Episode Amounts}}\). 

where

\(O_{ij}\) = observed episode cost for episode \(i\) in provider \(j\),

\(E_{ij}\) = expected episode cost for episode \(i\) in provider \(j\),

\(\bar{O}_{i \in I}\) = average observed episode cost across all episodes \(i\) nationally, and

\(n_j\) = total number of episodes for provider \(j\).

This methodology builds on that which was submitted to the MAP, in response to MAP feedback, and in order to yield a national episode-weighted measure. We proposed these Clinical Episode-Based Payment measures because they meet the following episode selection criteria we established for the purpose of selecting the best conditions and procedures to begin with, for Clinical Episode-Based Payment measures: (1) the condition constitutes a significant share of Medicare payments and potential savings for hospitalized patients during and surrounding a hospital stay; (2) there was a high degree of agreement among clinical experts consulted for this project that standardized Medicare payments for services provided during this episode can be linked to the care provided during the hospitalization; (3) episodes of care for the condition are comprised of a substantial proportion of payments and potential savings for postacute care, indicating episode payment differences are driven by utilization outside of the MS–DRG payment; (4) episodes of care for the condition reflect high variation in post-discharge payments, enabling differentiation among hospitals; and (5) the medical condition is managed by
general medicine physicians or hospitalists and the surgical conditions are managed by surgical subspecialists, enabling comparison between similar practitioners.

We discuss measure-specific comments after each measure discussion. However, because many comments apply to all of the proposed Clinical Episode-Based Payment measures, a discussion of comments that are not measure-specific can be found after the measure discussions.

(2) Kidney/Urinary Tract Infection Clinical Episode-Based Payment Measure

(A) Background

Inpatient hospital stays and associated services assessed by the Kidney/Urinary Tract Infection Clinical Episode-Based Payment measure have high costs with substantial variation. In CY 2012, Medicare FFS beneficiaries experienced over 234,000 kidney/urinary tract infection episodes triggered by related inpatient stays.\textsuperscript{164} Payment-standardized, risk-adjusted episode costs for these episodes (cost of the hospitalization plus the cost of clinically related services in the episode window) totaled more than $2.5 billion in 2012, with an average episode cost of over $10,000. There is substantial variation in kidney/urinary tract infection episode costs—ranging from approximately $4,800 at the 5th percentile to approximately $27,000 at the 95th—that is driven by variation in post-discharge costs clinically-related to the inpatient hospitalization. These clinically-related post-discharge costs are an indicator of the quality of care provided during the hospitalization.

\textsuperscript{164} The number of episodes and associated costs are calculated using the methodology for developing hospital-based episode measures proposed by Acumen LLC and outlined in the supplemental documentation for the FY 2015 IPPS and LTCH Prospective Payment System Proposed Rule. Available at: \url{http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/hospital-value-based-purchasing/index.html}. 
The MAP conditionally supported this measure pending NQF review and endorsement. Members noted that this measure addresses the cost of care for common conditions, but other members expressed caution that the most efficient providers may reduce overall hospitalizations and that the remaining hospitalizations may be a biased sample for measuring performance across providers. In response to this concern, we note that this measure is limited by design to the inpatient hospital, which means that resource use is evaluated only for patients that have been hospitalized for the episode condition, and providers are evaluated relative to other providers treating hospitalized patients. To address the concern that providers involved in the hospitalization of only the most complex cases might be disadvantaged under the measure, we note that the episode is risk-adjusted to account for differences in patient characteristics that may affect costs, such that expected costs for more complex patients will be higher and expected costs for less complex patients will be lower. Once the call for measures for the Cost and Resource Use project at NQF is announced, this measure will be submitted for endorsement.

We proposed this measure in the Hospital IQR Program under the exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act as previously discussed in section VIII.A.7. of the preamble of this final rule. We considered other existing measures related to efficiency that have been endorsed by the NQF and we were unable to identify any NQF-endorsed measures that assess kidney/urinary tract infection. We also are not aware of any other measures that assess kidney/urinary tract infection treatment efficiency and found no other feasible and practical measures on this topic.
(B) Overview of Measure

The Kidney/Urinary Tract Infection Clinical Episode-Based Payment measure includes the set of services provided to treat, manage, diagnose, and follow up on (including postacute care) a kidney/urinary tract infection-related hospital admission. This measure, like the NQF-endorsed MSPB measure (NQF #2158), assesses the cost of services initiated during an episode that spans the period immediately prior to, during, and following a beneficiary’s hospital stay (the “episode window”). In contrast to the MSPB measure, however, this measure includes Medicare payments for services during the episode window only if they are clinically related to the health condition that was treated during the index hospital stay.

(C) Data Sources

The Kidney/Urinary Tract Infection Clinical Episode-Based Payment measure is an administrative claims-based measure. It uses Part A and Part B Medicare administrative claims data from Medicare FFS beneficiaries hospitalized with an MS-DRG that identifies a kidney/urinary tract infection.

(D) Measure Calculation

The measure sums the Medicare payment amounts for clinically related Part A and Part B services provided during the episode window and attributes them to the hospital at which the index hospital stay occurred. Medicare payments included in this episode-based measure are standardized and risk-adjusted. The period of performance for the measure is 1 year, beginning with CY 2016. Similar to the MSPB measure’s construction, this measure is expressed as a risk-adjusted ratio, which allows for ease of
comparison over time, without need to adjust for inflation or any potential changes in CMS payment policy. The numerator is the Episode Amount, calculated as the average of the ratios of each episode’s observed costs to its expected costs multiplied by the national average observed episode cost. The denominator is the episode-weighted median of all providers’ Episode Amounts. A kidney/urinary tract infection episode begins 3 days prior to the initial (that is, index) admission and extends 30 days following the discharge from the index hospital stay.

(E) Cohort

The measure cohort includes Medicare FFS beneficiaries hospitalized with an MS-DRG that indicates a kidney/urinary tract infection. Additional details including the exclusion criteria are described in section VIII.A.7.b.(6) of the preamble of this final rule.

We invited public comment on our proposal to adopt the Kidney/Urinary Tract Infection Clinical Episode-Based Payment measure for the FY 2018 payment determination and subsequent years.

Comment: One commenter opposed the proposed addition of the Kidney/Urinary Tract Infection Clinical Episode-Based Payment measure and noted that it may be more appropriate in an outpatient setting. The commenter noted that kidney and urinary tract infection is often seen with comorbidities, resulting in a more severe episode of care. The commenter suggested that the measure be limited to a more specifically defined set of patients so that comparisons can be made.

Response: We appreciate the commenter’s concerns about the variety of clinical conditions associated with kidney and urinary tract infection. With regard to the
suggestion that the measure should be limited to the outpatient setting, we believe that this measure is appropriate for the hospital inpatient setting, because it does not include all cases of kidney/urinary tract infection, but rather, are limited to cases with infections whose severity required admission to a hospital. We also believe that risk adjustment will account for the heterogeneity present among patients hospitalized with kidney and urinary tract infections. The risk adjustment model includes demographics (for example, age) and a range of health conditions that are clinically related to kidney/urinary tract infections: diabetes, end-stage renal disease, and paralysis (which may be associated with neurogenic bladder), among others. Furthermore, services grouped to the episode are limited to those that are directly related to the episode condition. Creation of this episode was based on the observation that significant costs are associated with this condition.

Comment: One commenter expressed concern about how hospitals can determine when a kidney/urinary tract infection begins, which determines whether an index admission is triggered for the episode.

Response: Because this measure begins with a hospital admission for a kidney/urinary tract infection, the episode is triggered by the admission. Only infections that were serious enough to require hospitalization are included.

Comment: One commenter supported the proposal to include the Kidney/Urinary Tract Infection Clinical Episode-Based Payment measure, on the condition that the methodology is tested and validated.
Response: We appreciate the commenter’s support. The methodology has been tested on the population of 2012 Medicare beneficiaries. The testing was conducted with Medicare claims data and is therefore, expected to be valid. Historically, the NQF has found Medicare claims-based measures, such as the Hospital-Wide All-Cause Unplanned Readmission Measure (HWR) (NQF #1789), to be valid. For this all-cause readmission measure, ‘reliability and validity [at the data element level and at the measured score level] was generally received as adequate by the steering committee” (NQF: 2012 Proc. Feb 2012, available at: http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=70455).

The proposed Clinical Episode-Based Payment measures’ episodes were created using the methodology for grouping treatment and post-discharge services as well as the risk adjustment model all outlined in the supplemental documentation for the FY 2016 IPPS and LTCH Prospective Payment System Proposed Rule available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/hospital-value-based-purchasing/index.html. After episodes were constructed, medical services grouped to the episodes were validated by a team of clinicians with expertise in Medicare claims data. However, in response to comments, we will give hospitals an opportunity to validate data included in the episodes during review of the confidential hospital-specific feedback reports discussed in more detail below.
(3) Cellulitis Clinical Episode-Based Payment Measure

(A) Background

Inpatient hospital stays and associated services assessed by the Cellulitis Clinical Episode-Based Payment measure have high costs with substantial variation. In CY 2012, Medicare FFS beneficiaries experienced more than 143,000 cellulitis episodes triggered by related inpatient stays. Payment-standardized, risk-adjusted episode costs for these episodes (cost of the hospitalization plus the cost of clinically related services in the episode window) totaled more than $1.4 billion in 2012, with an average episode cost of approximately $10,000. There is substantial variation in cellulitis episode costs—ranging from about $5,000 at the 5th percentile to about $24,000 at the 95th—that is driven by variation in post-discharge costs clinically-related to the inpatient hospitalization. These clinically related post-discharge costs are an indicator of the quality of care provided during the hospitalization.

The MAP conditionally supported this measure pending NQF review and endorsement. Members noted that this measure addresses the cost of care for an important condition. Other members expressed caution on the use of this measure noting that cellulitis is a highly variable condition that may be challenging to measure using an episode-based framework. Once the call for measures for the Cost and Resource Use project at NQF is announced, this measure will be submitted for endorsement. We note that there is substantial variation in cellulitis episode costs that is driven by variation in

\[165\] The number of episodes and associated costs are calculated using the methodology for developing hospital-based episode measures proposed by Acumen LLC and outlined in the supplemental documentation for the FY 2015 IPPS and LTCH Prospective Payment System Proposed Rule. Available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment- Instruments/hospital-value-based-purchasing/index.html.
post-discharge costs clinically-related to the inpatient hospitalization. This variation suggests that there may be opportunity to improve the efficiency of care for cellulitis treatment.

We proposed this measure in the Hospital IQR Program under the exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act as previously discussed in section VIII.A.7. of the preamble of this final rule. We considered other existing measures related to efficiency that have been endorsed by the NQF and we were unable to identify any NQF-endorsed measures that assess cellulitis. We also are not aware of any other measures that assess cellulitis treatment efficiency, and found no other feasible and practical measures on this topic.

(B) Overview of Measure

The Cellulitis Clinical Episode-Based Payment measure includes the set of services provided to treat, manage, diagnose, and follow up on (including post-acute care) a cellulitis-related hospital admission. The Cellulitis Clinical Episode-Based Payment measure, like the MSPB measure, assesses the cost of services initiated during an episode that spans the period immediately prior to, during, and following a beneficiary’s hospital stay (the “episode window”). In contrast to the MSPB measure, the Cellulitis Clinical Episode-Based Payment measure includes Medicare payments for services during the episode window only if they are clinically related to the health condition that was treated during the index hospital stay.
(C) Data Sources

The Cellulitis Clinical Episode-Based Payment measure is an administrative claims-based measure. It uses Part A and Part B Medicare administrative claims data from Medicare FFS beneficiaries hospitalized with an MS-DRG that identifies cellulitis.

(D) Measure Calculation

The measure sums the Medicare payment amounts for clinically related Part A and Part B services provided during this episode window and attributes them to the hospital at which the index hospital stay occurred. Medicare payments included in this episode-based measure are standardized and risk-adjusted. The period of performance is one year, beginning with calendar year 2016. Similar to the MSPB measure’s construction, this measure is expressed as a risk-adjusted ratio, which allows for ease of comparison over time, without need to adjust for inflation or any potential changes in CMS payment policy. The numerator is the Episode Amount, calculated as the average of the ratios of each episode’s observed costs to its expected costs multiplied by the national average observed episode cost. The denominator is the episode-weighted median of all providers’ Episode Amounts. A cellulitis episode begins 3 days prior to the initial (that is, index) admission and extends 30 days following the discharge from the index hospital stay.

(E) Cohort

The measure cohort includes Medicare FFS beneficiaries hospitalized with an MS-DRG that indicates cellulitis. Additional details including the exclusion criteria are described in section VIII.A.7.b.(6) of the preamble of this final rule.
We invited public comment on our proposal to adopt the Cellulitis Clinical Episode-Based Payment measure for the FY 2018 payment determination and subsequent years.

Comment: A few commenters opposed the proposed addition of the Cellulitis Clinical Episode-Based Payment measure and recommended that it may be more appropriate as an outpatient cost measure because treatment for cellulitis can largely be handled in the outpatient setting. The commenters also noted that patients with cellulitis often have comorbidities that might make it difficult to group all cellulitis patients together. One commenter specifically expressed concern that the cellulitis measure does not adequately capture differences in acute and chronic cellulitis.

Response: We appreciate the commenter’s concerns about the variety of clinical conditions associated with cellulitis. With regard to the suggestion that the measure would be better suited to an outpatient setting, we believe that this measure is appropriate for the hospital inpatient setting, because it does not include all cases of cellulitis. Rather, it is limited to either an exacerbation or acute flare of cellulitis whose severity requires admission to a hospital. Whether the cellulitis is chronic or acute, the design of the episode measure, which is limited to the inpatient hospitalization and the immediate follow-up period, allows for meaningful comparison across providers. Hospitalized cellulitis patients, with more serious soft tissue infections, are clinically distinct from patients who can be treated in other Medicare settings.

Furthermore, we do not agree that comorbidities might make it difficult to group all cellulitis patients together. The episode measure contains three clinical subtypes to
address the heterogeneity present among beneficiaries hospitalized for this condition: (1) cellulitis as a complication of diabetes; (2) cellulitis as a complication of decubitus pressure ulcers; and (3) other cellulitis. We note that beneficiaries with ulcers were not compared to beneficiaries with uncomplicated cellulitis. This breakdown creates more cohorts of beneficiaries for comparison. Risk adjustment is also applied to account for other comorbidities and complex issues in cellulitis patients. Finally, the episode focuses only on care that is directly related to those infections. The high frequency of cellulitis episodes highlights the importance of creating a measure for this condition.

(4) Gastrointestinal (GI) Hemorrhage Clinical Episode-Based Payment Measure

(A) Background

Inpatient hospital stays and associated services assessed by the Gastrointestinal (GI) Hemorrhage Clinical Episode-Based Payment measure have high costs with substantial variation. In calendar year 2012, Medicare FFS beneficiaries experienced 181,646 GI hemorrhage episodes triggered by related inpatient stays.\(^{166}\) Payment-standardized, risk-adjusted episode costs for these episodes (cost of the hospitalization plus the cost of clinically related services in the episode window) totaled nearly $2 billion in 2012, with an average episode cost of about $11,000. There is substantial variation in GI hemorrhage episode costs—ranging from approximately $6,500 at the 5th percentile to approximately $23,000 at the 95th—that is driven by variation in post-discharge costs clinically related to the inpatient hospitalization. These clinically related post-discharge costs

costs are an indicator of the quality of care provided during the hospitalization. For the purposes of reporting, and as suggested by the MAP, the GI hemorrhage episodes may be split into those treating an upper GI bleed and those treating a lower GI bleed due to clinical differences in patterns of care for those treatments. More information can be found in the supplemental documentation for the FY 2016 IPPS and LTCH Prospective Payment System Proposed Rule available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/hospital-value-based-purchasing/index.html.

The MAP conditionally supported this measure pending NQF review and endorsement. MAP members noted that this measure addresses the cost of care for GI bleeding. Several members expressed caution that the most efficient providers may reduce overall hospitalizations thus those inpatient hospitalizations that remain are a biased sample for measuring performance across providers. In response to these concerns, we note that this measure is limited by design to GI hemorrhage episodes treated in the inpatient hospital, which means that resource use is evaluated only for patients that have been hospitalized for the episode condition, and providers are evaluated relative to other providers treating hospitalized patients. With regard to the concern that efficient providers may reduce hospitalizations, leaving a biased sample of less efficient providers, we note that the episode is risk-adjusted to account for differences in patient characteristics that may affect costs, thus to the extent that variation in treatment prior to hospitalization results in patterns of sicker (or healthier) GI hemorrhage patients admitted to certain hospitals, risk adjustment addresses these differences. For example, for providers who admit comparatively less complex patients to the inpatient hospital for
treatment of GI bleeds, risk adjustment would cause their expected costs to be lower. Once the call for measures for the Cost and Resource Use project at NQF is announced, this measure will be submitted for endorsement.

We proposed this measure in the Hospital IQR Program under the exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act as previously discussed in section VIII.A.7. of the preamble of this final rule. We considered other existing measures related to efficiency that have been endorsed by the NQF and we were unable to identify any NQF-endorsed measures that assess GI hemorrhage. We also are not aware of any other measures that assess GI hemorrhage treatment efficiency, and found no other feasible and practical measures on this topic.

(B) Overview of Measure

The Gastrointestinal Hemorrhage Clinical Episode-Based Payment measure includes the set of services provided to treat, manage, diagnose, and follow up on (including postacute care) a gastrointestinal hemorrhage-related hospital admission. This measure, like the MSPB measure, assesses the cost of services initiated during an episode that spans the period immediately prior to, during, and following a beneficiary’s hospital stay (the “episode window”). In contrast to the MSPB measure, the Gastrointestinal Hemorrhage Clinical Episode-Based Payment measure includes Medicare payments for services during the episode window only if they are clinically related to the health condition that was treated during the index hospital stay.
(C) Data Sources

The Gastrointestinal Hemorrhage Clinical Episode-Based Payment measure is an administrative claims-based measure. It uses Part A and Part B Medicare administrative claims data from Medicare FFS beneficiaries hospitalized with an MS-DRG that identifies a gastrointestinal hemorrhage.

(D) Measure Calculation

The measure sums the Medicare payment amounts for clinically related Part A and Part B services provided during the episode window and attributes them to the hospital at which the index hospital stay occurred. Medicare payments included in this episode-based measure are standardized and risk-adjusted. The period of performance is 1 year, beginning with CY 2016. Similar to the MSPB measure’s construction, this measure is expressed as a risk-adjusted ratio, which allows for ease of comparison over time, without need to adjust for inflation or any potential changes in CMS payment policy. The numerator is the Episode Amount, calculated as the average of the ratios of each episode’s observed costs to its expected costs multiplied by the national average observed episode cost. The denominator is the episode-weighted median of all providers’ Episode Amounts. A gastrointestinal hemorrhage episode begins 3 days prior to the initial (that is, index) admission and extends 30 days following the discharge from the index hospital stay.
(E) Cohort

The measure cohort includes Medicare FFS beneficiaries hospitalized with an MS-DRG that indicates gastrointestinal hemorrhage. Additional details including the exclusion criteria are described in section VIII.A.7.b.(6) of the preamble of this final rule.

We invited public comment on our proposal to adopt the Gastrointestinal Hemorrhage Clinical Episode-Based Payment measure for the FY 2018 payment determination and subsequent years.

Comment: One commenter supported CMS’ proposed inclusion of Gastrointestinal Hemorrhage as part of the Clinical Episode-Based Payment measures and agreed that post-discharge care costs drive variation in spending for this condition.

Response: We thank the commenter for its support.

Comment: One commenter opposed the proposed addition of the GI Hemorrhage Clinical Episode-Based Payment measure, noting that the many conditions and medical situations may cause GI hemorrhage, and that these different conditions and causes cannot be compared against each other. The commenter suggested that the measure be limited to a more specifically defined set of patients so that comparisons can be made.

Response: We appreciate the commenter’s opinion that GI hemorrhage is a broad category. Rather than limit the patient set, and consequently the number of beneficiaries whose care could be captured in the measure, we have broken the overall measure down into clinical subtypes, which allows comparison among clinically similar beneficiary groups. This allows meaningful comparison of patients who have similar conditions and causes for GI hemorrhage. The measure, as it was proposed, includes four clinical
subtypes for the GI bleed episode measure: (1) upper GI bleeds; (2) lower GI bleeds; (3) upper and lower GI bleeds; and (4) GI bleeds of unknown source. Specifications can be found in the “Measure Methodology” report link found in section VIII.A.7.b.(7)(B) of the preamble of this final rule.

Furthermore, we believe that risk adjustment will account for other health and demographic factors that may impact a beneficiary’s episode costs. Risk adjustment factors in age, 70 severity of illness measures, and comorbidities that may affect a GI hemorrhage episode: diabetes, inflammatory bowel disease, hematological disorders, drug and alcohol dependence, liver cirrhosis, and intestinal obstruction/perforation, among others. The data showed that there was sufficient similarity in the experiences of these patients that episodes could be created. In selecting post-discharge services to group to the episode, clinicians focused on care that was directly related to the bleeding. Care was taken at this time to group only services that had a direct connection to the bleed that triggered the episode.

(5) Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment Measure

(A) Background

Inpatient hospital stays and associated services assessed by the Spinal Fusion/Refusion Clinical Episode-Based Payment measure have high costs with substantial variation. In CY 2012, Medicare FFS beneficiaries experienced about 69,000 spinal fusion/refusion episodes triggered by related inpatient stays.  

\(^{167}\) The number of episodes and associated costs are calculated using the methodology for developing hospital-based episode measures proposed by Acumen LLC and outlined in the supplemental documentation for the FY 2015 IPPS and LTCH Prospective Payment System Proposed Rule. Available
Payment-standardized, risk-adjusted episode costs for these episodes (cost of the hospitalization plus the cost of clinically related services in the episode window) totaled more than $2.6 billion in 2012, with an average episode cost of approximately $38,000. There is substantial variation in spinal fusion/refusion episode costs—ranging from approximately $28,000 at the 5\textsuperscript{th} percentile to approximately $60,000 at the 95\textsuperscript{th}—that is driven by variation in post-discharge costs clinically related to the inpatient hospitalization. These clinically related post-discharge costs are an indicator of the quality of care provided during the hospitalization.

The MAP conditionally supported this measure pending NQF review and endorsement. Some members raised concerns that patients with cancer should be excluded from this measure. Once the call for measures for the Cost and Resource Use project at NQF is announced, this measure will be submitted for endorsement. We note that this measure is titled “Spine Fusion/Refusion Clinical Episode-Based Payment measure” in the MAP spreadsheet. In addition, the episode is risk-adjusted to account for differences in patient characteristics, including the presence of cancer in the patient’s history, which may affect costs but are outside of providers’ control.

We proposed this measure in the Hospital IQR Program under the exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act as previously discussed in section VIII.A.7. of the preamble of this final rule. We considered other existing measures related to efficiency that have been endorsed by the NQF and we were unable to identify any NQF-endorsed measures that assess spinal fusion/refusion. We also are at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/hospital-value-based-purchasing/index.html.
not aware of any other measures that assess spinal fusion/refusion treatment efficiency, and found no other feasible and practical measures on this topic.

(B) Overview of Measure

The Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure includes the set of services provided to treat, manage, diagnose, and follow up on (including postacute care) a lumbar spine fusion/refusion-related hospital admission. The Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure, like the MSPB measure, assesses the cost of services initiated during an episode that spans the period immediately prior to, during, and following a beneficiary’s hospital stay (the “episode window”). In contrast to the MSPB measure, the Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure includes Medicare payments for services during the episode window only if they are clinically related to the health condition that was treated during the index hospital stay.

(C) Data Sources

The Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure is an administrative claims-based measure. It uses Part A and Part B Medicare administrative claims data from Medicare FFS beneficiaries hospitalized with an MS-DRG and ICD-9-CM procedure code that identify a lumbar spine fusion/refusion.

(D) Measure Calculation

The measure sums the Medicare payment amounts for clinically related Part A and Part B services provided during the episode window and attributes them to the hospital at which the index hospital stay occurred. Medicare payments included in this
episode-based measure are standardized and risk-adjusted. The period of performance is 1 year, beginning with calendar year 2016. Similar to the MSPB measure’s construction, this measure is expressed as a risk-adjusted ratio, which allows for ease of comparison over time, without need to adjust for inflation or any potential changes in CMS payment policy. The numerator is the Episode Amount, calculated as the average of the ratios of each episode’s observed costs to its expected costs multiplied by the national average observed episode cost. The denominator is the episode-weighted median of all providers’ Episode Amounts. A lumbar spine fusion/refusion episode begins 3 days prior to the initial (that is, index) admission and extends 30 days following the discharge from the index hospital stay.

(E) Cohort

The measure cohort includes Medicare FFS beneficiaries hospitalized with an MS-DRG and ICD-9 Procedure code that indicate lumbar spine fusion/refusion. Additional details including the exclusion criteria are described in section VIII.A.7.b.(6) of the preamble of this final rule.

We invited public comment on our proposal to adopt the Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure for the FY 2018 payment determination and subsequent years.

Comment: One commenter supported CMS’ proposed inclusion of Lumbar Spine Fusion/Refusion as part of the Episode-based-payment measures and agreed that post-discharge care costs drive variation in spending for this condition.

Response: We thank the commenter for its support.
Comment: A few commenters opposed the proposal to include the Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure, noting that refinements would be required, in order to account for patient variability and to ensure that surgeons are measured appropriately and also that stratification is needed to distinguish between elective surgery and emergency surgery, which is often more complex.

Response: We appreciate the commenters’ concerns and feedback from clinicians and specialty groups during this process. Upon further analysis, we agree that additional refinements, potentially including stratification or other specification to address differences in reasons for surgery (for example, elective vs. emergency), are needed for this measure to account for the variety of patient clinical presentations that could comprise the lumbar spine fusion/refusion measure and to ensure that hospitals are measured appropriately. Specifically, unlike the clinical subtypes in the Cellulitis and GI Hemorrhage Clinical Episode-Based Payment measures, we agree that the procedure codes included in each subtype of the proposed Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure are too broad and do not adequately account for the heterogeneity present among the population of beneficiaries who experience episodes for the measure. We note that the measure as proposed would measure hospitals, not individual surgeons, in the context of the Hospital IQR Program.

Therefore, in response to commenters’ concerns regarding the heterogeneity of the Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure, we are not finalizing it for the Hospital IQR Program at this time. We will continue development of this measure, and if after further refinement and discussion with clinical experts we
believe the measure should be included in the Hospital IQR Program, we would propose the measure again through future rulemaking.

**Comment:** Some commenters expressed concern that the proposed Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure may assess variations in cost that are caused by factors outside of providers' control, such as the quality of post-discharge care to which a patient has access. The commenters also expressed concern that the measure may incentivize providers to avoid certain post-discharge costs, such as those associated with imaging, and that the lower costs achieved may not reflect quality.

**Response:** This measure, like the other Clinical Episode-Based Payment measures, is payment-standardized and risk-adjusted to remove differences in Medicare payment policy and patient health status that can affect episode costs but are outside the control of the provider managing the episode. Payments are standardized to eliminate geographic differences and special program payments unrelated to resource use, such as disproportionate share hospital (DSH) payments. Payment standardization assigns a standardized allowed amount for each service to facilitate comparison across providers. Outliers in cost are also subject to clinical review to further understand these cases.

Currently, the risk adjustment used for these measures is the same as that of the NQF-endorsed MSPB measure (NQF #2158). Therefore, providers and hospitals that treat patients with greater complexity will be accounted for through payment standardization and risk adjustment.
As the commenters noted, the quality of post-discharge care can affect the hospital’s performance on the measure; therefore, hospitals involved in the provision of high-quality inpatient care as well as appropriate discharge planning and post-discharge care coordination would be expected to perform well on this measure. We believe that inclusion of other costs, such as those for post-discharge care is imperative to incentivizing improved care coordination and care transitions. We disagree that such costs are outside of the hospitals’ control. While the quality of post-discharge care may affect the measure, we believe that hospitals are in a position to influence the post-discharge experience and outcomes, which in turn impact costs, for the patients they serve.

With regard to the comments that the measure might incentivize hospitals to avoid needed post-discharge care and that lower cost does not necessarily indicate better quality, we note that this measure was proposed as one measure within the Hospital IQR Program, which includes numerous measures spanning various aspects of hospital quality. In addition to our belief that hospitals are interested in providing the best and most appropriate care for the Medicare beneficiaries they serve, cost measures are balanced by a wide array of quality measures. We do not believe that a hospital would avoid providing needed care (and forego the associated Medicare payments for such services), in the interest of improving performance on one payment measure. Rather, we believe that Clinical Episode-Based Payment measures incentivize hospitals to look for opportunities to gain efficiencies, avoid unnecessary services, which represent poor quality, and avoid unnecessary re-hospitalizations.
However, as discussed above in response to comments concerning the heterogeneity of the universe included in the Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure, we are not finalizing it for the FY 2018 payment determination and subsequent years for the Hospital IQR Program as proposed.

(6) Inclusion and Exclusion Criteria

A full list of the MS-DRG codes used to identify beneficiaries included in the final cohort for each of the proposed episode-based payment measures can be found in the “FY 2016 IPPS NPRM Episode Supplemental Documentation” report in the “Downloads” section at: “NPRM Episode Supplemental Documentation” report at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/hospital-value-based-purchasing/index.html.

The exclusion methodology applied to each of these measures is the same as the one used to calculate the previously adopted NQF-endorsed MSPB measure (NQF #2158) described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51626) and available in the “MSPB Measure Information Form” at: http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228772057350. Episodes for beneficiaries that meet any of the following criteria are excluded from the measure:

- Lack of continuous enrollment in Medicare Parts A and B from 90 days prior to index admission through the end of the episode with Medicare as the primary payer.

- Death date during episode window.

- Enrollment in Medicare Advantage during the episode window.
In addition, claims that meet any of the following criteria do not trigger, or open, an episode:

- Claims with data coding errors, including missing date of birth or death dates preceding the date of the trigger event.
- Claims with payment ≤ 0.
- Acute inpatient stays that involved a transfer.
- Claims from a non-IPPS or non-subsection (d) hospital.

Claims that meet the following criterion will not be included in an episode:

- Claims with payment ≤ 0.

(7) Standardization and Risk-Adjustment

(A) Standardization

Standardization, or payment standardization, is the process of adjusting the allowed charge for a Medicare service to facilitate comparisons of resource use across geographic areas. Medicare payments included in these proposed episode-based measures would be standardized according to the standardization methodology previously finalized for the Hospital IQR Program MSPB measure in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51626) and used for all of the payment measures included in the Value-Based Payment Modifier Program. The methodology removes geographic payment differences, such as wage index and geographic practice cost index, incentive payment adjustments, and other add-on payments that support broader Medicare program goals, such as add-on payments for indirect graduate medical
education (IME) and add-ons for serving a disproportionate share of uninsured patients (DSH).

(B) Risk Adjustment

Risk adjustment uses patient claims history to account for case-mix variation and other factors. The steps used to calculate risk-adjusted payments align with the NQF-endorsed MSPB measure (NQF #2158) method as specified in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51624 through 51626). Specifications for the risk-adjustment employed in the proposed episode-based payment measures are included in the “FY 2015 IPPS NPRM Episode Supplemental Documentation” report, Section 4, titled “Calculating the Hospital-Based Episode Measure,” which can be found in the “FY 2016 IPPS NPRM Episode Supplemental Documentation” report at:


We invited public comment on our proposals.

Comment: Some commenters suggested that the risk adjustment of these measures is not sufficient and recommended a risk adjustment model that is validated and tested before measure implementation. One commenter further suggested that the risk adjustment model cannot be sufficiently determined from claims data.

Response: We disagree with the comment that Medicare claims data is insufficient for the purpose for risk adjustment. Using the diagnosis codes billed on Medicare claims, each episode’s costs are risk adjusted to account for differences in patient characteristics (such as the presence of certain comorbidities) that may affect
costs. With regard to the comment that the risk adjustment methodology is insufficient, or that it has not been tested and validated, we disagree. The risk adjustment construct used is the same as the NQF-endorsed MSPB measure’s risk adjustment model (NQF #2158). The MSPB model has been validated, tested, and NQF endorsed. We refer readers to http://www.qualityforum.org/QPS/2158 for more information on the MSPB’s risk adjustment model.

Comment: One commenter questioned whether the proposed measures would accurately reflect health disparities, which could adversely impact care.

Response: Each episode’s costs are risk adjusted to account for differences in patient characteristics (such as the presence of certain pre-existing conditions) that may affect costs. This is to ensure that hospitals are not penalized for serving populations that are sicker or have higher incidences of chronic disease. The risk adjustment method used is the same as that used for the NQF-endorsed MSPB measure (NQF #2158). The MSPB measure description, including risk adjustment information, may be found in the measure information form located on the NQF’s Web site at:

We received a number of comments on the proposed measures in general. The following comments apply to all four of the proposed episode-based payment measures.

Comment: Many commenters opposed the addition of the Clinical Episode-Based Payment measures until they are NQF-endorsed, noting that the lack of endorsement poses questions about their reliability, validity, and feasibility. Some commenters specifically noted that these measures should not be publicly reported until they are
NQF-endorsed. One commenter expressed concern that there will be substantial variability in hospitals’ ability to report statistically reliable information on all of the proposed measures, given variation in volume.

**Response:** We do not agree that these measures should not be publicly reported until they are NQF-endorsed. We work closely with the NQF on issues related to measure endorsement but, as stated in previous rulemaking (for example, 79 FR 50222), we believe that consensus among affected parties also can be reflected by other means, including consensus achieved during the measure development process, consensus shown through broad acceptance and use of measures, and consensus through public comment. Under the authority of section 1886(b)(3)(B)(viii)(IX) of the Act, we may specify a measure that is not endorsed by NQF as long as due consideration is given to measures currently endorsed by the NQF or any other consensus organizations identified by the Secretary. We reviewed the NQF-endorsed measures, and we were unable to identify any other NQF-endorsed measures that are condition-specific episode based cost measures. We also are not aware of any other condition-specific episode based cost measures that have been endorsed or adopted by a consensus organization other than NQF.

The measures have been conditionally supported by the MAP, and the measures will be submitted to the NQF when the NQF opens a call for submission for episode-based measures. We think that these measures serve an important purpose and fill a gap in available resource use data. Public reporting will help consumers identify hospitals involved in the provision of efficient care for these conditions and procedures. In
addition, public reporting is an important tool to incentivize changes in behavior and encourage hospitals to look for opportunities for improved efficiency. Further, we believe that publicly displaying measure performance data allows us to provide the desired transparency to consumers and stakeholders.

In response to commenters’ concerns about validity and feasibility of the Clinical Episode-Based Payment measures, the measures follow the general construction of the previously adopted, NQF-endorsed, Hospital IQR Program measure, Payment-Standardized Medicare Spending per Beneficiary (MSPB) (NQF #2158), described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51626). Similar to the MSPB measure, the Clinical Episode-Based Payment measures are constructed using Medicare Parts A and B claims data. As in the MSPB measure, these episode-based payment measures group Parts A and B payment for three days prior to hospital admission to 30 days post-discharge and utilize a risk adjustment model that includes patient characteristics along with other factors (for example, attributes of inpatient stays) similar to the MSPB measure. The successful implementation of the MSPB measure provides evidence to the feasibility of the Clinical Episode-Based Payment measures.

As we noted in the FY 2013 IPPS/LTCH PPS final rule, published research indicates that spending for an episode of care varies “greatly” among hospitals (N Engl J Med. 2008; 359: 3–5) and measures for which there is a larger inter-hospital variability are more likely to be reliable (77 FR 53588 through 53589). The condition-specific cost measures we proposed were selected, in part, because they represent common conditions with evidence of large variation in payments. In addition to the positive correlation
between high variability and measure reliability, the selection of measures reflecting common conditions and procedures with large variation in cost encourages hospitals to work to provide higher value care where there is the most opportunity for improvement. This will allow the greatest number of patients to benefit from improvements, and will ensure the largest sample sizes to ensure reliability. Episodes were also chosen based on the ability of the initial hospital care provided for a condition or procedure to influence near-term patient outcomes. This selection criterion helps to ensure measure validity, because there is less chance that differences are due to chance, but rather, they are more likely to be due to the actions taken by the hospital. The proposed measures were fully tested and reviewed by physicians from a variety of specialties to ensure clinical validity. Data on episode cost, frequency, and variation in costs from measure testing, which reflect the validity of the measures are included in the “Measure Methodology” report for proposed episodic payment measures, available at: http://www.qualitynet.org > Hospital-Inpatient > Claims-Based Measures > Proposed episodic payment measures > Measure Methodology.

These measures are constructed using Medicare administrative claims data, which have been shown to be a reliable data element for measure construction. The NQF has found other resource use measures that are based on Medicare claims data to be reliable and valid. As one example, for the all-cause readmission measure (NQF #1789), "reliability and validity [at the data element level and at the measured score level] was generally received as adequate by the steering committee” (NQF, Feb. 2012: Patient Outcomes All Cause Readmissions Expedited Review Pre-voting Call Transcript),
Further, in a memorandum to the NQF Board of Directors, the NQF's Senior Vice President for Performance Measures report noted that the majority of NQF committee members stated that the Hospital-wide All Cause Readmission Measure was highly reliable (Burstin, June 2012: Appeal of All Cause Hospital-wide All Cause Readmission Measure), available at:


Although we believe the measures to be valid and reliable, in response to comments, we will post a measure reliability analysis and propose in future rulemaking a minimum number of cases for reporting to ensure reliability of publicly-reported data, prior to public reporting of these measures.

**Comment:** Some commenters noted the value of seeing these claims-based cost measures and suggested that CMS provide confidential individual hospital reports in order for hospitals to better understand the data and potentially determine interventions to improve processes of care.

**Response:** We appreciate the general support for moving toward efficiency measures, and we acknowledge that hospitals would benefit from the opportunity to review their results and develop a deeper understanding of the measures before the measures are publicly reported.

In response to comments, we are postponing implementation and we are finalizing these three measures for the FY 2019 payment determination and subsequent years.
(CY 2017 performance period and subsequent years), instead of for the FY 2018 payment determination and subsequent years (CY 2016 performance period and subsequent years) as proposed, in order to allow hospitals to gain experience with the measures through confidential feedback reports. During the interim FY 2018 payment determination (CY 2016 performance period) and prior to inclusion for public reporting, we will provide hospitals with confidential hospital-specific feedback reports and supplemental files containing performance data on the three Clinical Episode-Based Payment measures we are finalizing. We currently provide confidential hospital-specific feedback reports and supplemental files for the MSPB measure, and we intend to create similar reports and supplemental files for the three Clinical Episode-Based Payment measures. We believe that the confidential hospital-specific feedback reports and supplemental files will provide hospitals with valuable data to facilitate improvement in the efficiency of the care they provide.

Comment: Many commenters raised concerns about reporting a measure that reflects the factors that may be outside of the hospital’s control, including care performed in multiple settings and the clinical preferences of physicians. In addition, the commenters noted that the measure may not account for the national variation in the mix of services and degree of integration in health care delivery. One commenter specifically recommended that adoption of these measures be delayed until physicians and all post-acute care settings are assessed using similar measures. Some commenters opposed the inclusion of the four clinical episode-based measures to the Hospital IQR Program. Specifically, these commenters believed that these measures would be better suited for
Accountable Care Organizations or bundled payment programs, where they may be comparably applied across all of the relevant care settings.

**Response:** We appreciate the comments and seek to encourage increased care coordination across providers. We disagree that Medicare payments for services received after discharge from a hospital are outside of a hospital’s control. We addressed similar comments regarding the MSPB measure (NQF #2158), which is endorsed by the NQF, in the FY 2012 IPPS/LTCH PPS final rule and reiterated those comments in the FY 2013 IPPS/LTCH PPS final rule (76 FR 51623 through 51624 and 77 FR 53586 through 53587, respectively). We continue to believe, as stated in those rules, that hospitals providing quality inpatient care, conducting appropriate discharge planning, and working with providers and suppliers on appropriate follow-up care will realize efficiencies and perform well, because the Medicare beneficiaries they serve will have a reduced need for excessive post-discharge services.

With regard to the comment that the measures do not account for the degree of health system integration, the aforementioned opportunities for hospitals to exert control over post discharge expenditure and efficiency exists, regardless of the degree of integration of a health system, and in cases where systems are not well-integrated, there may be an even greater opportunity for redesign of care processes to achieve high performance on these measures. We are even more confident now that hospitals can exert influence over post-discharge expenditures in the case of the proposed episode-based payment measures, because the services within the episodes are only those that are clinically-related to the reason for admission.
To ensure that it would be appropriate to attribute the Medicare payments included in these measures to a discharging hospital, one of the selection criteria for episode development was the degree to which the clinical experts consulted agree that standardized Medicare payments for services provided during the episode can be linked to the care provided during the hospitalization. Hospital-based providers exert influence on referrals to post-acute care and service utilization, thus linking hospitalization with near-term outcomes. Measuring national variation in service utilization for these episodes would facilitate the identification of the clinical practices and arrangements that have best outcomes and efficiency. In addition, we have selected condition-specific cost measures for common conditions with evidence of large variation in payments to encourage higher value care where there is the most opportunity for improvement, the greatest number of patients to benefit from improvements, and the largest sample size to ensure reliability.

In response to the comment that the measures do not adequately address the variation in the mix of patients for whom Medicare expenditures are captured in the proposed measures, we note that the episodes within the measures are risk-adjusted, to account for the age and severity of illness of the beneficiary. This risk adjustment methodology is the same as that used for the NQF-endorsed MSPB measure (NQF #2158) and acknowledges the differences in a given hospital’s case mix, so that their performance can be compared to a national average.

Furthermore, while we agree with the commenters’ views regarding the value in aligning resource use measures across settings, we disagree that the reporting of these
important Medicare payment measures is not appropriate for hospital-level reporting or that they would be more appropriate in an Accountable Care Organization or bundled payments structure.

With regard to the comment that the measures should be delayed until physicians and post-acute care settings are addressed, we note that we currently have physician-based analogues of the measures in the Physician Feedback Program. While post-acute care measurement programs are under development, we will take the commenter’s suggestion that similar measures should be incorporated into them under consideration. We do not believe that it would be appropriate to delay the public reporting of this valuable and actionable payment information until such time as any similar, post-acute care measures are implemented. As noted above, these measures were developed in response to hospital stakeholders’ feedback that we should develop a more robust and clinically cohesive measure set for hospitals. Data for these measures were reported in the 2012 Supplemental Quality and Resource Use Reports (QRURs), which are confidential feedback reports for physicians and group practices, and will be reported again in the 2014 Supplemental QRURs (79 FR 40515). More information can be found at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Episode-Costs-and-Medicare-Episode-Grouper.html. Including these Clinical Episode-Based Payment measures in the hospital setting provides physicians with information they need to understand their role in driving the costs of episodes captured in Medicare payment measures. Physicians and groups of physicians receive data to help them more effectively target resources to realize
efficiencies in the care they provide their patients. This understanding of actionable data will facilitate coordination between physicians and hospitals to optimize the efficiency of the care they provide to Medicare beneficiaries and other patients they serve. In addition, we will also explore the potential use of these types of measures within the Medicare Shared Savings Program in the future.

Comment: Several commenters opposed the proposal of the four Clinical Episode-Based Payment measures because of concern over the use of the measures without corresponding measures of quality. One commenter noted that the measures themselves assess only volume and do not adequately consider the quality or appropriateness of the care provided.

Response: While we agree that observation of cost alongside quality is an important concept, we believe that resource use information provides useful information for consumers and other stakeholders as they seek to make informed decisions about facilities involved in the provision of efficient care, even in the absence of a corresponding quality measure.

These measures will be displayed on Hospital Compare along with other quality metrics. We note that, for public reporting purposes, the measures would provide valuable information regarding the cost of care for a particular condition or procedure, which is a reflection of the efficiency of that care.

Comment: Some commenters expressed concern with the Clinical Episode-Based Payment measures because they do not provide beneficiaries with information on their own financial obligations.
Response: We appreciate the suggestion that we should evaluate beneficiary expenditures and will consider that for future reporting. The proposed measures, like the MSPB measure (NQF # 2158) are calculated using Medicare allowed amounts. We believe that inclusion of Medicare allowed amounts, which include both Medicare payments and beneficiaries’ deductible and coinsurance, is the most appropriate and understandable approach at this time. Beneficiary expenditures are dependent on a number of aspects, including their deductibles, copay, and secondary insurers; so evaluating beneficiary expenditures at this time would be more confusing than utilizing Medicare allowed amounts, which are standardized to allow for comparison across hospitals nationwide.

Comment: One commenter expressed concern that these measures make it difficult to monitor and improve performance concurrently.

Response: We believe the commenter is suggesting that improving performance on the measures while concurrently improving quality would be difficult, and we disagree. We believe that improvement in care quality, care coordination, and discharge planning will be reflected in improved performance on these measures; so that hospitals will concurrently improve the care provided to the beneficiaries they serve and their performance on these measures. We believe that public reporting of quality, including resource use measures, is an important tool for quality improvement. The Clinical Episode-Based Payment measures are claims-based and therefore, require no additional reporting on behalf of providers.
Comment: One commenter expressed concern that the Clinical Episode-Based Payment measures overlap with the Medicare Spending per Patient measure.

Response: We developed the proposed condition-specific measures, as intended and stated in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53585), in response to commenters’ suggestions that CMS undertake development of a more robust efficiency measure set. Commenters had also suggested that we include only services related to the reason for admission in the MSPB measure, and we responded that determinations of clinical relatedness could be subjective and that inclusion of a broad range of services would best incentivize care coordination (76 FR 51621). As a result, we developed these Clinical Episode-Based Payment measures that include only services that are clinically related to the reason for admission. For each Clinical Episode-Based Payment measure, a panel of clinicians determined which services, when occurring in the 30 days post-discharge, could be considered clinically associated with the episode. Therefore, we believe that the condition-specific measures provide additional and more targeted information about patient care. These condition-specific measures will allow patients and payers to make more fully informed comparisons of hospitals’ performance. Including condition-specific cost measures alongside the total cost MSPB measure will also provide hospitals with actionable feedback that will better equip them to implement targeted improvements in comparison to an overall cost measure alone.

Comment: One commenter advised CMS to follow the advice of the appropriate stakeholders or specialties to refine or replace the Clinical Episode-Based Payment measures.
Response: We appreciate the commenter’s concerns and the valuable feedback from clinicians and specialty groups during this process. We have worked closely with clinicians and contractors experienced in health services research and payment policy to define and develop the Clinical Episode-Based Payment measures to allow patients and payers to make more fully informed comparisons of hospitals’ performance. We also note that the MAP conditionally supported these measures pending NQF endorsement. Accordingly, we intend to submit the measures for NQF endorsement when a call for episode-based payment measures is opened.

Comment: One commenter supported a movement towards the use of outcome measures over process-of-care measures, but noted their preference for a broad-all condition cost measure over the proposed condition-specific episode-based payment cost measures. Specifically, the commenter noted the proposed condition-specific cost measures would have smaller numbers of hospital-specific observations than an all-condition measure, which result in more random variation without providing additional useful information. The commenter supported the presentation of condition-specific cost measures, but did not support the use of the condition-specific cost measures for inclusion in determining financial incentives.

Response: We appreciate the commenter’s preference for outcome measures rather than process measures. Using outcome measures, such as rehospitalization rates, is important, but we believe that the condition-specific measures (Clinical Episode-Based Payment measures) provide additional and more targeted information about care. Unlike the Medicare Spending Per Beneficiary measure (NQF #2158), the condition-specific
cost measures only include costs from services/procedures related to the condition. These condition-specific measures will allow patients and payers to make more fully informed comparisons of hospitals’ performance. Including condition-specific cost measures will also provide hospitals with actionable feedback that will better equip them to implement targeted improvements versus an overall cost measure alone. As noted in previous comment responses, we developed these measures in response to commenters’ suggestions that we undertake development of a more robust efficiency measure set (77 FR 53585).

Comment: One commenter recommended that CMS work to improve the predictive power of the existing MSPB, instead of adopting these measures.

Response: Using total cost measures, such as the MSPB measure, is important, but we believe that the condition-specific measures in conjunction with the MSPB measure provide additional and more targeted information about care. Unlike the MSPB measure, the condition-specific cost measures only include costs from services/procedures related to the condition. These condition-specific Clinical Episode-Based Payment measures will allow patients and payers to make more fully informed comparisons of hospitals’ performance. Including condition-specific cost measures will also provide hospitals with actionable feedback that will better equip them to implement targeted improvements as compared to an overall cost measure alone. As noted in the response to previous comments, we developed these measures, as stated and planned in the FY 2013 IPPS/LTCH PPS final rule, in response to commenters’
suggestions that we undertake development of a more robust efficiency measure set (77 FR 53585).

Comment: A few commenters supported the proposal to include condition-specific episodes of care measures, noting that the measures align with the National Quality Strategy and address conditions that are drivers of cost for the Medicare program. In addition, commenters noted that the addition of these measures will promote better coordination of care.

Response: We thank the commenters for their support and agree that condition-specific episode measures address an area of need and will promote better care coordination.

After consideration of the public comments we received, we are finalizing a modification of our proposals for the episode-base payment measures. We are finalizing three of the four proposed measures (the Kidney/Urinary Tract Infection Clinical Episode-Based Payment measure, the Cellulitis Clinical Episode-Based Payment measure, and the Gastrointestinal Hemorrhage Clinical Episode-Based Payment measure). We are not finalizing the Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure.

In addition, we are postponing implementation and finalizing these three measures for the FY 2019 payment determination and subsequent years (CY 2017 performance period and subsequent years), instead of the FY 2018 payment determination and subsequent years (CY 2016 performance period and subsequent years) as proposed.
Furthermore, we will provide hospitals with confidential hospital-specific feedback reports containing performance data on these three measures during the interim FY 2018 payment determination (CY 2016 performance period) prior to inclusion for public reporting. Since we are not finalizing the Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure, it will not be included in the confidential hospital-specific feedback reports.

c. Hospital-Level, Risk-Standardized Payment Associated with a 90-Day Episode-of-Care for Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)

(1) Background

Between 2009 and 2012, there were 337,419 total hip arthroplasty (THA) procedures and 750,569 total knee arthroplasty (TKA) procedures for Medicare FFS patients 65 years and older. More than one-third of the US population 65 years and older suffers from osteoarthritis, a disabling condition for which elective THA/TKAs are most commonly performed. Estimates place the annual insurer cost of osteoarthritis in the United States at $149 billion, with Medicare payments to hospitals for THA/TKA exceeding $15 billion annually.

---


There is evidence of variation in payments at hospitals for patients undergoing THA and/or TKA. The mean 90-day risk-standardized payment among Medicare FFS patients aged 65 or older with a qualifying elective primary THA/TKA procedure in 2010–2012 was $23,248, and ranged from $16,421 to $35,123 across 2,614 hospitals.\(^{171}\) However, high or low payments to hospitals are difficult to interpret in isolation. Some high payment hospitals may have better clinical outcomes when compared with low payment hospitals while other high payment hospitals may not have better outcomes. Thus, CMS believes that this payment measure will provide complementary information to other THA/TKA quality measures in the Hospital IQR Program.

Quality measures for THA/TKA, such as: (1) Hospital-level risk-standardized complication rate (RSCR) following elective primary total hip arthroplasty (THA) and/or total knee arthroplasty (TKA) (NQF #1550) (77 FR 53515 through 53518), and (2) Hospital-level risk-standardized readmission rate (RSRR) following elective primary total hip arthroplasty (THA) and/or total knee arthroplasty (TKA) (NQF #1551) (77 FR 53519 through 53521), are already adopted in the Hospital IQR Program and publicly reported, making THA/TKA an ideal procedure for which to assess payments for Medicare patients and relative hospital value. Including this proposed measure in the Hospital IQR Program and publicly reporting it on Hospital Compare would provide stakeholders with additional information about a hospital’s cost of care for THA/TKA that will complement information about a hospital’s quality of care. By including

payments for 90 days after admission, this hospital-level resource use measure can capture the full spectrum of care and encourage collaboration and shared responsibility for patients’ health after their procedures.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24572 through 24574), we proposed to include this non-NQF-endorsed measure in the Hospital IQR Program under the exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act as previously discussed in section VIII.A.7. of the preamble of this final rule. Although the proposed measure is not currently NQF-endorsed, we considered available measures that have been endorsed by the NQF, and were unable to identify any measures that assess hospital risk-standardized payment associated with a 90-day episode-of-care for elective primary THA/TKA. We also are not aware of any other 90-day episode-of-care THA/TKA measures that have been endorsed or adopted by a consensus organization, and found no other feasible and practical measures on this topic.

The MAP conditionally supported this measure on December 10, 2014 pending a timely review by the NQF Cost and Resource Use Standing Committee. The MAP recommended harmonizing and determining the most parsimonious approach to measuring the costs of hip and knee replacements to minimize the burden and confusion of competing methodologies.¹⁷² Once the call for measures for the Cost and Resource Use project at NQF is announced, we will submit this measure for endorsement. In the meantime, we will consider ways to take these MAP recommendations into account.

(2) Overview of Measure and Rationale for Examining Payments for a 90-Day Episode-of-Care

The THA/TKA payment measure assesses hospital risk-standardized payment associated with a 90-day episode-of-care for elective primary THA/TKA for any hospital participating in the Hospital IQR Program.

When considering payments for Medicare patients, we focused on a 90-day episode-of-care triggered by admission for several key reasons. First, THA and TKA procedures require ongoing post-discharge care. Second, the 90-day preset window encourages hospitals to optimize post-discharge care. Third, mechanical complications and wound or joint infections may present after 30 days and rates of these complications remain elevated for at least 90 days. Fourth, the 90-day post-admission timeframe is consistent with CMS’ THA/TKA complication measure, which captures specific complications up to 90 days after admission. Furthermore, we obtained input from a national Technical Expert Panel (TEP) on the most appropriate window for the episode-of-care. Based on TEP feedback, we chose a measure follow-up period of 90 days that includes all payments for the initial 30 days of the episode, and all payments in a predefined set of care settings and services for days 31 through 90.

We refer readers to the measure methodology report and measure risk adjustment statistical model on our Measure Methodology page, under the “Downloads” section of the Web page. We refer readers to the “Hip and Knee Arthroplasty Payment” zip file on our Web site at: http://cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.
(3) Data Sources

The proposed Hospital-Level, Risk-Standardized Payment Associated with a 90-Day Episode-of-Care for Elective Primary THA and/or TKA measure uses Part A and Part B Medicare administrative claims data that contain payments for Medicare FFS beneficiaries who were hospitalized and underwent an elective THA/TKA. This measure will use 3 years of data.

(4) Outcome

The primary outcome of this measure is the hospital-level risk-standardized payment for an elective primary THA/TKA episode-of-care. This measure captures payments for Medicare patients across multiple care settings, services, and supplies (inpatient, outpatient, skilled nursing facility, home health, hospice, physician/clinical laboratory/ambulance services, and durable medical equipment, prosthetics/orthotics, and supplies). This measure includes patient copayments as well as payments from coinsurance. While the approach to standardization in calculating payments over the episode is very similar to the previously adopted Hospital IQR Program measure, Payment-Standardized Medicare Spending Per Beneficiary (MSPB) as described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51626), the THA/TKA measure has a different cohort and risk-model. For more information on how MSPB is calculated, we refer readers to the measure development reports found on the QualityNet Web site at http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228772057350.
To isolate payment variation that reflects practice patterns rather than CMS payment adjustments, this measure excludes policy and geography payment adjustments unrelated to clinical care decisions. We achieve this by “stripping” or “standardizing” payments for each care setting. Stripping refers to removing geographic differences and policy adjustments in payment rates for individual services from the total payment for that service. Standardizing refers to averaging payments across geographic areas for those services where geographic differences in payment cannot be stripped. Stripping and standardizing the payment amounts allows for a fair comparison across hospitals based solely on payments for decisions related to clinical care of THA/TKA.

By risk standardizing the payment measure, we are able to adjust for case-mix at any given hospital and compare a specific hospital’s risk-standardized payment (RSP) to an average hospital with a similar case-mix. We define our analytic timeframe as beginning with the index admission for an elective primary THA/TKA to 90 days post-admission. The measurement includes all payments for the first 30 days after admission and only certain payments based on a pre-defined set of care settings and services for days 31-90.

(5) Cohort

The measure includes Medicare FFS patients aged 65 or older admitted for elective primary THA and/or TKA, and calculates payments made on behalf of these patients (including payments made by CMS, patients, and other insurers) over a 90-day episode-of-care beginning with the index admission. The measure cohort aligns with another previously adopted Hospital IQR Program measure – 90-day hospital-level
risk-standardized complication rate (RSCR) following elective primary THA and/or TKA (NQF #1550) (77 FR 53516 through 53518). Consistent with this previously adopted measure, the proposed measure includes hospitalizations identified by a procedure code of either THA or TKA, as classified by the ICD-9-CM codes 81.51 and 81.54, respectively. The measure includes only those hospitalizations from short-stay acute care hospitals in the index cohort and restricts the cohort to patients enrolled in FFS Medicare Parts A and B (with no Medicare Advantage coverage).

(6) Inclusion and Exclusion Criteria

This proposed measure includes hospitalizations for patients 65 years and older at the time of index admission. An index admission/hospitalization is the initial admission for a qualifying elective primary THA/TKA that triggers the 90-day episode-of-care for this payment measure. An index admission is the hospitalization to which the RSP outcome is attributed and includes index admissions for patients having a qualifying elective primary THA/TKA procedure. The measure excludes the following admissions from the measure cohort: (1) admissions for patients without at least 90 days of post-admission enrollment in FFS Medicare Parts A and B because this is necessary to identify the outcome (payments) in the dataset over the analytic period; (2) admissions for patients discharged against medical advice (AMA) because hospitals had limited opportunity to implement high quality care; (3) admissions for patients transferred to federal hospitals because we do not have claims data for these hospitals, so including these patients would cause payments to be underestimated; (4) admissions for patients with more than two THA/TKA procedure codes during the index hospitalization because,
although clinically possible, it is highly unlikely that patients would receive more than two elective THA/TKA procedures in one hospitalization, and this may reflect a coding error; (5) admissions that could not be matched to admissions in the THA/TKA complication measure because, as part of our data processing, we matched our index THA/TKA admissions to the THA/TKA complication measure cohort to obtain the risk-adjustment variables; and (6) admissions without a DRG weight and the provider received no payment because, without either DRG weight or payment data, we cannot calculate a payment for the patient’s index admission.

(7) Risk Adjustment

The measure adjusts for differences across hospitals in how payments are affected by patient comorbidities relative to patients cared for by other hospitals. We refer readers to the measure risk adjustment statistical model on our Measure Methodology Web page, under the “Downloads” section of the Web page. Please see the “Hip and Knee Arthroplasty Payment” zip file on our Web site at: http://cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

(8) Calculating the Risk-Standardized Payment (RSP)

The measure is calculated using a hierarchical generalized linear model with a log link and an inverse Gaussian distribution, which is a widely accepted statistical method that enables fair evaluation of relative hospital performance by taking into account patient risk factors as well as the number of patients that a hospital treats. This statistical model accounts for the structure of the data (patients clustered within hospitals) and calculates:
(1) how much variation in hospital payment overall is accounted for by patients’
individual risk factors (such as age and other medical conditions); and (2) how much
variation is accounted for by hospital-specific performance. This approach appropriately
models a positive, continuous, right-skewed outcome like payment and also accounts for
the types of patients a hospital treats (that is, hospital case mix), the number of patients it
treats, and the quality of care it provides. This hierarchical generalized linear model is an
appropriate statistical approach to measuring quality based on patient outcomes when the
patients are clustered within hospitals and sample sizes vary across hospitals. Clustered
patients are within the same hospital, and the quality of care of the hospital affects all
patients, so the outcomes for each hospital’s patients are not fully independent (that is,
completely unrelated) as is assumed by many statistical models. As noted above, the
measure methodology defines hospital case mix based on the clinical diagnoses provided
in the hospital claims for their patients’ inpatient and outpatient visits for the 12 months
prior to the THA/TKA hospitalization as well as select conditions indicated by secondary
diagnosis codes on index admission. This methodology specifically does not, however,
account for diagnoses present in the index admission that may indicate complications of
care rather than patient comorbidities.

The RSP is calculated as the ratio of predicted payments to expected payments
and then the ratio is multiplied by the national unadjusted average payment for an
episode-of-care. The ratio is greater than one for hospitals that have higher payments
than would be expected for an average hospital with similar cases and less than one if the
hospital has lower payments than would be expected for an average hospital with similar
cases. This approach is analogous to a ratio of “observed” or “crude” rate to an “expected” or “risk-adjusted” rate used in other similar types of statistical analyses. The RSP is a point estimate—the best estimate of a hospital’s payment based on the hospital’s case-mix.

To calculate the measure result for the Hospital IQR Program, we computed an interval estimate, which is similar to the concept of a confidence interval, to characterize the level of uncertainty around the point estimate. We use the point estimate and interval estimate to determine hospital performance (for example, higher than expected, as expected, or lower than expected). The interval estimate indicates that the true value of the payment ratio lies between the lower limit and the upper limit of the interval. For more detailed information on the calculation methodology, we refer readers to our Measure Methodology Web page, under the “Downloads” section. We refer readers to the “Hip and Knee Arthroplasty Payment” zip file on our Web site at:


We invited public comment on our proposal to adopt the Hospital-Level, Risk-Standardized Payment Associated with a 90-Day Episode-of-Care for Elective Primary THA and/or TKA measure for the FY 2018 payment determination and subsequent years.

Comment: One commenter noted its appreciation that the proposed measure has a corresponding quality measure (THA/TKA Complications) in the Hospital IQR Program unlike previously developed episode-of-care payment measures and noted that this could help mitigate the potential for cost to be prioritized over quality improvements.
Response: We thank this commenter for its support of this measure and the corresponding THA/TKA complications measure. We note that we have developed three other episode-of-care payment measures for acute myocardial infarction (AMI), heart failure (HF), and pneumonia (PN), all of which also have a corresponding condition-specific mortality measure.

The THA/TKA episode-of-care payment measure’s results are intended to reflect differences in payments for patients over a 90-day period that are influenced by hospital care decisions. However, these results alone do not reflect the quality of care provided by hospitals. The payment measure’s results are more meaningful when presented in the context of other outcome measures to facilitate profiling hospital value (payments and quality). Accordingly, we aligned key specifications of the payment measure with those of the corresponding complication measure. We plan to report the results of the payment measure on Hospital Compare along with its corresponding complication measure results.

Comment: One commenter noted its appreciation that the proposed measure is limited to elective procedures.

Response: We appreciate this commenter’s support for measurement of elective total hip and knee arthroplasty procedures.

Comment: Several commenters noted that they will not support the proposed measure until it is NQF-endorsed; but that they would support the measure once it receives NQF endorsement. One commenter recommended that this measure may be appropriate for a robust trial period to inform the NQF’s decision to endorse the measure.
Response: We proposed to include this non-NQF-endorsed measure under the Hospital IQR Program exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act. This provision provides that, in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary.

We considered available measures that have been endorsed or adopted by the NQF. We also are not aware of any other similar measures that have been endorsed or adopted by a consensus organization, and found no other feasible and practical measures on this topic. We believe it is imperative to adopt this measure as it aims to address common elective procedures among Medicare beneficiaries with substantial variability in payments due to different practice patterns. In addition, the measure aligns with our priority objectives and the National Quality Strategy to transform the national healthcare system by measuring and rewarding affordable, quality care. This measure provides transparency on the payments made for Medicare beneficiaries undergoing THA/TKA. Hospitals receive detailed information on how they compare with other institutions regarding the amount and venues of resources expended on patients. Therefore, the measure provides insight to hospitals that is not otherwise possible. Given that hospitals have experience with similar payment measure methodology, such as the measures of
AMI, HF and PN payment that are reported on Hospital Compare, we do not believe a trial period is warranted.

The MAP conditionally supported this measure on December 10, 2014 pending a timely review by the NQF Cost and Resource Use Standing Committee. Although the measure is not currently NQF-endorsed, it is pending submission to NQF for initial endorsement and will be brought to the entity once an appropriate project is called.

Comment: Several commenters supported the efforts of CMS to assess quality of care being delivered to THA/TKA patients. One commenter endorsed initiatives to encourage both high-quality THA/TKA care and collaboration among providers to promote efficiencies, and expressed that the THA/TKA episode-of-care payment measure may promote efficient patient care management.

Response: We thank commenters for their support of the THA/TKA episode-of-care payment measure methodology and inclusion in the Hospital IQR Program. Further, we thank the commenters for their support of our initiative to assess the quality of care delivered to THA/TKA patients.

Comment: Some commenters questioned the reliability, validity and feasibility of the measure. Specifically, the commenters questioned the validity of the THA/TKA payment measure, and expressed that there are concerns within the provider community about the validity of the payment determination model. The commenters highlighted concerns with the breadth of costs incorporated into the measure.

Response: We thank the commenters for their input. We developed this measure in consultation with national guidelines for publicly reported outcome measures, outside
experts, and the public; we believe that the measure meets all validity, reliability, and feasibility requirements.

We ensure the measure reliability, in part, because this measure uses variables from claims data submitted by hospitals for payment, data from Medicare fee schedules, data from final rules for Medicare prospective payment systems and payment policies, and CMS-published wage index data. Our final rules dictate payment adjustments and fees for services for each year across care settings. By incorporating these publicly available final rules into our payment calculation, we ensure our payment calculations are reliably estimated for that year. In constructing the measure, we aimed to utilize only those data elements from the claims data that have both face validity and reliability. Moreover, we assess the measure reliability as part of the development process and found very strong reliability for this measure when comparing the results for hospitals measured with two different random samples.

In addition, during development of the THA/TKA payment measure, we convened a national TEP. We reviewed the cohort, outcome and risk-adjustment approach with the TEP as well as public comments on the measure. We asked the TEP to evaluate the face validity of the measure and the consensus of the TEP favored the face validity of the measure. Finally, the measure is consistent with the technical approach to outcomes measurement set forth in NQF guidance for outcomes measures, CMS Measure Management System (MMS) guidance, and the guidance articulated in the

---

American Heart Association scientific statement, “Standards for Statistical Models Used for Public Reporting of Health Outcomes.”

Regarding the validity of the payment determination model, please note that we applied the same approach to determining payments for THA/TKA payment measure as was used in the NQF-endorsed episode-of-care payment measures for acute myocardial infarction, heart failure, and pneumonia. The payment outcome is determined by using CMS claims and for actual payments which are then adjusted to identify comparable resource utilization (for example, stripping out wage adjustments), this is consistent with the manner that payments are determined for other CMS measures such as the Medicare Spending per Beneficiary measure.

Regarding the breadth of costs assessed in the THA/TKA payment measure, we believe this measure gives stakeholders the opportunity to gain insight into a cascade of medical events triggered by THA/TKA hospitalization and the payments associated with those events. The measure sums payments for Medicare patients, including index admission as well as post-discharge payments for: readmission or other post-discharge inpatient care, skilled nursing facilities, outpatient providers, home health agencies, hospice care, physician/clinical laboratory/ambulance services, and durable medical equipment, prosthetics/orthotics, and supplies. From days 0-30, the measure includes all payments for claims made in this time period. From days 31-90, the measure includes


only payments related to THA/TKA. The results show differences in the patterns of post-discharge care and associated payments for Medicare patients across a continuum of care beginning with a hospitalization for THA/TKA and following patients 90 days after admission. It is important to include this span of payment information to appropriately examine the patterns of post-discharge care. For full details, we refer readers to the Hospital-Level, Risk-Standardized Payment Associated with a 90-Day Episode of Care for Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) (Version 1.0) 2014 Measure Methodology Report located in the Hip and Knee Arthroplasty Payment zip file (http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html).

Comment: Some commenters expressed support for aspects of the THA/TKA payment measure specifications but recommended refinements to the proposed measure’s risk-adjustment model. Specifically, the commenters noted the measure should be refined to risk adjust for prior use of health services, admissions sources, and administrative data on support systems and demographic data. Another commenter raised concerns with the measure’s clinical risk adjustment specific to the scope and adequacy of the clinical risk adjustments variables.

Response: We appreciate the commenters’ support and suggestions to consider prior use of health services, admission source, support systems, and demographic data in the THA/TKA payment measure risk-adjustment model. We note that the THA/TKA payment measure utilizes administrative claims data that do not include some of this information such as support systems (such as living with a spouse). Moreover, outcomes
measures that are designed to highlight opportunities for more efficient care within a community generally do not include risk adjustment for factors such as the patient’s admission source or prior use of health services because such factors may be the result of the patterns of care in the local health care system that the measure aims to illuminate.

For instance, in a community with high rates of use of post-acute care services, more patients may come to the hospital from similar settings such as skilled nursing care in the pre-admission period. To incorporate prior use of skilled nursing care into the measures risk adjustment, could “risk adjust” away the high use of such services in the area in the measure. We note that the payment measure is intended to provide transparency into the variation of patterns of care that can be used to drive efficiency. Higher payments are not necessarily worse than lower payments.

We also note that the THA/TKA episode-of-care payment measure does include risk adjustment for 56 administrative claims-based variables to account for differences in patient case mix that could lead to differences in payments, including patient comorbidities. The measure includes risk variables that assess patient frailty, such as protein-calorie malnutrition, metastatic cancer, dementia, and age, and thus likely does capture the clinical risk factors most concerning to clinicians. In addition, the measure includes risk adjustment for demographic variables, including age and gender. For full details on the measure’s clinical variables included in the risk adjustment, we refer readers to Table 5 of the Hospital-Level, Risk-Standardized Payment Associated with a 90-Day Episode of Care for Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) (Version 1.0) 2014 Measure Methodology Report.
Comment: Some commenters urged CMS to comply with the MAP's recommendation of harmonizing and determining the most parsimonious approach to measure the cost of hip and knee replacements. Furthermore, the commenters noted the need to minimize the burden and confusion of competing methodologies.

Response: While the “MAP conditionally supported this measure pending a timely review of these measures by the NQF Cost and Resource Use Standing Committee to consider harmonization issues and determine the most parsimonious approach to measuring the costs of hip and knee replacements to minimize the burden and confusion of competing methodologies,” the Hospital IQR Program did not propose adopting other hip or knee replacement episode-of-care payment measures at this time. We do not agree that there are harmonization issues among competing measures for these procedures as it relates to this program. The measure approach is currently harmonized with the Hospital IQR Program AMI, HF, and PN payment measures that are publicly reported on Hospital Compare. As recommended by the MAP, we will work with NQF Cost and Resource Use Standing Committee to consider harmonization issues further when this measure is brought to NQF. In reference to the commenters’ concerns about burden, this is a claims-based measure; therefore, since hospitals do not have to separately submit or report any additional data to CMS, there is no burden on hospitals for data collection or calculation of the THA/TKA payment measure.

Key specifications of the THA/TKA payment measure have been harmonized and are aligned with the corresponding THA/TKA complications measure methodology.

Comment: Several commenters opposed the measure, noting it is reflective of post-discharge costs as well as the actions of multiple health care entities, which are beyond the discharging hospital’s control. The commenters stated that the measure is not actionable for hospitals, because the outcome includes costs that happen outside of the inpatient setting. One commenter further added that having a 90-day outcome timeframe is not reasonable as the hospital cannot affect Medicare program expenditures for this long period of time after the patient is discharged.

Response: We appreciate the commenters’ views. When considering payments to hospitals, we attributed payments for an episode-of-care to the hospital since the episode is triggered by admission to an inpatient hospitalization. We focused on a 90-day episode-of-care for several key reasons. First, THA and TKA procedures require ongoing post-discharge care. Second, a fixed 90-day timeframe incentivizes hospitals to optimize post-discharge care. Third, mechanical complications and wound or joint infections may present after 30 days and rates of these complications remain elevated for at least 90 days. Fourth, the 90-day post-admission timeframe is consistent with CMS’ THA/TKA complication measure, which captures specific complications up to 90 days after admission. Finally, a 90-day window was consistent with the timeframe recommended by members of our TEP.

The objective of this episode-of-care payment measure is to encourage efficiencies gained by well-coordinated care across a patient’s experience of total
hip/knee arthroplasty. Hospitalizations represent a brief period of care that requires ongoing management post-discharge and hospitals are often directly responsible for scheduling post-discharge follow-up. This measure includes only primary elective THA/TKA. Therefore, providers have an opportunity to plan for both the acute and post-acute care their patients will receive including follow-up visits, choice of rehabilitation facility or home health services, as well as necessary durable medical equipment. Hospital quality also influences the likelihood of costly prolonged hospital stay or returns to the hospital in the post-discharge period. Therefore, hospital care and decisions made at the admitting hospital affect not only the hospitalization payments, but also payments for care in the post-discharge period. We note that, to mitigate such concerns, only those payments that are considered directly related to the hip or knee replacement are included during the 31-90 day period. A full description of how related payments are determined can be found in the associated technical report at:


Comment: One commenter expressed concern about the accuracy of the administrative data sets used to develop the proposed measure.

Response: We thank the commenter for its concerns. For this measure, we have confidence in the ability to identify the cohort (patients with elective hip or knee replacement) using claims data as this measure uses the same cohort as the THA/TKA complication measure. The outcome of this measure is an assessment of payments made over the episode-of-care, which claims data are ideally suited for assessing. Finally, we
have demonstrated validity of claims-based measures for profiling hospitals' performance historically for a number of previously developed measures, including a medical record validation of the hospital-level risk-standardized complication rate (RSCR) following elective primary THA/TKA. Specifically, we have validated the adequacy of risk-adjustment of claims models by building comparable models using medical record data for risk adjustment for heart failure patients, AMI patients, PN patients, stroke patients and CABG patients. In all of these cases, when both models were applied to the same patient population, the hospital risk-standardized mortality and readmission rates estimated using the claims-based risk-adjustment models had a high level of agreement with the results based on the medical record model, thus supporting the use of the claims-based models for public reporting. In addition, we validated the THA/TKA complication measure outcome definition through a medical record review, which produced a 99 percent agreement between the current claims-based definition of complications and medical record data.\textsuperscript{177}

\textbf{Comment}: Some commenters expressed concern that the proposed measure does not add value for Medicare beneficiaries, because it doesn’t assess quality of care or give beneficiaries a sense of their own financial obligation. The commenters also noted that the proposed measure does not add utility to the THA/TKA readmission and complication measures. One commenter supported CMS providing the resource use data to hospitals, but using a mechanism other than the Hospital IQR Program.

Response: We disagree with commenters and believe that the THA/TKA episode-of-care payment measure adds value for Medicare beneficiaries and is appropriate for the Hospital IQR Program.

We believe that even though this measure does not only reflect beneficiaries’ own financial obligation, it still provides valuable information. This measure provides transparency on the payments made for Medicare beneficiaries undergoing THA/TKA. The THA/TKA episode-of-care payment measure’s results are intended to reflect differences in payments for patients over a 90-day period that are influenced by hospital care decisions. Consumers will be able to examine the payment measure results to determine if the payments for the 90 day episode-of-care following a hip or knee replacement at a given hospital are higher than would be expected at an average hospital. This measure includes payments made by Medicare, other insurers, as well as patients themselves. We believe this transparency will provide information about variation in costs of care for THA/TKA that can inform patient decisions for this primary, elective procedure.

Furthermore, we believe this measure will be beneficial to patients, and is more meaningful, when presented in the context of other outcome measures to facilitate profiling hospital value (payments and quality); and so its inclusion in the Hospital IQR Program is appropriate and beneficial. We aligned key specifications of the payment measure with those of the corresponding complication measure already adopted in the Hospital IQR Program. We plan to report the results of the payment measure on Hospital Compare along with its corresponding complication measure results, thus expanding the
utility of the readmission and complication measures by providing insight on payment and quality concurrently.

Comment: One commenter supported the THA/TKA payment measure’s 90-day outcome timeframe and stated that capturing and sharing data on the full spectrum of care after a surgical procedure will encourage collaboration and shared accountability across the spectrum of clinicians, institutions and providers that serve patients in these care settings and this should be the expectation.

Response: We appreciate the commenter’s support for assessing a 90-day outcome timeframe for the THA/TKA payment measure and agree that the measure will encourage collaboration and shared accountability for Medicare fee-for-service beneficiaries across the continuum of care beginning with a hospitalization for THA/TKA and following patients 90 days after admission.

Comment: A few commenters expressed the importance of having supportive educational materials for hospitals to learn the THA/TKA payment measure specifications. The commenters explained that implementing the THA/TKA payment measure will require sharing of granular resource use data in a manner that enables hospitals to identify opportunities to optimize clinical pathways.

Response: We appreciate the commenter’s recommendation to provide hospitals with robust education materials for the Hospital-Level, Risk-Standardized Payment Associated with the 90-Day Episode of Care for Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) measure. We are committed to supporting stakeholders in their understanding of the measure specifications and will provide
hospitals with the appropriate supporting resources. We note the measure technical report is currently available to access, and we refer readers to:


In addition, as already established in the Hospital IQR Program, hospitals have the opportunity to review its data before they are made public (79 FR 50203). During this preview period prior to public reporting, we will send hospitals hospital-specific reports (HSRs) that will provide patient-level data, as well as State and national results. This will give hospitals an opportunity to review granular resource use data for the THA/TKA payment measure.

Comment: One commenter stated that CMS should ensure there is consensus among stakeholders about the THA/TKA payment measure prior to the measure’s finalization and adoption into the Hospital IQR Program.

Response: We appreciate the commenter’s recommendation to ensure that stakeholders reach consensus on the THA/TKA payment measure prior to public reporting. As stated in previous rulemaking (74 FR 43861), we believe that consensus among affected parties also can be reflected by several means, including consensus achieved during the measure development process (which includes MAP input), consensus shown through broad acceptance and use of measures, via NQF endorsement, and consensus through public comment. This measure has been evaluated by a national TEP and has been subject to a public comment period held during the measure development period where stakeholders could comment on the technical specifications on
the measure. Several commenters expressed strong support of the development of this measure and CMS’ efforts to improve efficiency and incentivize high quality care for THA/TKA patients across a continuum of care. We did not make changes to the technical specifications of the measure due to comments received during the measure development public comment period, but we will take the comments into consideration during the annual measure reevaluation process.

The MAP conditionally supported this measure on December 10, 2014 pending a timely review by the NQF Cost and Resource Use Standing Committee. Although the measure is not currently NQF endorsed, it is pending submission to NQF for initial endorsement and will be brought to the entity once an appropriate project is called.

After consideration of the public comments we received, we are finalizing the Hospital Level, Risk-Standardized Payment Associated with a 90-Day Episode-of-Care for Elective Primary THA and/or TKA measure for the FY 2018 payment determination and subsequent years as proposed.

d. Excess Days in Acute Care After Hospitalization for Acute Myocardial Infarction

(1) Background

Acute myocardial infarction (AMI) is a priority area for outcomes measurement because it is a common condition associated with considerable morbidity, mortality, and healthcare spending. We note that AMI was the tenth most common principal discharge diagnosis among patients with Medicare in 2012.\(^{178}\) AMI also accounts for a large

fraction of hospitalization costs, and it was the sixth most expensive condition billed to Medicare in 2011.\textsuperscript{179}

Some of the costs for AMI can be attributed to high acute care utilization for post-discharge AMI patients in the form of readmissions, observation stays, and ED visits. We note that patients admitted for AMI have disproportionately high readmission rates, and that readmission rates following discharge for AMI are highly variable across hospitals in the United States.\textsuperscript{180, 181} For the previously adopted Hospital IQR Program measure, Hospital 30-Day All-Cause Risk-Standardized Readmission Rate (RSRR) following Acute Myocardial Infarction (AMI) Hospitalization (NQF #0505) (CY 2009 OPPS/ASC final rule with comment period; 73 FR 68780 through 68781) (hereinafter referred to as READM-30-AMI), publicly reported 30-day risk-standardized readmission rates for AMI ranged from 17.5 percent to 30.3 percent for the time period between July 2011 and June 2012.\textsuperscript{182} However, patients are not only at risk of requiring readmission in the post-discharge period. ED visits represent a significant proportion of post-discharge acute care utilization. Two recent studies conducted in patients of all ages have shown that 9.5 percent of patients return to the ED within 30 days of hospital discharge and that

\begin{thebibliography}{9}  
\end{thebibliography}
about 12 percent of these patients are discharged from the ED and are not captured by the previously adopted Hospital IQR Program READM-30-AMI measure.\textsuperscript{183, 184}

In addition, over the past decade, the use of observation stays has rapidly increased. Specifically, between 2001 and 2008, the use of observation services increased nearly three-fold\textsuperscript{185} and significant variation has been demonstrated in the use of observation services for conditions such as chest pain.\textsuperscript{186} These rising rates of observation stays among Medicare beneficiaries have gained the attention of patients, providers, and policymakers.\textsuperscript{187} For example, a report from OIG noted that in 2012, Medicare beneficiaries had 1.5 million observation stays.\textsuperscript{188} Many of these observation stays lasted longer than the intended one day. This OIG report also noted the potential relationship between hospital use of observation stays as an alternative to short-stay inpatient hospitalizations as a response to changing hospital payment incentives.\textsuperscript{189}

Thus, in the context of the previously adopted and publicly reported READM-30-AMI measure, the increasing use of ED visits and observation stays has raised concerns that the READM-30-AMI measure does not capture the full range of

\footnotesize
\begin{itemize}
  \item \textsuperscript{183} Rising KL, White LF, Fernandez WG, Boutwell AE.: Emergency Department Visits After Hospital Discharge: A Missing Part of the Equation. \textit{Annals of Emergency Medicine}. 2013(0).
  \item \textsuperscript{187} Feng Z, Wright B, Mor V.: Sharp rise in Medicare enrollees being held in hospitals for observation raises concerns about causes and consequences. \textit{Health Affairs}. Jun 2012;31(6):1251-1259.
  \item \textsuperscript{188} Wright S.: \textit{Hospitals' Use of Observation Stays and Short Inpatient Stays for Medicare Beneficiaries, OEI-02-12-00040}. Washington, DC: Department of Health and Human Services: Office of Inspector General July 29, 2013.
  \item \textsuperscript{189} Wright S.: \textit{Hospitals' Use of Observation Stays and Short Inpatient Stays for Medicare Beneficiaries, OEI-02-12-00040}. Washington, DC: Department of Health and Human Services: Office of Inspector General July 29, 2013.
\end{itemize}
unplanned acute care in the post-discharge period. In particular, there exists concern that high use of observation stays could in some cases replace readmissions, and hospitals with high rates of observation stays in the post-discharge period may therefore have low readmission rates that do not accurately reflect the quality of care.\(^{190}\)

In response to these concerns, CMS improved on a previously existing non-Hospital IQR Program measure entitled “30-Day Post-Hospital AMI Discharge Care Transition Composite” (NQF #0698). The improved measure (now called Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction) is a risk-adjusted outcome measure for AMI that incorporates the full range of acute care use that patients may experience post-discharge: hospital readmissions, observation stays, and ED visits.

The measure assesses all-cause acute care utilization for post-discharge AMI patients for several reasons. First, from the patient perspective, acute care utilization for any cause is undesirable. It is costly, exposes patients to additional risks of medical care, interferes with work and family care, and imposes significant burden on caregivers. Second, limiting the measure to inpatient utilization may make it susceptible to gaming. Finally, it is often hard to exclude quality concerns and accountability based on the documented cause of a hospital visit. Therefore, this measure includes all-cause utilization.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24574 through 24576), we proposed to include this improved measure under the exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act as previously discussed in section VIII.A.7. of the

\(^{190}\) Carlson J.: Faulty Gauge? Readmissions are down, but observational-status patients are up and that could skew Medicare numbers. Modern Healthcare. June 8, 2013 2013.
preamble of this final rule. We considered existing measures related to care transitions that have been endorsed by the NQF. Existing process measures capture many important domains of care transitions such as education, medication reconciliation and follow-up, but all require chart review and manual abstraction. Existing outcome measures are focused entirely on readmissions or complications and do not include observation stays or ED visits. We also are not aware of any other measures that assess the quality of transitional care by measuring 30-day risk-standardized days in acute care (hospital readmissions, observation stays, and ED visits) following hospitalization for AMI that have been endorsed or adopted by a consensus organization, and found no other feasible and practical measures on this topic.

The MAP conditionally supported this measure on the condition that this measure is reviewed by NQF and endorsed. We refer readers to the Spreadsheet of MAP 2015 Final Recommendations available at: http://www.qualityforum.org/map/, and note that in the document, this measure is entitled “Hospital 30-day, all-cause, unplanned risk-standardized days in acute care following acute myocardial infarction (AMI) hospitalization.” In particular, MAP members noted that the measure should be considered for SDS adjustment in the upcoming NQF trial period, reviewed for the empirical and conceptual relationship between SDS factors and risk-standardized days following acute care, and endorsed with appropriate consideration of SDS factors as determined by NQF standing committees. Some MAP members noted this measure could help address concerns about the growing use of observation stays. We note that this measure will be submitted to NQF with appropriate consideration for SDS, if
required, for endorsement proceedings once an appropriate measure endorsement project has a call for measures.

(2) Overview of Measure

This Excess Days in Acute Care after Hospitalization for AMI measure is a risk-standardized outcome measure that compares the number of days that patients are predicted to spend in acute care across the full spectrum of possible acute care events (hospital readmissions, observation stays, and ED visits) after discharge from a hospital for AMI, compared to the days expected based on their degree of illness.

(3) Data Sources

The proposed measure is administrative claims-based and will use 3 years of data. It uses Part A and Part B Medicare administrative claims data from Medicare FFS beneficiaries hospitalized for AMI.

(4) Outcome

The outcome of the measure is the excess number of days patients spend in acute care (hospital readmissions, observation stays, and ED visits) per 100 discharges during the first 30 days after discharge from the hospital, relative to the number spent by the same patients discharged from an average hospital. The measure defines days in acute care as days spent: (1) in an ED, (2) admitted to observation status, or (3) admitted as an unplanned readmission for any cause within 30 days from the date of discharge from the index AMI hospitalization. Readmission days are calculated as the discharge date minus the admission date. Admissions that extend beyond the 30-day follow-up period are truncated on day 30. Observation days are calculated by the hours in observation,
rounded up to the nearest half day. On the advice of our TEP, an ED treat-and-release visit is counted as one half day. ED visits are not counted as a full day because the majority of treat-and-release visits last fewer than 12 hours.

“Planned” readmissions are those planned by providers for anticipated medical treatment or procedures that must be provided in the inpatient setting. This measure excludes planned readmissions using the planned readmission algorithm previously developed for the READM-30-AMI measure. A more detailed discussion of exclusions follows below.

The measure counts all use of acute care occurring in the 30-day post-discharge period. For example, if a patient returns to the ED three times, the measure counts each ED visit as a half-day. Similarly, if a patient has two hospitalizations within 30 days, the days spent in each are counted. We take this approach to capture the full patient experience of need for acute care in the post-discharge period.

(5) Cohort

We defined the eligible cohort using the same criteria as the existing Hospital IQR Program measure, READM-30-AMI, except that this proposed measure does not include patients admitted to Veterans Administration hospitals. That is, the cohort includes Medicare FFS patients aged 65 years or older: (1) with a principal discharge diagnosis of AMI; (2) enrolled in Part A and Part B Medicare for the 12 months prior to the date of admission, and enrolled in Part A during the index admission; (3) who were discharged from a non-Federal acute care hospital; (4) who were not transferred to
another acute care facility; and (5) were alive at discharge. We defined the cohorts using the following ICD-9-CM diagnosis codes identified in inpatient claims data:

- 410.00 (Acute myocardial infarction of anterolateral wall, episode of care unspecified);
- 410.01 (Acute myocardial infarction of anterolateral wall, initial episode of care);
- 410.10 (Acute myocardial infarction of other anterior wall, episode of care unspecified);
- 410.11 (Acute myocardial infarction of other anterior wall, initial episode of care);
- 410.20 (Acute myocardial infarction of inferolateral wall, episode of care unspecified);
- 410.21 (Acute myocardial infarction of inferolateral wall, initial episode of care);
- 410.30 (Acute myocardial infarction of inferoposterior wall, episode of care unspecified);
- 410.31 (Acute myocardial infarction of inferoposterior wall, initial episode of care);
- 410.40 (Acute myocardial infarction of other inferior wall, episode of care unspecified);
- 410.41 (Acute myocardial infarction of other inferior wall, initial episode of care);
- 410.50 (Acute myocardial infarction of other lateral wall, episode of care unspecified);
- 410.51 (Acute myocardial infarction of other lateral wall, initial episode of care);
- 410.60 (True posterior wall infarction, episode of care unspecified);
- 410.61 (True posterior wall infarction, initial episode of care);
- 410.70 (Subendocardial infarction, episode of care unspecified);
- 410.71 (Subendocardial infarction, initial episode of care);
- 410.80 (Acute myocardial infarction of other specified sites, episode of care unspecified);
- 410.81 (Acute myocardial infarction of other specified sites, initial episode of care);
- 410.90 (Acute myocardial infarction of unspecified site, episode of care unspecified);
- 410.91 (Acute myocardial infarction of unspecified site, initial episode of care).

(6) Exclusion Criteria

The measure excludes the following admissions from the measure cohort:
(1) hospitalizations without at least 30 days of post-discharge enrollment in Part A and Part B FFS Medicare because the 30-day outcome cannot be assessed in this group since claims data are used to determine whether a patient was readmitted, was placed under observation, or visited the ED; (2) discharged against medical advice (AMA) because
providers did not have the opportunity to deliver full care and prepare the patient for
discharge; (3) hospitalizations for patients admitted and discharged on the same day (and
not transferred or deceased) because these patients likely did not suffer clinically
significant AMI; and (4) hospitalizations for patients with an index admission within
30 days of a previous index admission because additional AMI admissions within
30 days are part of the outcome, and we choose not to count a single admission both as an
index admission and a readmission for another index admission.
(7) Risk-Adjustment

The measure adjusts for variables that are clinically relevant and have strong
relationships with the outcome. The measure seeks to adjust for case-mix differences
among hospitals based on the clinical status of the patient at the time of the index
admission. Accordingly, only comorbidities that convey information about the patient at
that time or in the 12 months prior, and not complications that arise during the course of
the index hospitalization, are included in the risk adjustment. The measure does not
adjust for patients’ admission source or their discharge disposition (for example, skilled
nursing facility) because these factors are associated with the structure of the healthcare
system, not solely patients’ clinical comorbidities. Regional differences in the
availability of post-acute care providers and practice patterns might exert undue influence
on model results. In addition, these data fields are not audited and are not as reliable as
diagnosis codes.

The outcome is risk adjusted using a two-part random effects model. This
statistical model, often referred to as a “hurdle” model, accounts for the structure of the
data (patients clustered within hospitals) and the observed distribution of the outcome. Specifically, it models the number of acute care days for each patient as: (a) a probability that they have a non-zero number of days; and (b) a number of days, given that this number is non-zero. The first part is specified as a logit model, and the second part is specified as a Poisson model, with both parts having the same risk-adjustment variables and each part having a random effect. This is an accepted statistical method that explicitly estimates how much of the variation in acute care days is accounted for by patient risk factors, how much by the hospital where the patient is treated, and how much is explained by neither. This model is used to calculate the predicted (including random effects) and expected (assuming random effects are zero) number of days for each patient, and the average difference between these for each hospital is used to construct the risk-standardized Excess Acute Care Days.

(8) Calculating Excess Acute Care Days (EACD)

The EACD is calculated as the difference between the average of the predicted number of days spent in acute care for patients discharged from each hospital and the average number of days that would have been expected if those patients had been cared for at an average hospital, and then the difference is multiplied by 100 so that EACD represents EACD per 100 discharges. We multiply the final measure by 100 to be consistent with the reporting of the existing READM-30-AMI measure. A positive result indicates that patients spend more days in acute care post-discharge than expected; a negative result indicates that patients spend fewer days in acute care than expected.
We invited public comment on our proposal to adopt the Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction measure for the FY 2018 payment determination and subsequent years.

Because comments received apply to both the Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction measure and Excess Days in Acute Care after Hospitalization for Heart Failure measure, we discuss comments and our final policies for both measures at the end of section VIII.A.7.e.(8) of the preamble of this final rule.

e. Excess Days in Acute Care After Hospitalization for Heart Failure

(1) Background

Heart failure is a priority area for outcomes measurement because it is a common condition associated with considerable morbidity, mortality, and healthcare spending. Heart failure was the second most common principal discharge diagnosis among patients with Medicare in 2012.¹⁹¹ Heart failure also accounts for a large fraction of hospitalization costs, and it was the third most expensive condition billed to Medicare in 2011.¹⁹²

Some of the costs for heart failure can be attributed to high acute care utilization for post-discharge heart failure patients in the form of readmissions, observation stays, and ED visits. Patients admitted for heart failure have disproportionately high readmission rates. Readmission rates following discharge for heart failure are highly

variable across hospitals in the United States.\textsuperscript{193, 194} For the previously adopted Hospital IQR Program measure, Hospital 30-Day All-Cause Risk-Standardized Readmission Rate (RSRR) following Heart Failure Hospitalization (NQF #0330) (READM-30-HF) (73 FR 46806 through 48610), publicly reported 30-day risk-standardized readmission rates for heart failure ranged from 17.5 percent to 30.3 percent for the time period between July 2011 and June 2012.\textsuperscript{195} However, patients are not only at risk of requiring readmission in the post-discharge period. ED visits represent a significant proportion of post-discharge acute care utilization. Two recent studies conducted in patients of all ages have shown that 9.5 percent of patients return to the ED within 30 days of hospital discharge and that about 12 percent of these patients are discharged from the ED and are not captured by the previously adopted Hospital IQR Program READM-30-HF measure.\textsuperscript{196, 197} Patients returning to the ED after heart failure hospitalization most commonly return for heart failure recurrence and chest pain.\textsuperscript{198}

In addition, over the past decade, the use of observation stays has rapidly increased. Specifically, between 2001 and 2008, the use of observation services


increased nearly three-fold, and significant variation has been demonstrated in the use of observation services for conditions such as chest pain. These rising rates of observation stays among Medicare beneficiaries have gained the attention of patients, providers, and policymakers. For example, a report from the OIG noted that in 2012, Medicare beneficiaries had 1.5 million observation stays. Many of these observation stays lasted longer than the intended one day. The OIG report also noted the potential relationship between hospital use of observation stays as an alternative to short-stay inpatient hospitalizations as a response to changing hospital payment incentives.

Thus, in the context of the currently adopted and publicly reported Hospital IQR Program READM-30-HF measure, the increasing use of ED visits and observation stays has raised concerns that the READM-30-HF measure does not capture the full range of unplanned acute care in the post-discharge period. In particular, there exists concern that high use of observation stays could in some cases replace readmissions, and hospitals with high rates of observation stays in the post-discharge period may therefore have low readmission rates that do not accurately reflect the quality of care.

---

In response to these concerns, we improved on an existing non-Hospital IQR Program measure entitled “30-Day Post-Hospital HF Discharge Care Transition Composite” (NQF #0699). The improved measure (now called Excess Days in Acute Care after Hospitalization for Heart Failure) is a risk-adjusted outcome measure for heart failure that incorporates the full range of acute care use that patients may experience post-discharge: hospital readmissions, observation stays, and ED visits.

The measure assesses all-cause acute care utilization for post-discharge heart failure patients for several reasons. First, from the patient perspective, acute care utilization for any cause is undesirable. It is costly, exposes patients to additional risks of medical care, interferes with work and family care, and imposes significant burden on caregivers. Second, limiting the measure to inpatient utilization may make it susceptible to gaming. Finally, it is often hard to exclude quality concerns and accountability based on the documented cause of a hospital visit. Therefore, this measure includes all-cause utilization.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24576 through 234779), we proposed this improved measure in the Hospital IQR Program under the exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act as previously discussed in section VIII.A.7. of the preamble of this final rule. We considered other existing measures related to care transitions that have been endorsed by the NQF. Existing process measures capture many important domains of care transitions such as education, medication reconciliation and follow-up, but all require chart review and manual abstraction. Existing outcome measures are focused entirely on readmissions or
complications and do not include observation stays or ED visits. We also are not aware of any other measures that assess the quality of transitional care by measuring 30-day risk-standardized days in acute care (hospital readmissions, observation stays and ED visits) following hospitalization for heart failure that have been endorsed or adopted by a consensus organization, and found no other feasible and practical measures on this topic.

The MAP conditionally supported this measure on the condition that it is reviewed by NQF and endorsed, as detailed in the “Spreadsheet of MAP 2015 Final Recommendations” available at: http://www.qualityforum.org/map/. We note that this measure was entitled “Hospital 30-day, all-cause, unplanned risk-standardized days in acute care following heart failure hospitalization,” in the MAP Spreadsheet. In particular, MAP members noted that the measure should be considered for SDS adjustment in the upcoming NQF trial period, reviewed for the empirical and conceptual relationship between SDS factors and risk-standardized days following acute care, and endorsed with appropriate consideration of SDS factors as determined by NQF standing committees. Some MAP members noted this measure could help address concerns about the growing use of observation stays. We note that this measure will be submitted to NQF with appropriate consideration for SDS, if required, for endorsement proceedings once an appropriate measure endorsement project has a call for measures.

(2) Overview of Measure

This Excess Days in Acute Care after Hospitalization for Heart Failure measure is a risk-standardized outcome measure that compares the number of days that patients are predicted to spend in acute care across the full spectrum of possible acute care events.
(hospital readmissions, observation stays, and ED visits) after discharge from a hospital for heart failure, compared to the days expected at an average hospital, based on their degree of illness.

(3) Data Sources

The proposed measure is administrative claims-based and will use 3 years of data. It uses Part A and Part B Medicare administrative claims data from Medicare FFS beneficiaries hospitalized for heart failure.

(4) Outcome

The outcome of the measure is the excess number of days patients spend in acute care (hospital readmissions, observation stays, and ED visits) per 100 discharges during the first 30 days after discharge from the hospital, relative to the number spent by the same patients discharged from an average hospital. The measure defines days in acute care as days spent: (1) in an ED; (2) admitted to observation status; or (3) admitted as an unplanned readmission for any cause within 30 days from the date of discharge from the index heart failure hospitalization. Readmission days are calculated as the discharge date minus the admission date. Admissions that extend beyond the 30-day follow-up period are truncated on day 30. Observation days are calculated by the hours in observation, rounded up to the nearest half day. On the advice of our TEP, an ED treat-and-release visit is counted as one half day. ED visits are not counted as a full day because the majority of treat-and-release visits last fewer than 12 hours.

"Planned" readmissions are those planned by providers for anticipated medical treatment or procedures that must be provided in the inpatient setting. This measure
excludes planned readmissions using the planned readmission algorithm (78 FR 50786 through 50787), a set of criteria for classifying readmissions that are likely to be planned among the general Medicare population using Medicare claims data, previously developed for Hospital IQR Program 30-day readmission measures, including the previously adopted READM-30-HF measure.

The measure counts all use of acute care occurring in the 30-day post-discharge period. For example, if a patient returns to the ED three times, the measure counts each ED visit as a half-day. Similarly, if a patient has two hospitalizations within 30 days, the days spent in each are counted. We take this approach to capture the full patient experience of need for acute care in the post-discharge period.

(5) Cohort

We defined the eligible cohort using the same criteria as the previously adopted Hospital IQR Program READM-30-HF measure (73 FR 46806 through 48610). The READM-30-HF cohort criteria are included in a report posted on our Measure Methodology Web page, under the “Downloads” section in the “AMI, HF, PN, COPD, and Stroke Readmission Updates” zip file on our Web site at:

http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. This measure differs from the READM-30-HF measure cohort in that this measure does not include patients admitted to Veterans Administration hospitals. That is, the cohort includes Medicare FFS patients aged 65 years or older: (1) with a principal discharge diagnosis of heart failure; (2) enrolled in Part A and Part B Medicare for the 12 months prior to the date of
admission, and enrolled in Part A during the index admission; (3) who were discharged from a non-Federal acute care hospital; (4) who were not transferred to another acute care facility; and (5) were alive at discharge. We defined the cohorts using the following ICD-9-CM diagnosis codes identified in inpatient claims data:

- 402.01 (Malignant hypertensive heart disease with heart failure);
- 402.11 (Benign hypertensive heart disease with heart failure);
- 402.91 (Unspecified hypertensive heart disease with heart failure);
- 404.01 (Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified);
- 404.03 (Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease);
- 04.11 (Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified);
- 404.13 (Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease);
- 404.91 (Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified);
- 404.93 (Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease);
- 428.0 (Congestive heart failure, unspecified);
- 428.1 (Left heart failure);
- 428.20 (Systolic heart failure, unspecified);
- 428.21 (Acute systolic heart failure);
- 428.22 (Chronic systolic heart failure);
- 428.23 (Acute on chronic systolic heart failure);
- 428.30 (Diastolic heart failure, unspecified);
- 428.31 (Acute diastolic heart failure);
- 428.32 (Chronic diastolic heart failure);
- 428.33 (Acute on chronic diastolic heart failure)
- 428.40 (Combined systolic and diastolic heart failure, unspecified);
- 428.41 (Acute combined systolic and diastolic heart failure);
- 428.42 (Chronic combined systolic and diastolic heart failure);
- 428.43 (Acute on chronic combined systolic and diastolic heart failure);
- 428.9 (Heart failure, unspecified).

(6) Exclusion Criteria

The measure excludes the following admissions from the measure cohort:

(1) hospitalizations without at least 30 days of post-discharge enrollment in Part A and Part B FFS Medicare because the 30-day outcome cannot be assessed in this group because claims data are used to determine whether a patient was readmitted, was placed under observation, or visited the ED; (2) discharged against medical advice (AMA) because providers did not have the opportunity to deliver full care and prepare the patient for discharge; and (3) hospitalizations for patients with an index admission within 30 days of a previous index admission because additional heart failure admissions within
30 days are part of the outcome, and we choose not to count a single admission both as an index admission and a readmission for another index admission.

(7) Risk-Adjustment

The measure adjusts for variables that are clinically relevant and have strong relationships with the outcome. The measure seeks to adjust for case-mix differences among hospitals based on the clinical status of the patient at the time of the index admission. Accordingly, only comorbidities that convey information about the patient at that time or in the 12 months prior, and not complications that arise during the course of the index hospitalization, are included in the risk adjustment. The measure does not adjust for patients’ admission source or their discharge disposition (for example, skilled nursing facility) because these factors are associated with the structure of the health care system, not solely patients’ clinical comorbidities. Regional differences in the availability of post-acute care providers and practice patterns might exert undue influence on model results. In addition, these data fields are not audited and are not as reliable as diagnosis codes.

The outcome is risk adjusted using a two-part random effects model. This statistical model, often referred to as a “hurdle” model, accounts for the structure of the data (patients clustered within hospitals) and the observed distribution of the outcome. Specifically, it models the number of acute care days for each patient as: (a) a probability that they have a non-zero number of days and (b) a number of days, given that this number is non-zero. The first part is specified as a logit model, and the second part is specified as a Poisson model, with both parts having the same risk-adjustment variables.
and each part having a random effect. This is an accepted statistical method that explicitly estimates how much of the variation in acute care days is accounted for by patient risk factors, how much by the hospital where the patient is treated, and how much is explained by neither. This model is used to calculate the predicted (including random effects) and expected (assuming random effects are zero) number of days for each patient, and the average difference between these for each hospital is used to construct the risk-standardized Excess Acute Care Days.

(8) Calculating Excess Acute Care Days (EACD)

The EACD is calculated as the difference between the average of the predicted number of days spent in acute care for patients discharged from each hospital and the average number of days that would have been expected if those patients had been cared for at an average hospital, and then the difference is multiplied by 100 so that EACD represents EACD per 100 discharges. We multiply the final measure by 100 to be consistent with the reporting of the existing READM-30-HF measure. A positive result indicates that patients spend more days in acute care post-discharge than expected; a negative result indicates that patients spend fewer days in acute care than expected.

We invited public comment on our proposals to adopt both the Excess Days in Acute Care (EDAC) after Hospitalization for Heart Failure measure and the Excess Days in Acute Care (EDAC) after Hospitalization for Acute Myocardial Infarction measure (hereinafter, collectively referred to as the EDAC measures) for the FY 2018 payment determination and subsequent years.
Comment: One commenter supported the EDAC measures. The commenter believed that for some conditions, like AMI and HF, the increase in ED visits and observations stays raises the concern that readmission measures are not fully capturing the range of unplanned care post-discharge. The commenter noted that an all-cause acute care utilization measure is beneficial to patients as any cause for acute care is undesirable and exposure to medical care has risks. The commenter believed that the proposed measures also address the unintended consequence of shifting patients outside of inpatient care.

Response: We thank the commenter for its support.

Comment: Several commenters opposed the proposed addition of the EDAC measures, noting that the measures include a cohort of patients with multiple risk levels. The commenters also noted that the measures do not make adjustments for mortality and suggest that risks of death be included in this measure. Finally, the commenters expressed their concerns that large academic medical centers will be penalized because of the generally underserved populations that they serve and therefore, believed that there was a greater need for specific risk adjustment factors.

Response: We appreciate the commenters’ concern that the measures include patients with a wide range of severity or multiple risk levels. The EDAC measures’ cohorts were reviewed by clinical experts and a TEP and were subject to a separate public comment period prior to the proposed rule. Stakeholders agreed with harmonizing the cohorts and risk-adjustment models of the EDAC measures with those of the
readmission measures for heart failure and AMI. As a result, we believe these are clinically coherent cohorts.

Although the cohorts may contain patients with different disease severity, and therefore, different levels of risk, these measures are risk-adjusted to account for the fact that hospitals may have a different mix of patients with differing disease severity. For more details about the risk-adjustment methodology, we refer readers to the measures’ methodology reports on our Measure Methodology Web page, under the “Downloads” section of the Web page. Please see the “AMI Excess Days in Acute Care” and “HF Excess Days in Acute Care” zip files on our Web site at: http://cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. However, we will continue to monitor how hospital performance may be influenced by hospital type.

Regarding adjusting for mortality, although death is not included as an outcome in the EDAC measures, the risk of death is accounted for within the EDAC measures. The EDAC measures only assess whether patients return to acute care during post-discharge days in which a patient is alive and therefore, at risk of returning to acute care in the “denominator.” Because some patients do not survive 30 days, not all patients are at the same risk for an acute event for the same amount of time. Therefore, we calculated exposure time as the number of days each patient survives after discharge, which is incorporated as part of the outcome. Moreover, to ensure that mortality rates are considered, we also report separate measures of 30-day mortality for AMI and heart failure within the Hospital IQR Program.
Comment: One commenter asked for definitions of various "Discharge Disposition" designations, including Group Home (and how it differs from Disposition Home) and Assisted Living Facility. In addition, the commenter requested additional information on the definition of a State-designated Assisted Living Facility and how to determine if a facility is a disposition home or an intermediate care facility. Finally, the commenter requested clarification on which discharge disposition is to be used when a patient leaves against medical advice and either goes to another acute care hospital on the same day, in a few days, or it is unknown where the patient goes.

Response: The EDAC measures only use discharge disposition to identify patients who die during their hospitalization, or leave against medical advice. Patients whose discharge dispositions indicate that they left against medical advice are not included in the measure regardless of whether they go to another acute care hospital on the same day, in a few days, or it is unknown where the patient goes. Discharge disposition codes are not used to identify any other cases for exclusion from the measures or in the risk adjustment. We do not examine discharge disposition in the group home, assisted living facility, and intermediate care facility settings for this measure. We only examine returns to acute care settings and short-term acute care hospitals as well as if there are observation stays and emergency room visits.

Comment: Some commenters expressed concern that the measures may result in unintended consequences, including incentivizing hospitals to transition patients too quickly. Another commenter expressed concern that the proposed measures could create an incentive for hospitals to withhold specific types of medications that reduce mortality
and hospitalization in the long term but may destabilize and necessitate more urgent care for patients in the short-term.

**Response:** We appreciate the concern about potential unintended consequences of the EDAC measures. Although we believe it is unlikely that hospitals would be motivated by the measures to transition patients having higher-risk HF or AMI diagnoses too quickly, we will consider ways to monitor for shifts in their care. We also believe it is unlikely that hospitals would withhold necessary medications from their patients as a result of publicly reporting these measures. We recognize that some hospital returns are unavoidable. However, others may result from poor quality of care, overutilization of care or inadequate transitional care. Improving the number of excess days in acute care is the joint responsibility of hospitals and other clinicians. Actions taken by hospital staff while preparing to transition the patient to outpatient status can minimize a patient’s risk for adverse outcomes, as can collaboration and communication between the inpatient and outpatient providers within a community. Measuring excess days in acute care will support existing incentives to invest in interventions to improve hospital care, better assess the readiness of patients for discharge, and facilitate transitions to outpatient status.

**Comment:** A few commenters opposed the proposal to adopt the EDAC measures because they believe that hospitals are already penalized for extended stays through the cap on payments regardless of Length of Stay (LOS). The commenters also noted that there are external factors that influence length of stay, including issues placing patients, restrictions on ordering respiratory services, and appeals on discharge plans. One commenter stated that it did not believe that LOS is a valid proxy for resource use.
Response: The EDAC measures are not intended to penalize hospitals for extended stays and we recognize that some factors are partially outside of a hospital’s control, such as delays in placement as noted by the commenter. These measures are intended to help patients and providers understand variation among hospitals in the days that are spent by patients in acute care settings following a discharge for AMI and HF. The measures provide a broader perspective on post-discharge events than the current readmission measures and are intended to incentivize improvements in care transitions from the hospital so that patients are less likely to return to the acute setting. The measures examine both the utilization of services (that is, whether or not a patient returned to the hospital for an ED visit, observation stay, or readmission) as well as the amount of time in those acute care settings in the 30-day period following discharge from the hospital.

The measures are not intended as resource use measures, but do count the days in acute care. This reason for the use of a day count is two-fold: longer stays may reflect that patients are returning with greater severity of illness and also because it reflects the experience of patients; the longer the stay, the greater the direct impact on the patients in terms of lost days of work or caregiving, cost, and risk of complications.

Comment: A few commenters noted that these episodes each reflect different approaches to patient-centered care and should not be combined into a single number, especially because the “2-midnight” policy and MSBP measure already monitor these indicators. The commenters expressed serious reservations regarding the EDAC measures. One commenter believed that the proposed excess days measures would add
to an existing overlap where hospitals are already penalized for excess readmissions and all of the costs that would be included in the new EDAC measures would already be captured by the Medicare Spending per Beneficiary (MSPB) measure.

Several commenters were concerned that the inclusion of observation patients in the new excess acute care day measures masks the root causes of the increased use of observation stays which the commenter contended is the Recovery Audit Contractor process and the “2-midnight” policy. For this reason, the commenters encouraged CMS to further refine the RAC program as well as refine the assignment of patient status to ensure readmission measurement accuracy.

Response: The “2-midnight” policy provides guidance as to when an inpatient admission is appropriate for payment under Medicare Part A, but does not help beneficiaries to select providers or understand post-discharge acute care use. Although the MSPB measure may capture similar events, it provides a very different perspective based on the Medicare payments for such events. MSPB is focused on Medicare payments whereas the proposed EDAC measures are focused on excess days. The EDAC measures are intended to provide patients and providers a perspective on variation among hospitals in the number of days spent in acute care during the 30-day post-discharge period as compared to what would be expected at an average hospital. The EDAC measures capture a range of post-discharge outcomes that are important to patients.

The EDAC measures are not being finalized for use in a pay-for-performance program, only for use in the pay-for-reporting Hospital IQR Program. Although these measures and the readmission measures all count readmission, the EDAC measures
provide patients a more comprehensive and patient-centered perspective on the 30-day post-discharge experience. The Medicare spending measure (that is, MSPB measure) assess the payments made for care providing insight into costs, but do not directly assess the days that patients spend in an acute care setting following hospital discharge. For the Hospital IQR Program, hospitals would submit Medicare administrative claims for calculation of the EDAC measures, and regardless of the outcome of that data, hospitals would receive credit for submitting the information under the Program. Therefore, we do not believe hospitals would be “penalized” as they are not being asked to submit additional information and payment will not be adjusted based on results of these measures.

We understand that commenters have concerns about the interaction between Medicare payment policy regarding admissions spanning two midnights and the EDAC measures. However, the EDAC measures aim to capture all post-discharge acute care days, regardless of whether they are considered outpatient or inpatient. Therefore, the “2-midnight” policy or any changes to such policy will not influence the outcome of these measures, as all post-discharge days in acute care are captured whether they are billed as outpatient or inpatient days.

In the CY 2013 OPPS/ASC proposed rule (77 FR 45155 through 45157) and final rule with comment period (77 FR 68426 through 68433), we expressed concern about recent increases in the length of time that Medicare beneficiaries spend as hospital outpatients receiving observation services. Subsequently, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50906 through 50954), we addressed several of these concerns
through changes in Medicare’s policies regarding payment of hospital inpatient services under Part B, as well as the appropriateness of Part A payment for short hospital stays (that is, the “2-midnight” policy). In so doing, we clarified that Part A payment is appropriate for admissions where the medical record supports the admitting physician’s determination that the beneficiary either requires care at a hospital expected to transcend at least 2 midnights or that the stay will involve a procedure designated by the OPPS Inpatient-Only list as an inpatient-only procedure (or meets some other CMS designated exception). The “2-midnight” policy is a payment policy and does not limit or direct medical decision making.

At the same time, we imposed a moratorium on Recovery Auditor reviews related to patient status, which has been extended to impact dates of service spanning October 1, 2013 through September 30, 2015. In our CY 2016 OPPS/ASC proposed rule (80 FR 39350), we announced our plans to limit future Recovery Audit reviews surrounding patient status to providers with high denial rates, as determined through patient reviews conducted by CMS Quality Improvement Organizations, related to Part A payment policies for inpatient admission. In addition, Recovery Auditor patient status reviews will be performed under an abbreviated look-back period, if the provider bills the claim within 3 months of the date of service, to provide increased opportunities for denied Part A claims to receive inpatient Part B payment. We believe such ongoing and future initiatives address the commenters’ concerns regarding extended observation.

**Comment:** Many commenters opposed the addition of the EDAC measures. One commenter acknowledged CMS’ rationale for adoption to prevent hospitals keeping
patients in observation units or the ED to avoid them being counted in the 30-day readmission measure, but argued that there are other factors that could account for the observed variability that cannot be captured in claims data and will not be considered in calculating or risk-adjusting. The commenters noted that hospitals serving a disproportionate share of disadvantaged patients may face higher readmission rates or excess days due to conditions beyond the hospitals’ control.

Response: The goal of these measures is not to prevent hospitals from keeping patients in the ED or observation units; it is to help patients and providers understand variation among hospitals in the days that are spent by patients in acute care settings following a discharge for AMI and HF. The measures provide a broader perspective on post-discharge events than the current readmission measures and are intended to incentivize improvements in care transitions from the hospital so that patients are less likely to return to the acute setting.

Although the measures cannot capture all reasons for variability among hospitals, the EDAC measures incorporate risk adjustment using claims data to account for patient factors that could account for the observed variability. The measures use claims-based risk adjusters that are clinically relevant and have strong relationships with the outcome as has been done in other claims-based outcome measures in the Hospital IQR Program. This approach was supported by the TEP. As part of regular measure reevaluation, we monitor ongoing hospital performance to evaluate if certain hospitals are negatively affected by the measures.
Comment: Some commenters recommended that CMS not adopt the EDAC measures, noting that the publicly displayed measure data may not be useful to beneficiaries and that it is unclear if performance on the measure indicates better outcomes. One commenter opposed the proposed adoption of the EDAC measures because these measures combine day counts for readmissions, observation stays, and ED visits.

Response: We agree that the EDAC measures alone will not provide a complete picture of quality on all outcomes for a given hospital. However, we disagree that data from this measure would not be useful to beneficiaries. We believe that it is important to provide more information so that the public can look at results in conjunction with those of other quality measures, such as the readmission and mortality measures, to gain a more comprehensive view of the quality of care at a hospital. Our discussions with patients and the TEP, as well as published literature, indicate that acute care utilization after discharge (that is, return to the ED, observation stay, and readmission), for any reason, is disruptive to patients and caregivers, costly to the healthcare system, and puts patients at additional risk of hospital-acquired infections and complications. These measures are meant to provide patients with a more complete picture of potential post-discharge acute care use as they make choices for their care.

Regarding whether better performance indicates better outcomes, we disagree that it is unclear whether performance on the measure indicates better outcomes. We are confident that for most patients, remaining home or remaining in a non-acute setting rather than returning to the hospital indicates a better outcome. Although some hospital
returns are unavoidable, others may result from poor quality of care, overutilization of care or inadequate transitional care. Transitional care includes effective discharge planning, transfer of information at the time of discharge, patient assessment and education, and coordination-of-care and monitoring in the post-discharge period. When appropriate care transition processes are in place (for example, a patient is discharged to a suitable location, communication occurs between clinicians, medications are correctly reconciled, timely follow-up is arranged), fewer patients return to an acute care setting, either for an ED visit, observation stay, or hospital readmission during the 30 days post-discharge. Numerous studies have found an association between quality of inpatient or transitional care and early (typically 30-day) readmission rates.

and ED visits\textsuperscript{215,216,217,218,219} for a wide range of conditions including AMI and heart failure.

Regarding the commenters concern about combining the count of days for readmissions, observations stays or ED visits, we note that all acute care utilization is not equal in its disruption, cost or risk to patients. Longer returns to the hospital are more disruptive and impart greater risk to patients, and often represent greater severity of illness on return. This is why the EDAC measures’ outcomes are expressed in days. We believe from a patient perspective it is the count of total days that is most meaningful and representative of the disruption. This is also why we combine day counts for each type of event and do not separately report rates of each type of event. This is also valuable for hospitals, because a hospital with a high number of ED visits may still be able to achieve a low number of total days in acute care by actively coordinating care from the ED and avoiding rehospitalizations. The measure combines these three visit types based on the concept that the rate of each type of event is not as relevant to patients as the total days that they spend in acute care settings.

Comment: Many commenters opposed the proposal to adopt the EDAC measures, because they believed that these measures should be NQF-endorsed before being proposed for the Hospital IQR Program.

Response: We proposed to include these non-NQF-endorsed measures under the Hospital IQR Program exception authority in section 1886(b)(3)(B)(IX)(bb) of the Act. Although the proposed measures are not currently NQF-endorsed, we considered available measures that have been endorsed or adopted by the NQF. We also are not aware of any other similar measures that have been endorsed or adopted by a consensus organization, and found no other feasible and practical measures on this topic.

We note that the EDAC measures will be submitted to NQF with appropriate consideration for SDS, if required, for endorsement proceedings once an appropriate measure endorsement project has a call for measures. We believe it is important to move forward with these measures in this program because they fill an important measurement gap. These measures address measurement gaps by including a range of outcomes that are important to patients (that is, readmissions, ED visits, and observation stays), by capturing the total amount of time patients spend in acute care, and by accounting for time at risk of an event (that is, survival time). We anticipate that the measures will support hospital efforts to further optimize quality of care, particularly the quality of transitional care, by providing a more comprehensive picture of post-discharge events. The measures will also provide more detailed information to consumers on what to expect following discharge. These measures also addresses the NQS priority of care coordination. The MAP conditionally supported these measures. Some MAP members
noted these measures could help address concerns about the growing use of observation stays.

**Comment:** Some commenters opposed the proposed inclusion of the EDAC measures. One commenter noted that the proposed measures would include emergency department visits and observation stays, yet there is no consistent evidence to suggest that either is being substituted for readmissions by hospitals. One commenter noted that the proposed EDAC measures suggest that CMS is dismissive of the importance of hospital-level care and has reservations with the use of observation services to avoid a readmissions policy.

**Response:** The commenters suggested that the EDAC measures may have been developed out of concern for the use of observation stays in lieu of readmission without evidence that either are being substituted for readmissions. However, we did not develop these measures to primarily capture substitutions for readmissions; we developed these measures to provide a broad perspective on post-discharge events. The measures are intended to incentivize improvements in care transitions from the hospital so that patients are less likely to return to the acute setting unnecessarily.

We do not dismiss the importance of hospital-level care and support hospitals using the level of care most appropriate for each particular patient’s condition. Some returns to the acute care setting are necessary and the goal is not to avoid all post-discharge acute care service utilization. However, acute care utilization after discharge (that is, return to the ED, observation stay, and readmission), for any reason, is disruptive to patients and caregivers, costly to the healthcare system, and puts patients at additional
risk of hospital-acquired infections and complications. When appropriate care transition
processes are in place (for example, a patient is discharged to a suitable location,
communication occurs between clinicians, medications are correctly reconciled, timely
follow-up is arranged), fewer patients return to an acute care setting, whether for an ED
visit, observation stay, or hospital readmission during the 30 days post-discharge.
Numerous studies, which we cited in response to other comments, have found an
association between quality of inpatient or transitional care and early (typically 30-day)
readmission rates, and ED visits for a wide range of conditions including AMI and heart
failure.

Comment: One commenter expressed concern that physicians, not hospitals,
dictate discharge date.

Response: It is often true that physicians determine the discharge date for
patients. However, the EDAC measures are intended to support broad efforts by both
physicians and hospitals to improve the transitions of care from acute care at the time of
discharge to reduce the likelihood of patients’ needing to quickly return to the acute care
setting. Hospitals can work with physicians to reduce the likelihood of unnecessary
returns to the hospital in the immediate post-discharge period. The EDAC measures are
not intended to penalize hospitals for extended stays. The measures are intended to help
patients and providers understand variation among hospitals in the days that are spent by
patients in acute care settings following a discharge for AMI and HF.
Comment: One commenter opposed the proposed inclusion of the EDAC measures and noted that the measures are unduly burdensome to inpatient and outpatient providers as well as CMS.

Response: For the EDAC measures, there is no data collection burden for inpatient or outpatient providers because we calculate the measures using administrative claims data. Our hope is that the information provided to hospitals through these measures will help inpatient and outpatient providers better understand the trajectory of care for patients that have been discharged from their facility, including acute care visits to other sites, and will assist in targeting quality improvement activities aimed at improving transitions of care.

Comment: One commenter acknowledged the responsibility of the hospital in managing the patient through the transitions of care, but expressed concerns that patient anonymity and freedom of choice in the pursuit of post-acute care are factors to be concerned about.

Response: We agree with the commenter and recognize that patients’ choices will influence post-acute patterns of care. Patients choose where to receive post-discharge care, and some patients may elect to seek care in the acute care setting, for example, going to the emergency department rather than an outpatient physician office. However, as the commenter mentioned, there are actions hospitals can take to decrease the likelihood that patients will feel a need to seek acute care in the days following discharge. Actions taken by hospital staff while preparing to transition the patient to outpatient status can minimize a patient’s risk for adverse outcomes, as can collaboration and
communication between the inpatient and outpatient providers within a community. Measuring excess days in acute care will support existing incentives to invest in interventions to improve hospital care, better assess the readiness of patients for discharge, and facilitate transitions to outpatient status.

We do not believe this measure will limit patient anonymity in any fashion. We also note that the measure does not pose additional risks to patient confidentiality because the measure is based on claims data already collected.

**Comment:** Some commenters had significant reservations about composite measures and patients’ ability to understand them, as well as providers’ ability to take meaningful actions that would have an impact on patient outcomes.

**Response:** We have developed the EDAC measures to try to provide important patient-centered information. We clarify that although care in multiple different settings is included in the outcome, the EDAC measures are not composite measures, meaning that they do not include distinct measures that are combined. Instead, each of the EDAC measures is a single outcome measure that is meant to be conceptually straightforward. The measures indicate how many more (or fewer) days patients from a particular hospital spend in acute care following discharge than would be expected at an average hospital. Our hope is that beneficiaries will find this helps to provide a more complete picture of post-discharge outcomes. We will aim to present results of these measures in a straightforward manner on Hospital Compare for consumers to more easily understand. In addition, we disagree that providers do not have the ability to take meaningful actions that would have an impact on patient outcomes as a result of these measures. We believe
that these measures, which evaluate excess days in acute care, will support existing hospital incentives to further invest in interventions to improve hospital care, better assess the readiness of patients for discharge, and facilitate transitions to outpatient status.

Comment: Some commenters opposed the proposal to adopt the EDAC measures and stated that the measures ignore external factors, outside of a hospital's or clinician's control, and conflate the correlation between fewer post-discharge encounters and higher quality care. The commenters recommended that CMS work to fine-tune the proposed measures and consider moving away from all-cause measures to reflect the fact that certain readmissions specific to the initial encounter can be managed better than others.

Response: We recognize that some hospital returns are unavoidable and outside of a clinician or hospital’s control. However, as previously noted, other returns may result from poor quality of care, overutilization of care or inadequate transitional care. Transitional care includes effective discharge planning, transfer of information at the time of discharge, patient assessment and education, and coordination of care and monitoring in the post-discharge period. When appropriate care transition processes are in place (for example, patient is discharged to a suitable location, communication occurs between clinicians, medications are correctly reconciled, timely follow-up is arranged, etc.), fewer patients return to an acute care setting, either for an ED visit, observation stay, or hospital readmission during the 30 days post-discharge. Numerous studies, which we cited in response to other comments, have found an association between quality of inpatient or transitional care and early returns to the hospital.
We will continue to fine-tune the measure as we do with all measures, through the process of annual measure reevaluation. However, we measure all-cause acute care utilization for several reasons. First, from the patient perspective, acute care utilization for any cause is undesirable. Second, limiting the measures to acute care utilization for HF exacerbation and AMI may make them susceptible to gaming. Moreover, it is often hard to exclude quality concerns and accountability based on the documented cause of a hospital visit. Measuring all-cause acute care utilization encourages hospitals to evaluate the full range of factors that increase the risk of a patient’s return to the acute care setting.

Comment: One commenter opposed the proposed adoption of the proposed EDAC measures, noting the lack of transparency in their development.

Response: We do not agree that we developed these measures with a lack of transparency. We developed the measures in accordance with established measure development guidelines, and through assessment by external groups, a public comment period prior to the proposed rule, and a TEP of national experts and stakeholder organizations. In addition, the proposed measures were included on a publicly available document entitled “List of Measures Under Consideration for December 1, 2014” in compliance with section 1890A(a)(2) of the Act, and they were reviewed by the MAP as discussed in its MAP Pre-Rulemaking Report and Spreadsheet of MAP 2015 Final Recommendations. The MAP conditionally supported the EDAC measures. We have

---


also posted the measures’ methodology reports on our Web site at:


Comment: One commenter expressed concern with the decision to equate the costs and intensity in observation and emergency department care with that of inpatient care when they are treated differently for payment purposes. The commenter specifically disagreed with counting ED visits as half days, because the majority of ED visits last much less time than that.

Response: We appreciate the commenter’s concern about equating the cost and intensity of observation and ED care with that of inpatient care. Acute care utilization after discharge (that is, return to the ED, observation stay, and readmission), for any reason, is disruptive to patients and caregivers, costly to the healthcare system, and puts patients at additional risk of hospital-acquired infections and complications. We agree that all acute care utilization is not, however, equal in its disruption, cost, or risk to patients. Prolonged intensive care is worse from a patient perspective than a brief ED visit. That is why we elected to report each of the EDAC measures as a count of days: Events lasting longer with more cost and disruption (such as readmissions) therefore, naturally weigh more than brief events (such as ED visits) in the overall day count.

We appreciate the commenter’s feedback on considering ED treat-and-release visits as half a day. The average length of stay for a treat-and-release patient from the ED is approximately four hours. Thus, we received feedback from the TEP advising that we

consider a treat-and-release ED visit to be equivalent to one half day. A shorter length of stay may not capture the full burden on the patient to return to the hospital (for example, travel time and lost work time).

Comment: One commenter supported CMS’ proposed EDAC measures, and concurred with the rationale. However, the commenter believed that leaving these proposed measures separate from the Hospital Readmissions Reduction Program would allow hospitals to “game” the Hospital Readmissions Reduction Program measures by reclassifying patients as observation stays and ED visits.

Response: We thank the commenter for the support. While we acknowledge the commenter’s concern that attempts to improve EDAC measures might result in distortions in the Hospital Readmissions Reduction Program, we remind the commenter that the specific conditions for which readmissions are measured are only a small fraction of those subject to EDAC. We will continue to monitor trends to determine if there is systematic shifting and diversion of care (76 FR 51663) and will take appropriate action to minimize unintended consequences.

After consideration of the public comments we received, we are finalizing both the Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction and Excess Days in Acute Care after Hospitalization for Heart Failure measures for the FY 2018 payment determination and subsequent years as proposed.
f. Summary of Previously Adopted and Newly Adopted Hospital IQR Program Measure Set for the FY 2018 and FY 2019 Payment Determinations and Subsequent Years

The table below outlines the Hospital IQR Program measure set for the FY 2018 and FY 2019 payment determinations and subsequent years and includes both previously adopted measures and measures adopted in this final rule. We note that in past rules, we have included separate charts for each FY; however, here, we are combining the chart for the FY 2018 payment determination and subsequent years with that of the FY 2019 payment determination and subsequent years. We identify those measures that begin to be included in the program starting with the FY 2019 payment determination with a ±. In addition, all measures finalized for removal in this rule are not included in this chart.

<p>| Hospital IQR Program Measures for the FY 2018 Payment Determination and Subsequent Years |
|---------------------------------|-------------------------------------------------|------------------|</p>
<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NHSN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLABSI</td>
<td>National Healthcare Safety Network (NHSN)</td>
<td>0139</td>
</tr>
<tr>
<td></td>
<td>Central Line-Associated Bloodstream Infection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(CLABSI) Outcome Measure</td>
<td></td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI</td>
<td>American College of Surgeons – Centers for Disease Control and Prevention (ACS-CDC)</td>
<td>0753</td>
</tr>
<tr>
<td></td>
<td>Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure</td>
<td></td>
</tr>
<tr>
<td></td>
<td>● Colon Procedures</td>
<td></td>
</tr>
<tr>
<td></td>
<td>● Hysterectomy Procedures</td>
<td></td>
</tr>
<tr>
<td>CAUTI</td>
<td>National Healthcare Safety Network (NHSN)</td>
<td>0138</td>
</tr>
<tr>
<td></td>
<td>Catheter-associated Urinary Tract Infection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(CAUTI) Outcome Measure</td>
<td></td>
</tr>
<tr>
<td>MRSA Bacteremia</td>
<td>National Healthcare Safety Network (NHSN)</td>
<td>1716</td>
</tr>
<tr>
<td></td>
<td>Facility-wide Inpatient Hospital-onset</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Methicillin-resistant <em>Staphylococcus aureus</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(MRSA) Bacteremia Outcome Measure</td>
<td></td>
</tr>
<tr>
<td>Short Name</td>
<td>Measure Name</td>
<td>NQF #</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>CDI</td>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset <em>Clostridium difficile</em> Infection (CDI) Outcome Measure</td>
<td>1717</td>
</tr>
<tr>
<td>HCP</td>
<td>Influenza Vaccination Coverage Among Healthcare Personnel</td>
<td>0431</td>
</tr>
<tr>
<td>CDI</td>
<td>Based on estimated probability of the event occurring at 30 days after hospital discharge or the occurrence of the event during hospitalization. Inpatient and outpatient hospitalizations included. Medical bed and observation bed patients included. Ambulatory surgery and emergency department patients excluded. Inpatient hospitalizations in acute care hospitals included. Ambulatory care settings, long-term care settings, rural health centers, and critical access hospitals excluded.</td>
<td>1717</td>
</tr>
<tr>
<td>VTE</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Myocardial Infarction (AMI) Hospitalization. Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Heart Failure (HF) Hospitalization. Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization. Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization.</td>
<td>0230</td>
</tr>
<tr>
<td>VTE</td>
<td>Incidence of Potentially Preventable Venous Thromboembolism</td>
<td>N/A</td>
</tr>
<tr>
<td>STK</td>
<td>Stroke 30-day Mortality Rate</td>
<td>N/A</td>
</tr>
<tr>
<td>Short Name</td>
<td>Measure Name</td>
<td>NQF #</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>CABG Mortality</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Coronary Artery Bypass Graft (CABG) Surgery</td>
<td>2558</td>
</tr>
<tr>
<td>READM-30-AMI</td>
<td>Hospital 30-Day All-Cause Risk-Standardized Readmission Rate (RSRR) Following Acute Myocardial Infarction (AMI) Hospitalization</td>
<td>0505</td>
</tr>
<tr>
<td>READM-30-HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Heart Failure (HF) Hospitalization</td>
<td>0330</td>
</tr>
<tr>
<td>READM-30-PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization</td>
<td>0506</td>
</tr>
<tr>
<td>READM-30-THA/TKA</td>
<td>Hospital-Level 30-Day, All-Cause Risk-Standardized Readmission Rate (RSRR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)</td>
<td>1551</td>
</tr>
<tr>
<td>READM-30-HWR</td>
<td>Hospital-Wide All-Cause Unplanned Readmission Measure (HWR)</td>
<td>1789</td>
</tr>
<tr>
<td>COPD READMIT</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization</td>
<td>1891</td>
</tr>
<tr>
<td>STK READMIT</td>
<td>30-Day Risk Standardized Readmission Rate Following Stroke Hospitalization</td>
<td>N/A</td>
</tr>
<tr>
<td>CABG READMIT</td>
<td>Hospital 30-Day, All-Cause, Unplanned, Risk-Standardized Readmission Rate (RSRR) Following Coronary Artery Bypass Graft (CABG) Surgery</td>
<td>2515</td>
</tr>
<tr>
<td>MSPB</td>
<td>Payment-Standardized Medicare Spending Per Beneficiary (MSPB)</td>
<td>2158</td>
</tr>
<tr>
<td>AMI Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI)</td>
<td>2431</td>
</tr>
<tr>
<td>HF Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care For Heart Failure (HF)</td>
<td>2436</td>
</tr>
<tr>
<td>Short Name</td>
<td>Measure Name</td>
<td>NQF #</td>
</tr>
<tr>
<td>----------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>PN Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For Pneumonia</td>
<td>2579</td>
</tr>
<tr>
<td>Hip/knee complications</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)</td>
<td>1550</td>
</tr>
<tr>
<td>PSI 4 (PSI/NSI)</td>
<td>Death among Surgical Inpatients with Serious, Treatable Complications</td>
<td>0351</td>
</tr>
<tr>
<td>PSI 90</td>
<td>Patient Safety for Selected Indicators (Composite Measure)</td>
<td>0531</td>
</tr>
<tr>
<td>THA/TKA Payment**</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for Primary Elective Total Hip Arthroplasty and/or Total Knee Arthroplasty</td>
<td>N/A</td>
</tr>
<tr>
<td>AMI Excess Days**</td>
<td>Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction</td>
<td>N/A</td>
</tr>
<tr>
<td>HF Excess Days**</td>
<td>Excess Days in Acute Care after Hospitalization for Heart Failure</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Electronic Clinical Quality Measure (select at least 4)**

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMI-2</td>
<td>Aspirin Prescribed at Discharge for AMI</td>
<td>N/A</td>
</tr>
<tr>
<td>AMI-7a</td>
<td>Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival</td>
<td>0164</td>
</tr>
<tr>
<td>AMI-8a</td>
<td>Primary PCI Received Within 90 Minutes of Hospital Arrival</td>
<td>0163</td>
</tr>
<tr>
<td>AMI-10</td>
<td>Statin Prescribed at Discharge</td>
<td>N/A</td>
</tr>
<tr>
<td>CAC-3</td>
<td>Home Management Plan of Care Document Given to Patient/Caregiver</td>
<td>N/A</td>
</tr>
<tr>
<td>ED-1*</td>
<td>Median Time from ED Arrival to ED Departure for Admitted ED Patients</td>
<td>0495</td>
</tr>
<tr>
<td>ED-2*</td>
<td>Admit Decision Time to ED Departure Time for Admitted Patients</td>
<td>0497</td>
</tr>
<tr>
<td>EHDI-1a</td>
<td>Hearing Screening Prior to Hospital Discharge</td>
<td>1354</td>
</tr>
<tr>
<td>HTN</td>
<td>Healthy Term Newborn</td>
<td>0716</td>
</tr>
<tr>
<td>PC-01*</td>
<td>Elective Delivery (Collected in aggregate, submitted via Web-based tool or electronic clinical quality measure)</td>
<td>0469</td>
</tr>
<tr>
<td>PC-05</td>
<td>Exclusive Breast Milk Feeding and the Subset</td>
<td>0480</td>
</tr>
</tbody>
</table>
## Hospital IQR Program Measures for the FY 2018 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC-05a</td>
<td>Exclusive Breast Milk Feeding Considering Mother’s Choice</td>
<td></td>
</tr>
<tr>
<td>PN-6</td>
<td>Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients</td>
<td>0147</td>
</tr>
<tr>
<td>SCIP-Inf-1a</td>
<td>Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision</td>
<td>0527</td>
</tr>
<tr>
<td>SCIP-Inf-2a</td>
<td>Prophylactic Antibiotic Selection for Surgical Patients</td>
<td>0528</td>
</tr>
<tr>
<td>SCIP-Inf-9</td>
<td>Urinary catheter Removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with Day of Surgery Being Day Zero</td>
<td>N/A</td>
</tr>
<tr>
<td>STK-02</td>
<td>Discharged on Antithrombotic Therapy</td>
<td>0435</td>
</tr>
<tr>
<td>STK-03</td>
<td>Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>0436</td>
</tr>
<tr>
<td>STK-04*</td>
<td>Thrombolytic Therapy</td>
<td>0437</td>
</tr>
<tr>
<td>STK-05</td>
<td>Antithrombotic Therapy by the End of Hospital Day Two</td>
<td>0438</td>
</tr>
<tr>
<td>STK-06</td>
<td>Discharged on Statin Medication</td>
<td>0439</td>
</tr>
<tr>
<td>STK-08</td>
<td>Stroke Education</td>
<td>N/A</td>
</tr>
<tr>
<td>STK-10</td>
<td>Assessed for Rehabilitation</td>
<td>0441</td>
</tr>
<tr>
<td>VTE-1</td>
<td>Venous Thromboembolism Prophylaxis</td>
<td>0371</td>
</tr>
<tr>
<td>VTE-2</td>
<td>Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
<tr>
<td>VTE-3</td>
<td>Venous Thromboembolism Patients with Anticoagulation Overlap Therapy</td>
<td>0373</td>
</tr>
<tr>
<td>VTE-4</td>
<td>Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram</td>
<td>N/A</td>
</tr>
<tr>
<td>VTE-5*</td>
<td>Venous Thromboembolism Discharge Instructions</td>
<td>N/A</td>
</tr>
<tr>
<td>VTE-6*</td>
<td>Incidence of Potentially Preventable Venous Thromboembolism</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Patient Survey

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCAHPS</td>
<td>HCAHPS + 3-Item Care Transition Measure (CTM-3)</td>
<td>0166</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0228</td>
</tr>
</tbody>
</table>

### Structural

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Safety Culture**</td>
<td>Hospital Survey on Patient Safety Culture</td>
<td>N/A</td>
</tr>
<tr>
<td>Hospital IQR Program Measures for the FY 2018 Payment Determination and Subsequent Years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Short Name</strong></td>
<td><strong>Measure Name</strong></td>
<td><strong>NQF #</strong></td>
</tr>
<tr>
<td>Registry for Nursing Sensitive Care</td>
<td>Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care</td>
<td>N/A</td>
</tr>
<tr>
<td>Registry for General Surgery</td>
<td>Participation in a Systematic Clinical Database Registry for Registry for General Surgery</td>
<td>N/A</td>
</tr>
<tr>
<td>Safe Surgery Checklist</td>
<td>Safe Surgery Checklist Use</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* Measure is listed twice, as both chart-abstracted and electronic clinical quality measure.
** Measures we are adopting beginning with FY 2018 and for subsequent years.

<table>
<thead>
<tr>
<th>Hospital IQR Program Additional Measures for the FY 2019 Payment Determination and Subsequent Years</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short Name</strong></td>
</tr>
<tr>
<td>Kidney/UTI Payment</td>
</tr>
<tr>
<td>Cellulitis Payment</td>
</tr>
<tr>
<td>GI Payment</td>
</tr>
</tbody>
</table>

8. Electronic Clinical Quality Measures

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24581 through 245820), we clarified our policy for one previously adopted voluntarily reported electronic clinical quality measure for the FY 2017 payment determination. Specifically, we clarified our requirements for the submission of STK-01 for CY 2015/FY 2017 payment determination. In addition, we proposed to expand our electronic clinical quality measure policy in order to make reporting of electronic clinical quality measures required for the FY 2018 payment determination and subsequent years.
a. Previously Adopted Voluntarily Reported Electronic Clinical Quality Measures for the FY 2017 Payment Determination

For a discussion of our previously finalized electronic clinical quality measures and policies, we refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50811 through 50819), and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50241 through 50253; 50256 through 50259; and 50273 through 50276).

b. Clarification for the Venous Thromboembolism (VTE) Prophylaxis (STK – 01) Measure (NQF #0434)

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24581), we proposed to clarify reporting requirements for the Venous Thromboembolism (VTE) Prophylaxis (STK – 01) Measure (NQF #0434). In the FY 2016 IPPS/LTCH PPS final rule (78 FR 50808), we stated that hospitals need not report the STK-01 measure as part of the STK measure set if reporting electronically, because no electronic specification existed for STK-01. In other words, hospitals that successfully submit STK-02, STK-03, STK-04, STK-05, STK-06, STK-08, and STK-10 as electronic clinical quality measures are not required to also chart-abstract and submit STK-01 in order to meet Hospital IQR Program requirements for the FY 2016 payment determination. However, hospitals that do not submit the specified electronic clinical quality measures must continue to chart-abstract and submit STK-01 as previously required. To review the details in the 2014 IPPS/LTCH PPS final rule, we refer readers to our Web site at:

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-
We proposed to clarify that this policy continues for the CY 2015/FY 2017 payment determination. Hospitals that chose to submit the STK-02, STK-03, STK-04, STK-05, STK-06, STK-08, and STK-10 as electronic clinical quality measures are not required to also chart-abstract and submit STK-01 in order to meet Hospital IQR Program requirements for the FY 2017 payment determination. However, hospitals that do not submit the specified electronic clinical quality measures must continue to chart-abstract and submit STK-01 as previously required. We note that STK-01 is proposed for removal for CY 2016/FY 2018 payment determination and refer readers to section VIII.A.3.b. of the preamble of this final rule for more details.

We invited public comment on this proposal.

**Comment:** One commenter supported the idea that hospitals that successfully submit STK-02, STK-03, STK-04, STK-05, STK-06, STK-08, and STK-10 as electronic clinical quality measures would not be required to also chart-abstract and submit STK-01 in order to meet the Hospital IQR Program requirements for the FY 2016 payment determination.

**Response:** We thank the commenter for its support.

**Comment:** One commenter expressed concern that the STK measure set lacks NQF endorsement.
Response: We disagree with the commenter because STK-08 is the only STK measure that has lost endorsement. STK 02, STK-03, STK-04, STK-05, STK-06, and STK-10 are still currently endorsed. The stroke measures are stewarded by The Joint Commission, and to our knowledge, The Joint Commission is not planning to resubmit STK-08 for re-endorsement. Despite the fact that STK-08 has lost endorsement, we still believe it should remain in the Hospital IQR Program at the present time to promote alignment with the EHR Incentive Program.

Comment: A few commenters recommended that both CMS and TJC consider proposing the STK-01 measure as an electronic clinical quality measure because they believed this form will allow CMS to retain the measure for voluntary reporting.

Response: We thank the commenters for their suggestion and will consider it in future rulemaking.

After consideration of the public comments we received, we are finalizing our clarification that the policy regarding STK-01 continue for the CY 2015/FY 2017 payment determination. Hospitals that chose to submit the STK-02, STK-03, STK-04, STK-05, STK-06, STK-08, and STK-10 as electronic clinical quality measures are not required to also chart-abstract and submit STK-01 in order to meet Hospital IQR Program requirements for the FY 2017 payment determination. However, hospitals that do not submit the specified electronic clinical quality measures must continue to chart-abstract and submit STK-01 as previously required.

c. Requirements for Hospitals to Report Electronic Clinical Quality Measures for the FY 2018 Payment Determination and Subsequent Years

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24581 through 24582), we proposed to expand our electronic clinical quality measure policy in order to make reporting of electronic clinical quality measures required, rather than voluntary, under the Hospital IQR Program. Specifically, we proposed that, beginning in CY 2016/FY 2018 payment determination and subsequent years, we will require hospitals to select and submit 16 electronic clinical quality measures covering three NQS domains from the 28 available electronic clinical quality measures. For the FY 2018 payment determination and subsequent years, we proposed that hospitals must submit Q3 and Q4 data for 16 measures chosen by a hospital and reported as electronic clinical quality measures. For example, for the FY 2018 payment determination, hospitals would be required to submit Q3 and Q4 CY 2016 data for 16 measures of their choice. This proposal is in alignment with the Medicare EHR Incentive Program, as discussed in section VIII.D.2.b. of the preamble of this final rule.

Hospitals would not fail validation based on these data for CY 2016/FY 2018 payment determination reporting because validation for electronic measures is currently under development. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50269 through 50273), we finalized a proposal to conduct a validation pilot test for electronically specified measures in FY 2015. The pilot is currently underway and therefore, the results are not yet available.
We will delay publicly reporting electronic clinical quality measure data submitted by hospitals for CY 2016/FY 2018 payment determination in order to allow time for us to evaluate the effectiveness of electronically reported clinical quality measure data. In the meantime, measures reported via electronic clinical quality measure will be marked with a footnote on Hospital Compare noting that: (1) the hospital submitted data via EHR; (2) data are being processed and analyzed; and (3) CMS will eventually publicly report this data once CMS determines the data to be reliable and accurate.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50815 through 50818), we adopted a policy under which we would only publicly report electronic clinical quality measure data under the Hospital IQR Program if we determined that the data are accurate enough to be reported. We believe that our current proposal to delay public reporting of electronic clinical quality measure data submitted by hospitals for CY 2016/FY 2018 payment determination is also in line with our existing policies. In future rulemaking, we will continue to address our intent to ensure that measures meet the reliability and validity requirements set for public reporting and that the measures are accurate and understandable before measures are publicly reported on Hospital Compare.

As shown in the table above entitled “Hospital IQR Program Measures for the FY 2018 Payment Determination and Subsequent Years,” 6 measures (ED-1, ED-2, STK-04, VTE-5, VTE-6, and PC-01) may be reported either via chart-abstraction or as electronic clinical quality measures. For the FY 2018 payment determination and subsequent years, we proposed that hospitals may either report a full year of data (Q1
through Q4) in accordance with the submission requirements for chart-abstracted data, or electronically submit two quarters of data (Q3 and Q4) for each of these 6 measures. If hospitals chose to report these 6 measures electronically, the measures could be used to count toward the Hospital IQR Program’s 16 required electronic clinical quality measures. Hospitals choosing to report these 6 measures via chart-abstraction would have to select other electronic measures to meet the requirement to report 16 electronic clinical quality measures. Additional detail on submitting electronic data for measures can be found in section VIII.A.10.d.(3) of the preamble of this final rule.

We recognize that measure rates may not be comparable between measures reported via chart-abstraction and measures that are electronically specified. Collecting electronic measure data according to our proposal that hospitals must select and submit 16 electronic clinical quality measures will help us evaluate variations in data capture modes (chart-abstracted versus electronic clinical quality measures) in order to determine whether and what adjustments are necessary for the two different modes of collection. We refer readers to section VIII.A.3.b. of the preamble of this final rule, where we discuss CMS’ belief that, although the intent of a measure is the same whether it is reported via chart-abstraction or electronically, the submission modes and measure rates are not the same.

We also considered two alternative required electronic clinical quality measure reporting options. Alternative A would require hospitals to submit 10 of 28 quality measures: (1) VTE-1; (2) STK-02; (3) ED-1; (4) STK-05; (5) STK-06; (6) STK-10; (7) VTE-2; (8) STK-08; (9) ED-2; and (10) STK-03. Our data show that these measures
are most frequently reported with non-zero values among hospitals attesting under 2014 Meaningful Use. In addition, all 10 of these measures have been included in the Hospital IQR Program measure set as voluntary electronic clinical quality measures since CY 2014/FY 2016 payment determination (79 FR 50209 through 50211). Alternative B would require hospitals to submit 10 of 28 quality measures of each hospital’s choice. Both alternatives differ from our proposal only in the number and/or composition of the electronic clinical quality measures to be reported; that is, for both of these alternatives, the reporting periods and submission requirements would be the same as those proposed in the proposed rule.

However, we determined not to pursue these alternative reporting options as we believe that requiring hospitals to report more measures electronically is in line with our goals to move towards electronic clinical quality measure reporting and to align with the EHR Incentive Program, which requires reporting on 16 clinical quality measures covering at least three domains.

We believe that our proposals will ultimately decrease reporting burden to hospitals. Once capture is possible within EHR, the time and resources needed to submit quality measures data are significantly less compared to manual abstraction. Electronic clinical quality measure collection does not require hospital staff time to find and pull paper medical records and manually review them to abstract data elements used in measure calculation. We acknowledge that there are initial costs, but believe that long-term benefits associated with electronic data capture outweigh those costs.
We welcomed public comment on our proposal to require hospitals to select and submit 16 electronic clinical quality measures covering three NQS domains from the 28 available electronic clinical quality measures for eligible hospitals and CAHs for the FY 2018 payment determination and subsequent years. We refer readers to section VIII.A.10.d.(3) of the preamble of this final rule for details on reporting periods and submission deadlines for electronic clinical quality measures.

**Comment**: Many commenters supported CMS’ efforts to move towards electronic clinical quality measure reporting and to increase the number of required electronic clinical quality measures, noting the potential for electronic reporting to reduce provider burden, improve reporting efficiencies, and reduce measurement reporting costs.

**Response**: We thank the commenters for their support.

**Comment**: One commenter specifically supported the proposal to make reporting on a subset of 28 electronic clinical quality measures mandatory, but opposed CMS’ proposal to allow hospitals to select among the 28 measures.

**Response**: We thank the commenter for its support. In order to best facilitate electronic reporting during early implementation of the requirement, we believe that allowing hospitals the flexibility to select which of the 28 electronic clinical quality measures they wish to report is necessary at this time. We will consider whether to propose a specific set of electronic clinical quality measures in future rulemaking.

**Comment**: Many commenters expressed concern that hospitals are not prepared to submit electronic clinical quality measures and some noted that even hospitals leading in EHR implementation face challenging vendor-level issues outside their control.
Several commenters noted that electronic clinical quality measure reporting is difficult for hospitals due to the complexities involved in implementing EHRs. Some commenters noted that currently, data integration across hospitals' multiple information systems is lacking and many expressed concern that hospitals lack the resources to map the necessary data elements from the EHR to a QRDA format.

As a result of these concerns, many commenters requested an extension in the roll-out of this requirement, in order to allow hospitals time to prepare to meet reporting requirements and to allow more time for mapping and testing of this reporting approach. Many commenters recommended that CMS continue its current policy of voluntary electronic submission. Many of these commenters expressed support for CMS' goal to move towards electronic reporting, but specifically requested that CMS delay a requirement for hospitals to report electronic clinical quality measures until CY 2018, in order to align with the EHR Incentive Program. Other commenters recommended that CMS require electronic clinical quality measure reporting no sooner than CY 2017. One commenter recommended that we allow dual submission of electronic data on a voluntary basis for the Hospital IQR and EHR Incentive Programs until FY 2020.

Some commenters recommended that CMS require fewer than 16 electronic clinical quality measures. Specifically, the commenters recommended that CMS require either 2 to 3, 5, or 10 electronic clinical quality measures.

Response: We believe that requiring hospitals to report measures electronically is in line with our goals to move towards electronic clinical quality measure reporting and to align with the EHR Incentive Program. Furthermore, we believe that the
CY 2016/FY 2018 payment determination is the appropriate time to require electronic clinical quality measure reporting because hospitals have had several years to report data electronically for the EHR Incentive Program and Hospital IQR Program (2 years of pilot reporting and 2 years of voluntary reporting), and because currently 95 percent of hospitals attest to successful electronic clinical quality measure reporting under the EHR Incentive Program.

However, we recognize the challenges associated with electronic reporting and encourage hospitals to work with their vendors to achieve electronic capture and reporting despite mapping and integration issues. In response to comments, we are finalizing a modification of our proposals in order to reduce the effort for hospitals with vendor challenges. We believe that requiring a lesser number of eCQMs will reduce these burdens on hospitals because the burden associated with mapping issues, which is dependent on the number of measures required to be reported, were cited as a major concern among commenters. However, we anticipate increasing this number in future rules to propose the 16 measure requirement. We believe that a full year should be enough time for hospitals to address their mapping issues and that it is important to continue to make progress towards electronic reporting.

Therefore, instead of requiring hospitals to report 16 of the 28 electronic clinical quality measures for the CY 2016/FY 2018 payment determination as proposed, we will require hospitals to report a minimum of 4 of the 28 electronic clinical quality measures for CY 2016 reporting. Suggestions from commenters ranged from 2 to 10 regarding the number of electronic clinical quality measures that should be required. We believe that
requiring hospitals to report a minimum of 4 electronic clinical quality measures is reasonable because it significantly reduces burden for hospitals from the 16 proposed, but still allows us to collect data derived from EHRs to further our plans for electronic data collection and validation. Specifically, requiring only 4 electronic clinical quality measures reduces hospitals’ burden of reporting by 75 percent compared to the burden of submitting 16 electronic clinical quality measures.

Further, instead of requiring hospitals to report 2 quarters of data (Q3 and Q4) two months following the reporting period as proposed, we will require hospitals to report the 4 electronic clinical quality measures for only 1 quarter (either Q3 or Q4) of CY 2016/FY 2018 payment determination, with a submission deadline of February 28, 2017. We believe this will allow more time for hospitals to overcome vendor issues, such as mapping and testing. Under this modified version of the proposals, no NQS domain distribution will be required.

Comment: One commenter requested clarification on whether it needed to report 1 year of data for the PC-01 measure via chart abstraction for the Hospital VBP Program if they report 6-months of data for PC-01 as an electronic clinical quality measure for the Hospital IQR Program.

Response: Electronic clinical quality measure submissions are not a part of the Hospital VBP Program at this time. Therefore, all hospitals must submit PC-01 measure data based on chart abstraction for that program to be included in the scoring determination, irrespective of how hospitals submit data for the Hospital IQR Program.
Comment: Some commenters requested clarification on the reporting requirement for the eight chart-abstrated quality measures (ED-1, ED-2, PC-01, STK-4, VTE-5, VTE-6, SEP-1, IMM-2) in the Hospital IQR Program for the FY 2018 payment determination, and specifically, whether these measures must be reported via chart-abstraction if a hospital does not submit these measures electronically. (CMS notes that six of these eight measures overlap as electronic clinical quality measures, and that both the chart-abstrated and electronic versions of these measures are included in the Hospital IQR Program measure set.) Other commenters specifically asked for clarification on the reporting requirements and submission deadlines for those six Hospital IQR Program measures that can be reported either as electronic clinical quality measures, or via chart-abstraction (ED-1, ED-2, PC-01, STK-4, VTE-5 and VTE-6). One commenter asked if all six of these measures need to be reported via chart-abstraction or electronically, as a group.

Several commenters recommended allowing parallel reporting of chart-abstrated and electronically extracted measures during a transition period to ensure that eCQMs can be reported consistently, accurately and with a quality threshold. One commenter recommended that hospitals should be able to report the electronic clinical quality measures adopted under the Hospital IQR Program via chart-abstraction.

Response: We refer readers to our prior response describing modifications to our proposed policies. With respect to the ED-1, ED-2, PC-01, STK-4, VTE-5, and VTE-6 measures, instead of giving hospitals the option to either report the electronic clinical quality measure or submit via chart-abstraction as proposed, we will instead continue to
require hospitals to submit data for these measures via chart abstraction as previously required, and the results of which will be publicly displayed. However, hospitals may choose to submit electronic data on any of these six measures in addition to the chart-abstraction requirements to meet the requirement to report 4 of 28 electronic clinical quality measures. This allows for parallel reporting and continued public reporting for these important quality measures.

We note that we do not agree that hospitals should be able to report all electronic measures via chart-abstraction instead, because such a policy would not further our goals to move towards electronic clinical quality measure reporting and align with the EHR Incentive Program. We also note that SEP-1, IMM-2, which are chart-abstracted measures in the Hospital IQR Program measure set, are required for reporting in order for hospitals to successfully meet program requirements.

Comment: Some commenters expressed concern that electronic clinical quality measure reporting is difficult for small hospitals due to the complexities involved in implementing EHRs. In addition, some commenters specifically requested that CMS adopt a hardship exemption, similar to the one used for under the EHR Incentive Program, to consider allowing hospitals to receive an exemption from the electronic reporting requirements if a hardship is demonstrated. One commenter noted that failure to provide an exception process will unfairly expose hospitals to risk for payment penalties.

Response: We believe that requiring hospitals to report measures electronically is in line with our goals to move towards electronic clinical quality measure reporting and
to align with the EHR Incentive Program. We believe that the CY 2016/FY 2018 payment determination is the appropriate time to require electronic clinical quality measure reporting because hospitals have had several years to report data electronically for the EHR Incentive Program and Hospital IQR Program (2 years of pilot reporting and 2 years of voluntary reporting) and because currently 95 percent of hospitals attest to successful electronic clinical quality measure reporting under the EHR Incentive Program. In addition, requiring hospitals to report a minimum of 4 electronic clinical quality measures significantly reduces burden for hospitals as compared to our proposal, while still allowing us to collect statistically meaningful data to further our plans for electronic data collection.

However, we recognize the challenges associated with electronic reporting and encourage hospitals of all sizes to work with their vendors to achieve electronic capture and reporting. In response to comments and as stated above, we are finalizing a modification of our proposals in order to reduce the effort for hospitals with vendor challenges.

In addition, we will continue to allow hospitals to apply the zero denominator and case threshold exceptions described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50323 through 50324). Furthermore, we are expanding our previously established Extraordinary Circumstances Extensions/Exemptions policy (79 FR 50277) to address commenters’ suggestions. We are finalizing a policy, effective starting with the FY 2018 payment determination, to allow hospitals to utilize the existing Extraordinary Circumstances Exemption (ECE) form to request an exemption from the Hospital IQR
Program’s electronic clinical quality measure reporting requirement for the applicable program year based on hardships preventing hospitals from electronically reporting. Such hardships could include, but are not limited to, infrastructure challenges (hospitals must demonstrate that they are in an area without sufficient internet access or face insurmountable barriers to obtaining infrastructure) or unforeseen circumstances, such as vendor issues outside of the hospital’s control (including a vendor product losing certification). In addition, hospitals newly participating in the Hospital IQR Program, that are required to begin data submission under Hospital IQR Program procedural requirements at 42 CFR 412.140(c)(1), which describes submission and validation of Hospital IQR Program data, may also be considered undergoing hardship and can apply for an exemption. This expansion of our Extraordinary Circumstances Extensions/Exemptions policy is also discussed in section VIII.10.d.(3) of the preamble of this final rule.

Comment: Many commenters raised concerns about the reliability, feasibility, and validity of electronic clinical quality measure data reporting, noting that electronic data may not be the same as chart-abstracted data. A few commenters encouraged CMS to ensure the integrity of electronic clinical quality measures prior to requiring hospitals to report them. Some commenters recommended that CMS use the data reported for the EHR Incentive Program to provide insight on the feasibility, reliability and validity of eCQMs for future use in quality reporting programs. A few commenters also recommended that electronic clinical quality measure reporting remain voluntary until both providers and policymakers agree on the maturity of eCQM specifications and
federal regulators test and validate the accuracy and completeness of electronic clinical quality measures.

Response: We note that a validation pilot is currently under way and the results of that pilot are pending, as described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50269 through 50273). We are requiring electronic reporting before the results of the pilot, because we believe the CY 2016/FY 2018 payment determination is the appropriate timeframe for this policy because hospitals have already had several years to report data electronically for the EHR Incentive Program and Hospital IQR Program (2 years of pilot reporting and 2 years of voluntary reporting), and because currently 95 percent of hospitals attest to successful electronic clinical quality measure reporting under the EHR Incentive Program. We intend to use the results of this pilot to inform future rulemaking.

In addition, requiring eCQMs ensures that we will have data to address commenters’ concerns regarding the comparability of electronic and chart-abstracted data. We also refer readers to section VIII.A.3.b. of the preamble of this final rule, where we discuss our position that, although the intent of a measure is the same whether it is reported via chart- abstraction or electronically, we recognize that the submission modes and measure rates are not the same.

In regards to the suggestion that we utilize data reported for the EHR Incentive Program, we appreciate commenters’ suggestions, but note that hospitals have the option to report eCQMs by attestation, and 95 percent of hospitals chose to attest, under the EHR Incentive Program. Attestation data cannot inform measure validity.
We do not agree that electronic clinical quality measure reporting should remain voluntary until both providers and policymakers agree on the maturity of eCQM specifications. We believe that electronic clinical quality measures have matured since their inception, and we will address any specific eCQMs in future rulemaking. Our established policies about removing or suspending measures (section VIII.A.3. of the preamble of this final rule) also apply to eCQMs.

Comment: Some commenters opposed the proposal to require hospitals to report electronic clinical quality measures and indicated concern that the proposal does not address a national goal or objective in quality improvement. The commenters also believed that reliable and accurate performance data are a higher priority than advancing a particular measure submission approach.

Response: We disagree that promoting quality measure reporting from EHRs fails to meet any goals or objectives in quality improvement. Quality measures available now, as well as those being developed for the future, are increasingly based on electronic clinical quality measure standards. In the future, we anticipate that most, if not all, quality measures will be based on data derived from EHRs. Furthermore, the move to electronic reporting is a national priority. In addition, as we have explained in previous rulemaking (79 FR 50245), our aim to align the Hospital IQR Program with the Medicare EHR Incentive Program is in part so that we can attempt to minimize reporting burden on hospitals and ease the transition to reporting of electronic clinical quality measures.

Reliable, accurate data and electronic reporting are all important priorities to us. We believe that, with the advancement of technology and the use of electronic measures, even more precise, accurate, and reliable data will be captured for analysis.

Comment: Some commenters noted that CMS has not completed the validation pilot test for electronic measures, and recommended that CMS provide information on the number of hospitals that would fail to meet the Hospital IQR Program requirements because they cannot report data electronically.

Response: We anticipate completing the Hospital IQR Program electronic clinical quality measure validation pilot in 2015. Our intent is to carefully assess results of the validation pilot once available and make recommendations regarding the reporting of electronic data accordingly. In the meantime, we have observed the successes of hospitals meeting the Meaningful Use requirements. While we cannot speculate on the number of hospitals that would fail Hospital IQR Program requirements, our data show that 95 percent of hospitals already attest to successful electronic clinical quality measure reporting under the EHR Incentive Program.

Comment: Some commenters believed that the EHR Incentive Program is meant to drive electronic reporting and that requiring electronic data under the Hospital IQR Program could duplicate penalties to hospitals unable to meet Meaningful Use requirements. One commenter noted that the proposed electronic clinical quality measure policy is more aggressive than the requirements specified by either Stage 2 or Stage 3 Meaningful Use. One commenter recommended that electronic reporting should not be
mandated in the Hospital IQR Program before it is required for the Meaningful Use Program.

Response: We believe that it is appropriate to require reporting from EHRs through the Hospital IQR Program because measures available now and those being developed for the future are increasingly based on electronic clinical quality measure standards. In addition, we disagree that the requirements for electronic reporting in the Hospital IQR Program duplicates penalties. In an effort to align with the EHR Incentive Program, we have specified that hospitals meeting electronic reporting requirements for the Hospital IQR Program will be considered to have successfully reported the electronic clinical quality measure requirement to the EHR Incentive Program as well. In addition, we note that our data show that 95 percent of hospitals already attest to successful electronic clinical quality measure reporting under the EHR Incentive Program and, accordingly, we do believe that the majority of hospitals will successfully report electronic clinical quality measures, meeting both the EHR Incentive Program and the Hospital IQR Program requirements. Finally, for hospitals that meet our criteria for hardship, we are expanding our Extraordinary Circumstances Extensions/Exemptions policy as discussed above.

Comment: One commenter recommended that there should be consideration given to hospitals that do not have 16 non-zeros to report.

Response: We refer readers to our modified policy described above. We expect hospitals to make every effort to report at least 4 electronic CQMs by February 28, 2017 since this is a Hospital IQR Program requirement. Hospitals that meet this requirement
will be considered to have successfully reported. In addition, as is permitted under the EHR Incentive Program (79 FR 50323 through 50324), the zero denominator and case threshold exceptions apply to electronic reporting under the Hospital IQR Program (79 FR 50258). We also clarify here that we interpret “non-zeros” to be measures for which a hospital has at least one patient meeting the measure inclusion requirements.

Comment: Some commenters indicated that the resources required to establish functionality to produce QRDA files are limited due to other high-priority initiatives, including implementation of ICD-10 in October 2015. In addition, some commenters noted the learning curve associated with the transition to ICD-10 may impact the quality of electronic data.

Response: We note that while ICD-10 goes into effect October 1, 2015, we are not requiring submission of electronic clinical quality measure data until February 28, 2017. We believe that this provides hospitals with ample time to prepare to submit electronic data.

Comment: One commenter recommended that the proposed electronic clinical quality measure requirement be delayed until the 2014 Edition EHR technology is made widely available to hospitals.

Response: While there may be varying levels of accessibility as a result of a hospital’s available resources, the 2014 Edition of CEHRT is currently already widely available to hospitals.225

Comment: Some commenters recommended that CMS adopt the recommendations for streamlining national quality measurement efforts outlined in the Institute of Medicine’s Vital Signs report.

Response: We thank the commenters for their recommendation and will consider this approach for future rulemaking. In addition, we refer readers to the Institute of Medicine’s Vital Signs report for more information.\textsuperscript{226}

Comment: Several commenters encouraged CMS to engage stakeholders to develop a plan to transition to electronic reporting.

Response: We thank the commenters for their recommendation and note that we engage with stakeholders throughout the year through monthly calls with associations, vendors, and hospitals. We are nearing our fourth annual eCQM kaizen event where selected subject matter experts gather to apply Lean principles\textsuperscript{227} to further the evolution of these measures. We are aware that our external stakeholders would like information on how the Lean methodology has been applied to the development of electronic clinical quality measures (eCQMs). Therefore, we are in the process of identifying a central Web site where the public can access information resulting from the events we have conducted with internal and external stakeholders. There will be an announcement on the eCQI Resource Center when this information is ready for viewing (https://ecqi.healthit.gov/).

Comment: Some commenters suggested that electronic measures not be finalized until they have been endorsed by NQF.


\textsuperscript{227} ASQ: Lean Six Sigma in Healthcare. Available at: http://asq.org/healthcaresixsigma/lean-six-sigma.html.
Response: We refer readers to our table of eCQMs in section VIII.A.7. of the preamble of this final rule, above, for which measures are currently considered endorsed as eCQMs. We refer to these eCQMs as “legacy” eCQMs because they were re-specified as eCQMs after first being collected in chart abstracted form. These legacy eCQMs are considered endorsed until their next re-endorsement cycle. In communications with NQF, CMS and other measure stewards such as TJC were directed to submit the legacy eCQMs for endorsement during maintenance review in order for NQF to continue to consider the eCQM versions endorsed. We will take this information into consideration as our measures are due for their maintenance re-endorsement.

Comment: One commenter expressed concern that we do not have the infrastructure to accept patient-level data. Another commenter noted their concern that 2015 is the first year electronic QRDA I submission has been accepted by CMS.

Response: We note that 2015 is not the first year CMS has requested electronic QRDA I submission. As described in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50905), electronic reporting pilots for the EHR Incentive Program from 2012 and 2013 included electronic reporting via QRDA I. In addition, as described above, we note that we are specifically delaying required electronic clinical quality measure reporting until Q3 or Q4 of CY 2016 for the FY 2018 payment determination with a submission deadline of February 28, 2017 in order to provide hospitals with additional time to implement any necessary software. We refer readers to section VIII.A.10.d. of the preamble of this final rule for additional detail on our QRDA requirements.
Comment: Some commenters expressed concern about the public reporting implications of electronic data for hospitals in future years. These commenters noted that the proposed delay of public reporting acknowledges problems with electronic data accuracy.

Response: Because we currently do not have results available from the validation pilot, we cannot yet comment, either negatively or positively, on the implications of public reporting of electronic data. Our intent is to assess results of the validation pilot once available and make recommendations regarding the reporting of electronic data accordingly. We note that we will propose plans to publicly display electronic data in next year’s rulemaking, after the conclusion and assessment of the validation pilot. This timing would enable us to finalize public display details prior to the February 28, 2017 deadline for electronic clinical quality measure data submission.

Comment: Some commenters noted their belief that the Hospital IQR Program is not aligned with TJC’s core measure set and stated that the lack of quality measure harmonization and alignment creates inefficiencies and serves as a source of confusion. The commenters recommended that CMS align the electronic clinical quality measure set with the TJC core measure set.

Response: We appreciate the commenters’ promotion of measure alignment and will review TJC’s core measure set to assess future potential for measure alignment opportunities. However, in doing so, we must consider external alignment with CMS’ policy goals, including alignment with other CMS programs, CMS quality reporting programs, the EHR Incentive Program, and supporting efforts to move facilities towards
reporting electronic measures. The Hospital IQR Program’s requirements as finalized further our priorities while keeping hospital burden in mind.  

Comment: One commenter requested that CMS name e-measures distinctly, such that chart-abstracted or claims based measures will not be confused with these measures.

Response: We acknowledge the commenter’s concern around clear identification of electronic measures. Measures derived from EHRs are currently referred to as eCQMs (electronic clinical quality measures). We will take commenter’s suggestion into consideration.

Comment: One commenter noted its concern that the time required to complete electronic document templates is already burdensome and has impacted the amount of time providers have available for direct patient interaction. Rapidly increasing the amount of structured data required in order to support fully electronic clinical quality measure reporting would dramatically increase that burden.

Response: We recognize the commenter’s concern and we continue to work with stakeholders, specifically providers, to alleviate burden where possible. Once full data capture is possible within EHR, the time and resources needed to submit quality measures data are significantly less compared to manual abstraction.

After consideration of the public comments we received, we are finalizing a modified version of our proposal. Specifically, instead of requiring hospitals to report 16 electronic clinical quality measures as proposed, we are finalizing that hospitals must report at least 4 electronic clinical quality measures. However, we intend to propose to

---

increase the number of required electronic clinical quality measures in the FY 2017 IPPS/LTCH PPS proposed rule, as hospitals should have sufficient time to address the mapping issues by February 2017. In addition, instead of requiring that hospitals select and report electronic clinical quality measures across three NQS domains as proposed, under our finalized policy, we will not require that any of the 4 electronic clinical quality measures fall under any particular NQS domain.

Furthermore, instead of requiring two quarters of electronic clinical quality measure data (Q3 and Q4 of CY 2016) for the FY 2018 payment determination (CY 2016 reporting), we are finalizing that hospitals must submit electronic clinical quality measure data for only one quarter, either Q3 or Q4, of CY 2016 for the FY 2018 payment determination by February 28, 2017. We also note that, although we proposed to allow hospitals to report 6 measures (ED-1, ED-2, PC-01, STK-4, VTE-5, and VTE-6) either via chart-abstraction or electronically, these measures will remain required via chart-abstraction as previously required. However, hospitals may choose to submit electronic data, in addition to chart-abstracted data, on any of these 6 measures to meet the requirement to report 4 of 28 electronic clinical quality measures.

Finally, while we proposed that measures reported via electronic clinical quality measure would be marked with a footnote on Hospital Compare, we are finalizing instead that any data submitted electronically will not be posted on the Hospital Compare Web site. We will address public reporting of electronic data in next year’s rulemaking, after the conclusion and assessment of the validation pilot.
9. Future Considerations for Electronically Specified Measures: Consideration to Implement a New Type of Measure that Utilizes Core Clinical Data Elements

a. Background

We have implemented several claims-based measures comparing hospital performance on 30-day mortality, 30-day readmission, and complications following hospitalization for several conditions and procedures in the Hospital IQR, Hospital Readmissions Reductions, and Hospital VBP Programs. Although these measures have been shown to provide valid information about hospital performance, the clinical community continues to express the opinion that data gathered directly from patients and used by clinicians to guide diagnostic decisions and treatment are preferable for risk adjustment of hospital outcome measures. In response to clinicians and providers’ feedback in public comment periods during measure development, and keeping with our goal to move toward the use of electronic health records (EHRs) for electronic quality measure reporting throughout CMS programs, where feasible, we are considering:

(1) the use of core clinical data elements derived from EHRs for use in future quality measures (for example, risk adjustment of outcome measures); (2) the collection of additional administrative linkage variables to link a patient’s episode-of-care from EHR data with his administrative claim data, and (3) use of content exchange standards.

During a July 2014 public comment period on the CMS Call for Public Comment Web site\textsuperscript{229} for the hybrid hospital-wide readmission measure with administrative claims

\textsuperscript{229} CMS.gov. Measure Management System, Public Comment. Hybrid Hospital-Wide Readmission Measure with Claims and Electronic Health Record Data. Available at: \url{http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/CallforPublicComment.html}. 
and electronic health record data, we received supportive feedback on the importance of the use of clinical data in hospital outcome measures. Commenters supported our efforts in examining new approaches to provide a more accurate assessment and portrayal of services provided by clinicians and hospitals, and the feedback also indicated their belief that it is very important that enriched clinical data from an EHR be used to supplement the clinically limited datasets available from administrative claims data. We note that reviewers can find the public comment summary report within the Hybrid Hospital-Wide Readmission Measure with Electronic Health Record Extracted Risk Factors (Version 1.1), in the “Downloads” section of our Measure Methodology Web page. We refer readers to the Core Clinical Data Elements and Hybrid Measures zip file found on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

In response to this public feedback, as well as CMS policy goals, we have identified a set of 21 clinical variables, or core clinical data elements, which we note are routinely collected on hospitalized adults and feasibly extracted from hospital EHRs. We believe that these core clinical data elements can be adapted for future use as part of specific quality measures. During our testing, we found that these 21 core clinical data elements can be used to risk adjust 30-day mortality and 30-day readmission outcome measures. Although we have thus far only tested the core clinical data elements for use in the risk adjustment models of hospital-level outcome measures, they could be utilized in other ways in the future. We anticipate that EHRs will continue to improve capturing
of relevant clinical data and we also anticipate future expansion of the list of core clinical data elements.

In the future, one way in which we envision using core clinical data elements in conjunction with other sources of data, such as administrative claims, is to calculate “hybrid” outcome measures, which are quality measures that utilize more than one source of data. We believe that these types of hybrid measures could enhance the current CMS administrative claims-based outcome measures by utilizing patient clinical data captured in the EHR. We have shown that core clinical data elements captured in EHRs and used to risk adjust hospital outcome measures improve the discrimination of the measures, or the ability to distinguish good and poor performers, as assessed by the c-statistic, which evaluates the measure’s ability to discriminate or differentiate among high and low performing hospitals. Finally, hybrid measure results would need to be calculated by CMS to determine hospitals’ risk-adjusted rates relative to national rates used in public reporting. With hybrid measures, hospitals would forward data extracted from the EHR, and CMS would perform the measure calculations.

To illustrate one way in which the 21 core clinical data elements can be used, we developed two hybrid measures: (1) Hospital 30-Day Risk-Standardized Acute Myocardial Infarction (AMI) Mortality eMeasure (NQF #2473); and (2) a hybrid hospital-wide 30-day readmission measure, which has not yet undergone NQF endorsement proceedings. However, the latter measure’s development was encouraged

---

231 Hybrid Hospital-Wide Readmission Measure with Electronic Health Record Extracted Risk Factors (Version 1.1).
by the MAP.\textsuperscript{233} We note that the 2013 Core Clinical Data Elements Technical Report Version 1.1 (a methodology report) provides a more detailed review of the clinical core data elements. This document is posted on our Measure Methodology Web page, under the “Downloads” section in Core Clinical Data Elements and Hybrid Measures zip file, available on our Web site at: \url{http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html}.

b. Overview of Core Clinical Data Elements

Core clinical data elements are a set of clinical variables derived from EHRs that can be used to risk adjust hospital outcome measures. We have currently identified a set of 21 core clinical data elements that: (1) can be feasibly extracted from current EHR systems; (2) are available on most adult patients; and (3) are relevant to patient outcomes following hospitalization. These core clinical data elements are listed in the table below.

| Currently Identified Core Clinical Data Elements Considered for Risk-Adjustment of Hybrid Outcome Measures used in the Hospital setting |
|---|---|---|
| **Data Elements** | **Units of Measurement** | **Time Window for First Captured Values** |
| **Patient Characteristics** | | |
| Age at admission | Years | --- |
| Gender | Male or female | --- |
| **First-Captured Vital Signs** | | |
| Heart Rate | Beats per minute | 0-2 hours |
| Systolic Blood Pressure | mmHg | 0-2 hours |
| Diastolic Blood Pressure | mmHg | 0-2 hours |
| Respiratory Rate | Breath per minute | 0-2 hours |
| Temperature | Degrees Fahrenheit | 0-2 hours |

Currently Identified Core Clinical Data Elements Considered for Risk-Adjustment of Hybrid Outcome Measures used in the Hospital setting

<table>
<thead>
<tr>
<th>Data Elements</th>
<th>Units of Measurement</th>
<th>Time Window for First Captured Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygen Saturation</td>
<td>Percent</td>
<td>0-2 hours</td>
</tr>
<tr>
<td>Weight</td>
<td>Pounds</td>
<td>0-24 hours</td>
</tr>
</tbody>
</table>

First-Captured Laboratory Results

<table>
<thead>
<tr>
<th>Data Elements</th>
<th>Units of Measurement</th>
<th>Time Window for First Captured Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>g/dL</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>% red blood cells</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>Platelet</td>
<td>Count</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>WBC Count</td>
<td>Cells/mL</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>Potassium</td>
<td>mEq/L</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>Sodium</td>
<td>mEq/L</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>Chloride</td>
<td>mEq/L</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/L</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>BUN</td>
<td>mg/dL</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>Creatinine</td>
<td>mg/dL</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>Glucose</td>
<td>mg/dL</td>
<td>0-24 hours</td>
</tr>
<tr>
<td>Troponin</td>
<td>ng/mL</td>
<td>0-24 hours</td>
</tr>
</tbody>
</table>

This set of core clinical data elements consists of the first captured vital signs, and the results of a complete blood count and basic chemistry panel. These core clinical data elements were selected because they were empirically shown to be captured during routine clinical practice on most adult hospitalized patients. Among other ways, one way in which we envision using these core clinical data elements is to risk adjust outcomes measures, since the elements improve the discrimination of hospital outcome measures as assessed by c-statistic and enhances the face validity of measures for the

---

clinical community, which continue to express a preference for these types of data to account for patients’ severity of illness.\textsuperscript{235}

In the context of risk-adjustment, future hybrid measures would utilize some or all of the 21 core clinical data elements listed above, as well as any future feasible core clinical data elements. For example, the Hospital 30-day Risk-Standardized Acute Myocardial Infarction (AMI) Mortality eMeasure (NQF #2473) uses five core clinical data elements: age; heart rate; systolic blood pressure; troponin; and creatinine.\textsuperscript{236} In contrast, the hybrid hospital-wide measure uses 14 of the 21 core clinical data elements (age, heart rate, respiratory rate, temperature, systolic blood pressure, oxygen saturation, weight, hematocrit, white blood cell count, sodium, potassium, bicarbonate, creatinine and glucose).\textsuperscript{237} These two hybrid measures illustrate how specific core clinical data elements used in a given hybrid measure will vary depending on the core clinical data elements identified as relevant for and predictive of that measure outcome in the target cohort.

We note that the 21 core clinical data elements included are already routinely recorded in the EHR by clinical staff at the beginning of an inpatient encounter to

\textsuperscript{235} Hybrid 30-day Risk-standardized Acute Myocardial Infarction Mortality Measure with Electronic Health Record Extracted Risk Factors (Version 1.1) and Hybrid Hospital-Wide Readmission Measure with Electronic Health Record Extracted Risk Factors (Version 1.1). Available at: \url{http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html}.

\textsuperscript{236} Hybrid 30-day Risk-standardized Acute Myocardial Infarction Mortality Measure with Electronic Health Record Extracted Risk Factors (Version 1.1). Available at: \url{http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html}.

\textsuperscript{237} Hybrid Hospital-Wide Readmission Measure with Electronic Health Record Extracted Risk Factors (Version 1.1). Available at: \url{http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html}. 
diagnose and treat patients. Collection of these core clinical data elements are in response to stakeholder preference, and in particular, for the use of clinical information in risk models, but is not meant to guide or alter the care patients receive. We believe clinical staff should continue to only perform measurements or tests that are appropriate for diagnostic assessment or treatment of patients.

We assessed the feasibility of extraction of the 21 core clinical data elements in models of readmission and mortality outcome measures (Core Clinical Data Elements Development is discussed below). For additional detail on testing and the measure methodologies, we refer readers to the 2013 Core Clinical Data Elements Technical Report Version 1.1 methodology report posted on our Measure Methodology Web page, under the “Downloads” section in Core Clinical Data Elements and Hybrid Measures zip file, on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

c. Core Clinical Data Elements Development

To identify this set of core clinical data elements, we first focused on those data elements that can be used to risk adjust hospital outcome measures. We developed a systematic five-step approach in which we: (1) established a set of criteria to assess the feasibility of consistently identifying and extracting EHR data elements, and convened a diverse group of health information technology experts and end users to apply these criteria to EHR data; (2) conducted a systematic review of the literature to identify clinical data that has been shown to predict patient outcomes following acute care hospital admissions; (3) assessed the frequency and timing of capture of candidate data
elements using a dataset from an active EHR data warehouse of a large healthcare system serving over 3.3 million beneficiaries;\textsuperscript{238} (4) tested the utility of feasible data elements in risk-adjusted hierarchical models of 30-day mortality following hospitalization for a variety of common and costly medical conditions (for example, heart failure, pneumonia, and stroke); and (5) tested the core clinical data elements as risk-adjustment variables in the previously adopted Hospital IQR Program measure, CMS 30-Day Hospital-Wide All-Cause Unplanned Readmission Outcome measure (NQF #1789) finalized in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53521 through 53528), creating the hybrid hospital-wide readmission measure. These steps are discussed in more detail below.

To identify and test the core clinical data elements, a TEP was convened. TEP members applied feasibility criteria to each data type in the Quality Data Model (QDM) considering the context of adult hospitalized patients only. The QDM is an information model that provides a standardized description of the clinical information captured in EHRs, and provides a uniform framework to support quality measurement that utilizes EHR data. TEP members were asked to indicate whether at least one data element within each data type was: (1) consistently obtained in the target population (patients 18 years and older) based on current clinical practice; (2) captured with a standard definition and recorded in a standard format within the EHR; and (3) entered in structured fields that are feasibly retrieved from current EHR systems.

Next, we conducted a systematic review of the literature to identify clinical data shown to be predictive of mortality and readmission in statistical models. A thorough

\textsuperscript{238} 2013 Core Clinical Data Elements Technical Report Version 1.1. Available at: \url{http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html}.
review of studies revealed that several categories of clinical information from patient medical records captured during diagnostic assessment and treatment were commonly used to predict mortality and readmission. These included, but were not limited to, basic demographic information, laboratory test results, and vital sign findings. The results are described in the 2013 Core Clinical Data Elements Technical Report (Version 1.1) and is available on our Measure Methodology Web page, under the “Downloads” section in Core Clinical Data Elements and Hybrid Measures zip file found on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

In order to empirically establish the feasibility of potential clinical data elements identified by the TEP, we used a large multi-site database from a healthcare system serving over 3.3 million beneficiaries. We examined the format of the clinical data elements, the consistency and timing of capture, and the distribution of these extracted clinical data values across conditions, hospitals, and point of hospital entry. From the results of that analysis, we identified a list of clinical data elements that were consistently captured for more than 90 percent of adults admitted for common medical conditions. In addition, only the first clinical data elements captured close to the time a patient arrived at the facility were considered in order to reflect patients’ clinical status when they presented, and not the results of treatment received at the facility. Analyses showed that vital signs (heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, temperature, and oxygen saturation) were captured within 2 hours of arrival to the hospital for most patients who were subsequently admitted to the same facility. In
addition, analyses showed that weight and laboratory tests (hemoglobin, hematocrit, platelet, white blood cell (WBC) count, potassium, sodium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, and troponin) were captured within 24 hours of arrival to the hospital for most patients who were subsequently admitted to the same facility. This was true whether patients were first assessed in the emergency department, or an inpatient unit. From these analyses, we specified the units of measurement and time window for first captured values for each of the 21 feasible and relevant core clinical data elements.

d. Core Clinical Data Elements Feasibility Testing Using Readmission and Mortality Models

In order to demonstrate that the core clinical data elements improved hospital outcome measures, we tested them in models of 30-day mortality and 30-day readmission following hospitalization from a variety of conditions. The 21 core clinical data elements shown in the table above were statistically significant predictors in at least one measure of 30-day mortality after admission for eight common medical conditions: AMI; congestive heart failure; pneumonia; acute cerebrovascular disease; septicemia (except during labor); diabetes mellitus with complications; coronary atherosclerosis; and cardiac dysrhythmias. All of the core clinical data elements listed above were also statistically significant predictors of readmission in the risk-adjusted models of 30-day readmission in

---

a hospital-wide cohort.\textsuperscript{240} The testing results demonstrate that the core clinical data elements enhanced the discrimination (assessed using the c-statistic) when used either in combination with or in place of administrative claims data for risk adjustment of currently reported CMS 30-day mortality and readmission outcome measures. For more detailed information on testing, we refer readers to the methodology reports posted on our Measure Methodology Web page, under the “Downloads” section in Core Clinical Data Elements and Hybrid Measures zip file, found on our Web site at: 

e. Use of Core Clinical Data Elements in Hospital Quality Measures for the Hospital IQR Program

In the future, we are considering requiring hospitals to electronically submit core clinical data elements in several contexts. One use considered would be to risk-adjust claims-based hybrid quality measures similar to what is described in our discussion above. In addition, we are also considering using core clinical data elements for quality measures that apply more generally to an all-payer population (that is, a population greater than or equal to 18 years of age). As we learn more about this method of data collection, we will be able to give more information. As it stands, we envision that use of core clinical data elements for an all payer population would not be limited to merely risk-adjustment or in claims-based hybrid measures. However, should we require

\textsuperscript{240} Hybrid Hospital-Wide Readmission Measure with Electronic Health Record Extracted Risk Factors (Version 1.1). Available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.
reporting of core clinical data elements, it would be in the context of specific measures proposed through rulemaking for the Hospital IQR Program and potentially other CMS quality programs. Specific electronically submitted core clinical data elements required would depend on the individual measure adopted.

For claims-based hybrid measures, linking variables would be required to ensure that the datasets containing administrative claims data are correctly linked with EHR datasets containing the core clinical data elements for proper risk adjustment. The linkage variables would come from an additional requirement for hospitals to submit these variables. Such linkage variables, for example, might include admission and discharge dates, CMS certification number, and date of birth. Some of these linkage variables are already routinely collected by EHRs; however, actual linkage variables required for a specific hybrid measure would depend on empirical testing of approaches to linkage for individual measure cohorts.

f. Content Exchange Standard Considerations for Core Clinical Data Elements

Data can be collected in EHRs and health information technology (IT) systems using standardized formats to promote consistent representation and interpretation, as well as to allow for systems to compute data without needing human interpretation. These standards are referred to as content exchange standards, because the standard details how data should be represented and the relationships between data elements. This allows the data to be exchanged across EHRs and health IT systems while retaining their meaning. Commonly used content exchange standards include the Consolidated Clinical Data Architecture (C-CDA) and the Quality Reporting Data Architecture (QRDA). The
C-CDA standard is frequently used for the representation of summary care records and provides a format for electronically representing data within document templates and sections. The QRDA standard provides a document format and standard structure to electronically report quality measure data. QRDA allows for the use of CDA templates (the same underlying standard used in C-CDA) to represent quality measures using the QDM information model described above. Thus, QRDA could be considered a related standard to C-CDA for the specific quality reporting use case.

The core clinical data elements we are considering could be electronically reported to CMS formatted according to either the C-CDA or QRDA standard to promote consistent representation and more efficient calculation of hybrid measure results. These standards are also currently required for participation in the Medicare and Medicaid EHR Incentive Programs. Sections 1886(n) and 1814(l) of the Act, as added by the HITECH Act, authorize incentive payments under Medicare for eligible hospitals and critical access hospitals that successfully demonstrate the meaningful use of Certified EHR Technology (CEHRT). Section 1903(t)(6)(C) of the Act also requires that Medicaid providers adopt, implement, upgrade, or meaningfully use CEHRT if they are to receive incentives. We refer readers to the CEHRT definition adopted by the Office of the National Coordinator for Health IT (ONC) in its 2014 Edition standards and certification criteria final rule (77 FR 53972). ONC’s CEHRT definition is adopted in § 170.102 and includes the capabilities defined for the Base EHR, including certification to create

---


transitions of care documents using the C-CDA standard and to successfully report clinical quality measures using the QRDA standard (we refer readers to Table 6 of the ONC 2014 Edition standards and certification criteria final rule at 77 FR 54265).

We are specifically considering the use of QRDA Category I (QRDA I) as the transmission standard for core clinical data elements to CMS, because the core clinical data elements specified for risk adjustment need to be captured in relation to the start of an inpatient encounter, to be certain the data has been appropriately connected to the encounter. The QRDA I standard enables an individual patient-level quality report that contains quality data for one patient for one or more quality measures. For further detail on QRDA I, the most recently available QRDA I specifications can be found at: http://www.hl7.org/implement/standards/product_brief.cfm?product_id=35.

Regardless of whether C-CDA or QRDA I was used for the reporting of core clinical data elements, we note that these data exchange standards would enhance alignment across CMS programs, as well as reduce EHR developer and provider burden by adopting standards that are already in place for the exchange of electronically specified clinical and quality data.

As part of this comment solicitation, we are inviting comment on whether EHR technology should be required to be certified under the ONC Health IT Certification Program\(^\text{243}\) for the submission of the core clinical data elements for participation in the Hospital IQR Program using the most appropriate content exchange standard (such as, and not limited to, QRDA I or C-CDA). We believe that certification could test and

certify that EHR technology can properly collect the core clinical data elements formatted to the appropriate content exchange standard (such as, and not limited to QRDA I or C-CDA), promoting more standardized and consistently represented data that can be submitted to CMS to risk-adjust hybrid measures.

In summary, we sought public comment on the concept of collecting core clinical data elements, and in particular, we are interested in feedback specifically regarding:

(1) the use of the core clinical data elements derived from EHRs for use in risk adjustment of outcome measures as well as other types of measures; (2) the collection of additional administrative linkage variables to link a patient’s episode-of-care from EHR data with his/her administrative claim data; and (3) the use of content exchange standards for reporting these data elements. Regarding the use of content exchange standards, we welcome input on the benefits and implementation considerations if CMS were to require QRDA I, as well as the tradeoffs to requiring QRDA I instead of C-CDA or other content exchange standards.

Comment: Commenters noted either outright or conditional support for the future consideration to develop hybrid measures, including the collection of additional administrative linkage variables. A few commenters noted that collection of the core clinical data elements will not impose additional burden on hospitals.

Response: We thank the commenters for their support.

Comment: Many commenters supported submitting the core clinical data elements using an EHR technology certified by the ONC. One commenter specifically supported using C-CDA. Some commenters supported using QRDA I, and others stated
that they did not want CMS to use QRDA I as the content exchange standard for the core clinical data elements. Many commenters supported aligning the standards for data transmission requirements with those used in other reporting programs.

**Response:** We thank commenters for their suggestion to align standards across our programs. We agree that it is important to align these data collection requirements to reduce burden on hospitals and improve interoperability. We will take this feedback into consideration as we shape future proposals for the core clinical data elements.

**Comment:** One commenter expressed concern that hybrid measure scores may be calculated close to the end of the reporting period, which would not allow hospitals time to identify or correct discrepancies. The commenter suggested that CMS provide hospitals with timely feedback on hybrid measure results.

**Response:** Implementation planning for hybrid measures is ongoing and has not yet been finalized. The purpose of these measures is for comparison of hospital-level performance relative to national performance on a given outcome. These measures require a complete set of administrative claims and clinical data to reliably calculate results. The schedule for public reporting will likely be similar to the current schedule for reporting of other hospital outcome measures in the Hospital IQR Program, and would have the same lag time for data. Measures will not be calculated in real time. However, we acknowledge the importance of timely feedback and will take this into consideration.
Comment: Several commenters recommended that CMS engage stakeholders when developing hybrid measures. Several commenters requested a national provider call.

Response: We thank the commenters for their support and for encouraging stakeholder engagement during the development of hybrid measures. We note that the core clinical data elements were developed with input from a TEP and two public comment periods outside of rulemaking. Comments and responses from the latest comment period are posted on our Web site under the Download section in the “Archived public comment files” folder at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/CallforPublicComment.html. We intend to continue to seek input from all stakeholders in the development of the hybrid measures.

Comment: Several commenters recommended that the core clinical data elements should be discussed with the MAP’s Coordinating Committee and its Hospital Workgroup. Some commenters also suggested the core clinical data elements and hybrid measures should go through NQF review, or be endorsed by the NQF, prior to inclusion in a quality reporting program.

Response: As the core clinical data elements are only one piece of a quality measure, there is no formal mechanism to submit core clinical data elements independent from a measure to the MAP or for NQF endorsement. However, we will submit measures that include core clinical data elements to the MAP and NQF. We note that measures proposed in CMS quality reporting programs are included on a publicly available document entitled “List of Measures Under Consideration” in compliance with
section 1890A(a)(2) of the Act, which are reviewed by the MAP. The Hospital 30-day Risk-standardized Acute Myocardial Infarction (AMI) Mortality eMeasure (NQF #2473), which includes five of the core clinical data elements, was reviewed by the MAP in 2013 where it received conditional support pending NQF endorsement. This measure was then subsequently endorsed by the NQF in September of 2014. The Hybrid Hospital-wide 30-day Readmission measure, which includes the full core clinical data element set (with the exception of some data elements that were collinear with others), will be submitted to the NQF at the next available opportunity. The MAP encouraged further development of the Hybrid Hospital-wide 30-day Readmission measure in December 2014.

Comment: Some commenters suggested that CMS enhance certification and interoperability standards before requiring hybrid measures utilizing the core clinical data elements and that these standards should be specified in the EHR Incentive Program. Several commenters recommended that CMS focus efforts toward ascertaining reliable, consistent, and valid methods of reporting electronic data, so that the reporting of the core clinical data elements as a part of hybrid measures can be implemented successfully and accurately.

Response: One of the main tenets of the 2015 Edition Standards and Certification Criteria proposed rule is interoperability and adoption of updated standards. We note that

---


we have worked closely with ONC to enhance testing and validation of certified technology’s ability to capture, exchange, and report electronic patient data, such as through improved testing and certification through the Cypress CQM testing and certification tool.\footnote{http://projectcypress.org/} As another example, we note that ONC proposed a 2015 Edition “CQM – report” certification criterion in the FY 2016 IPPS/LTCH PPS proposed rule that sought stakeholder input on the standards for representing and reporting CQM data in certified health IT to improve the reliability and consistency of such data reporting (80 FR 24613 through 24614). Therefore, we thank commenters for their continued support of improving the electronic reporting process and plan to continue to make improvements as standards evolve. We thank commenters for the suggestion about including the core clinical data elements for voluntary eCQM reporting or in the EHR Incentive Program and will consider these for future rulemaking.

Comment: Several commenters recommended the continued collaboration between the ONC, the National Library of Medicine, providers, measure stewards, and electronic measure developers to improve the standardization of the terminology used to support the electronic capture of the proposed core clinical data elements. Several other commenters noted the need to ensure the alignment of the proposed data elements with data elements, definitions, and value sets used by other measures to reduce the burden on hospitals and vendors.

Response: We thank commenters for their suggestion to align the data elements across CMS, ONC (for example, the Common Clinical Data Set definition), and the healthcare industry. In an effort to ensure harmonization with other measures and
reporting requirements, the core clinical data elements use existing value sets where possible. We agree that it is important to align these data collection requirements to reduce burden on hospitals and improve interoperability, and we will take this feedback into consideration as we shape future proposals for the core clinical data elements.

Comment: Several commenters suggested that CMS test the feasibility of collecting non-clinical data elements that capture patient sociodemographic status.

Response: While we appreciate these comments and the importance of the role that sociodemographic status plays in the care of patients, as discussed in section VIII.A.7. of the preamble of this final rule, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of low sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures. To date, we have found that hospitals that care for large proportions of patients of low sociodemographic status are capable of performing well on our measures (we refer readers to the 2014 Chartbook pages 48-57, 70-73, and 78 at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Downloads/Medicare-Hospital-Quality-Chartbook-2014.pdf).

NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate for each measure. For 2 years, NQF will
conduct a trial of a temporary policy change that will allow inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will determine whether to make this policy change permanent. Measure developers must submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model.

Furthermore, ASPE is conducting research on the issue of risk adjustment for sociodemographic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of these reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

Comment: Some commenters noted their concern that the quality of data extracted from electronic health records for electronic clinical quality measures are not the same as the data garnered via chart abstraction. The commenters recommended that, before CMS requires the submission of the core clinical data elements, CMS conduct further testing and analysis to ensure the accuracy and completeness of the data being submitted. One commenter suggested a testing period.

Response: For clarification, hybrid measures are not electronic clinical quality measures. Hybrid measures are administrative claims-based measures that include one use of the electronically extracted core clinical data elements, which is in the risk adjustment models of claims-based hospital-level outcome measures. We appreciate the commenter’s concerns about thoroughly evaluating the core clinical data elements.
Expanding on the discussion above in section VIII.A.9.c. of the preamble of this final rule, we conducted testing in 21 hospitals and found that the core clinical data elements were reliably and consistently collected for more than 90 percent of adults admitted for treatment of medical conditions.247 We also are conducting testing of the electronic specifications of the core clinical data elements, specifically to compare the electronically exported data to chart abstracted data, at several hospitals to ensure validity of the data element codes and logic, which will be completed in 2015. Data quality and accuracy is a top concern for CMS. We will consider proposing a pilot test of data submission in future rulemaking.

Comment: One commenter was concerned that hospitals may have difficulty linking EHR data to administrative data and recommended there be stronger guidance provided around data capture and use of the core clinical data elements.

Response: Hospitals will not need to perform this linking or be responsible for calculating hybrid measure scores. Calculation of hybrid measures will require that hospitals submit some administrative data elements along with the core clinical data elements. We will then use these variables to link or merge clinical and administrative claims data for measure calculation. Such linkage variables, for example, might include admission and discharge dates, CMS certification number, and date of birth. Some of these linkage variables are already routinely collected by EHRs; however, actual linkage variables required for a specific hybrid measure would depend on empirical testing of

approaches to linkage for individual measure cohorts. We do not expect submission of these data to impose a significant burden on hospitals.

**Comment:** Several commenters expressed concerns about the specific core clinical data elements identified, and their use. One commenter supported the use of hybrid measures, and requested clarification on whether or not measure developers would be able to specify other types of measures that utilize laboratory results captured after the first 24 hours, as the core clinical data elements are designed to only capture laboratory results within the 24 hours of hospital arrival. Another commenter suggested including an additional laboratory clinical data element. One commenter was concerned about capturing clinical severity.

**Response:** We thank the commenters for their support and their suggestions. The core clinical data elements outlined here are currently developed for the risk adjustment of hybrid measures, which are hospital-level outcomes measures. Measure developers considering using the core clinical data elements would need to evaluate each data element in the context of any new measure. Measure developers are encouraged to consider using the core clinical data elements in their measures where appropriate, recognizing that this dataset only contains first captured values. The timeframes are specified to capture the patient’s condition on arrival to the hospital before care has been initiated. Capturing the first set of vital signs and laboratory results are intended to adjust for a patient’s overall severity of illness upon arrival at the hospital.

We thank the commenter’s suggestion to include another laboratory value. To reduce the reporting burden on hospitals, the core clinical data elements were developed
as a minimum dataset that could be used across a variety of condition cohorts and measures. However, not all core clinical data elements referenced might be needed for all hybrid measures, and there may be some additional measure-specific data elements that need to be collected. For example, patients who are suspected of having had an acute myocardial infarction have a troponin test added to their blood work. Therefore, the hybrid AMI mortality measure includes four core clinical data elements, and one measure-specific core clinical data element for troponin, in the risk model. Troponin is a core clinical data element that would assist in capturing the severity of a patient’s AMI. Similarly, other condition-specific data elements will be considered during development of future hybrid measures and will be included in the models if they are reliable, can be feasibly extracted, and are statistically significant in the models. We intend to continue seeking input from all stakeholders in the development of the hybrid measures.

Comment: One commenter recommended that CMS limit the core clinical data elements to only those needed for specific measures, and not impose the burden of collecting other information for potential purposes down the road that have yet to be defined. Similarly, several commenters were concerned that the volume of data collected might impact the validity and cause a submission burden. One commenter requested clarification around the use of an all-payer measure, while another commenter strongly supported hospitals reporting all of the core clinical data elements, including all-payer data.

Response: We thank the commenters for this feedback. We appreciate the commenters’ concerns about the validity and submission burden for hospitals regarding
the volume of data requested. We plan to propose submission of only those core clinical data elements that are used in specific hybrid quality measures. While we are considering using core clinical data elements for quality measures that apply more generally to an all-payer population, we will be able to give more information as we learn more about this method of data collection. We will take these comments into consideration as we develop future policy.

Comment: One commenter recommended that CMS develop a plan to reevaluate whether the required data elements continue to be valuable moving forward.

Response: The core clinical data elements were developed with input from ONC, the National Library of Medicine, and stakeholders from the provider and vendor communities relating to the feasibility of collection and value for quality measurement. In addition, each hybrid measure is developed to only include those variables in the risk models that contribute to improved statistical performance. We note that this was a Request For Comment in anticipation of future rulemaking, and we will develop a plan to gather input from stakeholders on whether the proposed data elements continue to retain value. We intend to formally propose any data element requirements for hospital risk-adjusted hybrid measures as part of future rulemaking in order to allow stakeholders an opportunity to comment on any proposed program requirements. We conduct annual and comprehensive reevaluation of the core clinical data elements as well as the hybrid measures according to the Blueprint for the Measures Management System. We will take this comment into consideration as we develop future policy.
Comment: One commenter recommended that CMS explore methods for obtaining patient transfer status, noting that the literature suggests that the health outcomes of patients experiencing inter-hospital transfers are different from patients receiving their entire course of care at a single institution.

Response: We thank the commenter for the suggestion. Regarding capture of transfer status as a discrete data element, we will reevaluate as advancements in electronic health record technology and interoperability may make this data element more feasible to collect in the future.

Comment: One commenter expressed concerns about obtaining historical electronic health record information from organizations that recently transitioned to a new electronic records system.

Response: We are sensitive to the potential burden on hospitals of mapping, extracting, and reporting the core clinical data elements from their EHRs. Although implementation planning is ongoing and has not yet been finalized, we are considering only prospective collection of the core clinical data elements.

We thank the commenters for their feedback and note that we will consider it in future rulemaking.
10. Form, Manner, and Timing of Quality Data Submission

a. Background

Sections 1886(b)(3)(B)(viii)(I) and (b)(3)(B)(viii)(II) of the Act state that the applicable percentage increase for FY 2015 and each subsequent year shall be reduced by one-quarter of such applicable percentage increase (determined without regard to sections 1886(b)(3)(B)(ix), (x), or (xii) of the Act) for any subsection (d) hospital that does not submit data required to be submitted on measures specified by the Secretary in a form and manner, and at a time, specified by the Secretary. Previously, the applicable percentage increase for FY 2007 and each subsequent fiscal year until FY 2015 was reduced by 2.0 percentage points for subsection (d) hospitals failing to submit data in accordance with the description above. In accordance with the statute, the FY 2015 payment determination begins the first year that the Hospital IQR Program will reduce the applicable percentage increase by one-quarter of such applicable percentage increase.

In order to participate in the Hospital IQR Program, hospitals must meet specific procedural, data collection, submission, and validation requirements. For each Hospital IQR Program year, we require that hospitals submit data on each measure in accordance with the measure’s specifications for a particular period of time. The data submission requirements, Specifications Manual, and submission deadlines are posted on the QualityNet Web site at: http://www.QualityNet.org/. Hospitals must register and submit quality data through the secure portion of the QualityNet Web site. There are safeguards in place in accordance with the HIPAA Security Rule to protect patient information submitted through this Web site.
b. Procedural Requirements for the FY 2018 Payment Determination and Subsequent Years

The Hospital IQR Program procedural requirements are codified in regulation at 42 CFR 412.140. We refer readers to the codified regulations for participation requirements, as further explained by the FY 2014 IPPS/LTCH PPS final rule (78 FR 50810 through 50811). We did not propose any changes to the procedural requirements.

c. Data Submission Requirements for Chart-Abstracted Measures

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51640 through 51641), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53536 through 53537), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50811) for details on the Hospital IQR Program data submission requirements for chart-abstracted measures.

Comment: One commenter requested clarification on the reporting requirements for the six measures which can be reported either via chart-abstraction or electronically.

Response: Although we proposed to allow hospitals to report 6 measures (ED-1, ED-2, PC-01, STK-4, VTE-5, and VTE-6) either via chart-abstraction or electronically, we are finalizing a modified policy and these measures will remain required via chart-abstraction as previously required. However, hospitals may choose to submit electronic data, in addition to chart-abstracted data, on any of these 6 measures to meet the requirement to report 4 of 28 electronic clinical quality measures. We refer readers to section VIII.A.8.c. of the preamble of this final rule for details.
d. Alignment of the Medicare EHR Incentive Program Reporting for Eligible Hospitals and CAHs with the Hospital IQR Program

(1) Background

We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50256 through 50259) for our policies to align electronic clinical quality measures data reporting and submission periods on a calendar year basis for the FY 2017 payment determination for both the Medicare EHR Incentive Program for eligible hospitals and CAHs, and the Hospital IQR Program. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24587 through 245888), we proposed to: (1) continue to require Certified Electronic Health Record Technology (CEHRT) 2014 Edition and (2) update reporting periods and submission deadlines, for the FY 2018 payment determination for the Hospital IQR Program.

(2) Electronic Clinical Quality Measure Certification for the FY 2018 Payment Determination

As described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50251), for the Hospital IQR Program, hospitals that submit electronic clinical quality measures data for the FY 2017 payment determination are required to submit data using CEHRT 2014 Edition, which is an Electronic Health Record certification. Although we required CEHRT, eligible hospitals were not required to ensure that their CEHRT products were recertified to the most recent version of the electronic specifications for the clinical quality measures. We also stated in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50251), that for the FY 2017 payment determination, a hospital could submit
electronic clinical quality measures for the Hospital IQR Program during CY 2015 even if they attest their aggregate measure numerators and denominators through the Medicare EHR Incentive Program. The hospital could submit as test data or production data. Test data submissions are submissions that do not count as submissions; they are practice submissions. Production data submissions are considered final submissions meant to fulfill Hospital IQR Program submission requirements.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24587), we proposed to continue the requirement for hospitals to use CEHRT 2014 Edition\(^\text{248}\) when submitting electronic clinical quality measures for the CY 2016/FY 2018 payment determination. The Office of the National Coordinator for Health Information Technology (ONC) has proposed a new Edition of EHR technology which may be available for some providers as early as 2016 in its “2015 Edition Health Information Technology (Health IT) Certification Criteria, 2015 Edition Base Electronic Health Record (EHR) Definition, and ONC Health IT Certification Program Modifications” (hereafter known as the “2015 Edition proposed rule”) (80 FR 16804 through 16921). However, we will require hospitals to continue to submit data for Hospital IQR Program purposes using the 2014 Edition for the FY 2018 payment determination. Any changes for the Hospital IQR Program because of ONC’s update will be proposed in future rule making. We invited public comments on this proposal.

**Comment:** A few commenters supported the proposed electronic quality measure certification requirements for the FY 2018 payment determination.

Response: We thank the commenters for their support.

Comment: One commenter supported the proposal to require that EHR technology be certified for data element submission in line with the EHR Incentive Program, and hoped that it will allow providers to further test and validate that their platforms can transmit data successfully.

Response: We thank the commenter for its support.

Comment: Several commenters requested general clarification on the CEHRT requirements for the submission of electronic clinical quality measures. Noting our proposal to require the CEHRT 2014 Edition, some commenters suggested that hospitals be able to report electronic clinical quality measures using the CEHRT 2015 Edition, if they are able, for CY 2016/FY 2018. These commenters suggested that either 2014 or 2015 CEHRT be accepted, and stated that hospitals will need ample time to adopt the CEHRT 2015 Edition in order to meet Stage 3 Meaningful Use requirements.

Response: In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24587), we proposed to continue the requirement for hospitals to use CEHRT 2014 Edition when submitting electronic clinical quality measures for the CY 2016/FY 2018 payment determination. However, in response to comments suggesting that hospitals be allowed to report using either the 2014 or 2015 edition of CEHRT, we are finalizing a modification to our proposal such that, for CY 2016/FY 2018 payment determination reporting of electronic clinical quality measures, hospitals can report using either the 2014 or 2015 edition of CEHRT.
Comment: One commenter asked if vendors certified to the ONC 2014 measure specifications must recertify for the May 2015 electronic clinical quality measure specifications to report electronic clinical quality measures. A few commenters specifically recommended that CMS allow hospitals to report electronic data via 2014 electronic clinical quality measure specifications, noting that some hospitals may not have the 2015 specifications available until early 2016.

Response: We require the most recent version of electronic measure specifications (the May 2015 version) for CY 2016/FY 2018 payment determination electronic reporting. We believe requiring use of the most recent electronic measure specifications is important in allowing us to collect relevant electronic data. We refer readers to section VIII.A.8.c. of the preamble of this final rule where we discuss our modified policies and note the later reporting periods (Q3 or Q4 of CY 2016) and extended submission deadline (by February 28, 2017) to provide hospitals with additional time to update to the 2015 measure specifications. The 2015 measure specifications are required whether hospitals use 2014 or 2015 CEHRT.

Comment: One commenter recommended that QRDA I data be required for the FY 2018 payment determination. One commenter expressed concern that the proposed requirement of transmitting QRDA I files is not technically feasible at present, and if implemented, as planned, in January 2016, will not leave EHR vendors or providers with sufficient time to prepare.

One commenter requested clarification on whether electronic clinical quality measures must be submitted via a QRDA I report, or if the electronic measures may be
submitted via a data submission vendor. One commenter requested clarification on whether hospitals may abstract data from non-certified sources and then input these data into a certified technology for calculation and noted that organizations may have difficulty collecting all the necessary data elements required for electronic clinical quality measure reporting using their CEHRT technology.

Response: We thank the commenters for their suggestion that we require QRDA I. Although we did not specify a QRDA version requirement in the FY 2016 IPPS/LTCH PPS proposed rule, in response to comments suggesting that QRDA I be required and other comments requesting clarification on our QRDA requirement, we are finalizing a modification of our proposal to include the requirement that hospitals must report via QRDA I.

Requiring hospitals to report via QRDA I is consistent with our previous policies (described below in the preamble of this rule). It has been a requirement of 2014 Edition CEHRT under the EHR Incentive Program (we refer readers to section VIII.D.2.b. of the preamble of this final rule). In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50206), we specified that hospitals that chose to voluntarily submit electronic clinical quality measures report using QRDA I. The electronic clinical quality measure validation pilot described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50269 through 50273) stated that participating hospitals must be able to produce QRDA Category 1 Revision 2 files extracted automatically from an EHR. Therefore, we disagree with the commenter’s concern that hospitals do not have sufficient time to prepare to submit data via QRDA I.
We believe that requiring data via QRDA I is important, because: (1) it allows for patient-level validation of data rather than aggregated data; and (2) CEHRT requires data capture and reporting in QRDA I. In summary, hospitals must report data via QRDA I for 4 of 28 available eCQMs for one quarter (either CY 2016 Q3 or Q4) by the submission deadline of February 28, 2017. We believe the delayed reporting period and submission deadlines finalized will provide hospitals with adequate time to prepare to report using QRDA I.

In response to comments regarding use of a data submission vendor, hospitals may use a third party to submit QRDA I files on their behalf. Hospitals may also use abstraction or may pull the data from non-certified sources and then input these data into CEHRT for capture and reporting (QRDA I).

Comment: One commenter opposed the proposal to require hospitals to use updated specifications for eCQM reporting, and indicated that certified EHR vendors are not currently required to be updated to electronic clinical quality measure specifications and that this proposed requirement increases burden and costs. Some commenters recommended delaying updated specifications for electronic clinical quality measures until EHR vendors are required to support the annual updates. Some commenters also noted that vendors’ inability to assist with technical mapping of data elements creates additional burden for hospitals. A few commenters recommended that CMS work closely with vendors to enable electronic reporting by hospitals.

Response: We thank the commenters’ for their recommendations but note that we believe requiring updated measure specifications for electronic clinical quality measure
reporting is appropriate in order to provide the most relevant electronic data. Further, we do not believe delaying updated specifications for electronic clinical quality measures until EHR vendors are required to support the annual updates is appropriate, because we do not have the authority to set certification requirements for vendors. However, we encourage hospitals to work closely with their vendors to ensure that a contract is in place which supports the hospital’s quality reporting requirements and the annual update of those measures.

In response to concerns about a lack of vendor assistance with technical mapping, we recognize that technical mapping may be potentially burdensome and encourage hospitals to work with their vendors to overcome these issues. Further, we believe that requiring hospitals to report 4 electronic clinical quality measures for only 1 quarter (in either Q3 or Q4) of CY 2016/FY2018 payment determination, with a submission deadline of February 28, 2017, will allow more time for hospitals to overcome vendor issues, such as mapping and testing. We note that by requiring only 4 electronic clinical quality measures, we have reduced the burden of reporting by 75 percent as compared to the proposal to require 16 electronic clinical quality measures. We believe the burden associated with mapping will also be reduced by our policy to require fewer electronic clinical quality measures. In addition, we are finalizing an expansion of our Extraordinary Circumstances Extensions and Exemptions policy to include an exemption based on hardships preventing hospitals from electronically reporting. We refer readers to section VII.A.8.c. of the preamble of this final rule for a discussion of this expansion.
In response to the suggestion that we work closely with vendors to enable electronic reporting by hospitals, we currently meet with associations on a monthly basis and invite vendors to participate in Lean initiatives.\textsuperscript{249} We will continue to work closely with the vendor community.

\textbf{Comment:} One commenter recommended adopting Release 3 of the HL7 QRDA Category I Implementation Guide (HL7 CDA® R2 Implementation Guide: Quality Reporting Document Architecture – Category I (QRDA I) DSTU Release 3 (US Realm) or “Release 3”).\textsuperscript{250,251} CMS is using QRDA Category I Release 3 for the 2015 Update electronic clinical quality measures for the 2016 reporting period, and the commenter suggested that ONC align with this version for program alignment.\textsuperscript{252} The commenter also indicated Release 3 best incorporates known issues, fixes mistakes, and adds missing content compared to earlier versions of the QRDA Category I standard. Release 3 also uses an incremental version of the underlying data model (the Quality Data Model 4.1.1) that is a step-wise approach toward the harmonized CQM and CDS standards that the industry is currently developing. The commenter also believed that CMS and ONC should both review responses to Request for Information (RFI) on the cycle and timeline for the introduction and certification of new measures before adopting additional certifications and finalizing the frequency of testing and reporting of certification requirements.

\textsuperscript{249} eCQI Resource Center. The one-stop shop for the most current resources to support electronic clinical quality improvement. Retrieved from: https://ecqi.healthit.gov/.
Response: We thank the commenter for these recommendations. We believe that Release 3 of the QRDA Category I IG will ultimately improve electronic clinical quality measure processing, reduce errors, and that it better aligns with the Consolidated CDA standard Release 2.1 for interoperability, as compared to QRDA Category I Release 2 with the 2014 Errata.\(^{253}\) Release 3 of the QRDA Category I IG also aligns with the forthcoming CMS 2015 update to eCQM measures for 2016 e-reporting. We refer readers to [https://ecqi.healthit.gov/ecqm](https://ecqi.healthit.gov/ecqm) for further details on technical requirements.

We also refer readers to the HITPC recommendations ([http://healthit.gov/FACAS/sites/faca/files/HITPC_QMTF_Presentation_2015-06-3.pdf](http://healthit.gov/FACAS/sites/faca/files/HITPC_QMTF_Presentation_2015-06-3.pdf)) for additional details regarding Clinical Quality Measurement (CQM) provisions in our payment rules, including the FY 2016 IPPS/LTCH PPS final rule. Finally, we appreciate the commenter’s suggestion that we review responses to the RFI with ONC before adopting certifications. We collaborate very closely with ONC in relation to certification and will continue to do so.

Comment: A few commenters asked for clarification on the frequency of required certification and, more specifically, the certification requirements for vendors as it relates to QRDA standards and the CMS Implementation Guide (whether vendors are required to certify to both the base QRDA standard and the CMS Implementation Guide). If the requirement is to certify to both, the commenters expressed concerns that this requires a duplicate effort. A few commenters recommended that CMS ensure that EHR vendors certify to one quality measurement submission format, preferably the CMS

Implementation Guide. The commenters also expressed concern that certification may be required every time CMS changes its Implementation Guide to correct errors or accommodate the annual measure updates. The commenters also noted that annual recertification across multiple programs will be a significant burden on vendors as well as limit the amount of time vendors have to invest in product development initiatives and enhancement for stage 3. The commenters also recommended that CMS allow a minimum of 18 months for stakeholders to implement any major changes to quality measurements standards and also believed that recertification should not be required unless there are substantial changes to be made.

Response: We note that specific guidance on the timing for certification is provided in ONC’s rule, and hospitals are encouraged to maintain updated certifications.

In response to the commenter that asked about certification requirements for vendors (that is, requirements for the base QRDA standard vs. the CMS Implementation Guide\textsuperscript{254,255}), we note that requirements are defined by ONC. For additional certification guidelines that hospitals must use to report electronic data, we refer readers to ONC’s Health IT Certification Criteria available in the eCQM library at:


\textsuperscript{255} The HL7 Implementation Guide is a document markup standard that specifies the structure and semantics of "clinical documents" for the purpose of exchange between healthcare providers and patients.
requiring use of CMS Implementation Guide for Quality Reporting Document
Architecture Category I and Category III Supplementary Implementation Guide for 2016.\textsuperscript{256}

In regard to commenter concerns about certification requirements potentially duplicating effort and limiting product development initiatives and enhancement for stage 3 and in response to suggestions that updates be limited to major changes to avoid increasing burden, we note that updating standards and requirements is necessary to reduce development efforts and ease burden associated with reporting electronic clinical quality measures.

In response to the request that 18 months be allowed for hospitals to implement standards, we are requiring hospitals to report just 4 electronic clinical quality measures for only 1 quarter (in either Q3 or Q4) of CY 2016/FY 2018 payment determination, with a submission deadline of February 28, 2017 (we refer readers to section VIII.A.8.c. of the preamble of this final rule for a further discussion of these requirements). We believe the extended submission deadline will provide more time for hospitals to update to the required specifications.

\textit{Comment}: Several commenters recommended that CMS continue to work with stakeholders to improve the process for annual updates to electronic clinical quality measures, including the testing infrastructure for electronic clinical quality measures.

\textsuperscript{256} Available in the eCQM library at: http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/eCQM_Library.html.
Response: We thank the commenters for their suggestion. We are currently engaged with stakeholders to beta test a pre-submission validation application that we anticipate making more widely available in CY 2016.

After consideration of the public comments we received, we are finalizing a modification of our proposals. Although we proposed to continue the requirement for hospitals to use CEHRT 2014 Edition for CY 2016 reporting/FY 2018 payment determination, we are finalizing that hospitals can report using either the 2014 or 2015 edition of CEHRT.

In addition, as discussed in this section above, we are finalizing that hospitals must submit electronic data via a QRDA Category I file.

(3) Reporting Periods and Electronic Submission Deadlines for the FY 2018 Payment Determination

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50256 through 50259), we finalized our policy that hospitals could voluntarily submit electronic clinical quality measure data for one calendar year (CY) quarter’s data for either CY Q1 (January 1–March 31, 2015), CY Q2 (April 1–June 30, 2015), or CY Q3 (July 1–September 30) by November 30, 2015.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24587 through 24588), for the FY 2018 payment determination, we proposed changes to both the reporting periods and the submission deadlines.

For the FY 2018 payment determination, we proposed that hospitals must submit both Q3 and Q4 of 2016 data for 16 measures reported as electronic clinical quality
measures. We also proposed that for the FY 2018 payment determination, hospitals must submit the electronic clinical quality measure data for these two quarters (Q3 and Q4 of 2016) within 2 months after the end of the applicable calendar year quarter. For CY 2016, these deadlines would be November 30, 2016 for Q3 and February 28, 2017 for Q4. We refer readers to the table entitled “Proposed CY 2016/FY 2018 Payment Determination Hospital IQR Program Electronic Reporting Periods and Submission Deadlines for Eligible Hospitals,” set out in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24588).

As part of our measure maintenance process, each year we make updates to the electronic specifications of the Clinical Quality Measures approved for submission in CMS programs. These annual updates are found on the CMS Web site at:

http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/eCQM_Library.html. In developing these reporting periods and submission timelines, we considered hospitals’ and vendors’ ability to report electronic clinical quality measures and the burden associated with implementing the 2015 annual update. The May 2015 annual update of electronic clinical quality measure specifications will include changes to the Quality Data Model (QDM) and the Health Quality Measure Format (HQMF), and we recognize that hospitals may require additional time to implement the associated software changes.

Because of this, we proposed that hospitals must adopt the most recent annual update prior to data submission. For example, for the CY 2016/FY 2018 payment determination,

---

hospitals would need to submit electronic clinical quality measure using the 2015 Annual Update. As a result and as stated above, we proposed to delay the required reporting of electronic clinical quality measures to begin with Q3 of 2016, with a reporting deadline of November 30, 2016. The table below shows the required electronic clinical quality measure reporting periods and submission deadlines for CY 2016.

<table>
<thead>
<tr>
<th>Discharge Reporting Periods</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1, 2016–March 31, 2016</td>
<td>N/A</td>
</tr>
<tr>
<td>April 1, 2016–June 30, 2016</td>
<td>N/A</td>
</tr>
<tr>
<td>July 1, 2016–September 30, 2016</td>
<td>November 30, 2016</td>
</tr>
<tr>
<td>October 1, 2016–December 31, 2016</td>
<td>February 28, 2017</td>
</tr>
</tbody>
</table>

We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50319 through 50321) for a detailed discussion of the final policy in the Medicare EHR Incentive Program for eligible hospitals and CAHs as well as section VIII.D. of the preamble of this final rule where the EHR Incentive Program discusses its proposals to further align with the Hospital IQR Program.

We invited public comments on our proposal to update our electronic clinical quality measure data reporting and submission periods for the CY 2016/FY 2018 payment determination.

**Comment**: One commenter supported the proposed submission deadlines for electronic clinical quality measures.

**Response**: We thank the commenter for its support.
Comment: One commenter requested clarification on the alignment of the reporting timeframes for electronic clinical quality measures for the Hospital IQR and the EHR Incentive Programs.

Response: Consistent with our modified policies we are finalizing in section VIII.A.8.c. of the preamble of this final rule, our deadline for eCQMs in the Hospital IQR Program is February 28, 2017 for either the Q3 or Q4 reporting period. Under the EHR Incentive Program, the reporting period is one calendar quarter from Q1, Q2, or Q3 of CY 2015 and the submission deadline is 2 calendar months after the close of the reporting CY quarter. For more detail on the EHR Incentive Program, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50319 through 50321) for a detailed discussion of the final policy regarding attesting in the Medicare EHR Incentive Program for eligible hospitals and CAHs as well as section VIII.D. of the preamble of this final rule where the EHR Incentive Program discusses its proposals to further align with the Hospital IQR Program.

Comment: A few commenters suggested that the window for reporting electronic clinical quality measure data be extended from the proposed two months after the end of a quarter, to 3 or 4 months, and noted that extending the deadline will allow more time to develop reports and provide more accurate information.

Response: We recognize that commenters requested an extended submission timeline for reporting electronic data. In response to comments, we are finalizing a modification of our proposal. Instead of requiring hospitals to report 2 quarters of data (Q3 and Q4) two months following the reporting period as proposed, we will require
hospitals to report the 4 electronic clinical quality measures for only 1 quarter (either Q3 or Q4) of CY 2016/FY 2018 payment determination, with a submission deadline of February 28, 2017. We also refer readers to section VIII.A.8.c. of the preamble of this rule where we discuss our modified policies. We believe that this modified submission deadline provides hospitals additional time to develop reports and provide accurate information. For example, if hospitals choose to report Q3 CY 2016 data, hospitals would have 5 months from the end of the reporting period (September 30, 2016) until the submission deadline (February 28, 2017).

Comment: Several commenters supported the options allowing simultaneous submission of electronic clinical quality measures for the Hospital IQR and EHR Incentive Programs during Q3 and Q4 of CY 2016 and noted their appreciation of CMS’ efforts to harmonize reporting and submission periods between the Hospital IQR Program and the EHR Incentive Program. Other commenters cited their appreciation that the number of required measures is consistent. Some commenters noted that the alignment could eventually streamline the quality measure reporting process, reduce provider reporting burdens, and support a transition towards healthcare systems focusing more on the measurement of patient-centered outcomes.

Response: We thank the commenters for their support.

Comment: Several commenters supported a long-term movement towards alignment between the Hospital IQR and the EHR Incentive Programs and urged CMS to employ a more patient-centered approach that prioritizes measures of patient outcomes that the commenter believes will reveal significant variation in performance.
Response: We thank the commenters for their support and their suggested approach. We believe that current Hospital IQR Program measures emphasize patient outcomes and we will continue to adopt new measures that do so in the future.

Comment: Several commenters noted that the Hospital IQR Program and the EHR Incentive Program are not aligned, given the proposal to require electronic reporting for the FY 2018 payment year under the Hospital IQR Program. A few commenters recommended that Meaningful Use and the Hospital IQR Programs share a single timeline for electronic reporting requirements, given that providers continue to exhibit significant challenges with electronic reporting. The commenters stated that generally, better alignment, or even outright consolidation between Meaningful-Use and Hospital IQR Program eMeasures reporting mechanisms would reduce provider burden.

Response: The Hospital IQR Program and the EHR Incentive Program were created under independent statutory authorities – section 1886(b)(3)(B)(viii) of the Act and section 1814(l)(3)(A) of the Act, respectively. The Secretary maintains the authority to determine the applicable policies under each program. We strive, to the extent possible, to align reporting periods and other policies across these programs, acknowledging that some provider burden exists with reporting for multiple programs. However, due to differences in statutes and policy goals between the programs, consolidation and exact alignment is not entirely feasible, thus, requiring the need for individual timelines for each program. However, we will continue to strive for greater alignment between the Hospital IQR and EHR Incentive Programs in future rulemaking.
Comment: One commenter requested detail on why certain “topped-out” measures in the Hospital IQR Program are being required by the EHR Incentive Program and asked for an explanation of the value added.

Response: We have attempted to align Hospital IQR Program measures with those in the EHR Incentive Program. Specifically, we proposed to retain the electronic versions of five measures otherwise deemed “topped out” (STK-06, STK-08, VTE-1, VTE-2, and VTE-3) under Hospital IQR Program standards in order to align with the EHR Incentive Program. We believe this approach allows for hospital flexibility and choice in reporting electronic clinical quality measures. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203 through 50204), we finalized our proposal to clarify the criteria for determining when a measure is “topped out.” However, we continue to believe that there are circumstances in which a measure that meets criteria for removal should be retained regardless, because the drawbacks of removing a measure could be outweighed by other benefits to retaining the measure.

Therefore, because of the continued need to balance benefits and drawbacks as well as our desire to increase transparency, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24556 through 24557), we proposed, and are finalizing in this final rule, additional factors to consider for measure removal and also include factors to consider in deciding whether to retain measures. Two of those factors are: (1) measure aligns with other CMS programs, including other quality reporting programs, or the EHR Incentive Program; and (2) measure supports efforts to move facilities towards reporting electronic
measures. We believe it is valuable and important to retain the electronic versions of these measures as hospitals learn to submit data in this form and manner.

After consideration of the public comments received, and in accordance with our modified electronic clinical quality measure reporting requirements finalized in this final rule, we are finalizing a modification of our electronic clinical quality measure reporting periods from those proposed. Specifically, we are finalizing that instead of requiring hospitals to submit both Q3 and Q4 of CY 2016 data within 2 months after the end of the applicable calendar year quarter (November 30, 2016 for Q3 and February 28, 2017 for Q4), hospitals are required to submit only one quarter (either Q3 or Q4) of CY 2016 data by February 28, 2017. We refer readers to the table below.
### Adopted CY 2016/FY 2018 Payment Determination Hospital IQR Program

#### Electronic Reporting Periods and Submission Deadlines for Eligible Hospitals

<table>
<thead>
<tr>
<th>Discharge Reporting Periods</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1, 2016–March 31, 2016</td>
<td>N/A</td>
</tr>
<tr>
<td>April 1, 2016–June 30, 2016</td>
<td>N/A</td>
</tr>
<tr>
<td>July 1, 2016–September 30, 2016</td>
<td>February 28, 2017</td>
</tr>
<tr>
<td>October 1, 2016–December 31, 2016</td>
<td>February 28, 2017</td>
</tr>
</tbody>
</table>

**e. Sampling and Case Thresholds for the FY 2018 Payment Determination and Subsequent Years**

We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50221), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53537), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50819) for details on our sampling and case thresholds for the FY 2016 payment determination and subsequent years. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24588), we made one proposal regarding our population and sampling policy. However, we did not propose any changes to case thresholds.

Currently, hospitals must submit to CMS quarterly aggregate population and sample size counts for Medicare and non-Medicare discharges for all measures in the topic areas for which chart-abstracted data must be submitted. Hospitals are required to submit their aggregate population and sample size count for each topic area. In accordance with the policy we first adopted in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50221), hospitals that have not treated patients in a specific topic area must still submit quarterly population and sample size counts for all Hospital IQR Program
chart-abstracted data topics. For example, if a hospital has not treated AMI patients, the hospital is still required to submit a zero for its quarterly aggregate population and sample count for that topic in order to meet the requirement.

In the proposed rule, we proposed to revise this policy so that, beginning with the FY 2018 payment determination and subsequent years, hospitals will be required to submit population and sample size data only for those measures that a hospital submits as chart-abstracted measures under the Hospital IQR Program. This differs from the current policy in that there may be instances where a hospital chooses to electronically submit a measure that can be submitted either via chart-abstraction or as an electronic clinical quality measure and under the proposed policy, we would not require population and sample size data in this case. Under the proposed policy, if a hospital submits a measure as an electronic clinical quality measure, or if a measure becomes voluntary or suspended, the population and sample data would not be required.

We invited public comments on this proposal.

Comment: One commenter supported the proposed sampling and case thresholds for FY 2018 payment determination and subsequent years.

Response: We thank the commenter for its support.

After consideration of the public comment we received, we are finalizing our policy that hospitals will be required to submit population and sample size data only for those measures that a hospital submits as chart-abstracted measures under the Hospital IQR Program as proposed.
We did not propose any changes to case thresholds. As stated in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we will continue to apply the zero denominator and case threshold exemption policies for the electronic clinical quality measures for the Hospital IQR Program. The zero denominator and case threshold exemptions are described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50323 through 50324).

f. HCAHPS Requirements for the FY 2018 Payment Determination and Subsequent Years

We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50220), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641 through 51643), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53537 through 53538), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50819 through 50820) for details on HCAHPS requirements. We did not propose any changes to HCAHPS requirements.

Hospitals and HCAHPS survey vendors should check the official HCAHPS Web site at http://www.hcahpsonline.org for new information and program updates regarding the HCAHPS Survey, its administration, oversight and data adjustments.

g. Data Submission Requirements for Structural Measures for the FY 2018 Payment Determination and Subsequent Years

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51643 through 51644) and the FY 2013 IPPS/LTCH PPS final rule (77 FR 53538 through 53539) for details on the data submission requirements for structural measures. We did not propose any changes to data submission requirements for structural measures.
h. Data Submission and Reporting Requirements for Healthcare-Associated Infection (HAI) Measures Reported via NHSN

For details on the data submission and reporting requirements for healthcare-associated infection (HAI) measures reported via the CDC’s National Healthcare Safety Network (NHSN) Web site, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51629 through 51633; 51644 through 51645), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53539), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50821 through 50822). Clarifications to the HAI data reporting and submission requirements policy can also be found in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50259 through 50262). The data submission deadlines are posted on the QualityNet Web site at: http://www.QualityNet.org/. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24588), we did not propose any changes to data submission and reporting requirements for HAI measures reported via the NHSN.

Comment: A few commenters requested that the reporting periods for the NHSN measures be aligned across programs and noted that the HAC Program uses 2 years of data while the Hospital IQR and Hospital VBP Programs use only 1 year of data.

Response: We appreciate the commenters’ feedback and suggestions. We strive, to the extent possible, to align reporting periods between our programs, acknowledging that some provider burden exists with reporting for multiple programs. However, given the varying policy, statutory, and data collections differences between these programs, exact alignment is not always feasible. For more details on the 2-year reporting period under the HAC Reduction Program, we refer readers to the FY 2014 IPPS/LTCH PPS
final rule (78 FR 50717). We also refer readers to FY 2014 IPPS/LTCH PPS final rule (78 FR 50496) for reporting requirements for the Hospital VBP Program. As these programs grow in future years, we will examine the possibility of greater alignment.

11. Modifications to the Existing Processes for Validation of Hospital IQR Program Data

a. Background

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53539 through 53553), we finalized the processes and procedures for validation of chart-abstracted measures in the Hospital IQR Program for the FY 2015 payment determination and subsequent years; the FY 2013 IPPS/LTCH PPS final rule also contains a comprehensive summary of all procedures finalized in previous years and still in effect. Several modifications to these processes were finalized for the FY 2016 and FY 2017 payment determinations in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50822 through 50835).

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50262 through 50273) for the FY 2017 payment determination and subsequent years, we finalized additional modifications to these processes. These changes fall into the following categories: (a) eligibility criteria for hospitals selected for validation; (b) number of charts to be submitted per hospital for validation; (c) combining scores for HAI and clinical process of care measures; (d) processes to submit patient medical records for chart-abstracted measures; and (e) plans to validate electronic clinical quality measure data.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50269 through 50273), we finalized a policy to conduct a validation pilot test for electronic clinical quality measures. We stated that we intended to complete pilot activities in CY 2015
(79 FR 50271) and that continues to be our intention. We did not propose any changes to our validation pilot test.

However, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24588 through 24589), we proposed modifications to existing processes for validation of chart-abstracted measures, specifically for the Influenza Immunization (NQF #1659) measure.

b. Modifications to the Existing Processes for Validation of Chart-Abstracted Hospital IQR Program Data

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50265 through 50273), we finalized a validation process, which included a separate validation stratum for the Influenza Immunization (NQF #1659) measure (the immunization measure validation stratum) because that measure overlapped with the Hospital VBP Program. The finalized validation process for chart-abstracted measures included three separate validation strata: HAI, Immunization, and Other/Clinical Process of Care (79 FR 50265 through 50273). The Immunization stratum includes only one measure, Immunization for Influenza (NQF #1659). This Immunization measure was included in its own stratum because it is used in the Hospital VBP Program and we wanted to ensure that every hospital selected for validation would be validated in this topic area.

As discussed in section IV.F.2.b.(1) of the preamble of this final rule, we proposed to remove the IMM-2 Influenza Immunization measure from the Hospital VBP Program. Given the proposed removal of the Influenza Immunization measure from the Hospital VBP Program, it would be no longer necessary to ensure validation of this topic
area by including a separate stratum for the Influenza measure. As a result, in the proposed rule, for the Hospital IQR Program beginning with the FY 2018 payment determination and for subsequent years, we proposed to remove the separate immunization validation stratum and include the Influenza Immunization measure in the clinical process of care measure validation stratum. Under this proposal, we would continue to apply our chart-abstracted measure validation processes only to those chart-abstracted measures that are required under the Hospital IQR Program in a chart-abstracted form (as opposed to those measures that a hospital reports as electronic clinical quality measures, for example). This proposal is consistent with our proposed policy to require population and sample size data only for those measures that are required under the Hospital IQR Program. We refer readers to section VIII.A.10.e. of the preamble of this final rule for more detail on that proposal.

Although this proposal includes an adjustment to the composition of the clinical process of care validation stratum, we did not propose any changes to the overall validation sample size. Under the existing validation process, a total of eight charts are drawn for validation—five of which are drawn from the clinical process of care measures stratum and three of which are drawn from the immunization measure stratum. Under this proposal, however, while the total number of charts drawn is the same (eight), all eight measures will be drawn from the clinical process of care measure stratum, which would then include the Influenza Immunization measure. Accordingly, one sample of charts will be drawn from the clinical process of care measures.
The proposed removal of the immunization validation stratum and inclusion of the Influenza Immunization measure in the clinical process of care validation stratum would result in an expanded pool of clinical process of care topic areas sampled for validation to include STK, VTE, ED, Sepsis, and Immunization. As described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50266), all chart-abstracted measure topic areas included in the Hospital IQR Program, with the exception of the Perinatal Care topic area, are automatically included in the validation process. We do not include this topic area because the Elective Delivery PC-01 (NQF#0469) measure is reported in aggregate form, which is not consistent with our patient-level validation process (79 FR 50266).

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50268 through 50269), we outlined the weighting of each of three validation topic areas: Healthcare-associated infection (66.7 percent); Immunization (22.2 percent); and Other/Clinical Process of Care (11.1 percent). The table below shows the proposed effect on topic area weighting of our proposal to remove the immunization measure validation stratum and to move the Influenza Immunization (NQF #1659) measure to the clinical process of care validation stratum.

<table>
<thead>
<tr>
<th>Proposed Topic Area Weighting for Validation for the FY 2018 Payment Determination and Subsequent Years</th>
<th>Weight (Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare-associated infection (HAI)</td>
<td>66.7</td>
</tr>
<tr>
<td>Other/Clinical Process of Care</td>
<td>33.3</td>
</tr>
<tr>
<td>Total</td>
<td>100.0</td>
</tr>
</tbody>
</table>
We invited public comments on our proposal to remove the immunization measure validation stratum, to move the Influenza Immunization (NQF #1659) measure to the clinical process of care validation stratum, and to reweight the topic areas for validation beginning with the FY 2018 payment determination and for subsequent years.

**Comment:** Several commenters supported the proposed removal of the separate immunization validation stratum and moving of the influenza immunization measure (IMM-2) to the clinical process of care measure validation stratum due to the removal of the measure from the Hospital VBP Program.

**Response:** We thank the commenters for their support.

**Comment:** One commenter recommended that CMS continue the electronic clinical quality measure validation pilot in 2016 to ensure that a diverse group of hospitals and certified EHRs are represented and to inform an assessment of the work required to make eCQM feasible, reliable and valid. A few commenters noted their concern that the proposed data validation methodology does not address the barriers associated with reporting electronic clinical quality measures.

**Response:** We thank commenters for the suggestion and will consider this approach in future rulemaking. We will allow for time to evaluate results of the pilot and particularly, the effectiveness of electronically reported clinical quality measure data once the pilot concludes. If analyses prove the need for an extension of the pilot, we will consider that approach. In addition, as described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we have only heard anecdotal comments about performance level differences between the chart-abstracted and electronic modes of collection. We
recognize the potential for barriers associated with electronic reporting and intend to assess for them, but at this time, we do not have sufficient data to confirm the aforementioned comments. However, once results of the validation pilot are available, we will share the results and adapt the pilot if necessary and as needed to ensure that all critical factors (such as reporting barriers) are adequately analyzed.

Comment: One commenter expressed appreciation for past education sessions clarifying the distinction between data collection methods and looked forward to seeing the results of the validation pilot.

Response: We are pleased that the commenter found value in the education sessions and note that data from the electronic clinical quality measure validation pilot will be used to inform future rulemaking.

After consideration of the public comments we received, we are finalizing our proposals to remove the immunization measure validation stratum, to move the Influenza Immunization (NQF #1659) measure to the clinical process of care validation stratum, and to reweight the topic areas for validation beginning with the FY 2018 payment determination and for subsequent years as proposed.

12. Data Accuracy and Completeness Acknowledgement Requirements for the FY 2018 Payment Determination and Subsequent Years

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53554) for details on Data Accuracy and Completeness Acknowledgement (DACA) requirements. We did not propose any changes to the DACA requirements.

\(^{258}\) Hospital Inpatient Data Collection & CART. Available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1138900279093
13. Public Display Requirements for the FY 2018 Payment Determination and Subsequent Years

We refer readers to the FY 2008 IPPS final rule (72 FR 47364), the FY 2011 IPPS/LTCH PPS final rule (75 FR 50230), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51650), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53554), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50836) for details on public display requirements.

The Hospital IQR Program quality measures are typically reported on the Hospital Compare Web site at: http://www.medicare.gov/hospitalcompare, but on occasion are reported on other CMS Web sites such as http://www.cms.gov and/or https://data.medicare.gov.

For the Mortality, Readmission, Complication, Payment and AHRQ measures, we will continue to replace publically reported data with a footnote for hospitals that do not have data for at least 25 cases combined during the reporting period. If there are fewer than 25 eligible cases, the measures are assigned to a separate category described as “The number of cases is too small (fewer than 25) to reliably tell how well the hospital is performing.” The measures are included in the calculation but are not publicly reported on Hospital Compare. For chart-abstracted or Web-based measures, if either the numerator or the denominator is greater than 0 and less than 11, the data are not reported on Hospital Compare, but rather data is displayed as “Not Available”. This guidance does not apply to calculated measures, only to those in which cases/patients could be identified. We also provide footnote explanations on the Hospital Compare Web site at: http://www.medicare.gov/hospitalcompare/Data/Footnotes.html.
We refer readers to section VIII.A.8.b. of the preamble of this final rule, where we discuss our proposal to delay publicly reporting electronic clinical quality measure data submitted by hospitals for CY 2016/FY 2018 payment determination in order to allow time for us to evaluate the effectiveness of electronically reported clinical quality measure data. In the meantime, measures reported via electronic clinical quality measures will be marked with a footnote on Hospital Compare noting that: (1) the hospital submitted data via EHR; (2) data are being processed and analyzed; and (3) we will eventually publicly report this data once we determine the data to be reliable and accurate.

**Comment:** One commenter expressed concern that patients may be confused by a lack of available data for measures that hospitals choose to report electronically, especially given that hospitals chart-abstracting a given measure will have data available. The commenter suggested that chart-abstracted data not be publicly displayed until electronic data is publicly displayed.

**Response:** We appreciate the commenter’s concern. The decision to delay the public display of electronic measures will allow for collaboration with measure developers and vendors as needed (per suggestions by other commenters) and an in-depth evaluation of the findings from the pilot. We recognize the importance of transparency, but also want to ensure the accuracy of the information being provided. This timing will enable us to finalize policies for public display prior to the February 28, 2017 deadline for electronic clinical quality measure data submission. In regards to the chart-abstracted data not be publicly displayed until electronic data is publicly displayed, we believe that
limiting the data available would not further our goals of transparency and informing the public.

**Comment:** One commenter requested general clarification regarding the public reporting of HAI results and requested clarification on whether the delay in publishing HAI results following the measurement period will be modified or continued.

**Response:** Results for HAI measures will be posted on Hospital Compare in accordance with our existing policy, which we are not changing. HAI measures are posted according to our current policy of reporting data from the Hospital IQR Program as soon as it is feasible. We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203) and the FY 2012 IPPS/LTCH PPS final rule (76 FR 51608) for details. Public reporting for HAI measures have not changed.

**Comment:** Several commenters supported the proposed public display requirements for the FY 2018 payment determination and subsequent years.

**Response:** We thank the commenters for their support.

**Comment:** Some commenters questioned the value of sharing the names of the hospitals that successfully submit electronic clinical quality measures data by the provided deadline. One commenter encouraged CMS to shift its focus to evaluate and publish the findings from the electronic clinical quality measure validation pilot. Another commenter requested clarification on what criteria and/or information will be used to establish a date for reporting on these measures going forward. Some commenters also requested additional detail on how and when electronic data will be available for public
review. One commenter opposed the delay in the public display of electronic measures on *Hospital Compare*, noting that data transparency should be CMS’ primary concern.

**Response:** We recognize the importance of transparency, but also want to ensure the accuracy of the information being provided. We refer readers to section VIII.A.8.c. of the preamble of this rule where we finalize a modified version of our proposed policy. While we proposed that measures reported via electronic clinical quality measure would be marked with a footnote on *Hospital Compare*, we are finalizing instead that any data submitted electronically will not be posted on the *Hospital Compare* Web site. We will address public reporting of electronic data in next year’s rulemaking, after the conclusion and assessment of the validation pilot. Therefore, we do not have plans to share the names of hospitals submitting electronic clinical quality measures. The decision to delay the public display of electronic measures will allow for collaboration with measure developers and vendors as needed (per suggestions received from other commenters) and an in-depth evaluation of the findings from the pilot. This timing will enable us to finalize public display details prior to the February 28, 2017 deadline for electronic clinical quality measure data submission.

After consideration of the public comments we received here and in our discussion of required eCQMs in section VIII.A.8.c. of the preamble of this final rule, we are modifying our proposal to publicly report electronic clinical quality measure data submitted by hospitals for CY 2016/the FY 2018 payment determination in order to allow time for us to evaluate the effectiveness of electronically reported clinical quality measure data. Instead of finalizing our proposal that measures reported via electronic
clinical quality measures will be marked with a footnote on Hospital Compare noting that: (1) The hospital submitted data via EHR; (2) data are being processed and analyzed; and (3) we will eventually publicly report this data once we determine the data to be reliable and accurate, we are finalizing a policy to delay any public reporting of electronic data. We will address plans to publicly report electronic clinical quality measure data submitted by hospitals for CY 2016/FY 2018 payment determination in the upcoming FY 2017 IPPS/LTCH PPS rulemaking.

14. Reconsideration and Appeal Procedures for the FY 2018 Payment Determination and Subsequent Years

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51650 through 51651), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50836), and at 42 CFR 412.140(e) for details on reconsideration and appeal procedures for the FY 2017 payment determination and subsequent years. We did not propose any changes to the reconsideration and appeals procedures.

15. Hospital IQR Program Extraordinary Circumstances Extensions or Exemptions

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51651 through 51652), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50836 through 50837), and 42 CFR 412.140(c)(2) for details on the Hospital IQR Program extraordinary circumstances extensions or exemptions policy.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50277), we indicated that we will refer to the process as the extraordinary circumstances extensions or exemptions process and, accordingly, finalized changes reflecting this updated language in the
corresponding regulation text. We did not propose any changes to the Hospital IQR Program’s extraordinary circumstances extensions or exemptions policy.

**Comment:** A few commenters opposed mandatory reporting of electronic clinical quality data unless a hardship exception is implemented, such as is allowed for under the EHR Incentive Program, given that some hospitals will be unable to achieve the electronic reporting requirements set forth in the Hospital IQR Program. In addition, a few commenters specifically requested that we adopt a hardship exemption, similar to the one used for under the EHR Incentive Program, to consider allowing hospitals to receive an exemption from the electronic reporting requirements if a hardship is demonstrated. One commenter noted that failure to provide an exception process will unfairly expose hospitals to risk for payment penalties.

**Response:** We recognize that there may be special circumstances that prevent a hospital from reporting electronic clinical quality measures. In response to public comments we received and as discussed in section VIII.A.8.c. of the preamble of this final rule, we are expanding our previously established Extraordinary Circumstances Extensions/Exemptions policy (79 FR 50277) to address commenters’ suggestions. We are finalizing a policy to allow hospitals to utilize the existing Extraordinary Circumstances Exemption (ECE) form to request an exemption from the Hospital IQR Program’s electronic clinical quality measure reporting requirement for the applicable program year based on hardships preventing hospitals from electronically reporting. Such hardships could include, but are not limited to, infrastructure challenges (hospitals must demonstrate that they are in an area without sufficient internet access or face
insurmountable barriers to obtaining infrastructure) or unforeseen circumstances, such as vendor issues outside of the hospital’s control (including a vendor product losing certification). In addition, hospitals newly participating in the Hospital IQR Program, that are required to begin data submission under Hospital IQR Program procedural requirements at 42 CFR 412.140(c)(1), which describes submission and validation of Hospital IQR Program data, may also be considered undergoing hardship and can apply for an exemption. Lastly, we will continue to allow hospitals to apply the zero denominator and case threshold exceptions described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50323 through 50324).

This policy is based on our previously established extraordinary circumstances extensions/exemptions policy (79 FR 50277). Under the policy we are finalizing, hospitals may use the existing ECE form, which is available on QualityNet at:


After consideration of the public comments we received, we are expanding the Hospital IQR Program’s Extraordinary Circumstances Extensions or Exemptions policy to include an exemption for hospitals that demonstrate hardship in reporting eCQMs according to the criteria discussed above. This expansion will be effective starting with the FY 2018 payment determination.
B. PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program

1. Statutory Authority

Section 3005 of the Affordable Care Act added new sections 1866(a)(1)(W) and (k) to the Act. Section 1866(k) of the Act establishes a quality reporting program for hospitals described in section 1886(d)(1)(B)(v) of the Act (referred to as “PPS-Exempt Cancer Hospitals” or “PCHs”) that specifically applies to PCHs that meet the requirements under 42 CFR 412.23(f). Section 1866(k)(1) of the Act states that, for FY 2014 and each subsequent fiscal year, a PCH must submit data to the Secretary in accordance with section 1866(k)(2) of the Act with respect to such a fiscal year. For additional background information, including previously finalized measures and other policies for the PCHQR Program, we refer readers to the following final rules: the FY 2015 IPPS/LTCH PPS final rule (79 FR 50277 through 50288); the FY 2014 IPPS/LTCH PPS final rule (78 FR 50838 through 50846); and the FY 2013 IPPS/LTCH PPS final rule (77 FR 53556 through 53561).

2. Removal of Six Surgical Care Improvement Project (SCIP) Measures from the PCHQR Program Beginning with Fourth Quarter (Q4) 2015 Discharges and for Subsequent Years

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24590), we proposed to remove six SCIP measures from the PCHQR Program beginning with fourth quarter (Q4) 2015 discharges and for subsequent years. Under this proposal, PCHs will meet reporting requirements for the FY 2016 and FY 2017 programs by submitting first quarter (Q1) through third quarter (Q3) 2015 data for these measures:
- Surgery Patients Who Received Appropriate Venous Thromboembolism Prophylaxis within 24 Hours Prior to Surgery to 24 Hours After Surgery (NQF #0218)
- Urinary Catheter Removed on Post-Operative Day One (POD1) or Post-Operative Day Two (POD2) with Day of Surgery Being Day Zero (formerly NQF #0453)
- Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision (NQF #0527)
- Prophylactic Antibiotic Selection for Surgical Patients (NQF #0528)
- Prophylactic Antibiotic Discontinued Within 24 Hours After Surgery End Time (NQF #0529)
- Surgery Patients on Beta-Blocker Therapy Prior to Admission who Received a Beta-Blocker During the Perioperative Period (NQF #0284)

We first adopted the six SCIP measures in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50840 through 50841) and refer readers to that rule for a detailed discussion of the measures. As described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50205), these measures have been determined to be topped-out in the Hospital IQR Program and were removed from that program. To meet FY 2016 and FY 2017 program requirements, we proposed that PCHs would continue to submit these six measures for first quarter (Q1) 2015 through third quarter (Q3) 2015 discharges in accordance with the submission timeline we finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50285). We proposed to remove these measures from the PCHQR Program because we have removed them from the Hospital IQR Program and, because they have been removed from that
program, it is no longer operationally feasible to collect these measures under the PCHQR Program. By removing these measures, we also would alleviate the maintenance costs and administrative burden for PCHs associated with reporting them (79 FR 50205).

We invited public comments on these proposals.

**Comment:** Many commenters supported this proposal, noting the benefits of alignment with the Hospital IQR program and the reduction in burden for PCHs.

**Response:** We thank these commenters for their support.

**Comment:** Several commenters supported the intent of the proposal, but recommended that CMS also suppress public reporting on these measures because, as indicated by one commenter, one-time reporting of three quarters of the SCIP measures would promote confusion among the intended audience.

**Response:** We thank these commenters for their support and recommendation. Under section 1866(k)(4) of the Act, we established a procedure for making the quality data submitted under the PCHQR Program available to the public. (We refer readers to section VIII.B.6. of the preamble to this final rule for a discussion of our public display procedure.) We believe that the commenters may be concerned that a short reporting period (only 3 quarters of data) may result in the public reporting of unreliable measure rates. We understand this concern and will address criteria for data suppression from public reporting in future rulemaking.

**Comment:** One commenter supported the proposal to remove the SCIP measures, but recommended immediate removal, rather than waiting until the proposed 2018 program.
Response: We thank the commenter for the support and recommendation. However we believe that since PCHs have already collected a large majority of 2015 reporting period data (approximately nine months (three quarters) of data) it will present minimum burden in submitting the rest of the data by the submission deadline which is outlined in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50851 through 50852). We believe these data will provide valuable information in establishing some baselines for future measure selection surrounding this topic (surgical infection measures), especially when surgical infection rates are highly prevalent.\footnote{259 CDC. Healthcare Associated Infection. Available at: http://www.cdc.gov/HAI/surveillance/index.html.}

Comment: One commenter recommended that CMS keep SCIP-VTE-2 in the PCHQR Program rather than extrapolate findings from the Hospital IQR Program.

Response: We thank the commenter for the recommendation. However, we are not extrapolating data for any of these measures from the Hospital IQR Program. Rather, we are removing the measures to improve alignment between these programs, reduce the reporting burden on PCHs, and focus our IT systems on PCHQR Program measures more closely linked with clinical outcomes.

Comment: One commenter requested that CMS clarify how removal from the Hospital IQR Program impacts the operational feasibility of SCIP-VTE-2 data in the PCHQR Program.

Response: The Hospital IQR and PCHQR Programs, among others, share the same IT infrastructure and system operation platform in collecting data. Therefore, as a result of finalizing our proposal to remove these measures from the Hospital IQR Program, we intend to remove all IT business requirements and functionalities from the...
IT data warehouse. This approach will allow us to free up “space” to allow us to include additional measures adopted for quality and incentive programs. We recognize that this approach, in this case, has a significant impact on the PCHQR Program. However, we believe that this approach is the most operationally feasible under the circumstances.

After consideration of the public comments we received, we are finalizing our proposal to remove these six SCIP measures from the PCHQR Program beginning with fourth quarter (Q4) 2015 discharges and for subsequent years.

3. New Quality Measures Beginning with the FY 2018 Program
   a. Considerations in the Selection of Quality Measures

      In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53556), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50837 through 50838), and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50278), we indicated that we have taken a number of principles into consideration when developing and selecting measures for the PCHQR Program, and that many of these principles are modeled on those we use for measure development and selection under the Hospital IQR Program. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24590 through 24591), we did not propose any changes to the principles we consider when developing and selecting measures for the PCHQR Program.

   b. Summary of New Measures

      For the FY 2018 PCHQR Program, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24591 through 24593), we proposed to adopt three new quality measures. These measures meet the requirement under section 1866(k)(3)(A) of the Act that
measures specified for the PCHQR Program be endorsed by the entity with a contract under section 1890(a) of the Act (currently the NQF).

The proposed measures are as follows:

- Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset *Clostridium difficile* Infection (CDI) Outcome Measure (NQF #1717) (CDC NHSN CDI Measure)
- CDC NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant *Staphylococcus aureus* (MRSA) Bacteremia Outcome Measure (NQF #1716) (CDC NHSN MRSA Measure)
- CDC NHSN Influenza Vaccination Coverage Among Healthcare Personnel (HCP) Measure (NQF #0431) (CDC NHSN HCP Measure)

The proposed measures were included on a publicly available document entitled “List of Measures Under Consideration (MUC) for December 1, 2014,” which is a list of quality and efficiency measures being considered for use in various Medicare programs. The proposed measures were also submitted to the Measure Applications Partnership (MAP), a public-private partnership convened by the NQF for the purpose of providing input to the Secretary on the selection of certain quality and efficiency measures. For the PCHQR Program, the MAP supported the inclusion of all three measures. The MAP’s recommendations can be found in the “Spreadsheet of MAP 2015 Final Recommendations.”

---


261 National Quality Forum “Process and Approach for MAP Pre-Rulemaking Deliberations 2015” Available at: [http://www.qualityforum.org/Publications/2015/01/Process_and_Approach_for_MAP_Pre-](http://www.qualityforum.org/Publications/2015/01/Process_and_Approach_for_MAP_Pre-)
In addition, all three of the proposed measures are currently reported under the Hospital IQR Program as described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51630 through 51631). We refer readers to CDC’s Web site for detailed measure information for these three measures. The sections below outline our rationale for proposing to adopt these measures.

c. CDC NHSN Facility-Wide Inpatient Hospital-Onset Clostridium difficile Infection (CDI) Outcome Measure (NQF #1717)

Healthcare-associated infections (HAIs), such as CDI and MRSA, are a significant cause of morbidity and mortality. At any given time, approximately one in every 25 inpatients has an infection related to hospital care. These infections cost the U.S. health care system billions of dollars each year and lead to the loss of tens of thousands of lives. In addition, HAIs can have devastating emotional, financial and medical consequences. As a result of these adverse outcomes, we are committed to increasing patient safety by partnering with hospitals (for example, the CMS Partnership for Patients) to make hospital care safer, more reliable, and less costly by preventing

---


266 CMS Innovation Center Partnership for Patients. Available at: http://innovation.cms.gov/initiatives/partnership-for-patients/.
injury and increased morbidity in patients, as well as allowing them to heal without complications.\textsuperscript{267}

CDC reports that prolonged antibiotic exposure, a long length of stay in a health care setting, and the existence of a serious underlying illness or immunocompromised condition (for example, cancer) increase the risk of CDI.\textsuperscript{268} As a result, we believe it is important to collect data on CDIs in the PCH setting, where cancer patients face increased exposure to these risk factors. In addition, in recent years, CDIs have become more frequent, more severe, and more difficult to treat.\textsuperscript{269} Each year, CDI is linked to 14,000 American deaths.\textsuperscript{270} Infection is especially common in older adults, but also affects some otherwise healthy people who are not hospitalized and/or taking antibiotics.\textsuperscript{271}

This proposed measure addresses the National Quality Strategy (NQS) Patient Safety domain. The measure reports the standardized infection ratio (SIR) of hospital-onset CDI Laboratory-identified events (LabID events) among all patients in the facility. The numerator includes the total number of observed hospital-onset CDI LabID events among all inpatients in the facility, excluding well baby-nurseries and Neonatal Intensive Care Units.\textsuperscript{272} The denominator includes the total number of predicted hospital-onset CDI LabID events, calculated by multiplying the number of inpatient days

\textsuperscript{267} HHS National Action Plan to Prevent Health Care-Associated Infections: Road Map to Elimination. Available at: \url{http://www.health.gov/hai/prevent_hai.asp#hai}.

\textsuperscript{268} CDC \textit{C. difficile} FAQ. Available at: \url{http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_infect.html}.

\textsuperscript{269} FY 2012 IPPS/LTCH PPS final rule (76 FR 51630 through 51631).

\textsuperscript{270} CDC Vital Signs. Available at: \url{http://www.cdc.gov/vitalsigns/pdf/2012-03-vitalsigns.pdf}.

\textsuperscript{271} FY 2012 IPPS/LTCH PPS final rule (76 FR 51630 through 51631).

\textsuperscript{272} NQF QPS. Available at: \url{http://www.qualityforum.org/Qps/MeasureDetails.aspx?standardID=1717&print=0&entityTypeID=1}. 
for the facility by the hospital-onset CDI LabID event rate for similar types of facilities (obtained from a standard population).  

Beginning with a 2010-2011 baseline SIR of 1.0, we set a national goal to reduce the incidence of facility-onset CDI overall by 30 percent (to a SIR of 0.70) by no later than 2013. However, we were not able to meet that goal, and the rate of facility-onset CDI decreased by only 2 percent as of 2012 (to a SIR of 0.98). Therefore, we believe it is critical to continue collecting data on CDI in the hospital setting, and to adopt this measure for the PCH setting, in order to ensure the highest quality of care for cancer patients and continue our effort to support HHS’ National Action Plan to Prevent Healthcare Associated Infections (HAIs) and our proposed 2020 goal to reduce facility-onset of CDI by 30 percent from the 2015 baseline. The collection and evaluation of CDI data will allow PCH staff to evaluate whether their infection control efforts need improvement. We recognize the severe impact of CDI, and aim to continue efforts to increase patient protection and safety, and at the same time prevent adverse infections in the PCH setting. 

By proposing this measure in the PCHQR Program, we aim to continue to provide a common mechanism (that is, reporting to CDC’s NHSN) that all hospitals, including PCHs, can use to uniformly submit and report measure data and inform their clinicians of the impact of targeted prevention efforts.

273 NQF QPS. Available at: http://www.qualityforum.org/Publications/2013/02/Patient_Safety_Measures_Comlications_-Phase_2.aspx.
274 FY 2012 IPPS/LTCH PPS final rule (76 FR 51630 through 51631).
276 Ibid.
We invited public comments on our proposal to add the CDC NHSN CDI Outcome Measure to the PCHQR Program beginning with the FY 2018 program.

Comment: Many commenters supported inclusion of the CDC NHSN CDI Outcome Measure in the PCHQR Program specifically citing the clinical significance of this measure.

Response: We thank these commenters for their support.

Comment: One commenter did not support this measure, and stated that individuals with cancer are more susceptible to infection because they are at higher risk of being infected due to the nature of their cancer condition (that is, immunocompromised). As a result, the commenter believed PCHs should not be compared with other settings.

Response: We thank the commenter for this input. We believe that PCHs should not be compared with other settings if critical components of care, including measure population, severity of illness and vulnerability to infections, significantly differ across settings of care and cannot be reliably adjusted through risk adjustment and other statistical modeling techniques. We note that PCHQR data is displayed separate from data reported by other settings. However, CDI is extremely prevalent and highly contagious,\textsuperscript{277} and we believe that PCH settings are as susceptible to this infectious disease as other settings where individuals with cancer or trauma (for example, burn patients) are treated. Therefore, we believe this measure could be applied to all settings and used to improve patient care. We are also fully committed to decreasing CDI rates

\textsuperscript{277} CDC. Healthcare Associated Infections (HAIs). Available at: http://www.cdc.gov/HAI/surveillance/index.html.
and support the HHS’ National Action Plan to Prevent Healthcare Associated Infections and Healthy People 2020 initiatives.

**Comment:** Several commenters supported the inclusion of this measure, but recommended that CMS monitor future novel diagnostic strategies for CDI (for example, new diagnostic ways to test *Clostridium difficile* bacteria.

**Response:** We thank the commenters for their support. We will monitor all PCHQR Program measures closely and work with the CDC to identify future novel diagnostic strategies for CDI.

After consideration of the public comments we received, we are finalizing our proposal to add the CDC NHSN CDI Outcome Measure to the PCHQR Program beginning with the FY 2018 program.

d. CDC NHSN Facility-Wide Inpatient Hospital-Onset Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia Outcome Measure (NQF #1716)

Invasive MRSA infections may cause approximately 18,000 deaths per year during a hospital stay. Cancer patients are at increased risk for MRSA infections, specifically older adults with weakened immune systems who are receiving hospital inpatient care. As a result, we believe it is important to collect data on MRSA in the PCH setting.

---


This proposed measure addresses the NQS Patient Safety domain. This measure reports the SIR of hospital-onset unique blood source MRSA LabID events among all inpatients in a facility. The numerator includes the total number of observed hospital-onset unique blood source MRSA LabID events among all inpatients in the facility. The denominator includes the total number of predicted hospital-onset unique blood source MRSA LabID events, calculated by multiplying the number of inpatient days for the facility by the hospital-onset MRSA bacteremia LabID event rate for similar types of facilities (obtained from a standard population).

Beginning with a 2009 baseline SIR of 1.0, we set a national goal to reduce the incidence of facility-onset MRSA infections by 50 percent by 2020. However, by 2012 the rate of facility-onset MRSA infections decreased by only 3 percent (to a SIR of 0.97). Therefore, we believe it is critical to continue collecting data on CDI in the hospital setting, and to adopt this measure for the PCH setting, to ensure the highest quality of care for cancer patients and continue our effort to support the HHS’ National Action Plan and the proposed 2020 goal to reduce facility-onset MRSA infections by 50 percent from the 2015 baseline.

The collection and evaluation of MRSA data will allow PCH staff to evaluate whether their infection control efforts need improvement. By proposing this measure in the PCHQR Program, we aim to continue to provide a common mechanism (CDC

---

281 NQF QPS. Available at: [http://www.qualityforum.org/Ops/MeasureDetails.aspx?standardID=1716&print=0&entityTypeID=1](http://www.qualityforum.org/Ops/MeasureDetails.aspx?standardID=1716&print=0&entityTypeID=1).

282 Ibid.

283 FY 2012 IPPS/LTCH PPS final rule (76 FR 51630).

CMS-1632-F & IFC  1617

NHSN) for all hospitals, including PCHs, to uniformly report measure data and inform their clinicians of the impact of targeted prevention efforts. Furthermore, we recognize the severe impact of MRSA and aim to continue our efforts to increase patient protection and safety, while at the same time preventing adverse infections in the PCH setting.

We invited public comments on our proposal to add the CDC NHSN MRSA Measure to the PCHQR Program beginning with the FY 2018 program.

Comment: Many commenters supported inclusion of the CDC NHSN MRSA Measure in the PCHQR Program specifically citing the clinical significance of this measure.

Response: We thank these commenters for their support.

Comment: Several commenters recommended postponing adoption of this measure until stratifications are adopted for cohorts of cancer patients (for example, bone marrow transplant, hematologic, and solid tumor). One commenter noted that this recommendation is consistent with recommendations from the NQF MAP Hospital Workgroup in terms of identifying benchmark calculations and risk adjustment methodologies to support valid comparisons among PCHs.

Response: We thank the commenters for their input. We would like to clarify that while the MAP Hospital Workgroup expressed concerns regarding the need for stratification of cohorts of cancer patients (BMT, Hematologic, and Solid tumor), the Coordinating Committee did not support that suggestion noting public comments
received from CMS. We refer readers to the NQF Web site for more public comment information.

In consultation with the CDC, we agree that the current risk models used for the calculation of MRSA bacteremia SIRs may not accurately predict these types of events in the cancer patient population, particularly within cancer hospitals. Until there are sufficient data with which to risk adjust MRSA bacteremia in this population, CDC plans to submit unadjusted, facility-specific healthcare facility-onset, incidence rates without comparison to a national benchmark. We further are clarifying that we have not provided any guidance surrounding the definition of a benchmark for any of the PCHQR Program measures.

Comment: One commenter did not support this measure and stated that individuals with cancer are more susceptible to infection because they are at higher risk of being infected due to the nature of their cancer condition (that is, immunocompromised). As a result, the commenter believed that PCHs should not be compared with other settings.

Response: We thank the commenter for this input. We believe that PCHs should not be compared with other settings if critical components of care, including measure population, severity of illness and vulnerability to infections, significantly differ across settings of care and cannot be reliably adjusted through risk adjustment and other statistical modeling techniques. We note that PCHQR data are displayed separately from data reported by other settings.

---

However, MRSA is extremely prevalent and highly contagious, and we believe that PCH settings are as susceptible as other settings where individuals with cancer or trauma (for example, burn patients) are treated. Therefore, we believe this measure could be applied to all settings and used to improve patient care. We also are fully committed to decreasing MRSA rates and support the HHS’ National Action Plan to Prevent Healthcare Associated Infections and Healthy People 2020 initiatives.

After consideration of the public comments we received, we are finalizing our proposal to add the CDC NHSN MRSA Measure to the PCHQR Program beginning with the FY 2018 program.

e. CDC NHSN Influenza Vaccination Coverage Among Healthcare Personnel [HCP] Measure (NQF #0431) (CDC NHSN HCP Measure)

CDC estimates that in the United States, each year, on average 5 to 20 percent of the population gets influenza and more than 200,000 people are hospitalized from seasonal influenza-related complications. Influenza seasons are unpredictable and can be severe. Over a period of 30 years, between 1976 and 2006, estimates of influenza-associated deaths per year in the United States ranged from a low of approximately 3,000 to a high of approximately 49,000 people. Because influenza can become widespread and have serious consequences, the Advisory Committee on Immunization Practices (ACIP) recommends that all health care personnel (HCP) and persons in training for

---

288 CDC. Seasonal Influenza Q&A. Available at: http://www.cdc.gov/flu/about/qa/disease.html.
health care professions be vaccinated annually against influenza.\textsuperscript{290} Persons who are infected with the influenza virus, including those with subclinical infection, can transmit the influenza virus to persons at higher risk for complications, such as immunocompromised cancer patients. In addition, vaccination of HCP has been associated with reduced work absenteeism and fewer deaths among patients. Results of several studies also indicate that higher vaccination coverage among HCP is associated with lower incidence of nosocomial influenza.\textsuperscript{291, 292, 293} Such findings have led researchers to call for mandatory influenza vaccination of HCP.\textsuperscript{294}

This proposed measure addresses the NQS Patient Safety domain. The measure reports the percent of HCP who receive the influenza vaccination.\textsuperscript{295} The numerator includes HCP in the denominator population who during the time from October 1 (or when the vaccine became available) through March 31 of the following year, either: (a) received an influenza vaccination administered at the facility, or reported in writing (paper or electronic) or provided documentation that the influenza vaccination was received elsewhere; (b) were determined to have a medical contraindication or history of Guillain-Barré Syndrome within 6 weeks after a previous influenza vaccination;

\begin{thebibliography}{99}
\footnotesize
\bibitem{291} Salgado CD, Giannetta ET, Hayden FG, Farr BM.: Preventing influenza by improving the vaccine acceptance rate of clinicians. Infection Control and Hospital Epidemiology 2004; 25: 923–928.
\bibitem{295} NQF QPS. Available at: http://www.qualityforum.org/Qps/0431.
\end{thebibliography}
(c) declined the influenza vaccination; or (d) had an unknown vaccination status.\textsuperscript{296} The denominator includes the number of HCP who are working in the health care facility for at least 1 working day between October 1 and March 31 of the following year, regardless of clinical responsibility or patient contact, and includes: (a) employees; (b) licensed independent practitioners; and (c) adult students/trainees and volunteers.\textsuperscript{297, 298} Numerators and denominators are collected separately for each of the specified groups.

We believe it is important to collect data on this measure in order to ensure the highest quality of care for cancer patients in our effort to support one of the Healthy People 2020 goals of immunizing 90 percent of health care personnel nationally by 2020.\textsuperscript{299} Overall, final 2013-14 influenza vaccination coverage among HCP was 75.2 percent, similar to coverage of 72.0 percent in the 2012-13 season.\textsuperscript{300} We aim to increase patient protection and safety and at the same time prevent adverse outcomes (for example, transmitting influenza to patients, specifically high risk cancer patients, and premature death due to influenza) in the PCH setting.

We believe that this measure is applicable to the PCH setting based on CDC guidelines that patients who currently have cancer or who have had certain types of cancer in the past (such as lymphoma or leukemia), are at high risk for complications

\textsuperscript{296} Ibid.
\textsuperscript{297} Ibid.
\textsuperscript{298} FY 2012 IPPS/LTCH PPS final rule (76 FR 51631).
\textsuperscript{300} CDC. Influenza Vaccination Information for Health Care Workers. Available at: http://www.cdc.gov/flu/healthcareworkers.html.
from influenza, including hospitalization and death.\textsuperscript{301} The involvement of HCP in influenza transmission has been a longstanding concern.\textsuperscript{302} 303 Vaccination is an effective preventive measure against influenza, and can prevent many illnesses, deaths, and losses in productivity.\textsuperscript{304}

By proposing this measure in the PCHQR Program, we aim to not only provide a common mechanism (CDC NHSN) for all hospitals, including PCHs, to uniformly report the measure data, but also to inform their clinicians of the impact of targeted prevention efforts. In addition, and most importantly, we believe that collecting this measure data in the PCH setting is necessary to support our effort to prevent unnecessary additional or prolonged hospitalizations (and associated costs), and to decrease premature death among cancer patients.

We invited public comments on our proposal to add the CDC NHSN HCP Measure to the PCHQR Program beginning with the FY 2018 program.

\textbf{Comment:} Many commenters supported inclusion of the CDC NHSN HCP Measure in the PCHQR Program, specifically citing the clinical significance of this measure.

\textbf{Response:} We thank these commenters for their support.

\textsuperscript{301} CDC Preventing Infections in Cancer Patients. Available at: \url{http://www.cdc.gov/cancer/flu/}.
Comment: One commenter supported this measure, but recommended against comparing PCH measure rates to those with a different patient population when this measure is applied across programs.

Response: We thank the commenter for the comment. We believe that PCHs should not be compared with other settings if critical components of care, including measure population, severity of illness and vulnerability to infections, significantly differ across settings of care and cannot be reliably adjusted through risk adjustment and other statistical modeling techniques. We note that PCHQR data are displayed separate from data reported by other settings. However, influenza is extremely prevalent and highly contagious, and we believe that PCH settings are as susceptible to this disease as other settings where individuals with cancer or trauma (for example, burn patients) are treated. Therefore, we believe this measure could be applied to all settings and used to improve patient care. We also are fully committed to decreasing influenza rates and support the HHS’ National Action Plan to Prevent Healthcare Associated Infections and Healthy People 2020 initiatives.

Comment: One commenter recommended providing more specific direction for healthcare workers that decline and/or are medically excluded from influenza vaccination and have contact with patients. The commenter suggested refinement to the measure specifications to address clinical guidelines for health care workers who are excluded.

Response: For clarification purposes, the measure specification does address HCP who decline vaccination and have medical conditions that would prevent them from

---

receiving influenza vaccine. In addition, it further defines the time from October 1 (or when the vaccine became available) through March 31 of the following year, during which HCP either: (a) received an influenza vaccination administered at the facility, or reported in writing (paper or electronic) or provided documentation that the influenza vaccination was received elsewhere; (b) were determined to have a medical contraindication or history of Guillain-Barré Syndrome within 6 weeks after a previous influenza vaccination; (c) declined the influenza vaccination; or (d) had an unknown vaccination status.306

The CDC provides guidance on influenza infection control posted to their “Infection Control in Health Care Facilities” Web page, which is located at http://www.cdc.gov/flu/professionals/infectioncontrol/. These resources can be utilized for HCP with medical contraindications to influenza vaccine or decline influenza vaccination.

After consideration of the public comments we received, we are finalizing our proposal to add the CDC NHSN HCP Measure to the PCHQR Program beginning with the FY 2018 program.

In summary, we are finalizing the addition of three new measures for reporting beginning with the FY 2018 program and removing six SCIP measures beginning with Q4 2015 discharges. The PCHQR measure set will consist of 16 measures beginning with the FY 2018 program. Our policies regarding the form, manner, and timing of data collection for these measures are discussed in section VIII.B.7. of the preamble to this final rule.

The table below lists all adopted measures as well as the new measures we are finalizing for the PCHQR Program beginning with the FY 2018 program.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Summary of Adopted and Newly Finalized PCHQR Program Measures Beginning with the FY 2018 Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety and Healthcare-Associated Infection—HAI</td>
<td></td>
</tr>
<tr>
<td>• CDC NHSN Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (NQF #0139)*</td>
<td></td>
</tr>
<tr>
<td>• CDC NHSN Catheter-Associated Urinary Tract Infections (CAUTI) Outcome Measure (NQF #0138)*</td>
<td></td>
</tr>
<tr>
<td>• Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure [currently includes SSIs following Colon Surgery and Abdominal Hysterectomy Surgery] (NQF #0753)*</td>
<td></td>
</tr>
<tr>
<td>• CDC NHSN Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure (NQF #1717)**</td>
<td></td>
</tr>
<tr>
<td>• CDC NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia Outcome Measure (NQF #1716)**</td>
<td></td>
</tr>
<tr>
<td>• CDC NHSN Influenza Vaccination Coverage Among Healthcare Personnel [HCP] (NQF #0431)**</td>
<td></td>
</tr>
<tr>
<td>Clinical Process/Cancer-Specific Treatments</td>
<td></td>
</tr>
<tr>
<td>• Adjuvant Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis to Patients Under the Age of 80 with AJCC III (lymph node positive) Colon Cancer (NQF #0223)*</td>
<td></td>
</tr>
<tr>
<td>• Combination Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis for Women Under 70 with AJCC T1c, or Stage II or III Hormone Receptor Negative Breast Cancer (NQF #0559)*</td>
<td></td>
</tr>
<tr>
<td>• Adjuvant Hormonal Therapy (NQF #0220)*</td>
<td></td>
</tr>
<tr>
<td>Clinical Process/Oncology Care Measures</td>
<td></td>
</tr>
<tr>
<td>• Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382)*</td>
<td></td>
</tr>
<tr>
<td>• Oncology: Plan of Care for Pain (NQF #0383)*</td>
<td></td>
</tr>
<tr>
<td>• Oncology: Pain Intensity Quantified (NQF #0384)*</td>
<td></td>
</tr>
<tr>
<td>• Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Patients (NQF #0390)*</td>
<td></td>
</tr>
<tr>
<td>• Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Patients (NQF #0389)*</td>
<td></td>
</tr>
<tr>
<td>Patient Engagement/Experience of Care</td>
<td></td>
</tr>
<tr>
<td>• HCAHPS [Hospital Consumer Assessment of Healthcare Providers and Systems Survey] (NQF #0166)*</td>
<td></td>
</tr>
</tbody>
</table>
4. Possible New Quality Measure Topics for Future Years

Future quality measure topics and quality measure domain areas are discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50280). In addition, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24593), we welcomed public comment and specific suggestions for measure topics addressing the following CMS Quality Strategy domains: making care affordable; communication and coordination; and working with communities to promote best practices of healthy living.

**Comment**: Several commenters recommended that CMS give priority to developing outcome and quality-of-life measures that are most important to patients, including patient-reported outcome measures instead of process measures.

**Response**: We thank the commenters for their recommendation and will consider it in future years.

**Comment**: One commenter suggested considering the following three issues in the PCHQR Program: (1) use of multiple data sources; (2) continuing research in areas of concern that demonstrate gaps in clinical care; and (3) efforts to develop core metrics given the variation between cancer patients (diagnoses, conditions, and priorities).

**Response**: We recognize and acknowledge the burden in extracting data from multiple sources (for example, administrative data and chart abstraction). However, we
believe that our quality improvement effort (for example, improving quality of care and increasing life expectancy among cancer patients) outweighs the burden associated with data abstraction in selecting the most appropriate measures for the program. We will continue to engage and partner with all stakeholders in collaborating and corroborating on issues that address gaps in clinical care and developing core metrics specific to cancer treatment and care (for example, diagnoses, conditions, and priorities).

Comment: One commenter supported measure development to address cancer measurement gaps in care coordination, functional status, patient safety, patient and caregiver experience of care, population/community health, and efficiency. The commenter agreed that quality measurement strategies should be aligned with the three aims of the National Quality Strategy: better care; healthy people/healthy communities; and affordable care.

Response: We thank the commenter for this support.

Comment: Several commenters recommended that measures considered for the PCHQR Program be evaluated and risk-adjusted, prior to adoption.

Response: We thank the commenters for the recommendation. During our measure development and testing, we assess for necessity of risk-adjustment. Furthermore, measures that are not developed by CMS are also assessed for necessity of risk-adjustment when they undergo NQF endorsement and re-endorsement.

Comment: Some commenters expressed the concern that measures that are not tested in the PCH environment may result in invalid measurement due to lack of a
sufficient population for statistical significance and the lack of exclusions for this complex patient population.

**Response:** We thank the commenters for their input. Historically, we have adopted measures across settings. Whenever feasible, we have also tested all measures for the applicable environment. We agree that a small number of cases or lack of a sufficient population could result in erroneous and misleading results. We also agree that data collection is not only necessary but crucial for quality improvement purposes. We will continue to work on ensuring that measures are appropriate, reliable, and valid for the PCH setting prior to adopting them in the PCHQR Program.

**Comment:** One commenter recommended that CMS consider the following three measures for the PCHQR Program: (1) Post breast conservation surgery irradiation (E0219), (2) At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (E0225), and (3) Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection (E0221).

**Response:** We thank the commenter for this recommendation. These measures were submitted and reviewed by the MAP in December 2014. The MAP agreed to conditionally support these measures pending inclusion of these measures in the Hospital IQR Program for general acute care hospitals. The Workgroup also noted that these measures have extremely high levels of performance (that is, they are nearly topped out) for the PCHs. Due to this reason (that they are nearly topped out in the PCH setting), we did not to propose these measures for the PCHQR Program.

---

Comment: One commenter recommended that CMS exercise greater caution in the future when considering additional measures for PCHQR Program to avoid the undue burden associated with requiring PCHs to develop infrastructure to report for only a short time, such as with the SCIP measures.

Response: We thank the commenter for this recommendation. We will continue to try to avoid and reduce burden in future years.

Comment: Several commenters requested that CMS outline specific guidelines for determining when measures are “topped out” for the PCHQR Program.

Response: We thank the commenter for this comment and will provide some guidance on topped out criteria in future rulemaking.

Comment: One commenter recommended that CMS collaborate with the PCHs in developing PCHQR Program policies in the future.

Response: We thank the commenter for this suggestion. As with all of our programs, we are fully committed to engaging and partnering with all stakeholders to ensure success and most importantly to improve quality of care.

5. Maintenance of Technical Specifications for Quality Measures

We maintain technical specifications for the PCHQR Program measures, and we periodically update those specifications. The specifications may be found on the QualityNet Web site at:

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50281), we described a policy under which we use a subregulatory process to make nonsubstantive updates to measures used for the PCHQR Program. We did not propose any changes to this policy in the proposed rule.

6. Public Display Requirements

a. Background

Section 1866(k)(4) of the Act requires the Secretary to establish procedures for making the data submitted under the PCHQR Program available to the public. Such procedures must ensure that a PCH has the opportunity to review the data that are to be made public with respect to the PCH prior to such data being made public.

Section 1866(k)(4) of the Act also provides that the Secretary must report quality measures of process, structure, outcome, patients’ perspective on care, efficiency, and costs of care that relate to services furnished in such hospitals on the CMS Web site.

In order to meet these requirements, in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53562 through 53563), we finalized our policy to publicly display PCHQR Program data on the Hospital Compare Web site (http://www.hospitalcompare.hhs.gov/) and established a preview period of 30 days prior to making such data public.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50847 through 50848), we finalized our proposal to display publicly in 2014 and subsequent years the data for two measures. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50282), we finalized our proposal to display publicly in 2015 and subsequent years the data for one measure and our proposal to display publicly no later than 2017 the data for two additional measures.
In summary, we have finalized proposals to publicly display five PCHQR measures on *Hospital Compare*, including three Cancer Specific Treatment measures and two CDC NHSN HAI measures.

<table>
<thead>
<tr>
<th>Summary of Finalized Public Display Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measures</td>
</tr>
<tr>
<td>● Adjuvant Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis to Patients Under the Age of 80 with AJCC III (lymph node positive) Colon Cancer (NQF #0223)</td>
</tr>
<tr>
<td>● Combination Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis for Women Under 70 with AJCC T1c, or Stage II or III Hormone Receptor Negative Breast Cancer (NQF #0559)</td>
</tr>
<tr>
<td>● Adjuvant Hormonal Therapy (NQF #0220)</td>
</tr>
<tr>
<td>● CDC NHSN Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (NQF #0139)</td>
</tr>
<tr>
<td>● CDC NHSN Catheter-Associated Urinary Tract Infections (CAUTI) Outcome Measure (NQF #0138)</td>
</tr>
</tbody>
</table>

b. Additional Public Display Requirements

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24594), we proposed to publicly display six additional PCHQR measures beginning in 2016 and for subsequent years:

● Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382)

● Oncology: Plan of Care for Pain (NQF #0383)

● Oncology: Pain Intensity Quantified (NQF #0384)
Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Patients (NQF #0390)

Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Patients (NQF #0389)

HCAHPS (NQF #0166)

We invited public comment on these proposals.

Comment: Several commenters supported the display of these measures to improve public awareness and beneficiary choice. Some of these commenters also noted the benefits of alignment across programs in publicly reporting these data.

Response: We thank the commenters for their support.

Comment: One commenter recommended that CMS delay public reporting of the CDC NHSN CAUTI measure until this measure has been revised by the CDC to account for all cancer-specific risks and exclude all infections unrelated to catheter placement.

Response: We are collaborating, and will continue to collaborate, with the CDC to explore the best approach to account for all heterogeneous patient populations that are monitored and tracked using the NHSN, cancer patients being one of many such populations. As indicated in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50282), we have delayed public reporting of CAUTI until no later than 2017 so that reliable baseline estimates and expected rates can be determined. We agree with the commenter and believe this delay is necessary in order to provide meaningful and reliable data available for consumers to make informed health care decisions. For more information, we refer readers to that final rule.
Comment: One commenter expressed concerns regarding how CAUTI is defined in the measure specifications because currently the measure specification does not address conditions that are critical to PCHs, such as cancer patients with multiple instruments in the genitourinary tract, urine collection obtained from different sources, long-term catheter use, cancer patients with neobladders, and cancer patients with neutropenic fever. The commenter also stated that the measure does not exclude patients with bladder fistulas between the gastrointestinal and reproductive tracts.

Response: We thank the commenter for this input. For more information about this measure, we refer readers to the CDC’s measure specifications at the CDC’s Web site (http://www.cdc.gov/nhsn/acute-care-hospital/CAUTI/).

For clarification purposes, in consultation with the CDC, we learned that the CAUTI definition working group (WG) (comprised of internal and external subject-matter experts (for example, infection preventionists, microbiologists, and hospital epidemiologists and infection disease physicians)) takes into consideration all patients (including cancer patients) when they review the NHSN CAUTI surveillance measure. While the WG agreed that these patients may be at an increased risk of Urinary Tract Infection (UTI), they also agreed that information used to identify these patients and to exclude them from surveillance is often difficult to ascertain because of shortcomings in clinical documentation of presence and timing of instrumentation.

In addition, removing these patients from CAUTI surveillance would mean omitting their UTIs and their urinary catheter days. Separating these patients and excluding their data from surveillance would be labor intensive and beyond what is
logistically feasible for many, if not most, PCHs. We note that only in the case that a concomitant urine culture collected from the urethral catheter is negative, a positive urine culture from a nephrostomy tube will be excluded from surveillance for CAUTI in the NHSN. Such a scenario would suggest that the infection was not an ascending infection of the urinary tract, that is, not from the level of the urinary catheter, but rather is occurring from another source. This exclusion is feasible for surveillance because it only requires those performing surveillance to identify nephrostomy tubes when there is an infection, rather than requiring that they identify all patients with both nephrostomy tube and urethral catheter and remove any catheter days associated with those patients from CAUTI surveillance. For further information on this measure, we refer readers to the CDC’s Web site (http://www.cdc.gov/nhsn/acute-care-hospital/CAUTI/).

Comment: One commenter recommended that the CMS delay public reporting of the CDC NHSN CLABSI measure until this measure has been revised by the CDC to account for all cancer-specific risks and exclude all infections unrelated to central-line placement.

Response: We thank the commenter for this input. We are collaborating, and will continue to collaborate, with the CDC to explore the best approach to account for all heterogeneous patient populations that are monitored and tracked using the NHSN, cancer patients being one of many such populations. As indicated in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50282), we have delayed public reporting of CLABSI until no later than 2017 so that reliable baseline estimates and expected rates can be determined. We agree with the commenter and believe this delay is necessary in order to
provide meaningful and reliable data available for consumers to make informed health care decisions. For more information, we refer readers to the referenced page.

Comment: One commenter expressed specific concerns regarding how CLABSI is defined in the measure specifications because currently the measure specifications do not address conditions that are critical to PCHs. The commenter did not believe the exclusion criteria excluded cancer patients with mucosal barrier injury laboratory-confirmed bloodstream infections (MBI-LCBI) or excluded organisms that are part of the normal gastrointestinal (GI) flora, but said that cancer patients who are receiving cancer treatments (either of these combinations - chemotherapy or radiation or transplant) are at high risk of mucosal injury and highly susceptible to infection even from normal GI flora that normally are benign in healthy individuals.

Response: We thank the commenter for this input. For more information about this measure, we refer readers to the CDC’s measure specifications at the CDC’s Web site (http://www.cdc.gov/nhsn/acute-care-hospital/clabsi/).

For clarification purposes, in consultation with the CDC, we learned that the expert panel that the CDC worked with to develop the MBI-LCBI criteria developed the list of organisms which would be associated with MBI-LCBI events. This list was not intended to represent every organism that is common to the human gut, but rather to include only those which, when cultured from the bloodstream, were clinically most likely due to mucosal barrier injury rather than some other cause. Some organisms which are common to the human intestine are more commonly identified in the bloodstream due to other causes, including being associated with the presence of a central line. These
organisms, for instance Pseudomonas spp., were intentionally excluded from the list for this reason. As experience with MBI-LCBI surveillance continues, the MBI-LCBI list will be reconsidered.

In addition, excluding patients from developing a CLABSI simply because they have any of the symptoms listed in the measure specification manual could result in a CLABSI measure that is tremendously insensitive. The symptoms listed are often poorly defined; variation exists in the ways that clinicians identify them and rate them. They are therefore not good candidates for inclusion in surveillance definitions and protocols. For further information on this measure, we refer readers to the CDC’s Web site (http://www.cdc.gov/nhsn/acute-care-hospital/clabsi/index.html).

Comment: One commenter recommended that when CDC NHSN CLABSI and CDC NHSN CAUTI are publicly reported, the data be aggregated to report rates as ICU and non-ICU only versus at the inpatient unit level.

Response: We received a similar comment last year and we continue to believe our response in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50282) applies regarding this issue. We continue to collaborate with the CDC to account for all heterogeneous patient populations that are monitored and tracked using the NHSN, cancer patients being one of many such populations. We refer readers to the referenced final rule page for further discussion of this issue.

Comment: Several commenters requested that prior to requiring public reporting, CMS clarify whether the Radiation Dose Limits to Normal Tissues (NQF 0382) measure applies only to lung and pancreas cancer patients, or if breast and rectal cancer patients
should be included, since this cohort expansion was submitted by the measure steward in
the November 2014 for measure maintenance and update to NQF.

Response: At this time, this measure, which was finalized in FY 2014
IPPS/LTCH PPS final rule (78 FR 50842 through 50842), does not include patients with
breast or rectal cancer. However, we intend to address the expanded cohort issue in next
year’s rulemaking to include breast and rectal cancer patients after we receive
recommendations from the MAP.

Comment: One commenter requested that prior to publicly reporting, CMS
clarify the sampling protocol for the Plan of Care for Pain (NQF 0383) and Pain Intensity
Quantified (NQF 0384) measures because it appears that this sampling protocol may
require oversampling for the Pain Intensity Quantified (NQF 0384) measure.

Response: Because these are two “paired” measures, cancer patients that are
sampled for the Pain Intensity Quantified (NQF 0384) measure for the numerator case
count are also sampled to account for the Plan of Care for Pain (NQF 0383) measure
(denominator case count). This means that for any cancer patients that are reporting pain
and their pain are quantified (for example, assessed for severity on a scale of one to ten),
these cancer patients should have a care plan for pain management. We do not believe
this approach is “oversampling” but rather a step toward improving quality of care by
monitoring, managing, and controlling pain throughout the life cycle of cancer treatment.
We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50285) for further
guidance on sampling these measures.
Currently, we have in place outreach and education materials (for example, tools, Webinars, among others) to assist PCHs in their data abstraction (including sampling). Information on this outreach is available on our QualityNet Web site at:

(https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier2&cid=1228774479863). We also have established a dedicated PCHQR Help Desk hotline to assist PCHs in data abstraction (https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier2&cid=1228772864236). However, we will continue to work with our support contractor in providing additional education materials, including Webinars, on sampling for these measures.

After consideration of the public comments we received, we are finalizing our proposal to publicly display these six additional PCHQR measures beginning in 2016 and for subsequent years. A summary of previously adopted and newly finalized public display policies is listed in the table below.

| Summary of Previously Adopted and Newly Finalized Public Display Requirements |
|---|---|
| Measures | Public Reporting |
| ● Adjuvant Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis to Patients Under the Age of 80 with AJCC III (lymph node positive) Colon Cancer (NQF #0223) | 2014 and subsequent years |
| ● Combination Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis for Women Under 70 with AJCC T1c, or Stage II or III Hormone Receptor Negative Breast Cancer (NQF #0559) | 2015 and subsequent years |
| ● Adjuvant Hormonal Therapy (NQF #0220) | 2015 and subsequent years |
7. Form, Manner, and Timing of Data Submission

a. Background

Section 1866(k)(2) of the Act requires that, beginning with the FY 2014 PCHQR Program, each PCH must submit to the Secretary data on quality measures specified under section 1866(k)(3) of the Act in a form and manner, and at a time, as specified by the Secretary.

Data submission requirements and deadlines for the PCHQR Program are generally posted on the QualityNet Web site at:


b. Reporting Requirements for New Measures: CDC NHSN CDI (NQF #1717), CDC NHSN MRSA (NQF #1716), and CDC NHSN HCP (NQF #0431) Measures

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24594 through 24595), we proposed that PCHs submit CDC NHSN CDI, MRSA, and HCP measure data for all
patients to the CDC through the NHSN database. This is the same procedural/reporting mechanism used for the CDC NHSN CLABSI and CAUTI measures that we finalized in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53563 through 53564) and for the CDC SSI measure that we finalized in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50848 through 50850). The data submission and reporting procedures have been set forth by the CDC for NHSN participation in general and for submission of the CDC NHSN CDI, MRSA, and HCP measures to NHSN. We refer readers to the CDC’s Web site (http://www.cdc.gov/nhsn/cms/index.html) for detailed data submission and reporting procedures.

We proposed to adopt a quarterly submission process for the CDC NHSN CDI and MRSA measures as shown in the table below. We have successfully implemented this reporting mechanism in the Hospital IQR Program (77 FR 53539), and we strongly believe that this type of data submission is the most feasible option because PCHs are currently reporting the CDC NHSN CAUTI, CLABSI, and CDC SSI measures to the CDC NHSN this way.

<table>
<thead>
<tr>
<th>Program year (FY)</th>
<th>Reporting periods (CY)</th>
<th>Data submission deadlines (CY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Q1 2016 events</td>
<td>August 15, 2016</td>
</tr>
<tr>
<td></td>
<td>(January 1, 2016 – March 31, 2016)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Q2 2016 events</td>
<td>November 15, 2016</td>
</tr>
<tr>
<td></td>
<td>(April 1, 2016 – June 30, 2016)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Q3 2016 events</td>
<td>February 15, 2017</td>
</tr>
<tr>
<td></td>
<td>(July 1, 2016 – September 30, 2016)</td>
<td></td>
</tr>
</tbody>
</table>
For the CDC NHSN HCP measure, we proposed that data be submitted annually by May 15 of the applicable year as shown in the table below. The vaccination period runs from October through March. The proposed reporting period for FY 2018 will include Q4 2016 and Q1 2017 counts submitted by May 15, 2017.
We invited public comments on these proposals.

**Comment**: One commenter expressed support for the proposal to report the CDC NHSN MRSA and CDC NHSN CDI measures quarterly via CDC NHSN and the CDC NHSN HCP measure annually through the same process.

**Response**: We thank this commenter for the support.

After consideration of the public comments we received, we are finalizing our proposals for the form, manner, and timing of the CDC NHSN CDI, MRSA, and HCP measures.

As specified by CDC, the CDC NHSN CDI, MRSA, and HCP measures are reported on a facility-wide basis.\(^{308, 309}\) Accordingly, we did not propose a sampling methodology for these measures because CDC requirements are to collect data on all patients or HCP in the facility. However, measures specifications could be technically updated by the measure steward (CDC). We refer readers to the CDC Web site for technical changes and/or updates (http://www.cdc.gov/nhsn/acute-care-hospital/index.html).


We also intend to issue guidance to PCHs that will provide additional information regarding the specific data submission deadlines that we previously finalized for certain PCHQR measures. This guidance will be issued through the QualityNet Web site.
C. Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

1. Background and Statutory Authority

Section 3004(a) of the Affordable Care Act amended section 1886(m)(5) of the Act, requiring the Secretary to establish the Long-Term Care Hospital Quality Reporting Program (LTCH QRP). This program applies to all hospitals certified by Medicare as LTCHs. Beginning with the FY 2014 payment determination and subsequent years, the Secretary is required to reduce any annual update to the standard Federal rate for discharges occurring during such fiscal year by 2 percentage points for any LTCH that does not comply with the requirements established by the Secretary.

The Act requires that, for the FY 2014 payment determination and subsequent years, each LTCH submit data on quality measures specified by the Secretary in a form and manner, and at a time, specified by the Secretary. The Secretary is required to specify quality measures that are endorsed by the entity with a contract under section 1890(a) of the Act. This entity is currently the NQF. Information regarding the NQF is available at:


The Act authorizes an exception under which the Secretary may specify non-NQF-endorsed quality measures in the case of specified areas or medical topics determined appropriate by the Secretary for which a feasible or practical measure has not been endorsed by the NQF, as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We
refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50286) for a detailed discussion of the history of the LTCH QRP.

In addition, section 1206(c) of the Pathway for SGR Reform Act of 2013 added section 1886(m)(5)(D)(iv) of the Act, which requires the Secretary to establish, not later than October 1, 2015, a functional status quality measure under the LTCH QRP for change in mobility among inpatients requiring ventilator support. We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50298 through 50301) for a detailed discussion of the Functional Outcome Measure: Change in Mobility Among Long-Term Care Hospital Patients Requiring Ventilator Support (NQF #2632, endorsed on 7/23/15), which we adopted in the LTCH QRP for the FY 2018 payment determination and subsequent years to meet the requirements of section 1886(m)(5)(D)(iv) of the Act.

Finally, the Improving Medicare Post-Acute Care Transformation Act of 2014 (Pub. L. 113-185) (the IMPACT Act) amended the Act in ways that affect the LTCH QRP. Specifically, section 2(a) of the IMPACT Act added section 1899B of the Act, and section 2(c)(3) of the IMPACT Act amended section 1886(m)(5) of the Act.

New section 1899B of the Act is titled Standardized Post-Acute Care (PAC) Assessment Data for Quality, Payment and Discharge Planning. Under section 1899B(a)(1) of the Act, the Secretary must require post-acute care (PAC) providers (defined in section 1899B(a)(2)(A) of the Act to include HHAs, SNFs, IRFs, and LTCHs) to submit standardized patient assessment data in accordance with section 1899B(b) of the Act, data on quality measures required under section 1899B(c)(1) of the Act, and data on resource use and other measures required under section 1899B(d)(1) of
the Act. The Act also sets out specified application dates for each of the measures. The Secretary must specify the quality, resource use, and other measures not later than the applicable specified application date defined in section 1899B(a)(2)(E) of the Act.

Section 1899B(b) of the Act describes the standardized patient assessment data that PAC providers are required to submit in accordance with section 1899B(b)(1) of the Act; requires the Secretary, to the extent practicable, to match claims data with standardized patient assessment data in accordance with section 1899B(b)(2) of the Act; and requires the Secretary, as soon as practicable, to revise or replace existing patient assessment data to the extent that such data duplicate or overlap with standardized patient assessment data, in accordance with section 1899B(b)(3) of the Act.

Sections 1899B(c)(1) and (d)(1) of the Act direct the Secretary to specify measures that relate to at least five stated quality domains and three stated resource use and other measure domains. Section 1899B(c)(1) of the Act provides that the quality measures on which PAC providers, including LTCHs, are required to submit standardized patient assessment data and other necessary data specified by the Secretary must be with respect to at least the following domains:

- Functional status, cognitive function, and changes in function and cognitive function;
- Skin integrity and changes in skin integrity;
- Medication reconciliation;
- Incidence of major falls; and
• Accurately communicating the existence of and providing for the transfer of health information and care preferences of an individual to the individual, family caregiver of the individual, and providers of services furnishing items and services to the individual when the individual transitions (1) from a hospital or CAH to another applicable setting, including a PAC provider or the home of the individual, or (2) from a PAC provider to another applicable setting, including a different PAC provider, hospital, CAH, or the home of the individual.

Section 1899B(c)(2)(A) of the Act provides that, to the extent possible, the Secretary must require such reporting through the use of a PAC assessment instrument and modify the instrument as necessary to enable such use.

Section 1899B(d)(1) of the Act provides that the resource use and other measures on which PAC providers, including LTCHs, are required to submit any necessary data specified by the Secretary, which may include standardized assessment data in addition to claims data, must be with respect to at least the following domains:

• Resource use measures, including total estimated Medicare spending per beneficiary;

• Discharge to community; and

• Measures to reflect all-condition risk-adjusted potentially preventable hospital readmission rates.

Sections 1899B(c) and (d) of the Act indicate that data satisfying the eight measure domains in the IMPACT Act is the minimum data reporting requirement. Therefore, the Secretary may specify additional measures and additional domains.
Section 1899B(e)(1) of the Act requires that the Secretary implement the quality, resource use, and other measures required under sections 1899B(c)(1) and (d)(1) of the Act in phases consisting of measure specification, data collection, and data analysis; the provision of feedback reports to PAC providers in accordance with section 1899B(f) of the Act; and public reporting of PAC providers’ performance on such measures in accordance with section 1899B(g) of the Act. Section 1899B(e)(2) of the Act generally requires that each measure specified by the Secretary under section 1899B of the Act be NQF-endorsed, but authorizes an exception under which the Secretary may select non-NQF-endorsed quality measures in the case of specified areas or medical topics determined appropriate by the Secretary for which a feasible or practical measure has not been endorsed by the NQF, as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary.

Section 1899B(e)(3) of the Act provides that the pre-rulemaking process required by section 1890A of the Act applies to quality, resource use, and other measures specified under sections 1899B(c)(1) and (d)(1) of the Act, but authorizes exceptions under which the Secretary may (1) use expedited procedures, such as ad hoc reviews, as necessary in the case of a measure required with respect to data submissions during the 1-year period before the applicable specified application date, or (2) alternatively, waive section 1890A of the Act in the case of such a measure if applying section 1890A of the Act (including through the use of expedited procedures) would result in the inability of the Secretary to satisfy any deadline specified under section 1899B of the Act with respect to the measure.
Section 1899B(f)(1) of the Act requires the Secretary to provide confidential feedback reports to PAC providers on the performance of such PAC providers with respect to quality, resource use, and other measures required under sections 1899B(c)(1) and (d)(1) of the Act beginning 1 year after the applicable specified application date.

Section 1899B(g) of the Act requires the Secretary to establish procedures for making available to the public information regarding the performance of individual PAC providers with respect to quality, resource use, and other measures required under sections 1899B(c)(1) and (d)(1) of the Act beginning not later than 2 years after the applicable specified application date. The procedures must ensure, including through a process consistent with the process applied under section 1886(b)(3)(B)(viii)(VII) of the Act for similar purposes, that each PAC provider has the opportunity to review and submit corrections to the data and information that are to be made public with respect to the PAC provider prior to such data being made public.

Section 1899B(h) of the Act sets out requirements for removing, suspending, or adding quality, resource use, and other measures required under sections 1899B(c)(1) and (d)(1) of the Act.

Section 1899B(i) of the Act requires that not later than January 1, 2016, and periodically thereafter (but not less frequently than once every 5 years), the Secretary must promulgate regulations to modify the Medicare conditions of participation (CoP) and subsequent interpretative guidance applicable to PAC providers, hospitals, and CAHs to, among other things, take into account quality, resource use, and other measures in the discharge planning process.
Section 1899B(j) of the Act requires the Secretary to allow for stakeholder input, such as through town halls, open door forums, and mailbox submissions, before the initial rulemaking process to implement section 1899B of the Act.

Section 2(c)(3) of the IMPACT Act amended section 1886(m)(5) of the Act to address the payment consequences for LTCHs with respect to the additional data which LTCHs are required to submit under section 1899B of the Act. This section added new sections 1886(m)(5)(F) and (G) to the Act and made conforming changes. New section 1886(m)(5)(F) of the Act requires LTCHs (other than a hospital classified under section 1886(d)(1)(B)(iv)(II)) of the Act to submit the following additional data: (1) for the fiscal year beginning on the applicable specified application date and subsequent years, data on the quality, resource use, and other measures required under sections 1899B(c)(1) and (d)(1) of the Act; and (2) for FY 2019 and subsequent years, the standardized patient assessment data required under section 1899B(b)(1) of the Act. Such data must be submitted in the form and manner, and at the time, specified by the Secretary. Finally, new section 1886(m)(5)(G) of the Act generally provides that to the extent that the additional data required under section 1886(m)(5)(F) of the Act duplicates other data required under section 1886(m)(5)(C) of the Act, submission of the former must be in lieu of submission of the latter.

As stated above, the IMPACT Act adds a new section 1899B to the Act that imposes new data reporting requirements for certain PAC providers, including LTCHs. Sections 1899B(c)(1) and 1899B(d)(1) of the Act collectively require that the Secretary specify quality measures and resource use and other measures with respect to
certain domains not later than the specified application date that applies to each measure domain and PAC provider setting. Section 1899B(a)(2)(E) of the Act delineates the specified application dates for each measure domain and PAC provider. The IMPACT Act also amends various other sections of the Act, including section 1886(m)(5) of the Act, to require the Secretary to reduce the otherwise applicable PPS payment to a PAC provider that does not report the new data in a form and manner, and at a time, specified by the Secretary. For LTCHs, amended section 1886(m)(5)(A)(i) of the Act requires the Secretary to reduce the payment update for any LTCH that does not satisfactorily submit the new required data.

Under the current LTCH QRP, the general timeline and sequencing of measure implementation occurs as follows: specification of measures; proposal and finalization of measures through notice-and-comment rulemaking; LTCH submission of data on the adopted measures; analysis and processing of the submitted data; notification to LTCHs regarding their quality reporting compliance with respect to a particular rate year; consideration of any reconsideration requests; and imposition of a payment reduction in a particular rate year for failure to satisfactorily submit data with respect to that rate year. Any payment reductions that are taken with respect to a rate year begin approximately one year after the end of the data submission period for that rate year and approximately two years after we first adopt the measure.

To the extent that the IMPACT Act could be interpreted to shorten this timeline so as to require us to reduce an LTCH’s PPS payment for failure to satisfactorily submit data on a measure specified under section 1899B(c)(1) or (d)(1) of the Act beginning
with the same rate year as the specified application date for that measure, such a timeline would not be feasible. The current timeline discussed above reflects operational and other practical constraints, including the time needed to specify and adopt valid and reliable measures, collect the data, and determine whether an LTCH has complied with our quality reporting requirements. It also takes into consideration our desire to give LTCHs enough notice of new data reporting obligations so that they are prepared to timely start reporting the data. Therefore, we intend to follow the same timing and sequence of events for measures specified under sections 1899B(c)(1) and (d)(1) of the Act that we currently follow for other measures specified under the LTCH QRP. We intend to specify each of these measures no later than the specified application dates set forth in section 1899B(a)(2)(E) of the Act and, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24597), we proposed to adopt them consistent with the requirements in the Act and Administrative Procedure Act. To the extent that we finalize a proposal to adopt a measure for the LTCH QRP that satisfies an IMPACT Act measure domain, we intend to require LTCHs to report data on the measure for the rate year that begins two years after the specified application date for that measure. Likewise, we intend to require LTCHs to begin reporting any other data specifically required under the IMPACT Act for the rate year that begins two years after we adopt requirements that would govern the submission of that data.

We received several public comments regarding the IMPACT Act, which we summarize and respond to below.
Comment: One commenter stated that its LTCH has been exempted from other CMS regulations due to unique circumstances of being located in an underserved, small community/geographic area. The commenter stated that previous exemptions have allowed their LTCH to remain open and provide critical long-term care for the patients in the community and suggested that an exemption for LTCHs with grandfathered status from the previously finalized and proposed LTCH QRP requirements described in the FY 2016 IPPS/LTCH PPS proposed rule would help ensure that critical medical care is available for patients in their communities.

Response: In the FY 2016 IPPS/LTCH PPS proposed rule, we did not propose to adopt an exception from the LTCH QRP requirements due to an LTCH being located in an underserved or small community/geographic area. Therefore, we consider this comment to be outside the scope of the proposed rule. We note that in section VIII.C.9.b. of the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24606), we proposed that a new LTCH must begin reporting quality data under the LTCH QRP by no later than the first day of the calendar quarter subsequent to 30 days after the date on its CMS Certification Number (CCN) notification letter. If a hospital is classified as an LTCH for purposes of Medicare payments (as denoted by the last four digits of its six-digit CMS Certification Number [CCN] in the range of 2000–2299), it is subject to the requirements of the LTCH QRP. There is no statutory exemption from the LTCH QRP requirements due to an LTCH being located in an underserved or small community/geographic area, nor have we proposed any such exception in rulemaking.
**Comment:** Several commenters recommended that CMS develop a comprehensive plan for implementation of the IMPACT Act across all settings. The commenters stated that a comprehensive implementation plan would give PAC providers an opportunity to plan for the potential impacts to their operations and enable all stakeholders to understand CMS’ approach to implementing the IMPACT Act across care settings. The commenters requested that CMS describe an overall strategy for identifying cross-cutting measures, timelines for data collection, and timelines for reporting. One commenter requested that CMS communicate its plans as soon as possible and that CMS develop setting-specific communications to facilitate understanding of the IMPACT Act requirements.

**Response:** We appreciate the request for a comprehensive plan to allow PAC providers to plan for the implementation of the IMPACT Act, as well as the need for stakeholder input, the development of reliable, accurate measures, clarity on the level of standardization of items and measures, and avoidance of unnecessary burden on PAC providers. Our intent has been to comply with these principles in the implementation and rollout of the QRPs in the various settings and we will continue to adhere to these principles as the agency moves forward with implementing IMPACT Act requirements.

We will use the rulemaking process to communicate timelines for implementation, including timelines for the replacement of items in PAC assessment tools, timelines for implementation of new or revised quality measures, and timelines for public reporting. As described more fully above, the IMPACT Act requires us to specify
measures that relate to at least five stated quality domains and three stated resource use and other measure domains.

In addition, we must follow all processes in place for adoption of measures including the Measure Applications Partnership (MAP) and the notice and comment rulemaking process, subject to certain exceptions under section 1899B(e)(3) of the Act for expedited procedures or, alternatively, waiver of section 1890A of the Act. In our selection and specification of measures, we employ a transparent process in which we seek input from stakeholders and national experts and engage in a process that allows for pre-rulemaking input on each measure, as required by section 1890A of the Act. This process is based on a private-public partnership and it occurs via the MAP. The MAP is composed of multi-stakeholder groups convened by the NQF, our current contractor under section 1890 of the Act, to provide input on the selection of quality and efficiency measures described in section 1890(b)(7)(B) of the Act. The NQF must convene these stakeholders and provide us with the stakeholders’ input on the selection of such measures. We, in turn, must take this input into consideration in selecting such measures. In addition, the Secretary must make available to the public by December 1 of each year a list of such measures that the Secretary is considering under Title XVIII of the Act. In addition, proposed measures and specifications are to be announced through the rulemaking process in which proposed rules are published in the Federal Register and are available for public review and comment.

Comment: Commenters asked for more opportunities for stakeholder input into various aspects of the measure development process. The commenters requested
opportunities to provide input early and ongoing input into measure development. One commenter requested opportunities for input prior to the development of proposed measure specifications. Another commenter requested that CMS establish an advisory committee of PAC providers to meet on a frequent and regular basis to help develop measure specifications.

One commenter noted that CMS did provide opportunities for input into listening sessions and open door forums. However, the commenter expressed concern that these events did not provide an opportunity for substantive input. For example, the commenter noted that the open door forum call did not provide measure specifications for public input and that the listening sessions did not include a discussion of the proposed measures. One commenter specifically noted an appreciation for the listening sessions held by CMS thus far, but also requested opportunities for more extensive collaboration.

Response: It is our intent to move forward with IMPACT Act implementation in a manner in which the measure development process continues to be transparent, and includes input and collaboration from experts, the PAC provider community, and the public at large. It is of the utmost importance to CMS to continue to engage stakeholders, including patients and their families, throughout the measure development lifecycle through their participation in our measure development public comment periods; the pre-rulemaking process; participation in the TEPs provided by our measure development contractors, as well as open door forums and other opportunities. We have already provided multiple opportunities for stakeholder input, which include the following activities: our measure development contractor(s) convened a TEP that included
stakeholder experts on February 3, 2015; we convened two separate listening sessions on February 10th and March 24, 2015; we heard stakeholder input during the February 9th 2015 ad hoc MAP meeting provided for the sole purpose of reviewing the measures adopted in response to the IMPACT Act. In addition, we implemented a public mail box for the submission of comments in January 2015, PACQualityInitiative@cms.hhs.gov, which is listed on our post-acute care quality initiatives Web site at


Comment: Several commenters requested more information regarding the timing of the development of the IMPACT Act measures, the development of associated data elements, data collection and reporting. One commenter noted the considerable time constraints under which the Secretary is required to implement the provisions of the IMPACT Act. One commenter urged CMS to first specify the standardized patient assessment data being used across all PAC settings and requested that measures be developed from standardized patient assessment data that cut across PAC assessment instruments. A few commenters requested that CMS communicate estimated implementation timelines for all data collection and reporting requirements. Some commenters urged CMS to move quickly towards changes so as to reduce burden on
duplicate data collection and to allow for better cross-setting comparisons, as well as the evolution of better quality measures. However, other commenters stated that efforts had been made to move too quickly to implement IMPACT Act measures, potentially resulting in the inability to compare measures across settings. One commenter requested that CMS provide more information in the rule about the timing and sequencing of the specification of a common assessment tool, the replacement of existing data elements in the PAC assessment tool with the proposed common assessment tool, and the endorsement of quality measures. One commenter noted specifically the difficulty of the timing of specification of measures through rulemaking prior to NQF endorsement, noting that the NQF endorsement process typically resulted in changes in measure specifications.

Response: We believe that the commenter is requesting information pertaining to specific milestones related to our efforts to meet the statutory timelines which are specified within the IMPACT Act, as well as in the final rule. We intend to use the rulemaking process to establish and communicate timelines for implementation. In addition to using the rulemaking process to establish and communicate timelines for implementation, we will continue to provide ongoing education and outreach to stakeholders through Special Open Door Forums and periodic training sessions. We will also provide information about the measures at this Web site:

Because the IMPACT Act requires us to utilize the rulemaking process, prior notice of timeline and sequencing outside of the rulemaking process is not feasible. However, it should also be noted the IMPACT Act specifies a general timeline for standardization of patient assessment data. For example, the IMPACT Act specifies that LTCHs shall submit standardized patient assessment data to the Secretary for FY 2019 and for each subsequent fiscal year.

Also, as a part of the rulemaking process, we have made additional details regarding standardization of patient assessment data and the cross-setting measure specifications available at the following Web site:

http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html. We plan to continue to update this information as additional measures are specified.

Comment: Several commenters expressed concerns about the reliability and accuracy of the proposed cross-setting measures. Commenters supported the use of NQF-endorsed measures, while some of the commenters expressed concern that two of the proposed measures for FY 2018 lacked NQF endorsement as proposed. A few commenters requested that CMS only use measures that had been endorsed by NQF, while one commenter strongly recommended that CMS use only NQF-endorsed measures which are specified and NQF-endorsed for the specific PAC setting in which they will be used. One commenter expressed concern that the current interpretation of the IMPACT Act could allow potential circumvention of the NQF endorsement process. Another
commenter expressed concern that the due consideration process allowing CMS to select quality measures which are not NQF-endorsed is not well defined. Commenters suggested that, in the absence of NQF endorsement, to fulfill IMPACT Act requirements, CMS should implement measures that are fully supported by the MAP and a technical expert panel (TEP) that includes LTCH community input. One commenter further requested that additional consideration be given to quality measures that are proposed for implementation in the LTCH setting. The commenter stated that as the patient population in this particular setting is very different due to their medical complexity, it is of particular importance to determine whether the measure is appropriate for the LTCH setting, and if it should be modified for the LTCH setting.

**Response:** We intend to consider and propose appropriate measures that meet the requirements of the IMPACT Act measure domains and that have been adopted or endorsed by a consensus organization, whenever possible. However, when this is not feasible because there is no NQF-endorsed measure that meets all the requirements for a specified IMPACT Act measure domain, we intend to rely on the exception authority given to the Secretary in section 1899B(e)(2)(B) of the Act. This statutory exception, allows the Secretary to specify a measure for the LTCH QRP setting that is not NQF-endorsed where, as here, we have not been able to identify other measures on the topic that are endorsed or adopted by a consensus organization. With respect to the proposed measures for the LTCH QRP, we sought MAP review, as well as expert opinion, on the validity and reliability of those measures. Finally, we will take the
variations in patient populations treated in the different type of PAC settings into consideration when selecting cross-setting measures and assessment items.

Comment: Several commenters remarked on the level of standardization among PAC settings as required by the IMPACT Act. Most commenters recognized the need to have as much standardization of measures and data collection across PAC settings as possible, while recognizing that some variations among settings may be necessary. One commenter urged CMS to work for full standardization across measures adopted for PAC settings to allow for comparison.

Another commenter asked that CMS more clearly define the subregulatory process criteria for determining what constitutes a nonsubstantive change. In addition, the commenter requested that CMS consider any potential impacts that measure numerator or denominator changes would have on the relative ranking of LTCH providers on the measure. The commenter further noted that while a change may appear to be nonsubstantive, it might adversely affect an LTCH facility ranking.

Response: We agree that standardization is important, but would like to clarify that while the IMPACT Act requires the enablement of interoperability through the use of standardized data, there will be instances where some provider types may need more or fewer standardized items than other provider types. We will work to ensure that core items are standardized.

We believe that it is important to have in place a subregulatory process to incorporate nonsubstantive updates made by the NQF into the measure specifications so that the measures remain up-to-date. For example, we could use the CMS Web site as a
place to announce changes. As noted in the proposed rule, the subregulatory process proposed is the same process as we have adopted for the Hospital IQR Program and which has been used successfully in that program. We believe that the criteria for what constitutes a non-substantive change could vary widely and is best described by examples, as we have done in the proposed rule. As noted, what constitutes a substantive versus a nonsubstantive change is determined on a case-by-case basis.

Comment: Commenters requested that CMS consider minimizing the burden for PAC providers when available and avoid duplication in data collection efforts. Several commenters stated the need for improved risk adjustment. One commenter requested that CMS support an additional study to develop and improve upon existing risk adjustment methods for IMPACT Act quality and resource use measures so that the newly developed methods could be used to compare outcomes across PAC settings.

Response: We appreciate the importance of avoiding undue burden and will continue to evaluate and consider any burden the IMPACT Act and the LTCH QRP places on LTCHs. In implementing the IMPACT Act thus far, we have taken into consideration the new burden that our requirements place on PAC providers, and we believe that standardizing patient assessment data will allow for the exchange of data among PAC providers in order to facilitate care coordination and improve patient outcomes.

We also will continue to assess current risk adjustment methods for IMPACT Act quality and resource use measures. As a part of measure development and maintenance, CMS supports the ongoing evaluation of risk adjustment which includes obtaining expert
input, the review of relevant literature for identification of appropriate risk adjusters and appropriate testing through data analysis. We will continue these processes to promote appropriate utilization of measures in PAC settings.

Comment: One commenter requested that CMS develop a plan to revise the CoPs for hospitals to meet the IMPACT Act in an effort to align quality metrics and discharge information from inpatient settings.

Response: We recognize the necessity of a streamlined and efficient regulatory framework in order to allow the healthcare system to promote economic growth and innovation. As a part of an ongoing process, we review hospital CoPs to reduce any burden or inefficiencies imposed by actions resulting from the implementation of the IMPACT Act.

Comment: One commenter requested that CMS make data from the PAC PRD study publicly available to facilitate stakeholder analysis and input. The commenter suggested data could be made available through a research identifiable file (RIF) data request process, similar to the current process to obtain RIF data. In addition, the commenter stated the data, which would be used to develop payment recommendations, should be made available to stakeholders in a timely way.

Response: We appreciate the request for PAC PRD data to be made publicly available. Currently, we make claims and routinely collected PAC setting assessment data available to researchers via ResDAC. We will review the feasibility of making PAC PRD data available and will ensure that data released to the public is available in a timely manner.
We thank the commenters for their views, and we will consider them as we develop quality measures and future quality measure proposals for the LTCH QRP and other PAC settings, including those that are developed and proposed in order to meet the requirements of the IMPACT Act.

2. General Considerations Used for Selection of Quality, Resource Use, and Other Measures for the LTCH QRP

We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50286 through 50287) for a detailed discussion of the considerations we use for the selection of LTCH QRP quality measures. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24597), we applied the same considerations to the selection of quality, resource use, and other measures required under section 1899B of the Act for the LTCH QRP, in addition to the considerations discussed below.

The quality measures we proposed and are finalizing address some of the measure domains that the Secretary is required to specify under sections 1899B(c)(1) and (d)(1) of the Act. The totality of the measures considered to meet the requirements of the IMPACT Act will evolve, and additional measures will be proposed over time as they become available.

To meet the first specified application date applicable to LTCHs under section 1899B(a)(2)(E) of the Act, which is October 1, 2016, we have focused on measures that:
● Correspond to a measure domain in section 1899B(c)(1) or (d)(1) of the Act and are setting-agnostic: for example, falls with major injury and the incidence of pressure ulcers;

● Are currently adopted for one or more of our PAC quality reporting programs that are already either NQF-endorsed and in place or finalized for use, or already previewed by the MAP with support;

● Minimize added burden on LTCHs;

● Minimize or avoid, to the extent feasible, revisions to the existing items in assessment tools currently in use (for example, the LTCH CARE Data Set);

● Avoid, where possible, duplication of existing assessment items.

In our selection and specification of measures, we employ a transparent process in which we seek input from stakeholders and national experts and engage in a process that allows for pre-rulemaking input on each measure, as required by section 1890A of the Act. This process is based on a private-public partnership, and it occurs via the MAP. The MAP is composed of multi-stakeholder groups convened by the NQF, our current contractor under section 1890 of the Act, to provide input on the selection of quality and efficiency measures described in section 1890(b)(7)(B) of the Act. The NQF must convene these stakeholders and provide us with the stakeholders’ input on the selection of such measures. We, in turn, must take this input into consideration in selecting such measures. In addition, the Secretary must make available to the public by December 1 of each year a list of such measures that the Secretary is considering under title XVIII of the Act.
As discussed in section VIII.C.1. of the preamble of this final rule, section 1899B(e)(3) of the Act provides that the pre-rulemaking process required by section 1890A of the Act applies to the measures required under section 1899B of the Act, subject to certain exceptions for expedited procedures or, alternatively, waiver of section 1890A of the Act.

We initiated an Ad Hoc MAP process for the review of the quality measures under consideration for proposal in preparation for adoption of those quality measures into the LTCH QRP that are required by the IMPACT Act, and which must be specified by October 1, 2016. The List of Measures under Consideration (MUC List) under the IMPACT Act was made available to the public for comment during the MAP Meeting on February 9, 2015 (http://www.meeting-support.com/downloads/703163/4524/PACLTC%20Ad%20Hoc%20Slides.pdf). Under the IMPACT Act, these measures must be standardized so they can be applied across PAC settings and must correspond to measure domains specified in sections 1899B(c)(1) and (d)(1) of the Act. The specific cross-setting application of the measures under consideration for each such measure is discussed in the MAP Off-Cycle Deliberations 2015: Measures under Consideration to Implement Provisions of the IMPACT Act: Final Report available at: http://www.qualityforum.org/Setting_Priorities/Partnership/MAP_Final_Reports.aspx.

The MAP reviewed each IMPACT Act-related quality measure proposed in the proposed rule for the LTCH QRP, in light of its intended cross-setting use. We refer readers to
section VIII.C.6. of the preamble of this final rule for more information on the MAP’s recommendations.

As discussed in section VIII.C.1. of the preamble of this final rule, section 1899B(j) of the Act requires that we allow for stakeholder input as part of the pre-rulemaking process. To meet this requirement, we provided the following opportunities for stakeholder input: (1) our measure development contractor convened a TEP that included stakeholder experts and patient representatives on February 3, 2015; (2) we provided two separate listening sessions on February 10, 2015 and March 5, 2015; (3) we sought public input during the February 2015 Ad Hoc MAP process provided for the sole purpose of reviewing the measures we proposed in reaction to the IMPACT Act; and (4) we sought public comment as part of our NQF measure maintenance submissions. In addition, we implemented a mailbox for the submission of comments in January 2015, PACQualityInitiative@cms.hhs.gov, which is accessible from our PAC quality initiatives Web site: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014-and-Cross-Setting-Measures.html, and held a National Stakeholder Special Open Door Forum to seek input on the measures on February 25, 2015.

For measures that do not have NQF endorsement, or which are not fully supported by the MAP for the LTCH QRP, we proposed measures that most closely align with the national priorities discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50286 through 50287), and for which the MAP supports the measure concept. Further discussion as to the importance and high-priority status of these measures in the LTCH
setting is included under each quality measure proposal in the preamble of this final rule. In addition, for measures not endorsed by the NQF, we have sought, to the extent practicable, to adopt measures that have been endorsed or adopted by a national consensus organization, recommended by multi-stakeholder organizations, and/or developed with the input of providers, purchasers/payers, and other stakeholders.

While we did not solicit comments specifically regarding the general considerations used for selecting quality, resource use, and other measures for the LTCH QRP, we received several comments, most notably on the NQF MAP pre-rulemaking process and MAP review process, which are addressed under the comments and responses portion of section VIII.C.1. of the preamble of this final rule.

3. Policy for Retention of LTCH QRP Measures Adopted for Previous Payment Determinations

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53614 through 53615), for the LTCH QRP, we adopted a policy that once a quality measure is adopted, it will be retained for use in subsequent years, unless otherwise stated. For the purpose of streamlining the rulemaking process, when we initially adopt a measure for the LTCH QRP for a payment determination, this measure will be automatically adopted for all subsequent years or until we propose to remove, suspend, or replace the measure. For further information on how measures are considered for removal, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53614 through 53615).
In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24598), we did not propose any changes to this policy for retaining LTCH QRP measures adopted for previous payment determinations.

4. Policy for Adopting Changes to LTCH QRP Measures

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53615 through 53616), we finalized a policy that if the NQF updates an endorsed measure that we have adopted for the LTCH QRP in a manner that we consider to not substantively change the nature of the measure, we will use a subregulatory process to incorporate those updates to the measure specifications that apply to the LTCH QRP. Substantive changes will be proposed and finalized through rulemaking. We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53615 through 53616) for further information on what constitutes substantive and nonsubstantive changes to a measure. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24598), we did not propose any changes to the policy for adopting changes to LTCH QRP measures.

5. Previously Adopted Quality Measures

a. Previously Adopted Quality Measures for the FY 2015 and FY 2016 Payment Determinations and Subsequent Years

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53624 through 53636), for the FY 2014 payment determination and subsequent years, we adopted updated versions of National Healthcare Safety Network (NHSN) Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (NQF #0138) and the NHSN Central Line-Associated Blood Stream Infection (CLABSI) Outcome Measure (NQF #0139).
For the FY 2015 payment determination and subsequent years, we retained the application of Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure to the LTCH setting (initially adopted in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51745 through 51750)). We also adopted two new quality measures for the LTCH QRP for the FY 2016 payment determination and subsequent years, in addition to the three previously adopted measures (the CAUTI measure, CLABSI measure, and Pressure Ulcer measure): (1) Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680); and (2) Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) (77 FR 53624 through 53636).

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50861 through 50863), we adopted the NQF-endorsed version of the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure for the LTCH QRP for the FY 2015 payment determination and subsequent years.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50289 through 50305), we revised the data collection and submission period for the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) measure.

Set out below are the quality measures, both previously adopted measures retained in the LTCH QRP and measures adopted in FY 2013 and FY 2014 IPPS/LTCH PPS final rules, for the FY 2015 and FY 2016 payment determinations and subsequent years.
<table>
<thead>
<tr>
<th>NQF Measure ID</th>
<th>Measure Title</th>
<th>Payment Determination</th>
</tr>
</thead>
<tbody>
<tr>
<td>NQF #0138</td>
<td>National Healthcare Safety Network (NHSN) Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
<td>FY 2015 and Subsequent Fiscal Years</td>
</tr>
<tr>
<td>NQF #0139</td>
<td>National Healthcare Safety Network (NHSN) Central Line-Associated Blood Stream Infection (CLABSI) Outcome Measure</td>
<td>FY 2015 and Subsequent Fiscal Years</td>
</tr>
<tr>
<td>NQF #0678</td>
<td>Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay)</td>
<td>FY 2015 and Subsequent Fiscal Years</td>
</tr>
<tr>
<td>NQF #0680</td>
<td>Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay)</td>
<td>FY 2016 and Subsequent Fiscal Years</td>
</tr>
<tr>
<td>NQF #0431</td>
<td>Influenza Vaccination Coverage Among Healthcare Personnel</td>
<td>FY 2016 and Subsequent Fiscal Years</td>
</tr>
</tbody>
</table>

b. Previously Adopted Quality Measures for the FY 2017 and FY 2018 Payment Determinations and Subsequent Years

In the FY 2014 IPPS/LTCH PPS final rule, we adopted three additional measures—National Healthcare Safety Network (NHSN) Facility-Wide Inpatient Hospital-Onset Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia Outcome Measure (NQF #1716), National Healthcare Safety Network (NHSN) Facility-Wide Inpatient Hospital-Onset *Clostridium difficile* Infection (CDI) Outcome Measure (NQF #1717), and All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) (this measure was not NQF-endorsed at the time of its initial adoption)—for the FY 2017 payment determination and subsequent years (78 FR 50863 through 50874) and one additional measure, an application of Percent of Residents Experiencing One or More
Falls with Major Injury (Long Stay) (NQF #0674), for the FY 2018 payment determination and subsequent years (78 FR 50874 through 50877).

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50289 through 50305), we:

(1) revised the data collection and submission period for one measure, an application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674); and (2) adopted three new quality measures--Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), Functional Status Outcome Measure: Change in Mobility Among Long-Term Care Hospital Patients Requiring Ventilator Support (NQF #2632; endorsed on 7/23/15), and National Healthcare Safety Network (NHSN) Ventilator-Associated Event (VAE) Outcome Measure--for the FY 2018 payment determination and subsequent years.

These measures are set out in the table below.
### LTCH QRP Quality Measures Previously Adopted for the FY 2017 and FY 2018 Payment Determinations and Subsequent Years

<table>
<thead>
<tr>
<th>NQF Measure ID</th>
<th>Measure Title</th>
<th>Payment Determination</th>
</tr>
</thead>
<tbody>
<tr>
<td>NQF #1716</td>
<td>National Healthcare Safety Network (NHSN) Facility-Wide Inpatient Hospital-Onset Methicillin-Resistant <em>Staphylococcus aureus</em> (MRSA) Bacteremia Outcome Measure</td>
<td>FY 2017 and Subsequent Years</td>
</tr>
<tr>
<td>NQF #1717</td>
<td>National Healthcare Safety Network (NHSN) Facility-Wide Inpatient Hospital-Onset Clostridium difficile Infection (CDI) Outcome Measure</td>
<td>FY 2017 and Subsequent Years</td>
</tr>
<tr>
<td>NQF #2512</td>
<td>All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from Long-Term Care Hospitals</td>
<td>FY 2018 and Subsequent Years</td>
</tr>
<tr>
<td>Application of NQF #0674</td>
<td>Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay)</td>
<td>FY 2018 and Subsequent Years</td>
</tr>
<tr>
<td>NQF #2631*</td>
<td>Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function</td>
<td>FY 2018 and Subsequent Years</td>
</tr>
<tr>
<td>NQF #2632*</td>
<td>Functional Status Outcome Measure: Change in Mobility Among Long-Term Care Hospital Patients Requiring Ventilator Support</td>
<td>FY 2018 and Subsequent Years</td>
</tr>
<tr>
<td>Not NQF endorsed</td>
<td>National Healthcare Safety Network (NHSN) Ventilator-Associated Event (VAE) Outcome Measure</td>
<td>FY 2018 and Subsequent Years</td>
</tr>
</tbody>
</table>


---

6. Previously Adopted LTCH QRP Quality Measures Finalized for the FY 2018 Payment Determination and Subsequent Years

For the FY 2018 payment determination and subsequent years, in addition to the measures we are retaining under our policy described in VIII.C.3. of the preamble of this final rule, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24599 through 24605), we proposed four quality measures in order to reflect the NQF endorsement of one measure (NQF #2512) and three measures (NQF #0678; application of NQF #0674; application of...
CMS-1632-F & IFC

NQF #2631; endorsed on 07/23/2015) to meet the requirements of the IMPACT Act. Specifically, we proposed the following measures: (a) All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) to reflect NQF endorsement; (b) Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) to meet the requirements of the IMPACT Act; (c) an application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) to meet the requirements of the IMPACT Act; and (d) an application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) to meet the requirements of the IMPACT Act. These quality measures are discussed in more detail below.

a. Finalized Measure to Reflect NQF Endorsement: All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512)

The All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) was adopted for use in the LTCH QRP in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50868 through 50874). In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24600), we proposed to adopt this measure to reflect that it is NQF-endorsed for use in the LTCH setting as of December 2014. Current specifications of this NQF-endorsed measure are available for download on the NQF Web site at:


As adopted in the FY 2014 IPPS/LTCH PPS final rule, this is a Medicare FFS claims-based measure, and LTCHs are not required to report any additional data to CMS. Because we would calculate this measure based on claims data that are already reported
to the Medicare program for payment purposes, we believe there would be no additional data collection burden on LTCHs resulting from our implementation of this measure as part of the LTCH QRP. In the FY 2014 IPPS/LTCH PPS final rule, we stated that we will calculate this measure using claims data beginning with FY 2013 and FY 2014 and provide initial feedback to LTCHs prior to public reporting of this measure. However, the NQF-endorsed measure (NQF #2512) is based on 2 consecutive calendar years of Medicare FFS claims data. Therefore, in addition to our proposal to adopt the NQF-endorsed version of this measure, we proposed that the initial calculation of the measure and feedback to LTCHs, prior to public reporting of this measure, would be based on CY 2013 and CY 2014 Medicare FFS claims data related to readmissions post-LTCH discharge.

The description of this measure provided in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50868 through 50874) noted this measure is the ratio of the number of risk-adjusted predicted unplanned readmissions for each LTCH, including the estimated facility effect, to the average number of risk-adjusted predicted unplanned readmissions for the same patients if treated at a facility with the average effect on readmissions. This ratio is referred to as the standardized risk ratio or SRR. The NQF-endorsed specifications compute the risk-standardized readmission rate (RSRR) for this measure. The RSRR is the SRR multiplied by the overall national raw readmission rate for all LTCH stays; it is expressed as a percentage rate rather than a ratio.

This measure, which was developed to harmonize with the Hospital-Wide All-Cause Unplanned Readmission Measure (NQF #1789) that is currently in use in the
Hospital IQR Program, continues to use the CMS Planned Readmission Algorithm as the main component for identifying planned readmissions. This algorithm was refined in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50211 through 50216). The All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) for the LTCH QRP will utilize the most recently updated version of the algorithm. A complete description of the CMS Planned Readmission Algorithm, which includes lists of planned diagnoses and procedures, can be found on the CMS Web site at:

http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. The additional PAC planned readmission types specified for this measure remain the same as when first adopted through the FY 2014 IPPS/LTCH PPS final rule. Documentation on the additional PAC planned readmissions for this measure is available at:


We invited public comments on: (1) our proposal to adopt the NQF-endorsed version of All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) for the LTCH QRP and (2) our proposal that the initial feedback to LTCHs, prior to public reporting of this measure, would be based on CY 2013 and CY 2014 Medicare FFS claims data related to readmissions post-LTCH discharge.

Comment: One commenter supported the proposal to require continued reporting on this measure as part of LTCH QRP.

Response: We appreciate the commenter’s support of CMS proposal of this measure as a quality measure for the LTCH QRP.
Comment: Several commenters expressed concerns over the lack of risk adjustment for sociodemographic status (SDS) factors among LTCH patients, such as community factors including access to primary care, medications, and appropriate food. One commenter recommended using proxy data on these factors such as census-derived data on income and the proportion of facilities' patients that are dually eligible for Medicare and Medicaid.

Response: While we appreciate these comments and the importance of the role that sociodemographic status plays in the care of patients, we continue to have concerns about holding providers to different standards for the outcomes of their patients of low sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on facilities’ results on our measures.

NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate for each measure. For 2 years, NQF will conduct a trial of a temporary policy change that will allow inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will determine whether to make this policy change permanent. Measure developers must submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model.
Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of socioeconomic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of these reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

Comment: One commenter asked whether all LTCH cases would be included in the LTCH QRP measures (including the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512)) or only cases that qualify as site neutral cases.

Response: We appreciate this commenter’s inquiry. At this time, all LTCH patients that meet the sample inclusion criteria for this measure are included in this All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512). The inclusion criteria for this measure do not distinguish whether LTCH cases meet the site neutral qualification.

Comment: One commenter indicated that this measure was proposed to meet the requirements for the IMPACT Act and expressed concern that it does not meet all the statutory requirements, regarding quality measures, measure specifications, standardized patient assessments, and NQF endorsement.

Response: We appreciate this commenter’s feedback. However, we would like to clarify that we did not propose the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) to meet the requirements of the
IMPACT Act. This measure was not NQF-endorsed at the time of our initial adoption of the measure for the LTCH QRP in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50868 through 50874). Rather, we proposed this previously adopted measure in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24600) to reflect its NQF endorsement status.

Comment: One commenter noted that CMS had provided conflicting information on the date for the payment determination for this measure, noting that the year for the payment determination is reported as both FY 2017 and FY 2018 in the proposed rule.

Response: We appreciate this commenter’s concern, and appreciate the opportunity to provide a clarification. We refer readers to our adoption of non-NQF-endorsed version of this measure for the LTCH QRP for FY 2017 payment determination in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50868 through 50874), related to the use of the measure as it relates to FY 2017. We note that the discrepancy in the FY 2016 IPPS/LTCH PPS proposed rule regarding the applicable FY related to the endorsed version of this measure was a technical error, and the measure is effective relative to FY 2018.

After consideration of the public comments we received, we are finalizing our proposal to adopt the NQF-endorsed version of the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) for the LTCH QRP effective with the FY 2018 payment determination. We are also finalizing our proposal that the initial calculation of the measure and feedback to LTCHs, prior to public
reporting of this measure, would be based on CY 2013 and CY 2014 Medicare FFS claims data related to readmissions post-LTCH discharge.

b. Finalized Measure to Address the IMPACT Act: Quality Measure Addressing the Domain of Skin Integrity and Changes in Skin Integrity: Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678)

Section 1899B(c)(1) of the Act directs the Secretary to specify quality measures on which PAC providers are required under the applicable reporting provisions to submit standardized patient assessment data and other necessary data specified by the Secretary with respect to five quality domains, one of which is skin integrity and changes in skin integrity. The specified application date by which the Secretary must specify quality measures to address this domain for IRFs, SNFs, and LTCHs is October 1, 2016, and for HHAs is January 1, 2017. To satisfy these requirements, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24600 through 24601), we proposed to adopt the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure, that we have already adopted for the LTCH QRP, as a cross-setting quality measure that satisfies the domain of skin integrity and changes in skin integrity. The reporting of data for this measure would affect the FY 2018 payment determination and subsequent years. In the LTCH setting, the measure assesses the percent of patients with Stage 2 through Stage 4 pressure ulcers that are new or worsened since admission.

As described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51754 through 51756), pressure ulcers are high-cost adverse events and are an important measure of
quality. For information on the detailed rationale for relevance, evidence, appropriateness, importance, and applicability of this quality measure in the LTCH QRP, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51754 through 51756) and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50861 through 50863). Measure specifications are available on the NQF Web site at:


The IMPACT Act requires the implementation of quality measures and resource use and other measures that are standardized and interoperable across PAC settings as well as the reporting of standardized patient assessment data and other necessary data specified by the Secretary. This requirement is in line with the NQF Steering Committee report, which stated, “to understand the impact of pressure ulcers across settings, quality measures addressing prevention, incidence, and prevalence of pressure ulcers must be harmonized and aligned.”

The Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure is NQF-endorsed and has been successfully implemented using a harmonized set of data elements in three PAC settings (LTCHs, IRFs, and SNFs). As discussed in section VIII.C.6.b. of the preamble of this final rule, above, an application of this measure was adopted for the LTCH QRP in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51753 through 51756) for the FY 2014 payment determination, and the current NQF-endorsed version of the measure was adopted in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50861 through 50863) for the FY 2015 payment determination and subsequent years. The measure has been in use in

the LTCH QRP since October 1, 2012, and LTCHs are currently submitting data for this measure using the LTCH Continuity Assessment Record and Evaluation (CARE) Data Set.

The Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure was adopted for use in the IRF QRP in the FY 2012 IRF PPS final rule (76 FR 47876 through 47878) for the FY 2014 payment determination and subsequent years and has been successfully submitted by IRFs using the Inpatient Rehabilitation Facility – Patient Assessment Instrument (IRF-PAI) since October 2012. It has also been implemented in the CMS Nursing Home Quality Initiative, using the Minimum Data Set (MDS) Version 3.0 since 2011, and is currently publicly reported on CMS’ Nursing Home Compare at:


A TEP convened by our measure development contractor in February 2015, provided input on the technical specifications of this quality measure, as well as the applicability of this measure as a cross-setting measure across PAC settings, including the LTCH setting, to meet the requirements of the IMPACT Act. The TEP supported the applicability of this measure as a cross-setting measure across PAC settings and also supported our efforts to standardize items for data collection and submission of this measure as well as our efforts to standardize the measure for cross-setting development. In addition, on February 9, 2015, the MAP met to provide input to CMS on the measure. The MAP supported the use of Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure in the LTCH QRP as a cross-
setting quality measure. More information about the MAP’s recommendations for this measure is included in: The MAP Off-Cycle Deliberations 2015: Measures under Consideration to Implement Provisions of the IMPACT Act: Final Report which is available at:

http://www.qualityforum.org/Setting_Priorities/Partnership/MAP_Final_Reports.aspx.

We proposed that data collection for this measure continue to occur through the LTCH CARE Data Set submitted through the CMS Quality Improvement and Evaluation System (QIES) Assessment Submission and Processing (ASAP) system. LTCHs have been submitting data on the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure through the LTCH CARE Data Set since October 2012. By building on the existing reporting and submission infrastructure for LTCHs, we intend to minimize the administrative burden related to data collection and submission for this measure under the LTCH QRP. For more information on LTCH QRP reporting using the QIES ASAP system, we refer readers to our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCHTechnicalInformation.html.

We proposed that data collected using standardized items through the LTCH CARE Data Set would continue to be used to calculate this quality measure. LTCH CARE Data Set items used to identify new or worsened pressure ulcers consist of: M0800A (Worsening in Pressure Ulcer Status Since Prior Assessment, Stage 2);

---

311 For the April 1, 2016 release of the LTCH CARE Data Set version 3.00, item M0800A will be revised to Worsening in Pressure Ulcer Status Since Admission, Stage 2.
M0800B\textsuperscript{312} (Worsening in Pressure Ulcer Status Since Prior Assessment, Stage 3); and M0800C\textsuperscript{313} (Worsening in Pressure Ulcer Status Since Prior Assessment, Stage 4). In addition, we proposed to continue to use items from the LTCH CARE Data Set to risk-adjust this quality measure. These items consist of: GG0160C\textsuperscript{314} (Functional Mobility; Lying to Sitting on Side of Bed), H0400 (Bowel Continence); I0900 (Peripheral Vascular Disease (PVD) or Peripheral Arterial Disease (PAD); I2900 (Diabetes Mellitus), K0200A (Height); and K0200B (Weight). More information about the LTCH CARE Data Set items is available in the LTCH QRP Manual available at:


The specifications and data elements for the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure for LTCHs are available in the LTCH QRP Manual at:


We invited public comment on our proposal to adopt the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure for the FY 2018 payment determination and subsequent years to fulfill the requirements of the IMPACT Act.

\textsuperscript{312} For the April 1, 2016 release of the LTCH CARE Data Set version 3.00, item M0800B will be revised to Worsening in Pressure Ulcer Status Since Admission, Stage 3.

\textsuperscript{313} For the April 1, 2016 release of the LTCH CARE Data Set version 3.00, item M0800C will be revised to Worsening in Pressure Ulcer Status Since Admission, Stage 4.

\textsuperscript{314} For the April 1, 2016 release of LTCH CARE Data Set version 3.00, this item (GG0160C) will be renumbered to GG0170C.
Comment: Several commenters supported the proposal to implement the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) to fulfill the requirements of the IMPACT Act. Commenters noted that this measure is NQF-endorsed for the LTCH setting, data have been collected by LTCHs as part of the LTCH QRP since October 2012, and the NQF MAP supported the use of this measure in the LTCH QRP to meet the requirements of the IMPACT Act.

Response: We thank these commenters for their support of our proposal.

Comment: One commenter supported the proposal to implement this measure to fulfill the requirements of the IMPACT Act and stated that the implementation of this measure would not add any additional burden for LTCHs, because there are already mechanisms in place to collect and submit the pressure ulcer data. The commenter sought clarification regarding the coding instructions for the new or worsened unstageable pressure ulcer items added to Section M of the LTCH CARE Data Set version 3.00.

Response: We thank the commenter for its support of our proposal and recognition that the implementation of this measure does not add additional data collection and reporting burden for LTCHs. Regarding the commenter’s request related to coding the LTCH CARE Data Set version 3.00 new items, we are committed to providing additional guidance to support and allow LTCHs to accurately interpret and complete quality reporting items, including the new or worsened unstageable pressure ulcer items included in Section M of the LTCH CARE Data Set version 3.00. Similar to training and outreach efforts that we have conducted in the past, we will make available

In fall 2015, prior to the implementation of new quality measures and new items of LTCH CARE Data Set version 3.00, we intend to offer free trainings to LTCH providers and interested stakeholders. This training is part of our ongoing strategy to ensure successful implementation of the LTCH QRP. In addition, we will continue to maintain and provide guidance through the LTCH help desk via LTCHQualityQuestions@cms.hhs.gov. We invite LTCHs to submit specific inquires related to LTCH CARE Data Set version 3.00 via email at the address provided.

Comment: Several commenters supported the intent of this measure, but provided recommendations regarding risk adjustment of the pressure ulcer measure. Commenters suggested modifications, including risk adjustment for patients with multiple-organ failure, for patients on dialysis, and for patients with morbid obesity. One commenter recommended ongoing evaluation of the risk adjustment methodology to ensure it is appropriate for standardized cross-setting risk adjustment purposes.

Another commenter was concerned that the measure is limited to only high risk patients or residents, and that the denominator size is decreased by excluding individuals who are low risk. The commenter indicated that pressure ulcers do develop in low-risk individuals and that this exclusion will impact each PAC setting differently.
because the prevalence of low risk individuals varies across settings. The commenter suggested that CMS use a logistic regression model for risk adjustment to allow for an increase in the measure sample size by including all admissions, take into consideration low-volume providers, and capture the development of pressure ulcers in low-risk individuals. This commenter expressed concern that the current risk factors for this measure were selected for the SNF setting and are therefore inappropriate for the LTCH setting, and recommended use of an ordinal scale related to an increasing number and severity of risk factors rather than grading risk dichotomously (for example, high risk vs. low risk). The commenter further recommended additional risk stratification and expanding the list of risk factors to better capture variation across different PAC settings. Finally, the commenter noted that the TEP that evaluated this cross-setting pressure ulcer measure recommended that CMS consider modifying the risk adjustment model and either excluding or risk adjusting for Hospice patients and patients receiving end-of-life care.

Response: We thank the commenters for their support of this measure and for their specific recommendations to inform and improve risk adjustment for this measure. Section 1899B (c)(3)(B) of the IMPACT Act states that quality measures shall be risk-adjusted, as determined appropriate by the Secretary.

In regard to the commenter who recommended we risk adjust using a logistic regression model and incorporate low risk patients into the measure, we believe that this commenter may have submitted comments regarding the wrong quality measure. Their comments apply to the quality measure, Percent of High Risk Residents with Pressure
Ulcers (Long Stay) (NQF #0679), which is not the measure that we proposed for the LTCH QRP. The proposed measure is Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (NQF #0678). This measure is currently risk-adjusted using a logistic regression model and includes low-risk patients. In the model, patients are categorized as either high or low risk for four risk factors: functional limitation, bowel incontinence, diabetes or peripheral vascular disease (PVD)/peripheral arterial disease (PAD), and low body mass index (BMI). Low-risk patients are included in the measure calculation. An expected score is calculated for each patient or resident using that patient or resident’s risk level on the four risk factors described above. The patient/resident-level expected scores are then averaged to calculate the facility-level expected score, which is compared to the facility-level observed score to calculate the adjusted score for each facility. Additional detail regarding risk adjustment for this measure is available in the measure specifications, available at:


We have determined that the current risk-adjustment methodology is appropriate for this measure and have developed and implemented the risk adjustment model for this measure. To arrive at this determination, we rely on ongoing measure development and measure maintenance activities undertaken by our measure development contractor, RTI International. These activities include a review of the relevant literature, careful analyses to examine the appropriateness of current and additional risk factors using facility-level
data submitted by over 400 LTCHs nationwide by means of the LTCH CARE Data Set as part of the LTCH QRP, input from a LTCH-setting-specific TEP, input from a cross-setting TEP, and advise and clinical guidance of subject matter experts and other stakeholders to examine current risk factors and to identify additional risk factors.

We recognize that it is important to continue to examine additional risk-adjustment factors to ensure valid and reliable quality measures and to consider further improvement of the risk adjustment model for our quality measures for the LTCH QRP. To this end, we will take into consideration the TEP discussion and these commenters’ thoughtful feedback to inform our ongoing assessment of risk factors and future risk adjustment and stratification model for the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure, including consideration of the recommendation to exclude or adjust for hospice patients and patients receiving end-of-life care. We remain committed to conducting ongoing testing and measure development activities in an effort to improve the risk adjustment of quality measures implemented through the quality reporting programs. These activities will ensure that this quality measure remains valid and reliable and provides usable information to inform quality improvement activities within the LTCH setting as well as other PAC settings, and to fulfill the public reporting goals of the CMS quality reporting programs, including the LTCH QRP.

Comment: One commenter asked CMS to clarify how discharges paid under the LTCH PPS standard Federal payment rate versus the LTCH PPS site neutral rate will be included in the quality metrics in the future years. This commenter noted that if there is
no differentiation in the quality metrics for the two different types of payment methodologies, it is likely that the quality metrics could become skewed. The commenter also asked CMS whether the metrics can be reported separately for discharges that are paid under the LTCH PPS standard Federal payment rate versus the LTCH PPS site neutral rate and further recommended that all LTCH appropriate metrics should be risk-adjusted.

Response: We refer readers to our response to the preceding comment regarding current and future risk adjustment for this measure. At this time, all LTCH patients that meet the sample inclusion criteria for this measure, irrespective of payer source and payment methodology, are included in this measure. We will take commenter’s recommendations regarding analysis and separate reporting for discharges that are paid under the LTCH PPS standard Federal payment rate versus the LTCH PPS site neutral rate under advisement to inform future analyses of the data for the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure.

Comment: Several commenters expressed concern regarding the reliability and validity of this measure across the different PAC settings. The commenters were concerned that the reliability and validity testing for this measure were only conducted in the SNF setting. One commenter stated that the populations in which the data collection tools are used and risk factors in LTCH, IRF, and SNF settings are not similar. The commenter highlighted differences in LTCH clinical characteristics and susceptibility to pressure ulcers amongst LTCH patients as compared to IRF and SNF patient/resident
populations, stating that these differences make the application of reliability testing results from the SNF resident population to the LTCH and IRF patient populations inaccurate. The commenter encouraged CMS to conduct additional testing on the reliability and validity of this quality measure using data from LTCHs, IRFs, and SNFs to accurately assess the appropriate use of MDS 3.0 items across settings.

**Response:** We appreciate the commenters’ concern that the LTCH, IRF and SNF populations are not identical and that some differences may exist in the reliability and validity of the measure across settings. We are working towards standardizing data across PAC settings as mandated in the IMPACT Act. As such, we continue to conduct measure development and testing to explore the best way to standardize quality measures, while ensuring reliability and validity for the measures to appropriately account for the unique differences in populations across PAC settings.

The application of this quality measure for use in the LTCH QRP and IRF QRP was established in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51745 through 51750) and the IRF PPS FY 2012 (76 FR 47876 through 47878) when this quality measure was finalized for use in the LTCH QRP and IRF QRP, respectively. The NQF endorsement was expanded to the LTCH and IRF settings in 2012. The expanded measure was finalized in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50861 through 50863) and the FY 2014 IRF PPS final rule (78 FR 47911 through 47912) for use in the LTCH and IRF QRP, respectively. As part of NQF endorsement maintenance for this measure, CMS and our measure contractor will continue to perform reliability and validity testing.
Findings from early data analyses have shown that the measure continues to be valid and reliable for LTCH and IRF settings in addition to the SNF/NH setting.

**Comment:** One commenter was concerned that the pressure ulcer measure is not standardized across PAC settings. The commenter stated that although the measure appears to meet the goals and the intent of the IMPACT Act, it does not use a single data assessment tool.

The commenter specifically mentioned the frequency of assessments, highlighting the fact that the LTCH and IRF versions of the measure are calculated using data from assessments conducted at two points in time (admission and discharge), while the SNF version uses assessments at more than two points in time. The commenter expressed concern that the higher frequency of assessments for the MDS could potentially result in higher rates of pressure ulcer counts for SNFs. Another commenter voiced particular concerns regarding differences in the look back periods, for the items used on the IRF, SNF and LTCH assessments (MDS = 7-day assessment period; IRF = 3-day assessment period; LTCH = 3-day assessment period) and suggested that this would result in different rates of detection of new or worsened ulcers. Commenters encouraged CMS to address all of these discrepancies, and suggested that CMS should switch to using only an admission and discharge assessment in the SNF version of the measure.

**Response:** We appreciate the commenters’ review of the measure specifications across the post-acute care settings. We wish to clarify that while the IMPACT Act requires the modification of PAC assessment instruments to revise or replace certain existing patient assessment data with standardized patient assessment data as soon as
practicable, it does not require a single data collection tool. We intend to modify the existing PAC assessment instruments as soon as practicable to ensure the collection of standardized data. While we agree that it is possible that within the PAC assessment instruments certain sections could incorporate a standardized assessment data collection tool, for example, the Brief Interview for Mental Status (BIMS), we have not yet concluded whether this kind of modification of the PAC assessment instruments is necessary.

As to the concern that the pressure ulcer measure calculation is based on more frequent assessments in the SNF setting than in the LTCH and IRF settings, we wish to clarify that result of the measure calculation for all three PAC providers is the same. For all three PAC providers, the measure calculation ultimately shows the difference between the number of pressure ulcers present on admission and the number of new or worsened pressure ulcers present on discharge. While SNF measure calculation arrives at that number differently than does the measure calculation in the IRF and LTCH settings, ultimately all three settings report the same result - as noted, the difference between the number of pressure ulcers present on admission and the new or worsened pressure ulcers at discharge. To explain, in IRFs and LTCHs, pressure ulcer assessment data is obtained only at two points in time - on admission and on discharge. Therefore, the calculation of the measure includes all new or worsened pressure ulcers since admission. In contrast, in SNFs, pressure ulcer assessment data is obtained on admission, at intervals during the stay (referred to as “interim assessments”), and at discharge. Each interim assessment and the discharge assessment only look back to whether there were new or worsened
pressure ulcers since the last interim assessment. The sum of number of new or worsened pressure ulcers identified at each interim assessment and at the time of discharge yields the total number of new or worsened pressure ulcers that occurred during the stay and that were present on discharge. In other words, the collection of pressure ulcer data in LTCHs and IRFs is cumulative, whereas in SNFs, data collection is sequential. In both cases the calculation reaches the same result – the total number of new or worsened pressured ulcers between admission and discharge. Thus, this is the same result of the measure calculation for SNFs as is obtained for IRFs and LTCHs.

We interpret the commenter’s concern related to a higher frequency of assessments for the MDS potentially resulting in higher rates of pressure ulcer counts pertains to the potential inclusion of wounds that are new or worsened and are identified on such interim assessments but actually heal by the time of discharge. We wish to clarify that, as with the LTCH and IRF measure calculation that does not include pressure ulcers that heal, we will calculate the quality measure such that any new or worsened pressure ulcer wounds found on interim assessments but have healed will not be included.

In regard to the commenter’s concern about different look-back periods, we acknowledge that although the LTCH CARE Data Set and IRF-PAI allow up to the third day starting on the day of admission as the assessment period and the MDS allows for an assessment period of admission up to day 7, we note that the training manuals for SNFs, LTCHs and IRFs provide specific and equivalent-coding instructions related to the items used to calculate this measure (found in Section M - skin conditions for all three assessments). These instructions ensure that the assessment of skin integrity occurs at the
 initiation of patients’ or residents’ PAC stays regardless of setting. All three manuals direct providers to complete the skin assessment for pressure ulcers present on admission as close to admission as possible, ensuring a harmonized approach to the timing of the initial skin assessment. Regardless of differences in the allowed assessment periods, providers across PAC settings should adhere to best clinical practices, established standards of care, and the instructions in their respective training manuals, to ensure that skin integrity information is collected as close to admission as possible. Although the manual instructions are harmonized to ensure assessment at the beginning of the stay, based on the commenter’s feedback, we will take into consideration the incorporation of uniform assessment periods for this section of the assessments.

Comment: One commenter expressed concern that this measure is NQF-endorsed for the SNF setting and suggested that CMS delay implementing the cross-setting measure until it is NQF-endorsed across all PAC settings. The commenter urged CMS to request formal NQF review, using the Consensus Development Process rather than “time-limited review” of the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure for the LTCH setting before adopting the measure for the LTCH QRP. The commenter also encouraged CMS to convene a TEP that includes representatives from the LTCH setting to review the applicability of this measure to the LTCH setting, and noted that the NQF MAP only conditionally supported this quality measure for the LTCH QRP. In addition, the commenter expressed concern that the specifications available on the NQF Web site are dated October 2013.
Response: Although the proposed pressure ulcer measure was originally developed for the SNF/nursing home populations, it has been respecified for the LTCH and IRF settings, underwent review for expansion to the LTCH and IRF settings by the NQF Consensus Standards Approval Committee (CSAC) on July 11, 2012; and was subsequently ratified by the NQF Board of Directors for expansion to the LTCH and IRF settings on August 1, 2012. As reflected on the NQF Website, the endorsed settings for this measure include Post-Acute/Long Term Care Facility: Inpatient Rehabilitation Facility, Post-Acute/Long Term Care Facility: Long Term Acute Care Hospital, Post-Acute/Long Term Care Facility: Nursing Home/Skilled Nursing Facility.

NQF endorsement of this measure for the LTCH setting indicates that NQF supports the use of this measure in the LTCH and IRF settings, as well as in the SNF setting. This measure was fully supported by the MAP for cross-setting use at its meeting of February 9, 2015.

With regard to the comment regarding the measure specifications posted on the NQF Website, we note that the most up-to-date version of the measure specifications were posted for stakeholder review at the time of the proposed rule on the CMS Website at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/Downloads/Long-Term-Care-Hospital-Quality-Reporting-Program-Specifications-for-the-Quality-Measures-Proposed-through-the-Fiscal-Year-2016-Notice-of-Proposed-Rule-Making-report.pdf. The specifications posted on the NQF Website for the

---

317 National Quality Forum. Percent of Residents or Patients with Pressure Ulcers that are New or Worsened (Short -Stay). Available: http://www.qualityforum.org/QPS/0678.
quality measure, the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) during the comment period are computationally equivalent and have the same measure components as those posted on the CMS Web site at the time of the proposed rule. However, we provided more detail in the specifications posted with the proposed rule, in an effort to more clearly explain aspects of the measure that were not as clear in the NQF specifications. In addition, we clarified language to make phrasing more parallel across settings, and updated item numbers and labels to match the 2016 data sets (MDS 3.0, LTCH CARE Data Set, and IRF-PAI). We are working closely with NQF to make updates and ensure that the most current language and clearest version of the specifications are available on the NQF Web site.

In addition to NQF review, this measure has been reviewed by several TEPs, which included representatives from the LTCH setting. In June and November 2013, our measure development contractor convened a cross-setting pressure ulcer TEP, which included representatives from the LTCH setting and provided detailed input regarding the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678). An additional cross-setting TEP, which also included representatives from the LTCH setting, was convened in February 2015 and provided input on the technical specifications of this quality measure, as well as the applicability of this measure as a cross-setting measure applied across PAC settings, including the LTCH

setting, to meet the requirements of the IMPACT Act.\textsuperscript{319} Finally, an LTCH-specific TEP provided recommendations regarding this measure in January\textsuperscript{320} and September 2011.\textsuperscript{321}

As noted, this measure was fully supported by the MAP at their meeting on February 9, 2015 for use in the LTCH QRP as a cross-setting quality measure.\textsuperscript{322} The MAP noted that this measure is NQF-endorsed for, and already implemented in, the LTCH QRP. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51748 through 51750) for details on our efforts to solicit and engage technical experts from the LTCH setting as part of our adoption of this measure for the LTCH QRP. We also refer readers to our earlier response on our measure developer’s ongoing efforts to further develop this measure and note that we remain committed to soliciting ongoing input and working closely with LTCH, IRF, SNF/nursing home and cross-setting stakeholders and clinical experts as part of our ongoing measure development and maintenance efforts.

After consideration of the public comments we received, we are finalizing our proposal to adopt the Percent of Residents or Patients with Pressure Ulcers That Are New


or Worsened (Short Stay) (NQF #0678) measure for the FY 2018 payment determination and subsequent years to fulfill the requirements of the IMPACT Act.

c. Finalized Measure to Address the IMPACT Act: Quality Measure Addressing the Domain of Incidence of Major Falls: Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674)

Section 1899B of the Act directs the Secretary to specify quality measures on which PAC providers are required under the applicable reporting provisions to submit standardized patient assessment data and other necessary data specified by the Secretary with respect to five quality domains, one of which is the incidence of major falls. The specified application date by which the Secretary must specify quality measures to address this domain for IRFs, SNFs, and LTCHs is October 1, 2016, and for HHAs is January 1, 2019. To satisfy these requirements, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24601 through 24602), we proposed to adopt an application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure in the LTCH QRP as a cross-setting quality measure that addresses the domain of incidence of major falls. The purpose of our proposal was to establish this measure’s use as a cross-setting measure that satisfies the required adoption of such a measure under the domain of falls with major injury. There is no difference between this measure and the measure we previously adopted, beyond the proposed intent to use the measure to satisfy the requirements of the IMPACT Act. Data collection would start on April 1, 2016. The reporting of data for this measure would affect the payment determination for FY 2018 and subsequent years.
For the LTCH setting, this measure would report the percentage of patients who experienced one or more falls with major injury during the LTCH stay. This measure was developed by CMS and is NQF-endorsed, currently for long-stay residents of nursing facilities. It was adopted for the LTCH QRP in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50874 through 50877). In the FY 2015 IPPS/LTCH PPS final rule, we adopted a revised start for data collection of April 1, 2016 and affecting FY 2018 payment determination, and we adopted data collection and submission timelines for the FY 2018 payment determination and subsequent years. For information on the detailed rationale for relevance, evidence, appropriateness, importance, and applicability of this quality measure in the LTCH QRP, we refer readers to these final rules.

Measure specifications are available on the NQF Web site at: http://www.qualityforum/QPS/0674.

The IMPACT Act requires the implementation of quality measures and resource use and other measures that are standardized and interoperable across PAC settings as well as the reporting of standardized patient assessment data and other necessary data specified by the Secretary. The Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure is NQF-endorsed for long-stay residents of nursing facilities and has been successfully implemented in such settings. The NQF-endorsed measure has been in use as part of the CMS Nursing Home Quality Initiative since 2011. In addition, the measure is currently reported on the CMS Nursing Home Compare Web site at: http://www.medicare.gov/nursinghomecompare/search.html. As noted previously, this
measure was adopted for use in the LTCH QRP in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50874 through 50877). In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50290 through 50291), we revised the data collection start date for this measure with data collection to begin starting April 1, 2016, and we adopted data collection and submission timelines for the FY 2018 payment determination and subsequent years.

We reviewed the NQF’s consensus endorsed measures and did not identify any NQF-endorsed cross-setting quality measures focused on falls with major injury applicable to multiple PAC settings. We are unaware of any other cross-setting quality measures for falls with major injury that have been endorsed or adopted by another consensus organization. Therefore, we proposed an application of the measure, the Percent of Residents Experiencing One or More Fall (NQF #0674) measure under the Secretary’s authority to select non-NQF-endorsed measure.

A TEP convened by our measure development contractor provided input on the measure specifications, as well as the feasibility and clinical appropriateness of implementing the measure across PAC settings, including the LTCH setting. The TEP supported the implementation of this measure across PAC settings and also supported CMS’ efforts to standardize this measure for cross-setting development. In addition, the MAP met on February 9, 2015, and provided input to CMS on the measure. The MAP conditionally supported the use of an application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure in the LTCH QRP as a cross-setting quality measure. More information about the MAP’s
recommendations for this measure is included in The MAP Off-Cycle Deliberations 2015: Measures under Consideration to Implement Provisions of the IMPACT Act: Final Report which is available at:

http://www.qualityforum.org/Setting_Priorities/Partnership/MAP_Final_Reports.aspx.

More information on the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure can be found on the NQF Web site at: http://www.qualityforum.org/QPS/0674. Updated specifications and details regarding the changes made to further harmonize this measure across PAC settings are located at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/index.html.

We proposed that data for this proposed quality measure be collected using the LTCH CARE Data Set, with submission through the QIES ASAP system. For more information on LTCH QRP reporting through the QIES ASAP system, we refer readers to the CMS Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCHTechnicalInformation.html. Data collected through a revised LTCH CARE Data Set would be used to calculate this quality measure. Consistent with the LTCH CARE Data Set reporting requirements, the application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure would apply to all patients discharged from LTCHs. Data items in the revised LTCH CARE Data Set version 3.00 would include: J1800, Any Falls Since Admission; and J1900, Number of Falls Since Admission.
The calculation of the proposed application of the measure would be based on item J1900C, *Number of Falls with Major Injury Since Admission*. The measure specifications for the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure are available at: [http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/index.html](http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/index.html). We refer readers to section VIII.C.9.b. of the preamble of this final rule for more information on the data collection and submission timeline for this proposed quality measure.

We invited public comment on our proposal to adopt an application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure, with data collection beginning on April 1, 2016 for the FY 2018 payment determination and subsequent years to fulfill the requirements in the IMPACT Act.

**Comment:** One commenter supported the proposal to implement an application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure to fulfill the requirements of the IMPACT Act.

**Response:** We thank the commenter for their support of our proposal.

**Comment:** Several commenters supported the Application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure in concept, but suggested that risk adjustment is necessary to ensure reliable and valid comparisons across settings and to account for factors outside of the control of providers for public reporting purposes. One commenter stated that risk adjustment is
important when discussing and analyzing falls risk factors in other PAC settings. The
commenters also noted that the NQF MAP conditionally supported the falls measure if
risk-adjustment were performed.

Response: We appreciate the commenters’ concerns that the proposed application
of the quality measure, the Percent of Residents Experiencing One or More Falls with
Major Injury (Long Stay) (NQF #0674) should be risk-adjusted. The application of risk
adjustment, as stated by the IMPACT Act, is “as determined appropriate by the
Secretary” under section 1899B(c)(3)(B) of the Act.

While we acknowledge that patient characteristics that elevate the risk for falls
with major injury vary across the LTCH population, a TEP convened in 2009 by the
measurement development contractor asserted that risk adjustment of this quality
measure concept was inappropriate because it is each facility’s responsibility to take steps
to reduce the rate of injurious falls, especially since such events are considered to be
“never events.” We note that the PAC PRD did not analyze falls with major injury, as
falls with major injury was not an assessment item that was tested. However, as the
commenter pointed out, the prevalence of a history of falls prior to the PAC admission
did vary across post-acute settings (as assessed by Item B7 from the CARE tool:
“History of Falls. Has the patient had two or more falls in the past year or any fall with
injury in the past year?”). Nonetheless, we believe that as part of best clinical practice,
LTCHs should assess residents for falls risk and take steps to prevent future falls with
major injury.
A TEP of LTCH experts convened in 2011 agreed that falls with major injury are very important to track in LTCHs and did not recommend risk adjustment for this measure. The numerator, denominator, and exclusions definitions provided to the TEP in 2015 are virtually identical to the specifications we proposed to adopt for this measure, and did not include risk adjustment. Two out of 11 members of the 2015 TEP supported risk adjustment of the falls measure. For more information on the 2015 TEP, please visit http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/Downloads/SUMMARY-OF-FEEDBACK-FROM-THE-TECHNICAL-EXPERT-PANEL-TEP-REGARDING-CROSS-SETTING-MEASURES-ALIGNED-WITH-THE-IMPACT-ACT-OF-2014-Report.pdf.

We believe factors that increase the risk of falling, such as cognitive impairment, should be included by facilities in their risk assessment to support proper care planning. As cited in the proposed rule, research suggests that 78 percent of falls are anticipated falls, occurring in individuals who could have been identified as at-risk for a fall using a risk-assessment scale. Risk adjusting for falls with major injury could unintentionally lead to insufficient risk prevention by the provider. As required by the DRA, the Hospital Acquired Conditions-Present On Admission (HAC-POA) Indicator Reporting provision requires a quality adjustment in the Medicare Severity-Diagnosis Related Groups (MS-DRG) payments for certain Hospital Acquired Conditions (HACs), which include falls and trauma, and these payment reductions are not risk adjusted. The need for risk assessment, based on varying risk factors among patients, does not remove the obligation of providers to minimize that risk.
With regard to the MAP recommendation to risk adjust this measure cited by the commenter, the MAP feedback regarding risk adjustment for this quality measure applied to the home health setting, not to the SNF setting. We also refer readers to a more recent Cochrane review of 60 randomized controlled trials, which found that within care facilities, multifactorial interventions have the potential to reduce rates of falls and risk of falls. 323

Comment: One commenter stated that data collection and abstraction from the medical record for this measure would pose a burden on LTCHs because of separate systems for gathering data for such events.

Response: We appreciate the concerns related to any undue burden, including data collection, documentation, and reporting and we take such concerns under consideration when selecting measures for the LTCH QRP. The Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure includes the following two data elements in the LTCH CARE Data Set version 3.00: J1800, Any Falls Since Admission, and J1900, Number of Falls Since Admission. If the provider answers “No” to J1800, Any Falls Since Admission, then J1900, Number of Falls Since Admission, may be skipped. Based on evidence and rationale we presented in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50874 through 50877) to support our selection and finalization of our proposal to adopt this measure for the LTCH QRP, we believe the impact this measure could have on quality of care and patient outcomes in the

LTCH setting justifies additional resources needed for measure data collection and data submission.

In addition, we note that this measure was previously finalized for use in the LTCH QRP through the FY 2014 IPPS/LTCH PPS final rule (78 FR 50874 through 50877), and our proposal of this previously adopted measure to establish its cross-setting use, in order to address the domain of incidence of major falls to meet the requirements of the IMPACT Act, does not add any additional burden for LTCHs.

Comment: Several commenters recommended re-specifying and testing the measure in the LTCH setting and obtaining NQF endorsement specifically for the LTCH setting prior to implementation in the LTCH QRP.

Response: We appreciate the commenters' recommendations regarding NQF endorsement in the LTCH setting and recognize that it is an important step in the measure development process. However, because falls with major injury is an important patient safety concern in LTCHs, and because of the lack of availability of NQF-endorsed measures for the LTCH setting or measures endorsed by any other consensus organizations, we proposed this measure under the exception authority provided in section 1899B(e)(2)(B) of the Act, which allows us to apply a measure to the LTCH setting that is not NQF-endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization.

There is no difference between this measure and the measure we previously adopted through the FY 2014 IPPS/LTCH PPS final rule (78 FR 50874 through 50877).

We also are clarifying that while this measure is currently endorsed for the
nursing home setting, we believe the data collection items, measure definition, and measure specifications are applicable across multiple PAC settings, including the LTCH setting (78 FR 50876). With regard to the adequacy of the measure’s testing, the item-level testing during the development of the MDS 3.0 (data elements in the LTCH CARE Data Set were adapted from MDS 3.0) showed near-perfect inter-rater reliability for the MDS item (J1900C) used to identify falls with major injury. The NQF measure evaluation criteria do not require measure-level reliability if item reliability is high. However, we believe that, given the overlap in the populations and item-level testing results, the application of this measure for LTCH patients will be reliable. In addition, we intend to test the measure for the LTCH setting once data collection begins as part of LTCH QRP and as part of ongoing maintenance of the measure for NQF endorsement.

In addition, our measure development contractor convened a TEP in 2011 that supported the importance of a quality measure to address falls with a major injury in the LTCH setting. This measure on reports falls with major injuries which is an important patient safety concern for LTCH patients. For the reasons listed above, we have concluded that this measure is appropriate for LTCH patients.

Comment: One commenter stated that the falls measure is not fully specified as a cross-setting measure. This commenter suggested that CMS needs to more clearly specify the numerator, denominator and exclusions, including risk adjustment for this quality measure. Therefore, this measure should not be implemented as proposed since the specifications in the proposed rule differ from those in referenced documents, NQF applications for the measures, and the IRF and SNF proposed rules.
Response: This quality measure was proposed and specified as a cross-setting measure for LTCH, IRF, and SNF settings. The Application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure is the same measure for each setting. Additional details on the measure specifications for the application of this measure to the LTCH setting in order to harmonize this measure across LTCH, IRF, and SNF settings to meet the IMPACT Act requirements are available for download at: http://cms.hhs.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/index.html.

With regard to the measure specifications posted on the NQF Web site, the most up-to-date version of the measure specifications were posted for stakeholder review at the time of the proposed rule on the CMS Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/Downloads/Skilled-Nursing-Facility-Quality-Reporting-Program-Quality-Measure-Specifications-for-FY-2016-Notice-of-Proposed-Rule-Making-report.pdf. The specifications currently posted on the NQF Web site are computationally equivalent and have the same measure components as those posted on the CMS Web site at the time of the proposed rule. However, we provided more detail in the specifications posted with the proposed rule, in an effort to more clearly explain aspects of the measure that were not as clear in the NQF specifications. In addition, we clarified language to make phrasing more parallel across settings, and updated item numbers and labels to match the 2016 data sets (MDS 3.0, LTCH CARE Data Sets, and IRF-PAI). We are working closely with NQF to make updates and ensure that the most current language and clearest version of the specifications are available on the NQF Web site.
After consideration of the public comments we received, we are finalizing our proposal to adopt the application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure, with data collection beginning on April 1, 2016, for the FY 2018 payment determination and subsequent years to fulfill the requirements in the IMPACT Act.

d. Finalized Measure to Address the IMPACT Act: Quality Measure Addressing the Domain of Functional Status, Cognitive Function, and Changes in Function and Cognitive Function: Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015)

Section 1899B(c)(1) of the Act directs the Secretary to specify quality measures on which PAC providers are required under the applicable reporting provisions to submit standardized patient assessment data and other necessary data specified by the Secretary with respect to five quality domains, one of which is functional status, cognitive function, and changes in function and cognitive function. The specified application date by which the Secretary must specify quality measures to address this domain for IRFs and SNFs is October 1, 2016, for LTCHs is October 1, 2018, and for HHAs is January 1, 2019. To satisfy these requirements, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24602 through 24605), we proposed to adopt an application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan that Addresses Function (NQF #2631; endorsed on 07/23/2015) measure that we have already adopted in the LTCH QRP as a cross-setting quality measure that addresses the domain of functional
status, cognitive function, and changes in function and cognitive function. The reporting of data for this measure would affect the payment determination for FY 2018 and subsequent years. This quality measure reports the percent of patients with both an admission and a discharge functional assessment and a goal that addresses function.

The National Committee on Vital and Health Statistics, Subcommittee on Health, noted: “[i]nformation on functional status is becoming increasingly essential for fostering healthy people and a healthy population. Achieving optimal health and well-being for Americans requires an understanding across the life span of the effects of people’s health conditions on their ability to do basic activities and participate in life situations, in other words, their functional status.” This statement is supported by research showing that patient functioning is associated with important patient outcomes, such as discharge destination and length of stay in inpatient settings, as well as the risk of nursing home placement and hospitalization of older adults living in the community. Functioning is important to patients and their family members.

The majority of patients who receive PAC services, such as care provided by SNFs, HHAs, IRFs and LTCHs, have functional limitations, and many of these patients are at risk for further decline in function due to limited mobility and ambulation. The patient and resident populations treated by SNFs, HHAs, IRFs and LTCHs vary in terms of their functional abilities at the time of the PAC admission and their goals of care. For IRF patients and many SNF residents, treatment goals may include fostering the patient’s ability to manage his or her daily activities so that the patient can complete self-care and/or mobility activities as independently as possible, and, if feasible, return to a safe, active, and productive life in a community-based setting. For HHA patients, achieving independence within the home environment and promoting community mobility may be the goal of care. For other HHA patients, the goal of care may be to slow the rate of functional decline in order to allow the person to remain at home and avoid institutionalization.

Lastly, in addition to having complex medical care needs for an extended period of time, LTCH patients often have limitations in functioning because of the nature of their conditions, as well as deconditioning due to prolonged bed rest and treatment requirements (for example, ventilator use). The clinical practice guideline Assessment of Physical Function recommends that clinicians should document functional status at baseline and over time to validate capacity, decline, or progress. Therefore, assessment

---

of functional status at admission and discharge and establishing a functional goal for discharge as part of the care plan (that is, treatment plan) is an important aspect of patient care in all of these PAC settings.

Given the variation in patient and resident populations across the PAC settings, the functional activities that are typically assessed by clinicians for each type of PAC provider may vary. For example, the activity of rolling left and right in bed is an example of a functional activity that may be most relevant for low-functioning patients or residents who are chronically critically ill. Managing a full flight of stairs may be assessed for higher functioning patients or residents. However, certain functional activities, such as eating, oral hygiene, lying to sitting on the side of the bed, toilet transfers, and walking or wheelchair mobility, are important activities for patients in each PAC setting.

Although functional assessment data are currently collected by SNFs, HHAs, IRFs and LTCHs, this data collection has employed different assessment instruments, scales, and item definitions. The data collected cover similar topics, but are not standardized across PAC settings. Further, the different sets of functional assessment items are coupled with different rating scales, making communication about patient functioning challenging when patients transition from one type of setting to another. Collection of standardized functional assessment data across SNFs, HHAs, IRFs and LTCHs, using common data items, would establish a common language for patient functioning, which may facilitate communication and care coordination as patients transition from one type of provider to another. The collection of standardized functional
status data may also help improve patient or resident functioning during an episode of care by ensuring that basic daily activities are assessed at the start and end of each episode of care with the aim of determining whether at least one functional goal has been established.

The functional assessment items included in the proposed functional status quality measure were originally developed and tested as part of the Post-Acute Care Payment Reform Demonstration (PAC PRD) version of the Continuity Assessment Record and Evaluation (CARE) Item Set, which was designed to standardize the assessment of patients’ status across acute care and PAC settings, including SNFs, HHAs, IRFs and LTCHs. The functional status items on the CARE Item Set are daily activities that clinicians typically assess at the time of admission and/or discharge in order to determine patients’ or residents’ needs, evaluate patient progress and prepare patients or residents and families for a transition to home or to another setting.

The development of the CARE Item Set and a description and rationale for each item is described in a report entitled “The Development and Testing of the CARE Item Set: Final Report on the Development of the CARE Item Set: Volume 1 of 3.” Reliability and validity testing were conducted as part of CMS’ PAC PRD, and we concluded that the functional status items have acceptable reliability and validity. A description of the testing methodology and results are available in several reports, including the report entitled “The Development and Testing of the CARE Item Set: Final

---


The cross-setting function quality measure we proposed to adopt for the FY 2018 payment determination and subsequent years to meet the IMPACT Act requirements is a process measure that is an application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) measure. This quality measure was developed by the CMS. It reports the percent of patients with both an admission and a discharge functional assessment and a treatment goal that addresses function. The treatment goal provides documentation that a care plan with a goal has been established for the patient.

We proposed to use the data that will be collected and submitted using the LTCH CARE Data Set version 3.00 for the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) measure starting April 1, 2016 in order to calculate this cross-setting application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed...
on 07/23/2015) quality measure. The items in the cross-setting application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) measure are a subset of the items included in the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) measure, which was finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50291 through 50298). Therefore, the adoption of this quality measure to satisfy the requirements of the IMPACT Act would not result in the addition of new items to the LTCH CARE Data Set version 3.00 and, therefore, would not result in additional burden for data collection and data submission to LTCHs.

This process measure requires the collection of functional status admission and discharge assessment data using standardized clinical assessment items, or data elements that assess specific functional activities, that is, self-care, mobility activities. The self-care and mobility function activities on the LTCH CARE Data Set version 3.00 are coded using a 6-level rating scale that indicates the patient’s level of independence with the activity; higher scores indicate more independence. For this quality measure, documentation of a goal for one of the function items reflects that the patient’s care plan addresses function. The function goal is recorded at admission for at least one of the standardized self-care or mobility function items using the 6-level rating scale.

To the extent that a patient had an incomplete stay (for example, for the purpose of being admitted to an acute care facility), collection of discharge functional status data might not be feasible. Therefore, for patients with incomplete stays, admission functional
status data and at least one treatment goal would be required; however, discharge
functional status data would not be required to be reported.

A TEP convened by our measure development contractor provided input on the
technical specifications of this quality measure, as well as the feasibility of implementing
the measure across PAC settings, including the LTCH setting. The TEP supported the
implementation of this measure across PAC settings and also supported our efforts to
standardize this measure for cross-setting use.

In addition, the MAP met on February 9, 2015, and provided input to CMS on the
measure. The MAP conditionally supported the use of an application of the Percent of
LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan
That Addresses Function (NQF #2631; endorsed on 07/23/2015) measure for use in the
LTCH QRP as the cross-setting measure. The conditions stated by the MAP included
that the measure should be endorsed by the NQF. Finally, the MAP reiterated its support
for adding measures addressing function, noting the group’s special interest in this
PAC/LTC core concept. More information about the MAP’s recommendations for this
measure is discussed in The MAP Off-Cycle Deliberations 2015: Measures under
Consideration to Implement Provisions of the IMPACT Act: Final Report which is
available at:

http://www.qualityforum.org/Setting_Priorities/Partnership/MAP_Final_Reports.aspx.

The measure we proposed is an Application of the Percent of Long-Term Care
Hospital Patients with an Admission and Discharge Functional Assessment and a Care
Plan that Addresses Function (NQF #2631: endorsed on 07/23/2015). The proposed
measure is derived from the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan that Addresses Function quality measure. The specifications are available for review at the LTCH QRP Web site at:  

We reviewed the NQF's consensus endorsed measures and were unable to identify any NQF-endorsed cross-setting quality measures focused on assessment of function for PAC patients. We are also unaware of any other cross-setting quality measures for functional assessment that have been endorsed or adopted by another consensus organization. Therefore, we proposed to adopt this functional assessment measure for use in the LTCH QRP for the FY 2018 payment determination and subsequent years under the Secretary’s authority to select non-NQF-endorsed measures.

As discussed previously, we proposed that this cross-setting quality measure use a subset of data collected for Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) using the LTCH CARE Data Set, with submission through the QIES ASAP system. For more information on LTCH QRP reporting through the QIES ASAP system, we refer readers to the CMS Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCHTechnicalInformation.html.
We described the measure calculation algorithm for this measure in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24605).

This measure is calculated at two points in time, at admission and discharge (we refer readers to section VIII.C.9.b. of the preamble of this final rule, Form, Manner and Timing of Quality Data Submission, for more information on the proposed data collection and submission timeline for this proposed quality measure).

The items would assess specific self-care and mobility activities, and would be based on functional items included in the PAC PRD version of the CARE Item Set. The items have been developed and tested for reliability and validity in SNFs, HHAs, IRFs, and LTCHs. More information pertaining to item testing is available on our Post-Acute Care Quality Initiatives Web page at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/CARE-Item-Set-and-B-CARE.html.

We invited public comments on our proposal to adopt the Application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) measure that we have already adopted in the LTCH QRP as a cross-setting quality measure that addresses the domain of functional status, cognitive function, and changes in function and cognitive function to satisfy the requirement of the IMPACT Act, with data collection starting on April 1, 2016, for the FY 2018 payment determination and subsequent years. Further, we invited public comments on our proposal to use a subset of data collected for the Percent of LTCH Patients with an Admission and Discharge Functional Assessment
and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) measure to meet the requirements for this cross-setting quality measure that addresses the domain of functional status, cognitive function, and changes in function and cognitive function to satisfy the requirement of the IMPACT Act.

**Comment:** MedPAC did not support the adoption of the function process measure in the LTCH QRP, NQF #2631; endorsed on 07/23/2015 and urged CMS to adopt outcomes measures focused on changes in patient physical and cognitive functioning while under a provider’s care.

**Response:** We appreciate MedPAC’s preference for moving toward the use of functional outcome measures in order to assess the patient’s physical and cognitive functioning under a provider’s care. We believe that the use of this process measures at this time will give us the data we need to develop a more robust outcome-based quality measure on this topic in the future. The proposed function quality measure, an Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), has attributes to enable outcomes-based evaluation by the provider. Such attributes include the assessment of functional status at two points in time, admission and discharge, enabling the provider to identify, in real time, changes, improvement or decline, as well as maintenance. In addition, the proposed quality measure requires that the provider indicate at least one functional goal associated with a functional activity, and the provider can calculate the percent of patients who meet goals. Such real time use
enables providers to engage in person-centered goal setting and the ability to use the data for quality improvement efforts.

In addition, we note that for the LTCH QRP, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50301), we adopted an outcome measure, Functional Outcome Measure: Change in Mobility Among LTCH Patients Requiring Ventilator Support (NQF #2632; endorsed on 07/23/2015), for implementation starting April 1, 2016.

Comment: One commenter supported inclusion of the quality measure an Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015). The commenter noted that this cross-setting measure, which is focused on function, addresses measure shortcomings in the LTCH QRP and other QRPs.

Response: We appreciate the commenter’s support of this measure. We agree that patient functioning is an important area of quality in PAC settings, including the LTCH setting.

Comment: Several commenters expressed concern related to undue burden associated with data documentation for the functional status quality measure, an Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015).

Response: We appreciate the concerns related to any undue burden, including documentation, and take such concerns under consideration when selecting measures for
the LTCH QRP. We aim to adopt quality measures that rely on data that is already collected in clinical practice.

To reduce potential burden associated with collecting additional items, we have included several mechanisms in Section GG of the LTCH CARE Data Set that allow the clinician to skip questions in the data set that are not appropriate for an individual patient in order to reduce burden. We have instituted skip options so that the final number of items assessed per patient is limited depending on their complexity and capabilities. Therefore, although all of the items are available for assessment, we have built in a mechanism that enables the assessor to include assessment information as, and when, appropriate.

We further note that there is no new burden associated with this process measure since it will utilize data elements in the LTCH CARE Data Set that are already collected for the previously adopted measure, Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015).

Comment: Several commenters noted that the measure, an Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), does not capture functional outcomes. One commenter encouraged CMS to propose functional outcome measures for LTCHs, SNFs and HHAs in future rulemaking for quality of care and payment.
Response: We recognize stakeholder concerns for the development of outcome-based quality measures. We point out that we previously adopted the functional outcome measure Functional Status Outcome Measure: Change in Mobility Among LTCH Patients Requiring Ventilator Support (NQF #2632; endorsed on 07/23/2015) in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50301), and data collection for this outcome measure begins on April 1, 2016.

Further, as discussed above, the measure has attributes within the assessment and data collection that enables outcomes-based evaluation by the provider.

As discussed above, this function quality measure, NQF #2631; endorsed on 07/23/2015, has attributes within the assessment and data collection that enables outcomes-based evaluation by the provider.

The IMPACT Act specifically mentions goals of care as an important aspect of the use of standardized assessment data, quality measures, and resource use to inform discharge planning and incorporate patient preference. We are currently developing functional outcome measures, specifically self-care and mobility quality measures, which may be considered in the future for use in the LTCH setting as part of the LTCH QRP. These outcome function quality measures are being designed to use the same standardized functional assessment items that are included in the cross-setting person and family-centered function process measure in order to capitalize on the data collected for this process measure (that is, an Application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses
Function (NQF #2631; endorsed on 07/23/2015)), which will inform further development, while allowing for the consideration of limited additional burden.

**Comment:** One commenter noted that the measure, an Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), includes reporting of only one goal, even though patients often have multiple functional goals. The commenter indicated that goals may be to improve function or to maintain function.

Response: The quality measure requires a minimum of one goal per patient stay; however, clinicians can report goals for each self-care and mobility item included in Section GG of the LTCH CARE Data Set version 3.00.

We believe that assessing patient function goals should be part of clinical care and builds upon the conditions of participation (CoPs) for LTCH providers. The IMPACT Act also specifically mentions goals of care as an important aspect of the use of standardized assessment data, quality measures, and resource use to inform discharge planning and incorporate resident preference. We agree that, for many PAC patients, the goal of therapy is to improve function, and we also recognize that, for some patients, delaying decline may be the goal. We believe that individual, person-centered goals exist in relation to individual preferences and needs. We will provide instructions about reporting of goals in a training manual and in training sessions to better clarify that goals set at admission may be focused on improvement of function or maintenance of function.
Comment: One commenter noted that goal data was not included in the PAC PRD and expressed concerns about reliability and validity of these items. The commenter requested clarification on how CMS plans to use goal data.

Response: The function measure calls for documentation of a goal as evidence that there is a care plan with a goal in place for each patient. CMS will use the variable of patient goals for data collection and monitoring. By using the data collected in this quality measure, LTCHs can internally monitor functional outcomes, specifically the percent of patients who meet or exceed their discharge functional status goals, as established at admission in conjunction with the patient and family.

Comment: Several commenters expressed concern regarding the use of the CARE Tool (Item Set) as the data source for the functional status quality measures due to limited testing in LTCHs and reliability testing results. The commenters noted that several self-care and mobility items have Kappa statistics categorizing inter-rater reliability as “fair” or “moderate,” and were based on a small sample of 46 LTCH patients. The commenters stated that “fair” or “moderate” reliability, while acceptable for exploratory studies or internal quality improvement efforts, is insufficient for national use in the LTCH QRP. Commenters recommended that CMS explain the low Kappa statistics and/or re-test these items in significantly more LTCHs to address reliability issues. The commenters noted that measure testing should be oriented towards the intended setting of use of the measure and suggested additional testing in the LTCH setting be conducted.
Response: The reliability study results mentioned by these commenters were only one of several reliability analyses conducted as part of the PAC PRD. The referenced result was a reflection of the small sample size available for analysis. In addition to the inter-rater reliability study mentioned by these commenters, we also examined: (1) inter-rater reliability of the CARE items using videotaped case studies, which included 114 LTCH assessments from three LTCHs; and (2) internal consistency of the function data, which included more than 7,700 assessments from 28 LTCHs. The results of these analyses indicate moderate to substantial agreement on the CARE Tool (Item Set) items. The report describing these additional analyses and an interpretation of the Kappa statistics results is available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/Downloads/The-Development-and-Testing-of-the-Continuity-Assessment-Record-and-Evaluation-CARE-Item-Set-Final-Report-on-Reliability-Testing-Volume-2-of-3.pdf.

In addition to the PAC PRD analyses, as part of the NQF application process, we conducted additional analyses focused on the six submitted IRF and LTCH function quality measures, including item-level, scale-level and facility-level analyses testing the reliability and validity of the CARE function data. The members of this panel reviewed this measure and concluded that the measure does meet the scientific acceptability requirements at a moderate level. A description of the analyses and the results are available on the NQF Web site’s Person- and Family-Centered Care project at: http://www.qualityforum.org/ProjectMeasures.aspx?projectID=73867. Therefore, given the overall findings of the reliability and validity analysis, we believe these CARE items provide a scientifically sound set to measure quality for the LTCH QRP.
We understand the importance of education in assisting providers to collect accurate data, and we have worked in the past with public outreach including training sessions, training manuals, Webinars, open door forums and help desk support. Further, we note that, as part of the LTCH QRP, we intend to evaluate the national-level data for this quality measure submitted by LTCHs to CMS. These data will inform ongoing measure development and maintenance efforts, including further analysis of reliability and validity of the data elements and the quality measure. Finally, we agree that ongoing reliability and validity testing is critical for all items used to calculate quality measures.

Comment: One commenter suggested that several of the functional status assessment items had low or nonresponse rates and missing data when used as part of PAC PRD. The commenter requested that CMS provide additional information on how the measure has been updated to address these low response rates.

Response: With respect to the comments that some items had low response rates (defined as the utilization of coding responses for when a patient does not or cannot attempt a daily activity, the activity did not occur), the assessor appropriately reported a code indicating the reason that the activity was not attempted (for example, due to a medical condition or due to patient refusal). This is a good practice to ensure that bias is not introduced through missing data not otherwise specified. With some populations, there was a high use of the letter codes indicating that the activity was not able to be coded or collected at the time of the assessment due to patient condition, but there was a very low percentage of missing data.
While activities such as “toileting hygiene” and “walking” may have high rates of “activity not attempted” codes at the time of admission for LTCH patients, these activities are completed more often at discharge. Assessment of these activities is particularly important to assess for LTCH patients returning to their home. Using national Medicare FFS claims data from 2010 through 2013, we examined the percentage of LTCH patients who were admitted from an acute hospital and discharged home. The national percentage of LTCH patients discharged home was 40.1 percent in 2010, 39.5 percent in 2011, 38.4 percent in 2012, and 37.5 percent in 2013. These findings demonstrate that a large proportion of LTCH patients are discharged home directly from the LTCH setting. These data strongly support the importance of functional assessment in the LTCH setting, and ensuring patient safety from a functional perspective prior to discharge. Assessment of a patient’s level of independence and safety in performing functional activities such as walking is critical for a safe patient transition from the LTCH to the home setting.

Public input and a TEP in 2013 provided feedback to CMS pertaining to the pattern of scores including that of letter codes. TEP members included experts from LTCHs, as well as IRFs and SNFs. A report summarizing recent TEP meetings focused on functional status quality measures titled “Summary of Feedback from TEP on the Development of Cross-Setting Functional Status Quality Measures” is available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/. The functional status quality measure development built on work conducted as part of a project funded by ASPE, and that project also included a cross-

**Comment:** A few commenters noted that the proposed quality measure is an application of the LTCH measure under review at NQF, and that fewer functional assessment items are in the proposed measure when compared to the LTCH process measure. Therefore, the commenters believe the items in the LTCH CARE Data Set are limited, and functional issues addressed by clinicians may not be represented in this data set.

**Response:** The quality measure under NQF review, the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), was adopted for FY 2018 payment determination and subsequent years as part of the LTCH QRP in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50298). In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24602 through 24605), we proposed *an application* of this previously adopted quality measure. That is, the quality measure, *an Application* of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), is a cross-setting measure that is standardized across multiple settings (LTCHs, IRFs, SNFs). This quality measure includes only selected function items from the previously adopted quality measure.
We believe that standardization of assessment items across the spectrum of PAC settings is an important goal. In the cross-setting process measure, there is a common core subset of function items that will allow tracking of patients’ functional status across settings. We recognize that there are some differences in patients’ clinical characteristics, including medical acuity, across the LTCH, SNF and IRF settings, and that certain functional items may be more relevant for certain patients. Decisions regarding item selection for each quality measure were based on our review of the literature, input from a TEP convened by our measure contractor, our experiences and review of data in each setting from the PAC PRD, and public comments.

To clarify which specific items are included in each function measure for each QRP, we added a table to the document entitled, LTCH QRP: Specifications of Quality Measures Adopted in the FY 2016 Final Rule, which identifies which functional assessment items are used in the cross-setting process measure, as well as the setting-specific IRF and LTCH outcome quality measures. The document is available for download at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html.

**Comment:** Several commenters noted that only a few standardized assessment items were proposed by CMS in Section GG of the LTCH CARE Data Set version 3.00 and that the items proposed deviated from the original set of CARE items tested in the PAC PRD. One of these commenters noted the importance of consistent items and assessment instructions across the settings. The commenters also were concerned that the items proposed for IRFs, SNFs and LTCHs were not the same set of items. Some of the
Commenters questioned the validity of including only a subset of items from the CARE Tool (Item Set) tested in the PAC PRD, diminishing the comparability of the data.

Response: For this quality measure, a core set of function items are included in Section GG of the LTCH CARE Data Set version 3.00 for LTCHs. This core set of function items are also included in Section GG of the IRF-PAI for IRFs and Section GG of the MDS 3.0 for SNFs, respectively. This core set of items selected for cross-setting use were chosen for their applicability across all PAC settings, guided by the TEP convened by our measure development contractor. The core set of items nested in the Section GG were chosen from the set of function-related items tested in the PAC PRD.

The PAC PRD tested a range of items, some of which were duplicative, to identify the best performing items in each domain. Select items were removed from the item set where testing results and clinician feedback suggested the need for fewer items to be included in a particular measure or scale. We also received feedback on the items from a cross-setting TEP convened by our measure development contractor, RTI International. The measure is based on analyses which are available on our Web site at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Reports/Research-Reports-Items/PAC_Payment_Reform_Demo_Final.html.

We chose from this subset of data items to develop the function-based CARE measures, such as the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) measure. Additional function items are included on the LTCH CARE Data Set due to the adoption of additional outcome-based quality measure (Functional
Status Outcome Measure: Change in Mobility Among LTCH Patients Requiring Ventilator Support, NQF #2632; endorsed on 07/23/2015) in the LTCH setting. Therefore, we believe that the core set of items in Section GG are standardized to one another by item and through the use of the standardized 6-level rating scale. Further, we will continue to work to harmonize the assessment instructions to better guide the coding of the assessment, as we believe that this will lead to accurate and reliable data, allowing us to compare the data within each setting. We also believe that the assessment of these activities is part of routine clinical care at a minimum at the start of care and at the end of care.

We recognize that there are some differences in patients’ clinical characteristics, including medical acuity across the SNF, LTCH and IRF settings, and that certain functional items may be more relevant for certain patients. For example, one item, “Wash Upper Body” is included in the LTCH quality measure, Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), but is not included in the IRF outcome measures or the cross-setting measure, an Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), because this item overlaps with the item “Bathe/Shower Self,” which focused on washing the entire body. For the LTCH setting, where patients are chronically critically ill, bathing the upper body is more likely to occur than washing the entire body. In IRFs and SNFs, clinicians typically assess showering or bathing of the entire body.
To clarify which function items are included in each function measure for each QRP, we added a table to the document entitled, LTCH QRP: Specifications of Quality Measures Adopted in the FY 2016 Final Rule, which identifies which functional assessment items are used in the cross-setting process measure, as well as the setting-specific IRF and LTCH outcome quality measures. The document is available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html

Comment: One commenter noted there may be a challenge in determining the baseline cognitive function of LTCH patients, which is one of the items needed for the quality measure, Application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015).

Response: We appreciate the commenter’s feedback pertaining to the quality measure, an Application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015). We are clarifying that the Confusion Assessment Method (CAM©), which includes the item focused on baseline cognitive function, is not required as part of this cross-setting measure. It is required as part of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), which was adopted into the LTCH QRP in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50298). We have added a table entitled “Long-Term Care Hospital Quality Reporting Program – Specifications for the Quality Measures Adopted through the FY 2016 IPPS/LTCH PPS final rule” to the
CMS Web site to clarify which items are required for each functional quality measure, which is available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html.

We have addressed similar concerns with training in the past with public outreach including training sessions, training manuals, Webinars, open door forums, help desk support, and a Web site that hosts training information (http://www.youtube.com/user/CMSHHS.gov). We plan to conduct such activities to support the April 1, 2016 implementation for the new items included in the LTCH CARE Data Set version 3.00.

Comment: Several commenters expressed concern about the lack of risk-adjustment of this measure.

Response: The function quality measure, an Application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), is a process measure that focuses on the clinical process of completion of functional assessments and a care plan addressing function. Although the IMPACT Act requires that the cross-setting quality measures be risk-adjusted as determined appropriate by the Secretary, it does not limit the Secretary to adopting outcome measures. Some process measures are risk adjusted. In the development of an application of the measure, the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan that Addresses

---

336 For example, in the NQF-endorsed process measure Percent of Residents Who Have/Had a Catheter Inserted and Left in Their Bladder (long stay) (NQF#0686) for which we are the steward, resident-level limited covariates (Frequent bowel incontinence, or always incontinent on prior assessment; and Pressure ulcers at stages II, III, or IV on prior assessment) are used in a logistic regression model to calculate a resident-level expected quality measure score.
Function (NQF #2631; awaiting NQF endorsement), the TEP considered, but did not recommend, the application of a risk adjustment model. We agree with that conclusion because the completion of a functional assessment, which includes the use of “activity not attempted” codes, is not affected by the medical and functional complexity of the resident. Therefore, we believe that risk adjustment of this quality measure is not warranted.

Comment: One commenter was concerned that the measure, an Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) was not NQF-endorsed.

Response: We agree that the NQF endorsement is an important part of measure development process. We have proposed an application of the quality measure, the Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function. This quality measure has been endorsed by NQF on July 23, 2015. We have a rigorous process of construct testing and measure selection, guided by the TEPs, public comments from stakeholders, and recommendations by the PAC/LTC MAPs.

Comment: Several commenters expressed concern that the proposed function process measure, an Application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), does not meet the requirements of the IMPACT Act, because measures must be outcome-based. One commenter asserted that the proposed measure
did not satisfy the specified IMPACT Act domain, as the measure is not able to report on changes in function, and one other commenter claimed that the measure does not satisfy the reporting of data on functional status. One commenter suggested that the measure does not meet the mandate, as the measure does not have appropriate numerator, denominator, and exclusions specifications, it lacks NQF endorsement, the proposed quality measure fails to be based on a common standardized assessment tool, and the proposed quality measure lacks evidence that associates the measure with improved outcomes. One commenter claimed that because the specifications for the proposed measure are inconsistent with the measure specifications posted by the NQF for the measure that is under endorsement review, CMS failed to meet the requirements under the IMPACT Act to provide measure specifications to the public, further asserting that one cannot determine the specifications that are associated with the proposed measure, which is an application of the NQF version of the measure. Response: We agree that the use of outcome measures is important. We believe that the proposed function measure meets the requirements of the IMPACT Act. The statute requires, among other things, the submission of data on the quality measures specified in at least the domains identified in the Act, but does not require a particular type of measure (for example, outcome or process) for each measure domain. Further, as discussed above, the measure has attributes within the assessment and data collection that enables outcomes-based evaluation by the provider.

We also disagree with the comment that we failed to provide the specifications to the proposed measure. The proposed function process quality measure is an application
of the measure, the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan that Addresses Function (NQF #2631; endorsed on 7/23/2015). The quality measure was endorsed by NQF on July 23, 2015 and was proposed and finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50291 through 50298) for adoption in the LTCH QRP. An application of this measure was proposed in the FY 2016 SNF QRP proposed rule, and similarly it was proposed in the FY 2016 IPPS/LTCH PPS proposed rule and the FY 2016 IRF PPS proposed rule. We proposed the cross-setting version, an application of the LTCH QRP quality measure, based on guidance from multiple TEPs convened by our measure contractor, RTI International. The specifications for this measure are located on the LTCH Quality Reporting Program Measures Information Web page at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html. These specifications were posted at the time we issued the proposed rule.

As discussed in section VIII.C.6.c. of the preamble of this rule, prior to our consideration to propose this measure’s use in the LTCH QRP, we reviewed the NQF’s endorsed measures and were unable to identify any NQF-endorsed, cross-setting or standardized quality measures focused on assessment of function for PAC patients/residents. We were also unaware of any other cross setting quality measures for functional assessment that have been endorsed or adopted by another consensus organization. Therefore, we proposed a modified version of the quality measure, the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and
a Care Plan that Addresses Function (NQF #2631; endorsed on 7/23/2015), with such modifications to allow for its cross-setting application in the LTCH QRP for the FY 2018 payment determination and subsequent years under the Secretary’s authority to select a non-NQF-endorsed measure. Since the cross-setting measure is not identical to the measure recommended for NQF-endorsement, it is considered an application of the measure.

Comment: One commenter was concerned that the measure specifications posted with the FY 2016 IPPS/LTCH PPS proposed rule differ from those posted with the IRF and SNF proposed rules and that the public would be unable to determine which specifications CMS intends to use. The commenter also was concerned that these differences in specifications, including differences in the measure denominator would impede interoperability across settings. This commenter suggested measures include all patients across all settings, regardless of payer.

Response: As mentioned previously, the quality measure being proposed as a cross-setting measure for LTCH, IRF, and SNF settings, an Application of the Percent of LTCH Patients With an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), is the same measure for each setting. Additional function items are included on the IRF-PAI and LTCH CARE Data Set due to the proposal or adoption of various other outcome-based quality measures in those specific settings. The final specifications for this cross-setting measure are posted on the CMS Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-
Measures-Information.html. In the cross-setting process measure, there is a common core subset of function items that will allow tracking of patients’ functional status across settings that are identical across the settings. We have updated the specifications to include a table indicating which functional assessment items are used in the cross-setting process measure, as well as the setting-specific outcome measures.

We appreciate the commenters’ views pertaining to the differences in the function quality measure denominators by payer type across the IRF, SNF and LTCH settings. We also appreciate the commenters’ suggested expansion of the population used to calculate all measures to include payer sources beyond Medicare PPS and agree that quality measures that include all persons treated in a facility are better able to capture the health outcomes of that facility’s patients or residents, and that quality reporting on all patients or residents is a worthy goal. We believe that quality care is best represented through the inclusion of all patient data regardless of payer source and we agree that consistency in the data would reduce confusion in data interpretation and enable a more comprehensive evaluation of quality. We appreciate the commenter’s concerns and, although we had not proposed all payer data collection through this current rulemaking, we will take into consideration the expansion of the LTCH QRP to include all payer sources through future rulemaking.

Finally, we are clarifying that while the IMPACT Act requires the enablement of interoperability through the use of standardized data, there will be instances whereby some provider types may need more or less standardized items than other provider types.
Comment: One commenter was concerned that no data was provided clearly linking improved outcomes to this process measure.

Response: The NQF requirement for endorsing process measures is that the process should be evidence-based, such as processes that are recommended in clinical practice guidelines. As part of the NQF process, we submitted to the NQF several such clinical practice guidelines\textsuperscript{337,338,339} to support this measure and referenced another cross-cutting clinical practice guideline in the proposed rule. Due to this, we believe that there is evidence that this is a best practice based on several clinical practice guidelines. The clinical practice guideline Assessment of Physical Function\textsuperscript{340} recommends that clinicians should document functional status at baseline and over time to validate capacity, decline, or progress. Therefore, assessment of functional status at admission and discharge and establishing a functional goal for discharge as part of the care plan (that is, treatment plan) is an important aspect of patient/resident care for all of these PAC providers.

Comment: One commenter suggested that the PAC PRD data was collected only by therapists, and expressed concern that the items had not been tested using other care providers. In addition, this commenter had specific questions about scoring different


assessments during the time frame proposed. The commenter also asked CMS to specify which clinicians may complete function items in Section GG.

Response: We wish to clarify that during the PAC PRD, data were collected by clinicians from many different disciplines, including nurses, occupational therapists (OTs), physical therapists (PTs), speech-language pathologists (SLPs), and registered nurses (RNs). The reliability testing included testing by discipline, as well as testing by setting.

The items were developed with the input with who would be performing the assessments, which included OTs, PTs, SLPs, and RNs. Regarding the questions about scoring assessments and staff that will be trained to complete functional assessments, we have historically provided training for providers. As we prepare for this type of training, we have this type of information available to the public to increase transparency and readiness.

Comment: Several commenters encouraged CMS to provide standardized education to all providers that will be using the CARE items throughout the transition period. In addition, several commenters raised concerns about the scoring of Section GG of the LTCH CARE Data Set, and who would be trained to collect the items in Section GG, and how “usual performance” in the proposed Section GG is defined. The commenters also asked for CMS’ transparency through this process.

Response: We understand the importance of education and have worked in the past with public outreach including training sessions, training manuals, Webinars, open door forums, help desk support, and a Web site that hosts training information
We plan to conduct such activities for the new items.

**Comment:** Several commenters encouraged CMS to continue ongoing stakeholder engagement as the function quality measures evolve and as new function measures, including additional concepts for cognition and mobility, are considered.

**Response:** We thank the commenters for the suggestion, and appreciate the continued involvement of stakeholders in all phases of measure development and implementation. We will continue to engage stakeholders as we implement the IMPACT Act.

**Comment:** One commenter expressed concern about items related to cognitive functioning, including communication and swallowing, being included only as risk-adjustors. The commenter recommended that CMS engage stakeholders to develop future outcome measures in the area of cognitive function.

**Response:** We are clarifying that the proposed LTCH process measure, an Application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), is not risk adjusted. We agree that future development of outcome measurement should include other areas of function, such as cognition, expression, and swallowing. We will continue to engage stakeholders as we develop quality measures to meet the requirements of the IMPACT Act.

After consideration of the public comments we received, we are finalizing our proposal to adopt the application of the Percent of LTCH Patients with an Admission and
Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) measure for the FY 2018 payment determination and subsequent years to fulfill the requirements of the IMPACT Act.

7. LTCH QRP Quality Measures for the FY 2019 Payment Determination and Subsequent Years

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24605), we did not propose any additional LTCH QRP quality measures for the FY 2019 payment determination and subsequent years. Under our policy discussed in section VIII.C.3. of the preamble of this final rule, we will retain all previously adopted quality measures and, the additional finalized measures in this FY 2016 IPPS/LTCH PPS final rule for the FY 2019 payment determination and subsequent years.

8. LTCH QRP Quality Measures and Concepts under Consideration for Future Years

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24605), we invited public comments on importance, relevance, appropriateness, and applicability of each of the quality measures and quality measure concepts listed in the table below for future years in the LTCH QRP. Specifically, we invited public comments regarding the clinical importance to the LTCH patient population and the feasibility of data collection and implementation in the LTCH setting for these measures and measure concepts in order to inform and improve quality of care delivered to LTCH patients.
### Future Measures and Measure Concepts under Consideration for the LTCH QRP

<table>
<thead>
<tr>
<th>National Quality Strategy (NQS) Priority: Patient Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventilator Weaning (Liberation) Rate</td>
</tr>
<tr>
<td>Compliance with ventilator process Elements during LTCH Stay</td>
</tr>
<tr>
<td>Venous Thromboembolism Prophylaxis</td>
</tr>
<tr>
<td>Medication Reconciliation*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NQS Priority: Effective Communication and Coordination of Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfer of health information and care preferences when an individual transitions*</td>
</tr>
<tr>
<td>All-Condition Risk-Adjusted Potentially Preventable Hospital Readmission Rate*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NQS Priority: Patient- and Caregiver-Centered Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharge to community*</td>
</tr>
<tr>
<td>Patient Experience of Care</td>
</tr>
<tr>
<td>Percent of Patients with Moderate to Severe Pain</td>
</tr>
<tr>
<td>Advance Care Plan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NQS Priority: Affordable Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare Spending per Beneficiary*</td>
</tr>
</tbody>
</table>

* Indicates that this is a cross-setting measure domain listed in the IMPACT Act.

**Comment:** One commenter supported most of the measures and measure concepts under consideration for the LTCH QRP, as they are applicable to an LTCH population, clinically important, and potentially feasible to collect.

**Response:** We appreciate the commenter’s support of these future measures and measure concepts under consideration.

**Comment:** Some commenters provided recommendations about the Ventilator Weaning (Liberation) Rate measure. One commenter urged CMS to utilize the TEP in fully testing the ventilator weaning measure before it is considered for inclusion in the LTCH QRP. Another commenter stated that this measure is an appropriate quality measure for LTCHs; however, it will be important to carefully specify the inclusion and exclusion criteria and appropriately risk adjust. This commenter also noted examples where patients enter an LTCH without an expectation of successfully weaning, such as
patients with spinal cord injuries or ALS, and stated that, for some patients, terminal weaning is an appropriate outcome.

Response: We appreciate the commenters’ support and suggestions for this measure. We will take these into consideration to inform our ongoing measure development efforts. Our measure development contractor, RTI International, will continue to engage members of a TEP originally convened in April 2014 through a national call for TEP members. This TEP is providing ongoing advisement to our measure development contractor on all aspects, including this measure’s denominator, numerator, inclusion and exclusion criteria, risk adjustment, as well as development and feasibility of data elements.

Comment: One commenter expressed concerns that CMS is proposing Discharge to the Community, Medicare Spending per Beneficiary (MSPB), and All-Condition Risk-Adjusted Potentially Preventable Hospital Readmission Rate Hospital Readmissions as cross-cutting measures to fulfill the requirements of the IMPACT Act.

Response: We are clarifying that we did not propose these measures in the FY 2016 IPPS/LTCH PPS proposed rule. Rather, we included these measures and measure concepts as measures under consideration and measures under development for future years of the LTCH QRP to fulfill the requirements of the IMPACT Act. We and our measure development contractors are in the early stages of development of these quality measures to meet the requirements of the IMPACT Act.

Comment: One commenter expressed concern for the All-Condition Risk-Adjusted Potentially Preventable Hospital Readmission Rate since LTCH patients
are at a much higher severity level and, thus, have higher risk of readmission than other PAC settings. The commenter stated that to make valid comparison across settings, it is important to adequately risk adjust this measure. The commenter noted that CMS currently uses diagnosis information on claims to risk adjust its readmission measures, and the ability of claims data to fully capture the severity of the patient populations treated by LTCHs is limited as demonstrated by a number of studies showing the importance of controlling for risk factors that do not appear on the claim when assessing the performance of LTCHs relative to other providers. In conclusion, the commenter noted that it is important to assess the value of incorporating assessment data for risk adjustment before using this measure to assess performance across settings.

Response: We thank the commenter for its comments and suggestions. We agree with these comments and agree it is important to carefully examine and identify risk factors for the All-Condition Risk-Adjusted Potentially Preventable Hospital Readmission Rate measure before using this measure to assess and report on performance of LTCHs as part of LTCH QRP as well as for valid and reliable comparisons across settings. We will take these comments under advisement as we develop the All-Condition Risk-Adjusted Potentially Preventable Hospital Readmission Rate measure. We will also seek input from a panel of experts to inform our identification of risk factors and approach to risk adjustment for this measure. We agree with the commenter’s suggestion that we consider differences LTCH and other providers, and the implications of those differences on measure specification and intend to do so in our development of this measure, as well as for all future measures, for the LTCH QRP.
Comment: One commenter expressed concerns regarding the Discharge to Community measure, particularly if used to compare PAC settings. The commenter noted that many LTCH patients, given their severity and conditions, are not appropriate for returning to the community upon discharge but are, appropriately, transferred to a lower-level of care (such as a Skilled Nursing Facility). The commenter recommended that sufficient risk adjustment approaches that would standardize adequately for patient differences across settings to permit fair comparisons on this quality measure across PAC settings need to be developed. The commenter stated that, at a minimum, this measure needs to be carefully assessed for validity and reliability in all PAC settings. The commenter stated that risk adjustment should include not only information available from claims data but also information from assessment data, including functional status, and that it may be necessary to stratify patients based on condition and/or functional status rather than grouping all patients together. The commenter recommended that CMS move cautiously in developing and adopting a discharge to the community measure that covers all PAC settings.

This commenter also commented on the MSPB measure. The commenter expressed similar concerns on this measure as with the hospital readmission measure and discharge to the community measure. In addition, the commenter noted that a 30-days post-discharge episode is not sufficiently long to capture the consequences of receiving care in an LTCH. The commenter noted the importance of assessing an alternative definition of MSPB and the value of incorporating assessment data for risk adjustment before using this measure to assess performance across settings.
Response: We thank the commenter for the detailed recommendations to inform our efforts to develop a valid, reliable, and usable measure of Discharge to Community and Medicare Spending per Beneficiary measure for PAC settings. We agree with the commenter’s suggestion that we consider differences across PAC providers, and the implications of those differences on measure specifications and intend to do so in our development of these two measures, as well as for all future measures. We are at early stages of development of these measures and appreciate this commenter’s timely inputs to inform our measure development processes. We remain committed to employing an environmental scan and engaging a TEP to identify findings from prior work for the LTCH setting as well as other PAC settings to inform our development of resource use measures, including the development of the MSPB measure and the Discharge to Community measure, for the LTCH setting and other PAC settings in order to meet the requirements of the IMPACT Act. We also remain committed to following the same rigorous measure development process as the other publicly reported measures included in our current Quality Reporting Programs and will involve extensive input by stakeholders and clinical experts as well as follow the same scientific approach to evaluate this measure prior to public reporting to ensure meaningful and valid comparisons across settings.

Comment: One commenter encouraged CMS to consider implementing palliative care-related measures into the LTCH QRP. The commenter suggested that priority should be given to NQF-endorsed palliative care measures that address pain, dyspnea, patient values and goals, and care direction and coordination. The commenter noted that
existing measures should be revisited and expanded to include a broader population of sick patients across healthcare settings. The commenter also urged CMS to drive the development of patient-centered measures for shared accountability for care coordination through transitions, advance care planning and goals of care conversations and structural/process measures related to access to quality palliative care, utilization of quality of palliative care, and integration/continuity of palliative care across settings.

Another commenter recommended the implementation of a malnutrition quality measure because malnutrition is a patient safety issue which can negatively impact patient outcomes across healthcare settings. The commenter noted that early identification of patients at-risk for malnutrition, prompt nutrition intervention, and implementation of a care plan for patients diagnosed as malnourished or at-risk for malnutrition are critical to improve outcomes and patient safety by reducing complications, such as infections, falls, and pressure ulcers.

Response: We thank the commenters for the comments and suggestions and will take these into consideration as we develop future measures for the LTCH QRP and other quality reporting programs. We agree with the commenter’s recommendation and rationale for consideration of malnutrition is an important quality measure concept for the LTCH setting. Further, we agree that palliative care-related measures could be considered for the LTCH QRP and will examine the applicability, usability, feasibility, validity and reliability of existing quality measures and need for new measures of palliative care for the LTCH QRP.
Comment: One commenter noted additional areas of function that are key to patients, including cognition, communication, and swallowing. The commenter encouraged CMS to consider cognition and expressive and receptive language and swallowing as items of function, and offered its expertise to CMS for discussions and to develop goals. The commenter recommended that CMS engage stakeholders to develop future outcome measures in the area of cognitive function.

Response: We thank the commenter for its suggestions and expertise to inform our measure development efforts. We agree that future development of outcome measures should include other areas of function, such as cognition, communication, and swallowing, are important aspects of functional assessment and improvement for patients who receive care in PAC settings, including LTCHs. We will continue to engage stakeholders as we develop and implement quality measures to meet the requirements of the IMPACT Act. We will take these quality measure concepts into consideration for future measure selections and measure development activities for the LTCH QRP.

We thank the commenters for their views and we will consider them as we develop future measures and future proposals.

9. Form, Manner, and Timing of Quality Data Submission for the FY 2016 Payment Determination and Subsequent Years

a. Background

Section 1886(m)(5)(C) of the Act requires that, for the FY 2014 payment determination and subsequent years, each LTCH submit to the Secretary data on quality measures specified by the Secretary. In addition, section 1886(m)(5)(F) of the Act
requires that, for the fiscal year beginning on the specified application date, as defined in section 1899B of the Act, and each subsequent year, each LTCH submit to the Secretary data on measures specified by the Secretary under section 1899B of the Act. The data required under section 1886(m)(5)(C) and (F) of the Act must be submitted in a form and manner, and at a time, specified by the Secretary. As required by section 1886(m)(5)(A)(i) of the Act, for any LTCH that does not submit data in accordance with section 1886(m)(5)(C) of the Act with respect to a given rate year, any annual update to the standard Federal rate for discharges for the LTCH during the rate year must be reduced by 2 percentage points.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50857 through 50861 and 50878 through 50881), we finalized the data submission timelines and submission deadlines for measures for the FY 2016 and FY 2017 payment determinations. We refer readers to the FY 2014 IPPS/LTCH PPS final rule for a more detailed discussion of these timelines and deadlines. Specifically, we refer readers to the table at 78 FR 50878 of the FY 2014 IPPS/LTCH PPS final rule for the data collection period and submission deadlines for the FY 2016 payment determination and the tables at 78 FR 50881 of that final rule for the data collection timelines and submission deadlines for the FY 2017 payment determination.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50307 through 50311), we:

- Revised the previously adopted data collection period and submission deadlines for the Percent of Residents or Patients Who Were Assessed and Appropriately
Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) measure for the FY 2016 payment determination and subsequent years;

- Adopted data submission mechanisms for the FY 2018 payment determination and subsequent years for new LTCH QRP quality measures and for revisions to previously adopted quality measures;
- Adopted data collection periods and submission deadlines for certain measures under the LTCH QRP for the FY 2018 payment determination;
- Revised data collection timelines and submission deadlines for the application of the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) measure for the FY 2018 payment determination and subsequent years; and
- Adopted data collection timelines and submission deadlines under the LTCH QRP for the FY 2019 payment determination and subsequent years.

b. Timing for New LTCHs to Begin Reporting Data to CMS for the FY 2017 Payment Determination and Subsequent Years

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24606), beginning with the FY 2017 payment determination, we proposed that a new LTCH be required to begin reporting quality data under the LTCH QRP by no later than the first day of the calendar quarter subsequent to 30 days after the date on its (CCN) notification letter. For example, if an LTCH’s CCN notification letter is dated March 15, then the LTCH would be required to begin reporting quality data to CMS beginning on July 1 (March 15 + 30 days = April 14 (quarter 2)). The LTCH would be required to begin collecting quality data on
the first day of the quarter subsequent to quarter 2, which is quarter 3, or July 1. The collection of quality data would begin on the first day of the calendar year quarter identified as the start date, and would include all LTCH admissions and subsequent discharges beginning on, and subsequent to, that day; however, submission of quality data would be required by previously finalized or newly proposed quarterly deadlines.

In order to determine which quality measure data an LTCH would need to begin submitting, we refer readers to section VIII.C.9.c. of the preamble of this final rule, below, as it will vary depending upon the timing of the CY quarter identified as a start date. We also proposed to codify this requirement for the timing of new LTCHs to begin reporting for purposes of the LTCH QRP at new proposed § 412.560(a). We invited public comment on our proposals to add and codify this requirement for the timing of new LTCHs to begin reporting for purposes of the LTCH QRP.

We did not receive any public comments on these proposals. Therefore, we are finalizing our proposals regarding the timing for new LTCHs to being reporting quality data under the LTCH QRP for the FY 2017 payment determination and subsequent years.

c. Revisions to Previously Adopted Data Submission Timelines Under the LTCH QRP for the FY 2017 and FY 2018 Payment Determinations and Subsequent Years and Proposed Data Collection and Data Submission Timelines for Quality Measures Finalized in this Final Rule

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53636 through 53637), we finalized new quarterly quality data submission deadlines for LTCHs. We contracted the deadlines from the original 4.5-months post-CY quarter submission deadlines, to
1.5 months (approximately 45 days) deadlines. In order to align the data submission and correction deadlines with the IRF QRP and Hospital IQR Program as we near public reporting, and to meet the requirements of the IMPACT Act, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24606 through 24608), we proposed to revise the data submission and correction deadlines for quality measures previously adopted for the LTCH QRP for the FY 2017 and FY 2018 payment determinations and subsequent years.

We proposed to adopt new deadlines that allow 4.5 months (approximately 135 days) after the end of each calendar year quarter for quality data submission, beginning with quarter 4 2015 (October 2015 through December 2015). Under this new policy, LTCHs will have approximately 135 days following the end of each calendar year quarter, during which to submit, review, and correct their quality data for that CY quarter. We also proposed data collection and data submission timelines for quality measures that we proposed for the FY 2018 payment determination and subsequent years. Further, for the measures proposed in the proposed rule, and finalized within this final rule—Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678), the application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674), and the application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015)—we proposed that the data collection and data submission timelines align with the proposed data collection and data submission timelines for each respective measure starting with April 1, 2016. Because the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from
LTCHs (NQF #2512) is a Medicare FFS claims-based measure, the data collection and submission timelines are not applicable to this measure. In addition, we note that upon further consideration of how this policy affects the required reporting of quality measures under the LTCH QRP, that the application of this extended deadline to the measure Influenza Vaccination Coverage Among Healthcare Personnel (NQF # 0431), is not feasible. Data for this measure is only collected between the dates of October 1st and March 31st, and is only required to be submitted to CMS via the CDC’s NHSN once per year. Allowing the extended deadline of 135 days beyond the end of the data collection period for this measure would not allow the application of the appropriate FY APU determination, as previously finalized. Because of this, we are finalizing this policy with the exception of its application to the measures Influenza Vaccination Coverage Among Healthcare Personnel (NQF # 0431).

The tables below present the data collection period and data submission timelines for quality measures affecting the FY 2017 payment determination, as well as the revisions to the data collection period and data submission timelines for quality measures for the FY 2018 payment determination and subsequent years.

We would like to note that the tables below, as displayed in the proposed rule, contained technical errors with respect to the measure Influenza Vaccination Coverage Among Healthcare Personnel (NQF # 0431). In the FY 2016 IPPS/LTCH PPS proposed rule, we accidentally omitted this measure from the first table below, which refers to measures affecting the FY 2017 payment determination. We have added this measure (NQF #0431) back to the first table below, including the correct submission deadlines, as they
related to our decision to refrain from applying this policy to this measure. In the proposed rule we also listed the data submission deadlines as they pertain to this same measure (NQF #0431) related to the FY 2018 payment determination and subsequent years, but note that the data submission deadlines in table two have been corrected to reflect our decision to finalize this policy with exception of this measure.
<table>
<thead>
<tr>
<th>Quality Measure</th>
<th>NQF ID#</th>
<th>Submission Method</th>
<th>Data Collection Period</th>
<th>Proposed Data Submission Deadlines</th>
<th>APU Determination Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay)</td>
<td>#0678</td>
<td>LTCH CARE Data Set/QIES ASAP system</td>
<td>Q1: 1/1/15-3/31/15 Q2: 4/1/15-6/30/15 Q3: 7/1/15-9/30/15 Q4: 10/01/15-12/31/15</td>
<td>5/15/15 (Q1) 8/15/15 (Q2) 11/15/15 (Q3) Finalized in this final rule: 5/15/16 (Q4)</td>
<td>FY 2017</td>
</tr>
<tr>
<td>NHSN Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
<td>#0138</td>
<td>CDC NHSN</td>
<td>Q1: 1/1/15-3/31/15 Q2: 4/1/15-6/30/15 Q3: 7/1/15-9/30/15 Q4: 10/01/15-12/31/15</td>
<td>5/15/15 (Q1) 8/15/15 (Q2) 11/15/15 (Q3) Finalized in this final rule: 5/15/16 (Q4)</td>
<td>FY 2017</td>
</tr>
<tr>
<td>NHSN Central-Line Associated Bloodstream Infections (CLABSI) Outcome Measure</td>
<td>#0139</td>
<td>CDC NHSN</td>
<td>Q1: 1/1/15-3/31/15 Q2: 4/1/15-6/30/15 Q3: 7/1/15-9/30/15 Q4: 10/01/15-12/31/15</td>
<td>5/15/15 (Q1) 8/15/15 (Q2) 11/15/15 (Q3) Finalized in this final rule: 5/15/16 (Q4)</td>
<td>FY 2017</td>
</tr>
<tr>
<td>NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) Bacteremia Outcome Measure</td>
<td>#1716</td>
<td>CDC NHSN</td>
<td>Q1: 1/1/15-3/31/15 Q2: 4/1/15-6/30/15 Q3: 7/1/15-9/30/15 Q4: 10/01/15-12/31/15</td>
<td>5/15/15 (Q1) 8/15/15 (Q2) 11/15/15 (Q3) Finalized in this final rule: 5/15/16 (Q4)</td>
<td>FY 2017</td>
</tr>
<tr>
<td>NHSN Facility-wide Inpatient Hospital-onset <em>Clostridium difficile</em> Infection (CDI) Outcome Measure</td>
<td>#1717</td>
<td>CDC NHSN</td>
<td>Q1: 1/1/15-3/31/15 Q2: 4/1/15-6/30/15 Q3: 7/1/15-9/30/15 Q4: 10/01/15-12/31/15</td>
<td>5/15/15 (Q1) 8/15/15 (Q2) 11/15/15 (Q3) Finalized in this final rule: 5/15/16 (Q4)</td>
<td>FY 2017</td>
</tr>
</tbody>
</table>
### Details on Data Collection Period and Data Submission Timeline for Quality Measures Affecting the FY 2017 Payment Determination

<table>
<thead>
<tr>
<th>Quality Measure</th>
<th>NQF ID#</th>
<th>Submission Method</th>
<th>Data Collection Period</th>
<th>Proposed Data Submission Deadlines</th>
<th>APU Determination Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza Vaccination Coverage Among Healthcare Personnel</td>
<td>#0431</td>
<td>CDC NHSN</td>
<td>10/1/15 (or when vaccine becomes available)-3/31/16</td>
<td>5/15/16 **</td>
<td>FY 2017**</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td>10/1 (or when vaccine becomes available)-3/31</td>
<td>5/15 for subsequent years</td>
<td>Subsequent Years</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from Long-Term Care Hospitals*</td>
<td>#2512</td>
<td>Medicare FFS Claims Data</td>
<td>N/A</td>
<td>N/A</td>
<td>For future public reporting</td>
</tr>
</tbody>
</table>

* This measure will not be used in determining compliance for the LTCH QRP because it is a claims-based measure and LTCHs do not report additional data to CMS.

** We are finalizing the proposed policy to extend the current quarterly data submission deadlines from 45 days to 135 days with the exception of this quality measure. We refer readers to section VIII.C.9.c. of the preamble of this final rule for further information.

### Details on Data Collection and Submission Timeline for Quality Measures Affecting the FY 2018 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>Quality Measure</th>
<th>NQF ID#</th>
<th>Submission Method</th>
<th>Data Collection Period</th>
<th>Proposed Data Submission Deadlines</th>
<th>APU Determination Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay)</td>
<td>#0678</td>
<td>LTCH CARE Data Set/QIES ASAP system</td>
<td>Q1: 1/1/16-3/31/16 Q2: 4/1/16-6/30/16 Q3: 7/1/2016-9/30/16 Q4: 10/01/16-12/31/16</td>
<td>8/15/16 (Q1) 11/15/16 (Q2) 2/15/17 (Q3) 5/15/17 (Q4)</td>
<td>FY 2018 and Subsequent Years</td>
</tr>
<tr>
<td>NHSN Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
<td>#0138</td>
<td>CDC NHSN</td>
<td>Quarterly for each</td>
<td> </td>
<td> </td>
</tr>
</tbody>
</table>
# Details on Data Collection and Submission Timeline for Quality Measures Affecting the FY 2018 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>Quality Measure</th>
<th>NQF ID#</th>
<th>Submission Method</th>
<th>Data Collection Period</th>
<th>Proposed Data Submission Deadlines</th>
<th>APU Determination Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHSN Central-Line Associated Bloodstream Infections (CLABSI) Outcome Measure</td>
<td>#0139</td>
<td></td>
<td>subsequent calendar year</td>
<td>Approximately 135 days after the end of each quarter</td>
<td></td>
</tr>
<tr>
<td>NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) Bacteremia Outcome Measure</td>
<td>#1716</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHSN Facility-wide Inpatient Hospital-onset <em>Clostridium difficile</em> Infection (CDI) Outcome Measure</td>
<td>#1717</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine</td>
<td>#0680</td>
<td>LTCH CARE Data Set/QIES ASAP system</td>
<td>10/1/15-12/31/15 1/1/16-3/31/16 10/1-12/31 1/1-3/31 for subsequent years</td>
<td>5/15/16 8/15/16 5/15 8/15 for subsequent years</td>
<td>FY 2018 Subsequent Years</td>
</tr>
<tr>
<td>Influenza Vaccination Coverage Among Healthcare Personnel</td>
<td>#0431</td>
<td>CDC NHSN</td>
<td>10/1/16 (or when vaccine becomes available)-3/31/17 10/1 (or when vaccine becomes available)-3/31</td>
<td>5/15/17** 5/15 for subsequent years</td>
<td>FY 2018** Subsequent Years</td>
</tr>
<tr>
<td>All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from Long Term Care Hospitals*</td>
<td>#2512</td>
<td>Medicare FFS Claims Data</td>
<td>N/A</td>
<td>N/A</td>
<td>For future public reporting</td>
</tr>
</tbody>
</table>
### Details on Data Collection and Submission Timeline for Quality Measures Affecting the FY 2018 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>Quality Measure</th>
<th>NQF ID#</th>
<th>Submission Method</th>
<th>Data Collection Period</th>
<th>Proposed Data Submission Deadlines</th>
<th>APU Determination Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay)</td>
<td>#0674</td>
<td>LTCH CARE Data Set/QIES ASAP system</td>
<td>4/1/16-6/30/16 7/1/16-9/30/16 10/1/16-12/31/16</td>
<td>11/15/16 (Q2) 2/15/17 (Q3) 5/15/17 (Q4)</td>
<td>FY 2018</td>
</tr>
<tr>
<td>Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function</td>
<td>#2631 (endorsed on 07/23/2015)</td>
<td>quarterly for each subsequent calendar year</td>
<td>Quarterly for each subsequent calendar year</td>
<td>Quarterly approximately 135 days after the end of each quarter for subsequent years</td>
<td>Subsequent Years</td>
</tr>
<tr>
<td>Functional Status Outcome Measure: Change in Mobility Among Long-Term Care Hospital Patients Requiring Ventilator Support</td>
<td>#2632 (endorsed on 7/23/2015)</td>
<td>quarterly for each subsequent calendar year</td>
<td>Quarterly for each subsequent calendar year</td>
<td>Quarterly approximately 135 days after the end of each quarter for subsequent years</td>
<td>Subsequent Years</td>
</tr>
</tbody>
</table>
### Details on Data Collection and Submission Timeline for Quality Measures Affecting the FY 2018 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>Quality Measure</th>
<th>NQF ID#</th>
<th>Submission Method</th>
<th>Data Collection Period</th>
<th>Proposed Data Submission Deadlines</th>
<th>APU Determination Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventilator Associated Event</td>
<td>N/A</td>
<td>CDC NHSN</td>
<td>1/1/16-3/31/16 4/1/16-6/30/16 7/1/16-9/30/16 10/1/16-12/31/16</td>
<td>8/15/16 (Q1) 11/15/16 (Q2) 2/15/17 (Q3) 5/15/17 (Q4)</td>
<td>FY 2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Quarterly for each subsequent calendar year</td>
<td>Quarterly approximately 135 days after the end of each quarter for each subsequent year</td>
<td>Subsequent Years</td>
</tr>
<tr>
<td>Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function</td>
<td>#2631 (endorsed on 7/23/2015)</td>
<td>LTCH CARE Data Set/QIES ASAP system</td>
<td>4/1/16-6/30/16 7/1/16-9/30/16 10/1/16-12/31/16</td>
<td>11/15/16 (Q2) 2/15/17 (Q3) 5/15/17 (Q4)</td>
<td>FY 2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Quarterly for each subsequent calendar year</td>
<td>Quarterly approximately 135 days after the end of each quarter for subsequent years</td>
<td>Subsequent Years</td>
</tr>
</tbody>
</table>
### Details on Data Collection and Submission Timeline for Quality Measures Affecting the FY 2018 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>Quality Measure</th>
<th>NQF ID#</th>
<th>Submission Method</th>
<th>Data Collection Period</th>
<th>Proposed Data Submission Deadlines</th>
<th>APU Determination Affected</th>
</tr>
</thead>
</table>

* This measure will not be used in determining compliance for the LTCH QRP because it is a claims-based measure and LTCHs do not report additional data to CMS.

** We are finalizing the proposed policy to extend the current quarterly data submission deadlines from 45 days to 135 days with the exception of this quality measure. We refer readers to section VIII.C.9.c of the preamble of this final rule for further information.
We invited public comments on our proposals.

Comment: Several commenters supported the proposal to extend the data submission timeframes for the LTCH QRP measures from 45 days (1.5 months) to 4.5 months (approximately 135 days) from the end of a calendar year quarter for the FY 2017 and FY 2018 payment determinations and subsequent years. The commenters agreed that this change would align data submission and correction deadlines with other quality reporting programs and facilitate public reporting.

Response: We appreciate commenters’ support of this proposal.

After consideration of the public comments we received, we are finalizing our proposal to revise the data submission and correction timelines for the FY 2017 and FY 2018 payment determinations and subsequent years for all measures except the Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431). For the reasons stated above, for the measure Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431), we are retaining previously finalized data submission timelines for the FY 2017 and FY 2018 payment determinations and subsequent years. We refer readers to FY 2014 IPPS/LTCH PPS final rule (78 FR 50858 through 50858) for data submission deadlines for FY 2017 payment determination for the Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431). We refer readers to FY 2014 IPPS/LTCH PPS final rule (78 FR 50882 through 50883) for data submission deadlines for FY 2018 payment determination for the Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431). We refer readers to FY 2015 IPPS/LTCH PPS final
rule ((79 FR 50311)) for data submission deadlines for FY 2019 payment determination for the Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431).

10. Previously Adopted LTCH QRP Data Completion Thresholds for the FY 2016 Payment Determination and Subsequent Years

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50311 through 50314), we finalized specific LTCH QRP thresholds for completeness of LTCH data submissions. To ensure that LTCHs are meeting an acceptable standard for completeness of submitted data, we finalized the policy that, beginning with the FY 2016 payment determination and for each subsequent year, LTCHs must meet or exceed two separate data completeness thresholds: one threshold set at 80 percent for completion of quality measures data collected using the LTCH CARE Data Set and submitted through the QIES ASAP system; and a second threshold set at 100 percent for quality measures data collected and submitted using the CDC NHSN.

In addition, we stated that we would apply the same thresholds to all measures adopted as the LTCH QRP expands and LTCHs report data on the finalized measure sets. That is, as we finalize new measures through the regulatory process, LTCHs will be held accountable for meeting the previously finalized data completion threshold requirements for each measure until such time that updated threshold requirements are proposed and finalized through a subsequent regulatory cycle.

Further, we finalized the requirement that a LTCH must meet or exceed both thresholds in order to avoid receiving a 2-percentage point reduction to their annual payment update for a given fiscal year, beginning with FY 2016 and for all subsequent
payment updates. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24608), we did not propose any changes to these policies. We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50311 through 50314) for a detailed discussion of the finalized data completion requirements of the LTCH QRP.

11. Future LTCH QRP Data Validation Process

Historically, we have built consistency and internal validation checks into our data submission specifications to ensure that the data elements of the LTCH CARE Data Set assessments conform to requirements such as proper format and facility information. These internal consistency checks are automated and occur during the LTCH data entry and submission process, and help ensure the integrity of the data submitted by LTCHs by rejecting submissions or issuing warnings when LTCH data contain logical inconsistencies. These internal consistency checks are referred to as “system edits” and are further outlined in the LTCH Data Submission Specifications version 1.01, which are available for download on the LTCH Quality Reporting Technical Information Web page at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCHTechnicalInformation.html.

Validation is intended to provide added assurance of the accuracy of the data that will be reported to the public as required by sections 1886(m)(5)(E) and 1899B(g) of the Act. In the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28275 through 28276), we proposed, for the FY 2016 payment determination and subsequent years, to validate the data elements submitted to CMS for quality purposes. We also proposed policies
regarding the application of the 2-percentage point reduction for LTCHs that failed to meet the data accuracy threshold.

However, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50314 through 50316), we decided to further explore suggestions from commenters before finalizing the LTCH data validation process that we proposed. Therefore, we did not finalize the data validation proposals.

At this time, we are continuing to explore data accuracy validation methods and threshold policies that will limit the amount of burden and cost to LTCHs, while allowing us to establish estimations of the accuracy of LTCH QRP data. Therefore, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24608), we did not propose any new policies related to data accuracy validation, but we plan to do so in future rulemaking cycles.

While we did not solicit comments specifically regarding our policies related to data accuracy validation, we received a comment, which we summarize and respond to below.

Comment: One commenter supported CMS’ decision to continue to explore data validation methods that take provider burden into account.

Response: We thank the commenter for its support. We will take this comment into consideration in future rulemaking.

12. Public Display of Quality Measure Data for the LTCH QRP

Section 1886(m)(5)(E) of the Act requires the Secretary to establish procedures for making the LTCH QRP data available to the public. In so doing, the Secretary must
ensure that LTCHs have the opportunity to review any such data with respect to the LTCH prior to its release to the public. Section 1899B(g) of the Act requires the Secretary to establish procedures for making available to the public information regarding the performance of individual PAC providers with respect to the measures required under section 1899B of the Act beginning not later than 2 years after the applicable specified application date. The procedures must ensure, including through a process consistent with the process applied under section 1886(b)(3)(B)(viii)(VII) of the Act for similar purposes, that each PAC provider has the opportunity to review and submit corrections to the data and information that are to be made public with respect to the PAC provider prior to such data being made public.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24608 through 24610), we proposed to display performance data related to the LTCH QRP quality measures, as applicable, required by the LTCH QRP by fall 2016 on a CMS Web site, such as the Hospital Compare Web site (http://www.hospitalcompare.hhs.gov), after a 30-day preview period. Additional information about preview report content and delivery will be announced on the LTCH QRP Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/index.html.

LTCHs would be notified via CMS listservs, CMS mass e-mails and memorandums, LTCH QRP Web site announcements and Medicare Learning Network announcements regarding the release of preview reports, as well as the timing of the posting of provider data.
The Hospital Compare Web site is an interactive Web tool that assists beneficiaries by providing information on hospital quality of care to those who need to select a hospital. It further serves to encourage beneficiaries to work with their hospital to discuss the quality of care provided to patients, thereby providing an additional incentive to hospitals to improve the quality of care that they furnish. As we have done on some of the other CMS Compare Web sites, we will, at some point in the future, report public data using a quality rating system that gives each LTCH a rating of between one and five stars. Initially, however, we will not use the 5-star methodology, until such time that we are publicly reporting a sufficient number of quality metrics to allow for variation and the differentiation among LTCHs using this methodology. Decisions regarding how the rating system will determine an LTCH’s star rating and methods used for calculations, as well as a proposed timeline for implementation, will be announced via regular LTCH communication channels, including listening sessions, memos, email notification, provider association calls, open door forums, and Web postings.

The initial display of information would contain performance data on four quality measures: (1) NHSN CAUTI Outcome Measure (NQF #0138); (2) NHSN CLABSI Outcome Measure (NQF #0139); (3) Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678); and (4) All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512). We proposed to publicly report data beginning with data collected on these measures for the first quarter of 2015, or discharges beginning January 1, 2015, with exception of the All-Cause Unplanned Readmission Measure for 30 Days
Post-Discharge from LTCHs (NQF #2512). Rates would be displayed based on four (4) rolling quarters of data and would use discharges from January 1, 2015 through December 31, 2015 (CY 2015), for calculation, with exception of the measure All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512). With respect to LTCH performance related to the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512), proposed to publicly report readmission rates beginning with Medicare FFS claims data for patient discharges starting with January 1, 2013. Readmission rates will be calculated using Medicare FFS claims data for two consecutive years (for example, readmission rates will be calculated using Medicare FFS claims data for January 1, 2013 through December 31, 2014 (CY 2013 and CY 2014)) and displayed on a calendar year basis.

Calculations for the CAUTI and CLABSI measures adjust for differences in the characteristics of hospitals and patients using a Standardized Infection Ratio (SIR). The SIR is a summary measure that takes into account differences in the types of patients that a hospital treats. The SIR may take into account the type of patient care location, laboratory methods, hospital affiliation with a medical school, bed size of the hospital, patient age, and American Society of Anesthesiologists’ classification of physical health. It compares the actual number of HAIs in a facility or State to a national benchmark based on previous years of reported data and adjusts the data based on several factors. A confidence interval with a lower and upper limit is displayed around each SIR to indicate that there is a high degree of confidence that the true value of the SIR lies within that interval. A SIR with a lower limit that is greater than 1.0 means that there were more
HAIs in a facility or State than were predicted, and the facility is classified as “Worse than the U.S. National Benchmark.” If the SIR has an upper limit that is less than 1, the facility had fewer HAIs than were predicted and is classified as “Better than the U.S. National Benchmark.” If the confidence interval includes the value of 1, there is no statistical difference between the actual number of HAIs and the number predicted, and the facility is classified as “No Different than U.S. National Benchmark.” If the number of predicted infections is less than 1, the SIR and confidence interval cannot be calculated.

Calculations for the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (NQF #0678) would be risk-adjusted. Resident- or patient-level covariate risk adjustment is performed. Resident- or patient-level covariates are used in a logistic regression model to calculate a resident- or patient-level expected quality measure (QM) score (the probability that the resident or patient will evidence the outcome, given the presence or absence of patient characteristics measured by the covariates). Then, an average of all resident- or patient-level expected QM scores for the facility is calculated to create a facility-level expected QM score. The final facility-level adjusted QM score is based on a calculation which combines the facility-level expected score and the facility level observed score. Additional information about the covariates can be found at: http://www.qualityforum.org/QPS/0678.

Finally, calculation for performance on the measure All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) will also be risk-adjusted. The risk adjustment methodology is available, along with the

We are currently developing reports that will allow providers to view the data that is submitted to CMS via the QIES ASAP system and the CDC’s NHSN (Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678), the NHSN CAUTI Outcome Measure (NQF #0138) and the NHSN CLABSI Outcome Measure (NQF #0139), respectively). These reports, although not initially, will also include provider performance on any currently reported quality measure that is calculated based on CMS claims data that we plan on publicly reporting (All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512)). Although real time results will not be available, the report will refresh all of the data submitted at least once a month.

We proposed a process to give providers an opportunity to review and correct data submitted to the QIES ASAP system or to the CDC’s NHSN by utilizing that report. Under this proposed process, providers would have the opportunity to review and correct data they submit on all assessment-based measures. Providers can begin submitting data on the first admission of any reporting quarter. Providers are encouraged to submit data early in the submission schedule so that they can identify errors and resubmit data before the quarterly submission deadline. The data would be populated into reports that are updated at least once a month with all data that have been submitted.
That report would contain the provider’s performance on each measure calculated based on assessment submissions to the QIES ASAP system or CDC NHSN. We believe that the submission deadline timeframe, which we proposed in the proposed rule to extend from the current 1.5 month policy to 4.5 months beyond the end of each calendar year quarter, is sufficient time for providers to be able to submit, review data, make corrections to the data, and view their data. We proposed that once the provider has an opportunity to review and correct quarterly data related to measures submitted via the QIES ASAP system or CDC NHSN, we would consider the provider to have been given the opportunity to review and correct this data. We would not allow patient-level data correction after the submission deadline or for previous years. This is because we must set a deadline to ensure timely computation of measure rates and payment adjustment factors. Before we display this information, providers will be permitted 30 days to review their information as recorded in the QIES ASAP system or CDC NHSN.

We invited public comment on these proposals.

Comment: Several commenters supported the proposal to publicly report LTCH quality data beginning in fall 2016, although some urged that CMS allow for correction of LTCH data during the 30-day preview period. Other commenters supported the proposal but recommended that CMS set up a separate LTCH Compare Web site so that LTCHs are only compared to other LTCHs and the public can make an informed comparison without unnecessary confusion.

Response: We thank the commenters for their comments and support of our proposal to publicly report LTCH quality data beginning in fall 2016. In our proposal we
note that we have extended the post-calendar year (CY) quarter submission deadlines from the current 45 days beyond the end of each quarter to 135 days beyond the end of each quarter. We believe that this timeframe allows LTCHs sufficient time to submit, review, and correct their data prior to public reporting of that data. We have designed and will be issuing provider reports immediately following the end of each CY quarter, which will allow LTCHs to see the data they have submitted to CMS to date. LTCHs will then have the additional 135 days beyond the end of each CY quarter to correct any data they feel has been submitted in error, or is missing. While many LTCHs use the current post-CY quarter timeframe as an extended submission timeframe, the original intent of the post-CY quarter timeframe was to allow LTCHs to review and correct any data they had submitted for that particular CY quarter.

We have continually urged LTCHs to submit their quality data as soon as possible, thus allowing ample time for review and correction. We will not allow any correction of patient-level data during the 30-day preview period. We will issue a preview report at the beginning of this period that contains provider performance data, and LTCHs will have 30 days during which to refute any quality measure calculations they feel have been made in error. This policy aligns with that of the Hospital IQR Program and the IRF QRP. Allowing for patient level data correction at this time would have the effect of negating our data submission deadlines.

Regarding the comment that we should develop a separate LTCH Compare Web site, as opposed to posting LTCH QRP performance data on Hospital Compare, we would like to clarify that should we choose to post this data on Hospital Compare, it
would be under its own separate tab/Web page, and would be clearly separate from acute care hospital data. Because we have not made any final decision regarding this issue, we will take this comment into consideration as we move forward with the development of the Web site.

After consideration of the public comments we received, we are finalizing our proposals to display performance data for the quality beginning in fall 2016 on a CMS Web site, such as the Hospital Compare Web site (http://www.hospitalcompare.hhs.gov), after a 30-day preview period, and to give providers an opportunity to review and correct data submitted to the QIES ASAP system or to the CDC NHSN.

In addition to our proposal to publicly display LTCH performance data on the required quality measures under the LTCH QRP, we also proposed to publish a list of LTCHs that successfully meet the reporting requirements for the applicable payment determination on the LTCH QRP Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/. We proposed to update the list after reconsideration requests are processed on an annual basis. We proposed to codify the policy to publish a list of compliant LTCHs on the LTCH QRP Web site at new proposed § 412.560(d)(3).

We invited public comment on these proposals.

We did not receive any public comments on our proposals to publish a list of LTCHs that successfully meet the reporting requirements for each applicable payment determination on the LTCH QRP Web site, update the list after reconsideration requests are processed on an annual basis, and codify the policy to publish a list of compliant
LTCHs on the LTCH QRP Web site at new proposed § 412.560(d)(3). Therefore, we are finalizing these proposals.

13. Previously Adopted and Finalized LTCH QRP Reconsideration and Appeals Procedures for the FY 2017 Payment Determination and Subsequent Years

At the conclusion of each fiscal year reporting cycle, we review the data received from each LTCH to determine if the LTCH met the reporting requirements set forth for that reporting cycle. LTCHs that are found to be noncompliant will receive a reduction in the amount of 2 percentage points to their annual payment update for the applicable fiscal year. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50317 through 50318), we described and adopted an updated process that enables an LTCH to request a reconsideration of our initial noncompliance decision in the event that an LTCH believes that it was incorrectly identified as being subject to the 2-percentage point reduction to its annual payment due to noncompliance with the LTCH QRP reporting requirements for a given reporting period.

We are clarifying that any LTCH that wishes to submit a reconsideration request must do so by submitting an email to CMS containing all of the requirements listed on the LTCH QRP Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Reconsideration-and-Exception-and-Extension.html. Email sent to LTCHQRPReconsiderations@cms.hhs.gov is the only form of submission that will be accepted from an LTCH provider requesting reconsideration. Any reconsideration
requests received through another channel, including the U.S. Postal Service (USPS) or telephone, will not be considered as a valid reconsideration request.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24610 through 24611), we proposed to continue using the LTCH QRP reconsideration and appeals procedures that were adopted in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50317 through 50318) and that have been posted on the LTCH QRP Web site for the FY 2017 payment determination and subsequent years, with an exception regarding the way in which noncompliant LTCHs are notified of this determination.

Previously, only LTCHs found to be noncompliant with the reporting requirements set forth for a given payment determination received a notification of this finding along with instructions for requesting reconsideration in the form of a certified letter via the USPS. In an effort to communicate as quickly, efficiently, and broadly as possible with LTCHs regarding annual compliance, we proposed changes to our communications method regarding annual notification of reporting compliance in the LTCH QRP. In addition to sending a letter via regular USPS mail, beginning with the FY 2016 payment determination and for subsequent fiscal years, we proposed the QIES ASAP system as a mechanism to communicate to LTCHs regarding their compliance with the reporting requirements for the given reporting cycle.

We note that all LTCHs have been required to use the QIES ASAP system in order to report on required LTCH QRP measures since October 1, 2012. Therefore, we proposed that all Medicare-certified LTCH compliance letters be uploaded into the QIES ASAP system for each LTCH to access. Instructions to download files from QIES ASAP
system may be found on the Web site at: https://www.qtso.com/LTCH.html. We proposed to disseminate communications regarding the availability of compliance reports in LTCHs’ QIES ASAP system files through routine channels to LTCHs and vendors, including, but not limited to, issuing memos, emails, Medicare Learning Network announcements, and notices on the LTCH QRP Web site at:

The purpose of the compliance letter is to notify an LTCH that it has been identified as either being compliant or noncompliant with the LTCH QRP reporting requirements for the given reporting cycle. If the LTCH is determined to be noncompliant, the notification would indicate that the LTCH is scheduled to receive a 2 percentage point reduction to its upcoming annual payment update and that it may file a reconsideration request if it disagrees with this finding. LTCHs may request a reconsideration of a noncompliance determination through the CMS reconsideration request process.

We also proposed that the notification of our decision regarding received reconsideration requests will be made available through the QIES ASAP system. We did not propose to change the process or requirements for requesting reconsideration, and we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50317 through 50318) for a discussion of the LTCH QRP reconsideration and appeals procedures.

We also proposed to publish a list of LTCHs that successfully meet the reporting requirements for the applicable payment determination on the LTCH QRP Web site at:
We proposed updating the list after reconsideration requests are processed on an annual basis.

We proposed to codify the LTCH QRP reconsideration and appeal procedures at new proposed §§ 412.560(d) and (e).

We invited public comment on the proposals to change the communication mechanism to the QIES ASAP system for the dissemination of compliance notifications and reconsideration decisions, to publish a list of compliant LTCHs on the LTCH QRP Web site, and to codify these processes at new proposed §§ 412.560(d)(1) and (d)(3).

Comment: A few commenters supported the proposal to codify the reconsideration and appeals policy, although stated that CMS should clarify the exact requirements LTCHs need to meet to be in compliance with the LTCH QRP.

Response: We thank the commenters for their comments and support. While we appreciate the commenters’ concern that the requirements be listed in one place, we note that the reconsideration and appeals policy will be codified and that additional technical details will be listed on our LTCH QRP Web site, on which we post guidance documents that are updated regularly. LTCHs can access the CMS LTCH QRP Web site at http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/index.html?redirect=/LTCH-Quality-Reporting/.

After consideration of the public comments we received, we are finalizing our proposals to change the communication mechanism to the QIES system for the dissemination of compliance notifications and reconsideration decisions, to publish a list
of compliant LTCHs on the LTCH QRP Web site, to update the list after reconsideration requests are processed on an annual basis, and to codify the requirements for reconsideration and appeals, as proposed.

14. Previously Adopted and Proposed LTCH QRP Submission Exception and Extension Requirements for the FY 2017 Payment Determination and Subsequent Years

We refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50883 through 50885) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50316 through 50317) for a detailed discussion of the LTCH QRP Submission Exception and Extension requirements. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24611), for the FY 2017 payment determination and subsequent years, we did not propose any changes to the LTCH QRP requirements that we adopted in these final rules. However, we proposed to codify the LTCH QRP Submission Exception and Extension Requirements at new §§ 412.560(c) and (d).

We remind readers that, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50316 through 50317), we stated that LTCHs must submit request an exception or extension by submitting a written request along with all supporting documentation to CMS via email to the LTCH mailbox at LTCHQRPREconsiderations@cms.hhs.gov. We further stated that exception or extension requests sent to CMS through any other channel would not be considered as a valid request for an exception or extension from the LTCH QRP’s reporting requirements for any payment determination. In order to be considered, a request for an exception or extension must contain all of the requirements as outlined on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-
We invited public comments on our proposal to codify the LTCH QRP submission exception and extension requirements.

We did not receive any public comments on this proposal. Therefore, we are finalizing our proposal to codify the LTCH QRP submission exception and extension requirements at new §§ 412.560(c) and (d).
D. Clinical Quality Measurement for Eligible Hospitals and Critical Access Hospitals
(CAHs) Participating in the EHR Incentive Programs in 2016

1. Background

The HITECH Act (Title IV of Division B of the ARRA, together with Title XIII of Division A of the ARRA) authorizes incentive payments under Medicare and Medicaid for the adoption and meaningful use of certified electronic health record (EHR) technology (CEHRT). Eligible hospitals and CAHs may qualify for these incentive payments under Medicare (as authorized under sections 1886(n) and 1814(l) of the Act, respectively) if they successfully demonstrate meaningful use of CEHRT, which includes reporting on clinical quality measures (CQMs) using CEHRT.

Sections 1886(b)(3)(B) and 1814(l) of the Act also establish downward payment adjustments under Medicare, beginning with FY 2015, for eligible hospitals and CAHs that are not meaningful users of CEHRT for certain associated reporting periods. Section 1903(a)(3)(F)(i) of the Act establishes 100 percent Federal financial participation (FFP) to States for providing incentive payments to eligible Medicaid providers (described in section 1903(t)(2) of the Act) to adopt, implement, upgrade and meaningfully use CEHRT.

Under sections 1886(n)(3)(A) and 1814(l)(3)(A) of the Act and the definition of “meaningful EHR user” under 42 CFR 495.4, eligible hospitals and CAHs must report on CQMs selected by CMS using CEHRT, as part of being a meaningful EHR user under the Medicare EHR Incentive Program. The set of CQMs from which eligible hospitals
and CAHs will report under the EHR Incentive Program beginning in FY 2014 is listed in Table 10 of the EHR Incentive Program Stage 2 final rule (77 FR 54083).

In the EHR Incentive Program Stage 3 proposed rule\(^\text{341}\) (80 FR 16769), to further our alignment goal among CMS quality reporting programs for eligible hospitals and CAHs and avoid redundant or duplicative reporting among hospital programs, we stated our intent to address CQM reporting requirements for the Medicare and Medicaid EHR Incentive Program for eligible hospitals and CAHs for 2016, 2017, and future years in the IPPS rulemaking. We further stated our belief that receiving and reviewing public comments for various CMS quality programs at one time and finalizing the requirements for these programs simultaneously would allow us to better align these programs for eligible hospitals and CAHs, allow more flexibility into the Medicare and Medicaid EHR Incentive Programs, and add overall value and consistency by providing us the opportunity to address public comments that affect multiple programs at one time.

ONC, in its 2015 Edition proposed rule (80 FR 16844), also indicated that it intends to propose certification policy for the reporting of CQMs for eligible hospitals and CAHs in or with annual IPPS rulemaking to better align with the reporting goals of other CMS programs.

2. CQM Reporting for the Medicare and Medicaid EHR Incentive Programs in 2016

a. Background

In the EHR Incentive Program Stage 2 final rule, we outlined the CQMs available for use in the EHR Incentive Programs beginning in 2014 for eligible hospitals and CAHs.

\(^{341}\) Medicare and Medicaid Programs: Electronic Health Record Incentive Program – Stage 3; proposed rule (80 FR 16731 through 16804) (“EHR Incentive Program Stage 3 proposed rule”).
in Table 10 at 77 FR 54083 through 54087, as well as the form and method for submission at 77 FR 54087 through 54089. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24611 through 24613), for CQM reporting for the EHR Incentive Programs in 2016, we proposed to maintain the existing requirements established in earlier rulemaking for the reporting of CQMs, unless indicated otherwise in the proposed rule. These requirements include reporting on 16 CQMs covering at least 3 NQS domains for eligible hospitals and CAHs (77 FR 54079).

As we expand the current measures to align with the National Quality Strategy and the CMS Quality Strategy and incorporate updated standards and terminologies in current CQMs, including updating the electronic specifications for these CQMs, and creating de novo CQMs, we plan to expand the set of CQMs available for reporting under the EHR Incentive Programs in CY 2017 and subsequent years. We will continue to engage stakeholders to provide input on future proposals for CQMs as well as requesting comment on future electronic specifications for new and updated CQMs.

b. CQM Reporting Period for the Medicare and Medicaid EHR Incentive Programs in CY 2016

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50319 through 50321), we began to shift CQM reporting to a calendar year basis for eligible hospitals and CAHs for the Medicare EHR Incentive Program. We established that, for eligible hospitals and CAHs that submit CQMs electronically in 2015, the reporting period is one calendar quarter from Q1, Q2, or Q3 of CY 2015 (79 FR 50321).

Section 1886(n)(3)(B)(iii) of the Act requires that, in selecting measures for eligible hospitals and CAHs for the Medicare EHR Incentive Program, and establishing the form and manner for reporting measures, the Secretary shall seek to avoid redundant or duplicative reporting with reporting otherwise required, including reporting under section 1886(b)(3)(B)(viii) of the Act, the Hospital IQR Program.

In the Electronic Health Record Incentive Program—Modifications to Meaningful Use in 2015 Through 2017 proposed rule (80 FR 20353), beginning in 2015, we proposed to change the definition of “EHR reporting period” in § 495.4 for EPs, eligible hospitals, and CAHs such that the EHR reporting period would begin and end in relation to a calendar year. In connection with that proposal, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24611 through 24612), we proposed that the reporting period for CQMs in 2016 for eligible hospitals and CAHs for the Medicare and Medicaid EHR Incentive Programs also would be based on the calendar year. We stated that we believe it is important to continue our goal of aligning the EHR Incentive Program with the Hospital IQR Program because alignment of these programs will serve to reduce hospital reporting burden and encourage the adoption and meaningful use of CEHRT by eligible hospitals and CAHs.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24581 through 24582), we proposed to require quarterly reporting and submission periods of CQMs for the 3rd and 4th CY quarters of 2016 (for the FY 2018 payment determination) of the Hospital IQR Program. We also stated that we believe it is important for us to maintain our goal of alignment between the Hospital IQR and EHR Incentive Programs. Therefore, we
proposed to align the reporting period in CY 2016 for eligible hospitals and CAHs that report CQMs electronically for the Medicare EHR Incentive Program with that of the Hospital IQR Program and require quarterly reporting and submission periods for CQMs in the 3rd and 4th CY quarters. We refer readers to section VIII.A.8.c. of the preamble of this final rule for further discussion of the proposals and our finalized policies for the Hospital IQR Program.

In addition, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24587 through 24588), we proposed to change the Hospital IQR Program’s submission period for CQMs from annual to quarterly submission, and proposed to change the submission deadline from November 30, 2015 to ending 2 calendar months after the close of the reporting CY quarter (for CY 2016/FY 2018 payment determination, the proposed deadlines are November 30, 2016 for Q3 and February 28, 2017 for Q4). We refer readers to the Hospital IQR Program discussion in section VIII.A.10.d.(3) of the preamble of this final rule for more information about these proposals. Therefore, to coincide with the submission period in the Hospital IQR Program, we also proposed to align the Medicare EHR Incentive Program submission period for CY 2016 with the submission period proposed for the Hospital IQR Program.

We proposed the following CQM reporting periods and submission deadlines for eligible hospitals and CAHs participating in the Medicare EHR Incentive Program in CY 2016:

- Eligible hospitals and CAHs Reporting CQMs by Attestation
++ For eligible hospitals and CAHs demonstrating meaningful use for the first time in 2016, any continuous 90-day reporting period within CY 2016; or one full calendar year reporting period for CY 2016. Attestation by February 28, 2017.

++ For eligible hospitals and CAHs that demonstrated meaningful use in any year prior to 2016, one full calendar year reporting period for CY 2016. Attestation by February 28, 2017.

- Eligible hospitals and CAHs Reporting CQMs Electronically -- Two full quarters of data (Q3 and Q4 of CY 2016) submitted via electronic reporting within 2 months after the close of each quarter (Q3 by November 30, 2016; Q4 by February 28, 2017).

We also proposed that the CQM reporting period for eligible hospitals and CAHs participating in the Medicaid EHR Incentive Program would be any continuous 90-day reporting period within CY 2016 for eligible hospitals and CAHs demonstrating meaningful use for the first time; and one full calendar year reporting period of CY 2016 for eligible hospitals and CAHs that demonstrated meaningful use in any year prior to 2016. Providers should refer to their State Medicaid program for requirements on submission methods and deadlines.

We note that, beginning in CY 2017 and in subsequent years, we proposed in the EHR Incentive Program Stage 3 proposed rule (80 FR 16739 through 16740) to require a reporting period of one full calendar year for CQM reporting for all providers participating in the EHR Incentive Programs, with a limited exception for Medicaid providers demonstrating meaningful use for the first time.
We invited public comment on these proposals.

Comment: A few commenters supported the proposal to maintain the existing CQM requirement to report on 16 CQMs covering at least 3 NQS domains. Many commenters expressed concern that hospitals are not prepared to submit electronic CQMs. Several commenters noted that electronic CQM reporting is difficult for hospitals due to the complexities involved in implementing EHRs. As a result of these concerns, many commenters requested an extension in the roll-out of this requirement, if finalized, in order to allow hospitals time to prepare to meet reporting requirements and to allow more time to overcome the challenges associated with electronic reporting. Many of these commenters supported CMS’ goal to move towards electronic reporting, but specifically requested that CMS delay a requirement for hospitals to report CQMs electronically until CY 2018, in order to align with the EHR Incentive Program proposals in the Stage 3 proposed rule. Some commenters recommended that CMS require electronic CQM reporting no sooner than CY 2017.

Response: We appreciate the commenters’ support of our proposal to maintain the existing CQM requirement to report on 16 CQMs covering at least 3 NQS domains. In addition, we recognize the challenges associated with electronic reporting and appreciate the comments we received. In this final rule, we are modifying the proposed requirement for electronically submitted CQMs for the reporting period in CY 2016. In an effort to align with the Hospital IQR Program and reduce the burden for hospitals, rather than reporting on a minimum of 16 CQMs covering at least 3 NQS domains as proposed, we are requiring hospitals that submit CQMs electronically for the Medicare
EHR Incentive Program to report on a minimum of 4 CQMs for the reporting period in 2016 with no NQS domain distribution requirement. This reduction from a minimum of 16 CQMs to a minimum of 4 CQMs and the elimination of the NQS domain distribution requirement only apply for hospitals that choose to report CQMs through electronic submission. Hospitals that choose to report CQMs by attestation for the reporting period in 2016 are required to report on a minimum of 16 CQMs covering at least 3 NQS domains. Further, we are modifying our proposed requirement for hospitals reporting CQMs through electronic submission to report two full quarters of data (Q3 and Q4 of CY 2016) within 2 months after the close of each quarter. Instead, we are requiring only one full quarter of data (either Q3 or Q4 of CY 2016), with a submission deadline of February 28, 2017, to allow more time for hospitals to implement their EHR programs and overcome the challenges associated with electronic reporting of CQMs. We believe electronic reporting of CQMs is an important next step in the meaningful use of certified EHR technology, and anticipate that this lower reporting threshold and extended submission deadline for electronically submitted CQMs will reduce burden and encourage eligible hospitals and CAHs to report electronically for 2016. We also anticipate increasing this number in future rules to retain the 16 measure requirement.

We believe that a full year should be adequate time for hospitals to address their mapping issues and that it is important to continue to make progress towards electronic reporting.

We refer readers to the Hospital IQR Program discussion in section VIII.A.8.c. of the preamble of this final rule for further discussion of these and other related comments and our responses.
Comment: Several commenters supported the proposal to base the reporting period on the calendar year. Other commenters supported the proposal to require quarterly reporting and submission periods for electronically submitted CQMs as well as to change the submission period for CQMs from annual to quarterly submission. The commenters generally supported the alignment efforts between the EHR Incentive Program and the Hospital IQR Program. One commenter suggested that the submission timeline be extended to one full quarter instead of the proposed 2 calendar months.

Response: We refer readers to the Hospital IQR Program discussion in section VIII.A.10.d.(3) of the preamble of this final rule for further discussion of these and other related comments and our responses.

After consideration of the public comments we received, and with further consideration of the discussion in sections VIII.A.8.c. and VIII.A.10.d.(3) of the preamble of this final rule, we are aligning our reporting periods and requirements for electronically submitted CQMs for the Medicare EHR Incentive Program with the reporting periods and requirements for electronically submitted CQMs for the Hospital IQR Program. Specifically, we are not finalizing our proposals to require 16 CQMs across three NQS domains reported quarterly for Q3 and Q4 of 2016. Instead, for hospitals that choose to report CQMs electronically for the Medicare EHR Incentive Program for the reporting period in CY 2016, we are requiring a minimum of 4 electronically submitted CQMs in either Q3 or Q4 of CY 2016, with a submission deadline of February 28, 2017. We note that this final policy does not change the reporting periods or requirements for the meaningful use objectives and associated
measures under 42 CFR Part 495 or apply for CQMs that are reported by attestation via the Registration and Attestation System. We further note that providers should refer to their State Medicaid program for requirements on submission methods and deadlines for the Medicaid EHR Incentive Program.

c. CQM Reporting Form and Method for the Medicare EHR Incentive Program in 2016

In the EHR Incentive Program Stage 2 final rule (77 FR 54087 through 54089), we finalized the reporting methods for eligible hospitals and CAHs for the Medicare EHR Incentive Program, which included reporting electronically or by attestation. We finalized that eligible hospitals and CAHs that are beyond their first year of meaningful use will be required to electronically submit the selected 16 CQMs. Subsequent to the Stage 2 final rule, we determined that electronic submission of aggregate-level data using QRDA–III would not be feasible in 2014 and 2015, and thus, eligible hospitals and CAHs would have the option to continue to report aggregate CQM results through attestation for the reporting periods in 2014 and 2015 (78 FR 50904 through 50905; 79 FR 50321 through 50322).

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24612 through 24613), we proposed to continue our existing policy that eligible hospitals and CAHs in any year of participation in the Medicare EHR Incentive Program in 2016 may report CQMs by attestation or electronically using the options previously outlined for electronic reporting either for single program participation in the Medicare EHR Incentive Program, or for participation in multiple programs if the requirements of the aligned quality program are
met. The options for CQM submission for eligible hospitals and CAHs in the Medicare EHR Incentive Program are as follows:

- Eligible hospital and CAH options for Medicare EHR Incentive Program participation (single program participation)

  ++ Option 1: Attest to CQMs through the EHR Registration & Attestation System.

  ++ Option 2: Electronically report CQMs through QualityNet Portal.

- Eligible hospital and CAH options for electronic reporting for multiple programs (for example: EHR Incentive Program plus Hospital IQR Program participation)—Electronically report through QualityNet Portal.

For the Medicaid EHR Incentive Program, States will continue to be responsible for determining whether and how electronic reporting of CQMs would occur, or if they wish to allow reporting through attestation. Any changes that States make to their CQM reporting methods must be submitted through the State Medicaid Health IT Plan (SMHP) process for CMS review and approval prior to being implemented.

We proposed to continue our policy that electronic submission of CQMs will require the use of the most recent release of the CQM version for each CQM to which the EHR is certified. For electronic reporting in 2016, this means eligible hospitals and CAHs would be required to use the Spring 2015 release of the CQMs available at the CMS eCQM Library (http://cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/eCQM_Library.html). We noted that an EHR certified for CQMs under the 2014 Edition certification criteria does not need to be
recertified each time it is updated to a more recent version of the CQMs. (For further information on CQM reporting, we refer readers to the EHR Incentive Program Web site where guides and tip sheets are available for each reporting option (www.CMS.gov/ehrincentiveprograms).) However, we stated that we encourage EHR developers to test any updates, including any changes to the CQMs and changes to the CMS reporting requirements based on the CMS QRDA implementation guide, on an annual basis.

The form and method of electronic submission are further explained in subregulatory guidance and the certification process. For example, the following documents are updated annually to reflect the most recent CQM electronic specifications: the CMS QRDA Implementation Guide; program specific performance calculation guidance; and CQM electronic specifications and guidance documents. These documents are located on the CMS eCQM Library (http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/eCQM_Library.html).

We invited public comments on this proposal.

Comment: Several commenters supported the proposal to allow eligible hospitals and CAHs to report CQMs by attestation or electronically. A few commenters stated that they would prefer to attest to their CQMs than to submit them electronically.

Response: We appreciate the commenters’ support of our proposal.

Comment: Some commenters noted that the Hospital IQR Program is not required for CAHs, and requested clarification on how the alignment between the Hospital IQR Program and the EHR Incentive Program for electronically submitted
CQMs and the method of reporting would impact CAHs seeking to electronically submit their CQM data.

Response: We agree that the Hospital IQR Program is not required for CAHs. Only subsection (d) hospitals are subject to the requirements and payment reductions of the Hospital IQR Program. For the EHR Incentive Program, CAHs may continue to report their CQM data by attestation in CY 2016. However, we encourage CAHs to submit their CQMs electronically through the QualityNet portal. We believe electronic submission of CQMs is an important next step in the meaningful use of certified EHR technology, and encourage CAHs to begin submitting CQMs electronically in 2016. We further note that, in the Stage 3 proposed rule (80 FR 16770), CMS has proposed to require electronic submission of CQMs starting in 2018 and thus encourage CAHs to begin electronically reporting CQMs as soon as feasible.

Comment: Several commenters expressed concerns regarding the timing of the annual update cycle for CQMs and stated that EHR vendors need more time to update their EHRs. Some commenters suggested that updates be minimal, or that the new specifications for CQMs be released well in advance of their implementation.

Response: We appreciate the commenters’ concerns, and note that the CQM electronic specifications are posted at least 6 months prior to the reporting period. We believe it is important to reflect the most recent clinical guidance in CQMs, and therefore seek to find an appropriate balance between the timing of the posting of CQM electronic specifications and the reporting period for those CQMs.
Comment: Several commenters again requested clarification as to whether vendors would be required to recertify their EHRs when CQMs are updated. A few commenters suggested that recertification be required with each update to the CQMs.

Response: We appreciate this feedback and note that, under our policy stated in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50323), an EHR certified for CQMs under the 2014 Edition certification criteria does not need to be recertified each time it is updated to a more recent version of the CQMs. However, we encourage EHR developers to test any updates, including any changes to the CQMs and changes to the CMS reporting requirements based on the CMS QRDA implementation guide, on an annual basis.

After consideration of the public comments we received, we are finalizing our proposals to allow eligible hospitals and CAHs in any year of participation in the Medicare EHR Incentive Program in 2016 to report CQMs by attestation or electronically, and to continue our policy that electronic submission of CQMs will require the use of the most recent release of the CQM version. We note that an EHR certified for CQMs under the 2014 Edition certification criteria does not need to be recertified each time it is updated to a more recent version of the CQMs.

Several commenters sought clarification regarding the requirement to submit QRDA-I data, and asking whether the QRDA-III option would be available to eligible hospitals and CAHs for reporting to the EHR Incentive Program and the Hospital IQR Programs. We note that, in the EHR Incentive Program Stage 3 proposed rule (80 FR 16771), we proposed to remove the QRDA-III option for eligible hospitals and
CAHs. Therefore, we refer readers to that proposed rule for further discussion of this proposal. Due to the timing of the expected publication of the Stage 3 final rule and the questions raised concerning this topic in the public comments on the FY 2016 IPPS/LTCH PPS proposed rule, we are addressing our proposal to remove the QRDA-III option in this FY 2016 IPPS/LTCH PPS final rule instead of in the upcoming Stage 3 final rule. We note the public comment period for the Stage 3 proposed rule ended on May 29, 2015 (80 FR 16732). Below is a summary of the public comments we received in response to our proposal in the Stage 3 proposed rule to remove the QRDA-III option, as well as comments received on this topic in response to the FY 2016 IPPS/LTCH PPS proposed rule.

**Comment:** Many commenters stated concerns over patient privacy using the QRDA-I submission method and stated that no personally identifiable information should be collected for quality reporting purposes.

**Response:** While we appreciate the commenters’ concerns, we believe patient privacy is protected through the security precautions put in place to collect QRDA-I data. With the QualityNet Secure Portal’s release in July 2014, CMS complied with OMB Memorandum 04-04, which requires all Federal systems that collect Protected Health Information (PHI) and are accessed electronically to implement identity management processes, which include both identity proofing and user authentication. Identity proofing and user authentication also are requirements of the Federal Information Security Management Act (FISMA) and National Institute of Standards and Technology (NIST), as well as the HIPAA Security Rule. In addition, the system is required to have
multi-factor authentication which provides unambiguous identification of users by means of the combination of two different components. The use of two-factor authentication (a type of multifactor authentication) to prove one’s identity is based on the premise that an unauthorized actor is unlikely to be able to supply both factors required for access. If, in an authentication attempt, at least one of the components is missing or supplied incorrectly, the user’s identity is not established with sufficient certainty and access to the asset (for example, data) being protected by two-factor authentication then remains blocked.

Comment: Several commenters were concerned about the complexity of coding and build efforts of the QRDA-I functionality. The commenters stated that the development and implementation effort of the QRDA-I was more complex than QRDA-III. Some commenters stated that EHR vendors were not prepared to produce QRDA-I files. Some commenters requested that CMS maintain the QRDA-III format for hospital quality reporting. A few commenters outlined the benefits of the QRDA-III format, and stated that it is easier to implement than QRDA-I, less time-consuming to submit, provides transparency, and is a more mature standard.

Response: We understand and appreciate that some commenters prefer the QRDA-III over the QRDA-I. However, the QRDA-I provides patient-centric data and measure calculations independent of the EHR Incentive Program, which allows CMS to verify the data for future use in the Hospital VBP Program.

After consideration of the public comments we received, and in consideration of the limitations outlined above, we are finalizing our proposal to remove the QRDA-III as
an option for reporting under the Medicare EHR Incentive Program. For 2016 and future years, we are requiring QRDA-I for CQM electronic submissions for the Medicare EHR Incentive Program. We note that QRDA-I data are essential for data verification for the Hospital VBP Program, and are protected by CMS privacy standards. We also note that States would continue to have the option, subject to our prior approval, to allow or require QRDA-III for CQM reporting.


In the 2015 Edition proposed rule (80 FR 16814), ONC proposed a 2015 Edition certification criterion for “CQMs – report” at proposed new 45 CFR 170.315(c)(3) as part of the proposed 2015 Edition of certification criteria that would require a certified Health IT Module to enable a user to electronically create a data file for transmission of clinical quality measurement data using the “base” HL7 (that is, industry-wide, non-program-specific) QRDA Category I and Category III standards, at a minimum. ONC also proposed to allow optional certification for EHRs according to the CMS “form and manner” requirements defined in CMS’ QRDA Implementation Guide as part of this proposed criterion. We reiterate that this proposed certification criterion would apply to EPs, eligible hospitals, and CAHs.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24613 through 24614), for the requirements for the 2015 Edition certification criteria, ONC proposed the following

---

343 As noted in the 2015 Edition proposed rule, ONC proposed to title proposed new § 170.315(c)(3) “CQMs – report” to better align with the use of the term “report” throughout the 2015 Edition. Also, ONC proposed to discontinue to reference “electronic” in the title of certification criteria as it is assumes that all functions performed by certified health IT are done electronically. See 80 FR 16844.

at proposed new § 170.315(c)(3) for clinical quality measurement to state that technology certified to the 2015 Edition must enable a user to electronically create a data file for transmission of clinical quality measurement data which is:

- At a minimum, in accordance with the standards specified in § 170.205(h) and § 170.205(k); and
- Optionally, can be electronically accepted by CMS.

As detailed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24613 through 24614), ONC solicited public comment on the versions of the Quality Reporting Document Architecture – Category I standard that should be adopted under § 170.205(h) and the versions of the Quality Reporting Document Architecture – Category III standard that should be adopted under § 170.205(k) for individual patient level and aggregate level reports, respectively. In order to give full consideration to the public comments received on the versions of the standards that should be adopted under § 170.205(h) and (k), we are not finalizing the “CQMs-report” certification criterion in this FY 2016 IPPS/LTCH PPS final rule. We anticipate finalizing both the certification criterion and the versions of the standards that should be adopted for this criterion in a subsequent final rule later this year. We also intend to address public comments received on both the proposed “CQMs-report” certification criterion and the versions of the standards that should be adopted for this criterion in that same rule.

4. CQM Development and Certification Cycle

We stated in the EHR Incentive Program Stage 2 final rule (77 FR 54055) that we do not intend to use notice-and-comment rulemaking as the means to update or modify
CQM specifications. Given the necessity to update CQM specifications after they have been published to ensure their continued clinical relevance, accuracy, and validity, we publish annual updates to the electronic specifications for EHR submission. Although we require eligible hospitals and CAHs to submit the most updated versions of CQMs when reporting electronically, CEHRT is not required to be recertified on an annual basis. CMS and ONC understand that standards for electronically representing CQMs continue to evolve, and believe there may be value in retesting certified Health IT Modules (including CEHRT) periodically to ensure that CQMs are being accurately calculated and represented, and that they can be reported to CMS in the “form and manner” required for the Hospital IQR Program and EHR Incentive Program. As mentioned previously, CMS and ONC encourage health IT developers to retest their certified technology annually, and solicited public comments on the appropriate frequency for requiring retesting and recertification to the most updated versions of CQMs and most recent “form and manner” reporting requirements.

However, given the continuing evolution of technology and clinical standards, as well as the need for a predictable cycle from measure development to provider data submission, CMS intends to publish a request for information (RFI) on the establishment of an ongoing cycle for the introduction and certification of new measures, the testing of updated measures, and the testing and certification of submission capabilities. We encourage readers to submit their insights and recommendations for our consideration upon publication of that RFI.
Comment: Several commenters noted the upcoming RFI and stated their intention to comment further when that RFI becomes available.

Response: We look forward to the comments submitted via the upcoming RFI, and note that we will consider all comments before proposing a change to our policies.

Comment: Some commenters expressed concern with the timing of the annual update, stating that the publication date of the IPPS final rule in late summer, with an implementation date of the updates of January 1, does not allow adequate time to implement the CQM changes in the annual update. Some commenters stated that there should be a minimum of 18 months between the time of the annual update and when the updates need to be implemented. Some commenters suggested that CQMs changes in the annual update be limited only to nonsubstantive changes and those changes that do not require a change to provider work flows.

Response: We appreciate these comments and feedback. CQMs are updated routinely to account for changes, including, but not limited to, changes in billing and diagnosis codes and changes in medical practices. In order for CQMs to remain current and clinically valid, the specifications must be updated on a regular basis. We note that CQM electronic specifications are posted at least 6 months prior to the start of the reporting period, and well in advance of the submission window. While we understand that this does not allow the suggested 18 months for vendors to update their EHR products, we believe this timeframe allows an adequate amount of time to make those updates while ensuring that the CQMs are still current and clinically valid once implemented.
Comment: Several commenters suggested that use of the most recent CQM electronic specifications not be required unless EHR vendors also are required to update and recertify their EHR products.

Response: We appreciate the commenters’ feedback. However, we note that it is not technically feasible for CMS to accept multiple versions of the CQM specifications. In addition, we note that the most recent version of the CQM electronic specifications is required to ensure that the most current and clinically valid version of the CQM is being implemented and used. We also have received feedback from stakeholders regarding the difficulty and expense of having to test and recertify CEHRT products to the most recent version of the electronic specifications for the CQMs. While we still believe that vendors should test and certify their products to the most recent version of the electronic specifications for the CQMs when feasible, we understand the burdens associated with this requirement and therefore do not require that CEHRT products be recertified to the most recent version of the electronic specifications for the CQMs with the annual update.
IX. MedPAC Recommendations

Under section 1886(e)(4)(B) of the Act, the Secretary must consider MedPAC’s recommendations regarding hospital inpatient payments. Under section 1886(e)(5) of the Act, the Secretary must publish in the annual proposed and final IPPS rules the Secretary’s recommendations regarding MedPAC’s recommendations. We have reviewed MedPAC’s March 2015 “Report to the Congress: Medicare Payment Policy” and have given the recommendations in the report consideration in conjunction with the policies set forth in this final rule. MedPAC recommendations for the IPPS for FY 2016 are addressed in Appendix B to this final rule.

For further information relating specifically to the MedPAC reports or to obtain a copy of the reports, contact MedPAC at (202) 653-7226, or visit MedPAC’s Web site at: http://www.medpac.gov.

X. Other Required Information

A. Requests for Data from the Public

In order to respond promptly to public requests for data related to the prospective payment system, we have established a process under which commenters can gain access to raw data on an expedited basis. Generally, the data are now available on compact disc (CD) format. However, many of the files are available on the Internet at: http://www.cms.hhs.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. We listed the data files and the cost for each file, if applicable, in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24615 through 24616).
Commenters interested in discussing any data used in constructing this final rule should contact Chioma Obi at (410) 786-6050.

B. Collection of Information Requirements

1. Statutory Requirement for Solicitation of Comments

Under the Paperwork Reduction Act of 1995, we are required to provide 60-day notice in the Federal Register and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24616 through 24621), we solicited public comment on each of these issues for the following sections of this document that contain information collection requirements (ICRs).

2. ICRs for Add-On Payments for New Services and Technologies

Sections II.I.1. of the preambles of the proposed rule (80 FR 24418 through 24463) and this final rule discuss add-on payments for new services and technologies.
Specifically, this section states that applicants for add-on payments for new medical services or technologies for FY 2017 must submit a formal request. A formal request includes a full description of the clinical applications of the medical service or technology and the results of any clinical evaluations demonstrating that the new medical service or technology represents a substantial clinical improvement. In addition, the request must contain a significant sample of the data to demonstrate that the medical service or technology meets the high-cost threshold.

We believe the burden associated with this requirement is exempt from the PRA under 5 CFR 1320.3(c), which defines the agency collection of information subject to the requirements of the PRA as information collection imposed on 10 or more persons within any 12-month period. This information collection does not impact 10 or more entities in a 12-month period. For FYs 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, and 2016, we received 1, 4, 5, 3, 3, 5, 5, 7, and 9 applications, respectively. We note that two of the nine applications received for FY 2016 were withdrawn after publication of the proposed rule, as indicated in section III.I. of the preamble of this final rule.

We did not receive any public comments regarding this information collection.

3. ICRs for the Occupational Mix Adjustment to the FY 2016 Wage Index (Hospital Wage Index Occupational Mix Survey)

Sections III.E. and F. of the preambles of the proposed rule (80 FR 24465 through 24467) and this final rule discuss the occupational mix adjustment to the proposed and final FY 2016 wage index, respectively. While the preambles of these rules do not
contain any new ICRs, we note that there is an OMB approved information collection request associated with the hospital wage index.

Section 304(c) of Pub. L. 106–554 amended section 1886(d)(3)(E) of the Act to require CMS to collect data at least once every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program in order to construct an occupational mix adjustment to the wage index. We collect the data via the occupational mix survey.

The burden associated with this information collection requirement is the time and effort required to collect and submit the data in the Hospital Wage Index Occupational Mix Survey to CMS. The aforementioned burden is subject to the PRA; it is currently approved under OMB control number 0938-0907.

We did not receive any public comments regarding this information collection.

4. Hospital Applications for Geographic Reclassifications by the MGCRB

Sections III.J.2. of the preambles of the proposed rule (80 FR 24470 through 24471) and this final rule discuss proposed and finalized changes to the wage index based on hospital reclassifications, respectively. As stated in those sections, under section 1886(d)(10) of the Act, the MGCRB has the authority to accept short-term IPPS hospital applications requesting geographic reclassification for wage index and to issue decisions on these requests by hospitals for geographic reclassification for purposes of payment under the IPPS.

The burden associated with this application process is the time and effort necessary for an IPPS hospital to complete and submit an application for reclassification
to the MGCRB. The burden associated with this requirement is subject to the PRA. It is currently approved under OMB control number 0938–0573.

We did not receive any public comments regarding this information collection.

5. Simplified Cost Allocation Methodology for Hospitals

In sections IV.H. of the preamble of the proposed rule (80 FR 24514 through 24515), we discussed our proposal to amend the regulations at 42 CFR 412.302 (d)(4) to limit a hospital’s ability to elect the simplified cost allocation methodology under the terms and conditions provided in the instructions for CMS Form 2552 to cost reporting periods beginning before October 1, 2015. After consideration of the public comments we received, we are not finalizing our proposal to limit the election of the simplified cost allocation methodology in this final rule. Instead, we are retaining the simplified cost allocation methodology with some modifications to afford hospitals using the simplified cost allocation methodology flexibility to obtain approval from their MACs to use dollar value as an alternative statistical basis to square footage for capital-related moveable equipment. Based on FY 2013 HCRIS data, less than 100 hospitals have elected to use the simplified cost allocation methodology.

Although we are not finalizing our proposal to eliminate the simplified cost allocation methodology for hospitals, but instead are affording hospitals greater flexibility to obtain approval from their MAC to use dollar value as an alternative statistical basis to square footage for capital related moveable equipment, we believe the currently approved burden estimates for the Hospital and Health Care Complex Cost Report (OMB control number 0938-0050) are still applicable to hospitals completing the
Hospital and Health Care Complex Cost Report. The time required to address this revision will be subsumed in the total burden estimate for an entity to comply with all of the requirements in the cost report.

We did not receive any public comments regarding this information collection.

6. ICRs for the Hospital Inpatient Quality Reporting (IQR) Program

The Hospital IQR Program (formerly referred to as the Reporting Hospital Quality Data for Annual Payment (RHQDAPU) Program) was originally established to implement section 501(b) of the MMA, Pub. L. 108-173. This program expanded our voluntary Hospital Quality Initiative. The Hospital IQR Program originally consisted of a “starter set” of 10 quality measures. The collection of information associated with the original starter set of quality measures was previously approved under OMB control number 0938-0918. All of the information collection requirements previously approved under OMB control number 0938-0918 have been combined with the information collection request previously approved under OMB control number 0938-1022. We no longer use OMB control number 0938-0918.

We added additional quality measures to the Hospital IQR Program and submitted the information collection request to OMB for approval. This expansion of the Hospital IQR Program measures was part of our implementation of section 5001(a) of the DRA. Section 1886(b)(3)(B)(viii)(III) of the Act, added by section 5001(a) of the DRA, requires that the Secretary expand the “starter set” of 10 quality measures that were established by the Secretary as of November 1, 2003, to include measures that the Secretary determines to be appropriate for the measurement of the quality of care.
furnished by hospitals in inpatient settings. The burden associated with these reporting requirements is currently approved under OMB control number 0938-1022.

In section VIII.A.6. of the preamble of this final rule, we are finalizing modified versions of our proposed refinements to expand the measure cohorts for: (1) the Hospital 30-Day All-Cause, Risk-Standardized Mortality Rate (RSMR) following Pneumonia Hospitalization measure (NQF #0468); and (2) the Hospital 30-Day All-Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization measure (NQF #0506). Expanding the measure cohorts to include a broader population of patients adds a large number of patients, as well as additional hospitals, to these measures. However, this expansion will not affect the hospitals’ burden because these measures are claims-based and, therefore, require no additional effort on hospitals’ part to submit the required data.

In section VIII.A.7. of the preamble of this final rule, we are finalizing seven of the eight additional proposed measures to the Hospital IQR Program measure set. The seven new measures are: (1) Hospital Survey on Patient Safety Culture (structural); (2) Kidney/UTI Clinical Episode-Based Payment (claims-based);* (3) Cellulitis Clinical Episode-Based Payment (claims-based);* (4) Gastrointestinal Hemorrhage Clinical Episode-Based Payment (claims-based);* (5) Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for Primary Elective THA/TKA (claims-based); (6) Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction (claims-based); and (7) Excess Days in Acute Care after Hospitalization for Heart Failure (claims-based). We are not finalizing our proposal to add the Lumbar Spine
Fusion/Refusion Clinical Episode-Based Payment (claims-based) measure. Four of these seven measures are being finalized for the FY 2018 payment determination and subsequent years as proposed; however, the other three measures, addressing clinical episode-based payments and denoted with an (*), are being finalized for the FY 2019 payment determination and subsequent years – a modification to what was proposed.

One new measure is structural; the remaining six new measures are claims-based. The burden associated with collecting information on the structural measure we are finalizing, Hospital Survey on Patient Safety Culture, is expected to be minimal, as it involves filling out a one-time form to report on this measure for a given performance period; therefore, its addition will not result in a significant burden increase. In total, we estimate a burden of 15 minutes per hospital to complete other forms such as the ECE and Measure Exception form, and to report structural measures. The estimate of 15 minutes includes all previously finalized and newly required structural measures. Because the remaining measures we are finalizing are claims-based measures and can be calculated based on data that are already reported to the Medicare program for payment purposes, we believe no additional information collection will be required from the hospitals for the six newly finalized claims-based measures.

We also are finalizing our proposals to remove nine measures. We believe that there will be a reduction in collection of information burden for hospitals due to our removal of seven of these nine measures, which are chart-abstracted: (1) STK-01 Venous Thromboembolism Prophylaxis (NQF #0434); (2) STK-06: Discharged on Statin Medication** (NQF #0439); (3) STK-08: Stroke Education** (NQF endorsement
removed; (4) VTE-1: Venous Thromboembolism Prophylaxis** (NQF #0371); (5) VTE-2: Intensive Care Unit Venous Thromboembolism Prophylaxis** (NQF #0372); (6) VTE-3: Venous Thromboembolism Patients with Anticoagulation Overlap Therapy** (NQF #0373); and (7) AMI-7a Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival** (NQF #0164). (A double asterisk (**) indicates that we finalized our proposal to retain the measure as an electronic clinical quality measure for the FY 2018 payment determination and subsequent years in section VIII.A.8. of the preamble of this final rule.) Due to the burden associated with the collection of chart-abstracted data, we estimate that the removal of AMI-7a will result in a burden reduction of approximately 219,000 hours across all hospitals. In addition, we estimate that the removal of 6 VTE and STK chart-abstracted measures will result in an information collection burden reduction of approximately 522,000 hours across all hospitals.

The remaining two of the nine measures finalized for removal have been previously suspended from the Hospital IQR Program. Therefore, their removal will not affect information collection burden to hospitals. These measures are: IMM-1 Pneumococcal Immunization (NQF #1653); and SCIP-Inf-4 Cardiac Surgery Patients with Controlled Postoperative Blood Glucose (NQF #0300). The suspension of IMM-1 is currently reflected under OMB control number 0938-1022. The suspension of SCIP-Inf-4, which was formalized on January 9, 2015, will be reflected in the PRA package being submitted this year under OMB control number 0938-1022. In total, we

estimate that the removal of 9 measures will result in a total information collection burden reduction of approximately 741,000 hours for the FY 2018 payment determination across all hospitals.

For the FY 2018 payment determination, we also are finalizing a modification of our proposals regarding electronic clinical quality measures. Instead of requiring hospitals to report 16 electronic clinical quality measures, we are requiring a minimum of 4 electronic clinical quality measures. Under this modified policy, no NQS domain distribution will be required. In addition, for the FY 2018 payment determination, instead of requiring two quarters of data, we are requiring that hospitals submit only one quarter of eCQM data (either Q3 or Q4) of CY 2016, by February 28, 2017. We also anticipate increasing the number of required electronic clinical quality measures in future rules to propose a 16 measure requirement. We believe that a full year should be enough time for hospitals to address their mapping issues and that it is important to continue to make progress towards electronic reporting.

Lastly, in response to comments suggesting that QRDA I be required and other comments requesting clarification on our QRDA requirement, we are finalizing a modification of our proposal modifying our electronic clinical quality measure reporting requirements to include the a policy requirement that hospitals must report via QRDA I. We believe the delayed reporting period and submission deadlines finalized will provide hospitals with adequate time to prepare to report using QRDA I.

We believe that the total information collection burden associated with the electronic clinical quality measure reporting proposal can be drawn from the burden
outlined for hospitals in the EHR Incentive Program Stage 2 final rule (77 FR 54126 through 54133). In that final rule, the burden estimate for a hospital to attest and report 16 electronic clinical quality measures is 2 hours and 40 minutes per quarter (77 FR 54132). In total, we expect the burden associated with our finalized policy to require hospitals to report 4 electronic clinical quality measures for one quarter of data to be 40 minutes per hospital, and 2,200 hours total across the approximately 3,300 hospitals participating in the Hospital IQR Program. We do not anticipate any observed change in burden as it relates to the reporting via QRDA I.

We estimate that reporting these electronic clinical quality measures can be accomplished by staff with a mean hourly wage of $16.42 per hour. Under OMB Circular A-76, in calculating direct labor, agencies should not only include salaries and wages, but also “other entitlements” such as fringe benefits. This Circular provides that the civilian position full fringe benefit cost factor is 36.25 percent. Therefore, using these assumptions, we estimate an hourly labor cost of $22.37 ($16.42 base salary + $5.95 fringe) and a total cost of $49,214 (2,200 hours x $22.37 per hour) across approximately 3,300 hospitals participating in the Hospital IQR Program to report 4 electronic clinical quality measures for either Q3 or Q4 of CY 2016.

We are finalizing our proposal to change the requirements for population and sampling such that hospitals will be required to submit population and sample size data only for those measures that a hospital submits as chart-abstracted measures under the Hospital IQR Program. We believe this finalized proposal will result in a minimal

---

347 [http://www.whitehouse.gov/omb/circulars_a076_a76_incl_tech_correction](http://www.whitehouse.gov/omb/circulars_a076_a76_incl_tech_correction).
decrease in information collection burden as hospitals will not have to report population and sample size if they electronically report any of the measures that can be reported either as an electronic clinical quality measure or via chart-abstraction.

We also are finalizing our proposal to modify the existing processes for validation of chart-abstracted Hospital IQR Program data to remove one stratum. We anticipate that if there is any affect, it will be that this modification will minimally reduce hospital burden regarding the collection of information. For validation of chart-abstracted data for the FY 2018 payment determination and subsequent years, we require hospitals to provide 72 charts per hospital per year (with an average page length of 1,500), including 40 charts for HAI validation and 32 charts for clinical process of care validation, for a total of 108,000 pages per hospital per year. We reimburse hospitals at 12 cents per photocopied page (79 FR 50346) for a total per hospital cost of $12,960. For hospitals providing charts digitally via a re-writable disc, such as encrypted CD-ROMs, DVDs, or flash drives, we will reimburse hospitals at a rate of 40 cents per disc. We do not believe any additional burden is associated with data submitting this information via Web portal or PDF.

Under OMB number 0938-1022, we estimated that the total burden associated with collection of information and with other activities such as sampling and validation for the FY 2017 payment determination was 1,781 hours per hospital and 5.9 million hours across approximately 3,300 hospitals participating in the Hospital IQR Program. Using data on chart-abstracted measures from the 3rd quarter in 2013 through the 2nd quarter in 2014, we have revised our burden estimate to include updates to the number of
records reported per measure set, as well as the time associated with data collection. Considering the proposals finalized in this final rule, as well as our updated estimates for the number of records reported and the time associated with data reporting activities, we estimate a total burden of 2,289 hours per hospital and 7.6 million hours across approximately 3,300 hospitals participating in the Hospital IQR Program for the FY 2018 payment determination. Of the 7.6 million hours estimated for the total burden, 7.4 million hours are associated with collection of information activities and 0.2 million hours are associated with other activities such as population and sampling, and validation. This burden estimate includes the full measure set finalized for the Hospital IQR Program FY 2018 payment determination and accounts for burden changes associated with all newly finalized measures as well as measures finalized for removal, as discussed above in this section.

This burden estimate accounts for other activities such as population and sampling, reviewing reports for claims-based measure sets, HAI validation templates, as well as all other forms and structural measures. The estimate excludes the burden associated with the NHSN and HCAHPS measures, both of which are submitted under separate information collection requests and are approved under OMB control numbers 0920-0666 and 0938-0981, respectively. The burden estimates in this final rule are the estimates for which we are requesting OMB approval.

7. ICRs for PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program

As discussed in sections VIII.B. of the preambles of the proposed rule (80 FR 24590) and this final rule, section 1866(k)(1) of the Act requires, for purposes of
FY 2014 and each subsequent fiscal year, that a hospital described in section 1886(d)(1)(B)(v) of the Act (a PPS-exempt cancer hospital, or a PCH) submit data in accordance with section 1866(k)(2) of the Act with respect to such fiscal year.

In section VIII.B.3. of the preamble of this final rule, we are finalizing our policy that PCHs must submit data on three additional measures beginning with the FY 2018 program:  (1) CDC NHSN Facility-Wide Inpatient Hospital-Onset Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia Outcome Measure (NQF #1716); (2) CDC NHSN Facility-Wide Inpatient Hospital-Onset *Clostridium difficile* Infection (CDI) Outcome Measure (NQF #1717); and (3) CDC NHSN Influenza Vaccination Coverage Among Healthcare Personnel (HCP) Measure (NQF #0431). In conjunction with finalizing our policy in section VIII.B.2. of the preamble of this final rule to remove the six SCIP measures from the PCHQR Program beginning with fourth quarter (Q4) 2015 discharges and for subsequent years, the PCHQR measure set will consist of 16 measures beginning with the FY 2018 program.

With respect to finalizing our policy to add three measures beginning with the FY 2018 program, this estimate excludes the burden associated with two of these measures (the CDC NHSN MRSA measure and the CDC NHSN CDI measure), both of which are submitted under separate information collection requests and are approved under a separate OMB control number (0920-0666).348 Using the same methodology as the FY 2015 IPPS/LTCH PPS final rule,349 for the third finalized new measure (CDC

---


349 FY 2015 IPPS/LTCH PPS final rule (79 FR 50443 through 50444).
NHSN HCP measure), we estimate that it will take 10 minutes annually per PCH, or an additional 1.83 hours for all PCHs annually to report the measure.\textsuperscript{350}

Our finalized policy to remove six SCIP measures will reduce the burden experienced by PCHs. We estimate a reduction in hourly burden of 6,468\textsuperscript{351} hours per year beginning with Q4 2015 and for subsequent program years across the 11 PCHs.

In summary, as a result of our finalized policies, we estimate a reduction of 6,466.17\textsuperscript{352} hours of burden per year associated with the reporting for all 11 PCHs beginning with the FY 2018 program. Coupled with our estimated salary costs,\textsuperscript{353} we estimate that these changes will result in a reduction in annual labor costs of $426,767.22 beginning with the FY 2018 PCHQR Program.

\textbf{Comment:} One commenter supported CMS’ efforts to reduce reporting burden. However, the commenter stated that CMS had not considered the total burden associated with data collection for the hospital-wide surveillance efforts, the development of technical infrastructure, and resources to ensure consistent application of measures specifications.

\textbf{Response:} We appreciate the commenter’s support. Because we are leveraging the CDC NHSN system in data collection, we confirmed with the CDC that all burden associated with the three measures (CDC NHSN MRSA, CDC NHSN CDI, and CDC NHSN HCP measures) that we are finalizing, including the burden associated with the

\begin{itemize}
  \item \textsuperscript{350} Ibid.
  \item \textsuperscript{351} [(49 cases per measure x 4 quarters) + 0.5 (abstraction/training time)] x11 PCHs = 6,468 hours per year.
  \item \textsuperscript{352} 6,468 hours – 1.83 hours = 6,466.17 hours.
  \item \textsuperscript{353} 6,466.17 hours * $66/hour. [We are now estimating an hourly salary of $33 (http://swz.salary.com/salarywizard/Staff-Nurse-RN-Hourly-Salary-Details.aspx). After accounting for employee benefits and overhead, this results in a total cost of $66 per labor hour].
\end{itemize}
activities mentioned by the commenter, has been accounted for under the OMB control number 0920-0666.

8. ICRs for the Hospital Value-Based Purchasing (VBP) Program

In sections IV.F. of the preamble of the proposed rule (80 FR 24498 through 24509) and this final rule, we discuss requirements for the Hospital VBP Program. Specifically, in this final rule, we are finalizing our proposal to adopt one new measure beginning with the FY 2018 program year, the 3-Item Care Transition Measure (CTM-3) (NQF #0228). We also are finalizing our proposal to adopt one new measure beginning with the FY 2021 program year, the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization Measure (NQF #1893) (MORT-30-COPD).

As required under section 1886(o)(2)(A) of the Act, both of these additional measures are required for the Hospital IQR Program. Therefore, their inclusion in the Hospital VBP Program does not result in any additional burden because the Hospital VBP Program uses data that are required for the Hospital IQR Program.

9. ICRs for the Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

As discussed in sections VIII.C.5.a and VIII.C.5.b. of the preamble of this final rule, we are retaining the following 12 previously finalized quality measures for use in the LTCH QRP:
<table>
<thead>
<tr>
<th>NQF ID</th>
<th>Measure Title</th>
<th>Payment Determination</th>
<th>Final Rule(s) in which Measure was Finalized</th>
</tr>
</thead>
<tbody>
<tr>
<td>NQF #0138</td>
<td>National Healthcare Safety Network (NHSN) Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
<td>FY 2015 payment determination and subsequent years</td>
<td>FY 2012 IPPS/LTCH PPS final rule; updated in FY 2013 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>NQF #0139</td>
<td>National Healthcare Safety Network (NHSN) Central Line-Associated Blood Stream Infection (CLABSI) Outcome Measure</td>
<td>FY 2015 payment determination and subsequent years</td>
<td>FY 2012 IPPS/LTCH PPS final rule; updated in FY 2013 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>NQF #0678</td>
<td>Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay)</td>
<td>FY 2015 payment determination and subsequent years*</td>
<td>FY 2012 IPPS/LTCH PPS final rule; updated in FY 2014 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>NQF #0680</td>
<td>Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay)</td>
<td>FY 2016 payment determination and subsequent years</td>
<td>FY 2015 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>NQF #0431</td>
<td>Influenza Vaccination Coverage Among Healthcare Personnel</td>
<td>FY 2016 payment determination and subsequent years</td>
<td>FY 2015 IPPS/LTCH PPS final rule</td>
</tr>
</tbody>
</table>

* Adopted in this FY 2016 IPPS/LTCH PPS final rule for the FY 2018 payment determination and subsequent years

---

<table>
<thead>
<tr>
<th>NQF ID</th>
<th>Measure Title</th>
<th>Payment Determination</th>
<th>Final Rule(s) in which Measure was Finalized</th>
</tr>
</thead>
<tbody>
<tr>
<td>NQF #1716</td>
<td>National Healthcare Safety Network (NHSN) Facility-Wide Inpatient Hospital-Onset Methicillin-Resistant <em>Staphylococcus aureus</em> (MRSA)</td>
<td>FY 2017 and Subsequent Years</td>
<td>FY 2014 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>NQF ID</td>
<td>Measure Title</td>
<td>Payment Determination</td>
<td>Final Rule(s) in which Measure was Finalized</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Bacteremia Outcome Measure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #1717</td>
<td>National Healthcare Safety Network (NHSN) Facility-Wide Inpatient Hospital-Onset <em>Clostridium difficile</em> Infection (CDI) Outcome Measure</td>
<td>FY 2017 payment determination and subsequent years</td>
<td>FY 2014 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>NQF #2512</td>
<td>All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from Long-Term Care Hospitals**</td>
<td>FY 2017 payment determination and subsequent years**</td>
<td>FY 2014 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>Application of NQF #0674</td>
<td>Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay)</td>
<td>FY 2018 payment determination and subsequent years**</td>
<td>FY 2014 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>NQF #2631*</td>
<td>Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function</td>
<td>FY 2018 payment determination and subsequent years**</td>
<td>FY 2015 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>NQF #2632*</td>
<td>Functional Status Outcome Measure; Change in Mobility Among Long-Term Care Hospital Patients Requiring Ventilator Support</td>
<td>FY 2018 payment determination and subsequent years</td>
<td>FY 2015 IPPS/LTCH PPS final rule</td>
</tr>
<tr>
<td>Not NQF endorsed</td>
<td>National Healthcare Safety Network (NHSN) Ventilator-Associated Event (VAE) Outcome Measure</td>
<td>FY 2018 payment determination and subsequent years</td>
<td>FY 2015 IPPS/LTCH PPS final rule</td>
</tr>
</tbody>
</table>


** Adopted in this FY 2016 IPPS/LTCH PPS final rule for the FY 2018 payment determination and subsequent years.

As discussed in sections VIII.C.6.a. through c. of the preamble of this final rule, we are finalizing our proposal to use three previously finalized quality measures in the
LTCH QRP for the FY 2018 payment determination and subsequent years. We are finalizing our proposal to use two of these measures in order to establish their use as cross-setting measures that satisfy the required addition of quality measures under the domains of skin integrity and incidence of major falls, as mandated by section 1899B of the Act, as added by the IMPACT Act: Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678), and an Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674). We are finalizing our proposal to use a third previously finalized measure, All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge From LTCHs (NQF #2512), in order to establish the newly NQF-endorsed status of this measure.

Finally, as discussed in sections VIII.C.6.d. of the preamble of this final rule, for the FY 2018 payment determination and subsequent years, we are finalizing our proposal to add one new cross-setting functional status process measure quality measure to the LTCH QRP: an application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015). This measure satisfies the addition of a quality measure under the third initially required domain of functional status, as mandated by section 1899B of the Act as added by the IMPACT Act.

Six of the measures being retained in this FY 2016 IPPS/LTCH PPS final rule are currently collected via the CDC NHSN. The NHSN is a secure, Internet-based HAI tracking system maintained and managed by the CDC. NHSN data collection occurs via a Web-based tool hosted by the CDC and provided free of charge to facilities. In this
final rule, we have not adopted any new quality measures that are collected via the CDC’s NHSN. Therefore, at this time, there is no additional burden related to this submission method. Any burden related to NHSN-based quality measures we have retained in this final rule, has been previously discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50443 through 50445), and has been previously approved under OMB control number 0920-0666, with an expiration date of November 31, 2016.

The All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512), which we have finalized in this final rule, is a Medicare FFS claims-based measure. Because claims-based measures can be calculated based on data that are already reported to the Medicare program for payment purposes, we believe no additional information collection will be required from the LTCHs.

The remaining 6 measures will be collected utilizing the LTCH CARE Data Set. The LTCH CARE Data Set, in its current form (version 2.01), has been approved under OMB control number 0938-1163. Version 2.01 of the LTCH CARE Data Set contains data elements related to patient demographic data, various voluntary questions, as well as data elements related to the following quality measures:

- Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678)
- Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680)

Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html and contains those data elements included in version 2.01, as well as additional data elements in order to allow for the collection of data associated with the following quality measures:

- Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) (previously finalized in the FY 2015 IPPS/LTCH PPS final rule)

- Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015) (previously finalized in the FY 2015 IPPS/LTCH PPS final rule)

- Functional Status Outcome Measure: Change in Mobility Among LTCH Patients Requiring Ventilator Support (NQF #2632, endorsed on 07/23/2015) (previously finalized in the FY 2015 IPPS/LTCH PPS final rule)

Each time we add new data elements to the LTCH CARE Data Set related to newly proposed or finalized LTCH QRP quality measures, we are required by the Paperwork Reduction Act (PRA) to submit the expanded data collection instrument to OMB for review and approval. Section 1899B(m) of the Act, as added by IMPACT Act, provides that the PRA requirements do not apply to section 1899B of the Act and the sections referenced in subsection 1899B(a)(2)(B) of the Act that require modifications in order to achieve the standardization of patient assessment data. We believe that version 3.00 of the LTCH CARE Data Set falls under the PRA provisions in 1899B(m) of the Act. We believe that all additional data elements added to version 3.00 of the LTCH
CARE Data Set are for the purpose of standardizing patient assessment data, as required under section 1899B(a)(1)(B) of the Act.

A comprehensive list of all data elements included in version 3.00 of the LTCH CARE Data Set will be made available in the LTCH QRP Manual, as will be a change table outlining the differences between version 2.01 and version 3.00 of the LTCH CARE Data Set. The LTCH QRP Manual is accessible on the following LTCH Quality Reporting Measures Information Web page: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html. For a discussion of burden related to version 3.00 of the LTCH CARE Data Set, we refer readers to section I.M. of Appendix A of this final rule.

While the reporting of quality measures is an information collection, the PRA does not apply in accordance with the amendments to the Act made by IMPACT Act. More specifically, section 1899B(m) of the Act provides that the PRA requirements do not apply to section 1899B of the Act and the sections referenced in subsection 1899B(a)(2)(B) of the Act that require modifications in order to achieve the standardization of patient assessment data.

We did not receive public comments specific to this section of the FY 2016 IPPS/LTCH PPS proposed rule. However, we did receive several public comments related to the burden associated with specific proposed quality measures. Those comments and our responses are found in sections VIII.C.6.a. through VIII.C.6.d. of the preamble of this final rule.
10. ICRs for the Electronic Health Record (EHR) Incentive Program and Meaningful Use

In section VIII.D. of the preamble of this final rule, we discuss our proposals to align the Medicare EHR Incentive Program reporting and submission timelines for electronically submitted clinical quality measures for eligible hospitals and CAHs with the Hospital IQR Program’s reporting and submission timelines for 2016. Because these proposals for data collection which we are finalizing in this final rule will align with the reporting requirements in place for the Hospital IQR Program and eligible hospitals and CAHs still have the option to submit their clinical quality measures via attestation for the Medicare EHR Incentive Program, we do not believe there is any additional burden for this collection of information.
List of Subjects in 42 CFR Part 412

Administrative practice and procedure, Health facilities, Medicare, Puerto Rico, Reporting and recordkeeping requirements.

For the reasons stated in the preamble, the Centers for Medicare & Medicaid Services is amending 42 CFR Chapter IV as set forth below:

PART 412--PROSPECTIVE PAYMENT SYSTEMS FOR INPATIENT HOSPITAL SERVICES

1. The authority citation for Part 412 continues to read as follows:
   

2. Section 412.23 is amended by—
   
a. In paragraph (e)(3)(i), removing the cross-reference “paragraphs (e)(3)(ii) through (v)” wherever it appears and adding in its place the cross-reference “paragraphs (e)(3)(ii) through (vi)”.

b. Adding new paragraph (e)(3)(vi).

c. Revising paragraph (e)(6)(ii) introductory text.

The addition and revision reads as follows:

§ 412.23 Excluded hospitals: Classifications.

* * * * *

(e) * * *
(3)  *  *  *

(vi) For cost reporting periods beginning on or after October 1, 2015, the Medicare inpatient days and discharges that are paid at the site neutral payment rate specified at § 412.522(c)(1) or paid under a Medicare Advantage plan (Medicare Part C) will not be included in the calculation of the Medicare inpatient average length of stay specified under paragraph (e)(2)(i) of this section. The provisions of this paragraph (e)(3)(vi) only apply to a hospital that is classified as of December 10, 2013, as a long-term care hospital (as defined in this section) for purposes of determining whether the requirements of paragraph (e)(2)(i) or (e)(2)(ii) of this section are met.

*  *  *  *  *

(6)  *  *  *

(ii) Exception. The moratorium specified in paragraph (e)(6)(i) of this section is not applicable to the establishment and classification of a long-term care hospital that meets the requirements of paragraphs (e) introductory text and (e)(1) through (e)(5) of this section, or a long-term care hospital satellite facility that meets the requirements of § 412.22(h), if the long-term care hospital or long-term care satellite facility meets one or more of the following criteria on or before December 27, 2007, or prior to April 1, 2014, as applicable:

*  *  *  *  *

3. Section 412.64 is amended by revising paragraphs (d)(1)(vi), (h)(4) introductory text, and (h)(4)(vi) introductory text, to read as follows:
§ 412.64 Federal rates for inpatient operating costs for Federal fiscal year 2005 and subsequent fiscal years.

(d) * * *

(1) * * *

(vi) For fiscal years 2015 and 2016, the percentage increase in the market basket index (as defined in § 413.40(a)(3) of this chapter) for prospective payment hospitals, subject to the provisions of paragraphs (d)(2) and (3) of this section, less a multifactor productivity adjustment (as determined by CMS) and less 0.2 percentage point.

(h) * * *

(4) For discharges on or after October 1, 2004 and before October 1, 2016, CMS establishes a minimum wage index for each all-urban State, as defined in paragraph (h)(5) of this section. This minimum wage index value is computed using the following methodology:

(vi) For discharges on or after October 1, 2012 and before October 1, 2016, the minimum wage index value for the State is the higher of the value determined under paragraph (h)(4)(iv) of this section or the value computed using the following alternative methodology:
4. Section 412.101 is amended by revising paragraphs (b)(2)(i), (b)(2)(ii), (c)(1), (c)(2) introductory text, and (d) to read as follows:


* * * * *

(b) * * *

(2) * * *

(i) For FY 2005 through FY 2010 and FY 2018 and subsequent fiscal years, a hospital must have fewer than 200 total discharges, which includes Medicare and non-Medicare discharges, during the fiscal year, based on the hospital’s most recently submitted cost report, and be located more than 25 road miles (as defined in paragraph (a) of this section) from the nearest “subsection (d)” (section 1886(d) of the Act) hospital.

(ii) For FY 2011 through FY 2017, a hospital must have fewer than 1,600 Medicare discharges, as defined in paragraph (a) of this section, during the fiscal year, based on the hospital’s Medicare discharges from the most recently available MedPAR data as determined by CMS, and be located more than 15 road miles, as defined in paragraph (a) of this section, from the nearest “subsection (d)” (section 1886(d) of the Act) hospital.

* * * * *

(c) * * *

(1) For FY 2005 through FY 2010 and FY 2018 and subsequent fiscal years, the adjustment is an additional 25 percent for each Medicare discharge.
(2) For FY 2011 through FY 2017, the adjustment is as follows:

(d) Eligibility of new hospitals for the adjustment. For FYs 2005 through 2010 and FY 2018 and subsequent fiscal years, a new hospital will be eligible for a low-volume adjustment under this section once it has submitted a cost report for a cost reporting period that indicates that it meets discharge requirements during the applicable fiscal year and has provided its Medicare administrative contractor with sufficient evidence that it meets the distance requirement, as specified under paragraph (b)(2) of this section.

5. Section 412.106 is amended by revising paragraph (g)(1)(iii)(C) to read as follows:

§ 412.106 Special treatment: Hospitals that serve a disproportionate share of low-income patients.

(C) For fiscal years 2014 and 2015, CMS will base its estimates of the amount of hospital uncompensated care on the most recent available data on utilization for Medicaid and Medicare SSI patients, as determined by CMS in accordance with paragraphs (b)(2)(i) and (b)(4) of this section. For fiscal year 2016, CMS will base its estimates of the amount of hospital uncompensated care on utilization data for Medicaid and Medicare
SSI patients, as determined by CMS in accordance with paragraphs (b)(2)(i) and (b)(4) of this section, using data on Medicaid utilization from 2012 or 2011 cost reports from the most recent HCRIS database extract, the 2012 cost report data submitted to CMS by IHS hospitals, and the most recent available data on Medicare SSI utilization.

* * * * *

§ 412.108 [Amended]

6. In §412.108, paragraph (a)(1) introductory text and paragraph (c)(2)(iii) introductory text, remove the date “April 1, 2015” and add in its place the date “October 1, 2017”.

7. Section 412.503 is amended by adding a definition of “Subsection (d) hospital” in alphabetical order, to read as follows:

§ 412.503 Definitions.

* * * * *

Subsection (d) hospital means, for purposes of §412.526, a hospital defined in section 1886(d)(1)(B) of the Social Security Act and includes any hospital that is located in Puerto Rico and that would be a subsection (d) hospital as defined in section 1886(d)(1)(B) of the Social Security Act if it were located in one of the 50 States.

* * * * *

8. Section 412.507 is revised to read as follows:

§412.507 Limitation on charges to beneficiaries.

(a) Prohibited charges. Except as provided in paragraph (b) of this section, a long-term care hospital may not charge a beneficiary for any covered services for which
payment is made by Medicare, even if the hospital’s costs of furnishing services to that beneficiary are greater than the amount the hospital is paid under the prospective payment system. If Medicare has paid at the full LTCH prospective payment system standard Federal payment rate, that payment applies to the hospital’s costs for services furnished until the high-cost outlier threshold is met. If Medicare pays less than the full LTCH prospective payment system standard Federal payment rate and payment was not made at the site neutral payment rate, that payment only applies to the hospital’s costs for those costs or days used to calculate the Medicare payment. If Medicare has paid at the full site neutral payment rate, that payment applies to the hospital’s costs for services furnished until the high-cost outlier is met.

(b) Permitted charges. (1) A long-term care hospital that receives a payment at the full LTCH prospective payment system standard Federal payment rate or the site neutral payment rate may only charge the Medicare beneficiary for the applicable deductible and coinsurance amounts under §§ 409.82, 409.83, and 409.87 of this chapter, and for items and services as specified under § 489.20(a) of this chapter.

(2) A long-term care hospital that receives a payment at less than the full LTCH prospective payment system standard Federal payment rate for a short-stay outlier case, in accordance with § 412.529 (which would not include any discharge paid at the site neutral payment rate), may only charge the Medicare beneficiary for the applicable deductible and coinsurance amounts under §§ 409.82, 409.83, and 409.87 of this chapter, for items and services as specified under § 489.20(a) of this chapter, and for services provided during the stay that were not the basis for the short-stay adjusted payment.
9. Section 412.517 is amended by adding paragraph (c) to read as follows:

§ 412.517 Revision of LTC-DRG group classifications and weighting factors.
* * * * *

(c) Beginning in FY 2016, the annual recalibration of the weighting factors described in paragraph (a) of this section is determined using long-term care hospital discharges described in § 412.522(a)(2) (or that would have been described in such section had the application of the site neutral payment rate been in effect at the time of the discharge).

10. Section 412.521 is amended by revising paragraph (a)(2) to read as follows:

§ 412.521 Basis of payment.

(a) * * *

(2) Except as provided for in § 412.526, the amount of payment under the prospective payment system is based on either the long-term care hospital prospective payment system standard Federal payment rate established in accordance with § 412.523, including adjustments described in § 412.525, or the site neutral payment rate established in accordance with § 412.522(c), or, if applicable during a transition period, the blend of the LTCH PPS standard Federal payment rate and the applicable site neutral payment rate described in § 412.522(c)(3).
* * * * *

11. Section 412.522 is added to read as follows:

§ 412.522 Application of site neutral payment rate.
(a) General. For discharges in cost reporting periods beginning on or after October 1, 2015--

(1) Except as provided for in paragraph (b) of this section, all discharges are paid based on the site neutral payment rate as determined under the provisions of paragraph (c) of this section.

(2) Discharges that meet the criteria for exclusion from site neutral payment rate specified in paragraph (b) of this section are paid based on the standard Federal prospective payment rate established under § 412.523.

(b) Criteria for exclusion from the site neutral payment rate—(1) General. A discharge that meets the following criteria is excluded from the site neutral payment rate specified under this section.

(i) The discharge from the long-term care hospital does not have a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation based on the LTC-DRG assignment of the discharge under § 412.513; and

(ii) The admission to the long-term care hospital was immediately preceded by a discharge from a subsection (d) hospital and meets either the intensive care unit criterion specified in paragraph (b)(2) of this section or the ventilator criterion specified in paragraph (b)(3) of this section. In order for an admission to a long-term care hospital to be considered immediately preceded for purposes of this section, the patient discharged from the subsection (d) hospital must be directly admitted to the long-term care hospital.

(2) Intensive care unit criterion. In addition to meeting the requirements of paragraph (b)(1) of this section, the discharge from the subsection (d) hospital that
immediately preceded the admission to the long-term care hospital includes at least
3 days in an intensive care unit (as defined in § 413.53(d) of this chapter), as evidenced
by at least one of the revenue center codes on the claim for the discharge that indicate
such services were provided for the requisite number of days during the stay.

(3) **Ventilator criterion.** In addition to meeting the requirements of paragraph
(b)(1) of this section, the discharge from the long-term care hospital is assigned to a
LTC-DRG based on the patient’s receipt of ventilator services of at least 96 hours, as
evidenced by the procedure code on the discharge bill indicating such services were
provided during the stay.

(c) **Site neutral payment rate—** (1) **General.** Subject to the provisions of
paragraph (c)(2) of this section, the site neutral payment rate is the lower of—

(i) The inpatient hospital prospective payment system comparable per diem
amount determined under § 412.529(d)(4), including any applicable outlier payments
specified in § 412.525(a); or

(ii) 100 percent of the estimated cost of the case determined under the provisions
of § 412.529(d)(2). The provisions for cost-to-charge ratios at § 412.529(f)(4)(i) through

(iii) apply to the calculation of the estimated cost of the case under this paragraph.

(2) **Adjustments.** CMS adjusts the payment rate determined under paragraph
(c)(1) of this section to account for—

(i) Outlier payments, by applying a reduction factor equal to the estimated
proportion of outlier payments under § 412.525(a) payable for discharges from a long-
term care hospital described in paragraph (a)(1) of this section to total estimated
payments under the long-term care hospital prospective payment system to discharges from a long-term care hospital described in paragraph (a)(1) of this section. The adjustment under this paragraph (c)(2)(i) does not include the portion of the blended payment rate described in paragraph (c)(3)(ii) of this section.

(ii) A 3-day or less interruption of a stay and a greater than 3-day interruption of a stay, as provided for in § 412.531. For purposes of the application of the provisions of § 412.531 to discharges from a long-term care hospital described under paragraph (a)(1) of this section, the long-term care hospital prospective payment system standard Federal payment-related terms, such as “LTC-DRG payment,” “full Federal LTC-DRG prospective payment,” and “Federal prospective payment,” mean the site neutral payment rate calculated under paragraph (c) of this section.

(iii) The special payment provisions for long-term care hospitals-within-hospitals and satellite facilities of long-term care hospitals specified in § 412.534.

(iv) The special payment provisions for long-term care hospitals and satellite facilities of long-term care hospitals that discharged Medicare patients admitted from a hospital not located in the same building or on the same campus as the long-term care hospital or satellite facility of the long-term care hospital, as provided in § 412.536.

(3) Transition. For discharges in cost reporting periods beginning on or after October 1, 2015 and on or before September 30, 2017, payment for discharges under paragraph (c)(1) of this section are made using a blended payment rate, which is determined as--
(i) 50 percent of the site neutral payment rate amount for the discharge as
determined under paragraph (c)(1) of this section; and

(ii) 50 percent of the standard Federal prospective payment rate amount for the
discharge as determined under § 412.523.

(d) Discharge payment percentage. (1) For purposes of this section, the
discharge payment percentage is a ratio, expressed as a percentage, of Medicare
discharges that meet the criteria for exclusion from the site neutral payment rate as
described under paragraph (a)(2) of this section to total Medicare discharges paid under
this subpart during the cost reporting period.

(2) CMS will inform each long-term care hospital of its discharge payment
percentage, as determined under paragraph (d)(1) of this section, for each cost reporting
period beginning on or after October 1, 2015.

12. Section 412.523 is amended by adding paragraph (c)(3)(xii) and revising
paragraph (d)(1) to read as follows:

§ 412.523 Methodology for calculating the Federal prospective payment rates.

* * * * *

(c) * * * *

(3) * * * *

(xii) For long-term care hospital prospective payment system fiscal year
beginning October 1, 2015, and ending September 30, 2016. The LTCH PPS standard
Federal payment rate for the long-term care hospital prospective payment system
beginning October 1, 2015, and ending September 30, 2016, is the standard Federal
payment rate for the previous long-term care hospital prospective payment system fiscal year updated by 1.7 percent, and further adjusted, as appropriate, as described in paragraph (d) of this section.

* * * * *

(d) * * *

(1) **Outlier payments.** CMS adjusts the LTCH PPS standard Federal payment rate by a reduction factor of 8 percent, the estimated proportion of outlier payments under §412.525(a) payable for discharges described in § 412.522(a)(2).

* * * *

13. Section 412.525 is amended by revising paragraphs (a)(1), (2), and (3) and adding paragraph (a)(5), to read as follows:

**§ 412.525 Adjustments to the Federal prospective payment.**

(a) * * *

(1) CMS provides for an additional payment to a long-term care hospital if its estimated costs for a patient exceed the applicable long-term care hospital prospective payment system payment plus an applicable fixed-loss amount. For each long-term care hospital prospective payment system payment year, CMS annually establishes a fixed-loss amount that is the maximum loss that a long-term care hospital would incur under the long-term care hospital prospective payment system for a case with unusually high costs before receiving an additional payment.

(2) The fixed-loss amount for discharges from a long-term care hospital described under § 412.522(a)(2) is determined for the long-term care hospital prospective
payment system payment year, using the LTC-DRG relative weights that are in effect at
the start of the applicable long-term care hospital prospective payment system payment
year.

(3) The additional payment equals 80 percent of the difference between the
estimated cost of the patient's care (determined by multiplying the hospital-specific
cost-to-charge ratio by the Medicare allowable covered charge) and the sum of the
applicable long-term care hospital prospective payment system payment and the
applicable fixed-loss amount.

*   *   *   *   *

(5) For purposes of this paragraph (a)--

(i) Applicable long-term care hospital prospective payment system payment
means--

(A) The site neutral payment rate established under § 412.522(c) for long-term
care hospital discharges described under § 412.522(a)(1);

(B) The standard Federal prospective payment rates established under § 412.523
for long-term care hospital discharges described under § 412.522(a)(2); or

(C) The standard Federal prospective payment rates established under § 412.523
for discharges occurring on or after October 1, 2015, in a long-term care hospital cost
reporting period that begins before October 1, 2015.

(ii) Applicable fixed-loss amount means--

(A) For long-term care hospital discharges described under § 412.522(a)(1), the
fixed-loss amount established for such cases as provided at § 412.522(c)(2)(i);
(B) For long-term care hospital discharges described under § 412.522(a)(2), the fixed-loss amount established for such cases as provided at § 412.523(e); or

(C) For discharges occurring on or after October 1, 2015 in a long-term care hospital cost reporting period that begins before October 1, 2015, the fixed-loss amount payable to discharges described under § 412.522(a)(2) as set forth in paragraph (a)(5)(ii)(B) of this section.

* * * * *

14. Section § 412.560 is added to subpart O to read as follows:

§ 412.560 Participation, data submission, and other requirements under the Long-Term Care Hospital Quality Reporting (LTCHQR) Program.

(a) Participation in the LTCHQR Program. A long-term-care hospital must begin submitting quality data under the LTCHQR Program by no later than the first day of the calendar quarter subsequent to 30 days after the date on its CMS Certification Number (CCN) notification letter.

(b) Submission of data requirements and payment impact. (1) Except as provided in paragraph (c) of this section, a long-term care hospital must submit to CMS data on measures specified under sections 1886(m)(5)(D), 1899B(c)(1), and 1899B(d)(1) of the Act, as applicable, in a form and manner, and at a time, specified by CMS.

(2) A long-term care hospital that does not submit data in accordance with sections 1886(m)(5)(C) and 1886(m)(5)(F) of the Act with respect to a given fiscal year will have its annual update to the standard Federal rate for discharges for the long-term care hospital during the fiscal year reduced by 2 percentage points.
(c) Exception and extension request requirements. Upon request by a long-term care hospital, CMS may grant an exception or extension with respect to the quality data reporting requirements, for one or more quarters, in the event of certain extraordinary circumstances beyond the control of the long-term care hospital, subject to the following:

(1) A long-term care hospital that wishes to request an exception or extension with respect to quality data reporting requirements must submit its request to CMS within 30 days of the date that the extraordinary circumstances occurred.

(2) A long-term care hospital must submit its request for an exception or extension to CMS via e-mail. E-mail is the only form that may be used to submit to CMS a request for an exception or an extension.

(3) The e-mail request for an exception or extension must contain the following information:

(i) The CCN for the long-term care hospital.

(ii) The business name of the long-term care hospital.

(iii) The business address of the long-term care hospital.

(iv) Contact information for the long-term care hospital’s chief executive officer or designated personnel, including the name, telephone number, title, e-mail address, and physical mailing address. (The mailing address may not be a post office box.)

(v) A statement of the reason for the request for the exception or extension.

(vi) Evidence of the impact of the extraordinary circumstances, including, but not limited to, photographs, newspaper articles, and other media.
(vii) The date on which the long-term care hospital will be able to again submit quality data under the LTCHQR Program and a justification for the proposed date.

(4) CMS may grant an exception or extension to a long-term care hospital that has not been requested by the long-term care hospital if CMS determines that—

(i) An extraordinary circumstance affects an entire region or locale; or

(ii) A systemic problem with one of CMS’ data collection systems directly affected the ability of the long-term care hospital to submit quality data.

(d) Reconsiderations of noncompliance decisions—(1) Written notification of noncompliance decision. CMS will send a long-term care hospital written notification of a decision of noncompliance with the quality data reporting requirements for a particular fiscal year. CMS also will use the Quality Improvement and Evaluation system (QIES) Assessment Submission and Processing (ASAP) System to provide notification of noncompliance to the long-term care hospital.

(2) Request for reconsideration of noncompliance decision. A long-term care hospital may request a reconsideration of CMS’ decision of noncompliance no later than 30 calendar days from the date of the written notification of noncompliance. The reconsideration request by the long-term care hospital must be submitted to CMS via e-mail and must contain the following information:

(i) The CCN for the long-term care hospital.

(ii) The business name of the long-term care hospital.

(iii) The business address of the long-term care hospital.
(iv) Contact information for the long-term care hospital’s chief executive officer or designated personnel, including each individual’s name, title, e-mail address, telephone number, and physical mailing address. (The physical address may not be a post office box.)

(v) CMS’s identified reason(s) for the noncompliance decision from the written notification of noncompliance.

(vi) The reason for requesting reconsideration of CMS’ noncompliance decision.

(vii) Accompanying documentation that demonstrates compliance of the long-term care hospital with the quality reporting requirements. This documentation must be submitted electronically at the same time as the reconsideration request as an attachment to the e-mail. Any reconsideration request that fails to provide sufficient evidence of compliance will not be reviewed.

(3) CMS decision on reconsideration request. CMS will notify the long-term care hospital, in writing, of its final decision regarding any reconsideration request. CMS also will use the QIES ASAP System to provide notice of its final decision on the reconsideration request.

(e) Appeals of reconsideration requests. A long-term care hospital that is dissatisfied with a decision made by CMS on its reconsideration request may file an appeal with the Provider Reimbursement Review Board under Part 405, Subpart R, of this chapter.

______________________________
Andrew M. Slavitt,
Acting Administrator, Centers for
Medicare & Medicaid Services

Dated: July 29, 2015.

______________________________
Sylvia M. Burwell,
Secretary, Department of Health and Human
Services.

BILLING CODE 4120-01-P
Note: The following Addendum and Appendixes will not appear in the Code of Federal Regulations.

Addendum—Schedule of Standardized Amounts, Update Factors, Rate-of-Increase Percentages Effective with Cost Reporting Periods Beginning on or after October 1, 2015, and Payment Rates for LTCHs Effective for Discharges Occurring on or after October 1, 2015

I. Summary and Background

In this Addendum, we are setting forth a description of the methods and data we used to determine the prospective payment rates for Medicare hospital inpatient operating costs and Medicare hospital inpatient capital-related costs for FY 2016 for acute care hospitals. We also are setting forth the rate-of-increase percentage for updating the target amounts for certain hospitals excluded from the IPPS for FY 2016. We note that, because certain hospitals excluded from the IPPS are paid on a reasonable cost basis subject to a rate-of-increase ceiling (and not by the IPPS), these hospitals are not affected by the figures for the standardized amounts, offsets, and budget neutrality factors. Therefore, in this final rule, we are setting forth the rate-of-increase percentage for updating the target amounts for certain hospitals excluded from the IPPS that are effective for cost reporting periods beginning on or after October 1, 2015.

In addition, we are setting forth a description of the methods and data we used to determine the standard Federal rate that will be applicable to Medicare LTCHs for FY 2016.
In general, except for SCHs, MDHs, and hospitals located in Puerto Rico, for FY 2016, each hospital’s payment per discharge under the IPPS is based on 100 percent of the Federal national rate, also known as the national adjusted standardized amount. This amount reflects the national average hospital cost per case from a base year, updated for inflation.

SCHs are paid based on whichever of the following rates yields the greatest aggregate payment: the Federal national rate (including, as discussed in section IV.D. of the preamble of this final rule, uncompensated care payments under section 1886(r)(2) of the Act); the updated hospital-specific rate based on FY 1982 costs per discharge; the updated hospital-specific rate based on FY 1987 costs per discharge; the updated hospital-specific rate based on FY 1996 costs per discharge; or the updated hospital-specific rate based on FY 2006 costs per discharge.

We note that section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114-10, enacted on April 16, 2015) extended the MDH program (which, under previous law, was to be in effect for discharges on or before March 31, 2015 only) for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017).

Under section 1886(d)(5)(G) of the Act, MDHs historically were paid based on the Federal national rate or, if higher, the Federal national rate plus 50 percent of the difference between the Federal national rate and the updated hospital-specific rate based on FY 1982 or FY 1987 costs per discharge, whichever was higher. However, section 5003(a)(1) of Pub. L. 109-171 extended and modified the MDH special payment...
provision that was previously set to expire on October 1, 2006, to include discharges occurring on or after October 1, 2006, but before October 1, 2011. Under section 5003(b) of Pub. L. 109-171, if the change results in an increase to an MDH’s target amount, we must rebase an MDH’s hospital-specific rates based on its FY 2002 cost report. Section 5003(c) of Pub. L. 109-171 further required that MDHs be paid based on the Federal national rate or, if higher, the Federal national rate plus 75 percent of the difference between the Federal national rate and the updated hospital-specific rate. Further, based on the provisions of section 5003(d) of Pub. L. 109-171, MDHs are no longer subject to the 12-percent cap on their DSH payment adjustment factor.

For hospitals located in Puerto Rico, the payment per discharge is based on the sum of 25 percent of an updated Puerto Rico-specific rate based on average costs per case of Puerto Rico hospitals for the base year and 75 percent of the Federal national rate. (We refer readers to section II.D.2. of this Addendum for a complete description.)

As discussed in section II. of this Addendum, we are making changes in the determination of the prospective payment rates for Medicare inpatient operating costs for acute care hospitals for FY 2016. In section III. of this Addendum, we discuss our policy changes for determining the prospective payment rates for Medicare inpatient capital-related costs for FY 2016. In section IV. of this Addendum, we are setting forth the rate-of-increase percentage for determining the rate-of-increase limits for certain hospitals excluded from the IPPS for FY 2016. In section V. of this Addendum, we discuss policy changes for determining the standard Federal rate for LTCHs paid under the LTCH PPS for FY 2016. The tables to which we refer in the preamble of this final
rule are listed in section VI. of this Addendum and are available via the Internet on the CMS Web site.

II. Changes to Prospective Payment Rates for Hospital Inpatient Operating Costs for Acute Care Hospitals for FY 2016

The basic methodology for determining prospective payment rates for hospital inpatient operating costs for acute care hospitals for FY 2005 and subsequent fiscal years is set forth under 42 CFR 412.64. The basic methodology for determining the prospective payment rates for hospital inpatient operating costs for hospitals located in Puerto Rico for FY 2005 and subsequent fiscal years is set forth under 42 CFR 412.211 and 412.212. Below we discuss the factors we are using for determining the prospective payment rates for FY 2016.

In summary, the standardized amounts set forth in Tables 1A, 1B, and 1C that are listed and published in section VI. of this Addendum (and available via the Internet on the CMS Web site) reflect—

- Equalization of the standardized amounts for urban and other areas at the level computed for large urban hospitals during FY 2004 and onward, as provided for under section 1886(d)(3)(A)(iv)(II) of the Act.

- The labor-related share that is applied to the standardized amounts and Puerto Rico-specific standardized amounts to give the hospital the highest payment, as provided for under sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act. For FY 2016, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act (hereafter referred to as a hospital
that submits quality data) and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act (hereafter referred to as a hospital that is a meaningful EHR user), there are four possible applicable percentage increases that can be applied to the national standardized amount. We refer readers to section IV.A. of the preamble of this final rule for a complete discussion on the FY 2016 inpatient hospital update. Below is a table with these four options:

<table>
<thead>
<tr>
<th>FY 2016</th>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Basket</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Rate-of-Increase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjustment for Failure to Submit Quality Data under Section 1886(b)(3)(B)(viii) of the Act</td>
<td>0.0</td>
<td>0.0</td>
<td>-0.6</td>
<td>-0.6</td>
</tr>
<tr>
<td>Adjustment for Failure to be a Meaningful EHR User under Section 1886(b)(3)(B)(ix) of the Act</td>
<td>0.0</td>
<td>-1.2</td>
<td>0.0</td>
<td>-1.2</td>
</tr>
<tr>
<td>MFP Adjustment under Section 1886(b)(3)(B)(xi) of the Act</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
</tr>
<tr>
<td>Statutory Adjustment under Section 1886(b)(3)(B)(xii) of the Act</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
</tr>
<tr>
<td>Applicable Percentage Increase Applied to Standardized Amount</td>
<td>1.7</td>
<td>0.5</td>
<td>1.1</td>
<td>-0.1</td>
</tr>
</tbody>
</table>
● An update of 1.7 percent to the Puerto Rico-specific standardized amount (that is, the FY 2016 estimate of the market basket rate-of-increase of 2.4 percent less an adjustment of 0.5 percentage point for MFP and less 0.2 percentage point), in accordance with section 1886(d)(9)(C)(i) of the Act, as amended by section 401(c) of Pub. L. 108-173, which sets the update to the Puerto Rico-specific standardized amount equal to the applicable percentage increase set forth under section 1886(b)(3)(B)(i) of the Act.

● An adjustment to the standardized amount to ensure budget neutrality for DRG recalibration and reclassification, as provided for under section 1886(d)(4)(C)(iii) of the Act.

● An adjustment to ensure the wage index changes are budget neutral, as provided for under section 1886(d)(3)(E)(i) of the Act. We note that section 1886(d)(3)(E)(i) of the Act requires that when we compute such budget neutrality, we assume that the provisions of section 1886(d)(3)(E)(ii) of the Act (requiring a 62 percent labor-related share in certain circumstances) had not been enacted.

● An adjustment to ensure the effects of geographic reclassification are budget neutral, as provided for under section 1886(d)(8)(D) of the Act, by removing the FY 2015 budget neutrality factor and applying a revised factor.

● As discussed below and in section III.G. of the preamble of this final rule, an adjustment to offset the cost of the 3-year hold harmless transitional wage index
provisions provided by CMS as a result of the implementation of the new OMB labor market area delineations (beginning with FY 2015).

- An adjustment to ensure the effects of the rural community hospital demonstration program required under section 410A of Pub. L. 108-173, as amended by sections 3123 and 10313 of Pub. L. 111-148, which extended the demonstration program for an additional 5 years, are budget neutral as required under section 410A(c)(2) of Pub. L. 108-173.

- An adjustment to remove the FY 2015 outlier offset and apply an offset for FY 2016, as provided for under section 1886(d)(3)(B) of the Act.

- As discussed below and in section II.D. of the preamble of this final rule, a recoupment to meet the requirements of section 631 of the ATRA to adjust the standardized amount to offset the estimated amount of the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Pub. L. 110-90 until FY 2013.

For FY 2016, consistent with current law, we are applying the rural floor budget neutrality adjustment to hospital wage indexes. Also, consistent with section 3141 of the Affordable Care Act, instead of applying a State level rural floor budget neutrality adjustment to the wage index, we are applying a uniform, national budget neutrality adjustment to the FY 2016 wage index for the rural floor. We note that, in section III.G.2.b. of the preamble to this final rule, we are extending the imputed floor policy (both the original methodology and alternative methodology) for another year, through September 30, 2016. Therefore, for FY 2016, in this final rule, we are continuing to
include the imputed floor (calculated under the original and alternative methodologies) in calculating the uniform, national rural floor budget neutrality adjustment, which are reflected in the FY 2016 wage index.

A. Calculation of the Adjusted Standardized Amount

1. Standardization of Base-Year Costs or Target Amounts

   In general, the national standardized amount is based on per discharge averages of adjusted hospital costs from a base period (section 1886(d)(2)(A) of the Act), updated and otherwise adjusted in accordance with the provisions of section 1886(d) of the Act. For Puerto Rico hospitals, the Puerto Rico-specific standardized amount is based on per discharge averages of adjusted target amounts from a base period (section 1886(d)(9)(B)(i) of the Act), updated and otherwise adjusted in accordance with the provisions of section 1886(d)(9) of the Act. The September 1, 1983 interim final rule (48 FR 39763) contained a detailed explanation of how base-year cost data (from cost reporting periods ending during FY 1981) were established for urban and rural hospitals in the initial development of standardized amounts for the IPPS. The September 1, 1987 final rule (52 FR 33043 and 33066) contains a detailed explanation of how the target amounts were determined and how they are used in computing the Puerto Rico rates.

   Sections 1886(d)(2)(B) and 1886(d)(2)(C) of the Act require us to update base-year per discharge costs for FY 1984 and then standardize the cost data in order to remove the effects of certain sources of cost variations among hospitals. These effects include case-mix, differences in area wage levels, cost-of-living adjustments for Alaska
and Hawaii, IME costs, and costs to hospitals serving a disproportionate share of low-income patients.

For FY 2016, we are continuing to use the national and Puerto Rico-specific labor-related and nonlabor-related shares (which are based on the FY 2010-based hospital market basket) that were used in FY 2015. Specifically, under section 1886(d)(3)(E) of the Act, the Secretary estimates, from time to time, the proportion of payments that are labor-related and adjusts the proportion (as estimated by the Secretary from time to time) of hospitals’ costs which are attributable to wages and wage-related costs of the DRG prospective payment rates. We refer to the proportion of hospitals’ costs that are attributable to wages and wage-related costs as the “labor-related share.” For FY 2016, as discussed in section III. of the preamble of this final rule, we are continuing to use a labor-related share of 69.6 percent for the national standardized amounts, and 63.2 percent for the Puerto Rico-specific standardized amount, if the hospital has a wage index value that is greater than 1.0000. Consistent with section 1886(d)(3)(E) of the Act, we are applying the wage index to a labor-related share of 62 percent of the national standardized amount for all IPPS hospitals whose wage index values are less than or equal to 1.0000. For all IPPS hospitals whose wage indexes are greater than 1.0000, we are applying the wage index to a labor-related share of 69.6 percent of the national standardized amount.

For FY 2016, all Puerto Rico hospitals have a wage index value that is less than 1.0000 because the average hourly rate of every hospital in Puerto Rico divided by the national average hourly rate (the sum of all salaries and hours for all hospitals in the 50
United States and Puerto Rico) results in a wage index that is below 1.0000. However, when we divide the average hourly rate of every hospital located in Puerto Rico by the Puerto Rico-specific national average hourly rate (the sum of all salaries and hours for all hospitals located only in Puerto Rico), the result is a Puerto Rico-specific wage index value for some hospitals that is either above, or below 1.0000, depending on the hospital’s location within Puerto Rico. Therefore, for hospitals located in Puerto Rico, we are applying a labor-related share of 63.2 percent if its Puerto Rico-specific wage index is greater than 1.0000. For hospitals located in Puerto Rico whose Puerto Rico-specific wage index values are less than or equal to 1.0000, we are applying a labor share of 62 percent.

The standardized amounts for operating costs appear in Tables 1A, 1B, and 1C that are listed and published in section VI. of the Addendum to this final rule and are available via the Internet on the CMS Web site.

2. Computing the National Average Standardized Amount and Puerto Rico-Specific Standardized Amount

Section 1886(d)(3)(A)(iv)(II) of the Act requires that, beginning with FY 2004 and thereafter, an equal standardized amount be computed for all hospitals at the level computed for large urban hospitals during FY 2003, updated by the applicable percentage update. Section 1886(d)(9)(A)(ii)(II) of the Act equalizes the Puerto Rico-specific urban and rural area rates. Accordingly, we are calculating the FY 2016 national average standardized amount and Puerto Rico-specific standardized amount irrespective of whether a hospital is located in an urban or rural location.
3. Updating the National Average Standardized Amount and Puerto Rico-Specific Standardized Amount

Section 1886(b)(3)(B) of the Act specifies the applicable percentage increase used to update the standardized amount for payment for inpatient hospital operating costs. We note that, in compliance with section 404 of the MMA, in this final rule, we are using the revised and rebased FY 2010-based IPPS operating and capital market baskets for FY 2016 (which replaced the FY 2006-based IPPS operating and capital market baskets in FY 2014). As discussed in section IV.A. of the preamble of this final rule, in accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, we are reducing the FY 2016 applicable percentage increase (which is based on IHS Global Insight, Inc.'s (IGI's) second quarter 2015 forecast of the FY 2010-based IPPS market basket) by the MFP adjustment (the 10-year moving average of MFP for the period ending FY 2016) of 0.5 percentage point, which is calculated based on IGI's second quarter 2015 forecast.

In addition, in accordance with section 1886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act, we are further updating the standardized amount for FY 2016 by the estimated market basket percentage increase less 0.2 percentage point for hospitals in all areas. Sections 1886(b)(3)(B)(xi) and (xii) of the Act, as added and amended by sections 3401(a) and 10319(a) of the Affordable Care Act, further state that these adjustments may result in the applicable percentage increase being less than zero. The percentage increase in the market basket reflects the average change
in the price of goods and services comprising routine, ancillary, and special care unit
hospital inpatient services.

Based on IGI’s 2015 second quarter forecast of the hospital market basket
increase (as discussed in Appendix B of this final rule), the most recent forecast of the
hospital market basket increase for FY 2016 is 2.4 percent. As discussed above, for
FY 2016, depending on whether a hospital submits quality data under the rules
established in accordance with section 1886(b)(3)(B)(viii) of the Act and is a meaningful
EHR user under section 1886(b)(3)(B)(ix) of the Act, there are four possible applicable
percentage increases that could be applied to the standardized amount. We refer readers
to section IV.A. of the preamble of this final rule for a complete discussion on the
FY 2016 inpatient hospital update to the standardized amount. We also refer readers to
the table above for the four possible applicable percentage increases that are applied to
update the national standardized amount. The standardized amounts shown in Tables 1A
through 1C that are published in section VI. of this Addendum and that are available via
the Internet on the CMS Web site reflect these differential amounts.

Section 401(c) of Pub. L. 108-173 amended section 1886(d)(9)(C)(i) of the Act
and states that, for discharges occurring in a fiscal year (beginning with FY 2004), the
Secretary shall compute an average standardized amount for hospitals located in any area
of Puerto Rico that is equal to the average standardized amount computed under
subclause (I) for FY 2003 for hospitals in a large urban area (or, beginning with FY 2005,
for all hospitals in the previous fiscal year) increased by the applicable percentage
increase under subsection (b)(3)(B) for the fiscal year involved. Therefore, the update to
the Puerto Rico-specific operating standardized amount is subject to the applicable percentage increase set forth under section 1886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act (that is, the same update factor as for all other hospitals subject to the IPPS). Accordingly, we are establishing an applicable percentage increase to the Puerto Rico-specific standardized amount of 1.7 percent for FY 2016.

Although the update factors for FY 2016 are set by law, we are required by section 1886(e)(4) of the Act to recommend, taking into account MedPAC’s recommendations, appropriate update factors for FY 2016 for both IPPS hospitals and hospitals and hospital units excluded from the IPPS. Section 1886(e)(5)(A) of the Act requires that we publish our proposed recommendations in the Federal Register for public comment. Our recommendation on the update factors is set forth in Appendix B of this final rule.

4. Other Adjustments to the Average Standardized Amount

As in the past, we are adjusting the FY 2016 standardized amount to remove the effects of the FY 2015 geographic reclassifications and outlier payments before applying the FY 2016 updates. We then apply budget neutrality offsets for outliers and geographic reclassifications to the standardized amount based on finalized FY 2016 payment policies.

We do not remove the prior year’s budget neutrality adjustments for reclassification and recalibration of the DRG relative weights and for updated wage data because, in accordance with sections 1886(d)(4)(C)(iii) and 1886(d)(3)(E) of the Act,
estimated aggregate payments after updates in the DRG relative weights and wage index should equal estimated aggregate payments prior to the changes. If we removed the prior year's adjustment, we would not satisfy these conditions.

Budget neutrality is determined by comparing aggregate IPPS payments before and after making changes that are required to be budget neutral (for example, changes to MS-DRG classifications, recalibration of the MS-DRG relative weights, updates to the wage index, and different geographic reclassifications). We include outlier payments in the simulations because they may be affected by changes in these parameters.

In order to appropriately estimate aggregate payments in our modeling, we make several inclusions and exclusions so that the appropriate universe of claims and charges are included. We discuss IME Medicare Advantage payment amounts, fee-for-service only claims, and charges for anti-hemophilic blood factor and organ acquisition below.

Consistent with our methodology established in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50422 through 50433), because IME Medicare Advantage payments are made to IPPS hospitals under section 1886(d) of the Act, we believe these payments must be part of these budget neutrality calculations. However, we note that it is not necessary to include Medicare Advantage IME payments in the outlier threshold calculation or the outlier offset to the standardized amount because the statute requires that outlier payments be not less than 5 percent nor more than 6 percent of total "operating DRG payments," which does not include IME and DSH payments. We refer readers to the FY 2011 IPPS/LTCH PPS final rule for a complete discussion on our methodology of
identifying and adding the total Medicare Advantage IME payment amount to the budget neutrality adjustments.

In addition, consistent with the methodology in the FY 2012 IPPS/LTCH PPS final rule, in order to ensure that we capture only fee-for-service claims, we are only including claims with a “Claim Type” of 60 (which is a field on the MedPAR file that indicates a claim is a fee-for-service claim).

Finally, consistent with our methodology established in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50422 through 50423), we examined the MedPAR file and removed pharmacy charges for anti-hemophilic blood factor (which are paid separately under the IPPS) with an indicator of “3” for blood clotting with a revenue code of “0636” from the covered charge field for the budget neutrality adjustments. We also removed organ acquisition charges from the covered charge field for the budget neutrality adjustments because organ acquisition is a pass-through payment not paid under the IPPS.

The Bundled Payments for Care Improvement (BPCI) initiative, developed under the authority of section 3021 of the Affordable Care Act (codified at section 1115A of the Act), is comprised of four broadly defined models of care, which link payments for multiple services beneficiaries receive during an episode of care. Under the BPCI initiative, organizations enter into payment arrangements that include financial and performance accountability for episodes of care. On January 31, 2013, CMS announced the first set of health care organizations selected to participate in the BPCI initiative. Additional organizations were selected in 2014. For additional information on the BPCI
initiative, we refer readers to the CMS Center for Medicare and Medicaid Innovation’s Web site at: http://innovation.cms.gov/initiatives/Bundled-Payments/index.html.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53341 through 53343), for FY 2013 and subsequent fiscal years, we finalized a methodology to treat hospitals that participate in the BPCI initiative the same as prior fiscal years for the IPPS payment modeling and ratesetting process (which includes recalibration of the MS-DRG relative weights, ratesetting, calculation of the budget neutrality factors, and the impact analysis) without regard to a hospital’s participation within these bundled payment models (that is, as if they are not participating in those models under the BPCI initiative). For FY 2016, we are continuing to include all applicable data from subsection (d) hospitals participating in BPCI Models 1, 2, and 4 in our IPPS payment modeling and ratesetting calculations.

The Affordable Care Act established the Hospital Readmissions Reduction Program and the Hospital VBP Program which adjust payments to certain IPPS hospitals beginning with discharges on or after October 1, 2012. Because the adjustments made under these programs affect the estimation of aggregate IPPS payments, in this final rule, consistent with our methodology established in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53687 through 53688), we believe that it is appropriate to include adjustments for these programs within our budget neutrality calculations. We discuss the treatment of these two programs in the context of budget neutrality adjustments below.

Section 1886(q) of the Act establishes the “Hospital Readmissions Reduction Program” effective for discharges from an “applicable hospital” beginning on or after
October 1, 2012, under which payments to those hospitals under section 1886(d) of the Act are reduced to account for certain excess readmissions. Under the Hospital Readmissions Reduction Program, for discharges beginning on October 1, 2012 discharges from an “applicable hospital” are paid at an amount equal to the product of the “base operating DRG payment amount” and an “adjustment factor” that accounts for excess readmissions for the hospital for the fiscal year plus any applicable add-on payments. We refer readers to section IV.E. of the preamble of this final rule for full details of our FY 2016 policy changes to the Hospital Readmissions Reduction Program. We also note that the Hospital Readmissions Reduction Program provided for under section 1886(q) of the Act is not budget neutral.

Section 1886(o) of the Act requires the Secretary to establish a Hospital VBP Program under which, for discharges beginning on October 1, 2012, value-based incentive payments are made in a fiscal year to eligible subsection (d) hospitals based on their performance on measures established for a performance period for that fiscal year. As specified under section 1886(o)(7)(B)(i) of the Act, these value-based incentive payments are funded by a reduction applied to each eligible hospital’s base-operating DRG payment amount, for each discharge occurring in the fiscal year. As required by section 1886(o)(7)(A) of the Act, the total amount of allocated funds available for value-based incentive payments with respect to a fiscal year is equal to the total amount of base-operating DRG payment reductions, as estimated by the Secretary. In a given fiscal year, hospitals may earn a value-based incentive payment amount for a fiscal year that is greater than, equal to, or less than the reduction amount, based on their
performance on quality measures under the Hospital VBP Program. Thus, the Hospital VBP Program is estimated to have no net effect on overall payments. We refer readers to section IV.F. of the preamble of this final rule for details regarding the Hospital VBP Program.

Both the hospital readmissions payment adjustment (reduction) and the hospital VBP payment adjustment (redistribution) are applied on a claim-by-claim basis by adjusting, as applicable, the base-operating DRG payment amount for individual subsection (d) hospitals, which affects the overall sum of aggregate payments on each side of the comparison within the budget neutrality calculations. For example, when we calculate the budget neutrality factor for MS-DRG reclassification and recalibration of the relative weights, we compare aggregate payments estimated using the prior year’s GROUPER and relative weights to estimated payments using the new GROUPER and relative weights. (We refer readers to section II.A.4.a. of this Addendum for details.) Other factors, such as the DSH and IME payment adjustments, are the same on both sides of the comparison because we are only seeking to ensure that aggregate payments do not increase or decrease as a result of the changes of MS-DRG reclassification and recalibration.

In order to properly determine aggregate payments on each side of the comparison, as we did for FY 2014 and FY 2015, for FY 2016 and subsequent years, we are continuing to apply the hospital readmissions payment adjustment and the hospital VBP payment adjustment on each side of the comparison, consistent with the methodology that we adopted in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53687
through 53688). That is, we are applying the readmissions payment adjustment factor and the hospital VBP payment adjustment factor on both sides of our comparison of aggregate payments when determining all budget neutrality factors described in section II.A.4. of this Addendum.

For the purpose of calculating the FY 2016 readmissions payment adjustment factors, we are using excess readmission ratios and aggregate payments for excess readmissions based on admissions from the prior fiscal year’s applicable period because hospitals have had the opportunity to review and correct these data before the data were made public under the policy we adopted regarding the reporting of hospital-specific readmission rates, consistent with section 1886(q)(6) of the Act. For FY 2016, in this final rule, we are calculating the readmissions payment adjustment factors using excess readmission ratios and aggregate payments for excess readmissions based on admissions from the finalized applicable period for FY 2016 as hospitals have had the opportunity to review and correct these data under our policy regarding the reporting of hospital-specific readmission rates consistent with section 1886(q)(6) of the Act. We discuss our policy regarding the reporting of hospital-specific readmission rates for FY 2016 in section IV.E.3.f. of the preamble of this final rule. (For additional information on our general policy for the reporting of hospital-specific readmission rates, consistent with section 1886(q)(6) of the Act, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53399 through 53400).)

In addition, for FY 2016, in this final rule, for the purpose of modeling aggregate payments when determining all budget neutrality factors, we are using proxy hospital
VBP payment adjustment factors for FY 2016 that are based on data from a historical period because hospitals have not yet had an opportunity to review and submit corrections for their data from the FY 2016 performance period. (For additional information on our policy regarding the review and correction of hospital-specific measure rates under the Hospital VBP Program, consistent with section 1886(o)(10)(A)(ii) of the Act, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53578 through 53581), the CY 2012 OPPS/ASC final rule with comment period (76 FR 74544 through 74547), and the Hospital Inpatient VBP final rule (76 FR 26534 through 26536).)

The Affordable Care Act also established section 1886(r) of the Act, which modifies the methodology for computing the Medicare DSH payment adjustment beginning in FY 2014. Beginning in FY 2014, IPPS hospitals receiving Medicare DSH payment adjustments will receive an empirically justified Medicare DSH payment equal to 25 percent of the amount that would previously have been received under the statutory formula set forth under section 1886(d)(5)(F) of the Act governing the Medicare DSH payment adjustment. In accordance with section 1886(r)(2) of the Act, the remaining amount, equal to an estimate of 75 percent of what otherwise would have been paid as Medicare DSH payments, reduced to reflect changes in the percentage of individuals under age 65 who are uninsured and an additional statutory adjustment, will be available to make additional payments to Medicare DSH hospitals based on their share of the total amount of uncompensated care reported by Medicare DSH hospitals for a given time period. In order to properly determine aggregate payments on each side of the
comparison for budget neutrality, prior to FY 2014, we included estimated Medicare DSH payments on both sides of our comparison of aggregate payments when determining all budget neutrality factors described in section II.A.4. of this Addendum.

To do this for FY 2016 (as we did for FY 2014 and FY 2015), we are including estimated empirically justified Medicare DSH payments that will be paid in accordance with section 1886(r)(1) of the Act and estimates of the additional uncompensated care payments made to hospitals receiving Medicare DSH payment adjustments as described by section 1886(r)(2) of the Act. That is, we consider estimated empirically justified Medicare DSH payments at 25 percent of what would otherwise have been paid, and also the estimated additional uncompensated care payments for hospitals receiving Medicare DSH payment adjustments on both sides of our comparison of aggregate payments when determining all budget neutrality factors described in section II.A.4. of this Addendum.

We note that, when calculating total payments for budget neutrality, to determine total payments for SCHs, we model total hospital-specific rate payments and total Federal rate payments and then include whichever one of the total payments is greater. As discussed in section IV.D. of the preamble to this final rule and below, we are continuing the FY 2014 finalized methodology under which we take into consideration uncompensated care payments in the comparison of payments under the Federal rate and the hospital-specific rate for SCHs. Therefore, we include estimated uncompensated care payments in this comparison.

Similarly, for MDHs, as discussed in section IV. of the preamble to this final rule, when computing payments under the Federal national rate plus 75 percent of the
difference between the payments under the Federal national rate and the payments under the updated hospital-specific rate, we are continuing to take into consideration uncompensated care payments in the computation of payments under the Federal rate and the hospital-specific rate for MDHs.

In addition, we are including an adjustment to the standardized amount for those hospitals that are not meaningful EHR users in our modeling of aggregate payments for budget neutrality for FY 2016. We did not include this adjustment for FY 2015 because that was the first year hospitals experienced a reduction to their applicable percentage increase due to whether they are meaningful EHR users and data were not available at that time. However, we believe it is appropriate to include this adjustment for FY 2016 because FY 2016 is the second year for which hospitals will experience this reduction and data on the prior year’s performance are now available. Payments for hospitals are estimated based on the applicable standardized amount in Tables 1A and 1B for discharges occurring in FY 2016.

a. Recalibration of MS-DRG Relative Weights and Updated Wage Index--Budget Neutrality Adjustment

Section 1886(d)(4)(C)(iii) of the Act specifies that, beginning in FY 1991, the annual DRG reclassification and recalibration of the relative weights must be made in a manner that ensures that aggregate payments to hospitals are not affected. As discussed in section II.H of the preamble of this final rule, we normalized the recalibrated MS-DRG relative weights by an adjustment factor so that the average case relative weight after recalibration is equal to the average case relative weight prior to
recalibration. However, equating the average case relative weight after recalibration to the average case relative weight before recalibration does not necessarily achieve budget neutrality with respect to aggregate payments to hospitals because payments to hospitals are affected by factors other than average case relative weight. Therefore, as we have done in past years, we are making a budget neutrality adjustment to ensure that the requirement of section 1886(d)(4)(C)(iii) of the Act is met.

Section 1886(d)(3)(E)(i) of the Act requires us to update the hospital wage index on an annual basis beginning October 1, 1993. This provision also requires us to make any updates or adjustments to the wage index in a manner that ensures that aggregate payments to hospitals are not affected by the change in the wage index. Section 1886(d)(3)(E)(i) of the Act requires that we implement the wage index adjustment in a budget neutral manner. However, section 1886(d)(3)(E)(ii) of the Act sets the labor-related share at 62 percent for hospitals with a wage index less than or equal to 1.0000, and section 1886(d)(3)(E)(i) of the Act provides that the Secretary shall calculate the budget neutrality adjustment for the adjustments or updates made under that provision as if section 1886(d)(3)(E)(ii) of the Act had not been enacted. In other words, this section of the statute requires that we implement the updates to the wage index in a budget neutral manner, but that our budget neutrality adjustment should not take into account the requirement that we set the labor-related share for hospitals with wage indexes less than or equal to 1.0000 at the more advantageous level of 62 percent. Therefore, for purposes of this budget neutrality adjustment, section 1886(d)(3)(E)(i) of the Act prohibits us from taking into account the fact that hospitals with a wage index
less than or equal to 1.0000 are paid using a labor-related share of 62 percent. Consistent with current policy, for FY 2016, we are adjusting 100 percent of the wage index factor for occupational mix. We describe the occupational mix adjustment in section III.E. of the preamble of this final rule.

For FY 2016, to comply with the requirement that MS-DRG reclassification and recalibration of the relative weights be budget neutral for the Puerto Rico standardized amount and the hospital-specific rates, we used FY 2014 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2015 labor-related share percentages, the FY 2015 relative weights, and the FY 2015 pre-reclassified wage data, and applied the FY 2016 hospital readmissions payment adjustments and estimated FY 2016 hospital VBP payment adjustments; and

- Aggregate payments using the FY 2015 labor-related share percentages, the FY 2016 relative weights, and the FY 2015 pre-reclassified wage data, and applied the same FY 2016 hospital readmissions payment adjustments and estimated FY 2016 hospital VBP payment adjustments applied above.

Based on this comparison, we computed a budget neutrality adjustment factor equal to 0.998399. As discussed in section IV. of this Addendum, we also are applying the MS-DRG reclassification and recalibration budget neutrality factor of 0.998399 to the hospital-specific rates that are effective for cost reporting periods beginning on or after October 1, 2015.
In order to meet the statutory requirements that we do not take into account the labor-related share of 62 percent when computing wage index budget neutrality adjustment factor, it was necessary to use a three-step process to comply with the requirements that MS-DRG reclassification and recalibration of the relative weights and the updated wage index and labor-related share have no effect on aggregate payments for IPPS hospitals. Under the first step, we determined an MS-DRG reclassification and recalibration budget neutrality adjustment factor of 0.998399 (by using the same methodology described above to determine the MS-DRG reclassification and recalibration budget neutrality factor for the Puerto Rico standardized amount and hospital-specific rates). Under the second step, to compute a budget neutrality adjustment factor for wage index and labor-related share percentage changes we used FY 2014 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2016 relative weights and the FY 2015 pre-reclassified wage indexes, applied the FY 2015 labor-related share of 69.6 percent to all hospitals (regardless of whether the hospital’s wage index was above or below 1.0000), and applied the FY 2016 hospital readmissions payment adjustment and the estimated FY 2016 hospital VBP payment adjustment; and

- Aggregate payments using the FY 2016 relative weights and the FY 2016 pre-reclassified wage indexes, applied the labor-related share for FY 2016 of 69.6 percent to all hospitals (regardless of whether the hospital’s wage index was above or below 1.0000), and applied the same FY 2016 hospital readmissions payment adjustments and estimated FY 2016 hospital VBP payment adjustments applied above.
In addition, we applied the MS-DRG reclassification and recalibration budget neutrality adjustment factor (derived in the first step) to the payment rates that were used to simulate payments for this comparison of aggregate payments from FY 2015 to FY 2016. By applying this methodology, we determined a budget neutrality adjustment factor of 0.998749 for changes to the wage index. Finally, we multiplied the MS-DRG reclassification and recalibration budget neutrality adjustment factor of 0.998399 (derived in the first step) by the budget neutrality adjustment factor of 0.998749 for changes to the wage index (derived in the second step) to determine the MS-DRG reclassification and recalibration and updated wage index budget neutrality adjustment factor of 0.997150.

b. Reclassified Hospitals—Budget Neutrality Adjustment

Section 1886(d)(8)(B) of the Act provides that certain rural hospitals are deemed urban. In addition, section 1886(d)(10) of the Act provides for the reclassification of hospitals based on determinations by the MGCRB. Under section 1886(d)(10) of the Act, a hospital may be reclassified for purposes of the wage index.

Under section 1886(d)(8)(D) of the Act, the Secretary is required to adjust the standardized amount to ensure that aggregate payments under the IPPS after implementation of the provisions of sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act are equal to the aggregate prospective payments that would have been made absent these provisions. We note that the wage index adjustments provided for under section 1886(d)(13) of the Act are not budget neutral. Section 1886(d)(13)(H) of the Act provides that any increase in a wage index under section 1886(d)(13) shall not be taken into account in applying any budget neutrality adjustment with respect to such index.
under section 1886(d)(8)(D) of the Act. To calculate the budget neutrality adjustment factor for FY 2016, we used FY 2014 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2016 labor-related share percentages, FY 2016 relative weights, and FY 2016 wage data prior to any reclassifications under sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act, and applied the FY 2016 hospital readmissions payment adjustments and the estimated FY 2016 hospital VBP payment adjustments; and

- Aggregate payments using the FY 2016 labor-related share percentages, FY 2016 relative weights, and FY 2016 wage data after such reclassifications, and applied the same FY 2016 hospital readmissions payment adjustments and the estimated FY 2016 hospital VBP payment adjustments applied above.

We note that the reclassifications applied under the second simulation and comparison are those listed in Table 2 associated with this final rule, which is available via the Internet on the CMS Web site. This table reflects reclassification crosswalks for FY 2016, and applies the policies explained in section III. of the preamble to this final rule. Based on these simulations, we calculated a budget neutrality adjustment factor of 0.987905 to ensure that the effects of these provisions are budget neutral, consistent with the statute.

The FY 2016 budget neutrality adjustment factor was applied to the standardized amount after removing the effects of the FY 2015 budget neutrality adjustment factor. We note that the FY 2016 budget neutrality adjustment reflects FY 2016 wage index
reclassifications approved by the MGCRB or the Administrator at the time of development of the final rule.

c. Rural Floor Budget Neutrality Adjustment

Under § 412.64(e)(4), we make an adjustment to the wage index to ensure that aggregate payments after implementation of the rural floor under section 4410 of the BBA (Pub. L. 105-33) and the imputed floor under § 412.64(h)(4) are equal to the aggregate prospective payments that would have been made in the absence of such provisions. Consistent with section 3141 of the Affordable Care Act and as discussed in section III.H. of the preamble of this final rule and codified at § 412.64(e)(4)(ii), the budget neutrality adjustment for the rural and imputed floor is a national adjustment to the wage index.

As noted above and as discussed in section III.H.2. of the preamble of this final rule, in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51594), we extended the imputed floor calculated under the original methodology through FY 2013. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53368 through 53369), we established an alternative methodology for calculating the imputed floor and established a policy that the minimum wage index value for an all-urban State would be the higher of the value determined under the original methodology or the value computed using the alternative methodology. Consistent with the methodology for treating the imputed floor, similar to the methodology we used in the FY 2013 IPPS/LTCH PPS final rule, we included this alternative methodology for computing the imputed floor index in the calculation of the uniform, national rural floor budget neutrality adjustment for FY 2014. For FY 2015, as
discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49969 through 49971), we extended the imputed floor for another year using the higher of the value determined under the original methodology or the alternative methodology. As discussed in section III.H.2. of the preamble of this final rule, we are extending the imputed floor using the higher of the value determined under the original methodology or the alternative methodology for FY 2016. Therefore, in order to ensure that aggregate payments to hospitals are not affected, similar to prior years, we follow our policy of including the imputed floor in the rural floor budget neutrality adjustment to the wage index.

Under the new OMB labor market area delineations adopted beginning with the FY 2015 wage indexes, New Jersey, Rhode Island, and Delaware are all-urban States. Therefore, for FY 2016, the imputed floor was applied to the wage index for hospitals located in these three States.

Similar to our calculation in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50369 through 50370), for FY 2016, we are calculating a national rural Puerto Rico wage index (used to adjust the labor-related share of the national standardized amount for hospitals located in Puerto Rico which receive 75 percent of the national standardized amount) and a rural Puerto Rico-specific wage index (which is used to adjust the labor-related share of the Puerto Rico-specific standardized amount for hospitals located in Puerto Rico that receive 25 percent of the Puerto Rico-specific standardized amount). Because there are no rural Puerto Rico hospitals with established wage data, our calculation of the FY 2016 rural Puerto Rico wage index is based on the policy adopted in the FY 2008 IPPS final rule with comment period (72 FR 47323).
is, we use the unweighted average of the wage indexes from all CBSAs (urban areas) that are contiguous (share a border with) to the rural counties to compute the rural floor (72 FR 47323; 76 FR 51594). Under the new OMB labor market area delineations, except for Arecibo, Puerto Rico (CBSA 11640), all other Puerto Rico urban areas are contiguous to a rural area. Therefore, based on our existing policy, the FY 2016 rural Puerto Rico wage index is calculated based on the average of the FY 2016 wage indexes for the following urban areas: Aguadilla-Isabela, PR (CBSA 10380); Guayama, PR (CBSA 25020); Mayaguez, PR (CBSA 32420); Ponce, PR (CBSA 38660), San German, PR (CBSA 41900) and San Juan-Carolina-Caguas, PR (CBSA 41980).

To calculate the national rural floor and imputed floor budget neutrality adjustment factors and the Puerto Rico-specific rural floor budget neutrality adjustment factor, we used FY 2014 discharge data to simulate payments and the post-reclassified national and Puerto Rico-specific wage indexes and compared the following:

- The national and Puerto Rico-specific simulated payments without the national rural floor and imputed floor and Puerto Rico-specific rural floor applied; and
- The national and Puerto Rico-specific simulated payments with the national rural floor and imputed floor and Puerto Rico-specific rural floor applied.

Based on this comparison, we determined a national rural budget neutrality adjustment factor of 0.990298 and the Puerto Rico-specific budget neutrality adjustment factor of 0.987646. The national adjustment was applied to the national wage indexes to produce a national rural floor budget neutral wage index and the Puerto Rico-specific.
adjustment was applied to the Puerto Rico-specific wage indexes to produce a Puerto Rico-specific rural floor budget neutral wage index.

d. Wage Index Transition Budget Neutrality

As discussed in section III.G. of the preamble of this final rule, in the past, we have provided for transition periods when adopting changes that have significant payment implications, particularly large negative impacts.

Similar to FY 2005, for FY 2015, we determined that the transition to using the new OMB labor market area delineations would have the largest impact on hospitals that were located in an urban county that became rural under the new OMB delineations or hospitals deemed urban where the urban area became rural under the new OMB delineations. To alleviate the decreased payments associated with having a rural wage index, in calculating the area wage index, similar to the transition provided in the FY 2005 IPPS final rule, we finalized a policy to generally assign these counties the urban wage index value of the CBSA to which they are physically located in for FY 2014 for FYs 2015, 2016, and 2017. Fiscal year 2016 is the second year of this 3-year transition policy. We note that the 1-year blended wage index transitional policy for all hospitals that would experience any decrease in their wage index value expires in FY 2015.

As discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50372 through 50373), in the past, CMS has budget neutralized transitional wage indexes. We stated that because we established a policy that allows for the application of a transitional wage index only when it benefits the hospital, we believe that it would be appropriate to ensure
that such a transitional policy does not increase aggregate Medicare payments beyond the payments that would be made had we simply adopted the OMB delineations without any transitional provisions. Therefore, as we did for FY 2015, for FY 2016, we are using our exceptions and adjustments authority under section 1886(d)(5)(I)(i) of the Act to make an adjustment to the national and Puerto Rico-specific standardized amounts to ensure that total payments for the effect of the 3-year transitional wage index provisions will equal what payments would have been if we had fully adopted the new OMB delineations without providing these transitional provisions. To calculate the transitional wage index budget neutrality factor for FY 2016, we used FY 2014 discharge data to simulate payments and compared the following:

- Aggregate payments using the OMB delineations for FY 2016, the FY 2016 relative weights, the FY 2016 wage data after such reclassifications under sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act, application of the rural floor budget neutrality adjustment factor to the wage index, and application of the FY 2016 hospital readmissions payment adjustments and the estimated FY 2016 hospital VBP payment adjustments; and

- Aggregate payments using the OMB delineations for FY 2016, the FY 2016 relative weights, the FY 2016 wage data after such reclassifications under sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act, application of the rural floor budget neutrality adjustment factor to the wage index, application of the 3-year transitional wage indexes, and application of the same FY 2016 hospital readmissions payment adjustments and the estimated FY 2016 hospital VBP payment adjustments applied above.
Based on these simulations, we calculated a budget neutrality adjustment factor of 0.999996. Therefore, for FY 2016, we applied a transitional wage index budget neutrality adjustment factor of 0.999996 to the national average and Puerto Rico-specific standardized amounts to ensure that the effects of these transitional wage indexes are budget neutral.

We note that the budget neutrality adjustment factor calculated above is based on the increase in payments in FY 2016 that would result from the second year of the 3-year transitional wage index policies. Therefore, we applied this budget neutrality adjustment factor as a one-time adjustment to the FY 2016 national and Puerto Rico-specific standardized amounts in order to offset the increase in payments in FY 2016 as a result of this second year of the 3-year transitional wage index. For subsequent fiscal years, we will not take into consideration the adjustment factor applied to the national and Puerto Rico-specific standardized amounts in the previous fiscal year’s update when calculating the current fiscal year transitional wage index budget neutrality adjustment factor (that is, this adjustment will not be applied cumulatively).

e. Case-Mix Budget Neutrality Adjustment

(1) Background

Below we summarize the recoupment adjustment to the FY 2016 payment rates, as required by section 631 of ATRA, to account for the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Pub. L. 110-90 until FY 2013. We refer readers to section II.D. of the preamble of this final rule for a complete discussion regarding our policies for FY 2016 in this final rule.
and previously finalized policies (including our historical adjustments to the payment rates) relating to the effect of changes in documentation and coding that do not reflect real changes in case-mix.
(2) Recoupment or Repayment Adjustment Authorized by Section 631 of the American Taxpayer Relief Act of 2012 (ATRA) to the National Standardized Amount

Section 631 of the ATRA amended section 7(b)(1)(B) of Pub. L. 110-90 to require the Secretary to make a recoupment adjustment totaling $11 billion by FY 2017. Our actuaries estimated that if CMS were to fully account for the $11 billion recoupment required by section 631 of the ATRA in FY 2014, a one-time -9.3 percent adjustment to the standardized amount would be necessary. It is often our practice to delay or phase-in payment rate adjustments over more than 1 year, in order to moderate the effect on payment rates in any 1 year. Therefore, consistent with the policies that we have adopted in many similar cases, for FY 2014 and FY 2015, we applied a -0.8 percent adjustment to the standardized amount. For FY 2016, as we proposed, we are applying a -0.8 percent adjustment to the standardized amount. We note that, as section 631 of the ATRA instructs the Secretary to make a recoupment adjustment only to the standardized amount, this adjustment does not apply to the Puerto Rico-specific standardized amount and hospital-specific payment rates.

f. Rural Community Hospital Demonstration Program Adjustment

As discussed in section IV.L. of the preamble of this final rule, section 410A of Pub. L. 108-173 originally required the Secretary to establish a demonstration program that modifies reimbursement for inpatient services for up to 15 small rural hospitals. Section 410A(c)(2) of Pub. L. 108-173 requires that, in conducting the demonstration program under this section, the Secretary shall ensure that the aggregate payments made
by the Secretary do not exceed the amount which the Secretary would have paid if the demonstration program under this section was not implemented.

Sections 3123 and 10313 of the Affordable Care Act extended the demonstration program for an additional 5-year period, and allowed up to 30 hospitals to participate in 20 States with low population densities determined by the Secretary. (In determining which States to include in the expansion, the Secretary is required to use the same criteria and data that the Secretary used to determine the States for purposes of the initial 5-year period.) In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50141 through 50145), in order to achieve budget neutrality, we adjusted the national IPPS payment rates by an amount sufficient to account for the added costs of this demonstration program as described in section IV.L. of that final rule. In other words, we applied budget neutrality across the payment system as a whole rather than merely across the participants of this demonstration program, consistent with past practice. We stated that we believe the language of the statutory budget neutrality requirement permits the agency to implement the budget neutrality provision in this manner. The statutory language requires that aggregate payments made by the Secretary do not exceed the amount which the Secretary would have paid if the demonstration was not implemented, but does not identify the range across which aggregate payments must be held equal.

For FY 2016, we are calculating a budget neutrality offset amount, according to the methodology set forth in section IV.I. of the preamble of this final rule, to account for the estimated additional costs of the demonstration program for FY 2016. In addition, as explained in section IV.I. of the preamble of this final rule, we are subtracting from this
budget neutrality offset amount the following: (1) the amount by which the budget
neutrality offset that was finalized in the FY 2009 IPPS final rule exceeded the actual
costs of the demonstration for FY 2009 (as shown in finalized cost reports for hospitals
that participated in FY 2009 and had cost reporting periods beginning in FY 2009), and
(2) the amount by which the budget neutrality offset that was finalized for FY 2010 to
account for the demonstration costs in FY 2010 (as set forth in the FY 2010 and 2011
IPPS final rules) exceeded the actual costs of the demonstration for FY 2010 (as shown in
finalized cost reports for hospitals that participated in FY 2010 and had cost reporting
periods beginning in FY 2010). The total budget neutrality offset amount for which the
adjustment to the FY 2016 IPPS rates is calculated is $12,835,618. Accordingly, using
the most recent data available to account for the estimated costs of the demonstration
program, for FY 2016, we have computed a factor of 0.999861 for the rural community
g. Outlier Payments

hospital demonstration program budget neutrality adjustment that will be applied to the
IPPS standard Federal payment rate.

Section 1886(d)(5)(A) of the Act provides for payments in addition to the basic
prospective payments for “outlier” cases involving extraordinarily high costs. To qualify
for outlier payments, a case must have costs greater than the sum of the prospective
payment rate for the DRG, any IME and DSH payments, any new technology add-on
payments, and the “outlier threshold” or “fixed-loss” amount (a dollar amount by which
the costs of a case must exceed payments in order to qualify for an outlier payment). We
refer to the sum of the prospective payment rate for the DRG, any IME and DSH
payments, any new technology add-on payments, and the outlier threshold as the outlier “fixed-loss cost threshold.” To determine whether the costs of a case exceed the fixed-loss cost threshold, a hospital’s CCR is applied to the total covered charges for the case to convert the charges to estimated costs. Payments for eligible cases are then made based on a marginal cost factor, which is a percentage of the estimated costs above the fixed-loss cost threshold. The marginal cost factor for FY 2016 is 80 percent, the same marginal cost factor we have used since FY 1995 (59 FR 45367).

In accordance with section 1886(d)(5)(A)(iv) of the Act, outlier payments for any year are projected to be not less than 5 percent nor more than 6 percent of total operating DRG payments (which does not include IME and DSH payments) plus outlier payments. When setting the outlier threshold, we compute the 5.1 percent target by dividing the total operating outlier payments by the total operating DRG payments plus outlier payments. We do not include any other payments such as IME and DSH within the outlier target amount. Therefore, it is not necessary to include Medicare Advantage IME payments in the outlier threshold calculation. Section 1886(d)(3)(B) of the Act requires the Secretary to reduce the average standardized amount by a factor to account for the estimated proportion of total DRG payments made to outlier cases. Similarly, section 1886(d)(9)(B)(iv) of the Act requires the Secretary to reduce the average standardized amount applicable to hospitals located in Puerto Rico to account for the estimated proportion of total DRG payments made to outlier cases. More information on outlier payments may be found on the CMS Web site at:
http://www.cms.gov/Medicare/Medicare-Fee-for-Service-
Payment/AcuteInpatientPPS/outlier.html.

(1) FY 2016 Outlier Fixed-Loss Cost Threshold

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50977 through 50983), in response to public comments on the FY 2013 IPPS/LTCH PPS proposed rule, we made changes to our methodology for projecting the outlier fixed-loss cost threshold for FY 2014. We refer readers to the FY 2014 IPPS/LTCH PPS final rule for detailed discussion of the changes.

For FY 2016, we proposed to continue to use the same methodology that we used in FY 2015. As we have done in the past, to calculate the proposed FY 2016 outlier threshold, we simulated payments by applying proposed FY 2016 payment rates and policies using cases from the FY 2014 MedPAR file. Therefore, in order to determine the proposed FY 2016 outlier threshold, we inflated the charges on the MedPAR claims by 2 years, from FY 2014 to FY 2016. As discussed in the FY 2014 IPPS/LTCH PPS final rule, we believe a methodology that is based on 1-year of charge data will provide a more stable measure to project the average charge per case because our prior methodology used a 6-month measure, which inherently uses fewer claims than a 1-year measure and makes it more susceptible to fluctuations in the average charge per case as a result of any significant charge increases or decreases by hospitals.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50375), we stated that commenters were concerned that they were unable to replicate the calculation of the charge inflation factor that CMS used in the proposed rule. In response to those
comments, we stated that, consistent with our longstanding policy since FY 2005, we continue to believe that it is optimal to use the most recent period of charge data available to measure charge inflation. We also stated we would consider how best to provide additional information on the charge inflation factor for future years. In response to those comments, in the proposed rule, we provided the following table that displays covered charges and cases by quarter in the periods used to calculate the charge inflation factor.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$126,534,546,428</td>
<td>2,640,744</td>
<td>$125,988,476,809</td>
<td>2,480,809</td>
</tr>
<tr>
<td>2</td>
<td>$118,741,812,697</td>
<td>2,507,483</td>
<td>$121,297,544,913</td>
<td>2,433,390</td>
</tr>
<tr>
<td>3</td>
<td>$115,745,380,133</td>
<td>2,425,636</td>
<td>$116,785,744,335</td>
<td>2,321,731</td>
</tr>
<tr>
<td>4</td>
<td>$119,331,676,066</td>
<td>2,406,770</td>
<td>$89,923,763,220</td>
<td>1,764,002</td>
</tr>
<tr>
<td>Total</td>
<td>$480,353,415,324</td>
<td>9,980,633</td>
<td>$453,995,529,277</td>
<td>8,999,932</td>
</tr>
</tbody>
</table>

Under this new methodology, to compute the 1-year average annualized rate-of-change in charges per case for FY 2016, we proposed to compare the average covered charge per case of $48,129 ($480,353,415,324 / 9,980,633) from the second quarter of FY 2013 through the first quarter of FY 2014 (January 1, 2013, through December 31, 2013) to the average covered charge per case of $50,444 ($453,995,529,277 / 8,999,932) from the second quarter of FY 2014 through the first quarter of FY 2015 (January 1, 2014, through December 31, 2014). This rate-of-change was 4.8 percent (1.048116) or 9.8 percent (1.098547) over 2 years.
Comment: Many commenters were concerned that they were unable to replicate the calculation of the charge inflation factor that CMS used in the proposed rule. One commenter requested that CMS add the claims data used to compute the charge inflation factor to the list of limited data set (LDS) files that can be ordered through the usual LDS data request process. Another commenter who was also focusing on replicating the charge inflation factor stated that it was unable to match the figures in the table from the proposed rule with publicly available data sources. The commenter further stated that CMS has not made the necessary data available, or any guidance that describes whether and how it edited such data to arrive at the total of quarterly charges and charges per case it used to measure charge inflation. Consequently, the commenter stated that the table provided in the proposed rule is not useful in assessing the accuracy of the charge inflation figure that CMS used in the proposed rule to calculate the outlier threshold. In the absence of such data and how it was edited by CMS to arrive at the totals used in its charge inflation calculation, the commenter asserted that CMS has violated a principal tenet of the Administrative Procedure Act by not providing adequate notice to allow for meaningful comment.

Response: As stated in last year’s rule, we continue to believe that it is optimal to use the most recent period of charge data available to measure charge inflation. The commenters did not suggest that CMS use charge data from a different period to compute the charge inflation factor. If we computed the charge inflation factor using the latest data available to the public at the time of issuance of this final rule, we would need to compare charge data from FY 2013 (October 2012 – September 2013) to FY 2014
(October 2013 – September 2014), data which would be at least 10 months old compared to the charge data we currently use, which is 4 months old. Furthermore, we note that, with regard to CCRs (as summarized below), the commenters suggested that CMS use the most recent data available when it calculates the outlier threshold. We share the commenters’ view. Therefore, we are continuing to use the most recent charge data available to us at the time of this final rule to compute the charge inflation factor.

With respect to commenters who expressed concern that they were unable to replicate the calculation of the charge inflation factor that CMS used in the proposed rule, the information we provided in the proposed rule was sufficient for meaningful comment on our proposal and balances the commenter’s requests that we use the latest claims data to compute the charge inflation factor with the current limitations of the LDS file. We note that we responded to similar comments on the replication of the charge inflation factor in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50375) and refer readers to that final rule.

Nevertheless, in response to the request for additional information, we are taking two actions. For the quarterly charge data table, we grouped claims data by quarter in order that the public would be able to replicate the claims summary for the claims with discharge dates through September 30, 2014, that are available under the current LDS structure. In order to provide even more information in response to the commenters’ request, we will make available on the CMS Web site at

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-
Payment/AcuteInpatientPPS/index.html (click on the link on the left titled “FY 2016
IPPS Final Rule Home Page” and then click the link “FY 2016 Final Rule Data Files”) a more detailed summary table by provider with the monthly charges that were used to compute the charge inflation factor. The second action we will take is to work with our systems teams and privacy office to explore expanding the information available in the current LDS, perhaps through the provision of a supplemental data file for future rulemaking.

In response to the commenters who requested additional detail on our calculation, we note that section II. A. 4. of this Addendum describes the inclusion and exclusion of claims and charges used in the outlier calculation and charge inflation calculation. As we have done in the past, in the FY 2016 IPPS/LTCH PPS proposed rule, we proposed to establish the FY 2016 outlier threshold using hospital CCRs from the December 2014 update to the Provider-Specific File (PSF)--the most recent available data at the time of the proposed rule. We also proposed that if more recent data became available, we would use that data to calculate the final FY 2016 outlier threshold. For FY 2016, we also proposed to continue to apply an adjustment factor to the CCRs to account for cost and charge inflation (as explained below).

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we adopted a new methodology to adjust the CCRs. Specifically, we finalized a policy to compare the national average case-weighted operating and capital CCR from the most recent update of the PSF to the national average case-weighted operating and capital CCR from the same period of the prior year.
Therefore, as we did for FY 2014 and FY 2015, we proposed to adjust the CCRs from the December 2014 update of the PSF by comparing the percentage change in the national average case-weighted operating CCR and capital CCR from the December 2013 update of the PSF to the national average case-weighted operating CCR and capital CCR from the December 2014 update of the PSF. We note that, in the proposed rule, we used total transfer-adjusted cases from FY 2014 to determine the national average case-weighted CCRs for both sides of the comparison. As stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we believe that it is appropriate to use the same case count on both sides of the comparison because this will produce the true percentage change in the average case-weighted operating and capital CCR from one year to the next without any effect from a change in case count on different sides of the comparison.

Using the proposed methodology above, for the proposed rule, we calculated a December 2013 operating national average case-weighted CCR of 0.288792 and a December 2014 operating national average case-weighted CCR of 0.280581. We then calculated the percentage change between the two national operating case-weighted CCRs by subtracting the December 2013 operating national average case-weighted CCR from the December 2014 operating national average case-weighted CCR and then dividing the result by the December 2013 national operating average case-weighted CCR. This resulted in a proposed national operating CCR adjustment factor of 0.971568.

We used the same methodology proposed above to adjust the capital CCRs. Specifically, for the proposed rule we calculated a December 2013 capital national
average case-weighted CCR of 0.025014 and a December 2014 capital national average case-weighted CCR of 0.024500. We then calculated the percentage change between the two national capital case-weighted CCRs by subtracting the December 2013 capital national average case-weighted CCR from the December 2014 capital national average case-weighted CCR and then dividing the result by the December 2013 capital national average case-weighted CCR. This resulted in a proposed national capital CCR adjustment factor of 0.979474.

Consistent with our methodology used in the past and as stated in the FY 2009 IPPS final rule (73 FR 48763), we continue to believe that it is appropriate to apply only a 1-year adjustment factor to the CCRs. On average, it takes approximately 9 months for a MAC to tentatively settle a cost report from the fiscal year end of a hospital’s cost reporting period. The average “age” of hospitals’ CCRs from the time the fiscal intermediary or the MAC inserts the CCR in the PSF until the beginning of FY 2016 is approximately 1 year. Therefore, as stated above, we believe a 1-year adjustment factor to the CCRs is appropriate.

As stated above, for FY 2016, we applied the FY 2016 payment rates and policies from the proposed rule using cases from the FY 2014 MedPAR files in calculating the outlier threshold.

As discussed above, for FY 2016, we are applying the second year of the 3-year transitional wage index because of the adoption of the new OMB labor market area delineations. Also, as discussed in section III.B.3. of the preamble to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50160 and 50161) and in section III.H.3. of the
preamble of this final rule, in accordance with section 10324(a) of the Affordable Care Act, we created a wage index floor of 1.0000 for all hospitals located in States determined to be frontier States. We note that the frontier State floor adjustments are calculated and applied after rural and imputed floor budget neutrality adjustments are calculated for all labor market areas, in order to ensure that no hospital in a frontier State receives a wage index less than 1.0000 due to the rural and imputed floor adjustment. In accordance with section 10324(a) of the Affordable Care Act, the frontier State adjustment will not be subject to budget neutrality, and will only be extended to hospitals geographically located within a frontier State. However, for purposes of estimating the proposed outlier threshold for FY 2016, it was necessary to apply the 3-year transitional wage indexes and adjust the wage index of those eligible hospitals in a frontier State when calculating the outlier threshold that results in outlier payments being 5.1 percent of total payments for FY 2016. If we did not take the above into account, our estimate of total FY 2016 payments would be too low, and, as a result, our proposed outlier threshold would be too high, such that estimated outlier payments would be less than our projected 5.1 percent of total payments.

As we did in establishing the FY 2009 outlier threshold (73 FR 57891), in our projection of FY 2016 outlier payments, we proposed not to make any adjustments for the possibility that hospitals’ CCRs and outlier payments may be reconciled upon cost report settlement. We stated that we continue to believe that, due to the policy implemented in the June 9, 2003 Outlier final rule (68 FR 34494), CCRs will no longer fluctuate significantly and, therefore, few hospitals will actually have these ratios
reconciled upon cost report settlement. In addition, it is difficult to predict the specific hospitals that will have CCRs and outlier payments reconciled in any given year. We note that we have instructed MACs to identify for CMS any instances where (1) a hospital’s actual CCR for the cost reporting period fluctuates plus or minus 10 percentage points compared to the interim CCR used to calculate outlier payments when a bill is processed; and (2) the total outlier payments for the hospital exceeded $500,000.00 for that period. Our simulations assume that CCRs accurately measure hospital costs based on information available to us at the time we set the outlier threshold. For these reasons, we proposed not to make any assumptions regarding the effects of reconciliation on the outlier threshold calculation.

Comment: Commenters were concerned with CMS’ decision not to consider outlier reconciliation in developing the outlier threshold and stated that it has not provided objective data concerning the number of hospitals that have been subjected to reconciliation and the amounts recovered during this process. The commenters’ views were similar to comments received and responded to in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50376 through 50377).

Another commenter submitted the same comment as last year and cited CMS’ response from the FY 2015 IPPS/LTCH PPS final rule (79 FR 50377). The commenter questioned CMS’ response with the following comments: The commenter asked what is the basis for CMS’ claim “that the CCRs will reflect low costs and high charges that the commenter referred to, and when applied to the charges on the claim will result in less outlier payments for such cases because the costs of the case will be lower when
compared to the total MS-DRG payments excluding outlier payments.” The commenter cited the 2013 OIG Report and stated that the report seems to state the opposite of CMS’ position when it states that “high-outlier hospitals charged Medicare substantially more for the same MS-DRGs, yet had similar average lengths of stay and CCRs.” The commenter further cited the same 2013 OIG report which stated “that high-outlier hospitals had similar average CCRs, compared to all other hospitals, which means that the higher charges by the hospitals directly resulted in larger and more frequent outlier payments. As mentioned, Medicare applies a hospital’s CCR to the covered charges on a claim to determine the estimated cost of services covered by the claim. The amount of the estimated cost determines whether Medicare makes an outlier payment and the amount received. In 2008, the average CCR at high-outlier hospitals was the same as the average CCR for all other hospitals, 0.35. CCRs declined, on average, during 2008-2011, to 0.30 at high-outlier hospitals and to 0.33 at all other hospitals. Although the high-outlier hospitals had higher charges, their CCR (that is, 0.30) was not significantly lower than the CCR of all other hospitals (that is, 0.33). Therefore, the higher charges led Medicare to calculate higher estimated costs for the high-outlier hospitals, and paying larger, more frequent outlier payments.”

The commenter concluded that it is neither consistent with the outlier statute nor reasonable for CMS, in modeling outlier payments for the upcoming fiscal year, to include outlier payments that were based on excessively high charges for particular MS-DRGs and not based on truly unusually high costs. The commenter suggested that, if CMS claims that such payments will not be recouped because they do not trigger
reconciliation under current criteria, CMS explain how it plans to address the matter in setting the outlier fixed-loss cost threshold. The commenter suggested the following possibilities: Chapter 3, Section 20.1.2 of the Medicare Claims Processing Manual authorizes CMS to “direct Medicare contractors to use an alternative CCR if CMS believes this will result in a more accurate CCR” or a Medicare contractor “may specify an alternative CCR if it believes that the CCR being applied is inaccurate.”

Response: We responded to similar comments in the FY 2015 IPPS/LTCH final rule (79 FR 50376 through 50377) and refer readers to that final rule. With regard to the OIG report that the commenter believed contradicted our statement in last year’s final rule, we note that the OIG report used CCRs from 2008-2011. The CCRs are updated in the PSF at the time the MAC tentatively settles the hospital cost report, which is approximately 6 to 7 months after the cost report has been submitted. Thus, there is a lag in CCRs with the possibility that a CCR may be 18 months old from the time the cost report is submitted by the provider to the MAC until it is updated at the following tentative settlement. Because hospitals typically increase their charges, over time CCRs will decrease but, due to the lag these lower CCRs will not be reflected in the PSF until the following tentative settlement. Thus, it is possible that the PSF will reflect CCRs that are similar for hospitals with high and low outlier payments. In addition, providers determine what they will charge for items, services, and procedures provided to patients, and these charges are the amount that the providers bill for an item, service, or procedure. Moreover, different hospitals can have similar lengths of stay but different CCRs. We encourage transparency with respect to hospital charges and have posted hospital charge
data on the CMS Web site at [https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data](https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data). In addition, as the commenter noted, there are mechanisms to avoid outlier overpayments or underpayments as CMS and the MACs have the authority to specify an alternative CCR. Also, in addition to the examples cited by the commenter, as we note in every proposed and final rule, hospitals can also request alternative CCRs. Therefore, if hospitals make these requests, these CCRs would be reflected in the PSF which would be used to compute the fixed-loss threshold.

As described in sections IV.H. and IV.I., respectively, of the preamble of this final rule, sections 1886(q) and 1886(o) of the Act establish the Hospital Readmissions Reduction Program and the Hospital VBP Program, respectively. We do not believe that it is appropriate to include the hospital VBP payment adjustments and the hospital readmissions payment adjustments in the outlier threshold calculation or the outlier offset to the standardized amount. Specifically, consistent with our definition of the base operating DRG payment amount for the Hospital Readmissions Reduction Program under § 412.152 and the Hospital VBP Program under § 412.160, outlier payments under section 1886(d)(5)(A) of the Act are not affected by these payment adjustments. Therefore, outlier payments will continue to be calculated based on the unadjusted base DRG payment amount (as opposed to using the base-operating DRG payment amount adjusted by the hospital readmissions payment adjustment and the hospital VBP payment adjustment). Consequently, we proposed to exclude the hospital VBP payment
adjustments and the hospital readmissions payment adjustments from the calculation of the outlier fixed-loss cost threshold.

We noted that, to the extent section 1886(r) of the Act modifies the existing DSH payment methodology under section 1886(d)(5)(F) of the Act, the new uncompensated care payment under section 1886(r)(2) of the Act, like the empirically justified Medicare DSH payment under section 1886(r)(1) of the Act, may be considered an amount payable under section 1886(d)(5)(F) of the Act such that it would be reasonable to include the payment in the outlier determination under section 1886(d)(5)(A) of the Act. As we did for FY 2014 and FY 2015, for FY 2016, we proposed to allocate an estimated per-discharge uncompensated care payment amount to all cases for the hospitals eligible to receive the uncompensated care payment amount in the calculation of the outlier fixed-loss cost threshold methodology. We stated that we continue to believe that allocating an eligible hospital’s estimated uncompensated care payment to all cases equally in the calculation of the outlier fixed-loss cost threshold would best approximate the amount we would pay in uncompensated care payments during the year because, when we make claim payments to a hospital eligible for such payments, we would be making estimated per-discharge uncompensated care payments to all cases equally. Furthermore, we stated that we continue to believe that using the estimated per-claim uncompensated care payment amount to determine outlier estimates provides predictability as to the amount of uncompensated care payments included in the calculation of outlier payments. Therefore, consistent with the methodology used in FY 2014 and FY 2015 to calculate the outlier fixed-loss cost threshold, for FY 2016, we
proposed to include estimated FY 2016 uncompensated care payments in the computation of the proposed outlier fixed-loss cost threshold. Specifically, we proposed to use the estimated per-discharge uncompensated care payments to hospitals eligible for the uncompensated care payment for all cases in the calculation of the outlier fixed-loss cost threshold methodology.

Using this methodology, we proposed an outlier fixed-loss cost threshold for FY 2016 equal to the prospective payment rate for the MS-DRG, plus any IME, empirically justified Medicare DSH payments, estimated uncompensated care payment, and any add-on payments for new technology, plus $24,485.

In the proposed rule, we noted that the proposed FY 2016 fixed-loss cost threshold is lower than the FY 2015 final outlier fixed-loss cost threshold of $24,626. We stated that we believe that the decrease in the charge inflation factor (compared to the FY 2015 charge inflation factor) contributed to a lower outlier fixed-loss threshold for FY 2016. As charges decrease, so does the amount of outlier payments. As a result, it was necessary for us to lower the proposed outlier fixed-loss cost threshold to increase the amount of outlier payments expended in order to reach the 5.1 percent target.

Comment: One commenter believed that it is important that CMS accurately calculate prior year actual payment comparisons to the 5.1 percent target. The commenter asserted that it is not possible for CMS to appropriately modify its methodology to achieve an accurate result if it is not aware of, or misinformed about, inaccuracies resulting from prior the prior year methodology. The commenter cited the FY 2014 IPPS/LTCH PPS proposed rule as an example where CMS indicated that using
partial year data for FY 2013 demonstrated that outlier payments would equal about 5.17 percent of overall payments, while in the FY 2015 IPPS/LTCH PPS final rule, CMS indicated that, for FY 2013, outlier payments would equal about 4.81 percent of MS-DRG payments. The commenter stated that this demonstrates that CMS’ early estimate for FY 2013 was too high, as has often been the case. The commenter also cited the FY 2015 IPPS/LTCH PPS final rule correction notice (79 FR 59681) as another example where using the FY 2013 MedPAR file, CMS estimated actual FY 2014 outlier payments would be approximately 5.68 percent of actual total MS–DRG payments, while the current estimate, using available FY 2014 claims data, is that actual outlier payments for FY 2014 were approximately 5.34 percent of actual total MS–DRG payments.

The commenter stated that it was concerned that CMS believed it was over shooting its target amount for FY 2014 by 0.58 percent and this motivated CMS to dramatically increase the threshold for FY 2015, only to learn this year that its estimate was grossly overstated. The commenter concluded that it is critical that CMS not allow the use of incomplete data from prior years to affect its calculation of current period thresholds.

Another commenter noted that the final outlier threshold established by CMS is always significantly lower than the threshold set forth in the proposed rule. The commenter believed the decline is most likely due to the use of updated CCRs or other data in calculating the final threshold. The commenter stated that this emphasizes that CMS must use the most recent data available when it calculates the outlier threshold. The commenter cited as an example that, in the proposed rule, CMS used data from the
December 2014 PSF file, but at the time the proposed rule was issued, the March 2015 PSF file was available.

Response: We responded to similar comments in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50378 through 50379) and refer the reader to that rule for our response.

Comment: One commenter stated CMS’ explanation of why the threshold decreased from FY 2015 to FY 2016 conflicts with its historical adjustments to the outlier fixed-loss cost threshold. The commenter noted that, from FY 2013 to FY 2014, CMS decreased the outlier fixed-loss cost threshold even though the charge inflation factor increased compared to the previous year. Moreover, the commenter stated that CMS is incorrect that its model assumes that charges will decrease in FY 2016 when compared to FY 2015 for several reasons. First, the average charge per case from the FY 2014 MedPAR file (used to calculate the FY 2016 outlier fixed-loss cost threshold) is approximately 5 percent higher than the average charge per case from the FY 2013 MedPAR file (used to calculate the FY 2015 outlier fixed-loss cost threshold; 79 FR 50375 and 50379). Second, the proposed rule establishes a 1-year charge inflation factor of 4.8116 percent, which is only 0.2801 percent lower than the FY 2015 1-year charge inflation factor of 5.0917 percent (80 FR 24632 and 79 FR 50379). Accordingly, the commenter stated that the proposed rule is proposing to lower the outlier fixed-loss cost threshold even though charges are projected to increase (that is, net charge inflation) in FY 2016 (when compared to FY 2015). The commenter requested that CMS explain this reduction because the proposed reduction in the outlier fixed-loss cost threshold cannot be attributed to a decrease in charges (because charges increased).
Response: In our description comparing the proposed FY 2016 outlier threshold to the FY 2015 final threshold, we stated that the decrease in charges contributed to a lower threshold. We did not state that this was the only reason. When we conduct our modeling to determine the outlier threshold, we factor in all payments and policies that would affect actual payments for the upcoming fiscal year in order to estimate that outlier payments are 5.1 percent of total MS-DRG payments. As a result, there are many components of the payment system that can contribute to the increase and decrease of outlier payments. Also, we believe the commenter, by only comparing the 1-year change, is inadvertently distorting the variance of the charge inflation factor. For FY 2016, we are using claims from FY 2014, which requires a 2-year inflation factor. The actual variance in the charge inflation factor from FY 2015 to FY 2016 is 0.5880 percent (FY 2015 IPPS/LTCH PPS final rule 2-year inflation factor of 1.104427 minus FY 2016 IPPS/LTCH PPS proposed rule 2-year inflation factor 1.098547).

Comment: One commenter believed that the outlier threshold should be further reduced because outlier payments this year are on target to fall below the 5.1 percent target. The commenter suggested that CMS consider calculating the threshold with a target of 5.5 percent of inpatient spending in order to ensure that the final total of outlier payment is between the statutory requirements of 5 to 6 percent of total payments.

Another commenter recommended that that threshold be maintained at the FY 2014 level of $21,748 until CMS develops a more reliable methodology for meeting the 5.1 percent target. One other commenter also noted that CMS’ estimate of FY 2015 outlier payments in the proposed rule was 4.88 percent, which is below the 5.1 percent
target. The commenter believed that the proposed FY 2016 threshold was understated. As a result, the commenter suggested that CMS apply the following formula to compute the FY 2016 outlier threshold: Step 1--FY 2015 Difference = (5.1 percent Target - 4.88 percent estimate from FY 2015 = 0.22 percent) / 4.88 percent estimate from FY 2015 = 4.51 percent; Step 2--Suggested FY 2016 Threshold = Threshold from FY 2015 of $24,626 * (100 – 4.51 from Step 1 = 95.49 percent) = $23,515.

Response: As we responded to similar comments in the FY 2015 IPPS/LTCH PPS final rule (78 FR 50379), section 1886(d)(5)(A)(iv) of the Act requires outlier payments to be not less than 5 percent nor more than 6 percent of total estimated or projected payments in that year. Therefore, we cannot adopt the commenters’ suggestions of using a target of 5.5 percent, maintaining the threshold at the FY 2014 level, or using a forecast correction to compute the outlier threshold. When we calculate the threshold, we use the latest data that are available at the time of the development of the proposed and final rules in order to estimate that outlier payments are 5.1 percent of total payments.

Comment: One commenter was concerned that CMS constantly misses the 5.1 percent target. The commenter recommended that CMS conduct additional analysis to evaluate the methodology for incorporating uncompensated care and DSH payment into the outlier threshold calculation.

Response: As discussed above, we include uncompensated care payments in our calculation of the fixed-loss outlier threshold. Without additional information or data analysis, we are unsure what exactly the commenter is referencing when the commenter
stated that CMS should further evaluate the methodology for incorporating uncompensated care and DSH payments into the outlier threshold calculation.

After consideration of the public comments we received, we are not making any changes to our methodology in this final rule for FY 2016. Therefore, we are using the same methodology we proposed to calculate the final outlier threshold.

As described above, we used the latest claims data from the MedPAR file to compute the charge inflation factor. Similar to the table provided in the proposed rule, for this final rule, we are providing the following table that displays covered charges and cases by quarter in the periods used to calculate the charge inflation factor.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$126,565,555,412</td>
<td>2,486,502</td>
<td>$100,567,278,074</td>
<td>1,932,720</td>
</tr>
<tr>
<td>2</td>
<td>$118,792,100,497</td>
<td>2,505,875</td>
<td>$121,989,001,463</td>
<td>2,444,426</td>
</tr>
<tr>
<td>3</td>
<td>$115,796,137,233</td>
<td>2,424,262</td>
<td>$118,516,052,865</td>
<td>2,351,444</td>
</tr>
<tr>
<td>4</td>
<td>$119,439,461,865</td>
<td>2,405,925</td>
<td>$122,175,830,268</td>
<td>2,396,231</td>
</tr>
<tr>
<td>Total</td>
<td>$480,593,255,007</td>
<td>9,822,564</td>
<td>$463,248,162,670</td>
<td>9,124,821</td>
</tr>
</tbody>
</table>

Under our current methodology, to compute the 1-year average annualized rate-of-change in charges per case for FY 2016, based on the data from the table above, we compared the average covered charge per case of $48,927 ($480,593,255,007/9,822,564) from the third quarter of FY 2013 through the second quarter of FY 2014 (April 1, 2013, through March 31, 2014) to the average covered charge per case of $50,768 ($463,248,162,670/9,124,821) from the third quarter of FY 2014 through the
second quarter of FY 2015 (April 1, 2014, through March 31, 2015). This rate-of-change is 3.7 percent (1.037616) or 7.7 percent (1.076647) over 2 years.

As we have done in the past, we are establishing the FY 2016 outlier threshold using hospital CCRs from the March 2015 update to the Provider-Specific File (PSF)--the most recent available data at the time of development of this final rule. For FY 2016, we also are continuing to apply an adjustment factor to the CCRs to account for cost and charge inflation (as explained below). In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we adopted a new methodology to adjust the CCRs. Specifically, we finalized a policy to compare the national average case-weighted operating and capital CCR from the most recent update of the PSF to the national average case-weighted operating and capital CCR from the same period of the prior year.

Therefore, as we did for FY 2014 and for FY 2015, we are adjusting the CCRs from the March 2015 update of the PSF by comparing the percentage change in the national average case-weighted operating CCR and capital CCR from the March 2014 update of the PSF to the national average case-weighted operating CCR and capital CCR from the March 2015 update of the PSF. We note that we used total transfer-adjusted cases from FY 2014 to determine the national average case-weighted CCRs for both sides of the comparison. As stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we believe that it is appropriate to use the same case count on both sides of the comparison as this will produce the true percentage change in the average case-weighted operating and capital CCR from one year to the next without any effect from a change in case count on different sides of the comparison.
Using the methodology above, we calculated a March 2014 operating national average case-weighted CCR of 0.287139 and a March 2015 operating national average case-weighted CCR of 0.278565. We then calculated the percentage change between the two national operating case-weighted CCRs by subtracting the March 2014 operating national average case-weighted CCR from the March 2015 operating national average case-weighted CCR and then dividing the result by the March 2014 national operating average case-weighted CCR. This resulted in a national operating CCR adjustment factor of 0.970141.

We also used the same methodology above to adjust the capital CCRs. Specifically, we calculated a March 2014 capital national average case-weighted CCR of 0.024879 and a March 2015 capital national average case-weighted CCR of 0.024243. We then calculated the percentage change between the two national capital case-weighted CCRs by subtracting the March 2014 capital national average case-weighted CCR from the March 2015 capital national average case-weighted CCR and then dividing the result by the March 2014 capital national average case-weighted CCR. This resulted in a national capital CCR adjustment factor of 0.974442.

Consistent with our methodology in the past and as stated in the FY 2009 IPPS final rule (73 FR 48763), we continue to believe that it is appropriate to apply only a 1-year adjustment factor to the CCRs. On average, it takes approximately 9 months for a MAC to tentatively settle a cost report from the fiscal year end of a hospital’s cost reporting period. The average “age” of hospitals’ CCRs from the time the fiscal intermediary or the MAC inserts the CCR in the PSF until the beginning of FY 2016 is
approximately 1 year. Therefore, as stated above, we believe a 1-year adjustment factor to the CCRs is appropriate.

As stated above, for FY 2016, we applied the FY 2016 payment rates and policies using cases from the FY 2014 MedPAR files in calculating the outlier threshold.

As discussed above, for FY 2016, we are applying the second year of the 3-year transitional wage index because of the adoption of the new OMB labor market area delineations. Also, as discussed in section III.B.3. of the preamble to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50160 and 50161) and in section III.H.3. of the preamble of this final rule, in accordance with section 10324(a) of the Affordable Care Act, we created a wage index floor of 1.0000 for all hospitals located in States determined to be frontier States. We note that the frontier State floor adjustments are calculated and applied after rural and imputed floor budget neutrality adjustments are calculated for all labor market areas, in order to ensure that no hospital in a frontier State receives a wage index less than 1.0000 due to the rural and imputed floor adjustment. In accordance with section 10324(a) of the Affordable Care Act, the frontier State adjustment will not be subject to budget neutrality, and will only be extended to hospitals geographically located within a frontier State. However, for purposes of estimating the outlier threshold for FY 2016, it was necessary to apply the 3-year transitional wage indexes and adjust the wage index of those eligible hospitals in a frontier State when calculating the outlier threshold that results in outlier payments being 5.1 percent of total payments for FY 2016. If we did not take the above into account, our estimate of total FY 2016 payments would be too low, and, as a result, our outlier threshold would be too
high, such that estimated outlier payments would be less than our projected 5.1 percent of total payments.

As we did in establishing the FY 2009 outlier threshold (73 FR 57891), as we proposed and for the reasons discussed above, in our projection of FY 2016 outlier payments, we are not making any adjustments for the possibility that hospitals’ CCRs and outlier payments may be reconciled upon cost report settlement.

As described in sections IV.E. and IV.F. respectively, of the preamble of this final rule, sections 1886(q) and 1886(o) of the Act establish the Hospital Readmissions Reduction Program and the Hospital VBP Program, respectively. We do not believe that it is appropriate to include the hospital VBP payment adjustments and the hospital readmissions payment adjustments in the outlier threshold calculation or the outlier offset to the standardized amount. Specifically, consistent with our definition of the base operating DRG payment amount for the Hospital Readmissions Reduction Program under § 412.152 and the Hospital VBP Program under § 412.160, outlier payments under section 1886(d)(5)(A) of the Act are not affected by these payment adjustments. Therefore, outlier payments will continue to be calculated based on the unadjusted base DRG payment amount (as opposed to using the base-operating DRG payment amount adjusted by the hospital readmissions payment adjustment and the hospital VBP payment adjustment). Consequently, we excluded the hospital VBP payment adjustments and the hospital readmissions payment adjustments from the calculation of the outlier fixed-loss cost threshold.
We note that, to the extent section 1886(r) of the Act modifies the DSH payment methodology under section 1886(d)(5)(F) of the Act, the new uncompensated care payment under section 1886(r)(2) of the Act, like the empirically justified Medicare DSH payment under section 1886(r)(1) of the Act, may be considered an amount payable under section 1886(d)(5)(F) of the Act such that it would be reasonable to include the payment in the outlier determination under section 1886(d)(5)(A) of the Act. As we did for FYs 2014 and 2015, we also for FY 2016 allocated an estimated per-discharge uncompensated care payment amount to all cases for the hospitals eligible to receive the uncompensated care payment amount in the calculation of the outlier fixed-loss cost threshold methodology. We continue to believe that allocating an eligible hospital’s estimated uncompensated care payment to all cases equally in the calculation of the outlier fixed-loss cost threshold best approximates the amount we will pay in uncompensated care payments during the year because, when we make claim payments to a hospital eligible for such payments, we will be making estimated per-discharge uncompensated care payments to all cases equally. Furthermore, we continue to believe that using the estimated per-claim uncompensated care payment amount to determine outlier estimates provides predictability as to the amount of uncompensated care payments included in the calculation of outlier payments. Therefore, consistent with the methodology used in FYs 2014 and 2015 to calculate the outlier fixed-loss cost threshold, for FY 2016, we included estimated FY 2016 uncompensated care payments in the computation of the outlier fixed-loss cost threshold. Specifically, we used the estimated per-discharge uncompensated care payments to hospitals eligible for the uncompensated
care payment for all cases in the calculation of the outlier fixed-loss cost threshold methodology.

Using this methodology, we calculated a final outlier fixed-loss cost threshold for FY 2016 equal to the prospective payment rate for the MS-DRG, plus any IME, empirically justified Medicare DSH payments, estimated uncompensated care payments, and any add-on payments for new technology, plus $22,544.

(2) Other Changes Concerning Outliers

As stated in the FY 1994 IPPS final rule (58 FR 46348), we establish an outlier threshold that is applicable to both hospital inpatient operating costs and hospital inpatient capital-related costs. When we modeled the combined operating and capital outlier payments, we found that using a common threshold resulted in a lower percentage of outlier payments for capital-related costs than for operating costs. We project that the thresholds for FY 2016 will result in outlier payments that will equal 5.1 percent of operating DRG payments and 6.35 percent of capital payments based on the Federal rate.

In accordance with section 1886(d)(3)(B) of the Act, we reduced the FY 2016 standardized amount by the same percentage to account for the projected proportion of payments paid as outliers.

The outlier adjustment factors that were applied to the standardized amount based on the FY 2016 outlier threshold are as follows:

<table>
<thead>
<tr>
<th></th>
<th>Operating Standardized Amounts</th>
<th>Capital Federal Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>0.949000</td>
<td>0.936519</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>0.935042</td>
<td>0.919230</td>
</tr>
</tbody>
</table>
We applied the outlier adjustment factors to the FY 2016 payment rates after removing the effects of the FY 2015 outlier adjustment factors on the standardized amount.

To determine whether a case qualifies for outlier payments, we apply hospital-specific CCRs to the total covered charges for the case. Estimated operating and capital costs for the case are calculated separately by applying separate operating and capital CCRs. These costs are then combined and compared with the outlier fixed-loss cost threshold.

Under our current policy at § 412.84, we calculate operating and capital CCR ceilings and assign a statewide average CCR for hospitals whose CCRs exceed 3.0 standard deviations from the mean of the log distribution of CCRs for all hospitals. Based on this calculation, for hospitals for which the MAC computes operating CCRs greater than 1.21 or capital CCRs greater than 0.175, or hospitals for which the MAC is unable to calculate a CCR (as described under § 412.84(i)(3) of our regulations), statewide average CCRs are used to determine whether a hospital qualifies for outlier payments. Table 8A listed in section VI. of this Addendum (and available only via the Internet on the CMS Web site) contains the statewide average operating CCRs for urban hospitals and for rural hospitals for which the MAC is unable to compute a hospital-specific CCR within the above range. Effective for discharges occurring on or after October 1, 2015, these statewide average ratios will replace the ratios posted on our Web site at "http://www.cms.gov/Medicare/Medicare-Fee-for-Service-"
Table 8B listed in section VI. of this Addendum (and available via the Internet on the CMS Web site) contains the comparable statewide average capital CCRs. As previously stated, the CCRs in Tables 8A and 8B will be used during FY 2016 when hospital-specific CCRs based on the latest settled cost report either are not available or are outside the range noted above. Table 8C listed in section VI. of this Addendum (and available via the Internet on the CMS Web site) contains the statewide average total CCRs used under the LTCH PPS as discussed in section V. of this Addendum.

We finally note that we published a manual update (Change Request 3966) to our outlier policy on October 12, 2005, which updated Chapter 3, Section 20.1.2 of the Medicare Claims Processing Manual. The manual update covered an array of topics, including CCRs, reconciliation, and the time value of money. We encourage hospitals that are assigned the statewide average operating and/or capital CCRs to work with their MAC on a possible alternative operating and/or capital CCR as explained in Change Request 3966. Use of an alternative CCR developed by the hospital in conjunction with the MAC can avoid possible overpayments or underpayments at cost report settlement, thereby ensuring better accuracy when making outlier payments and negating the need for outlier reconciliation. We also note that a hospital may request an alternative operating or capital CCR ratio at any time as long as the guidelines of Change Request 3966 are followed. In addition, we published an additional manual update (Change Request 7192) to our outlier policy on December 3, 2010, which also updated Chapter 3,

(3) FY 2014 and FY 2015 Outlier Payments

In the FY 2015 IPPS/LTCH PPS final rule correction notice (79 FR 59681), we stated that, based on available data, we estimated that actual FY 2014 outlier payments would be approximately 5.68 percent of actual total MS-DRG payments. This estimate was computed based on simulations using the FY 2013 MedPAR file (discharge data for FY 2013 claims). That is, the estimate of actual outlier payments did not reflect actual FY 2014 claims, but instead reflected the application of FY 2014 payment rates and policies to available FY 2013 claims.

Our current estimate, using available FY 2014 claims data, is that actual outlier payments for FY 2014 were approximately 5.38 percent of actual total MS-DRG payments. Therefore, the data indicate that, for FY 2014, the percentage of actual outlier payments relative to actual total payments is higher than we projected for FY 2014. Consistent with the policy and statutory interpretation we have maintained since the inception of the IPPS, we do not make retroactive adjustments to outlier payments to ensure that total outlier payments for FY 2014 are equal to 5.1 percent of total MS-DRG payments.

We currently estimate that, using the latest CCRs from the March 2015 update of the PSF, actual outlier payments for FY 2015 will be approximately 4.65 percent of
actual total MS-DRG payments, approximately 0.45 percentage point lower than the 5.1 percent we projected when setting the outlier policies for FY 2015. This estimate of 4.65 percent is based on simulations using the FY 2014 MedPAR file (discharge data for FY 2014 claims).

Comment: One commenter requested that CMS clarify its methodology used to calculate historical outlier payments. The commenter noted that CMS used FY 2014 claims data to model the total estimated actual outlier payments for FY 2014. The commenter stated that commenters have repeatedly noted that CMS’ model overestimates the amount of total outlier payments, as compared to using actual claims data. The commenter further stated that in the FYs 2013 and 2014 IPPS/LTCH PPS final rules (77 FR 53698 and 78 FR 50983, respectively), one commenter used cost report data from the HCRIS to analyze the historical actual outlier payout from 2003 through 2010 and 2012 through 2014, which demonstrated that total outlier payments as a percentage of total MS-DRG payments are substantially lower than what CMS has “modeled.”

The commenter stated that actual outlier payment estimates should be objectively calculated independent of HHS’s “modeling” methodology. The commenter further stated that, in setting the fixed-loss cost threshold, CMS considers prior fiscal years’ outlier payments and therefore it is important to have an accurate tally of those payments. The commenter concluded that CMS’ estimates are unreliable and commenters have demonstrated far more reliable methods.

Response: As stated above, we do not rely upon historical actual outlier payments to determine the fixed-loss cost threshold. When we calculate the threshold, we use the
latest data that are available at the time of the proposed and final rule in order to estimate that outlier payments are 5.1 percent of total payments. With regard to the remainder of the commenter’s views, we have responded to similar comments in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51796) and refer readers to that final rule.

Comment: One commenter asked if CMS can confirm if calculations of historical actual outlier payments based on HCRIS data produce lower total outlier payments than CMS’ methodology. The commenter stated that the correct calculation of actual outlier payments is important because CMS relies upon historical actual outlier payments to determine the fixed-loss cost threshold and general IPPS payments. The commenter noted that, in the proposed rule (80 FR 24665), CMS stated that “The impact of moving from our estimate of FY 2015 outlier payments, 4.9 percent, to the proposed estimate of FY 2016 outlier payments, 5.1 percent, would result in an increase of 0.2 percent in FY 2016 payments relative to FY 2015.” Based on this statement, the commenter stated that if the estimate of FY 2015 outlier payments was lower than 4.9 percent, CMS would need to make a corresponding upward adjustment in FY 2016 payments relative to FY 2015. The commenter further stated that if CMS’ modeling efforts to calculate historical outlier payments have consistently underestimated actual outlier payments, CMS should adjust FY 2016 payments to compensate for the miscalculation of historical outlier payments. The commenter believed that such a correction would not be retroactive per se as CMS would simply be making the adjustment for upcoming fiscal year payments.
Response: Contrary to the commenter’s statement, as stated above, we do not rely upon historical actual outlier payments to determine the fixed-loss cost threshold. When we calculate the threshold, we use the latest data that are available at the time of the proposed and final rule in order to estimate that outlier payments are 5.1 percent of total payments. For purposes of impacts and assessing whether or not potential changes to the outlier methodology may be warranted, we estimate outlier payments from the preceding fiscal year. However, this estimate does not impact the calculation of the fixed-loss threshold for the upcoming fiscal year. With regard to using HCRIS data to measure actual outlier payments, hospitals’ cost reporting periods do not match the period of the Federal fiscal year. For example, many hospitals submit cost reports based on a calendar year (January 1 through December 31), while the Federal fiscal year runs from October 1 through September 30. Outlier payments are reported in the aggregate on the cost report, and it is currently not possible to break out outlier payments from the cost report to a Federal fiscal year if the cost report submitted by the provider is using a different reporting period.

5. FY 2016 Standardized Amount

The adjusted standardized amount is divided into labor-related and nonlabor-related portions. Tables 1A and 1B listed and published in section VI. of this Addendum (and available via the Internet on the CMS Web site) contain the national standardized amounts that we are applying to all hospitals, except hospitals located in Puerto Rico, for FY 2016. The Puerto Rico-specific amounts are shown in Table 1C listed and published in section VI. of this Addendum (and available via the Internet on
the CMS Web site). The amounts shown in Tables 1A and 1B differ only in that the
labor-related share applied to the standardized amounts in Table 1A is 69.6 percent, and
the labor-related share applied to the standardized amounts in Table 1B is 62 percent. In
accordance with sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act, we are
applying a labor-related share of 62 percent, unless application of that percentage will
result in lower payments to a hospital than would otherwise be made. In effect, the
statutory provision means that we will apply a labor-related share of 62 percent for all
hospitals whose wage indexes are less than or equal to 1.0000.

In addition, Tables 1A and 1B include the standardized amounts reflecting the
applicable percentage increases for FY 2016.

Under section 1886(d)(9)(A)(ii) of the Act, the Federal portion of the Puerto Rico
payment rate is based on the discharge-weighted average of the national large urban
standardized amount (this amount is set forth in Table 1A). The labor-related and
nonlabor-related portions of the national average standardized amounts for Puerto Rico
hospitals for FY 2016 are set forth in Table 1C listed and published in section VI. of this
Addendum (and available via the Internet on the CMS Web site). This table also includes
the Puerto Rico-specific standardized amounts. The labor-related share applied to the
Puerto Rico-specific standardized amount is the labor-related share of 63.2 percent, or
62 percent, depending on which provides higher payments to the hospital.

(Section 1886(d)(9)(C)(iv) of the Act, as amended by section 403(b) of Pub. L. 108-173,
provides that the labor-related share for hospitals located in Puerto Rico be 62 percent,
unless the application of that percentage would result in lower payments to the hospital.)
The following table illustrates the changes from the FY 2015 national standardized amount to the FY 2016 national standardized amount. The second through fifth columns display the changes from the FY 2015 standardized amounts for each applicable FY 2016 standardized amount. The first row of the table shows the updated (through FY 2015) average standardized amount after restoring the FY 2015 offsets for outlier payments, demonstration budget neutrality, geographic reclassification budget neutrality, new labor market delineation wage Index transition budget neutrality and the retrospective documentation and coding adjustment under section 7(b)(1)(B) of Pub. L. 110-90. The MS-DRG reclassification and recalibration and wage index budget neutrality adjustment factors are cumulative. Therefore, those FY 2015 adjustment factors are not removed from this table.
## COMPARISON OF FY 2015 STANDARDIZED AMOUNTS TO THE FY 2016 STANDARDIZED AMOUNTS

<table>
<thead>
<tr>
<th></th>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2015 Base Rate after removing:</td>
<td>1. FY 2015 Geographic Reclassification Budget Neutrality (0.990429)</td>
<td>2. FY 2015 Rural Community Hospital Demonstration Program Budget Neutrality (0.999313)</td>
<td>3. Cumulative FY 2008, FY 2009, FY 2012, FY 2013 and FY 2014, FY 2015 Documentation and Coding Adjustment as Required under Sections 7(b)(1)(A) and 7(b)(1)(B) of Pub. L. 110-90 and Documentation and Coding Recoupment Adjustment as required under Section 631 of the American Taxpayer Relief Act of 2012 (0.9329)</td>
<td>4. FY 2015 Operating Outlier Offset (0.948999) 5. FY 2015 New Labor Market Delineation Wage Index Transition Budget Neutrality Factor (0.998854)</td>
</tr>
<tr>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6%):</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6%):</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6%):</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6%):</td>
<td></td>
</tr>
<tr>
<td>Nonlabor (30.4%):</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6%):</td>
<td>Nonlabor (30.4%):</td>
<td>Nonlabor (30.4%):</td>
<td></td>
</tr>
<tr>
<td>$4,324.23</td>
<td>$4,324.23</td>
<td>$4,324.23</td>
<td>$4,324.23</td>
<td></td>
</tr>
<tr>
<td>$1,888.74</td>
<td>$1,888.74</td>
<td>$1,888.74</td>
<td>$1,888.74</td>
<td></td>
</tr>
<tr>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%):</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%):</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%):</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%):</td>
<td></td>
</tr>
<tr>
<td>Nonlabor (38%):</td>
<td>Nonlabor (38%):</td>
<td>Nonlabor (38%):</td>
<td>Nonlabor (38%):</td>
<td></td>
</tr>
<tr>
<td>$3,852.04</td>
<td>$3,852.04</td>
<td>$3,852.04</td>
<td>$3,852.04</td>
<td></td>
</tr>
<tr>
<td>$2,360.93</td>
<td>$2,360.93</td>
<td>$2,360.93</td>
<td>$2,360.93</td>
<td></td>
</tr>
<tr>
<td>FY 2016 Update Factor</td>
<td>1.017</td>
<td>1.005</td>
<td>1.011</td>
<td>0.999</td>
</tr>
</tbody>
</table>

| FY 2016 MS-DRG Recalibration and Wage Index Budget Neutrality Factor | 0.997150 | 0.997150 | 0.997150 | 0.997150 |

| FY 2016 Reclassification Budget Neutrality Factor | 0.987905 | 0.987905 | 0.987905 | 0.987905 |
The following table illustrates the changes from the FY 2015 Puerto Rico-specific payment rate for hospitals located in Puerto Rico. The second column shows the changes from the FY 2015 Puerto Rico specific payment rate for hospitals with a Puerto Rico-specific wage index greater than 1.0000. The third column shows the changes from the FY 2015 Puerto Rico specific payment rate for hospitals with a Puerto Rico-specific wage index less than or equal to 1.0000.

<table>
<thead>
<tr>
<th></th>
<th>FY 2016 Rural Community Demonstration Program Budget Neutrality Factor</th>
<th>FY 2016 Operating Outlier Factor</th>
<th>Cumulative Factor: FY 2008, FY 2009, FY 2012, FY 2013, FY 2014, FY 2015 and FY 2016 Documentation and Coding Adjustment as Required under Sections 7(b)(1)(A) and 7(b)(1)(B) of Pub. L. 110-90 and Documentation and Coding Recoupment Adjustment as required under Section 631 of the American Taxpayer Relief Act of 2012</th>
<th>FY 2016 New Labor Market Delineation Wage Index 3-Year Hold Harmless Transition Budget Neutrality Factor</th>
<th>National Standardized Amount for FY 2016 if Wage Index is Greater Than 1.0000; Labor/Non-Labor Share Percentage (69.6/30.4)</th>
<th>National Standardized Amount for FY 2016 if Wage Index is less Than or Equal to 1.0000; Labor/Non-Labor Share Percentage (62/38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2016 Rural Community Demonstration Program Budget Neutrality Factor</td>
<td>0.999861</td>
<td>0.999861</td>
<td>0.999861</td>
<td>0.999861</td>
<td>0.999996</td>
<td>0.999996</td>
</tr>
<tr>
<td>FY 2016 Operating Outlier Factor</td>
<td>0.949000</td>
<td>0.949000</td>
<td>0.949000</td>
<td>0.949000</td>
<td>0.9255</td>
<td>0.9255</td>
</tr>
<tr>
<td>Cumulative Factor: FY 2008, FY 2009, FY 2012, FY 2013, FY 2014, FY 2015 and FY 2016 Documentation and Coding Adjustment as Required under Sections 7(b)(1)(A) and 7(b)(1)(B) of Pub. L. 110-90 and Documentation and Coding Recoupment Adjustment as required under Section 631 of the American Taxpayer Relief Act of 2012</td>
<td>0.9255</td>
<td>0.9255</td>
<td>0.9255</td>
<td>0.9255</td>
<td>0.9255</td>
<td>0.9255</td>
</tr>
<tr>
<td>FY 2016 New Labor Market Delineation Wage Index 3-Year Hold Harmless Transition Budget Neutrality Factor</td>
<td>0.999996</td>
<td>0.999996</td>
<td>0.999996</td>
<td>0.999996</td>
<td>0.999996</td>
<td>0.999996</td>
</tr>
<tr>
<td>National Standardized Amount for FY 2016 if Wage Index is Greater Than 1.0000; Labor/Non-Labor Share Percentage (69.6/30.4)</td>
<td>Labor: $3,804.40</td>
<td>Labor: $3,759.51</td>
<td>Labor: $3,781.96</td>
<td>Labor: $3,737.07</td>
<td>Labor: $1,661.69</td>
<td>Labor: $1,642.08</td>
</tr>
<tr>
<td>National Standardized Amount for FY 2016 if Wage Index is less Than or Equal to 1.0000; Labor/Non-Labor Share Percentage (62/38)</td>
<td>Labor: $3,388.98</td>
<td>Labor: $3,348.99</td>
<td>Labor: $3,368.99</td>
<td>Labor: $3,329.00</td>
<td>Labor: $2,077.11</td>
<td>Labor: $2,052.60</td>
</tr>
</tbody>
</table>
wage index less than or equal to 1.0000. The first row of the table shows the updated (through FY 2015) Puerto Rico-specific payment rate after restoring the FY 2015 offsets for Puerto Rico-specific outlier payments, rural community hospital demonstration program budget neutrality, and the geographic reclassification budget neutrality. The MS-DRG recalibration budget neutrality adjustment factor is cumulative and is not removed from this table.

### COMPARISON OF FY 2015 PUERTO RICO-SPECIFIC PAYMENT RATE TO THE FY 2016 PUERTO RICO-SPECIFIC PAYMENT RATE

<table>
<thead>
<tr>
<th></th>
<th>Update (1.7 percent); Wage index is greater than 1.0000; Labor/Non-Labor Share Percentage (63.2/36.8)</th>
<th>Update (1.7 percent); Wage index is less than or equal to 1.0000; Labor/Non-Labor Share Percentage (62/38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2015 Puerto Rico Base Rate, after removing:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. FY 2015 Geographic Reclassification Budget Neutrality (0.990429)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. FY 2015 Rural Community Hospital Demonstration Program Budget Neutrality (0.999313)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. FY 2015 Puerto Rico Operating Outlier Offset (0.926334)</td>
<td>Labor: $1,758.02 Nonlabor: $1,023.66</td>
<td>Labor: $1,724.64 Nonlabor: $1,057.04</td>
</tr>
<tr>
<td>4. FY 2015 New Labor Market Delineation Wage Index Transition Budget Neutrality Factor (0.998854)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2016 Update Factor</td>
<td>1.017</td>
<td>1.017</td>
</tr>
<tr>
<td>FY 2016 MS-DRG Recalibration Budget Neutrality Factor</td>
<td>0.998399</td>
<td>0.998399</td>
</tr>
<tr>
<td>FY 2016 Reclassification Budget Neutrality Factor</td>
<td>0.987905</td>
<td>0.987905</td>
</tr>
<tr>
<td>FY 2016 Rural Community Hospital Demonstration Program Budget Neutrality Factor</td>
<td>0.999861</td>
<td>0.999861</td>
</tr>
</tbody>
</table>
B. Adjustments for Area Wage Levels and Cost-of-Living

Tables 1A through 1C, as published in section VI. of this Addendum (and available via the Internet on the CMS Web site), contain the labor-related and nonlabor-related shares that we used to calculate the prospective payment rates for hospitals located in the 50 States, the District of Columbia, and Puerto Rico for FY 2016. This section addresses two types of adjustments to the standardized amounts that are made in determining the prospective payment rates as described in this Addendum.

1. Adjustment for Area Wage Levels

Sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act require that we make an adjustment to the labor-related portion of the national and Puerto Rico prospective payment rates, respectively, to account for area differences in hospital wage levels. This adjustment is made by multiplying the labor-related portion of the adjusted standardized amounts by the appropriate wage index for the area in which the hospital is located. In section III. of the preamble of this final rule, we discuss the data and methodology for the FY 2016 wage index.
2. Adjustment for Cost-of-Living in Alaska and Hawaii

Section 1886(d)(5)(H) of the Act provides discretionary authority to the Secretary to make such adjustments as the Secretary deems appropriate to take into account the unique circumstances of hospitals located in Alaska and Hawaii. Higher labor-related costs for these two States are taken into account in the adjustment for area wages described above. To account for higher nonlabor-related costs for these two States, we multiply the nonlabor-related portion of the standardized amount for hospitals located in Alaska and Hawaii by an adjustment factor.

In the FY 2013 IPPS/LTCH PPS final rule, we established a methodology to update the COLA factors for Alaska and Hawaii that were published by the U.S. Office of Personnel Management (OPM) every 4 years (at the same time as the update to the labor-related share of the IPPS market basket), beginning in FY 2014. We refer readers to the FY 2013 IPPS/LTCH PPS proposed and final rules for additional background and a detailed description of this methodology (77 FR 28145 through 28146 and 77 FR 53700 through 53701, respectively).

For FY 2014, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50985 through 50987), we updated the COLA factors published by OPM for 2009 (as these are the last COLA factors OPM published prior to transitioning from COLAs to locality pay) using the methodology that we finalized in the FY 2013 IPPS/LTCH PPS final rule.

Based on the policy finalized in the FY 2013 IPPS/LTCH PPS final rule, we are continuing to use the same COLA factors in FY 2016 that were used in FY 2015 to adjust
the nonlabor-related portion of the standardized amount for hospitals located in Alaska and Hawaii. Below is a table listing the COLA factors for FY 2016.

### FY 2016 Cost-of-Living Adjustment Factors:
Alaska and Hawaii Hospitals

<table>
<thead>
<tr>
<th>Area</th>
<th>Cost of Living Adjustment Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alaska:</td>
<td></td>
</tr>
<tr>
<td>City of Anchorage and 80-kilometer (50-mile) radius by road</td>
<td>1.23</td>
</tr>
<tr>
<td>City of Fairbanks and 80-kilometer (50-mile) radius by road</td>
<td>1.23</td>
</tr>
<tr>
<td>City of Juneau and 80-kilometer (50-mile) radius by road</td>
<td>1.23</td>
</tr>
<tr>
<td>Rest of Alaska</td>
<td>1.25</td>
</tr>
<tr>
<td>Hawaii:</td>
<td></td>
</tr>
<tr>
<td>City and County of Honolulu</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Hawaii</td>
<td>1.19</td>
</tr>
<tr>
<td>County of Kauai</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Maui and County of Kalawao</td>
<td>1.25</td>
</tr>
</tbody>
</table>

Based on the policy finalized in the FY 2013 IPPS/LTCH PPS final rule, the next update to the COLA factors for Alaska and Hawaii will occur in FY 2018.

C. Calculation of the Prospective Payment Rates

General Formula for Calculation of the Prospective Payment Rates for FY 2016

In general, the operating prospective payment rate for all hospitals paid under the IPPS located outside of Puerto Rico, except SChs and MDHs, for FY 2016 equals the Federal rate (which includes uncompensated care payments).

We note that section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114-10, enacted on April 16, 2015) extended the MDH program (which, under previous law, was to be in effect for discharges on or before
March 31, 2015 only) for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017).

SCHs are paid based on whichever of the following rates yields the greatest aggregate payment: the Federal national rate (which, as discussed in section IV.D. of the preamble of this final rule, includes uncompensated care payments); the updated hospital-specific rate based on FY 1982 costs per discharge; the updated hospital-specific rate based on FY 1987 costs per discharge; the updated hospital-specific rate based on FY 1996 costs per discharge; or the updated hospital-specific rate based on FY 2006 costs per discharge to determine the rate that yields the greatest aggregate payment.

The prospective payment rate for SCHs for FY 2016 equals the higher of the applicable Federal rate, or the hospital-specific rate as described below. The prospective payment rate for MDHs for FY 2016 equals the higher of the Federal rate, or the Federal rate plus 75 percent of the difference between the Federal rate and the hospital-specific rate as described below. For MDHs, the updated hospital-specific rate is based on FY 1982, FY 1987 or FY 2002 costs per discharge, whichever yields the greatest aggregate payment.

The prospective payment rate for hospitals located in Puerto Rico for FY 2016 equals 25 percent of the Puerto Rico-specific payment rate plus 75 percent of the applicable national rate.

1. Federal Rate

The Federal rate is determined as follows:
Step 1--Select the applicable average standardized amount depending on whether
the hospital submitted qualifying quality data and is a meaningful EHR user, as described
above.

Step 2--Multiply the labor-related portion of the standardized amount by the
applicable wage index for the geographic area in which the hospital is located or the area
to which the hospital is reclassified.

Step 3--For hospitals located in Alaska and Hawaii, multiply the nonlabor-related
portion of the standardized amount by the applicable cost-of-living adjustment factor.

Step 4--Add the amount from Step 2 and the nonlabor-related portion of the
standardized amount (adjusted, if applicable, under Step 3).

Step 5--Multiply the final amount from Step 4 by the relative weight
corresponding to the applicable MS-DRG (Table 5 listed in section VI. of this Addendum
and available via the Internet on the CMS Web site).

The Federal payment rate as determined in Step 5 may then be further adjusted if
the hospital qualifies for either the IME or DSH adjustment. In addition, for hospitals
that qualify for a low-volume payment adjustment under section 1886(d)(12) of the Act
and 42 CFR 412.101(b), the payment in Step 5 would be increased by a specified
formula. The base-operating DRG payment amount may be further adjusted by the
hospital readmissions payment adjustment and the hospital VBP payment adjustment as
described under sections 1886(q) and 1886(o) of the Act, respectively. Finally, we add
the uncompensated care payment to the total claim payment amount. We note that, as
discussed above, we take uncompensated care payments into consideration when calculating outlier payments.

2. Hospital-Specific Rate (Applicable Only to SCHs and MDHs)

a. Calculation of Hospital-Specific Rate

Section 1886(b)(3)(C) of the Act provides that SCHs are paid based on whichever of the following rates yields the greatest aggregate payment: the Federal rate (which, as discussed in section IV.D. of the preamble of this final rule, includes uncompensated care payments); the updated hospital-specific rate based on FY 1982 costs per discharge; the updated hospital-specific rate based on FY 1987 costs per discharge; the updated hospital-specific rate based on FY 1996 costs per discharge; or the updated hospital-specific rate based on FY 2006 costs per discharge to determine the rate that yields the greatest aggregate payment.

As noted above, section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114-10, enacted on April 16, 2015) extended the MDH program (which, under previous law, was to be in effect for discharges on or before March 31, 2015 only) for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017). As discussed previously, currently MDHs are paid based on the Federal national rate or, if higher, the Federal national rate plus 75 percent of the difference between the Federal national rate and the greater of the updated hospital-specific rates based on either FY 1982, FY 1987 or FY 2002 costs per discharge.
For a more detailed discussion of the calculation of the hospital-specific rates, we refer readers to the FY 1984 IPPS interim final rule (48 FR 39772); the April 20, 1990 final rule with comment period (55 FR 15150); the FY 1991 IPPS final rule (55 FR 35994); and the FY 2001 IPPS final rule (65 FR 47082). We also refer readers to section IV.D. of the preamble of this final rule for a complete discussion on empirically justified Medicare DSH and uncompensated care payments.


Section 1886(b)(3)(B)(iv) of the Act provides that the applicable percentage increase applicable to the hospital-specific rates for SCHs and MDHs equals the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS). Because the Act sets the update factor for SCHs and MDHs equal to the update factor for all other IPPS hospitals, the update to the hospital-specific rates for SCHs and MDHs is subject to the amendments to section 1886(b)(3)(B) of the Act made by sections 3401(a) and 10319(a) of the Affordable Care Act. Accordingly, the applicable percentage increases to the hospital-specific rates applicable to SCHs and MDHs are the following:
<table>
<thead>
<tr>
<th>FY 2016</th>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Basket Rate-of-Increase</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Adjustment for Failure to Submit Quality Data under Section 1886(b)(3)(B)(viii) of the Act</td>
<td>0.0</td>
<td>0.0</td>
<td>-0.6</td>
<td>-0.6</td>
</tr>
<tr>
<td>Adjustment for Failure to be a Meaningful EHR User under Section 1886(b)(3)(B)(ix) of the Act</td>
<td>0.0</td>
<td>-1.2</td>
<td>0.0</td>
<td>-1.2</td>
</tr>
<tr>
<td>MFP Adjustment under Section 1886(b)(3)(B)(xi) of the Act</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
</tr>
<tr>
<td>Statutory Adjustment under Section 1886(b)(3)(B)(xii) of the Act</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
</tr>
<tr>
<td>Applicable Percentage Increase Applied to Hospital-specific rate</td>
<td>1.7</td>
<td>0.5</td>
<td>1.1</td>
<td>-0.1</td>
</tr>
</tbody>
</table>

For a complete discussion of the applicable percentage increase applied to the hospital-specific rates for SCHs and MDHs, we refer readers to section IV.A. of the preamble of this final rule.

In addition, because SCHs and MDHs use the same MS-DRGs as other hospitals when they are paid based in whole or in part on the hospital-specific rate, the hospital-specific rate is adjusted by a budget neutrality factor to ensure that changes to
the MS-DRG classifications and the recalibration of the MS-DRG relative weights are made in a manner so that aggregate IPPS payments are unaffected. Therefore, a SCH’s and MDH’s hospital-specific rate is adjusted by the proposed MS-DRG reclassification and recalibration budget neutrality factor of 0.998399, as discussed in section III. of this Addendum. The resulting rate is used in determining the payment rate that an SCH and an MDH will receive for its discharges beginning on or after October 1, 2015. We note that, in this final rule, for FY 2016, we are not making a documentation and coding adjustment to the hospital-specific rate. We refer readers to section II.D. of the preamble of this final rule for a complete discussion regarding our finalized policies and previously finalized policies (including our historical adjustments to the payment rates) relating to the effect of changes in documentation and coding that do not reflect real changes in case-mix.

3. General Formula for Calculation of Prospective Payment Rates for Hospitals Located in Puerto Rico Beginning on or after October 1, 2015, and before October 1, 2016

Section 1886(d)(9)(E)(iv) of the Act provides that, effective for discharges occurring on or after October 1, 2004, hospitals located in Puerto Rico are paid based on a blend of 75 percent of the national prospective payment rate and 25 percent of the Puerto Rico-specific rate.

a. Puerto Rico-Specific Rate

The Puerto Rico-specific prospective payment rate is determined as follows:
Step 1--Select the applicable average standardized amount considering the applicable wage index (obtained from Table 1C published in section VI. of this Addendum and available via the Internet on the CMS Web site).

Step 2--Multiply the labor-related portion of the standardized amount by the applicable Puerto Rico-specific wage index.

Step 3--Add the amount from Step 2 and the nonlabor-related portion of the standardized amount.

Step 4--Multiply the amount from Step 3 by the applicable MS-DRG relative weight (obtained from Table 5 listed in section VI. of this Addendum and available via the Internet on the CMS Web site).

Step 5--Multiply the result in Step 4 by 25 percent.

b. National Prospective Payment Rate

The national prospective payment rate is determined as follows:

Step 1--Select the applicable national average standardized amount.

Step 2--Multiply the labor-related portion of the national average standardized amount by the applicable wage index for the geographic area in which the hospital is located or the area to which the hospital is reclassified.

Step 3--Add the amount from Step 2 and the nonlabor-related portion of the national average standardized amount.

Step 4--Multiply the amount from Step 3 by the applicable MS-DRG relative weight (obtained from Table 5 listed in section VI. of this Addendum and available via the Internet on the CMS Web site).
Step 5--Multiply the result in Step 4 by 75 percent.

The sum of the Puerto Rico-specific rate and the national prospective payment rate computed above equals the prospective payment rate for a given discharge for a hospital located in Puerto Rico. This payment rate is then further adjusted if the hospital qualifies for either the IME or DSH adjustment.

Finally, we add the uncompensated care payment to the total claim payment amount. We note that, as discussed above, we take uncompensated care payments into consideration when calculating outlier payments.
III. Changes to Payment Rates for Acute Care Hospital Inpatient Capital-Related Costs for FY 2016

The PPS for acute care hospital inpatient capital-related costs was implemented for cost reporting periods beginning on or after October 1, 1991. Effective with that cost reporting period, over a 10-year transition period (which extended through FY 2001) the payment methodology for Medicare acute care hospital inpatient capital-related costs changed from a reasonable cost-based methodology to a prospective methodology (based fully on the Federal rate).

The basic methodology for determining Federal capital prospective rates is set forth in the regulations at 42 CFR 412.308 through 412.352. Below we discuss the factors that we used to determine the capital Federal rate for FY 2016, which is effective for discharges occurring on or after October 1, 2015.

The 10-year transition period ended with hospital cost reporting periods beginning on or after October 1, 2001 (FY 2002). Therefore, for cost reporting periods beginning in FY 2002, all hospitals (except “new” hospitals under § 412.304(c)(2)) are paid based on the capital Federal rate. For FY 1992, we computed the standard Federal payment rate for capital-related costs under the IPPS by updating the FY 1989 Medicare inpatient capital cost per case by an actuarial estimate of the increase in Medicare inpatient capital costs per case. Each year after FY 1992, we update the capital standard Federal rate, as provided at § 412.308(c)(1), to account for capital input price increases and other factors. The regulations at § 412.308(c)(2) also provide that the capital Federal rate be adjusted annually by a factor equal to the estimated proportion of outlier payments under the
capital Federal rate to total capital payments under the capital Federal rate. In addition, § 412.308(c)(3) requires that the capital Federal rate be reduced by an adjustment factor equal to the estimated proportion of payments for exceptions under § 412.348. (We note that, as discussed in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53705), there is generally no longer a need for an exceptions payment adjustment factor.) However, in limited circumstances, an additional payment exception for extraordinary circumstances is provided for under § 412.348(f) for qualifying hospitals. Therefore, in accordance with § 412.308(c)(3), an exceptions payment adjustment factor may need to be applied if such payments are made. Section 412.308(c)(4)(ii) requires that the capital standard Federal rate be adjusted so that the effects of the annual DRG reclassification and the recalibration of DRG weights and changes in the geographic adjustment factor (GAF) are budget neutral.

Section 412.374 provides for blended payments to hospitals located in Puerto Rico under the IPPS for acute care hospital inpatient capital-related costs. Accordingly, under the capital PPS, we compute a separate payment rate specific to hospitals located in Puerto Rico using the same methodology used to compute the national Federal rate for capital-related costs. In accordance with section 1886(d)(9)(A) of the Act, under the IPPS for acute care hospital operating costs, hospitals located in Puerto Rico are paid for operating costs under a special payment formula. Effective October 1, 2004, in accordance with section 504 of Pub. L. 108-173, the methodology for operating payments made to hospitals located in Puerto Rico under the IPPS was revised to make payments based on a blend of 25 percent of the applicable standardized amount specific to Puerto
Rico hospitals and 75 percent of the applicable national average standardized amount. In conjunction with this change to the operating blend percentage, effective with discharges occurring on or after October 1, 2004, we also revised the methodology for computing capital payments made to hospitals located in Puerto Rico to be based on a blend of 25 percent of the Puerto Rico capital rate and 75 percent of the national capital Federal rate (69 FR 49185).

A. Determination of the Federal Hospital Inpatient Capital-Related Prospective Payment Rate Update

In the discussion that follows, we explain the factors that we used to determine the capital Federal rate for FY 2016. In particular, we explain why the FY 2016 capital Federal rate increases approximately 0.85 percent, compared to the FY 2015 capital Federal rate. As discussed in the impact analysis in Appendix A to this final rule, we estimate that capital payments per discharge will increase approximately 2.3 percent during that same period. Because capital payments constitute about 10 percent of hospital payments, a percent change in the capital Federal rate yields only about a 0.1 percent change in actual payments to hospitals.

1. Projected Capital Standard Federal Rate Update

a. Description of the Update Framework

Under § 412.308(c)(1), the capital standard Federal rate is updated on the basis of an analytical framework that takes into account changes in a capital input price index (CIPI) and several other policy adjustment factors. Specifically, we adjust the projected CIPI rate-of-increase as appropriate each year for case-mix index-related changes, for
intensity, and for errors in previous CIPI forecasts. The update factor for FY 2016 under that framework is 1.3 percent based on the best data available at this time. The update factor under that framework is based on a projected 1.3 percent increase in the FY 2010-based CIPI, a 0.0 percentage point adjustment for intensity, a 0.0 percentage point adjustment for case-mix, a 0.0 percentage point adjustment for the DRG reclassification and recalibration, and a forecast error correction of 0.0 percentage point. As discussed below in section III.C. of this Addendum, we continue to believe that the CIPI is the most appropriate input price index for capital costs to measure capital price changes in a given year. We also explain the basis for the FY 2016 CIPI projection in that same section of this Addendum. Below we describe the policy adjustments that we are applying in the update framework for FY 2016.

The case-mix index is the measure of the average DRG weight for cases paid under the IPPS. Because the DRG weight determines the prospective payment for each case, any percentage increase in the case-mix index corresponds to an equal percentage increase in hospital payments.

The case-mix index can change for any of several reasons:

- The average resource use of Medicare patients changes ("real" case-mix change);

- Changes in hospital documentation and coding of patient records result in higher-weighted DRG assignments ("coding effects"); and

- The annual DRG reclassification and recalibration changes may not be budget neutral ("reclassification effect").
We define real case-mix change as actual changes in the mix (and resource requirements) of Medicare patients as opposed to changes in documentation and coding behavior that result in assignment of cases to higher-weighted DRGs, but do not reflect higher resource requirements. The capital update framework includes the same case-mix index adjustment used in the former operating IPPS update framework (as discussed in the May 18, 2004 IPPS proposed rule for FY 2005 (69 FR 28816)). (We no longer use an update framework to make a recommendation for updating the operating IPPS standardized amounts as discussed in section II. of Appendix B to the FY 2006 IPPS final rule (70 FR 47707).)

For FY 2016, we are projecting a 0.5 percent total increase in the case-mix index. We estimated that the real case-mix increase will equal 0.5 percent for FY 2016. The net adjustment for change in case-mix is the difference between the projected real increase in case-mix and the projected total increase in case-mix. Therefore, as we proposed, the net adjustment for case-mix change in FY 2016 is 0.0 percentage point.

The capital update framework also contains an adjustment for the effects of DRG reclassification and recalibration. This adjustment is intended to remove the effect on total payments of prior year’s changes to the DRG classifications and relative weights, in order to retain budget neutrality for all case-mix index-related changes other than those due to patient severity of illness. Due to the lag time in the availability of data, there is a 2-year lag in data used to determine the adjustment for the effects of DRG reclassification and recalibration. For example, we have data available to evaluate the effects of the FY 2014 DRG reclassification and recalibration as part of our update for FY 2016. We
estimate that FY 2014 DRG reclassification and recalibration resulted in no change in the case-mix when compared with the case-mix index that would have resulted if we had not made the reclassification and recalibration changes to the DRGs. Therefore, as we proposed, we are making a 0.0 percentage point adjustment for reclassification and recalibration in the update framework for FY 2016.

The capital update framework also contains an adjustment for forecast error. The input price index forecast is based on historical trends and relationships ascertainable at the time the update factor is established for the upcoming year. In any given year, there may be unanticipated price fluctuations that may result in differences between the actual increase in prices and the forecast used in calculating the update factors. In setting a prospective payment rate under the framework, we make an adjustment for forecast error only if our estimate of the change in the capital input price index for any year is off by 0.25 percentage point or more. There is a 2-year lag between the forecast and the availability of data to develop a measurement of the forecast error. Historically, when a forecast error of the CIPI is greater than 0.25 percentage point in absolute terms, it is reflected in the update recommended under this framework. A forecast error of 0.0 percentage point was calculated for the FY 2014 update, for which there is historical data. That is, current historical data indicate that the forecasted FY 2014 CIPI (1.2 percent) used in calculating the FY 2014 update factor was equal to the actual realized price increases (also 1.2 percent). Therefore, as we proposed, we are not making an adjustment for a forecast error in the update for FY 2016.
Under the capital IPPS update framework, we also make an adjustment for changes in intensity. Historically, we calculated this adjustment using the same methodology and data that were used in the past under the framework for operating IPPS. The intensity factor for the operating update framework reflected how hospital services are utilized to produce the final product, that is, the discharge. This component accounts for changes in the use of quality-enhancing services, for changes within DRG severity, and for expected modification of practice patterns to remove noncost-effective services. Our intensity measure is based on a 5-year average.

We calculate case-mix constant intensity as the change in total cost per discharge, adjusted for price level changes (the CPI for hospital and related services) and changes in real case-mix. Without reliable estimates of the proportions of the overall annual intensity increases that are due, respectively, to ineffective practice patterns and the combination of quality-enhancing new technologies and complexity within the DRG system, we assume that one-half of the annual increase is due to each of these factors. The capital update framework thus provides an add-on to the input price index rate of increase of one-half of the estimated annual increase in intensity, to allow for increases within DRG severity and the adoption of quality-enhancing technology.

In this final rule, we are continuing to use a Medicare-specific intensity measure that is based on a 5-year adjusted average of cost per discharge for FY 2016 (we refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50436) for a full description of our Medicare-specific intensity measure). Specifically, for FY 2016, we are using an intensity measure that is based on an average of cost per discharge data from the 5-year
period beginning with FY 2009 and extending through FY 2013. Based on these data, we estimated that case-mix constant intensity declined during FYs 2009 through 2013. In the past, when we found intensity to be declining, we believed a zero (rather than a negative) intensity adjustment was appropriate. Consistent with this approach, because we estimate that intensity declined during that 5-year period, we believe it is appropriate to continue to apply a zero intensity adjustment for FY 2016. Therefore, as we proposed, we are making a 0.0 percentage point adjustment for intensity in the update for FY 2016.

Above, we described the basis of the components used to develop the 1.3 percent capital update factor under the capital update framework for FY 2016 as shown in the table below.

**CMS FY 2016 UPDATE FACTOR TO THE CAPITAL FEDERAL RATE**

<table>
<thead>
<tr>
<th>Component</th>
<th>Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital Input Price Index*</td>
<td>1.3</td>
</tr>
<tr>
<td>Intensity</td>
<td>0.0</td>
</tr>
<tr>
<td>Case-Mix Adjustment Factors:</td>
<td></td>
</tr>
<tr>
<td>Real Across DRG Change</td>
<td>0.5</td>
</tr>
<tr>
<td>Projected Case-Mix Change</td>
<td>0.5</td>
</tr>
<tr>
<td>Subtotal</td>
<td>1.3</td>
</tr>
<tr>
<td>Effect of FY 2014 Reclassification and Recalibration</td>
<td>0.0</td>
</tr>
<tr>
<td>Forecast Error Correction</td>
<td>0.0</td>
</tr>
<tr>
<td>Total Update</td>
<td>1.3</td>
</tr>
</tbody>
</table>

*The capital input price index is based on the FY 2010-based CIPI.

b. Comparison of CMS and MedPAC Update Recommendation

In its March 2015 Report to Congress, MedPAC did not make a specific update recommendation for capital IPPS payments for FY 2016. (We refer readers to
2. Outlier Payment Adjustment Factor

Section 412.312(c) establishes a unified outlier payment methodology for inpatient operating and inpatient capital-related costs. A single set of thresholds is used to identify outlier cases for both inpatient operating and inpatient capital-related payments. Section 412.308(c)(2) provides that the standard Federal rate for inpatient capital-related costs be reduced by an adjustment factor equal to the estimated proportion of capital-related outlier payments to total inpatient capital-related PPS payments. The outlier thresholds are set so that operating outlier payments are projected to be 5.1 percent of total operating IPPS DRG payments.

For FY 2015, we estimated that outlier payments for capital would equal 6.18 percent of inpatient capital-related payments based on the capital Federal rate in FY 2015. Based on the thresholds as set forth in section II.A. of this Addendum, we estimate that outlier payments for capital-related costs will equal 6.35 percent for inpatient capital-related payments based on the capital Federal rate in FY 2016. Therefore, we are applying an outlier adjustment factor of 0.9365 in determining the capital Federal rate for FY 2016. Thus, we estimate that the percentage of capital outlier payments to total capital Federal rate payments for FY 2016 will be higher than the percentage for FY 2015.

The outlier reduction factors are not built permanently into the capital rates; that is, they are not applied cumulatively in determining the capital Federal rate. The
FY 2016 outlier adjustment of 0.9365 is a -0.18 percent change from the FY 2015 outlier adjustment of 0.9382. Therefore, the net change in the outlier adjustment to the capital Federal rate for FY 2016 is 0.9982 (0.9365/0.9382). Thus, the outlier adjustment will decrease the FY 2016 capital Federal rate by 0.18 percent compared to the FY 2015 outlier adjustment.

3. Budget Neutrality Adjustment Factor for Changes in DRG Classifications and Weights and the GAF

Section 412.308(c)(4)(ii) requires that the capital Federal rate be adjusted so that aggregate payments for the fiscal year based on the capital Federal rate after any changes resulting from the annual DRG reclassification and recalibration and changes in the GAF are projected to equal aggregate payments that would have been made on the basis of the capital Federal rate without such changes. Because we implemented a separate GAF for Puerto Rico, we apply separate budget neutrality adjustments for the national GAF and the Puerto Rico GAF. We apply the same budget neutrality factor for DRG reclassifications and recalibration nationally and for Puerto Rico. Separate adjustments were unnecessary for FY 1998 and earlier because the GAF for Puerto Rico was implemented in FY 1998.

To determine the factors for FY 2016, we compared (separately for the national capital rate and the Puerto Rico capital rate) estimated aggregate capital Federal rate payments based on the FY 2015 MS-DRG classifications and relative weights and the FY 2015 GAF to estimated aggregate capital Federal rate payments based on the FY 2015 MS-DRG classifications and relative weights and the FY 2016 GAFs. To
achieve budget neutrality for the changes in the national GAFs, based on calculations using updated data, we are applying an incremental budget neutrality adjustment factor of 0.9979 for FY 2016 to the previous cumulative FY 2015 adjustment factor of 0.9884, yielding an adjustment factor of 0.9864 through FY 2016. For the Puerto Rico GAFs, we are applying an incremental budget neutrality adjustment factor of 0.9993 for FY 2016 to the previous cumulative FY 2015 adjustment factor of 1.0082, yielding a cumulative adjustment factor of 1.0075 through FY 2016.

We then compared estimated aggregate capital Federal rate payments based on the FY 2015 MS-DRG relative weights and the FY 2016 GAFs to estimated aggregate capital Federal rate payments based on the cumulative effects of the FY 2016 MS-DRG classifications and relative weights and the FY 2016 GAFs. The incremental adjustment factor for DRG classifications and changes in relative weights is 0.9994 both nationally and for Puerto Rico. The cumulative adjustment factors for MS-DRG classifications and changes in relative weights and for changes in the GAFs through FY 2016 are 0.9858 nationally and 1.0069 for Puerto Rico. (We note that all the values are calculated with unrounded numbers.) The GAF/DRG budget neutrality adjustment factors are built permanently into the capital rates; that is, they are applied cumulatively in determining the capital Federal rate. This follows the requirement under § 412.308(c)(4)(ii) that estimated aggregate payments each year be no more or less than they would have been in the absence of the annual DRG reclassification and recalibration and changes in the GAFs.
The methodology used to determine the recalibration and geographic adjustment factor (GAF/DRG) budget neutrality adjustment is similar to the methodology used in establishing budget neutrality adjustments under the IPPS for operating costs. One difference is that, under the operating IPPS, the budget neutrality adjustments for the effect of geographic reclassifications are determined separately from the effects of other changes in the hospital wage index and the MS-DRG relative weights. Under the capital IPPS, there is a single GAF/DRG budget neutrality adjustment factor (the national capital rate and the Puerto Rico capital rate are determined separately) for changes in the GAF (including geographic reclassification) and the MS-DRG relative weights. In addition, there is no adjustment for the effects that geographic reclassification has on the other payment parameters, such as the payments for DSH or IME.

The cumulative adjustment factor of 0.9973 (the product of the incremental national GAF budget neutrality adjustment factor of 0.9979 and the incremental DRG budget neutrality adjustment factor of 0.9994) accounts for the MS-DRG reclassifications and recalibration and for changes in the GAFs. It also incorporates the effects on the GAFs of FY 2016 geographic reclassification decisions made by the MGCRB compared to FY 2015 decisions. However, it does not account for changes in payments due to changes in the DSH and IME adjustment factors.


For FY 2015, we established a capital Federal rate of $434.97 (79 FR 59684). We are establishing an update of 1.3 percent in determining the FY 2016 capital Federal rate for all hospitals. As a result of this update and the budget neutrality factors discussed
above, we are establishing a national capital Federal rate of $438.65 for FY 2016. The national capital Federal rate for FY 2016 was calculated as follows:

- The FY 2016 update factor is 1.013, that is, the update is 1.3 percent.
- The FY 2016 budget neutrality adjustment factor that is applied to the capital Federal rate for changes in the MS-DRG classifications and relative weights and changes in the GAFs is 0.9973.
- The FY 2016 outlier adjustment factor is 0.9365.

(We note that, as discussed in section VI.C. of the preamble of this final rule, we are not making an additional MS-DRG documentation and coding adjustment to the capital IPPS Federal rates for FY 2016.)

Because the FY 2016 capital Federal rate has already been adjusted for differences in case-mix, wages, cost-of-living, indirect medical education costs, and payments to hospitals serving a disproportionate share of low-income patients, we are not making additional adjustments in the capital Federal rate for these factors, other than the budget neutrality factor for changes in the MS-DRG classifications and relative weights and for changes in the GAFs.

We are providing the following chart that shows how each of the factors and adjustments for FY 2016 affects the computation of the FY 2016 national capital Federal rate in comparison to the FY 2015 national capital Federal rate. The FY 2016 update factor has the effect of increasing the capital Federal rate by 1.3 percent compared to the FY 2015 capital Federal rate. The GAF/DRG budget neutrality adjustment factor has the effect of decreasing the capital Federal rate by 0.27 percent. The FY 2016 outlier
adjustment factor has the effect of decreasing the capital Federal rate by 0.18 percent compared to the FY 2015 capital Federal rate. The combined effect of all the changes will increase the national capital Federal rate by approximately 0.85 percent compared to the FY 2015 national capital Federal rate.

**COMPARISON OF FACTORS AND ADJUSTMENTS: FY 2015 CAPITAL FEDERAL RATE AND FY 2016 CAPITAL FEDERAL RATE**

<table>
<thead>
<tr>
<th></th>
<th>FY 2015</th>
<th>FY 2016</th>
<th>Change</th>
<th>Percent Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Update Factor(^1)</td>
<td>1.0150</td>
<td>1.0130</td>
<td>1.0130</td>
<td>1.3</td>
</tr>
<tr>
<td>GAF/DRG Adjustment Factor(^1)</td>
<td>0.9993</td>
<td>0.9973</td>
<td>0.9973</td>
<td>-0.27</td>
</tr>
<tr>
<td>Outlier Adjustment Factor(^2)</td>
<td>0.9382</td>
<td>0.9365</td>
<td>0.9982</td>
<td>-0.18</td>
</tr>
<tr>
<td>Capital Federal Rate</td>
<td>$434.97</td>
<td>$438.65</td>
<td>1.0085</td>
<td>0.85</td>
</tr>
</tbody>
</table>

\(^1\) The update factor and the GAF/DRG budget neutrality adjustment factors are built permanently into the capital Federal rates. Thus, for example, the incremental change from FY 2015 to FY 2016 resulting from the application of the 0.9973 GAF/DRG budget neutrality adjustment factor for FY 2016 is a net change of 0.9973 (or -0.27 percent).

\(^2\) The outlier reduction factor is not built permanently into the capital Federal rate; that is, the factor is not applied cumulatively in determining the capital Federal rate. Thus, for example, the net change resulting from the application of the FY 2016 outlier adjustment factor is 0.9365/0.9382, or 0.9982 (or -0.18 percent).

In this final rule, we also are providing the following chart that shows how the final FY 2016 capital Federal rate differs from the proposed FY 2016 capital Federal rate as presented in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24640).
COMPARISON OF FACTORS AND ADJUSTMENTS:
PROPOSED FY 2016 CAPITAL FEDERAL RATE AND
FINAL FY 2016 CAPITAL FEDERAL RATE

<table>
<thead>
<tr>
<th>Factor</th>
<th>Proposed FY 2016</th>
<th>Final FY 2016</th>
<th>Change</th>
<th>Percent Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Update Factor</td>
<td>1.0130</td>
<td>1.0130</td>
<td>1.0000</td>
<td>0.00</td>
</tr>
<tr>
<td>GAF/DRG Adjustment Factor</td>
<td>0.9976</td>
<td>0.9973</td>
<td>0.9997</td>
<td>-0.30</td>
</tr>
<tr>
<td>Outlier Adjustment Factor</td>
<td>0.9357</td>
<td>0.9365</td>
<td>1.0008</td>
<td>0.08</td>
</tr>
<tr>
<td>Capital Federal Rate</td>
<td>438.40</td>
<td>438.65</td>
<td>1.006</td>
<td>0.06</td>
</tr>
</tbody>
</table>

5. Special Capital Rate for Puerto Rico Hospitals

Section 412.374 provides for the use of a blended payment system for payments made to hospitals located in Puerto Rico under the PPS for acute care hospital inpatient capital-related costs. Accordingly, under the capital PPS, we compute a separate payment rate specific to hospitals located in Puerto Rico using the same methodology used to compute the national Federal rate for capital-related costs. Under the broad authority of section 1886(g) of the Act, beginning with discharges occurring on or after October 1, 2004, capital payments made to hospitals located in Puerto Rico are based on a blend of 25 percent of the Puerto Rico capital rate and 75 percent of the capital Federal rate. The Puerto Rico capital rate is derived from the costs of Puerto Rico hospitals only, while the capital Federal rate is derived from the costs of all acute care hospitals participating in the IPPS (including Puerto Rico).

To adjust hospitals’ capital payments for geographic variations in capital costs, we apply a GAF to both portions of the blended capital rate. The GAF is calculated using the operating IPPS wage index, and varies depending on the labor market area or rural
area in which the hospital is located. We use the Puerto Rico wage index to determine the GAF for the Puerto Rico part of the capital-blended rate and the national wage index to determine the GAF for the national part of the blended capital rate.

Because we implemented a separate GAF for Puerto Rico in FY 1998, we also apply separate budget neutrality adjustment factors for the national GAF and for the Puerto Rico GAF. However, we apply the same budget neutrality adjustment factor for MS-DRG reclassifications and recalibration nationally and for Puerto Rico. The budget neutrality adjustment factors for the national GAF and for the Puerto Rico GAF and the budget neutrality factor for MS-DRG reclassifications and recalibration (which is the same nationally and for Puerto Rico) are discussed in section III.A.3. of this Addendum.

In computing the payment for a particular Puerto Rico hospital, the Puerto Rico portion of the capital rate (25 percent) is multiplied by the Puerto Rico-specific GAF for the labor market area in which the hospital is located, and the national portion of the capital rate (75 percent) is multiplied by the national GAF for the labor market area in which the hospital is located (which is computed from national data for all hospitals in the United States and Puerto Rico).

For FY 2015, the special capital rate for hospitals located in Puerto Rico was $209.45 (79 FR 59683). With the changes we are making to the factors used to determine the capital Federal rate, the FY 2016 special capital rate for hospitals in Puerto Rico is $212.56.
B. Calculation of the Inpatient Capital-Related Prospective Payments for FY 2016

For purposes of calculating payments for each discharge during FY 2016, the capital Federal rate is adjusted as follows: (Standard Federal Rate) x (DRG weight) x (GAF) x (COLA for hospitals located in Alaska and Hawaii) x (1 + DSH Adjustment Factor + IME Adjustment Factor, if applicable). The result is the adjusted capital Federal rate.

Hospitals also may receive outlier payments for those cases that qualify under the thresholds established for each fiscal year. Section 412.312(c) provides for a single set of thresholds to identify outlier cases for both inpatient operating and inpatient capital-related payments. The outlier thresholds for FY 2016 are in section II.A. of this Addendum. For FY 2016, a case would qualify as a cost outlier if the cost for the case plus the (operating) IME and DSH payments (including both the empirically justified Medicare DSH payment and the estimated uncompensated care payment, as discussed in section II.A.4.g.(1) of this Addendum) is greater than the prospective payment rate for the MS-DRG plus the fixed-loss amount of $22,544.

Currently, as provided under § 412.304(c)(2), we pay a new hospital 85 percent of its reasonable costs during the first 2 years of operation unless it elects to receive payment based on 100 percent of the capital Federal rate. Effective with the third year of operation, we pay the hospital based on 100 percent of the capital Federal rate (that is, the same methodology used to pay all other hospitals subject to the capital PPS).
C. Capital Input Price Index

1. Background

Like the operating input price index, the capital input price index (CIPI) is a fixed-weight price index that measures the price changes associated with capital costs during a given year. The CIPI differs from the operating input price index in one important aspect—the CIPI reflects the vintage nature of capital, which is the acquisition and use of capital over time. Capital expenses in any given year are determined by the stock of capital in that year (that is, capital that remains on hand from all current and prior capital acquisitions). An index measuring capital price changes needs to reflect this vintage nature of capital. Therefore, the CIPI was developed to capture the vintage nature of capital by using a weighted-average of past capital purchase prices up to and including the current year.

We periodically update the base year for the operating and capital input price indexes to reflect the changing composition of inputs for operating and capital expenses. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50603 through 50607), we rebased and revised the CIPI to a FY 2010 base year to reflect the more current structure of capital costs in hospitals. For a complete discussion of this rebasing, we refer readers to the FY 2014 IPPS/LTCH PPS final rule.

2. Forecast of the CIPI for FY 2016

Based on the latest forecast by IHS Global Insight, Inc. (second quarter of 2015), we are forecasting the FY 2010-based CIPI to increase 1.3 percent in FY 2016. This reflects a projected 1.8 percent increase in vintage-weighted depreciation prices (building
and fixed equipment, and movable equipment), and a projected 2.6 percent increase in other capital expense prices in FY 2016, partially offset by a projected 1.4 percent decline in vintage-weighted interest expense prices in FY 2016. The weighted average of these three factors produces the forecasted 1.3 percent increase for the FY 2010-based CIPI as a whole in FY 2016.
IV. Changes to Payment Rates for Excluded Hospitals: Rate-of-Increase Percentages for FY 2016

Payments for services furnished in children’s hospitals, 11 cancer hospitals, and hospitals located outside the 50 States, the District of Columbia and Puerto Rico (that is, short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa) that are excluded from the IPPS are made on the basis of reasonable costs based on the hospital’s own historical cost experience, subject to a rate-of-increase ceiling. A per discharge limit (the target amount as defined in §413.40(a) of the regulations) is set for each hospital based on the hospital’s own cost experience in its base year, and updated annually by a rate-of-increase percentage. (We note that, in accordance with §403.752(a), RNHCIs are also subject to the rate-of-increase limits established under §413.40 of the regulations.)

As discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24641), the FY 2016 rate-of-increase percentage for updating the target amounts for the 11 cancer hospitals, children’s hospitals, the short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, and RNHCIs is the estimated percentage increase in the IPPS operating market basket for FY 2016, in accordance with applicable regulations at §413.40. Based on IHS Global Insight, Inc.’s 2015 first quarter forecast, we estimated that the FY 2010-based IPPS operating market basket update for FY 2016 would be 2.7 percent (that is, the estimate of the market basket rate-of-increase). However, we proposed that if more recent data became available for the final rule, we would use them to calculate the IPPS operating market basket update...
for FY 2016. Therefore, based on IHS Global Insight, Inc.’s 2015 second quarter forecast, with historical data through the first quarter of 2015, we estimate that the FY 2010-based IPPS operating market basket update for FY 2016 is 2.4 percent (that is, the estimate of the market basket rate-of-increase). For children’s hospitals, the 11 cancer hospitals, hospitals located outside the 50 States, the District of Columbia and Puerto Rico (that is, short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa), and RNHCIs, the FY 2016 rate-of-increase percentage that will be applied to the FY 2015 target amounts in order to determine the final FY 2016 target amounts is 2.4 percent.

The IRF PPS, the IPF PPS, and the LTCH PPS are updated annually. We refer readers to section VII. of the preamble of this final rule and section V. of the Addendum to this final rule for the update changes to the Federal payment rates for LTCHs under the LTCH PPS for FY 2016. The annual updates for the IRF PPS and the IPF PPS are issued by the agency in separate Federal Register documents.
V. Updates to the Payment Rates for the LTCH PPS for FY 2016

A. LTCH PPS Standard Federal Payment Rate for FY 2016

1. Background

In section VII. of the preamble of this final rule, we discuss our annual updates to the payment rates, factors, and specific policies under the LTCH PPS for FY 2016.

Under § 412.523(c)(3)(ii) of the regulations, for LTCH PPS rate years beginning RY 2004 through RY 2006, we updated the standard Federal rate annually by a factor to adjust for the most recent estimate of the increases in prices of an appropriate market basket of goods and services for LTCHs. We established this policy of annually updating the standard Federal rate because, at that time, we believed that was the most appropriate method for updating the LTCH PPS standard Federal rate for years after the initial implementation of the LTCH PPS in FY 2003. Therefore, under § 412.523(c)(3)(ii), for RYs 2004 through 2006, the annual update to the LTCH PPS standard Federal rate was equal to the previous rate year’s Federal rate updated by the most recent estimate of increases in the appropriate market basket of goods and services included in covered inpatient LTCH services.

In determining the annual update to the standard Federal rate for RY 2007, based on our ongoing monitoring activity, we believed that, rather than solely using the most recent estimate of the LTCH PPS market basket update as the basis of the annual update factor, it was appropriate to adjust the standard Federal rate to account for the effect of documentation and coding in a prior period that was unrelated to patients’ severity of illness (71 FR 27818). Accordingly, we established under § 412.523(c)(3)(iii) that the
annual update to the standard Federal rate for RY 2007 was zero percent based on the most recent estimate of the LTCH PPS market basket at that time, offset by an adjustment to account for changes in case-mix in prior periods due to the effect of documentation and coding that were unrelated to patients’ severity of illness. For RY 2008 through FY 2011, we also made an adjustment to account for the effect of documentation and coding that was unrelated to patients’ severity of illness in establishing the annual update to the standard Federal rate as set forth in the regulations at §§ 412.523(c)(3)(iv) through (c)(3)(vii). For FYs 2012, 2013, 2014, and 2015, we updated the standard Federal rate by the most recent estimate of the LTCH PPS market basket at that time, including additional statutory adjustments required by section 1886(m)(3)(A) of the Act as set forth in the regulations at §§ 412.523(c)(3)(viii) through (c)(3)(ix).

Section 1886(m)(3)(A) of the Act, as added by section 3401(c) of the Affordable Care Act, specifies that, for rate year 2010 and each subsequent rate year, any annual update to the standard Federal rate shall be reduced:

- For rate year 2010 through 2019, by the other adjustment specified in section 1886(m)(3)(A)(ii) and (m)(4) of the Act; and

- For rate year 2012 and each subsequent year, by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act (which we refer to as “the multifactor productivity (MFP) adjustment”) as discussed in section VII.D.2. of the preamble of this final rule.

Section 1886(m)(3)(B) of the Act provides that the application of paragraph (3) of section 1886(m) of the Act may result in the annual update being less than zero for a rate
year, and may result in payment rates for a rate year being less than such payment rates for the preceding rate year. (As noted in section VII.D.2.a. of the preamble of this final rule, the annual update to the LTCH PPS occurs on October 1 and we have adopted the term “fiscal year” (FY) rather than “rate year” (RY) under the LTCH PPS beginning October 1, 2010. Therefore, for purposes of clarity, when discussing the annual update for the LTCH PPS, including the provisions of the Affordable Care Act, we use the term “fiscal year” rather than “rate year” for 2011 and subsequent years.)

For FY 2015, consistent with our historical practice, we established an update to the LTCH PPS standard Federal rate based on the full estimated LTCH PPS market basket increase of 2.9 percent and the 0.7 percentage point reductions required by sections 1886(m)(3)(A)(i) and 1886(m)(3)(A)(ii) with 1886(m)(4)(E) of the Act. Accordingly, at § 412.523(c)(3)(xi) of the regulations, we established an annual update of 2.2 percent to the standard Federal rate for FY 2015 (79 FR 50391 through 50392).

For FY 2016, as discussed in greater detail in section VII.D.2. of the preamble of this final rule, we are establishing an annual update to the LTCH PPS standard Federal payment rate based on the full estimated increase in the LTCH PPS market basket, less the MFP adjustment consistent with section 1886(m)(3)(A)(i) of the Act, and less the 0.2 percentage point required by sections 1886(m)(3)(A)(ii) and (m)(4)(E) of the Act. In addition, as discussed in greater detail in section VII.D.2. of the preamble of this final rule, the annual update is further reduced by 2.0 percentage points for LTCHs that fail to submit quality reporting data in accordance with the requirements of the LTCH QRP under section 1886(m)(5) of the Act.
Specifically, in this final rule, consistent with our proposal and based on the best available data, we are establishing an annual update to the LTCH PPS standard Federal payment rate of 1.7 percent, which is based on the full estimated increase in the LTCH PPS market basket of 2.4 percent, less the MFP adjustment of 0.5 percentage point consistent with section 1886(m)(3)(A)(i) of the Act, and less the 0.2 percentage point required by sections 1886(m)(3)(A)(ii) and (m)(4)(E) of the Act. For LTCHs that fail to submit the required quality reporting data for FY 2016 in accordance with the LTCH QRP, the annual update is further reduced by 2.0 percentage points as required by section 1886(m)(5) of the Act (as discussed in greater detail in section VII.D.2.c. of the preamble of this final rule). Accordingly, we are establishing an annual update to the LTCH PPS standard Federal payment rate of -0.3 percent for LTCHs that fail to submit the required quality reporting data for FY 2016. This -0.3 percent update was calculated based on the full estimated increase in the LTCH PPS market basket of 2.4 percent, less a MFP adjustment of 0.5 percentage point, less an additional adjustment of 0.2 percentage point required by the statute, and less 2.0 percentage points for failure to submit quality reporting data as required by section 1886(m)(5) of the Act.

2. Development of the FY 2016 LTCH PPS Standard Federal Payment Rate

We continue to believe that the annual update to the LTCH PPS standard Federal payment rate should be based on the most recent estimate of the increase in the LTCH PPS market basket, including any statutory adjustments. Consistent with our historical practice, for FY 2016, we are applying the annual update to the LTCH PPS standard Federal payment rate from the previous year. Furthermore, in determining the LTCH
PPS standard Federal payment rate for FY 2016, we also are making certain regulatory adjustments, consistent with past practices. Specifically, in determining the FY 2016 LTCH PPS standard Federal payment rate, as we proposed, we are applying a budget neutrality adjustment factor for the changes related to the area wage adjustment (that is, changes to the wage data and labor-related share) in accordance with § 412.523(d)(4). We also, as proposed, used more recent data to determine the update to the LTCH PPS standard Federal payment rate for FY 2016 in this final rule.

For FY 2015, we established an annual update to the LTCH PPS standard Federal rate of 2.2 percent for FY 2015 based on the full estimated LTCH PPS market basket increase of 2.9 percent, less the MFP adjustment of 0.5 percentage point consistent with section 1886(m)(3)(A)(i) of the Act and less the 0.2 percentage point required by sections 1886(m)(3)(A)(ii) and (m)(4)(E) of the Act. Accordingly, at § 412.523(c)(3)(xi), we established an annual update to the standard Federal rate for FY 2015 of 2.2 percent. That is, we applied an update factor of 1.022 to the FY 2014 Federal rate of $40,607.31 to determine the FY 2015 standard Federal rate. The standard Federal rate for FY 2015 was further adjusted by an adjustment factor of 0.98734 for FY 2015 under the final year of the 3-year phase-in of the one-time prospective adjustment at § 412.523(d)(3)(ii). We also applied an area wage level budget neutrality factor for FY 2015 of 1.0016703 to the standard Federal rate to ensure that any changes to the area wage level adjustment would not result in any change in estimated aggregate LTCH PPS payments. Consequently, we established a standard Federal rate for FY 2015 of $41,043.71 (calculated as $40,607.31 \times 1.022 \times 0.98734 \times 1.001670) (79 FR 50392).
In this final rule, we are establishing an annual update to the LTCH PPS standard Federal payment rate of 1.7 percent, which was determined consistent with our proposal and using the methodology previously described. Accordingly, under § 412.523(c)(3)(xii), we are applying a factor of 1.017 to the FY 2015 standard Federal rate of $41,043.71 to determine the FY 2016 LTCH PPS standard Federal payment rate. These factors are based on IGI’s second quarter 2015 forecast, which are the best available data at this time. For LTCHs that fail to submit quality reporting data for FY 2016 under the LTCH QRP, under § 412.523(c)(3)(xii), applied in conjunction with the provisions of § 412.523(c)(4), we are reducing the annual update to the LTCH PPS standard Federal payment rate by an additional 2.0 percentage points consistent with section 1886(m)(5) of the Act. In those cases, the LTCH PPS standard Federal payment rate is updated by -0.3 percent (that is, a update factor of 0.997) for FY 2016 for LTCHs that fail to submit the required quality reporting data for FY 2016 as required under the LTCH QRP. Consistent with § 412.523(d)(4), we also are applying an area wage level budget neutrality factor to the FY 2016 LTCH PPS standard Federal payment rate of 1.000513, which was determined using the methodology previously described. We are applying this area wage level budget neutrality factor to the FY 2016 LTCH PPS standard Federal payment rate to ensure that any changes to the area wage level adjustment (that is, the annual update of the wage index values and labor-related share) will not result in any change (increase or decrease) in estimated aggregate LTCH PPS standard Federal payment rate payments. Accordingly, we are establishing a LTCH PPS standard Federal payment rate of $41,762.85 (calculated as $41,043.71× 1.017 × 1.000513) for FY 2016.
For LTCHs that fail to submit quality reporting data for FY 2016 in accordance with the requirements of the LTCHQRP under section 1886(m)(5) of the Act, we are establishing a LTCH PPS standard Federal payment rate of $40,941.55 (calculated as $41,043.71 × 0.997 × 1.000513) for FY 2016. We note, as discussed in section VII.B. of the preamble of this final rule, under our application of the site neutral payment rate required under section 1886(m)(6) of the Act, this LTCH PPS standard Federal payment rate will only be used to determine payments for LTCH PPS standard Federal payment rate cases (that is, those LTCH PPS cases that meet the statutory criteria to be excluded from the site neutral payment rate).

B. Adjustment for Area Wage Levels for the LTCH PPS Standard Federal Payment Rate for FY 2016

1. Background

Under the authority of section 123 of the BBRA, as amended by section 307(b) of the BIPA, we established an adjustment to the LTCH PPS standard Federal rate to account for differences in LTCH area wage levels under § 412.525(c). The labor-related share of the LTCH PPS standard Federal rate is adjusted to account for geographic differences in area wage levels by applying the applicable LTCH PPS wage index. The applicable LTCH PPS wage index is computed using wage data from inpatient acute care hospitals without regard to reclassification under section 1886(d)(8) or section 1886(d)(10) of the Act.

When we implemented the LTCH PPS, we established a 5-year transition to the full area wage level adjustment. The area wage level adjustment was completely
phased-in for cost reporting periods beginning in FY 2007. Therefore, for cost reporting periods beginning on or after October 1, 2006, the applicable LTCH area wage index values are the full LTCH PPS area wage index values calculated based on acute care hospital inpatient wage index data without taking into account geographic reclassification under section 1886(d)(8) and section 1886(d)(10) of the Act. For additional information on the phase-in of the area wage level adjustment under the LTCH PPS, we refer readers to the August 30, 2002 LTCH PPS final rule (67 FR 56015 through 56019) and the RY 2008 LTCH PPS final rule (72 FR 26891).

2. Geographic Classifications (Labor Market Areas) for the LTCH PPS Standard Federal Payment Rate

In adjusting for the differences in area wage levels under the LTCH PPS, the labor-related portion of an LTCH's Federal prospective payment is adjusted by using an appropriate area wage index based on the geographic classification (labor market area) in which the LTCH is located. Specifically, the application of the LTCH PPS area wage level adjustment under existing § 412.525(c) is made based on the location of the LTCH--either in an “urban area,” or a “rural area,” as defined in § 412.503. Under § 412.503, an “urban area” is defined as a Metropolitan Statistical Area (MSAs) (which includes a Metropolitan division, where applicable), as defined by the Executive OMB and a “rural area” is defined as any area outside of an urban area.

The CBSA-based geographic classifications (labor market area definitions) currently used under the LTCH PPS, effective for discharges occurring on or after October 1, 2014, are based on the new OMB labor market area delineations based on the
2010 Decennial Census data. We made these revisions because we believe that these OMB delineations are based on the best available data that reflect the local economies and area wage levels of the hospitals that are currently located in these geographic areas. We also believe that these OMB delineations will ensure that the LTCH PPS area wage level adjustment most appropriately accounts for and reflects the relative hospital wage levels in the geographic area of the hospital as compared to the national average hospital wage level. We noted that this policy was consistent with the IPPS policy adopted in FY 2015 under § 412.64(b)(1)(ii)(D) of the regulations (79 FR 49951 through 49963).

(For additional information on the CBSA-based labor market area (geographic classification) delineations currently used under the LTCH PPS and the history of the labor market area definitions used under the LTCH PPS, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50180 through 50185).)

In general, it is our historical practice to update the CBSA-based labor market area delineations annually based on the most recent updates issued by OMB. At the time of the development of this proposed rule, OMB had not issued any further updates subsequent to OMB Bulletin No. 13–01, which was dated February 28, 2013, and established revised delineations based on 2010 Census Bureau data that were subsequently adopted in the FY 2015 IPPS/LTCH PPS final rule. (The OMB bulletins are available on the OMB Web site at: http://www.whitehouse.gov/omb. Go to “Information For Agencies” and click on “Bulletins”.) Therefore, for FY 2016, as proposed, we are continuing to use the CBSA-based labor market area delineations currently used under the LTCH PPS (as adopted in the FY 2015 IPPS/LTCH PPS final
rule (79 FR 50180 through 50185). We believe that these CBSA-based labor market area delineations will ensure that the LTCH PPS area wage level adjustment most appropriately accounts for and reflects the relative hospital wage levels in the geographic area of the hospital as compared to the national average hospital wage level based on the best available data that reflect the local economies and area wage levels of the hospitals that are currently located in these geographic areas.

3. Labor-Related Share for the LTCH PPS Standard Federal Payment Rate

Under the payment adjustment for the differences in area wage levels under § 412.525(c), the labor-related share of an LTCH’s PPS Federal prospective payment is adjusted by the applicable wage index for the labor market area in which the LTCH is located. The LTCH PPS labor-related share currently represents the sum of the labor-related portion of operating costs (Wages and Salaries; Employee Benefits; Professional Fees Labor-Related, Administrative and Business Support Services; and All-Other: Labor-Related Services) and a labor-related portion of capital costs using the applicable LTCH PPS market basket. Additional background information on the historical development of the labor-related share under the LTCH PPS and the development of the RPL market basket can be found in the RY 2007 LTCH PPS final rule (71 FR 27810 through 27817 and 27829 through 27830) and the FY 2012 IPPS/LTCH PPS final rule (76 FR 51766 through 51769 and 51808).

For FY 2013, we revised and rebased the market basket used under the LTCH PPS by adopting the newly created FY 2009-based LTCH-specific market basket. In addition, we determined the labor-related share for FY 2013 as the sum of the FY 2013
relative importance of each labor-related cost category of the FY 2009-based LTCH-specific market basket. For more details, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53477 through 53479). Consistent with our historical practice, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50393 through 50394), we determined the LTCH PPS labor-related share for FY 2015 based on the FY 2015 relative importance of each labor-related cost category, which reflected the different rates of price change for these cost categories between the base year (FY 2009) and FY 2015. Specifically, based on IGI’s second quarter 2014 forecast of the FY 2009-based LTCH-specific market basket, we established a labor-related share under the LTCH PPS for FY 2015 of 62.306 percent.

For FY 2016, we are establishing a labor-related share for the LTCH PPS standard Federal payment rate payments based on IGI’s second quarter 2015 forecast of the FY 2009-based LTCH-specific market basket. Consistent with our historical practice, as proposed, we also are using more recent data to determine the final FY 2016 labor-related share. In addition, as proposed, we are specifying the labor-related share to one decimal place, which is consistent with the IPPS labor-related share and the LTCH market basket update. The following table shows the FY 2016 labor-related share relative importance using IGI’s second quarter 2015 forecast of the FY 2009-based LTCH-specific market basket. The sum of the relative importance for FY 2016 for operating costs (Wages and Salaries; Employee Benefits; Professional Fees; Labor-Related, Administrative and Business Support Services; and All Other: Labor-Related Services) is 57.9 percent. We are establishing that the portion of capital-
related costs that is influenced by the local labor market would continue to be estimated to be 46 percent. Because the relative importance for capital-related costs would be 9.0 percent of the FY 2009-based LTCH-specific market basket in FY 2016, we are taking 46 percent of 9.0 percent to determine the labor-related share of capital-related costs for FY 2016, which would result in 4.1 percent (0.46 x 9.0). We then added that 4.1 percent for the capital-related cost amount to the 57.9 percent for the operating cost amount to determine the total labor-related share for FY 2016. Therefore, under the broad authority of section 123 of the BBRA, as amended by section 307(b) of BIPA, to determine appropriate payment adjustments under the LTCH PPS, we are establishing a labor-related share under the LTCH PPS for FY 2016 of 62.0 percent. Consistent with our proposal, this labor-related share is determined using the same methodology as used in calculating all previous fiscal years LTCH labor-related shares.
FY 2016 LABOR-RELATED SHARE RELATIVE IMPORTANCE BASED ON THE FY 2009-BASED LTCH-SPECIFIC MARKET BASKET

<table>
<thead>
<tr>
<th>Wages and Salaries</th>
<th>44.6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employee Benefits</td>
<td>8.1</td>
</tr>
<tr>
<td>Professional Fees: Labor-Related</td>
<td>2.2</td>
</tr>
<tr>
<td>Administrative and Business Support Services</td>
<td>0.5</td>
</tr>
<tr>
<td>All Other: Labor-Related Services</td>
<td>2.5</td>
</tr>
<tr>
<td>Subtotal</td>
<td>57.9</td>
</tr>
<tr>
<td>Labor-Related Portion of Capital Costs (46 percent)</td>
<td>4.1</td>
</tr>
<tr>
<td><strong>Total Labor-Related Share</strong></td>
<td><strong>62.0</strong></td>
</tr>
</tbody>
</table>

4. Wage Index for FY 2016 for the LTCH PPS Standard Federal Payment Rate

Historically, we have established LTCH PPS area wage index values calculated from acute care IPPS hospital wage data without taking into account geographic reclassification under sections 1886(d)(8) and 1886(d)(10) of the Act (67 FR 56019). The area wage level adjustment established under the LTCH PPS is based on an LTCH’s actual location without regard to the “urban” or “rural” designation of any related or affiliated provider.

In the FY 2015 LTCH PPS final rule (79 FR 50394 through 50396), we calculated the FY 2015 LTCH PPS area wage index values using the same data used for the FY 2015 acute care hospital IPPS (that is, data from cost reporting periods beginning during FY 2011), without taking into account geographic reclassification under sections
1886(d)(8) and 1886(d)(10) of the Act, as these were the most recent complete data available at that time. In that same final rule, we indicated that we computed the FY 2015 LTCH PPS area wage index values consistent with the urban and rural geographic classifications (labor market areas) that were in place at that time, and consistent with the pre-reclassified IPPS wage index policy (that is, our historical policy of not taking into account IPPS geographic reclassifications in determining payments under the LTCH PPS). As with the IPPS wage index, wage data for multicampus hospitals with campuses located in different labor market areas (CBSAs) are apportioned to each CBSA where the campus (or campuses) are located. We also continued to use our existing policy for determining area wage index values for areas where there are no IPPS wage data.

Consistent with our historical methodology, to determine the applicable area wage index values for the FY 2016 LTCH PPS standard Federal payment rate, under the broad authority of section 123 of the BBRA, as amended by section 307(b) of the BIPA, as we proposed, we are using wage data collected from cost reports submitted by IPPS hospitals for cost reporting periods beginning during FY 2012, without taking into account geographic reclassification under sections 1886(d)(8) and 1886(d)(10) of the Act. We are using FY 2012 wage data because these data are the most recent complete data available. We also note that these are the same data used to compute the FY 2016 acute care hospital inpatient wage index, as discussed in section III. of the preamble of this final rule. We are computing the FY 2016 LTCH PPS standard Federal payment rate area wage index values consistent with the “urban” and “rural” geographic classifications (that
is, labor market area delineations, as previously discussed in section V.B.2. of this Addendum) and our historical policy of not taking into account IPPS geographic reclassifications under sections 1886(d)(8) and 1886(d)(10) of the Act in determining payments under the LTCH PPS, as we proposed. We also are, as we proposed, continuing to apportion wage data for multicampus hospitals with campuses located in different labor market areas to each CBSA where the campus or campuses are located, consistent with the IPPS policy. Lastly, under our methodology for determining the FY 2016 LTCH PPS standard Federal payment rate area wage index values, as we proposed, we are continuing to use our existing policy for determining area wage index values for areas where there are no IPPS wage data.

Under our existing methodology, the LTCH PPS wage index value for urban CBSAs with no IPPS wage data would be determined by using an average of all of the urban areas within the State and the LTCH PPS wage index value for rural areas with no IPPS wage data would be determined by using the unweighted average of the wage indices from all of the CBSAs that are contiguous to the rural counties of the State.

Based on the FY 2012 IPPS wage data that we are using to determine the FY 2016 LTCH PPS standard Federal payment rate area wage index values in this final rule, there are no IPPS wage data for the urban area of Hinesville, GA (CBSA 25980). Consistent with the methodology discussed above, we calculated the FY 2016 wage index value for CBSA 25980 as the average of the wage index values for all of the other urban areas within the State of Georgia (that is, CBSAs 10500, 12020, 12060, 12260, 15260, 16860, 17980, 19140, 23580, 31420, 40660, 42340, 46660 and 47580), as shown
in Table 12A, which is listed in section VI. of the Addendum to this final rule and available via the Internet on the CMS Web site). We note that, as IPPS wage data are dynamic, it is possible that urban areas without IPPS wage data will vary in the future.

Based on the FY 2012 IPPS wage data that we are using to determine the FY 2016 LTCH PPS standard Federal payment rate area wage index values in this final rule, there are no rural areas without IPPS hospital wage data. Therefore, it is not necessary to use our established methodology to calculate a LTCH PPS standard Federal payment rate wage index value for rural areas with no IPPS wage data for FY 2016. We note that, as IPPS wage data are dynamic, it is possible that the number of rural areas without IPPS wage data will vary in the future. The FY 2016 LTCH PPS standard Federal payment rate wage index values that are applicable for LTCH PPS standard Federal payment rate discharges occurring on or after October 1, 2015, through September 30, 2016, are presented in Table 12A (for urban areas) and Table 12B (for rural areas), which are listed in section VI. of the Addendum of this final rule and available via the Internet on the CMS Web site.

5. Budget Neutrality Adjustment for Changes to the LTCH PPS Standard Federal Payment Rate Area Wage Level Adjustment

Historically, the LTCH PPS wage index and labor-related share are updated annually based on the latest available data. Under § 412.525(c)(2), any changes to the area wage index values or labor-related share are to be made in a budget neutral manner such that estimated aggregate LTCH PPS payments are unaffected; that is, will be neither greater than nor less than estimated aggregate LTCH PPS payments without such changes
to the area wage level adjustment. Under this policy, we determine an area wage-level adjustment budget neutrality factor that will be applied to the standard Federal rate to ensure that any changes to the area wage level adjustments are budget neutral such that any changes to the area wage index values or labor-related share would not result in any change (increase or decrease) in estimated aggregate LTCH PPS payments. Accordingly, under § 412.523(d)(4), we apply an area wage level adjustment budget neutrality factor in determining the standard Federal rate, and we also established a methodology for calculating an area wage level adjustment budget neutrality factor. (For additional information on the establishment of our budget neutrality policy for changes to the area wage level adjustment, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51771 through 51773 and 51809).)

In this final rule, for FY 2016 LTCH PPS standard Federal payment rate cases, in accordance with § 412.523(d)(4), as we proposed, we are applying an area wage level adjustment budget neutrality factor to adjust the standard Federal rate to account for the estimated effect of the adjustments or updates to the area wage level adjustment under § 412.525(c)(1) on estimated aggregate LTCH PPS payments using a methodology that is consistent with the methodology we established in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51773). Specifically, as we proposed, we are determining an area wage level adjustment budget neutrality factor that will be applied to the LTCH PPS standard Federal payment rate under § 412.523(d)(4) for FY 2016 using the following methodology:
Step 1—We simulated estimated aggregate LTCH PPS standard Federal payment rate payments using the FY 2015 wage index values, including the 50/50 blended area wage index values, as applicable, and the FY 2015 labor-related share of 62.306 percent (as established in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50393 and 50397).

Step 2—We simulated estimated aggregate LTCH PPS standard Federal payment rate payments using the FY 2016 wage index values (as shown in Tables 12A and 12B listed in the Addendum to this final rule and available via the Internet on the CMS Website) and the FY 2016 labor-related share of 62.0 percent (based on the latest available data as previously discussed previously in this Addendum).

Step 3—We calculated the ratio of these estimated total LTCH PPS standard Federal payment rate payments by dividing the estimated total LTCH PPS standard Federal payment rate payments using the FY 2015 area wage level adjustments (calculated in Step 1) by the estimated total LTCH PPS standard Federal payment rate payments using the FY 2016 area wage level adjustments (calculated in Step 2) to determine the area wage level adjustment budget neutrality factor for FY 2016 LTCH PPS standard Federal payment rate payments.

Step 4—We then applied the FY 2016 area wage level adjustment budget neutrality factor from Step 3 to determine the FY 2016 LTCH PPS standard Federal payment rate after the application of the FY 2016 annual update (discussed previously in section V.A.2. of this Addendum).

We note that, with the exception of cases subject to the transitional blend payment rate provisions in the first 2 years, under the dual rate LTCH PPS payment structure, only
LTCH PPS cases that meet the statutory criteria to be excluded from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) will be paid based on the LTCH PPS standard Federal payment rate. Because the area wage level adjustment under § 412.525(c) is an adjustment to the LTCH PPS standard Federal payment rate, we only used data from claims that would have qualified for payment at the LTCH PPS standard Federal payment rate if such rate were in effect at the time of discharge to calculate the FY 2016 LTCH PPS standard Federal payment rate area wage level adjustment budget neutrality factor described above. (For additional information on our application of site neutral payment rate required under section 1886(m)(6) of the Act, we refer readers to section VII.B. of the preamble of this final rule.)

For this final rule, using the steps in the methodology described above, we determined a FY 2016 LTCH PPS standard Federal payment rate area wage level adjustment budget neutrality factor of 1.000513. Accordingly, in section V.A.2. of the Addendum to this final rule, to determine the FY 2016 LTCH PPS standard Federal payment rate, we are applying an area wage level adjustment budget neutrality factor of 1.000513, in accordance with § 412.523(d)(4). The FY 2016 LTCH PPS standard Federal payment rate shown in Table 1E of the Addendum to this final rule reflects this adjustment factor.

C. LTCH PPS Cost-of-Living Adjustment (COLA) for LTCHs Located in Alaska and Hawaii

Under § 412.525(b), a cost-of-living adjustment (COLA) is provided for LTCHs located in Alaska and Hawaii to account for the higher costs incurred in those States.
Specifically, we apply a COLA to payments to LTCHs located in Alaska and Hawaii by multiplying the nonlabor-related portion of the standard Federal payment rate by the applicable COLA factors established annually by CMS. Higher labor-related costs for LTCHs located in Alaska and Hawaii are taken into account in the adjustment for area wage levels described above.

Under our current methodology, we update the COLA factors for Alaska and Hawaii every 4 years (at the same time as the update to the labor-related share of the IPPS market basket) (77 FR 53712 through 53713). This methodology is based on a comparison of the growth in the Consumer Price Indexes (CPIs) for Anchorage, Alaska, and Honolulu, Hawaii, relative to the growth in the CPI for the average U.S. city as published by the Bureau of Labor Statistics (BLS). It also includes a 25-percent cap on the CPI-updated COLA factors. (For additional details on our current methodology for updating the COLA factors for Alaska and Hawaii, we refer readers to section VII.D.3. of the preamble of the FY 2013 IPPS/LTCH PPS final rule (77 FR 53481 through 53482).)

We continue to believe that determining updated COLA factors using this methodology would appropriately adjust the nonlabor-related portion of the LTCH PPS standard Federal payment rate for LTCHs located in Alaska and Hawaii. Under our current policy, we update the COLA factors using the methodology described above every 4 years; the first year began in FY 2014 (77 FR 53482). Therefore, in this final rule, as we proposed, for FY 2016, under the broad authority conferred upon the Secretary by section 123 of the BBRA, as amended by section 307(b) of the BIPA, to determine appropriate payment adjustments under the LTCH PPS, we are continuing to
use the COLA factors based on the 2009 OPM COLA factors updated through 2012 by the comparison of the growth in the CPIs for Anchorage, Alaska, and Honolulu, Hawaii, relative to the growth in the CPI for the average U.S. city as established in the FY 2014 IPPS/LTCH PPS final rule. (We refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50998) for a discussion of the FY 2014 COLA factors.) Consistent with our historical practice and as we proposed, we are establishing that the COLA factors shown in the following table will be used to adjust the nonlabor-related portion of the LTCH PPS standard Federal payment rate for LTCHs located in Alaska and Hawaii under § 412.525(b).

**Cost-of-Living Adjustment Factors for Alaska and Hawaii Hospitals under the LTCH PPS for FY 2016**

<table>
<thead>
<tr>
<th>Alaska:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>City of Anchorage and 80-kilometer (50-mile) radius by road</td>
<td>1.23</td>
</tr>
<tr>
<td>City of Fairbanks and 80-kilometer (50-mile) radius by road</td>
<td>1.23</td>
</tr>
<tr>
<td>City of Juneau and 80-kilometer (50-mile) radius by road</td>
<td>1.23</td>
</tr>
<tr>
<td>All other areas of Alaska</td>
<td>1.25</td>
</tr>
<tr>
<td>Hawaii:</td>
<td></td>
</tr>
<tr>
<td>City and County of Honolulu</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Hawaii</td>
<td>1.19</td>
</tr>
<tr>
<td>County of Kauai</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Maui and County of Kalawao</td>
<td>1.25</td>
</tr>
</tbody>
</table>

D. Adjustment for LTCH PPS High-Cost Outlier (HCO) Cases

1. Overview

a. Background

Under the broad authority conferred upon the Secretary by section 123 of the BBRA as amended by section 307(b) of the BIPA, in the regulations at § 412.525(a), we
established an adjustment for additional payments for outlier cases that have extraordinarily high costs relative to the costs of most discharges. We refer to these cases as high cost outliers (HCOs). Providing additional payments for outliers strongly improves the accuracy of the LTCH PPS in determining resource costs at the patient and hospital level. These additional payments reduce the financial losses that would otherwise be incurred when treating patients who require more costly care and, therefore, reduce the incentives to underserve these patients. Under our current HCO policy at § 412.525(a), we set the outlier threshold before the beginning of the applicable rate year so that total estimated outlier payments are projected to equal 8 percent of total estimated payments under the LTCH PPS.

Under the current HCO policy, we make outlier payments for any discharges if the estimated cost of a case exceeds the adjusted payment under the LTCH PPS standard Federal payment rate plus a fixed-loss amount. Specifically, in accordance with existing § 412.525(a)(3), we make an additional payment for an HCO case that is equal to 80 percent of the difference between the estimated cost of the patient case and the outlier threshold, which is the sum of the adjusted payment under the LTCH PPS standard Federal payment rate and the fixed-loss amount. The fixed-loss amount is the amount used to limit the loss that a hospital incurs under the outlier policy for a case with unusually high costs before the LTCH will receive any additional payments. This results in Medicare and the LTCH sharing financial risk in the treatment of extraordinarily costly cases. Under the current LTCH PPS HCO policy, the LTCH's loss is limited to the fixed-loss amount and a fixed percentage of costs above the outlier threshold (the
adjusted LTCH PPS standard Federal payment rate payment plus the fixed-loss amount). The fixed percentage of costs is called the marginal cost factor. We calculate the estimated cost of a case by multiplying the Medicare allowable covered charge by the hospital’s overall hospital cost-to-charge ratio (CCR).

Under the current HCO policy at § 412.525(a), we determine a fixed-loss amount, that is, the maximum loss that an LTCH can incur under the LTCH PPS for a case with unusually high costs before the LTCH will receive any additional payments. We calculate the fixed-loss amount by estimating aggregate payments with and without an outlier policy. The fixed-loss amount results in estimated total outlier payments being projected to be equal to 8 percent of projected total LTCH PPS payments. Currently, MedPAR claims data and CCRs based on data from the most recent Provider-Specific File (PSF) (or from the applicable statewide average CCR if an LTCH’s CCR data are faulty or unavailable) are used to establish a fixed-loss threshold amount under the LTCH PPS.

b. Application of the Site Neutral Payment Rate

Section 1206 of Pub. L. 113-67 establishes a new dual rate LTCH PPS payment structure with two distinct payment rates for LTCH discharges, beginning in FY 2016. To implement this statutory change, as discussed in section VII.B. of the preamble of this final rule, we will pay hospitals for LTCH discharges that meet the criteria for exclusion from site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) based on the LTCH PPS standard Federal payment rate, which includes HCO payments determined under existing § 412.525(a). Furthermore, we are establishing that the site
neutral payment rate is the lower of the IPPS comparable per diem amount as determined under § 412.529(d)(4) (including any applicable adjustments, such as outlier payments), or 100 percent of the estimated cost of the case as determined under existing § 412.529(d)(2), consistent with the statute.

Under the new dual rate LTCH PPS payment structure, as discussed in section VII.B.7.b. of the preamble of this final rule, as we proposed, we are establishing two separate HCO targets—one for LTCH PPS standard Federal payment rate cases and one for site neutral payment rate cases. We are revising the regulations by making changes to the HCO policy to account for the new dual rate LTCH PPS payment structure by revising paragraphs (a)(1), (a)(2), and (a)(3), and adding a new paragraph (a)(4) to existing § 412.525 of the regulations. Under our HCO policy revised in accordance with the new dual rate LTCH PPS payment structure, we are establishing a fixed-loss amount and target for LTCH PPS standard Federal payment rate cases using the current LTCH PPS HCO policy, but limiting the data used under that policy to LTCH cases that would have been LTCH PPS standard Federal payment rate cases if the statutory changes had been in effect at the time of those discharges. Therefore, we are not making any modifications to the HCO methodology as it applies to LTCH PPS standard Federal payment rate cases other than determining a fixed-loss amount using only data from LTCH PPS standard Federal payment rate cases. Specifically, under our finalized policy, LTCH PPS standard Federal payment rate cases will receive an additional payment for an HCO case that is equal to 80 percent of the difference between the estimated cost of the case and the HCO threshold, which is the sum of the LTCH PPS payment for the LTCH
PPS standard Federal payment rate case and the fixed-loss amount for such cases. The fixed-loss amount for LTCH PPS standard Federal payment rate cases will continue to be determined so that estimated HCO payments would be projected to be equal to 8 percent of estimated total LTCH PPS payments for LTCH PPS standard Federal payment rate cases.

Furthermore, as we proposed, we are revising the HCO policy under existing § 412.525(a) to provide for high-cost outlier payments under the site neutral payment rate. Specifically, we are establishing that site neutral payment rate cases will receive an additional payment for HCOs that is equal to 80 percent of the difference between the estimated cost of the case and the HCO threshold for site neutral payment rate discharges, which we are establishing as the sum of site neutral payment rate for the case and the IPPS fixed-loss amount. In addition, in order to maintain budget neutrality, as we proposed and as discussed in section VII.B.7.b. of the preamble of this final rule, we are making the HCO payments for site neutral payment rate cases budget neutral by applying a budget neutrality factor to the LTCH PPS payments for those site neutral payment rate cases. (Additional details on the calculation of the budget neutrality adjustment for HCO payments to site neutral payment rate cases is discussed subsequently in section V.D.4. of this Addendum.)

2. Determining LTCH CCRs under the LTCH PPS

a. Background

The following is a discussion of CCRs that are used in determining payments for HCO cases under § 412.525(a), SSO cases paid under the LTCH PPS in accordance with
§ 412.529, and site neutral payment rate cases paid in accordance with proposed § 412.522(c) (as discussed in section VII.B.4. of the preamble of this final rule). Although this section is specific to HCO cases, because CCRs and the policies and methodologies pertaining to them are used in determining payments for HCO, SSO, and site neutral payment rate cases (to determine the estimated costs of these cases), we are discussing the determination of CCRs under the LTCH PPS for these three types of cases simultaneously in this section.

In determining HCO payments in accordance with § 412.525(a), SSO payments in accordance with § 412.529 and site neutral payment rate payments in accordance with § 412.522(c), we calculate the estimated cost of the case by multiplying the LTCH's overall CCR by the Medicare allowable charges for the case. In general, we use the LTCH's overall CCR, which is computed based on either the most recently settled cost report or the most recent tentatively settled cost report, whichever is from the latest cost reporting period, in accordance with § 412.525(a)(4)(iv)(B), for HCOs, § 412.529(f)(4)(ii) for SSOs, and § 412.522(c)(1)(ii) for site neutral payment rate cases. (We note that, in some instances under the provisions of the regulations at § 412.525(a)(4)(iv) and § 412.529(f)(4), and § 412.522(c)(1)(ii), we may use an alternative CCR, such as the statewide average CCR, a CCR that is specified by CMS, or that is requested by the hospital.) Under the LTCH PPS, a single prospective payment per discharge is made for both inpatient operating and capital-related costs. Therefore, we compute a single “overall” or “total” LTCH-specific CCR based on the sum of LTCH operating and capital costs (as described in Section 150.24, Chapter 3, of the Medicare Claims Processing
Manual (Pub. 100-4)) as compared to total charges. Specifically, an LTCH's CCR is calculated by dividing an LTCH's total Medicare costs (that is, the sum of its operating and capital inpatient routine and ancillary costs) by its total Medicare charges (that is, the sum of its operating and capital inpatient routine and ancillary charges).

b. LTCH Total CCR Ceiling

Generally, an LTCH is assigned the applicable statewide average CCR if, among other things, an LTCH's CCR is found to be in excess of the applicable maximum CCR threshold (that is, the LTCH CCR ceiling). This is because CCRs above this threshold are most likely due to faulty data reporting or entry, and CCRs based on erroneous data should not be used to identify and make payments for outlier cases. Therefore, under our established policy, generally, if an LTCH's calculated CCR is above the applicable ceiling, the applicable LTCH PPS statewide average CCR is assigned to the LTCH instead of the CCR computed from its most recent (settled or tentatively settled) cost report data.

In this final rule, using our established methodology for determining the LTCH total CCR ceiling, based on IPPS total CCR data from the March 2015 update of the PSF, we are establishing a total CCR ceiling of 1.335 under the LTCH PPS for FY 2016 in accordance with § 412.525(a)(4)(iv)(C)(2) for HCOs, § 412.529(f)(4)(iii)(B) for SSOs, and § 412.522(c)(1)(ii) for site neutral payment rate cases. We also are, as proposed, using more recent data to determine the LTCH PPS CCR ceiling for this FY 2016 final rule.
c. LTCH Statewide Average CCRs

Our general methodology established for determining the statewide average CCRs used under the LTCH PPS is similar to our established methodology for determining the LTCH total CCR ceiling (described above) because it is based on “total” IPPS CCR data. Under the LTCH PPS HCO policy at § 412.525(a)(4) (iv)(C) the SSO policy at § 412.529(f)(4)(iii), and the site neutral payment rate policy at § 412.522(c)(1)(ii), the MAC may use a statewide average CCR, which is established annually by CMS, if it is unable to determine an accurate CCR for an LTCH in one of the following circumstances: (1) new LTCHs that have not yet submitted their first Medicare cost report (for this purpose, consistent with current policy, a new LTCH is defined as an entity that has not accepted assignment of an existing hospital's provider agreement in accordance with § 489.18); (2) LTCHs whose CCR is in excess of the LTCH CCR ceiling; and (3) other LTCHs for whom data with which to calculate a CCR are not available (for example, missing or faulty data). (Other sources of data that the MAC may consider in determining an LTCH's CCR include data from a different cost reporting period for the LTCH, data from the cost reporting period preceding the period in which the hospital began to be paid as an LTCH (that is, the period of at least 6 months that it was paid as a short-term, acute care hospital), or data from other comparable LTCHs, such as LTCHs in the same chain or in the same region.)

Consistent with our historical practice of using the best available data and as we proposed, in this final rule, using our established methodology for determining the LTCH statewide average CCRs, based on the most recent complete IPPS “total CCR” data from
the March 2015 update of the PSF, we are establishing LTCH PPS statewide average total CCRs for urban and rural hospitals that will be effective for discharges occurring on or after October 1, 2015 through September 30, 2016, in Table 8C listed in section VI. of the Addendum to this final rule (and available via the Internet). We also, as proposed, are using more recent data to determine the LTCH PPS statewide average total CCRs for FY 2016.

Under the current LTCH PPS labor market areas, all areas in Delaware, the District of Columbia, New Jersey, and Rhode Island are classified as urban. Therefore, there are no rural statewide average total CCRs listed for those jurisdictions in Table 8C. This policy is consistent with the policy that we established when we revised our methodology for determining the applicable LTCH statewide average CCRs in the FY 2007 IPPS final rule (71 FR 48119 through 48121) and is the same as the policy applied under the IPPS. In addition, although Connecticut and Massachusetts have areas that are designated as rural, there are no short-term, acute care IPPS hospitals or LTCHs located in those areas as of March 2015. Therefore, consistent with our existing methodology and as we proposed, we are using the national average total CCR for rural IPPS hospitals for rural Connecticut and Massachusetts in Table 8C listed in section VI. of the Addendum to this final rule (and available via the Internet). In addition, consistent with our existing methodology as we proposed, in determining the urban and rural statewide average total CCRs for Maryland LTCHs paid under the LTCH PPS, we are continuing to use, as a proxy, the national average total CCR for urban IPPS hospitals and the national average total CCR for rural IPPS hospitals, respectively. We are using
this proxy because we believe that the CCR data in the PSF for Maryland hospitals may not be entirely accurate (as discussed in greater detail in the FY 2007 IPPS final rule (71 FR 48120)).

d. Reconciliation of HCO and SSO Payments

Under the HCO policy at § 412.525(a)(4)(iv)(D) and the SSO policy at § 412.529(f)(4)(iv), the payments for HCO and SSO, cases are subject to reconciliation. Specifically, any reconciliation of payments is based on the CCR that is calculated based on a ratio of cost-to-charge data computed from the relevant cost report determined at the time the cost report coinciding with the discharge is settled. (As discussed section VII.B.4.a. of the preamble of this final rule, after consideration of public comments we received, we are not finalizing our proposal to establish a reconciliation process for site neutral payment rate payments. However, we are finalizing the portion of our proposal to apply the existing HCO reconciliation policy to the HCO payments made to site neutral payment rate cases. For additional information on the existing reconciliation policy, we refer readers to sections 150.26 through 150.28 of the Medicare Claims Processing Manual (Pub. 100-4) as added by Change Request 7192 (Transmittal 2111; December 3, 2010) and the RY 2009 LTCH PPS final rule (73 FR 26820 through 26821).

3. High-Cost Outlier Payments for LTCH PPS Standard Federal Payment Rate Cases

a. Establishment of the LTCH PPS Fixed-Loss Amount for LTCH PPS Standard Federal Payment Rate Cases for FY 2016

When we implemented the LTCH PPS, under the broad authority of section 123 of the BBRA as amended by section 307(b) of BIPA, we established a fixed-loss amount
so that total estimated outlier payments are projected to equal 8 percent of total estimated payments under the LTCH PPS (67 FR 56022 through 56026). To determine the fixed-loss amount, we estimate outlier payments and total LTCH PPS payments for each case using claims data from the MedPAR files. Specifically, we estimate the cost of the case by multiplying the Medicare covered charges from the claim by the LTCH’s CCR. Under the HCO policy at § 412.525(a), if the estimated cost of the case exceeds the outlier threshold, we make an outlier payment equal to 80 percent of the difference between the estimated cost of the case and the outlier threshold (that is, the sum of the adjusted standard Federal rate payment and the fixed-loss amount).

As noted above and as discussed in greater detail in section VII.B.7.b. of the preamble of this final rule, under the new dual rate LTCH PPS payment structure, we are establishing two separate HCO targets—one for LTCH PPS standard Federal payment rate cases and one for site neutral payment rate cases. Under this finalized policy, for LTCH PPS standard Federal payment rate cases, we are establishing a fixed-loss amount and target using the current LTCH PPS HCO policy, but to limit the data used under that policy to LTCH cases that would have been paid as LTCH PPS standard Federal payment rate cases, if that payment rate had been in effect at the time of those discharges. Therefore, as we proposed, we are not making any modifications to the existing LTCH PPS HCO payment methodology as it applies to LTCH PPS standard Federal payment rate cases, other than determining a fixed-loss amount using only data from LTCH PPS standard Federal payment rate cases (or cases that would have been LTCH PPS standard Federal payment rate cases had the new dual rate LTCH PPS payment structure been in
effect at the time of those discharges). As such, LTCH PPS standard Federal payment rate cases will continue to receive an additional payment for any HCO case that is equal to 80 percent of the difference between the estimated cost of the case and the HCO threshold, which is the sum of the LTCH PPS payment for the LTCH PPS standard Federal payment rate case and the fixed-loss amount. The fixed-loss amount for LTCH PPS standard Federal payment rate cases will continue to be determined so that estimated HCO payments would be projected to equal 8 percent of estimated total LTCH PPS standard Federal payment rate cases, and a budget neutrality factor will continue to be applied to LTCH PPS standard Federal payment rate cases to offset that 8 percent so that HCO payments for LTCH PPS standard Federal payment rate cases will be budget neutral. Below we present our calculation of the LTCH PPS fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2016, which is consistent with the methodology used to establish the FY 2015 LTCH PPS fixed-loss amount. (Additional discussion of our HCO payment policy proposals for site neutral payment rate cases is discussed subsequently in section V.D.4. of this Addendum.)

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50399 through 50400), we presented our policies regarding the methodology and data we used to establish a fixed-loss amount of $14,972 for FY 2015, which was calculated using our existing methodology (based on the data and the rates and policies presented in that final rule) in order to maintain estimated HCO payments at the projected 8 percent of total estimated LTCH PPS payments. Consistent with our historical practice of using the best data available, in determining the fixed-loss amount for FY 2015, we used the most recent
available LTCH claims data and CCR data, that is, LTCH claims data from the March 2014 update of the FY 2013 MedPAR file and CCRs from the March 2014 update of the PSF, as these data were the most recent complete LTCH data available at that time.

In this final rule, as we proposed, we are continuing to use our existing methodology to calculate a fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2016 using the best available data that will maintain estimated HCO payments at the projected 8 percent of total estimated LTCH PPS payments for LTCH PPS standard Federal payment rate cases (based on the rates and policies for these cases presented in this final rule). Specifically, based on the most recent complete LTCH data available (that is, LTCH claims data from the March 2015 update of the FY 2014 MedPAR file and CCRs from the March 2015 update of the PSF), we determined a fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2016 that will result in estimated outlier payments projected to be equal to 8 percent of estimated FY 2016 payments for such cases. Under the broad authority of section 123(a)(1) of the BBRA and section 307(b)(1) of the BIPA, we are establishing a fixed-loss amount of $16,423 for LTCH PPS standard Federal payment rate cases for FY 2016. We also will continue to make an additional HCO payment for the cost of an LTCH PPS standard Federal payment rate case that exceeds the HCO threshold amount that is equal to 80 percent of the difference between the estimated cost of the case and the outlier threshold (the sum of the adjusted LTCH PPS standard Federal payment rate payment and the fixed-loss amount for LTCH PPS standard Federal payment rate cases of $16,423).
We note that the fixed-loss amount of $16,423 for FY 2016 for LTCH PPS standard Federal payment rate cases is lower than the proposed FY 2016 fixed-loss amount for LTCH PPS standard Federal payment rate cases of $18,768. This decrease is primarily a result of updated data used to calculate the fixed-loss amount in this final rule, such as the most recent available LTCH claims data in the MedPAR file, CCRs in the PSF, and the estimate of the LTCH market basket increase. We also note that the fixed-loss amount of $16,423 for LTCH PPS standard Federal payment rate cases for FY 2016 is higher than the FY 2015 fixed-loss amount of $14,792. This increase is largely attributable to the implementation of the new dual rate LTCH PPS payment structure, under which we have established separate HCO target amounts for LTCH PPS standard Federal payment rate cases and site neutral payment rate cases. The FY 2015 fixed-loss amount was determined based on data from all LTCH cases—both those that would have been paid as site neutral payment rate cases and those that would have been paid as LTCH PPS standard Federal payment rate cases if the new dual rate LTCH PPS payment structure had been in effect at that time. However, under our finalized policy, the fixed-loss amount of $16,423 for FY 2016 will only be used to determine HCO payments made for LTCH PPS standard Federal payment rate cases. We currently estimate that the FY 2015 fixed-loss amount of $14,972 results in estimated HCO payments for LTCH PPS standard Federal payment rate cases of approximately 8.1 percent of total estimated FY 2015 LTCH PPS payments to those cases, which exceeds the 8 percent target. Therefore, we believe that it is necessary and appropriate to increase the fixed-loss amount to maintain that, for LTCH PPS standard Federal payment rate cases, estimated
HCO payments would equal 8 percent of estimated total LTCH PPS payments for those cases as required under the revisions to § 412.525(a). (For further information on the existing 8 percent HCO “target” requirement, we refer readers to the August 30, 2002 LTCH PPS final rule (67 FR 56022 through 56024).) Maintaining the fixed-loss amount at the current level would result in HCO payments that are more than the current regulatory 8-percent target that we are applying to total payments for LTCH PPS standard Federal payment rate cases because a lower fixed-loss amount would result in more cases qualifying as outlier cases, as well as higher outlier payments for qualifying HCO cases because the maximum loss that an LTCH must incur before receiving an HCO payment (that is, the fixed-loss amount) would be smaller.

b. Application of the High-Cost Outlier Policy to SSO Cases

Under our finalized policies to implement the new dual rate LTCH PPS payment structure required by statute, we are establishing that LTCH PPS standard Federal payment rate cases (that is, LTCH discharges that meet the criteria for exclusion from the site neutral payment rate) will continue to be paid based on the LTCH PPS standard Federal payment rate, and will include all of the existing payment adjustments under § 412.525(d), such as the adjustments for SSO cases under § 412.529. (For additional information on our payments for LTCH PPS standard Federal payment rate cases, we refer readers to section VII.B.4.c. of the preamble of this final rule.) Under some rare circumstances, an LTCH discharge can qualify as an SSO case (as defined in the regulations at § 412.529 in conjunction with § 412.503) and also as an HCO case, as discussed in the August 30, 2002 final rule (67 FR 56026). In this scenario, a patient
could be hospitalized for less than five-sixths of the geometric average length of stay for the specific MS-LTC-DRG, and yet incur extraordinarily high treatment costs. If the estimated costs exceeded the HCO threshold (that is, the SSO payment plus the fixed-loss amount), the discharge is eligible for payment as an HCO. Therefore, for an SSO case in FY 2016, the HCO payment will be 80 percent of the difference between the estimated cost of the case and the outlier threshold (the sum of the fixed-loss amount of $16,423 and the amount paid under the SSO policy as specified in § 412.529).

4. High-Cost Outlier Payments for Site Neutral Payment Rate Cases

Under the new dual rate LTCH PPS payment structure, the statute establishes two distinct payment rates for LTCH discharges beginning in FY 2016. Under this statutory change, as discussed in section VII.B. of the preamble of this final rule, we will pay for LTCH discharges that meet the criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) based on the LTCH PPS standard Federal payment rate. In addition, consistent with the statute, we are establishing that the site neutral payment rate is the lower of the IPPS comparable per diem amount as determined under § 412.529(d)(4), including any applicable outlier payments as specified in § 412.525(a); or 100 percent of the estimated cost of the case as determined under existing § 412.525(d)(2). Furthermore, we are establishing two separate HCO targets—one for LTCH PPS standard Federal payment rate cases and one for site neutral payment rate cases.

For site neutral payment rate cases, as we proposed, we are establishing that such cases will receive an additional HCO payment for costs that exceed the HCO threshold.
that is equal to 80 percent of the difference between the estimated cost of the case and the applicable HCO threshold. We are establishing that the applicable HCO threshold for site neutral payment rate cases is the sum of the site neutral payment rate for the case and the IPPS fixed-loss amount. As discussed in section II.A.4.g.(1) of this Addendum, we are establishing a fixed-loss amount of $22,544 under the IPPS for FY 2016.

Accordingly, under our finalized policies, for FY 2016 we will calculate HCO payments for site neutral payment rate cases with costs that exceed the HCO threshold amount, which is equal to 80 percent of the difference between the estimated cost of the case and the outlier threshold (the sum of site neutral payment rate payment and the fixed-loss amount for site neutral payment rate cases of $22,544). (We note that, as discussed in section VII.B.7.b. of the preamble of this final rule, in light of our HCO policies and in accordance with our implementation of the new dual rate LTCH PPS payment structure, any site neutral payment rate case that is paid 100 percent of the estimated cost of the case (because that amount is lower than the IPPS comparable per diem amount) will not be eligible to receive a HCO payment because, by definition, the estimated costs of such cases would never exceed the IPPS comparable per diem amount by any threshold.)

Furthermore, under our finalized policy, after consideration of public comments as discussed in section VII.B.7.b. of the preamble of this final rule, we are establishing that HCO payments for site neutral payment rate cases will be budget neutral, such that the site neutral payment rate HCO payments will not result in any change in estimated aggregate LTCH PPS payments. (For additional details on our HCO policy for site neutral payment rate cases, we refer readers to section VII.B.7.b. of the preamble of this
In order to achieve this, in the proposed rule (80 FR 24648 through 24649), under proposed new § 412.522(c)(2)(i), we proposed to apply a budget neutrality factor to the payments for all site neutral payment rate cases, which would be established on an estimated basis. In addition, in order to estimate the magnitude a budget neutrality adjustment for HCO payments for site neutral payment rate cases, we relied on the assumption by our actuaries that site neutral payment rate cases would have lengths of stay and costs comparable to IPPS cases assigned to the same MS-DRG. Because site neutral payment rate cases are expected to have lengths of stay and costs comparable to IPPS cases assigned to the same MS-DRG, we project that our policy to use the IPPS fixed-loss threshold for the site neutral payment rate cases will result in HCO payments for site neutral payment rate cases that are similar in proportion as is seen in IPPS cases assigned to the same MS-DRG; that is, 5.1 percent. Therefore, under new § 412.522(c)(2)(i), we proposed to adjust all payments for site neutral payment rate cases by a budget neutrality factor so that the estimated HCO payments payable for site neutral payment rate cases do not result in any increase in aggregate LTCH PPS payments. That is, for FY 2016 we proposed to apply a budget neutrality adjustment for estimated HCO payments for site neutral payment rate cases to both the site neutral payment rate and the LTCH PPS standard Federal payment rate portions of the FY 2016 transitional blended rate paid to site neutral payment rate cases. (We refer readers to section VII.B.7.b. of this preamble for our discussion of the public comments we received, our responses to those comments, and our finalized policy for a budget neutrality requirement for site neutral payment rate cases’ HCO payments.) Because the statutory LTCH PPS payment changes
required by section 1886(m)(6) of the Act (that is, the application of the site neutral payment rate) are effective for LTCH PPS discharges occurring in cost reporting periods beginning on or after October 1, 2015, in the proposed rule, our site neutral payment rate case HCO budget neutrality calculations also included a proposed approach to account for when LTCHs’ first cost reporting period begins on or after October 1, 2015.

Under our proposed approach (summarized above and described in more detail in section V.D.4. of the Addendum of the proposed rule (80 FR 24649)) and based on the site neutral payment rate LTCH cases in our database from the FY 2014 MedPAR files (that is, cases that would have met the new criteria had they been in effect at the time of the discharge), we estimated that site neutral payment rate HCO payments would be approximately 2.3 percent of total LTCH PPS payments for site neutral payment rate cases in FY 2016. Accordingly, we proposed to applying a budget neutrality factor of 0.976996 to all payments for site neutral payment rate cases in FY 2016 so that the estimated HCO payments payable to those cases would not result any increase in aggregate LTCH PPS payments.

Comment: Several commenters disagreed with our proposed approach of adjusting all payments for site neutral payment rate cases in FY 2016 (that is, both the site neutral payment rate and the LTCH PPS standard Federal payment rate portions of the transitional blended rate payment) by a budget neutrality factor for estimated HCO payments payable to site neutral payment rate cases. The reasons for the commenters’ opposition to this proposal include: the LTCH PPS standard Federal payment rate portion under transitional blended rate would be lower than the LTCH PPS standard
Federal payment rate used to pay cases that are excluded from the site neutral payment rate; and the comingling of site neutral payment rate and LTCH PPS standard Federal payment rate elements unnecessarily convolutes the proposed site neutral payment rate HCO calculations. Consequently, these commenters recommended that, if CMS finalizes its proposal to apply a budget neutrality factor to account for estimated site neutral payment case HCO payments, the site neutral payment rate and the LTCH PPS standard Federal payment rate portions of the transitional blended rate should be treated separately. That is, the budget neutrality adjustment for estimated HCO payments to site neutral payment rate cases should only be applied to the site neutral payment rate portion of the transitional blended rate payment (and not applied to the LTCH PPS standard Federal payment rate portion of the transitional blended rate payment).

Furthermore, some commenters stated that the description of the calculation of the estimated percentage of site neutral payment rate case HCO payments for FY 2016 was too brief, and requested that CMS provide additional details on the steps used to calculate the budget neutrality adjustment for estimated HCO payments to site neutral payment rate cases. In addition, commenters believed that our proposed calculation of our estimate in the proposed rule of HCO payments to site neutral payment rate cases includes a technical error. That is, the commenters stated that the calculation of the percentage of estimated site neutral payment rate case HCO payments for FY 2016 of 2.3 percent appears to be based on estimated HCO payments for site neutral payment rate cases before applying the transitional blended rate payment (rather than only 50 percent, consistent with the calculation of the transitional blended rate that is comprised of only
50 percent of the site neutral payment rate payment amount). Lastly, some commenters agreed with the proposed approach to account for when LTCHs’ first cost reporting period begins on or after October 1, 2015 in estimating site neutral payment rate payments in FY 2016.

**Response:** We agree that the approach recommended by commenters would lessen the complexity and increase the transparency of the calculation of the site neutral payment rate HCO payment budget neutrality adjustment. Such an approach simplifies the calculation because the adjustment to account for additional HCO payments to site neutral payment rate cases would only be applied to the portion of the blended rate payment that is based on the site neutral payment rate calculation under new § 412.522(c)(1). Therefore, after consideration of public comments we received, we are modifying our proposal by adopting the commenters’ recommended approach of applying the budget neutrality adjustment for estimated HCO payments for site neutral payment rate cases only to the site neutral payment rate portion of the transitional blended rate payment. As a result of this modification, we are making conforming changes to our proposed codification of this policy under new § 412.522(c)(2)(i) to specify that the site neutral payment rate HCO budget neutrality adjustment does not include the portion of the blended payment rate described in new § 412.522(c)(3)(ii).

This modification to our proposed approach for applying the budget neutrality adjustment to the site neutral payment rate portion of the transitional blended rate payment eliminates the need to perform any calculation of the site neutral payment rate cases HCO payment budget neutrality adjustment under our finalized policy. This is, as
discussed above and in greater detail in section VII.B.7.b. of the preamble of this final rule, because based on our actuarial assumptions we project that our finalized policy to use the IPPS fixed-loss threshold for the site neutral payment rate cases will result in HCO payments for those cases that are similar in proportion as is seen in IPPS cases assigned to the same MS-DRG; that is, 5.1 percent. In other words, we estimated that HCO payments for site neutral payment rate cases will be 5.1 percent of the site neutral payment rate payments. As noted above, payments to site neutral payment rate cases in FY 2016 will be paid under the blended transitional rate. As such, estimated HCO payments for site neutral payment rate cases in FY 2016 under our finalized policies are equal to 5.1 percent of the portion of the blended rate payment that is based on the estimated site neutral payment rate payment amount (and does not include the LTCH PPS standard Federal payment rate payment amount, as we proposed). Therefore, to ensure that estimated HCO payments payable to site neutral payment rate cases in FY 2016 do not result any increase in estimated aggregate FY 2016 LTCH PPS payments, it is necessary to reduce the site neutral payment rate portion of the blended rate payment by 5.1 percent to account for the estimated additional HCO payments payable to those cases in FY 2016. In order to achieve this, under § 412.522(c)(2)(i) for FY 2016, we are applying a budget neutrality factor of 0.949 (that is, the decimal equivalent of a 5.1 percent reduction, determined as 1.0 - 5.1/100 = 0.949). (We note, because this adjustment is intended to ensure that estimated HCO payments payable to site neutral payment rate cases are budget neutral (that is, do not result in any increase in aggregate LTCH PPS payments), the magnitude of the reduction is larger than it would be under
our proposed approach as the adjustment is now only being applied to half of the transitional blended rate payment (rather than the whole transitional blended rate payment as it was under our proposal).

Upon review of our calculation in the proposed rule of the estimated percentage of site neutral payment rate case HCO payments for FY 2016, we determined that our calculation of the proposed budget neutrality adjustment for estimated HCO payments for site neutral payment rate cases inadvertently contained the technical error pointed out by the commenters. We appreciate the commenters bringing that inadvertent error to our attention, and we have included the necessary correction in the calculation of our estimate of HCO payments for site neutral payment rate cases, which we discuss in the regulatory impact analyses presented in section I.J. of Appendix A of this final rule. (We note, as explained above, the modification to the proposed approach for applying the budget neutrality adjustment for estimated HCO payments for site neutral payment rate cases that we are adopting in this final rule eliminates the need for calculation of the budget neutrality adjustment under our finalized policy.)

We appreciate the commenters’ support of our proposed approach to account for the fact that LTCHs whose cost reporting periods begin on or after October 1, 2015, will receive the LTCH PPS standard Federal payment rates for all of their LTCH PPS cases, including their cases that would be site neutral payment rate cases, until the start of their next cost reporting period when estimating site neutral payment rate payments in FY 2016. Because we are adopting a different, more direct approach in this final rule (as discussed above), in the applying the budget neutrality requirement for estimated HCO
payments payable to site neutral payment rate cases in for FY 2016, it is no longer necessary to account for when LTCHs’ first cost reporting period begins on or after October 1, 2015 (as we did to calculate the budget neutrality adjustment under our proposed approach). We note, however, for purposes of the impact analyses presented in section I.J. of Appendix A of this final rule, to estimate site neutral payment rate payments for FY 2016, it is still necessary to account for when LTCHs’ first cost reporting period begins on or after October 1, 2015. Accordingly, in this final rule, when estimating total LTCH PPS site neutral payment rate payments in Federal FY 2016, as we proposed, we are applying an adjustment to account for the varying effective dates of the new dual rate LTCH PPS payment structure. We describe our application of this approach for purposes of the impact analyses presented in this final rule in section I.J. of Appendix A of this final rule. (For a description of our proposed approach to account for the statutory rolling effective date of the revisions to the LTCH PPS, we refer readers to section V.D.4. of the Addendum of the proposed rule (80 FR 24649).)

In summary, after consideration of public comments we received, for the reasons discussed above, we are modifying our proposed application of the site neutral payment rate HCO payment budget neutrality adjustment. In this final rule, we are adopting an approach under which the budget neutrality adjustment for estimated HCO payments to site neutral payment rate cases will be applied to the site neutral payment rate portion of the transitional blended rate payment in FY 2016 (and will not applied to the LTCH PPS standard Federal payment rate portion of the transitional blended rate payment).

Accordingly, to ensure that estimated HCO payments payable to site neutral payment rate
cases in FY 2016 do not result any increase in estimated aggregate FY 2016 LTCH PPS payments, we are reducing the site neutral payment rate portion of the blended rate payment in FY 2016 by 5.1 percent. In order to achieve this, we are applying a budget neutrality factor of 0.949 to the site neutral payment rate portion of the blended rate payment in FY 2016, in accordance with new § 412.522(c)(2)(i).

E. Update to the IPPS Comparable/Equivalent Amounts to Reflect the Statutory Changes to the IPPS DSH Payment Adjustment Methodology

In the FY 2014 IPPS/LTCH PPS final rule, we established a policy for reflecting the changes to the Medicare IPPS DSH payment adjustment methodology provided for by section 3133 of the Affordable Care Act in the calculation of the “IPPS comparable amount” under the SSO policy at § 412.529 and the “IPPS equivalent amount” under the 25-percent threshold payment adjustment policy at § 412.534 and § 412.536. Historically, the determination of both the “IPPS comparable amount” and the “IPPS equivalent amount” includes an amount for inpatient operating costs “for the costs of serving a disproportionate share of low-income patients.” Under the statutory changes to the Medicare DSH payment adjustment methodology that began in FY 2014, in general, eligible IPPS hospitals receive an empirically justified Medicare DSH payment equal to 25 percent of the amount they otherwise would have received under the statutory formula for Medicare DSH payments prior to the amendments made by the Affordable Care Act. The remaining amount, equal to an estimate of 75 percent of the amount that otherwise would have been paid as Medicare DSH payments, reduced to reflect changes in the percentage of individuals under the age of 65 who are uninsured, is made available to
make additional payments to each hospital that qualifies for Medicare DSH payments and that has uncompensated care. The additional uncompensated care payments are based on the hospital’s amount of uncompensated care for a given time period relative to the total amount of uncompensated care for that same time period reported by all IPPS hospitals that receive Medicare DSH payments.

To reflect the statutory changes to the Medicare DSH payment adjustment methodology in the calculation of the “IPPS comparable amount” and the “IPPS equivalent amount” under the LTCH PPS, we stated that we will include a reduced Medicare DSH payment amount that reflects the projected percentage of the payment amount calculated based on the statutory Medicare DSH payment formula prior to the amendments made by the Affordable Care Act that will be paid to eligible IPPS hospitals as empirically justified Medicare DSH payments and uncompensated care payments in that year (that is, a percentage of the operating DSH payment amount that has historically been reflected in the LTCH PPS payments that is based on IPPS rates). We also stated that the projected percentage will be updated annually, consistent with the annual determination of the amount of uncompensated care payments that will be made to eligible IPPS hospitals. As explained in the FY 2014 IPPS/LTCH PPS final rule (79 FR 50766 through 50767), we believe that this approach results in appropriate payments under the LTCH PPS and is consistent with our intention that the “IPPS comparable amount” and the “IPPS equivalent amount” under the LTCH PPS closely resemble what an IPPS payment would have been for the same episode of care, while
recognizing that some features of the IPPS cannot be translated directly into the LTCH PPS.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50400 through 50401), we discussed that, for FY 2015, based on the latest data available at that time, we projected that the reduction in the amount of Medicare DSH payments pursuant to section 1886(r)(1) of the Act, along with the proposed payments for uncompensated care under section 1886(r)(2) of the Act, would result in overall Medicare DSH payments equaling 85.26 percent of the amount of Medicare DSH payments that would otherwise have been made in the absence of amendments made by the Affordable Care Act. Therefore, the calculation of the “IPPS comparable amount” under § 412.529 and the “IPPS equivalent amount” under § 412.534 and § 412.536 for FY 2015 includes an applicable operating Medicare DSH payment amount that would be equal to 85.26 percent of the operating Medicare DSH payment amount based on the statutory Medicare DSH payment formula prior to the amendments made by the Affordable Care Act.

For FY 2016, as discussed in greater detail in section IV.D.3.d.(2) of the preamble of this final rule, based on the most recent data available, our estimate of 75 percent of the amount that would otherwise have been paid as Medicare DSH payments (under the methodology outlined in section 1886(r)(2) of the Act) is adjusted to 63.69 percent of that amount to reflect the change in the percentage of individuals who are uninsured. The resulting amount is then used to determine the amount of uncompensated care payments that will be made to eligible IPPS hospitals in FY 2016. In other words, Medicare DSH payments prior to the amendments made by the Affordable Care Act will be adjusted to
47.77 percent (the product of 75 percent and 63.69 percent) and the resulting amount will be used to calculate the uncompensated care payments to eligible hospitals. As a result, for FY 2016, we project that the reduction in the amount of Medicare DSH payments pursuant to section 1886(r)(1) of the Act, along with the payments for uncompensated care under section 1886(r)(2) of the Act, will result in overall Medicare DSH payments of 72.77 percent of the amount of Medicare DSH payments that would otherwise have been made in the absence of amendments made by the Affordable Care Act (that is, 25 percent + 47.77 percent = 72.77 percent).

As we proposed and consistent with our historical practice of using the most recent data available, in this final rule, for FY 2016, we are establishing that the calculation of the “IPPS comparable amount” under § 412.529 and the “IPPS equivalent amount” under § 412.534 and § 412.536 will include an applicable operating Medicare DSH payment amount that is equal to 72.77 percent of the operating Medicare DSH payment amount that would have been paid based on the statutory Medicare DSH payment formula but for the amendments made by the Affordable Care Act.

F. Computing the Adjusted LTCH PPS Federal Prospective Payments for FY 2016

Section 412.525 sets forth the adjustments to the LTCH PPS standard Federal payment rate. Under the new dual rate LTCH PPS payment structure that begins in FY 2016, only LTCH PPS cases that meet the statutory criteria to be excluded from the site neutral payment rate will be paid based on the LTCH PPS standard Federal payment rate (as discussed in section VII.B. of the preamble of this final rule). Under § 412.525(c), the LTCH PPS standard Federal payment rate is adjusted to account for
differences in area wages by multiplying the labor-related share of the LTCH PPS standard Federal payment for a case by the applicable LTCH PPS wage index (FY 2016 values are shown in Tables 12A through 12B listed in section VI. of the Addendum of this final rule and are available via the Internet). The LTCH PPS standard Federal payment is also adjusted to account for the higher costs of LTCHs located in Alaska and Hawaii by the applicable COLA factors (the FY 2016 factors are shown in the chart in section V.D. of this Addendum) in accordance with § 412.525(b). In this final rule, we are establishing an LTCH PPS standard Federal payment rate for FY 2016 of $41,762.85, as discussed in section V.A.2. of the Addendum to this final rule. We illustrate the methodology to adjust the LTCH PPS standard Federal payment rate for FY 2016 in the following example:

Example:

During FY 2016, a Medicare discharge that meets the criteria to be excluded from the site neutral payment rate, that is an LTCH PPS standard Federal payment rate case, is from an LTCH that is located in Chicago, Illinois (CBSA 16974). The FY 2016 LTCH PPS wage index value for CBSA 16974 is 1.0401 (obtained from Table 12A listed in section VI. of the Addendum of this final rule and available via the Internet on the CMS Web site). The Medicare patient case is classified into MS-LTC-DRG 189 (Pulmonary Edema & Respiratory Failure), which has a relative weight for FY 2016 of 0.91548 (obtained from Table 11 listed in section VI. of the Addendum of this final rule and available via the Internet on the CMS Web site). The LTCH submitted quality reporting data for FY 2016 in accordance with the LTCHQRP under section 1886(m)(5) of the Act.
To calculate the LTCH’s total adjusted Federal prospective payment for this Medicare patient case in FY 2016, we computed the wage-adjusted Federal prospective payment amount by multiplying the unadjusted FY 2016 LTCH PPS standard Federal payment rate ($41,762.85) by the labor-related share (62.0 percent) and the wage index value (1.0401). This wage-adjusted amount was then added to the nonlabor-related portion of the unadjusted LTCH PPS standard Federal payment rate (38.0 percent; adjusted for cost of living, if applicable) to determine the adjusted LTCH PPS standard Federal payment rate, which was then multiplied by the MS-LTC-DRG relative weight (0.9148) to calculate the total adjusted LTCH PPS standard Federal prospective payment for FY 2016 ($39,154.50). The table below illustrates the components of the calculations in this example.

<table>
<thead>
<tr>
<th>LTCH PPS Standard Federal Prospective Payment Rate</th>
<th>$ 41,762.85</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor-Related Share</td>
<td>x 0.620</td>
</tr>
<tr>
<td>Labor-Related Portion of the LTCH PPS Standard Federal Payment Rate</td>
<td>= $ 25,892.97</td>
</tr>
<tr>
<td>Wage Index (CBSA 16974)</td>
<td>x 1.0401</td>
</tr>
<tr>
<td>Wage-Adjusted Labor Share of LTCH PPS Standard Federal Payment Rate</td>
<td>= $ 26,931.28</td>
</tr>
<tr>
<td>Nonlabor-Related Portion of the LTCH PPS Standard Federal Payment Rate ($41,762.85x 0.380)</td>
<td>+ $ 15,869.88</td>
</tr>
<tr>
<td>Adjusted LTCH PPS Standard Federal Payment Amount</td>
<td>= $ 42,801.16</td>
</tr>
<tr>
<td>MS-LTC-DRG 189 Relative Weight</td>
<td>x 0.9148</td>
</tr>
<tr>
<td>Total Adjusted LTCH PPS Standard Federal Prospective Payment</td>
<td>= $ 39,154.50</td>
</tr>
</tbody>
</table>
VI. Tables Referenced in this Final Rule and Available Only through the Internet on the CMS Web Site

This section lists the tables referred to throughout the preamble of this final rule and in this Addendum. In the past, a majority of these tables were published in the Federal Register as part of the annual proposed and final rules. However, similar to FYs 2012 through 2015, for the FY 2016 rulemaking cycle, the IPPS and LTCH tables will not be published in the Federal Register in the annual IPPS/LTCH PPS proposed and final rules and will be available only through the Internet. Specifically, all IPPS tables listed below, with the exception of IPPS Tables 1A, 1B, 1C, and 1D, and LTCH PPS Table 1E will be available only through the Internet. IPPS Tables 1A, 1B, 1C, and 1D, and LTCH PPS Table 1E are displayed at the end of this section and will continue to be published in the Federal Register as part of the annual proposed and final rules.

As discussed in section III.I. of the preamble to this final rule, we proposed to streamline and consolidate the wage index tables for FY 2016 and subsequent fiscal years. In previous fiscal years, the wage index tables have consisted of the following 12 tables: Table 2 (acute care hospitals’ case-mix indexes; hospital wage indexes; hospital average hourly wages, and 3-year average of hospital average hourly wages); Table 3A (relevant fiscal year and 3-year average hourly wage for acute care hospitals in urban areas by CBSA); Table 3B (relevant fiscal year and 3-year average hourly wage for acute care hospitals in rural areas by CBSA); Table 4A (wage index and capital geographic adjustment factor (GAF) for acute care hospitals in urban areas by CBSA and by State); Table 4B (wage index and capital GAF for acute care hospitals in rural areas by CBSA...
and by State); Table 4C (wage index and capital GAF for acute care hospitals that are reclassified by CBSA and by State); Table 4D (States designated as frontier, with acute care hospitals receiving at a minimum the frontier State floor wage index; urban areas with acute care hospitals receiving the statewide rural floor or imputed rural floor wage index); Table 4E (urban CBSAs and constituent counties for acute care hospitals); Table 4F (Puerto Rico wage index and capital GAF for acute care hospitals by CBSA); Table 4J (out-migration adjustment for acute care hospitals); Table 9A (hospital reclassifications and redesignations); and Table 9C (hospitals redesignated as rural under section 1886(d)(8)(e) of the Act). With the exception of Table 4E, we proposed to consolidate the information from the 11 other tables listed above into 2 new tables. The wage index tables provided in previous fiscal years either display information by CMS Certification Number (CCN) or by CBSA number. The new Table 2 contains information by CCN and information from the following tables that have been provided in previous fiscal years: Tables 2, 4J, 9A, and 9C. The new Table 3 contains information by CBSA and information from the following tables that have been provided in previous fiscal years: Tables 3A, 3B, 4A, 4B, 4C, 4D, and 4F. We believe these two new tables will be easier for the public to navigate and find all the relevant data and information from the tables provided in previous fiscal years. Finally, in previous fiscal years, Table 4E provided a list of urban CBSAs and constituent counties. Because of formatting technicalities, we found it difficult to consolidate the information from Table 4E into the two new tables. Therefore, we proposed to provide the data previously published as Table 4E for each
annual proposed and final rule as one of our data files on our Web page (the same Web page where the county to CBSA crosswalk is posted).

We did not receive any public comments on our proposals for the tables. Therefore, we are finalizing our proposals to streamline and consolidate the wage index tables for FY 2016 and subsequent fiscal years by consolidating the information from the 11 tables listed above (excluding Table 4E) into 2 new tables. The new Table 2 contains information by CCN and information from the following tables that have been provided in previous fiscal years: Tables 2, 4J, 9A, and 9C. The new Table 3 contains information by CBSA and information from the following tables that have been provided in previous fiscal years: Tables 3A, 3B, 4A, 4B, 4C, 4D, and 4F. We are providing the data previously published as Table 4E for each annual proposed and final rule as one of our data files on the CMS Web page.

As discussed in sections II.G.3.e., II.G.10.a., II.G.11., and II.G.13. of the preamble of this final rule, we developed the following ICD-10-CM and ICD-10-PCS code tables for FY 2016: Table 6B--New Procedure Codes; Table 6I--Complete MCC List; Table 6J--Complete CC List; Table 6K--Complete List of CC Exclusions; Table 6L--Principal Diagnosis Is Its Own MCC List; Table 6M--Principal Diagnosis Is Its Own CC List; Table 6M.1--Additions to the Principal Diagnosis Is Its Own CC List; and Table 6P--ICD-10-PCS Code Translations for MS-DRG Changes. Table 6P contains multiple tables 6P.1a through 6P.2a that list the ICD-10-PCS code translations relating to specific MS-DRG changes. In addition, under the HAC Reduction Program established by section 3008 of the Affordable Care Act, a hospital’s total payment may be reduced by
1 percent if it is in the lowest HAC performance quartile. However, as discussed in section IV.G. of the preamble of this final rule, we are not providing the hospital-level data as a table associated with this final rule. The hospital-level data for the FY 2016 HAC Reduction Program will be made publicly available once it has undergone the review and corrections process.

Finally, a hospital’s Factor 3 is the proportion of the uncompensated care amount that a DSH eligible hospital will receive under section 3133 of the Affordable Care Act. Factor 3 is the hospital’s estimated number of Medicaid days and Medicare SSI days relative to the estimate of all DSH hospitals’ Medicaid days and Medicare SSI days. Table 18 associated with this final rule contains the FY 2016 Medicare DSH uncompensated care payment Factor 3 for all hospitals and identifies whether or not a hospital is projected to receive DSH and, therefore, eligible to receive the additional payment for uncompensated care for FY 2016.

Readers who experience any problems accessing any of the tables that are posted on the CMS Web sites identified below should contact Michael Treitel at (410) 786-4552.

The following IPPS tables for this FY 2016 final rule are available only through the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Click on the link on the left side of the screen titled, “FY 2016 IPPS Final Rule Home Page” or “Acute Inpatient--Files for Download”.

Table 2.--Case-Mix Index and Wage Index Table by CCN--FY 2016

Table 3.--Wage Index Table by CBSA--FY 2016
Table 5.—List of Medicare Severity Diagnosis-Related Groups (MS-DRGs), Relative Weighting Factors, and Geometric and Arithmetic Mean Length of Stay—FY 2016.

Table 6B.—New Procedure Codes—FY 2016

Table 6L.—Complete Major CC List—FY 2016

Table 6J.—Complete CC List—FY 2016

Table 6K.—Complete List of CC Exclusions—FY 2016

Table 6L.—Principal Diagnosis Is Its Own MCC List—FY 2016

Table 6M.—Principal Diagnosis Is Its Own CC List—FY 2016

Table 6M.1.—Additions to the Principal Diagnosis Is Its Own CC List—FY 2016

Table 6P.—ICD-10-PCS Code Translations for MS-DRG Changes—FY 2016

Table 7A.—Medicare Prospective Payment System Selected Percentile Lengths of Stay: FY 2014 MedPAR Update—March 2015 GROUPER V32.0 MS-DRGs

Table 7B.—Medicare Prospective Payment System Selected Percentile Lengths of Stay: FY 2014 MedPAR Update—March 2015 GROUPER V33.0 MS-DRGs

Table 8A.—FY 2016 Statewide Average Operating Cost-to-Charge Ratios (CCRs) for Acute Care Hospitals (Urban and Rural)

Table 8B.—FY 2016 Statewide Average Capital Cost-to-Charge Ratios (CCRs) for Acute Care Hospitals

Table 10.—New Technology Add-On Payment Thresholds for Applications for FY 2017
Table 14.—List of Hospitals with Fewer Than 1,600 Medicare Discharges Based on the March 2015 Update of the FY 2014 MedPAR File and Potentially Eligible Hospitals for the FY 2016 Low-Volume Hospital Payment Adjustment (Eligibility for the low-volume hospital payment adjustment is also dependent upon meeting the mileage criteria specified at 42 CFR 412.101(b)(2)(ii))

Table 15.—FY 2016 Readmissions Adjustment Factors

Table 16A.—Updated Proxy Hospital Value-Based Purchasing (VBP) Program Adjustment Factors for FY 2016

Table 18.—FY 2016 Medicare DSH Uncompensated Care Payment Factor 3

The following LTCH PPS tables for this FY 2016 final rule are available only through the Internet on the CMS Web site at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/LongTermCareHospitalPPS/index.html under the list item for Regulation Number CMS-1632-F:

Table 8C.—FY 2016 Statewide Average Total Cost-to-Charge Ratios (CCRs) for LTCHs (Urban and Rural)

Table 11.—MS-LTC-DRGs, Relative Weights, Geometric Average Length of Stay, Short-Stay Outlier (SSO) Threshold, and “IPPS Comparable Threshold” for LTCH PPS Discharges Occurring from October 1, 2015 through September 30, 2016

Table 12A.—LTCH PPS Wage Index for Urban Areas for Discharges Occurring from October 1, 2015 through September 30, 2016

Table 12B.—LTCH PPS Wage Index for Rural Areas for Discharges Occurring from October 1, 2015 through September 30, 2016
Table 13A.—Composition of Low-Volume Quintiles for MS-LTC-DRGs—

FY 2016

Table 13B.—No-Volume MS-LTC-DRG Crosswalk for FY 2016

**TABLE 1A.—NATIONAL ADJUSTED OPERATING STANDARDIZED AMOUNTS, LABOR/NONLABOR (69.6 PERCENT LABOR SHARE/30.4 PERCENT NONLABOR SHARE IF WAGE INDEX IS GREATER THAN 1)—FY 2016**

<table>
<thead>
<tr>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User (Update = 1.7 Percent)</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User (Update = 1.1 Percent)</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User (Update = 0.5 Percent)</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User (Update = -0.1 Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor</td>
<td>Nonlabor</td>
<td>Labor</td>
<td>Nonlabor</td>
</tr>
<tr>
<td>$3,804.40</td>
<td>$1,466.69</td>
<td>$3,781.96</td>
<td>$1,651.89</td>
</tr>
</tbody>
</table>

**TABLE 1B.—NATIONAL ADJUSTED OPERATING STANDARDIZED AMOUNTS, LABOR/NONLABOR (62 PERCENT LABOR SHARE/38 PERCENT NONLABOR SHARE IF WAGE INDEX IS LESS THAN OR EQUAL TO 1)—FY 2016**

<table>
<thead>
<tr>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User (Update = 1.7 Percent)</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User (Update = 1.1 Percent)</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User (Update = 0.5 Percent)</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User (Update = -0.1 Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor</td>
<td>Nonlabor</td>
<td>Labor</td>
<td>Nonlabor</td>
</tr>
<tr>
<td>$3,388.98</td>
<td>$2,077.11</td>
<td>$3,368.99</td>
<td>$2,064.86</td>
</tr>
</tbody>
</table>
### TABLE 1C.—ADJUSTED OPERATING STANDARDIZED AMOUNTS FOR PUERTO RICO, LABOR/NONLABOR (NATIONAL: 62 PERCENT LABOR SHARE/38 PERCENT NONLABOR SHARE BECAUSE WAGE INDEX IS LESS THAN OR EQUAL TO 1; PUERTO RICO: 63.2 PERCENT LABOR SHARE/36.8 PERCENT NONLABOR SHARE IF WAGE INDEX IS GREATER THAN 1 OR 62 PERCENT LABOR SHARE/38 PERCENT NONLABOR SHARE IF WAGE INDEX IS LESS THAN OR EQUAL TO 1—FY 2016

<table>
<thead>
<tr>
<th>Standardized Amount</th>
<th>Rates if Wage Index is Greater Than 1</th>
<th>Rates if Wage Index is Less Than or Equal to 1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Labor</td>
<td>Nonlabor</td>
</tr>
<tr>
<td>National</td>
<td>Not Applicable</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>$1,648.66</td>
<td>$959.98</td>
</tr>
</tbody>
</table>

1 For FY 2016, there are no CBSAs in Puerto Rico with a national wage index greater than 1.

### TABLE 1D.—CAPITAL STANDARD FEDERAL PAYMENT RATES—FY 2016

<table>
<thead>
<tr>
<th></th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>$438.65</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>$212.56</td>
</tr>
</tbody>
</table>

### TABLE 1E.—LTCH PPS STANDARD FEDERAL RATE—FY 2016

<table>
<thead>
<tr>
<th>Standard Federal Rate</th>
<th>Full Update (1.7 Percent)</th>
<th>Reduced Update* (-0.3 Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$41,762.85</td>
<td>$40,941.55</td>
</tr>
</tbody>
</table>

* For LTCHs that fail to submit quality reporting data for FY 2016 in accordance with the LTCH Quality Reporting Program (LTCH QRP), the annual update is reduced by 2.0 percentage points as required by section 1886(m)(5) of the Act.
Appendix A: Economic Analyses

I. Regulatory Impact Analysis

A. Introduction

We have examined the impacts of this final rule as required by Executive Order 12866 on Regulatory Planning and Review (September 30, 1993), Executive Order 13563 on Improving Regulation and Regulatory Review (February 2, 2011), the Regulatory Flexibility Act (RFA) (September 19, 1980, Pub. L. 96-354), section 1102(b) of the Social Security Act, section 202 of the Unfunded Mandates Reform Act of 1995 (March 22, 1995, Pub. L. 104-4), Executive Order 13132 on Federalism (August 4, 1999), and the Congressional Review Act (5 U.S.C. 804(2)).

Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). Executive Order 13563 emphasizes the importance of quantifying both costs and benefits, of reducing costs, of harmonizing rules, and of promoting flexibility. A regulatory impact analysis (RIA) must be prepared for major rules with economically significant effects ($100 million or more in any 1 year).

We have determined that this final rule is a major rule as defined in 5 U.S.C. 804(2). We estimate that the final changes for FY 2016 acute care hospital operating and capital payments will redistribute amounts in excess of $100 million to acute care hospitals. The applicable percentage increase to the IPPS rates required by the
statute, in conjunction with other payment changes in this final rule, will result in an estimated $378 million increase in FY 2016 operating payments (or 0.4 percent change) and an estimated $187 million increase in FY 2016 capital payments (or 2.3 percent change). These changes are relative to payments made in FY 2015. The impact analysis of the capital payments can be found in section I.I. of this Appendix. In addition, as described in section I.J. of this Appendix, LTCHs are expected to experience a decrease in payments by $250 million in FY 2016 relative to FY 2015.

Our operating impact estimate includes the -0.8 percent documentation and coding adjustment applied to the IPPS standardized amount, which represents part of the recoupment required under section 631 of the ATRA. In addition, our operating payment impact estimate includes the 1.7 percent hospital update to the standardized amount (which includes the estimated 2.4 percent market basket update less 0.5 percentage point for the multifactor productivity adjustment and less 0.2 percentage point required under the Affordable Care Act). The estimates of IPPS operating payments to acute care hospitals do not reflect any changes in hospital admissions or real case-mix intensity, which will also affect overall payment changes.

The analysis in this Appendix, in conjunction with the remainder of this document, demonstrates that this final rule is consistent with the regulatory philosophy and principles identified in Executive Orders 12866 and 13563, the RFA, and section 1102(b) of the Act. This final rule will affect payments to a substantial number of small rural hospitals, as well as other classes of hospitals, and the effects on some hospitals
may be significant. Finally, in accordance with the provisions of Executive Order 12866, the Executive Office of Management and Budget has reviewed this final rule.

B. Statement of Need

This final rule is necessary in order to make payment and policy changes under the Medicare IPPS for Medicare acute care hospital inpatient services for operating and capital-related costs as well as for certain hospitals and hospital units excluded from the IPPS. This final rule also is necessary to make payment and policy changes for Medicare hospitals under the LTCH PPS payment system.

C. Objectives of the IPPS

The primary objective of the IPPS is to create incentives for hospitals to operate efficiently and minimize unnecessary costs while at the same time ensuring that payments are sufficient to adequately compensate hospitals for their legitimate costs in delivering necessary care to Medicare beneficiaries. In addition, we share national goals of preserving the Medicare Hospital Insurance Trust Fund.

We believe that the changes in this final rule will further each of these goals while maintaining the financial viability of the hospital industry and ensuring access to high quality health care for Medicare beneficiaries. We expect that these changes will ensure that the outcomes of the prospective payment systems are reasonable and equitable while avoiding or minimizing unintended adverse consequences.

D. Limitations of Our Analysis

The following quantitative analysis presents the projected effects of our policy changes, as well as statutory changes effective for FY 2016, on various hospital groups.
We estimate the effects of individual proposed policy changes by estimating payments per case while holding all other payment policies constant. We use the best data available, but, generally, we do not attempt to make adjustments for future changes in such variables as admissions, lengths of stay, or case-mix.

E. Hospitals Included in and Excluded from the IPPS

The prospective payment systems for hospital inpatient operating and capital-related costs of acute care hospitals encompass most general short-term, acute care hospitals that participate in the Medicare program. There were 32 Indian Health Service hospitals in our database, which we excluded from the analysis due to the special characteristics of the prospective payment methodology for these hospitals. Among other short-term, acute care hospitals, hospitals in Maryland are paid in accordance with the Maryland All-Payer Model, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, 5 short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa) receive payment for inpatient hospital services they furnish on the basis of reasonable costs, subject to a rate-of-increase ceiling.

As of July 2015, there were 3,369 IPPS acute care hospitals included in our analysis. This represents approximately 56 percent of all Medicare-participating hospitals. The majority of this impact analysis focuses on this set of hospitals. There also are approximately 1,334 CAHs. These small, limited service hospitals are paid on the basis of reasonable costs rather than under the IPPS. IPPS-excluded hospitals and units, which are paid under separate payment systems, include IPFs, IRFs, LTCHs,
RNHCIs, children's hospitals, 11 cancer hospitals, and 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa. Changes in the prospective payment systems for IPFs and IRFs are made through separate rulemaking. Payment impacts for these IPPS-excluded hospitals and units are not included in this final rule. The impact of the update and policy changes to the LTCH PPS for FY 2016 is discussed in section I.J. of this Appendix.

F. Effects on Hospitals and Hospital Units Excluded From the IPPS

As of July 2015, there were 98 children's hospitals, 11 cancer hospitals, 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands and American Samoa, and 18 RNHCIs being paid on a reasonable cost basis subject to the rate-of-increase ceiling under § 413.40. (In accordance with § 403.752(a) of the regulation, RNHCIs are paid under § 413.40.) Among the remaining providers, 251 rehabilitation hospitals and 884 rehabilitation units, and approximately 429 LTCHs, are paid the Federal prospective per discharge rate under the IRF PPS and the LTCH PPS, respectively, and 495 psychiatric hospitals and 1,122 psychiatric units are paid the Federal per diem amount under the IPF PPS. As stated above, IRFs and IPFs are not affected by the rate updates discussed in this rule. The impacts of the changes on LTCHs are discussed in section I.J. of this Appendix.

For children’s hospitals, the 11 cancer hospitals, the 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, and RNHCIs, the update of the rate-of-increase limit (or target amount) is the estimated FY 2016 percentage increase in the IPPS operating market basket,
consistent with section 1886(b)(3)(B)(ii) of the Act, and §§ 403.752(a) and 413.40 of the regulations. As discussed in section IV. of the preamble of the FY 2014 IPPS/LTCH PPS final rule, we rebased the IPPS operating market basket to a FY 2010 base year.

Therefore, we are using the percentage increase in the FY 2010-based IPPS operating market basket to update the target amounts for FY 2016 and subsequent fiscal years for children’s hospitals, the 11 cancer hospitals, the 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, and RNCHIs that are paid based on reasonable costs subject to the rate-of-increase limits.

Consistent with current law, based on IHS Global Insight, Inc.’s second quarter 2015 forecast of the FY 2010-based market basket increase, we are estimating that the FY 2016 update based on the IPPS operating market basket is 2.4 percent (that is, the current estimate of the market basket rate-of-increase). However, the Affordable Care Act requires an adjustment for multifactor productivity (currently estimated to be 0.5 percentage point for FY 2016) and a 0.2 percentage point reduction to the market basket update resulting in a 1.7 percent applicable percentage increase for IPPS hospitals that submit quality data and are meaningful EHR users, as discussed in section IV.A. of the preamble of this final rule. Children’s hospitals, the 11 cancer hospitals, the 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, and RNCHIs that continue to be paid based on reasonable costs subject to rate-of-increase limits under § 413.40 of the regulations are not subject to the reductions in the applicable percentage increase required under the Affordable Care Act. Therefore, for those hospitals paid under § 413.40 of the regulations, the update is the...
percentage increase in the FY 2016 IPPS operating market basket, estimated at 2.4 percent, without the reductions described above under the Affordable Care Act.

The impact of the update in the rate-of-increase limit on those excluded hospitals depends on the cumulative cost increases experienced by each excluded hospital since its applicable base period. For excluded hospitals that have maintained their cost increases at a level below the rate-of-increase limits since their base period, the major effect is on the level of incentive payments these excluded hospitals receive. Conversely, for excluded hospitals with cost increases above the cumulative update in their rate-of-increase limits, the major effect is the amount of excess costs that will not be paid.

We note that, under § 413.40(d)(3), an excluded hospital that continues to be paid under the TEFRA system and whose costs exceed 110 percent of its rate-of-increase limit receives its rate-of-increase limit plus the lesser of: (1) 50 percent of its reasonable costs in excess of 110 percent of the limit, or (2) 10 percent of its limit. In addition, under the various provisions set forth in § 413.40, hospitals can obtain payment adjustments for justifiable increases in operating costs that exceed the limit.

G. Quantitative Effects of the Policy Changes under the IPPS for Operating Costs

1. Basis and Methodology of Estimates

In this final rule, we are announcing final policy changes and final payment rate updates for the IPPS for FY 2016 for operating costs of acute care hospitals. The FY 2016 updates to the capital payments to acute care hospitals are discussed in section I.I. of this Appendix.
Based on the overall percentage change in payments per case estimated using our payment simulation model, we estimate that total FY 2016 operating payments will increase by 0.4 percent compared to FY 2015. In addition to the applicable percentage increase, this amount reflects the FY 2016 recoupment adjustment for documentation and coding described in section II.D. of the preamble of this final rule of -0.8 percent to the IPPS national standardized amounts. The impacts do not reflect changes in the number of hospital admissions or real case-mix intensity, which will also affect overall payment changes.

We have prepared separate impact analyses of the changes to each system. This section deals with the changes to the operating inpatient prospective payment system for acute care hospitals. Our payment simulation model relies on the most recent available data to enable us to estimate the impacts on payments per case of certain changes in this final rule. However, there are other changes for which we do not have data available that will allow us to estimate the payment impacts using this model. For those changes, we have attempted to predict the payment impacts based upon our experience and other more limited data.

The data used in developing the quantitative analyses of changes in payments per case presented below are taken from the FY 2014 MedPAR file and the most current Provider-Specific File (PSF) that is used for payment purposes. Although the analyses of the changes to the operating PPS do not incorporate cost data, data from the most recently available hospital cost reports were used to categorize hospitals. Our analysis has several qualifications. First, in this analysis, we do not make adjustments for future changes in
such variables as admissions, lengths of stay, or underlying growth in real case-mix. Second, due to the interdependent nature of the IPPS payment components, it is very difficult to precisely quantify the impact associated with each change. Third, we use various data sources to categorize hospitals in the tables. In some cases, particularly the number of beds, there is a fair degree of variation in the data from the different sources. We have attempted to construct these variables with the best available source overall. However, for individual hospitals, some miscategorizations are possible.

Using cases from the FY 2014 MedPAR file, we simulated payments under the operating IPPS given various combinations of payment parameters. As described above, Indian Health Service hospitals and hospitals in Maryland were excluded from the simulations. The impact of payments under the capital IPPS, or the impact of payments for costs other than inpatient operating costs, are not analyzed in this section. Estimated payment impacts of the capital IPPS for FY 2016 are discussed in section I.I. of this Appendix.

We discuss the following changes below:

- The effects of the application of the documentation and coding adjustment and the applicable percentage increase (including the market basket update, the multifactor productivity adjustment, and the applicable percentage reduction in accordance with the Affordable Care Act) to the standardized amount and hospital-specific rates.

- The effects of the changes to the relative weights and MS-DRG GROUPER.
- The effects of the changes in hospitals’ wage index values reflecting updated wage data from hospitals’ cost reporting periods beginning during FY 2012, compared to the FY 2011 wage data, to calculate the FY 2016 wage index.

- The combined effects of the recalibration of the MS-DRG relative weights as required by section 1886(d)(4)(C) of the Act and the wage index (including the updated wage data and the continued implementation of the new OMB labor market area delineations), including the wage and recalibration budget neutrality factors.

- The effects of the geographic reclassifications by the MGCRB (as of publication of this final rule) that will be effective for FY 2016.

- The effects of the rural floor and imputed floor with the application of the national budget neutrality factor to the wage index.

- The effects of the second year of the 3-year transition for urban hospitals that were located in an urban county that become rural under the new OMB delineations or hospitals deemed urban where the urban area became rural under the new OMB delineations.

- The effects of the frontier State wage index adjustment under the statutory provision that requires that hospitals located in States that qualify as frontier States to not have a wage index less than 1.0. This provision is not budget neutral.

- The effects of the implementation of section 1886(d)(13) of the Act, as added by section 505 of Pub. L. 108-173, which provides for an increase in a hospital’s wage index if a threshold percentage of residents of the county where the hospital is located
commute to work at hospitals in counties with higher wage indexes. This provision is not budget neutral.

- The total estimated change in payments based on the FY 2016 policies relative to payments based on FY 2015 policies that include the applicable percentage increase of 1.7 percent (or 2.4 percent market basket update with a reduction of 0.5 percentage point for the multifactor productivity adjustment, and a 0.2 percentage point reduction, as required under the Affordable Care Act).

To illustrate the impact of the FY 2016 changes, our analysis begins with a FY 2015 baseline simulation model using: the FY 2015 applicable percentage increase of 2.2 percent and the documentation and coding recoupment adjustment of -0.8 percent to the Federal standardized amount; the FY 2015 MS-DRG GROUPE (Version 32); the FY 2015 CBSA designations for hospitals based on the new OMB definitions; the FY 2015 wage index; and no MGCRB reclassifications. Outlier payments are set at 5.1 percent of total operating MS-DRG and outlier payments for modeling purposes.

Section 1886(b)(3)(B)(viii) of the Act, as added by section 5001(a) of Pub. L. 109-171, as amended by section 4102(b)(1)(A) of the ARRA (Pub. L. 111-5) and by section 3401(a)(2) of the Affordable Care Act (Pub. L. 111-148), provides that, for FY 2007 and each subsequent year through FY 2014, the update factor will include a reduction of 2.0 percentage points for any subsection (d) hospital that does not submit data on measures in a form and manner and at a time specified by the Secretary. Beginning in FY 2015, the reduction is one-quarter of such applicable percentage increase determined without regard to section 1886(b)(3)(B)(ix), (xi), or (xii) of the Act.
or one-quarter of the market basket update. Therefore, for FY 2016, we are establishing that hospitals that do not submit quality information under rules established by the Secretary and that are meaningful EHR users under section 1886(b)(3)(B)(ix) of the Act will receive an applicable percentage increase of 1.1 percent. At the time that this impact was prepared, 26 hospitals are estimated to not receive the full market basket rate-of-increase for FY 2015 because they failed the quality data submission process or did not choose to participate. For purposes of the simulations shown below, we modeled the payment changes for FY 2016 using a reduced update for these 26 hospitals. However, we do not have enough information at this time to determine which hospitals will not receive the full update factor for FY 2016.

For FY 2016, in accordance with section 1886(b)(3)(B)(ix) of the Act, a hospital that has been identified as not a meaningful EHR user will be subject to a reduction of one-half of such applicable percentage increase determined without regard to section 1886(b)(3)(B)(ix), (xi), or (xii) of the Act. Therefore, for FY 2016, we are establishing that hospitals that are identified as not meaningful EHR users and do submit quality information under section 1886(b)(3)(B)(viii) of the Act will receive an applicable percentage increase of 0.5 percent. At the time that this impact analysis was prepared, 153 hospitals are estimated to not receive the full market basket rate-of-increase for FY 2015 because they are identified as not meaningful EHR users that do submit quality information under section 1886(b)(3)(B)(viii) of the Act. For purposes of the simulations shown below, we modeled the payment changes for FY 2016 using a reduced update for these 153 hospitals. We did not include these hospitals in the
model for estimation purposes for FY 2015 because that was the first year hospitals experienced a reduction to their applicable percentage increase due to whether they are meaningful EHR users and data were not available at that time. However, we believe it is appropriate to include these 153 hospitals for estimation purposes in FY 2016 because FY 2016 will be the second year in which hospitals will experience this reduction and data on the prior year’s performance are now available. For purposes of the simulations shown below, we modeled the payment changes for FY 2016 using a reduced update for these 153 hospitals. However, we do not have enough information at this time to determine which hospitals will not receive the full update increase for FY 2016.

Hospitals that are identified as not meaningful EHR users under section 1886(b)(3)(B)(ix) of the Act and also do not submit quality data under section 1886(b)(3)(B)(viii) of the Act will receive an applicable percentage increase of -0.1 percent, which reflects a one-quarter reduction of the market basket update for failure to submit quality data and a one-half reduction of the market basket update for being identified as not a meaningful EHR user. At the time that this impact was prepared, 24 hospitals are estimated to not receive the full market basket rate-of-increase for FY 2016 because they are identified as not meaningful EHR users that do not submit quality data under section 1886(b)(3)(B)(viii) of the Act. We did not include these hospitals in the model for estimation purposes for FY 2015 because that was the first year hospitals experienced a reduction to their applicable percentage increase due to whether they are meaningful EHR users and data were not available at that time. However, we believe it is appropriate to include these 24 hospitals for estimation purposes in FY 2016.
because FY 2016 will be the second year in which hospitals will experience this reduction and data on the prior year’s performance are now available. For purposes of the simulations shown below, we modeled the payment changes for FY 2016 using a reduced update for these 24 hospitals. However, we do not have enough information at this time to determine which hospitals will not receive the full update increase for FY 2016.

Each policy change, statutory or otherwise, is then added incrementally to this baseline, finally arriving at an FY 2016 model incorporating all of the changes. This simulation allows us to isolate the effects of each change.

Our final comparison illustrates the percent change in payments per case from FY 2015 to FY 2016. Three factors not discussed separately have significant impacts here. The first factor is the update to the standardized amount. In accordance with section 1886(b)(3)(B)(i) of the Act, we are updating the standardized amounts for FY 2016 using an applicable percentage increase of 1.7 percent. This includes our forecasted IPPS operating hospital market basket increase of 2.4 percent with a reduction of 0.5 percentage point for the multifactor productivity adjustment and a 0.2 percentage point reduction as required under the Affordable Care Act. Hospitals that fail to comply with the quality data submission requirements and are meaningful EHR users will receive an update of 1.1 percent. This update includes a reduction of one-quarter of the market basket update for failure to submit these data. Hospitals that do comply with the quality data submission requirements but are not meaningful EHR users will receive an update of 0.5 percent, which includes a reduction of one-half of the market basket update.
Furthermore, hospitals that do not comply with the quality data submission requirements and also are not meaningful EHR users will receive an update of -0.1 percent. Under section 1886(b)(3)(B)(iv) of the Act, the update to the hospital-specific amounts for SCHs and MDHs also are equal to the applicable percentage increase, or 1.7 percent if the hospital submits quality data and is a meaningful EHR user. In addition, we are updating the Puerto Rico-specific amount by an applicable percentage increase of 1.7 percent.

A second significant factor that affects the changes in hospitals’ payments per case from FY 2015 to FY 2016 is the change in hospitals’ geographic reclassification status from one year to the next. That is, payments may be reduced for hospitals reclassified in FY 2015 that are no longer reclassified in FY 2016. Conversely, payments may increase for hospitals not reclassified in FY 2015 that are reclassified in FY 2016.

A third significant factor is that we currently estimate that actual outlier payments during FY 2015 will be 4.6 percent of total MS-DRG payments. When the FY 2015 IPPS/LTCH PPS final rule was published, we projected FY 2015 outlier payments would be 5.1 percent of total MS-DRG plus outlier payments; the average standardized amounts were offset correspondingly. The effects of the lower than expected outlier payments during FY 2015 (as discussed in the Addendum to this final rule) are reflected in the analyses below comparing our current estimates of FY 2015 payments per case to estimated FY 2016 payments per case (with outlier payments projected to equal 5.1 percent of total MS-DRG payments).
2. Analysis of Table I

Table I displays the results of our analysis of the changes for FY 2016. The table categorizes hospitals by various geographic and special payment consideration groups to illustrate the varying impacts on different types of hospitals. The top row of the table shows the overall impact on the 3,369 acute care hospitals included in the analysis.

The next four rows of Table I contain hospitals categorized according to their geographic location: all urban, which is further divided into large urban and other urban; and rural. There are 2,533 hospitals located in urban areas included in our analysis. Among these, there are 1,393 hospitals located in large urban areas (populations over 1 million), and 1,140 hospitals in other urban areas (populations of 1 million or fewer). In addition, there are 836 hospitals in rural areas. The next two groupings are by bed-size categories, shown separately for urban and rural hospitals. The final groupings by geographic location are by census divisions, also shown separately for urban and rural hospitals.

The second part of Table I shows hospital groups based on hospitals’ FY 2016 payment classifications, including any reclassifications under section 1886(d)(10) of the Act. For example, the rows labeled urban, large urban, other urban, and rural show that the numbers of hospitals paid based on these categorizations after consideration of geographic reclassifications (including reclassifications under sections 1886(d)(8)(B) and 1886(d)(8)(E) of the Act that have implications for capital payments) are 2,476; 1,386; 1,090; and 893, respectively.
The next three groupings examine the impacts of the changes on hospitals grouped by whether or not they have GME residency programs (teaching hospitals that receive an IME adjustment) or receive Medicare DSH payments, or some combination of these two adjustments. There are 2,326 nonteaching hospitals in our analysis, 794 teaching hospitals with fewer than 100 residents, and 249 teaching hospitals with 100 or more residents.

In the DSH categories, hospitals are grouped according to their DSH payment status, and whether they are considered urban or rural for DSH purposes. The next category groups together hospitals considered urban or rural, in terms of whether they receive the IME adjustment, the DSH adjustment, both, or neither.

The next three rows examine the impacts of the changes on rural hospitals by special payment groups (SCHs, RRCs, and MDHs). There were 189 RRCs, 327 SCHs, 150 MDHs, 126 hospitals that are both SCHs and RRCs, and 13 hospitals that are both MDHs and RRCs.

The next series of groupings are based on the type of ownership and the hospital's Medicare utilization expressed as a percent of total patient days. These data were taken from the FY 2013 or FY 2012 Medicare cost reports.

The next two groupings concern the geographic reclassification status of hospitals. The first grouping displays all urban hospitals that were reclassified by the MGCRB for FY 2016. The second grouping shows the MGCRB rural reclassifications. The final category shows the impact of the policy changes on the 14 cardiac hospitals.
## TABLE I.—IMPACT ANALYSIS OF CHANGES TO THE IPPS FOR OPERATING COSTS FOR FY 2016

<table>
<thead>
<tr>
<th>Number of Hospitals</th>
<th>Hospital Rate Update and Documentation and Coding Adjustment (1)</th>
<th>Rural and Imputed Floor with Application of National Rural and Imputed Floor Budget Neutrality (6)</th>
<th>Application of the Frontier Wage Index and Out-Migration Adjustment (7)</th>
<th>All FY 2016 Changes (8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Hospitals</td>
<td>3,369</td>
<td>0.9</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>By Geographic Location:</td>
<td></td>
<td></td>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,533</td>
<td>0.9</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>Large urban areas</td>
<td>1,393</td>
<td>0.9</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Other urban areas</td>
<td>1,140</td>
<td>0.9</td>
<td>-0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>836</td>
<td>1.3</td>
<td>-0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Bed Size (Urban):</td>
<td></td>
<td></td>
<td></td>
<td>0.2</td>
</tr>
<tr>
<td>0-99 beds</td>
<td>668</td>
<td>0.9</td>
<td>-0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>778</td>
<td>0.9</td>
<td>0.1</td>
<td>0.3</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>445</td>
<td>0.9</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>300-499 beds</td>
<td>428</td>
<td>0.9</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>214</td>
<td>0.9</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Bed Size (Rural):</td>
<td></td>
<td></td>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td>0-49 beds</td>
<td>329</td>
<td>1.3</td>
<td>-0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>297</td>
<td>1.4</td>
<td>-0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>121</td>
<td>1.4</td>
<td>-0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>48</td>
<td>1.2</td>
<td>-0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>41</td>
<td>1.1</td>
<td>-0.1</td>
<td>0.3</td>
</tr>
<tr>
<td>Urban by Region:</td>
<td></td>
<td></td>
<td></td>
<td>0.1</td>
</tr>
<tr>
<td>New England</td>
<td>120</td>
<td>0.9</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>318</td>
<td>0.9</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>407</td>
<td>0.9</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>East North Central</td>
<td>396</td>
<td>0.9</td>
<td>0</td>
<td>0.5</td>
</tr>
<tr>
<td>East South Central</td>
<td>150</td>
<td>0.9</td>
<td>-0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>West North Central</td>
<td>166</td>
<td>0.9</td>
<td>-0.4</td>
<td>0.8</td>
</tr>
<tr>
<td>West South Central</td>
<td>384</td>
<td>0.9</td>
<td>-0.4</td>
<td>0.8</td>
</tr>
<tr>
<td>Mountain</td>
<td>161</td>
<td>1</td>
<td>-0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Pacific</td>
<td>380</td>
<td>0.9</td>
<td>0</td>
<td>0.2</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Rural by Region:</td>
<td></td>
<td></td>
<td></td>
<td>-0.4</td>
</tr>
<tr>
<td>New England</td>
<td>22</td>
<td>1.2</td>
<td>-0.1</td>
<td>1.7</td>
</tr>
</tbody>
</table>

Notes:
1. Number of Hospitals
2. Hospital Rate Update and Documentation and Coding Adjustment
3. FY 2016 Wage Data under New CBSA Designations with Application of Wage Budget Neutrality
4. FY 2016 DRG, Rel. Wts., Wage Index Changes with Recalibration Budget Neutrality
5. FY 2016 MGCRRB Reclassifications
6. Urban and Imputed Floor with Application of National Rural and Imputed Floor Budget Neutrality
7. Application of the Frontier Wage Index and Out-Migration Adjustment
8. All FY 2016 Changes

Other notes:
- CMS-1632-F & IFC
- 2025
<table>
<thead>
<tr>
<th>By Payment Classification:</th>
<th>Number of Hospitals</th>
<th>Hospital Rate Update and Documentation and Coding Adjustment (1)</th>
<th>FY 2016 Weights and DRG Changes with Application of Recalibration Budget Neutrality (2)</th>
<th>FY 2016 Wage Data under New CHS Designations with Application of Wage Budget Neutrality (3)</th>
<th>FY 2016 DRG, Rel. Wts., Wage Index Changes with Wage and Recalibration Budget Neutrality (4)</th>
<th>FY 2016 MGCRR Reclassifications (5)</th>
<th>Rural and Imputed Floor with Application of National Rural and Imputed Floor Budget Neutrality (6)</th>
<th>Application of the Frontier Wage Index and Out-Migration Adjustment (7)</th>
<th>All FY 2016 Changes (8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urban hospitals</td>
<td>2,476</td>
<td>0.9</td>
<td>0</td>
<td>0</td>
<td>0.1</td>
<td>-0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.4</td>
</tr>
<tr>
<td>Large urban areas</td>
<td>1,386</td>
<td>0.9</td>
<td>0.1</td>
<td>0.1</td>
<td>0.2</td>
<td>-0.3</td>
<td>0.2</td>
<td>0.2</td>
<td>0.4</td>
</tr>
<tr>
<td>Other urban areas</td>
<td>1,090</td>
<td>0.9</td>
<td>0</td>
<td>-0.1</td>
<td>-0.1</td>
<td>-0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.4</td>
</tr>
<tr>
<td>Rural areas</td>
<td>893</td>
<td>1.3</td>
<td>-0.2</td>
<td>-0.3</td>
<td>-0.4</td>
<td>1.1</td>
<td>-0.2</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Teaching Status:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-teaching</td>
<td>2,326</td>
<td>1</td>
<td>-0.1</td>
<td>-0.1</td>
<td>-0.1</td>
<td>0.1</td>
<td>0.2</td>
<td>0.1</td>
<td>0.3</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>794</td>
<td>0.9</td>
<td>0</td>
<td>-0.1</td>
<td>-0.1</td>
<td>-0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.4</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>249</td>
<td>0.9</td>
<td>0.2</td>
<td>0.1</td>
<td>0.3</td>
<td>0</td>
<td>-0.2</td>
<td>0.1</td>
<td>0.4</td>
</tr>
<tr>
<td>Urban DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-DSH</td>
<td>653</td>
<td>0.9</td>
<td>-0.2</td>
<td>0</td>
<td>-0.1</td>
<td>0.1</td>
<td>-0.1</td>
<td>0.1</td>
<td>1.1</td>
</tr>
<tr>
<td>100 or more beds</td>
<td>1,593</td>
<td>0.9</td>
<td>0.1</td>
<td>0</td>
<td>0.1</td>
<td>-0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.3</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>328</td>
<td>0.9</td>
<td>-0.1</td>
<td>0</td>
<td>-0.1</td>
<td>-0.7</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>Rural DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCH</td>
<td>260</td>
<td>1.6</td>
<td>-0.3</td>
<td>0</td>
<td>-0.4</td>
<td>0</td>
<td>0.4</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>RRC</td>
<td>347</td>
<td>1.3</td>
<td>-0.2</td>
<td>-0.3</td>
<td>-0.4</td>
<td>1.5</td>
<td>-0.2</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>100 or more beds</td>
<td>31</td>
<td>0.7</td>
<td>0.1</td>
<td>-0.6</td>
<td>-0.5</td>
<td>2.4</td>
<td>-0.5</td>
<td>0.1</td>
<td>-0.9</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>157</td>
<td>0.8</td>
<td>0.7</td>
<td>-0.6</td>
<td>-0.6</td>
<td>1.2</td>
<td>-0.5</td>
<td>0.6</td>
<td>-1.2</td>
</tr>
<tr>
<td>Urban teaching and DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both teaching and DSH</td>
<td>855</td>
<td>0.9</td>
<td>0.1</td>
<td>0</td>
<td>0.1</td>
<td>-0.2</td>
<td>-0.1</td>
<td>0.1</td>
<td>0.3</td>
</tr>
<tr>
<td>Teaching and no DSH</td>
<td>122</td>
<td>0.9</td>
<td>-0.1</td>
<td>0</td>
<td>-0.1</td>
<td>0.8</td>
<td>0.1</td>
<td>0.1</td>
<td>1.3</td>
</tr>
<tr>
<td>No teaching and DSH</td>
<td>1,066</td>
<td>0.9</td>
<td>0</td>
<td>0</td>
<td>-0.1</td>
<td>-0.1</td>
<td>0.4</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>No teaching and no DSH</td>
<td>433</td>
<td>0.9</td>
<td>-0.2</td>
<td>0.1</td>
<td>-0.1</td>
<td>-0.4</td>
<td>-0.2</td>
<td>0.1</td>
<td>1.1</td>
</tr>
</tbody>
</table>
### Special Hospital Types:

<table>
<thead>
<tr>
<th>Type</th>
<th>Number of Hospitals</th>
<th>Hospital Rate Update and Documentation (1)^2</th>
<th>FY 2016 Weights and DRG Changes with Application of Recalibration Budget Neutrality (2)^3</th>
<th>FY 2016 Wage Data under New CBSA Designations with Application of Wage Budget Neutrality (3)^4</th>
<th>FY 2016 DRG, Rel. Wts., Wage Index Changes with Application of Wage and Recalibration Budget Neutrality (4)^5</th>
<th>FY 2016 MGCRB Reclassifications (5)^6</th>
<th>Rural and Imputed Floor with Application of Recalibration Budget Neutrality (6)^7</th>
<th>Application of the Frontier Wage Index and Out-Migration Adjustment (7)^8</th>
<th>All FY 2016 Changes (8)^9</th>
</tr>
</thead>
<tbody>
<tr>
<td>RRC</td>
<td>189</td>
<td>0.9</td>
<td>-0.1</td>
<td>-0.6</td>
<td>-0.1</td>
<td>2.1</td>
<td>-0.3</td>
<td>0.6</td>
<td>-0.4</td>
</tr>
<tr>
<td>SCH</td>
<td>327</td>
<td>1.6</td>
<td>-0.3</td>
<td>-0.3</td>
<td>-0.1</td>
<td>0</td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDH</td>
<td>150</td>
<td>1.3</td>
<td>-0.3</td>
<td>-0.2</td>
<td>-0.4</td>
<td>0.2</td>
<td>-0.2</td>
<td>0.2</td>
<td>0.6</td>
</tr>
<tr>
<td>SCH and RRC</td>
<td>126</td>
<td>1.6</td>
<td>-0.3</td>
<td>-0.1</td>
<td>-0.4</td>
<td>0.4</td>
<td>0</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>MDH and RRC</td>
<td>13</td>
<td>1.5</td>
<td>-0.3</td>
<td>0</td>
<td>-0.4</td>
<td>0.1</td>
<td>-0.2</td>
<td>0.6</td>
<td></td>
</tr>
</tbody>
</table>
| Type of Ownership:
|               |                     |                                              |                                                                                       |                                                                                     |                                                                                        |                                                                                     |                                                                                     |                                                                                     |
| Voluntary     | 1,934               | 0.9                                           | 0                                                                                 | 0                                                                                  | 0                                                                                     | 0                                                                               | 0.1                                                                                     | 0.5                                                                               |                          |
| Proprietary   | 879                 | 0.9                                           | 0                                                                                 | -0.1                                                                               | -0.1                                                                                   | 0                                                                               | 0.1                                                                                     | 0.1                                                                               | -0.1                    |
| Government    | 529                 | 0.9                                           | 0.1                                                                                 | -0.1                                                                               | 0                                                                                     | -0.2                                                                               | 0.1                                                                                     | 0.1                                                                               |                          |
| Medicare Utilization as a Percent of Inpatient Days:
|               |                     |                                              |                                                                                       |                                                                                     |                                                                                        |                                                                                     |                                                                                     |                                                                                     |
| 0-25          | 533                 | 0.9                                           | 0.1                                                                                 | -0.1                                                                               | 0                                                                                     | -0.4                                                                               | 0.2                                                                                     | 0.6                                                                               |                          |
| 25-50         | 2,134               | 0.9                                           | 0                                                                                 | 0                                                                                  | 0                                                                                     | 0                                                                               | 0.1                                                                                     | 0.3                                                                               |                          |
| 50-65         | 571                 | 1                                             | -0.1                                                                                 | 0                                                                                 | -0.6                                                                                   | 0                                                                               | 0.1                                                                                     | 0.8                                                                               |                          |
| Over 65       | 97                  | 1.1                                           | -0.1                                                                                 | -0.2                                                                               | -0.4                                                                                   | -0.4                                                                               | 0.3                                                                                     | 0.1                                                                               | 0.4                     |
| FY 2016 Reclassifications by the Medicare Geographic Classification Review Board:
<p>| | | | | | | | | |
|               |                     |                                              |                                                                                       |                                                                                     |                                                                                        |                                                                                     |                                                                                     |                                                                                     |
| All Reclassified Hospitals | 830 | 1 | 0 | -0.1 | -0.1 | 2.2 | 0.1 | 0 | 0.7 |
| Non-Reclassified Hospitals | 2,539 | 0.9 | 0 | 0 | 0.1 | -0.9 | 0 | 0.2 | 0.2 |
| Urban Hospitals Reclassified | 551 | 0.9 | 0 | -0.1 | 0 | 2.2 | 0.1 | 0 | 0.8 |
| Urban Nonreclassified Hospitals | 1,925 | 0.9 | 0 | 0.1 | 0.1 | -0.9 | 0 | 0.1 | 0.2 |
| Rural Hospitals Reclassified Full Year | 279 | 1.2 | -0.2 | -0.3 | -0.5 | 2.3 | -0.2 | 0 | 0.4 |
| Rural Nonreclassified Hospitals Full Year | 504 | 1.4 | -0.3 | -0.3 | -0.5 | -0.3 | -0.2 | 0.3 | 0 |</p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Number of Hospitals</th>
<th>Hospital Rate Update and Documentation Adjustment (1)</th>
<th>FY 2016 Weights and DRG Changes with Application of Recalibration Budget Neutrality (2)</th>
<th>FY 2016 Wage Data under New CBSA Designations with Application of Wage Budget Neutrality (3)</th>
<th>FY 2016 DRG, Rel. Wts., Wage Index Change with Wage and Recalibration Budget Neutrality (4)</th>
<th>FY 2016 MGCRB Reclassifications (5)</th>
<th>Rural and Imputed Floor with Application of National Rural and Imputed Floor Budget Neutrality (6)</th>
<th>Application of the Frontier Wage Index and Out-Migration Adjustment (7)</th>
<th>All FY 2016 Changes (8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Section 401 Reclassified Hospitals</td>
<td>64</td>
<td>1.4</td>
<td>-0.3</td>
<td>0</td>
<td>-0.2</td>
<td>-0.4</td>
<td>0</td>
<td>1.4</td>
<td>0.6</td>
</tr>
<tr>
<td>Other Reclassified Hospitals (Section 1886(d)(8)(B))</td>
<td>53</td>
<td>1</td>
<td>-0.1</td>
<td>-0.5</td>
<td>-0.6</td>
<td>3.4</td>
<td>-0.4</td>
<td>0</td>
<td>-0.3</td>
</tr>
<tr>
<td>Specialty Hospitals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac specialty Hospitals</td>
<td>14</td>
<td>0.9</td>
<td>0.2</td>
<td>-0.9</td>
<td>-0.6</td>
<td>-1.1</td>
<td>0</td>
<td>0.9</td>
<td>0.7</td>
</tr>
</tbody>
</table>

1. Because data necessary to classify some hospitals by category were missing, the total number of hospitals in each category may not equal the national total. Discharge data are from FY 2014, and hospital cost report data are from reporting periods beginning in FY 2013 and FY 2012.
2. This column displays the payment impact of the hospital rate update and the documentation and coding adjustment including the 1.7 percent adjustment to the national standardized amount and hospital-specific rate (the estimated 2.4 percent market basket update reduced by the 0.5 percentage point for the multifactor productivity adjustment and the 0.2 percentage point reduction under the Affordable Care Act) and the -0.8 percent documentation and coding adjustment to the national standardized amount.
3. This column displays the payment impact of the changes to the Version 33 GROUPER, the changes to the relative weights and the recalibration of the MS-DRG weights based on FY 2014 MedPAR data in accordance with section 1886(d)(4)(C)(iii) of the Act. This column displays the application of the recalibration budget neutrality factor of 0.998399 in accordance with section 1886(d)(4)(C)(iii) of the Act.
4. This column displays the payment impact of the update to wage index data using FY 2012 cost report data and the OMB labor market area delineations based on 2010 Decennial Census data. This column displays the payment impact of the application of the wage budget neutrality factor, which is calculated separately from the recalibration budget neutrality factor, and is calculated in accordance with section 1886(d)(3)(E)(i) of the Act. The wage budget neutrality factor is 0.998749.
5. This column displays the combined payment impact of the changes in Columns 2 through 3 and the cumulative budget neutrality factor for MS-DRG and wage changes in accordance with section 1886(d)(4)(C)(iii) of the Act and section 1886(d)(3)(E) of the Act. The cumulative wage and recalibration budget neutrality factor of 0.997150 is the product of the wage budget neutrality factor and the recalibration budget neutrality factor.
6. Shown here are the effects of geographic reclassifications by the Medicare Geographic Classification Review Board (MGCRB) along with the effects of the continued implementation of the new OMB labor market area delineations on these reclassifications. The effects demonstrate the FY 2016 payment impact of going from no reclassifications to the reclassifications scheduled to be in effect for FY 2016. Reclassification for prior years has no bearing on the payment impacts shown here. This column reflects the geographic budget neutrality factor of 0.987905.
This column displays the effects of the rural floor and imputed floor based on the continued implementation of the new OMB labor market area delineations. The Affordable Care Act requires the rural floor budget neutrality adjustment to be 100 percent national level adjustment. The rural floor budget neutrality factor (which includes the imputed floor) applied to the wage index is 0.990298. This column also shows the effect of the 3-year transition for hospitals that were located in urban counties that became rural under the new OMB delineations or hospitals deemed urban where the urban area became rural under the new OMB delineations, with a budget neutrality factor of 0.999996.

This column shows the combined impact of the policy required under section 10324 of the Affordable Care Act that hospitals located in frontier States have a wage index no less than 1.0 and of section 1886(d)(13) of the Act, as added by section 505 of Pub. L. 108-173, which provides for an increase in a hospital’s wage index if a threshold percentage of residents of the county where the hospital is located commute to work at hospitals in counties with higher wage indexes. These are nonbudget neutral policies.

This column shows the changes in payments from FY 2015 to FY 2016. It reflects the impact of the FY 2016 hospital update and the adjustment for documentation and coding. It also reflects changes in hospitals’ reclassification status in FY 2016 compared to FY 2015. It incorporates all of the changes displayed in Columns 1, 4, 5, 6, and 7, (the changes displayed in Columns 2 and 3 are included in Column 4). The sum of these impacts may be different from the percentage changes shown here due to rounding and interactive effects.
a. Effects of the Hospital Update and Documentation and Coding Adjustment (Column 1)

As discussed in section II.D. of the preamble of this final rule, this column includes the hospital update, including the 2.4 percent market basket update, the reduction of 0.5 percentage point for the multifactor productivity adjustment, and the 0.2 percentage point reduction in accordance with the Affordable Care Act. In addition, this column includes the FY 2016 documentation and coding recoupment adjustment of -0.8 percent on the national standardized amount as part of the recoupment required by section 631 of the ATRA. As a result, we are making a 0.9 percent update to the national standardized amount. This column also includes the 1.7 percent update to the hospital-specific rates which includes the 2.4 percent market basket update, the reduction of 0.5 percentage point for the multifactor productivity adjustment, and the 0.2 percentage point reduction in accordance with the Affordable Care Act.

Overall, hospitals will experience a 0.9 percent increase in payments primarily due to the combined effects of the hospital update and the documentation and coding adjustment on the national standardized amount and the hospital update to the hospital-specific rate. Hospitals that are paid under the hospital-specific rate, namely SCHs, will experience a 1.6 percent increase in payments; therefore, hospital categories with SCHs paid under the hospital-specific rate will experience increases in payments of more than 0.9 percent.
b. Effects of the Changes to the MS-DRG Reclassifications and Relative Cost-Based Weights with Recalibration Budget Neutrality (Column 2)

Column 2 shows the effects of the changes to the MS-DRGs and relative weights with the application of the recalibration budget neutrality factor to the standardized amounts. Section 1886(d)(4)(C)(i) of the Act requires us annually to make appropriate classification changes in order to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources. Consistent with section 1886(d)(4)(C)(iii) of the Act, we are calculating a recalibration budget neutrality factor to account for the changes in MS-DRGs and relative weights to ensure that the overall payment impact is budget neutral.

As discussed in section II.E. of the preamble of this final rule, the FY 2016 MS-DRG relative weights will be 100 percent cost-based and 100 percent MS-DRGs. For FY 2016, the MS-DRGs are calculated using the FY 2014 MedPAR data grouped to the Version 33 (FY 2016) MS-DRGs. The methodology to calculate the relative weights and the reclassification changes to the GROUPER are described in more detail in section II.H. of the preamble of this final rule.

The “All Hospitals” line in Column 2 indicates that changes due to the MS-DRGs and relative weights will result in a 0.0 percent change in payments with the application of the recalibration budget neutrality factor of 0.998399 on to the standardized amount. Hospital categories that generally treat more surgical cases than medical cases will experience increases in their payments under the relative weights. Rural hospitals will experience a 0.2 percent decrease in payments because rural hospitals tend to treat fewer
surgical cases than medical cases, while teaching hospitals with more than 100 residents will experience an increase in payments by 0.2 percent as those hospitals treat more surgical cases than medical cases.

c. Effects of the Wage Index Changes (Column 3)

Column 3 shows the impact of updated wage data using FY 2012 cost report data, with the application of the wage budget neutrality factor. The wage index is calculated and assigned to hospitals on the basis of the labor market area in which the hospital is located. Under section 1886(d)(3)(E) of the Act, beginning with FY 2005, we delineate hospital labor market areas based on the Core Based Statistical Areas (CBSAs) established by OMB. The current statistical standards used in FY 2016 are based on OMB standards published on February 28, 2013 (75 FR 37246 and 37252), and 2010 Decennial Census data (OMB Bulletin No. 13-01). (We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951 through 49963) for a full discussion on our adoption of the OMB labor market area delineations based on the 2010 Decennial Census data, effective beginning with the FY 2015 IPPS wage index).

Section 1886(d)(3)(E) of the Act requires that, beginning October 1, 1993, we annually update the wage data used to calculate the wage index. In accordance with this requirement, the wage index for acute care hospitals for FY 2016 is based on data submitted for hospital cost reporting periods beginning on or after October 1, 2011 and before October 1, 2012. The estimated impact of the updated wage data using the FY 2012 cost report data and the OMB labor market area delineations on hospital payments is isolated in Column 3 by holding the other payment parameters constant in
this simulation. That is, Column 3 shows the percentage change in payments when going from a model using the FY 2015 wage index, based on FY 2011 wage data, the labor-related share of 69.6 percent, under the OMB delineations and having a 100-percent occupational mix adjustment applied, to a model using the FY 2016 pre-reclassification wage index based on FY 2012 wage data with the labor-related share of 69.6 percent, under the OMB delineations, also having a 100-percent occupational mix adjustment applied, while holding other payment parameters such as use of the Version 33 MS-DRG GROUPER constant. The FY 2016 occupational mix adjustment is based on the CY 2013 occupational mix survey.

In addition, the column shows the impact of the application of the wage budget neutrality to the national standardized amount. In FY 2010, we began calculating separate wage budget neutrality and recalibration budget neutrality factors, in accordance with section 1886(d)(3)(E) of the Act, which specifies that budget neutrality to account for wage index changes or updates made under that subparagraph must be made without regard to the 62 percent labor-related share guaranteed under section 1886(d)(3)(E)(ii) of the Act. Therefore, for FY 2016, we are calculating the wage budget neutrality factor to ensure that payments under updated wage data and the labor-related share of 69.6 percent are budget neutral without regard to the lower labor-related share of 62 percent applied to hospitals with a wage index less than or equal to 1.0. In other words, the wage budget neutrality is calculated under the assumption that all hospitals receive the higher labor-related share of the standardized amount. The FY 2016 wage budget neutrality factor is 0.998749, and the overall payment change is 0.0 percent.
Column 3 shows the impacts of updating the wage data using FY 2012 cost reports. Overall, the new wage data and the labor-related share, combined with the wage budget neutrality adjustment, will lead to no change for all hospitals as shown in Column 3.

In looking at the wage data itself, the national average hourly wage increased 1.03 percent compared to FY 2015. Therefore, the only manner in which to maintain or exceed the previous year’s wage index was to match or exceed the national 1.03 percent increase in average hourly wage. Of the 3,328 hospitals with wage data for both FYs 2015 and 2016, 1,594 or 47.9 percent will experience an average hourly wage increase of 1.03 percent or more.

The following chart compares the shifts in wage index values for hospitals due to changes in the average hourly wage data for FY 2016 relative to FY 2015. Among urban hospitals, 5 will experience a decrease of 10 percent or more, and 13 urban hospitals will experience an increase of 10 percent or more. One hundred and forty-four urban hospitals will experience an increase or decrease of at least 5 percent or more but less than 10 percent. Among rural hospitals, 9 will experience a decrease of at least 5 percent but less than 10 percent, but no rural hospitals will experience an increase of greater than or equal to 5 percent but less than 10 percent. No rural hospital will experience increases or decreases of 10 percent or more. However, 809 rural hospitals will experience increases or decreases of less than 5 percent, while 2,341 urban hospitals will experience increases or decreases of less than 5 percent. Seven urban hospitals will not experience a change in their wage index, and all rural hospitals will experience a change in their wage
indexes. These figures reflect changes in the “pre-reclassified, occupational mix-adjusted wage index,” that is, the wage index before the application of geographic reclassification, the rural and imputed floors, the out-migration adjustment, and other wage index exceptions and adjustments. (We refer readers to sections III.G.2. through III.I. of the preamble of this final rule for a complete discussion of the exceptions and adjustments to the wage index.) We note that the “post-reclassified wage index” or “payment wage index,” which is the wage index that includes all such exceptions and adjustments (as reflected in Tables 2 and 3 associated with this final rule, which are available via the Internet on the CMS Web site) is used to adjust the labor-related share of a hospital’s standardized amount, either 69.6 percent or 62 percent, depending upon whether a hospital’s wage index is greater than 1.0 or less than or equal to 1.0. Therefore, the pre-reclassified wage index figures in the chart below may illustrate a somewhat larger or smaller change than will occur in a hospital’s payment wage index and total payment.

The following chart shows the projected impact of changes in the area wage index values for urban and rural hospitals.
### FY 2016 Percentage Change in Area Wage Index Values

<table>
<thead>
<tr>
<th>Values</th>
<th>Urban</th>
<th>Rural</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase 10 percent or more</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>Increase greater than or equal to 5 percent and less than 10 percent</td>
<td>64</td>
<td>0</td>
</tr>
<tr>
<td>Increase or decrease less than 5 percent</td>
<td>2,341</td>
<td>809</td>
</tr>
<tr>
<td>Decrease greater than or equal to 5 percent and less than 10 percent</td>
<td>80</td>
<td>9</td>
</tr>
<tr>
<td>Decrease 10 percent or more</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Unchanged</td>
<td>7</td>
<td>0</td>
</tr>
</tbody>
</table>

### d. Combined Effects of the MS-DRG and Wage Index Changes (Column 4)

Section 1886(d)(4)(C)(iii) of the Act requires that changes to MS-DRG reclassifications and the relative weights cannot increase or decrease aggregate payments. In addition, section 1886(d)(3)(E) of the Act specifies that any updates or adjustments to the wage index are to be budget neutral. We computed a wage budget neutrality factor of 0.998749 and a recalibration budget neutrality factor of 0.998399 (which is also applied to the Puerto Rico-specific standardized amount and the hospital-specific rates). The product of the two budget neutrality factors is the cumulative wage and recalibration budget neutrality factor. The cumulative wage and recalibration budget neutrality adjustment is 0.997150, or approximately 0.3 percent, which is applied to the national standardized amounts. Because the wage budget neutrality and the recalibration budget neutrality are calculated under different methodologies according to the statute, when the two budget neutralities are combined and applied to the standardized amount, the overall payment impact is not necessarily budget neutral. However, in this final rule, we are...
estimating that the changes in the MS-DRG relative weights and updated wage data with wage and budget neutrality applied will result in a 0.0 percent change in payments.

e. Effects of MGCRB Reclassifications (Column 5)

Our impact analysis to this point has assumed acute care hospitals are paid on the basis of their actual geographic location (with the exception of ongoing policies that provide that certain hospitals receive payments on bases other than where they are geographically located). The changes in Column 5 reflect the per case payment impact of moving from this baseline to a simulation incorporating the MGCRB decisions for FY 2016.

By spring of each year, the MGCRB makes reclassification determinations that will be effective for the next fiscal year, which begins on October 1. The MGCRB may approve a hospital’s reclassification request for the purpose of using another area’s wage index value. Hospitals may appeal denials of MGCRB decisions to the CMS Administrator. Further, hospitals have 45 days from publication of the IPPS proposed rule in the Federal Register to decide whether to withdraw or terminate an approved geographic reclassification for the following year.

The overall effect of geographic reclassification is required by section 1886(d)(8)(D) of the Act to be budget neutral. Therefore, for purposes of this impact analysis, we are applying an adjustment of 0.987905 to ensure that the effects of the reclassifications under section 1886(d)(10) of the Act are budget neutral (section II.A. of the Addendum to this final rule). Geographic reclassification generally benefits hospitals in rural areas. We estimate that the geographic reclassification will increase
payments to rural hospitals by an average of 1.4 percent. By region, all the rural hospital categories will experience increases in payments due to MGCRB reclassifications.

New Table 2 listed in section VI. of the Addendum to this final rule and available via the Internet on the CMS Web site reflects the reclassifications for FY 2016.

f. Effects of the Rural and Imputed Floor, Including Application of National Budget Neutrality (Column 6)

As discussed in section III.B. of the preamble of the FY 2009 IPPS final rule, the FY 2010 IPPS/RY 2010 LTCH PPS final rule, the FYs 2011, 2012, 2013, 2014, and 2015 IPPS/LTCH PPS final rules, and this final rule, section 4410 of Pub. L. 105-33 established the rural floor by requiring that the wage index for a hospital in any urban area cannot be less than the wage index received by rural hospitals in the same State. We apply a uniform budget neutrality adjustment to the wage index. The imputed floor, which is also included in the calculation of the budget neutrality adjustment to the wage index, was extended in FY 2012 for 2 additional years and in FY 2014 and FY 2015 for 1 additional year. Prior to FY 2013, only urban hospitals in New Jersey received the imputed floor. As discussed in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53369), we established an alternative temporary methodology for the imputed floor, which resulted in an imputed floor for Rhode Island for FY 2013. For FY 2014 and FY 2015, we extended the imputed rural floor, as calculated under the original methodology and the alternative methodology. Due to the adoption of the new OMB labor market area delineations in FY 2015, the State of Delaware also became an all-urban state and thus eligible for an imputed floor. For FY 2016, we are extending the imputed rural floor for
1 year, as calculated under the original methodology and the alternative methodology.

As a result, New Jersey, Rhode Island, and Delaware are able to receive an imputed floor. In New Jersey, 21 out of 64 hospitals will receive the imputed floor, and 4 out of 11 hospitals in Rhode Island will receive the imputed floor for FY 2016. For FY 2016, no hospitals will benefit from the imputed floor in Delaware because the CBSA wage index for each CBSA in Delaware under the new OMB delineations is equal to or higher than the imputed rural floor.

The Affordable Care Act requires that we apply one rural floor budget neutrality factor to the wage index nationally, and the imputed floor is part of the rural floor budget neutrality factor applied to the wage index nationally. We have calculated a FY 2016 rural floor budget neutrality factor to be applied to the wage index of 0.990298, which will reduce wage indexes by 0.99 percent.

Column 6 shows the projected impact of the rural floor and imputed floor with the national rural floor budget neutrality factor applied to the wage index based on the OMB labor market area delineations. The column compares the post-reclassification FY 2016 wage index of providers before the rural floor and imputed floor adjustment and the post-reclassification FY 2016 wage index of providers with the rural floor and imputed floor adjustment based on the OMB labor market area delineations. Only urban hospitals can benefit from the rural and imputed floors. Because the provision is budget neutral, all other hospitals (that is, all rural hospitals and those urban hospitals to which the adjustment is not made) will experience a decrease in payments due to the budget neutrality adjustment that is applied nationally to their wage index.
We estimate that 371 hospitals will benefit from the rural and imputed floors in FY 2016, while the remaining 2,998 IPPS hospitals in our model will have their wage index reduced by the rural floor budget neutrality adjustment of 0.990298 (or 0.99 percent). We project that, in aggregate, rural hospitals will experience a 0.2 percent decrease in payments as a result of the application of the rural floor budget neutrality because the rural hospitals do not benefit from the rural floor, but have their wage indexes downwardly adjusted to ensure that the application of the rural floor is budget neutral overall. We project hospitals located in urban areas will experience no change in payments because increases in payments by hospitals benefitting from the rural floor offset decreases in payments by nonrural floor urban hospitals whose wage index is downwardly adjusted by the rural floor budget neutrality factor. Urban hospitals in the New England region will experience a 1.6 percent increase in payments primarily due to the application of the rural floor in Massachusetts. Thirty-nine urban providers in Massachusetts are expected to receive the rural floor wage index value, including the rural floor budget neutrality of 0.990298, increasing payments overall to Massachusetts by an estimated $98 million. We estimate that Massachusetts hospitals will receive approximately a 3.1 percent increase in IPPS payments due to the application of the rural floor in FY 2016.

Urban Puerto Rico hospitals are expected to experience a 0.1 percent change in payments as a result of the application of the Puerto Rico rural floor with the application of the Puerto Rico rural floor budget neutrality adjustment. We are applying a rural floor budget neutrality factor to the Puerto Rico-specific wage index of 0.987646 or 1.2
percent. The Puerto Rico-specific wage index adjusts the Puerto Rico-specific standardized amount, which represents 25 percent of payments to Puerto Rico hospitals. The increases in payments experienced by the urban Puerto Rico hospitals that benefit from a rural floor are offset by the decreases in payments by the urban Puerto Rico hospitals that do not benefit from the rural floor that have their wage indexes downwardly adjusted by the rural floor budget neutrality adjustment. As a result, overall, urban Puerto Rico hospitals will experience a 0.1 percent change in payments due to the application of the rural floor with rural floor budget neutrality.

There are 21 hospitals out of the 64 hospitals in New Jersey that will benefit from the extension of the imputed floor and will receive the imputed floor wage index value under the OMB labor market area delineations, including the rural floor budget neutrality of 0.990298 which we estimate will increase payments to those imputed floor hospitals by $27 million (overall, the State will receive an increase of $9 million in payments due to the other hospitals in the State that will experience decreases in payments due to the rural floor budget neutrality adjustment). Four Rhode Island hospitals will benefit from the imputed rural floor calculated under the alternative methodology and will receive an additional $4.5 million (overall, the State will receive an additional $2.6 million). While some hospitals in Delaware are geographically located in CBSAs that are assigned the imputed floor, none of these hospitals benefit from the imputed floor since they are reclassifying to CBSAs with a higher wage index than the imputed floor.

Column 6 also shows the projected effects of the second year of the 3-year hold harmless provision for hospitals that were located in an urban county that became rural
under the new OMB delineations or hospitals deemed urban where the urban area became rural under the new OMB delineations. As discussed in section III.G.2. of the preamble of this final rule, under this transition, hospitals that were located in an urban county that became rural under the new OMB delineations will generally be assigned the urban wage index value of the CBSA in which they are physically located in FY 2014 for a period of 3 fiscal years (that is, FYs 2015, 2016, and 2017). In addition, as discussed in section III.G.3. of the preamble of this final rule, under this transition, hospitals that were deemed urban where the urban area became rural under the new OMB delineations will generally be assigned the area wage index value of hospitals reclassified to the urban CBSA (that is, the attaching wage index, if applicable) to which they were designated in FY 2014. For FY 2016, we are applying the 3-year transition wage index adjustments in a budget neutral manner, with a budget neutrality factor of 0.999996.

In response to a public comment addressed in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51593), we are providing the payment impact of the rural floor and imputed floor with budget neutrality at the State level. Column 1 of the table below displays the number of IPPS hospitals located in each State. Column 2 displays the number of hospitals in each State that will receive the rural floor or imputed floor wage index for FY 2016. Column 3 displays the percentage of total payments each State will receive or contribute to fund the rural floor and imputed floor with national budget neutrality. The column compares the post-reclassification FY 2016 wage index of providers before the rural floor and imputed floor adjustment and the post-reclassification FY 2016 wage index of providers with the rural floor and imputed floor adjustment. Column 4 displays
the estimated payment amount that each State will gain or lose due to the application of the rural floor and imputed floor with national budget neutrality.
<table>
<thead>
<tr>
<th>State</th>
<th>Number of Hospitals (1)</th>
<th>Number of Hospitals That Will Receive the Rural Floor or Imputed Floor (2)</th>
<th>Percent Change in Payments due to Application of Rural Floor and Imputed Floor with Budget Neutrality (3)</th>
<th>Difference (in millions) (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alabama</td>
<td>86</td>
<td>3</td>
<td>-0.4</td>
<td>$-6.72</td>
</tr>
<tr>
<td>Alaska</td>
<td>6</td>
<td>1</td>
<td>-0.3</td>
<td>$-0.51</td>
</tr>
<tr>
<td>Arizona</td>
<td>55</td>
<td>5</td>
<td>-0.3</td>
<td>$-5.65</td>
</tr>
<tr>
<td>Arkansas</td>
<td>46</td>
<td>0</td>
<td>-0.4</td>
<td>$-4.43</td>
</tr>
<tr>
<td>California</td>
<td>303</td>
<td>203</td>
<td>2.2</td>
<td>$220.65</td>
</tr>
<tr>
<td>Colorado</td>
<td>47</td>
<td>5</td>
<td>0.4</td>
<td>$4.51</td>
</tr>
<tr>
<td>Connecticut</td>
<td>31</td>
<td>7</td>
<td>-0.5</td>
<td>$-8.06</td>
</tr>
<tr>
<td>Delaware</td>
<td>6</td>
<td>0</td>
<td>-0.5</td>
<td>$-2.41</td>
</tr>
<tr>
<td>Washington, D.C.</td>
<td>7</td>
<td>0</td>
<td>-0.5</td>
<td>$-2.37</td>
</tr>
<tr>
<td>Florida</td>
<td>170</td>
<td>14</td>
<td>-0.3</td>
<td>$-18.34</td>
</tr>
<tr>
<td>Georgia</td>
<td>105</td>
<td>0</td>
<td>-0.5</td>
<td>$-11.96</td>
</tr>
<tr>
<td>Hawaii</td>
<td>12</td>
<td>1</td>
<td>-0.4</td>
<td>$-1.11</td>
</tr>
<tr>
<td>Idaho</td>
<td>14</td>
<td>0</td>
<td>-0.4</td>
<td>$-1.15</td>
</tr>
<tr>
<td>Illinois</td>
<td>127</td>
<td>2</td>
<td>-0.5</td>
<td>$-24.07</td>
</tr>
<tr>
<td>Indiana</td>
<td>91</td>
<td>0</td>
<td>-0.5</td>
<td>$-11.65</td>
</tr>
<tr>
<td>Iowa</td>
<td>35</td>
<td>0</td>
<td>-0.4</td>
<td>$-4.15</td>
</tr>
<tr>
<td>Kansas</td>
<td>53</td>
<td>0</td>
<td>-0.4</td>
<td>$-3.5</td>
</tr>
<tr>
<td>Kentucky</td>
<td>65</td>
<td>1</td>
<td>-0.4</td>
<td>$-6.76</td>
</tr>
<tr>
<td>Louisiana</td>
<td>99</td>
<td>3</td>
<td>-0.5</td>
<td>$-6.39</td>
</tr>
<tr>
<td>Maine</td>
<td>20</td>
<td>0</td>
<td>-0.5</td>
<td>$-2.22</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>61</td>
<td>39</td>
<td>3.1</td>
<td>$97.64</td>
</tr>
<tr>
<td>Michigan</td>
<td>96</td>
<td>0</td>
<td>-0.5</td>
<td>$-21.43</td>
</tr>
<tr>
<td>Minnesota</td>
<td>50</td>
<td>0</td>
<td>-0.3</td>
<td>$-5.99</td>
</tr>
<tr>
<td>Mississippi</td>
<td>64</td>
<td>0</td>
<td>-0.5</td>
<td>$-4.75</td>
</tr>
<tr>
<td>Missouri</td>
<td>78</td>
<td>0</td>
<td>-0.4</td>
<td>$-9.54</td>
</tr>
<tr>
<td>Montana</td>
<td>12</td>
<td>2</td>
<td>0.1</td>
<td>$0.19</td>
</tr>
<tr>
<td>Nebraska</td>
<td>26</td>
<td>0</td>
<td>-0.4</td>
<td>$-2.43</td>
</tr>
<tr>
<td>Nevada</td>
<td>24</td>
<td>3</td>
<td>0.2</td>
<td>$1.8</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>13</td>
<td>3</td>
<td>-0.1</td>
<td>$-0.53</td>
</tr>
<tr>
<td>New Jersey</td>
<td>64</td>
<td>21</td>
<td>0.2</td>
<td>$8.95</td>
</tr>
<tr>
<td>New Mexico</td>
<td>25</td>
<td>0</td>
<td>-0.3</td>
<td>$-1.35</td>
</tr>
<tr>
<td>New York</td>
<td>156</td>
<td>2</td>
<td>-0.6</td>
<td>$-43.23</td>
</tr>
<tr>
<td>North Carolina</td>
<td>84</td>
<td>0</td>
<td>-0.4</td>
<td>$-13.95</td>
</tr>
<tr>
<td>North Dakota</td>
<td>6</td>
<td>0</td>
<td>-0.3</td>
<td>$-0.8</td>
</tr>
<tr>
<td>Ohio</td>
<td>132</td>
<td>6</td>
<td>-0.4</td>
<td>$-16.71</td>
</tr>
<tr>
<td>Oklahoma</td>
<td>86</td>
<td>4</td>
<td>-0.3</td>
<td>$-4.21</td>
</tr>
<tr>
<td>Oregon</td>
<td>34</td>
<td>0</td>
<td>-0.5</td>
<td>$-4.65</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>153</td>
<td>3</td>
<td>-0.5</td>
<td>$-21.99</td>
</tr>
</tbody>
</table>
FY 2016 IPPS Estimated Payments Due to Rural Floor and Imputed Floor with National Budget Neutrality

<table>
<thead>
<tr>
<th>State</th>
<th>Number of Hospitals (1)</th>
<th>Number of Hospitals That Will Receive the Rural Floor or Imputed Floor (2)</th>
<th>Percent Change in Payments due to Application of Rural Floor and Imputed Floor with Budget Neutrality (3)</th>
<th>Difference (in millions) (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>10</td>
<td>0.1</td>
<td>$0.17</td>
</tr>
<tr>
<td>Rhode Island</td>
<td>11</td>
<td>4</td>
<td>0.7</td>
<td>$2.57</td>
</tr>
<tr>
<td>South Carolina</td>
<td>56</td>
<td>5</td>
<td>-0.2</td>
<td>-$2.73</td>
</tr>
<tr>
<td>South Dakota</td>
<td>19</td>
<td>0</td>
<td>-0.3</td>
<td>-$0.97</td>
</tr>
<tr>
<td>Tennessee</td>
<td>99</td>
<td>10</td>
<td>-0.4</td>
<td>-$9.69</td>
</tr>
<tr>
<td>Texas</td>
<td>318</td>
<td>3</td>
<td>-0.5</td>
<td>-$29.15</td>
</tr>
<tr>
<td>Utah</td>
<td>34</td>
<td>2</td>
<td>-0.4</td>
<td>-$1.91</td>
</tr>
<tr>
<td>Vermont</td>
<td>6</td>
<td>0</td>
<td>-0.3</td>
<td>-$0.57</td>
</tr>
<tr>
<td>Virginia</td>
<td>78</td>
<td>1</td>
<td>-0.4</td>
<td>-$11.13</td>
</tr>
<tr>
<td>Washington</td>
<td>49</td>
<td>6</td>
<td>0.1</td>
<td>$1.47</td>
</tr>
<tr>
<td>West Virginia</td>
<td>29</td>
<td>2</td>
<td>0.1</td>
<td>$1.04</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>66</td>
<td>0</td>
<td>-0.5</td>
<td>-$7.85</td>
</tr>
<tr>
<td>Wyoming</td>
<td>11</td>
<td>0</td>
<td>-0.2</td>
<td>-$0.22</td>
</tr>
</tbody>
</table>


**g. Effects of the Application of the Frontier State Wage Index and Out-Migration Adjustment (Column 7)**

This column shows the combined effects of the application of section 10324(a) of the Affordable Care Act, which requires that we establish a minimum post-reclassified wage-index of 1.00 for all hospitals located in “frontier States,” and the effects of section 1886(d)(13) of the Act, as added by section 505 of Pub. L. 108-173, which provides for an increase in the wage index for hospitals located in certain counties that have a relatively high percentage of hospital employees who reside in the county, but work in a different area with a higher wage index. These two wage index provisions are not budget neutral and increase payments overall by 0.1 percent compared to the provisions not being in effect.
The term “frontier States” is defined in the statute as States in which at least 50 percent of counties have a population density less than 6 persons per square mile. Based on these criteria, 4 States (Montana, North Dakota, South Dakota, and Wyoming) are considered frontier States and 48 hospitals located in those States will receive a frontier wage index of 1.0000. Nevada is also, by definition, a frontier State and was assigned a frontier floor value of 1.0000 for FY 2012, but since then and including in this final rule, its rural floor value has been greater than 1.0000 so it has not been subject to the frontier wage index. Overall, this provision is not budget neutral and is estimated to increase IPPS operating payments by approximately $60 million. Rural and urban hospitals located in the West North Central region will experience an increase in payments by 0.3 and 0.8 percent, respectively, because many of the hospitals located in this region are frontier State hospitals.

In addition, section 1886(d)(13) of the Act, as added by section 505 of Pub. L. 108-173, provides for an increase in the wage index for hospitals located in certain counties that have a relatively high percentage of hospital employees who reside in the county, but work in a different area with a higher wage index. Hospitals located in counties that qualify for the payment adjustment are to receive an increase in the wage index that is equal to a weighted average of the difference between the wage index of the resident county, post-reclassification and the higher wage index work area(s), weighted by the overall percentage of workers who are employed in an area with a higher wage index. There are an estimated 336 providers that will receive the out-migration wage adjustment in FY 2016. Rural hospitals generally qualify for the adjustment, resulting in
a 0.1 percent increase in payments. This provision appears to benefit Section 401 hospitals and RRCs in that they will experience a 1.4 percent and 0.6 percent increase in payments, respectively. This out-migration wage adjustment also is not budget neutral, and we estimate the impact of these providers receiving the out-migration increase will be approximately $45 million.

h. Effects of All FY 2016 Changes (Column 8)

Column 8 shows our estimate of the changes in payments per discharge from FY 2015 and FY 2016, resulting from all changes reflected in this final rule for FY 2016. It includes combined effects of the previous columns in the table.

The average increase in payments under the IPPS for all hospitals is approximately 0.4 percent for FY 2016 relative to FY 2015. As discussed in section II.D. of the preamble of this final rule, this column includes the FY 2016 documentation and coding recoupment adjustment of -0.8 percent on the national standardized amount as part of the recoupment required under section 631 of the ATRA. In addition, this column includes the annual hospital update of 1.7 percent to the national standardized amount. This annual hospital update includes the 2.4 percent market basket update, the reduction of 0.5 percentage point for the multifactor productivity adjustment, and the 0.2 percentage point reduction under section 3401 of the Affordable Care Act. Hospitals paid under the hospital-specific rate will receive a 1.7 percent hospital update described above. As described in Column 1, the annual hospital update with the documentation and coding recoupment adjustment for hospitals paid under the national standardized amount combined with the annual hospital update for hospitals paid under the hospital-specific
rate will result in a 0.9 percent increase in payments in FY 2016 relative to FY 2015. The impact of moving from our estimate of FY 2015 outlier payments, 4.6 percent, to the estimate of FY 2016 outlier payments, 5.1 percent, will result in an increase of 0.4 percent in FY 2016 payments relative to FY 2015. There also might be interactive effects among the various factors comprising the payment system that we are not able to isolate. For these reasons, the values in Column 8 may not equal the sum of the estimated percentage changes described above.

Overall payments to hospitals paid under the IPPS due to the applicable percentage increase and changes to policies related to MS-DRGs, geographic adjustments, and outliers are estimated to increase by 0.4 percent for FY 2016. Hospitals in urban areas will experience a 0.4 percent increase in payments per discharge in FY 2016 compared to FY 2015. Hospital payments per discharge in rural areas are estimated to increase by 0.2 percent in FY 2016.

3. Impact Analysis of Table II

Table II presents the projected impact of the changes for FY 2016 for urban and rural hospitals and for the different categories of hospitals shown in Table I. It compares the estimated average payments per discharge for FY 2015 with the estimated average payments per discharge for FY 2016, as calculated under our models. Therefore, this table presents, in terms of the average dollar amounts paid per discharge, the combined effects of the changes presented in Table I. The estimated percentage changes shown in the last column of Table II equal the estimated percentage changes in average payments per discharge from Column 8 of Table I.
TABLE II.--IMPACT ANALYSIS OF CHANGES FOR FY 2016 ACUTE CARE HOSPITAL OPERATING PROSPECTIVE PAYMENT SYSTEM (PAYMENTS PER DISCHARGE)

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2015 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2016 Payment Per Discharge (3)</th>
<th>FY 2016 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Hospitals</td>
<td>3,369</td>
<td>11,329</td>
<td>11,370</td>
<td>0.4</td>
</tr>
<tr>
<td>By Geographic Location:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,533</td>
<td>11,680</td>
<td>11,724</td>
<td>0.4</td>
</tr>
<tr>
<td>Large urban areas</td>
<td>1,393</td>
<td>12,434</td>
<td>12,482</td>
<td>0.4</td>
</tr>
<tr>
<td>Other urban areas</td>
<td>1,140</td>
<td>10,766</td>
<td>10,804</td>
<td>0.4</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>836</td>
<td>8,424</td>
<td>8,441</td>
<td>0.2</td>
</tr>
<tr>
<td>Bed Size (Urban):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-99 beds</td>
<td>668</td>
<td>9,254</td>
<td>9,273</td>
<td>0.2</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>778</td>
<td>9,863</td>
<td>9,900</td>
<td>0.4</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>445</td>
<td>10,589</td>
<td>10,633</td>
<td>0.4</td>
</tr>
<tr>
<td>300-499 beds</td>
<td>428</td>
<td>11,927</td>
<td>11,972</td>
<td>0.4</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>214</td>
<td>14,285</td>
<td>14,340</td>
<td>0.4</td>
</tr>
<tr>
<td>Bed Size (Rural):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-49 beds</td>
<td>329</td>
<td>7,048</td>
<td>7,043</td>
<td>-0.1</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>297</td>
<td>7,972</td>
<td>7,988</td>
<td>0.2</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>121</td>
<td>8,290</td>
<td>8,325</td>
<td>0.4</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>48</td>
<td>9,109</td>
<td>9,132</td>
<td>0.3</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>41</td>
<td>9,996</td>
<td>10,004</td>
<td>0.1</td>
</tr>
<tr>
<td>Urban by Region:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>120</td>
<td>12,850</td>
<td>12,836</td>
<td>-0.1</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>318</td>
<td>13,156</td>
<td>13,282</td>
<td>1</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>407</td>
<td>10,387</td>
<td>10,410</td>
<td>0.2</td>
</tr>
<tr>
<td>East North Central</td>
<td>396</td>
<td>10,950</td>
<td>11,009</td>
<td>0.5</td>
</tr>
<tr>
<td>East South Central</td>
<td>150</td>
<td>9,998</td>
<td>9,958</td>
<td>-0.4</td>
</tr>
<tr>
<td>West North Central</td>
<td>166</td>
<td>11,438</td>
<td>11,470</td>
<td>0.3</td>
</tr>
<tr>
<td>West South Central</td>
<td>384</td>
<td>10,590</td>
<td>10,548</td>
<td>-0.4</td>
</tr>
<tr>
<td>Mountain</td>
<td>161</td>
<td>12,013</td>
<td>12,036</td>
<td>0.2</td>
</tr>
<tr>
<td>Pacific</td>
<td>380</td>
<td>14,889</td>
<td>15,035</td>
<td>1</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>7,648</td>
<td>7,469</td>
<td>-2.4</td>
</tr>
<tr>
<td>Rural by Region:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>22</td>
<td>11,441</td>
<td>11,429</td>
<td>-0.1</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>55</td>
<td>8,545</td>
<td>8,565</td>
<td>0.2</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>128</td>
<td>7,868</td>
<td>7,916</td>
<td>0.6</td>
</tr>
<tr>
<td>East North Central</td>
<td>116</td>
<td>8,775</td>
<td>8,852</td>
<td>0.9</td>
</tr>
<tr>
<td>East South Central</td>
<td>164</td>
<td>7,524</td>
<td>7,449</td>
<td>-1</td>
</tr>
<tr>
<td>Region</td>
<td>Number of Hospitals (1)</td>
<td>Estimated Average FY 2015 Payment Per Discharge (2)</td>
<td>Estimated Average FY 2016 Payment Per Discharge (3)</td>
<td>FY 2016 Changes (4)</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------------------</td>
<td>-----------------------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>West North Central</td>
<td>101</td>
<td>9,280</td>
<td>9,350</td>
<td>0.8</td>
</tr>
<tr>
<td>West South Central</td>
<td>165</td>
<td>7,218</td>
<td>7,160</td>
<td>-0.8</td>
</tr>
<tr>
<td>Mountain</td>
<td>61</td>
<td>9,730</td>
<td>9,796</td>
<td>0.7</td>
</tr>
<tr>
<td>Pacific</td>
<td>24</td>
<td>11,500</td>
<td>11,671</td>
<td>1.5</td>
</tr>
<tr>
<td>By Payment Classification:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,476</td>
<td>11,700</td>
<td>11,743</td>
<td>0.4</td>
</tr>
<tr>
<td>Large urban areas</td>
<td>1,386</td>
<td>12,440</td>
<td>12,488</td>
<td>0.4</td>
</tr>
<tr>
<td>Other urban areas</td>
<td>1,090</td>
<td>10,771</td>
<td>10,809</td>
<td>0.4</td>
</tr>
<tr>
<td>Rural areas</td>
<td>893</td>
<td>8,687</td>
<td>8,709</td>
<td>0.3</td>
</tr>
<tr>
<td>Teaching Status:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonteaching</td>
<td>2,326</td>
<td>9,450</td>
<td>9,479</td>
<td>0.3</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>794</td>
<td>10,999</td>
<td>11,041</td>
<td>0.4</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>249</td>
<td>16,424</td>
<td>16,493</td>
<td>0.4</td>
</tr>
<tr>
<td>Urban DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-DSH</td>
<td>653</td>
<td>9,946</td>
<td>10,052</td>
<td>1.1</td>
</tr>
<tr>
<td>100 or more beds</td>
<td>1,593</td>
<td>12,080</td>
<td>12,114</td>
<td>0.3</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>328</td>
<td>8,526</td>
<td>8,546</td>
<td>0.2</td>
</tr>
<tr>
<td>Rural DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCH</td>
<td>260</td>
<td>8,859</td>
<td>8,917</td>
<td>0.7</td>
</tr>
<tr>
<td>RRC</td>
<td>347</td>
<td>9,023</td>
<td>9,055</td>
<td>0.4</td>
</tr>
<tr>
<td>100 or more beds</td>
<td>31</td>
<td>7,544</td>
<td>7,479</td>
<td>-0.9</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>157</td>
<td>6,774</td>
<td>6,696</td>
<td>-1.2</td>
</tr>
<tr>
<td>Urban teaching and DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both teaching and DSH</td>
<td>855</td>
<td>13,217</td>
<td>13,261</td>
<td>0.3</td>
</tr>
<tr>
<td>Teaching and no DSH</td>
<td>122</td>
<td>11,161</td>
<td>11,300</td>
<td>1.3</td>
</tr>
<tr>
<td>No teaching and DSH</td>
<td>1,066</td>
<td>9,878</td>
<td>9,894</td>
<td>0.2</td>
</tr>
<tr>
<td>No teaching and no DSH</td>
<td>433</td>
<td>9,415</td>
<td>9,511</td>
<td>1</td>
</tr>
<tr>
<td>Special Hospital Types:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RRC</td>
<td>189</td>
<td>9,449</td>
<td>9,408</td>
<td>-0.4</td>
</tr>
<tr>
<td>SCH</td>
<td>327</td>
<td>9,951</td>
<td>10,034</td>
<td>0.8</td>
</tr>
<tr>
<td>MDH</td>
<td>150</td>
<td>6,968</td>
<td>7,010</td>
<td>0.6</td>
</tr>
<tr>
<td>SCH and RRC</td>
<td>126</td>
<td>10,591</td>
<td>10,691</td>
<td>0.9</td>
</tr>
<tr>
<td>MDH and RRC</td>
<td>13</td>
<td>8,621</td>
<td>8,669</td>
<td>0.6</td>
</tr>
<tr>
<td>Type of Ownership:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td>1,934</td>
<td>11,498</td>
<td>11,559</td>
<td>0.5</td>
</tr>
<tr>
<td>Proprietary</td>
<td>879</td>
<td>9,997</td>
<td>9,984</td>
<td>-0.1</td>
</tr>
<tr>
<td>Government</td>
<td>529</td>
<td>12,240</td>
<td>12,243</td>
<td>0</td>
</tr>
<tr>
<td>Medicare Utilization as a Percent of Inpatient Days:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Number of Hospitals

<table>
<thead>
<tr>
<th>Number of Hospitals</th>
<th>Estimated Average FY 2015 Payment Per Discharge</th>
<th>Estimated Average FY 2016 Payment Per Discharge</th>
<th>FY 2016 Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-25</td>
<td>533</td>
<td>14,719</td>
<td>14,625</td>
</tr>
<tr>
<td>25-50</td>
<td>2,134</td>
<td>11,265</td>
<td>11,321</td>
</tr>
<tr>
<td>50-65</td>
<td>571</td>
<td>9,180</td>
<td>9,249</td>
</tr>
<tr>
<td>Over 65</td>
<td>97</td>
<td>6,883</td>
<td>6,909</td>
</tr>
<tr>
<td>FY 2016 Reclassifications by the Medicare Geographic Classification Review Board:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Reclassified Hospitals</td>
<td>830</td>
<td>11,288</td>
<td>11,370</td>
</tr>
<tr>
<td>Non-Reclassified Hospitals</td>
<td>2,539</td>
<td>11,346</td>
<td>11,370</td>
</tr>
<tr>
<td>Urban Hospitals Reclassified</td>
<td>551</td>
<td>11,925</td>
<td>12,020</td>
</tr>
<tr>
<td>Urban Nonreclassified Hospitals</td>
<td>1,925</td>
<td>11,620</td>
<td>11,646</td>
</tr>
<tr>
<td>Rural Hospitals Reclassified Full Year</td>
<td>279</td>
<td>8,836</td>
<td>8,870</td>
</tr>
<tr>
<td>Rural Nonreclassified Hospitals Full Year</td>
<td>504</td>
<td>7,926</td>
<td>7,924</td>
</tr>
<tr>
<td>All Section 401 Reclassified Hospitals:</td>
<td>64</td>
<td>10,427</td>
<td>10,492</td>
</tr>
<tr>
<td>Other Reclassified Hospitals (Section 1886(d)(8)(B))</td>
<td>53</td>
<td>7,855</td>
<td>7,830</td>
</tr>
<tr>
<td>Specialty Hospitals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac specialty Hospitals</td>
<td>14</td>
<td>12,640</td>
<td>12,723</td>
</tr>
</tbody>
</table>

**H. Effects of Other Policy Changes**

In addition to those policy changes discussed above that we are able to model using our IPPS payment simulation model, we are making various other changes in this final rule. Generally, we have limited or no specific data available with which to estimate the impacts of these changes. Our estimates of the likely impacts associated with these other changes are discussed below.
1. Effects of Policy on MS-DRGs for Preventable HACs, Including Infections

In section II.F. of the preamble of this final rule, we discuss our implementation of section 1886(d)(4)(D) of the Act, which requires the Secretary to identify conditions that are: (1) high cost, high volume, or both; (2) result in the assignment of a case to an MS-DRG that has a higher payment when present as a secondary diagnosis; and (3) could reasonably have been prevented through application of evidence-based guidelines. For discharges occurring on or after October 1, 2008, hospitals will not receive additional payment for cases in which one of the selected conditions was not present on admission, unless, based on data and clinical judgment, it cannot be determined at the time of admission whether a condition is present. That is, the case will be paid as though the secondary diagnosis were not present. However, the statute also requires the Secretary to continue counting the condition as a secondary diagnosis that results in a higher IPPS payment when doing the budget neutrality calculations for MS-DRG recategorizations and recalibration. Therefore, we will perform our budget neutrality calculations as though the payment provision did not apply, but Medicare will make a lower payment to the hospital for the specific case that includes the secondary diagnosis. Thus, the provision results in cost savings to the Medicare program.

We note that the provision will only apply when one or more of the selected conditions are the only secondary diagnosis or diagnoses present on the claim that will lead to higher payment. Medicare beneficiaries will generally have multiple secondary diagnoses during a hospital stay, such that beneficiaries having one MCC or CC will frequently have additional conditions that also will generate higher payment. Only a
small percentage of the cases will have only one secondary diagnosis that would lead to a higher payment. Therefore, if at least one nonselected secondary diagnosis that leads to higher payment is on the claim, the case will continue to be assigned to the higher paying MS-DRG and there will be no Medicare savings from that case. In addition, as discussed in section II.F.3. of the preamble of this final rule, it is possible to have two severity levels where the HAC does not affect the MS-DRG assignment or for an MS-DRG not to have severity levels. In either of these circumstances, the case will continue to be assigned to the higher paying MS-DRG and there will be no Medicare savings from that case.

As discussed in section II.F. of the preamble of this final rule, for FY 2016, we are not adding or removing any categories of HACs for FY 2016.

The HAC payment provision went into effect on October 1, 2008. Our savings estimates for the next 5 fiscal years are shown below:

<table>
<thead>
<tr>
<th>Year</th>
<th>Savings (in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2016</td>
<td>$28</td>
</tr>
<tr>
<td>FY 2017</td>
<td>$29</td>
</tr>
<tr>
<td>FY 2018</td>
<td>$31</td>
</tr>
<tr>
<td>FY 2019</td>
<td>$32</td>
</tr>
<tr>
<td>FY 2020</td>
<td>$34</td>
</tr>
</tbody>
</table>

2. Effects of Policy Relating to New Medical Service and Technology Add-On Payments

In section II.I. of the preamble to this final rule, we discuss six applications (Blinatumomab (BLINCYTO™), DIAMONDBACK® 360 Coronary Orbital Atherectomy System, CRESEMBA® (Isavuconazonium), LUTONIX® Drug Coated
Balloon (DCB) Percutaneous Transluminal Angioplasty (PTA) and IN.PACT™ Admira™ Paclixel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, VERASENSE™ Knee Balancer System (VKS), and WATCHMAN® Left Atrial Appendage Closure Technology) for add-on payments for new medical services and technologies for FY 2016, as well as the status of the new technologies that were approved to receive new technology add-on payments in FY 2015. We note that two of the applications (the Angel Medical Guardian® Ischemia Monitoring Device and Ceftazidime Avibactam (AVYCAZ)) discussed in the proposed rule withdrew their applications prior to the publication of this final rule. In addition, Idarucizumab did not receive FDA approval by July 1, 2015 in accordance with the regulations under § 412.87(c) and, therefore, is ineligible for consideration for new technology add-on payments for FY 2016.

As explained in the preamble to this final rule, add-on payments for new medical services and technologies under section 1886(d)(5)(K) of the Act are not required to be budget neutral. As discussed in section II.I.4. of the preamble of this final rule, we are approving two of the six applications (BLINCYTO™ and LUTONIX® DCB PTA and IN.PACT™ Admira™ Paclixel Coated PTA Balloon Catheter) for new technology add-on payments for FY 2016. As we proposed, in this final rule, we also are continuing to make new technology add-on payments in FY 2016 for Kcentra™, Argus® II Retinal Prosthesis System, the CardioMEMS™ HF (Heart Failure) Monitoring System, MitraClip® System, and the Responsive Neurostimulator (RNS®) System (because all of these technologies are still within the 3-year anniversary of the product’s entry onto the
market). We note that new technology add-on payments per case are limited to the lesser of: (1) 50 percent of the costs of the new technology; or (2) 50 percent of the amount by which the costs of the case exceed the standard MS-DRG payment for the case. Because it is difficult to predict the actual new technology add-on payment for each case, our estimates below are based on the increase in add-on payments for FY 2016 as if every claim that would qualify for a new technology add-on payment would receive the maximum add-on payment. Based on the applicant’s estimate for FY 2014, we currently estimate that new technology add-on payments for Kcentra™ will increase overall FY 2016 payments by $5,449,888. Based on the applicant’s estimate for FY 2014, we currently estimate that new technology add-on payments for the Argus® II Retinal Prosthesis System will increase overall FY 2016 payments by $3,601,437. Based on the applicant’s estimate for FY 2015, we currently estimate that new technology add-on payments for the CardioMEMSTM HF Monitoring System will increase overall FY 2016 payments by $11,315,625. Based on the applicant’s estimate for FY 2015, we currently estimate that new technology add-on payments for the MitraClip® System will increase overall FY 2016 payments by $27,000,000. Based on the applicant’s estimate for FY 2015, we currently estimate that new technology add-on payments for the RNS® System will increase overall FY 2015 payments by $12,932,500. Based on the applicant’s estimate for FY 2016, we currently estimate that new technology add-on payments for BLINCYTO™ will increase overall FY 2016 payments by $4,593,034 (maximum add-on payment of $27,017.85 * 170 patients). Based on the weighted cost average for FY 2016 described in section II.I.4. of the preamble to this final rule, we
currently estimate that new technology add-on payments for LUTONIX® DCB PTA and IN.PACT™Admiral™ Paclixel Coated PTA Balloon Catheter will increase overall FY 2016 payments by $36,120,735 (maximum add-on payment of $1,035.72 * 8,875 patients for LUTONIX® DCB PTA Balloon Catheter; maximum add-on payment of $1,035.72 * 26,000 patients for IN.PACT™Admiral™ Paclixel Coated PTA Balloon Catheter).

3. Effects of the Changes to Medicare DSH Payments for FY 2016

As discussed in section IV.D. of the preamble of this final rule, under section 3133 of the Affordable Care Act, hospitals that are eligible to receive Medicare DSH payments will receive 25 percent of the amount they previously would have received under the former statutory formula for Medicare DSH payments. The remainder, equal to an estimate of 75 percent of what formerly would have been paid as Medicare DSH payments (Factor 1), reduced to reflect changes in the percentage of individuals under age 65 who are uninsured and additional statutory adjustments (Factor 2), is available to make additional payments to each hospital that qualifies for Medicare DSH payments and that has uncompensated care. Each Medicare DSH hospital will receive an additional payment based on its estimated share of the total amount of uncompensated care for all Medicare DSH hospitals. The uncompensated care payment methodology has redistributive effects based on the proportion of a Medicare DSH hospital’s low-income insured patient days (sum of Medicaid patient days and Medicare SSI patient days) relative to the low-income insured patient days for all Medicare DSH hospitals (Factor 3).
The reduction to Medicare DSH payments under section 3133 of the Affordable Care Act is not budget neutral.

In this FY 2016 IPPS/LTCH PPS final rule, we are establishing the amount to be distributed as uncompensated care payments to DSH eligible hospitals, which for FY 2016 is $6,406,145,534.04, or 75 percent of what otherwise would have been paid for Medicare DSH payment adjustments adjusted by a Factor 2 of 63.69 percent; for FY 2015, the amount available to be distributed for uncompensated care was $7,647,644,885.18, or 75 percent of what otherwise would have been paid for Medicare DSH payment adjustments adjusted by a Factor 2 of 76.19 percent. To calculate Factor 3 for FY 2016, we are using Medicaid days from the more recent of hospitals’ full year 2012 or full year 2011 cost reports from the March 2015 update of the HCRIS database (that is, we are holding constant the 2012 and 2011 cost report years used in the FY 2015 IPPS/LTCH PPS final rule, but using updated cost report data from a later extract of the HCRIS), Medicaid days from 2012 cost report data submitted to CMS by IHS hospitals, and SSI days from the 2013 SSI ratios. This is in contrast to FY 2015, when we used Medicaid days from the hospitals’ full year 2012 or 2011 cost reports from the March 2014 update of the HCRIS database, Medicaid days from 2012 cost report data submitted to CMS by IHS hospitals, and SSI days from the 2012 SSI ratios to calculate Factor 3.

The uncompensated care payment methodology is discussed in more detail in section IV.D. of the preamble of this final rule.

To estimate the impact of the combined effect of reductions in the percent of individuals under age 65 who are uninsured and additional statutory adjustments
(Factor 2) and changes in Medicaid and SSI patient days (components of Factor 3) on the calculation of Medicare DSH payments, including both empirically justified Medicare DSH payments and uncompensated care payments, we compared total DSH payments estimated in the FY 2015 IPPS/LTCH PPS final rule and correction notice to total DSH payments estimated in this FY 2016 IPPS/LTCH PPS final rule. For FY 2015, for each hospital, we calculated the sum of (I) 25 percent of the estimated amount of what would have been paid as Medicare DSH in FY 2015 in the absence of section 3133 of the Affordable Care Act and (II) 75 percent of the estimated amount of what would have been paid as Medicare DSH payments in the absence of section 3133, adjusted by a Factor 2 of 76.19 percent and multiplied by a Factor 3 as stated in the FY 2015 IPPS/LTCH PPS final rule and correction notice. For FY 2016, we calculated the sum of (I) 25 percent of the estimated amount of what would be paid as Medicare DSH payments in FY 2016 absent section 3133 and (II) 75 percent of the estimated amount of what would have been paid as Medicare DSH payments absent section 3133, adjusted by a Factor 2 of 63.69 percent and multiplied by a Factor 3 as stated above.

Our analysis included 2,418 hospitals that are projected to be eligible for DSH in FY 2016. It did not include hospitals in the Rural Community Hospital Demonstration, hospitals that departed the Medicare program as of July 7, 2015, Maryland hospitals, and SCHs that are expected to be paid based on their hospital-specific rates. In addition, low-income insured days from merged or acquired hospitals were combined into the surviving hospital’s CCN, and the nonsurviving CCN was excluded from the analysis.
The estimated impact of changes in Factors 1, 2, and 3 across all FY 2016 DSH eligible hospitals, by hospital characteristic, is presented in the table below.

| Modeled Disproportionate Share Hospital Payments for Estimated FY2016 DSH Hospitals by Hospital Type: Model DSH $ (in millions) from FY 2015 to FY 2016 |
|---|---|---|---|
| | (1) | (2) | (3) | (4) |
| Number of Estimated FY 2016 DSH Hospitals | FY 2015 Estimated DSH $* | FY 2016 Estimated DSH $* | Percentage Change ** |
| Total | 2,418 | $10,993 | $9,733 | -11.5% |
| By Geographic Location | | | | |
| Urban Hospitals | | | | |
| Large Urban Areas | 1,892 | $10,453 | $9,260 | -11.4% |
| Other Urban Areas | 1,024 | $6,629 | $5,858 | -11.6% |
| Rural Hospitals | 868 | $3,823 | $3,402 | -11.0% |
| Bed Size (Urban) | | | | |
| 0 to 99 Beds | 327 | $211 | $186 | -11.8% |
| 100 to 249 Beds | 827 | $2,514 | $2,196 | -12.6% |
| 250 to 499 Beds | 738 | $7,728 | $6,878 | -11.0% |
| Bed Size (Rural) | | | | |
| 0 to 99 Beds | 392 | $235 | $206 | -12.1% |
| 100 to 249 Beds | 120 | $246 | $211 | -14.5% |
| 250 to 499 Beds | 14 | $59 | $56 | -5.6% |
| Urban by Region | | | | |
| East North Central | 308 | $1,421 | $1,268 | -10.8% |
| East South Central | 131 | $649 | $575 | -11.4% |
| Middle Atlantic | 231 | $1,804 | $1,603 | -11.1% |
| Mountain | 115 | $504 | $447 | -11.3% |
| New England | 86 | $440 | $388 | -11.9% |
| Pacific | 298 | $1,649 | $1,454 | -11.8% |
| Puerto Rico | 39 | $108 | $100 | -8.1% |
| South Atlantic | 318 | $2,012 | $1,772 | -11.9% |
| West North | 105 | $507 | $455 | -10.1% |
Modelf Disproportionate Share Hospital Payments for Estimated FY2016 DSH Hospitals by Hospital Type: Model DSH $ (in millions) from FY 2015 to FY 2016

<table>
<thead>
<tr>
<th>Number of Estimated FY 2016 DSH Hospitals</th>
<th>FY 2015 Estimated DSH $*</th>
<th>FY 2016 Estimated DSH $*</th>
<th>Percentage Change **</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>West South Central</td>
<td>261</td>
<td>$1,357</td>
<td>$1,197</td>
</tr>
<tr>
<td>Rural by Region</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>East North Central</td>
<td>67</td>
<td>$55</td>
<td>$49</td>
</tr>
<tr>
<td>East South Central</td>
<td>147</td>
<td>$174</td>
<td>$149</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>27</td>
<td>$40</td>
<td>$34</td>
</tr>
<tr>
<td>Mountain</td>
<td>22</td>
<td>$18</td>
<td>$16</td>
</tr>
<tr>
<td>New England</td>
<td>10</td>
<td>$17</td>
<td>$15</td>
</tr>
<tr>
<td>Pacific</td>
<td>10</td>
<td>$6</td>
<td>$8</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>88</td>
<td>$107</td>
<td>$96</td>
</tr>
<tr>
<td>West North Central</td>
<td>38</td>
<td>$27</td>
<td>$21</td>
</tr>
<tr>
<td>West South Central</td>
<td>117</td>
<td>$97</td>
<td>$84</td>
</tr>
<tr>
<td>By Payment Classification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban Hospitals</td>
<td>1,860</td>
<td>$10,448</td>
<td>$9,205</td>
</tr>
<tr>
<td>Large Urban Areas</td>
<td>1,021</td>
<td>$6,640</td>
<td>$5,856</td>
</tr>
<tr>
<td>Other Urban Areas</td>
<td>839</td>
<td>$3,809</td>
<td>$3,349</td>
</tr>
<tr>
<td>Rural Hospitals</td>
<td>558</td>
<td>$545</td>
<td>$527</td>
</tr>
<tr>
<td>Teaching Status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonteaching</td>
<td>1,548</td>
<td>$3,578</td>
<td>$3,106</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>630</td>
<td>$3,585</td>
<td>$3,194</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>240</td>
<td>$3,831</td>
<td>$3,432</td>
</tr>
<tr>
<td>Type of Ownership</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Modeled Disproportionate Share Hospital Payments for Estimated FY2016 DSH Hospitals by Hospital Type: Model DSH $ (in millions) from FY 2015 to FY 2016

<table>
<thead>
<tr>
<th>(1) Number of Estimated FY 2016 DSH Hospitals</th>
<th>(2) FY 2015 Estimated DSH $*</th>
<th>(3) FY 2016 Estimated DSH $*</th>
<th>(4) Percentage Change **</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voluntary</td>
<td>1,388</td>
<td>$6,770</td>
<td>$6,028</td>
</tr>
<tr>
<td>Proprietary</td>
<td>541</td>
<td>$1,904</td>
<td>$1,661</td>
</tr>
<tr>
<td>Government</td>
<td>487</td>
<td>$2,290</td>
<td>$2,017</td>
</tr>
<tr>
<td>Unknown</td>
<td>2</td>
<td>$30</td>
<td>$27</td>
</tr>
</tbody>
</table>

* Dollar DSH calculated by \[0.25 \times \text{estimated section 1886(d)(5)(F) payments} \times \{0.75 \times \text{estimated section 1886(d)(5)(F) payments} \times \text{Factor 2} \times \text{Factor 3}\]. When summed across all hospitals projected to receive DSH payments, the Model DSH is $10,993 million in FY 2015 and $9,733 million in FY 2016.

** Percentage change is determined as the difference between Medicare DSH payments modeled for the FY 2016 IPPS/LTCH PPS final rule (column 3) and Medicare DSH payments modeled for the FY 2015 IPPS/LTCH PPS final rule (column 2) divided by Medicare DSH payments modeled for the FY 2015 final rule (column 3) times 100 percent.

The impact analysis found that changes from the FY 2015 IPPS/LTCH PPS final rule were primarily driven by three components: (1) a reduction in Factor 2 from 76.19 percent in the FY 2015 IPPS/LTCH PPS final rule to 63.69 percent in this FY 2016 IPPS/LTCH PPS final rule, (2) changes in the number of Medicaid days for 2012 (or 2011) obtained from the March 2014 HCRIS update of providers’ Medicare cost report (used in the FY 2015 IPPS/LTCH PPS final rule) to the number of Medicaid days reported in the March 2015 HCRIS update of providers’ Medicare cost report (used in this FY 2016 final rule); and (3) changes in SSI days from 2012 (used in the FY 2015 IPPS/LTCH PPS final rule and correction notice) to 2013 (used in this FY 2016 IPPS/LTCH PPS final rule).

The change in the percentage of individuals who are uninsured is a national estimate...
affecting all hospitals equally, while the change in Medicaid days and SSI days is hospital-specific and drives the change in the Factor 3 computed for each hospital. Additionally, we note that several hospitals had a change in at least one of their payment or geographic characteristics from FY 2015 to FY 2016. Therefore, the number of hospitals within a given hospital characteristic may have changed from the FY 2015 final rule and correction notice. These changes also impact the distribution of Medicare DSH payments.

The impact analysis table above shows that across all DSH-eligible hospitals, FY 2016 DSH payments, including both empirically justified DSH payments and uncompensated care payments, are estimated at approximately $9.733 billion, or a decrease of approximately 11.5 percent from FY 2015 DSH payments ($10.993 billion). As a result, we project that payments for FY 2016 to hospitals paid under the IPPS will be reduced by 1.0 percent overall as compared to overall payments to hospitals paid under the IPPS in FY 2015.

Percent reductions greater than 11.5 percent in column 4 of the table above indicate that hospitals within the specified category are projected to experience a greater reduction in DSH payments, on average, relative to all of the FY 2016 DSH hospitals included in this analysis. Likewise, reductions less than 11.5 percent indicate that hospitals within each category, on average, are projected to receive a smaller reduction in DSH payments relative to all FY 2016 DSH hospitals. The variation in DSH payment reductions by hospital characteristic, as shown in column 4, is largely dependent on the change in a given hospital’s number of SSI and Medicaid days, as well as variations in
hospital characteristics or classification between FY 2015 and FY 2016 and the number of DSH-eligible hospitals. On average across all hospitals, the number of SSI days increased by 0.026 percent from FY 2015. On average across all hospitals, the number of Medicaid days increased by 0.621 percent from FY 2015. In conjunction with this FY 2016 IPPS/LTCH PPS final rule, we will publish an impact table as well as a supplemental data file that can be used to further analyze the distribution of DSH payments and variation in DSH payment reductions.

4. Effects of Reduction under the Hospital Readmissions Reduction Program

In section IV.E. of the preamble of this final rule, we discuss our policies for FY 2016 for the Hospital Readmissions Reduction Program (established under section 3025 of the Affordable Care Act), which requires a reduction to a hospital’s base operating DRG payments to account for excess readmissions. For FY 2016, the reduction is based on a hospital’s risk-adjusted readmission rate during a 3-year period for five applicable conditions: acute myocardial infarction, heart failure, pneumonia, total hip and total knee arthroplasty and chronic obstructive pulmonary disease. This provision is not budget neutral. A hospital’s readmission adjustment is the higher of a ratio of the hospital’s aggregate payments for excess readmissions to their aggregate payments for all discharges, or a floor, which has been defined in the statute as 0.97 (or a 3.0 percent reduction). A hospital’s base operating DRG payment (that is, wage-adjusted DRG payment amount, as discussed in section IV.E. of the preamble of this final rule) is the portion of the IPPS payment subject to the readmissions payment adjustment (DSH, IME, outliers and low-volume add-on payments are not subject to the readmissions
adjustment). In this final rule, we estimate that 2,666 hospitals will have their base operating DRG payments reduced by their proxy FY 2016 hospital-specific readmissions adjustment. As a result, we estimate that the Hospital Readmissions Reduction Program will save approximately $420 million in FY 2016, an increase of $6 million over the estimated FY 2015 savings.

5. Effects of Changes under the FY 2016 Hospital Value-Based Purchasing (VBP) Program

In section IV.F. of the preamble of this final rule, we discuss the Hospital VBP Program under which the Secretary makes value-based incentive payments to hospitals based on their performance on measures during the performance period with respect to a fiscal year. These incentive payments will be funded for FY 2016 through a reduction to the FY 2016 base operating DRG payment for each discharge of 1.75 percent, as required by section 1886(o)(7)(B) of the Act. The applicable percentage for FY 2017 and subsequent years is 2 percent. The total amount available for value-based incentive payments must be equal to the total amount of reduced payments for all hospitals for the fiscal year, as estimated by the Secretary.

We estimate the available pool of funds for value-based incentive payments in the FY 2016 program year, which, in accordance with section 1886(o)(7)(C)(iv) of the Act, will be 1.75 percent of base operating DRG payments, or a total of approximately $1.50 billion. This estimated available pool for FY 2016 is based on the historical pool of hospitals that were eligible to participate in the FY 2015 program year and the payment information from the March 2015 update to the FY 2014 MedPAR file.
The estimated impacts of the FY 2016 program year by hospital characteristic, found in the table below, are based on historical TPSs. We used the FY 2015 program year’s TPSs to calculate the proxy adjustment factors used for this impact analysis. These are the most recently available scores that hospitals were given an opportunity to review and correct. The proxy adjustment factors use estimated annual base operating DRG payment amounts derived from the March 2015 update to the FY 2014 MedPAR file. The proxy adjustment factors can be found in Table 16A associated with this final rule (available via the Internet on the CMS Web site).

The impact analysis shows that, for the FY 2016 program year, the number of hospitals that will receive an increase in base operating DRG payment amount is higher than the number of hospitals that will receive a decrease. Among urban hospitals, those in the New England, South Atlantic, East North Central, East South Central, West North Central, West South Central, Mountain, and Pacific regions will have an increase, on average, in the base operating DRG payment amount. Urban hospitals in the Middle Atlantic region will receive an average decrease in the base operating payment amount. Among rural hospitals, those in all regions will have an increase, on average, in base operating DRG payment amounts.

On average, hospitals that receive a higher percent of DSH payments will receive decreases in the base operating DRG payment amount. With respect to hospitals’ Medicare utilization (MCR), those hospitals with an MCR above 65 percent will have the largest increase, on average, in base operating DRG payment amounts.
Nonteaching hospitals will have an average increase, and teaching hospitals will experience an average decrease, in the base operating DRG payment amount.
## Impact Analysis of Base Operating DRG Payment Amount Changes Resulting from the FY 2016 Hospital VBP Program

### BY GEOGRAPHIC LOCATION:

<table>
<thead>
<tr>
<th>Location</th>
<th>Number of Hospitals</th>
<th>Average Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Hospitals</td>
<td>3,089</td>
<td>0.132%</td>
</tr>
<tr>
<td>Large Urban</td>
<td>1,263</td>
<td>0.046%</td>
</tr>
<tr>
<td>Other Urban</td>
<td>1,066</td>
<td>0.137%</td>
</tr>
<tr>
<td>Rural Area</td>
<td>760</td>
<td>0.269%</td>
</tr>
</tbody>
</table>

### Urban hospitals

<table>
<thead>
<tr>
<th>Number of Beds</th>
<th>Number of Hospitals</th>
<th>Average Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-99 beds</td>
<td>524</td>
<td>0.492%</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>735</td>
<td>0.028%</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>437</td>
<td>-0.054%</td>
</tr>
<tr>
<td>300-499 beds</td>
<td>422</td>
<td>-0.079%</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>211</td>
<td>-0.082%</td>
</tr>
</tbody>
</table>

### Rural hospitals

<table>
<thead>
<tr>
<th>Number of Beds</th>
<th>Number of Hospitals</th>
<th>Average Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-49 beds</td>
<td>258</td>
<td>0.445%</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>298</td>
<td>0.251%</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>119</td>
<td>0.079%</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>46</td>
<td>0.035%</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>39</td>
<td>0.094%</td>
</tr>
</tbody>
</table>

### BY REGION:

#### Urban By Region

<table>
<thead>
<tr>
<th>Region</th>
<th>Number of Hospitals</th>
<th>Average Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>New England</td>
<td>116</td>
<td>0.045%</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>306</td>
<td>-0.058%</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>389</td>
<td>0.037%</td>
</tr>
<tr>
<td>East North Central</td>
<td>376</td>
<td>0.106%</td>
</tr>
<tr>
<td>East South Central</td>
<td>139</td>
<td>0.042%</td>
</tr>
<tr>
<td>West North Central</td>
<td>154</td>
<td>0.366%</td>
</tr>
<tr>
<td>West South Central</td>
<td>332</td>
<td>0.178%</td>
</tr>
<tr>
<td>Mountain</td>
<td>157</td>
<td>0.047%</td>
</tr>
<tr>
<td>Pacific</td>
<td>360</td>
<td>0.095%</td>
</tr>
</tbody>
</table>

#### Rural By Region

<table>
<thead>
<tr>
<th>Number of Hospitals</th>
<th>Average Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>760</td>
<td>0.269%</td>
</tr>
</tbody>
</table>
## Impact Analysis of Base Operating DRG Payment Amount Changes Resulting from the FY 2016 Hospital VBP Program

<table>
<thead>
<tr>
<th>Region</th>
<th>Number of Hospitals</th>
<th>Average Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>New England</td>
<td>20</td>
<td>0.384%</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>55</td>
<td>0.170%</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>123</td>
<td>0.330%</td>
</tr>
<tr>
<td>East North Central</td>
<td>114</td>
<td>0.280%</td>
</tr>
<tr>
<td>East South Central</td>
<td>135</td>
<td>0.269%</td>
</tr>
<tr>
<td>West North Central</td>
<td>93</td>
<td>0.333%</td>
</tr>
<tr>
<td>West South Central</td>
<td>140</td>
<td>0.161%</td>
</tr>
<tr>
<td>Mountain</td>
<td>56</td>
<td>0.346%</td>
</tr>
<tr>
<td>Pacific</td>
<td>24</td>
<td>0.228%</td>
</tr>
</tbody>
</table>

### By MCR Percent

<table>
<thead>
<tr>
<th>MCR Percent</th>
<th>Number of Hospitals</th>
<th>Average Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-25</td>
<td>583</td>
<td>0.110%</td>
</tr>
<tr>
<td>25-50</td>
<td>2,041</td>
<td>0.107%</td>
</tr>
<tr>
<td>50-65</td>
<td>322</td>
<td>0.204%</td>
</tr>
<tr>
<td>Over 65</td>
<td>72</td>
<td>0.323%</td>
</tr>
<tr>
<td>Missing</td>
<td>71</td>
<td>0.513%</td>
</tr>
</tbody>
</table>

### BY DSH Percent:

<table>
<thead>
<tr>
<th>DSH Percent</th>
<th>Number of Hospitals</th>
<th>Average Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-25</td>
<td>1,462</td>
<td>0.254%</td>
</tr>
<tr>
<td>25-50</td>
<td>1,336</td>
<td>0.054%</td>
</tr>
<tr>
<td>50-65</td>
<td>149</td>
<td>-0.107%</td>
</tr>
<tr>
<td>Over 65</td>
<td>142</td>
<td>-0.139%</td>
</tr>
</tbody>
</table>

### BY TEACHING STATUS:

<table>
<thead>
<tr>
<th>Teaching Status</th>
<th>Number of Hospitals</th>
<th>Average Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Teaching</td>
<td>2,077</td>
<td>0.208%</td>
</tr>
<tr>
<td>Teaching</td>
<td>1,012</td>
<td>-0.023%</td>
</tr>
</tbody>
</table>

Actual FY 2016 program year’s TPSs will not be reviewed and corrected by hospitals until after this FY 2016 IPPS/LTCH PPS final rule has been published.
Therefore, the same historical universe of eligible hospitals and corresponding TPSs from the FY 2015 program year are used for the updated impact analysis in this final rule.

6. Effects of Changes to the HAC Reduction Program for FY 2016

In section IV.G. of the preamble of this final rule, we discuss the changes to the HAC Reduction Program for FY 2016. We note that section 3008 of the Affordable Care Act added section 1886(p) to the Act to provide an incentive for certain hospitals to reduce the incidence of HACs. Section 1886(p) of the Act requires the Secretary to make an adjustment to payments to “applicable hospitals” effective beginning on October 1, 2014 and for subsequent program years. We refer readers to section V.I.1.a. of the FY 2014 IPPS/LTCH PPS final rule (78 FR 50707 through 50708) for a general overview of the HAC Reduction Program. For a further description of our policies for the HAC Reduction Program, we refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50707 through 50729) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50087 through 50104). These policies describe the general framework for implementation of the HAC Reduction Program including: (a) the relevant definitions applicable to the program; (b) the payment adjustment under the program; (c) the measure selection and conditions for the program, including a risk-adjustment and scoring methodology; (d) performance scoring; (e) the process for making hospital-specific performance information available to the public, including the opportunity for a hospital to review the information and submit corrections; and (f) limitation of administrative and judicial review. We are not making any changes to these policies for the implementation of the FY 2016 HAC Reduction Program.
We note that hospitals received a payment reduction for the first time in FY 2015. The table and analysis that we are presenting below are a simulation of the FY 2016 HAC Reduction Program using historical data. We note that, as described earlier in this final rule, because scores will undergo 30-day review and correction by the hospitals that will not conclude until after the publication of this final rule, we are not providing hospital-level data or a hospital-level payment impact in conjunction with this FY 2016 IPPS/LTCH PPS final rule.

For FY 2016, we note that we finalized a Total HAC Score methodology in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50087 through 50104) that assigns weights for Domain 1 and Domain 2 at 25 percent and 75 percent, respectively. The table below presents data on the estimated proportion of hospitals in the worst-performing quartile of the Total HAC Score by hospital characteristic, based on this methodology.

To estimate the impact of the FY 2016 HAC Reduction Program, we used AHRQ Patient Safety Indicator (PSI) 90 measure results based on Medicare fee-for-service (FFS) discharges from July 2012 through June 2014 and version 4.5a of the AHRQ software. For CDC Central Line-Associated Bloodstream Infection (CLABSI), Catheter-Associated Urinary Tract Infection (CAUTI), and Surgical Site Infection (SSI) measure results, we used standardized infection ratios (SIRs) calculated with hospital surveillance data reported to the National Healthcare Safety Network (NHSN) for infections occurring between January 1, 2013 and December 31, 2014. To analyze the results by hospital characteristic, we used the FY 2016 Proposed Rule Impact File. Of the 3,272 hospitals included in this analysis, 3,269 hospitals had information for geographic location, region, bed size, DSH percent, and teaching status; 3,256 had information for ownership; and 3,137 had information for MCR percent. These differences in the number of hospitals listed for
each characteristic are due to the source of the hospital characteristic data. Maryland hospitals and hospitals without a Total HAC score are not included in the identification of the worst-performing quartile for the HAC Reduction Program in FY 2016, and therefore are not represented in the table below. (For a discussion of the program’s applicability to Maryland hospitals, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50089.)

The third column in the table (Percent) indicates the percent of hospitals in each category of the specified characteristic. For example, within geographic location, 40.5 percent of hospitals (or 1,323 hospitals) are characterized as large urban, 33.9 percent of hospitals (or 1,109 hospitals) are characterized as other urban, and 25.6 percent of hospitals (or 837 hospitals) are characterized as rural. The fifth column in the table (Percent with characteristic) indicates the proportion of hospitals for each characteristic that we estimate will be in the worst-performing quartile of Total HAC Scores and will receive a payment reduction under the FY 2016 HAC Reduction Program. For example, with regards to geographic location, 27.4 percent of hospitals (or 362 hospitals) characterized as large urban will be subject to a payment reduction; 25.2 percent of hospitals (or 279 hospitals) characterized as other urban will be subject to a payment reduction; and 19.5 percent of hospitals (or 163 hospitals) characterized as rural will be subject to a payment reduction.
<table>
<thead>
<tr>
<th>Hospital Characteristic</th>
<th>Number of Hospitals(^a)</th>
<th>Percent(^b)</th>
<th>Number of Hospitals in the Worst-Performing Quartile</th>
<th>Percent of Hospitals in the Worst-Performing Quartile(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total (^d)</td>
<td>3,272</td>
<td>100.0</td>
<td>807</td>
<td>24.4</td>
</tr>
<tr>
<td>By Geographic Location</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All hospitals:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large urban (^e)</td>
<td>1,323</td>
<td>40.5</td>
<td>362</td>
<td>27.4</td>
</tr>
<tr>
<td>Other urban</td>
<td>1,109</td>
<td>33.9</td>
<td>279</td>
<td>25.2</td>
</tr>
<tr>
<td>Rural</td>
<td>837</td>
<td>25.6</td>
<td>163</td>
<td>19.5</td>
</tr>
<tr>
<td>Urban hospitals:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-99 beds</td>
<td>619</td>
<td>25.5</td>
<td>140</td>
<td>22.6</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>739</td>
<td>30.4</td>
<td>158</td>
<td>21.4</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>438</td>
<td>18.0</td>
<td>108</td>
<td>24.7</td>
</tr>
<tr>
<td>300-399 beds</td>
<td>272</td>
<td>11.2</td>
<td>87</td>
<td>32.0</td>
</tr>
<tr>
<td>400-499</td>
<td>152</td>
<td>6.3</td>
<td>67</td>
<td>44.1</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>212</td>
<td>8.7</td>
<td>81</td>
<td>38.2</td>
</tr>
<tr>
<td>Rural hospitals:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-49 beds</td>
<td>332</td>
<td>39.7</td>
<td>90</td>
<td>27.1</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>298</td>
<td>35.6</td>
<td>46</td>
<td>15.4</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>120</td>
<td>14.3</td>
<td>10</td>
<td>8.3</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>47</td>
<td>5.6</td>
<td>8</td>
<td>17.0</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>40</td>
<td>4.8</td>
<td>9</td>
<td>22.5</td>
</tr>
<tr>
<td>By Region</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban by region</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>115</td>
<td>4.7</td>
<td>42</td>
<td>36.5</td>
</tr>
<tr>
<td>Mid-Atlantic</td>
<td>315</td>
<td>13.0</td>
<td>102</td>
<td>32.4</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>397</td>
<td>16.3</td>
<td>94</td>
<td>23.7</td>
</tr>
<tr>
<td>East North Central</td>
<td>388</td>
<td>16.0</td>
<td>79</td>
<td>20.4</td>
</tr>
<tr>
<td>East South Central</td>
<td>147</td>
<td>6.0</td>
<td>31</td>
<td>21.1</td>
</tr>
<tr>
<td>West North Central</td>
<td>161</td>
<td>6.6</td>
<td>35</td>
<td>21.7</td>
</tr>
<tr>
<td>West South Central</td>
<td>369</td>
<td>15.2</td>
<td>87</td>
<td>23.6</td>
</tr>
<tr>
<td>Mountain</td>
<td>165</td>
<td>6.8</td>
<td>54</td>
<td>32.7</td>
</tr>
<tr>
<td>Pacific</td>
<td>375</td>
<td>15.4</td>
<td>117</td>
<td>31.2</td>
</tr>
<tr>
<td>Rural by region</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**ESTIMATED PROPORTION OF HOSPITALS IN THE WORST-PERFORMING QUARTILE (>75th PERCENTILE) OF THE TOTAL HAC SCORE FOR THE FY 2016 HAC REDUCTION PROGRAM (by hospital characteristic)**

<table>
<thead>
<tr>
<th>Hospital Characteristic</th>
<th>Number of Hospitals&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Percent&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Number of Hospitals in the Worst-Performing Quartile</th>
<th>Percent of Hospitals in the Worst-Performing Quartile&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>New England</td>
<td>20</td>
<td>2.4</td>
<td>7</td>
<td>35.0</td>
</tr>
<tr>
<td>Mid-Atlantic</td>
<td>55</td>
<td>6.6</td>
<td>11</td>
<td>20.0</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>127</td>
<td>15.2</td>
<td>21</td>
<td>16.5</td>
</tr>
<tr>
<td>East North Central</td>
<td>115</td>
<td>13.7</td>
<td>22</td>
<td>19.1</td>
</tr>
<tr>
<td>West South Central</td>
<td>157</td>
<td>18.8</td>
<td>17</td>
<td>10.8</td>
</tr>
<tr>
<td>East North Central</td>
<td>105</td>
<td>12.5</td>
<td>34</td>
<td>32.4</td>
</tr>
<tr>
<td>West South Central</td>
<td>162</td>
<td>19.4</td>
<td>28</td>
<td>17.3</td>
</tr>
<tr>
<td>Mountain</td>
<td>70</td>
<td>8.4</td>
<td>20</td>
<td>28.6</td>
</tr>
<tr>
<td>Pacific</td>
<td>26</td>
<td>3.1</td>
<td>3</td>
<td>11.5</td>
</tr>
<tr>
<td><strong>By DSH Percent&lt;sup&gt;f&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-24</td>
<td>1,563</td>
<td>47.8</td>
<td>349</td>
<td>22.3</td>
</tr>
<tr>
<td>25-49</td>
<td>1,379</td>
<td>42.2</td>
<td>342</td>
<td>24.8</td>
</tr>
<tr>
<td>50-64</td>
<td>163</td>
<td>5.0</td>
<td>55</td>
<td>33.7</td>
</tr>
<tr>
<td>65 and over</td>
<td>164</td>
<td>5.0</td>
<td>58</td>
<td>35.4</td>
</tr>
<tr>
<td><strong>By Teaching Status&lt;sup&gt;g&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-teaching</td>
<td>2,247</td>
<td>68.7</td>
<td>464</td>
<td>20.6</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>776</td>
<td>23.7</td>
<td>216</td>
<td>27.8</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>246</td>
<td>7.5</td>
<td>124</td>
<td>50.4</td>
</tr>
<tr>
<td><strong>By Urban Teaching and DSH&lt;sup&gt;h&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teaching and DSH</td>
<td>841</td>
<td>25.7</td>
<td>298</td>
<td>35.4</td>
</tr>
<tr>
<td>Teaching and no DSH</td>
<td>126</td>
<td>3.9</td>
<td>33</td>
<td>26.2</td>
</tr>
<tr>
<td>No teaching and DSH</td>
<td>1,043</td>
<td>31.9</td>
<td>212</td>
<td>20.3</td>
</tr>
<tr>
<td>No teaching and no DSH</td>
<td>422</td>
<td>12.9</td>
<td>98</td>
<td>23.2</td>
</tr>
<tr>
<td>Non-urban</td>
<td>837</td>
<td>25.6</td>
<td>163</td>
<td>19.5</td>
</tr>
</tbody>
</table>
## ESTIMATED PROPORTION OF HOSPITALS IN THE WORST-PERFORMING QUARTILE (>75th PERCENTILE) OF THE TOTAL HAC SCORE FOR THE FY 2016 HAC REDUCTION PROGRAM (by hospital characteristic)

<table>
<thead>
<tr>
<th>Hospital Characteristic</th>
<th>Number of Hospitals&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Percent&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Number of Hospitals in the Worst-Performing Quartile</th>
<th>Percent of Hospitals in the Worst-Performing Quartile&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>By Type of Ownership:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td>1,889</td>
<td>58.0</td>
<td>467</td>
<td>24.7</td>
</tr>
<tr>
<td>Proprietary</td>
<td>856</td>
<td>26.3</td>
<td>186</td>
<td>21.7</td>
</tr>
<tr>
<td>Government</td>
<td>511</td>
<td>15.7</td>
<td>142</td>
<td>27.8</td>
</tr>
<tr>
<td>By MCR Percent:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-24</td>
<td>637</td>
<td>20.3</td>
<td>208</td>
<td>32.7</td>
</tr>
<tr>
<td>25-49</td>
<td>2,081</td>
<td>66.3</td>
<td>465</td>
<td>22.3</td>
</tr>
<tr>
<td>50-64</td>
<td>328</td>
<td>10.5</td>
<td>55</td>
<td>16.8</td>
</tr>
<tr>
<td>65 and over</td>
<td>91</td>
<td>2.9</td>
<td>18</td>
<td>19.8</td>
</tr>
</tbody>
</table>

**Source:** Scores are based on AHRQ PSI 90 data from July 2012 through June 2014 and CLABSI, CAUTI, and SSI results from January 2013 to December 2014. Hospital Characteristics are based on the FY 2016 Proposed Rule Impact File.

<sup>a</sup>The total number of non-Maryland hospitals with a Total HAC Score and hospital characteristic data (3,269 for geographic location, bed size, and teaching status; 3,256 for type of ownership; and 3,137 for MCR) does not add up to the total number of non-Maryland hospitals with a Total HAC Score for the FY 2016 HAC Reduction Program (3,272) because 3 hospitals are not included in the FY 2016 Proposed Rule Impact File and not all hospitals have data for all characteristics.

<sup>b</sup>This column is the percent of all non-Maryland hospitals with each characteristic that have a Total HAC Score for the FY 2016 HAC Reduction Program and are included in the FY 2016 Proposed Rule Impact File. Percentages may not sum to 100 due to rounding.

<sup>c</sup>This column is the percent of hospitals within each characteristic that we estimate would be in the worst-performing quartile.

<sup>d</sup>Total excludes the 47 Maryland hospitals and 36 hospitals without a Total HAC Score for FY 2016.

<sup>e</sup>Large urban hospitals are hospitals located in large urban areas (populations over 1 million).

<sup>f</sup>A hospital is considered to be a DSH hospital if it has a DSH patient percentage greater than zero.

<sup>g</sup>A hospital is considered to be a teaching hospital if it has an IME adjustment factor for Operation PPS (TCHOP) greater than zero.
7. Effects of Modification of the Simplified Cost Allocation Methodology Used by Hospitals

In section IV.H. of the preamble of this final rule, we discuss our modification of the simplified cost allocation methodology set forth in CMS Pub. 15-2, Chapter 40, Section 4020. In the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24514 through 24515), we had proposed to limit the election of the simplified cost allocation methodology to cost reporting periods beginning before October 1, 2015, because the allocation of the costs of capital-related movable equipment using this methodology yields less precise calculated CCRs. After consideration of the public comments we received, we are not finalizing the proposal to limit the election of the simplified cost allocation methodology. Instead, we are retaining the simplified cost allocation methodology with some modifications to afford hospitals using the simplified cost allocation methodology flexibility to obtain approval from their MACs to use dollar value as an alternative statistical basis to square footage for capital-related moveable equipment. Based on FY 2013 HCRIS data, less than 100 hospitals are using the simplified cost allocation methodology. Hospitals using the simplified cost allocation methodology (that is, hospitals using each and every statistical basis within the list of cost centers under the simplified cost allocation methodology) may continue their use of these statistical bases, with the added flexibility to request approval from their MACs to use the dollar value statistical basis for capital-related moveable equipment in accordance with the instructions set forth in CMS Pub. 15-1, Section 2313. In this regard, hospitals using
the simplified cost allocation methodology will no longer be required to use the square footage statistical basis for capital-related moveable equipment but will be provided greater flexibility to request approval to use the statistical basis of dollar value, which may be better suited to their cost allocation needs. With this modification, we believe there will be no disruption of cost reporting practices for hospitals, regardless of whether or not they use the simplified cost allocation methodology. Hospitals using one or more, but not all, of the statistical bases under the simplified cost allocation methodology are not considered to be using the simplified cost allocation methodology. Rather, they are considered to be using the standard cost-finding methodology with approved alternative bases. These hospitals may continue to use these previously approved statistical bases, consistent with current manual instructions set forth in CMS Pub. 15-1, Section 2313. We believe that these finalized changes will not have a significant impact on the operations of a substantial number of small rural hospitals. We also do not believe that the finalized changes will affect beneficiary access to care, as affected hospitals will continue to be paid for services provided to Medicare beneficiaries.

8. Effects of Implementation of Rural Community Hospital Demonstration Program

In section IV.I. of the preamble of this final rule, for FY 2016, we discuss our implementation of section 410A of Pub. L. 108-173, as amended, which requires the Secretary to conduct a demonstration that would modify reimbursement for inpatient services for up to 30 rural community hospitals. Section 410A(c)(2) requires that in conducting the demonstration program under this section, the Secretary shall ensure that the aggregate payments made by the Secretary do not exceed the amount which the
Secretary would have paid if the demonstration program under this section was not implemented. As discussed in section IV.I. of the preamble of this final rule, in the IPPS final rules for each of the previous 11 fiscal years, we have estimated the additional payments made by the program for each of the participating hospitals as a result of the demonstration. In order to achieve budget neutrality, we are adjusting the national IPPS rates by an amount sufficient to account for the added costs of this demonstration. In other words, we are applying budget neutrality across the payment system as a whole rather than across the participants of this demonstration. The language of the statutory budget neutrality requirement permits the agency to implement the budget neutrality provision in this manner. The statutory language requires that aggregate payments made by the Secretary do not exceed the amount which the Secretary would have paid if the demonstration was not implemented but does not identify the range across which aggregate payments must be held equal.

We are adjusting the national IPPS rates according to the methodology set forth in section IV.I.2. of the preamble of this final rule. We note that the phase-out of the demonstration has begun with the 7 “pre-expansion” participating hospitals that were selected for the demonstration during 2004 and 2008 concluding their participation during FY 2015. Therefore, we have not included the financial experience of these hospitals in the estimated demonstration cost for FY 2016. Of the 15 hospitals that entered the demonstration in 2011 and 2012 under the Affordable Care Act expansion, 11 hospitals are scheduled to end their participation in the demonstration during FY 2016. Eight of these 11 hospitals are scheduled to end their participation in the demonstration
prior to September 30, 2016. For each of these 8 hospitals, we estimate the reasonable cost amount and the amount that would otherwise be paid without the demonstration for FY 2016 on a prorated basis, multiplying the estimated amounts for each hospital (as derived from “as submitted” cost reports for cost reporting periods ending in CY 2013) by the fraction of the number of months that it will participate in the demonstration during FY 2016 in relation to the total 12-month period. Accordingly, the budget neutrality offset amount used to determine the adjustment to the national IPPS rates to account for estimated demonstration costs for FY 2016 for these 15 hospitals is $26,044,620. In addition, in this final rule, we are subtracting from the budget neutrality offset amount for FY 2016 the following: (1) the amount by which the budget neutrality offset amount that was finalized in the FY 2009 IPPS/LTCH PPS final rule exceeded the actual costs of the demonstration for FY 2009 (as shown in the finalized cost reports for hospitals that participated in FY 2009 and had cost reporting periods beginning in FY 2009) ($8,457,452); and (2) the amount by which the budget neutrality offset amount that was finalized for FY 2010 to account for the demonstration costs in FY 2010 (as set forth in the FY 2010 and 2011 IPPS final rules) exceeded the actual costs of the demonstration during FY 2010 (similarly as shown in the finalized cost reports for hospitals that participated in FY 2010 and had for cost reporting periods beginning in 2010). This amount is $4,751,550. Therefore, the resulting total ($12,835,618) is the amount for which an adjustment to the IPPS rates for FY 2016 is calculated.

9. Effects of the Changes to MS-DRGs Subject to the Postacute Care Transfer Policy and the Special Payment Policy
In section IV.J. of the preamble to this final rule, we discuss changes to the list of MS-DRGs subject to the postacute care transfer policy and the DRG special payment policy. As reflected in Table 5 listed in section VI. of the Addendum to this final rule (which is available via the Internet on the CMS Web site), using criteria set forth in regulations at § 412.4, we evaluated MS-DRG charge, discharge, and transfer data to determine which MS-DRGs qualify for the postacute care transfer and DRG special payment policies. We note that we are not making any changes in these payment policies in this FY 2016 final rule. We are including two new MS-DRGs on the list of MS-DRGs subject to the postacute care transfer policy and the DRG special payment policy as a result of our revisions of the MS-DRG classifications for FY 2016. Specifically, we are establishing that two new MS-DRGs will qualify for the postacute care transfer policy and the DRG special payment policy in FY 2016. Column 4 of Table I in this Appendix A shows the effects of the changes to the MS-DRGs and the relative payment weights and the application of the recalibration budget neutrality factor to the standardized amounts. Section 1886(d)(4)(C)(i) of the Act requires us annually to make appropriate DRG classification changes in order to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources. The analysis and methods for determining the changes due to the MS-DRGs and relative payment weights account for and include changes in the status of MS-DRG postacute care transfer and special payment policies. We refer readers to section I.G. of this Appendix A for a detailed discussion of payment impacts due to MS-DRG reclassification policies.
I. Effects of Changes in the Capital IPPS

1. General Considerations

For the impact analysis presented below, we used data from the March 2015 update of the FY 2014 MedPAR file and the March 2015 update of the Provider-Specific File (PSF) that is used for payment purposes. Although the analyses of the changes to the capital prospective payment system do not incorporate cost data, we used the March 2015 update of the most recently available hospital cost report data (FYs 2012 and 2013) to categorize hospitals. Our analysis has several qualifications. We use the best data available and make assumptions about case-mix and beneficiary enrollment as described below.

Due to the interdependent nature of the IPPS, it is very difficult to precisely quantify the impact associated with each change. In addition, we draw upon various sources for the data used to categorize hospitals in the tables. In some cases (for instance, the number of beds), there is a fair degree of variation in the data from different sources. We have attempted to construct these variables with the best available sources overall. However, it is possible that some individual hospitals are placed in the wrong category.

Using cases from the March 2015 update of the FY 2014 MedPAR file, we simulated payments under the capital IPPS for FY 2015 and FY 2016 for a comparison of total payments per case. Any short-term, acute care hospitals not paid under the general IPPS (for example, Indian Health Service hospitals and hospitals in Maryland) are excluded from the simulations.
The methodology for determining a capital IPPS payment is set forth at § 412.312. The basic methodology for calculating the capital IPPS payments in FY 2016 is as follows:

\[(\text{Standard Federal Rate}) \times (\text{DRG weight}) \times (\text{GAF}) \times (\text{COLA for hospitals located in Alaska and Hawaii}) \times (1 + \text{DSH Adjustment Factor + IME adjustment factor, if applicable}).\]

In addition to the other adjustments, hospitals may receive outlier payments for those cases that qualify under the threshold established for each fiscal year. We modeled payments for each hospital by multiplying the capital Federal rate by the GAF and the hospital's case-mix. We then added estimated payments for indirect medical education, disproportionate share, and outliers, if applicable. For purposes of this impact analysis, the model includes the following assumptions:

- We estimate that the Medicare case-mix index will increase by 0.5 percent in both FYs 2015 and 2016.
- We estimate that Medicare discharges will be approximately 11.3 million in FY 2015 and 11.2 million in FY 2016.
- The capital Federal rate was updated beginning in FY 1996 by an analytical framework that considers changes in the prices associated with capital-related costs and adjustments to account for forecast error, changes in the case-mix index, allowable changes in intensity, and other factors. As discussed in section III.A.1.a. of the Addendum to this final rule, the update is 1.3 percent for FY 2016.
• In addition to the FY 2016 update factor, the FY 2016 capital Federal rate was calculated based on a GAF/DRG budget neutrality adjustment factor of 0.9973 and an outlier adjustment factor of 0.9365. As discussed in section VI.C. of the preamble of this final rule, we are not making an additional MS-DRG documentation and coding adjustment to the capital IPPS Federal rates for FY 2016.

2. Results

We used the actuarial model described above to estimate the potential impact of our changes for FY 2016 on total capital payments per case, using a universe of 3,369 hospitals. As described above, the individual hospital payment parameters are taken from the best available data, including the March 2015 update of the FY 2014 MedPAR file, the March 2015 update to the PSF, and the most recent cost report data from the March 2015 update of HCRIS. In Table III, we present a comparison of estimated total payments per case for FY 2015 and estimated total payments per case for FY 2016 based on the FY 2016 payment policies. Column 2 shows estimates of payments per case under our model for FY 2015. Column 3 shows estimates of payments per case under our model for FY 2016. Column 4 shows the total percentage change in payments from FY 2015 to FY 2016. The change represented in Column 4 includes the 1.3 percent update to the capital Federal rate and other changes in the adjustments to the capital Federal rate. The comparisons are provided by: (1) geographic location; (2) region; and (3) payment classification.

The simulation results show that, on average, capital payments per case in FY 2016 are expected to increase as compared to capital payments per case in FY 2015.
This expected increase is due to the approximately 0.85 percent increase in the capital Federal rate for FY 2016 as compared to the FY 2015 capital Federal rate and, to a lesser degree, changes to the MS-DRG reclassifications and recalibrations and changes in outlier payments. (For a discussion of the determination of the capital Federal rate, we refer readers to section III.A. of the Addendum to this final rule.) The increase in capital payments per case due to the effects of changes to the MS-DRG reclassifications and recalibrations is expected to be slightly greater for urban hospitals, as are the increases in capital payments per case due to changes in outlier payments. However, half of the urban areas and most of the rural areas are expected to experience a somewhat smaller projected increase in capital payments per case due to the effects of changes to the GAFs. These regional effects of the changes to the GAFs on capital payments are consistent with the projected changes in payments due to changes in the wage index (and policies affecting the wage index) as shown in Table I in section I.G. of this Appendix.

The net impact of these changes is an estimated 2.3 percent change in capital payments per case from FY 2015 to FY 2016 for all hospitals (as shown below in Table III).

The geographic comparison shows that, on average, hospitals in all classifications (urban and rural) will experience an increase in capital IPPS payments per case in FY 2016 as compared to FY 2015. Capital IPPS payments per case for hospitals in “large urban areas” have an estimated increase of 2.5 percent, while hospitals in rural areas, on average, are expected to experience a 1.4 percent increase in capital payments per case from FY 2015 to FY 2016. Capital IPPS payments per case for “other urban
hospitals” are estimated to increase 2.1 percent. The primary factor contributing to the difference in the projected increase in capital IPPS payments per case for urban hospitals as compared to rural hospitals is the changes in the GAFs. Rural hospitals in all but two rural regions are projected to experience a decrease in capital payments due to the effect of changes in the GAFs, while hospitals in only half of the urban regions are projected to experience a decrease in capital payments due to the effect of the changes in the GAFs.

The comparisons by region show that the estimated increases in capital payments per case from FY 2015 to FY 2016 in urban areas range from a 3.1 percent increase for the Pacific urban region to a 1.1 percent increase for the New England urban region. For rural regions, the Pacific rural region is projected to experience the largest increase in capital IPPS payments per case of 3.0 percent; the West South Central rural region is projected to experience the smallest increase in capital IPPS payments per case of 0.1 percent. The change in the GAFs is the main factor for the West South Central rural region experiencing the smallest projected increase in capital IPPS payments among rural regions, and it is also the main contributor for the smallest projected increase in capital IPPS payments for the New England urban region. However, the changes in the GAFs have the opposite effect for both the Pacific urban and Pacific rural regions where they are a primary contributor to the expected larger than average increase in capital IPPS payments per case.

Hospitals of all types of ownership (that is, voluntary hospitals, government hospitals, and proprietary hospitals) are expected to experience an increase in capital payments per case from FY 2015 to FY 2016. The increase in capital payments for
voluntary and proprietary hospitals is estimated to be 2.3 percent. For government hospitals, the increase is estimated to be 2.4 percent.

Section 1886(d)(10) of the Act established the MGCRB. Hospitals may apply for reclassification for purposes of the wage index for FY 2016. Reclassification for wage index purposes also affects the GAFs because that factor is constructed from the hospital wage index. To present the effects of the hospitals being reclassified as of the publication of this final rule for FY 2016, we show the average capital payments per case for reclassified hospitals for FY 2016. Urban reclassified hospitals are expected to experience an increase in capital payments of 2.8 percent; urban nonreclassified hospitals are expected to experience an increase in capital payments of 2.2 percent. The estimated percentage increase for rural reclassified hospitals is 1.8 percent, and for rural nonreclassified hospitals, the estimated percentage increase is 1.1 percent.
<table>
<thead>
<tr>
<th>By Geographic Location:</th>
<th>Number of hospitals</th>
<th>Average FY 2015 payments/case</th>
<th>Average FY 2016 payments/case</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>All hospitals</td>
<td>3,369</td>
<td>871</td>
<td>890</td>
<td>2.3</td>
</tr>
<tr>
<td>Large urban areas (populations over 1 million)</td>
<td>1,393</td>
<td>963</td>
<td>987</td>
<td>2.5</td>
</tr>
<tr>
<td>Other urban areas (populations of 1 million of fewer)</td>
<td>1,140</td>
<td>833</td>
<td>851</td>
<td>2.1</td>
</tr>
<tr>
<td>Rural areas</td>
<td>836</td>
<td>591</td>
<td>599</td>
<td>1.4</td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,533</td>
<td>904</td>
<td>925</td>
<td>2.3</td>
</tr>
<tr>
<td>0-99 beds</td>
<td>668</td>
<td>736</td>
<td>750</td>
<td>1.9</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>778</td>
<td>788</td>
<td>805</td>
<td>2.2</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>445</td>
<td>825</td>
<td>844</td>
<td>2.3</td>
</tr>
<tr>
<td>300-499 beds</td>
<td>428</td>
<td>920</td>
<td>943</td>
<td>2.4</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>214</td>
<td>1,080</td>
<td>1,106</td>
<td>2.4</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>836</td>
<td>591</td>
<td>599</td>
<td>1.4</td>
</tr>
<tr>
<td>0-49 beds</td>
<td>329</td>
<td>490</td>
<td>497</td>
<td>1.5</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>297</td>
<td>549</td>
<td>557</td>
<td>1.6</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>121</td>
<td>591</td>
<td>598</td>
<td>1.2</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>48</td>
<td>645</td>
<td>652</td>
<td>1.0</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>41</td>
<td>706</td>
<td>715</td>
<td>1.3</td>
</tr>
<tr>
<td>By Region:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban by Region</td>
<td>2,533</td>
<td>904</td>
<td>925</td>
<td>2.3</td>
</tr>
<tr>
<td>New England</td>
<td>120</td>
<td>996</td>
<td>1,008</td>
<td>1.1</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>318</td>
<td>1,001</td>
<td>1,032</td>
<td>3.0</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>407</td>
<td>805</td>
<td>823</td>
<td>2.2</td>
</tr>
<tr>
<td>East North Central</td>
<td>396</td>
<td>868</td>
<td>889</td>
<td>2.3</td>
</tr>
<tr>
<td>East South Central</td>
<td>150</td>
<td>768</td>
<td>780</td>
<td>1.6</td>
</tr>
<tr>
<td>West North Central</td>
<td>166</td>
<td>887</td>
<td>902</td>
<td>1.6</td>
</tr>
<tr>
<td>West South Central</td>
<td>384</td>
<td>817</td>
<td>835</td>
<td>2.1</td>
</tr>
<tr>
<td>Mountain</td>
<td>161</td>
<td>936</td>
<td>956</td>
<td>2.0</td>
</tr>
<tr>
<td>Pacific</td>
<td>380</td>
<td>1,150</td>
<td>1,186</td>
<td>3.1</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>403</td>
<td>408</td>
<td>1.4</td>
</tr>
<tr>
<td>Rural by Region</td>
<td>836</td>
<td>591</td>
<td>599</td>
<td>1.4</td>
</tr>
<tr>
<td>New England</td>
<td>22</td>
<td>822</td>
<td>828</td>
<td>0.7</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>55</td>
<td>580</td>
<td>582</td>
<td>0.3</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>128</td>
<td>554</td>
<td>566</td>
<td>2.3</td>
</tr>
<tr>
<td>East North Central</td>
<td>116</td>
<td>616</td>
<td>626</td>
<td>1.6</td>
</tr>
<tr>
<td>East South Central</td>
<td>164</td>
<td>536</td>
<td>542</td>
<td>1.1</td>
</tr>
<tr>
<td>West North Central</td>
<td>101</td>
<td>635</td>
<td>643</td>
<td>1.3</td>
</tr>
<tr>
<td>West South Central</td>
<td>165</td>
<td>524</td>
<td>524</td>
<td>0.1</td>
</tr>
<tr>
<td>Mountain</td>
<td>61</td>
<td>660</td>
<td>674</td>
<td>2.1</td>
</tr>
<tr>
<td>Pacific</td>
<td>24</td>
<td>768</td>
<td>791</td>
<td>3.0</td>
</tr>
<tr>
<td>By Payment Classification:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All hospitals</td>
<td>3,369</td>
<td>871</td>
<td>890</td>
<td>2.3</td>
</tr>
<tr>
<td>Large urban areas (populations over 1 million)</td>
<td>1,386</td>
<td>964</td>
<td>988</td>
<td>2.5</td>
</tr>
<tr>
<td>Other urban areas (populations of 1 million of fewer)</td>
<td>1,090</td>
<td>837</td>
<td>855</td>
<td>2.2</td>
</tr>
<tr>
<td>Rural areas</td>
<td>893</td>
<td>608</td>
<td>615</td>
<td>1.0</td>
</tr>
<tr>
<td>Teaching Status:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-teaching</td>
<td>2,326</td>
<td>739</td>
<td>754</td>
<td>2.1</td>
</tr>
<tr>
<td>Fewer than 100 Residents</td>
<td>794</td>
<td>848</td>
<td>866</td>
<td>2.2</td>
</tr>
<tr>
<td>100 or more Residents</td>
<td>249</td>
<td>1,227</td>
<td>1,259</td>
<td>2.6</td>
</tr>
<tr>
<td>Urban DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100 or more beds</td>
<td>1,593</td>
<td>928</td>
<td>950</td>
<td>2.4</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>328</td>
<td>662</td>
<td>677</td>
<td>2.3</td>
</tr>
<tr>
<td>Rural DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sole Community (SCH/EACH)</td>
<td>260</td>
<td>576</td>
<td>580</td>
<td>0.7</td>
</tr>
<tr>
<td>Referral Center (RRC/EACH)</td>
<td>347</td>
<td>639</td>
<td>647</td>
<td>1.2</td>
</tr>
<tr>
<td>Other Rural:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100 or more beds</td>
<td>31</td>
<td>575</td>
<td>573</td>
<td>-0.4</td>
</tr>
<tr>
<td>Hospital Type</td>
<td>Number of hospitals</td>
<td>Average FY 2015 payments/case</td>
<td>Average FY 2016 payments/case</td>
<td>Change</td>
</tr>
<tr>
<td>---------------------------------------------------</td>
<td>---------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>157</td>
<td>504</td>
<td>512</td>
<td>1.7</td>
</tr>
<tr>
<td>Urban teaching and DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both teaching and DSH</td>
<td>855</td>
<td>1,003</td>
<td>1,027</td>
<td>2.5</td>
</tr>
<tr>
<td>Teaching and no DSH</td>
<td>122</td>
<td>899</td>
<td>919</td>
<td>2.2</td>
</tr>
<tr>
<td>No teaching and DSH</td>
<td>1,066</td>
<td>780</td>
<td>797</td>
<td>2.3</td>
</tr>
<tr>
<td>No teaching and no DSH</td>
<td>433</td>
<td>797</td>
<td>816</td>
<td>2.3</td>
</tr>
<tr>
<td>Rural Hospital Types:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non special status hospitals</td>
<td>2,562</td>
<td>904</td>
<td>926</td>
<td>2.4</td>
</tr>
<tr>
<td>RRC/EACH</td>
<td>189</td>
<td>729</td>
<td>737</td>
<td>1.1</td>
</tr>
<tr>
<td>SCH/EACH</td>
<td>327</td>
<td>665</td>
<td>672</td>
<td>1.1</td>
</tr>
<tr>
<td>SCH, RRC and EACH</td>
<td>126</td>
<td>721</td>
<td>733</td>
<td>1.6</td>
</tr>
<tr>
<td>Hospitals Reclassified by the Medicare Geographic Classification Review Board:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY2016 Reclassifications:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Urban Reclassified</td>
<td>551</td>
<td>923</td>
<td>948</td>
<td>2.8</td>
</tr>
<tr>
<td>All Urban Non-Reclassified</td>
<td>1,925</td>
<td>902</td>
<td>922</td>
<td>2.2</td>
</tr>
<tr>
<td>All Rural Reclassified</td>
<td>279</td>
<td>623</td>
<td>634</td>
<td>1.8</td>
</tr>
<tr>
<td>All Rural Non-Reclassified</td>
<td>504</td>
<td>545</td>
<td>551</td>
<td>1.1</td>
</tr>
<tr>
<td>Other Reclassified Hospitals (Section 1886(d)(8)(B))</td>
<td>46</td>
<td>600</td>
<td>589</td>
<td>-1.8</td>
</tr>
<tr>
<td>Type of Ownership:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td>1,934</td>
<td>884</td>
<td>904</td>
<td>2.3</td>
</tr>
<tr>
<td>Proprietary</td>
<td>879</td>
<td>785</td>
<td>803</td>
<td>2.3</td>
</tr>
<tr>
<td>Government</td>
<td>529</td>
<td>917</td>
<td>938</td>
<td>2.4</td>
</tr>
<tr>
<td>Medicare Utilization as a Percent of Inpatient Days:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-25</td>
<td>533</td>
<td>1,046</td>
<td>1,074</td>
<td>2.7</td>
</tr>
<tr>
<td>25-50</td>
<td>2,134</td>
<td>876</td>
<td>896</td>
<td>2.3</td>
</tr>
<tr>
<td>50-65</td>
<td>571</td>
<td>717</td>
<td>731</td>
<td>1.9</td>
</tr>
<tr>
<td>Over 65</td>
<td>97</td>
<td>523</td>
<td>534</td>
<td>2.1</td>
</tr>
</tbody>
</table>
J. Effects of Payment Rate Changes and Policy Changes under the LTCH PPS

1. Introduction and General Considerations

In section VII. of the preamble of this final rule and section V. of the Addendum to this final rule, we set forth the annual update to the payment rates for the LTCH PPS for FY 2016. In the preamble of this final rule, we specify the statutory authority for the provisions that are presented, identify those policies, and present rationales for our final decisions as well as alternatives that were considered. In this section of Appendix A to this final rule, we discuss the impact of the changes to the payment rate, factors, and other payment rate policies related to the LTCH PPS that are presented in the preamble of this final rule in terms of their estimated fiscal impact on the Medicare budget and on LTCHs.

There are 419 LTCHs included in this impacts analysis, which includes data for 78 nonprofit (voluntary ownership control) LTCHs, 326 proprietary LTCHs, and 15 LTCHs that are government-owned and operated. (We note that, although there are currently approximately 430 LTCHs, for purposes of this impact analysis, we excluded the data of all-inclusive rate providers consistent with the development of the FY 2016 MS-LTC-DRG relative weights (discussed in section VII.C.3.c. of the preamble of this final rule)). In the impact analysis, we used the payment rate, factors, and policies presented in this final rule, including the application of the new site neutral payment rate required by section 1886(m)(6)(A) of the Act (discussed in section VII.B. of the preamble of this final rule), the 1.7 percent annual update to the LTCH PPS standard Federal payment rate in accordance with section 1886(m)(5)(C) of the Act (which is
based on the full estimated increase of the LTCH PPS market basket and the reductions required by sections 1886(m)(3) and (m)(4) of the Act, the update to the MS-LTC-DRG classifications and relative weights for the LTCH PPS standard Federal payment rate cases, the update to the wage index values and labor-related share for the LTCH PPS standard Federal payment rate cases, and the best available claims and CCR data to estimate the change in payments for FY 2016.

Under the new dual rate LTCH PPS payment structure, there will be two distinct payment rates for LTCH discharges beginning in FY 2016. Under this statutory change, as discussed in section VII.B. of the preamble of this final rule, we provide payment for LTCH discharges that meet the criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) based on the LTCH PPS standard Federal payment rate. In addition, consistent with the statute, we are establishing that the site neutral payment rate is the lower of the IPPS comparable per diem amount as determined under §412.529(d)(4), including any applicable outlier payments as specified in §412.525(a); or 100 percent of the estimated cost of the case as determined under existing §412.529(d)(2). In addition, under our finalized policies, there are two separate HCO targets -- one for LTCH PPS standard Federal payment rate cases and one for site neutral payment rate cases. The statute also establishes a transitional payment method for cases that will be paid the site neutral payment rate for LTCH discharges occurring in cost reporting periods beginning during FY 2016 or FY 2017. As discussed more fully in section VII.B.4.b. of the preamble of this final rule, the transitional payment amount for site neutral payment rate cases is a blended payment
rate, which will be calculated as 50 percent of the applicable site neutral payment rate amount for the discharge as determined under new § 412.522(c)(1) and 50 percent of the applicable LTCH PPS standard Federal payment rate for the discharge determined under § 412.523.

Based on the best available data for the 419 LTCHs in our database that were considered in the analyses used for this final rule, we estimate that overall LTCH PPS payments in FY 2016 will decrease by approximately 4.6 percent (or approximately $250 million). This projection takes into account estimated payments for LTCH cases that would have met the new patient-level criteria and been paid the LTCH PPS standard Federal payment rate if that rate had been in effect at the time of the discharge, and estimated payments for LTCH cases that would not have met those new patient-level criteria and been paid under the site neutral payment rate if that rate had been in effect at the time of the discharge described below.

Because the statute specifies that the site neutral payment rate effective date for a given LTCH is determined based on the date on which that LTCH’s cost reporting period begins on or after October 1, 2015, our estimate of FY 2016 LTCH PPS payments for site neutral payment rate cases includes an adjustment to account for this rolling effective date. Our approach, applied to the FY 2014 data that were used for the analyses in this final rule, accounts for the fact that LTCHs with cost reporting periods that begin after October 1, 2015, will continue to be paid for all discharges (including those that do not meet the patient-level criteria for exclusion from the site neutral payment rate) at the LTCH PPS standard Federal payment rate until the start of their first cost reporting period.
beginning after October 1, 2015. Therefore, in order to estimate total LTCH PPS payments for site neutral payment rate cases in FY 2016, we first identified LTCHs with cost reporting periods that would begin in the first quarter of FY 2016 (that is, October through December 2015), and modeled those LTCHs estimated FY 2016 site neutral payment rate payments based on the transitional blended payment rate. We then modeled the estimated first quarter FY 2016 payments to LTCHs with cost reporting periods that would begin after the first quarter of FY 2016 using the LTCH PPS standard Federal payment rate. We then identified the LTCHs with cost reporting periods that would begin in each of the remaining three quarters of FY 2016, and applied an analogous analysis to estimate payments in each respective quarter of FY 2016. (For full details on our method of estimating payments under our finalized policies for FY 2016, we refer readers to the description presented in section V.D.4. of the Addendum to the proposed rule.) We believe that this approach is a reasonable means of taking the rolling effective date into account when estimating FY 2016 payments. Based on the fiscal year start dates recorded in the March update of the Provider Specific File, of the 419 LTCHs in our database of LTCH claims from the March 2015 update of the FY 2014 MedPAR files used for this final rule, the following percentages apply in the approach described above: 11.24 percent of site neutral payment rate cases are from LTCHs whose cost reporting periods begin in the first quarter of FY 2016; 29.88 percent of site neutral payment rate cases are from LTCHs whose cost reporting periods begin in the second quarter of FY 2016; 10.73 percent of site neutral payment rate cases are from LTCHs whose cost reporting periods begin in the third quarter of FY 2016; and 48.15 percent of site neutral
payment rate cases are from LTCHs whose cost reporting periods begin in the fourth quarter of FY 2016.

Based on the FY 2014 LTCH cases that were used for the analyses in this final rule, approximately 46 percent of LTCH cases would have been classified as site neutral payment rate cases if the site neutral payment rate had been in effect in FY 2014 (that is, 46 percent of such LTCH cases would not have met the patient-level criteria for exclusion from the site neutral payment rate). Our Office of the Actuary estimates that the percent of LTCH PPS cases that will be paid at the site neutral payment rate in FY 2016 will not change significantly from the historical data. Taking into account the transitional blended payment rate and other policies applicable to the site neutral payment rate cases in FY 2016, and our approach to account for the rolling effective date for the new site neutral payment rate, we estimate that aggregate LTCH PPS payments for these site neutral payment rate cases will decrease by approximately 14.8 percent (or approximately $300 million).

Approximately 54 percent of LTCH cases are expected to meet the patient-level criteria for exclusion from the site neutral payment rate in FY 2016, and will be paid based on the LTCH PPS standard Federal payment rate for the full year. We estimate that total LTCH PPS payments for these LTCH PPS standard Federal payment rate cases in FY 2016 will increase approximately 1.5 percent (or approximately $50 million). This estimated increase in LTCH PPS payments for LTCH PPS standard Federal payment rate cases in FY 2016 is primarily a result of the 1.7 percent annual update to the LTCH PPS
standard Federal payment rate for FY 2016 (discussed in section V.A. of the Addendum to this final rule) and an estimated decrease in HCO payments for these cases.

Based on the 419 LTCHs that were represented in the FY 2014 LTCH cases that were used for the analyses in this final rule, we estimate that aggregate FY 2016 LTCH PPS payments will be approximately $5.150 billion, as compared to estimated aggregate FY 2015 LTCH PPS payments of approximately $5.400 billion, resulting in an estimated overall decrease in LTCH PPS payments of approximately $250 million. Because the combined distributional effects and estimated payment changes exceed $100 million, this final rule is a major economic rule. We note that this estimated $250 million decrease in LTCH PPS payments in FY 2016 (which includes estimated payments for LTCH PPS standard Federal payment rate cases and site neutral payment rate cases) does not reflect changes in LTCH admissions or case-mix intensity, which will also affect the overall payment effects of what is in this rule.

The LTCH PPS standard Federal payment rate for FY 2015 is $41,043.71. For FY 2016, we are establishing a LTCH PPS standard Federal payment rate of $41,762.85, which reflects the 1.7 percent annual update to the LTCH PPS standard Federal payment rate and the area wage budget neutrality factor of 1.000513 to ensure that the changes in the wage indexes and labor-related share do not influence aggregate payments. For LTCHs that fail to submit data for the LTCH QRP, in accordance with section 1886(m)(5)(C) of the Act, we are establishing an LTCH PPS standard Federal payment rate of $40,941.55. This reduced LTCH PPS standard Federal payment rate reflects the updates described above as well as the required 2.0 percentage point reduction to the
annual update for failure to submit data to the LTCH QRP. We note that the factors described above to determine the FY 2016 LTCH PPS standard Federal payment rate are applied to the FY 2015 LTCH PPS standard Federal rate set forth under § 412.523(c)(3)(xi) (that is, $41,762.85).

Table IV (column 6) shows that the estimated change attributable solely to the annual update to the LTCH PPS standard Federal payment rate is projected to result in an increase of 1.4 percent in payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016, on average, for all LTCHs. In addition to the annual update to the LTCH PPS standard Federal payment rate for FY 2016, this estimated increase in aggregate LTCH PPS payments to LTCH PPS standard Federal payment rate cases of 1.4 percent shown in column 6 of Table IV also includes estimated payments for SSO cases that will be paid using special methodologies that are not affected by the annual update to the LTCH PPS standard Federal payment rate, as well as the penalty that is applied to the annual update of LTCHs that do not submit the required LTCH QRP data. Therefore, for all hospital categories, the projected increase in payments based on the LTCH PPS standard Federal payment rate to LTCH PPS standard Federal payment rate cases is somewhat less than the 1.7 percent annual update for FY 2016.

As discussed in section V.B. of the Addendum to this final rule, we are updating the wage index values for FY 2016 based on the most recent available data, and we are continuing to use labor market areas based on the OMB CBSA delineations. In addition, we are slightly lowering the labor-related share from 62.306 percent to 62.0 percent
under the LTCH PPS for FY 2016, based on the most recent available data on the relative importance of the labor-related share of operating and capital costs based on the FY 2009-based LTCH-specific market basket. We also are applying an area wage level budget neutrality factor of 1.000513 to ensure that the changes to the wage data and labor-related share do not result in a change in estimated aggregate LTCH PPS payments to LTCH PPS standard Federal payment rate cases, which increases the LTCH PPS standard Federal payment rate by approximately 0.095 percent.

We currently estimate total HCO payments for LTCH PPS standard Federal payment rate cases are projected to decrease from FY 2015 to FY 2016. Using the FY 2014 LTCH cases that were used for the analyses in this final rule, we estimate that the FY 2015 HCO threshold of $14,972 (as established in the FY 2015 IPPS/LTCH PPS final rule) will result in estimated HCO payments for LTCH PPS standard Federal payment rate cases in FY 2015 that are above the estimated 8 percent target. Specifically, we currently estimate that HCO payments for LTCH PPS standard Federal payment rate cases will be approximately 8.1 percent of the estimated total LTCH PPS standard Federal payment rate payments in FY 2015. Combined with our estimate that FY 2016 HCO payments for LTCH PPS standard Federal payment rate cases would be 8.0 percent of estimated total LTCH PPS standard Federal payment rate payments in FY 2016, this results in the estimated decrease of approximately 0.1 percent between FY 2015 and FY 2016.

In calculating these estimated HCO payments we increased estimated costs by our actuaries’ projected market basket percentage increase factor. This increase in estimated
costs also results in a projected increase in SSO payments in FY 2016. We estimate that these increased SSO payments in FY 2016 will increase total payments for LTCH PPS standard Federal payment rate cases by 0.2 percent. (Payments for SSO cases represent approximately 13 percent of the estimated total payments for LTCH PPS standard Federal payment rate cases.)

Table IV below shows the estimated impact of the payment rate and policy changes on LTCH PPS payments for LTCH PPS standard Federal payment rate cases for FY 2016 by comparing estimated FY 2015 LTCH PPS payments to estimated FY 2016 LTCH PPS payments. (As noted earlier, our analysis does not reflect changes in LTCH admissions or case-mix intensity.) The projected increase in payments from FY 2015 to FY 2016 for LTCH PPS standard Federal payment rate cases of 1.5 percent is attributable to the impacts of the change to the LTCH PPS standard Federal payment rate (1.4 percent in Column 6) and the effect of the estimated decrease in HCO payments for LTCH PPS standard Federal payment cases (-0.1 percent), and the estimated increase in payments for SSO cases (0.2 percent).

As we discuss in detail throughout this final rule, based on the most recent available data, we believe that the provisions of this final rule relating to the LTCH PPS, which are projected to result in an overall decrease in estimated aggregate LTCH PPS payments, and the resulting LTCH PPS payment amounts will result in appropriate Medicare payments that are consistent with the statute.
2. Impact on Rural Hospitals

For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of an urban area and has fewer than 100 beds. As shown in Table IV, we are projecting a 1.5 percent increase in estimated payments for LTCH PPS standard Federal payment rate cases. This estimated impact is based on the FY 2014 data for the 21 rural LTCHs (out of 419 LTCHs) that were used for the analyses in this final rule. We note that these impacts do not include LTCH PPS site neutral payment rate cases for the reasons discussed in section I.J.3. of this Appendix.

3. Anticipated Effects of LTCH PPS Payment Rate Changes and Policy Changes

a. Budgetary Impact

Section 123(a)(1) of the BBRA requires that the PPS developed for LTCHs “maintain budget neutrality.” We believe that the statute’s mandate for budget neutrality applies only to the first year of the implementation of the LTCH PPS (that is, FY 2003). Therefore, in calculating the FY 2003 standard Federal rate under § 412.523(d)(2), we set total estimated payments for FY 2003 under the LTCH PPS so that estimated aggregate payments under the LTCH PPS were estimated to equal the amount that would have been paid if the LTCH PPS had not been implemented.

Section 1886(m)(6)(A) of the Act establishes a new dual rate LTCH PPS payment structure with two distinct payment rates for LTCH discharges beginning in FY 2016. As discussed in section VII.B. of the preamble of this final rule, under this statutory change, LTCH discharges that meet the patient-level criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) will be paid based
on the LTCH PPS standard Federal payment rate. LTCH discharges that will be paid at the site neutral payment rate will generally be paid the lower of the IPPS comparable per diem amount, including any applicable HCO payments or 100 percent of the estimated cost of the case. The statute also establishes a transitional payment method for cases that will be paid at the site neutral payment rate for LTCH discharges occurring in cost reporting periods beginning during FY 2016 or FY 2017, under which the site neutral payment rate cases will be paid a blended payment rate calculated as 50 percent of the applicable site neutral payment rate amount for the discharge and 50 percent of the applicable LTCH PPS standard Federal payment rate for the discharge. (For additional details on the application of the site neutral payment rate beginning in FY 2016, we refer readers to section VII.B. of the preamble of this final rule.)

As discussed above in section I.J.1. of this Appendix, we project a decrease in aggregate LTCH PPS payments in FY 2016 of approximately $250 million. This estimated decrease in payments reflects the projected increase in payments to LTCH PPS standard Federal payment rate cases of approximately $50 million and the projected decrease in payments to site neutral payment rate cases of approximately $300 million under the new dual rate LTCH PPS payment rate structure required by the statute beginning in FY 2016.

As discussed in section VII.B.7.b. of the preamble of this final rule, our actuaries project cost and resource changes for site neutral payment rate cases due to the site neutral payment rates required under the statute. Specifically, our actuaries project that the costs and resource use for cases paid at the site neutral payment rate will likely be
lower, on average, than the costs and resource use for cases paid at the LTCH PPS standard Federal payment rate, and will likely mirror the costs and resource use for IPPS cases assigned to the same MS-DRG. While we are able to incorporate this projection at an aggregate level into our payment modeling, because the historical claims data that we are using in this final rule to project estimated FY 2016 LTCH PPS payments (that is, FY 2014 LTCH claims data) do not reflect this actuarial projection, we are unable to model the impact of the change in LTCH PPS payments for site neutral payment rate cases at the same level of detail with which we are able to model the impacts of the changes to LTCH PPS payments for LTCH PPS standard Federal payment rate cases. Therefore, Table IV below only reflects changes in LTCH PPS payments for LTCH PPS standard Federal payment rate cases and, unless otherwise noted, the remaining discussion in section I.J.3 of this Appendix refers only to the impact on LTCH PPS payments for LTCH PPS standard Federal payment rate cases. Below we present our provider impact analysis for the changes that affect LTCH PPS payments for LTCH PPS standard Federal payment rate cases.

b. Impact on Providers

Under the new dual rate LTCH PPS payment structure, the statute establishes two distinct payment rates for LTCH discharges occurring in cost reporting periods beginning on or after October 1, 2015. Under that statute, any discharges that occur on or after October 1, 2015, but prior to the start of the LTCH’s FY 2016 cost reporting period will be paid at the LTCH PPS standard Federal payment rate. On or after the start of an LTCH’s FY 2016 cost reporting period, discharges are paid based on the nature of the
case. As described previously, LTCH PPS standard Federal payment rate cases are defined as LTCH discharges that will meet the patient-level criteria to be excluded from the typically lower site neutral payment rate, and site neutral payment rate cases are defined as LTCH discharges that will not meet the patient-level criteria and will generally be paid the generally lower site neutral payment rate. For discharges occurring in cost reporting periods beginning in FY 2016 or 2017, however, the statute specifies that site neutral payment rate cases will be paid based on a transitional payment method that will be calculated as 50 percent of the applicable site neutral payment rate amount and 50 percent of the applicable LTCH PPS standard Federal payment rate.

The basic methodology for determining a per discharge payment for LTCH PPS standard Federal payment rate cases is set forth under § 412.515 through § 412.536. In addition to adjusting the LTCH PPS standard Federal payment rate by the MS-LTC-DRG relative weight, we make adjustments to account for area wage levels and SSOs. LTCHs located in Alaska and Hawaii also have their payments adjusted by a COLA. As explained previously, under our application of the new dual rate LTCH PPS payment structure required under section 1886(m)(6) of the Act, the LTCH PPS standard Federal payment rate would generally only be used to determine payments for LTCH PPS standard Federal payment rate cases (that is, those LTCH PPS cases that meet the statutory criteria to be excluded from the site neutral payment rate). Under the new statutory changes to the LTCH PPS, LTCH discharges that will not meet the patient-level criteria for exclusion will be paid the site neutral payment rate, which we are calculating as the lower of the IPPS comparable per diem amount as determined under
§ 412.529(d)(4), including any applicable outlier payments, or 100 percent of the estimated cost of the case as determined under existing § 412.529(d)(2). In addition, when certain thresholds are met, LTCHs also will be able to receive HCO payments for both LTCH PPS standard Federal payment rate cases and site neutral payment rate cases that are paid at the IPPS comparable per diem amount.

To understand the impact of the changes to the LTCH PPS payments for LTCH PPS standard Federal payment rate cases presented in this final rule on different categories of LTCHs for FY 2016, it is necessary to estimate payments per discharge for FY 2015 using the rates, factors, and the policies established in the FY 2015 IPPS/LTCH PPS final rule and estimate payments per discharge for FY 2016 using the rates, factors, and the policies finalized in this FY 2016 IPPS/LTCH PPS final rule (as discussed in section VII. of the preamble of this final rule and section V. of the Addendum to this final rule). As discussed elsewhere in this rule, these estimates are based on the best available LTCH claims data and other factors, such as the application of inflation factors to estimate costs for SSO and HCO cases in each year. The resulting analyses can then be used to compare how our finalized policies applicable to LTCH PPS standard Federal payment rate cases affect different groups of LTCHs.

For the following analysis, we group hospitals based on characteristics provided in the OSCAR data, FY 2012 through FY 2013 cost report data in HCRIS, and PSF data. Hospital groups included the following:

- Location: large urban/other urban/rural.
- Participation date.
Ownership control.

Census region.

Bed size.

c. Calculation of LTCH PPS Payments for LTCH PPS Standard Federal Payment Rate Cases

For purposes of this impact analysis, to estimate the per discharge payment effects of our finalized policies on payments for LTCH PPS standard Federal payment rate cases, we simulated FYs 2015 and 2016 payments on a case-by-case basis using historical LTCH claims from the FY 2014 MedPAR files that would have met the criteria to be paid at the LTCH PPS standard Federal payment rate if the statutory patient-level criteria had been in effect at the time of discharge for those cases. For modeling FY 2015 LTCH PPS payments, we used the FY 2015 standard Federal rate of $41,043.71, or $40,240.51 for LTCHs that failed to submit quality data as required under the requirements of the LTCH QRP, which reflects the 2.0 percentage points reduction required by section 1886(m)(5)(C) of the Act. Similarly, for modeling FY 2016 LTCH PPS standard Federal payment rate payments, we used the FY 2016 standard Federal payment rate of $41,762.85, or $40,941.55 for LTCHs that failed to submit quality data as required under the requirements of the LTCH QRP, again, to reflect the 2.0 percentage points reduction required by section 1886(m)(5)(C) of the Act. In each case, we applied the applicable adjustments for area wage levels and the COLA for LTCHs located in Alaska and Hawaii. Specifically, for modeling FY 2015 LTCH PPS payments, we used the current FY 2015 labor-related share (62.306 percent); the wage index values established in the
Tables 12A through 12D listed in the Addendum to the FY 2015 IPPS/LTCH PPS final rule (which are available via the Internet on the CMS Web site), including the transitional blended wage index for the implementation of the CBSA delineations in FY 2015; the FY 2015 fixed-loss amount for LTCH PPS standard Federal payment rate cases of $14,972 (as discussed in section V.D. of the Addendum to that final rule) and the FY 2015 COLA factors (shown in the table in section V.C. of the Addendum to that final rule) to adjust the FY 2015 nonlabor-related share (37.694 percent) for LTCHs located in Alaska and Hawaii. Similarly, for modeling FY 2016 LTCH PPS payments, we used the FY 2016 LTCH PPS labor-related share (62.0 percent), the FY 2016 wage index values from Tables 12A and 12B listed in section VI. of the Addendum to this final rule (which are also available via the Internet on the CMS Web site), the FY 2016 fixed-loss amount for LTCH PPS standard Federal payment rate cases of $16,423 (as discussed in section V.D.3. of the Addendum to this final rule), and the FY 2016 COLA factors (shown in the table in section V.C. of the Addendum to this final rule) to adjust the FY 2016 nonlabor-related share (38.0 percent) for LTCHs located in Alaska and Hawaii.

As discussed above, our impact analysis reflects an estimated change in payments for SSO cases, as well as an estimated decrease in HCO payments for LTCH PPS standard Federal payment rate cases (as described previously in section I.J.1. of this Appendix). In modeling payments for SSO and HCO cases for LTCH PPS standard Federal payment rate cases, we applied an inflation factor of 4.6 percent (determined by the Office of the Actuary) to update the 2014 costs of each case.
The impacts presented below reflect the estimated “losses” or “gains” among the various classifications of LTCHs from FY 2015 to FY 2016 based on the payment rates and policy changes applicable to LTCH PPS standard Federal payment rate cases presented in this final rule. Table IV illustrates the estimated aggregate impact of the change in LTCH PPS payments for LTCH PPS standard Federal payment rate cases among various classifications of LTCHs. (As discussed previously, these impacts do not include LTCH PPS site neutral payment rate cases.)

- The first column, LTCH Classification, identifies the type of LTCH.
- The second column lists the number of LTCHs of each classification type.
- The third column identifies the number of LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria.
- The fourth column shows the estimated FY 2015 payment per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria (as described above).
- The fifth column shows the estimated FY 2016 payment per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria (as described above).
- The sixth column shows the percentage change in estimated payments per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria from FY 2015 to FY 2016 due to the annual update to the standard Federal rate (as discussed in section V.A.2. of the Addendum to this final rule).
The seventh column shows the percentage change in estimated payments per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria from FY 2015 to FY 2016 for changes to the area wage level adjustment (that is, the wage indexes and the labor-related share), including the application of an area wage level budget neutrality factor (as discussed in section V.B. of the Addendum to this final rule).

The eighth column shows the percentage change in estimated payments per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria from FY 2015 (Column 4) to FY 2016 (Column 5) for all changes (and includes the effect of estimated changes to HCO and SSO payments).
### TABLE IV: IMPACT OF PAYMENT RATE AND POLICY CHANGES TO LTCH PPS PAYMENTS FOR STANDARD PAYMENT RATE CASES FOR FY 2016 (ESTIMATED FY 2015 PAYMENTS COMPARED TO ESTIMATED FY 2016 PAYMENTS)

<table>
<thead>
<tr>
<th>LTCH Classification (1)</th>
<th>Number of LTCHs (2)</th>
<th>Number of LTCH PPS Standard Federal Payment Rate Cases (3)</th>
<th>Average FY 2015 LTCH PPS Payment Per Case (4)</th>
<th>Average FY 2016 LTCH PPS Standard Federal Payment Rate Per Case (5)</th>
<th>Percent Change in Payments Per Case Due to the Annual Update to the LTCH PPS Standard Federal Rate (6)</th>
<th>Percent Change in Payments Per Case Due to Changes to the Area Wage Level Adjustment with Budget Neutrality* (7)</th>
<th>Percent Change in Payments Per Case from FY 2015 to FY 2016 for All Changes* (8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL PROVIDERS</td>
<td>419</td>
<td>73,745</td>
<td>$45,764</td>
<td>$46,448</td>
<td>1.4</td>
<td>0.0</td>
<td>1.5</td>
</tr>
<tr>
<td>BY LOCATION:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RURAL</td>
<td>21</td>
<td>2,167</td>
<td>$38,203</td>
<td>$38,565</td>
<td>1.3</td>
<td>-0.8</td>
<td>0.9</td>
</tr>
<tr>
<td>URBAN</td>
<td>398</td>
<td>71,578</td>
<td>$45,993</td>
<td>$46,687</td>
<td>1.4</td>
<td>0.0</td>
<td>1.5</td>
</tr>
<tr>
<td>LARGE</td>
<td>200</td>
<td>42,605</td>
<td>$48,296</td>
<td>$48,995</td>
<td>1.4</td>
<td>0.0</td>
<td>1.4</td>
</tr>
<tr>
<td>OTHER</td>
<td>198</td>
<td>28,973</td>
<td>$42,606</td>
<td>$43,293</td>
<td>1.5</td>
<td>0.0</td>
<td>1.4</td>
</tr>
<tr>
<td>BY PARTICIPATION DATE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BEFORE OCT. 1983</td>
<td>14</td>
<td>2,077</td>
<td>$42,350</td>
<td>$43,513</td>
<td>1.5</td>
<td>0.5</td>
<td>2.7</td>
</tr>
<tr>
<td>OCT. 1983- SEPT. 1993</td>
<td>43</td>
<td>9,068</td>
<td>$51,140</td>
<td>$51,812</td>
<td>1.4</td>
<td>0.0</td>
<td>1.3</td>
</tr>
<tr>
<td>OCT. 1993- SEPT. 2002</td>
<td>180</td>
<td>32,620</td>
<td>$44,461</td>
<td>$45,190</td>
<td>1.5</td>
<td>-0.1</td>
<td>1.6</td>
</tr>
<tr>
<td>OCTOBER 2002 and AFTER</td>
<td>182</td>
<td>29,980</td>
<td>$45,793</td>
<td>$46,398</td>
<td>1.4</td>
<td>0.1</td>
<td>1.3</td>
</tr>
<tr>
<td>BY OWNERSHIP TYPE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VOLUNTARY</td>
<td>78</td>
<td>9,900</td>
<td>$46,891</td>
<td>$47,628</td>
<td>1.4</td>
<td>0.0</td>
<td>1.6</td>
</tr>
<tr>
<td>PROPRIETARY</td>
<td>326</td>
<td>62,265</td>
<td>$45,412</td>
<td>$46,081</td>
<td>1.4</td>
<td>0.0</td>
<td>1.5</td>
</tr>
<tr>
<td>GOVERNMENT</td>
<td>15</td>
<td>1,580</td>
<td>$52,605</td>
<td>$53,544</td>
<td>1.4</td>
<td>0.1</td>
<td>1.8</td>
</tr>
<tr>
<td>BY REGION:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW ENGLAND</td>
<td>13</td>
<td>2,924</td>
<td>$41,298</td>
<td>$42,367</td>
<td>1.4</td>
<td>0.4</td>
<td>2.6</td>
</tr>
<tr>
<td>MIDDLE ATLANTIC</td>
<td>29</td>
<td>5,315</td>
<td>$51,549</td>
<td>$51,942</td>
<td>1.5</td>
<td>-0.2</td>
<td>0.8</td>
</tr>
<tr>
<td>SOUTH ATLANTIC</td>
<td>61</td>
<td>12,159</td>
<td>$45,783</td>
<td>$46,357</td>
<td>1.4</td>
<td>0.0</td>
<td>1.3</td>
</tr>
<tr>
<td>EAST NORTH CENTRAL</td>
<td>69</td>
<td>12,214</td>
<td>$46,310</td>
<td>$46,961</td>
<td>1.5</td>
<td>-0.1</td>
<td>1.4</td>
</tr>
<tr>
<td>EAST SOUTH CENTRAL</td>
<td>34</td>
<td>5,181</td>
<td>$44,398</td>
<td>$44,929</td>
<td>1.5</td>
<td>0.0</td>
<td>1.2</td>
</tr>
<tr>
<td>WEST NORTH CENTRAL</td>
<td>25</td>
<td>3,759</td>
<td>$45,421</td>
<td>$46,069</td>
<td>1.4</td>
<td>-0.4</td>
<td>1.4</td>
</tr>
<tr>
<td>WEST SOUTH CENTRAL</td>
<td>130</td>
<td>19,351</td>
<td>$40,235</td>
<td>$40,932</td>
<td>1.4</td>
<td>-0.2</td>
<td>1.7</td>
</tr>
<tr>
<td>MOUNTAIN</td>
<td>33</td>
<td>4,281</td>
<td>$47,101</td>
<td>$47,782</td>
<td>1.4</td>
<td>-0.1</td>
<td>1.4</td>
</tr>
<tr>
<td>PACIFIC</td>
<td>25</td>
<td>8,381</td>
<td>$56,045</td>
<td>$57,071</td>
<td>1.4</td>
<td>0.5</td>
<td>1.8</td>
</tr>
<tr>
<td>BY BED SIZE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BEDS: 0-24</td>
<td>26</td>
<td>1,286</td>
<td>$41,622</td>
<td>$42,489</td>
<td>1.4</td>
<td>0.4</td>
<td>2.1</td>
</tr>
<tr>
<td>BEDS: 25-49</td>
<td>195</td>
<td>25,083</td>
<td>$43,495</td>
<td>$44,099</td>
<td>1.4</td>
<td>-0.1</td>
<td>1.4</td>
</tr>
<tr>
<td>BEDS: 50-74</td>
<td>113</td>
<td>20,406</td>
<td>$46,794</td>
<td>$47,390</td>
<td>1.4</td>
<td>-0.1</td>
<td>1.3</td>
</tr>
<tr>
<td>BEDS: 75-124</td>
<td>47</td>
<td>13,003</td>
<td>$49,000</td>
<td>$49,719</td>
<td>1.5</td>
<td>0.1</td>
<td>1.5</td>
</tr>
<tr>
<td>BEDS: 125-199</td>
<td>21</td>
<td>7,734</td>
<td>$45,647</td>
<td>$46,458</td>
<td>1.5</td>
<td>0.1</td>
<td>1.8</td>
</tr>
<tr>
<td>BEDS: 200+</td>
<td>12</td>
<td>6,235</td>
<td>$45,778</td>
<td>$46,805</td>
<td>1.5</td>
<td>0.3</td>
<td>2.2</td>
</tr>
</tbody>
</table>

* Estimated FY 2016 LTCH PPS payments to LTCH cases that are expected to meet the LTCH PPS standard Federal payment rate criteria based on the payment rate and factor changes applicable to LTCH PPS standard Federal payment rate cases presented in the preamble of and the Addendum to this final rule.
Percent change in estimated payments per discharge for LTCH cases that are expected to meet the LTCH PPS standard Federal payment rate criteria from FY 2015 to FY 2016 for the annual update to the LTCH PPS standard Federal payment rate.

Percent change in estimated payments per discharge for LTCH cases that are expected to meet the LTCH PPS standard Federal payment rate criteria from FY 2015 to FY 2016 for changes to the area wage level adjustment under § 412.525(c) (as discussed in section V.B. of the Addendum to this final rule).

Percent change in estimated payments per discharge for LTCH cases that are expected to meet the LTCH PPS standard Federal payment rate criteria from FY 2015 to FY 2016, including all of the changes to the rates and factors applicable to LTCH PPS standard Federal payment rate cases presented in the preamble and the Addendum to this final rule. Note, this column, which shows the percent change in estimated payments per discharge for all changes, does not equal the sum of the percent changes in estimated payments per discharge for the annual update to the LTCH PPS standard Federal payment rate (column 6) and the changes to the area wage level adjustment with budget neutrality (Column 7) due to the effect of estimated changes in both estimated payments to SSO cases that are paid based on estimated costs and aggregate HCO payments for LTCH cases that are expected to meet the LTCH PPS standard Federal payment rate criteria (as discussed in this impact analysis), as well as other interactive effects that cannot be isolated.

d. Results

Based on the FY 2014 LTCH cases (from 419 LTCHs) that were used for the analyses in this final rule, we have prepared the following summary of the impact (as shown above in Table IV) of the LTCH PPS payment rate and finalized policy changes for LTCH PPS standard Federal payment rate cases presented in this final rule. The impact analysis in Table IV shows that estimated payments per discharge for LTCH PPS standard Federal payment rate cases are expected to increase 1.5 percent, on average, for all LTCHs from FY 2015 to FY 2016 as a result of the payment rate and policy changes applicable to LTCH PPS standard Federal payment rate cases presented in this final rule. This estimated 1.5 percent increase in LTCH PPS payments per discharge to LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016 for all LTCHs (as shown in Table IV) was determined by comparing estimated FY 2016 LTCH PPS payments (using the payment rates and factors discussed in this final rule) to estimated FY 2015 LTCH PPS payments for LTCH discharges which would be LTCH PPS standard Federal
payment rate cases if the new dual rate LTCH PPS payment structure had been in effect at the time of the discharge (as described in section I.J.3. of this Appendix).

As stated previously, we are updating the LTCH PPS standard Federal payment rate for FY 2016 by 1.7 percent based on the latest estimate of the LTCH PPS market basket increase (2.4 percent), the reduction of 0.5 percentage point for the MFP adjustment, and the 0.2 percentage point reduction consistent with sections 1886(m)(3) and (m)(4) of the Act. For LTCHs that fail to submit quality data under the requirements of the LTCH QRP, as required by section 1886(m)(5)(C) of the Act, a 2.0 percentage point reduction would be applied to the annual update to the LTCH PPS standard Federal rate. As explained earlier in this section, for most categories of LTCHs (as shown in Table IV, Column 6), the payment increase due to the 1.7 percent annual update to the LTCH PPS standard Federal payment rate is projected to result in approximately a 1.4 percent increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases for all LTCHs from FY 2015 to FY 2016. This is because our estimate of the changes in payments due to the update to the LTCH PPS standard Federal payment rate also reflects estimated payments for SSO cases that will be paid using special methodologies that are not affected by the update to the LTCH PPS standard Federal payment rate. Consequently, we estimate that payments to LTCH PPS standard Federal payment rate cases may increase by less than 1.7 percent for certain hospital categories due to the annual update to the LTCH PPS standard Federal payment rate for FY 2016.
(1) Location

Based on the most recent available data, the vast majority of LTCHs are located in urban areas. Only approximately 5 percent of the LTCHs are identified as being located in a rural area, and approximately 3 percent of all LTCH PPS standard Federal payment rate cases are expected to be treated in these rural hospitals. The impact analysis presented in Table IV shows that the overall average percent increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016 for all hospitals is 1.5 percent. For rural LTCHs, the overall percent change for LTCH PPS standard Federal payment rate cases is estimated to be a 0.9 percent increase, while for urban LTCHs, we estimate the increase will be 1.5 percent. Large urban LTCHs are projected to experience an increase of 1.4 percent in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016, and other urban LTCHs are projected to experience an increase of 1.6 percent in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016, as shown in Table IV.

(2) Participation Date

LTCHs are grouped by participation date into four categories: (1) before October 1983; (2) between October 1983 and September 1993; (3) between October 1993 and September 2002; and (4) October 2002 and after. Based on the most recent available data, the categories of LTCHs with the largest expected percentage of LTCH PPS standard Federal payment rate cases (approximately 44 percent) are in LTCHs that began participating in the Medicare program between October 1993 and September 2002, and
they are projected to experience a 1.6 percent increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016, as shown in Table IV.

Approximately 3 percent of LTCHs began participating in the Medicare program before October 1983, and these LTCHs are projected to experience a higher than average percent increase (2.6 percent) in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016, as shown in Table IV, which is primarily due to a projected larger than average increase in payments due to the changes to the area wage adjustment. Approximately 10 percent of LTCHs began participating in the Medicare program between October 1983 and September 1993. These LTCHs are projected to experience a 1.3 percent increase in estimated payments for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016. LTCHs that began participating in the Medicare program after October 1, 2002, which treat approximately 40 percent of all LTCH PPS standard Federal payment rate cases, are projected to experience a 1.3 percent increase in estimated payments from FY 2015 to FY 2016.

(3) Ownership Control

LTCHs are grouped into three categories based on ownership control type: voluntary, proprietary, and government. Based on the most recent available data, approximately 18 percent of LTCHs are identified as voluntary (Table IV). The majority (nearly 78 percent) of LTCHs are identified as proprietary while government-owned and operated LTCHs represent approximately 4 percent of LTCHs. Based on ownership type,
voluntary LTCHs are expected to experience an average increase in payments to LTCH PPS standard Federal payment rate cases of 1.6 percent; proprietary LTCHs are expected to experience an increase of 1.5 percent in payments to LTCH PPS standard Federal payment rate cases, while government-owned and operating LTCHs are expected to experience an increase in payments to LTCH PPS standard Federal payment rate cases of 1.8 percent from FY 2015 to FY 2016.

(4) Census Region

Estimated payments per discharge for LTCH PPS standard Federal payment rate cases for FY 2016 are projected to increase for LTCHs located in all regions in comparison to FY 2015. Of the 9 census regions, we project that the increase in estimated payments per discharge to LTCH PPS standard Federal payment rate cases would have the largest positive impact on LTCHs in the New England region (2.6 percent as shown in Table IV), which is largely attributable to the changes in the area wage level adjustment.

In contrast, LTCHs located in the Middle Atlantic region are projected to experience the smallest increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016. The lower than national average estimated increase in payments of 0.8 percent is primarily due to estimated decreases in payments associated with the changes to the area wage level adjustment.

(5) Bed Size

LTCHs are grouped into six categories based on bed size: 0-24 beds; 25-49 beds; 50-74 beds; 75-124 beds; 125-199 beds; and greater than 200 beds. All bed size
categories are projected to receive an increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016. We project that large LTCHs (200+ beds) will experience a 2.2 percent increase in payments for LTCH PPS standard Federal payment rate cases, which is higher than the national average mostly due to a larger than average increase from the area wage level adjustment. Similarly, we project that both small LTCHs (0 - 24 beds) and relatively large LTCHs (125 – 199 beds) will experience a 2.1 percent increase and 1.8 percent increase, respectively, in payments for LTCH PPS standard Federal payment rate cases, which is also higher than the national average mostly due to increases in the area wage level adjustment. LTCHs with 25 to 49 beds and 75 to 124 beds are expected to experience a nearly average increase in payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016 (1.4 percent and 1.5 percent, respectively), while LTCHs with between 50 and 74 beds are expected to experience a smaller than average increase in payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2015 to FY 2016 (1.3 percent).

4. Effect on the Medicare Program

As stated previously, we project that the provisions of this final rule will result in an increase in estimated aggregate LTCH PPS payments to LTCH PPS standard Federal payment rate cases in FY 2016 relative to FY 2015 of approximately $50 million (or approximately 1.5 percent) for the 419 LTCHs in our database. Although, as stated previously, the hospital-level impacts do not include LTCH PPS site neutral payment rate cases, we estimate that the provisions of this final rule will result in a decrease in
estimated aggregate LTCH PPS payments to site neutral payment rate cases in FY 2016 relative to FY 2015 of approximately $300 million (or approximately 14.8 percent) for the 419 LTCHs in our database. Therefore, we project that the provisions of this final rule will result in a decrease in estimated aggregate LTCH PPS payments to all cases in FY 2016 relative to FY 2015 of approximately $250 million (or approximately 4.6 percent) for the 419 LTCHs in our database.

5. Effect on Medicare Beneficiaries

Under the LTCH PPS, hospitals receive payment based on the average resources consumed by patients for each diagnosis. We do not expect any changes in the quality of care or access to services for Medicare beneficiaries as a result of this final rule, but we continue to expect that paying prospectively for LTCH services will enhance the efficiency of the Medicare program.
K. Effects of Requirements for the Hospital Inpatient Quality Reporting (IQR) Program

In section VIII.A. of the preamble of this final rule, we discuss our requirements for hospitals to report quality data under the Hospital IQR Program in order to receive the full annual percentage increase for the FY 2018 payment determination.

In this final rule, we are finalizing our proposals to remove nine measures from the Hospital IQR Program for the FY 2018 payment determination and subsequent years:

- STK-01 Venous Thromboembolism (VTE) Prophylaxis (NQF #0434);
- STK-06: Discharged on Statin Medication* (NQF #0439);
- STK-08: Stroke Education* (NQF endorsement removed);
- VTE-1: Venous Thromboembolism Prophylaxis* (NQF #0371);
- VTE-2: Intensive Care Unit Venous Thromboembolism Prophylaxis* (NQF #0372);
- VTE-3: Venous Thromboembolism Patients with Anticoagulation Overlap Therapy* (NQF #0373);
- AMI-7a Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival* (NQF #0164);
- IMM-1 Pneumococcal Immunization (NQF #1653); and
- SCIP-Inf-4 Cardiac Surgery Patients with Controlled Postoperative Blood Glucose (NQF #0300).

(An asterisk (*) indicates that the measure is finalized for retention as an electronic clinical quality measure for the FY 2018 payment determination and subsequent years in section VIII.A.8. of the preamble of this final rule.)
The anticipated effect of removing these measures will be a reduction in the burden associated with the collection of chart-abstracted data. Due to the burden associated with the collection of chart-abstracted data, we estimate that the removal of AMI-7a will result in a burden reduction of approximately 219,000 hours across all hospitals. We estimate that the removal of the 6 VTE and STK chart-abstracted measures will result in a burden reduction of approximately 522,000 hours across all hospitals. The remaining two measures we are finalizing for removal have been previously suspended from the Hospital IQR Program. Therefore, their removal will not affect burden to hospitals. In total, we estimate that the removal of 9 measures will result in a total burden reduction of approximately 741,000 hours for the FY 2018 payment determination across all hospitals.

We are retaining six of the chart-abstracted measures finalized for removal as electronic clinical quality measures. We believe retaining some measures as electronic clinical quality measures will not affect the overall burden, as these measures were available for electronic reporting under previous requirements.

In this final rule, we are finalizing refinements, modified from what was proposed, to expand the measure cohorts for: (1) the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization measure (NQF #0468); and (2) the Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization measure (NQF #0506). Expanding the measure cohorts to include a broader population of patients adds a large number of patients, as well as additional hospitals, to these measures. However, this
expansion will not affect the burden on hospitals or hospital performance on the Hospital IQR Program because these measures are claims-based and, therefore, require no additional effort on hospitals’ part to submit the required data.

We also are finalizing our proposal to add seven of the eight measures we proposed to the Hospital IQR Program measure set. Four of these seven measures are added beginning with the FY 2018 payment determination and for subsequent years; three of these measures, addressing clinical episode-based payments, are added beginning with the FY 2019 payment determination and for subsequent years. Six of these measures are claims-based, and one measure is structural. The seven new measures are:

- Hospital Survey on Patient Safety Culture (structural);
- Kidney/UTI Clinical Episode-Based Payment (claims-based);
- Cellulitis Clinical Episode-Based Payment (claims-based);
- Gastrointestinal Hemorrhage Clinical Episode-Based Payment (claims-based);
- Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for Primary Elective THA/TKA (claims-based);
- Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction (claims-based); and
- Excess Days in Acute Care after Hospitalization for Heart Failure (claims-based).

We are not finalizing our proposal to add the Lumbar Spine Fusion/Refusion Clinical Episode-Based Payment measure (claims-based).
We believe adopting the six claims-based measures above will have no effect on hospital burden because they do not require additional effort on the part of hospitals. We further believe adopting the Hospital Survey on Patient Safety Culture measure will have a minimal effect on hospital burden, as it involves filling out a one-time form to report on this measure for a given performance period. In total we estimate a burden of 15 minutes per hospital to complete other forms such as the ECE and Measure Exception form, and to report structural measures. The estimate of 15 minutes includes all previously finalized and newly required structural measures.

For the FY 2018 payment determination and subsequent years, we also are finalizing a modification of our proposal to require hospitals to report 16 electronic clinical quality measures to instead require hospitals to report a minimum of 4 electronic clinical quality measures. Under this modified policy, no NQS domain distribution will be required. We also are requiring that hospitals submit one quarter of data (either Q3 or Q4) for CY 2016/FY 2018 payment determination and subsequent years by February 28, 2017. We believe the finalized requirement will increase the burden associated with electronic clinical quality measure reporting because electronic reporting was previously voluntary. The total burden increase is estimated to be approximately 40 minutes per hospital to report 4 electronic clinical quality measures for one quarter. For hospitals choosing to submit more electronic clinical quality measures, the total burden increase for hospitals to report 16 electronic clinical quality measures would be approximately 2 hours and 40 minutes per hospital for one quarter.
We are finalizing our proposal to change the requirements for population and sampling such that hospitals will be required to submit population and sample size data only for those measures that a hospital submits as chart-abstracted measures under the Hospital IQR Program. We believe this finalized proposal will result in a minimal decrease in burden as hospitals will not have to report population and sample size if they electronically report any of the measures that can be reported either as an electronic clinical quality measure or via chart-abstraction.

We also are finalizing our proposal to modify the existing processes for validation of chart-abstracted Hospital IQR Program data to remove one stratum. This modification will not affect hospital burden. For validation of chart-abstracted data for the FY 2018 payment determination and subsequent years, we require hospitals to provide 72 charts per hospital per year (with an average page length of 1,500), including 40 charts for HAI validation and 32 charts for clinical process of care validation, for a total of 108,000 pages per hospital per year. We reimburse hospitals at 12 cents per photocopied page (79 FR 50346) for a total per hospital cost of $12,960. For hospitals providing charts digitally via a re-writable disc, such as encrypted CD-ROMs, DVDs, or flash drives, we will reimburse hospitals at a rate of 40 cents per disc. We do not believe any additional burden is associated with data submitting this information via Web portal or PDF.

In addition to the activities described above, participation in the Hospital IQR Program requires hospitals to participate in a number of other activities, including: (1) reviewing reports for claims-based measure sets; (2) completing HAI validation templates for CLABSI and CAUTI; (3) completing HAI validation templates for MRSA
bacteremia and CDI; and (4) completing other forms and structural measures. The cumulative effects of these activities on facility burden are expected to be substantially similar to that stated for FY 2017. Considering the proposals finalized in this final rule, as well as our updated estimates for the number of records reported and the time associated with data reporting activities, we estimate a total burden of 2,289 hours per hospital and 7.6 million hours across approximately 3,300 hospitals participating in the Hospital IQR Program for the FY 2018 payment determination.

In general, however, we anticipate that, because of the new requirements we are finalizing for reporting for the FY 2018 payment determination, the number of hospitals not receiving the full annual percentage increase may be higher than average. Information is not available to determine the precise number of hospitals that will not meet the requirements to receive the full annual percentage increase for the FY 2018 payment determination. Historically, 100 hospitals, on average, of those participating in the Hospital IQR Program do not receive the full annual percentage increase in any fiscal year. The highest number of hospitals failing to meet program requirements was approximately 200 after the introduction of new NHSN reporting requirements. If the number of hospitals failing does increase because of the new requirements, we anticipate that, over the long run, this number will decline as hospitals gain more experience with these requirements.

Finally, under OMB Control Number 0938-1022, we estimated that the total burden for the FY 2017 payment determinations was 1,781 hours per hospital and 5.9 million hours across approximately 3,300 hospitals participating in the Hospital IQR
Program. We estimate here that the total burden for the FY 2018 payment determination will increase to 2,289 hours per hospital and 7.6 million hours across approximately 3,300 hospitals due to the proposals discussed above and updates to the historical data used to determine the number of cases reported and time for reporting per measure set.

The table below describes the hospital burden associated with the Hospital IQR Program requirements.

<table>
<thead>
<tr>
<th>Hospital IQR Program Requirement</th>
<th>Number of hospitals impacted</th>
<th>Burden per hospital for previously finalized requirements</th>
<th>Burden per hospital for all requirements as adopted (continuing, removed, added)</th>
<th>Net change in burden per hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chart-abstracted and structural measures, forms</td>
<td>3,300</td>
<td>1,131 hours</td>
<td>906 hours</td>
<td>-225 hours</td>
</tr>
<tr>
<td>Review reports for claims-based measures</td>
<td>3,300</td>
<td>4 hours</td>
<td>4 hours</td>
<td>0</td>
</tr>
<tr>
<td>Electronic Clinical Quality Measure Reporting</td>
<td>3,300</td>
<td>0 hours (electronic clinical quality measure reporting voluntary for FY 2017)</td>
<td>40 minutes</td>
<td>+ 40 minutes</td>
</tr>
<tr>
<td>Validation templates</td>
<td>Up to 600</td>
<td>72 hours</td>
<td>72 hours</td>
<td>0</td>
</tr>
<tr>
<td>Electronic Clinical Quality Measure validation test</td>
<td>Up to 100</td>
<td>16 hours</td>
<td>0 hours (no test this year)</td>
<td>- 16 hours</td>
</tr>
<tr>
<td>Validation charts photocopying</td>
<td>Up to 600</td>
<td>$8,496</td>
<td>$12,960</td>
<td>+$4,464</td>
</tr>
</tbody>
</table>
In implementing the Hospital IQR Program and other quality reporting programs, we have focused on measures that have high impact and support CMS and HHS priorities for improved quality and efficiency of care for Medicare beneficiaries.

L. Effects of Requirements for the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program for FY 2018

In section VIII.B. of the preamble of this final rule, we discuss our policies for the quality data reporting program for PPS-exempt cancer hospitals (PCHs), which we refer to as the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program. The PCHQR Program is authorized under section 1866(k) of the Act, which was added by section 3005 of the Affordable Care Act.

In section VIII.B.3. of the preamble of this final rule, we are finalizing our proposal that PCHs must submit data on three additional measures beginning with the FY 2018 program: (1) the CDC NHSN Facility-Wide Inpatient Hospital-Onset Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia Outcome Measure (NQF #1716); (2) the CDC NHSN Facility-Wide Inpatient Hospital-Onset *Clostridium difficile* Infection (CDI) Outcome Measure (NQF #1717); and, (3) the CDC NHSN Influenza Vaccination Coverage Among Healthcare Personnel Measure (NQF #0431). In conjunction with our finalized proposal in section VIII.B.2. of the preamble of this final rule to remove the six SCIP measures from the PCHQR Program beginning with fourth quarter (Q4) 2015 discharges and for subsequent years, the PCHQR measure set will consist of 16 measures for the FY 2018 program.
The impact of the new requirements for the PCHQR Program is expected to be minimal overall because all 11 PCHs are already submitting quality measure data to the CDC NHSN and are familiar with this reporting process. Beginning with Q1 2013 events, PCHs have been submitting Central Line-associated Bloodstream Infection (CLABSI) and Catheter-Associated Urinary Tract Infection (CAUTI) data to the CDC NHSN (77 FR 53566). Similarly, beginning with Q1 2014 events, PCHs have been submitting Surgical Site Infections (SSI) data to the CDC NHSN (78 FR 50849). As a result, PCHs are familiar with the CDC NHSN IT infrastructure and programmatic operations. In addition to fostering transparency and facilitating public reporting, we believe our requirements uphold our goals in improving quality of care and achieving better health outcomes, which outweigh burden.

One expected effect of the PCHQR Program is to keep the public informed of the quality of care provided by PCHs. We will publicly display quality measure data collected under the PCHQR Program as required under the Act. These data will be displayed on the Hospital Compare Web site. The goals of making these data available to the public in a user-friendly and relevant format include, but are not limited to: (1) allowing the public to compare PCHs in order to make informed health care decisions regarding care setting; and (2) providing information about current trends in health care. Furthermore, PCHs can use their own health care quality data for many purposes such as in risk management programs, healthcare associated infection prevention programs, and research and development activities, among others.
M. Effects of Requirements for the Long-Term Care Hospital Quality Reporting Program (LTCH QRP) for FY 2018

In section VIII.C.1. of the preamble of this final rule, we discuss the implementation of section 1886(m)(5) of the Act, which was added by section 3004(a) of the Affordable Care Act. Section 1886(m)(5) of the Act provides that, for rate year 2014 and each subsequent year, any LTCH that does not submit data to the Secretary in accordance with section 1886(m)(5)(C) and (F) of the Act shall receive a two (2) percentage point reduction to the annual update to the standard Federal rate for discharges for the hospital during the applicable fiscal year.

In the FY 2015 IPPS/LTCH PPS final rule (76 FR 50443 through 50445), we estimated that only a few LTCHs will not receive the full annual percentage increase in any fiscal year as a result of failure to submit data under the LTCH QRP. There are approximately 442 LTCHs currently reporting quality data to CMS. At the time that this analysis was prepared, 47, or approximately 10 percent, of these LTCHs did not receive the full annual percentage increase for the FY 2015 annual payment update determination. Information is not available to determine the precise number of LTCHs that will not meet the requirements to receive the full annual percentage increase for the FY 2016 payment determination.

We believe that a majority of LTCHs will continue to collect and submit data for the FY 2017 payment determination and subsequent years because they will continue to view the LTCH QRP as an important step in improving the quality of care patients
receive in the LTCHs. We believe that the burden associated with the LTCH QRP is the time and effort associated with data collection.

In this FY 2016 IPPS/LTCH PPS final rule, we are retaining 12 previously finalized measures, 2 of which we are adopting in order to establish their use as cross-setting measures that satisfy the required addition of quality measures under the domains of skin integrity and incidence of major falls, as mandated by the section 1899B of the Act: Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678), and an Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674). We are adopting a third previously finalized measure, All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512), in order to establish the newly NQF-endorsed status of this measure. Finally, we are finalizing an Application of Percent of LTCH Patients With an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015), which satisfies the addition of a quality measure under the third initially required domain of functional status, cognitive function, and changes in function and cognitive function, as mandated by section 1899B of the Act.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50443 through 50445) we discussed burden estimates that were inclusive of the 12 previously finalized measures we are retaining in this final rule. We previously estimated the total cost for all 12 quality measures to be $17,410 per LTCH annually, or $7,695,423 for all LTCHs annually (79 FR 50443 through 50445); or $2,992,384 for all quality measures reported.
via the CDC’s NHSN; and $4,703,039 for all quality measures reported to CMS using the LTCH CARE Data Set version 2.01. For a list of the 12 previously finalized measures included in the above burden estimate, we refer readers to the FY 2015 IPPS/LTCH PPS final rule.

The burden calculation discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50443 through 50445) accounts for any burden associated with newly finalized measures in this FY 2016 IPPS/LTCH PPS final rule. The measure, the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678), is currently being reported by LTCHs using version 2.01 of the LTCH CARE Data Set, which has burden approval under OMB control number 0938-1163. The burden associated with the application of the measure, the Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674), is discussed at length in the FY 2015 IPPS/LTCH PPS final rule, and is included in the above total annual burden figures in that rule, as well as listed above.

The measure, All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512), is calculated based on CMS FFS claims data, and therefore does not have any associated data reporting burden for LTCH providers.

The new quality measure we are finalizing for inclusion in the LTCH QRP, the cross-setting functional status process measure: an Application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function, is not specifically discussed in the FY 2015 IPPS/LTCH PPS final rule. However, the data elements used to report this quality measure to CMS are
included in that discussion and burden estimate in that final rule, because we are finalizing our proposal to use a subset of the same data elements that are used to report the previously finalized measure, the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function, which is included in that burden estimate. Therefore, the addition of this quality measure to the LTCH QRP does not increase burden on LTCHs.

Currently, LTCHs use two separate data collection mechanisms to report quality data to CMS: the CDC’s NHSN, which is used to report all Healthcare Associated Infection (HAI) and vaccination data (used to calculate CAUTI, CLABSI, MRSA, CDI, VAE, and Healthcare Personnel Influenza vaccination measures); and the Quality Improvement and Evaluation System Assessment Submission and Processing (QIES ASAP) system, which is used by LTCHs to report quality data via the LTCH CARE Data Set.

The data collection burden associated with the reporting of the quality measures (HAI and vaccination) reported via the CDC’s NHSN is discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50443 through 50445). However, we note that these measures are stewarded by the CDC, and the reporting burden is approved under OMB control number 0920-0666.

The remaining quality measures are reported to CMS by LTCHs using the LTCH CARE Data Set. Currently, LTCHs are using version 2.01 of the LTCH CARE Data Set (approved under OMB control number 0938-1163) which includes data elements related to two quality measures: Percent of Residents or Patients with Pressure Ulcers That Are
New or Worsened (NQF #0678) and Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (NQF #0680).

We have developed a subsequent iteration of the LTCH CARE Data Set (version 3.00), which will also include data elements for the three quality measures we previously finalized in the FY 2015 IPPS/LTCH PPS final rule: Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674); Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015); and Functional Status Outcome Measure: Change in Mobility Among LTCH Patients Requiring Ventilator Support (NQF #2632; endorsed on 07/23/2015). We refer readers to section X.B.9. of the preamble of this final rule for a discussion of the additional data elements in version 3.00 of the LTCH CARE Data Set.

Version 3.00 of the LTCH CARE Data Set will also be used to report the newly finalized cross-setting functional status process measure, an Application of the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015). However, the data items that will inform this measure are a subset of the data elements currently used to report the LTCH-specific measure, Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631; endorsed on 07/23/2015). Therefore, this measure will not add any data collection burden beyond that discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50443 through 50445), in which NQF #2631 was finalized.
We discussed the LTCH burden related to the submission using the LTCH CARE Data Set version 3.00 in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50443 through 50445), and this burden is included in the total annual burden noted in that final rule, which is $17,410 per LTCH annually, or $7,695,423 for all LTCHs annually. We believe that this estimate remains unchanged as a result of the LTCH QRP proposals we are finalizing in this final rule. We received several comments on these proposals, which we summarize and respond to below.

Comment: One commenter recommended that CMS modify the LTCH CARE Data Set to ensure consistent and necessary data will appropriately and accurately populate the required quality measures for the implementation of the IMPACT Act of 2014 as well as ongoing implementation of the LTCH QRP.

Response: We appreciate and agree with the commenter’s recommendations. As evidenced from our efforts to develop and successfully implement the LTCH CARE Data Set version 1.01 to support the implementation of the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF # 0678) measure starting on October 1, 2012, and our subsequent revisions and implementation of LTCH CARE Data Set version 2.01 starting on July 1, 2014 to support the implementation of an additional quality measure the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680), we have developed the LTCH CARE Data Set version 3.00 to support the implementation of additional quality measures as part of the LTCH QRP starting on April 1, 2016. We intend to continue to further revise and develop the LTCH CARE Data Set in order to
support CMS efforts to successfully implement quality measures we adopt for the LTCH QRP through future rulemaking. At this time, we believe the LTCH CARE Data Set version 3.00 includes the necessary items required to support data collection to appropriately and accurately capture patient-level data for each of the quality measures adopted for April 1, 2016 implementation, for the LTCH QRP.

Comment: One commenter suggested combining several items in Section GG of the LTCH CARE Data Set version 3.00. Specifically, the commenter suggested combining the three walking items and the two wheelchair items.

Response: We appreciate the commenter’s review of the LTCH CARE Data Set. Based on our analyses of the PAC PRD data and our feedback from the PAC PRD participants, we believe it is important to document the walking and wheeling distances as well as assistance needed for the activities of walking and wheelchair mobility. Therefore, we will not make changes to the LTCH CARE Data Set version 3.00 in response to this suggestion.

Comment: Several commenters were concerned that, in the process of trying to limit some of the data fields that made up the LTCH CARE Data Set, CMS has inappropriately collapsed response categories, such as in the section focused on Active Diagnoses, Comorbidities and Co-Existing Conditions. For example, the commenters asked for clarification of Severe Cancers and Opportunistic Infections as they considered the term to be subjective and could lead to inconsistent reporting across facilities.

Response: We appreciate the commenters’ review of the LTCH CARE Data Set. We will provide detailed instructions in the LTCH QRP Manual version 3.0, including
providing examples of severe cancers and opportunistic infections. The diagnosis groupings that we include on the LTCH CARE Data Set version 3.00 are the labels and definitions from the Hierarchical Condition Categories (HCCs), and some HCCs were further merged based on sample size requirements and the regression analysis results. Severe cancers can include, but are not limited to, cancer of stomach; cancer of liver; cancer of pancreas; cancer of trachea, bronchus, lung, and pleura; and multiple myeloma. Opportunistic infections include, but are not limited to, cytomegaloviral disease, including pneumonia; candidiasis of lung, esophagus, or disseminated; opportunistic mycoses (aspergillosis, cryptococcosis, zygomycosis, etc.); and pneumocystis pneumonia. We understand the importance of education and have worked in the past with public outreach, including training sessions, training manuals, Webinars, open door forums, help desk support and a Web site that hosts training information (http://www.youtube.com/user/CMSHHSgov). We plan to conduct such activities for the new items.

Comment: A few commenters suggested that, for patients who are in a coma/persistent vegetative state, the LTCH CARE Data Set include a skip pattern that allows the clinician to skip the Confusion Assessment Method (CAM©) items.

Response: We appreciate the commenters’ suggestion to add a skip pattern that would reduce burden. We have taken this suggestion into consideration and determined that skipping the CAM© for patients in a coma is appropriate and therefore, we will implement this skip pattern.
Comment: One commenter noted that many of the data elements in the LTCH CARE Data Set will engender codes indicating “Not applicable” and “Activity did not occur due to medical condition or safety concerns.”

Response: We agree with the commenter and are aware that for several of the data elements in the LTCH CARE Data Set, codes “Not applicable” and “Activity did not occur due to medical condition or safety concerns” may be appropriate. We anticipate that in the instances when a patient is unable to respond and family members are not able to provide the information, these codes would be appropriate. We invite readers to review the data submission specifications for information on specific codes (including “Not applicable” and “Activity did not occur due to medical condition or safety concerns”) allowed for each data element of the LTCH CARE Data Set version 3.00, available for download on the CMS Web site at: [http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Technical-Information.html](http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Technical-Information.html).

Comment: One commenter noted that the CARE Item Set would take 60 minutes to complete in the LTCH setting although Pilot 2 of the PAC PRD (available at: [http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Reports/Research-Reports-Items/PAC_Payment_Reform_Demo_Final.html](http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Reports/Research-Reports-Items/PAC_Payment_Reform_Demo_Final.html)) stated that, despite the request for time estimates at the end of each CARE tool domain, “The amount of time taken to fill out the form was completed for up to half the records for some sections, and not at all for others.”
Response: We thank the commenter for reviewing and drawing upon the PAC PRD reports to inform their concern and feedback on burden estimates. We would like to clarify that the burden associated with the CARE Tool (which was used in PAC PRD) is not directly applicable to the LTCH CARE Data Set (which has been in use as part of LTCH QRP since October 1, 2012). Specifically, we are clarifying that we pay careful attention to and make every attempt to reduce LTCH burden for compliance with the LTCH QRP (including completion of LTCH CARE Data Set to submit data on quality measures adopted for the LTCH QRP). This is among several reasons why we have taken an incremental approach to develop and implement the LTCH CARE Data Set to include only those items that support data collection for quality measures adopted for the LTCH QRP and why we have not implemented the CARE Tool in its entirety.

Further, we are clarifying that there is no new burden associated with the additions to Section GG of the LTCH CARE Data Set, since the measures adopted through this final rule will utilize data elements that are collected under the LTCH CARE Data Set version 3.00. These data elements were previously finalized through rulemaking in order to inform quality measures that were previously finalized, and for which data collection will begin on April 1, 2016.

After consideration of the public comments we received, we are finalizing our estimates of the burden associated with the use of LTCH CARE Data Set version 3.00 for implementation starting April 1, 2016. Further, we are finalizing our use of CDC’s burden estimates for using NHSN for data collection and submission of NHSN-based quality measures.
II. Alternatives Considered

This final rule contains a range of policies. It also provides descriptions of the statutory provisions that are addressed, identifies the finalized policies, and presents rationales for our decisions and, where relevant, alternatives that were considered.

III. Overall Conclusion

1. Acute Care Hospitals

Table I of section I.G. of this Appendix demonstrates the estimated distributional impact of the IPPS budget neutrality requirements for the MS-DRG and wage index changes, and for the wage index reclassifications under the MGCRB. Table I also shows an overall increase of 0.4 percent in operating payments. As discussed in section I.G. of this Appendix, we estimate that operating payments will increase by approximately $378 million in FY 2016 relative to FY 2015. However, when we account for the impact of the changes in Medicare DSH payments and the impact of the new additional payments based on uncompensated care in accordance with section 3133 of the Affordable Care Act, based on estimates provided by the CMS Office of the Actuary, consistent with our policy discussed in section IV.D. of the preamble of this final rule, we estimate that operating payments will increase by approximately $75 million relative to FY 2015. We currently estimate that the changes in new technology add-on payments for FY 2016 will increase spending by approximately $9.5 million due to the expiration of three new technology add-on payments and the additional approval of two new technology add-on payments. This estimate, combined with our estimated increase in FY 2016 operating payment of $75 million, results in an estimated increase of approximately $85 million for
FY 2016. We estimate that hospitals will experience a 2.3 percent increase in capital payments per case, as shown in Table III of section I.I. of this Appendix. We project that there will be a $187 million increase in capital payments in FY 2016 compared to FY 2015. The cumulative operating and capital payments will result in a net increase of approximately $272 million to IPPS providers. The discussions presented in the previous pages, in combination with the rest of this final rule, constitute a regulatory impact analysis.

2. LTCHs

   Overall, LTCHs are projected to experience a decrease in estimated payments per discharge in FY 2016. In the impact analysis, we are using the rates, factors, and policies presented in this final rule, including updated wage index values and relative weights, and the best available claims and CCR data to estimate the change in payments under the LTCH PPS for FY 2016. Accordingly, based on the best available data for the 419 LTCHs in our database, we estimate that FY 2016 LTCH PPS payments will decrease approximately $250 million relative to FY 2015 as a result of the payment rates and factors presented in this final rule.

IV. Accounting Statements and Tables

A. Acute Care Hospitals

As required by OMB Circular A-4 (available at http://www.whitehouse.gov/omb/circulars/a004/a-4.pdf), in Table V below, we have prepared an accounting statement showing the classification of the expenditures associated with the provisions of this final rule as they relate to acute care hospitals. This
table provides our best estimate of the change in Medicare payments to providers as a result of the changes to the IPPS presented in this final rule. All expenditures are classified as transfers to Medicare providers.

The cost to the Federal Government associated with the policies in this final rule are estimated at $272 million.

**Table V.—Accounting Statement: Classification of Estimated Expenditures under the IPPS from FY 2015 to FY 2016**

<table>
<thead>
<tr>
<th>Category</th>
<th>Transfers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annualized Monetized Transfers</td>
<td>-$272 million</td>
</tr>
<tr>
<td>From Whom to Whom</td>
<td>Federal Government to IPPS Medicare Providers</td>
</tr>
</tbody>
</table>

**B. LTCHs**

As discussed in section I.J. of this Appendix, the impact analysis of the payment rates and factors presented in this final rule under the LTCH PPS, is projected to result in a decrease in estimated aggregate LTCH PPS payments in FY 2016 relative to FY 2015 of approximately $250 million based on the data for 419 LTCHs in our database that are subject to payment under the LTCH PPS. Therefore, as required by OMB Circular A-4 (available at [http://www.whitehouse.gov/omb/circulars/a004/a-4.pdf](http://www.whitehouse.gov/omb/circulars/a004/a-4.pdf)), in Table VI below, we have prepared an accounting statement showing the classification of the expenditures associated with the provisions of this final rule as they relate to the changes to the LTCH PPS. Table VI provides our best estimate of the estimated change in Medicare payments under the LTCH PPS as a result of the payment rates and factors and other provisions presented in this final rule based on the data for the 419 LTCHs in our database. All expenditures are classified as transfers to Medicare providers (that is, LTCHs).
The savings to the Federal Government associated with the policies for LTCHs in this final rule are estimated at $250 million.

**TABLE VI.—Accounting Statement: Classification of Estimated Expenditures from the FY 2015 LTCH PPS to the FY 2016 LTCH PPS**

<table>
<thead>
<tr>
<th>Category</th>
<th>Transfers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annualized Monetized Transfers</td>
<td>-$250 million</td>
</tr>
<tr>
<td>From Whom to Whom</td>
<td>Federal Government to LTCH Medicare Providers</td>
</tr>
</tbody>
</table>

V. Regulatory Flexibility Act (RFA) Analysis

The RFA requires agencies to analyze options for regulatory relief of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small government jurisdictions. We estimate that most hospitals and most other providers and suppliers are small entities as that term is used in the RFA. The great majority of hospitals and most other health care providers and suppliers are small entities, either by being nonprofit organizations or by meeting the SBA definition of a small business (having revenues of less than $7.5 million to $38.5 million in any 1 year). (For details on the latest standards for health care providers, we refer readers to page 36 of the Table of Small Business Size Standards for NAIC 622 found on the SBA Web site at: [http://www.sba.gov/sites/default/files/files/Size_Standards_Table.pdf](http://www.sba.gov/sites/default/files/files/Size_Standards_Table.pdf).)

For purposes of the RFA, all hospitals and other providers and suppliers are considered to be small entities. Individuals and States are not included in the definition of a small entity. We believe that the provisions of this final rule relating to acute care hospitals would have a significant impact on small entities as explained in this Appendix. Because we lack data on individual hospital receipts, we cannot determine the number of
small proprietary LTCHs. Therefore, we are assuming that all LTCHs are considered small entities for the purpose of the analysis in section I.J. of this Appendix. MACs are not considered to be small entities. Because we acknowledge that many of the affected entities are small entities, the analysis discussed throughout the preamble of this final rule constitutes our regulatory flexibility analysis. In FY 2016 IPPS/LTCH PPS proposed rule, we solicited public comments on our estimates and analysis of the impact of our proposals on those small entities. Any public comments that we received and our responses are presented throughout this final rule.

VI. Impact on Small Rural Hospitals

Section 1102(b) of the Social Security Act requires us to prepare a regulatory impact analysis for any proposed or final rule that may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 603 of the RFA. With the exception of hospitals located in certain New England counties, for purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of an urban area and has fewer than 100 beds. Section 601(g) of the Social Security Amendments of 1983 (Pub. L. 98-21) designated hospitals in certain New England counties as belonging to the adjacent urban area. Thus, for purposes of the IPPS and the LTCH PPS, we continue to classify these hospitals as urban hospitals. (We refer readers to Table I in section I.G. of this Appendix for the quantitative effects of the policy changes under the IPPS for operating costs.)
VII. Unfunded Mandates Reform Act Analysis

Section 202 of the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4) also requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of $100 million in 1995 dollars, updated annually for inflation. In 2015, that threshold level is approximately $144 million. This final rule will not mandate any requirements for State, local, or tribal governments, nor will it affect private sector costs.

VIII. Executive Order 12866

In accordance with the provisions of Executive Order 12866, the Executive Office of Management and Budget reviewed this final rule.
Appendix B: Recommendation of Update Factors for Operating Cost Rates of Payment for Inpatient Hospital Services

I. Background

Section 1886(e)(4)(A) of the Act requires that the Secretary, taking into consideration the recommendations of MedPAC, recommend update factors for inpatient hospital services for each fiscal year that take into account the amounts necessary for the efficient and effective delivery of medically appropriate and necessary care of high quality. Under section 1886(e)(5) of the Act, we are required to publish update factors recommended by the Secretary in the proposed and final IPPS rules, respectively.

Accordingly, this Appendix provides the recommendations for the update factors for the IPPS national standardized amount, the Puerto Rico-specific standardized amount, the hospital-specific rate for SCHs and MDHs, and the rate-of-increase limits for certain hospitals excluded from the IPPS, as well as LTCHs. In prior years, we have made a recommendation in the IPPS proposed rule and final rule for the update factors for the payment rates for IRFs and IPFs. However, for FY 2016, we plan to include the Secretary’s recommendation for the update factors for IRFs and IPFs in separate Federal Register documents at the time that we announce the annual updates for IRFs and IPFs. We also discuss our response to MedPAC’s recommended update factors for inpatient hospital services.
II. Inpatient Hospital Update for FY 2016

A. FY 2016 Inpatient Hospital Update

As discussed in section IV.A. of the preamble to this final rule, for FY 2016, consistent with section 1886(b)(3)(B) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act, we are setting the applicable percentage increase by applying the following adjustments in the following sequence. Specifically, the applicable percentage increase under the IPPS is equal to the rate-of-increase in the hospital market basket for IPPS hospitals in all areas, subject to a reduction of one-quarter of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals that fail to submit quality information under rules established by the Secretary in accordance with section 1886(b)(3)(B)(viii) of the Act and a 66 2/3 percent reduction to three-fourths of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals not considered to be meaningful electronic health record (EHR) users in accordance with section 1886(b)(3)(B)(ix) of the Act, and then subject to an adjustment based on changes in economy-wide productivity (the multifactor productivity (MFP) adjustment), and an additional reduction of 0.2 percentage point as required by section 1886(b)(3)(B)(xii) of the Act. Sections 1886(b)(3)(B)(xi) and (b)(3)(B)(xii) of the Act, as added by section 3401(a) of the Affordable Care Act, state that application of the MFP adjustment and the additional
FY 2016 adjustment of 0.2 percentage point may result in the applicable percentage increase being less than zero.

In the FY 2016 IPPS/LTCH PPS proposed rule, based on the most recent data available at that time, in accordance with section 1886(b)(3)(B) of the Act, we proposed to establish the FY 2016 market basket update used to determine the applicable percentage increase for the IPPS based on IHS Global Insight, Inc.’s (IGI’s) first quarter 2015 forecast of the FY 2010-based IPPS market basket rate-of-increase with historical data through fourth quarter 2014, which was estimated to be 2.7 percent. Based on the most recent data available for this FY 2016 final rule, in accordance with section 1886(b)(3)(B) of the Act, we are establishing the FY 2016 market basket update used to determine the applicable percentage increase for the IPPS based on IHS Global Insight, Inc.’s (IGI’s) second quarter 2015 forecast of the FY 2010-based IPPS market basket rate-of-increase, which is estimated to be 2.4 percent.

In accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, in section IV.A. of the preamble of the FY 2016 IPPS/LTCH PPS proposed rule, we proposed a multifactor productivity (MFP) adjustment (the 10-year moving average of MFP for the period ending FY 2016) of 0.6 percent. Therefore, based on IGI’s first quarter 2015 forecast of the FY 2010-based IPPS market basket, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act (hereafter referred to as a hospital that submits quality data) and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act (hereafter referred to as a hospital that is a meaningful EHR
user), we presented in the proposed rule four possible applicable percentage increases that could be applied to the standardized amount. Based on the most recent data available for this FY 2016 IPPS/LTCH PPS final rule, in accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, in section IV.A. of the preamble of this final rule, we are establishing a MFP adjustment (the 10-year moving average of MFP for the period ending FY 2016) of 0.5 percentage point.

In accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, as discussed in section IV.A. of the preamble of this final rule, we are establishing the applicable percentages increases for the FY 2016 updates based on IGI’s second quarter 2015 forecast of the FY 2010-based IPPS market basket, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act, as outlined in the table below.
### B. Update for SCHs and MDHs for FY 2016

Section 1886(b)(3)(B)(iv) of the Act provides that the FY 2016 applicable percentage increase in the hospital-specific rate for SCHs and MDHs equals the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS).

As discussed in section IV.L. of the preamble of this final rule, section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114-10,

<table>
<thead>
<tr>
<th>FY 2016</th>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Basket Rate-of-Increase</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Adjustment for Failure to Submit Quality Data under Section 1886(b)(3)(B)(viii) of the Act</td>
<td>0.0</td>
<td>0.0</td>
<td>-0.6</td>
<td>-0.6</td>
</tr>
<tr>
<td>Adjustment for Failure to be a Meaningful EHR User under Section 1886(b)(3)(B)(ix) of the Act</td>
<td>0.0</td>
<td>-1.2</td>
<td>0.0</td>
<td>-1.2</td>
</tr>
<tr>
<td>MFP Adjustment under Section 1886(b)(3)(B)(xi) of the Act</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
</tr>
<tr>
<td>Statutory Adjustment under Section 1886(b)(3)(B)(xii) of the Act</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
</tr>
<tr>
<td>Applicable Percentage Increase Applied to Standardized Amount</td>
<td>1.7</td>
<td>0.5</td>
<td>1.1</td>
<td>-0.1</td>
</tr>
</tbody>
</table>
enacted on April 16, 2015) extended the MDH program (which, under previous law, was to be in effect for discharges on or before March 31, 2015 only) for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017).

As mentioned above, the update to the hospital specific rate for SCHs and MDHs is subject to section 1886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act. Accordingly, depending on whether a hospital submits quality data and is a meaningful EHR user, we are establishing the same four applicable percentage increases in the table above for the hospital-specific rate applicable to SCHs and MDHs.

C. FY 2016 Puerto Rico Hospital Update

Section 401(c) of Pub. L. 108-173 amended section 1886(d)(9)(C)(i) of the Act and states that, for discharges occurring in a fiscal year (beginning with FY 2004), the Secretary shall compute an average standardized amount for hospitals located in any area of Puerto Rico that is equal to the average standardized amount computed under subclause (I) for FY 2003 for hospitals in a large urban area (or, beginning with FY 2005, for all hospitals in the previous fiscal year) increased by the applicable percentage increase under subsection (b)(3)(B) for the fiscal year involved. Therefore, the update to the Puerto Rico-specific operating standardized amount is subject to the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act as amended by sections 3401(a) and 10319(a) of the Affordable Care Act (that is, the same update factor
as for all other hospitals subject to the IPPS). Accordingly, we are making an applicable percentage increase to the Puerto Rico-specific standardized amount of 1.7 percent.

D. Update for Hospitals Excluded from the IPPS for FY 2016

Section 1886(b)(3)(B)(ii) of the Act is used for purposes of determining the percentage increase in the rate-of-increase limits for children’s hospitals, cancer hospitals, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa). Section 1886(b)(3)(B)(ii) of the Act sets the percentage increase in the rate-of-increase limits equal to the market basket percentage increase. In accordance with § 403.752(a) of the regulations, RNHCIs are paid under the provisions of § 413.40, which also use section 1886(b)(3)(B)(ii) of the Act to update the percentage increase in the rate-of-increase limits.

Currently, children’s hospitals, PPS-excluded cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa are among the remaining types of hospitals still paid under the reasonable cost methodology, subject to the rate-of-increase limits. We are applying the FY 2016 percentage increase in the IPPS operating market basket to the target amount for children’s hospitals, PPS-excluded cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa. For this final rule, the current estimate of the FY 2016 IPPS operating market basket percentage increase is 2.4 percent.
E. Update for LTCHs for FY 2016

As discussed in section V.A. of the Addendum to this final rule, we are establishing an update to the LTCH PPS standard Federal rate for FY 2016 based on the full LTCH PPS market basket increase estimate (for the proposed rule, we estimated this to be 2.7 percent; for this final rule, we estimate this to be 2.4 percent), subject to an adjustment based on changes in economy-wide productivity and an additional reduction required by sections 1886(m)(3)(A)(ii) and (m)(4)(E) of the Act. In accordance with the LTCH QRP under section 1886(m)(5) of the Act, we are reducing the annual update to the LTCH PPS standard Federal rate by 2.0 percentage points for failure of a LTCH to submit the required quality data. The MFP adjustment described under section 1886(b)(3)(B)(xi)(ii) of the Act is currently estimated to be 0.5 percent for FY 2016. In addition, section 1886(m)(3)(A)(ii) of the Act requires that any annual update for FY 2016 be reduced by the “other adjustment” at section 1886(m)(4)(E) of the Act, which is 0.2 percentage point. Therefore, based on more recent data from the proposed rule, that is, the IGI’s second quarter 2015 forecast of the FY 2016 LTCH PPS market basket increase, we are establishing an annual update to the LTCH PPS standard Federal rate of 1.7 percent (that is, the current FY 2016 estimate of the market basket rate-of-increase of 2.4 percent less an adjustment of 0.5 percentage point for MFP and less 0.2 percentage point). Accordingly, we are applying an update factor of 1.7 percent in determining the LTCH PPS standard Federal rate for FY 2016. For LTCHs that fail to submit quality data for FY 2016, we are applying an annual update to the LTCH PPS standard Federal rate of –0.3 percent (that is, the annual update for FY 2016 of 1.7
percent less 2.0 percentage points for failure to submit the required quality data in accordance with section 1886(m)(5)(C) of the Act and our rules) by applying an update factor of –0.3 percent in determining the LTCH PPS standard Federal rate for FY 2016.

III. Secretary’s Recommendations

MedPAC is recommending an inpatient hospital update equal to 3.25 percent for FY 2016. MedPAC’s rationale for this update recommendation is described in more detail below. As mentioned above, section 1886(e)(4)(A) of the Act requires that the Secretary, taking into consideration the recommendations of MedPAC, recommend update factors for inpatient hospital services for each fiscal year that take into account the amounts necessary for the efficient and effective delivery of medically appropriate and necessary care of high quality. Consistent with current law, depending on whether a hospital submits quality data and is a meaningful EHR user, we are recommending the four applicable percentage increases to the standardized amount listed in the table under section II. of this Appendix B. We are recommending that the same applicable percentage increases apply to SCHs and MDHs. For the Puerto Rico-specific standardized amount, we are recommending an update of 1.7 percent.

In addition to making a recommendation for IPPS hospitals, in accordance with section 1886(e)(4)(A) of the Act, we are recommending update factors for certain other types of hospitals excluded from the IPPS. Consistent with our policies for these facilities, we are recommending an update to the target amounts for children's hospitals, cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa of 2.4 percent.
For FY 2016, consistent with policy set forth in section VII. of the preamble of this final rule, for LTCHs that submit quality data, we are recommending an update of 1.7 percent to the LTCH PPS standard Federal rate. For LTCHs that fail to submit quality data for FY 2016, we are applying an annual update to the LTCH PPS standard Federal rate of –0.3 percent.

IV. MedPAC Recommendation for Assessing Payment Adequacy and Updating Payments in Traditional Medicare

In its March 2015 Report to Congress, MedPAC assessed the adequacy of current payments and costs and the relationship between payments and an appropriate cost base. MedPAC recommended an update to the hospital inpatient rates equal to 3.25 percent concurrent with changes to the outpatient prospective payment system and with initiating change to the LTCH PPS. We refer the reader to the March 2015 MedPAC report, which is available on the Web site at http://www.medpac.gov for a complete discussion on this recommendation. MedPAC expects Medicare margins to remain low in 2015. At the same time, MedPAC’s analysis finds that efficient hospitals have been able to maintain positive Medicare margins while maintaining a relatively high quality of care. However, under current law, payment margins are projected to decline which could result in negative Medicare margins industry wide. Specifically, MedPAC noted several current law policy changes are scheduled to reduce payments in FY 2015 and FY 2016. Because of these changes and reduced payments, MedPAC asserted that an update of 3.25 percent in the base payment is warranted. MedPAC maintains that Medicare payment rates should be determined by analysis of payment adequacy rather than an across-the-board
sequester reduction. Therefore, MedPAC recommended that hospitals receive base payment rates that are 3.25 percent higher than the FY 2015 base payment rates, and there should be no sequester adjustment. However, MedPAC concluded that if the Congress increases hospital payments by reinstating expiring special payments, the full 3.25 percent update would not be warranted.

Response: With regard to MedPAC’s recommendation of an update to the hospital inpatient rates equal to 3.25 percent, for FY 2016, as discussed above, section 1886(b)(3)(B) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act, sets the requirements for the FY 2016 applicable percentage increase. Therefore, we are applying an applicable percentage increase for FY 2016 of 1.7 percent, provided the hospital submits quality data and is a meaningful EHR user, consistent with these statutory requirements.

We note that, because the operating and capital prospective payment systems remain separate, we are continuing to use separate updates for operating and capital payments. The update to the capital rate is discussed in section III. of the Addendum to this final rule.

[FR Doc. 2015-19049 Filed: 7/31/2015 04:15 pm; Publication Date: 8/17/2015]